<SEC-DOCUMENT>0001062822-15-000013.txt : 20150312
<SEC-HEADER>0001062822-15-000013.hdr.sgml : 20150312
<ACCEPTANCE-DATETIME>20150312161840
ACCESSION NUMBER:		0001062822-15-000013
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150312
DATE AS OF CHANGE:		20150312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		15696133

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k12312014.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Form 10K 12.31.2014</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sD3EC35695D51963C29E8A09F3F6400DE"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.78544061302682%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="10%"></td><td width="90%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Mark One)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Wingdings 2;font-size:9pt;">R</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Fiscal Year Ended December 31, 2014</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">or</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="10%"></td><td width="90%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Wingdings 2;font-size:9pt;">&#163;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Transition Period from _____________ to _____________</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Commission File Number:&#160;&#160;000-30111</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="2%"></td><td width="45%"></td><td width="5%"></td><td width="45%"></td><td width="3%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">76-0474169</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(State or Other Jurisdiction of Incorporation or Organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(I.R.S. Employer Identification Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="2%"></td><td width="45%"></td><td width="5%"></td><td width="45%"></td><td width="3%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">8800 Technology Forest Place</font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">The Woodlands, Texas 77381</font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Address of Principal Executive Offices and Zip Code)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(281) 863-3000</font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Registrant&#8217;s Telephone Number,</font></div><div style="font-size:9pt;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Including Area Code)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.46743295019157%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="8%"></td><td width="38%"></td><td width="7%"></td><td width="38%"></td><td width="9%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Name of Each Exchange on which Registered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Common Stock, par value $0.001 per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Nasdaq Global Select Market</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act:</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;None</font></div><div style="line-height:100%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act of 1933.&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;No </font><font style="font-family:Wingdings 2;font-size:9pt;">R</font></div><div style="line-height:100%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;No </font><font style="font-family:Wingdings 2;font-size:9pt;">R</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings 2;font-size:9pt;">R</font><font style="font-family:inherit;font-size:9pt;">&#32;No </font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings 2;font-size:9pt;">R</font><font style="font-family:inherit;font-size:9pt;">&#32;No </font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160;</font><font style="font-family:Wingdings 2;font-size:9pt;">R</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.&#160;&#160;See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Securities Exchange Act of 1934.&#160;&#160;(check one):&#160;&#160;Large accelerated filer </font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;Accelerated filer&#160;&#160;</font><font style="font-family:Wingdings 2;font-size:9pt;">R </font><font style="font-family:inherit;font-size:9pt;">Non-accelerated filer </font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;Smaller reporting company </font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).&#160;&#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:inherit;font-size:9pt;">&#32;No&#160;</font><font style="font-family:Wingdings 2;font-size:9pt;">R</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The aggregate market value of voting stock held by non-affiliates of the registrant as of the last day of the registrant&#8217;s most recently completed second quarter was approximately </font><font style="font-family:inherit;font-size:9pt;">$368.0 million</font><font style="font-family:inherit;font-size:9pt;">, based on the closing price of the common stock on the Nasdaq Global Select Market on </font><font style="font-family:inherit;font-size:9pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:9pt;">&#32;of </font><font style="font-family:inherit;font-size:9pt;">$1.61</font><font style="font-family:inherit;font-size:9pt;">&#32;per share.&#160;&#160;For purposes of the preceding sentence only, our directors, executive officers and controlling stockholders are assumed to be affiliates.&#160;&#160;As of </font><font style="font-family:inherit;font-size:9pt;">March 9, 2015</font><font style="font-family:inherit;font-size:9pt;">, </font><font style="font-family:inherit;font-size:9pt;">725,145,313</font><font style="font-family:inherit;font-size:9pt;">&#32;shares of common stock were outstanding.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Documents Incorporated by Reference</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certain sections of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s </font><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:9pt;">&#32;annual meeting of stockholders, which proxy statement will be filed under the Securities Exchange Act of 1934 within 120 days of the end of the registrant&#8217;s fiscal year ended </font><font style="font-family:inherit;font-size:9pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:9pt;">, are incorporated by reference into Part III of this annual report on Form 10-K.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.78544061302682%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><a name="sB4B6117E898BC6A78480A09F3FC1B501"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="6%"></td><td width="1%"></td><td width="89%"></td><td width="4%"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Item</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s398387CAE101A05E6238A09F400F191C"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s398387CAE101A05E6238A09F400F191C"> 1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1A.</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s74CB79709D67281DFACDA09F41B4C361"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s74CB79709D67281DFACDA09F41B4C361"> 1</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1B.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2338C8E673A627494A58A09F41D455C5"><font style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2338C8E673A627494A58A09F41D455C5"> 1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD766CC42765E49BCC3ACA09F42020C1A"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD766CC42765E49BCC3ACA09F42020C1A"> 1</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA401AA8C1639E1A567D9A09F42221640"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA401AA8C1639E1A567D9A09F42221640"> 1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC773FEA5A927A6168B29A09F42601058"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC773FEA5A927A6168B29A09F42601058"> 1</a></div></td></tr><tr><td colspan="4" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s31D7F3591BB89B6F12C8A09F42AE0F5B"><font style="font-family:inherit;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s31D7F3591BB89B6F12C8A09F42AE0F5B"> 2</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5DB9767FC08609647ADFA09F3B7D5309"><font style="font-family:inherit;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5DB9767FC08609647ADFA09F3B7D5309"> 4</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2656051852826BC0A221A09F3B2F3F0A"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2656051852826BC0A221A09F3B2F3F0A"> 5</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7A.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s664EB00B4699D77715FAA09F433AFA01"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s664EB00B4699D77715FAA09F433AFA01"> 14</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB8757D4B07FAF45018ECA09F435A7BAB"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB8757D4B07FAF45018ECA09F435A7BAB"> 15</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FA26E3164CD197F9FE6A09F4379F97A"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8FA26E3164CD197F9FE6A09F4379F97A"> 15</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9A.</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s08C76942D007762294D8A09F43A8BA5C"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s08C76942D007762294D8A09F43A8BA5C"> 15</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9B.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5C8851249B7A25D5FAA8A09F43C7C4BB"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5C8851249B7A25D5FAA8A09F43C7C4BB"> 15</a></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBD071FA30D9F3F6D6428A09F44152B97"><font style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBD071FA30D9F3F6D6428A09F44152B97"> 15</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62A32EA200E1D7A2E2D6A09F4453268F"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62A32EA200E1D7A2E2D6A09F4453268F"> 15</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5D4ABF2A70BB8547009AA09F44723EEC"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5D4ABF2A70BB8547009AA09F44723EEC"> 15</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s93C4DB98F599BF29BCD5A09F44A1FEFC"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s93C4DB98F599BF29BCD5A09F44A1FEFC"> 15</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A576F087E0D47B8605EA09F44C09089"><font style="font-family:inherit;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A576F087E0D47B8605EA09F44C09089"> 15</a></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAFE5DF16F1E0C28E68E0A09F450EF76F"><font style="font-family:inherit;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAFE5DF16F1E0C28E68E0A09F450EF76F"> 16</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAC07943A934BCB088583A09F454D074A"><font style="font-family:inherit;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAC07943A934BCB088583A09F454D074A"> 18</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Lexicon name and logo are registered trademarks and Genome5000</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;is a trademark of Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_____________________________________________________</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In this annual report on Form 10-K, &#8220;Lexicon Pharmaceuticals,&#8221; &#8220;Lexicon,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Lexicon Pharmaceuticals, Inc. and its subsidiaries.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_____________________________________________________</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This annual report on Form 10-K contains forward-looking statements.&#160;&#160;These statements relate to future events or our future financial performance.&#160;&#160;We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Item 1A.&#160;&#160;Risk Factors,&#8221; that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We are not under any duty to update any of the forward-looking statements after the date of this annual report on Form 10-K to conform these statements to actual results, unless required by law.</font></div><br><div></div><hr style="page-break-after:always"><a name="s8BBDDB534AEBD66AFBB7A09F3FE08C4A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s398387CAE101A05E6238A09F400F191C"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sE921789B8C9F9891F96DA09F402E61CE"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development of breakthrough treatments for human disease.&#160;&#160;We have advanced multiple drug candidates into clinical development.  We are presently devoting most of our resources to the development of our two most advanced drug candidates:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing telotristat etiprate, or LX1032, an orally-delivered small molecule drug candidate, as a treatment for carcinoid syndrome.  We have completed two Phase 2 clinical trials and are presently conducting a single pivotal Phase 3 clinical trial of telotristat etiprate in carcinoid syndrome patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing sotagliflozin, or LX4211, an orally-delivered small molecule drug candidate, as a treatment for type&#160;1 and type&#160;2 diabetes.  We have completed two Phase&#160;2 clinical trials of sotagliflozin in type&#160;2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment.  We have also completed a Phase&#160;2 clinical trial of sotagliflozin in type 1 diabetes patients.  We are initiating a Phase&#160;2 clinical trial of sotagliflozin in a younger adult type 1 diabetes population in collaboration with JDRF.  We are also initiating Phase&#160;3 development of sotagliflozin in type&#160;1 diabetes.  We do not intend to continue development of sotagliflozin in type 2 diabetes unless we enter into a collaboration partnership.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our most advanced drug candidates, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We identified and validated in living animals, or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">, more than 100 targets with promising profiles for drug discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally and to collaborate with other pharmaceutical and biotechnology companies with respect to the development and commercialization of drug candidates from other programs, particularly when the collaboration may provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals was incorporated in Delaware in July 1995, and commenced operations in September 1995.&#160;&#160;Our corporate headquarters are located at 8800 Technology Forest Place, The Woodlands, Texas 77381, and our telephone number is (281) 863-3000.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are made available free of charge on our corporate website located at www.lexpharma.com as soon as reasonably practicable after the filing of those reports with the Securities and Exchange Commission.&#160;&#160;Information found on our website should not be considered part of this annual report on Form 10-K.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s7DE17AA3FE09A9C81C41A09F406DCD55"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Drug Development Programs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have advanced multiple drug candidates into clinical development.  We are presently devoting most of our resources to the development of our two most advanced drug candidates, telotristat etiprate for carcinoid syndrome and sotagliflozin for type 1 and type 2 diabetes.  We have also advanced a number of additional compounds into various stages of clinical and preclinical development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Telotristat etiprate (LX1032</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Telotristat etiprate, or LX1032, is an orally-delivered small molecule compound that we are developing for the treatment of carcinoid syndrome.  Telotristat etiprate was internally generated by our medicinal chemists and inhibits tryptophan hydroxylase, or TPH, the rate-limiting enzyme for serotonin production found primarily in enterochromaffin, or EC, cells of the gastrointestinal tract.  Our scientists found that mice lacking the non-neuronal form of this enzyme, TPH1, have virtually no serotonin in the gastrointestinal tract, but maintain normal levels of serotonin in the brain.  Telotristat etiprate was specifically designed to achieve enhanced systemic exposure to address disorders such as carcinoid syndrome that require regulation of serotonin levels beyond the EC cells in the gastrointestinal tract without impacting brain serotonin production.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We completed enrollment in March 2015 of a single pivotal Phase 3 clinical trial of telotristat etiprate evaluating the safety and tolerability of telotristat etiprate and its effect on symptoms associated with carcinoid syndrome.  The trial enrolled 135 patients with inadequately controlled carcinoid syndrome on background somatostatin analog therapy in a randomized, double-blind, placebo-controlled study of 250mg three times daily and 500mg three times daily doses of telotristat etiprate over a 12-week treatment period, followed by a 36-week, open-label extension where all patients receive 500mg three times daily doses of telotristat etiprate.  The primary efficacy endpoint under evaluation in the trial is the number of daily bowel movements, with secondary efficacy endpoints including changes in urinary 5-HIAA, the primary metabolite of serotonin and a biomarker for serotonin synthesis, flushing episodes, abdominal pain and quality of life measures.  The Phase 3 program of telotristat etiprate also includes an additional companion study in carcinoid syndrome patients who do not meet certain of the inclusion criteria for the pivotal Phase 3 clinical trial.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We reported top-line data in October 2012 from an open-label Phase 2 clinical trial evaluating the safety and tolerability of telotristat etiprate and its effects on symptoms associated with carcinoid syndrome.  The trial enrolled 15 patients with metastatic carcinoid syndrome who were refractory to or could not tolerate somatostatin analog therapy in an open-label study of ascending doses of 150mg, 250mg, 350mg and 500mg of telotristat etiprate, administered three times daily, for 14 days on each dose until reaching the maximal dose, which was then continued until the completion of 12 weeks of therapy.  The primary efficacy endpoint under evaluation in the trial was the reduction of bowel movements from baseline to week 12, with secondary endpoints including relief of symptoms and reduction in serotonin synthesis.  Top-line data from the study showed that patients experienced a 46.4% median reduction from baseline at week 12, with the number of daily bowel movements steadily decreasing over time.  All observed changes from baseline were statistically significant at p&lt;0.001.  This change corresponded with an increased proportion of patients reporting adequate relief of their carcinoid symptoms, a global assessment which also improved over time, with 75% of the patients with data at week 12 reporting improvement.  Clinically relevant decreases from baseline were likewise seen for a number of key secondary endpoints, including statistically significant improvements in stool consistency (p&lt;0.001) and trends of reductions which did not achieve statistical significance in abdominal pain and the number of cutaneous flushing episodes.  The median percentage reductions from baseline of urinary 5&#8209;HIAA at weeks 8 and 12 were 68.3% and 72.7%, respectively (each, p&lt;0.05).  Telotristat etiprate was well tolerated in the study, with no dose-limiting toxicity observed.  Three patients reported serious adverse events, none of which were related to telotristat etiprate, and no patient discontinued from the study due to an adverse event.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We reported top-line data in August 2011 from a Phase 2 clinical trial evaluating the safety and tolerability of telotristat etiprate and its effects on symptoms associated with carcinoid syndrome.  The trial enrolled 23 patients with symptomatic carcinoid syndrome who were refractory to octreotride therapy in a double-blind, randomized, placebo-controlled study of 150mg, 250mg, 350mg and 500mg doses of telotristat etiprate, each administered three times daily over a 28-day treatment period in combination with octreotide therapy.  The efficacy endpoints under evaluation in the trial included the number of daily bowel movements, stool form, urgency, a global assessment of symptoms associated with carcinoid syndrome, flushing episodes and an assessment of pain and discomfort.  Top-line data from the trial showed evidence of efficacy across multiple endpoints, including improvements in bowel movement frequency, decreased levels of urinary 5&#8209;HIAA and improvements in the assessment of pain and discomfort.  Telotristat etiprate demonstrated a favorable safety profile in the trial, with no dose-limiting toxicity observed.&#160;&#160;Adverse events were generally mild to moderate and similarly distributed across all groups, including the placebo group.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Telotristat etiprate has received Fast Track status and Orphan Drug designation from the United States Food and Drug Administration, or FDA, for the treatment of gastrointestinal symptoms associated with carcinoid syndrome in patients who no longer respond to standard care.  Telotristat etiprate has also received Orphan Drug designation from the Committee for Orphan Medical Products of the European Medicines Agency for the treatment of carcinoid tumors.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into a license and collaboration agreement with Ipsen Pharma SAS under which we granted Ipsen an exclusive, royalty-bearing right and license to commercialize telotristat etiprate outside of the United States, Canada and Japan.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sotagliflozin (LX4211)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sotagliflozin, or LX4211, is an orally-delivered small molecule compound that we are developing for the treatment of type&#160;1 and type 2 diabetes mellitus.  Sotagliflozin was internally generated by our medicinal chemists and inhibits both sodium-glucose cotransporter type&#160;2, or SGLT2, a transporter responsible for most of the glucose reabsorption performed by the kidney, and sodium-glucose cotransporter type&#160;1, or SGLT1, a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney.  Our scientists identified mice lacking SGLT1, SGLT2 or both as having potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism, and found that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Type 1 Diabetes</font><font style="font-family:inherit;font-size:10pt;">.  We reported top-line data in April 2014 from a Phase 2 clinical trial evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type 1 diabetes.  The Phase&#160;2 trial enrolled 36 patients with type 1 diabetes.  An initial cohort consisted of three patients treated with a 400 mg once daily dose of sotagliflozin for a period of four weeks.  A subsequent cohort of 33 patients were enrolled in the randomized, double-blind, placebo-controlled portion of the study and were treated with a 400mg once daily dose of sotagliflozin or placebo for a period of four weeks.  The primary efficacy endpoint under evaluation in the trial was reduction in bolus insulin use.  Secondary endpoints included multiple parameters of glycemic control, basal and total insulin use and other metabolic, pharmacodynamic and pharmacokinetic parameters.  Top-line data from the study showed that treatment with sotagliflozin demonstrated statistically significant benefits in the primary and multiple secondary endpoints.  Patients treated with sotagliflozin experienced a reduction in their total daily mealtime bolus insulin dose of 32% compared to 6% for patients who received placebo (p=0.007).  We also observed a significant improvement in glycemic control, with a mean hemoglobin A1c, or A1C, reduction of 0.55% in the sotagliflozin-treated group compared to a reduction of 0.06% in the placebo-treated group (p=0.002).  These observations were also accompanied by significant improvement in the time spent in a glucose range of 70-180 mg/dl, a significant reduction in time in hyperglycemic range (&gt;180 mg/dl) and no increase in hypoglycemia.  Multiple measures also indicated that patients treated with sotagliflozin experienced reduced variability in blood glucose levels.  Sotagliflozin was well tolerated with no discontinuations of study medication due to adverse events.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are initiating a Phase 2 clinical trial of sotagliflozin in a younger adult type&#160;1 diabetes population in collaboration with JDRF.  We are also initiating Phase 3 development of sotagliflozin in type&#160;1 diabetes, which is expected to include three Phase 3 studies, including two pivotal Phase 3 studies.  Each of the pivotal Phase&#160;3 studies are 24-week, placebo controlled studies of approximately 750 patients, which will be followed by 28-week extensions.  Two dose levels of sotagliflozin, 200mg and 400mg once daily, will be tested along with placebo.  The primary efficacy endpoint under evaluation will be reduction of A1C versus placebo on optimized insulin treatment at 24 weeks, with secondary endpoints including percentage of patients achieving A1C levels of less than 7%, reduction in meal-time, or bolus, insulin use and weight loss.  The third Phase 3 study is expected to enroll approximately 1,400 patients and involve a glycemic control primary endpoint and an evaluation of safety.  We also plan to conduct a dose-ranging study of sotagliflozin in patients with type&#160;1 diabetes concurrently with our planned Phase 3 studies.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Type 2 Diabetes.  </font><font style="font-family:inherit;font-size:10pt;">We reported top-line data in June 2012 from a Phase 2b clinical trial evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type 2 diabetes.  The Phase 2b trial enrolled 299 patients with type 2 diabetes who were not adequately controlled on metformin monotherapy in a double-blind, randomized, placebo-controlled study of 75mg once daily, 200mg once daily, 200mg twice daily and 400mg once daily doses of sotagliflozin, each administered in combination with standard metformin therapy over a 12&#8209;week treatment period.  The primary efficacy endpoint under evaluation in the trial was the change in A1C from baseline to week&#160;12.  Secondary efficacy endpoints included percentage of patients achieving A1C levels of less than 7%, as well as changes in fasting plasma glucose levels, weight, blood pressure and triglyceride levels.  Top-line data from the study showed that treatment with sotagliflozin demonstrated statistically significant benefits in the primary and multiple secondary endpoints.  Patients in each of the 75mg once daily, 200mg once daily, 200mg twice daily and 400mg once daily sotagliflozin treatment arms had mean A1C reductions from baseline of 0.43, 0.52, 0.79 and 0.95 percent, respectively (p&lt;0.001 for all treatment arms), while in patients randomized to placebo, A1C decreased by 0.09 percent.  We also observed that patients treated with sotagliflozin showed significant reductions in body weight and blood pressure.  Sotagliflozin was well tolerated and adverse events were generally mild to moderate, with the overall incidence of adverse events with sotagliflozin being similar to placebo.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We reported top-line data in October 2013 from a clinical trial evaluating the safety and tolerability of sotagliflozin and its effects on glycemic parameters associated with type 2 diabetes in patients with moderate renal impairment.  The clinical trial enrolled 30 patients with type 2 diabetes and moderate to severe renal impairment in a randomized, double-blind, placebo-controlled study of a 400mg once daily dose of sotagliflozin over a seven-day treatment period.  The primary efficacy endpoint under evaluation in the trial was the change in postprandial glucose from baseline to day seven, with secondary endpoints including a variety of glycemic control parameters.  Top-line data from the study showed that treatment with sotagliflozin provided clinically meaningful and statistically significant reductions (p&lt;0.05) in post-prandial glucose and produced significant elevations in GLP-1, a hormone involved in control of glucose and appetite.  Sotagliflozin was well tolerated and adverse events were generally mild to moderate, with the overall incidence of adverse events with sotagliflozin being similar to placebo.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We previously completed a Phase 2a clinical trial in type 2 diabetes patients, in which sotagliflozin provided improvements in glycemic control, demonstrated statistically significant benefits in the primary and multiple secondary efficacy endpoints and demonstrated a favorable safety profile.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not intend to continue development of sotagliflozin in type 2 diabetes unless we enter into a collaboration partnership.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Clinical and Preclinical Development Programs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">LX1033</font><font style="font-family:inherit;font-size:10pt;">.  LX1033 is an orally-delivered small molecule compound that is in development for the treatment of irritable bowel syndrome.  LX1033 was internally generated by our medicinal chemists as an inhibitor of TPH, the same target as telotristat etiprate, but LX1033 is chemically distinct and was designed to reduce production of serotonin locally in the gastrointestinal tract without affecting serotonin synthesis elsewhere in the body.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We previously completed a Phase 2 clinical trial in patients suffering from diarrhea-predominant irritable bowel syndrome in which all treatment groups, including placebo, showed significant improvements in the primary efficacy endpoint over time.  Such improvements in patients treated with LX1033 were not statistically significant relative to those treated with placebo, but LX1033 reduced the production of plasma 5&#8209;HIAA significantly more than placebo, with the greatest reductions observed in patients treated with 500mg of LX1033 three times daily.  LX1033 was well tolerated and adverse events were evenly distributed among all LX1033 and placebo treatment groups.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">LX2931</font><font style="font-family:inherit;font-size:10pt;">.  LX2931 is an orally-delivered small molecule compound that is in development for the treatment of autoimmune disease.  LX2931 was internally generated by our medicinal chemists to target sphingosine-1-phosphate lyase, or S1P lyase, an enzyme in the sphingosine-1 phosphate (S1P) pathway associated with the activity of lymphocytes.  Lymphocytes are a cellular component and key driver of the immune system, and are involved in a number of autoimmune and inflammatory disorders.  Our scientists discovered that mice lacking this enzyme have increased retention of immune cells in the thymus and spleen with a corresponding reduction in the deployment of T-cells and B-cells into the circulating blood.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We previously completed a Phase 2 clinical trial in rheumatoid arthritis patients who were also taking methotrexate, a standard therapy, in which patients treated with 150mg of LX2931 once daily showed an improvement in the primary efficacy endpoint which did not achieve statistical significance.  Patients treated with 70mg and 110mg of LX2931 once daily did not indicate improvement relative to placebo.  LX2931 was well tolerated, with no notable differences in adverse events observed between placebo and any of the treatment groups.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">LX7101.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;LX7101 is a topically-delivered small molecule compound that is under evaluation as a potential treatment for glaucoma.  LX7101 was internally generated by our medicinal chemists to target LIMK2, a kinase associated with the regulation of intraocular pressure, and is designed to lower intraocular pressure by enhancing the fluid outflow facility of the eye.  Our scientists discovered that mice lacking LIMK2 exhibited lower intraocular pressure compared to normal mice.  We previously completed a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of LX7101 in glaucoma patients, as well as intraocular pressure.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical Development Programs</font><font style="font-family:inherit;font-size:10pt;">.  We have advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development, including LX2761, an orally-delivered small molecule compound for the treatment of diabetes that is designed to inhibit SGLT1 locally in the gastrointestinal tract without any significant inhibition of SGLT2 in the kidney.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Drug Target Discoveries</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our most advanced drug candidates, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We identified and validated in living animals, or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">, more than 100 targets with promising profiles for drug discovery.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sDE841EF0E3F8769D28AAA09F407CD1BF"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Commercialization Strategy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries, and we intend to pursue the same strategy for our drug candidates in clinical development.  Consistent with this approach, we seek to retain exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally and to collaborate with other pharmaceutical and biotechnology companies with respect to the development and commercialization of drug candidates from other programs, particularly when the collaboration may provide us with access to expertise and resources that we do not possess internally or are complementary to our own.  We also seek to collaborate with other pharmaceutical and biotechnology companies, research institutes and academic institutions to capitalize on our drug target discoveries.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Strategic Collaborations</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ipsen</font><font style="font-family:inherit;font-size:10pt;">.  We entered into a license and collaboration agreement with Ipsen Pharma SAS in October 2014 under which we granted Ipsen an exclusive, royalty-bearing right and license to commercialize telotristat etiprate outside of the United States, Canada and Japan.  We received a $23&#160;million upfront payment under the agreement and we are eligible to receive up to approximately $30&#160;million upon the achievement of specified regulatory and commercial launch milestones and up to &#8364;72&#160;million upon the achievement of specified sales milestones.  We are also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of telotristat etiprate in the licensed territory, subject to a credit for Ipsen&#8217;s payments to us for the manufacture and supply of such units of telotristat etiprate.  Our receipt of these payments from Ipsen will trigger our obligation to make certain contingent payments to Symphony Icon Holdings LLC, or Holdings, pursuant to our prior arrangement with Holdings for the financing of the clinical development of telotristat etiprate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bristol-Myers Squibb</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We established a drug discovery alliance with Bristol-Myers Squibb Company in December 2003 to discover, develop and commercialize small molecule drugs in the neuroscience field.&#160;&#160;Bristol-Myers Squibb extended the target discovery term of the alliance in May 2006.&#160;&#160;We initiated the alliance with a number of neuroscience drug discovery programs at various stages of development and used our gene knockout technologies to identify additional drug targets with promise in the neuroscience field.&#160;&#160;For those targets that were selected for the alliance, we and Bristol-Myers Squibb are working together, on an exclusive basis, to identify, characterize and carry out the preclinical development of small molecule drugs, and share equally both in the costs and in the work attributable to those efforts.&#160;&#160;As drugs resulting from the alliance enter clinical trials, Bristol-Myers Squibb will have the first option to assume full responsibility for clinical development and commercialization.  We received $86&#160;million in upfront payments and research funding under the agreement during the target discovery portion of the alliance, which expired in October 2009. &#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the timing and extent of our efforts in the alliance, up to $76&#160;million for each drug developed by Bristol-Myers Squibb under the alliance.&#160;&#160;We will also earn royalties on sales of drugs commercialized by Bristol-Myers Squibb under the alliance.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Genentech</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We established a drug discovery alliance with Genentech, Inc. in December 2002 to discover novel therapeutic proteins and antibody targets.&#160;&#160;We and Genentech expanded the alliance in November 2005 for the advanced research, development and commercialization of new biotherapeutic drugs.&#160;&#160;Under the original alliance agreement, we used our target validation technologies to discover the functions of secreted proteins and potential antibody targets identified through Genentech&#8217;s internal drug discovery research.&#160;&#160;In the expanded alliance, we conducted additional, advanced research on a broad subset of those proteins and targets.&#160;&#160;We have exclusive rights to develop and commercialize biotherapeutic drugs for two of these targets, while Genentech has exclusive rights to develop and commercialize biotherapeutic drugs for the other targets.&#160;&#160;We retain certain other rights to discoveries made in the alliance, including non-exclusive rights, along with Genentech, for the development and commercialization of small molecule drugs addressing the targets included in the alliance.  We received $58&#160;million in upfront payments, research funding and research milestone payments under the agreement during the research collaboration term, which expired in November 2008.&#160;&#160;In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the extent of our efforts in the alliance, up to $25&#160;million for each drug target for which Genentech develops a biotherapeutic drug under the alliance.&#160;&#160;We will also earn royalties on sales of biotherapeutic drugs commercialized by Genentech under the alliance.&#160;&#160;Genentech is entitled to receive milestone payments and royalties on sales of biotherapeutic drugs which we develop or commercialize under the alliance.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have established collaborations with a number of pharmaceutical and biotechnology companies, research institutes and academic institutions under which we have received fees in exchange for generating knockout mice for genes requested by the collaborator, providing phenotypic data with respect to such knockout mice or otherwise granting access to some of our technologies and discoveries.&#160;&#160;In some cases, we remain eligible to receive milestone or royalty payments on the sale of mice and phenotypic data or on products that our collaborators discover or develop using our technology.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sB5948AD4D21025E0801EA09F40BB5AA4"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Executive Officers</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our executive officers and their ages and positions are listed below.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="28%"></td><td width="7%"></td><td width="65%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Age</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Position with the Company</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lonnel Coats</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer and Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pablo Lapuerta, M.D.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and Chief Medical Officer</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alan J. Main, Ph.D.</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, CMC and Supply Operations</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Wade, J.D.</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John P. Northcott</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President of Marketing, Commercial Strategy and Operations</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James F. Tessmer</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Finance and Accounting</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lonnel Coats</font><font style="font-family:inherit;font-size:10pt;">&#32;has been our president and chief executive officer and a director since July 2014. From 1996 through June 2014, Mr. Coats served in a series of leadership positions at Eisai Inc. and Eisai Corporation of North America, most recently as chief executive officer from 2010 to June 2014 and president and chief operating officer from 2004 to 2010.  Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson &amp; Johnson, where he held a variety of management and sales positions.  Mr. Coats received his B.P.A. from Oakland University.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pablo Lapuerta, M.D.</font><font style="font-family:inherit;font-size:10pt;">&#160;has been our executive vice president and chief medical officer since February 2015.  Dr. Lapuerta served as our executive vice president, safety, pharmacovigilance and medical affairs and chief medical officer from August 2014 until February 2015 and was our executive vice president, clinical development and chief medical officer from February 2013 until August 2014 and senior vice president, clinical development and chief medical officer from 2011 until February 2013. From 2009 through 2010, Dr. Lapuerta served as vice president at Bristol-Myers Squibb Company with responsibility for global development of an Alzheimer&#8217;s disease drug candidate. From 2007 through 2009, Dr. Lapuerta was senior vice president, clinical strategy and chief medical officer of Cogentus Pharmaceuticals, Inc. and prior to that served in a variety of clinical development leadership roles at Bristol-Myers Squibb, where he worked for 11&#160;years before joining Cogentus. He holds a B.A. in biology from Harvard College and an M.D. from Harvard Medical School.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Alan J. Main, Ph.D</font><font style="font-family:inherit;font-size:10pt;">. has been our executive vice president, CMC and supply operations since February 2015.  Dr. Main served as our executive vice president of pharmaceutical research from 2007 until February 2015 and was our senior vice president, Lexicon Pharmaceuticals from 2001 to 2007.&#160;&#160;Dr.&#160;Main was president and chief executive officer of Coelacanth Corporation, a leader in using proprietary chemistry technologies to rapidly discover new chemical entities for drug development, from 2000 until our acquisition of Coelacanth in 2001.&#160;&#160;Dr.&#160;Main was formerly senior vice president, U.S.&#160;Research at Novartis Pharmaceuticals Corporation, where he worked for 20&#160;years before joining Coelacanth.&#160;&#160;Dr.&#160;Main holds a B.S. from the University of Aberdeen, Scotland and a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies at the Woodward Research Institute.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Jeffrey L. Wade, J.D.</font><font style="font-family:inherit;font-size:10pt;">&#32;has been our executive vice president, corporate and administrative affairs and chief financial officer since February 2015.  Mr. Wade served as our executive vice president, corporate development and chief financial officer from May 2010 until February 2015 and was our executive vice president and general counsel from 2000 until May 2010 and senior vice president and chief financial officer from 1999 to 2000.&#160;&#160;From 1988 through 1998, Mr.&#160;Wade was a corporate securities and finance attorney with the law firm of Andrews&#160;&amp; Kurth&#160;L.L.P., for the last two years as a partner, where he represented companies in the biotechnology, information technology and energy industries.&#160;&#160;Mr.&#160;Wade is a member of the board of directors of the Texas Healthcare and Bioscience Institute.&#160;&#160;He received his B.A. and J.D. from the University of Texas.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">John P. Northcott</font><font style="font-family:inherit;font-size:10pt;">&#32;has been our vice president of marketing, commercial strategy and operations since June 2013.  From May 2011 through May 2013, Mr. Northcott served as International Business Leader for F. Hoffman-La Roche Ltd. with responsibility for the global strategy, commercialization and life cycle management of Avastin, an approved cancer drug product.  From 2007 through May 2011, Mr. Northcott was Oncology Group Product Manager at Roche with responsibility for the commercialization of Avastin in the United States. Prior to joining Roche, Mr. Northcott spent five years in a variety of management and sales positions with Pfizer Inc., Pharmacia Corporation and Merck&#160;&amp; Co.  Mr. Northcott received his B.B.A. from St. Francis Xavier University.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">James F. Tessmer</font><font style="font-family:inherit;font-size:10pt;">&#32;has been our vice president, finance and accounting since November 2007 and previously served as our senior director of finance from 2004 to November 2007 and director of finance from 2001 to 2004.&#160;&#160;From January 1997 to 2001, Mr. Tessmer was assistant controller for Mariner Health Network, Inc. and prior to that served in a variety of financial and accounting management positions for HWC Distribution Corp. and American General Corporation.&#160;&#160;Mr. Tessmer is a certified public accountant and received his B.B.A. from the University of Wisconsin &#8211; Milwaukee and his M.B.A. from the University of Houston.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sF4877099116DB895AC6AA09F40DA8202"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Patents and Proprietary Rights</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that those rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. Accordingly, patents and other proprietary rights are an essential element of our business.&#160;&#160;We own patent applications, and in some cases issued patents, covering each of our drug candidates in clinical development, including:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">worldwide patent applications that claim telotristat etiprate, or LX1032, and associated crystalline forms, pharmaceutical compositions, and methods of manufacture and use, from which patents have granted in multiple jurisdictions, including ten in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">worldwide patent applications that claim sotagliflozin, or LX4211, and associated crystalline forms, pharmaceutical compositions, and methods of manufacture and use, from which patents have granted in multiple jurisdictions, including four in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">worldwide patent applications that claim LX1033 and associated crystalline forms, pharmaceutical compositions, and methods of manufacture and use, from which patents have granted in multiple jurisdictions, including ten in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">worldwide patent applications that claim LX2931 and associated crystalline forms, pharmaceutical compositions, and methods of manufacture and use, from which patents have granted in multiple jurisdictions, including five in the United States; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">worldwide patent applications that claim LX7101 and associated crystalline forms, pharmaceutical compositions, and methods of manufacture and use, from which patents have granted in multiple jurisdictions, including two in the United States.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we hold rights to a number of patents and patent applications under license agreements with third parties.&#160;&#160;Many of these licenses are nonexclusive, although some are exclusive in specified fields.&#160;&#160;Most of the licenses have terms that extend for the life of the licensed patents.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.&#160;&#160;We have filed patent applications and hold issued patents covering each of our drug candidates in clinical development.&#160;&#160;No United States patent that has issued or may issue based on a patent application we have filed relating to one of our drug candidates in clinical development has a normal expiration date earlier than 2026.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our employees, consultants and advisors are required to execute a proprietary information agreement upon the commencement of employment or consultation. In general, the agreement provides that all inventions conceived by the employee or consultant, and all confidential information developed or made known to the individual during the term of the agreement, shall be our exclusive property and shall be kept confidential, with disclosure to third parties allowed only in specified circumstances. We cannot assure you, however, that these agreements will provide useful protection of our proprietary information in the event of unauthorized use or disclosure of such information.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our patent and intellectual property rights are subject to certain rights and uncertainties.  See &#8220;Risks Related to Our Intellectual Property&#8221; under &#8220;Item 1A.&#160;Risk Factors.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s118C6E1B0F64B62B0227A09F41097A5D"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The biotechnology and pharmaceutical industries are highly competitive and characterized by rapid technological change.&#160;&#160;We face significant competition in each of the aspects of our business from other pharmaceutical and biotechnology companies.  Many of our competitors have substantially greater research, development and commercialization capabilities and financial, scientific, marketing and human resources than we do.&#160;&#160;As a result, our competitors may succeed in developing products earlier than we do, obtaining approvals from the FDA or other regulatory agencies for those products more rapidly than we do, developing products that are more effective than those we propose to develop or commercializing products more effectively and profitably than we do.&#160;&#160;Similarly, our collaborators face similar competition from other competitors who may succeed in developing products more quickly, developing products that are more effective than those developed by our collaborators or commercialize products more effectively and profitably than our collaborators.&#160;&#160;Any products that we or our collaborators may develop or discover are likely to be in highly competitive markets.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The competition for our drug candidates includes both marketed products and drug candidates that are being developed by others, including drug candidates that are currently in a more advanced stage of clinical development or commercialization than are our own drug candidates.&#160;&#160;These competitive marketed products and drug candidates include compounds that employ different mechanisms of action in addressing diseases and conditions for which we are developing our own drug candidates and, in some cases such as sotagliflozin, that employ the same or similar mechanisms of action.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our ability to successfully compete with these potentially competitive drug candidates and other competitive products currently on the market will depend on, among other things:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the efficacy, safety and reliability of our drug candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability, and the ability of our collaborators, to complete nonclinical testing and clinical development and obtain regulatory approvals for our drug candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and scope of regulatory approvals for our drug candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability, and the ability of our collaborators, to obtain product acceptance by physicians and other health care providers and reimbursement for product use in approved indications;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability, and the ability of our collaborators, to manufacture and sell commercial quantities of our products;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the skills of our employees and our ability to recruit and retain skilled employees;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">protection of our intellectual property; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of substantial capital resources to fund development and commercialization activities.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sB77B04D2FE521FC572B2A09F41284C5F"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulation of Pharmaceutical Products</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development, manufacture and sale of any products developed by us or our collaborators will be subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.&#160;&#160;In the United States, new drugs are subject to regulation under the Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or the FDC Act, and biologic products are subject to regulation both under certain provisions of the FDC Act and under the Public Health Services Act and the regulations promulgated thereunder, or the PHS Act.&#160;&#160;The FDA regulates, among other things, the development, preclinical and clinical testing, manufacture, safety, efficacy, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution and export of small molecule and biotherapeutic drugs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The standard process required by the FDA before a drug candidate may be marketed in the United States includes:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">nonclinical laboratory and animal tests performed under the FDA&#8217;s current Good Laboratory Practices regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">submission to the FDA of an Investigational New Drug application, or IND, which must become effective before human clinical trials may commence;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for its intended use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for drug candidates regulated as small molecule drugs, submission of a New Drug Application, or NDA, and, for drug candidates regulated as biotherapeutic drugs, submission of a Biologic License Application, or BLA, with the FDA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA approval of the NDA or BLA prior to any commercial sale or shipment of the product.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;This process for the testing and approval of drug candidates requires substantial time, effort and financial resources.&#160;&#160;Preclinical development of a drug candidate can take from one to several years to complete, with no guarantee that an IND based on those studies will become effective to even permit clinical testing to begin.&#160;&#160;Before commencing the first clinical trial of a drug candidate in the United States, we must submit an IND to the FDA.&#160;&#160;The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial.&#160;&#160;In such a case, we and the FDA must resolve any outstanding concerns before the clinical trial may begin.&#160;&#160;A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, and the FDA must grant permission for each clinical trial to start and continue.&#160;&#160;Further, an independent institutional review board for each medical center proposing to participate in the clinical trial must review and approve the plan for any clinical trial before it commences at that center.&#160;&#160;Regulatory authorities or an institutional review board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For purposes of NDA or BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 1 clinical trials are conducted in a limited number of healthy human volunteers or, in some cases, patients, to evaluate the safety, dosage tolerance, absorption, metabolism, distribution and excretion of the drug candidate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 clinical trials are conducted in groups of patients afflicted with a specified disease or condition to obtain preliminary data regarding efficacy as well as to further evaluate safety and optimize dosing of the drug candidate; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 3 clinical trials are conducted in larger patient populations at multiple clinical trial sites to obtain statistically significant evidence of the efficacy of the drug candidate for its intended use and to further test for safety in an expanded patient population.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the FDA may require, or companies may pursue, additional clinical trials after a product is approved.&#160;&#160;These so-called Phase&#160;4 studies may be made a condition to be satisfied after a drug receives approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Completion of the clinical trials necessary for an NDA or BLA submission typically takes many years, with the actual time required varying substantially based on, among other things, the nature and complexity of the drug candidate and of the disease or condition.&#160;&#160;Success in earlier-stage clinical trials does not ensure success in later-stage clinical trials.&#160;&#160;Furthermore, data obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent proceeding with further clinical trials, filing or acceptance of an NDA or BLA, or obtaining marketing approval.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After completion of clinical trials, FDA approval of an NDA or BLA must be obtained before a new drug may be marketed in the United States.&#160;&#160;An NDA or BLA, depending on the submission, must contain, among other things, information on chemistry, manufacturing controls and potency and purity, non-clinical pharmacology and toxicology, human pharmacokinetics and bioavailability and clinical data.&#160;&#160;There can be no assurance that the FDA will accept an NDA or BLA for filing and, even if filed, that approval will be granted.&#160;&#160;Among other things, the FDA reviews an NDA to determine whether a product is safe and effective for its intended use and a BLA to determine whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.&#160;&#160;The FDA may deny approval of an NDA or BLA if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or an additional pivotal Phase 3 clinical trial.&#160;&#160;Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for approval.&#160;&#160;Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market.&#160;&#160;In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products which have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.&#160;&#160;Limited indications for use or other conditions could also be placed on any approvals that could restrict the commercial applications of a product or impose costly procedures in connection with the commercialization or use of the product.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to obtaining FDA approval for each product, each drug manufacturing establishment must be inspected and approved by the FDA.&#160;&#160;All manufacturing establishments are subject to inspections by the FDA and by other federal, state and local agencies and must comply with current Good Manufacturing Practices requirements.&#160;&#160;Non-compliance with these requirements can result in, among other things, total or partial suspension of production, failure of the government to grant approval for marketing and withdrawal, suspension or revocation of marketing approvals.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once the FDA approves a product, a manufacturer must provide certain updated safety and efficacy information.&#160;&#160;Product changes as well as certain changes in a manufacturing process or facility would necessitate additional FDA review and approval.&#160;&#160;Other post-approval changes may also necessitate further FDA review and approval.&#160;&#160;Additionally, a manufacturer must meet other requirements including those related to adverse event reporting and record keeping.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA closely regulates the marketing and promotion of drugs.&#160;&#160;A company can make only those claims relating to safety and efficacy that are approved by the FDA.&#160;&#160;Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Violations of the FDC Act, the PHS Act or regulatory requirements may result in agency enforcement action, including voluntary or mandatory recall, license suspension or revocation, product seizure, fines, injunctions and civil or criminal penalties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to regulatory approvals that must be obtained in the United States, drugs are also subject to regulatory approval in other countries in which they are marketed.&#160;&#160;The conduct of clinical trials of drugs in countries other than the United States is likewise subject to regulatory oversight in such countries.&#160;&#160;The requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary widely from country to country.&#160;&#160;No action can be taken to market any drug in a country until the regulatory authorities in that country have approved an appropriate application.&#160;&#160;FDA approval does not assure approval by other regulatory authorities.&#160;&#160;The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval.&#160;&#160;In some countries, the sale price of a drug or biologic product must also be approved.&#160;&#160;The pricing review period often begins after marketing approval is granted.&#160;&#160;Even if a foreign regulatory authority approves a drug, it may not approve satisfactory prices for the product.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Regulations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the foregoing, our business is subject to regulation under various state and federal environmental laws, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act.&#160;&#160;These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in and wastes generated by our operations.&#160;&#160;We believe that we are in material compliance with applicable environmental laws and that our continued compliance with these laws will not have a material adverse effect on our business.&#160;&#160;We cannot predict, however, whether new regulatory restrictions will be imposed by state or federal regulators and agencies or whether existing laws and regulations will adversely affect us in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s7427BAC1F46A44276A31A09F4166F1C1"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively, we incurred expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$89.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$89.7&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$82.6&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in company-sponsored as well as collaborative research and development activities, including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.0&#160;million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.4&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.7&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;of stock-based compensation expense in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sAD17C1ED8B75EB9A5849A09F41868951"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees and Consultants</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">February&#160;27, 2015</font><font style="font-family:inherit;font-size:10pt;">, we employed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">106</font><font style="font-family:inherit;font-size:10pt;">&#32;persons, of whom </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">24</font><font style="font-family:inherit;font-size:10pt;">&#32;hold M.D. or Ph.D. degrees and another </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;hold other advanced degrees.&#160;&#160;We believe that our relationship with our employees is good.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s74CB79709D67281DFACDA09F41B4C361"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risk Factors </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.&#160;&#160;The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Need for Additional Financing and Our Financial Results</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We will need additional capital in the future and, if it is unavailable, we will be forced to significantly curtail or cease our operations.&#160;&#160;If it is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$339.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and investments.&#160;&#160;We anticipate that our existing capital resources and the cash and revenues we expect to derive from collaborations and other sources will enable us to fund our currently planned operations for at least the next 12&#160;months.  However, we caution you that we may generate less cash and revenues or incur expenses more rapidly than we currently anticipate.  Our currently planned operations for the next twelve months consist of (a) the completion of our single pivotal Phase&#160;3 clinical trial of telotristat etiprate in carcinoid syndrome patients and, if successful, continued preparations for the commercialization of telotristat etiprate, (b) a companion Phase&#160;3 clinical trial of telotristat etiprate to study safety and 5-HIAA in a separate patient population, with a targeted enrollment of approximately 60 patients, (c) a Phase&#160;2 clinical trial of sotagliflozin in a younger adult type&#160;1 diabetes population and (d) three concurrent Phase&#160;3 clinical trials for sotagliflozin in type&#160;1 diabetes, which we expect to enroll an aggregate of approximately 2,900 patients, and a dose-ranging study of sotagliflozin. In addition, we cannot be certain as to what type and how many clinical trials the FDA, or equivalent foreign regulatory agencies, will require us to conduct in order to gain approval to market either telotristat etiprate or sotagliflozin.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although difficult to accurately predict, the amount of our future capital requirements will be substantial and will depend on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and progress of our single pivotal Phase&#160;3 clinical trial of telotristat etiprate in carcinoid syndrome patients, including completing enrollment in the trial and our ability to obtain priority review on any potential NDA submission;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if approved, our ability to commercialize telotristat etiprate on the timeline anticipated;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount and timing of payments, if any, under existing and any future collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount and timing of our nonclinical and clinical development expenditures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and progress of the clinical development of telotristat etiprate and sotagliflozin, including the timing of any required regulatory actions, the outcome of our anticipated discussions with regulators and the outcome of our sotagliflozin dose-ranging study, which we are planning to conduct concurrently with our two pivotal Phase&#160;3 efficacy trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">future results from clinical trials of our drug candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of regulatory approvals and commercialization of drug candidates that we successfully develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">market acceptance of products that we successfully develop and commercially launch;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effect of competing programs and products, and of technological and market developments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of establishing or contracting for sales, marketing and distribution capabilities of any approved drug candidate.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our capital requirements have and will continue to increase substantially as our drug candidates progress into more advanced stage clinical development.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary products and technologies.&#160;&#160;For all of these reasons, our future capital requirements cannot easily be quantified.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our capital resources are insufficient to meet future capital requirements, we will need to raise additional funds to continue our currently planned operations.&#160;&#160;If we raise additional capital by issuing equity securities, our then-existing stockholders will experience dilution and the terms of any new equity securities may have preferences over our common stock.&#160;&#160;We cannot be certain that additional financing, whether debt or equity, will be available in amounts or on terms acceptable to us, if at all.&#160;&#160;We may be unable to raise sufficient additional capital on reasonable terms, and if so, we will be forced to significantly curtail or cease our operations or obtain funds, if at all, by entering into financing agreements on unattractive terms.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred net losses since our inception, including net losses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$100.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$104.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$110.2&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.1&#160;billion</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We are unsure when we will become profitable, if ever.&#160;&#160;The size of our net losses will depend, in part, on the rate of decline or growth in our revenues and on the amount of our expenses.  We expect net losses to increase significantly over the next several years as we expect to make significant investments in the development and commercialization of telotristat etiprate and sotagliflozin.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have derived substantially all of our revenues from drug discovery and development collaborations and other collaborations and technology licenses.&#160;&#160;Future revenues from our existing collaborations are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from any future products developed under the collaborations.&#160;&#160;As a result, we depend, in part, on securing new collaboration agreements.&#160;&#160;Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our clinical drug candidates, including telotristat etiprate (in the United States, Canada and Japan) and sotagliflozin, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase our expenses.&#160;&#160;Given the current stage of our operations, we do not currently derive any revenues from sales of pharmaceutical products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A large portion of our expenses is fixed, including expenses related to facilities and equipment.&#160;&#160;In addition, we expect to spend significant amounts to fund our nonclinical and clinical development activities, including the conduct of ongoing and planned clinical trials for telotristat etiprate and sotagliflozin.&#160;&#160;If successful, we will also be required to incur substantial expenditures in preparation for and to conduct commercialization activities with respect to telotristat etiprate and sotagliflozin.  As a result, we will need to generate substantial additional revenues to achieve profitability.&#160;&#160;Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our operating results have been and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to establish new collaborations and technology licenses, and the timing of such arrangements;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the success rate of our discovery and development efforts leading to opportunities for new collaborations and licenses, as well as milestone payments and royalties;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and willingness of our collaborators to commercialize pharmaceutical products that would result in milestone payments and royalties; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general and industry-specific economic conditions, which may affect our and our collaborators&#8217; research and development expenditures.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of these and other factors, including the risks and uncertainties described in this section, our operating results have fluctuated in the past and are likely to do so in the future.&#160;&#160;Due to the likelihood of fluctuations in our revenues and expenses, we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have substantial indebtedness that may limit cash flow available to invest in the ongoing needs of our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred </font><font style="font-family:inherit;font-size:10pt;">$107.7&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;of indebtedness and could in the future incur additional indebtedness beyond such amount.  We are not restricted under the terms of our existing debt instruments from incurring additional debt.  Our substantial debt combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requiring us to dedicate a substantial portion of cash flow from operations to the payment of interest on, and principal of, our debt, which will reduce the amounts available to fund working capital, capital expenditures, product development efforts and other general corporate purposes;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obligating us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents and marketable securities and funds from external sources.  However, we may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under our existing debt.  Funds from external sources may not be available on acceptable terms, if at all.  In addition, a failure to comply with the covenants under our existing debt instruments could result in an event of default under those instruments.  In the event of an acceleration of amounts due under our debt instruments as a result of an event of default, including upon the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations, properties, assets or condition or a failure to pay any amount due, we may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness or to make any accelerated payments, and the lenders could seek to enforce security interests in the collateral securing such indebtedness.  In addition, the covenants under our existing debt instruments and the pledge of our assets as collateral limit our ability to obtain additional debt financing.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may not have the ability to raise the funds necessary to repurchase the notes evidencing our existing indebtedness upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the notes.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of the notes evidencing our existing indebtedness have the right to require us to repurchase their notes upon the occurrence of a fundamental change at a repurchase price equal to 100% of their principal amount, plus accrued and unpaid interest, if any.  However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of notes surrendered therefor.  In addition, our ability to repurchase the notes may be limited by law, by regulatory authority or by agreements governing our future indebtedness.  Our failure to repurchase notes at a time when the repurchase is required by the indenture pursuant to which the notes were issued would constitute a default under the indenture.  A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness.  If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the notes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Development of Our Drug Candidates</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have not proven our ability to successfully develop and commercialize our drug candidates.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend upon our ability, on our own or through collaborations, to successfully develop and select an appropriate commercialization strategy for our drug candidates.  We have not proven our ability to develop or commercialize drug candidates based on our drug target discoveries, and we do not know that any pharmaceutical products based on our drug target discoveries can be successfully developed or commercialized.&#160;&#160;Our strategy was historically focused principally on the discovery and development of drug candidates for targets that have not been clinically validated in humans by drugs or drug candidates generated by others.&#160;&#160;As a result, our drug candidates are subject to uncertainties as to the effects of modulating the human drug target as well as to those relating to the characteristics and activity of the particular compound.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to obtain regulatory approvals for the commercial sale of any products that we may develop, we will be required to complete extensive clinical trials in humans to demonstrate the safety and efficacy of our drug candidates.&#160;&#160;We or our collaborators may not be able to obtain authority from the FDA, or other equivalent foreign regulatory agencies to initiate or complete any clinical trials.&#160;&#160;In addition, we have limited internal resources for making regulatory filings and interacting with regulatory authorities.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials are inherently risky and the results from nonclinical testing of a drug candidate that is under development may not be predictive of results that will be obtained in human clinical trials.&#160;&#160;In addition, the results of early human clinical trials may not be predictive of results that will be obtained in larger-scale, advanced stage clinical trials.&#160;&#160;A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after achieving positive results in earlier trials.&#160;&#160;Although the results of our Phase&#160;2 proof-of-concept study of sotagliflozin in type&#160;1 diabetes patients were positive, we cannot assure you that the planned Phase&#160;3 clinical trials of sotagliflozin will achieve positive results.  A number of factors could contribute to a lack of positive results in such Phase&#160;3 clinical trials, including a primary endpoint in such planned Phase&#160;3 clinical trials which has not previously been utilized for such purpose.  Negative or inconclusive results from a nonclinical study or a clinical trial could cause us, one of our collaborators or the FDA to terminate a nonclinical study or clinical trial or require that we repeat or modify it.&#160;&#160;For example, concurrently with our planned Phase&#160;3 clinical trials in our type&#160;1 diabetes program, we plan to conduct a dose-ranging study of sotagliflozin in patients with type&#160;1 diabetes as required by the FDA.  If the results of the dose-ranging study are inconsistent with the design of our Phase&#160;3 trials of sotaglifozin, such as suggesting that there is an effective dose of sotagliflozin in patients with type&#160;1 diabetes lower than the doses we are studying in our Phase&#160;3 clinical trials of sotagliflozin, we may be required to modify those Phase&#160;3 clinical trials, which could significantly delay the completion of the trials.  Furthermore, we, one of our collaborators or a regulatory agency with jurisdiction over the trials may suspend clinical trials at any time if the subjects or patients participating in such trials are being exposed to unacceptable health risks or for other reasons.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any nonclinical or clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities.&#160;&#160;Nonclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval.  For example, the FDA suggested we study sotaglifozin in both type&#160;1 and type&#160;2 diabetes concurrently rather than only in type&#160;1 diabetes.  This could influence the way in which the FDA interprets the results of our trials of sotaglifozin.  The FDA or institutional review boards at the medical institutions and healthcare facilities where we sponsor clinical trials may suspend any trial indefinitely if they find deficiencies in the conduct of these trials.&#160;&#160;Clinical trials must be conducted in accordance with the FDA&#8217;s current Good Clinical Practices.&#160;&#160;The FDA and these institutional review boards have authority to oversee our clinical trials, and the FDA may require large numbers of subjects or patients.&#160;&#160;In addition, we must manufacture, or contract for the manufacture of, the drug candidates that we use in our clinical trials under the FDA&#8217;s current Good Manufacturing Practices.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rate of completion of clinical trials is dependent, in part, upon the rate of enrollment of patients.&#160;&#160;Patient accrual is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the study, the nature of the study, the existence of competitive clinical trials and the availability of alternative treatments.&#160;&#160;Delays in planned patient enrollment may result in increased costs and prolonged clinical development, which in turn could allow our competitors to bring products to market before we do and impair our ability to commercialize our products or potential products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We or our collaborators may not be able to successfully complete any clinical trial of a potential product within any specified time period.&#160;&#160;In some cases, we or our collaborators may not be able to complete the trial at all. Moreover, clinical trials may not show our potential products to be both safe and effective.&#160;&#160;Thus, the FDA and other regulatory authorities may not approve any products that we develop for any indication or may limit the approved indications or impose other conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Regulatory Approval of Our Drug Candidates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our ability to commercialize products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our drug candidates, including telotristat etiprate and sotagliflozin, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries.&#160;&#160;Failure to obtain regulatory approval for a drug candidate would prevent us from commercializing that drug candidate.&#160;&#160;We have not received regulatory approval to market any of our drug candidates in any jurisdiction and have only limited experience in preparing and filing the applications necessary to gain regulatory approvals.&#160;&#160;The process of obtaining regulatory approvals is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the drug candidates involved.&#160;&#160;Before a new drug application can be filed with the FDA, the drug candidate must undergo extensive clinical trials, which can take many years and may require substantial expenditures.&#160;&#160;Any clinical trial may fail to produce results satisfactory to the FDA.&#160;&#160;For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results.&#160;&#160;Furthermore, prior to approving a new drug, the FDA typically requires that the efficacy of the drug be demonstrated in two double-blind, controlled studies.  In light of the unmet medical need in carcinoid syndrome, the results of our Phase&#160;2 clinical trials of telotristat etiprate and our interactions with the FDA regarding those results, we believe a single Phase&#160;3 clinical trial of telotristat etiprate will be sufficient.  However, the FDA has indicated that the trial must demonstrate statistically robust evidence of important clinical benefit and an acceptable safety profile in order to warrant consideration for marketing approval.  If the FDA determines that our Phase&#160;3 results do not have statistically robust results or clinically meaningful benefit, or if the FDA requires us to conduct additional Phase 3 clinical trials of telotristat etiprate prior to seeking marketing approval, we will incur significant additional development costs and commercialization of telotristat etiprate may be prevented or delayed.  The regulatory process also requires nonclinical testing, and data obtained from nonclinical and clinical activities are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.&#160;&#160;For example, we will need to complete certain nonclinical studies on a pre-approval basis in connection with our diabetes program, including carcinogenicity and toxicology.  In our carcinoid syndrome program, we will need to conduct carcinogenicity studies on a post-approval basis and drug interaction studies on a pre-approval basis.  Negative results in any of these nonclinical studies could delay or prevent approval of our product candidates.  In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review.&#160;&#160;Changes in regulatory approval policy, regulations or statutes or the process for regulatory review during the development or approval periods of our drug candidates may cause delays in the approval or rejection of an application.  For example, the FDA may expand to Phase&#160;3 programs for type&#160;1 diabetes its current requirement that Phase&#160;3 programs for type&#160;2 diabetes include studies designed to measure cardiovascular outcomes.  The FDA has asked that we submit a cardiovascular risk assessment of sotagliflozin.  If the risk assessment suggests a higher than acceptable cardiovascular risk or if the FDA requests that we submit cardiovascular outcome data for sotagliflozin, it could significantly delay or prevent approval.  Even if the FDA or a comparable authority in another country approves a drug candidate, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing requirements for post-approval studies, including additional research and development and clinical trials.&#160;&#160;These agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If our potential products receive regulatory approval, we or our collaborators will remain subject to extensive and rigorous ongoing regulation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we or our collaborators obtain initial regulatory approvals from the FDA or foreign regulatory authorities for any products that we may develop, we or our collaborators will be subject to extensive and rigorous ongoing domestic and foreign government regulation of, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of our products and drug candidates.&#160;&#160;The failure to comply with these requirements or the identification of safety problems during commercial marketing could lead to the need for product marketing restrictions, product withdrawal or recall or other voluntary or regulatory action, which could delay further marketing until the product is brought into compliance.&#160;&#160;The failure to comply with these requirements may also subject us or our collaborators to stringent penalties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Commercialization of Products</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The commercial success of any products that we may develop will depend upon the degree of market acceptance of our products among physicians, patients, health care payors, private health insurers and the medical community.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if approved by the relevant regulatory authority, our ability to commercialize any products that we may develop will be highly dependent upon the extent to which these products gain market acceptance among physicians, patients, health care payors, such as Medicare and Medicaid, private health insurers, including managed care organizations and group purchasing organizations, and the medical community.&#160;&#160;If these products do not achieve an adequate level of acceptance, we may not generate adequate product revenues, if at all, and we may not become profitable.&#160;&#160;The degree of market acceptance of our drug candidates, if approved for commercial sale, will depend upon a number of factors, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effectiveness, or perceived effectiveness, of our products in comparison to competing products;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the existence of any significant side effects, as well as their severity in comparison to any competing products;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential advantages over alternative treatments;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability to offer our products for sale at competitive prices;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">relative convenience and ease of administration;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the strength of marketing and distribution support; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sufficient third-party coverage or reimbursement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, we may be unable to generate product revenues.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no experience as a company in the sales, marketing and distribution of pharmaceutical products and do not currently have a sales and marketing organization.&#160;&#160;Developing a sales and marketing force would be expensive and time-consuming, could delay any product launch, and we may never be able to develop this capacity.&#160;&#160;To the extent that we enter into arrangements with third parties to provide sales, marketing and distribution services, our product revenues are likely to be lower than if we market and sell any products that we develop ourselves.&#160;&#160;If we are unable to establish adequate sales, marketing and distribution capabilities, independently or with others, we may not be able to generate product revenues.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are unable to obtain adequate coverage and reimbursement from third-party payors for any products that we may develop, our revenues and prospects for profitability will suffer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to commercialize any products that we may develop will be highly dependent on the extent to which coverage and reimbursement for our products will be available from third-party payors, including governmental payors, such as Medicare and Medicaid, and private health insurers, including managed care organizations and group purchasing organizations.&#160;&#160;Many patients will not be capable of paying themselves for some or all of the products that we may develop and will rely on third-party payors to pay for, or subsidize, their medical needs.&#160;&#160;If third-party payors do not provide coverage or reimbursement for any products that we may develop, our revenues and prospects for profitability will suffer.&#160;&#160;In addition, even if third-party payors provide some coverage or reimbursement for our products, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans often varies based on the type of contract or plan purchased.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Another factor that may negatively affect the pricing of drugs is any action regarding drug reimportation into the United States.  For example, the Medicare Prescription Drug, Improvement and Modernization Act of 2003 gives discretion to the Secretary of Health and Human Services to allow drug reimportation into the United States under some circumstances from foreign countries, including countries where drugs are sold at a lower price than in the United States.  Proponents of drug reimportation may attempt to pass additional legislation, which would allow direct reimportation under certain circumstances.&#160;&#160;If legislation or regulations were passed allowing the reimportation of drugs, it could decrease the price we receive for any products that we may develop, thereby negatively affecting our revenues and prospects for profitability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in some foreign countries, particularly the countries in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control.&#160;&#160;In these countries, price negotiations with governmental authorities can take six to 12&#160;months or longer after the receipt of regulatory marketing approval for a product.&#160;&#160;To obtain reimbursement and/or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our drug candidates or products to other available therapies.&#160;&#160;The conduct of such a clinical trial could be expensive and result in delays in the commercialization of our drug candidates.&#160;&#160;Third-party payors are challenging the prices charged for medical products and services, and many third-party payors limit reimbursement for newly approved health care products.&#160;&#160;In particular, third-party payors may limit the indications for which they will reimburse patients who use any products that we may develop.&#160;&#160;Cost-control initiatives could decrease prices we might establish for products that we may develop, which would result in lower product revenues to us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Current and future healthcare laws and regulations may negatively affect our revenues and prospects for profitability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A primary trend in the United States and some foreign countries is toward reform and cost containment in the health care industry.&#160;&#160;The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals that may have the effect of reducing the prices that we are able to charge for products we develop.  For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the PPACA, substantially modifies the framework by which healthcare is financed by both governmental and private insurers in the United States.  A number of provisions contained in the PPACA have the potential to significantly affect the pharmaceutical industry, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain governmental health programs;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expansion of eligibility criteria and increases in the rebates manufacturers must pay under certain Medicaid programs;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a new Medicare Part D coverage program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during any coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">certain reporting requirements relating to financial arrangements with, and drug samples provided to, physicians.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The PPACA and other healthcare reform measures which may be adopted in the future in the United States and foreign jurisdictions may result in more rigorous coverage criteria and significant downward pressure on the prices drug manufacturers may charge.  As a result, our revenues and prospects for profitability could be significantly harmed.</font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our competitors may develop products that make our products obsolete.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The biotechnology industry is highly fragmented and is characterized by rapid technological change.&#160;&#160;We face, and will continue to face, intense competition from biotechnology and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research and development activities similar to ours.&#160;&#160;In addition, significant delays in the development of our drug candidates could allow our competitors to bring products to market before us, which would impair our ability to commercialize our drug candidates.&#160;&#160;Any products that we develop will compete in highly competitive markets.&#160;&#160;Further, our competitors may be more effective at using their technologies to develop commercial products.&#160;&#160;Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and marketing capabilities.&#160;&#160;As a result, our competitors may be able to more easily develop products that would render our products, and those of our collaborators, obsolete and noncompetitive.&#160;&#160;For example, drug candidates are currently being developed by other pharmaceutical companies for the treatment of type 2 diabetes that act through SGLT2, one of the targets of sotagliflozin, which are in more advanced stages of development than sotagliflozin or have been approved for commercial sale by the FDA or other regulatory agencies. &#160;In addition, there may be drug candidates of which we are not aware at an earlier stage of development that may compete with our drug candidates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may not be able to manufacture our drug candidates in commercial quantities, which would prevent us from commercializing our drug candidates.</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, our drug candidates have been manufactured in small quantities for nonclinical and clinical trials.&#160;&#160;If any of these drug candidates are approved by the FDA or other regulatory agencies for commercial sale, we will need to manufacture them in larger quantities.&#160;&#160;We may not be able to successfully increase the manufacturing capacity, whether in collaboration with third-party manufacturers or on our own, for any of our drug candidates in a timely or economic manner, or at all.&#160;&#160;Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and approve.&#160;&#160;If we are unable to successfully increase the manufacturing capacity for a drug candidate, the regulatory approval or commercial launch of that drug candidate may be delayed or there may be a shortage in supply.&#160;&#160;Our drug candidates require precise, high-quality manufacturing.&#160;&#160;The failure to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously hurt our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Relationships with Third Parties</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We are dependent in many ways upon our collaborations with major pharmaceutical companies, including Ipsen.&#160;&#160;If we are unable to establish new collaborations, if milestones are not achieved under our collaborations or if our collaborators&#8217; efforts fail to yield pharmaceutical products on a timely basis, our opportunities to generate revenues and earn royalties will be reduced.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have derived a substantial majority of our revenues to date from collaborative drug discovery and development alliances with a limited number of major pharmaceutical companies, including Ipsen.&#160;&#160;In addition, we currently intend to seek a collaboration partner for Phase&#160;3 development of sotagliflozin in type&#160;2 diabetes and we cannot be certain that we will be successful in establishing such a collaborative alliance on terms acceptable to us, if at all.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future revenues from our existing drug discovery and development alliances depend upon the achievement of milestones and payment of royalties we earn from any future products developed under the collaborations.&#160;&#160;If our relationship terminates with any of our collaborators, our reputation in the business and scientific community may suffer and revenues will be negatively impacted to the extent such losses are not offset by additional collaboration agreements.&#160;&#160;If milestones are not achieved under our collaborations or our collaborators are unable to successfully develop products from which royalties are payable, we will not earn the revenues contemplated by those drug discovery and development collaborations.&#160;&#160;In addition, some of our alliances are exclusive and preclude us from entering into additional collaborative arrangements with other parties in the field of exclusivity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have limited or no control over the resources that any collaborator may devote to the development and commercialization of products under our alliances.&#160;&#160;Any of our present or future collaborators may not perform their obligations as expected.&#160;&#160;These collaborators may breach or terminate their agreements with us or otherwise fail to conduct discovery, development or commercialization activities successfully or in a timely manner.&#160;&#160;Further, our collaborators may elect not to develop pharmaceutical products arising out of our collaborative arrangements or may not devote sufficient resources to the development, approval, manufacture, marketing or sale of these products.&#160;&#160;If any of these events occurs, we may not be able to develop or commercialize potential pharmaceutical products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may pursue opportunities in specific disease and therapeutic modality fields that could result in conflicts with our collaborators, if any of our collaborators takes the position that our internal activities overlap with those activities that are exclusive to our collaboration.&#160;&#160;Moreover, disagreements could arise with our collaborators over rights to our intellectual property or our rights to share in any of the future revenues of compounds or therapeutic approaches developed by our collaborators.&#160;&#160;Any conflict with or among our collaborators could result in the termination of our collaborative agreements, delay collaborative research or development activities, impair our ability to renew or obtain future collaborative agreements or lead to costly and time consuming litigation.&#160;&#160;Conflicts with our collaborators could also have a negative impact on our relationship with existing collaborators, materially impairing our business and revenues.&#160;&#160;Some of our collaborators are also potential competitors or may become competitors in the future.&#160;&#160;Our collaborators could develop competing products, preclude us from entering into collaborations with their competitors or terminate their agreements with us prematurely.&#160;&#160;Any of these events could harm our product development efforts.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We rely on third parties to carry out drug development activities.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on clinical research organizations and other third party contractors to carry out many of our drug development activities, including the performance of nonclinical laboratory and animal tests under the FDA&#8217;s current Good Laboratory Practices regulations and the conduct of clinical trials of our drug candidates in accordance with protocols we establish.&#160;&#160;If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, our drug development activities may be delayed, suspended or terminated.&#160;&#160;Such a failure by these third parties could significantly impair our ability to develop and commercialize the affected drug candidates.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We lack the capability to manufacture materials for nonclinical studies, clinical trials or commercial sales and rely on third parties to manufacture our drug candidates, which may harm or delay our product development and commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently do not have the manufacturing capabilities or experience necessary to produce materials for nonclinical studies, clinical trials or commercial sales and intend in the future to continue to rely on collaborators and third-party contractors to produce such materials.&#160;&#160;We will rely on selected manufacturers to deliver materials on a timely basis and to comply with applicable regulatory requirements, including the current Good Manufacturing Practices of the FDA, which relate to manufacturing and quality control activities.&#160;&#160;These manufacturers may not be able to produce material on a timely basis or manufacture material at the quality level or in the quantity required to meet our development timelines and applicable regulatory requirements.&#160;&#160;In addition, there are a limited number of manufacturers that operate under the FDA&#8217;s current Good Manufacturing Practices and that are capable of producing such materials, and we may experience difficulty finding manufacturers with adequate capacity for our needs.&#160;&#160;If we are unable to contract for the production of sufficient quantity and quality of materials on acceptable terms, our product development and commercialization efforts may be delayed.&#160;&#160;Moreover, noncompliance with the FDA&#8217;s current Good Manufacturing Practices can result in, among other things, fines, injunctions, civil and criminal penalties, product recalls or seizures, suspension of production, failure to obtain marketing approval and withdrawal, suspension or revocation of marketing approvals.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our products and technologies.&#160;&#160;The patent positions of biotechnology companies, including our patent position, are generally uncertain and involve complex legal and factual questions.&#160;&#160;We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our products and technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets.&#160;&#160;We will continue to apply for patents covering our  products and technologies as and when we deem appropriate.&#160;&#160;Pending patent applications do not provide protection against competitors because they are not enforceable until they issue as patents.&#160;&#160;Further, the disclosures contained in our current and future patent applications may not be sufficient to meet statutory requirements for patentability.&#160;&#160;Once issued, patents still may not provide commercially meaningful protection.&#160;&#160;Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from developing competing products and technologies.&#160;&#160;Furthermore, others may independently develop similar or alternative products or technologies or design around our patents.&#160;&#160;If anyone infringes upon our or our collaborators&#8217; patent rights, enforcing these rights may be difficult, costly and time-consuming and, as a result, it may not be cost-effective or otherwise expedient to pursue litigation to enforce those patent rights.&#160;&#160;In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for these inventions.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because patent applications can take many years to issue, there may be currently pending applications which may later result in issued patents that cover the production, manufacture, commercialization or use of our drug targets or drug candidates.&#160;&#160;&#160;If any such patents are issued to other entities, we will be unable to obtain patent protection for the same or similar discoveries that we make relating to our drug targets or drug candidates.&#160;&#160;Moreover, we may be blocked from using our drug targets or drug candidates or developing or commercializing our drug candidates, or may be required to obtain a license that may not be available on reasonable terms, if at all.&#160;&#160;Further, others may discover uses for our drug targets and drug candidates other than those covered in our issued or pending patents, and these other uses may be separately patentable.&#160;&#160;Even if we have a patent claim on a particular technology or product, the holder of a patent covering the use of that technology or product could exclude us from selling a product that is based on the same use of that product.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions.&#160;&#160;Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, if the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements).&#160;&#160;In addition, many countries limit the enforceability of patents against government agencies or government contractors.&#160;&#160;In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent.&#160;&#160;Compulsory licensing of life-saving drugs is also becoming increasingly popular in developing countries either through direct legislation or international initiatives.&#160;&#160;Such compulsory licenses could be extended to include some of our drug candidates, which could limit our potential revenue opportunities.&#160;&#160;Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on trade secret protection for our confidential and proprietary information.&#160;&#160;We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection.&#160;&#160;While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets.&#160;&#160;In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.&#160;&#160;We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our nonclinical and clinical development efforts as well as our potential products and those of our collaborators may give rise to claims that they infringe the patents of others.&#160;&#160;We are aware that other companies and institutions are developing products acting through the same drug targets through which some of our drug candidates currently in clinical development act, have conducted research on many of the same targets that we have identified and have filed patent applications potentially covering drug targets that we have identified and certain therapeutic products addressing such targets.&#160;&#160;In some cases, patents have issued from these applications.&#160;&#160;In addition, many companies and institutions have well-established patent portfolios directed to common techniques, methods and means of developing, producing and manufacturing pharmaceutical products.&#160;&#160;These or other companies or institutions could bring legal actions against us or our collaborators for damages or to stop us or our collaborators from engaging in certain nonclinical or clinical development activities or from manufacturing and marketing therapeutic products that allegedly infringe their patent rights.&#160;&#160;If any of these actions are successful, in addition to our potential liability for damages, these entities would likely require us or our collaborators to obtain a license in order to continue engaging in the infringing activities or to manufacture or market the infringing therapeutic products or may force us to terminate such activities or manufacturing and marketing efforts.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may need to pursue litigation against others to enforce our patents and intellectual property rights and may be the subject of litigation brought by third parties to enforce their patent and intellectual property rights.&#160;&#160;In addition, we may become involved in litigation based on intellectual property indemnification undertakings that we have given to certain of our collaborators.&#160;&#160;Patent litigation is expensive and requires substantial amounts of management attention.&#160;&#160;The eventual outcome of any such litigation is uncertain and involves substantial risks.</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that there will continue to be significant litigation in our industry regarding patent and other intellectual property rights.&#160;&#160;We have expended and many of our competitors have expended and are continuing to expend significant amounts of time, money and management resources on intellectual property litigation.&#160;&#160;If we become involved in future intellectual property litigation, it could consume a substantial portion of our resources and could negatively affect our results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have not sought patent protection outside of the United States for some of our inventions, and some of our licensed patents only provide coverage in the United States.&#160;&#160;As a result, our international competitors could be granted foreign patent protection with respect to our discoveries.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have decided not to pursue patent protection with respect to some of our inventions outside the United States, both because we do not believe it is cost-effective and because of confidentiality concerns.&#160;&#160;Accordingly, our international competitors could develop, and receive foreign patent protection for, genes or gene sequences, uses of those genes or gene sequences, gene products and drug targets, assays for identifying potential therapeutic products, potential therapeutic products and methods of treatment for which we are seeking United States patent protection.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our employees and independent contractors were previously employed at universities, other biotechnology or pharmaceutical companies, including our competitors or potential competitors.&#160;&#160;We may be subject to claims that these employees, independent contractors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers.&#160;&#160;Litigation may be necessary to defend against these claims.&#160;&#160;Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention.&#160;&#160;If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel.&#160;&#160;A loss of key research personnel and/or their work product could hamper or prevent our ability to commercialize certain drug candidates, which could severely harm our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Employees, Advisors and Facilities Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to expand our operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are highly dependent upon the principal members of our management and scientific staff, the loss of whose services might adversely impact the achievement of our objectives.&#160;&#160;Recruiting and retaining qualified medical, clinical and scientific personnel will be critical to support activities related to advancing our nonclinical and clinical development programs, and to support our collaborative arrangements.&#160;&#160;Competition is intense for experienced medical and clinical personnel, in particular, and we may be unable to retain or recruit medical and clinical personnel with the expertise or experience necessary to allow us to pursue collaborations, develop our products or expand our operations to the extent otherwise possible.&#160;&#160;Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our collaborations with outside scientists may be subject to restriction and change.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We work with scientific and clinical advisors and collaborators at academic and other institutions that assist us in our nonclinical and clinical development efforts.&#160;&#160;These advisors and collaborators are not our employees and may have other commitments that limit their availability to us.&#160;&#160;Although these advisors and collaborators generally agree not to perform competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services.&#160;&#160;In such a circumstance, our development efforts with respect to the matters on which they were working may be significantly delayed or otherwise adversely affected.&#160;&#160;In addition, although our advisors and collaborators sign agreements not to disclose our confidential information, it is possible that valuable proprietary knowledge may become publicly known through them.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Security breaches may disrupt our operations and harm our operating results.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our network security and data recovery measures may not be adequate to protect against computer viruses, break-ins, and similar disruptions from unauthorized tampering with our computer systems.  The misappropriation, theft, sabotage or any other type of security breach with respect to any of our proprietary and confidential information that is electronically stored, including research or clinical data, could have a material adverse impact on our business, operating results and financial condition.  Additionally, any break-in or trespass of our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets could have a material adverse impact on our business, operating results and financial condition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Environmental and Product Liability</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We use hazardous chemicals and radioactive and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development processes have historically involved the controlled use of hazardous materials, including chemicals and radioactive and biological materials.&#160;&#160;Our operations have produced hazardous waste products.&#160;&#160;We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials.&#160;&#160;Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials.&#160;&#160;We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and such liability may exceed our insurance coverage and our total assets.&#160;&#160;Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, these hazardous materials used by these parties.&#160;&#160;Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may be sued for product liability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We or our collaborators may be held liable if any product that we or our collaborators develop, or any product that is made with the use or incorporation of any of our technologies, causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale.&#160;&#160;Although we currently have and intend to maintain product liability insurance, this insurance may become prohibitively expensive or may not fully cover our potential liabilities.&#160;&#160;Our inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of products developed by us or our collaborators.&#160;&#160;If we are sued for any injury caused by our or our collaborators&#8217; products, our liability could exceed our total assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Invus, L.P., Invus C.V. and their affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Invus, L.P. and Invus C.V., which we collectively refer to as Invus, and their affiliates currently own approximately 59.8% of the outstanding shares of our common stock and are thereby able to control the election and removal of our directors and determine our corporate and management policies, including potential mergers or acquisitions, asset sales, the amendment of our articles of incorporation or bylaws and other significant corporate transactions.  This concentration of ownership may delay or deter possible changes in control of our company, which may reduce the value of an investment in our common stock.  The interests of Invus and its affiliates may not coincide with the interests of other holders of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion of the notes evidencing our current indebtedness may dilute the ownership interest of our existing stockholders, including holders who had previously converted their notes, or may otherwise depress the price of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The conversion of some or all of the notes evidencing our current indebtedness will dilute the ownership interests of existing stockholders to the extent we deliver shares upon conversion of any of the notes.  Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock.  In addition, the existence of the notes may encourage short selling by market participants because the conversion of the notes could be used to satisfy short positions, or anticipated conversion of the notes into shares of our common stock could depress the price of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Invus has additional rights under our stockholders</font><font style="font-family:inherit;font-size:10pt;">&#8217;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;agreement with Invus, L.P. which provides Invus with substantial influence over certain significant corporate matters. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our stockholders&#8217; agreement with Invus, L.P., Invus has the right to designate a number of directors equal to the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates, rounded up to the nearest whole number of directors.  Invus has designated three of the nine current members of our board of directors.  While Invus has not presently exercised its director designation rights in full, it may exercise them at any time in the future in its sole discretion.  To facilitate the exercise of such rights, we have agreed, upon written request from Invus, to take all necessary steps in accordance with our obligations under the stockholders&#8217; agreement to (1) increase the number of directors to the number specified by Invus (which number shall be no greater than reasonably necessary for the exercise of Invus&#8217; director designation rights under the stockholders&#8217; agreement) and (2) cause the appointment to the newly created directorships of directors so designated by Invus pursuant to its rights under the stockholders&#8217; agreement.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Invus also has the right to require proportionate representation of Invus-appointed directors on the audit, compensation and corporate governance committees of our board of directors, subject to certain restrictions.  Invus-designated directors currently serve as one of the three members of each of the compensation committee and the corporate governance committee of our board of directors.  No Invus-designated directors currently serve on the audit committee of our board of directors.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of the stockholders&#8217; agreement relating to Invus&#8217; rights to designate members of our board of directors and its audit, compensation and corporate governance committees will terminate if the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates falls below 10%.  Invus also has the right to terminate these provisions at any time in its discretion.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Invus has preemptive rights under the stockholders&#8217; agreement to participate in future equity issuances by us, subject to certain exceptions, so as to maintain its then-current percentage ownership of our capital stock.  Subject to certain limitations, Invus will be required to exercise its preemptive rights in advance with respect to certain marketed offerings, in which case it will be obligated to buy its pro rata share of the number of shares being offered in such marketed offering, including any overallotment (or such lesser amount specified in its exercise of such rights), so long as the sale of the shares were priced within a range within 10% above or below the market price on the date we notified Invus of the offering and we met certain other conditions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of the stockholders&#8217; agreement relating to preemptive rights will terminate on the earlier to occur of August&#160;28, 2017 and the date on which the percentage of all the outstanding shares of our common stock owned by Invus and its affiliates falls below 10%.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Invus is entitled to certain consent rights under the stockholders&#8217; agreement, including with respect to (a) the creation or issuance of any new class or series of shares of our capital stock (or securities convertible into or exercisable for shares of our capital stock) having rights, preferences or privileges senior to or on parity with our common stock, (b) any amendment to our certificate of incorporation or bylaws, or amendment to the certificate of incorporation or bylaws of any of our subsidiaries, in a manner adversely affecting Invus&#8217; rights under the securities purchase agreement and the related agreements, (c) the repurchase, retirement, redemption or other acquisition of our or our subsidiaries&#8217; capital stock (or securities convertible into or exercisable for shares of our or our subsidiaries&#8217; capital stock), (d) any increase in the size of our board of directors to more than 12&#160;members and (e) the adoption or proposed adoption of any stockholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement, unless Invus is exempt from the provisions of such plan or agreement. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions of the stockholders&#8217; agreement relating to those consent rights will terminate on the earlier to occur of August&#160;28, 2017 and the date on which Invus and its affiliates hold less than 15% of the total number of outstanding shares of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our stock price may be extremely volatile.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse results or delays in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcement of FDA approval or non-approval, or delays in the FDA review process, of our or our collaborators&#8217; product candidates or those of our competitors or actions taken by regulatory agencies with respect to our, our collaborators&#8217; or our competitors&#8217; clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the announcement of new products by us or our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">quarterly variations in our or our competitors&#8217; results of operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conflicts or litigation with our collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to achieve operating results projected by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in earnings estimates or recommendations by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">financing transactions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developments in the biotechnology or pharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">departures of key personnel or board members;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developments concerning current or future collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA or international regulatory actions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party reimbursement policies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">acquisitions of other companies or technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disposition of any of our subsidiaries, drug programs or other technologies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other factors, including factors unrelated to our operating performance or the operatin</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">g</font><font style="font-family:inherit;font-size:10pt;">&#32;performance of our competitors.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These factors, as well as general economic, political and market conditions, may materially adversely affect the market price of our common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted.&#160;&#160;A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material and adverse effect on our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may engage in future acquisitions, which may be expensive and time consuming and from which we may not realize anticipated benefits.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may acquire additional businesses, technologies and products if we determine that these businesses, technologies and products complement our existing technology or otherwise serve our strategic goals.&#160;&#160;If we do undertake any transactions of this sort, the process of integrating an acquired business, technology or product may result in operating difficulties and expenditures and may not be achieved in a timely and non-disruptive manner, if at all, and may absorb significant management attention that would otherwise be available for ongoing development of our business.&#160;&#160;If we fail to integrate acquired businesses, technologies or products effectively or if key employees of an acquired business leave, the anticipated benefits of the acquisition would be jeopardized.&#160;&#160;Moreover, we may never realize the anticipated benefits of any acquisition, such as increased revenues and earnings or enhanced business synergies.&#160;&#160;Future acquisitions could result in potentially dilutive issuances of our equity securities, the incurrence of debt and contingent liabilities and amortization expenses related to intangible assets, which could materially impair our results of operations and financial condition.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Future sales of our common stock may depress our stock price.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our stockholders sell substantial amounts of our common stock (including shares issued upon the exercise of options) in the public market, the market price of our common stock could fall.&#160;&#160;These sales also might make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.&#160;&#160;For example, following an acquisition, a significant number of shares of our common stock held by new stockholders may become freely tradable or holders of registration rights could cause us to register their shares for resale.&#160;&#160;Sales of these shares of common stock held by existing stockholders could cause the market price of our common stock to decline.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are unable to meet Nasdaq continued listing requirements, Nasdaq may take action to delist our common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock trades on The Nasdaq Global Select Market, which has qualitative and quantitative listing criteria, including operating results, net assets, corporate governance, minimum trading price and minimums for public float, which is the amount of stock not held by our affiliates.&#160;&#160;If we are unable to meet Nasdaq continued listing requirements, Nasdaq may take action to delist our common stock. A delisting of our common stock could negatively impact us and our shareholders by reducing the liquidity and market price of our common stock and potentially reducing the number of investors willing to hold or acquire our common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><a name="s2338C8E673A627494A58A09F41D455C5"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1B. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unresolved Staff Comments</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><a name="sD766CC42765E49BCC3ACA09F42020C1A"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.&#160; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Properties</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently own approximately 260,000 square feet of space for our corporate offices and laboratories in buildings located in The Woodlands, Texas, a suburb of Houston, Texas, and lease approximately 42,000 square feet of space for offices and laboratories near Princeton, New Jersey.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2004, we obtained a $34.0&#160;million mortgage on our facilities in The Woodlands, Texas.&#160;&#160;The mortgage loan originally had a ten-year term with a  20-year amortization and a fixed rate of 8.23%.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan&#8217;s monthly payment amount and fixed interest rate each remaining unchanged.&#160;&#160;The mortgage had a principal balance outstanding of </font><font style="font-family:inherit;font-size:10pt;">$20.2&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we agreed to sell our facilities in The Woodlands, Texas for a purchase price of $24.5&#160;million.  This sales agreement was terminated in January 2015.  We intend to explore other strategic alternatives with respect to the facilities consistent with our strategy to reduce facilities costs, including the potential sale of the facilities to an alternative third party.  Upon any such sale, we intend to enter into a long-term lease for alternative facilities in The Woodlands, Texas appropriate for our ongoing operations and consistent with our strategy to reduce facilities costs.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2002, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. entered into a lease for our facility in Hopewell, New Jersey.  In March 2015, our subsidiary entered into a termination agreement whereby the lease will terminate in June 2015.&#160; The lease provides for a current yearly base rent payment of $878,000.&#160;&#160;We are the guarantor of the obligations of our subsidiary under the lease.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our facilities are well-maintained, in good operating condition and acceptable for our current operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sA401AA8C1639E1A567D9A09F42221640"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><a name="sC773FEA5A927A6168B29A09F42601058"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Mine Safety Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;1</font></div></div><hr style="page-break-after:always"><a name="sFFAE9DBDBEA1270257AFA09F427F233F"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s31D7F3591BB89B6F12C8A09F42AE0F5B"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is quoted on The Nasdaq Global Select Market under the symbol &#8220;LXRX.&#8221;&#160;&#160;The following table sets forth, for the periods indicated, the high and low sales prices for our common stock as reported on The Nasdaq Global Select Market.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="71%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">February&#160;27, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">316</font><font style="font-family:inherit;font-size:10pt;">&#32;holders of record of our common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never paid cash dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the expansion and operation of our business and do not anticipate paying cash dividends in the foreseeable future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following performance graph compares the performance of our common stock to the Nasdaq Composite Index and the Nasdaq Biotechnology Index for the period beginning </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2009</font><font style="font-family:inherit;font-size:10pt;">&#32;and ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. The graph assumes that the value of the investment in our common stock and each index was $100 at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2009</font><font style="font-family:inherit;font-size:10pt;">, and that all dividends were reinvested.</font></div><div style="line-height:120%;text-align:left;"><img src="form10k12312014.jpg" style="height:226px;width:682px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="35%"></td><td width="10%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="10%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2009</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nasdaq Composite Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nasdaq Biotechnology Index</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing stock price performance comparisons shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference by any general statement incorporating by reference this annual report on Form 10-K into any filing under the Securities Act of 1933 or under the Securities Exchange Act of 1934, except to the extent that we specifically incorporate such comparisons by reference.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;3</font></div></div><hr style="page-break-after:always"><a name="s5DB9767FC08609647ADFA09F3B7D5309"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selected Financial Data</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The statements of comprehensive loss data for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;and the balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;have been derived from our audited financial statements included elsewhere in this annual report on Form&#160;10-K.&#160;&#160;The statements of comprehensive loss data for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2011</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2010</font><font style="font-family:inherit;font-size:10pt;">, and the balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2011</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2010</font><font style="font-family:inherit;font-size:10pt;">&#32;have been derived from our audited financial statements not included in this annual report on Form 10-K.&#160;&#160;Our historical results are not necessarily indicative of results to be expected for any future period.&#160;&#160;The data presented below has been derived from financial statements that have been prepared in accordance with accounting principles generally accepted in the United States and should be read with our financial statements, including the notes, and with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this annual report on Form 10-K.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="46%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements of Comprehensive Loss Data:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share data)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,089</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development, including stock-based compensation of $4,020 in 2014, $4,376 in 2013, $3,673 in 2012, $3,249 in 2011 and $3,170 in 2010</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">89,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,428</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,210</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,887</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,710</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">General and administrative, including stock-based compensation of $3,061 in 2014, $3,045 in 2013, $2,822 in 2012, $2,458 in 2011 and $2,308 in 2010</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Impairment loss on buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,102</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">123,220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">104,593</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,504</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,944</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,626</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100,366</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(102,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(108,415</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(114,095</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(95,718</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest and other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,755</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,796</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,083</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Consolidated net loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100,364</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(104,126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(110,211</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(116,215</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(101,801</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(104,126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(110,211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(116,215</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(101,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">534,432</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">513,117</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">489,707</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">340,761</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">302,844</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="46%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash, cash equivalents and short-term investments, including restricted cash and investments of $430</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">339,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">223,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">281,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">211,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Working capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">324,018</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,260</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">212,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">264,400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">203,963</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">471,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">274,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">371,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">430,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">366,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Long-term debt, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,451</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,345</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,104,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,003,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(899,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(789,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(673,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lexicon Pharmaceuticals, Inc. stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,018</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">170,163</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">266,678</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">297,568</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">247,024</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;4</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion and analysis should be read with &#8220;Selected Financial Data&#8221; and our financial statements and notes included elsewhere in this annual report on Form 10-K.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company focused on the development of breakthrough treatments for human disease.&#160;&#160;We have advanced multiple drug candidates into clinical development.  We are presently devoting most of our resources to the development of our two most advanced drug candidates:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing telotristat etiprate, or LX1032, an orally-delivered small molecule drug candidate, as a treatment for carcinoid syndrome.  We have completed two Phase 2 clinical trials and are presently conducting a single pivotal Phase 3 clinical trial of telotristat etiprate in carcinoid syndrome patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing sotagliflozin, or LX4211, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes.  We have completed two Phase 2 clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment.  We have also completed a Phase 2 clinical trial of sotagliflozin in type 1 diabetes patients.  We are initiating a Phase 2 clinical trial of sotagliflozin in a younger adult type 1 diabetes population in collaboration with JDRF.  We are also initiating Phase&#160;3 development of sotagliflozin in type 1 diabetes.  We do not intend to continue development of sotagliflozin in type 2 diabetes unless we enter into a collaboration partnership.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our most advanced drug candidates, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally and to collaborate with other pharmaceutical and biotechnology companies with respect to the development and commercialization of drug candidates from other programs, particularly when the collaboration may provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have derived substantially all of our revenues from drug discovery and development collaborations and other research collaborations and technology licenses, and will continue to do so for the foreseeable future.&#160;&#160;To date, we have generated a substantial portion of our revenues from a limited number of sources.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including our success in establishing new collaborations and licenses, the success rate of our development efforts leading to opportunities for new collaborations and licenses, the timing and willingness of collaborators to commercialize products that would result in milestone payments and royalties and their success in such efforts, and general and industry-specific economic conditions which may affect research and development expenditures.&#160;&#160;Future revenues from our existing collaborations are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from any future products developed under the collaboration.  As a result, we depend, in part, on securing new collaborations and license agreements.&#160;&#160;Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our clinical drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception, we have incurred significant losses and, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.1 billion</font><font style="font-family:inherit;font-size:10pt;">. Our losses have resulted principally from costs incurred in research and development, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock granted to employees and consultants.&#160;&#160;Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. General and administrative expenses consist primarily of salaries and related expenses for executive and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities.&#160;&#160;We expect to incur significant research and development costs in connection with the continuing development of our drug candidates.  As a result, we will need to generate significantly higher revenues to achieve profitability.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectibility is reasonably assured.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements revenues include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The delivered item or items have value to the customer on a stand-alone basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&#8217;s control.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;5</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It can only be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It would result in additional payments being due to the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subscription and license fees are recognized as revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A change in our revenue recognition policy or changes in the terms of contracts under which we recognize revenues could have an impact on the amount and timing of our recognition of revenues.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist of costs incurred for research and development activities solely sponsored by us as well as collaborative research and development activities.&#160;&#160;These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have advanced multiple drug candidates into clinical development.  We are presently devoting most of our resources to the development of our two most advanced drug candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Telotristat etiprate, or LX1032, an orally-delivered small molecule drug candidate that we are developing as a treatment for carcinoid syndrome; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:14px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sotagliflozin, or LX4211, an orally-delivered small molecule drug candidate that we are developing as a treatment for type 1 and type 2 diabetes</font></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our most advanced drug candidates, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We identified and validated in living animals, or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">, more than 100 targets with promising profiles for drug discovery. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The drug development process takes many years to complete.&#160;&#160;The cost and length of time varies due to many factors including the type, complexity and intended use of the drug candidate.&#160;&#160;We estimate that drug development activities are typically completed over the following periods:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="48%"></td><td width="5%"></td><td width="47%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Phase</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Completion Period</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical development</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-2 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 1 clinical trials</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-2 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 clinical trials</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-2 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 3 clinical trials</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2-4 years</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect research and development costs to increase in the future as our existing clinical drug candidates advance to later stage clinical trials and new drug candidates enter clinical development.&#160;&#160;Due to the variability in the length of time necessary for drug development, the uncertainties related to the cost of these activities and ultimate ability to obtain governmental approval for commercialization, accurate and meaningful estimates of the ultimate costs to bring our potential drug candidates to market are not available.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record significant accrued liabilities related to unbilled expenses for products or services that we have received from service providers, specifically related to ongoing nonclinical studies and clinical trials.&#160;&#160;These costs primarily relate to clinical study management, monitoring, laboratory and analysis costs, drug supplies, toxicology studies and investigator grants.&#160;&#160;We have multiple drugs in concurrent nonclinical studies and clinical trials at clinical sites throughout the world.&#160;&#160;In order to ensure that we have adequately provided for ongoing nonclinical and clinical development costs during the period in which we incur such costs, we maintain accruals to cover these expenses.&#160;&#160;Substantial portions of our nonclinical studies and </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;6</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For nonclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the vendors and clinical site visits.  Our estimates depend on the timeliness and accuracy of the data provided by our vendors regarding the status of each program and total program spending.  We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.&#160;&#160;Although we use consistent milestones or subject or patient enrollment to drive expense recognition, the assessment of these costs is a subjective process that requires judgment.&#160;&#160;Upon settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record our research and development costs by type or category, rather than by project.&#160;&#160;Significant categories of costs include personnel, facilities and equipment costs, laboratory supplies and third-party and other services.&#160;&#160;In addition, a significant portion of our research and development expenses is not tracked by project as it benefits multiple projects. Consequently, fully-loaded research and development cost summaries by project are not available.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation Expense</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation expense in our statements of comprehensive loss for share-based payments, including stock options issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;We had stock-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, stock-based compensation cost for all outstanding unvested options was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average vesting period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.3 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is estimated at the date of grant using the Black-Scholes option-pricing model.&#160;&#160;For purposes of determining the fair value of stock options, we segregate our options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&#160;&#160;Expected volatility is based on the historical volatility in our stock price.&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td width="49%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Risk-free Interest Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Dividend</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Rate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2013:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2012:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long-lived assets include property, plant and equipment, intangible assets and goodwill.  We regularly review long-lived assets for impairment.  The recoverability of long-lived assets, other than goodwill, is measured by comparing the assets carrying amount to the expected undiscounted future cash flows that the asset is expected to generate.  Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount, and the asset's residual value, if any.  We use internal cash flow estimates, quoted market prices when available and independent appraisals as appropriate to determine fair value.  We derive the required cash flow estimates from our historical experience and our internal business plans and apply an appropriate discount rate.  </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;7</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets, composed primarily of in-process research and development (&#8220;IPR&amp;D&#8221;) projects acquired in business combinations which have not reached technological feasibility, are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.  Estimating future cash flows of an IPR&amp;D product candidate for purposes of an impairment analysis requires us to make significant estimates and assumptions regarding the amount and timing of costs to complete the project and the amount, timing and probability of achieving revenues from the completed product similar to how the acquisition date fair value of the project was determined.    </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, we reclassified our buildings and land to assets held for sale. We estimated the fair value of the net assets to be sold at approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$23.8&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, which represents estimated selling price less costs to sell. This resulted in an impairment loss on the assets held for sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, which was recorded in impairment loss on buildings in the accompanying consolidated statement of comprehensive loss for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  There were no significant impairments of long-lived assets in </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;We have determined that the reporting unit is the single operating segment disclosed in our current financial statements.&#160;&#160;Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;We determined that the market capitalization approach is the most appropriate method of measuring fair value of the reporting unit.&#160;&#160;Under this approach, fair value is calculated as the average closing price of our common stock for the 30 days preceding the date that the annual impairment test is performed, multiplied by the number of outstanding shares on that date.&#160;&#160;A control premium, which is representative of premiums paid in the marketplace to acquire a controlling interest in a company, is then added to the market capitalization to determine the fair value of the reporting unit.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if we encounter events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We allocate the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date.  The purchase price allocation process requires management to make significant estimates and assumptions, especially at acquisition date with respect to intangible assets and in-process research and development.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These assumptions are based in part on historical experience and are inherently uncertain.  Examples of critical estimates in valuing certain of the intangible assets we have acquired or may acquire in the future include but are not limited to: the feasibility and timing of achievement of development, regulatory and commercial milestones; expected costs to develop the in-process research and development into commercially viable products; and future expected cash flows from product sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the purchase price allocations for acquisitions, we estimate the fair value of the contingent payments.  The estimated fair value of any contingent payments is determined utilizing a probability-based income approach inclusive of an estimated discount rate.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unanticipated events and circumstances may occur which may affect the accuracy or validity of such assumptions, estimates or actual results.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 3, Recent Accounting Pronouncements, of the Notes to Consolidated Financial Statements, for a discussion of the impact of new accounting standards on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations &#8211; Comparison of Years Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar increase&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage increase &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;8</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative agreements </font><font style="font-family:inherit;font-size:10pt;">&#8211; Revenue from collaborative agreements increased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">971%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$22.6 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to revenues recognized from the license and collaboration agreement with Ipsen Pharma SAS.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Subscription and license fees</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Revenues from subscriptions and license fees increased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">131%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to increases in technology license fees.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative agreements</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Revenue from collaborative agreements increased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">169%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to revenues recognized from a collaboration with a non-profit institute supporting the Phase 2 development of sotagliflozin in type 1 diabetes.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Subscription and license fees</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Revenue from subscriptions and license fees decreased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">63%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to decreases in technology license fees.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, </font><font style="font-family:inherit;font-size:10pt;">Ipsen Pharma SAS</font><font style="font-family:inherit;font-size:10pt;">&#32;represented </font><font style="font-family:inherit;font-size:10pt;">94%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues.  In 2013, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">McNair Medical Institute, LLC</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Taconic Farms, Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;represented </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">57%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues, respectively.  In 2012, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Taconic Farms</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Deltagen</font><font style="font-family:inherit;font-size:10pt;">&#32;represented </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">68%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues, respectively.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar increase (decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage increase (decrease)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, facility and equipment costs, stock-based compensation and laboratory supplies expenses.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Third-party and other services &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Third-party and other services increased 22% in 2014 to $51.0 million, primarily due to increases in our external clinical and nonclinical research and development costs.  Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Personnel &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Personnel costs decreased 13% in 2014 to $22.6 million, primarily due to reductions in our personnel in 2014, partially offset by increased severance costs as a result of those reductions (see Note 17, Restructuring Charges, of the Notes to Consolidated Financial Statements, for more information).  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities and equipment &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Facilities and equipment costs decreased 22% in 2014 to $6.8 million, primarily due to reductions in laboratory equipment costs and reductions in depreciation expense.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Stock-based compensation expense decreased 8% in 2014 to $4.0 million.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Laboratory supplies &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Laboratory supplies expense decreased 92% in 2014 to $0.3 million, primarily due to reductions in research activities.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Other costs decreased 12% to $4.6 million.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;9</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Third-party and other services &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Third-party and other services increased 27% in 2013 to $42.0 million, primarily due to an increase in our external clinical research and development costs, partially offset by a decrease in external nonclinical research and development costs. </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Personnel &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Personnel costs decreased 2% in 2013 to $25.8 million. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities and equipment &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Facilities and equipment costs decreased 24% in 2013 to $8.7 million, primarily due to decreases in depreciation expense and rent costs.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Stock-based compensation expense increased 19% in 2013 to $4.4 million.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Laboratory supplies &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Laboratory supplies expense increased 3% in 2013 to $3.6 million.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Other costs increased 14% to $5.2 million.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Increase (Decrease) in Fair Value of Symphony Icon Liability</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Symphony Icon purchase liability increased by </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, decreased by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, respectively (see Note 11, Arrangements with Symphony Icon, Inc., of the Notes to Consolidated Financial Statements, for more information).  The decrease in 2013 was primarily attributable to a reduction in the liability associated with our LX1033 development program in diarrhea-predominant irritable bowel syndrome.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses and dollar and percentage changes as compared to the prior year are as follows (dollar amounts are presented in millions):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total general and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollar increase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage increase</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses consist primarily of personnel costs to support our research and development activities, professional fees such as legal fees, stock-based compensation expense, and facility and equipment costs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Personnel</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Personnel costs increased 24% in 2014 to $9.5 million, primarily due to increased severance costs as a result of reductions in personnel in 2014 (see Note 17, Restructuring Charges, of the Notes to Consolidated Financial Statements, for more information).  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional fees</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Professional fees increased 19% in 2014 to $3.9 million, primarily due to increased consulting costs in preparation for commercialization of telotristat etiprate.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Stock-based compensation expense increased 1% in 2014 to $3.1 million.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities and equipment</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Facilities and equipment costs decreased 10% in 2014 to $1.5 million. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Other costs in 2014 were $1.4 million, consistent with the prior year.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Years Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Personnel</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Personnel costs decreased 4% in 2013 to $7.7 million. </font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;10</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional fees</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Professional fees increased 16% in 2013 to $3.3 million, primarily due to increased patent-related legal costs.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Stock-based compensation expense increased 8% in 2013 to $3.0 million.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities and equipment</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Facilities and equipment costs decreased 14% in 2013 to $1.7 million, primarily due to reduced rent costs and depreciation expense. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Other costs in 2013 were $1.4 million, consistent with the prior year.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment Loss on Buildings</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, Lexicon determined its buildings and land should be classified as assets held for sale on its consolidated balance sheet.  The Company recognized an impairment loss on its buildings of </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">$13.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, as a result of writing down the buildings to the estimated net selling price (see Note 6, Assets Held for Sale, of the Notes to Consolidated Financial Statements, for more information).</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense and Interest and Other Income (Expense), Net</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Interest expense increased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and decreased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">7%</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest and Other Income (Expense), Net.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Interest and other income, net was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The increase in interest and other income in </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to gains from sales of excess property and equipment.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Tax Benefit</font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax benefit for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$70,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">, respectively.  </font></div><div style="line-height:120%;padding-bottom:14px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidated Net Loss and Consolidated Net Loss&#160;per Common Share</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss decreased to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$100.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$104.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$110.2&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Net loss per common share was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.19</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.20</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.23</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments to us under our drug discovery and development collaborations, target validation, database subscription and technology license agreements, government grants and contracts and financing under debt and lease arrangements.&#160;&#160;We have also financed certain of our research and development activities under our agreements with Symphony Icon, Inc.&#160;&#160;From our inception through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had received net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.2 billion</font><font style="font-family:inherit;font-size:10pt;">&#32;from issuances of common and preferred stock.&#160;&#160;In addition, from our inception through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, we received </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$481.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash payments from drug discovery and development collaborations, target validation, database subscription and technology license agreements, sales of compound libraries and reagents and government grants and contracts, of which </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$462.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;had been recognized as revenues through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$339.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and investments.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$129.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and short-term investments.&#160;&#160;We used cash of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$75.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in operations in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">. This consisted primarily of the consolidated net loss for the year of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$100.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and gain from disposal of property and equipment of </font><font style="font-family:inherit;font-size:10pt;">$1.6&#160;million</font><font style="font-family:inherit;font-size:10pt;">, partially offset by non-cash charges of impairment of assets of </font><font style="font-family:inherit;font-size:10pt;">$13.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to stock-based compensation expense, a net decrease in other operating assets net of liabilities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.9&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to depreciation expense, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the increase in fair value of the Symphony Icon purchase liability.&#160;&#160;Investing activities used cash of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$108.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, primarily due to net purchases of investments of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$110.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">, partially offset by proceeds from disposal of property and equipment of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Financing activities provided cash of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$283.8&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily due to net proceeds from issuance of common stock of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$202.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and net proceeds from debt borrowings of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$82.4&#160;million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;11</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Symphony Drug Development Financing Agreements.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In June 2007, we entered into a series of related agreements providing for the financing of the clinical development of certain drug programs, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates.&#160;&#160;Under the financing arrangement, we licensed to Symphony Icon, Inc., a then wholly-owned subsidiary of Symphony Icon Holdings LLC, our intellectual property rights related to the programs and Holdings contributed $45 million to Symphony Icon in order to fund the clinical development of the programs.&#160;&#160;We also issued and sold to Holdings shares of our common stock in exchange for $15&#160;million and received an exclusive option to acquire all of the equity of Symphony Icon, thereby allowing us to reacquire the programs.&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the recommendation of Symphony Icon&#8217;s development committee, which was comprised of an equal number of representatives from us and Symphony Icon, Symphony Icon&#8217;s board of directors had the right to require us to pay Symphony Icon up to $15 million for Symphony Icon&#8217;s use in the development of the programs in accordance with a specified development plan and related development budget.&#160;&#160;Through July 2010, Symphony Icon&#8217;s board of directors requested us to pay Symphony Icon $9.3&#160;million under the agreement, all of which was paid prior to the exercise of the purchase option in July 2010.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2010, we entered into an amended and restated purchase option agreement with Symphony Icon and Holdings and simultaneously exercised our purchase option. Pursuant to the amended terms of the purchase option, we paid Holdings $10&#160;million in July 2010 and issued 13,237,519 shares of common stock to designees of Holdings in July 2012 in satisfaction of an additional $35 million base payment obligation.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also agreed to make up to $45 million in additional contingent payments, which will consist of 50% of any consideration we receive pursuant to any licensing transaction under which we grant a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates, which we refer to as the &#8220;LG103 programs,&#8221; subject to certain exceptions. The contingent payments will be due if and when we receive such consideration from such a licensing transaction. In the event we receive regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 programs prior to entering into such a licensing transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a licensing transaction, we will pay Holdings the sum of $15 million and the amount of certain expenses we incurred after our exercise of the purchase option which are attributable to the development of such product, reduced by up to 50% of such sum on account of any contingent payments paid prior to such United States regulatory approval attributable to any such licensing transaction outside of the United States with respect to such product. In the event we make any such payment upon United States regulatory approval, we will have no obligation to make subsequent contingent payments attributable to any such licensing transactions for the commercialization of such product outside the United States until the proceeds of such licensing transactions exceed 50% of the payment made as a result of such United States regulatory approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contingent payments may be paid in cash or a combination of cash and common stock, in our discretion, provided that no more than 50% of any contingent payment will be paid in common stock.  On December 4, 2014, we paid </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and issued </font><font style="font-family:inherit;font-size:10pt;">4,662,780</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to designees of Holdings in satisfaction of a </font><font style="font-family:inherit;font-size:10pt;">$11.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;contingent payment obligation as a result of receiving a </font><font style="font-family:inherit;font-size:10pt;">$23 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment pursuant to our license and collaboration agreement with Ipsen Pharma SAS (see Note 16, Collaboration and License Agreements, of the Notes to Consolidated Financial Statements, for more information).</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Texas Institute for Genomic Medicine.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In July 2005, we received an award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine, or TIGM, using our proprietary gene trapping technology, which we completed in 2007.&#160;&#160;We also equipped TIGM with the bioinformatics software required for the management and analysis of data relating to the library.&#160;&#160;The Texas Enterprise Fund made an additional award to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of our award, we are responsible for the creation of a specified number of jobs beginning in 2012, reaching an aggregate of 1,616 new jobs in Texas by December 31, 2016.  We will receive credits against those job obligations based on funding received by TIGM and certain related parties from sources other than the State of Texas.&#160;&#160;We will also receive credits against those jobs obligations for any surplus jobs we create.  We may be required to repay the state a portion of the award if we fail to meet those job obligations.  Subject to these credits, if we fail to create the specified number of jobs, the State may require us to repay $2,415 for each job we fall short beginning in 2013.&#160;&#160;Our maximum aggregate exposure for such payments, if we fail to create any new jobs, is approximately $14.2&#160;million, including </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through 2015, without giving effect to any credits to which we may be entitled. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;12</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Facilities.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In April 2004, we obtained a $34.0 million mortgage on our facilities in The Woodlands, Texas.&#160;&#160;The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of 8.23%.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan&#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  The mortgage has a principal balance of </font><font style="font-family:inherit;font-size:10pt;">$20.2&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  The buildings that serve as collateral for the mortgage have been classified as assets held for sale as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, and management has reclassified all of the mortgage loan as current liabilities as the loan will be repaid upon sale of the buildings and land; however, the contractual obligations table below show the legal payment obligations.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2002, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 76,000 square-foot laboratory and office space in Hopewell, New Jersey.  Effective December 31, 2012, this lease was amended to decrease the space to approximately 42,000 square feet and extend the term until June&#160;30, 2018.  In March 2015, our subsidiary entered into a termination agreement whereby the lease will terminate on June 30, 2015.&#160;&#160;The amended lease provides for a current yearly base rent payment of $878,000.&#160;&#160;We are the guarantor of the obligations of our subsidiary under the lease.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Including the lease and debt obligations described above, we had incurred the following contractual obligations as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, without regard to the lease termination agreement entered into in March 2015:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="36%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments due by period (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Contractual Obligations</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2-3 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">4-5 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">More than 5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest payment obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">147.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">96.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing table does not include any potential payments related to the award we received from the Texas Enterprise Fund.  Under the terms of the award, we are responsible for the creation of jobs beginning in 2012.  Subject to credits, if we fail to create the specified number of jobs, the State of Texas may require us to repay $2,415 for each job we fall short beginning in 2013 and continuing until 2019.  Our maximum aggregate exposure for such payment, if we fail to create any new jobs, is approximately $14.2 million,  including </font><font style="font-family:inherit;font-size:10pt;">$2.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;through 2015, without giving effect to any credits to which we may be entitled.  See Note 16, Collaboration and License Agreements, of the Notes to Consolidated Financial Statements, for further discussion.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future capital requirements will be substantial and will depend on many factors, including our ability to obtain drug discovery and development collaborations and other collaborations and technology license agreements, the amount and timing of payments under such agreements, the level and timing of our research and development expenditures, market acceptance of our products, the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to devote substantial capital resources to continue our development efforts, to expand our support and product development activities, and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from drug discovery and development collaborations, other collaborations and technology licenses and other sources will be sufficient to fund our operations for at least the next 12 months.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.&#160;&#160;Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure about Market Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase.&#160;&#160;We maintain a short-term investment portfolio which consists of U.S. Treasury bills, money market accounts, and certificates of deposit that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk.&#160;&#160;We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;13</font></div></div><hr style="page-break-after:always"><a name="s2656051852826BC0A221A09F3B2F3F0A"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$339.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and cash equivalents and short-term investments as of&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.&#160; We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; </font></div><a name="s664EB00B4699D77715FAA09F433AFA01"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7A.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 7. Management&#8217;s Discussion and Analysis</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;14</font></div></div><hr style="page-break-after:always"><a name="sB8757D4B07FAF45018ECA09F435A7BAB"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.&#160; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Statements and Supplementary Data</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements required by this Item are incorporated under Item 15 in Part IV of this report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s8FA26E3164CD197F9FE6A09F4379F97A"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s08C76942D007762294D8A09F43A8BA5C"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9A.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to our evaluation, there were no significant changes in internal controls or other factors that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management assessed the effectiveness of our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control-Integrated Framework </font><font style="font-family:inherit;font-size:10pt;">(1992 Framework)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on such assessment using those criteria, management believes that, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, our internal control over financial reporting is effective.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our independent auditors have also audited our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;as stated in the audit report which appears on page F-2 and is incorporated under Item&#160;15 in Part&#160;IV of this report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s5C8851249B7A25D5FAA8A09F43C7C4BB"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9B.&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Information</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s35C87D5A32F6DC912FA7A09F43F67DA8"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sBD071FA30D9F3F6D6428A09F44152B97"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 10.&#160; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Directors, Executive Officers and Corporate Governance</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item is hereby incorporated by reference from (a) the information appearing under the captions &#8220;Election of Directors,&#8221; &#8220;Stock Ownership of Certain Beneficial Owners and Management,&#8221; &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and (b)&#160;the information appearing under Item&#160;1 in Part&#160;I</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">of this report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s62A32EA200E1D7A2E2D6A09F4453268F"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 11.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Executive Compensation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Executive and Director Compensation&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding the foregoing, in accordance with the instructions to Item 407(e)(5) of Regulation S-K, the information contained in our proxy statement under the sub-heading &#8220;Compensation Committee Report&#8221; shall not be deemed to be filed as part of or incorporated by reference into this annual report on Form 10-K.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s5D4ABF2A70BB8547009AA09F44723EEC"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 12.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Stock Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s93C4DB98F599BF29BCD5A09F44A1FEFC"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 13.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item is hereby incorporated by reference from the information appearing under the captions &#8220;Corporate Governance&#8221; and &#8220;Transactions with Related Persons&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s5A576F087E0D47B8605EA09F44C09089"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 14.&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principal Accounting Fees and Services</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item as to the fees we pay our principal accountant is hereby incorporated by reference from the information appearing under the caption &#8220;Ratification and Approval of Independent Auditors&#8221; in our definitive proxy statement which involves the election of directors and is to be filed with the Commission pursuant to the Securities Exchange Act of 1934 within 120 days of the end of our fiscal year on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;15</font></div></div><hr style="page-break-after:always"><a name="sE78C767172A073DA443FA09F44EF80FC"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sAFE5DF16F1E0C28E68E0A09F450EF76F"></a><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exhibits and Financial Statement Schedules</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Documents filed as a part of this report:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Financial Statements</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="636px"></td><td width="46px"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0E57213A8FC9E23EBCADA09F459B39E4"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0E57213A8FC9E23EBCADA09F459B39E4"><font style="font-family:inherit;font-size:10pt;">F-1</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s804F612EB51B10F7C15DA09F36012E19"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s804F612EB51B10F7C15DA09F36012E19"><font style="font-family:inherit;font-size:10pt;">F-2</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBF8D8D57BAEE198C1021A09F3611A048"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBF8D8D57BAEE198C1021A09F3611A048"><font style="font-family:inherit;font-size:10pt;">F-3</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCC208CDAABC970086B9BA09F3640DAEA"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Loss</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCC208CDAABC970086B9BA09F3640DAEA"><font style="font-family:inherit;font-size:10pt;">F-4</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD3C204084F6DBC3B8A54A09F365FEBF8"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD3C204084F6DBC3B8A54A09F365FEBF8"><font style="font-family:inherit;font-size:10pt;">F-5</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s07F588D587C47C705430A09F36DC318B"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s07F588D587C47C705430A09F36DC318B"><font style="font-family:inherit;font-size:10pt;">F-6</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC8BBA832B6A6CA1C5FD5A09F46E2069D"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC8BBA832B6A6CA1C5FD5A09F46E2069D"><font style="font-family:inherit;font-size:10pt;">F-7</font></a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statement Schedules</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other financial statement schedules are omitted because they are not applicable or not required, or because the required information is included in the financial statements or notes thereto.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:144px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="11%"></td><td width="1%"></td><td width="3%"></td><td width="85%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K dated April 26, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Amended and Restated Bylaws (filed as Exhibit 3.2 to the Company&#8217;s Current Report on Form&#160;8&#8209;K dated April 26, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities Purchase Agreement, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment, dated October 7, 2009, to Securities Purchase Agreement, dated June&#160;17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated October 7, 2009 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Rights Agreement, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; Agreement, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplement to Transaction Agreements, dated March 15, 2010, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated March 15, 2010 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplement No. 2 to Transaction Agreements, dated February 23, 2012, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated February 23, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Purchase Option Agreement, dated July 30, 2010, with Symphony Icon Holdings LLC and Symphony Icon, Inc. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated July 30, 2010 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Registration Rights Agreement, dated July 30, 2010, with Symphony Icon Holdings LLC (filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K dated July 30, 2010 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indenture related to the 5.25% Convertible Senior Notes due 2021, dated as of November&#160;26, 2014, with Wells Fargo Bank, N.A. (filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K dated November 26, 2014 and incorporated by reference herein).</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="11%"></td><td width="1%"></td><td width="3%"></td><td width="85%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of 5.25% Convertible Senior Notes due 2021 (filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K dated November 26, 2014 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offer Letter, dated July 1, 2014, with Lonnel Coats (filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K dated July 7, 2014 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offer Letter, dated March 10, 2011, with Pablo Lapuerta, M.D. (filed as Exhibit 10.5 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2011 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement with Alan Main, Ph.D. (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2001 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement with Jeffrey L. Wade, J.D. (filed as Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restated Employment Agreement with Arthur T. Sands, M.D., Ph.D. (filed as Exhibit 10.1 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2005 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separation Agreement, dated July 7, 2014, with Arthur T. Sands, M.D., Ph.D. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated July 7, 2014 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting Agreement, dated July 7, 2014, with Arthur T. Sands, M.D., Ph.D. (filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K dated July 7, 2014 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement with Brian P. Zambrowicz, Ph.D. (filed as Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting Agreement, dated February 20, 2015, with Brian P. Zambrowicz, Ph.D. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated February 20, 2015 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting Agreement with Alan S. Nies, M.D. dated February 19, 2003, as amended (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September&#160;30, 2010 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting Agreement with Robert J. Lefkowitz, M.D. dated March 31, 2003 (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2003 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement with Officers and Directors (filed as Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-96469) and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summary of Non-Employee Director Compensation (filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K dated April 26, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity Incentive Plan, as amended (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated April 26, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-Employee Directors&#8217; Equity Incentive Plan, as amended (filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K dated April 26, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Stock Option Agreement with Chairman of Board of Directors under the Equity Incentive Plan (filed as Exhibit 10.17 to the Company&#8217;s Annual Report on Form 10-K for the period ended December&#160;31, 2005 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Stock Option Agreement with Directors under the Non-Employee Directors&#8217; Equity Incentive Plan (filed as Exhibit 10.13 to the Company&#8217;s Annual Report on Form 10-K for the period ended December&#160;31, 2013 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Stock Option Agreement with Officers under the Equity Incentive Plan, as amended (filed as Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2011 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Restricted Stock Unit Agreement with Officers under the Equity Incentive Plan, as amended (filed as Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2012 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License and Collaboration Agreement, dated October 21, 2014, with Ipsen Pharma SAS (filed as Exhibit 10.1 to the amendment to the Company&#8217;s Quarterly Report on Form 10-Q/A for the period ended September 30, 2014, as filed on December 23, 2014, and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration and License Agreement, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.15 to the amendment to the Company&#8217;s Annual Report on Form 10-K/A for the period ended December 31, 2003, as filed on July 16, 2004, and incorporated by reference herein).</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="12%"></td><td width="3%"></td><td width="85%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.22</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Amendment, dated May 30, 2006, to Collaboration and License Agreement, dated December&#160;17, 2003, with Bristol-Myers Squibb Company (filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2006, and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.23</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Amended and Restated Collaboration and License Agreement, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.22 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2005 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.24</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment, dated June 8, 2009, to Second Amended and Restated Collaboration and License Agreement, dated November 30, 2005, with Genentech, Inc. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K/A dated June 8, 2009 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.25</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Economic Development Agreement dated July 15, 2005, with the State of Texas and the Texas A&amp;M University System (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2005 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.26</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment, dated April 30, 2008, to Economic Development Agreement, dated July 15, 2005, with the State of Texas and the Texas A&amp;M University System (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated April 30, 2008 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loan and Security Agreement, dated April 21, 2004, between Lex-Gen Woodlands, L.P. and iStar Financial Inc., as amended (filed as Exhibit 10.23 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2014 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsidiaries (filed as Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2010 and incorporated by reference herein).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*23.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consent of Independent Registered Public Accounting Firm.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*24.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Power of Attorney (contained in signature page).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*31.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*31.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*32.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.INS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.SCH</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.CAL</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.DEF</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.LAB</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*101.PRE</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_____________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="2%"></td><td width="98%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment has been requested for a portion of this exhibit.&#160;&#160;The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sAC07943A934BCB088583A09F454D074A"></a><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signatures</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="5%"></td><td width="50%"></td><td width="6%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals, Inc.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">LONNEL COATS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lonnel Coats</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">JEFFREY L. WADE</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Wade</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Power of Attorney</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lonnel Coats and Jeffrey L. Wade, or either of them, each with the power of substitution, his or her attorney-in-fact, to sign any amendments to this Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, here ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="29%"></td><td width="3%"></td><td width="39%"></td><td width="29%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ LONNEL COATS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief Executive Officer and Director</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lonnel Coats</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">JEFFREY L. WADE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer (Principal Financial Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Wade</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">JAMES F. TESSMER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Finance and Accounting</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James F. Tessmer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">RAYMOND DEBBANE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman of the Board of Directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raymond Debbane</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/ PHILIPPE J. AMOUYAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Philippe J. Amouyal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">SAMUEL L. BARKER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Samuel L. Barker, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">ROBERT J. LEFKOWITZ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Robert J. Lefkowitz, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">ALAN S. NIES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alan S. Nies, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">FRANK P. PALANTONI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Frank P. Palantoni</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">CHRISTOPHER J. SOBECKI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Christopher J. Sobecki</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:9pt;">JUDITH L. SWAIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Judith L. Swain, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s3DD6006EE41314DD5BA5A09F455CF13E"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s0E57213A8FC9E23EBCADA09F459B39E4"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors and Stockholders</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Lexicon Pharmaceuticals, Inc.:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Lexicon Pharmaceuticals, Inc. as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, and the related consolidated statements of comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;These financial statements are the responsibility of the Company&#8217;s management.&#160;&#160;Our responsibility is to express an opinion on these financial statements based on our audits.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Lexicon Pharmaceuticals, Inc. as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, and the consolidated results of its operations and its cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, in conformity with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Lexicon Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework) and our report dated </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;12, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Houston, Texas</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;12, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;18</font></div></div><hr style="page-break-after:always"><a name="s804F612EB51B10F7C15DA09F36012E19"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors and Stockholders</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Lexicon Pharmaceuticals, Inc.:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited Lexicon Pharmaceuticals, Inc.&#8217;s&#160;&#160;internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission 1992 framework (the COSO criteria). Lexicon Pharmaceuticals, Inc.&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company&#8217;s internal control over financial reporting based on our audit.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;&#160;Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, Lexicon Pharmaceuticals, Inc. maintained, in all material respects, effective internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, based on the COSO criteria.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Lexicon Pharmaceuticals, Inc. and subsidiaries as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, and the related consolidated statements of comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and our report dated </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;12, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Houston, Texas</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;12, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><a name="sBF8D8D57BAEE198C1021A09F3611A048"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except par value)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.9453125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="76%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments, including restricted investments of $430</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,073</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,629</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net of allowances of $35</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,849</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,764</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,554</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net of accumulated depreciation and amortization of $36,274 and $81,945, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,409</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,376</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,160</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and Equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,064</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,715</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,710</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,969</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,535</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,386</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,358</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $.001 par value; 900,000 shares authorized; 725,641 and 514,349 shares issued, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,389,997</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,175,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,104,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,003,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive gain (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury stock, at cost, 1,281 and 814 shares, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,018</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,163</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,376</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,160</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><a name="sCC208CDAABC970086B9BA09F3640DAEA"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except per share amounts)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,593</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">783</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subscription and license fees</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,854</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,222</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,089</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development, including stock-based compensation of $4,020, $4,376 and $3,673, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,682</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,574</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,210</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,887</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative, including stock-based compensation of $3,061, $3,045 and $2,822, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,121</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,043</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment loss on buildings</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,593</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,504</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,366</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,371</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108,415</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,253</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,971</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,114</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss before taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,364</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104,126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,211</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104,126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.23</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">534,432</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,117</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">489,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive gain (loss):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104,147</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><a name="sD3C204084F6DBC3B8A54A09F365FEBF8"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td width="32%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-In</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Treasury</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Par Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">480,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,087,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(789,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">297,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock to designees of Symphony Icon Holdings LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">34,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">35,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock under Equity Incentive Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,248</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,054</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock, net of fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">17,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">37,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">37,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchase of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(110,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(110,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized gain on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">512,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,166,605</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(899,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">266,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,421</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,421</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock under Equity Incentive Plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchase of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(873</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(873</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(104,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(104,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">514,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,175,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,003,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">170,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,081</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,081</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock to designees of Symphony Icon Holdings LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock under Equity Incentive Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">321</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">323</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock, net of fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">204,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">201,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">201,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Repurchase of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(887</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(887</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(100,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(100,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">725,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,389,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,104,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">284,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s07F588D587C47C705430A09F36DC318B"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="65%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100,294</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104,126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,211</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,190</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,210</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,887</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,631</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Increase) decrease in accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,028</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Increase) decrease in prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Increase) decrease in other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in accounts payable and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in deferred revenue&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">697</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(293</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from disposal of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(221,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(233,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of investments&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,444</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">212,625</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock, net of fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repurchase of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(887</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(873</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from debt borrowings, net of fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repayment of debt borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,710</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,574</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,443</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283,808</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,389</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,381</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,423</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,761</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,897</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,028</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of noncash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued in satisfaction of Symphony Icon payment obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><a name="sC8BBA832B6A6CA1C5FD5A09F46E2069D"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexicon Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sBBD59C74A5C7A8D546F1A09F371A97FC"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under drug discovery and development collaborations, target validation, database subscription and technology license agreements, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, its ability to discover and develop pharmaceutical products for the treatment of human disease, establish new collaboration and license agreements, achieve milestones under such agreements, obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s4A0B92077EFE27B58F1EA09F371A9D74"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation:</font><font style="font-family:inherit;font-size:10pt;">&#32;The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;">&#32;The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash, Cash Equivalents and Short-Term Investments:</font><font style="font-family:inherit;font-size:10pt;">&#32;Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, short-term investments consist of U.S. treasury bills and certificates of deposit.  The certificates of deposits are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash and Investments:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon is required to maintain restricted cash or investments to collateralize standby letters of credit for the lease on its office and laboratory facilities in Hopewell, New Jersey (see Note&#160;12).&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, restricted cash and investments were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;">&#32;Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.&#160;&#160;In </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, customers in France and the United States represented </font><font style="font-family:inherit;font-size:10pt;">94%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue, respectively.  In </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">, customers in the United States represented </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue, respectively.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, management believes that the Company has no significant concentrations of credit risk.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information and Significant Customers:</font><font style="font-family:inherit;font-size:10pt;">&#32;Lexicon operates in one business segment, which primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, government grants and contracts and compound library sales.  In 2014, </font><font style="font-family:inherit;font-size:10pt;">Ipsen Pharma SAS</font><font style="font-family:inherit;font-size:10pt;">&#32;represented </font><font style="font-family:inherit;font-size:10pt;">94%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues.  In 2013, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">McNair Medical Institute, LLC</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Taconic Farms, Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;represented </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">57%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues, respectively.  In 2012, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Taconic Farms</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Deltagen</font><font style="font-family:inherit;font-size:10pt;">&#32;represented </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">68%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenues, respectively.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment:</font><font style="font-family:inherit;font-size:10pt;">&#32;Property and equipment are carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-Lived Assets:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Indefinite lived intangible assets are also tested at least annually for impairment.  Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition.&#160;&#160;In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values.  In </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, Lexicon reclassified its buildings as assets held for sale, and recorded an impairment loss of </font><font style="font-family:inherit;font-size:10pt;">$13.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(see Note 6, Assets Held for Sale)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill Impairment:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition:</font><font style="font-family:inherit;font-size:10pt;">&#32;Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements revenues include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The delivered item or items have value to the customer on a stand-alone basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&#8217;s control.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It can only be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It would result in additional payments being due to the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subscription and license fees are recognized as revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses:</font><font style="font-family:inherit;font-size:10pt;">&#32;Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, stock-based compensation cost for all outstanding unvested options and restricted stock units was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;years.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&#160;&#160;Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td width="49%"></td><td width="12%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Risk-free Interest Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Dividend</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Rate</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2013:</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2012:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss per Common Share:</font><font style="font-family:inherit;font-size:10pt;">&#32;Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options, restricted stock units and warrants are not included because they are antidilutive.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="saa1ee38ae9634265b824d6c9cd5a57a8"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-09, &#8220;Revenue from Contracts with Customers&#8221;, which amends FASB ASC Topic 606. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. This standard contains principles for the determination of the measurement of revenue and the timing of when such revenue is recognized. Revenue recognition will reflect the transfer of goods or services to customers at an amount that is expected to be earned in exchange for those goods or </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">services. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December&#160;15, 2016, and early adoption is not permitted. Management is currently evaluating the impact of this pronouncement on Lexicon&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15, &#8220;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.&#8221; ASU 2014-15 will explicitly require management to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted.  Management does not expect the adoption of this pronouncement to have a material impact on Lexicon&#8217;s consolidated financial statements.</font></div><a name="s598CF52F97C4BA1AEEFDA09F376870D1"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents and Investments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of cash and cash equivalents and investments held at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="306px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,584</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,521</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="306px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,075</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,077</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,627</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,126</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,128</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;realized gains or losses for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;realized gains or losses for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;realized gains or losses for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s33C0AE9E52B808A80E4CA09F37B6D93D"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.)</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; significant unobservable inputs (including the Company&#8217;s own assumptions in determining the fair value of assets and liabilities)</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,521</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,073</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338,787</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,339</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:676px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="293px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td><td width="5px"></td><td width="9px"></td><td width="79px"></td><td width="4px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,077</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,576</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,128</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not have any Level 3 assets during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  The Company&#8217;s Level&#160;3 liabilities are estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon (&#8220;Symphony Icon&#8221;) purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, decreased by </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.  The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="80%"></td><td width="1%"></td><td width="18%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Long-term Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,887</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of base payment obligation with common stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2012</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,920</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2013</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent payment obligation with common stock and cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.&#160;&#160;These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon on July 30, 2010 and intangible assets associated with the acquisition of Symphony Icon on July 30, 2010.&#160;&#160;For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sdd39f391be4f4cd38a2a9a09f1c1d9e7"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.&#160;Assets Held for Sale</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon&#8217;s buildings and land have been reclassified as assets held for sale on the consolidated balance sheet as of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. The Company estimated the fair value of the net assets to be sold at approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$23.8&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, which represents estimated selling price less costs to sell. This resulted in an impairment loss on the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">assets held for sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.1&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, which was recorded in impairment loss on</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">buildings in the accompanying consolidated statement of comprehensive loss for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  The fair value of the net assets to be sold was determined using Level 2 inputs using sales prices in similar real estate sales and offers received from potential purchasers of the building.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s22E4BAD868520FBD70A2A09F38238D09"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="57%"></td><td width="5%"></td><td width="2%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Useful Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">In Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5-7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,032</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,315</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,952</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7-10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,117</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,092</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15-40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,274</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81,945</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,362</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings of </font><font style="font-family:inherit;font-size:10pt;">$59.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and land of </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, as well as </font><font style="font-family:inherit;font-size:10pt;">$38.0&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;of related accumulated depreciation, have been reclassified to assets held for sale (see Note 6, Assets Held for Sale) as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s61A1AD529AB13802325CA09F3842A3D4"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of Lexicon&#8217;s deferred tax assets (liabilities) at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="71%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255,518</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,608</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,946</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,457</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,681</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability related to acquisition of Symphony Icon</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,745</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(412,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(376,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,745</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;deferred tax liability relates to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.  Lexicon does not believe it can estimate the reversal of the temporary difference related to the assets acquired with sufficient certainty such that the related deferred tax liability could be considered as a source of taxable income in assessing the Company&#8217;s need for a valuation allowance.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, Lexicon had both federal and state NOL carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$715.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$460.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The federal and state NOL carryforwards began to expire in 2011 and continued to expire in 2012.&#160;&#160;The Company&#8217;s R&amp;D tax credit carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$40.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;began to expire in 2012.&#160;&#160;Utilization of the NOL and R&amp;D credit carryforwards may be subject to a significant annual limitation due to ownership changes that have occurred previously or could occur in the future provided by Section&#160;382 of the Internal Revenue Code.&#160;&#160;Based on the federal tax law limits and the Company&#8217;s cumulative loss position, Lexicon concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the valuation allowance increased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35.8 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to the Company&#8217;s current year net loss.&#160;&#160;Lexicon recorded income tax benefits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$70,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0</font><font style="font-family:inherit;font-size:10pt;">&#32;in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.  During the year ended December 31, 2013, the Company recorded certain revisions to its deferred tax assets.  The revisions reduced the deferred tax assets and valuation allowance by </font><font style="font-family:inherit;font-size:10pt;">$13.8 million</font><font style="font-family:inherit;font-size:10pt;">.  There was no impact to the Company&#8217;s equity or operating results for any period.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company did not have any unrecognized tax benefits.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1995 to current remain open to examination by U.S. federal authorities and 2004 to current remain open to examination by state authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company had no accruals for interest or penalties related to income tax matters.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><a name="sD2A382F090DEC9842CA3A09F3862917D"></a><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$25.8 million</font><font style="font-family:inherit;font-size:10pt;">, which represents the excess of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$36.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 30, 2010, Lexicon exercised its Purchase Option (as defined in Note 11) and completed the acquisition of Symphony Icon.  Goodwill associated with the acquisition of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;">, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sC106B53EB81AFA21CCABA09F38627995"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Obligations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Debt.</font><font style="font-family:inherit;font-size:10pt;">&#32;In November 2014, Lexicon completed an offering of </font><font style="font-family:inherit;font-size:10pt;">$87.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;Convertible Senior Notes due 2021 (the &#8220;Notes&#8221;).  In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheet.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Notes bear interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;">&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Notes mature on December&#160;1, 2021. The Company may not redeem the Notes prior to the maturity date, and no sinking fund is provided for the Notes.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of the Notes may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially </font><font style="font-family:inherit;font-size:10pt;">829.1874</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$1.206</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Notes in connection with such a corporate event in certain circumstances.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the issuance of the Notes, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of debt issuance costs, which is included in other assets on the consolidated balance sheets.  The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Notes.  As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the balance of unamortized debt issuance costs was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Notes was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$81.0&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mortgage Loan. </font><font style="font-family:inherit;font-size:10pt;">In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$34.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;third-party mortgage financing and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash.&#160;&#160;The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8.23%</font><font style="font-family:inherit;font-size:10pt;">.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan&#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  The mortgage had a principal balance of </font><font style="font-family:inherit;font-size:10pt;">$20.2&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#160;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  This entire balance has been classified as current liabilities on the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;as management intends to repay the mortgage when the assets that serve as collateral for the mortgage loan are sold.  These assets have been reclassified to assets held for sale as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, as discussed in Note 6, Assets Held for Sale.  The buildings and land that serve as collateral for the mortgage loan are included in assets held for sale at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$59.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, before accumulated depreciation, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  The fair value of Lexicon&#8217;s mortgage loan approximates its carrying value.&#160;&#160;The fair value of Lexicon&#8217;s mortgage loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes the aggregate future principal payments of the Company&#8217;s long-term debt as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  As discussed above, all of the principal due in 2015, 2016 and 2017 relate to the mortgage loan and have been classified as current portion of long-term debt in the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="82%"></td><td width="1%"></td><td width="16%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,015</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sAB17BE067FEC96592727A09F38815BCD"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arrangements with Symphony Icon, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the &#8220;Programs&#8221;). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (&#8220;Holdings&#8221;), the Company&#8217;s intellectual property rights related to the Programs. Holdings contributed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to Symphony Icon in order to fund the clinical development of the Programs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">7,650,622</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock on June&#160;15, 2007 in exchange for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and an exclusive purchase option (the &#8220;Purchase Option&#8221;) that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.  On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;">&#32;on July&#160;30, 2010 and issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13,237,519</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to designees of Holdings on July&#160;30, 2012 in satisfaction of an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;base payment obligation.   </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon also agreed to make up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in additional contingent payments, which will consist of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of any consideration Lexicon receives pursuant to any licensing transaction (a &#8220;Licensing Transaction&#8221;) under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates (the &#8220;LG103 Programs&#8221;), subject to certain exceptions. The contingent payments will be due if and when Lexicon receives such consideration from a Licensing Transaction. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of such sum on account of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the payment made as a result of such United States regulatory approval.  The contingent payments may be paid in cash or a combination of cash and common stock, in Lexicon&#8217;s discretion, provided that no more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of any contingent payment will be paid in common stock.  On December 4, 2014, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and issued </font><font style="font-family:inherit;font-size:10pt;">4,662,780</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to designees of Holdings in satisfaction of a </font><font style="font-family:inherit;font-size:10pt;">$11.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;contingent payment obligation as a result of receiving a </font><font style="font-family:inherit;font-size:10pt;">$23 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment pursuant to the license and collaboration agreement with Ipsen Pharma SAS (see Note 16, Collaboration and License Agreements).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, and has also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration payments was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level&#160;3 inputs. Key assumptions include: (1)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the base payments; (2)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">18%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the contingent payments; and (3)&#160;a probability adjusted contingency.  The discount rate assumptions have not changed through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, and as programs progress, the probability adjusted contingency is adjusted as necessary.  Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, decreased by </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s354633B84E27F38A7020A09F3890B54D"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Lease Obligations</font><font style="font-family:inherit;font-size:10pt;">:&#160;&#160;A Lexicon subsidiary leases laboratory and office space in Hopewell, New Jersey under an amended lease agreement which previously had an expiration date in June 2018.  In March 2015, the subsidiary entered into a termination agreement whereby the lease will terminate in June 2015. &#160;The amended lease includes escalating lease payments.  Rent expense is recognized on a straight-line basis over the amended lease term.&#160;&#160;Lexicon is the guarantor of the obligation of its subsidiary under this lease.&#160;&#160;The Company is required to maintain restricted investments to collateralize a standby letter of credit for this lease.&#160;&#160;The Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in restricted investments as collateral as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;Additionally, Lexicon leases certain equipment under operating leases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for all operating leases was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The following table includes non-cancelable, escalating future lease payments for the facility in New Jersey, without regard to the termination agreement entered into in March 2015:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="82%"></td><td width="1%"></td><td width="16%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">572</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employment Arrangements:</font><font style="font-family:inherit;font-size:10pt;">&#32;Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. The arrangements also provide for a termination clause, which requires either a six or 12-month payment based on the officer&#8217;s salary and, in some cases, payment of a specified portion of the officer&#8217;s bonus target for such year, in the event of termination.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sB69452D345DE7D038033A09F38A0B74C"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Capital Stock Agreements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock:</font><font style="font-family:inherit;font-size:10pt;">&#32;In October 2012, Lexicon sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">17,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.25</font><font style="font-family:inherit;font-size:10pt;">&#32;per share in a public offering, resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$37.1 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.0&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;and offering expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.  Invus, L.P., Lexicon&#8217;s largest stockholder, purchased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of these shares.  All of the net proceeds of this offering are reflected as issuance of common stock in the accompanying financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, Lexicon sold </font><font style="font-family:inherit;font-size:10pt;">55,608,930</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$1.005</font><font style="font-family:inherit;font-size:10pt;">&#32;per share in a public offering, and sold </font><font style="font-family:inherit;font-size:10pt;">149,253,731</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$1.005</font><font style="font-family:inherit;font-size:10pt;">&#32;per share in a private placement to Artal International S.C.A, an affiliate of Invus, L.P., resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$201.9&#160;million</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions of </font><font style="font-family:inherit;font-size:10pt;">$3.4&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;and offering expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.6&#160;million</font><font style="font-family:inherit;font-size:10pt;">.  All of the net proceeds of these offerings are reflected as issuance of common stock in the accompanying financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sE814B246354F962D9F3EA09F38B06948"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Incentive Awards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Incentive Plans</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Incentive Plan:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and restated in February 2000 and renamed the 2000 Equity Incentive Plan, subsequently amended and restated in April 2009 and renamed the Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;), and subsequently amended in April 2012.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit (phantom stock) awards and stock appreciation rights. Incentive and nonstatutory stock options have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;or more of the fair market value of our common stock on the date of grant.&#160;&#160;The purchase price of restricted stock awards may not be less than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">85%</font><font style="font-family:inherit;font-size:10pt;">&#32;of fair market value.&#160;&#160;However, the plan administrator may award stock bonus awards in consideration of past services or phantom stock awards without a purchase payment. Shares may be subject to a repurchase option in the discretion of the plan administrator.&#160;&#160;Most options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Options granted under the Equity Incentive Plan have a term of ten years from the date of grant.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares.&#160;&#160;No more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares may be issued pursuant to awards other than stock options and stock appreciation rights.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock had been reserved for issuance, options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">22,533,242</font><font style="font-family:inherit;font-size:10pt;">&#32;shares and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,130,720</font><font style="font-family:inherit;font-size:10pt;">&#32;restricted stock units were outstanding, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,881,815</font><font style="font-family:inherit;font-size:10pt;">&#32;shares had been issued upon the exercise of stock options, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,224,339</font><font style="font-family:inherit;font-size:10pt;">&#32;shares had been issued pursuant to restricted stock units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">797,700</font><font style="font-family:inherit;font-size:10pt;">&#32;shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Employee Directors&#8217; Equity Incentive Plan:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and restated in April 2009 and renamed the Non-Employee Directors&#8217; Stock Option Plan, and subsequently amended in April 2012 and renamed the Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors receive an initial option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock.&#160;&#160;In addition, on the day following each of the Company&#8217;s annual meetings of stockholders, each non-employee director who has been a director for at least six months is automatically granted an option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and a restricted stock award of the number of shares of common stock having a fair market value on the date of grant of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;">, rounded down to the nearest whole share number.&#160;&#160;Initial option grants become vested and exercisable over a period of five years and annual option grants become vested over a period of 12&#160;months from the date of grant.&#160;&#160;Options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of ten years from the date of grant.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock had been reserved for issuance, options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,070,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were outstanding, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">none</font><font style="font-family:inherit;font-size:10pt;">&#32;had been issued upon the exercise of stock options and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">277,480</font><font style="font-family:inherit;font-size:10pt;">&#32;shares had been issued pursuant to restricted stock awards granted under the Directors&#8217; Plan.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Option Activity:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The following is a summary of option activity under Lexicon&#8217;s equity incentive plans:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td width="34%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except exercise price data)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,502</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,490</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,441</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,334</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.98</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,231</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(648</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(525</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at end of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,603</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,306</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,525</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at end of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,921</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,378</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,582</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average estimated grant date fair value of options granted during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.23</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.59</font><font style="font-family:inherit;font-size:10pt;">&#32;and&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.37</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The total intrinsic value of options exercised during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$43,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$325,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$462,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The weighted average remaining contractual term of options outstanding and exercisable was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5.8</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">4.7</font><font style="font-family:inherit;font-size:10pt;">&#32;years, respectively, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of the outstanding options and the exercisable options was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">zero</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Bonus and Restricted Stock Unit Activity:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended December 31, 2014, 2013 and 2012, Lexicon granted its non-employee directors </font><font style="font-family:inherit;font-size:10pt;">102,560</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">80,808</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">94,112</font><font style="font-family:inherit;font-size:10pt;">&#32;shares, respectively, of restricted stock awards.  The restricted stock awards had weighed average grant date fair values of </font><font style="font-family:inherit;font-size:10pt;">$1.56</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.98</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.70</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, respectively, and vested immediately.  During the year ended December&#160;31, 2014, Lexicon granted a consultant </font><font style="font-family:inherit;font-size:10pt;">57,400</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of restricted stock awards.  The restricted stock awards had a weighted average grant date fair value of </font><font style="font-family:inherit;font-size:10pt;">$1.60</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and vested immediately.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="66%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,131</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aggregate Shares Reserved for Issuance</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">26,733,962</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14,584,704</font><font style="font-family:inherit;font-size:10pt;">&#32;additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s9BBC44517E8FDAF3EF3BA09F390D47E2"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Benefit Plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$511,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$490,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after four years of service.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s0FCE0CC90FB01E7B593EA09F390DFBFC"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and License Agreements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ipsen Pharma SAS.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;In October 2014, Lexicon entered into a License and Collaboration Agreement (the &#8220;Agreement&#8221;)with Ipsen Pharma SAS (&#8220;Ipsen&#8221;)&#160;for the development and commercialization of Lexicon&#8217;s drug candidate telotristat etiprate (LX1032) outside of the United States, Canada and Japan (the &#8220;Licensed Territory&#8221;).  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize telotristat etiprate in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize telotristat etiprate in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon will be responsible for conducting clinical trials required to obtain regulatory approval for telotristat etiprate for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and will have the first right to conduct most other clinical trials of telotristat etiprate.  Lexicon is responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Agreement, Ipsen paid Lexicon an upfront payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$23 million</font><font style="font-family:inherit;font-size:10pt;">.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$30&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8364;72&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of specified sales milestones.  Due to the uncertainty surrounding the achievement of the future regulatory and sales milestones, these payments will not be recognized as revenue unless and until they are earned as the Company is not able to reasonably predict if and when the milestones will be achieved.  Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of telotristat etiprate in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of telotristat etiprate.  Lexicon&#8217;s receipt of these payments under the Agreement triggers its obligation to make certain contingent payments to Holdings (see Note 11, Arrangements with Symphony Icon, Inc.).  Lexicon and Ipsen will enter into a commercial supply agreement pursuant to which Lexicon will supply Ipsen&#8217;s commercial requirements of telotristat etiprate, and Ipsen will pay an agreed upon transfer price for such commercial supply.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considered the following deliverables with respect to the revenue recognition of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$23 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The exclusive license granted to Ipsen to develop and commercialize telotristat etiprate in the Licensed </font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Territory;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The development services Lexicon is performing for telotristat etiprate;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The obligation to participate in committees which govern the development of telotristat</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">etiprate until commercialization; and</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The obligation to supply commercial supply of telotristat etiprate, under a commercial supply agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the license had stand-alone value because it is an exclusive license that gives Ipsen the right to develop and commercialize telotristat etiprate or to sublicense its rights.  In addition, telotristat etiprate is currently in development and it is possible that Ipsen or another third party could conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Agreement to be separate units of accounting.  The Company recognized the portion of the consideration allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performs services, currently expected to be through mid-2017.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the inherent uncertainty in obtaining regulatory approval, the applicability of the commercial supply agreement is outside the control of Lexicon and Ipsen.  Accordingly, the Company has determined the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  As a result, the Company has determined the commercial supply </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">agreement does not meet the definition of a deliverable that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the initial allocable arrangement consideration was the </font><font style="font-family:inherit;font-size:10pt;">$23 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment because it was the only payment that was fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the allocable consideration based on the relative best estimate of selling price of each unit of accounting.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">As a result of the allocation, the Company recognized </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$21.2 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">of the</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$23 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment for the license in 2014.  The Company is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;allocated to the development services deliverable over the estimated period of performance as development occurs, and is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;allocated to the committee participation deliverable ratably over the estimated period of performance.  Revenue recognized under the Agreement was </font><font style="font-family:inherit;font-size:10pt;">$21.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Texas Institute for Genomic Medicine</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;&#160;In July 2005, Lexicon received a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine (&#8220;TIGM&#8221;) using Lexicon&#8217;s proprietary gene trapping technology, which Lexicon completed in 2007.&#160;&#160;Lexicon also equipped TIGM with the bioinformatics software required for the management and analysis of data relating to the library.&#160;&#160;The Texas Enterprise Fund also awarded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the award, Lexicon is responsible for the creation of a specified number of jobs beginning in 2012, reaching an aggregate of 1,616 new jobs in Texas by December 31, 2016.&#160;&#160;Lexicon will obtain credits based on funding received by TIGM and certain related parties from sources other than the State of Texas that it may offset against its potential liability for any job creation shortfalls.&#160;&#160;Lexicon will also obtain credits against future jobs commitment liabilities for any surplus jobs it creates.&#160;&#160;Subject to these credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,415</font><font style="font-family:inherit;font-size:10pt;">&#32;for each job Lexicon falls short beginning in 2013.&#160;&#160;Lexicon&#8217;s maximum aggregate exposure for such payments, if Lexicon fails to create any new jobs, is approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$14.2 million</font><font style="font-family:inherit;font-size:10pt;">, including </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through 2015, without giving effect to any credits to which Lexicon may be entitled.&#160;&#160;Lexicon has recorded this obligation as deferred revenue and accounts payable in the accompanying consolidated balance sheets.&#160;&#160;The Texas A&amp;M University System, together with TIGM, has independent job creation obligations and is obligated for an additional period to maintain an aggregate of 5,000 jobs, inclusive of those Lexicon creates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="sCE488907AA0C0165B2D4A09F392C2824"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17. Restructuring Charges</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, Lexicon&#8217;s board of directors committed to narrow its strategic initiatives and focus resources on its late-stage drug development programs, principally sotagliflozin (LX4211) for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, in preparation for the transition to commercialization.  The decision resulted in a workforce reduction of approximately 125 employees, primarily in research, discovery and support positions, representing approximately 50% of the Company&#8217;s total workforce.  The Company completed the majority of the workforce reduction by the end of the second quarter of 2014.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently expects that the total charges associated with the restructuring which will result in cash expenditures will be approximately </font><font style="font-family:inherit;font-size:10pt;">$5.7&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;(which includes charges for severance of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;and other restructuring costs of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4&#160;million</font><font style="font-family:inherit;font-size:10pt;">), of which </font><font style="font-family:inherit;font-size:10pt;">$5.6&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;was incurred through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  Of this charge, </font><font style="font-family:inherit;font-size:10pt;">$4.9&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;was recorded in research and development expense and </font><font style="font-family:inherit;font-size:10pt;">$0.7&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;was recorded in general and administrative expense in the accompanying consolidated statement of comprehensive loss for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sB4B6117E898BC6A78480A09F3FC1B501"><font style="font-family:inherit;font-size:9pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">.  In addition, the Company recorded stock-based compensation expense on the acceleration of vesting relating to the restructuring of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  Future payments of restructuring charges, which have been recorded in accrued liabilities in the accompanying consolidated balance sheet, were </font><font style="font-family:inherit;font-size:10pt;">$0.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sB4EA671B3F76D272463CA09F391DE0DA"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Quarterly Financial Data</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2014</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,472</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,336</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,447</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">593,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,216</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,976</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">512,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exh231ernst_youngconsent10.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exh 23.1 Ernst_Young Consent 10K 2014</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s6894D8819684CC7BF67CA09F5D302497"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Form S-8 Nos. 333-41532, 333-168678 and 333-183020) pertaining to the Equity Incentive Plan and to the Non-Employee Directors' Equity Incentive Plan of Lexicon Pharmaceuticals, Inc., and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Form S-3 Nos. 333-182859, 333-198493 and 333-200699) of Lexicon Pharmaceuticals, Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of our reports dated </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;12, 2015</font><font style="font-family:inherit;font-size:10pt;">, with respect to the consolidated financial statements of Lexicon Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Lexicon Pharmaceuticals, Inc., included in this annual report (Form 10-K) of Lexicon Pharmaceuticals, Inc. for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Houston, Texas</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;12, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exh311certificationofprinc.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exh 31.1 Certification of Principal Executive Officer 10K 2014</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sB0E8206256A48F838C1DA09F5F04F227"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">I, Lonnel Coats, certify that:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="4%"></td><td width="5%"></td><td width="6%"></td><td width="85%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;12, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="54%"></td><td width="46%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lonnel Coats</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lonnel Coats</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President and Chief Executive Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exh312certificationofprinc.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exh 31.2 Certification of Principal Financial Officer 10K 2014</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s3A5B331C2AE5B1685462A09F60B91636"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Jeffrey L. Wade, certify that:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="4%"></td><td width="5%"></td><td width="6%"></td><td width="85%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Lexicon Pharmaceuticals, Inc.;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">March&#160;12, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="54%"></td><td width="46%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jeffrey L. Wade</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Wade</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Office</font><font style="font-family:inherit;font-size:10pt;">r</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exh321certificationofprinc.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE AND PRINCIPAL FINANCIAL OFFICERS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exh 32.1 Certification of Principal Executive and Principal Financial Officers 10K 2014</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sA445E1CCCEED74B0053CA09F63861F91"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.1875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="7%"></td><td width="8%"></td><td width="85%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon's Annual Report on Form 10-K for the year ended December 31, 2014, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the </font><font style="font-family:inherit;font-size:10pt;">12th day of March, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="55%"></td><td width="4%"></td><td width="41%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lonnel Coats</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lonnel Coats</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="55%"></td><td width="4%"></td><td width="41%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jeffrey L. Wade</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Wade</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>lxrx-20141231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!--p:b541cbae997941c180b88d7bbde712a1,x:2c27ee4247984d0cb86471a64a6ad5c9-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20141231" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="lxrx-20141231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_invest_InvestmentAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_invest_InvestmentAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2001Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2001-07-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2004Q2SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2004-04-01</xbrli:startDate>
			<xbrli:endDate>2004-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-01</xbrli:startDate>
			<xbrli:endDate>2014-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2007Q2SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2007-06-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Dec4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-04</xbrli:startDate>
			<xbrli:endDate>2014-12-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Oct1toOct31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q4SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-10-01</xbrli:startDate>
			<xbrli:endDate>2012-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2005Q3SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2005-07-01</xbrli:startDate>
			<xbrli:endDate>2005-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-07-01</xbrli:startDate>
			<xbrli:endDate>2013-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-04-01</xbrli:startDate>
			<xbrli:endDate>2013-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="ratio">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="eur">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2014Q4YTD" id="Fact-44A114082BDBC01DCE6AD182716E806A">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2014Q4YTD" id="Fact-A36A5B3EC40526C6B7DCD182717E00D7">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2014Q4YTD" id="Fact-33624DA28C6AA6FCA0E9D182717EB049">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2014Q4YTD" id="Fact-CA2F28040C70D23ABEECE17165F2D880">2014</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2014Q4YTD" id="Fact-F95DF7B96EC499872073E575300BF3DD">2014-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2014Q4YTD" id="Fact-7AFD64EE0F5217184BC1D182717EF069">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2014Q4YTD" id="Fact-23BA05391D136D645367D182717E52AC">0001062822</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2015Q1SharesOutstanding" decimals="0" id="Fact-EEC603D6D8712C9847B3D182717ECA67" unitRef="shares">725145313</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2014Q4YTD" id="Fact-439B5C91357E54F108CFD182716E8DD6">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2014Q4YTD" id="Fact-8A2E9E5084955338E37AD182716E8BE4">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2014Q2" decimals="0" id="Fact-7868FB454AAD92D21041D182717EB93B" unitRef="usd">368000000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2014Q4YTD" id="Fact-AA34BE3A33BDC449701AD182717E81BD">LEXICON PHARMACEUTICALS, INC./DE</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2014Q4YTD" id="Fact-F51D5689946FC8408BEFD182717EC479">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2014Q4YTD" id="Fact-203195D3A998E0940041D182717E036E">No</dei:EntityWellKnownSeasonedIssuer>
	<lxrx:AccumulatedDepreciationReclassifiedToHeldForSale contextRef="FI2014Q4" decimals="-5" id="Fact-A069DBB4B8CF652EC8A1D35E31C669F7" unitRef="usd">38000000</lxrx:AccumulatedDepreciationReclassifiedToHeldForSale>
	<lxrx:BuildingsCollateral contextRef="FI2014Q4" decimals="-5" id="Fact-1E1556501CD0C2124B92D182717E8B20" unitRef="usd">59100000</lxrx:BuildingsCollateral>
	<lxrx:BuildingsReclassifiedToHeldForSale contextRef="FI2014Q4" decimals="-5" id="Fact-8A68F24B2A0909B8D29BDC321D8D23E9" unitRef="usd">59100000</lxrx:BuildingsReclassifiedToHeldForSale>
	<lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability contextRef="FD2012Q4YTD" decimals="-3" id="Fact-5425212DD6D1FA444D77D182717E0475" unitRef="usd">9887000</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
	<lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability contextRef="FD2013Q4YTD" decimals="-3" id="Fact-CD0D6B344C66150161DED182715F65E3" unitRef="usd">-2210000</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
	<lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability contextRef="FD2014Q4YTD" decimals="-3" id="Fact-4A32AC59432E425B383BD182717E25A9" unitRef="usd">1428000</lxrx:ChangeInFairValueOfSymphonyIconIncPurchaseLiability>
	<lxrx:CoelacanthGoodwill contextRef="I2001Q3SD" decimals="-5" id="Fact-39B6E40BADFC6AAFC4B0D182715FAC94" unitRef="usd">25800000</lxrx:CoelacanthGoodwill>
	<lxrx:CoelacanthPurchasePrice contextRef="I2001Q3SD" decimals="-5" id="Fact-B9C92C3C7F1A367798F6D182716EB28E" unitRef="usd">36000000</lxrx:CoelacanthPurchasePrice>
	<lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage contextRef="FI2014Q4" decimals="4" id="Fact-7816400B16929900AEA4DB4D97430B64" unitRef="ratio">0.0525</lxrx:ConvertibleDebtInstrumentInterestRateStatedPercentage>
	<lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon contextRef="FI2013Q4" decimals="-3" id="Fact-31F59FB3491CCE717AB5D182716E300C" unitRef="usd">-18745000</lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon>
	<lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon contextRef="FI2014Q4" decimals="-3" id="Fact-74D5A7AA1A8F8831B401D182716EE5C6" unitRef="usd">-18675000</lxrx:DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon>
	<lxrx:DirectorsAnnualOptionGrant contextRef="FI2014Q4" decimals="0" id="Fact-3C182E9F1CF541571718D182715F5C0C" unitRef="shares">20000</lxrx:DirectorsAnnualOptionGrant>
	<lxrx:DirectorsAnnualRestrictedStockAwardValue contextRef="FI2014Q4" decimals="0" id="Fact-0B65B799756DE3CF3ACBD182717EC32E" unitRef="usd">20000</lxrx:DirectorsAnnualRestrictedStockAwardValue>
	<lxrx:DirectorsIntialOptionGrant contextRef="FI2014Q4" decimals="0" id="Fact-35A2A831E683B7291EF3D182716E1D2F" unitRef="shares">30000</lxrx:DirectorsIntialOptionGrant>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent contextRef="FD2012Q4YTD" decimals="2" id="Fact-5478171FD8CC4490E12BD182716E3B13" unitRef="ratio">1.00</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent contextRef="FD2013Q4YTD" decimals="2" id="Fact-F2F63B8311F96F527814D182716E3130" unitRef="ratio">1.00</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent contextRef="FD2014Q4YTD" decimals="2" id="Fact-E0167780C1ED6577DD10D182716E5232" unitRef="ratio">0.06</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent>
	<lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance contextRef="FD2014Q4YTD" decimals="2" id="Fact-A626A5DBE4DDE8B9C858D212A5C94897" unitRef="ratio">0.94</lxrx:DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance>
	<lxrx:EntityWideRevenueDeltagenPercentage contextRef="FD2012Q4YTD" decimals="2" id="Fact-639709166AB31062C570D182716E3BAF" unitRef="ratio">0.25</lxrx:EntityWideRevenueDeltagenPercentage>
	<lxrx:EntityWideRevenueIpsenPercentage contextRef="FD2014Q4YTD" decimals="2" id="Fact-6A56D27CBF8D7EA5CD00D217CA219503" unitRef="ratio">0.94</lxrx:EntityWideRevenueIpsenPercentage>
	<lxrx:EntityWideRevenueMcNairMedicalInstitutePercentage contextRef="FD2013Q4YTD" decimals="2" id="Fact-AFC3479DAAF9F5E50505D182716EE51B" unitRef="ratio">0.57</lxrx:EntityWideRevenueMcNairMedicalInstitutePercentage>
	<lxrx:EntityWideRevenueTaconicFarmsPercentage contextRef="FD2012Q4YTD" decimals="2" id="Fact-A769A58BF06AC524CAC1D182716E87CF" unitRef="ratio">0.68</lxrx:EntityWideRevenueTaconicFarmsPercentage>
	<lxrx:EntityWideRevenueTaconicFarmsPercentage contextRef="FD2013Q4YTD" decimals="2" id="Fact-709ACA2DBDEB2ED8997FD182716EC3B1" unitRef="ratio">0.33</lxrx:EntityWideRevenueTaconicFarmsPercentage>
	<lxrx:HoldingsContributionToIcon contextRef="I2007Q2SD" decimals="-6" id="Fact-1AC407E9223B89170B1BD182717E272F" unitRef="usd">45000000</lxrx:HoldingsContributionToIcon>
	<lxrx:IpsenMaximumRegulatoryAndCommercialMilestones contextRef="D2014Q4Oct1toOct31" decimals="-6" id="Fact-F2482839C6221D510A03DC362DC2D5FB" unitRef="usd">30000000</lxrx:IpsenMaximumRegulatoryAndCommercialMilestones>
	<lxrx:IpsenMaximumSalesMilestones contextRef="D2014Q4Oct1toOct31" decimals="-6" id="Fact-77A28A2D1FA60B281E4DDC378B7A1B2C" unitRef="eur">72000000</lxrx:IpsenMaximumSalesMilestones>
	<lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable contextRef="D2014Q4Oct1toOct31" decimals="-5" id="Fact-C61AAB72FC6AA08F15DBDC3D3375ECED" unitRef="usd">100000</lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable>
	<lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable contextRef="D2014Q4Oct1toOct31" decimals="-5" id="Fact-4313B9E5E19EC603E07DDC3BD4283938" unitRef="usd">1600000</lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable>
	<lxrx:IpsenRevenueAllocatedtoLicenseDeliverable contextRef="D2014Q4Oct1toOct31" decimals="-5" id="Fact-7507253DAE9C4263243CDC393045340A" unitRef="usd">21200000</lxrx:IpsenRevenueAllocatedtoLicenseDeliverable>
	<lxrx:IpsenRevenueRecognized contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0DE20008137281DB6EDADC39B0674B64" unitRef="usd">21400000</lxrx:IpsenRevenueRecognized>
	<lxrx:IpsenUpfrontPayment contextRef="D2014Q4Oct1toOct31" decimals="-6" id="Fact-9B82CCE0784EED04593ADB68EBE310C1" unitRef="usd">23000000</lxrx:IpsenUpfrontPayment>
	<lxrx:LandCollateral contextRef="FI2014Q4" decimals="-5" id="Fact-04656C8EEB09679EA342D182717E357C" unitRef="usd">2700000</lxrx:LandCollateral>
	<lxrx:LandReclassifiedToHeldForSale contextRef="FI2014Q4" decimals="-5" id="Fact-0EFA647B21E7CE9B4571DC329A4B2641" unitRef="usd">2700000</lxrx:LandReclassifiedToHeldForSale>
	<lxrx:LexiconPaidHoldingsCash contextRef="I2010Q3SD" decimals="-5" id="Fact-AD61272BC383E138185ED182716E0D7F" unitRef="usd">10000000</lxrx:LexiconPaidHoldingsCash>
	<lxrx:LexiconReceivedCashFromHoldings contextRef="I2007Q2SD" decimals="-6" id="Fact-BFDCBD01CBEE7D586CDED182717E4945" unitRef="usd">15000000</lxrx:LexiconReceivedCashFromHoldings>
	<lxrx:LexiconSoldSharesToHoldings contextRef="I2007Q2SD" decimals="0" id="Fact-84A125AA5E14462EF638D182717E842A" unitRef="shares">7650622</lxrx:LexiconSoldSharesToHoldings>
	<lxrx:LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-089D1AD4B8332D0C5158D182717ECCB0" unitRef="shares">15000000</lxrx:LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan>
	<lxrx:NetProceedsFromStockOffering contextRef="D2012Q4SD" decimals="-5" id="Fact-BEAAC6D38D4EF04AF1D4D182717E9D79" unitRef="usd">37100000</lxrx:NetProceedsFromStockOffering>
	<lxrx:NetProceedsFromStockOffering contextRef="D2014Q4SD" decimals="-5" id="Fact-0722898C27CA568BC483D377A9D73C64" unitRef="usd">201900000</lxrx:NetProceedsFromStockOffering>
	<lxrx:OfferingPricePerShare contextRef="D2012Q4SD" decimals="2" id="Fact-22765D2EF1D51B586B3CD182717EFFF9" unitRef="usdPerShare">2.25</lxrx:OfferingPricePerShare>
	<lxrx:OfferingPricePerShare contextRef="D2014Q4SD" decimals="3" id="Fact-52288840397487A2BA0DD3769D7F0343" unitRef="usdPerShare">1.005</lxrx:OfferingPricePerShare>
	<lxrx:OptionsOutstandingEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-EDBF904F44552AE1E54AD182717E68A5" unitRef="shares">22533242</lxrx:OptionsOutstandingEquityIncentivePlan>
	<lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-922E8CFFB536016EB019D182717E72CB" unitRef="shares">1070000</lxrx:OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan>
	<lxrx:PaymentsOfUnderwritingDiscountsAndCommissions contextRef="D2012Q4SD" decimals="-5" id="Fact-B451AD1FC952FA8AB0E7D182717E2313" unitRef="usd">2000000</lxrx:PaymentsOfUnderwritingDiscountsAndCommissions>
	<lxrx:PaymentsOfUnderwritingDiscountsAndCommissions contextRef="D2014Q4SD" decimals="-5" id="Fact-E6BF57A3B0E565C76068D37816985661" unitRef="usd">3400000</lxrx:PaymentsOfUnderwritingDiscountsAndCommissions>
	<lxrx:RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock contextRef="FD2014Q4YTD" decimals="2" id="Fact-DC5AC1909BCDA0E5342AD182715FAE70" unitRef="ratio">0.85</lxrx:RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock>
	<lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-1A740C2B81F12C8BDC5DD182716E177C" unitRef="shares">3130720</lxrx:RestrictedStockUnitsOutstandingEquityIncentivePlan>
	<lxrx:RestructuringCostSeveranceCosts contextRef="FD2014Q4YTD" decimals="-5" id="Fact-61CCE48EDDF736832959D72A307F2B76" unitRef="usd">5300000</lxrx:RestructuringCostSeveranceCosts>
	<lxrx:RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B7DB0937D29769E8CBABD72C85BE459D" unitRef="usd">700000</lxrx:RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative>
	<lxrx:RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment contextRef="FD2014Q4YTD" decimals="-5" id="Fact-D8736F9D6E693F629F2AD72C1A022D94" unitRef="usd">4900000</lxrx:RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment>
	<lxrx:RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-47E404D3CBD39215A189D72D4011C224" unitRef="usd">100000</lxrx:RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation>
	<lxrx:RevisiontoDeferredTaxAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9805B8A0495168EC33C0D182717E5B9C" unitRef="usd">13800000</lxrx:RevisiontoDeferredTaxAssets>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-2A2FCD6C791A6063A49AD182717EEF68" unitRef="usdPerShare">1.92</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-B319A84D9CAB35A89ECAD182716E03E0" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-2850F403AC9FFA4235FDD182717ED19D" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-D8DBC3A6AAE21B9AD361D182716EF44F" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-282D5E9471D917EC6F35D182715FF2A4" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-0F7424A8314743356EAAD182716EA772" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-32B0246FBE252A44F583D182715F305A" unitRef="ratio">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-763C08B4EBC68FA0292FD182715FD92D">P5Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-70C7B13E8B5FC8D3F4CCD182715F6912">P5Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-13EED45EAD625E88783FD182716EC905">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-02604587ED15912824C1D182717E5007">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-07861B263B0D8A245C3AD182717E44EF">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-22674150C7A4518C6D79D182716EDCAB">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-A83AF3EC9895E9184328D182715FA32D" unitRef="ratio">0.81</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-1AE249BD21648C507527D182716EC6C9" unitRef="ratio">0.81</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-65871CA9C26D73A254CFD182717E19E5" unitRef="ratio">0.80</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-017A780A5820920490D7D182715F173C" unitRef="ratio">0.93</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-25B155597DA879AC1BF3D182715FC23B" unitRef="ratio">0.85</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="2" id="Fact-AEC1CDDB5CA944FDEF87D182717E12DA" unitRef="ratio">0.66</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-E5FB9F94F14F63CAC464D182715F1503" unitRef="ratio">0.008</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-A2839569498DEE097763D182717E167B" unitRef="ratio">0.009</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-42198F61BFD62B80187DD182717EAB2E" unitRef="ratio">0.012</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-65ADFF16040604762349D182715F2A23" unitRef="ratio">0.015</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-6624DEA03BCB3F5D9A6AD182715F76C7" unitRef="ratio">0.016</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" decimals="3" id="Fact-A24DE9019B7F17714711D182716E3EA9" unitRef="ratio">0.023</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod contextRef="FD2012Q4YTD" decimals="0" id="Fact-6D6C531AC99681290C50D182716ECA7D" unitRef="shares">94112</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod contextRef="FD2013Q4YTD" decimals="0" id="Fact-5F6D6CD2EF4F901934A1D182717EF202" unitRef="shares">80808</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod contextRef="FD2014Q4YTD" decimals="0" id="Fact-6AD9F876EA564FCADAE2D717CD31C96C" unitRef="shares">102560</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2012Q4YTD" decimals="2" id="Fact-1660613C08BC9A75AB2FD182717E59B9" unitRef="usdPerShare">1.70</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2013Q4YTD" decimals="2" id="Fact-572CE523FF5EC79652F9D182715FBA9A" unitRef="usdPerShare">1.98</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue>
	<lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD" decimals="2" id="Fact-48CFC2856472AC38E5F2D71842FECFC4" unitRef="usdPerShare">1.56</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue>
	<lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod contextRef="FD2014Q4YTD" decimals="0" id="Fact-BB613708D58305A3CE56D71AB3C4B7E6" unitRef="shares">57400</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod>
	<lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD" decimals="2" id="Fact-FF3CA8CE4D2E28BCE3F0D71B31ADC37D" unitRef="usdPerShare">1.60</lxrx:SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue>
	<lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-99C8323CB804297BE5D2D182715F6450" unitRef="shares">277480</lxrx:SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan>
	<lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-3214B3846695EFECBCB8D182715F70F1" unitRef="shares">3224339</lxrx:SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan>
	<lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-ACB1EC6D78DB9678F02ED182717E88FA" unitRef="shares">797700</lxrx:SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2012Q4YTD" decimals="-3" id="Fact-46F694967F5A98304C1ED1E6B9489483" unitRef="usd">35000000</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-9F050BAF9FF210DFD93FD1E6B5E4978E" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CC9E62F3FBD1EA41437AD1E6B2ACCAC4" unitRef="usd">34987000</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5B8815027A9E2730941BD1E6B08FE0D1" unitRef="usd">13000</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-800ADF6AA5D8FC42AB7FD1E6B4526106" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-C88930A932FD18D325E0D1E6B78AA079" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-4693B595B826447E4DDAD182717E6C67" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-CBFB1CF9C72C12D8D698D1E7647560F9" unitRef="usd">5750000</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-41EA69F775ADCDF9605FD1E7603B9B10" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-ED3771EABE847405F26BD1E75A0A5250" unitRef="usd">5745000</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2EF7CBD260D5FF4CEB5CD1E757F6B6C9" unitRef="usd">5000</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-55EB153BA3ABE6D0AE81D1E75DBBD715" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedToSymphonyDesigneesValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-F235D3203CB0D6E53158D1E76262A9F4" unitRef="usd">0</lxrx:SharesIssuedToSymphonyDesigneesValue>
	<lxrx:SharesIssuedtoSymphonyDesigneesShares contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-91A79F7AD9B5BF1BDD0CD1E6AED8DFDC" unitRef="shares">13238000</lxrx:SharesIssuedtoSymphonyDesigneesShares>
	<lxrx:SharesIssuedtoSymphonyDesigneesShares contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A68515C01E6FBCD6EEF4D1E756212E9F" unitRef="shares">4663000</lxrx:SharesIssuedtoSymphonyDesigneesShares>
	<lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense contextRef="FD2012Q4YTD" decimals="-3" id="Fact-7B695687C71A3CAAF4E2D182716E05F9" unitRef="usd">2822000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-3D56C599716BCBB5E961D182717ED267" unitRef="usd">3045000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DD55A589887DF0E9F2B0D182716E4E33" unitRef="usd">3061000</lxrx:StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense contextRef="FD2012Q4YTD" decimals="-3" id="Fact-FACB08B405D4C5B8396AD182717E4CB8" unitRef="usd">3673000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-3A7279598FC50E2E6E50D182716E28DB" unitRef="usd">4376000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
	<lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-645E0F66AC61ADE4DD8FD182717EBADB" unitRef="usd">4020000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
	<lxrx:StockIssuedDuringPeriodToInvusShares contextRef="D2012Q4SD" decimals="0" id="Fact-CCF47CE8E81336884C16D182717E24F5" unitRef="shares">3000000</lxrx:StockIssuedDuringPeriodToInvusShares>
	<lxrx:StockIssuedDuringPeriodToInvusShares contextRef="D2014Q4SD" decimals="0" id="Fact-4BE66426720EA3F97535D3772EC90397" unitRef="shares">149253731</lxrx:StockIssuedDuringPeriodToInvusShares>
	<lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock contextRef="FD2014Q4YTD" decimals="2" id="Fact-CB30F4DF3211022CE76AD182717EC2E4" unitRef="ratio">1.00</lxrx:StockOptionExercisePriceAsPercentOfValueOfCommonStock>
	<lxrx:StockOptionsExercisedEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-037CB743636686066E7AD182717E38C4" unitRef="shares">5881815</lxrx:StockOptionsExercisedEquityIncentivePlan>
	<lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan contextRef="FI2014Q4" decimals="-3" id="Fact-1985193622590F05A2B9D182716E0DA8" unitRef="shares">0</lxrx:StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan>
	<lxrx:SymphonFairValueOfBaseAndContingentPayments contextRef="I2010Q3SD" decimals="-5" id="Fact-6C3403343DA8468FEE9FD182717ED56C" unitRef="usd">45600000</lxrx:SymphonFairValueOfBaseAndContingentPayments>
	<lxrx:SymphonyBasePaymentDiscountRate contextRef="I2010Q3SD" decimals="2" id="Fact-3B4A01198DFDAE029C85D182717E7E4A" unitRef="ratio">0.14</lxrx:SymphonyBasePaymentDiscountRate>
	<lxrx:SymphonyBasePaymentInShares contextRef="I2012Q3SD" decimals="0" id="Fact-9C9FC77F68CD9E2BCDE2D182717E77E1" unitRef="shares">13237519</lxrx:SymphonyBasePaymentInShares>
	<lxrx:SymphonyBasePaymentObligation contextRef="I2012Q3SD" decimals="-5" id="Fact-07B6CFFE157138A3DA8AD182716EBFF6" unitRef="usd">35000000</lxrx:SymphonyBasePaymentObligation>
	<lxrx:SymphonyContingentPaymentDiscountRate contextRef="I2010Q3SD" decimals="2" id="Fact-7971B691B5833639A8A4D182717ED656" unitRef="ratio">0.18</lxrx:SymphonyContingentPaymentDiscountRate>
	<lxrx:SymphonyContingentPaymentInCash contextRef="D2014Q4Dec4" decimals="-5" id="Fact-DD6750521EF525FBC4D1DC449EA831B9" unitRef="usd">5800000</lxrx:SymphonyContingentPaymentInCash>
	<lxrx:SymphonyContingentPaymentMaximum contextRef="I2010Q3SD" decimals="-6" id="Fact-26FB8C54252A346553B9D182717EAF09" unitRef="usd">45000000</lxrx:SymphonyContingentPaymentMaximum>
	<lxrx:SymphonyContingentPaymentPercentage contextRef="I2010Q3SD" decimals="2" id="Fact-0819B9D754779C566CB8D182716EB97A" unitRef="ratio">0.50</lxrx:SymphonyContingentPaymentPercentage>
	<lxrx:SymphonyContingentPaymentTotal contextRef="D2014Q4Dec4" decimals="-5" id="Fact-7ADE3F674D260F96C8FEDC48EB30D22F" unitRef="usd">11500000</lxrx:SymphonyContingentPaymentTotal>
	<lxrx:SymphonyContingentPaymentinShares contextRef="D2014Q4Dec4" decimals="0" id="Fact-179FE54D046E8AD2EBB8DC464488BFA8" unitRef="shares">4662780</lxrx:SymphonyContingentPaymentinShares>
	<lxrx:SymphonyIconGoodwill contextRef="I2010Q3SD" decimals="-5" id="Fact-AA6EB1E049FBBF800CEFD182715F2845" unitRef="usd">18700000</lxrx:SymphonyIconGoodwill>
	<lxrx:SymphonyPaymentInStockLimitation contextRef="I2010Q3SD" decimals="2" id="Fact-2B20F22AAC4A187DFDBAD182716E931B" unitRef="ratio">0.50</lxrx:SymphonyPaymentInStockLimitation>
	<lxrx:SymphonyRegulatoryApprovalPayment contextRef="I2010Q3SD" decimals="-6" id="Fact-BF63099BE5B9262C8107D182717E4714" unitRef="usd">15000000</lxrx:SymphonyRegulatoryApprovalPayment>
	<lxrx:SymphonyRegulatoryApprovalPercentageLimit contextRef="I2010Q3SD" decimals="2" id="Fact-7A18FA27FBF9FF835F82D182716E2A83" unitRef="ratio">0.50</lxrx:SymphonyRegulatoryApprovalPercentageLimit>
	<lxrx:SymphonyRegulatoryApprovalReductionPercentage contextRef="I2010Q3SD" decimals="2" id="Fact-8AD5EC7C6CE87C176438D182716E8E92" unitRef="ratio">0.50</lxrx:SymphonyRegulatoryApprovalReductionPercentage>
	<lxrx:TIGMMaximumExposureThroughReportingDate contextRef="FI2014Q4" decimals="-5" id="Fact-0E2FBCD48D417254F67CD182717EE700" unitRef="usd">2500000</lxrx:TIGMMaximumExposureThroughReportingDate>
	<lxrx:TigmMaximumExposure contextRef="FI2014Q4" decimals="-5" id="Fact-2B2D318BEA25CF866526D182717E034B" unitRef="usd">14200000</lxrx:TigmMaximumExposure>
	<lxrx:TigmPerJobPaymentAmount contextRef="FI2014Q4" decimals="0" id="Fact-F37FAE62EC62D8A9FE09D182717EB3B5" unitRef="usd">2415</lxrx:TigmPerJobPaymentAmount>
	<lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-55677B476DCD8A8AAA06D182715FC3DE" unitRef="shares">50000000</lxrx:TotalSharesThatMayBeIssuedEquityIncentivePlan>
	<lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan contextRef="FI2014Q4" decimals="0" id="Fact-207DFABB698E289EB19FD182715FD711" unitRef="shares">1500000</lxrx:TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan>
	<lxrx:TxEnterpriseFundAward contextRef="D2005Q3SD" decimals="-5" id="Fact-CEC51FCE6E364BD96817D182717E58C5" unitRef="usd">35000000</lxrx:TxEnterpriseFundAward>
	<lxrx:TxEnterpriseFundAwardToTexasAmUniversitySystem contextRef="D2005Q3SD" decimals="-5" id="Fact-6F9174D49AF70D8BE2CCD182717E3AA7" unitRef="usd">15000000</lxrx:TxEnterpriseFundAwardToTexasAmUniversitySystem>
	<lxrx:WoodlandsCashPaid contextRef="D2004Q2SD" decimals="-5" id="Fact-07F033D456839AB02296D182716EE40F" unitRef="usd">20800000</lxrx:WoodlandsCashPaid>
	<lxrx:WoodlandsMortgage contextRef="D2004Q2SD" decimals="-5" id="Fact-6D873FDB0BBB98F5D07FD182716EBF6B" unitRef="usd">34000000</lxrx:WoodlandsMortgage>
	<us-gaap:AccountsPayableCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-0A4D3C8E374A094D4F58D182717ED5FD" unitRef="usd">9715000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-E30477C76F7C2D93A66CD182715F6D86" unitRef="usd">13064000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-3EA865CC4B5943A5AAEDD182715F027A" unitRef="usd">790000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-A74386040B0F0A16E1AAD182715FF3E4" unitRef="usd">1035000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-DF7B31E389399AC6AEC8D182717E6EDA" unitRef="usd">7674000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-055914A07E371650DB5AD182715F137A" unitRef="usd">10120000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2013Q4" decimals="-3" id="Fact-AFAC58EB2F5E1C1B85E2D182715F506B" unitRef="usd">81945000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2014Q4" decimals="-3" id="Fact-DE595E110CC2F2A30CE8D182716EABFE" unitRef="usd">36274000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4" decimals="-3" id="Fact-3C366617573CA48364E1D182716E81D7" unitRef="usd">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4" decimals="-3" id="Fact-223ABB69AD827B4428C7D182716E3F1E" unitRef="usd">-63000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2013Q4" decimals="-3" id="Fact-C17875237FD52F9F4347D182716EC769" unitRef="usd">1175108000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2014Q4" decimals="-3" id="Fact-9A5040797CA231BBC5AFD182716E915B" unitRef="usd">1389997000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2012Q4YTD" decimals="-3" id="Fact-411562986E445715B5C9D182716EC5E1" unitRef="usd">6495000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-4911A1106276C2670ADFD182716E7BFD" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E4EAB94B2F2C7F1158B8D182716E06AF" unitRef="usd">6495000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F0970E00110ECEB27391D182716EC2D5" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-CC776C3701D834435732D182715FE8F9" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-4C9C8668C8B71AFFEDFDD182716EE0B3" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-C83EA0833C6755AA98B1D182716EB07F" unitRef="usd">7421000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-21D0C0FA707BC9DFC8D8D182715F38EC" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-60822A70703ECF28C8DBD182716E64FE" unitRef="usd">7421000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-03D9F4E605CEF3DEFB68D182715FD73A" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-B413FA0336952342393ED182716E3719" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-88F233AC987009B78192D182716EF354" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9EB0EBB2A764D9608171D182716E46F5" unitRef="usd">7081000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-4E45D3AB101BFFCDD3B5D182715FB6A7" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-EC05B2458C0E25E24F4ED182716E8A75" unitRef="usd">7081000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-4FC696CA61CAE5A715CDD182716EDFA3" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-4613ECF974EEFA86FEDCD182717E7EA2" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-8026678F135654080070D182716EE630" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-58C89BFF7154FF45CDF7D182716EDB95" unitRef="usd">35000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-1CBD970C1667D129157DD182717EF02F" unitRef="usd">35000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2012Q4YTD" decimals="-3" id="Fact-1049810DB0CADECB8781D1F04812F6D0" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2013Q4YTD" decimals="-3" id="Fact-635427770163D48313F2D1F0480E19F2" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DA5415531CFED7C94AE2D1F0481012D0" unitRef="usd">100000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AssetImpairmentCharges contextRef="FD2012Q4YTD" decimals="-3" id="Fact-F3189702A8605CE2A6A1D19E5D42BB25" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2013Q4YTD" decimals="-3" id="Fact-8453CFA06960167994F5D19E5D4A5528" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A631AFAD3E90A809EABED19E5D44CCDF" unitRef="usd">13102000</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2013Q4" decimals="-3" id="Fact-92A31DED1555729AE6A2D182715F53D7" unitRef="usd">274160000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2014Q4" decimals="-3" id="Fact-831A6098CA37D9DF157FD182716E019A" unitRef="usd">471376000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-465BFEB8332D7ED11E3AD182715F70F6" unitRef="usd">134554000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-207C95B6A1273D0DE954D182716ED8B9" unitRef="usd">368987000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure contextRef="FI2013Q4" decimals="-3" id="Fact-E29D5DA95DF483B50024D19B3493CD76" unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
	<us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure contextRef="FI2014Q4" decimals="-3" id="Fact-ADF007701905804CAED0D19B348A94DC" unitRef="usd">23849000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-FA3CD69A0541EE6991C3D182715F83B2" unitRef="usd">91629000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-19B92466A13375D27FB2D182717E4677" unitRef="usd">91077000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-C03C9BDE9DE8658EE5B5D182715FDD11" unitRef="usd">552000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-A42403DA9CCED56EA533D182716E904D" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-EBD613BA3E73338F7CE7D182717E9D88" unitRef="usd">202073000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-6E8F4E303B3A58059DE9D182716E8AED" unitRef="usd">201521000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-C151C61801E6A3B3D92FD182717E149C" unitRef="usd">552000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-59EB27724C840A17B316D182717E2432" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-7A406C24DA116C746986D182716EEF47" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-D7E57D8114F260928CEFD182717E5665" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-ADEB6FC755903A71B060D182716E5CBA" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-219BEDFE41947164A28ED182717E70F8" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-D399FF5F2A6957288528D182716E965A" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-A886635CE7F8DDDF41FFD182716E0612" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-88120201CF74C776D90FD182717EF417" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-6E8E327788D618D647E2D182716ED521" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-065EFC661E43DA5C59AED182715FD62B" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-C1B86C544755AABF9F7DD182715F1E8E" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-228C9FEC264D37AA7F6BD182716E04DF" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-6B6AFBADD0082BFE63F0D182716E17E7" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-16C617A90F7FE9D88E77D182717E0335" unitRef="usd">-1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-450332CBB9D05C115398D182716EBD30" unitRef="usd">-1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-561075A7EA1A1E11D570D182717E825A" unitRef="usd">-1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-2FB202105FF4F50785AED182716E0CA7" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-8DE5E6C707F58AD490A5D182716E6B68" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-6EDD056FE0BF71425252D182717E2393" unitRef="usd">-66000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-27F69F3402BC82BB2A75D182716E344C" unitRef="usd">-66000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-715480F1704BA2EF1D1BD182717E17D4" unitRef="usd">-66000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-0239381251029BBD8CACD182715FC5DB" unitRef="usd">37499000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-CD52C833FB4A0011910AD182716EE39B" unitRef="usd">552000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-87C6AE5B0A3D57276E8ED182717ECD57" unitRef="usd">129126000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-CF5999CD41E1779B087ED182715FB078" unitRef="usd">91627000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-E4505FA15A8879B57247D182717E72A8" unitRef="usd">91075000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-1AE4E8906691AFAA98B8D182717E7EDF" unitRef="usd">137266000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-F2E4A9B5EEAE7CB36276D182715FE949" unitRef="usd">552000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-185EF979DFC737C1CF0ED182717E29A4" unitRef="usd">339402000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-C071A330832CD35CB2C3D182717E9408" unitRef="usd">202136000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-3DBBB8BD08D92C42B4FBD182716EED0C" unitRef="usd">201584000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-A62510C991E35F9D8960D182716E127D" unitRef="usd">37499000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-4B992B5FE1E1929AB6B0D182716E18E6" unitRef="usd">552000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-E2D177459CD7DE0AAC86D182715F853A" unitRef="usd">129128000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-DEE9EC9B168444429A8BD182717E93BD" unitRef="usd">91629000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2013Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-C4B2AECBCB2F63C05568D182717E35A0" unitRef="usd">91077000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_CashMember" decimals="-3" id="Fact-E982EE1A176C3A113620D182715F1887" unitRef="usd">137266000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_CertificatesOfDepositMember" decimals="-3" id="Fact-BE2305DA275DAE32E989D182717EA2FB" unitRef="usd">552000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_InvestmentsMember" decimals="-3" id="Fact-0E5A1FC1C925E547379ED182716E4056" unitRef="usd">339339000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-36CB5DDE36B9068323F2D182716ECDBA" unitRef="usd">202073000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2014Q4_invest_InvestmentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-C12B76D70013552456ABD182715F7CC0" unitRef="usd">201521000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2011Q4" decimals="-3" id="Fact-988254F476BF0A92C174D182715F0651" unitRef="usd">186309000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2012Q4" decimals="-3" id="Fact-7305382D098A1644E84DD182715FC742" unitRef="usd">30423000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-3" id="Fact-CDCACE08F76E1D8274ACD182715F0DF6" unitRef="usd">37499000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-AE450AA140DEE75BF58ED182716E2647" unitRef="usd">137266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-709EB6777DF341BEB9A4D182716E8F63" unitRef="usd">37499000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-661268934328BAFC9B75D182717EE191" unitRef="usd">37499000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-DD510621254A743BE30FD182717E0AE7" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-06CBF260A04BD8978C85D182716EFDCF" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-A0CC2206C0DD43F4B3FCD182717EAA75" unitRef="usd">137266000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-D24B1162E23EA12794C4D182716ED200" unitRef="usd">137266000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-BB535C3E2755F3888822D182715FFD18" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-FD48F17B1FBCFDDCF106D182717E9FD2" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2012Q4YTD" decimals="-3" id="Fact-E1AB3A925EBFDC498908D182716E06C2" unitRef="usd">-155886000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2013Q4YTD" decimals="-3" id="Fact-9823689B5B5F66C20DABD182715FED5A" unitRef="usd">7076000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q4YTD" decimals="-3" id="Fact-78F4AA30F8B36C4F2C0BD182717E41EC" unitRef="usd">99767000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2013Q4" id="Fact-AD7DF25EC6BD162408C2D182715F39A7" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2014Q4" id="Fact-34C5650E7DF7E23F8F83D182716EC65B" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2013Q4" decimals="3" id="Fact-C55D16193CE0B023B2A8D182717E91CB" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="3" id="Fact-84D21D04F735219A77A5D182716E721C" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2013Q4" decimals="-3" id="Fact-CD7F3F26FEBFD8EC4B2CD182717EF49B" unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2014Q4" decimals="-3" id="Fact-F83407FE12ED02772636D182716E96DA" unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6FADBB64BAD77BDE17DED182717E64E9" unitRef="shares">514349000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DC2BB640E287F5AF1FC7D182717E2D8E" unitRef="shares">725641000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-011ACB28F8E7868AFA96D182716EF57A" unitRef="shares">480389000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F335BE885BE09DDFAD7ED182715F7A4A" unitRef="shares">512375000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FED5C1ECB9D650A338A1D182716E5B2D" unitRef="shares">514349000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-249F1D4EEEE4EE8F0F20D182715F5814" unitRef="shares">725641000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2013Q4" decimals="-3" id="Fact-A737E25075915CFFFE06D182715F80A0" unitRef="usd">514000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-AB4A2A60BB698D0CF19AD182716E8143" unitRef="usd">726000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2012Q4YTD" decimals="-3" id="Fact-18E66F0E57E960F45363D182716EF790" unitRef="usd">-110209000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F63C96290C7208EB1A86D182717E44E8" unitRef="usd">-104147000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-4701A33D04D4423DE2C8D182716E7A12" unitRef="usd">-100359000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContractsRevenue contextRef="FD2012Q4YTD" decimals="-3" id="Fact-DD32A50B9C2F7769FF7CD182717EEFCA" unitRef="usd">783000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-925910EBA97286F25DCED182717EC279" unitRef="usd">2109000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DAB5E1F6D358CDAFBB23D182717E3A72" unitRef="usd">22593000</us-gaap:ContractsRevenue>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2014Q4" decimals="3" id="Fact-212449E55E7108F9F6CCDB506B77B5A2" unitRef="usdPerShare">1.206</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="D2014Q4SD" decimals="4" id="Fact-38173D03FB851855B862DB4FA0820E08" unitRef="ratio">829.1874</us-gaap:DebtInstrumentConvertibleConversionRatio1>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2014Q4" decimals="-5" id="Fact-67A999788485C400CC06DB541D4CA111" unitRef="usd">81000000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2014Q4" decimals="4" id="Fact-49990F987B70AD8023ABD182716E8115" unitRef="ratio">0.0823</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtIssuanceCosts contextRef="D2014Q4SD" decimals="-5" id="Fact-BB64F646BD0A9C2D28CFDB52135A7C91" unitRef="usd">3400000</us-gaap:DebtIssuanceCosts>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2012Q4YTD" decimals="-3" id="Fact-DDB8B34693B2DBF72FF2D1F0949B0CB4" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-3" id="Fact-E053497DCA262D80627AD1F0949DA56E" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-393FC58707A2FAE13E73D1F09499C926" unitRef="usd">70000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2013Q4" decimals="-3" id="Fact-81229C132D0342DD455ED182717EE010" unitRef="usd">-18745000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2014Q4" decimals="-3" id="Fact-66CDB46D2A31E2564B50D182716E5380" unitRef="usd">-18675000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-34AF01353E18E8DC5950D182715FFAE6" unitRef="usd">195000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-840A286AE22FEF0DE66FD182715F70CB" unitRef="usd">1618000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2013Q4" decimals="-3" id="Fact-793CA1C81AFB1B8DA294D182715FBDC0" unitRef="usd">13405000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-F47E67EB168F3CA6FEDAD182716EC1B5" unitRef="usd">12679000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2013Q4" decimals="-3" id="Fact-C431CFD4E494E119BA2FD182717EA297" unitRef="usd">4760000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2014Q4" decimals="-3" id="Fact-C5BDA98CA9AFB5A445B2D182716E6300" unitRef="usd">4457000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2013Q4" decimals="-3" id="Fact-202B42566C985DC9556AD182716E6144" unitRef="usd">376611000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2014Q4" decimals="-3" id="Fact-EF307900CC018168B67CD182716E1B86" unitRef="usd">412423000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2013Q4" decimals="-3" id="Fact-B86578DD806ED92FE2ABD182716E4101" unitRef="usd">83375000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2014Q4" decimals="-3" id="Fact-9EF5ABEAC64AEE2F877FD182717E990D" unitRef="usd">95946000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2013Q4" decimals="-3" id="Fact-7B3EDCEED1B69F3DF5A2D182716EE847" unitRef="usd">238608000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2014Q4" decimals="-3" id="Fact-12AEF896E7C2CC3B8FD9D182716E9F07" unitRef="usd">255518000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2014Q4" decimals="-5" id="Fact-C1B791F605DC04412314D182716E5B8A" unitRef="usd">460200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2013Q4" decimals="-3" id="Fact-36148BE951DDD588B1D1D182716EAF8D" unitRef="usd">4712000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2014Q4" decimals="-3" id="Fact-4F9F2FD015832E9BCD49D182716EA7F7" unitRef="usd">8681000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2013Q4" decimals="-3" id="Fact-A1E276B1A895C843A168D182716EED27" unitRef="usd">37453000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2014Q4" decimals="-3" id="Fact-CDFF340ECB591D105AA0D182716E7A22" unitRef="usd">40173000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2013Q4" decimals="-3" id="Fact-55A256478B6851FC8938D182716E98C9" unitRef="usd">7703000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2014Q4" decimals="-3" id="Fact-2B963D70497D4EEEEBECD182717E2287" unitRef="usd">7648000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2013Q4" decimals="-3" id="Fact-DB0BDB11C7F38D9121DFD182716E2079" unitRef="usd">-376611000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2014Q4" decimals="-3" id="Fact-11C5E457F2EFE5F18006D182716E676D" unitRef="usd">-412423000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2013Q4" decimals="-3" id="Fact-F8209EFBA8058692A700D182717E1264" unitRef="usd">-18745000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2014Q4" decimals="-3" id="Fact-CC11BB26CF5EC993C64ED182717E066F" unitRef="usd">-18675000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2013Q4" decimals="-3" id="Fact-DB6DF4A502BE3AC6678CD182716E59E7" unitRef="usd">18745000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-F866618CB5C3D6AC3E87D182716EEC4B" unitRef="usd">18675000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2012Q4YTD" decimals="0" id="Fact-377AFE090FEA77AFD91DD182717E4AA5" unitRef="usd">490000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2013Q4YTD" decimals="0" id="Fact-C942A87ABD974C00E977D182716EDCDD" unitRef="usd">511000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2014Q4YTD" decimals="0" id="Fact-7EC9863A375E1D18EC22D182717E2290" unitRef="usd">376000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2012Q4YTD" decimals="-3" id="Fact-93ED517EAB94AB752CAAD182717E2B36" unitRef="usd">4190000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2013Q4YTD" decimals="-3" id="Fact-EDAFD74A96A4FD733B92D182715F5A27" unitRef="usd">2863000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8007365EB354085579B1D182716EA044" unitRef="usd">1928000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2012Q4YTD" decimals="2" id="Fact-4C1982DAA93B2F1319CFD182717E806C" unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2013Q1QTD" decimals="2" id="Fact-E6EF690703C96A3B4CA1D182717E5C66" unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2013Q2QTD" decimals="2" id="Fact-F96D26CD9D2F2421B995D182715F5EF5" unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2013Q3QTD" decimals="2" id="Fact-A0C2384C40EC14521A25D182715F3851" unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2013Q4QTD" decimals="2" id="Fact-717F951A31F1B0D5CF96D182717E449A" unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2013Q4YTD" decimals="2" id="Fact-DBC331AE41D6D0C50214D182716ED190" unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q1QTD" decimals="2" id="Fact-E13B9AD16FF1CBB9AD54D182717E9A73" unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q2QTD" decimals="2" id="Fact-9893809F032D9990F20CD182717EB95B" unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q3QTD" decimals="2" id="Fact-3AE40386C8A8D9C0B312D182715F25CF" unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q4QTD" decimals="2" id="Fact-D64FCC3CB07D4374F47AD182715F8693" unitRef="usdPerShare">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-E16BE092FBBC5A40308CD182717EACCF" unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2014Q4" decimals="-5" id="Fact-FDA491786B59ABB32DBAD182716E97C1" unitRef="usd">10400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2014Q4YTD" id="Fact-E81EE174661F0D888828D182716EE2DA">P1Y4M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2012Q4YTD" decimals="-3" id="Fact-72206D73F23BD7A09E1ED182717EB3B9" unitRef="usd">9887000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2013Q4YTD" decimals="-3" id="Fact-DD22FFB9B6C80F7E30EFD182717E140D" unitRef="usd">-2210000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2129E276FC54225DC6D7D182716E16C2" unitRef="usd">1428000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2012Q4YTD" decimals="-3" id="Fact-BBAF578E5FB85B42D487D3338F0142CE" unitRef="usd">-35000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B9AF6638D357CCFBDD70D333B18B0332" unitRef="usd">-11500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2011Q4" decimals="-3" id="Fact-F7E8CCBECA56CE7C6FA4D182717EB987" unitRef="usd">55033000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2012Q4" decimals="-3" id="Fact-F11EC9E548EE89DF8A7CD182716EE0CA" unitRef="usd">29920000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2013Q4" decimals="-3" id="Fact-CDD3F1833083247B2CA3D182717EA409" unitRef="usd">27710000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2014Q4" decimals="-3" id="Fact-30C0AFE4C845F6A19C6CD182716E6E4D" unitRef="usd">17638000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:GainLossOnDispositionOfAssets contextRef="FD2012Q4YTD" decimals="-3" id="Fact-2B9A9227241DD5156378D1EF2FCBAE81" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
	<us-gaap:GainLossOnDispositionOfAssets contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F5A091B851BC26951497D1EF2FAC63A0" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
	<us-gaap:GainLossOnDispositionOfAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-50A40F5659BAC46D89C3D1EF2FBEDCFA" unitRef="usd">1631000</us-gaap:GainLossOnDispositionOfAssets>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2012Q4YTD" decimals="-3" id="Fact-C97CB011A7E566E25E89D182717ECBB7" unitRef="usd">17043000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-A6E8E3EF51E33CE7890DD182717E2C98" unitRef="usd">17121000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A6C9FBF66CADFFD2A0F6D182716E4FEE" unitRef="usd">19411000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2013Q4" decimals="-3" id="Fact-0CAC5C707538A3AEA63AD182716EE1A7" unitRef="usd">44543000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2014Q4" decimals="-3" id="Fact-CA24C10B5F2018093A9BD182715F6670" unitRef="usd">44543000</us-gaap:Goodwill>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2012Q4YTD" decimals="-3" id="Fact-6C9C95F42DCD67E665F4D182717E9E77" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2013Q4YTD" decimals="-3" id="Fact-224F221CF3D56FD04167D182717E54A5" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2014Q4YTD" decimals="-3" id="Fact-642B822EAE813A400214D182715F9D33" unitRef="usd">13544000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2012Q4YTD" decimals="-3" id="Fact-A905534C07E44853B8EED182716ED444" unitRef="usd">-110211000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2013Q4YTD" decimals="-3" id="Fact-B29A6D9FAAE85C4126D3D182715FB0E6" unitRef="usd">-104126000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2014Q4YTD" decimals="-3" id="Fact-131FA74FD8576FD09BDAD182717EF26C" unitRef="usd">-100364000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2012Q4YTD" decimals="-3" id="Fact-C4C41F6CF593878D9CF5D182717EFDF8" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-3" id="Fact-6C96FCF91AF4706A86B4D182717EDCB1" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-203AD8EA584620FBF394D182715F49E4" unitRef="usd">-70000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2012Q4YTD" decimals="-3" id="Fact-87C529C8F845DA249A3FD182717E8FFA" unitRef="usd">995000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-328A0B9CFF755EDE5499D182716E06D1" unitRef="usd">-3119000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-63E407D55EF4134D71F8D182716EDEF9" unitRef="usd">-1266000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2012Q4YTD" decimals="-3" id="Fact-76F5699A9382EC687148D182716E9151" unitRef="usd">1028000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2013Q4YTD" decimals="-3" id="Fact-1908F7F089C44D0D9214D182717ED229" unitRef="usd">-588000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5D77BFB2C94EFD175137D182715F25B8" unitRef="usd">-457000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2012Q4YTD" decimals="-3" id="Fact-D51E737DCFA8026A8BC9D182715F2AD1" unitRef="usd">293000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-C956CD1F63C6D488249CD182717E3ECF" unitRef="usd">438000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-4B64FFC0D294ECA174E6D182717E1419" unitRef="usd">-697000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2012Q4YTD" decimals="-3" id="Fact-CFE16882BFDDAB1DD091D182717E4BD3" unitRef="usd">96000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2013Q4YTD" decimals="-3" id="Fact-362FC1BE056E430819E9D182717E8B55" unitRef="usd">-9000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8CE6365D78D20E4BBE5FD182715F098F" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2012Q4YTD" decimals="-3" id="Fact-9AE16AF413DC5BE5EF7BD182717EAF14" unitRef="usd">-2601000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2013Q4YTD" decimals="-3" id="Fact-5596034EBAEEE9839487D182717E25B8" unitRef="usd">1713000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9538C6F5FA684FDEB1FED182717E8983" unitRef="usd">-128000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestExpense contextRef="FD2012Q4YTD" decimals="-3" id="Fact-D56A92B5A1BD0FE01C40D182717E71D0" unitRef="usd">2114000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-80E60F283FAA5E66E751D182715F4DFB" unitRef="usd">1971000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-692954BD4CA474C4D337D182715FA92A" unitRef="usd">2253000</us-gaap:InterestExpense>
	<us-gaap:InterestPaidNet contextRef="FD2012Q4YTD" decimals="-3" id="Fact-9BBAA41DD345CCFAC686D182715FA957" unitRef="usd">2028000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2013Q4YTD" decimals="-3" id="Fact-251FF0C841FD3D447599D182717E57D3" unitRef="usd">1897000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D98CB2E345690518D5D2D182717E161E" unitRef="usd">1761000</us-gaap:InterestPaidNet>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-C4FE50135FEE53D55CC9D182716EDC75" unitRef="usd">129128000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-53772FC8BC7E051475CCD182716E284E" unitRef="usd">128576000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-D2A95345147DA15D8922D182716E8E24" unitRef="usd">552000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-E6850E802CF256550EC3D182715FAC6B" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-BDB7F91ED2CE74F62D10D182716E33C2" unitRef="usd">339339000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-60F555408443503481C4D182716E3922" unitRef="usd">338787000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-CC89B8573BC9309CA80DD182717EAFA4" unitRef="usd">552000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-79BB3A69D9CB72C063C1D182716E60B6" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2012Q4YTD" decimals="-5" id="Fact-F3EC081CDC41DA1B9363D182717ED021" unitRef="usd">2200000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-1D7D0B2837199CC5EAD5D182717E7F5A" unitRef="usd">900000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C6B3267D10130098F68DD182717ECF2F" unitRef="usd">1000000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:Liabilities contextRef="FI2013Q4" decimals="-3" id="Fact-6D4E5598D0C264A6F326D182716E8186" unitRef="usd">103997000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2014Q4" decimals="-3" id="Fact-8D18EE3E1173AA11C74AD182717ED383" unitRef="usd">187358000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2013Q4" decimals="-3" id="Fact-4AAFCFB34DE66F9E45A6D182716E15BB" unitRef="usd">274160000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-34FA2862EB5012C677FAD182716E3A04" unitRef="usd">471376000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-E96251AF587DE875E96BD182716E8AE4" unitRef="usd">19294000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-71534990A5A0AE7A7452D182715F97E8" unitRef="usd">44969000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-98D833474CA89385F8AFD182716E9056" unitRef="usd">27710000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-2BD5A304510BA724ACD6D182716E4442" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-21237ADC812DE2057E12D182716E3EA7" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-8F3B609A37DA6AB8E6CAD182716EF7E6" unitRef="usd">27710000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-1300779547C2B8955809D182716EA46C" unitRef="usd">17638000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-64B6A7E50CB0A56784BCD182716EA9B5" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-3473777F0B996E1D4DFDD182717E3EF1" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-AD3220A1B3B26FFA59ABD182717E6F86" unitRef="usd">17638000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LicensesRevenue contextRef="FD2012Q4YTD" decimals="-3" id="Fact-3ED3161E79BBE578A798D182717EF127" unitRef="usd">306000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-6EB3B72FC10C56463F67D182715F03D4" unitRef="usd">113000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C17757B1F801E2E37753D182716E4EDC" unitRef="usd">261000</us-gaap:LicensesRevenue>
	<us-gaap:LongTermDebt contextRef="FI2014Q4" decimals="-3" id="Fact-3EDB3BB66C70AA2DF880D182717EBA7C" unitRef="usd">107667000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-1CF6A8FE56EC1E021058D182716EB103" unitRef="usd">1710000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-DB019BA134EB958FDF98D182716EA667" unitRef="usd">20167000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="FI2014Q4" decimals="-3" id="Fact-E167999D00844BE6FD8ADB49EB9F5B3A" unitRef="usd">87500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2014Q4" decimals="-3" id="Fact-056D9F3D75AE6C6849AED182717EC5FB" unitRef="usd">1859000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2014Q4" decimals="-3" id="Fact-1EF17F472B82981A9927DB4935B4EDC2" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2014Q4" decimals="-3" id="Fact-1B779D3A7B6251271A8FD182717EA28C" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2014Q4" decimals="-3" id="Fact-204FFDFC2C8ED1DB2F9FD182715FD101" unitRef="usd">16293000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2014Q4" decimals="-3" id="Fact-A6158E3A0C547C610D8CD182717EBDB1" unitRef="usd">2015000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2013Q4" decimals="-3" id="Fact-E64C772B521FEAE4235ED182715F1043" unitRef="usd">20167000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-D74F7719513368B79348D182717EEC18" unitRef="usd">87500000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:MortgageLoansOnRealEstateCarryingAmountOfMortgages contextRef="FI2014Q4" decimals="-5" id="Fact-E7AA4D7C22BA038A9D4ADB552B28A7D0" unitRef="usd">20200000</us-gaap:MortgageLoansOnRealEstateCarryingAmountOfMortgages>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2012Q4YTD" decimals="-3" id="Fact-FA155BBED8EB38DB5641D182717EB197" unitRef="usd">36381000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-54145E5F9391AEF998B6D182717EC2CD" unitRef="usd">-1389000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7AB4B2B4F49967025831D182717E1F28" unitRef="usd">283808000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2012Q4YTD" decimals="-3" id="Fact-355A898470B88BC042BDD182717E76D6" unitRef="usd">-97807000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-0990C181E8B1C9C82120D182717E15F2" unitRef="usd">99544000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B5E3BD6BDA9078C95C44D182715F7CE7" unitRef="usd">-108419000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2012Q4YTD" decimals="-3" id="Fact-1F682B6B24292D5F92E2D182717E888D" unitRef="usd">-94460000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-967A42F2E9A3CD487F9BD182717EA1A1" unitRef="usd">-91079000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B6F8AA3D9D1435AC912FD182716EF852" unitRef="usd">-75622000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q4YTD" decimals="-3" id="Fact-B8A869CA4516A2100908D182717E8A71" unitRef="usd">-110211000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-E3F0B3063DC329F6C361D182716EC7A1" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8047F74E1776D5D410D9D182716ED1CE" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C24F82DE28FF836DD896D182715FE12E" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E84348A6D9B2D819F082D182716E60C5" unitRef="usd">-110211000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-DC2C0E3EECCC9CC724F4D182715F561C" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q1QTD" decimals="-3" id="Fact-297F00F9B251A13DD1E5D182717E0C03" unitRef="usd">-25974000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q2QTD" decimals="-3" id="Fact-05B7BADFE1DB048AFE08D182717E7EFC" unitRef="usd">-29080000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q3QTD" decimals="-3" id="Fact-0264BF5F2FC1990067F8D182715FF7E4" unitRef="usd">-31658000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4QTD" decimals="-3" id="Fact-CE976BE27B6A1E74BBF6D182715F8F5F" unitRef="usd">-17414000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-5F7643E481BFD8894911D182717E7401" unitRef="usd">-104126000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-9B3481550FE5590394AED182717E64C5" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0E87B7C0685E3026777AD182715F28F9" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-EA126AE7602897C55EF7D182716ED497" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-FC623F88C06E86397398D182717EF9BE" unitRef="usd">-104126000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-EEABD21247FD4F7A07B9D182716E9EFB" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q1QTD" decimals="-3" id="Fact-CA912C01DE77E89555A5D182717EB261" unitRef="usd">-30835000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q2QTD" decimals="-3" id="Fact-1E505519DB915D150443D182717E8C45" unitRef="usd">-26028000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-DDBC019ED3176DFEE890D182717E2DF4" unitRef="usd">-40498000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4QTD" decimals="-3" id="Fact-3943515C0EA8A01A4E52D182717E08F3" unitRef="usd">-2933000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E1625ADD47C90C4EA952D182717E522D" unitRef="usd">-100294000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-8D4DEC5C86F4E2832BFDD182716EAB0F" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F8FDA4ECC518AFF8A118D182716E32F6" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-EDD870334DD77A1F19DDD182716ECEC6" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-4C58EAB2FD0FA8C17B70D182716EF73F" unitRef="usd">-100294000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-55A54B6D5AC5EE115ACFD182716E13D7" unitRef="usd">0</us-gaap:NetIncomeLoss>
	<us-gaap:OperatingExpenses contextRef="FD2012Q4YTD" decimals="-3" id="Fact-A5004DBAE6B4313877D6D182717E371D" unitRef="usd">109504000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2013Q4YTD" decimals="-3" id="Fact-0C24A4948BE1EE8AC5D7D182716EE08A" unitRef="usd">104593000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-099CD9937E03D6A44E79D182717EFE91" unitRef="usd">123220000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2012Q4YTD" decimals="-3" id="Fact-19D212CAD83816D6039DD182716E2F74" unitRef="usd">-108415000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2013Q1QTD" decimals="-3" id="Fact-5A89C6E38D2822FBA7D1D182717E2D07" unitRef="usd">-25555000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2013Q2QTD" decimals="-3" id="Fact-E5BA9BC18CFBFA7D468BD182716E03C6" unitRef="usd">-28624000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2013Q3QTD" decimals="-3" id="Fact-95AA220632468F2140E4D182717ECE0B" unitRef="usd">-31216000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2013Q4QTD" decimals="-3" id="Fact-48BB92FFD242D9CA2009D182717E157F" unitRef="usd">-16976000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-2A0845AE3E98EF4F1B5BD182717E41BD" unitRef="usd">-102371000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q1QTD" decimals="-3" id="Fact-3ED0F672F116017C9FB7D182717EBBE5" unitRef="usd">-30472000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q2QTD" decimals="-3" id="Fact-09336D736760889BDF18D182715F479E" unitRef="usd">-26111000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-B862B0D29FD6D284A532D182717EC6B3" unitRef="usd">-40336000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4QTD" decimals="-3" id="Fact-15BE8C186159B5575135D182715FDE1F" unitRef="usd">-3447000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C02F2595EC49171C068CD182715F6264" unitRef="usd">-100366000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2014Q4" decimals="-3" id="Fact-361733BD7652509BE1D9D182716EAF52" unitRef="usd">3876000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-C96F0C81676BDE30D3C7D182717E4273" unitRef="usd">1075000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2014Q4" decimals="-3" id="Fact-E454289BDE22E139E888D182717E50E3" unitRef="usd">572000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2014Q4" decimals="-3" id="Fact-074F5BA6CCEA44C5927ED182716E9263" unitRef="usd">1128000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2014Q4" decimals="-3" id="Fact-D50F892BF89D43056CE5D182717E1ADD" unitRef="usd">1101000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2014Q4" decimals="-5" id="Fact-904B65753A17F5154AB0D182715F4EE3" unitRef="usd">715800000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAssetsCurrent contextRef="FI2013Q4" decimals="-3" id="Fact-9F1118CE34624685B7A2D182716E78F6" unitRef="usd">4636000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-D086AECBA03F1C02E8DDD182715F7C41" unitRef="usd">4764000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2013Q4" decimals="-3" id="Fact-C94CA024E1437DCEC006D182716E786B" unitRef="usd">144000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-24FCEE4FD7D56F0C9798D182717E5B23" unitRef="usd">3409000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2012Q4YTD" decimals="-3" id="Fact-C7154D0024C2D4DD8AD5D182715F9C1B" unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-9143D83AC67E6715811FD182715F65C7" unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-DAE7577FD3A4FA474D36D182716EFB73" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DE6515C382B71A789D80D182716EEC2E" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-1F987C7CDDCE1490DFD3D182716E6564" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-4A94116D053C9EA4403CD182716ED146" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2013Q4YTD" decimals="-3" id="Fact-1AC06460328826A23A94D182716E2667" unitRef="usd">-21000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-A071134E98CFC3F9BF70D182716EBD1D" unitRef="usd">-21000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9A90B1E9D9A988F2621AD182715FE671" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6B18D02C610D5FB80493D182715FE568" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E704D833A37BB184E803D182716EDF72" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-5C0F527CF65134F62F07D182716EE6B7" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7120CF58D03FCF562FCED182717EF650" unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-436A7FB49A20AB13B494D182716EAC32" unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FBDF8E11861752D9DFCAD182716ED3E7" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E8E0193A1FE22AF0F9B6D182716EEECA" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-AE7AAF9D85DD12AC67E2D182716EA021" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-FE15149BC1471308A381D182715FD4F3" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherIntangibleAssetsNet contextRef="FI2013Q4" decimals="-3" id="Fact-E722A7131B2D7EF8EB95D182716E1710" unitRef="usd">53557000</us-gaap:OtherIntangibleAssetsNet>
	<us-gaap:OtherIntangibleAssetsNet contextRef="FI2014Q4" decimals="-3" id="Fact-37F2EE0902CC369367C4D182716EE7A7" unitRef="usd">53357000</us-gaap:OtherIntangibleAssetsNet>
	<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-468C786F5D722859A53FD182716E0082" unitRef="usd">27710000</us-gaap:OtherLiabilitiesFairValueDisclosure>
	<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-5487CD8E6D004A172424D182716EDA23" unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
	<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-17AA8AFE19177DEAE5BBD182716E57DC" unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
	<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="FI2013Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-D65F490ECF65C61570C2D182716E6296" unitRef="usd">27710000</us-gaap:OtherLiabilitiesFairValueDisclosure>
	<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-133EC23AA37050ABDAD0D182717E7034" unitRef="usd">17638000</us-gaap:OtherLiabilitiesFairValueDisclosure>
	<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-E2EA6642B0C13B02C041D182716E864A" unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
	<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-58C651EDE5B9597F01B0D182716EB34B" unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
	<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-06E1982149D2E9BEB64CD182716E0EA2" unitRef="usd">17638000</us-gaap:OtherLiabilitiesFairValueDisclosure>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2013Q4" decimals="-3" id="Fact-0A07C1B6549D9494DDB4D182715F49CB" unitRef="usd">32386000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-E7514F2EA3827F44AE41D182717E6260" unitRef="usd">23535000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2012Q4YTD" decimals="-3" id="Fact-CA0ED50AC12FAECBFB2AD182715F0C70" unitRef="usd">318000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-20C3E478AF895834382AD182717E1253" unitRef="usd">216000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-34FA5A1A7AA0A9EEC0C4D182716EB7E0" unitRef="usd">2255000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherRestructuringCosts contextRef="FD2014Q4YTD" decimals="-5" id="Fact-08FD6E28D70D1BF2DE7FD72ACDC4AFA1" unitRef="usd">400000</us-gaap:OtherRestructuringCosts>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2012Q4YTD" decimals="-3" id="Fact-E80F22AE4FFA83D99952D182717E9911" unitRef="usd">285000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2013Q4YTD" decimals="-3" id="Fact-D2EDD42F249D34387951D182716E61B9" unitRef="usd">873000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D7958FE1FAC3FD2C75C8D182715FBCF7" unitRef="usd">887000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2012Q4SD" decimals="-5" id="Fact-E82E3F18EDE23B029FDCD182717E79AC" unitRef="usd">200000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2014Q4SD" decimals="-5" id="Fact-2DB78F95DCC3A64DB521D37859A1F978" unitRef="usd">600000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2012Q4YTD" decimals="-3" id="Fact-8055BBD71896441042D8D182717E77EE" unitRef="usd">233250000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2013Q4YTD" decimals="-3" id="Fact-450D5196D05469FF529FD182717EBBE4" unitRef="usd">111490000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-74938BA576C56B86B889D182717EDFCB" unitRef="usd">221953000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2012Q4YTD" decimals="-3" id="Fact-033387471FA57747E4D0D182717EF7B7" unitRef="usd">492000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2013Q4YTD" decimals="-3" id="Fact-8761DF5F9B60E280BCB2D182717E42C7" unitRef="usd">1721000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8E3311A9052E656C588ED182716E1F54" unitRef="usd">80000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2013Q4" decimals="2" id="Fact-8CED02F54837F0EDCFEBD182716EB179" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="2" id="Fact-305C6ACC7E4624BAB759D182716EF6EE" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2013Q4" decimals="-3" id="Fact-68F593B1A7F184AE4A8BD182716EF224" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2014Q4" decimals="-3" id="Fact-D0CDD05536FA6EB0441BD182717E37BA" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2013Q4" decimals="-3" id="Fact-04BCD2487F0FCAA71C54D182717E4CE3" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2014Q4" decimals="-3" id="Fact-E868674E33449ADE1AF7D182716E8AB0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2013Q4" decimals="-3" id="Fact-F0EC2323EFAB839ECCADD182715F06B7" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2014Q4" decimals="-3" id="Fact-A1C1D6C38E8A8577445DD182717EC748" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2013Q4" decimals="-3" id="Fact-966D93E3EF1F5820190DD182717ED019" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-EA0F598C08A3A94D3E79D182717E123E" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:ProceedsFromConvertibleDebt contextRef="D2014Q4SD" decimals="-5" id="Fact-D106FA5B28FE2FD8F454DB4CC3CDFE91" unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2012Q4YTD" decimals="-3" id="Fact-8622BF2D81ECA664AA1BD182717ECB6F" unitRef="usd">38109000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2013Q4YTD" decimals="-3" id="Fact-1C11E2A8D0EDB23C28E1D182717E5DCE" unitRef="usd">1084000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2014Q4YTD" decimals="-3" id="Fact-65CC18FEE5D602A3035DD182715F79D3" unitRef="usd">202270000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2012Q4YTD" decimals="-3" id="Fact-3F2FEC80E29AB59357E2D182716E2829" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2013Q4YTD" decimals="-3" id="Fact-22063A82BCB0122BE807D182717E8064" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2014Q4YTD" decimals="-3" id="Fact-BAC7695222D0C5E69161D182715F4020" unitRef="usd">84135000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2012Q4YTD" decimals="-3" id="Fact-61868AEAF842CF388CB8D182715F330C" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-A2B959BA46666ACBB5A7D182717ED464" unitRef="usd">-26000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C3B57264919198FC8934D182717ECF7E" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="FD2012Q4YTD" decimals="-3" id="Fact-64994EA098E43D7203E1D182717E384F" unitRef="usd">135850000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="FD2013Q4YTD" decimals="-3" id="Fact-333ED3675DBA569165E9D182717ED2C5" unitRef="usd">212625000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-3EF45B7EEA7BF26F99C0D182716E59CB" unitRef="usd">111444000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2012Q4YTD" decimals="-3" id="Fact-8DB6F8D74393752477FBD182717EBE7D" unitRef="usd">85000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2013Q4YTD" decimals="-3" id="Fact-E0AFF0F7C97116917B04D182717E918E" unitRef="usd">130000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-328A1F8B1D0A865C22D2D182717E52D7" unitRef="usd">2170000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProfitLoss contextRef="FD2012Q4YTD" decimals="-3" id="Fact-75411C7617A87C3BE4B5D182717E4901" unitRef="usd">-110211000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-E91F838377127B24D8ECD182717ECCCE" unitRef="usd">-104126000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-79515C40D72308EAC5E3D182717EA4DD" unitRef="usd">-100294000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2013Q4" decimals="-3" id="Fact-D5A64F6B75ED6F6FDDD8D182716EACEA" unitRef="usd">123307000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" decimals="-3" id="Fact-FC062A752C9976681855D182716EB9C5" unitRef="usd">59104000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-C26A12D256FDDA9DE7D5D182716E74EC" unitRef="usd">11180000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-615AA8D1718D339E6055D182717E6DE5" unitRef="usd">34952000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-7730ECE494B5F558F4EAD182715F4C69" unitRef="usd">7315000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-3" id="Fact-4ECAE1723E1D2185F155D182717E9C6F" unitRef="usd">2664000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2013Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" decimals="-3" id="Fact-E6CAC3AD6FDE770D7545D182716E66F2" unitRef="usd">8092000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4" decimals="-3" id="Fact-834D55F5FF55FA4EC992D182715F8C7D" unitRef="usd">37354000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" decimals="-3" id="Fact-38BA4C012EBF90A4726AD182716E14C4" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-C94660249A6D393D82FAD182716E2FC5" unitRef="usd">9468000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-B5F539996B3783E5B467D182716EC24D" unitRef="usd">12737000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-6CFA446B6637869F0EC1D182716E80A2" unitRef="usd">7032000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-3" id="Fact-95EDE7B16FE451210044D182717E73D7" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" decimals="-3" id="Fact-54E58D422E75684D20C9D182717E0AAB" unitRef="usd">8117000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2013Q4" decimals="-3" id="Fact-0F08A0BDBB70FC9578CED182716E8531" unitRef="usd">41362000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4" decimals="-3" id="Fact-985AA5BA74197C71E542D182715F553B" unitRef="usd">1080000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:RealizedInvestmentGainsLosses contextRef="FD2012Q4YTD" decimals="-3" id="Fact-C0F6329EC8B436C6F44FD182716E9AC5" unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
	<us-gaap:RealizedInvestmentGainsLosses contextRef="FD2013Q4YTD" decimals="-3" id="Fact-8B6CB4075448BC4A27B7D182716EF00D" unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
	<us-gaap:RealizedInvestmentGainsLosses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B717138EF65A8D624162D182716E5467" unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2012Q4YTD" decimals="-3" id="Fact-F39B2484F3EFBDC4AB4ED182717E4C6E" unitRef="usd">1443000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2013Q4YTD" decimals="-3" id="Fact-9DB47F9AE677C7AD74D0D182715F3FEB" unitRef="usd">1574000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C7A5D09775DC5BFDD335D182717E4B35" unitRef="usd">1710000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2012Q4YTD" decimals="-3" id="Fact-2F37D31321732BCFC95FD182717EA45A" unitRef="usd">82574000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-A39C1AA1AD8804C33A7DD182715FF203" unitRef="usd">89682000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F0D5420BE32E3D8334E3D182716E7D73" unitRef="usd">89279000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedInvestments contextRef="FI2013Q4" decimals="-3" id="Fact-5EA948E22D54998B6B03D182717E2EA7" unitRef="usd">430000</us-gaap:RestrictedInvestments>
	<us-gaap:RestrictedInvestments contextRef="FI2014Q4" decimals="-3" id="Fact-B9613638498986A5D2E6D182717E755C" unitRef="usd">430000</us-gaap:RestrictedInvestments>
	<us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="FI2014Q4" decimals="-5" id="Fact-9CD96F421F3B66EE2ED5D72B6F8CEA24" unitRef="usd">5600000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
	<us-gaap:RestructuringCosts contextRef="FD2014Q4YTD" decimals="-5" id="Fact-80D8EFB5E0D9AA92A3AFD729977BF074" unitRef="usd">5700000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringReserve contextRef="FI2014Q4" decimals="-5" id="Fact-49446C9F831ABD9DC0D8D72DC157C75F" unitRef="usd">300000</us-gaap:RestructuringReserve>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2013Q4" decimals="-3" id="Fact-2B5C7D8A86FE1E1975D4D182715F5462" unitRef="usd">-1003958000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2014Q4" decimals="-3" id="Fact-A1A63D02722710B4DC1BD182717EB1AC" unitRef="usd">-1104252000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2012Q4YTD" decimals="-3" id="Fact-F333C735A4D06196155CD182717EBC7F" unitRef="usd">1089000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2013Q1QTD" decimals="-3" id="Fact-030F020038A58ABD99CDD182716E6FEC" unitRef="usd">360000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2013Q2QTD" decimals="-3" id="Fact-F679B2CF78FBDA509AC1D182717E3716" unitRef="usd">214000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2013Q3QTD" decimals="-3" id="Fact-AB15E4DEBEA787ED1900D182717E07DD" unitRef="usd">238000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2013Q4QTD" decimals="-3" id="Fact-2EC18E3B7340D7D4215CD182715FEF65" unitRef="usd">1410000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2013Q4YTD" decimals="-3" id="Fact-DB1ADE5B10427CF3C4E6D182717EBD29" unitRef="usd">2222000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q1QTD" decimals="-3" id="Fact-D76B5688DC8A3E9966CDD182717E59D6" unitRef="usd">277000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q2QTD" decimals="-3" id="Fact-AE682EDA002018AC785FD182715F7454" unitRef="usd">676000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q3QTD" decimals="-3" id="Fact-0CF2ED9E9C728BCCB3B1D182716ECDFC" unitRef="usd">419000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q4QTD" decimals="-3" id="Fact-7BE5F7BF2531C022FACCD182715FBFAE" unitRef="usd">21482000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1E18CDE8C2B3FF9E9825D182716EAC1C" unitRef="usd">22854000</us-gaap:Revenues>
	<us-gaap:ShareBasedCompensation contextRef="FD2012Q4YTD" decimals="-3" id="Fact-9146E3894113941C799BD182717EC478" unitRef="usd">6495000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2013Q4YTD" decimals="-3" id="Fact-76563F40EB998E957489D182717E8FC9" unitRef="usd">7421000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-189F7DF96EA6048C2DA0D182717EC2B8" unitRef="usd">7081000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-0AE341A109C51B674AD9D182717ECD9B" unitRef="shares">1331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-4D6D2C0381BBFFAA652ED182717E70A9" unitRef="shares">1604000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-03E99814656769ADD30CD182717E2879" unitRef="usdPerShare">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2013Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-D29B99FE21199B50FE5FD182717EC758" unitRef="shares">4242000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-4D8907235ABBF574FD6BD182717ED07B" unitRef="shares">3131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2013Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-FDC585E6798A2969DFC4D182717E1044" unitRef="usdPerShare">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-633E84B46DE1F000C744D182717E6061" unitRef="usdPerShare">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-28AF53701E30AE425AF8D182717E27A6" unitRef="shares">1384000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-E7BEA850E55D51A5137CD182717E0566" unitRef="usdPerShare">1.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2014Q4" decimals="0" id="Fact-E1A00DDB610F03AB7160D182716E376F" unitRef="shares">26733962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2014Q4" decimals="0" id="Fact-48A6B580ACF0B3560798D182716EB77E" unitRef="shares">14584704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2012Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-13095E0ABC874B637CC7D182717EFEA4" unitRef="shares">15582000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2013Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-21A87B4F4D3C654B7E80D182715FEB62" unitRef="shares">17378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-B0907136B130688B52EAD182715F6E90" unitRef="shares">16921000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2012Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-541CEC0435C4E47663D0D182717EB199" unitRef="usdPerShare">2.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2013Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-718B1D5098830BA34474D182717E3B70" unitRef="usdPerShare">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-C3C7797918AF554B409BD182717E4486" unitRef="usdPerShare">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2012Q4YTD" decimals="0" id="Fact-F5D8309421FBC5354D5DD182716E83D5" unitRef="usd">462000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2013Q4YTD" decimals="0" id="Fact-EE7559D3CAB266F65C3AD182717E4D5D" unitRef="usd">325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2014Q4YTD" decimals="0" id="Fact-CD351F7CBC8941C72FE6D182717EFF99" unitRef="usd">43000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-485C76D6476860EC57E5D182717ECE84" unitRef="shares">-1231000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-2323C9172D5589EFFE57D182717EFB59" unitRef="shares">-950000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-E37A4A7557BC6BE22E6AD182715F677A" unitRef="shares">-3334000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-1EE567516B354B3ECD6BD182717E5826" unitRef="shares">-525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-ABF5566DC890055B1F2CD182717E5A72" unitRef="shares">-187000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-D6467478C324E03B0416D182715FD381" unitRef="shares">-648000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-9816CA983B04C337E9C9D182716EE809" unitRef="shares">1248000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2662E644C7B74A80276DD182716E8CBB" unitRef="shares">1974000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-29057B18C665F94FBCB6D182716E3E7B" unitRef="shares">1766000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-29BB8C3861B3E5355A29D182717EDCEA" unitRef="shares">3441000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-0F437FED046DEC79EEEBD182717EEA92" unitRef="shares">3490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-BA7DACB13618EF57A816D182717ECCBB" unitRef="shares">4502000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2012Q4YTD" decimals="2" id="Fact-14620B3F6E5D8A5C4F16D182716E97AD" unitRef="usdPerShare">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2013Q4YTD" decimals="2" id="Fact-E004C298A5A15FC315A7D182716E9278" unitRef="usdPerShare">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD" decimals="2" id="Fact-F261F9180B6CD2E975BBD182717E17A4" unitRef="usdPerShare">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2014Q4" decimals="-5" id="Fact-A9DBD90F1708F536FF51D182717E1127" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2011Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-780EB166D87E37EBC3F3D182715F1365" unitRef="shares">20476000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2012Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-D176CAC93EDE825207BDD182717EAC99" unitRef="shares">21525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2013Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-A090561213A6EB6CD8CFD182717E1CC9" unitRef="shares">23306000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-4B9F44B4F32EAAECB0D3D182717E8B63" unitRef="shares">23603000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2011Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-92FFCC382EF612A0B602D182715F2224" unitRef="usdPerShare">2.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2012Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-B5F06475BB3CAC0F9781D182717E49D4" unitRef="usdPerShare">2.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2013Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-00805448DB23705F0145D182717ED1B9" unitRef="usdPerShare">2.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-E14A23EAA6ED2654CA9CD182715F6DC2" unitRef="usdPerShare">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-09D49BF84EF0B080C60FD182717E7005" unitRef="usdPerShare">1.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-3B44520E57658F0FA45AD182715F93F6" unitRef="usdPerShare">1.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-97EB8433124D661D6605D182717E9C31" unitRef="usdPerShare">1.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-DF2C3FEAFAA4404A1DF5D182717E7565" unitRef="usdPerShare">6.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-565A8CC89BB0ECF70F52D182717EECAC" unitRef="usdPerShare">3.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-6FCE3FAA166760CA3C87D182717E0401" unitRef="usdPerShare">3.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-31B1767879175BD174DBD182717E323D" unitRef="usdPerShare">1.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-8E89058F49CBD436E462D182717EA7FA" unitRef="usdPerShare">1.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-3CA00C7A3268B751A6E8D182715F6D71" unitRef="usdPerShare">1.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-347A6A6F5871627CA9B5D182717E2CAB" unitRef="usdPerShare">1.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-4ACDBB4C45A0533A1A88D182716EF68D" unitRef="usdPerShare">2.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-2EDFA7722B503CA444F4D182717E5940" unitRef="usdPerShare">1.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2014Q4" decimals="-5" id="Fact-53D291CF63346476BB5CD182717EDF9E" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2014Q4YTD" id="Fact-A0E85E49CD3D258160CFD182716EBB26">P4Y8M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2014Q4YTD" id="Fact-8F378C7A3F874EF44AC8D182717EC222">P5Y10M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:ShortTermInvestments contextRef="FI2013Q4" decimals="-3" id="Fact-4E0A6668396C38B24217D182715F7AB2" unitRef="usd">91629000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2014Q4" decimals="-3" id="Fact-DEC7AC811AF7BDC86480D182716E4B8B" unitRef="usd">202073000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2012Q4SD" decimals="0" id="Fact-C62F2B8BA5F374299A9ED182717E0D22" unitRef="shares">17500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q4SD" decimals="0" id="Fact-17B29B493CAFAC1658BED375B9EC9B19" unitRef="shares">55608930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-68CACF84BF2D01A94548D182716E9C31" unitRef="shares">17500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8447CFD13C87D7876045D1E8438BDBA1" unitRef="shares">204863000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2012Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-0B8E4C6A21FC7B14EECAD182717E69C4" unitRef="shares">-636000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-2F714C7038B0BBD2F670D182717E0BBE" unitRef="shares">-572000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-A9A225B8DE842E5400B2D182715F097F" unitRef="shares">-223000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2012Q4YTD" decimals="-3" id="Fact-F87D9BBB19B15FF93D5DD182716E1A31" unitRef="usd">37055000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-7B962987542B688F6447D182716E0A50" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2B9CBD60D3C86DA0BB48D182715FDCD9" unitRef="usd">37037000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-BD59E45B79A36A8422A9D182715F804F" unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-11E97D60ACFF32CCD24AD182715F9704" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-B450D8A6D4CA38923931D182716E3B0D" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C921EEC4A685CCC96F1CD1E84D5438A4" unitRef="usd">201947000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-C2A701594BFB7730EB69D1E84A684557" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A7BF2F7095149F5DFB6ED1E846DB231A" unitRef="usd">201742000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-82C09CCE9DF936A22817D1E845696757" unitRef="usd">205000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-F9B77A03CC8EFC069757D1E848552E7C" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-986D1780F5E1CA26901DD1E84BE9B060" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2012Q4YTD" decimals="-3" id="Fact-2D907E864C757D284ED5D182716E65A6" unitRef="usd">1054000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-DB1C94D83F8D36D1ED56D182715FF69F" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-85C61B0E9DBE1CDB6708D182716ED97F" unitRef="usd">1053000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-448D415824349C745639D182716E44E0" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D7ECF29C0F9BA851AFEFD182716E18AC" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-E303BD2D7D7F82D3A046D182715F3E40" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2013Q4YTD" decimals="-3" id="Fact-7942CA41AB6C35A53A97D182716E544B" unitRef="usd">1084000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-D74A578CA71A32A37EF8D182716EF61A" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-BF3A64DB2099C442B46AD182716EFA43" unitRef="usd">1082000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DD4F9DD566099F4F7D92D182716ED307" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C829A88379263E4D73B4D182715F01D4" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-4973513E954C6562193ED182716E7392" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-29D7EE92A41C0F51E75BD182716E7BF1" unitRef="usd">323000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-F1EC52550CD0671B925ED182716EF954" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-158B7654E8739A8A5FD4D182716EA716" unitRef="usd">321000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-85FF80D73EB105CB1526D182716E04D4" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-3D3183812B3ABD2111B7D182716EE7FA" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-602E5BB70BE8EE2FEF09D182716EA347" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockholdersEquity contextRef="FI2011Q4" decimals="-3" id="Fact-64C6AC22AC9E145C2D97D182715F1C41" unitRef="usd">297568000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-45A4F1636176F7BC6F82D182716E3284" unitRef="usd">21000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2452797875C75ED6051CD182715F1A84" unitRef="usd">1087033000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-36F811DF7D1CDBDE0120D182716E19CF" unitRef="usd">480000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-38DD9135CE47DC6335F3D182716E48CA" unitRef="usd">-789621000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2011Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-E346A67987690A4592D2D182715F44B8" unitRef="usd">-345000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4" decimals="-3" id="Fact-3D978E2C8874110F1B20D182716E031D" unitRef="usd">266678000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-F62282DE92A0E8FA1804D182716ED66A" unitRef="usd">23000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C13468CF07152BF5104AD182716E857C" unitRef="usd">1166605000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A8927F530ACFA1F80EE5D182716EF633" unitRef="usd">512000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D932BBAD1A415C7EF647D182716EE017" unitRef="usd">-899832000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-D02EE01ACE57CEB952A4D182715F6DD2" unitRef="usd">-630000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4" decimals="-3" id="Fact-2A8A04B9309C827B7D46D182716E6A8C" unitRef="usd">170163000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-610E2505591C5D96D8AAD182716E0227" unitRef="usd">2000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A637C472129154966015D182716E9145" unitRef="usd">1175108000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-9F5C9FD3122DBD1C8947D182716EB604" unitRef="usd">514000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-3B29C2164B4E111F8886D182716E8A83" unitRef="usd">-1003958000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-B4702E2B0E1557CFC857D182715F0AAF" unitRef="usd">-1503000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-6FA22F66AD2526795CD8D182716E7B9A" unitRef="usd">284018000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-4E374CB34DF35E1BCEB4D182716E34BC" unitRef="usd">-63000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-114A5961D86D25F65D74D182716E7482" unitRef="usd">1389997000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D064202207FCCABCE5CFD182716E6413" unitRef="usd">726000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-6F2CD011DC059CBF41B2D182716EE190" unitRef="usd">-1104252000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-C31F684977A7AA362DD2D182715F2D5D" unitRef="usd">-2390000</us-gaap:StockholdersEquity>
	<us-gaap:TreasuryStockShares contextRef="FI2013Q4" decimals="-3" id="Fact-FC2174E0E1630AA83D0AD182716EE374" unitRef="shares">814000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2014Q4" decimals="-3" id="Fact-EBA7A339CCAE23C291A7D182717E580C" unitRef="shares">1281000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockValue contextRef="FI2013Q4" decimals="-3" id="Fact-9F3CE80765CB61AD7D32D182716E6CB8" unitRef="usd">1503000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-11DB1B978F0F4958269ED182717E2712" unitRef="usd">2390000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2012Q4YTD" decimals="-3" id="Fact-D1E04E37813CBB90A860D182716E473E" unitRef="usd">-285000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-12A7CD21A9401E46F242D182716EBC98" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0B753D370997372ED348D182716E5B3F" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F47500966A03DE1CA219D182716E7DF3" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-1C63488BA168EB83821DD182716ED212" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2012Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-05DB52BFB27C0AF4888FD182717E9F17" unitRef="usd">-285000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2013Q4YTD" decimals="-3" id="Fact-3C386A7315B797BE0320D182715F341E" unitRef="usd">-873000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-DD78BD73AF8D09B1FE7DD182715F69F5" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-51A06A4BB5BC294C9F02D182716E0E59" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-696BD66030DFAD72DD1AD182716EDDC8" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E0CB1A0F4C2EE93E79DBD182716E30C1" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-24B503A1B93B4F406E9ED182716EE931" unitRef="usd">-873000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD" decimals="-3" id="Fact-008951D0D12FAC9EE090D182716EC45D" unitRef="usd">-887000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-954F2D07E9F52C2A47A6D182716E5112" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-99663FE74FA766C03575D182716E1225" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FE3083124BC71FC2487BD182716EB271" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-F735C9C427036206BB4FD182716E9F46" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-B2407EFF2CB509830F3DD182716E619D" unitRef="usd">-887000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:UnamortizedDebtIssuanceExpense contextRef="FI2014Q4" decimals="-5" id="Fact-5EDDCE7C584369C79010DB52D1D48B53" unitRef="usd">3300000</us-gaap:UnamortizedDebtIssuanceExpense>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2012Q4YTD" decimals="-3" id="Fact-7B10F970EB810C168810D182717E607C" unitRef="usd">2000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2013Q4YTD" decimals="-3" id="Fact-94D59224B69205F3A0E5D182715F6390" unitRef="usd">-21000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F531E417FB47AF820C11D182717E8074" unitRef="usd">-65000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2014Q4YTD" decimals="-5" id="Fact-07495F2A0AF45012D9ABD182715FC4E9" unitRef="usd">35800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2012Q4YTD" decimals="-3" id="Fact-E08C07FBC4823442CFEDD182717E3276" unitRef="shares">489707000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2013Q1QTD" decimals="-3" id="Fact-3145900CFE729CCF2304D182717E8984" unitRef="shares">512428000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2013Q2QTD" decimals="-3" id="Fact-180C3617ABD314ADC826D182717E0FBF" unitRef="shares">513083000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2013Q3QTD" decimals="-3" id="Fact-91CA261B18E783E646A4D182717EC87E" unitRef="shares">513419000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2013Q4QTD" decimals="-3" id="Fact-AAD58676362B2FD7AEA6D182717E98B1" unitRef="shares">513523000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2013Q4YTD" decimals="-3" id="Fact-B905F476C9A63A8C8CAED182716E2B41" unitRef="shares">513117000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q1QTD" decimals="-3" id="Fact-4B5A0F010640C7A1EF22D182717EF4D7" unitRef="shares">513955000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q2QTD" decimals="-3" id="Fact-FEA3B2022853AE64529ED182717EECC9" unitRef="shares">514623000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q3QTD" decimals="-3" id="Fact-2A972F2BD227F1E329F0D182716E8673" unitRef="shares">514796000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q4QTD" decimals="-3" id="Fact-6D7E4C2480E7E151503DD182715FD634" unitRef="shares">593694000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F15A10DFBB85C28E1BF6D182715FDFBE" unitRef="shares">534432000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<lxrx:ArrangementsWithSymphonyIconIncTextBlock contextRef="FD2014Q4YTD" id="Fact-8FBC576233CD5A76C3B1D182716EFE9B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Arrangements with Symphony Icon, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the &amp;#8220;Programs&amp;#8221;). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (&amp;#8220;Holdings&amp;#8221;), the Company&amp;#8217;s intellectual property rights related to the Programs. Holdings contributed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$45 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Symphony Icon in order to fund the clinical development of the Programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;7,650,622&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock on June&amp;#160;15, 2007 in exchange for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$15 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and an exclusive purchase option (the &amp;#8220;Purchase Option&amp;#8221;) that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.  On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on July&amp;#160;30, 2010 and issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;13,237,519&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to designees of Holdings on July&amp;#160;30, 2012 in satisfaction of an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$35.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; base payment obligation.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon also agreed to make up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$45 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in additional contingent payments, which will consist of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of any consideration Lexicon receives pursuant to any licensing transaction (a &amp;#8220;Licensing Transaction&amp;#8221;) under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates (the &amp;#8220;LG103 Programs&amp;#8221;), subject to certain exceptions. The contingent payments will be due if and when Lexicon receives such consideration from a Licensing Transaction. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$15 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of such sum on account of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the payment made as a result of such United States regulatory approval.  The contingent payments may be paid in cash or a combination of cash and common stock, in Lexicon&amp;#8217;s discretion, provided that no more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of any contingent payment will be paid in common stock.  On December 4, 2014, Lexicon paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash and issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,662,780&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to designees of Holdings in satisfaction of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.5&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; contingent payment obligation as a result of receiving a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment pursuant to the license and collaboration agreement with Ipsen Pharma SAS (see Note 16, Collaboration and License Agreements).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash, and has also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration payments was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$45.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level&amp;#160;3 inputs. Key assumptions include: (1)&amp;#160;a discount rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;14%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the base payments; (2)&amp;#160;a discount rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;18%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the contingent payments; and (3)&amp;#160;a probability adjusted contingency.  The discount rate assumptions have not changed through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and as programs progress, the probability adjusted contingency is adjusted as necessary.  Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, decreased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</lxrx:ArrangementsWithSymphonyIconIncTextBlock>
	<us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-B61C9E2182E4FDE72439D182716EAE2C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cash and Cash Equivalents and Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of cash and cash equivalents and investments held at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="306px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Securities maturing within one year:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201,584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;202,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;202,073&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339,402&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="306px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Securities maturing within one year:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,629&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; realized gains or losses for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; realized gains or losses for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; realized gains or losses for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2014Q4YTD" id="Fact-06708C00FD83A9BAFE0CD182716EF37F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, short-term investments consist of U.S. treasury bills and certificates of deposit.  The certificates of deposits are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&amp;#160;&amp;#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&amp;#160;&amp;#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&amp;#8217; equity.&amp;#160;&amp;#160;Net realized gains and losses, interest and dividends are included in interest income.&amp;#160;&amp;#160;The cost of securities sold is based on the specific identification method.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="FD2014Q4YTD" id="Fact-DE77C51A531411F3F2E0D182716EE40E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Cash and Investments:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Lexicon is required to maintain restricted cash or investments to collateralize standby letters of credit for the lease on its office and laboratory facilities in Hopewell, New Jersey (see Note&amp;#160;12).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-092F91E20EE1C41845BBD182717E3E79">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaboration and License Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Ipsen Pharma SAS.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  In October 2014, Lexicon entered into a License and Collaboration Agreement (the &amp;#8220;Agreement&amp;#8221;)with Ipsen Pharma SAS (&amp;#8220;Ipsen&amp;#8221;)&amp;#160;for the development and commercialization of Lexicon&amp;#8217;s drug candidate telotristat etiprate (LX1032) outside of the United States, Canada and Japan (the &amp;#8220;Licensed Territory&amp;#8221;).  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize telotristat etiprate in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize telotristat etiprate in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon will be responsible for conducting clinical trials required to obtain regulatory approval for telotristat etiprate for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and will have the first right to conduct most other clinical trials of telotristat etiprate.  Lexicon is responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Agreement, Ipsen paid Lexicon an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$23 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$30&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8364;72&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of specified sales milestones.  Due to the uncertainty surrounding the achievement of the future regulatory and sales milestones, these payments will not be recognized as revenue unless and until they are earned as the Company is not able to reasonably predict if and when the milestones will be achieved.  Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of telotristat etiprate in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of telotristat etiprate.  Lexicon&amp;#8217;s receipt of these payments under the Agreement triggers its obligation to make certain contingent payments to Holdings (see Note 11, Arrangements with Symphony Icon, Inc.).  Lexicon and Ipsen will enter into a commercial supply agreement pursuant to which Lexicon will supply Ipsen&amp;#8217;s commercial requirements of telotristat etiprate, and Ipsen will pay an agreed upon transfer price for such commercial supply.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considered the following deliverables with respect to the revenue recognition of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$23 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The exclusive license granted to Ipsen to develop and commercialize telotristat etiprate in the Licensed &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Territory;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The development services Lexicon is performing for telotristat etiprate;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The obligation to participate in committees which govern the development of telotristat&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;etiprate until commercialization; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The obligation to supply commercial supply of telotristat etiprate, under a commercial supply agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the license had stand-alone value because it is an exclusive license that gives Ipsen the right to develop and commercialize telotristat etiprate or to sublicense its rights.  In addition, telotristat etiprate is currently in development and it is possible that Ipsen or another third party could conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Agreement to be separate units of accounting.  The Company recognized the portion of the consideration allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performs services, currently expected to be through mid-2017.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Due to the inherent uncertainty in obtaining regulatory approval, the applicability of the commercial supply agreement is outside the control of Lexicon and Ipsen.  Accordingly, the Company has determined the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  As a result, the Company has determined the commercial supply agreement does not meet the definition of a deliverable that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the initial allocable arrangement consideration was the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment because it was the only payment that was fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the allocable consideration based on the relative best estimate of selling price of each unit of accounting.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;As a result of the allocation, the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;$21.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;of the&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment for the license in 2014.  The Company is recognizing the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allocated to the development services deliverable over the estimated period of performance as development occurs, and is recognizing the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allocated to the committee participation deliverable ratably over the estimated period of performance.  Revenue recognized under the Agreement was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Texas Institute for Genomic Medicine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;&amp;#160;In July 2005, Lexicon received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$35.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine (&amp;#8220;TIGM&amp;#8221;) using Lexicon&amp;#8217;s proprietary gene trapping technology, which Lexicon completed in 2007.&amp;#160;&amp;#160;Lexicon also equipped TIGM with the bioinformatics software required for the management and analysis of data relating to the library.&amp;#160;&amp;#160;The Texas Enterprise Fund also awarded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the Texas A&amp;amp;M University System for the creation of facilities and infrastructure to house the library.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the award, Lexicon is responsible for the creation of a specified number of jobs beginning in 2012, reaching an aggregate of 1,616 new jobs in Texas by December 31, 2016.&amp;#160;&amp;#160;Lexicon will obtain credits based on funding received by TIGM and certain related parties from sources other than the State of Texas that it may offset against its potential liability for any job creation shortfalls.&amp;#160;&amp;#160;Lexicon will also obtain credits against future jobs commitment liabilities for any surplus jobs it creates.&amp;#160;&amp;#160;Subject to these credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2,415&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each job Lexicon falls short beginning in 2013.&amp;#160;&amp;#160;Lexicon&amp;#8217;s maximum aggregate exposure for such payments, if Lexicon fails to create any new jobs, is approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$14.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through 2015, without giving effect to any credits to which Lexicon may be entitled.&amp;#160;&amp;#160;Lexicon has recorded this obligation as deferred revenue and accounts payable in the accompanying consolidated balance sheets.&amp;#160;&amp;#160;The Texas A&amp;amp;M University System, together with TIGM, has independent job creation obligations and is obligated for an additional period to maintain an aggregate of 5,000 jobs, inclusive of those Lexicon creates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-8D95074D446759EF09B0D182717E63C4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Operating Lease Obligations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&amp;#160;&amp;#160;A Lexicon subsidiary leases laboratory and office space in Hopewell, New Jersey under an amended lease agreement which previously had an expiration date in June 2018.  In March 2015, the subsidiary entered into a termination agreement whereby the lease will terminate in June 2015. &amp;#160;The amended lease includes escalating lease payments.  Rent expense is recognized on a straight-line basis over the amended lease term.&amp;#160;&amp;#160;Lexicon is the guarantor of the obligation of its subsidiary under this lease.&amp;#160;&amp;#160;The Company is required to maintain restricted investments to collateralize a standby letter of credit for this lease.&amp;#160;&amp;#160;The Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in restricted investments as collateral as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;Additionally, Lexicon leases certain equipment under operating leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rent expense for all operating leases was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The following table includes non-cancelable, escalating future lease payments for the facility in New Jersey, without regard to the termination agreement entered into in March 2015:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employment Arrangements:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. The arrangements also provide for a termination clause, which requires either a six or 12-month payment based on the officer&amp;#8217;s salary and, in some cases, payment of a specified portion of the officer&amp;#8217;s bonus target for such year, in the event of termination.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Legal Proceedings:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-86D9E1F71206BA0741B8D182716ED5B7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentration of Credit Risk:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon&amp;#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&amp;#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&amp;#160;&amp;#160;The Company has not experienced any significant credit losses to date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2014Q4YTD" id="Fact-B5D46B1D1162A31EB0D5D182716E3B81">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-13BFB479175B2D757D33D182716EEA17">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Debt Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Debt.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; In November 2014, Lexicon completed an offering of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$87.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in aggregate principal amount of its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Convertible Senior Notes due 2021 (the &amp;#8220;Notes&amp;#8221;).  In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as long-term debt on the Company&amp;#8217;s consolidated balance sheet.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Notes are governed by an indenture (the &amp;#8220;Indenture&amp;#8221;), dated as of November&amp;#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Notes bear interest at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;per year, payable semiannually in arrears on June&amp;#160;1 and December&amp;#160;1 of each year, beginning on June&amp;#160;1, 2015. The Notes mature on December&amp;#160;1, 2021. The Company may not redeem the Notes prior to the maturity date, and no sinking fund is provided for the Notes.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Holders of the Notes may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;829.1874&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.206&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Notes in connection with such a corporate event in certain circumstances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the issuance of the Notes, the Company incurred &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of debt issuance costs, which is included in other assets on the consolidated balance sheets.  The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Notes.  As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the balance of unamortized debt issuance costs was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$3.3&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the Notes was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$81.0&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and was determined using Level&amp;#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Mortgage Loan. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$34.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; third-party mortgage financing and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$20.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash.&amp;#160;&amp;#160;The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;8.23%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan&amp;#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  The mortgage had a principal balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.2&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  This entire balance has been classified as current liabilities on the accompanying consolidated balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as management intends to repay the mortgage when the assets that serve as collateral for the mortgage loan are sold.  These assets have been reclassified to assets held for sale as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as discussed in Note 6, Assets Held for Sale.  The buildings and land that serve as collateral for the mortgage loan are included in assets held for sale at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$59.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, before accumulated depreciation, as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The fair value of Lexicon&amp;#8217;s mortgage loan approximates its carrying value.&amp;#160;&amp;#160;The fair value of Lexicon&amp;#8217;s mortgage loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&amp;#8217;s estimated current incremental borrowing rate.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table includes the aggregate future principal payments of the Company&amp;#8217;s long-term debt as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  As discussed above, all of the principal due in 2015, 2016 and 2017 relate to the mortgage loan and have been classified as current portion of long-term debt in the accompanying consolidated balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,859&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2014Q4YTD" id="Fact-02718AE6511F3E4775A8D182716E96E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity Incentive Awards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity Incentive Plan:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and restated in February 2000 and renamed the 2000 Equity Incentive Plan, subsequently amended and restated in April 2009 and renamed the Equity Incentive Plan (the &amp;#8220;Equity Incentive Plan&amp;#8221;), and subsequently amended in April 2012.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit (phantom stock) awards and stock appreciation rights. Incentive and nonstatutory stock options have an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or more of the fair market value of our common stock on the date of grant.&amp;#160;&amp;#160;The purchase price of restricted stock awards may not be less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;85%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of fair market value.&amp;#160;&amp;#160;However, the plan administrator may award stock bonus awards in consideration of past services or phantom stock awards without a purchase payment. Shares may be subject to a repurchase option in the discretion of the plan administrator.&amp;#160;&amp;#160;Most options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&amp;#160;&amp;#160;Options granted under the Equity Incentive Plan have a term of ten years from the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares.&amp;#160;&amp;#160;No more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;15,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares may be issued pursuant to awards other than stock options and stock appreciation rights.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock had been reserved for issuance, options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;22,533,242&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;3,130,720&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; restricted stock units were outstanding, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;5,881,815&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares had been issued upon the exercise of stock options, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;3,224,339&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares had been issued pursuant to restricted stock units and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;797,700&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Non-Employee Directors&amp;#8217; Equity Incentive Plan:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&amp;#8217; Stock Option Plan, which was subsequently amended and restated in April 2009 and renamed the Non-Employee Directors&amp;#8217; Stock Option Plan, and subsequently amended in April 2012 and renamed the Non-Employee Directors&amp;#8217; Equity Incentive Plan (the &amp;#8220;Directors&amp;#8217; Plan&amp;#8221;).&amp;#160;&amp;#160;Under the Directors&amp;#8217; Plan, non-employee directors receive an initial option to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;30,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock.&amp;#160;&amp;#160;In addition, on the day following each of the Company&amp;#8217;s annual meetings of stockholders, each non-employee director who has been a director for at least six months is automatically granted an option to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and a restricted stock award of the number of shares of common stock having a fair market value on the date of grant of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, rounded down to the nearest whole share number.&amp;#160;&amp;#160;Initial option grants become vested and exercisable over a period of five years and annual option grants become vested over a period of 12&amp;#160;months from the date of grant.&amp;#160;&amp;#160;Options granted under the Directors&amp;#8217; Plan have an exercise price equal to the fair market value of the Company&amp;#8217;s common stock on the date of grant and a term of ten years from the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&amp;#8217; Plan shall not exceed in the aggregate &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock had been reserved for issuance, options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1,070,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were outstanding, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;none&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; had been issued upon the exercise of stock options and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;277,480&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares had been issued pursuant to restricted stock awards granted under the Directors&amp;#8217; Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Option Activity:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;The following is a summary of option activity under Lexicon&amp;#8217;s equity incentive plans:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="34%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands, except exercise price data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,476&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,231&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(648&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average estimated grant date fair value of options granted during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.23&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.59&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.37&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The total intrinsic value of options exercised during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$43,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$325,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$462,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The weighted average remaining contractual term of options outstanding and exercisable was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;5.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;4.7&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, respectively, as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the aggregate intrinsic value of the outstanding options and the exercisable options was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Bonus and Restricted Stock Unit Activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the years ended December 31, 2014, 2013 and 2012, Lexicon granted its non-employee directors &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;102,560&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,808&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;94,112&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares, respectively, of restricted stock awards.  The restricted stock awards had weighed average grant date fair values of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.56&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.98&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.70&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, respectively, and vested immediately.  During the year ended December&amp;#160;31, 2014, Lexicon granted a consultant &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,400&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of restricted stock awards.  The restricted stock awards had a weighted average grant date fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.60&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and vested immediately.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon&amp;#8217;s stock-based compensation plans for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="66%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nonvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Aggregate Shares Reserved for Issuance&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;26,733,962&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;14,584,704&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional shares were available for future grants under Lexicon&amp;#8217;s equity incentive plans.&amp;#160;&amp;#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock contextRef="FD2014Q4YTD" id="Fact-FED70B132B33F55DF8ECD33BE9951419">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets Held for Sale&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon&amp;#8217;s buildings and land have been reclassified as assets held for sale on the consolidated balance sheet as of&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company estimated the fair value of the net assets to be sold at approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$23.8&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which represents estimated selling price less costs to sell. This resulted in an impairment loss on the&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;assets held for sale of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$13.1&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was recorded in impairment loss on&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;buildings in the accompanying consolidated statement of comprehensive loss for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The fair value of the net assets to be sold was determined using Level 2 inputs using sales prices in similar real estate sales and offers received from potential purchasers of the building.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2014Q4YTD" id="Fact-66DC27F7FA66415E91DBD182716E2CDE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Loss per Common Share:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options, restricted stock units and warrants are not included because they are antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="FD2014Q4YTD" id="Fact-1231566E7A118DB37F24D182716E6E91">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets and Liabilities at Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;202,073&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;338,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:676px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="293px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets and Liabilities at Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,629&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;128,576&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2014Q4YTD" id="Fact-CC80020E5FF8025EC76CD182717EF220">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&amp;#160;&amp;#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&amp;#160;&amp;#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 &amp;#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 &amp;#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 &amp;#8211; significant unobservable inputs (including the Company&amp;#8217;s own assumptions in determining the fair value of assets and liabilities)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&amp;#160;&amp;#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets and Liabilities at Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;202,073&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;338,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:676px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="293px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets and Liabilities at Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,629&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;128,576&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company did not have any Level 3 assets during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  The Company&amp;#8217;s Level&amp;#160;3 liabilities are estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon (&amp;#8220;Symphony Icon&amp;#8221;) purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, decreased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="80%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of base payment obligation with common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of contingent payment obligation with common stock and cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.&amp;#160;&amp;#160;These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon on July 30, 2010 and intangible assets associated with the acquisition of Symphony Icon on July 30, 2010.&amp;#160;&amp;#160;For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2014Q4YTD" id="Fact-1A72F16CB78412FFF097D182717EC3F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="80%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2011&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of base payment obligation with common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation of purchase consideration payable to former Symphony Icon stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payment of contingent payment obligation with common stock and cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-8E4A306A00C828717B33D182716EAA8B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&amp;#8217;s division responsible for small molecule compound discovery.&amp;#160;&amp;#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&amp;#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$25.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which represents the excess of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$36.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July 30, 2010, Lexicon exercised its Purchase Option (as defined in Note 11) and completed the acquisition of Symphony Icon.  Goodwill associated with the acquisition of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$18.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&amp;#8217;s single operating segment.&amp;#160;&amp;#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&amp;#160;&amp;#160;This test did not result in an impairment of goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2014Q4YTD" id="Fact-90769EA3CE736C5AF850D182716EDAD2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill Impairment:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&amp;#160;&amp;#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&amp;#160;&amp;#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&amp;#160;&amp;#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&amp;#160;&amp;#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2014Q4YTD" id="Fact-CDB96816E3835BF38B65D182716E05E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Impairment of Long-Lived Assets:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Indefinite lived intangible assets are also tested at least annually for impairment.  Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition.&amp;#160;&amp;#160;In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-A325190364DAC65FBEE1D182716EA59F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of Lexicon&amp;#8217;s deferred tax assets (liabilities) at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="71%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;255,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,648&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,681&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;412,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;376,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability related to acquisition of Symphony Icon&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(412,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(376,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$18.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; deferred tax liability relates to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.  Lexicon does not believe it can estimate the reversal of the temporary difference related to the assets acquired with sufficient certainty such that the related deferred tax liability could be considered as a source of taxable income in assessing the Company&amp;#8217;s need for a valuation allowance.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Lexicon had both federal and state NOL carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$715.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$460.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The federal and state NOL carryforwards began to expire in 2011 and continued to expire in 2012.&amp;#160;&amp;#160;The Company&amp;#8217;s R&amp;amp;D tax credit carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$40.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; began to expire in 2012.&amp;#160;&amp;#160;Utilization of the NOL and R&amp;amp;D credit carryforwards may be subject to a significant annual limitation due to ownership changes that have occurred previously or could occur in the future provided by Section&amp;#160;382 of the Internal Revenue Code.&amp;#160;&amp;#160;Based on the federal tax law limits and the Company&amp;#8217;s cumulative loss position, Lexicon concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&amp;#160;&amp;#160;During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the valuation allowance increased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$35.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, primarily due to the Company&amp;#8217;s current year net loss.&amp;#160;&amp;#160;Lexicon recorded income tax benefits of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$70,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.  During the year ended December 31, 2013, the Company recorded certain revisions to its deferred tax assets.  The revisions reduced the deferred tax assets and valuation allowance by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  There was no impact to the Company&amp;#8217;s equity or operating results for any period.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company did not have any unrecognized tax benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&amp;#160;&amp;#160;The tax years 1995 to current remain open to examination by U.S. federal authorities and 2004 to current remain open to examination by state authorities.&amp;#160;&amp;#160;The Company&amp;#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had no accruals for interest or penalties related to income tax matters.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="FD2014Q4YTD" id="Fact-F8C3A12C5EFE87A9F802D225877C848A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2014-09, &amp;#8220;Revenue from Contracts with Customers&amp;#8221;, which amends FASB ASC Topic 606. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. This standard contains principles for the determination of the measurement of revenue and the timing of when such revenue is recognized. Revenue recognition will reflect the transfer of goods or services to customers at an amount that is expected to be earned in exchange for those goods or services. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December&amp;#160;15, 2016, and early adoption is not permitted. Management is currently evaluating the impact of this pronouncement on Lexicon&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued ASU No. 2014-15, &amp;#8220;Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern.&amp;#8221; ASU 2014-15 will explicitly require management to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted.  Management does not expect the adoption of this pronouncement to have a material impact on Lexicon&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-3C80AC2E536ADE58507CD182717E7C40">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Organization and Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon Pharmaceuticals, Inc. (&amp;#8220;Lexicon&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a Delaware corporation incorporated on July&amp;#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under drug discovery and development collaborations, target validation, database subscription and technology license agreements, government grants and contracts and financing under debt and lease arrangements. The Company&amp;#8217;s future success is dependent upon many factors, including, but not limited to, its ability to discover and develop pharmaceutical products for the treatment of human disease, establish new collaboration and license agreements, achieve milestones under such agreements, obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&amp;#160;&amp;#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&amp;#8217;s future success.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-B06FAE86C6E1143C2A48D182717E8F9E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Benefit Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&amp;#160;&amp;#160;The plan covers substantially all full-time employees.&amp;#160;&amp;#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&amp;#160;&amp;#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&amp;#160;&amp;#160;The matching contributions totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$376,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$511,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$490,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;Company contributions are vested based on the employee&amp;#8217;s years of service, with full vesting after four years of service.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-799FA822EF211210A724D182717EFC4A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="57%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;In Years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3-5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5-7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,315&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3-7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7-10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15-40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,354&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;123,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(81,945&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Buildings of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$59.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and land of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as well as &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$38.0&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of related accumulated depreciation, have been reclassified to assets held for sale (see Note 6, Assets Held for Sale) as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2014Q4YTD" id="Fact-50189F2E98541B9354F8D182716EBAFF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property and Equipment:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Property and equipment are carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&amp;#160;&amp;#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&amp;#160;&amp;#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&amp;#160;&amp;#160;Significant renewals and betterments are capitalized.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2014Q4YTD" id="Fact-82C238AE7B3A1DD44157D182717EAA4D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="57%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="2%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;In Years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3-5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5-7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,315&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3-7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7-10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15-40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,354&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;123,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(81,945&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2014Q4YTD" id="Fact-D688F90C1885B02321B9D182717E187C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Selected Quarterly Financial Data&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands, except per share data)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;March 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;June 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;September 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;676&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,472&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(26,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(40,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(26,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(40,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares used in computing consolidated net loss per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;513,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;514,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;514,796&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;593,694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,555&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31,216&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,976&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31,658&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,414&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consolidated net loss per common share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares used in computing consolidated net loss per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;512,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;513,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;513,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;513,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2014Q4YTD" id="Fact-F795E6123309DB2A1D97D182716EB566">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&amp;#160;&amp;#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&amp;#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&amp;#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-437D1BE3B63A1EE49EF9D182715F94E4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Restructuring Charges&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2014, Lexicon&amp;#8217;s board of directors committed to narrow its strategic initiatives and focus resources on its late-stage drug development programs, principally sotagliflozin (LX4211) for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, in preparation for the transition to commercialization.  The decision resulted in a workforce reduction of approximately 125 employees, primarily in research, discovery and support positions, representing approximately 50% of the Company&amp;#8217;s total workforce.  The Company completed the majority of the workforce reduction by the end of the second quarter of 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company currently expects that the total charges associated with the restructuring which will result in cash expenditures will be approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.7&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (which includes charges for severance of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.3&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and other restructuring costs of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;), of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.6&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was incurred through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Of this charge, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.9&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was recorded in research and development expense and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was recorded in general and administrative expense in the accompanying consolidated statement of comprehensive loss for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  In addition, the Company recorded stock-based compensation expense on the acceleration of vesting relating to the restructuring of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Future payments of restructuring charges, which have been recorded in accrued liabilities in the accompanying consolidated balance sheet, were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2014Q4YTD" id="Fact-42E381DD29773D2C1B65D182716E6705">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaborative agreements revenues include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The delivered item or items have value to the customer on a stand-alone basis.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&amp;#8217;s control.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;It can only be achieved based in whole or in part on either the Company&amp;#8217;s performance or on the occurrence of a specific outcome resulting from the Company&amp;#8217;s performance;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;It would result in additional payments being due to the Company.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subscription and license fees are recognized as revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="FD2014Q4YTD" id="Fact-801AA13E20AA21077664D182716EA8C3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="306px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;137,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Securities maturing within one year:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201,584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;202,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;202,073&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339,402&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;339,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="306px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="79px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4px" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Gross Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Securities maturing within one year:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certificates of deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;552&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,629&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash and cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2014Q4YTD" id="Fact-611DD7A518C1037DA72ED182717E1014">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="71%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;255,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,648&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,681&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;412,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;376,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liability related to acquisition of Symphony Icon&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(412,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(376,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2014Q4YTD" id="Fact-0CC6DE17FBFAC2187EBDD182717E49DD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,075&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2014Q4YTD" id="Fact-14947143053DB480052CD182716E92C6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;For the Year Ending&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,859&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="FD2014Q4YTD" id="Fact-401F6181329BE914FEFFD182715FF3B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="66%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,384&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nonvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2014Q4YTD" id="Fact-6A34208F2A902E16508DD182715FC9DC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="34%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands, except exercise price data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,476&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,502&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,231&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(648&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2014Q4YTD" id="Fact-7F97DA8B6C036193AEA6D182716E852B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="49%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expected Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Risk-free Interest Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expected Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;"&gt;Dividend&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;"&gt;Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2013:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2012:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.8%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SegmentReportingDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-D84D9342D474F3D2F1DFD182716E16F6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segment Information and Significant Customers:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon operates in one business segment, which primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Substantially all of the Company&amp;#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, government grants and contracts and compound library sales.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2014Q4YTD" id="Fact-A2C24503F34D0B9DD264D182716EA62A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&amp;#160;&amp;#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, stock-based compensation cost for all outstanding unvested options and restricted stock units was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1.3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&amp;#160;&amp;#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&amp;#160;&amp;#160;Because the Company&amp;#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&amp;#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&amp;#160;&amp;#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&amp;#160;&amp;#160;Expected volatility is based on the historical volatility in the Company&amp;#8217;s stock price.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2014Q4YTD" id="Fact-967AD3AB86B2D8821E23D182716E108C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, short-term investments consist of U.S. treasury bills and certificates of deposit.  The certificates of deposits are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&amp;#160;&amp;#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&amp;#160;&amp;#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&amp;#8217; equity.&amp;#160;&amp;#160;Net realized gains and losses, interest and dividends are included in interest income.&amp;#160;&amp;#160;The cost of securities sold is based on the specific identification method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Cash and Investments:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Lexicon is required to maintain restricted cash or investments to collateralize standby letters of credit for the lease on its office and laboratory facilities in Hopewell, New Jersey (see Note&amp;#160;12).&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, restricted cash and investments were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts Receivable:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&amp;#160;&amp;#160;&amp;#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&amp;#160;&amp;#160;Write-offs are evaluated on a case by case basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentration of Credit Risk:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon&amp;#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&amp;#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&amp;#160;&amp;#160;The Company has not experienced any significant credit losses to date.&amp;#160;&amp;#160;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, customers in France and the United States represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue, respectively.  In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, customers in the United States represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue, respectively.&amp;#160;&amp;#160;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, management believes that the Company has no significant concentrations of credit risk.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segment Information and Significant Customers:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Lexicon operates in one business segment, which primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Substantially all of the Company&amp;#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, government grants and contracts and compound library sales.  In 2014, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Ipsen Pharma SAS&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenues.  In 2013, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;McNair Medical Institute, LLC&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;Taconic Farms, Inc.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;57%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;33%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenues, respectively.  In 2012, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;Taconic Farms&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;Deltagen&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;68%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenues, respectively.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property and Equipment:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Property and equipment are carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&amp;#160;&amp;#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&amp;#160;&amp;#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&amp;#160;&amp;#160;Significant renewals and betterments are capitalized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Impairment of Long-Lived Assets:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Indefinite lived intangible assets are also tested at least annually for impairment.  Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition.&amp;#160;&amp;#160;In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values.  In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Lexicon reclassified its buildings as assets held for sale, and recorded an impairment loss of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (see Note 6, Assets Held for Sale)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill Impairment:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&amp;#160;&amp;#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&amp;#160;&amp;#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&amp;#160;&amp;#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&amp;#160;&amp;#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&amp;#160;&amp;#160;There was no impairment of goodwill in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collaborative agreements revenues include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The delivered item or items have value to the customer on a stand-alone basis.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&amp;#8217;s control.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;It can only be achieved based in whole or in part on either the Company&amp;#8217;s performance or on the occurrence of a specific outcome resulting from the Company&amp;#8217;s performance;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;It would result in additional payments being due to the Company.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subscription and license fees are recognized as revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&amp;#160;&amp;#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&amp;#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&amp;#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&amp;#160;&amp;#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, stock-based compensation cost for all outstanding unvested options and restricted stock units was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1.3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&amp;#160;&amp;#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&amp;#160;&amp;#160;Because the Company&amp;#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&amp;#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&amp;#160;&amp;#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&amp;#160;&amp;#160;Expected volatility is based on the historical volatility in the Company&amp;#8217;s stock price.&amp;#160;&amp;#160;The following weighted-average assumptions were used for options granted in the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="49%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expected Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Risk-free Interest Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expected Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;"&gt;Dividend&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;"&gt;Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2013:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2012:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.8%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Officers and non-employee directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Loss per Common Share:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options, restricted stock units and warrants are not included because they are antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2014Q4YTD" id="Fact-0F4DC6AEF4BEDDC44725D182717E1E2D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Other Capital Stock Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; In October 2012, Lexicon sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;17,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.25&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share in a public offering, resulting in net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$37.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.0&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and offering expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Invus, L.P., Lexicon&amp;#8217;s largest stockholder, purchased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;3,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of these shares.  All of the net proceeds of this offering are reflected as issuance of common stock in the accompanying financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2014, Lexicon sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,608,930&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.005&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share in a public offering, and sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;149,253,731&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.005&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share in a private placement to Artal International S.C.A, an affiliate of Invus, L.P., resulting in net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$201.9&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and offering expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  All of the net proceeds of these offerings are reflected as issuance of common stock in the accompanying financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="FD2014Q4YTD" id="Fact-53158B794B87E3D6926ED182716EBA53">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts Receivable:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&amp;#160;&amp;#160;&amp;#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&amp;#160;&amp;#160;Write-offs are evaluated on a case by case basis.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UseOfEstimates contextRef="FD2014Q4YTD" id="Fact-1DDB77E3DED980164429D182716E2B7B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>lxrx-20141231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20141231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20141231" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-roles-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20141231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20141231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20141231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20141231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="ArrangementsWithSymphonyIconInc" roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc">
        <link:definition>2134100 - Disclosure - Arrangements with Symphony Icon, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ArrangementsWithSymphonyIconIncDetails" roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails">
        <link:definition>2434402 - Disclosure - Arrangements with Symphony Icon, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ArrangementsWithSymphonyIconIncTables" roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables">
        <link:definition>2334301 - Disclosure - Arrangements with Symphony Icon, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsHeldForSale" roleURI="http://www.lexpharma.com/role/AssetsHeldForSale">
        <link:definition>2119100 - Disclosure - Assets Held for Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsHeldForSaleDetails" roleURI="http://www.lexpharma.com/role/AssetsHeldForSaleDetails">
        <link:definition>2419402 - Disclosure - Assets Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsHeldForSaleTables" roleURI="http://www.lexpharma.com/role/AssetsHeldForSaleTables">
        <link:definition>2319301 - Disclosure - Assets Held for Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetParentheticals" roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals">
        <link:definition>1001500 - Statement - Balance Sheet Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlan" roleURI="http://www.lexpharma.com/role/BenefitPlan">
        <link:definition>2149100 - Disclosure - Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanDetails" roleURI="http://www.lexpharma.com/role/BenefitPlanDetails">
        <link:definition>2449402 - Disclosure - Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlanTables" roleURI="http://www.lexpharma.com/role/BenefitPlanTables">
        <link:definition>2349301 - Disclosure - Benefit Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalentsAndInvestments" roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments">
        <link:definition>2113100 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalentsAndInvestmentsDetails" roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails">
        <link:definition>2413402 - Disclosure - Cash and Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndCashEquivalentsAndInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables">
        <link:definition>2313301 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements">
        <link:definition>2150100 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails">
        <link:definition>2450402 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreementsTables" roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsTables">
        <link:definition>2350301 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsAndContingencies">
        <link:definition>2137100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails1" roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1">
        <link:definition>2437402 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails2" roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2">
        <link:definition>2437403 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2337301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>2131100 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails1" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1">
        <link:definition>2431402 - Disclosure - Debt Obligations (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails2" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails2">
        <link:definition>2431403 - Disclosure - Debt Obligations (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsTables">
        <link:definition>2331301 - Disclosure - Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformationDocument" roleURI="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument">
        <link:definition>0001000 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwards" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards">
        <link:definition>2146100 - Disclosure - Equity Incentive Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails1" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1">
        <link:definition>2446402 - Disclosure - Equity Incentive Awards (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails2" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2">
        <link:definition>2446403 - Disclosure - Equity Incentive Awards (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails3" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3">
        <link:definition>2446404 - Disclosure - Equity Incentive Awards (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsDetails4" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4">
        <link:definition>2446405 - Disclosure - Equity Incentive Awards (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables">
        <link:definition>2346301 - Disclosure - Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>2116100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>2416402 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2">
        <link:definition>2416403 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2316301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.lexpharma.com/role/Goodwill">
        <link:definition>2128100 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.lexpharma.com/role/GoodwillDetails">
        <link:definition>2428402 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.lexpharma.com/role/GoodwillTables">
        <link:definition>2328301 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lexpharma.com/role/IncomeTaxes">
        <link:definition>2125100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1">
        <link:definition>2425402 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2">
        <link:definition>2425403 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.lexpharma.com/role/IncomeTaxesTables">
        <link:definition>2325301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndOperations" roleURI="http://www.lexpharma.com/role/OrganizationAndOperations">
        <link:definition>2101100 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndOperationsDetails" roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsDetails">
        <link:definition>2401402 - Disclosure - Organization and Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndOperationsTables" roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsTables">
        <link:definition>2301301 - Disclosure - Organization and Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalStockAgreements" roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreements">
        <link:definition>2143100 - Disclosure - Other Capital Stock Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalStockAgreementsDetails" roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails">
        <link:definition>2443402 - Disclosure - Other Capital Stock Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalStockAgreementsTables" roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables">
        <link:definition>2343301 - Disclosure - Other Capital Stock Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.lexpharma.com/role/PropertyAndEquipment">
        <link:definition>2122100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails1" roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1">
        <link:definition>2422402 - Disclosure - Property and Equipment (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails2" roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails2">
        <link:definition>2422403 - Disclosure - Property and Equipment (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentTables">
        <link:definition>2322301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncements" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements">
        <link:definition>2110100 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsDetails" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails">
        <link:definition>2410402 - Disclosure - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsTables" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables">
        <link:definition>2310301 - Disclosure - Recent Accounting Pronouncements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringCharges" roleURI="http://www.lexpharma.com/role/RestructuringCharges">
        <link:definition>2151100 - Disclosure - Restructuring Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesDetails" roleURI="http://www.lexpharma.com/role/RestructuringChargesDetails">
        <link:definition>2451402 - Disclosure - Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesTables" roleURI="http://www.lexpharma.com/role/RestructuringChargesTables">
        <link:definition>2351301 - Disclosure - Restructuring Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialData" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData">
        <link:definition>2152100 - Disclosure - Selected Quarterly Financial Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataDetails" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails">
        <link:definition>2452402 - Disclosure - Selected Quarterly Financial Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataTables" roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables">
        <link:definition>2352301 - Disclosure - Selected Quarterly Financial Data (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfComprehensiveLossParentheticalsParentheticals" roleURI="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals">
        <link:definition>1003500 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2104100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAccountsReceivable" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivable">
        <link:definition>2204205 - Disclosure - Summary of Significant Accounting Policies Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments">
        <link:definition>2204203 - Disclosure - Summary of Significant Accounting Policies Cash, Cash Equivalents and Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk">
        <link:definition>2204206 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
        <link:definition>2404417 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesGoodwillImpairment" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillImpairment">
        <link:definition>2204210 - Disclosure - Summary of Significant Accounting Policies Goodwill Impairment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets">
        <link:definition>2204209 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails">
        <link:definition>2404419 - Disclosure - Summary of Significant Accounting Policies Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare">
        <link:definition>2204214 - Disclosure - Summary of Significant Accounting Policies Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipment">
        <link:definition>2204208 - Disclosure - Summary of Significant Accounting Policies Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses">
        <link:definition>2204212 - Disclosure - Summary of Significant Accounting Policies Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments">
        <link:definition>2204204 - Disclosure - Summary of Significant Accounting Policies Restricted Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails">
        <link:definition>2404416 - Disclosure - Summary of Significant Accounting Policies Restricted Cash and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRevenueRecognition" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognition">
        <link:definition>2204211 - Disclosure - Summary of Significant Accounting Policies Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails">
        <link:definition>2404418 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers">
        <link:definition>2204207 - Disclosure - Summary of Significant Accounting Policies Segment Information and Significant Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesStockBasedCompensation" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensation">
        <link:definition>2204213 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1">
        <link:definition>2404420 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2">
        <link:definition>2404421 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2304315 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesUseOfEstimates" roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimates">
        <link:definition>2204202 - Disclosure - Summary of Significant Accounting Policies Use of Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lxrx_AccumulatedDepreciationReclassifiedToHeldForSale" name="AccumulatedDepreciationReclassifiedToHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_ArrangementsWithSymphonyIconIncAbstract" name="ArrangementsWithSymphonyIconIncAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ArrangementsWithSymphonyIconIncTextBlock" name="ArrangementsWithSymphonyIconIncTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_AssetsAndLiabilitiesAtFairValueAbstract" name="AssetsAndLiabilitiesAtFairValueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_AssetsHeldforSaleAbstract" name="AssetsHeldforSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_BalanceSheetParentheticalsAbstract" name="BalanceSheetParentheticalsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_BenefitPlanAbstract" name="BenefitPlanAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_BuildingsCollateral" name="BuildingsCollateral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_BuildingsReclassifiedToHeldForSale" name="BuildingsReclassifiedToHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" name="ChangeInFairValueOfSymphonyIconIncPurchaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_CoelacanthGoodwill" name="CoelacanthGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_CoelacanthPurchasePrice" name="CoelacanthPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_CollaborationAndLicenseAgreementsAbstract" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConcentrationOfCreditRiskAbstract" name="ConcentrationOfCreditRiskAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedBalanceSheetsAbstract" name="ConsolidatedBalanceSheetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedStatementsOfCashFlowsAbstract" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedStatementsOfOperationsAbstract" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" name="ConsolidatedStatementsOfOperationsParentheticalsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" name="ConvertibleDebtInstrumentInterestRateStatedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_DebtObligationsAbstract" name="DebtObligationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" name="DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_DeiAbstract" name="DeiAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_DirectorsAnnualOptionGrant" name="DirectorsAnnualOptionGrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_DirectorsAnnualRestrictedStockAwardValue" name="DirectorsAnnualRestrictedStockAwardValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_DirectorsIntialOptionGrant" name="DirectorsIntialOptionGrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" name="DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_EntityWideRevenueDeltagenPercentage" name="EntityWideRevenueDeltagenPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_EntityWideRevenueIpsenPercentage" name="EntityWideRevenueIpsenPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage" name="EntityWideRevenueMcNairMedicalInstitutePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_EntityWideRevenueTaconicFarmsPercentage" name="EntityWideRevenueTaconicFarmsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_EquityIncentiveAwardsAbstract" name="EquityIncentiveAwardsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_FairValueMeasurementsAbstract" name="FairValueMeasurementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_GoodwillAbstract" name="GoodwillAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_HoldingsContributionToIcon" name="HoldingsContributionToIcon" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_IncomeTaxesAbstract" name="IncomeTaxesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" name="IpsenMaximumRegulatoryAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenMaximumSalesMilestones" name="IpsenMaximumSalesMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" name="IpsenRevenueAllocatedtoCommitteeDeliverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" name="IpsenRevenueAllocatedtoLicenseDeliverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenRevenueRecognized" name="IpsenRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_IpsenUpfrontPayment" name="IpsenUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_LandCollateral" name="LandCollateral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_LandReclassifiedToHeldForSale" name="LandReclassifiedToHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_LexiconPaidHoldingsCash" name="LexiconPaidHoldingsCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_LexiconReceivedCashFromHoldings" name="LexiconReceivedCashFromHoldings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_LexiconSoldSharesToHoldings" name="LexiconSoldSharesToHoldings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan" name="LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_NetProceedsFromStockOffering" name="NetProceedsFromStockOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_OfferingPricePerShare" name="OfferingPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_OptionsOutstandingEquityIncentivePlan" name="OptionsOutstandingEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" name="OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_OrganizationAndOperationsAbstract" name="OrganizationAndOperationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_OtherCapitalStockAgreementsAbstract" name="OtherCapitalStockAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_PaymentsOfUnderwritingDiscountsAndCommissions" name="PaymentsOfUnderwritingDiscountsAndCommissions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_PropertyAndEquipmentAbstract" name="PropertyAndEquipmentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_RecentAccountingPronouncementsAbstract" name="RecentAccountingPronouncementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock" name="RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" name="RestrictedStockUnitsOutstandingEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_RestructuringCostSeveranceCosts" name="RestructuringCostSeveranceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative" name="RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment" name="RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation" name="RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_RevisiontoDeferredTaxAssets" name="RevisiontoDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_SegmentInformationAndSignificantCustomersAbstract" name="SegmentInformationAndSignificantCustomersAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_SelectedQuarterlyFinancialDataAbstract" name="SelectedQuarterlyFinancialDataAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" name="SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" name="SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" name="SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" name="SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SharesIssuedToSymphonyDesigneesValue" name="SharesIssuedToSymphonyDesigneesValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SharesIssuedtoSymphonyDesigneesShares" name="SharesIssuedtoSymphonyDesigneesShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lxrx_StockBasedCompensationAbstract" name="StockBasedCompensationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" name="StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_StockIssuedDuringPeriodToInvusShares" name="StockIssuedDuringPeriodToInvusShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" name="StockOptionExercisePriceAsPercentOfValueOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_StockOptionsExercisedEquityIncentivePlan" name="StockOptionsExercisedEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" name="StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lxrx_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SymphonFairValueOfBaseAndContingentPayments" name="SymphonFairValueOfBaseAndContingentPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyBasePaymentDiscountRate" name="SymphonyBasePaymentDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyBasePaymentInShares" name="SymphonyBasePaymentInShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyBasePaymentObligation" name="SymphonyBasePaymentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyContingentPaymentDiscountRate" name="SymphonyContingentPaymentDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyContingentPaymentInCash" name="SymphonyContingentPaymentInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SymphonyContingentPaymentMaximum" name="SymphonyContingentPaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyContingentPaymentPercentage" name="SymphonyContingentPaymentPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyContingentPaymentTotal" name="SymphonyContingentPaymentTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SymphonyContingentPaymentinShares" name="SymphonyContingentPaymentinShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="lxrx_SymphonyIconGoodwill" name="SymphonyIconGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyPaymentInStockLimitation" name="SymphonyPaymentInStockLimitation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyRegulatoryApprovalPayment" name="SymphonyRegulatoryApprovalPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyRegulatoryApprovalPercentageLimit" name="SymphonyRegulatoryApprovalPercentageLimit" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_SymphonyRegulatoryApprovalReductionPercentage" name="SymphonyRegulatoryApprovalReductionPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TIGMMaximumExposureThroughReportingDate" name="TIGMMaximumExposureThroughReportingDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TigmMaximumExposure" name="TigmMaximumExposure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TigmPerJobPaymentAmount" name="TigmPerJobPaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" name="TotalSharesThatMayBeIssuedEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" name="TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="lxrx_TxEnterpriseFundAward" name="TxEnterpriseFundAward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem" name="TxEnterpriseFundAwardToTexasAmUniversitySystem" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_WoodlandsCashPaid" name="WoodlandsCashPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lxrx_WoodlandsMortgage" name="WoodlandsMortgage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>lxrx-20141231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:href="lxrx-20141231.xsd#ArrangementsWithSymphonyIconInc" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:href="lxrx-20141231.xsd#ArrangementsWithSymphonyIconIncDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:href="lxrx-20141231.xsd#ArrangementsWithSymphonyIconIncTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/AssetsHeldForSale" xlink:href="lxrx-20141231.xsd#AssetsHeldForSale" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/AssetsHeldForSaleDetails" xlink:href="lxrx-20141231.xsd#AssetsHeldForSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/AssetsHeldForSaleTables" xlink:href="lxrx-20141231.xsd#AssetsHeldForSaleTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:href="lxrx-20141231.xsd#BalanceSheetParentheticals" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:href="lxrx-20141231.xsd#BenefitPlan" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:href="lxrx-20141231.xsd#BenefitPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:href="lxrx-20141231.xsd#BenefitPlanTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:href="lxrx-20141231.xsd#CashAndCashEquivalentsAndInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:href="lxrx-20141231.xsd#CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:href="lxrx-20141231.xsd#CashAndCashEquivalentsAndInvestmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:href="lxrx-20141231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:href="lxrx-20141231.xsd#CollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsTables" xlink:href="lxrx-20141231.xsd#CollaborationAndLicenseAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:href="lxrx-20141231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="lxrx-20141231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="lxrx-20141231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="lxrx-20141231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:href="lxrx-20141231.xsd#DebtObligations" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:href="lxrx-20141231.xsd#DebtObligationsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:href="lxrx-20141231.xsd#DebtObligationsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:href="lxrx-20141231.xsd#DebtObligationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:href="lxrx-20141231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwards" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails4" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:href="lxrx-20141231.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:href="lxrx-20141231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:href="lxrx-20141231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:href="lxrx-20141231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:href="lxrx-20141231.xsd#Goodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:href="lxrx-20141231.xsd#GoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:href="lxrx-20141231.xsd#GoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:href="lxrx-20141231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:href="lxrx-20141231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:href="lxrx-20141231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:href="lxrx-20141231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:href="lxrx-20141231.xsd#OrganizationAndOperations" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:href="lxrx-20141231.xsd#OrganizationAndOperationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:href="lxrx-20141231.xsd#OrganizationAndOperationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:href="lxrx-20141231.xsd#OtherCapitalStockAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:href="lxrx-20141231.xsd#OtherCapitalStockAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:href="lxrx-20141231.xsd#OtherCapitalStockAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:href="lxrx-20141231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:href="lxrx-20141231.xsd#PropertyAndEquipmentDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails2" xlink:href="lxrx-20141231.xsd#PropertyAndEquipmentDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:href="lxrx-20141231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:href="lxrx-20141231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:href="lxrx-20141231.xsd#RecentAccountingPronouncementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:href="lxrx-20141231.xsd#RecentAccountingPronouncementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RestructuringCharges" xlink:href="lxrx-20141231.xsd#RestructuringCharges" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RestructuringChargesDetails" xlink:href="lxrx-20141231.xsd#RestructuringChargesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RestructuringChargesTables" xlink:href="lxrx-20141231.xsd#RestructuringChargesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:href="lxrx-20141231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="lxrx-20141231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="lxrx-20141231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:href="lxrx-20141231.xsd#StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivable" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesAccountsReceivable" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillImpairment" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesGoodwillImpairment" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognition" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognition" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensation" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimates" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesUseOfEstimates" xlink:type="simple" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/AssetsHeldForSale" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/AssetsHeldForSaleDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/AssetsHeldForSaleTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_96e417a6-7446-6031-787d-9a81025423eb" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_ShortTermInvestments_96e417a6-7446-6031-787d-9a81025423eb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_86c70b34-73b4-abf0-060e-396e6f4dc54f" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_86c70b34-73b4-abf0-060e-396e6f4dc54f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_14f3514d-b887-3e26-e467-f2a9d9f3f19e" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_OtherAssetsCurrent_14f3514d-b887-3e26-e467-f2a9d9f3f19e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_c75200fe-521b-9637-2f11-cee27cd67a0d" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_c75200fe-521b-9637-2f11-cee27cd67a0d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4599c23a-11f0-4277-ea32-9886d26f8792" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4599c23a-11f0-4277-ea32-9886d26f8792" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dcbd5d14-4ec6-06fe-e5c1-a41efced6761" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dcbd5d14-4ec6-06fe-e5c1-a41efced6761" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d60b95b-a2a9-55da-7eaa-2ca718a58484" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d60b95b-a2a9-55da-7eaa-2ca718a58484" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_719740e5-b138-f870-281f-ac4786e101c2" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_TreasuryStockValue_719740e5-b138-f870-281f-ac4786e101c2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_c952180c-d37a-a6b0-3e18-a18cd8328eee" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_DeferredRevenueCurrent_c952180c-d37a-a6b0-3e18-a18cd8328eee" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0601d697-1537-c3cb-caaf-11141ac92b39" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_LongTermDebtCurrent_0601d697-1537-c3cb-caaf-11141ac92b39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_e71e7b37-2828-6759-f8ce-a5ac289c852b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_e71e7b37-2828-6759-f8ce-a5ac289c852b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_89b83a57-ffbc-fc48-170d-f8b25d163e54" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_89b83a57-ffbc-fc48-170d-f8b25d163e54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_43aaac76-959d-69e2-234b-7c7a89d77345" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_43aaac76-959d-69e2-234b-7c7a89d77345" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f7fce5cd-2d53-a8b3-a485-6d0f3635b8fe" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f7fce5cd-2d53-a8b3-a485-6d0f3635b8fe" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_25c27778-3634-0405-2ad7-97f542e360cf" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_ProfitLoss_25c27778-3634-0405-2ad7-97f542e360cf" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_76f611bf-6cac-2837-6d7c-3028d488fc3b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_76f611bf-6cac-2837-6d7c-3028d488fc3b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9a4ddcf9-8ba5-9758-7a76-5726e68b3edf" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9a4ddcf9-8ba5-9758-7a76-5726e68b3edf" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_f6bae0c7-3d16-9a94-91a8-5a527791e2c8" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_f6bae0c7-3d16-9a94-91a8-5a527791e2c8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_2ce8accf-e09c-efa1-9d09-9b291f4dca51" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_2ce8accf-e09c-efa1-9d09-9b291f4dca51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cad4dd20-f895-7d13-fef5-2f2bffdf14ac" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cad4dd20-f895-7d13-fef5-2f2bffdf14ac" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b14e4ab6-e003-13d4-eacd-26899afc8b93" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b14e4ab6-e003-13d4-eacd-26899afc8b93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fc73bf45-b7cf-c894-bf3a-f56c9d39cbe4" xlink:type="locator" />
    <calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fc73bf45-b7cf-c894-bf3a-f56c9d39cbe4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="locator" />
    <calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dd041a01-1df8-a5e2-f301-eb34433bea02" xlink:type="locator" />
    <calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dd041a01-1df8-a5e2-f301-eb34433bea02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_af8dcf28-5bbb-ce71-1ed2-41689425cc96" xlink:type="locator" />
    <calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_af8dcf28-5bbb-ce71-1ed2-41689425cc96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_54734d8c-7af1-eb6f-7e56-5940fde2abb1" xlink:type="locator" />
    <calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_54734d8c-7af1-eb6f-7e56-5940fde2abb1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_90abc8df-a70a-7c23-5fff-9b3d9bc98c9b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_90abc8df-a70a-7c23-5fff-9b3d9bc98c9b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_45a45f69-277f-2291-6c62-42864f544476" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_45a45f69-277f-2291-6c62-42864f544476" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b73f9d6-c772-e0cc-1022-75b64509c54f" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b73f9d6-c772-e0cc-1022-75b64509c54f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b5a6c95e-5e73-5e4d-9c67-665fb27c338e" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b5a6c95e-5e73-5e4d-9c67-665fb27c338e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_77fb0894-8e98-8acd-7d89-0f52e26449e8" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_77fb0894-8e98-8acd-7d89-0f52e26449e8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_555855ee-67fc-e384-4c0f-c30d34ed47e5" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_555855ee-67fc-e384-4c0f-c30d34ed47e5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b84bc21b-66ef-bfa0-eb10-9e22319e83fe" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b84bc21b-66ef-bfa0-eb10-9e22319e83fe" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cc64ed8f-51e0-4a92-b0c8-acb3ad13358b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cc64ed8f-51e0-4a92-b0c8-acb3ad13358b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cc64ed8f-51e0-4a92-b0c8-acb3ad13358b" xlink:to="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_6e350f7a-ab47-e4cf-c75e-0634d95fc8b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:to="loc_us-gaap_ContractsRevenue_6e350f7a-ab47-e4cf-c75e-0634d95fc8b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_897c0d66-1163-53d3-0580-29e565de71d0" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:to="loc_us-gaap_LicensesRevenue_897c0d66-1163-53d3-0580-29e565de71d0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_f6bae0c7-3d16-9a94-91a8-5a527791e2c8" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_f6bae0c7-3d16-9a94-91a8-5a527791e2c8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_e0c47166-10e0-b00a-6c1c-0a652da2ca7e" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_AssetImpairmentCharges_e0c47166-10e0-b00a-6c1c-0a652da2ca7e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_cefe1779-647b-11ee-28a9-2740d86c056b" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cc64ed8f-51e0-4a92-b0c8-acb3ad13358b" xlink:to="loc_us-gaap_InterestExpense_cefe1779-647b-11ee-28a9-2740d86c056b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_27b74f5e-bc16-8d0b-2d8b-f8fb77af5bf6" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cc64ed8f-51e0-4a92-b0c8-acb3ad13358b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_27b74f5e-bc16-8d0b-2d8b-f8fb77af5bf6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8aeb26df-09df-f3e3-fe25-1f144575031f" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8b4412aa-455f-b7d3-8adf-f66634c77e8d" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8aeb26df-09df-f3e3-fe25-1f144575031f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8b4412aa-455f-b7d3-8adf-f66634c77e8d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ad4f2e2d-d7b9-d8d5-e82c-6a6778aca9f5" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8aeb26df-09df-f3e3-fe25-1f144575031f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ad4f2e2d-d7b9-d8d5-e82c-6a6778aca9f5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_aa2d7ff9-45b1-9481-fb63-629536037f9e" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8aeb26df-09df-f3e3-fe25-1f144575031f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_aa2d7ff9-45b1-9481-fb63-629536037f9e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_246a5aeb-cc88-5075-fb74-47db30cfce28" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8aeb26df-09df-f3e3-fe25-1f144575031f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_246a5aeb-cc88-5075-fb74-47db30cfce28" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2735bf02-162d-ed5e-65f5-9d4d3ec06d1b" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8aeb26df-09df-f3e3-fe25-1f144575031f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2735bf02-162d-ed5e-65f5-9d4d3ec06d1b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_87679f98-2bb2-0018-e1ed-94d3d1464a8b" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8aeb26df-09df-f3e3-fe25-1f144575031f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_87679f98-2bb2-0018-e1ed-94d3d1464a8b" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/GoodwillTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3a1af413-3358-8911-7861-13a95e291501" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3a1af413-3358-8911-7861-13a95e291501" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3e717722-0b52-e881-05b7-c662c9bc4582" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3e717722-0b52-e881-05b7-c662c9bc4582" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e1c2bebf-75e5-2bbc-1a24-ece98e3cb811" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e1c2bebf-75e5-2bbc-1a24-ece98e3cb811" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_772f9e14-fdcf-0b3c-d185-e9c8ad74796e" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_772f9e14-fdcf-0b3c-d185-e9c8ad74796e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_9f110c72-2314-b477-9ead-2d2caab54bc9" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_9f110c72-2314-b477-9ead-2d2caab54bc9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a52f840f-bf1f-9973-7bec-feb61e7fa225" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a52f840f-bf1f-9973-7bec-feb61e7fa225" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_576d5a77-ba10-3881-36d9-b5e9bdaefd1b" xlink:type="locator" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_8ea6cd4a-d74e-13b3-ebf0-d1828af720e7" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_576d5a77-ba10-3881-36d9-b5e9bdaefd1b" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_8ea6cd4a-d74e-13b3-ebf0-d1828af720e7" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/RestructuringCharges" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/RestructuringChargesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/RestructuringChargesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivable" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillImpairment" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognition" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimates" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>lxrx-20141231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:href="lxrx-20141231.xsd#ArrangementsWithSymphonyIconInc" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:href="lxrx-20141231.xsd#ArrangementsWithSymphonyIconIncDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:href="lxrx-20141231.xsd#ArrangementsWithSymphonyIconIncTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/AssetsHeldForSale" xlink:href="lxrx-20141231.xsd#AssetsHeldForSale" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/AssetsHeldForSaleDetails" xlink:href="lxrx-20141231.xsd#AssetsHeldForSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/AssetsHeldForSaleTables" xlink:href="lxrx-20141231.xsd#AssetsHeldForSaleTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:href="lxrx-20141231.xsd#BalanceSheetParentheticals" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:href="lxrx-20141231.xsd#BenefitPlan" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:href="lxrx-20141231.xsd#BenefitPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:href="lxrx-20141231.xsd#BenefitPlanTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:href="lxrx-20141231.xsd#CashAndCashEquivalentsAndInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:href="lxrx-20141231.xsd#CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:href="lxrx-20141231.xsd#CashAndCashEquivalentsAndInvestmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:href="lxrx-20141231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:href="lxrx-20141231.xsd#CollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsTables" xlink:href="lxrx-20141231.xsd#CollaborationAndLicenseAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:href="lxrx-20141231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="lxrx-20141231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="lxrx-20141231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="lxrx-20141231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:href="lxrx-20141231.xsd#DebtObligations" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:href="lxrx-20141231.xsd#DebtObligationsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:href="lxrx-20141231.xsd#DebtObligationsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:href="lxrx-20141231.xsd#DebtObligationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:href="lxrx-20141231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwards" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails4" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:href="lxrx-20141231.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:href="lxrx-20141231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:href="lxrx-20141231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:href="lxrx-20141231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:href="lxrx-20141231.xsd#Goodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:href="lxrx-20141231.xsd#GoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:href="lxrx-20141231.xsd#GoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:href="lxrx-20141231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:href="lxrx-20141231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:href="lxrx-20141231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:href="lxrx-20141231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:href="lxrx-20141231.xsd#OrganizationAndOperations" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:href="lxrx-20141231.xsd#OrganizationAndOperationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:href="lxrx-20141231.xsd#OrganizationAndOperationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:href="lxrx-20141231.xsd#OtherCapitalStockAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:href="lxrx-20141231.xsd#OtherCapitalStockAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:href="lxrx-20141231.xsd#OtherCapitalStockAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:href="lxrx-20141231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:href="lxrx-20141231.xsd#PropertyAndEquipmentDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails2" xlink:href="lxrx-20141231.xsd#PropertyAndEquipmentDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:href="lxrx-20141231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:href="lxrx-20141231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:href="lxrx-20141231.xsd#RecentAccountingPronouncementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:href="lxrx-20141231.xsd#RecentAccountingPronouncementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RestructuringCharges" xlink:href="lxrx-20141231.xsd#RestructuringCharges" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RestructuringChargesDetails" xlink:href="lxrx-20141231.xsd#RestructuringChargesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RestructuringChargesTables" xlink:href="lxrx-20141231.xsd#RestructuringChargesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:href="lxrx-20141231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="lxrx-20141231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="lxrx-20141231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:href="lxrx-20141231.xsd#StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivable" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesAccountsReceivable" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillImpairment" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesGoodwillImpairment" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognition" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognition" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensation" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimates" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesUseOfEstimates" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:to="loc_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:to="loc_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_HoldingsContributionToIcon" xlink:label="loc_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LexiconSoldSharesToHoldings" xlink:label="loc_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LexiconReceivedCashFromHoldings" xlink:label="loc_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LexiconPaidHoldingsCash" xlink:label="loc_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonFairValueOfBaseAndContingentPayments" xlink:label="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyBasePaymentDiscountRate" xlink:label="loc_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentDiscountRate" xlink:label="loc_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyBasePaymentInShares" xlink:label="loc_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyBasePaymentObligation" xlink:label="loc_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentMaximum" xlink:label="loc_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentPercentage" xlink:label="loc_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyRegulatoryApprovalPayment" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyRegulatoryApprovalReductionPercentage" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyRegulatoryApprovalPercentageLimit" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyPaymentInStockLimitation" xlink:label="loc_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentInCash" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentinShares" xlink:label="loc_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentTotal" xlink:label="loc_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenUpfrontPayment" xlink:label="loc_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/AssetsHeldForSale" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/AssetsHeldForSaleDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/AssetsHeldForSaleTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:to="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:to="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:to="loc_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_C55AC5DC65042708ED1AE16F6BDCFC0F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:to="loc_us-gaap_StatementScenarioAxis_C55AC5DC65042708ED1AE16F6BDCFC0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7736E42CEB975B46AB7DE16F6BDC47FD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_C55AC5DC65042708ED1AE16F6BDCFC0F" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7736E42CEB975B46AB7DE16F6BDC47FD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7736E42CEB975B46AB7DE16F6BDC47FD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_C55AC5DC65042708ED1AE16F6BDCFC0F" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7736E42CEB975B46AB7DE16F6BDC47FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8241E29C38BE6225F4CBE16F6BDC5C95" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8241E29C38BE6225F4CBE16F6BDC5C95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_76ACE5871BEE071AF93BE16F6BDC4CAB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8241E29C38BE6225F4CBE16F6BDC5C95" xlink:to="loc_us-gaap_ClassOfStockDomain_76ACE5871BEE071AF93BE16F6BDC4CAB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_76ACE5871BEE071AF93BE16F6BDC4CAB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8241E29C38BE6225F4CBE16F6BDC5C95" xlink:to="loc_us-gaap_ClassOfStockDomain_76ACE5871BEE071AF93BE16F6BDC4CAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_256D11B0A5DFD8F4464EE16F6BDC4A9B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_256D11B0A5DFD8F4464EE16F6BDC4A9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis" xlink:label="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:to="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:to="loc_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:to="loc_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/BenefitPlanTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:to="loc_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="loc_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:to="loc_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenUpfrontPayment" xlink:label="loc_lxrx_IpsenUpfrontPayment_9624E9D9E00121599020E162CF0179B6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenUpfrontPayment_9624E9D9E00121599020E162CF0179B6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueRecognized" xlink:label="loc_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenMaximumSalesMilestones" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TxEnterpriseFundAward" xlink:label="loc_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem" xlink:label="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TigmPerJobPaymentAmount" xlink:label="loc_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TigmMaximumExposure" xlink:label="loc_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TIGMMaximumExposureThroughReportingDate" xlink:label="loc_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_3B0064B6926C016035D8D182D53F15FF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_D0160C48066696D32426D182D53F5DE7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3B0064B6926C016035D8D182D53F15FF" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_D0160C48066696D32426D182D53F5DE7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_D0160C48066696D32426D182D53F5DE7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_A2B1F787FA0BF3B36B87D182D53F22DE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_A2B1F787FA0BF3B36B87D182D53F22DE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_A2B1F787FA0BF3B36B87D182D53F22DE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_A2B1F787FA0BF3B36B87D182D53F22DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_52EF1BCC0A4AC9C3B5FAD182D53F4523" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3B0064B6926C016035D8D182D53F15FF" xlink:to="loc_us-gaap_RestrictedInvestments_52EF1BCC0A4AC9C3B5FAD182D53F4523" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3B0064B6926C016035D8D182D53F15FF" xlink:to="loc_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5EFF5AA99CC6FF2757D9DB9AD05C6A92" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_StatementTable_5EFF5AA99CC6FF2757D9DB9AD05C6A92" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5890A092D902DC8CA74BDB9AD05CCA52" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5EFF5AA99CC6FF2757D9DB9AD05C6A92" xlink:to="loc_us-gaap_StatementScenarioAxis_5890A092D902DC8CA74BDB9AD05CCA52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_88AC964DB539C7BFFC01DB9AD05DF00A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_5890A092D902DC8CA74BDB9AD05CCA52" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_88AC964DB539C7BFFC01DB9AD05DF00A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_88AC964DB539C7BFFC01DB9AD05DF00A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_5890A092D902DC8CA74BDB9AD05CCA52" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_88AC964DB539C7BFFC01DB9AD05DF00A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F604AED8D7369C3B8B66DB9AD05D9072" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5EFF5AA99CC6FF2757D9DB9AD05C6A92" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F604AED8D7369C3B8B66DB9AD05D9072" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CB7E350FF709E0884468DB9AD05D02E1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F604AED8D7369C3B8B66DB9AD05D9072" xlink:to="loc_us-gaap_ClassOfStockDomain_CB7E350FF709E0884468DB9AD05D02E1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CB7E350FF709E0884468DB9AD05D02E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F604AED8D7369C3B8B66DB9AD05D9072" xlink:to="loc_us-gaap_ClassOfStockDomain_CB7E350FF709E0884468DB9AD05D02E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F8DA91E9FADB010AF412DB9AD05E6A71" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F8DA91E9FADB010AF412DB9AD05E6A71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_40764E415C2C1BFC329ADBA54799864C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_40764E415C2C1BFC329ADBA54799864C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_E7362298A17331FC9F7ADB9AD05F5E62" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_E7362298A17331FC9F7ADB9AD05F5E62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_E2774CE443C42C9737AEDB9AD06061CD" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_LongTermDebtCurrent_E2774CE443C42C9737AEDB9AD06061CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1372AD2238E4079DC386DB9AD060A3CE" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1372AD2238E4079DC386DB9AD060A3CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6D1909BB62EA186E662BDB906168471C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_StatementTable_6D1909BB62EA186E662BDB906168471C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5AA293DE8C7943ADB78CDB906168FB5E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6D1909BB62EA186E662BDB906168471C" xlink:to="loc_us-gaap_StatementScenarioAxis_5AA293DE8C7943ADB78CDB906168FB5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_A2252AE00776E3BE4737DB9061684CDB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_5AA293DE8C7943ADB78CDB906168FB5E" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_A2252AE00776E3BE4737DB9061684CDB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_A2252AE00776E3BE4737DB9061684CDB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_5AA293DE8C7943ADB78CDB906168FB5E" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_A2252AE00776E3BE4737DB9061684CDB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:to="loc_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_B7BD3C026634A36BBF69DB90616AC707" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_B7BD3C026634A36BBF69DB90616AC707" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:to="loc_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:to="loc_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:to="loc_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:to="loc_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:to="loc_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_5DA73F06451BB44DFBEDDB8FAE1361F3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_5DA73F06451BB44DFBEDDB8FAE1361F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9DD226DD146E6B6FF54FD1C11EE2626C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StatementTable_9DD226DD146E6B6FF54FD1C11EE2626C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_13E20B243801297423F1D1C11EE2DAD1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9DD226DD146E6B6FF54FD1C11EE2626C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_13E20B243801297423F1D1C11EE2DAD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_13E20B243801297423F1D1C11EE2DAD1" xlink:to="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_13E20B243801297423F1D1C11EE2DAD1" xlink:to="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4A38CBF5E8FBE0B8B14DD1C11EE2D714" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_CommonStockMember_4A38CBF5E8FBE0B8B14DD1C11EE2D714" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0E74C66F34C86B7E31F7D1C11EF2DCE7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StockholdersEquity_0E74C66F34C86B7E31F7D1C11EF2DCE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedtoSymphonyDesigneesShares" xlink:label="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_87C94CC8C8ABA0919581D1C11EF23746" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_87C94CC8C8ABA0919581D1C11EF23746" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_087C07D3A69FE940E33DD1C11EF298C3" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_087C07D3A69FE940E33DD1C11EF298C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15334D65DBCF3617570CD1C11EF2727B" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_NetIncomeLoss_15334D65DBCF3617570CD1C11EF2727B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_19E714469FC4A7A5A845D1C11EF25559" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_19E714469FC4A7A5A845D1C11EF25559" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_256A6EBB5DA060C23203DB4AAC94F927" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_256A6EBB5DA060C23203DB4AAC94F927" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EB6BC9518267DCB7EBDEDB4AAC9460EA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_256A6EBB5DA060C23203DB4AAC94F927" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_EB6BC9518267DCB7EBDEDB4AAC9460EA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EB6BC9518267DCB7EBDEDB4AAC9460EA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_256A6EBB5DA060C23203DB4AAC94F927" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_EB6BC9518267DCB7EBDEDB4AAC9460EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:to="loc_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_WoodlandsMortgage" xlink:label="loc_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_WoodlandsCashPaid" xlink:label="loc_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_BuildingsCollateral" xlink:label="loc_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LandCollateral" xlink:label="loc_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A4C01A524EC17885C587D182D696F8D0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_FFA4E93C27276F95C574D182D69646B6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A4C01A524EC17885C587D182D696F8D0" xlink:to="loc_us-gaap_DebtInstrumentTable_FFA4E93C27276F95C574D182D69646B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2C862EDE2EFF5CECDDB8D182D6967321" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_FFA4E93C27276F95C574D182D69646B6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2C862EDE2EFF5CECDDB8D182D6967321" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1FA5DB709091CF9D8CF5D182D6962B0F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2C862EDE2EFF5CECDDB8D182D6967321" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1FA5DB709091CF9D8CF5D182D6962B0F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1FA5DB709091CF9D8CF5D182D6962B0F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2C862EDE2EFF5CECDDB8D182D6967321" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1FA5DB709091CF9D8CF5D182D6962B0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3E07EF66573B90468EDBD182D696900F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_FFA4E93C27276F95C574D182D69646B6" xlink:to="loc_us-gaap_DebtInstrumentAxis_3E07EF66573B90468EDBD182D696900F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0C9B81F2F67620155219D182D6963D07_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3E07EF66573B90468EDBD182D696900F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0C9B81F2F67620155219D182D6963D07_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0C9B81F2F67620155219D182D6963D07" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3E07EF66573B90468EDBD182D696900F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0C9B81F2F67620155219D182D6963D07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A4C01A524EC17885C587D182D696F8D0" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:to="loc_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:to="loc_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:to="loc_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1320E1CEF974EC430241D182D5EB4BCE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:to="loc_us-gaap_PlanNameAxis_1320E1CEF974EC430241D182D5EB4BCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_AC99E8DA706BA719BF5BD182D5EB6C5C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1320E1CEF974EC430241D182D5EB4BCE" xlink:to="loc_us-gaap_PlanNameDomain_AC99E8DA706BA719BF5BD182D5EB6C5C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_AC99E8DA706BA719BF5BD182D5EB6C5C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1320E1CEF974EC430241D182D5EB4BCE" xlink:to="loc_us-gaap_PlanNameDomain_AC99E8DA706BA719BF5BD182D5EB6C5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1D21D0429BAF4B99BDFAD182D5EBACC7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:to="loc_us-gaap_AwardTypeAxis_1D21D0429BAF4B99BDFAD182D5EBACC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BF8DE4617997E6B30322D182D5EBD02E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1D21D0429BAF4B99BDFAD182D5EBACC7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BF8DE4617997E6B30322D182D5EBD02E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BF8DE4617997E6B30322D182D5EBD02E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1D21D0429BAF4B99BDFAD182D5EBACC7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BF8DE4617997E6B30322D182D5EBD02E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F7EC8B747238D610BA56D182D5EB0EDF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F7EC8B747238D610BA56D182D5EB0EDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D16D70F1597836B155CED182D5EB66AE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F7EC8B747238D610BA56D182D5EB0EDF" xlink:to="loc_us-gaap_ClassOfStockDomain_D16D70F1597836B155CED182D5EB66AE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D16D70F1597836B155CED182D5EB66AE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F7EC8B747238D610BA56D182D5EB0EDF" xlink:to="loc_us-gaap_ClassOfStockDomain_D16D70F1597836B155CED182D5EB66AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CB3680686D3487623B68D182D5EBD3C8" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:to="loc_us-gaap_RangeAxis_CB3680686D3487623B68D182D5EBD3C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8DDEC27B044D29946EF5D182D5EB3970_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_CB3680686D3487623B68D182D5EBD3C8" xlink:to="loc_us-gaap_RangeMember_8DDEC27B044D29946EF5D182D5EB3970_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8DDEC27B044D29946EF5D182D5EB3970" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_CB3680686D3487623B68D182D5EBD3C8" xlink:to="loc_us-gaap_RangeMember_8DDEC27B044D29946EF5D182D5EB3970" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock" xlink:label="loc_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan" xlink:label="loc_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DirectorsIntialOptionGrant" xlink:label="loc_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DirectorsAnnualOptionGrant" xlink:label="loc_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DirectorsAnnualRestrictedStockAwardValue" xlink:label="loc_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="loc_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:to="loc_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:to="loc_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="loc_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:to="loc_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="loc_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:to="loc_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:to="loc_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="loc_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:to="loc_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:to="loc_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_B0E33224D29B6B2A8E0BD71946444166" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:to="loc_us-gaap_PlanNameAxis_B0E33224D29B6B2A8E0BD71946444166" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E38D625BF5A317421C73D7194644F3C0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_B0E33224D29B6B2A8E0BD71946444166" xlink:to="loc_us-gaap_PlanNameDomain_E38D625BF5A317421C73D7194644F3C0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E38D625BF5A317421C73D7194644F3C0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_B0E33224D29B6B2A8E0BD71946444166" xlink:to="loc_us-gaap_PlanNameDomain_E38D625BF5A317421C73D7194644F3C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5541A5008B1551943859D7194644F3F6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:to="loc_us-gaap_AwardTypeAxis_5541A5008B1551943859D7194644F3F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1601312F8D9FB03FB7BD71946445BAA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5541A5008B1551943859D7194644F3F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1601312F8D9FB03FB7BD71946445BAA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1601312F8D9FB03FB7BD71946445BAA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5541A5008B1551943859D7194644F3F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1601312F8D9FB03FB7BD71946445BAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ECBD4A55673C8B16941ED71946446131" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ECBD4A55673C8B16941ED71946446131" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CCE3249012B44A6A252BD71946448B37_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ECBD4A55673C8B16941ED71946446131" xlink:to="loc_us-gaap_ClassOfStockDomain_CCE3249012B44A6A252BD71946448B37_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CCE3249012B44A6A252BD71946448B37" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ECBD4A55673C8B16941ED71946446131" xlink:to="loc_us-gaap_ClassOfStockDomain_CCE3249012B44A6A252BD71946448B37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9E80A844F0268D151B3FD719464420F0" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:to="loc_us-gaap_RangeAxis_9E80A844F0268D151B3FD719464420F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A1A7A002080D687276B6D71946448347_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9E80A844F0268D151B3FD719464420F0" xlink:to="loc_us-gaap_RangeMember_A1A7A002080D687276B6D71946448347_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A1A7A002080D687276B6D71946448347" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9E80A844F0268D151B3FD719464420F0" xlink:to="loc_us-gaap_RangeMember_A1A7A002080D687276B6D71946448347" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_26B6F77B7AB2397DCE5DD182D6C516CE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:to="loc_us-gaap_PlanNameAxis_26B6F77B7AB2397DCE5DD182D6C516CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A4219BDF2709AE37C6E2D182D6C5BDD7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_26B6F77B7AB2397DCE5DD182D6C516CE" xlink:to="loc_us-gaap_PlanNameDomain_A4219BDF2709AE37C6E2D182D6C5BDD7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A4219BDF2709AE37C6E2D182D6C5BDD7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_26B6F77B7AB2397DCE5DD182D6C516CE" xlink:to="loc_us-gaap_PlanNameDomain_A4219BDF2709AE37C6E2D182D6C5BDD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_169CD0E66BAF09FAF7E4D182D6C55698" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:to="loc_us-gaap_AwardTypeAxis_169CD0E66BAF09FAF7E4D182D6C55698" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0020A4A07B10738A143AD182D6C573E4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_169CD0E66BAF09FAF7E4D182D6C55698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0020A4A07B10738A143AD182D6C573E4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0020A4A07B10738A143AD182D6C573E4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_169CD0E66BAF09FAF7E4D182D6C55698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0020A4A07B10738A143AD182D6C573E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0020A4A07B10738A143AD182D6C573E4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_18D2333DEA4BB5D60515D182D6C59B7E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:to="loc_us-gaap_StatementClassOfStockAxis_18D2333DEA4BB5D60515D182D6C59B7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3E5BB52E606F07D8A9B7D182D6C53A5E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_18D2333DEA4BB5D60515D182D6C59B7E" xlink:to="loc_us-gaap_ClassOfStockDomain_3E5BB52E606F07D8A9B7D182D6C53A5E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3E5BB52E606F07D8A9B7D182D6C53A5E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_18D2333DEA4BB5D60515D182D6C59B7E" xlink:to="loc_us-gaap_ClassOfStockDomain_3E5BB52E606F07D8A9B7D182D6C53A5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_BAE00F08F5432FDAB6E0D182D6C56980" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:to="loc_us-gaap_RangeAxis_BAE00F08F5432FDAB6E0D182D6C56980" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3BDEC8A13A4B39F863C1D182D6C59CA9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_BAE00F08F5432FDAB6E0D182D6C56980" xlink:to="loc_us-gaap_RangeMember_3BDEC8A13A4B39F863C1D182D6C59CA9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3BDEC8A13A4B39F863C1D182D6C59CA9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_BAE00F08F5432FDAB6E0D182D6C56980" xlink:to="loc_us-gaap_RangeMember_3BDEC8A13A4B39F863C1D182D6C59CA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_20B11856C42A940C7392D333960DDF04" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_20B11856C42A940C7392D333960DDF04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:to="loc_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:to="loc_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CoelacanthGoodwill" xlink:label="loc_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:to="loc_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CoelacanthPurchasePrice" xlink:label="loc_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:to="loc_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyIconGoodwill" xlink:label="loc_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:to="loc_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/GoodwillTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RevisiontoDeferredTaxAssets" xlink:label="loc_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BC7865F388D5F543E148E56947F6DC16" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_BC7865F388D5F543E148E56947F6DC16" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B4E32FBEBB93E05D3395D37303299C33_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:to="loc_us-gaap_EquityComponentDomain_B4E32FBEBB93E05D3395D37303299C33_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B4E32FBEBB93E05D3395D37303299C33" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:to="loc_us-gaap_EquityComponentDomain_B4E32FBEBB93E05D3395D37303299C33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_OfferingPricePerShare" xlink:label="loc_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_NetProceedsFromStockOffering" xlink:label="loc_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="loc_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockIssuedDuringPeriodToInvusShares" xlink:label="loc_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_BAF948A9507ADF5CC1B5D182D54F7CF1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:to="loc_us-gaap_RangeAxis_BAF948A9507ADF5CC1B5D182D54F7CF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2B8424C7F1742505BF1CD182D54F3B9A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_BAF948A9507ADF5CC1B5D182D54F7CF1" xlink:to="loc_us-gaap_RangeMember_2B8424C7F1742505BF1CD182D54F3B9A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2B8424C7F1742505BF1CD182D54F3B9A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_BAF948A9507ADF5CC1B5D182D54F7CF1" xlink:to="loc_us-gaap_RangeMember_2B8424C7F1742505BF1CD182D54F3B9A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_423C1D9F1D327A985D99DC2E3B09EFCD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_423C1D9F1D327A985D99DC2E3B09EFCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_59C81361A7C62791D381DC2E3B09946E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_423C1D9F1D327A985D99DC2E3B09EFCD" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_59C81361A7C62791D381DC2E3B09946E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_59C81361A7C62791D381DC2E3B09946E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_423C1D9F1D327A985D99DC2E3B09EFCD" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_59C81361A7C62791D381DC2E3B09946E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/RestructuringCharges" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/RestructuringChargesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/RestructuringChargesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InformationByFinancialStatementLineItemAxis" xlink:label="loc_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:to="loc_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain" xlink:label="loc_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:to="loc_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain" xlink:label="loc_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:to="loc_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_154A2356914C4B7B6E8BE5694780A4B5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_Revenues_154A2356914C4B7B6E8BE5694780A4B5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CF45A1567AAA21BAC39CE56947807787" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_OperatingIncomeLoss_CF45A1567AAA21BAC39CE56947807787" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1C275BAA8566BFD91BF1E56947801F84" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_NetIncomeLoss_1C275BAA8566BFD91BF1E56947801F84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B0B9CAAF6A978B172C66E56947806BCC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_B0B9CAAF6A978B172C66E56947806BCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_177FA5092A048873611FE5694780F795" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_177FA5092A048873611FE5694780F795" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0D3665678629F5088842D182D6399B20" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4E0C5542C464B929135CD182D639EC50" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0D3665678629F5088842D182D6399B20" xlink:to="loc_us-gaap_StatementTable_4E0C5542C464B929135CD182D639EC50" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_23BE307D7F6D8139A45FD182D6399E12" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4E0C5542C464B929135CD182D639EC50" xlink:to="loc_us-gaap_StatementScenarioAxis_23BE307D7F6D8139A45FD182D6399E12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0ED37F4C7A8F434FF5A3D182D639AF39_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_23BE307D7F6D8139A45FD182D6399E12" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_0ED37F4C7A8F434FF5A3D182D639AF39_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0ED37F4C7A8F434FF5A3D182D639AF39" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_23BE307D7F6D8139A45FD182D6399E12" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_0ED37F4C7A8F434FF5A3D182D639AF39" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D3665678629F5088842D182D6399B20" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0D3665678629F5088842D182D6399B20" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivable" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:to="loc_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillImpairment" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_13888E414E2F379F7648D182D6675ED5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_13888E414E2F379F7648D182D6675ED5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_38F7FB08A0D028BB2AFDD182D6670977_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_13888E414E2F379F7648D182D6675ED5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_38F7FB08A0D028BB2AFDD182D6670977_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_38F7FB08A0D028BB2AFDD182D6670977" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_13888E414E2F379F7648D182D6675ED5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_38F7FB08A0D028BB2AFDD182D6670977" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_591FABD0D44AAB03C208D182D6677CD5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:to="loc_us-gaap_RestrictedInvestments_591FABD0D44AAB03C208D182D6677CD5" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognition" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:to="loc_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueIpsenPercentage" xlink:label="loc_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="loc_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage" xlink:label="loc_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="loc_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueTaconicFarmsPercentage" xlink:label="loc_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="loc_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueDeltagenPercentage" xlink:label="loc_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="loc_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8F7D70D21D33A2145E02D182D6A6F95F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8F7D70D21D33A2145E02D182D6A6F95F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2E12ACD33F7EB28DAA63D182D6A696B8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8F7D70D21D33A2145E02D182D6A6F95F" xlink:to="loc_us-gaap_AwardTypeAxis_2E12ACD33F7EB28DAA63D182D6A696B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7C392B162025169E391CD182D6A640A3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2E12ACD33F7EB28DAA63D182D6A696B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7C392B162025169E391CD182D6A640A3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7C392B162025169E391CD182D6A640A3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2E12ACD33F7EB28DAA63D182D6A696B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7C392B162025169E391CD182D6A640A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7C392B162025169E391CD182D6A640A3" xlink:to="loc_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimates" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>lxrx-20141231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_F430E442963B38F76CF9D219D52C1C81_label_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_F430E442963B38F76CF9D219D52C1C81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_F430E442963B38F76CF9D219D52C1C81_documentation_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_F430E442963B38F76CF9D219D52C1C81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_F430E442963B38F76CF9D219D52C1C81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_F430E442963B38F76CF9D219D52C1C81" xlink:to="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_F430E442963B38F76CF9D219D52C1C81" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:to="lab_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCosts_1DAE2D0972AA42490D76D729976C0B02_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts_1DAE2D0972AA42490D76D729976C0B02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_1DAE2D0972AA42490D76D729976C0B02_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts_1DAE2D0972AA42490D76D729976C0B02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_1DAE2D0972AA42490D76D729976C0B02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts_1DAE2D0972AA42490D76D729976C0B02" xlink:to="lab_us-gaap_RestructuringCosts_1DAE2D0972AA42490D76D729976C0B02" xlink:type="arc" />
    <link:label id="lab_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B_terseLabel_en-US" xlink:label="lab_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost, Severance Costs</link:label>
    <link:label id="lab_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B_label_en-US" xlink:label="lab_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost, Severance Costs</link:label>
    <link:label id="lab_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B_documentation_en-US" xlink:label="lab_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount expected to be recognized in earnings for severance costs.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_RestructuringCostSeveranceCosts" xlink:label="loc_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B" xlink:to="lab_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherRestructuringCosts_5154567F37F994AAE075D72ACDC4F3CC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts_5154567F37F994AAE075D72ACDC4F3CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_5154567F37F994AAE075D72ACDC4F3CC_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts_5154567F37F994AAE075D72ACDC4F3CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherRestructuringCosts" xlink:label="loc_us-gaap_OtherRestructuringCosts_5154567F37F994AAE075D72ACDC4F3CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts_5154567F37F994AAE075D72ACDC4F3CC" xlink:to="lab_us-gaap_OtherRestructuringCosts_5154567F37F994AAE075D72ACDC4F3CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_CB4320E6D188F707FD06D72B6F7D6934_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_CB4320E6D188F707FD06D72B6F7D6934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_CB4320E6D188F707FD06D72B6F7D6934_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_CB4320E6D188F707FD06D72B6F7D6934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_CB4320E6D188F707FD06D72B6F7D6934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_CB4320E6D188F707FD06D72B6F7D6934" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_CB4320E6D188F707FD06D72B6F7D6934" xlink:type="arc" />
    <link:label id="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C_terseLabel_en-US" xlink:label="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs, Cost Incurred to Date, Research and Development</link:label>
    <link:label id="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C_label_en-US" xlink:label="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs, Cost Incurred to Date, Research and Development</link:label>
    <link:label id="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C_documentation_en-US" xlink:label="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of costs incurred to date for the specified type of restructuring cost in research and development expense.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment" xlink:label="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C" xlink:to="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C" xlink:type="arc" />
    <link:label id="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E_terseLabel_en-US" xlink:label="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs, Cost Incurred to Date, General and Administrative</link:label>
    <link:label id="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E_label_en-US" xlink:label="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs, Cost Incurred to Date, General and Administrative</link:label>
    <link:label id="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E_documentation_en-US" xlink:label="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of costs incurred to date for the specified type of restructuring cost in general and administrative expense.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative" xlink:label="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E" xlink:to="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E" xlink:type="arc" />
    <link:label id="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758_terseLabel_en-US" xlink:label="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs, Cost Incurred to Date, Stock-based Compensation</link:label>
    <link:label id="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758_label_en-US" xlink:label="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs, Cost Incurred to Date, Stock-based Compensation</link:label>
    <link:label id="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758_documentation_en-US" xlink:label="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of costs incurred to date for restructuring costs as stock-based compensation.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation" xlink:label="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758" xlink:to="lab_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_DED5F108C81B095C1159D72DC147EF7A_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_DED5F108C81B095C1159D72DC147EF7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_DED5F108C81B095C1159D72DC147EF7A_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_DED5F108C81B095C1159D72DC147EF7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_DED5F108C81B095C1159D72DC147EF7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_DED5F108C81B095C1159D72DC147EF7A" xlink:to="lab_us-gaap_RestructuringReserve_DED5F108C81B095C1159D72DC147EF7A" xlink:type="arc" />
    <link:label id="lab_lxrx_StockBasedCompensationAbstract_2D3FB047398647788504D182D5CB689C_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationAbstract_2D3FB047398647788504D182D5CB689C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation [Abstract]</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationAbstract_2D3FB047398647788504D182D5CB689C_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationAbstract_2D3FB047398647788504D182D5CB689C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_StockBasedCompensationAbstract" xlink:label="loc_lxrx_StockBasedCompensationAbstract_2D3FB047398647788504D182D5CB689C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationAbstract_2D3FB047398647788504D182D5CB689C" xlink:to="lab_lxrx_StockBasedCompensationAbstract_2D3FB047398647788504D182D5CB689C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64" xlink:type="arc" />
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_EB0D33683EFB62CE9C3BD182D56E14DF_label_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract_EB0D33683EFB62CE9C3BD182D56E14DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_lxrx_CommitmentsAndContingenciesAbstract_EB0D33683EFB62CE9C3BD182D56E14DF_documentation_en-US" xlink:label="lab_lxrx_CommitmentsAndContingenciesAbstract_EB0D33683EFB62CE9C3BD182D56E14DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_EB0D33683EFB62CE9C3BD182D56E14DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_EB0D33683EFB62CE9C3BD182D56E14DF" xlink:to="lab_lxrx_CommitmentsAndContingenciesAbstract_EB0D33683EFB62CE9C3BD182D56E14DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13F4D304417EC03F3E0ED182D56E6840_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13F4D304417EC03F3E0ED182D56E6840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13F4D304417EC03F3E0ED182D56E6840_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13F4D304417EC03F3E0ED182D56E6840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13F4D304417EC03F3E0ED182D56E6840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13F4D304417EC03F3E0ED182D56E6840" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13F4D304417EC03F3E0ED182D56E6840" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_DA417EDAA189A882B49ED182D5CB13DD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_DA417EDAA189A882B49ED182D5CB13DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_DA417EDAA189A882B49ED182D5CB13DD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_DA417EDAA189A882B49ED182D5CB13DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_DA417EDAA189A882B49ED182D5CB13DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_DA417EDAA189A882B49ED182D5CB13DD" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_DA417EDAA189A882B49ED182D5CB13DD" xlink:type="arc" />
    <link:label id="lab_lxrx_OtherCapitalStockAgreementsAbstract_9A39B95337E35C4BBB24D182D677A07E_label_en-US" xlink:label="lab_lxrx_OtherCapitalStockAgreementsAbstract_9A39B95337E35C4BBB24D182D677A07E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Capital Stock Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_OtherCapitalStockAgreementsAbstract_9A39B95337E35C4BBB24D182D677A07E_documentation_en-US" xlink:label="lab_lxrx_OtherCapitalStockAgreementsAbstract_9A39B95337E35C4BBB24D182D677A07E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Capital Stock Agreements [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_OtherCapitalStockAgreementsAbstract" xlink:label="loc_lxrx_OtherCapitalStockAgreementsAbstract_9A39B95337E35C4BBB24D182D677A07E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OtherCapitalStockAgreementsAbstract_9A39B95337E35C4BBB24D182D677A07E" xlink:to="lab_lxrx_OtherCapitalStockAgreementsAbstract_9A39B95337E35C4BBB24D182D677A07E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B7AC2BA43B13972C2699D182D67739C0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B7AC2BA43B13972C2699D182D67739C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Capital Stock Agreements</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B7AC2BA43B13972C2699D182D67739C0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B7AC2BA43B13972C2699D182D67739C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B7AC2BA43B13972C2699D182D67739C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B7AC2BA43B13972C2699D182D67739C0" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B7AC2BA43B13972C2699D182D67739C0" xlink:type="arc" />
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_28C7A746FD46B1387CD3DC4268864642_label_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_28C7A746FD46B1387CD3DC4268864642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements with Symphony Icon Inc [Abstract]</link:label>
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_28C7A746FD46B1387CD3DC4268864642_documentation_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_28C7A746FD46B1387CD3DC4268864642" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arrangements with Symphony Icon Inc [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ArrangementsWithSymphonyIconIncAbstract" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_28C7A746FD46B1387CD3DC4268864642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_28C7A746FD46B1387CD3DC4268864642" xlink:to="lab_lxrx_ArrangementsWithSymphonyIconIncAbstract_28C7A746FD46B1387CD3DC4268864642" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:to="lab_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404" xlink:to="lab_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="lab_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:type="arc" />
    <link:label id="lab_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5_terseLabel_en-US" xlink:label="lab_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Holdings Contribution To Icon</link:label>
    <link:label id="lab_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5_label_en-US" xlink:label="lab_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Holdings Contribution To Icon</link:label>
    <link:label id="lab_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5_documentation_en-US" xlink:label="lab_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On June 15, 2007, Symphony Icon Holdings LLC contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_HoldingsContributionToIcon" xlink:label="loc_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:to="lab_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:type="arc" />
    <link:label id="lab_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03_terseLabel_en-US" xlink:label="lab_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lexicon Sold Shares To Holdings</link:label>
    <link:label id="lab_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03_label_en-US" xlink:label="lab_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lexicon Sold Shares To Holdings</link:label>
    <link:label id="lab_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03_documentation_en-US" xlink:label="lab_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_LexiconSoldSharesToHoldings" xlink:label="loc_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:to="lab_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:type="arc" />
    <link:label id="lab_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856_terseLabel_en-US" xlink:label="lab_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lexicon Received Cash From Holdings</link:label>
    <link:label id="lab_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856_label_en-US" xlink:label="lab_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lexicon Received Cash From Holdings</link:label>
    <link:label id="lab_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856_documentation_en-US" xlink:label="lab_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_LexiconReceivedCashFromHoldings" xlink:label="loc_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:to="lab_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:type="arc" />
    <link:label id="lab_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC_terseLabel_en-US" xlink:label="lab_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lexicon Paid Holdings Cash</link:label>
    <link:label id="lab_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC_label_en-US" xlink:label="lab_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lexicon Paid Holdings Cash</link:label>
    <link:label id="lab_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC_documentation_en-US" xlink:label="lab_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the cash paid to Holdings.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_LexiconPaidHoldingsCash" xlink:label="loc_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:to="lab_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A_terseLabel_en-US" xlink:label="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Fair Value Of Base And Contingent Payments</link:label>
    <link:label id="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A_label_en-US" xlink:label="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphon Fair Value Of Base And Contingent Payments</link:label>
    <link:label id="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A_documentation_en-US" xlink:label="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date fair value.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonFairValueOfBaseAndContingentPayments" xlink:label="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:to="lab_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Base Payment Discount Rate</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82_label_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Base Payment Discount Rate</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82_documentation_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date discount rate for the base payment.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyBasePaymentDiscountRate" xlink:label="loc_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:to="lab_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Discount Rate</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Discount Rate</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date discount rate for the contingent payments.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentDiscountRate" xlink:label="loc_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:to="lab_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Base Payment In Shares</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853_label_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Base Payment In Shares</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853_documentation_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the 13,237,519 shares of common stock issued to designees of Holdings on July 30, 2012 in satisfaction of the base payment obligation.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyBasePaymentInShares" xlink:label="loc_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:to="lab_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Base Payment Obligation</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E_label_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Base Payment Obligation</link:label>
    <link:label id="lab_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E_documentation_en-US" xlink:label="lab_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the $35 million base payment obligation that was paid in common stock.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyBasePaymentObligation" xlink:label="loc_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:to="lab_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Maximum</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Maximum</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the maximum amount for any contingent payment.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentMaximum" xlink:label="loc_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:to="lab_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Percentage</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Percentage</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the percentage of consideration received that will be paid to Holdings.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentPercentage" xlink:label="loc_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:to="lab_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Payment</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474_label_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Payment</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474_documentation_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and any Recapture Eligible Amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  This represents the payment that will be made upon regulatory approval.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyRegulatoryApprovalPayment" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:to="lab_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Reduction Percentage</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6_label_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Reduction Percentage</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6_documentation_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  This represents the percentage reduction of the regulatory approval payment by previous contingent payments.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyRegulatoryApprovalReductionPercentage" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:to="lab_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Percentage Limit</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045_label_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Regulatory Approval Percentage Limit</link:label>
    <link:label id="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045_documentation_en-US" xlink:label="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval.  This represents the percentage by which proceeds of Licensing Transactions must exceed regulatory approval payments in order for Lexicon to have an obligation to make subsequent contingent payments.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyRegulatoryApprovalPercentageLimit" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:to="lab_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Payment In Stock Limitation</link:label>
    <link:label id="lab_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9_label_en-US" xlink:label="lab_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Payment In Stock Limitation</link:label>
    <link:label id="lab_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9_documentation_en-US" xlink:label="lab_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The contingent payments to Holdings may be paid in cash or a combination of cash and common stock, in Lexicon's discretion, provided that no more than 50% of any payment will be paid in common stock.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyPaymentInStockLimitation" xlink:label="loc_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:to="lab_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment In Cash</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment In Cash</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent payments to Symphony Icon Holdings in the form of cash.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentInCash" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:to="lab_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment in Shares</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment in Shares</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent payments to Symphony Icon Holdings in the form of stock.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentinShares" xlink:label="loc_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:to="lab_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Total</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7_label_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Contingent Payment Total</link:label>
    <link:label id="lab_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7_documentation_en-US" xlink:label="lab_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent payments to Symphony Icon Holdings, in total.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentTotal" xlink:label="loc_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:to="lab_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658_terseLabel_en-US" xlink:label="lab_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Upfront Payment</link:label>
    <link:label id="lab_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658_label_en-US" xlink:label="lab_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Upfront Payment</link:label>
    <link:label id="lab_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658_documentation_en-US" xlink:label="lab_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the upfront payment under the agreement.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenUpfrontPayment" xlink:label="loc_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:to="lab_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:type="arc" />
    <link:label id="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1_terseLabel_en-US" xlink:label="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</link:label>
    <link:label id="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1_label_en-US" xlink:label="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of Symphony Icon Inc. purchase liability</link:label>
    <link:label id="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1_documentation_en-US" xlink:label="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:to="lab_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:type="arc" />
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_11104DECAF1082BAFE7ED182D5AC899C_label_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract_11104DECAF1082BAFE7ED182D5AC899C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:label id="lab_lxrx_EquityIncentiveAwardsAbstract_11104DECAF1082BAFE7ED182D5AC899C_documentation_en-US" xlink:label="lab_lxrx_EquityIncentiveAwardsAbstract_11104DECAF1082BAFE7ED182D5AC899C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive Awards [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_11104DECAF1082BAFE7ED182D5AC899C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_11104DECAF1082BAFE7ED182D5AC899C" xlink:to="lab_lxrx_EquityIncentiveAwardsAbstract_11104DECAF1082BAFE7ED182D5AC899C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:to="lab_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73" xlink:to="lab_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:to="lab_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B" xlink:to="lab_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:to="lab_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B" xlink:to="lab_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D_label_en-US" xlink:label="lab_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:to="lab_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB_label_en-US" xlink:label="lab_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB" xlink:to="lab_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C" xlink:type="arc" />
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_4A9F97467CBEAE6659BCD182D5ACCC25_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_4A9F97467CBEAE6659BCD182D5ACCC25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_4A9F97467CBEAE6659BCD182D5ACCC25_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_4A9F97467CBEAE6659BCD182D5ACCC25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_4A9F97467CBEAE6659BCD182D5ACCC25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_4A9F97467CBEAE6659BCD182D5ACCC25" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_4A9F97467CBEAE6659BCD182D5ACCC25" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_EBCA81B7F9CB751704B8D182D5AC1BA3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_EBCA81B7F9CB751704B8D182D5AC1BA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_EBCA81B7F9CB751704B8D182D5AC1BA3_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_EBCA81B7F9CB751704B8D182D5AC1BA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_EBCA81B7F9CB751704B8D182D5AC1BA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_EBCA81B7F9CB751704B8D182D5AC1BA3" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_EBCA81B7F9CB751704B8D182D5AC1BA3" xlink:type="arc" />
    <link:label id="lab_lxrx_AssetsHeldforSaleAbstract_93BEA4A32677F44F1EC2D33BAB8303FD_label_en-US" xlink:label="lab_lxrx_AssetsHeldforSaleAbstract_93BEA4A32677F44F1EC2D33BAB8303FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held for Sale [Abstract]</link:label>
    <link:label id="lab_lxrx_AssetsHeldforSaleAbstract_93BEA4A32677F44F1EC2D33BAB8303FD_documentation_en-US" xlink:label="lab_lxrx_AssetsHeldforSaleAbstract_93BEA4A32677F44F1EC2D33BAB8303FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Held for Sale [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_AssetsHeldforSaleAbstract" xlink:label="loc_lxrx_AssetsHeldforSaleAbstract_93BEA4A32677F44F1EC2D33BAB8303FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AssetsHeldforSaleAbstract_93BEA4A32677F44F1EC2D33BAB8303FD" xlink:to="lab_lxrx_AssetsHeldforSaleAbstract_93BEA4A32677F44F1EC2D33BAB8303FD" xlink:type="arc" />
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_6F6CD98961BBFE551403D2255B219759_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract_6F6CD98961BBFE551403D2255B219759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_6F6CD98961BBFE551403D2255B219759_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract_6F6CD98961BBFE551403D2255B219759" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_RecentAccountingPronouncementsAbstract" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_6F6CD98961BBFE551403D2255B219759" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_6F6CD98961BBFE551403D2255B219759" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract_6F6CD98961BBFE551403D2255B219759" xlink:type="arc" />
    <link:label id="lab_lxrx_IncomeTaxesAbstract_ACB387A30D591540E39FE56947FB84C1_label_en-US" xlink:label="lab_lxrx_IncomeTaxesAbstract_ACB387A30D591540E39FE56947FB84C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:label id="lab_lxrx_IncomeTaxesAbstract_ACB387A30D591540E39FE56947FB84C1_documentation_en-US" xlink:label="lab_lxrx_IncomeTaxesAbstract_ACB387A30D591540E39FE56947FB84C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_ACB387A30D591540E39FE56947FB84C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACB387A30D591540E39FE56947FB84C1" xlink:to="lab_lxrx_IncomeTaxesAbstract_ACB387A30D591540E39FE56947FB84C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:to="lab_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B" xlink:to="lab_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B_verboseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="lab_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B" xlink:type="arc" />
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE_terseLabel_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE_label_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability Related to Acquisition of Symphony Icon</link:label>
    <link:label id="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE_documentation_en-US" xlink:label="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:to="lab_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72" xlink:to="lab_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DA2FC4BE2927535010BFDD4CD57D8EF4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DA2FC4BE2927535010BFDD4CD57D8EF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DA2FC4BE2927535010BFDD4CD57D8EF4_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DA2FC4BE2927535010BFDD4CD57D8EF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DA2FC4BE2927535010BFDD4CD57D8EF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DA2FC4BE2927535010BFDD4CD57D8EF4" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DA2FC4BE2927535010BFDD4CD57D8EF4" xlink:type="arc" />
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_8E009C9FAF19E8723C4FD182D5DB3C4E_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract_8E009C9FAF19E8723C4FD182D5DB3C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_8E009C9FAF19E8723C4FD182D5DB3C4E_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract_8E009C9FAF19E8723C4FD182D5DB3C4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_FairValueMeasurementsAbstract" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_8E009C9FAF19E8723C4FD182D5DB3C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_8E009C9FAF19E8723C4FD182D5DB3C4E" xlink:to="lab_lxrx_FairValueMeasurementsAbstract_8E009C9FAF19E8723C4FD182D5DB3C4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_303133D0124EDFCE5A1BD182D5DB7163_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_303133D0124EDFCE5A1BD182D5DB7163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_303133D0124EDFCE5A1BD182D5DB7163_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_303133D0124EDFCE5A1BD182D5DB7163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_303133D0124EDFCE5A1BD182D5DB7163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_303133D0124EDFCE5A1BD182D5DB7163" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_303133D0124EDFCE5A1BD182D5DB7163" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_F63C2CB49EC6A6572843DB8FAE12C278_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_F63C2CB49EC6A6572843DB8FAE12C278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_F63C2CB49EC6A6572843DB8FAE12C278_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_F63C2CB49EC6A6572843DB8FAE12C278" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_F63C2CB49EC6A6572843DB8FAE12C278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_F63C2CB49EC6A6572843DB8FAE12C278" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_F63C2CB49EC6A6572843DB8FAE12C278" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367_label_en-US" xlink:label="lab_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:to="lab_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:to="lab_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="lab_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:to="lab_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64_terseLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64_label_en-US" xlink:label="lab_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64" xlink:to="lab_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E_terseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription and license fees</link:label>
    <link:label id="lab_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E_label_en-US" xlink:label="lab_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E" xlink:to="lab_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8_label_en-US" xlink:label="lab_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8" xlink:to="lab_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="lab_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development, including stock-based compensation of $4,020, $4,376 and $3,673, respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative, including stock-based compensation of $3,061, $3,045 and $2,822, respectively</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss on buildings</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E" xlink:to="lab_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2" xlink:to="lab_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310" xlink:to="lab_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392_label_en-US" xlink:label="lab_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392" xlink:to="lab_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8" xlink:to="lab_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss per common share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing consolidated net loss per common share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BD6A411EC6006909795CD182D677CF5E_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BD6A411EC6006909795CD182D677CF5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BD6A411EC6006909795CD182D677CF5E_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BD6A411EC6006909795CD182D677CF5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BD6A411EC6006909795CD182D677CF5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BD6A411EC6006909795CD182D677CF5E" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BD6A411EC6006909795CD182D677CF5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_FD37E3842FF92F0DAB6ED182D6B516FD_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_FD37E3842FF92F0DAB6ED182D6B516FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_FD37E3842FF92F0DAB6ED182D6B516FD_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_FD37E3842FF92F0DAB6ED182D6B516FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_FD37E3842FF92F0DAB6ED182D6B516FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_FD37E3842FF92F0DAB6ED182D6B516FD" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_FD37E3842FF92F0DAB6ED182D6B516FD" xlink:type="arc" />
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7_label_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Exercise Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7_documentation_en-US" xlink:label="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:to="lab_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:type="arc" />
    <link:label id="lab_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B_terseLabel_en-US" xlink:label="lab_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Purchase Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B_label_en-US" xlink:label="lab_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Purchase Price as Percent of Value of Common Stock</link:label>
    <link:label id="lab_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B_documentation_en-US" xlink:label="lab_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The purchase price of restricted stock awards may not be less than 85% of fair market value.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock" xlink:label="loc_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:to="lab_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:type="arc" />
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shares That May be Issued, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:type="arc" />
    <link:label id="lab_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6_terseLabel_en-US" xlink:label="lab_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limit On Shares That May Be Issued Other Than Stock Options or SARs, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6_label_en-US" xlink:label="lab_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Limit On Shares That May Be Issued Other Than Stock Options or SARs, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6_documentation_en-US" xlink:label="lab_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Under the Equity Incentive Plan, no more than this amount of shares may be issued pursuant to awards other than stock options and stock appreciation rights.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan" xlink:label="loc_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:to="lab_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:type="arc" />
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options to purchase shares outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:to="lab_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:type="arc" />
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39_terseLabel_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39_label_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Outstanding, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39_documentation_en-US" xlink:label="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:to="lab_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:type="arc" />
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Exercised, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued upon the exercise of stock options under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:to="lab_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:to="lab_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:type="arc" />
    <link:label id="lab_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9_terseLabel_en-US" xlink:label="lab_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Directors Intial Option Grant</link:label>
    <link:label id="lab_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9_label_en-US" xlink:label="lab_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors Intial Option Grant</link:label>
    <link:label id="lab_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9_documentation_en-US" xlink:label="lab_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Under the Non-Employee Directors' Equity Incentive Plan, non-employee directors receive an initial option to purchase shares of common stock.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_DirectorsIntialOptionGrant" xlink:label="loc_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:to="lab_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:type="arc" />
    <link:label id="lab_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3_terseLabel_en-US" xlink:label="lab_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Directors Annual Option Grant</link:label>
    <link:label id="lab_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3_label_en-US" xlink:label="lab_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors Annual Option Grant</link:label>
    <link:label id="lab_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3_documentation_en-US" xlink:label="lab_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Under the Non-Employee Directors' Equity Incentive Plan, non-employee directors receive an annual option to purchase shares of common stock.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_DirectorsAnnualOptionGrant" xlink:label="loc_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:to="lab_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:type="arc" />
    <link:label id="lab_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099_terseLabel_en-US" xlink:label="lab_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Directors Annual Restricted Stock Award Value</link:label>
    <link:label id="lab_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099_label_en-US" xlink:label="lab_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors Annual Restricted Stock Award Value</link:label>
    <link:label id="lab_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099_documentation_en-US" xlink:label="lab_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Under the Non-Employee Directors' Equity Incentive Plan, non-employee directors receive an annual restricted stock award of the number of shares of common stock having a set fair market value on the date of grant rounded down to the nearest whole share number.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_DirectorsAnnualRestrictedStockAwardValue" xlink:label="loc_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:to="lab_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:type="arc" />
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA_terseLabel_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA_label_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA_documentation_en-US" xlink:label="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:to="lab_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:type="arc" />
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837_terseLabel_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837_label_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Outstanding, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837_documentation_en-US" xlink:label="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:to="lab_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:type="arc" />
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C_terseLabel_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C_label_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C_documentation_en-US" xlink:label="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:to="lab_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178_label_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</link:label>
    <link:label id="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:to="lab_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B" xlink:type="arc" />
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_20F470CF7EC0C9D79347D182D54FF43A_label_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract_20F470CF7EC0C9D79347D182D54FF43A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:label id="lab_lxrx_PropertyAndEquipmentAbstract_20F470CF7EC0C9D79347D182D54FF43A_documentation_en-US" xlink:label="lab_lxrx_PropertyAndEquipmentAbstract_20F470CF7EC0C9D79347D182D54FF43A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property and Equipment [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_PropertyAndEquipmentAbstract" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_20F470CF7EC0C9D79347D182D54FF43A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_20F470CF7EC0C9D79347D182D54FF43A" xlink:to="lab_lxrx_PropertyAndEquipmentAbstract_20F470CF7EC0C9D79347D182D54FF43A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers and Software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940" xlink:to="lab_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD" xlink:to="lab_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9_label_en-US" xlink:label="lab_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9" xlink:to="lab_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_6D0F9A7746A7400D3DD4D182D53F7C2F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract_6D0F9A7746A7400D3DD4D182D53F7C2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_6D0F9A7746A7400D3DD4D182D53F7C2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_6D0F9A7746A7400D3DD4D182D53F7C2F" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract_6D0F9A7746A7400D3DD4D182D53F7C2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11F57EAAB4EB18404B9AD182D53F1239_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11F57EAAB4EB18404B9AD182D53F1239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11F57EAAB4EB18404B9AD182D53F1239_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11F57EAAB4EB18404B9AD182D53F1239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11F57EAAB4EB18404B9AD182D53F1239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11F57EAAB4EB18404B9AD182D53F1239" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11F57EAAB4EB18404B9AD182D53F1239" xlink:type="arc" />
    <link:label id="lab_lxrx_DeiAbstract_CBE2DC219FC0E2283426E5830EB0B375_label_en-US" xlink:label="lab_lxrx_DeiAbstract_CBE2DC219FC0E2283426E5830EB0B375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DEI [Abstract]</link:label>
    <link:label id="lab_lxrx_DeiAbstract_CBE2DC219FC0E2283426E5830EB0B375_documentation_en-US" xlink:label="lab_lxrx_DeiAbstract_CBE2DC219FC0E2283426E5830EB0B375" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DEI [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_DeiAbstract" xlink:label="loc_lxrx_DeiAbstract_CBE2DC219FC0E2283426E5830EB0B375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DeiAbstract_CBE2DC219FC0E2283426E5830EB0B375" xlink:to="lab_lxrx_DeiAbstract_CBE2DC219FC0E2283426E5830EB0B375" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D_label_en-US" xlink:label="lab_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:to="lab_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE_label_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:to="lab_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599_terseLabel_en-US" xlink:label="lab_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document [Domain]</link:label>
    <link:label id="lab_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599_label_en-US" xlink:label="lab_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599" xlink:to="lab_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599" xlink:type="arc" />
    <link:label id="lab_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="lab_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF_label_en-US" xlink:label="lab_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF" xlink:to="lab_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2" xlink:to="lab_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851" xlink:to="lab_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8_label_en-US" xlink:label="lab_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8" xlink:to="lab_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8_terseLabel_en-US" xlink:label="lab_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8_label_en-US" xlink:label="lab_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8" xlink:to="lab_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F" xlink:to="lab_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E" xlink:to="lab_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA" xlink:to="lab_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4_label_en-US" xlink:label="lab_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4" xlink:to="lab_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7" xlink:to="lab_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624" xlink:to="lab_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007_label_en-US" xlink:label="lab_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007" xlink:to="lab_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007" xlink:type="arc" />
    <link:label id="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_BAB5F5417ED5F77B9822D182D54F0F78_label_en-US" xlink:label="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_BAB5F5417ED5F77B9822D182D54F0F78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data [Abstract]</link:label>
    <link:label id="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_BAB5F5417ED5F77B9822D182D54F0F78_documentation_en-US" xlink:label="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_BAB5F5417ED5F77B9822D182D54F0F78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SelectedQuarterlyFinancialDataAbstract" xlink:label="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_BAB5F5417ED5F77B9822D182D54F0F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_BAB5F5417ED5F77B9822D182D54F0F78" xlink:to="lab_lxrx_SelectedQuarterlyFinancialDataAbstract_BAB5F5417ED5F77B9822D182D54F0F78" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EA9DC7A0F028856C377AD182D54F8EDD_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EA9DC7A0F028856C377AD182D54F8EDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EA9DC7A0F028856C377AD182D54F8EDD_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EA9DC7A0F028856C377AD182D54F8EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_EA9DC7A0F028856C377AD182D54F8EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_EA9DC7A0F028856C377AD182D54F8EDD" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EA9DC7A0F028856C377AD182D54F8EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_F698C7224D4576B66C72DD4CD6594B82_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_F698C7224D4576B66C72DD4CD6594B82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Long Lived Assets Held-for-sale [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_F698C7224D4576B66C72DD4CD6594B82_label_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_F698C7224D4576B66C72DD4CD6594B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Long Lived Assets Held-for-sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_F698C7224D4576B66C72DD4CD6594B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_F698C7224D4576B66C72DD4CD6594B82" xlink:to="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_F698C7224D4576B66C72DD4CD6594B82" xlink:type="arc" />
    <link:label id="lab_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038_label_en-US" xlink:label="lab_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation [Abstract]</link:label>
    <link:label id="lab_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038_documentation_en-US" xlink:label="lab_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of Presentation [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_BasisOfPresentationAbstract" xlink:label="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="lab_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_468101FBA58CDFBC3DA7D182D5DB99CC_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_468101FBA58CDFBC3DA7D182D5DB99CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation, Policy</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_468101FBA58CDFBC3DA7D182D5DB99CC_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_468101FBA58CDFBC3DA7D182D5DB99CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_468101FBA58CDFBC3DA7D182D5DB99CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_468101FBA58CDFBC3DA7D182D5DB99CC" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_468101FBA58CDFBC3DA7D182D5DB99CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_D89D5AA70E8B6642DC74D182D5DB689E_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_D89D5AA70E8B6642DC74D182D5DB689E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_D89D5AA70E8B6642DC74D182D5DB689E_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_D89D5AA70E8B6642DC74D182D5DB689E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_D89D5AA70E8B6642DC74D182D5DB689E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_D89D5AA70E8B6642DC74D182D5DB689E" xlink:to="lab_us-gaap_UseOfEstimates_D89D5AA70E8B6642DC74D182D5DB689E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75B41C1CAB9A7EA368A1D182D5DBD336_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75B41C1CAB9A7EA368A1D182D5DBD336" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75B41C1CAB9A7EA368A1D182D5DBD336_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75B41C1CAB9A7EA368A1D182D5DBD336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75B41C1CAB9A7EA368A1D182D5DBD336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75B41C1CAB9A7EA368A1D182D5DBD336" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75B41C1CAB9A7EA368A1D182D5DBD336" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_893EFB658813A9B4C95FD182D5DBC2E2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_893EFB658813A9B4C95FD182D5DBC2E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_893EFB658813A9B4C95FD182D5DBC2E2_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_893EFB658813A9B4C95FD182D5DBC2E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_893EFB658813A9B4C95FD182D5DBC2E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_893EFB658813A9B4C95FD182D5DBC2E2" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_893EFB658813A9B4C95FD182D5DBC2E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1CBC2781EE8C25D4030FD182D5DB6AF6_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1CBC2781EE8C25D4030FD182D5DB6AF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1CBC2781EE8C25D4030FD182D5DB6AF6_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1CBC2781EE8C25D4030FD182D5DB6AF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1CBC2781EE8C25D4030FD182D5DB6AF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1CBC2781EE8C25D4030FD182D5DB6AF6" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1CBC2781EE8C25D4030FD182D5DB6AF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_15BE5B1B5E3A128A0A86D182D5DB0277_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_15BE5B1B5E3A128A0A86D182D5DB0277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_15BE5B1B5E3A128A0A86D182D5DB0277_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_15BE5B1B5E3A128A0A86D182D5DB0277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_15BE5B1B5E3A128A0A86D182D5DB0277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_15BE5B1B5E3A128A0A86D182D5DB0277" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_15BE5B1B5E3A128A0A86D182D5DB0277" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_B8BC9DE38517E490153AD182D5DB97CD_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_B8BC9DE38517E490153AD182D5DB97CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_B8BC9DE38517E490153AD182D5DB97CD_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_B8BC9DE38517E490153AD182D5DB97CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_B8BC9DE38517E490153AD182D5DB97CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_B8BC9DE38517E490153AD182D5DB97CD" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_B8BC9DE38517E490153AD182D5DB97CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34D448AAAEC03DC7D8D4D182D5DB4297_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34D448AAAEC03DC7D8D4D182D5DB4297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34D448AAAEC03DC7D8D4D182D5DB4297_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34D448AAAEC03DC7D8D4D182D5DB4297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34D448AAAEC03DC7D8D4D182D5DB4297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34D448AAAEC03DC7D8D4D182D5DB4297" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34D448AAAEC03DC7D8D4D182D5DB4297" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9E8A51576AE87B6933F2D182D5DB17A8_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9E8A51576AE87B6933F2D182D5DB17A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9E8A51576AE87B6933F2D182D5DB17A8_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9E8A51576AE87B6933F2D182D5DB17A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9E8A51576AE87B6933F2D182D5DB17A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9E8A51576AE87B6933F2D182D5DB17A8" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9E8A51576AE87B6933F2D182D5DB17A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_485BA0245859756BB471D182D5DB7D6A_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_485BA0245859756BB471D182D5DB7D6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_485BA0245859756BB471D182D5DB7D6A_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_485BA0245859756BB471D182D5DB7D6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_485BA0245859756BB471D182D5DB7D6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_485BA0245859756BB471D182D5DB7D6A" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_485BA0245859756BB471D182D5DB7D6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_B96CD586515DDDED2E02D182D5DB29A2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_B96CD586515DDDED2E02D182D5DB29A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_B96CD586515DDDED2E02D182D5DB29A2_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_B96CD586515DDDED2E02D182D5DB29A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_B96CD586515DDDED2E02D182D5DB29A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_B96CD586515DDDED2E02D182D5DB29A2" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_B96CD586515DDDED2E02D182D5DB29A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FD194FDDA2BDB0FA4C92D182D5DB74B4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FD194FDDA2BDB0FA4C92D182D5DB74B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FD194FDDA2BDB0FA4C92D182D5DB74B4_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FD194FDDA2BDB0FA4C92D182D5DB74B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_FD194FDDA2BDB0FA4C92D182D5DB74B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_FD194FDDA2BDB0FA4C92D182D5DB74B4" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_FD194FDDA2BDB0FA4C92D182D5DB74B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C6E6D7043A781A3B9EC7D182D5DBF1A2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C6E6D7043A781A3B9EC7D182D5DBF1A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C6E6D7043A781A3B9EC7D182D5DBF1A2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C6E6D7043A781A3B9EC7D182D5DBF1A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C6E6D7043A781A3B9EC7D182D5DBF1A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C6E6D7043A781A3B9EC7D182D5DBF1A2" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C6E6D7043A781A3B9EC7D182D5DBF1A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E475FACEC9447B377CA6D182D5DBA096_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E475FACEC9447B377CA6D182D5DBA096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E475FACEC9447B377CA6D182D5DBA096_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E475FACEC9447B377CA6D182D5DBA096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E475FACEC9447B377CA6D182D5DBA096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_E475FACEC9447B377CA6D182D5DBA096" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_E475FACEC9447B377CA6D182D5DBA096" xlink:type="arc" />
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_F707CBEA5D636025F946D182D5BCF3FB_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_F707CBEA5D636025F946D182D5BCF3FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_F707CBEA5D636025F946D182D5BCF3FB_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_F707CBEA5D636025F946D182D5BCF3FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_F707CBEA5D636025F946D182D5BCF3FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_F707CBEA5D636025F946D182D5BCF3FB" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_F707CBEA5D636025F946D182D5BCF3FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C4552999369DD7A9C430D182D5BC47EC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C4552999369DD7A9C430D182D5BC47EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C4552999369DD7A9C430D182D5BC47EC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C4552999369DD7A9C430D182D5BC47EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C4552999369DD7A9C430D182D5BC47EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C4552999369DD7A9C430D182D5BC47EC" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C4552999369DD7A9C430D182D5BC47EC" xlink:type="arc" />
    <link:label id="lab_lxrx_DebtObligationsAbstract_AECE9716C13AC1AD1F21DB48D866D593_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract_AECE9716C13AC1AD1F21DB48D866D593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_AECE9716C13AC1AD1F21DB48D866D593_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract_AECE9716C13AC1AD1F21DB48D866D593" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_AECE9716C13AC1AD1F21DB48D866D593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract_AECE9716C13AC1AD1F21DB48D866D593" xlink:to="lab_lxrx_DebtObligationsAbstract_AECE9716C13AC1AD1F21DB48D866D593" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:to="lab_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="lab_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A" xlink:to="lab_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D" xlink:to="lab_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_EF539FE826B4737D4CA2DB906168A838_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_EF539FE826B4737D4CA2DB906168A838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_EF539FE826B4737D4CA2DB906168A838_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_EF539FE826B4737D4CA2DB906168A838" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_EF539FE826B4737D4CA2DB906168A838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_EF539FE826B4737D4CA2DB906168A838" xlink:to="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_EF539FE826B4737D4CA2DB906168A838" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85" xlink:to="lab_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D" xlink:to="lab_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Financing Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3DE6B1A82992EA1F967DDB90616CE61B_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3DE6B1A82992EA1F967DDB90616CE61B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3DE6B1A82992EA1F967DDB90616CE61B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3DE6B1A82992EA1F967DDB90616CE61B" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3DE6B1A82992EA1F967DDB90616CE61B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927" xlink:to="lab_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307_verboseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued in satisfaction of Symphony Icon base payment obligation</link:label>
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307_label_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued to Symphony Designees, Value</link:label>
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the shares issued to designees of Holdings during the period.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:to="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_FD6B83474A4466E0EE50D182D5CB5317_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_FD6B83474A4466E0EE50D182D5CB5317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Obligations</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_FD6B83474A4466E0EE50D182D5CB5317_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_FD6B83474A4466E0EE50D182D5CB5317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_FD6B83474A4466E0EE50D182D5CB5317" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_FD6B83474A4466E0EE50D182D5CB5317" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_FD6B83474A4466E0EE50D182D5CB5317" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7212048F06AB691432D7E17284E00A8A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7212048F06AB691432D7E17284E00A8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7212048F06AB691432D7E17284E00A8A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7212048F06AB691432D7E17284E00A8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7212048F06AB691432D7E17284E00A8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7212048F06AB691432D7E17284E00A8A" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7212048F06AB691432D7E17284E00A8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_81028B907B7E89C7C865E17284E0D7BF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_81028B907B7E89C7C865E17284E0D7BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_81028B907B7E89C7C865E17284E0D7BF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_81028B907B7E89C7C865E17284E0D7BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_81028B907B7E89C7C865E17284E0D7BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_81028B907B7E89C7C865E17284E0D7BF" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_81028B907B7E89C7C865E17284E0D7BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719_terseLabel_en-US" xlink:label="lab_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719_label_en-US" xlink:label="lab_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:to="lab_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4_label_en-US" xlink:label="lab_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4" xlink:to="lab_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8" xlink:to="lab_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F" xlink:to="lab_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="loc_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA" xlink:to="lab_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Tax Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Tax Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Tax Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Tax Information</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:type="arc" />
    <link:label id="lab_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C_terseLabel_en-US" xlink:label="lab_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision to Deferred Tax Assets</link:label>
    <link:label id="lab_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C_label_en-US" xlink:label="lab_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision to Deferred Tax Assets</link:label>
    <link:label id="lab_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C_documentation_en-US" xlink:label="lab_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Company recorded certain revisions to its deferred tax assets.  The revisions reduced the deferred tax assets and valuation allowance.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_RevisiontoDeferredTaxAssets" xlink:label="loc_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:to="lab_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change in Amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Federal</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66" xlink:to="lab_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, State</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_BC7865F388D5F543E148E56947F6DC16_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_BC7865F388D5F543E148E56947F6DC16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BC7865F388D5F543E148E56947F6DC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_BC7865F388D5F543E148E56947F6DC16" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_BC7865F388D5F543E148E56947F6DC16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C" xlink:type="arc" />
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_88153028A2626168048CE16F6BDC4AA5_label_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract_88153028A2626168048CE16F6BDC4AA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_BalanceSheetParentheticalsAbstract_88153028A2626168048CE16F6BDC4AA5_documentation_en-US" xlink:label="lab_lxrx_BalanceSheetParentheticalsAbstract_88153028A2626168048CE16F6BDC4AA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Sheet Parentheticals [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_BalanceSheetParentheticalsAbstract" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract_88153028A2626168048CE16F6BDC4AA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract_88153028A2626168048CE16F6BDC4AA5" xlink:to="lab_lxrx_BalanceSheetParentheticalsAbstract_88153028A2626168048CE16F6BDC4AA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:to="lab_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE" xlink:to="lab_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D" xlink:to="lab_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_256D11B0A5DFD8F4464EE16F6BDC4A9B_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_256D11B0A5DFD8F4464EE16F6BDC4A9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_256D11B0A5DFD8F4464EE16F6BDC4A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_256D11B0A5DFD8F4464EE16F6BDC4A9B" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_256D11B0A5DFD8F4464EE16F6BDC4A9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807" xlink:to="lab_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value per share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC" xlink:to="lab_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612" xlink:to="lab_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F18067B87A124F54F52DD4CD696E1B9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F18067B87A124F54F52DD4CD696E1B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F18067B87A124F54F52DD4CD696E1B9_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F18067B87A124F54F52DD4CD696E1B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F18067B87A124F54F52DD4CD696E1B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F18067B87A124F54F52DD4CD696E1B9" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F18067B87A124F54F52DD4CD696E1B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2C4F64901192F3EB7B56D182D5BC66F6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2C4F64901192F3EB7B56D182D5BC66F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2C4F64901192F3EB7B56D182D5BC66F6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2C4F64901192F3EB7B56D182D5BC66F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2C4F64901192F3EB7B56D182D5BC66F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2C4F64901192F3EB7B56D182D5BC66F6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2C4F64901192F3EB7B56D182D5BC66F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2E66C4AEB768286B282BD182D5FA6EAF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2E66C4AEB768286B282BD182D5FA6EAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2E66C4AEB768286B282BD182D5FA6EAF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2E66C4AEB768286B282BD182D5FA6EAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2E66C4AEB768286B282BD182D5FA6EAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2E66C4AEB768286B282BD182D5FA6EAF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2E66C4AEB768286B282BD182D5FA6EAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedInvestments_52EF1BCC0A4AC9C3B5FAD182D53F4523_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestments_52EF1BCC0A4AC9C3B5FAD182D53F4523" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_52EF1BCC0A4AC9C3B5FAD182D53F4523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments_52EF1BCC0A4AC9C3B5FAD182D53F4523" xlink:to="lab_us-gaap_RestrictedInvestments_52EF1BCC0A4AC9C3B5FAD182D53F4523" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0" xlink:to="lab_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_50094D880FF90B53E2A1DB9ACFA7C5B6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_50094D880FF90B53E2A1DB9ACFA7C5B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets Held-for-sale, Long Lived, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_50094D880FF90B53E2A1DB9ACFA7C5B6_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_50094D880FF90B53E2A1DB9ACFA7C5B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held-for-sale, Long Lived, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_50094D880FF90B53E2A1DB9ACFA7C5B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_50094D880FF90B53E2A1DB9ACFA7C5B6" xlink:to="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_50094D880FF90B53E2A1DB9ACFA7C5B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1CD8C1596815AB2FDCE3E209F75F1B26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1CD8C1596815AB2FDCE3E209F75F1B26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1CD8C1596815AB2FDCE3E209F75F1B26_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1CD8C1596815AB2FDCE3E209F75F1B26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1CD8C1596815AB2FDCE3E209F75F1B26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1CD8C1596815AB2FDCE3E209F75F1B26" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1CD8C1596815AB2FDCE3E209F75F1B26" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6BA8CF058596BC940869E209F75FE7C3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6BA8CF058596BC940869E209F75FE7C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6BA8CF058596BC940869E209F75FE7C3_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6BA8CF058596BC940869E209F75FE7C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6BA8CF058596BC940869E209F75FE7C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6BA8CF058596BC940869E209F75FE7C3" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6BA8CF058596BC940869E209F75FE7C3" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average grant date fair value for grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:type="arc" />
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882_terseLabel_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882_label_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882_documentation_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:to="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:type="arc" />
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE_terseLabel_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE_label_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE_documentation_en-US" xlink:label="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:to="lab_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents Items</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:to="lab_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Information by Financial Statement Line Item [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3_label_en-US" xlink:label="lab_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Information by Financial Statement Line Item [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InformationByFinancialStatementLineItemAxis" xlink:label="loc_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:to="lab_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79_label_en-US" xlink:label="lab_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain" xlink:label="loc_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79" xlink:to="lab_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79" xlink:type="arc" />
    <link:label id="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1_terseLabel_en-US" xlink:label="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements, Captions</link:label>
    <link:label id="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1_label_en-US" xlink:label="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="lab_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_154A2356914C4B7B6E8BE5694780A4B5_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_154A2356914C4B7B6E8BE5694780A4B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_154A2356914C4B7B6E8BE5694780A4B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_154A2356914C4B7B6E8BE5694780A4B5" xlink:to="lab_us-gaap_Revenues_154A2356914C4B7B6E8BE5694780A4B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_CF45A1567AAA21BAC39CE56947807787_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_CF45A1567AAA21BAC39CE56947807787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss From Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CF45A1567AAA21BAC39CE56947807787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_CF45A1567AAA21BAC39CE56947807787" xlink:to="lab_us-gaap_OperatingIncomeLoss_CF45A1567AAA21BAC39CE56947807787" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_1C275BAA8566BFD91BF1E56947801F84_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1C275BAA8566BFD91BF1E56947801F84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Net Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1C275BAA8566BFD91BF1E56947801F84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1C275BAA8566BFD91BF1E56947801F84" xlink:to="lab_us-gaap_NetIncomeLoss_1C275BAA8566BFD91BF1E56947801F84" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_B0B9CAAF6A978B172C66E56947806BCC_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_B0B9CAAF6A978B172C66E56947806BCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Net Loss Per Common Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B0B9CAAF6A978B172C66E56947806BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_B0B9CAAF6A978B172C66E56947806BCC" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_B0B9CAAF6A978B172C66E56947806BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_177FA5092A048873611FE5694780F795_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_177FA5092A048873611FE5694780F795" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares Used In Computing Consolidated Net Loss Per Common Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_177FA5092A048873611FE5694780F795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_177FA5092A048873611FE5694780F795" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_177FA5092A048873611FE5694780F795" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED" xlink:to="lab_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Lived Assets Held-for-sale by Asset Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Lived Assets Held-for-sale by Asset Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Lived Assets Held-for-sale, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Lived Assets Held-for-sale, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:to="lab_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16" xlink:type="arc" />
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:to="lab_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519" xlink:to="lab_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347" xlink:to="lab_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347" xlink:type="arc" />
    <link:label id="lab_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F_terseLabel_en-US" xlink:label="lab_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Woodlands Mortgage</link:label>
    <link:label id="lab_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F_label_en-US" xlink:label="lab_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Woodlands Mortgage</link:label>
    <link:label id="lab_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F_documentation_en-US" xlink:label="lab_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a $34.0 million third-party mortgage financing and $20.8 million in cash. This represents the original $34.0 million mortgage.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_WoodlandsMortgage" xlink:label="loc_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:to="lab_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:type="arc" />
    <link:label id="lab_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161_terseLabel_en-US" xlink:label="lab_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Woodlands Cash Paid</link:label>
    <link:label id="lab_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161_label_en-US" xlink:label="lab_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Woodlands Cash Paid</link:label>
    <link:label id="lab_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161_documentation_en-US" xlink:label="lab_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a $34.0 million third-party mortgage financing and $20.8 million in cash. This represents the $20.8 million cash paid.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_WoodlandsCashPaid" xlink:label="loc_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:to="lab_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784" xlink:type="arc" />
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mortgage Loans on Real Estate, Carrying Amount of Mortgages</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage Loans on Real Estate, Carrying Amount of Mortgages</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72" xlink:to="lab_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72" xlink:type="arc" />
    <link:label id="lab_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B_terseLabel_en-US" xlink:label="lab_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings Collateral</link:label>
    <link:label id="lab_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B_label_en-US" xlink:label="lab_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings Collateral</link:label>
    <link:label id="lab_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B_documentation_en-US" xlink:label="lab_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The buildings that serve as collateral for Lexicon's mortgage loan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_BuildingsCollateral" xlink:label="loc_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:to="lab_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:type="arc" />
    <link:label id="lab_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554_terseLabel_en-US" xlink:label="lab_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land Collateral</link:label>
    <link:label id="lab_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554_label_en-US" xlink:label="lab_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Collateral</link:label>
    <link:label id="lab_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554_documentation_en-US" xlink:label="lab_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The land that serves as collateral for Lexicon's mortgage loan.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_LandCollateral" xlink:label="loc_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:to="lab_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_E76BC33D9E940E050C7ED182D639D599_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_E76BC33D9E940E050C7ED182D639D599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_E76BC33D9E940E050C7ED182D639D599_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_E76BC33D9E940E050C7ED182D639D599" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations Parentheticals [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_E76BC33D9E940E050C7ED182D639D599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_E76BC33D9E940E050C7ED182D639D599" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_E76BC33D9E940E050C7ED182D639D599" xlink:type="arc" />
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:type="arc" />
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense associated with general and administrative expense.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:type="arc" />
    <link:label id="lab_lxrx_GoodwillAbstract_885FE57935E7406485CAD182D639F505_label_en-US" xlink:label="lab_lxrx_GoodwillAbstract_885FE57935E7406485CAD182D639F505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:label id="lab_lxrx_GoodwillAbstract_885FE57935E7406485CAD182D639F505_documentation_en-US" xlink:label="lab_lxrx_GoodwillAbstract_885FE57935E7406485CAD182D639F505" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_GoodwillAbstract" xlink:label="loc_lxrx_GoodwillAbstract_885FE57935E7406485CAD182D639F505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GoodwillAbstract_885FE57935E7406485CAD182D639F505" xlink:to="lab_lxrx_GoodwillAbstract_885FE57935E7406485CAD182D639F505" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0A33BA81A1D3F873BEBAD182D63950BC_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0A33BA81A1D3F873BEBAD182D63950BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0A33BA81A1D3F873BEBAD182D63950BC_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0A33BA81A1D3F873BEBAD182D63950BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0A33BA81A1D3F873BEBAD182D63950BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0A33BA81A1D3F873BEBAD182D63950BC" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0A33BA81A1D3F873BEBAD182D63950BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ADCF7B3DB0DF83B968AAD182D56E88FC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_ADCF7B3DB0DF83B968AAD182D56E88FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ADCF7B3DB0DF83B968AAD182D56E88FC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_ADCF7B3DB0DF83B968AAD182D56E88FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ADCF7B3DB0DF83B968AAD182D56E88FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_ADCF7B3DB0DF83B968AAD182D56E88FC" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_ADCF7B3DB0DF83B968AAD182D56E88FC" xlink:type="arc" />
    <link:label id="lab_lxrx_ConcentrationOfCreditRiskAbstract_6048B9B7C7FDBE379FEDE569486F4319_label_en-US" xlink:label="lab_lxrx_ConcentrationOfCreditRiskAbstract_6048B9B7C7FDBE379FEDE569486F4319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk [Abstract]</link:label>
    <link:label id="lab_lxrx_ConcentrationOfCreditRiskAbstract_6048B9B7C7FDBE379FEDE569486F4319_documentation_en-US" xlink:label="lab_lxrx_ConcentrationOfCreditRiskAbstract_6048B9B7C7FDBE379FEDE569486F4319" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ConcentrationOfCreditRiskAbstract" xlink:label="loc_lxrx_ConcentrationOfCreditRiskAbstract_6048B9B7C7FDBE379FEDE569486F4319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConcentrationOfCreditRiskAbstract_6048B9B7C7FDBE379FEDE569486F4319" xlink:to="lab_lxrx_ConcentrationOfCreditRiskAbstract_6048B9B7C7FDBE379FEDE569486F4319" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:to="lab_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:type="arc" />
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to France</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure On Geographic Areas Revenue From External Customers Attributed to France</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from external customers attributed to France as a percentage of total revenue.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:type="arc" />
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B_terseLabel_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B_label_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</link:label>
    <link:label id="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B_documentation_en-US" xlink:label="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:to="lab_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization, Equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD" xlink:type="arc" />
    <link:label id="lab_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA_terseLabel_en-US" xlink:label="lab_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering Price Per Share</link:label>
    <link:label id="lab_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA_label_en-US" xlink:label="lab_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Price Per Share</link:label>
    <link:label id="lab_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA_documentation_en-US" xlink:label="lab_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lexicon completed the public offering and sale of shares of its common stock. This represents the price per share.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_OfferingPricePerShare" xlink:label="loc_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:to="lab_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:type="arc" />
    <link:label id="lab_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C_terseLabel_en-US" xlink:label="lab_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Proceeds From Stock Offering</link:label>
    <link:label id="lab_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C_label_en-US" xlink:label="lab_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Stock Offering</link:label>
    <link:label id="lab_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C_documentation_en-US" xlink:label="lab_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net proceeds from stock offerings, after deducting fees and expenses.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_NetProceedsFromStockOffering" xlink:label="loc_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:to="lab_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:type="arc" />
    <link:label id="lab_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520_terseLabel_en-US" xlink:label="lab_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Underwriting Discounts and Commissions</link:label>
    <link:label id="lab_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520_label_en-US" xlink:label="lab_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Underwriting Discounts and Commissions</link:label>
    <link:label id="lab_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520_documentation_en-US" xlink:label="lab_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow for costs incurred related to underwriting discounts and commissions incurred directly with the issuance of an equity security.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="loc_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:to="lab_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6" xlink:type="arc" />
    <link:label id="lab_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77_terseLabel_en-US" xlink:label="lab_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period to Invus, Shares</link:label>
    <link:label id="lab_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77_label_en-US" xlink:label="lab_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period to Invus, Shares</link:label>
    <link:label id="lab_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77_documentation_en-US" xlink:label="lab_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new stock issued during the period to Invus, L.P. and its affiliates.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_StockIssuedDuringPeriodToInvusShares" xlink:label="loc_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:to="lab_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:to="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Lived Assets Held-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Lived Assets Held-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE" xlink:type="arc" />
    <link:label id="lab_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66_terseLabel_en-US" xlink:label="lab_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings Reclassified To Held For Sale</link:label>
    <link:label id="lab_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66_label_en-US" xlink:label="lab_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings Reclassified To Held For Sale</link:label>
    <link:label id="lab_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66_documentation_en-US" xlink:label="lab_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Buildings gross carrying value that has been reclassified to assets held for sale.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_BuildingsReclassifiedToHeldForSale" xlink:label="loc_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66" xlink:to="lab_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66" xlink:type="arc" />
    <link:label id="lab_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F_terseLabel_en-US" xlink:label="lab_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land Reclassified To Held For Sale</link:label>
    <link:label id="lab_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F_label_en-US" xlink:label="lab_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Reclassified To Held For Sale</link:label>
    <link:label id="lab_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F_documentation_en-US" xlink:label="lab_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Land gross carrying value that has been reclassified to assets held for sale.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_LandReclassifiedToHeldForSale" xlink:label="loc_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F" xlink:to="lab_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F" xlink:type="arc" />
    <link:label id="lab_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC_terseLabel_en-US" xlink:label="lab_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation Reclassified To Held For Sale</link:label>
    <link:label id="lab_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC_label_en-US" xlink:label="lab_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation Reclassified To Held For Sale</link:label>
    <link:label id="lab_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC_documentation_en-US" xlink:label="lab_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Buildings accumulated depreciation that has been reclassified to assets held for sale.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_AccumulatedDepreciationReclassifiedToHeldForSale" xlink:label="loc_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC" xlink:to="lab_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC" xlink:type="arc" />
    <link:label id="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_DA3A07FA16A12FCF1DC3E171ED003EC7_label_en-US" xlink:label="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_DA3A07FA16A12FCF1DC3E171ED003EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Information and Significant Customers [Abstract]</link:label>
    <link:label id="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_DA3A07FA16A12FCF1DC3E171ED003EC7_documentation_en-US" xlink:label="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_DA3A07FA16A12FCF1DC3E171ED003EC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Information and Significant Customers [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SegmentInformationAndSignificantCustomersAbstract" xlink:label="loc_lxrx_SegmentInformationAndSignificantCustomersAbstract_DA3A07FA16A12FCF1DC3E171ED003EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SegmentInformationAndSignificantCustomersAbstract_DA3A07FA16A12FCF1DC3E171ED003EC7" xlink:to="lab_lxrx_SegmentInformationAndSignificantCustomersAbstract_DA3A07FA16A12FCF1DC3E171ED003EC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:to="lab_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:type="arc" />
    <link:label id="lab_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Wide Revenue Ipsen Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Revenue Ipsen Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of revenue generated from Ipsen Pharma SAS that accounts for 10 percent or more of an entity's revenues.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueIpsenPercentage" xlink:label="loc_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:to="lab_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:type="arc" />
    <link:label id="lab_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity-Wide Revenue, McNair Medical Institute, Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity-Wide Revenue, McNair Medical Institute, Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of revenue generated from McNair Medical Institute, LLC that accounts for 10 percent or more of an entity&#8217;s revenues.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage" xlink:label="loc_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:to="lab_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:type="arc" />
    <link:label id="lab_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity-Wide Revenue, Taconic Farms, Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity-Wide Revenue, Taconic Farms, Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of revenue generated from Taconic Farms, Inc. that accounts for 10 percent or more of an entity&#8217;s revenues.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueTaconicFarmsPercentage" xlink:label="loc_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:to="lab_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:type="arc" />
    <link:label id="lab_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA_terseLabel_en-US" xlink:label="lab_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity-Wide Revenue, Deltagen, Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA_label_en-US" xlink:label="lab_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity-Wide Revenue, Deltagen, Percentage</link:label>
    <link:label id="lab_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA_documentation_en-US" xlink:label="lab_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of revenue generated from Deltagen, Inc. that accounts for 10 percent or more of an entity&#8217;s revenues.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueDeltagenPercentage" xlink:label="loc_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:to="lab_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:type="arc" />
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA_terseLabel_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements with Symphony Icon, Inc.</link:label>
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA_label_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements with Symphony Icon Inc [Text Block]</link:label>
    <link:label id="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA_documentation_en-US" xlink:label="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about a series of related agreements in 2007 providing for the financing of the clinical development of certain of its drug candidates.  These agreements were amended in 2010, when Lexicon exercised is purchase option and reaquired the clinical programs.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ArrangementsWithSymphonyIconIncTextBlock" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA" xlink:to="lab_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA" xlink:type="arc" />
    <link:label id="lab_lxrx_BenefitPlanAbstract_CAD983C7095413D8B9F1D182D5CBBEF1_label_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract_CAD983C7095413D8B9F1D182D5CBBEF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:label id="lab_lxrx_BenefitPlanAbstract_CAD983C7095413D8B9F1D182D5CBBEF1_documentation_en-US" xlink:label="lab_lxrx_BenefitPlanAbstract_CAD983C7095413D8B9F1D182D5CBBEF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Benefit Plan [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_BenefitPlanAbstract" xlink:label="loc_lxrx_BenefitPlanAbstract_CAD983C7095413D8B9F1D182D5CBBEF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BenefitPlanAbstract_CAD983C7095413D8B9F1D182D5CBBEF1" xlink:to="lab_lxrx_BenefitPlanAbstract_CAD983C7095413D8B9F1D182D5CBBEF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A206E8036353CB5921CED182D5CB9702_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A206E8036353CB5921CED182D5CB9702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A206E8036353CB5921CED182D5CB9702_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A206E8036353CB5921CED182D5CB9702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A206E8036353CB5921CED182D5CB9702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A206E8036353CB5921CED182D5CB9702" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A206E8036353CB5921CED182D5CB9702" xlink:type="arc" />
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_BEE9FC355F01095DCC48D182D54FA974_label_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract_BEE9FC355F01095DCC48D182D54FA974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_OrganizationAndOperationsAbstract_BEE9FC355F01095DCC48D182D54FA974_documentation_en-US" xlink:label="lab_lxrx_OrganizationAndOperationsAbstract_BEE9FC355F01095DCC48D182D54FA974" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and Operations [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_OrganizationAndOperationsAbstract" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract_BEE9FC355F01095DCC48D182D54FA974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract_BEE9FC355F01095DCC48D182D54FA974" xlink:to="lab_lxrx_OrganizationAndOperationsAbstract_BEE9FC355F01095DCC48D182D54FA974" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9875B9D037221DEE5627D182D54FF801_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9875B9D037221DEE5627D182D54FF801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9875B9D037221DEE5627D182D54FF801_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9875B9D037221DEE5627D182D54FF801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9875B9D037221DEE5627D182D54FF801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9875B9D037221DEE5627D182D54FF801" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9875B9D037221DEE5627D182D54FF801" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:to="lab_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This is the amount of the upfront payment allocated to the committee participation deliverable.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueRecognized" xlink:label="loc_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:to="lab_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D_label_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the maximum regulatory and commercial launch milestone payments.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:to="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:type="arc" />
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the maximum sales milestones payments</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenMaximumSalesMilestones" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:type="arc" />
    <link:label id="lab_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991_terseLabel_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TX Enterprise Fund Award</link:label>
    <link:label id="lab_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991_label_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TX Enterprise Fund Award</link:label>
    <link:label id="lab_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991_documentation_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In July 2005, Lexicon received a $35.0 million award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine using Lexicon's proprietary gene trappying technology, which Lexicon completed in 2007.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_TxEnterpriseFundAward" xlink:label="loc_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:to="lab_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:type="arc" />
    <link:label id="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907_terseLabel_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TX Enterprise Fund Award to Texas AM University System</link:label>
    <link:label id="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907_label_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TX Enterprise Fund Award to Texas AM University System</link:label>
    <link:label id="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907_documentation_en-US" xlink:label="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In July 2005, the Texas Enterprise Fund awarded $15.0 million to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem" xlink:label="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:to="lab_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:type="arc" />
    <link:label id="lab_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7_terseLabel_en-US" xlink:label="lab_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TIGM Per Job Payment Amount</link:label>
    <link:label id="lab_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7_label_en-US" xlink:label="lab_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TIGM Per Job Payment Amount</link:label>
    <link:label id="lab_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7_documentation_en-US" xlink:label="lab_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Under the terms of the Texas Enterprise Fund award, subject to certain credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay $2,415 for each job Lexicon falls short.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_TigmPerJobPaymentAmount" xlink:label="loc_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:to="lab_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:type="arc" />
    <link:label id="lab_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A_terseLabel_en-US" xlink:label="lab_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TIGM Maximum Exposure</link:label>
    <link:label id="lab_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A_label_en-US" xlink:label="lab_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TIGM Maximum Exposure</link:label>
    <link:label id="lab_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A_documentation_en-US" xlink:label="lab_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_TigmMaximumExposure" xlink:label="loc_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:to="lab_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:type="arc" />
    <link:label id="lab_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC_terseLabel_en-US" xlink:label="lab_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TIGM Maximum Exposure Through Reporting Date</link:label>
    <link:label id="lab_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC_label_en-US" xlink:label="lab_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TIGM Maximum Exposure Through Reporting Date</link:label>
    <link:label id="lab_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC_documentation_en-US" xlink:label="lab_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits.  This is the amount through the specified reporting date.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_TIGMMaximumExposureThroughReportingDate" xlink:label="loc_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:to="lab_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AF502E83A795254D22A7D182D5DBD101_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AF502E83A795254D22A7D182D5DBD101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AF502E83A795254D22A7D182D5DBD101_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AF502E83A795254D22A7D182D5DBD101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AF502E83A795254D22A7D182D5DBD101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AF502E83A795254D22A7D182D5DBD101" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AF502E83A795254D22A7D182D5DBD101" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis" xlink:label="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:to="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans [Domain]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan and Other Postretirement Benefit Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C" xlink:to="lab_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost Recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_A978DE21C54439FF081CDB9AD05C6FEA_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract_A978DE21C54439FF081CDB9AD05C6FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_A978DE21C54439FF081CDB9AD05C6FEA_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract_A978DE21C54439FF081CDB9AD05C6FEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_A978DE21C54439FF081CDB9AD05C6FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_A978DE21C54439FF081CDB9AD05C6FEA" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract_A978DE21C54439FF081CDB9AD05C6FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="lab_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F8DA91E9FADB010AF412DB9AD05E6A71_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F8DA91E9FADB010AF412DB9AD05E6A71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F8DA91E9FADB010AF412DB9AD05E6A71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F8DA91E9FADB010AF412DB9AD05E6A71" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F8DA91E9FADB010AF412DB9AD05E6A71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments, including restricted investments of $430</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4" xlink:to="lab_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowances of $35</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_40764E415C2C1BFC329ADBA54799864C_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_40764E415C2C1BFC329ADBA54799864C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_40764E415C2C1BFC329ADBA54799864C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_40764E415C2C1BFC329ADBA54799864C" xlink:to="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_40764E415C2C1BFC329ADBA54799864C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB" xlink:to="lab_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1" xlink:to="lab_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_E7362298A17331FC9F7ADB9AD05F5E62_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_E7362298A17331FC9F7ADB9AD05F5E62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $36,274 and $81,945, respectively</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_E7362298A17331FC9F7ADB9AD05F5E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_E7362298A17331FC9F7ADB9AD05F5E62" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_E7362298A17331FC9F7ADB9AD05F5E62" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762_label_en-US" xlink:label="lab_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762" xlink:to="lab_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98_label_en-US" xlink:label="lab_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98" xlink:to="lab_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A" xlink:to="lab_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182" xlink:to="lab_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_E2774CE443C42C9737AEDB9AD06061CD_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_E2774CE443C42C9737AEDB9AD06061CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_E2774CE443C42C9737AEDB9AD06061CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_E2774CE443C42C9737AEDB9AD06061CD" xlink:to="lab_us-gaap_LongTermDebtCurrent_E2774CE443C42C9737AEDB9AD06061CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D" xlink:to="lab_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1372AD2238E4079DC386DB9AD060A3CE_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_1372AD2238E4079DC386DB9AD060A3CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1372AD2238E4079DC386DB9AD060A3CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_1372AD2238E4079DC386DB9AD060A3CE" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_1372AD2238E4079DC386DB9AD060A3CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029_label_en-US" xlink:label="lab_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029" xlink:to="lab_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F" xlink:to="lab_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="lab_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4" xlink:to="lab_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $.001 par value; 900,000 shares authorized; 725,641 and 514,349 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114" xlink:to="lab_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6" xlink:to="lab_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 1,281 and 814 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B" xlink:to="lab_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D" xlink:to="lab_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9" xlink:type="arc" />
    <link:label id="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_538ED338AFD58FADB174E21572D4B90B_label_en-US" xlink:label="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_538ED338AFD58FADB174E21572D4B90B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities at Fair Value [Abstract]</link:label>
    <link:label id="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_538ED338AFD58FADB174E21572D4B90B_documentation_en-US" xlink:label="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_538ED338AFD58FADB174E21572D4B90B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets and Liabilities at Fair Value [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_AssetsAndLiabilitiesAtFairValueAbstract" xlink:label="loc_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_538ED338AFD58FADB174E21572D4B90B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_538ED338AFD58FADB174E21572D4B90B" xlink:to="lab_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_538ED338AFD58FADB174E21572D4B90B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Total</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65" xlink:to="lab_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642" xlink:type="arc" />
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_C9CBABAF52C38E93A908D1C11EE2B089_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_C9CBABAF52C38E93A908D1C11EE2B089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_C9CBABAF52C38E93A908D1C11EE2B089_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_C9CBABAF52C38E93A908D1C11EE2B089" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_C9CBABAF52C38E93A908D1C11EE2B089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_C9CBABAF52C38E93A908D1C11EE2B089" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_C9CBABAF52C38E93A908D1C11EE2B089" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65" xlink:to="lab_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4" xlink:to="lab_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_0E74C66F34C86B7E31F7D1C11EF2DCE7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0E74C66F34C86B7E31F7D1C11EF2DCE7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0E74C66F34C86B7E31F7D1C11EF2DCE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_0E74C66F34C86B7E31F7D1C11EF2DCE7" xlink:to="lab_us-gaap_StockholdersEquity_0E74C66F34C86B7E31F7D1C11EF2DCE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to designees of Symphony Icon Holdings LLC, shares</link:label>
    <link:label id="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541_label_en-US" xlink:label="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued to Symphony Designees, Shares</link:label>
    <link:label id="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541_documentation_en-US" xlink:label="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the shares issued to designees of Holdings during the period.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedtoSymphonyDesigneesShares" xlink:label="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:to="lab_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:type="arc" />
    <link:label id="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_87C94CC8C8ABA0919581D1C11EF23746_terseLabel_en-US" xlink:label="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_87C94CC8C8ABA0919581D1C11EF23746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_87C94CC8C8ABA0919581D1C11EF23746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_87C94CC8C8ABA0919581D1C11EF23746" xlink:to="lab_lxrx_SharesIssuedToSymphonyDesigneesValue_87C94CC8C8ABA0919581D1C11EF23746" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_087C07D3A69FE940E33DD1C11EF298C3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_087C07D3A69FE940E33DD1C11EF298C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of fees, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_087C07D3A69FE940E33DD1C11EF298C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_087C07D3A69FE940E33DD1C11EF298C3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_087C07D3A69FE940E33DD1C11EF298C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of fees, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_15334D65DBCF3617570CD1C11EF2727B_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_15334D65DBCF3617570CD1C11EF2727B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15334D65DBCF3617570CD1C11EF2727B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_15334D65DBCF3617570CD1C11EF2727B" xlink:to="lab_us-gaap_NetIncomeLoss_15334D65DBCF3617570CD1C11EF2727B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_150A372E74768BF2DE8CD1C11EF287D9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_150A372E74768BF2DE8CD1C11EF287D9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_150A372E74768BF2DE8CD1C11EF287D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_150A372E74768BF2DE8CD1C11EF287D9" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_150A372E74768BF2DE8CD1C11EF287D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_3B7A03C2CF52FD1C9D07D1C11EF22A03_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_3B7A03C2CF52FD1C9D07D1C11EF22A03" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3B7A03C2CF52FD1C9D07D1C11EF22A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_3B7A03C2CF52FD1C9D07D1C11EF22A03" xlink:to="lab_us-gaap_StockholdersEquity_3B7A03C2CF52FD1C9D07D1C11EF22A03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1" xlink:to="lab_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:to="lab_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:type="arc" />
    <link:label id="lab_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8_label_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coelacanth Goodwill</link:label>
    <link:label id="lab_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8_documentation_en-US" xlink:label="lab_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.  This represents the goodwill.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_CoelacanthGoodwill" xlink:label="loc_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:to="lab_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:type="arc" />
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870_terseLabel_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870_label_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coelacanth Purchase Price</link:label>
    <link:label id="lab_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870_documentation_en-US" xlink:label="lab_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.  This represents the purchase price.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_CoelacanthPurchasePrice" xlink:label="loc_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:to="lab_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:type="arc" />
    <link:label id="lab_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408_terseLabel_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408_label_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symphony Icon Goodwill</link:label>
    <link:label id="lab_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408_documentation_en-US" xlink:label="lab_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyIconGoodwill" xlink:label="loc_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:to="lab_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6" xlink:type="arc" />
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</link:label>
    <link:loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BA88F159119496D86EC0D182D60A2E3D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BA88F159119496D86EC0D182D60A2E3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BA88F159119496D86EC0D182D60A2E3D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BA88F159119496D86EC0D182D60A2E3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BA88F159119496D86EC0D182D60A2E3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BA88F159119496D86EC0D182D60A2E3D" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BA88F159119496D86EC0D182D60A2E3D" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>lxrx-20141231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva, formerly WebFilings-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:href="lxrx-20141231.xsd#ArrangementsWithSymphonyIconInc" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:href="lxrx-20141231.xsd#ArrangementsWithSymphonyIconIncDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncTables" xlink:href="lxrx-20141231.xsd#ArrangementsWithSymphonyIconIncTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/AssetsHeldForSale" xlink:href="lxrx-20141231.xsd#AssetsHeldForSale" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/AssetsHeldForSaleDetails" xlink:href="lxrx-20141231.xsd#AssetsHeldForSaleDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/AssetsHeldForSaleTables" xlink:href="lxrx-20141231.xsd#AssetsHeldForSaleTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:href="lxrx-20141231.xsd#BalanceSheetParentheticals" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BenefitPlan" xlink:href="lxrx-20141231.xsd#BenefitPlan" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:href="lxrx-20141231.xsd#BenefitPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/BenefitPlanTables" xlink:href="lxrx-20141231.xsd#BenefitPlanTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:href="lxrx-20141231.xsd#CashAndCashEquivalentsAndInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:href="lxrx-20141231.xsd#CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:href="lxrx-20141231.xsd#CashAndCashEquivalentsAndInvestmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:href="lxrx-20141231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:href="lxrx-20141231.xsd#CollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsTables" xlink:href="lxrx-20141231.xsd#CollaborationAndLicenseAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="lxrx-20141231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:href="lxrx-20141231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="lxrx-20141231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="lxrx-20141231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="lxrx-20141231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:href="lxrx-20141231.xsd#DebtObligations" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:href="lxrx-20141231.xsd#DebtObligationsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:href="lxrx-20141231.xsd#DebtObligationsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:href="lxrx-20141231.xsd#DebtObligationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:href="lxrx-20141231.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwards" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsDetails4" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:href="lxrx-20141231.xsd#EquityIncentiveAwardsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:href="lxrx-20141231.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:href="lxrx-20141231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:href="lxrx-20141231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:href="lxrx-20141231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/Goodwill" xlink:href="lxrx-20141231.xsd#Goodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/GoodwillDetails" xlink:href="lxrx-20141231.xsd#GoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/GoodwillTables" xlink:href="lxrx-20141231.xsd#GoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxes" xlink:href="lxrx-20141231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:href="lxrx-20141231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:href="lxrx-20141231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:href="lxrx-20141231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:href="lxrx-20141231.xsd#OrganizationAndOperations" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsDetails" xlink:href="lxrx-20141231.xsd#OrganizationAndOperationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OrganizationAndOperationsTables" xlink:href="lxrx-20141231.xsd#OrganizationAndOperationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:href="lxrx-20141231.xsd#OtherCapitalStockAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:href="lxrx-20141231.xsd#OtherCapitalStockAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalStockAgreementsTables" xlink:href="lxrx-20141231.xsd#OtherCapitalStockAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:href="lxrx-20141231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:href="lxrx-20141231.xsd#PropertyAndEquipmentDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentDetails2" xlink:href="lxrx-20141231.xsd#PropertyAndEquipmentDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:href="lxrx-20141231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:href="lxrx-20141231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:href="lxrx-20141231.xsd#RecentAccountingPronouncementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:href="lxrx-20141231.xsd#RecentAccountingPronouncementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RestructuringCharges" xlink:href="lxrx-20141231.xsd#RestructuringCharges" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RestructuringChargesDetails" xlink:href="lxrx-20141231.xsd#RestructuringChargesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/RestructuringChargesTables" xlink:href="lxrx-20141231.xsd#RestructuringChargesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:href="lxrx-20141231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="lxrx-20141231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="lxrx-20141231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:href="lxrx-20141231.xsd#StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivable" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesAccountsReceivable" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillImpairment" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesGoodwillImpairment" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognition" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognition" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensation" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimates" xlink:href="lxrx-20141231.xsd#SummaryOfSignificantAccountingPoliciesUseOfEstimates" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ArrangementsWithSymphonyIconIncAbstract" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_3A935E07FF35E961A659D182D677F7CD" xlink:type="locator" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ArrangementsWithSymphonyIconIncTextBlock" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_3A935E07FF35E961A659D182D677F7CD" xlink:to="loc_lxrx_ArrangementsWithSymphonyIconIncTextBlock_87A0343752770ED29211D182D6776FDA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ArrangementsWithSymphonyIconIncAbstract" xlink:label="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_28C7A746FD46B1387CD3DC4268864642" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ArrangementsWithSymphonyIconIncAbstract_28C7A746FD46B1387CD3DC4268864642" xlink:to="loc_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_8D2B2AEFADEB9F98DF83DC426886E68C" xlink:to="loc_us-gaap_LossContingencyNatureDomain_EF924D052A000BD7EA45DC4268862404" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_C3475964A49AD7CB9033DC426886D8CD" xlink:to="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_HoldingsContributionToIcon" xlink:label="loc_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_HoldingsContributionToIcon_0D3B9C7B8517941C4F26DC42688C9FA5" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LexiconSoldSharesToHoldings" xlink:label="loc_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_LexiconSoldSharesToHoldings_F7A0D09FC8AC30221658DC42688CFB03" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LexiconReceivedCashFromHoldings" xlink:label="loc_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_LexiconReceivedCashFromHoldings_51C8210EB1C7710610C7DC42688C8856" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LexiconPaidHoldingsCash" xlink:label="loc_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_LexiconPaidHoldingsCash_38618B692BA134588649DC42688CA8CC" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonFairValueOfBaseAndContingentPayments" xlink:label="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonFairValueOfBaseAndContingentPayments_ED516F0E8CE188263985DC42688D4E3A" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyBasePaymentDiscountRate" xlink:label="loc_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyBasePaymentDiscountRate_7FC2CD281A16F600D61DDC42688DCD82" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentDiscountRate" xlink:label="loc_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentDiscountRate_20EB5F80C35FD0CF4E37DC42688DF2A9" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyBasePaymentInShares" xlink:label="loc_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyBasePaymentInShares_17B9A0F814DEB7FC9525DC42688D9853" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyBasePaymentObligation" xlink:label="loc_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyBasePaymentObligation_CF9F1CD9C481D3B997A8DC42688D496E" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentMaximum" xlink:label="loc_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentMaximum_CE3F458AFBA868B9102EDC42688D18F0" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentPercentage" xlink:label="loc_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentPercentage_9FB3C2EDC46D14B7BE75DC42688D396B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyRegulatoryApprovalPayment" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyRegulatoryApprovalPayment_3744AE6FCE2438B320EFDC42688DC474" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyRegulatoryApprovalReductionPercentage" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyRegulatoryApprovalReductionPercentage_91203E8399DA17CC48F5DC42688DD2F6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyRegulatoryApprovalPercentageLimit" xlink:label="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyRegulatoryApprovalPercentageLimit_F66AB37A4040BC5CC6FCDC42688E9045" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyPaymentInStockLimitation" xlink:label="loc_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyPaymentInStockLimitation_D0E43895280E481040CBDC42688ED5F9" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentInCash" xlink:label="loc_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentInCash_FE345F4B2B93309223B0DC449E8F4983" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentinShares" xlink:label="loc_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentinShares_8F6CF624F8D5DE1D0C15DC46446F0BE4" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyContingentPaymentTotal" xlink:label="loc_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_SymphonyContingentPaymentTotal_1B1C47CFE8DE26E8373BDC48EAE9B8F7" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenUpfrontPayment" xlink:label="loc_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_IpsenUpfrontPayment_F3680CA0FE0918B313CEDC428336E658" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_78EDDDDC0F55991C74B1DC42688B822C" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_409D571DA0A738D394DFDC42688E2CB1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/AssetsHeldForSale" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_AssetsHeldforSaleAbstract" xlink:label="loc_lxrx_AssetsHeldforSaleAbstract_B2762070558A1D1275EEDD4CD65930AE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_F698C7224D4576B66C72DD4CD6594B82" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AssetsHeldforSaleAbstract_B2762070558A1D1275EEDD4CD65930AE" xlink:to="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_F698C7224D4576B66C72DD4CD6594B82" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/AssetsHeldForSaleDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_AssetsHeldforSaleAbstract" xlink:label="loc_lxrx_AssetsHeldforSaleAbstract_EC216048044D8EB4DD8BDB9ACFA79082" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_50094D880FF90B53E2A1DB9ACFA7C5B6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AssetsHeldforSaleAbstract_EC216048044D8EB4DD8BDB9ACFA79082" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_50094D880FF90B53E2A1DB9ACFA7C5B6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/AssetsHeldForSaleTables" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/BalanceSheetParentheticals" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_BalanceSheetParentheticalsAbstract" xlink:label="loc_lxrx_BalanceSheetParentheticalsAbstract_88153028A2626168048CE16F6BDC4AA5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BalanceSheetParentheticalsAbstract_88153028A2626168048CE16F6BDC4AA5" xlink:to="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_627003617FDD7A328B89E16F6BDCD529" xlink:to="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CF000A6A4DA10C0BA17CE16F6BDCE9AD" xlink:to="loc_us-gaap_CommonStockMember_CA9539D13CC1880D3AABE16F6BDC36FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_C55AC5DC65042708ED1AE16F6BDCFC0F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:to="loc_us-gaap_StatementScenarioAxis_C55AC5DC65042708ED1AE16F6BDCFC0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7736E42CEB975B46AB7DE16F6BDC47FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_C55AC5DC65042708ED1AE16F6BDCFC0F" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7736E42CEB975B46AB7DE16F6BDC47FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8241E29C38BE6225F4CBE16F6BDC5C95" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8241E29C38BE6225F4CBE16F6BDC5C95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_76ACE5871BEE071AF93BE16F6BDC4CAB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8241E29C38BE6225F4CBE16F6BDC5C95" xlink:to="loc_us-gaap_ClassOfStockDomain_76ACE5871BEE071AF93BE16F6BDC4CAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_10ECDA66DBC167318A1AE16F6BDC2162" xlink:to="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_RestrictedInvestments_DA6AA41BC231C4669262E16F6BDC116D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_AD72AF299E2E873D95F8E16F6BDC1768" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_256D11B0A5DFD8F4464EE16F6BDC4A9B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_256D11B0A5DFD8F4464EE16F6BDC4A9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5D98C2BECE5F8071F86BE16F6BDCAEA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2F635E244592B6392440E16F6BEC6962" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_PreferredStockSharesIssued_A280D2F5CAB56401F266E16F6BECF807" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_54343A717D7F7F905821E16F6BEC2CA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1F39269F048F896B8505E16F6BEC74AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_19D36E66D92DC9F1FCCBE16F6BEC7FAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_CommonStockSharesIssued_768F9C7CA5DCDC906271E16F6BEC54DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C43050153AA1E9DA876FE16F6BDC298D" xlink:to="loc_us-gaap_TreasuryStockShares_7735F8C86934A8D39C66E16F6BEC4612" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlan" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_BenefitPlanAbstract" xlink:label="loc_lxrx_BenefitPlanAbstract_CAD983C7095413D8B9F1D182D5CBBEF1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A206E8036353CB5921CED182D5CB9702" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_CAD983C7095413D8B9F1D182D5CBBEF1" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_A206E8036353CB5921CED182D5CB9702" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/BenefitPlanDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_BenefitPlanAbstract" xlink:label="loc_lxrx_BenefitPlanAbstract_0B404CBB950FC123DC81D182D56EC979" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BenefitPlanAbstract_0B404CBB950FC123DC81D182D56EC979" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis" xlink:label="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:to="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_4D3EE9D163F898E26007D182D56E70DA" xlink:to="loc_us-gaap_DefinedBenefitPlansDomain_1EF75A4DBB9A2A3B5C17D182D56E2A6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_48F082F3820E4E0B4A72D182D56E0F4C" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7BD880DD7DAE15ED16A7D182D56E1A0D" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_5ED09E2CDE572794694DD182D56EBA77" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_7B01DB4FE33C537A5B69D182D60AF0B5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BA88F159119496D86EC0D182D60A2E3D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_7B01DB4FE33C537A5B69D182D60AF0B5" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_BA88F159119496D86EC0D182D60A2E3D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_84D9EB217F0CF94A3583D182D629920D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_84D9EB217F0CF94A3583D182D629920D" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:to="loc_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentAxis_34481A0A697B644FD07FD182D6297719" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_CashMember_C588F99FFC5E71D67911D182D62948D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_CertificatesOfDepositMember_356115FE83BC9C58783ED182D6299BA8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_A58D7572BA9AC8EE7CD9D182D6292B5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_9EA2CDE828B11462C433D182D6294F6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsMember" xlink:label="loc_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D81EFA370F4EF1A2ED13D182D6292173" xlink:to="loc_us-gaap_InvestmentsMember_7692813C874EA972E8A2D182D629ABCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_38A7D8EF5468848BC17FD182D629723F" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40D7334FDEA14728956DD182D6294C80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_D18F84685B1B027185C3D182D629CFC0" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_40FB8721D4DB17368FB2D182D6298372" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_5314C723014FD3C02D68D182D6295D65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D470F21338B67E5ABB5CD182D6297EAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_208FA690D2969D7A29F7D182D629F2DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_099DB9DAC318784FDCD9D182D6298758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_745794E784C08E4ECFE8D182D6291E23" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_F707CBEA5D636025F946D182D5BCF3FB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C4552999369DD7A9C430D182D5BC47EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_F707CBEA5D636025F946D182D5BCF3FB" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C4552999369DD7A9C430D182D5BC47EC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreements" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_4A9F97467CBEAE6659BCD182D5ACCC25" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_EBCA81B7F9CB751704B8D182D5AC1BA3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_4A9F97467CBEAE6659BCD182D5ACCC25" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_EBCA81B7F9CB751704B8D182D5AC1BA3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_7D79A3641CE3DB5EC9AFE162CF01DF37" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_7D79A3641CE3DB5EC9AFE162CF01DF37" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:to="loc_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D3C3722BEE3DDE5FC179E162CF01D2BD" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AE7946E390A41331FB95E162CF01F4FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_895B996BC774A69A0E58E162CF014924" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenUpfrontPayment" xlink:label="loc_lxrx_IpsenUpfrontPayment_9624E9D9E00121599020E162CF0179B6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenUpfrontPayment_9624E9D9E00121599020E162CF0179B6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_0D65E13E891C1608C374E162CF01D995" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_7E05465485AA8B974984E162CF01377C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_DC7D3A4758E5EB4081D9E162CF013EFC" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenRevenueRecognized" xlink:label="loc_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenRevenueRecognized_7D1DDCE87E1388A5D9BCE162CF014E0F" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_F1337AB9A39EFF8D8DCBE162CF01522D" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IpsenMaximumSalesMilestones" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_228420D1A5B16B9BFD60E162CF01B9F4" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TxEnterpriseFundAward" xlink:label="loc_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TxEnterpriseFundAward_911B17B51201ECDDDB6FE162CF01C991" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem" xlink:label="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem_7E8E0E644A68402AB297E162CF011907" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TigmPerJobPaymentAmount" xlink:label="loc_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TigmPerJobPaymentAmount_2797CC709B06FAE89F9DE162CF01D8F7" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TigmMaximumExposure" xlink:label="loc_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TigmMaximumExposure_9D5B0F642D223DABF860E162CF01005A" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TIGMMaximumExposureThroughReportingDate" xlink:label="loc_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4CDE70C7B4FCDEB79E1EE162CF015B5F" xlink:to="loc_lxrx_TIGMMaximumExposureThroughReportingDate_664F052AE6BA4D67AFA5E162CF01B8EC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_EB0D33683EFB62CE9C3BD182D56E14DF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13F4D304417EC03F3E0ED182D56E6840" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_EB0D33683EFB62CE9C3BD182D56E14DF" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_13F4D304417EC03F3E0ED182D56E6840" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_2518672FD7785CD970A9D182D53F4D1D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_D0160C48066696D32426D182D53F5DE7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_2518672FD7785CD970A9D182D53F4D1D" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_D0160C48066696D32426D182D53F5DE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_D0160C48066696D32426D182D53F5DE7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_A2B1F787FA0BF3B36B87D182D53F22DE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_F512438F2EDAFBC5BE76D182D53F8746" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_A2B1F787FA0BF3B36B87D182D53F22DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_3B0064B6926C016035D8D182D53F15FF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_D0160C48066696D32426D182D53F5DE7" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_3B0064B6926C016035D8D182D53F15FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_52EF1BCC0A4AC9C3B5FAD182D53F4523" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3B0064B6926C016035D8D182D53F15FF" xlink:to="loc_us-gaap_RestrictedInvestments_52EF1BCC0A4AC9C3B5FAD182D53F4523" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_3B0064B6926C016035D8D182D53F15FF" xlink:to="loc_us-gaap_LeaseAndRentalExpense_96A91A84899D1BF98051D182D53FE4C0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_1653A1B797E4986D56A2D36E4928B417" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_1653A1B797E4986D56A2D36E4928B417" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_53C3BA7E050710314AA4D36E492986D9" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_D094B5FDC25436081060D36E492972E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ABDD3D0B617D5D40CCF3D36E49297C57" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8553B8A3BDE0F02D37C9D36E4929F291" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FEB918E1CDC75BB6DBC3D37169D89894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_D85CC1E021EE384B6725D371C1357A92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3331D9D9CF734F4F3BEAD3721BAF1EFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E70F81B4426E70F07E49D36E49295BB0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9CF0B573EBBCCAE32F97D36E492FD38C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CommitmentsAndContingenciesAbstract" xlink:label="loc_lxrx_CommitmentsAndContingenciesAbstract_3EE3EBE8946C439DA723D182D5CB0C69" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_DA417EDAA189A882B49ED182D5CB13DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CommitmentsAndContingenciesAbstract_3EE3EBE8946C439DA723D182D5CB0C69" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_DA417EDAA189A882B49ED182D5CB13DD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedBalanceSheetsAbstract" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_A978DE21C54439FF081CDB9AD05C6FEA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5EFF5AA99CC6FF2757D9DB9AD05C6A92" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_A978DE21C54439FF081CDB9AD05C6FEA" xlink:to="loc_us-gaap_StatementTable_5EFF5AA99CC6FF2757D9DB9AD05C6A92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5890A092D902DC8CA74BDB9AD05CCA52" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5EFF5AA99CC6FF2757D9DB9AD05C6A92" xlink:to="loc_us-gaap_StatementScenarioAxis_5890A092D902DC8CA74BDB9AD05CCA52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_88AC964DB539C7BFFC01DB9AD05DF00A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_5890A092D902DC8CA74BDB9AD05CCA52" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_88AC964DB539C7BFFC01DB9AD05DF00A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F604AED8D7369C3B8B66DB9AD05D9072" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5EFF5AA99CC6FF2757D9DB9AD05C6A92" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F604AED8D7369C3B8B66DB9AD05D9072" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CB7E350FF709E0884468DB9AD05D02E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F604AED8D7369C3B8B66DB9AD05D9072" xlink:to="loc_us-gaap_ClassOfStockDomain_CB7E350FF709E0884468DB9AD05D02E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5EFF5AA99CC6FF2757D9DB9AD05C6A92" xlink:to="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F8DA91E9FADB010AF412DB9AD05E6A71" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F8DA91E9FADB010AF412DB9AD05E6A71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_ShortTermInvestments_81FCE208A5118715932FDB9AD05E72F4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9F08E1D705639C4FE2F3DB9AD05E33CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_40764E415C2C1BFC329ADBA54799864C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_40764E415C2C1BFC329ADBA54799864C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_OtherAssetsCurrent_D73DB74AEF70B92984DCDB9AD05FDEEB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_92CC410EA02BA7BC58ACDB9AD05D8DE3" xlink:to="loc_us-gaap_AssetsCurrent_0F709FD7FFF54AE269FCDB9AD05F53E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_E7362298A17331FC9F7ADB9AD05F5E62" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_E7362298A17331FC9F7ADB9AD05F5E62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_Goodwill_57EF5D34A5BD61C10E8ADB9AD05FF762" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_EC2738DEC8B38973E2CDDB9AD05FD852" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_103E402C8DC4D8216DB3DB9AD05F671C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_Assets_50336906BB63579104EBDB9AD05FDC98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_AccountsPayableCurrent_8098CC22DC1E09FC93C2DB9AD05F8E5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6F14208D12A02A4BE64EDB9AD05F3FD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_DeferredRevenueCurrent_CCA26E111FA4B6B19653DB9AD05FC182" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_E2774CE443C42C9737AEDB9AD06061CD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_LongTermDebtCurrent_E2774CE443C42C9737AEDB9AD06061CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5A4F366F765CA8E2E55BDB9AD05FE3C0" xlink:to="loc_us-gaap_LiabilitiesCurrent_D1C146E2BCE263F56EBCDB9AD060962D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_3983B56F91B83E43B60FDB9AD060AB0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1372AD2238E4079DC386DB9AD060A3CE" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1372AD2238E4079DC386DB9AD060A3CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_48F5C9DDD8427A8ECA13DB9AD0608EB3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8D95DDA64D3FB1FA4318DB9AD0602B53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_Liabilities_527538E57FBCF6026365DB9AD0609029" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_CommitmentsAndContingencies_F4DE85E7ADF41C63C884DB9AD060E98F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_PreferredStockValue_88C812030CE5A39A0206DB9AD06079C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_CommonStockValue_03359D9CEF28DA712FCEDB9AD0604114" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_B0046711732264E47A7BDB9AD06151E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3EEE3DEDE70DF505657BDB9AD0619F8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A0FF8A68892606A99DB6DB9AD06102EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_TreasuryStockValue_F95104D606D7704CB5EBDB9AD0619B6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78614583C2AAEDB15A09DB9AD06001D3" xlink:to="loc_us-gaap_StockholdersEquity_A7482F7CB2502ED7086FDB9AD061EC1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2B5919DC645E986C53A3DB9AD05DE52C" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_68DB6C73B86D65D8EEEFDB9AD0611FE9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_EF539FE826B4737D4CA2DB906168A838" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6D1909BB62EA186E662BDB906168471C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_EF539FE826B4737D4CA2DB906168A838" xlink:to="loc_us-gaap_StatementTable_6D1909BB62EA186E662BDB906168471C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5AA293DE8C7943ADB78CDB906168FB5E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6D1909BB62EA186E662BDB906168471C" xlink:to="loc_us-gaap_StatementScenarioAxis_5AA293DE8C7943ADB78CDB906168FB5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_A2252AE00776E3BE4737DB9061684CDB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_5AA293DE8C7943ADB78CDB906168FB5E" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_A2252AE00776E3BE4737DB9061684CDB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6D1909BB62EA186E662BDB906168471C" xlink:to="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:to="loc_us-gaap_ProfitLoss_7B9117FB3E080A98F636DB906169AA85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5983BC930688DCD71B4BDB9061696183" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9B7DEF9590A154CC349ADB9061696830" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_B7BD3C026634A36BBF69DB90616AC707" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_B7BD3C026634A36BBF69DB90616AC707" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_ShareBasedCompensation_9EA7C7A6C035C42E597ADB90616AB45D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_929DBB282A03B45379CCDB90616AFB80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_CFEE811AD8D1134E4CF4DB90616A510C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_AFC565DB815123EB96AFDB90616A7043" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8090011F1DD06A949E49DB9061693A78" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6FAE72E6A9167D560F1ADB90616A52F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_E076926DFD634A6DE30EDB90616AD2CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6DB568ED402FB84A36E4DB90616AEE6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_090EB559B707213779A1DB90616A8A4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9DAFF409484054659064DB90616A8F4C" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_D63EF5577EBCCB2092E5DB90616BF3BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_C10F2B703A6701852FCEDB906169430E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136A7CF5051EE3B56617DB90616B2D04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77C72EFDE4DB47FE3DC2DB90616B1E72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1B655B1BDEC9E49FD832DB90616B0231" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_573D9E907D292A664CB7DB90616B9413" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_E6066A71F0DA1B25088CDB90616B9B62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33A5A0B1BAFC3BC066FCDB90616BEF87" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6C690FD32BDFF8673706DB90616B9C48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_92A069754EACAA4BBDF7DB90616B33D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_73131BE96EAB4FE69DE1DB90616C4FFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15A2775F02C1E5BE34C6DB90616C797D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_A1E3207DAA35E4E1B781DB90616C831A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9BE49717F37240ABD9D7DB90616C154A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C242DC96979B5560CC73DB90616B78E6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5F0780E09A1C52838A67DB90616C02D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_43A689D47F350E52CA70DB90616C649F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0F7EC24495DD0C217998DB90616C6BC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3DE6B1A82992EA1F967DDB90616CE61B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3DE6B1A82992EA1F967DDB90616CE61B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_60B017EF8CE155C1A9F1DB90616C1B7B" xlink:to="loc_us-gaap_InterestPaidNet_14A130D03919922121FFDB90616D9927" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97C1E52366CB7AB3A9C2DB9061697FD7" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_5F28D969E44628C73253DB90616D2D67" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_72E2A9C6D1439BD4E56CDB90616DAF2C" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_9D00D310C9D0CD0A0057DB90616DC307" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_F63C2CB49EC6A6572843DB8FAE12C278" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_F63C2CB49EC6A6572843DB8FAE12C278" xlink:to="loc_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:to="loc_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_7EBB36E7652CE4D74752DB8FAE124404" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_950BCA7EA3B9B651A862DB8FAE12BB6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1D0DD77EB659F0FCF637DB8FAE121367" xlink:to="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:to="loc_us-gaap_ContractsRevenue_B0A28F59DFB4475E3C47DB8FAE124A64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:to="loc_us-gaap_LicensesRevenue_AAE53E83C48DC87A0B14DB8FAE137B4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_226837DCAB66614E7FD6DB8FAE126E98" xlink:to="loc_us-gaap_Revenues_564D262537EAF59170C2DB8FAE134FC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_FD49A1AE52C4FBE3BD95DB8FAE13BC9D" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_5DA73F06451BB44DFBEDDB8FAE1361F3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_5DA73F06451BB44DFBEDDB8FAE1361F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8281967D285E39ECA7BEDB8FAE133FCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_us-gaap_AssetImpairmentCharges_FCC30BEEDBDE9E6AFC88DBA7DFEF926E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7A583110AE965267094BDB8FAE131C77" xlink:to="loc_us-gaap_OperatingExpenses_656FE02B0FF806BB0531DB8FAE13DFE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_OperatingIncomeLoss_562C23A2A8B52E3FA737DB8FAE135310" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_InterestExpense_4B63D49FC7980EA354BADB8FAE14E392" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C698DE485F026180E282DB8FAE1420B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0F9175D8F6F850C65AD3DB8FAE14AD24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6CB04D4F48BC7CCB06B2DB8FAE1440DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_NetIncomeLoss_7156D8D78EA268E60597DB8FAE1429E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_CF2A28AC7456FCC8954BDB8FAE142E92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92E3DCAB4A68804E6DC1DB8FAE141450" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_DDEB5E32907C43D7B875DB8FAE126B6C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A6CA4808B5773D0D5689DB8FAE142A99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_388EDE525A203F94E132DB8FAE149C12" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0EDB9E3B9B699A2985BEDB8FAE146A61" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_C9CBABAF52C38E93A908D1C11EE2B089" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9DD226DD146E6B6FF54FD1C11EE2626C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_C9CBABAF52C38E93A908D1C11EE2B089" xlink:to="loc_us-gaap_StatementTable_9DD226DD146E6B6FF54FD1C11EE2626C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_13E20B243801297423F1D1C11EE2DAD1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9DD226DD146E6B6FF54FD1C11EE2626C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_13E20B243801297423F1D1C11EE2DAD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_13E20B243801297423F1D1C11EE2DAD1" xlink:to="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4A38CBF5E8FBE0B8B14DD1C11EE2D714" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_CommonStockMember_4A38CBF5E8FBE0B8B14DD1C11EE2D714" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_C99282570B6CFAE88573D1C11EE24264" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_RetainedEarningsMember_9CB9CFAFBA298AB30A52D1C11EE22B65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3003D3922BC01898FEB6D1C11EE25BB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_39452C50D9F33744A5E8D1C11EE2DA4D" xlink:to="loc_us-gaap_TreasuryStockMember_0283B66F67119B215DCED1C11EF255A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9DD226DD146E6B6FF54FD1C11EE2626C" xlink:to="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_685062E776E4E81CC17ED1C11EF286FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0E74C66F34C86B7E31F7D1C11EF2DCE7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StockholdersEquity_0E74C66F34C86B7E31F7D1C11EF2DCE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7E3F07FD58441402C7DAD1C11EF2E0F6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedtoSymphonyDesigneesShares" xlink:label="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_lxrx_SharesIssuedtoSymphonyDesigneesShares_3473D3C6AF338F7DAB2ED1C11EF29541" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedToSymphonyDesigneesValue" xlink:label="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_87C94CC8C8ABA0919581D1C11EF23746" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_lxrx_SharesIssuedToSymphonyDesigneesValue_87C94CC8C8ABA0919581D1C11EF23746" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_C91202109E6B8ABA7780D1C11EF296CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1CFE711B87E1EDBF030CD1C11EF24CEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_087C07D3A69FE940E33DD1C11EF298C3" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_087C07D3A69FE940E33DD1C11EF298C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3EEDD1839EA71A7B8D20D1C11EF2EE48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6211D96391FF397631E6D1C11EF24F93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15334D65DBCF3617570CD1C11EF2727B" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_NetIncomeLoss_15334D65DBCF3617570CD1C11EF2727B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_19E714469FC4A7A5A845D1C11EF25559" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_19E714469FC4A7A5A845D1C11EF25559" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_150A372E74768BF2DE8CD1C11EF287D9" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_150A372E74768BF2DE8CD1C11EF287D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3B7A03C2CF52FD1C9D07D1C11EF22A03" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D026C728DEFBB6141B2D1C11EF2C7D5" xlink:to="loc_us-gaap_StockholdersEquity_3B7A03C2CF52FD1C9D07D1C11EF22A03" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_FBA7A333E205A4CF6A9DD182D5CB60BF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_FD6B83474A4466E0EE50D182D5CB5317" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_FBA7A333E205A4CF6A9DD182D5CB60BF" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_FD6B83474A4466E0EE50D182D5CB5317" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails1" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_AECE9716C13AC1AD1F21DB48D866D593" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_AECE9716C13AC1AD1F21DB48D866D593" xlink:to="loc_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_81CA33E2F69BA240C09CDB48D8766BFC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FE222A65DED93E41A93ADB48D876B8D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1A2ACDF28A00DEEAB09FDB48D876AF4B" xlink:to="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4492863E945DF65EF2ABDB48D876C003" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6611D0A626B42AD78289DB48D876E694" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20F9A4E567242D0899A4DB48D876A1B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_48335D36B20F65E2632CDB48D87657D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_54780E17AF6AC28B498BDB493585371A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2704C21B033576270166DB49EB9066D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebt_D4DA0A89454758F26726DB48D876F60A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtCurrent_F3D76102726270719C23DB48D876115D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72CDE3DAED46432F6D7FDB48D8768620" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_B3B76DF4A0F9CF0A6D4ADB48D8767DFB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails2" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_F4D001B99C01E4A11527DB4AAC94CEDC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_F4D001B99C01E4A11527DB4AAC94CEDC" xlink:to="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_13D53C9F9100A2E601E8DB5C342D68F0" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_0CB4077378D721E2B1EADB5C34B9513A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_256A6EBB5DA060C23203DB4AAC94F927" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_256A6EBB5DA060C23203DB4AAC94F927" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EB6BC9518267DCB7EBDEDB4AAC9460EA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_256A6EBB5DA060C23203DB4AAC94F927" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_EB6BC9518267DCB7EBDEDB4AAC9460EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:to="loc_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_087CB124380D08EB5793DB4AAC94D9D9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7442917A9063F61D05B5DB4AAC94000E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_987CA7D88C9A2FB2905CDB4AAC9464A7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_58477280ABFA9D107817DB4CC3BE2F16" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" xlink:label="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage_773A0EB6D07616C1B728DB597CB1C3C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_50D77880E40E98992193DB4FA044AE89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_217C15109B5BB4B3F70BDB506B4862B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtIssuanceCosts_365B2CA64E078F8A9569DB52132C4519" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_7151683107CA851209FDDB52D1C57CF5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtInstrumentFairValue_A0625E1E677590A80C28DB541D3CC347" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_WoodlandsMortgage" xlink:label="loc_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_WoodlandsMortgage_0C51916B05A3947916B5DB4AAC94454F" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_WoodlandsCashPaid" xlink:label="loc_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_WoodlandsCashPaid_92F2F13B1577A8B63D40DB4AAC944161" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53F8BE0F99B4EED48439DB4AAC943784" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages_238751C0BC2B310F2AC0DB552AE9DA72" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_BuildingsCollateral" xlink:label="loc_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_BuildingsCollateral_F5DE1AD8AB5429D33114DB5E9F0BCD6B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LandCollateral" xlink:label="loc_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AFB5885AC60D28BE7146DB4AAC94E0D9" xlink:to="loc_lxrx_LandCollateral_359B6402EBBEC0787EFBDB4AAC943554" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DebtObligationsAbstract" xlink:label="loc_lxrx_DebtObligationsAbstract_F0C154BB79E3E8A749A3D182D6966B72" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_FFA4E93C27276F95C574D182D69646B6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_F0C154BB79E3E8A749A3D182D6966B72" xlink:to="loc_us-gaap_DebtInstrumentTable_FFA4E93C27276F95C574D182D69646B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2C862EDE2EFF5CECDDB8D182D6967321" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FFA4E93C27276F95C574D182D69646B6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2C862EDE2EFF5CECDDB8D182D6967321" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1FA5DB709091CF9D8CF5D182D6962B0F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2C862EDE2EFF5CECDDB8D182D6967321" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1FA5DB709091CF9D8CF5D182D6962B0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3E07EF66573B90468EDBD182D696900F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FFA4E93C27276F95C574D182D69646B6" xlink:to="loc_us-gaap_DebtInstrumentAxis_3E07EF66573B90468EDBD182D696900F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0C9B81F2F67620155219D182D6963D07" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3E07EF66573B90468EDBD182D696900F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0C9B81F2F67620155219D182D6963D07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_A4C01A524EC17885C587D182D696F8D0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FFA4E93C27276F95C574D182D69646B6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_A4C01A524EC17885C587D182D696F8D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_A4C01A524EC17885C587D182D696F8D0" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_A43647D34B32BC3236B9D182D696B0F9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/DocumentAndEntityInformationDocument" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DeiAbstract" xlink:label="loc_lxrx_DeiAbstract_CBE2DC219FC0E2283426E5830EB0B375" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DeiAbstract_CBE2DC219FC0E2283426E5830EB0B375" xlink:to="loc_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:to="loc_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationDocumentAxis_284827101ED4131565AAE5830EB2E3AE" xlink:to="loc_dei_DocumentDomain_1CF235B4932ECF8F285FE5830EB22599" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_89FAABE62A9DFFD81E86E5830EB26E5D" xlink:to="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityRegistrantName_734C16DDD4F72465C8C7E5830EB30FDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityCentralIndexKey_3339B3B3C08936757D93E5830EB3A3E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_CurrentFiscalYearEndDate_62BC30C8F383BF39979BE5830EB38851" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityFilerCategory_B5417376336AA1CFD4D6E5830EB366F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_DocumentType_8F6B759D61F216E95034E5830EB34CA8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_DocumentPeriodEndDate_D0F8CD0D64AA8907F38AE5830EB2412F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_DocumentFiscalYearFocus_ABB9CA619924A6D5699EE5830EB25A8E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_DocumentFiscalPeriodFocus_BE9B4E092A303CAF5F97E5830EB35CDA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_AmendmentFlag_C010461BEA4D480DC1F4E5830EB3F1D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_490CF52CB065C9C3ADE3E5830EB3EFD3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7CD33D057DCA97B68554E5830EB3E1A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityVoluntaryFilers_8821A740D023D09515F9E5830EB321F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityCurrentReportingStatus_7E67903B73D54794565BE5830EB3A624" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_3B7AEA0039DC0F5C5546E5830EB2AE0D" xlink:to="loc_dei_EntityPublicFloat_02B28657185F119B2B69E5830EB31007" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwards" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_B8DB76FA8519C1BABA6CD182D677EE1A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BD6A411EC6006909795CD182D677CF5E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_B8DB76FA8519C1BABA6CD182D677EE1A" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_BD6A411EC6006909795CD182D677CF5E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_BD4E5D3B40690D283803D182D5EB9E97" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_BD4E5D3B40690D283803D182D5EB9E97" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1320E1CEF974EC430241D182D5EB4BCE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:to="loc_us-gaap_PlanNameAxis_1320E1CEF974EC430241D182D5EB4BCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_AC99E8DA706BA719BF5BD182D5EB6C5C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1320E1CEF974EC430241D182D5EB4BCE" xlink:to="loc_us-gaap_PlanNameDomain_AC99E8DA706BA719BF5BD182D5EB6C5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1D21D0429BAF4B99BDFAD182D5EBACC7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:to="loc_us-gaap_AwardTypeAxis_1D21D0429BAF4B99BDFAD182D5EBACC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BF8DE4617997E6B30322D182D5EBD02E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1D21D0429BAF4B99BDFAD182D5EBACC7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BF8DE4617997E6B30322D182D5EBD02E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F7EC8B747238D610BA56D182D5EB0EDF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F7EC8B747238D610BA56D182D5EB0EDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D16D70F1597836B155CED182D5EB66AE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F7EC8B747238D610BA56D182D5EB0EDF" xlink:to="loc_us-gaap_ClassOfStockDomain_D16D70F1597836B155CED182D5EB66AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CB3680686D3487623B68D182D5EBD3C8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:to="loc_us-gaap_RangeAxis_CB3680686D3487623B68D182D5EBD3C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8DDEC27B044D29946EF5D182D5EB3970" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_CB3680686D3487623B68D182D5EBD3C8" xlink:to="loc_us-gaap_RangeMember_8DDEC27B044D29946EF5D182D5EB3970" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD75B2CF405A1E74AF15D182D5EBF470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" xlink:label="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock_24D9D80C2CBDF2947EB6D182D5EB2AF7" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock" xlink:label="loc_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock_F7E207AB5E6C9F025592D182D5EB627B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan_A9A78DDC1223B9A6BCA4D182D5EB6456" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan" xlink:label="loc_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan_DE58022C2047ECB028BED182D5EBA5E6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_OptionsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_OptionsOutstandingEquityIncentivePlan_3981E220C33B98931657D182D5EB0984" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" xlink:label="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan_7AC05B3F25FCE9CAEE70D182D5FA8A39" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockOptionsExercisedEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_StockOptionsExercisedEquityIncentivePlan_FB9BA054CA8EB1187A9ED182D5FA3C1B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan_25094C2A4F0497CD2A60D182D5FA70A4" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan_6B6B2B4F2F88312F6CFFD182D5FA08B3" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DirectorsIntialOptionGrant" xlink:label="loc_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_DirectorsIntialOptionGrant_A1F64B5FA22CB7BCDD24D182D5FA32F9" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DirectorsAnnualOptionGrant" xlink:label="loc_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_DirectorsAnnualOptionGrant_0DF5F3EA353A167FBEBAD182D5FA87A3" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DirectorsAnnualRestrictedStockAwardValue" xlink:label="loc_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_DirectorsAnnualRestrictedStockAwardValue_249FDCFA298793656879D182D5FA4099" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan_1E7C9E4A47D2574F402CD182D5FA37EA" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan_A03E940D1DF280815E4AD182D5FAA837" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan_A31EB7C90B0D9362FF01D182D5FAE63C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" xlink:label="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan_57986ABCF43650D06E69D182D5FA9178" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4FEDF9590E4DEE374384D182D5FA2667" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EF37EFB3E9E5C4C9241CD182D5EB8D42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2CC68A773045F9CED33CD182D5FA180B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_11104DECAF1082BAFE7ED182D5AC899C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_11104DECAF1082BAFE7ED182D5AC899C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="loc_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4DE26E1E83006C83C697D182D5AC7FD3" xlink:to="loc_us-gaap_PlanNameDomain_950858A69C88D371D420D182D5AC8E73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="loc_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_984EDEF49EDC76B2A1A5D182D5ACC026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_278BE554A19E82D09763D182D5ACB3BD" xlink:to="loc_us-gaap_EmployeeStockOptionMember_E9EBF98C8DAFA78A3AC7D182D5AC152B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="loc_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_173B9D43D8FBA5C14E7DD182D5ACB9C0" xlink:to="loc_us-gaap_ClassOfStockDomain_ADE817E5124D80D841E7D182D5ACE52B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="loc_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_CF0081B2FC426D1FA76AD182D5ACD08D" xlink:to="loc_us-gaap_RangeMember_676E653FD96E87E5264CD182D5ACDCBB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DFBD6D5E83B5E1680059D182D5ACDA01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_EFE356BDE630FFD2DA91D182D5AC4C41" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CA4D59801B76E1B0DE04D182D5ACB4A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66514F8A0C9A4E248417D182D5AC0C88" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEE2B0E7DD7C70088A4D182D5ACABBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F04D682796E7ACE1EFF3D182D5AC33E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6103F1911AC26560021CD182D5AC2EF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EA4B21639E2F44E2585D182D5AC3D9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5247DF099DF1D5A021CDD182D5AC366B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60435F4A80914996B524D182D5AC0815" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_49C448D7C0E981DBE0E9D182D5AC292F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0A23E9D8A75E93946BA4D182D5ACA028" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2F6DB2EA7EC49A14098CD182D5ACC19C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_A202B25266CB210EBF95D182D5AC6A56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35248EABD999FAAA8A1FD182D5AC1D04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5688EFC7EEF7BF909334D182D5AC869E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_D5DCA7E55A659D3663FDD182D5ACBF00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_29459454ED792994505BD182D5ACD0D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BCB4871A60FA34BE8D02D182D5AC5F3E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_BDECEB983081BED75E14D182D5AC173C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_21C26AE5A137238BB346D7194644514D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_21C26AE5A137238BB346D7194644514D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_B0E33224D29B6B2A8E0BD71946444166" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:to="loc_us-gaap_PlanNameAxis_B0E33224D29B6B2A8E0BD71946444166" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E38D625BF5A317421C73D7194644F3C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_B0E33224D29B6B2A8E0BD71946444166" xlink:to="loc_us-gaap_PlanNameDomain_E38D625BF5A317421C73D7194644F3C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5541A5008B1551943859D7194644F3F6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:to="loc_us-gaap_AwardTypeAxis_5541A5008B1551943859D7194644F3F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1601312F8D9FB03FB7BD71946445BAA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5541A5008B1551943859D7194644F3F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A1601312F8D9FB03FB7BD71946445BAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ECBD4A55673C8B16941ED71946446131" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ECBD4A55673C8B16941ED71946446131" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CCE3249012B44A6A252BD71946448B37" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ECBD4A55673C8B16941ED71946446131" xlink:to="loc_us-gaap_ClassOfStockDomain_CCE3249012B44A6A252BD71946448B37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9E80A844F0268D151B3FD719464420F0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:to="loc_us-gaap_RangeAxis_9E80A844F0268D151B3FD719464420F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A1A7A002080D687276B6D71946448347" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9E80A844F0268D151B3FD719464420F0" xlink:to="loc_us-gaap_RangeMember_A1A7A002080D687276B6D71946448347" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4B6D06DFB796D049F2C2D7194644A695" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod_B9CA94D14446642A0B2ED7194644D997" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue_621AC5F7D64D39436881D719464462FF" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod_54FE7461531D3AF472F2D71AB386F882" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4FB00354389A22239CFCD7194644A378" xlink:to="loc_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue_83F619182E1C23CFD06ED71B319D94AE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_37AEB2AC4372DEF80442D182D6C5438A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_37AEB2AC4372DEF80442D182D6C5438A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_26B6F77B7AB2397DCE5DD182D6C516CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:to="loc_us-gaap_PlanNameAxis_26B6F77B7AB2397DCE5DD182D6C516CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A4219BDF2709AE37C6E2D182D6C5BDD7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_26B6F77B7AB2397DCE5DD182D6C516CE" xlink:to="loc_us-gaap_PlanNameDomain_A4219BDF2709AE37C6E2D182D6C5BDD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_169CD0E66BAF09FAF7E4D182D6C55698" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:to="loc_us-gaap_AwardTypeAxis_169CD0E66BAF09FAF7E4D182D6C55698" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0020A4A07B10738A143AD182D6C573E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_169CD0E66BAF09FAF7E4D182D6C55698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0020A4A07B10738A143AD182D6C573E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0020A4A07B10738A143AD182D6C573E4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_13D5026B724CC3923E41D182D6C5E372" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_18D2333DEA4BB5D60515D182D6C59B7E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:to="loc_us-gaap_StatementClassOfStockAxis_18D2333DEA4BB5D60515D182D6C59B7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3E5BB52E606F07D8A9B7D182D6C53A5E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_18D2333DEA4BB5D60515D182D6C59B7E" xlink:to="loc_us-gaap_ClassOfStockDomain_3E5BB52E606F07D8A9B7D182D6C53A5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_BAE00F08F5432FDAB6E0D182D6C56980" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:to="loc_us-gaap_RangeAxis_BAE00F08F5432FDAB6E0D182D6C56980" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3BDEC8A13A4B39F863C1D182D6C59CA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_BAE00F08F5432FDAB6E0D182D6C56980" xlink:to="loc_us-gaap_RangeMember_3BDEC8A13A4B39F863C1D182D6C59CA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46EBDE311F959FEE113FD182D6C5A048" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68B71AA26F171D04F0F3D182D6C58735" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3B80C362EA72C138A43CD182D6C5926A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A733FFBF105A4B3265BED182D6C505DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6A7E91C4DDBC57E2BC49D182D6C52FAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_53CD9D8423DE042C1DCFD182D6C51214" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3E3C80DE28260F29FC53D182D6C5AA10" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B269E15A13CDF4097ED1D182D6C569E6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D372620038F3EA31467D182D6C55AAF" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue_3B4D1D90B720E65A3D47D182D6C5673F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/EquityIncentiveAwardsTables" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EquityIncentiveAwardsAbstract" xlink:label="loc_lxrx_EquityIncentiveAwardsAbstract_819A875105C83B650841E17284E0A89E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7212048F06AB691432D7E17284E00A8A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_819A875105C83B650841E17284E0A89E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7212048F06AB691432D7E17284E00A8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_81028B907B7E89C7C865E17284E0D7BF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_EquityIncentiveAwardsAbstract_819A875105C83B650841E17284E0A89E" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_81028B907B7E89C7C865E17284E0D7BF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_FairValueMeasurementsAbstract" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_8E009C9FAF19E8723C4FD182D5DB3C4E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_303133D0124EDFCE5A1BD182D5DB7163" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_8E009C9FAF19E8723C4FD182D5DB3C4E" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_303133D0124EDFCE5A1BD182D5DB7163" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_AssetsAndLiabilitiesAtFairValueAbstract" xlink:label="loc_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_538ED338AFD58FADB174E21572D4B90B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AssetsAndLiabilitiesAtFairValueAbstract_538ED338AFD58FADB174E21572D4B90B" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C1B02D34B39834937EE1E21572D5EF8F" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_829002F77573613AEEB9E21572D5B99D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7A4D016A945F06B6798DE21572D53BC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6E786127BBBC5169F1B5E21572D59274" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8C45A364332BA193D263E21572D54C4E" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_F42E8A6EA8F9523B894CE21572D58CD0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1DD6DAA63C400F474D60E21572D5E410" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7AC2F3808E95B40BF84EE217808ACFD5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1F84DFD4463173FBEF28E217CEAC22FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9AF12B1347631052E50DE21572D4DD48" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8697F42CF7AAD884756EE21572D64E47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_AvailableForSaleSecurities_428335E43F4C65C1BA7DE21572D6FF65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_2D3CB3CA6B8C0794C97EE21572D69D59" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_735DA9359CB885105C59E21572D6DB98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2C465A723A3FD1FC1CB6E21572D6374C" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_D8E9B140B7A85863CDD2E21572D63642" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_FairValueMeasurementsAbstract" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_46ECB563AC20F258600AD3339606EF2B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_46ECB563AC20F258600AD3339606EF2B" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D6BADD9DC71EFB76F73AD33396061316" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_E4388929855A0D179F1CD333960CAC6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_12A9297141ACBC6C5C34D3339606614F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" xlink:label="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_20B11856C42A940C7392D333960DDF04" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="loc_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability_20B11856C42A940C7392D333960DDF04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_E9E4950E042A705209DBD333960D94E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_588A069A6D7F9E1D6799D333960D31BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_D663EA08A43CD3F2B01FD333960DADAA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4AC3FB57D7272C84FE02D333960D36DA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_FairValueMeasurementsAbstract" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_EEE40B9000281ECE349BE209F75D39ED" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1CD8C1596815AB2FDCE3E209F75F1B26" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_EEE40B9000281ECE349BE209F75D39ED" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1CD8C1596815AB2FDCE3E209F75F1B26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6BA8CF058596BC940869E209F75FE7C3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_EEE40B9000281ECE349BE209F75D39ED" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6BA8CF058596BC940869E209F75FE7C3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/Goodwill" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_GoodwillAbstract" xlink:label="loc_lxrx_GoodwillAbstract_885FE57935E7406485CAD182D639F505" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0A33BA81A1D3F873BEBAD182D63950BC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_885FE57935E7406485CAD182D639F505" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0A33BA81A1D3F873BEBAD182D63950BC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/GoodwillDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_GoodwillAbstract" xlink:label="loc_lxrx_GoodwillAbstract_3CFF3E771BA730F234A7D182D56E5017" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_GoodwillAbstract_3CFF3E771BA730F234A7D182D56E5017" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_D27AA37A0ED5E4BD00FDD182D56E6000" xlink:to="loc_us-gaap_SegmentDomain_3B67B8432AD1D936EBA7D182D56E22C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6EB075DAEB8CE2616205D182D56EB46F" xlink:to="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CoelacanthGoodwill" xlink:label="loc_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:to="loc_lxrx_CoelacanthGoodwill_5C68580ECA493B48CDABD182D56EB5A8" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_CoelacanthPurchasePrice" xlink:label="loc_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:to="loc_lxrx_CoelacanthPurchasePrice_C75BE63F758FDECA6228D182D56E1870" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SymphonyIconGoodwill" xlink:label="loc_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_27CDC45F1B2D1FD2F5F4D182D56E2C50" xlink:to="loc_lxrx_SymphonyIconGoodwill_5B09D096745D1A8635ACD182D56EE408" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_6CD81B69533C4EBC686BD182D56EA0F1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ADCF7B3DB0DF83B968AAD182D56E88FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_6CD81B69533C4EBC686BD182D56EA0F1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ADCF7B3DB0DF83B968AAD182D56E88FC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_ACB387A30D591540E39FE56947FB84C1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FederalIncomeTaxNoteTable" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_ACB387A30D591540E39FE56947FB84C1" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_0F7C272EEB8157A4A4D2E56947FB88EB" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_07ADC47B34A3C08C1CB5E56947FB705B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_EA5656F8B70BB7BED2E0E56947FB8AD3" xlink:to="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30EBB3BF5DD683B845ECE56947FB1E1C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1935447DE9D4E023A33FE56947FCA883" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_224C21E87222AB081F62E56947FC79A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9555910C2CE34E806F69E56947FC3683" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_29834F6E2A430A745319E56947FC2420" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_CD6A249C67BEF6B89B01E56947FCACEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_65B6488004F649833352E56947FC4C8B" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" xlink:label="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon_FB99E18B3A014EE4C9CBE56947FC7BEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_DEE6B808A172878FA42AE56947FCE392" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8B886E82879FBC29F862E56947FC99BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_D9DEDDAB7C14B342D3C6E56947FB922B" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4F72FF92D782D813FC57E56947FC6B72" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_3A4E392A3B8270B7DCA1E56947F66E1D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_3A4E392A3B8270B7DCA1E56947F66E1D" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_165810FFFD753368A596E56947F6B956" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D7F785C279627E4A481E56947F6770F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35DF0049E34F78946E47E56947F60706" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8FEE970E8AD92326F32DE56947F669D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_A8B4243954D9C04DCD35E56947F63559" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RevisiontoDeferredTaxAssets" xlink:label="loc_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_lxrx_RevisiontoDeferredTaxAssets_85E0863FEAAA29DA0003E56947F6259C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B345D38DA823D8DE3857E56947F61E9C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3944F65978D67F2CC974E56947F65C66" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7CF98F5E46252ABE9E65E56947F63073" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BC7865F388D5F543E148E56947F6DC16" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2F513C342D3C3E2CB6F0E56947F6CCB0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_BC7865F388D5F543E148E56947F6DC16" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_IncomeTaxesAbstract" xlink:label="loc_lxrx_IncomeTaxesAbstract_FA7356D88AE4907F4BCED182D5DBAC73" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AF502E83A795254D22A7D182D5DBD101" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_IncomeTaxesAbstract_FA7356D88AE4907F4BCED182D5DBAC73" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_AF502E83A795254D22A7D182D5DBD101" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/OrganizationAndOperations" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_OrganizationAndOperationsAbstract" xlink:label="loc_lxrx_OrganizationAndOperationsAbstract_BEE9FC355F01095DCC48D182D54FA974" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9875B9D037221DEE5627D182D54FF801" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OrganizationAndOperationsAbstract_BEE9FC355F01095DCC48D182D54FA974" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9875B9D037221DEE5627D182D54FF801" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreements" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_OtherCapitalStockAgreementsAbstract" xlink:label="loc_lxrx_OtherCapitalStockAgreementsAbstract_9A39B95337E35C4BBB24D182D677A07E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B7AC2BA43B13972C2699D182D67739C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OtherCapitalStockAgreementsAbstract_9A39B95337E35C4BBB24D182D677A07E" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B7AC2BA43B13972C2699D182D67739C0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_OtherCapitalStockAgreementsAbstract" xlink:label="loc_lxrx_OtherCapitalStockAgreementsAbstract_3F45FAC21B82994E60A7D37303291052" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_OtherCapitalStockAgreementsAbstract_3F45FAC21B82994E60A7D37303291052" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B4E32FBEBB93E05D3395D37303299C33" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38BC39AF20AB8CE922B5D37303298B2E" xlink:to="loc_us-gaap_EquityComponentDomain_B4E32FBEBB93E05D3395D37303299C33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_1D848B3CDEEA82991184D37303291948" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_831298D7D0C6A45F7F16D373032974FD" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_OfferingPricePerShare" xlink:label="loc_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_lxrx_OfferingPricePerShare_FEDED64326B834C49B5ED37303293EDA" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_NetProceedsFromStockOffering" xlink:label="loc_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_lxrx_NetProceedsFromStockOffering_B1BA98C6850D3C4FDF4CD3730329816C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="loc_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions_54FD2ADA15525343423BD37303291520" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_BD34C466D30C38D46655D373032964C6" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockIssuedDuringPeriodToInvusShares" xlink:label="loc_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_DBE3BE4503A2BB731AE7D37303290762" xlink:to="loc_lxrx_StockIssuedDuringPeriodToInvusShares_695A079EB3604A9F545DD373032A7C77" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipment" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_PropertyAndEquipmentAbstract" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_213040850927583E7618D182D5BCBDB8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2C4F64901192F3EB7B56D182D5BC66F6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_213040850927583E7618D182D5BCBDB8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2C4F64901192F3EB7B56D182D5BC66F6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentDetails1" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_PropertyAndEquipmentAbstract" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_20F470CF7EC0C9D79347D182D54FF43A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_20F470CF7EC0C9D79347D182D54FF43A" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8AB07C76B814B810BEE6D182D54F9F16" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_ComputerEquipmentMember_243C191A3E0AA92185BBD182D54FF940" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2F52D1B187CDEB92A91DD182D54FF873" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_EquipmentMember_277547AC152298442C5BD182D54FBCCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_124698AC63EB6E18AD50D182D54F6E75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_95FB6776AD3110B35908D182D54F245F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C98FE301809544AD6D22D182D54FCF70" xlink:to="loc_us-gaap_LandMember_A7AC2D4B1C2E699B3C26D182D54FDAF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_BAF948A9507ADF5CC1B5D182D54F7CF1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:to="loc_us-gaap_RangeAxis_BAF948A9507ADF5CC1B5D182D54F7CF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2B8424C7F1742505BF1CD182D54F3B9A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_BAF948A9507ADF5CC1B5D182D54F7CF1" xlink:to="loc_us-gaap_RangeMember_2B8424C7F1742505BF1CD182D54F3B9A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2466F881D591AC4BDF0AD182D54FEA63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_25E285D34E9C956CF09AD182D54FE3FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_344E2D12CA9C5F6BF66DD182D54F6CDA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0F447A037FD310DF7A26D182D54F7DFA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_472EE3F5EE513D9BBB28D182D54F67A0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_423C1D9F1D327A985D99DC2E3B09EFCD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_423C1D9F1D327A985D99DC2E3B09EFCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_59C81361A7C62791D381DC2E3B09946E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_423C1D9F1D327A985D99DC2E3B09EFCD" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_59C81361A7C62791D381DC2E3B09946E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_14ECA8FCF9628464A577DC2E3B096027" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_9449C4ADED6BD9647D85DC2E3B090ADE" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_BuildingsReclassifiedToHeldForSale" xlink:label="loc_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155" xlink:to="loc_lxrx_BuildingsReclassifiedToHeldForSale_F426AA03900B9D921ACEDC2E3B092C66" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_LandReclassifiedToHeldForSale" xlink:label="loc_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155" xlink:to="loc_lxrx_LandReclassifiedToHeldForSale_30D600C7853D6219293DDC2E3B09BA2F" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_AccumulatedDepreciationReclassifiedToHeldForSale" xlink:label="loc_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_177C73122AE28BCAB0F4DC2E3B09D155" xlink:to="loc_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale_40C911709BE19B4CF543DC2E3B09F9DC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_PropertyAndEquipmentAbstract" xlink:label="loc_lxrx_PropertyAndEquipmentAbstract_EF46A8DFAF0D1469EF9DD182D5FA7806" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2E66C4AEB768286B282BD182D5FA6EAF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_PropertyAndEquipmentAbstract_EF46A8DFAF0D1469EF9DD182D5FA7806" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2E66C4AEB768286B282BD182D5FA6EAF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncements" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RecentAccountingPronouncementsAbstract" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_308E56718F74FBE061E7DD4CD696EA0E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F18067B87A124F54F52DD4CD696E1B9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_308E56718F74FBE061E7DD4CD696EA0E" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F18067B87A124F54F52DD4CD696E1B9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsTables" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/RestructuringCharges" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_54B234AA22D7AA4D7CB3DD4CD57D667F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DA2FC4BE2927535010BFDD4CD57D8EF4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_54B234AA22D7AA4D7CB3DD4CD57D667F" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_DA2FC4BE2927535010BFDD4CD57D8EF4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/RestructuringChargesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_1DAE2D0972AA42490D76D729976C0B02" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:to="loc_us-gaap_RestructuringCosts_1DAE2D0972AA42490D76D729976C0B02" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RestructuringCostSeveranceCosts" xlink:label="loc_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:to="loc_lxrx_RestructuringCostSeveranceCosts_2EB34FC3D2133A9050ABD72A3070433B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherRestructuringCosts" xlink:label="loc_us-gaap_OtherRestructuringCosts_5154567F37F994AAE075D72ACDC4F3CC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:to="loc_us-gaap_OtherRestructuringCosts_5154567F37F994AAE075D72ACDC4F3CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_CB4320E6D188F707FD06D72B6F7D6934" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_CB4320E6D188F707FD06D72B6F7D6934" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment" xlink:label="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:to="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment_51A59D87BCA94E408E6FD72C19F2AB7C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative" xlink:label="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:to="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative_EE6FAD3D29E08FA40316D72C85517B9E" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation" xlink:label="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:to="loc_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation_735BE9BC4366DF1C1AB2D72D4002A758" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_DED5F108C81B095C1159D72DC147EF7A" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A8B8769F5B91F1C4FB7CD7278D90F957" xlink:to="loc_us-gaap_RestructuringReserve_DED5F108C81B095C1159D72DC147EF7A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/RestructuringChargesTables" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialData" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SelectedQuarterlyFinancialDataAbstract" xlink:label="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_BAB5F5417ED5F77B9822D182D54F0F78" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_EA9DC7A0F028856C377AD182D54F8EDD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_BAB5F5417ED5F77B9822D182D54F0F78" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_EA9DC7A0F028856C377AD182D54F8EDD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SelectedQuarterlyFinancialDataAbstract" xlink:label="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_17EDCB82CC95FE3812A2E569477D58E0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_17EDCB82CC95FE3812A2E569477D58E0" xlink:to="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InformationByFinancialStatementLineItemAxis" xlink:label="loc_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:to="loc_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain" xlink:label="loc_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByFinancialStatementLineItemAxis_8F9A6F2D468D19C8FC6EE569477FD3B3" xlink:to="loc_us-gaap_FinancialStatementLineItemsWithDifferencesInReportedAmountAndReportingCurrencyDenominatedAmountsDomain_4FE75F8827FB540A6D31E5694780CE79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTable_2BF3F4F0B922D11E6C00E569477F932E" xlink:to="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_154A2356914C4B7B6E8BE5694780A4B5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_Revenues_154A2356914C4B7B6E8BE5694780A4B5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CF45A1567AAA21BAC39CE56947807787" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_OperatingIncomeLoss_CF45A1567AAA21BAC39CE56947807787" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1C275BAA8566BFD91BF1E56947801F84" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_NetIncomeLoss_1C275BAA8566BFD91BF1E56947801F84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B0B9CAAF6A978B172C66E56947806BCC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_B0B9CAAF6A978B172C66E56947806BCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_177FA5092A048873611FE5694780F795" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedFinancialStatementsCaptionsLineItems_25044093592077A92AC0E5694780E0C1" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_177FA5092A048873611FE5694780F795" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SelectedQuarterlyFinancialDataAbstract" xlink:label="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_A495B11E207832A8A0ADD182D5FA7B56" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_75889DECDDF750E909C9D182D5FA000A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SelectedQuarterlyFinancialDataAbstract_A495B11E207832A8A0ADD182D5FA7B56" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_75889DECDDF750E909C9D182D5FA000A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_E76BC33D9E940E050C7ED182D639D599" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4E0C5542C464B929135CD182D639EC50" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsParentheticalsAbstract_E76BC33D9E940E050C7ED182D639D599" xlink:to="loc_us-gaap_StatementTable_4E0C5542C464B929135CD182D639EC50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_23BE307D7F6D8139A45FD182D6399E12" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4E0C5542C464B929135CD182D639EC50" xlink:to="loc_us-gaap_StatementScenarioAxis_23BE307D7F6D8139A45FD182D6399E12" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0ED37F4C7A8F434FF5A3D182D639AF39" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_23BE307D7F6D8139A45FD182D6399E12" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_0ED37F4C7A8F434FF5A3D182D639AF39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0D3665678629F5088842D182D6399B20" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4E0C5542C464B929135CD182D639EC50" xlink:to="loc_us-gaap_StatementLineItems_0D3665678629F5088842D182D6399B20" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D3665678629F5088842D182D6399B20" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_134383A2D6D8A967E448D182D6398001" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0D3665678629F5088842D182D6399B20" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense_DB24C850CC44838919DAD182D6393BF9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_41E854784B24369A51CCD182D6B55B83" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_FD37E3842FF92F0DAB6ED182D6B516FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_41E854784B24369A51CCD182D6B55B83" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_FD37E3842FF92F0DAB6ED182D6B516FD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivable" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndShortTermInvestments" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRisk" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ConcentrationOfCreditRiskAbstract" xlink:label="loc_lxrx_ConcentrationOfCreditRiskAbstract_6048B9B7C7FDBE379FEDE569486F4319" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConcentrationOfCreditRiskAbstract_6048B9B7C7FDBE379FEDE569486F4319" xlink:to="loc_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_BF6A99B2A9F377CAEA7CE5694870D01B" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_854075A011310E69C238E56948705864" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_B4D5DAED95B963C24872E5694870EA4E" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance_FBC101C076EC6D2951F5E569487253BD" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" xlink:label="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_E9BA5E46093191BE95F5E56948715ACE" xlink:to="loc_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent_D9F5E8C5120B6916AFC2E5694872BA3B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesGoodwillImpairment" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssets" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShare" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_BasisOfPresentationAbstract" xlink:label="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_468101FBA58CDFBC3DA7D182D5DB99CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_468101FBA58CDFBC3DA7D182D5DB99CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_D89D5AA70E8B6642DC74D182D5DB689E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_UseOfEstimates_D89D5AA70E8B6642DC74D182D5DB689E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75B41C1CAB9A7EA368A1D182D5DBD336" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75B41C1CAB9A7EA368A1D182D5DBD336" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_893EFB658813A9B4C95FD182D5DBC2E2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_893EFB658813A9B4C95FD182D5DBC2E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1CBC2781EE8C25D4030FD182D5DB6AF6" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1CBC2781EE8C25D4030FD182D5DB6AF6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_15BE5B1B5E3A128A0A86D182D5DB0277" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_15BE5B1B5E3A128A0A86D182D5DB0277" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_B8BC9DE38517E490153AD182D5DB97CD" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_B8BC9DE38517E490153AD182D5DB97CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34D448AAAEC03DC7D8D4D182D5DB4297" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_34D448AAAEC03DC7D8D4D182D5DB4297" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9E8A51576AE87B6933F2D182D5DB17A8" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9E8A51576AE87B6933F2D182D5DB17A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_485BA0245859756BB471D182D5DB7D6A" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_485BA0245859756BB471D182D5DB7D6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_B96CD586515DDDED2E02D182D5DB29A2" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_B96CD586515DDDED2E02D182D5DB29A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_FD194FDDA2BDB0FA4C92D182D5DB74B4" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_FD194FDDA2BDB0FA4C92D182D5DB74B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C6E6D7043A781A3B9EC7D182D5DBF1A2" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_C6E6D7043A781A3B9EC7D182D5DBF1A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E475FACEC9447B377CA6D182D5DBA096" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_21EF217C26874166DCFDD182D5DB7038" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_E475FACEC9447B377CA6D182D5DBA096" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipment" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentExpenses" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestments" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_BasisOfPresentationAbstract" xlink:label="loc_lxrx_BasisOfPresentationAbstract_19C134BEDCDD3FE96E9CD182D667D725" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_BasisOfPresentationAbstract_19C134BEDCDD3FE96E9CD182D667D725" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_13888E414E2F379F7648D182D6675ED5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_13888E414E2F379F7648D182D6675ED5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_38F7FB08A0D028BB2AFDD182D6670977" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_13888E414E2F379F7648D182D6675ED5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_38F7FB08A0D028BB2AFDD182D6670977" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_28B725684A5FF110DABBD182D6674C25" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_591FABD0D44AAB03C208D182D6677CD5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7DFF378D23194553695CD182D66757FE" xlink:to="loc_us-gaap_RestrictedInvestments_591FABD0D44AAB03C208D182D6677CD5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognition" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_SegmentInformationAndSignificantCustomersAbstract" xlink:label="loc_lxrx_SegmentInformationAndSignificantCustomersAbstract_DA3A07FA16A12FCF1DC3E171ED003EC7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SegmentInformationAndSignificantCustomersAbstract_DA3A07FA16A12FCF1DC3E171ED003EC7" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:to="loc_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_80ABE1E3EA3083943494E171ED007603" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_7AB02853F80C85EBAE4DE171ED00AB02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7D3AA47F3A7576DC3EECE171ED00F1E8" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueIpsenPercentage" xlink:label="loc_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="loc_lxrx_EntityWideRevenueIpsenPercentage_0A2DFD154CF11A7AAC96E171ED00CFCA" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage" xlink:label="loc_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="loc_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage_2E0A9E69CA4D3C4DFBF3E171ED0F9CBE" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueTaconicFarmsPercentage" xlink:label="loc_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="loc_lxrx_EntityWideRevenueTaconicFarmsPercentage_9702B3C0D53E495A5778E171ED0FE39C" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_EntityWideRevenueDeltagenPercentage" xlink:label="loc_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_45088428D97C1AC7D1ACE171ED00E0BB" xlink:to="loc_lxrx_EntityWideRevenueDeltagenPercentage_26A39D4B624500ADF7CCE171ED0FC8FA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignificantCustomers" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensation" xlink:type="extended" />
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockBasedCompensationAbstract" xlink:label="loc_lxrx_StockBasedCompensationAbstract_AE86AE8B48D716B7F55CD182D6A6969F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8F7D70D21D33A2145E02D182D6A6F95F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_StockBasedCompensationAbstract_AE86AE8B48D716B7F55CD182D6A6969F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8F7D70D21D33A2145E02D182D6A6F95F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2E12ACD33F7EB28DAA63D182D6A696B8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8F7D70D21D33A2145E02D182D6A6F95F" xlink:to="loc_us-gaap_AwardTypeAxis_2E12ACD33F7EB28DAA63D182D6A696B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7C392B162025169E391CD182D6A640A3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2E12ACD33F7EB28DAA63D182D6A696B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7C392B162025169E391CD182D6A640A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7C392B162025169E391CD182D6A640A3" xlink:to="loc_us-gaap_StockOptionMember_F2E56F5BECC23E5758E7D182D6A610ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8F7D70D21D33A2145E02D182D6A6F95F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_F5C753CEC914A82A0B1FD182D6A6C4CB" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_418903E8CDBA37285612D182D6A6918E" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4EEEFB3DE15A5C82AE9ED182D6A6D1FF" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_9100C5E90DC01BEFC4FDD182D6A6D016" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_183D0917000B71D9C53DD182D6A62BC0" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_1BA8DFCB39E6F0981792D182D6A65AB2" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_CF59F745DF8620FE1D66D182D6A6C03E" xlink:type="arc" />
    <loc xlink:href="lxrx-20141231.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3BE5F88B46ADD3C9F8E7D182D6A68510" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_FBFFC541E2143BE18B21D182D6A665EC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2" xlink:type="extended">
    <loc xlink:href="lxrx-20141231.xsd#lxrx_StockBasedCompensationAbstract" xlink:label="loc_lxrx_StockBasedCompensationAbstract_2D3FB047398647788504D182D5CB689C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_StockBasedCompensationAbstract_2D3FB047398647788504D182D5CB689C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1225CF353FEFE3347BA3D182D5CBDC5B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2BE567BD253E812F7557D182D5CB3818" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_FC03F49199EFB3C3649FD182D5CBF4C0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_158B7E47508853CFE642D182D5CB4956" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BB81D1E54C5D6AF6E324D182D5CBCB34" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27610CEB1303775CB58CD182D5CBBA64" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_6D0F9A7746A7400D3DD4D182D53F7C2F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11F57EAAB4EB18404B9AD182D53F1239" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_6D0F9A7746A7400D3DD4D182D53F7C2F" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11F57EAAB4EB18404B9AD182D53F1239" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimates" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10k12312014.jpg
<TEXT>
begin 644 form10k12312014.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`#B`JH#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MKBOB-\0?"OPI\"^*?B+XWU6ST7PKX/T6]US6=1OKW3]/ABMK2/*0K=:K>:?I
MZ75]<M!I]A'=7MM%<7]W:VYFC,P8>#>&?VJ[?5_!7@GQ#XJ^!_QL^%?C;XE^
M.M4\`_#WX)?$"#X3/\5/%^I:/H&I>*[W5]-7P'\6_'/P[M?#$?AC1-<U]]>U
M?XAZ=9V^F:4\EY]FN-1T2VU0`^KJ*^29_P!M#X/MI7]K:+#XP\3QZ5X%\6?$
MKQ[8Z'X?0ZM\+O!/@/Q;KW@+QIJ_CS2M4U'2[VTO?#WC;PCXT\+3>%M!B\0^
M+]5U;P5XN3P[H.LVWA^_N4^I]*U33=<TS3]9T>^M-4TG5K&TU/3-2L+B*[L=
M0TZ_MX[NQOK*ZA9X;FTO+6:*XMIXG:.:&5)$8JP-`%^B@G`SS^`)/Y#)I`P/
M'/XJP_4@"@!:***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/,/C&L,WP]UVSO/A
M%=_'33-1.GZ;J_PQLH?A]=S>(])OM2M8-1+:?\4=>\,^!]3@TNW9M6N=-UG6
MK3[;!920V*W.H&UM9OS>^'/[&7B/X,^(OA'\4_A]X!U#P]X+^&'[0WQZ\?\`
MA#]E7P]XHT%K7X3_``?^/OP?TKP+K'@KX=V\VNV/PTT>XTGXH:%/\5X/A[H6
MN6W@/PA8_$7QQX5\!ZU-:Z3I-IJ_ZX44`?CAX"_9(^.?P>F_:0\4:7X6M_%_
MB/\`;%^%_P`6]+UO1;?QK8OI/P@^)/CC]H7]J3XS^$[75[K7KW3HY_`%IH?[
M3QT'Q?JW@B#6]4BUWP#=WNC^&]:M?$FGR6_Z@_!3X;P?!WX._"GX26VIW&LV
MWPO^&O@/X=6^L78D%UJL'@?PII'A>+4KGSIKB;[1?QZ4MW-YL\\OF3,))9&!
M<^G44`<OXR\':#X]\.W_`(6\2P7UQHVI&U:[AT[6]=\/7C&RNX+ZW\K5O#>I
MZ1K%KMN+>)G%IJ$`GC#03B6WDEB?\1?CKI=W\$?^"Q'_``2J^%?PR\8?$WPU
M\-/C3\'?^"B-W\5O`(^+7Q1UGP?X^O?ASX!^$6J>`[[Q+X>\1>,-7TO4;WPA
MJ&LZI>>'KR2V%UI=S?7,UK-&TG'[Q5^&G[9?_*<;_@BW_P!D6_X*B_\`JLO@
M?0!^UO\`PC>E?\\[K_P::M_\GT?\(WI7_/.Z_P#!IJW_`,GUO44`8/\`PC>E
M?\\[K_P::M_\GT?\(WI7_/.Z_P#!IJW_`,GUO44`8/\`PC>E?\\[K_P::M_\
MGT?\(WI7_/.Z_P#!IJW_`,GUO44`8/\`PC>E?\\[K_P::M_\GU6O/#VF1VEW
M(B7:NEM.Z,-4U8%66)RK#_3NH(!'N*Z>JE__`,>-[_UZ7/\`Z)>@#DO#>AV%
MYX>T&ZN?MLUQ<Z+I4\\TFJZJ9)9IM/MY)97;[<-SR2,SLV,EF)/-;7_"-Z5_
MSSNO_!IJW_R?3/"7_(K>&_\`L`:+_P"FRUKH:`,'_A&]*_YYW7_@TU;_`.3Z
M/^$;TK_GG=?^#35O_D^MZB@#!_X1O2O^>=U_X--6_P#D^C_A&]*_YYW7_@TU
M;_Y/K>HH`P?^$;TK_GG=?^#35O\`Y/H_X1O2O^>=U_X--6_^3ZWJ*`//X=&L
MF\67]BS7QM(O#NDW4=O_`&KJOE)<3ZIKD4LP7[=_K)(K>"-FR25B0=!@]%_P
MC>E?\\[K_P`&FK?_`"?5*W_Y';4_^Q6T3_T\>(JZN@#!_P"$;TK_`)YW7_@T
MU;_Y/H_X1O2O^>=U_P"#35O_`)/K>HH`P?\`A&]*_P">=U_X--6_^3Z/^$;T
MK_GG=?\`@TU;_P"3ZWJ*`,'_`(1O2O\`GG=?^#35O_D^C_A&]*_YYW7_`(--
M6_\`D^MZB@#@?%FBV-EX7\0WEH;V"ZMM&U&>WGBU75EDAFBM9'CD1OMQVNC*
M&4CH0#[5T'_"-Z3_`,\[K_P::M_\GU5\;_\`(G>*/^P#JO\`Z135U%`&#_PC
M>E?\\[K_`,&FK?\`R?1_PC>E?\\[K_P::M_\GUO44`8/_"-Z5_SSNO\`P::M
M_P#)]'_"-Z5_SSNO_!IJW_R?6]10!@_\(WI7_/.Z_P#!IJW_`,GT?\(WI7_/
M.Z_\&FK?_)];U%`&#_PC>E?\\[K_`,&FK?\`R?7-:3H]G/KOBBVF:]D@L[K2
M$M8FU352D"3:-;SRK&/MPVB29VE?'WG)9LGFO0ZY'1/^1C\8_P#7YHG_`*8;
M6@#0_P"$;TK_`)YW7_@TU;_Y/H_X1O2O^>=U_P"#35O_`)/K>HH`P?\`A&]*
M_P">=U_X--6_^3Z/^$;TK_GG=?\`@TU;_P"3ZWJ*`,'_`(1O2O\`GG=?^#35
MO_D^C_A&]*_YYW7_`(--6_\`D^MZB@#!_P"$;TK_`)YW7_@TU;_Y/K#\0:3:
MZ986UY8M>6]S'KOAB-9%U+4V_=W/B72;:XC9)+QXWCGMYI894=&1XY&5@0:[
MJN8\7_\`('B_[#_A'_U+-$H`Z>BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`#(R!D9.<#N<=<#VR,_6BOR]_P""@/Q6UCX(_$#]FKXF+\1KFTT3PSXMUC4K
MGX+Z;^T=\$OV?9OB9;1VJ:=XEN]9T_XX_$[X1^$_BYHVD:)K%O8V?AF_\9PZ
M7X4\0:GI_BJYT75=7.@ZCX?^AOV$/&GCKXB_LK?"[QU\1_&WP_\`'WBKQ5_P
MF^MW&L_"_P`?Z=\5O!>E:1>_$CQC)X6\!Z?\4-(MK/3/B/J/PN\+?V-\-/$O
MCNQMTM_%GB?PEK&N1M/]L-S.`?3WBCQ+H_@[P_JWB;7KH6>DZ-9R7MY-L>65
ME3"16UI;1!I[V_O;AX;+3M/MDDN]1U"XMK&TBEN;B*-OSC^%'[=GC#XJQ^%/
M!;>#?"W@GXN?$7]K7]K_`/9]\.Z9J.H:AXBT'PKX*_9,\6>/--\2>._$4%C>
MZ3?>)=<FT?PKH%C<^&]`U32-.'BSQ?!#!KT>@:5/J5W]U_%KX/\`@KXV>%[?
MPAXZ/BY-)L_$&A>*;*X\$?$7XA?"[Q!9Z]X:O1J.B7]KXK^&7BCPCXG@^PWP
M2Z%M%JZV<\T4$ES;S-;P&/X/^"?_``3?TS]GZR36?`GQ(UK7/B/H'[6'[2G[
M2?@[Q#\2=7^)7Q%TVUT7]HV_\9VNN_##6H_&_P`1_$GB.:TA\*^*--76?%FA
M^(-'U3Q;X^\+:;\0O$5GJ6HW^NV>I@%GPY^W=XG^(\?Q6TOX>^#O"DGB_P#9
MI^'OQ&\9?'O1M4UZYOK)O$WPZ^,'QI^#*?#?P;J5A)8S6%SXQUG]GSXF>(M+
M\9^(=/O+70M#_P"$1AO_``KJ=WKNHR:!^@7PW\?>'?BK\/?`OQ.\(7$MWX4^
M(O@WPOX[\,74\:137/A[QAH6G^(]$N)8XY9HTEFTS4K621(YI461F5)'4!C\
M1:=^PC+X.M/&[_#[XEKH_B+XX?#SQ_\`#[X_^)-5\(VE[<^+)OB-\4/BS\8-
M3\>^$K+3]4TV+PUXN\/^+_CI\58/"MIK%QXHT&WT/7]%L=7M]5/A6!M6^Z?!
M'@[P_P##SP;X3\!>%+(:9X7\$^&M!\(^'-.5WD6PT#PSI-GH>C62R2$O(+33
M;"UMP['<_E[VY)H`D\6^,?"?@'0+WQ5XW\2:)X2\-::;9=0U_P`1:G::1I%D
MU[=0V-H+K4+Z6"U@-S>7$%K`))5\VXFBB3+NJG\$?VE?C#\*/B3_`,%O_P#@
MCA=?#WXD>!_&UMH7P5_X*='6I_"WB?1]=BTG[?\`#'X-M8_VE)IMW<+9&\73
MKYK87!C,RVEPT881.1_0D1D8Y_`D'\Q@U^&?[90Q_P`%QO\`@BWU_P"2+?\`
M!47J2?\`FF?P/]2?7^0Z`4`?MC_PDOA[_H-Z5_X'VW_QRC_A)?#W_0;TK_P/
MMO\`XY6W10!B?\)+X>_Z#>E?^!]M_P#'*/\`A)?#W_0;TK_P/MO_`(Y6W10!
MB?\`"2^'O^@WI7_@?;?_`!RC_A)?#W_0;TK_`,#[;_XY6W10!B?\)+X>_P"@
MWI7_`('VW_QRJM]XC\/M97BKK>E$FTN0`+^VR3Y+\#]YU/8=SP*Z6JE__P`>
M-[_UZ7/_`*)>@#D?"WB'08O#/AV.36=,21-!T971KZV#*PTVU!5@9,AE.0P/
M((((!!%;W_"2^'O^@WI7_@?;?_'*A\)?\BMX;_[`&B_^FRUKH:`,3_A)?#W_
M`$&]*_\``^V_^.4?\)+X>_Z#>E?^!]M_\<K;HH`Q/^$E\/?]!O2O_`^V_P#C
ME'_"2^'O^@WI7_@?;?\`QRMNB@#$_P"$E\/?]!O2O_`^V_\`CE'_``DOA[_H
M-Z5_X'VW_P`<K;HH`\]@\0:$/&6I3'6-,$3>&-&59#?6VQF36/$!9`WF8+*'
M0E?O!65B-I!KI_\`A)?#W_0;TK_P/MO_`(Y6?;_\CMJ?_8K:)_Z>/$5=70!B
M?\)+X>_Z#>E?^!]M_P#'*/\`A)?#W_0;TK_P/MO_`(Y6W10!B?\`"2^'O^@W
MI7_@?;?_`!RC_A)?#W_0;TK_`,#[;_XY6W10!B?\)+X>_P"@WI7_`('VW_QR
MC_A)?#W_`$&]*_\``^V_^.5MT4`>?^,_$.@R^$?$T<>LZ9)(^AZFJ(E[;LS,
MUI*JJJB0EF)(``!))KI?^$E\/?\`0;TK_P`#[;_XY5+QO_R)WBC_`+`.J_\`
MI%-744`8G_"2^'O^@WI7_@?;?_'*/^$E\/?]!O2O_`^V_P#CE;=%`&)_PDOA
M[_H-Z5_X'VW_`,<H_P"$E\/?]!O2O_`^V_\`CE;=%`&)_P`)+X>_Z#>E?^!]
MM_\`'*/^$E\/?]!O2O\`P/MO_CE;=%`&)_PDOA[_`*#>E?\`@?;?_'*Y71M?
MT-/$/BZ1]8TQ4DN]$*,;ZV"N/["M@2I\S#`,"K$9VL"K8;BO1:Y'1/\`D8_&
M/_7YHG_IAM:`-/\`X27P]_T&]*_\#[;_`..4?\)+X>_Z#>E?^!]M_P#'*VZ*
M`,3_`(27P]_T&]*_\#[;_P".4?\`"2^'O^@WI7_@?;?_`!RMNB@#$_X27P]_
MT&]*_P#`^V_^.4?\)+X>_P"@WI7_`('VW_QRMND+`<9YQG`!+8]=HR<?A0!B
M_P#"2^'O^@WI7_@?;?\`QRN>\3Z[HMUIMM;VVK:=<7$OB#PDL4,-Y!)+(P\5
M:,Q"(CEF(568@`D`$]`:\D^*_P"V'^S5\%=7C\,>/_BYX8M?&\Y"V?PV\-M?
M^/OBIJ#-@1KIOPN\`V7B;Q_?F61EAC:W\.M&TK!/,!SC\1/^"H'_``5L^+GP
MHL/@YX4^#OP'^-'PUUO6O'/A+XJW6J_%W0='\*:EXR^'/P_\5BYN/#:?#VQU
MG7_'GAC1?'FO:?:Z3>WOC[1_!NKW&CVFKV=AH<QFFN[3Y/B+C;A[AK!8S&8[
M'1K/`\JKX7`KZYBJ=2I4A2ITZM*AS_5I5)U(Q@\2Z,)/12;T/Z#\'?HP>,?C
M;Q/PYPWPKPO7RZ/%'MZF59]Q3)<.9!B\)A,+B,;C,7@,?FBPZSFGA,+AJM;$
M4\DIYCB*4%&=2E"F^=?TI45Y7\#_`(O^%/C[\(OAW\9O`\L\GA;XD>%-)\5:
M5'=QM%?6"ZC;AKO2-2A95,.JZ)?I=Z/JL&/W.HV-S&"54,?5*^GH5Z.)H4<3
MAZD*U#$4J=>A5IOFA5HU8*I3J0DM'"<)1E%K=-,_"\URO,<CS/,<ES?!U\NS
M;*,?B\LS/+\5!TL5@<PP&(J87&X/$TGK3KX;$TJE&M3>L*D)1>J"BBBM3@"B
MBB@`HHHH`****`"BF2RQPQR332)%%$CR2RR.L<<<<:EW=W<JJ(B@LS,0JJ"S
M$`$U0TO6=(UN![K1M4T[5;9)3"]QIM]:7\"2A$D,336<TT:R".2-RC,'".C%
M=K*2`:5%%9]_JVEZ6]A'J6I6&GR:KJ$6E:8E]>6UH^HZI/#<7$&G6"W$L;7E
M_-!:74T5G;"6YDBMKB5(F2&1E`-"BCKTHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`*"0.OJ!^).!^IHH_S^=`'Y`_M`?MG?!;QEXRT
M5?AA\?/V>?#ESX/3QQX5\6:E\6OV.?C[^T'K$NMZ?XJTK3)]`\+7_A7Q!\+-
M-\/Z1INJ^'=:C\3S+J7B3^UM<L=&BMHK!=)FN;K[7_8LNM%OOV;_``)?^'OB
M-%\5])O]3^(E]#XWLOAW>?"71K^ZO/B=XSGU32O"WPVU.6YU7P9X,\*ZJ]]X
M4\%Z#JU_JNJ67A;1=)6_UG6+AGU*Y^??C;H%Y^U;X@\*:E\%OBGXBO\`P_X(
MC^)FC:_X.\%?M-?'']F'6=.\?>"/'-M:L?$VE_!Z[\.^*_'&@>+-5\#:_P#"
M>\N?$E_::3X'TK7;SXC>"[3Q5=W*(?H[]CSP!XT^&/[/?@SPA\0="A\,^*K?
M5OB)K=[X>3XI>,OC??:1:>+_`(F>,?%^BV7B/XO_`!`EF\5_$;QE'HFNZ=_P
MFWBK4'%KJ7BPZP^C+_8BZ>6`/IHD`$D@`<DDX`'J2>E`92-P8%3T(((/..O3
MKQ]:X?XE>%KCQKX'\1^%[?Q1XS\&MK&GO:R^(?AYJ=EHGC6SMMRRW47AO6[Z
MVNH]&U._@CDL(M5@6"_L!<M<Z9J&EZA';ZE:_C?^S9\=/B!XFM_V>?V<=1^(
MG[1>KV^K_M6?ME?#/XJZE\:;;3?"W[0_@3P_\`-`\1>-_`7P%\:_$CP+KFHV
M?B?5+S1]>\#:[8_&/P1XBU+5?B!\.=,@D;Q3/J.IZSJTX!^Y&Y1C)`STY'/T
M]:6OQ$^&_P`?_C7\6I_VJ_"NO^._&GA,?LB_"+XV7WP_\8V<MCHLWQ(\6>#_
M`-J#]K_X0>$OB;XF_LR6+3O%]AX9\(_LS>%[+6/#.K6*^$->\0>*/%VI:YH=
MU+-H1T7]8_@-X_U;XK?!#X._$_7M%_X1O7/B-\+/AWX\UGP]M=3H.J^,?!VB
M^)-1T4K)-<.ITN\U.>QVM/,RB`!I9&!<@'K%?AI^V7_RG&_X(M_]D6_X*B_^
MJR^!]?M+XPUO6/#OA^^U?0?"&L>.M4M3:BV\,:#J'AG2M4U$3W<-O,UM?>+]
M<\.>'X19P2R7LPOM7M3)!;R16HGNWAMY?P/_`&D_&WB_Q1_P6^_X(XS>)/A%
MXQ^',NG_``4_X*<FQMO$OB#X9ZQ+KIN/AC\'3<?V?)X'\<^*K>V%@;6W2X.K
MS:;YK7\/V,7*P7C0`']"U%8/]K:E_P!"WJ7_`(&Z%_\`+:C^UM2_Z%O4O_`W
M0O\`Y;4`;U%8/]K:E_T+>I?^!NA?_+:C^UM2_P"A;U+_`,#="_\`EM0!O45@
M_P!K:E_T+>I?^!NA?_+:C^UM2_Z%O4O_``-T+_Y;4`;U5+__`(\;W_KTN?\`
MT2]9G]K:E_T+>I?^!NA?_+:JM]JNI&RO`?#FI*#:7.3]MT,@?N7Y(&JDX'?`
M)QT!Z4`3^$O^16\-_P#8`T7_`--EK70UP?A;4]03PSX=1/#VHRJN@Z,!(MYH
MBJX&FVOS*LFJ*X5NHWJK8(W*IR!O?VMJ7_0MZE_X&Z%_\MJ`-ZBL'^UM2_Z%
MO4O_``-T+_Y;4?VMJ7_0MZE_X&Z%_P#+:@#>HK!_M;4O^A;U+_P-T+_Y;4?V
MMJ7_`$+>I?\`@;H7_P`MJ`-ZBL'^UM2_Z%O4O_`W0O\`Y;4?VMJ7_0MZE_X&
MZ%_\MJ`*5O\`\CMJ?_8K:)_Z>/$5=77G<&I:@/&6HN-`U$N?#&C`Q"[T7<H7
M6/$&'+'5!&5;<0-KEPR,&15*,W3?VMJ7_0MZE_X&Z%_\MJ`-ZBL'^UM2_P"A
M;U+_`,#="_\`EM1_:VI?]"WJ7_@;H7_RVH`WJ*P?[6U+_H6]2_\``W0O_EM1
M_:VI?]"WJ7_@;H7_`,MJ`-ZBL'^UM2_Z%O4O_`W0O_EM1_:VI?\`0MZE_P"!
MNA?_`"VH`J^-_P#D3O%'_8!U7_TBFKJ*\\\9:GJ+^$O$RMX>U&)6T/4PTC7F
MBLJ`VDH+,(]4=RJ@Y(1&8@8522!72_VKJ7_0MZE_X&Z%_P#+:@#>HK!_M;4O
M^A;U+_P-T+_Y;4?VMJ7_`$+>I?\`@;H7_P`MJ`-ZBL'^UM2_Z%O4O_`W0O\`
MY;4?VMJ7_0MZE_X&Z%_\MJ`-ZBL'^UM2_P"A;U+_`,#="_\`EM1_:VI?]"WJ
M7_@;H7_RVH`WJY'1/^1C\8_]?FB?^F&UK0_M;4O^A;U+_P`#="_^6U>1Z5\6
M/"$/BOXP6;ZGI4=[\/;KPBWCZTN/$?ABR?P4-9\'66M:2?$LM[K-O;Z6FI:/
M+%JEE+<3+%-8R";>A#(,YU:5+E]K4IT^>4HP]I.,.>4:<ZLHPYFN:4:5*I5E
M&-VJ=.I-I1A)KKPN`QV.]O\`4L%B\9]5I4Z^)^JX>MB%AJ-;%X7+Z-;$.E":
MHTJN/QN"P5.I4Y83QF+PN&C)UL12A/WJBO@^[_X*&_!+5]4?P]\%M"^)O[4?
MB6*\^PW>G_LT>$H_B;X>TJX!5777?BO_`&GHOP3T(0R.D<_]I_$J"2%RR/$'
M5E&=<>(_^"A?Q7\R+1/A_P#!S]DWPO.)(SJ_C77D_:+^,H@8JT<EIX)\*:KX
M"^$7AK50A*[]0^(_Q%T^V?YFL=0'R5Y#X@R^I)PP#KYQ5U2CE-)XRCSIZTJF
M8*4,KPU5=88O'8=JSO9GZ+3\(N+\)3AB>+HY9X<8%J%2=;Q!Q\>',R^JU%>&
M.P?"$Z>(X\SO`RNE'$\/<+9M3DY1Y6T[K[^>6.-6=W540,78D!455+,SL?E1
M54%F9RJ@#)(%?'OC?]O+]F;PCK]YX(T3QW<?&#XE6BRJ_P`+OV?_``WXA^.O
MCZ*[B8H;#5='^&6G>(K7PI<$JS/+XTU+PW96\2M/=W<$"M(//!^Q!X6\:R?;
M/VE?%OQ\_:KNY9[>\GT+XK_$31=!^$JW4&<1P?`;X57G@+X27EBF=L<'BKPS
MXKNV4`W-_</EC]>>"_"WACX;Z#:^%OAY\*='\!^&+$NUEX;\&:7X*\+:#9E_
MO_9M'T*YL-/AW]6*6X+'DDFI]IQ#B_X='+\GI/53Q<JF:8UQ;LXU,)A9X/!X
M:JE=QG#,LPI)V4J<U<U6%\'^'[?7<SXN\1L=!*-3#Y!1PO`?#,:T8J<:^%S_
M`#W!\1<1YS@9S?LZN$Q7!7!V-E34Y4\90FX-?+C_`!3_`&X?BJ9$^%G[.W@C
M]GWP]*UNUMXU_:H\;0>)?&+6DX`DNK/X%?`K4M=M9)(E)DCM/$_QQ\)79<!+
MJQAVLM`_8P\3?$/?)^TY^T_\</C1;3QS6]UX`\%:TW[-OP;DM)65VM)?!_P9
MO-(\:^(K-V!66U\?_%#QG;S0GR9(2FX-]HC5=2`P/#6I`#H!>Z"`/P_M6C^U
MM2_Z%O4O_`W0O_EM1_8&'KZYGB\?G#V=+&UXPP4HMW]G4RS`T\'EN(@G\+Q>
M%Q%5)*]635P_XBUF^5I0X&X?X4\.E&SIX[AC*JN*XFI5E&,/K>#XVXIQG$?&
MF3XJ<4_:QX?S_)\%)SJ>SP5*$N1<)\*?@/\`!;X%Z3)HGP<^%?@#X8Z;<)"M
M]!X&\*:+X;DU1X!A+G6+S3+.WOM9O#]Z2]U:ZO;N9R7EG=V9CV/BY5&D1D``
MMK_A'<0`"?\`BJ]%ZD<GJ>OK5K^UM2_Z%O4O_`W0O_EM7/\`B;4;Z;3K:*;0
M[ZTC?Q!X2#W$MUI$D<0'BK1B"R6^HS3L"0%`CB<Y8$@*"P]BA0H8:E"AAJ-+
M#T*:Y:=&A3A2I4X_RPITXQA%>44D?G6:9MFN>8_$YKG69YAF^9XR?M<9F.:8
MS$9AC\75LH^TQ.,Q=2KB*]2T8ISJU)R:25]$=Z`!T`')/`QR3DGZD\D]S2T4
M5J>>%%%%`!17D'QWB^/4WPP\0Q_LSZA\(M,^,K2Z-_PBM[\=-%\:>(/AE#"-
M:L&\0#Q#I7P^USP[XKN9)/#HU.+1SINKVJ0:T]A/?"XL8[BWE_/C^S?^"Y7_
M`$/7_!*'_P`,]^V)_P#/GK]`X5X#H<3Y=5S"IQWP#PQ*EC*F$_L_BG-\RP&8
MU53HX>JL72HX/)<QI2P=3V[I4ZCKQG*M0Q$72BH1E/DKXIT9J"PN+K7BI<]"
MG"<%=M<K<JD'S*UVK6LT[[V_68D#DG`]3358-D#(([,K*?J`P!(]QD5^#O[5
M&A_\%_+[]G'XV6GP^\<?\$^)?&5Q\-O%,.@0_`KX=_M'^&/C+<7CZ>XDMOA=
MXB^(?Q4UCP=HGCZXL_M4/A34M;T^:"UUI[1X);.^^RWUK^$'_!"KX??\%]M"
M^)?QPO;'_A)/`G@"3PO;6VOV_P#P4G\,_M&ZMX$U/QVFN6)TV?X<>&G\2>%O
M'C^-X--&L)KNOZ)?GPHNC%K'Q4E]K+^%OL?]&<(?1$R_BGPG\1O$Z?TBO`O*
MZG`6)RK#4^':_$6/EB<V>8U*$'.=>OE^#QF"]I[?V65K"Y/F\<SQE#%864\$
MJ$JS\G$9_.ACL'@O[(S.:Q:F_;*C!1I\B>EE.496M>?-4I\D7&7O7L?WAT5^
M3/\`9O\`P7*_Z'K_`()0_P#AGOVQ/_GSUZG\%+'_`(*P1?$_PK)^T1XM_P""
M>6H_!I9]1_X3:R^"_P`-/VE]"^)L]L=&U$:2/"VJ^.OBAK_A2SG3Q`=)DU%M
M7TB\CET9-1@MEBOI;6>+\,S#PKPV`P&.QT?%/PHQ\L%@\3BU@<OX@SFMC\:\
M-1G66$P5&KPW0IU<7B'#V.&IU*U&$ZTH1E5IQ?.O2ACI3G&/U''PYI1CS3HT
MU&/,TN:359M15[R=FTD]'9GZ'3`%,$`@O&I!&05:1%8$'@AE)!!X()!X-?C/
M_P`$B/&?A#X8_P#!-7PGJ$<>D?;O^%^?MX0:-X6TFXTJSUGQ?XF_X;A_:>.@
M>$]"L5>-]1\1Z[%ID.E:+8PQ2W$BQ1(D?V:U?ROV5NQ:M:7*WXMVLVMYA>+=
M",VK6QB87`N!/^Z-N8=XF$O[LQ;A)\N:^=O"WPL_9(\*W$WCOP7\.OV=O#EU
MX%;4?$-QXQ\+^$/A?H\_A!Y[#4)-4UJ?Q%H^FVTGAUIM-O=4>^U.2]LFDL;J
M_:YN&MY[DO\`DQWGYQ?"']K/]L#]H/\`9_U3XX_#+QO^RE8VOCG]GOX/_&SX
M1Z=>>*X_B!>P?%'7]<EB\8?!3Q/I'A:UT*71?!/B>&YTOX8>%_%&KZM>?$OP
M+\9+?Q$NM>'O'>F:>/"\7:+^VEX[\2^"OV2?B!I-YX0NKSXW?M_:9\!_B3\,
M/%G@6WL/'O[/%L/A_P#%^^\1_`7Q$B>+KJ&Q^/GPW\5^!]/TKQ!XV=Y]`U^T
MU.>]\(Z3)X1U[P]XLO?T9\,?`_X!Z/!J^I^#?A)\(M,MO''BS3/BGKU_X:\`
M^";*#Q?XZMYDU72/B+J]WI.CQ1^(/%D-P\>HZ;XOO9+S68IF2\M-161A*=1_
M@K\'9-4N=<D^%'PUDUJ\\9V_Q&N]7?P'X4?5+GX@6EDFFVOCBXU!M)-W/XPM
MM/1+&W\3RS/KD-FBVL5^MNJQ@`_*SPS^WWX_U#]FOP1^U<GQ0^!FL^"/C/X%
M_9HO)_!5MI,[^(?V9_&WQG^/G@_X0_$C6?'^H:?XLC-_\,O@=I_CE=/\;6?B
M6RTCQ/I_Q(^'_BQ=4UO2O#NHSZ1X-V_%O[4W[4GA7X_>%OV;4UCP/+8ZC^VU
MX3_9]C^,U_\`#\W%UKWPY^)7[#GQL_:7L[-M#L?%.F^'-.^+GPQ\;?#?2],U
MZZLK67PUXE\&>(O"NH_\(SH=_J6HQ']-]&^"?P<\.'XBMX?^%'PUT)OB_>WF
MI?%AM&\!^%-+;XGZEJ-O<6FHZA\0S8Z1`?&U]?VEU<VE[=>)_P"U)[NVN)X)
MWDBGE5Y[;X._"2RM/"MA:?"_X>6UEX%U637/!-I#X*\-1VWA#6I;=K275_#$
M*Z8$T#59;5VMY=2TH6E])`S0O<-$2A`/#?V&/C/XV^/?[-?A;X@_$:70[KQM
M:>.?CM\,/$>J>'-+DT/1_$&H?`KX^_$_X'MXIM=$DU/61HC^+(/AW!XDN]&A
MU2]M=)OM4NK"SN'M+>`+]<US7A3P9X0\":4VA>"/"OAOP=HC7^H:HVC^%="T
MOP]I;:EJMU)>ZGJ#:?H]I969OM1O)9+J^NS";B\N7>>YDEF=G/2T`%%5+_4+
M'2K&]U/4[VTT[3M.M+F_U"_O[F&SLK&QLX7N+N\O+NY>*WM;6UMXI)[BXGDC
MA@AC>65T1&82V]Q!=P0W5K-%<VUQ%'/;W$$B303P3(LD4T,L;-'+%+&ZR1R(
MS(Z,KJQ4@D`FHK*US7=$\,Z3?Z_XCUC2]`T/2K=KO4]9UO4;/2=*TZU0JKW-
M]J.H3VUE9P*S*&FN)XHU+`%@2`=6@`HK-U76-)T.U-]K.IZ?I-D)$B-WJ=]:
MZ?:B67(CC-Q>2PPB23:VQ"^Y\':#@U<M[BWO+>"[M9X;FUN8HY[>XMY8YH)X
M)4$D4T,T3/'+%(C*\<D;,CJ0RL5(-`$U%%%`!1110`4444`%%%%`!1110`4'
M^H_GS110!^6/BKX4?MZ_M3ZIK.B^.]8^"'[&_P`(M$\8>,])\->(?AEH,?QW
M_:O\7>%-.\7:_H^@>-/#GB[XCZ#I7PE_9BU;Q9X3ATGQ%!9Z9X0^/WBG0KB^
M22#Q)X>U:$P6?Z*_#/P./AIX`\(^`5\6>./'2^$M"L=#'C'XE>))_&'C[Q(+
M&+RO[7\6^*+F"UGUW7;S_67^I2V\#7$I+>4@PH^9/VF/VE?&?P0\>_#SP;\.
M_AWJWQV\<?$CPAX\N?"_P/\`".EZGIWB;4;[PQJW@R*?XC^(?BC>6USX`^''
MPC\#6VOFT^(%UXECN?%>K3^(?#]I\*_#_CSQPFG_``]\5>Q?LWZ]XZ\3?!SP
MMK?Q,\;_``[^(?CN]N_%O_"2^)/A/I&L:'\/EU&V\:>(K1O#?AS3O$-]J'B"
M*#P1#!#X)O9]=N1K5]JOAV_O]5MK"_NKC3[0`]$\<^#-.\?^'+OPSJFJ>+-&
MM;JYTV[&I>"?&/B;P)XBMKC2M1MM3M&M/$7A+4])UB&![FTCBU"P^UMIVL:>
M]SI6KVE]I=Y=6DW"ZA^S_P#"R_\`#UAX>7P_/IHTKQE?_$;2_$&C:UK6D>,[
M#X@ZK!JMIJ_C>W\:6-_#XF_X2G6=/US6=(UG5YM3FGU;0]5U#0=0^T:+=26!
M]=U#4+'2K&\U/4[RUT[3=.M9[V_O[ZXAM+*RL[6)IKF[N[NX>*WMK:WA1Y9[
MB>2.&&)&DE=$5F&#%XX\&S^%8?','BSPU-X+N+&+4X/%T6O:3)X7FTV=E6'4
M(O$*7C:/)8S,Z+%>)>M;2.RHDI9@"`>/ZG^RE\!]3TG1-#_X06WTS2M%\+:W
MX%DL]"U;7=#7Q'X%\3:B^L^)_!?C>;2]3M;KQUX8\3ZW+<:WXCTOQ;<:Q'K>
MKW^KZAJ+W%QKVNOJ?T+##%;Q10011PP0QI%##$BQQ111J$CCCC0*D<<:*J(B
M*J(BA5`4`#(OO$OA[3%TEM1US1[!=?O+?3]#:]U.QM!K-_=Q--:V6E&XN(_[
M2O+F%6EM[6R\^>>,&2*-T!:MN@`K\-/VR_\`E.-_P1;_`.R+?\%1?_59?`^O
MW+K\-/VR_P#E.-_P1;_[(M_P5%_]5E\#Z`/W+HHHH`****`"BBB@`JI?_P#'
MC>_]>ES_`.B7JW52_P#^/&]_Z]+G_P!$O0!D^$O^16\-_P#8`T7_`--EK70U
MSWA+_D5O#?\`V`-%_P#39:UT-`!1110`4444`%%%%`'*6_\`R.VI_P#8K:)_
MZ>/$5=77*6__`".VI_\`8K:)_P"GCQ%75T`%%%%`!1110`4444`<OXW_`.1.
M\4?]@'5?_2*:NHKE_&__`")WBC_L`ZK_`.D4U=10`444A8#J>>N.I./0#)/X
M`T`+17S/\7/VP/V=O@GK5OX0\:?$C3;GXBW^P:3\)?`]AK'Q+^,.M/*/]'72
MOA3\/=/\2^/+F.X?$:WKZ%!IT3$O<WL$222)Y"/B]^VE\9L)\&_V??#_`.SU
MX2NO):+XE?M:ZK_:'C%[.:1HI;O0_P!G+X4:U=ZJTJQ@W%O:_$CXL?#?4(F:
M);[0@?-A'CU\]RZE6GA:-2IC\;3?+/!9;2GCL12G9<L<5[!2I8!3NE&KF%7"
MT;O6JK-K]&RGPJXQS#+\+G>88/"\)<-8RG&OA>)>-<?A>%LHQ^%YFJE?(GFM
M2AC^*Y4$G.M@N$<#GV9*"O#`SDXQE]Y22QQ(\DCJB1JSR.S!4C15+,\C'"QH
MJJ69G*JH!)(`-?&/BW]O7X`:7KU_X(^&NH^)OVD?B5ILIM[[X=_LU>&KKXOZ
MSI5TKF*6V\5^)-#EB^&_P_D@E`BN&^(/CGPND#,!)@A@.>B_83T7X@M'?_M8
M_&+XJ?M4W;&*6;P7XKU6'X=_`*WGAN?/CCM/@+\,?^$?\)Z]8(H2&.'XJ7WQ
M/OC&I\_49GDD9OLWPEX*\'^`=`L?"O@7PKX;\&>%]+C,6F>&_">AZ7X<T#3H
MF()BL=&T:ULM-M4R!\L%L@.`3D\UESY_C?@HX3)*#UYL4UF>9.+T<7A\-5I9
M?A*L=90JK'9K2>G/0>J/2^K>$7#.F+S'B'Q/S2F[.CD5.?!'!<*L+3A6IYQG
M>!QO%_$.`K.U'$X&?"O`..A%5'ALU3]G4/BBYNO^"@GQF@G;3]-^%'[''A26
M*8Q+J]S:?M"_'N\\E3)#$;>P_LOX%?#V[O-R0FYFO?C;!8L&E>PN=HB;\A_V
M0?\`@E-^UOX<_;0\2_&_]LNY_9L_:7\%^,K_`%.[^*VB^,=<U[QS?/XEU31O
MM_A#QSH?A;7?A1HG@;4?$OA6:.TT*U%W8:1I^G>&]2UNU\/VU@!8Q)_3K7(Z
M)_R,?C'_`*_-$_\`3#:UY&8<"Y7F^+RK'9KCLYS#$Y1BUC<.L3CD\)5KQY4G
MB,LIT*>5N/LXSI-4,%0<Z56K&HYRES+]"X/^E3QWX></<?<+<`<+^&W!V3>(
M?#\N&<VEDW"U5<0X#*YJM.<,JXWQN:8SCI57BZE#,*<\UXES6.&QN!P-3"0P
M].@Z4][3-)TS1=.LM)TC3K'2M*TZVBM+#3-.M;>QTZQM8%"PVUG8VL<-I:P1
M*`L<4$,<:*`%4`8K0HHK[-)12C%)122222225DDEHDEHDM$C^:*E2I5G.K5G
M.I4J3E4J5*DG.<YS;E.<Y2;E*4I-N4FVVW=ML****9`4444`%<QXO_Y`\7_8
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M<Y0E&3****Z3K"BBB@`(!!!&0>"#T(]#2!0.@Y]223CT!.2![#@=A2T4`%%%
M%`$<H!3!&07B!!Z$&1`0?4$$@CH02#P:_D`^#?[*GB/QW_P3BM/VB-"/PZ^'
M7@+]GWX=_P#!>(>,)_#$FH3^/OV@M/\`BC\0?VROAUI/PO\`'EE9:!H'AS3O
MAEX/U#^S_B,8]5\0^/)]0\6>"/`2Z9I'AR/3[V\/]?\`-##<0RV]Q%'/!/&\
M,T$T:RPS12H4DBEC<,DD<B,R.CJ5=&*L""17":7\*/A?H?A#4_A_HWPX\!:3
MX$UO^T?[9\%Z9X.\.:?X3U;^UV9M5_M/PW9Z9#HM_P#VDSLVH?:[&;[:S,;K
MS2Q)`/R`^&?[4GQ;^&EFGP1U?XA?#]8F_9P_X)A>-?A/KEWX'D@U/2;S]J'Q
MWXW^!/B/X5:191>)[BQ\8>+]8C^$9U/X4:[XNFT/P[I7C'Q5,_Q!O9_`NCL+
M:Y\#/VQ/VEOCU\3/V??A-9^-_A_X+_X2O4?^"FGAWQQXD_X5_I'BK7]6OOV$
M?VO?A%\&?`]];6^F^.F\(Z5/X[^'WC+4CX[M-$;5M-CU^;^V_"6H:;IJV%A;
M_JOJOP"^!FNV6HZ9K?P9^%&LZ;K'A[0O".KZ?JOPY\&:C8ZIX5\,7MOJ7AOP
MUJ-I>:)-!?>']`U&TM;_`$31;F.73-)O;:WNM/M;:>&.1='3O@S\(=(UB/Q#
MI7PL^'&FZ]%+XDGCUO3_``+X5LM72?QEY8\73)J=KI,5\DOBD0Q#Q'(DZOKG
MEQ_VH;O8N`#\%O"W_!0;]L3Q3\$-`^)3^._A+I^M>-O^"8'[2/[;]O;6WPG:
M;3O#GQ#_`&4_B7X)T6Y\,V,,_CUYM2\%_%30_'L.GZ_%J=U+J_A63P^+WPUK
M27.I3O9_3_Q+_;Y^)&E>,?A+K/@[6O`-[X=UKXK_`/!.GX<^.?AY:Z6EU<>%
M8?VW/$^G:)KP\9^*=<U31]3F\26FA^*M$\5_"BU^'&GZK96MCX>U>X^)4=S:
M^)-,BT7].X?@)\#K>TMK"#X-_"J&QL_#FK>#[2RB^'7@V.TM?">O7)O-;\,6
M]LFBK#!X>UB[8W.J:)$B:7J-P3/>VD\I+TMW\!O@A?ZA:ZM??!WX5WNJV6A>
M&/"UGJ5W\._!USJ%IX9\%:S%XB\'>';:\FT5[F#0O"?B&"#7O#6D12)I^@ZS
M#%JFDVUI>QI.H!^35Y_P46^(EG^S3XO_`&P++QI\&;CP[8:'XOT+QA\`=?1=
M*\:_L_\`CGP_^U;X.^!&I>)?'7BVSUB>?1O`WP7\'Z[XDUS]HA/&GALR:?K^
MBZ5K'A[4O#WAF34M(E].\(?M._M,:7\<OV;OAMX_\4?`_5?`GQI^,W[4?@-?
M$W@75;+QMJT'@+P)^SYH_P`8OA1=^*?%.E67A?P1HGQ9L]=7Q98^(M(\/Z'J
M?A;Q%X&L_#^NP6>B:S<:W9V/Z2V'P:^$>E:U\0/$FE_"[X=:;XB^*\"6OQ1U
M^P\#^%[/6OB1;1V3Z;%;^/=5M])CO_&4$6G22:?'#XDN-3C6RD>T"^0[1G.L
M?@%\#-,\&>$_ASIOP9^%&G_#[P'K=EXF\#^!;'X<^#;3P;X-\1Z9<7-YINO^
M%/"\&BQZ'X=UK3KN]O+JQU71["RO[2YN[F>"XCEN)F<`_`'X7?MY_M1?$SPI
MXZ^/NK?$'P0R:-_P1+\2_M06/PQ3P5;W/PMU7X[:3\1?VA=(O_$[Z:WB<:U=
MZ3);_#/PK:ZUX<D\074$6FO=Z;;W^FC4+B>?]`/A+^UO\0?C#\3IO`^E?$OX
M-?"_6_A-K'[(:^*?ASXTT<7.H?&'X=?M`?!3PI\0?$/BGP3';Z]I.N:-=7_B
M;Q/JW@'X2ZAH\6H^&K7Q5\+/&]AXKT_Q';W?E^%_T$D^!7P3EM=-LI?A!\+I
M+/1O#7B'P9H]K)\/?"#VVD^#_%MU!?>*O"NF0-HQAL?#?B6\MK:[\0:%:I%I
M6M7-M;W&I6EU+$CBT/@Q\(1XI\'>.1\+/AP/&GP[T&?PKX`\7#P-X6'B?P/X
M8ND,5UX<\'^(/[)_M?PQH-S'^[N-'T.\L-.F0;)+9E)!`/YT?VO/VQ_B%\9?
MV6OVR?A=XIUSP!\0/A_\2/\`@EM\2?VI?"7C'PQH$6A>'GN].^+^H_#BRD^'
MUOJ.J77BJ_\`AMJ>A7/AW4]*U+XE:5IOC%O$FCZCK%J]OI.LVFB:!^L]M^TO
MXYTC]LX_"+Q[J^G>'_AKXFU?XB:+\+-8T32O#/B_P+XTG\`?"?PIX]\1>#_$
MWC+2O$:^.?@Y\;_`\S>.?%7B#PW\0O"2?#KQG\,H_#E[X&\61^)M/\0:3<_5
M<7[./[/L%G?Z?!\#/@[!8:K!XBMM3LH?A?X%CM-1M_%^MV?B;Q9!?6R:`(+R
M'Q/XCTZP\0>(HKB.2/6];LK35=32ZO[:"XCO:A\"/@UJ'_"82M\+?AS!J'CW
MP]JOA;Q?JL7@+P<^H^(]`UO2+/0=3TG7IKK0[E->TV]T?3M.TV[TW6X=1TZ\
ML-.L+"]L[FQL[>VC`/SP_P""YL=G>_\`!)G]MI;A+6YM7^$,,RBX6":V9U\:
M>$)+:4"8-"65]CPR=5?:T;!MIKB?CS^V1\??AE\7?VL;'PUKOPYTSX:_LJ_%
MO_@G)HNF>$[CP(9M0\5^"?VK/&'AWX>?$C0M>\3OXIA&CW.DGQ+)XE\'Z[H^
MCV;:9<Z9I^FW^G:QIHOX]2_5RX^%'PWO_A]I/PJUKP5X:\2_#S1=%T3P_8>$
M?%>BZ=XIT-=*\.6=M8Z-;W&G>(+;4K6]-A;6ENL,UY%/,'C$I<R?/5&\^"/P
M9U%-:CO_`(2_#*]C\2?\(_\`\)#'=^`?"5RFN_\`")^7_P`(N-96?1Y%U3_A
M'/*B_L'[>+C^QO+3^S?LNQ<`'Q[^R]^TMXM^/?B=O&L_Q.^%6E>$H_$G[47P
MV\<_L_7NGP)\6?AKXU^!'QJOOA]X?EEUBR\0O=6#V/AGP]K%]\6]+\8Z"UN^
MJ>)_`NH>#+[0M($UMXC_`$2!!&0<@\@CH1ZUYG;_``7^#]KK_COQ7;?"OX;V
M_BCXI:7!HGQ,\1P>!?"L6O?$31K:Q_LRUTCQUK,>DKJ7B_3+;32=/M]/\0W.
MHVD-B?LD<*P?NZ]+55151%"JH"JJ@*JJHP%4#`````````P*`%HHHH`****`
M"BBB@`HHHH`*/\_GTHH_S^72@#\A?VR/VB/"NE_$WX(_$OX6?''P=X_;X0^-
M=2M_&7P1^'W[7/P%^$FHZ])+]KTO7K?QUI?Q!^*7@#PM\1+"UL?M>E6/@OQC
MXIM=.\)^)5_X2N+P[JOB.TTO4/#OV'^PMXA\>^+OV6_AEXJ^)GC3X>^//&7B
M63QUKVHZQ\+/'=G\4O!.DV6K?$GQC>^'O`6F?$VPM+"U^(U[\+?#DVD_#+Q#
MX]2T@?Q?XD\(ZOK\ZM<7TLDGRA^V'HOP%^!'C3P1XE\$?#[X`S_&/7/#7Q$&
MC?#'Q%^S+\2OBS;ZUH.H^*O#NM>-/B&;/]G#X7?$7QUX)D@\6:GI-OXC\7:M
MX4O-"\77^O6>B7NH6>MM:7I^J/V#[6"U_9;^'8A\02>)GN=3^)6HW^I+\'O$
MGP`TN#6=5^*WCC4M>T/PM\&?&4,'B_X<^!O#&MW6H>&O`7AKQ4C>([7P;I.B
M3:U<76H7$]S*`>H_M$:C\!=(^$OB75/VFM6^'&C_``6L)-&N?&%S\7=6\/Z1
M\.93%K-@VA67BA_%=W:>&]0MKSQ"-*ALM'UIIK+5=6;3[-K6YE>*(_D;\(]$
M^!?A[Q_\!/$/P$\?_`K7OV6/%_[9_P"T+\3/B=X7^$'B_P`">)_@A\'?C#XK
M_9OCT_X.>"A)X'U34?A]X<FGGT35O'NN::7MM)D^//Q!B\0Z:C:_X@\-WVH?
MN)X@\->'O%>G/H_B?0M&\1Z5)+#/)IFO:58:QI[SV[^9;S/9:E;W5JTL$GSP
MR-$7B?YHV5N:SM-\!^"-&T.Z\,:1X/\`"VE^&[Z66>]\/Z=X>T>QT2[FG$0G
MENM(M+*'3KB6800>;)-;.\GDP[RWE1[0#\#?AHDUE8_M8S?&G[,OPKU?]FG]
MI"+]BZVU.#7(8I?AQ>?M<?M>78TOX?0ZF29O$5]X!NOV5Y?!=IX6`UZY\&'X
M6Q^'86M[;3EC_<'X`1?$.#X%_!F#XN2R3_%6'X4?#B'XF32MNDF^(,?@S1$\
M:RNQ>0L[^)EU1G)D<ERQ+MG)]-NM)TN^-@U[IUC=MI=U'?::;JTM[@Z?>PQR
M0PWEB9HW-G=Q12R117-N8IXXY'C214=E.A0!SOBJV\67>A7L'@C6/#N@>)7-
MM_9^J^*O#6I>+M"M@MS"UV+W0-(\5^"=0OC-9K/!;&#Q+IXMKF2&ZE%W%"]G
M/^"?[3.G?%BR_P""W_\`P1O7XA>,OAYXEN9O@M_P4Z_L67P;\-?$O@>#3RGP
MQ^#0OAJD&M_%CX@R:Q]H+6#6AM+G0_L8@O$F%\;J%[/^@ZOPT_;+_P"4XW_!
M%O\`[(M_P5%_]5E\#Z`/VQ\CQ%_T$]%_\$=]_P#-#1Y'B+_H)Z+_`.".^_\`
MFAK:HH`Q?(\1?]!/1?\`P1WW_P`T-'D>(O\`H)Z+_P"".^_^:&MJB@#%\CQ%
M_P!!/1?_``1WW_S0T>1XB_Z">B_^".^_^:&MJB@#%\CQ%_T$]%_\$=]_\T-5
M;Z#Q#]BO-VI:,1]DN<@:'?`D>2_`)\0$#ZX./0]*Z2JE_P#\>-[_`->ES_Z)
M>@#DO"L.OGPSX=,6HZ0L9T+1RBR:+>NZK_9MKM#.NO1JS`8!8(@8@D*N<#>\
MCQ%_T$]%_P#!'??_`#0U!X2_Y%;PW_V`-%_]-EK70T`8OD>(O^@GHO\`X([[
M_P":&CR/$7_03T7_`,$=]_\`-#6U10!B^1XB_P"@GHO_`(([[_YH:/(\1?\`
M03T7_P`$=]_\T-;5%`&+Y'B+_H)Z+_X([[_YH:/(\1?]!/1?_!'??_-#6U10
M!Y[!#KW_``F>I`:CI'F_\(QHQ9CHUX8RG]K^(-JB/^W@P8$.6<R,&#*H12I9
M^H\CQ%_T$]%_\$=]_P#-#69;NO\`PG.J1[EWCPIH;E-RE@K:SXC`8KG<%)#`
M,1@E6`.00.KW+G&Y<^F1G\LT#L^SVO\`+OZ&/Y'B+_H)Z+_X([[_`.:&CR/$
M7_03T7_P1WW_`,T-:[RH@9G;8J*69W!5%4=2SL`@`[DL`.IXKQ/QC^TS^SG\
M/)7@\>_'KX,^"[A.#;>*?BAX(T&ZSOV8%KJ6N6]RS!_E(6$D'.0,'&%?%8;"
MP]IBL10PU/\`GKU:=&'_`(%4E&/XGIY5D>=9[B%A,DR?-,YQ;2:PN59?B\PQ
M#3=E:AA*-:J[O:T=3U7R/$7_`$$]%_\`!'??_-#1Y'B+_H)Z+_X([[_YH:^3
M4_;\_9AU&1H/!OB_Q?\`%*X!98H_@Y\&_C1\7(+AUBEE"0ZI\/OA_P"(-%RP
MBD59)-3CA#(X>10DA0B_:P\::]YJ>`_V-_VL/$[986U[XA\+_#/X0:9*`R@/
M-_PM_P"*?@[7[6,AT?\`>>&VGVLP%N7@N4A\W_6#)I:4,PH8R6ON9=SYE4NK
M:.E@(8FHGKUAY;GVG_$(/$JC=YIPCFG#-)*+^L\9_5N",&U/:4<;Q=7R7"2C
MU;C7:BM79(^LO(\1?]!/1?\`P1WW_P`T-'D>(O\`H)Z+_P"".^_^:&ODN'XD
M?MO^)8W70_V8O@YX"!QY=U\5/VEKZ^O4&`Q#Z'\*_@YXPLY&R&C(7Q9&%)#A
MV4,I$\'_`+>7B2W9-8^-W[-?PU$K8,7@?X#?$#X@:I!'B0$0:_XZ^,_A_2GE
M^9&22X\#O$)%4M;NBO',+.8U+?5<LSC%.S=OJ$\O:MTOG,LM@_52:[-C?AM5
MP=WGW&_AQD$%*,5-<787BY24K/F5/PWH\;5XI7U]I2@UUU/?/B9JDWAOX>>-
MM>\2>)?#&CZ#H_A;6]1UC5-2L9=,L-/TZUL)I;N\O-0N_$/V:RMH(59Y;F<&
M*%1O?*@BN8^+OQX^&WP%T2+Q%\9/C+\+?AOI=WYB:8_BV5=*O-=N(E#&P\-Z
M1+XG.L>)M3D4C[/I?A_3]3U&Y9E2WMI790?QG_X*N?`G]K'5OV=K3X<Z;^V0
MGB4?$35IT\?:;\5O$_[.G[._P]G\$>'8K'4KK2=)T_3?`VD^,?$.H:GXBGT=
M#$/'UUI]AIEHUIK%IJ$NIP32?7/_``2Y_9V\(>"_@+X,\=>/O`_P@\1?M+:?
M_:7A?QW\=?"WC;2_CIXD\9'2Y(X=)U&+XM7EYXAU[3(;OPW+HT5YX/LM8LM)
MT>XMV73M,M-,GLH4^6I\8X_'<4XKA;!Y73P%:A@*>(ECLVQ%*JJ6*M1KXC"Q
MP66UL1'%UJ>#QN`Q,:3S'!?NZTY3JQM3C4^_GX?^`N0>'>7<99S](/@SCCC.
MKQ5F.48OP5\-\ZRO#<>0R.CEV&Q.79]FF'XR65<4<*Y=B,5#'T\1CZOAYQ#&
M&&Q7#V+HX*I@\V6+I>GK^U+^T/\`%@-:?LO_`+-7B+7M*N9#%:_&/]I+3M<_
M9J^%*P/"LL6I:1X3UP>(?V@?&,$@8?9OL_PI\,Z->CYH?$J1LLM3R_LI?'[X
MMNMW^TW^U=XIU31;F*&2Z^#?[-^E:O\`L[_"[S71Q=Z?K'B[0_%>I_'WQCI[
M!EAE2;XI>%M-U&)";C0($GDMA]I>(OB!X"\'`GQ9XT\)>&!C);Q#XCT;1B0!
M_P!1*]MG8^@P3V`S@'SC_AI+X3W;21>&]6U[QU.F0L?P\\#^-_'44I!QA-1\
M->'M0TA03T>748X^^_%:9AFG"N#Q#P_%7&F63Q3O_P`)6,SG`95AFVKRHPR>
MCB*-?'4IW7+A\RJ9I-Z*,I,_(LU^D3P3P37>6\*2\.O#/&Q]RGF./S;+L^\1
MJTJ:BZ&)I<0<3U\1B<DSFG;3&^'>2\$RK2>F$4G9M^$/[//PV^`>BRZ!\&?`
M/PO^&VG7?E/J?_")^`QI>H:Y<Q%B+_Q)K46N'6_$VINSN\^J>(-1U/4;B1WD
MGNI'=F/KX@\0@8&I:(!Z#0KX#_U(:\?/Q<\=ZK&&\*_`#XE70+86\\8:CX$\
M`V!!QAWAU'Q1J7B2-#W!\->:O3RR<X<;O]I36'1H-'^#/@2W<<F_UKQI\2;^
M('C,EII^E?#C3S(O78FJ31EN/,(&6WH<7Y)3HT\-DN3\18R$(Q6%P^6\(YW@
M\#.G)Z?5<QQ^7Y;D2I7?Q+,84];\UM3\GS7Q<AQ-F.*S2O'Q"XSSO,*D:];,
ML1PQQ?B*F:U*BC%8B7$_$>!P.3XIN*BOK%?.^5Q2_>.*NO7O)\1?]!/1?_!'
M??\`S0TGE>(<9&IZ*1_LZ%?M_+Q":\A7X:_%O5'D_P"$D^/^NVD,H^>T^'?@
M/P1X2A`/\$=YXFL_B'K$:CH'CU&*7N''0)_PSKX&OXMGBS6?B5X\8G++XP^*
M/CJ_L)#G)#Z#IVMZ1X;*D\F,:,(^VS``K;^V^*\5I@.":V#DD^:7$_$&49;1
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MB=0,[03R!9WN))`YWDL<Y^9/A7^PK\!?AY\3%\8>'+'Q3'K7@36-(OM"DO/$
M]Q=VZW$VAB20W=NUJBW";[F0A"R#&T`JHV'\:\2,E^DSG'$_`V,\/^)>#N%>
M','CXSXSRN36:RQF!_M#+9RA'$YED$,5CG]2AF%/V6!EP]4?/R+%*I4IU\-_
M/WBYP_\`3"S[C+PVQ_A;Q?P!P7PE@<TA4\0<EE;.Y8_+?[4R>I*G'%YOPO#&
M9B_[.IYK2]CETN%:C53V?UU5:M'$83V67X[2/G^RO"OQ2UO!5<V?[/GQ.L(R
MVW=*/.\1W.@P`P#`<-(I=B([<3N&4/B^+?Q+O%)TSX'_`!.NF*JR'4=#^'_A
MN(F0_NA(^M?&>*XB5ER\S"SDDM5`6>!92(J^C-JX`(!``'(!X'2@`#H`/H,5
M^S_V-Q57ES8KC.>&3O[N2</Y5A$KVUC_`&U_K'JGHN;F7+HTY/F7]"+A_C;$
M3<L;X@SPB::Y>'>%LEP*3?6*XA?%FJ>W-S+ET:<GSKYT/CO]H:Y8K8?`[2[4
M99E;Q+\1O#6GGRU&`)(O#LWBXI/(Y!C1)9H##EY;B*7$%#7O[6%VP\OP[\`-
M%B(16^T^*_B)KLZ'[SRK':>$]%AE`R(E@-Q$2P:7SRNV,_1E%-\,YK43CB..
M^+<1![P5#@[!.VS2JY9PC@<0K])*LIIV:DGJQ\'YU53ABO$OCG%4Y/6G]7X!
MP'NM6<56RC@;+L4E;:4<0IQ>L9)ZG@]OIG[2]W&!>>,O@EHKF([A8?#SQUKY
M61SMVK-??$C0580K\ZRM:KY\AV/;Q(I+T;OX??M`7DA/_#0FF:8AV<:)\&/#
MD1&Q<<-KOB;Q&?WK<SY#9``@^S<D_0U%3_J3E<U'ZQF?%^(G'>I_KOQ=@W)]
MW2RW.L%AU>R]V-&,%;2*U)_XAWDU11^M9SQWBJD;-UEXC<=8!RDMVZ.4<09=
MA4G9>[##Q@ND4[M_.G_"FOB9>(%UO]I/XF7N45732-%^'WA:-@S;KA5?1_"B
MWD0D("0R1W@N;2,;8;@NS2'\^OVL/V!_BO\`$?QSI?C#PO\`$#3]>TJ#0?#W
MARXO/B5XH\0W?B/^U+GQ'>VZ1VPMM!U*R@T6$:Q8ND5M+;;9/M\YLWN)&EN?
MV0KF/%__`"!XO^P_X1_]2S1*^-X^\"O#[Q)X?GPWQ1AL[Q6`GB\+C76_UCSG
M$9@JV#<W14<=F>+S"M&'OR4TG>47R\RCH?G_`(G_`$:O"SQ=X6J<(\98/B+&
M994QV"S!XC_6SB#%YJJ^`E.5!1S'.,=FF(C3?M)1J13O*#Y.91T/)_V7/A9X
MA^"OP)\!_#+Q5=:3>Z_X9AUU-0N=#N+NZTJ1M3\3ZUK,'V2XOK+3[J0):ZC`
MDIELX-LZRJ@9%5V]_HHK])X<R'+^%N'LAX8RF-6.5\.9-EF19;'$577KQP&4
M8*AE^#C6K-)UJJP^'IJI5:3J3YI-*]C]=X2X9RO@KA7AK@[(XUX9+PGP_DW#
M640Q-9XC$PRO(LNPV5X".(Q#C%UZ\<)A:2JUG&+JS4IM)RL%%%%>R?0!1129
M'J/S%`"T5G:KK&DZ%IUWJ^MZIIVC:581>??:GJM];:=I]G#N5/-NKV\EAMK>
M+>Z)YDTJ)O=5SE@#S6A?$KX=>*-0&E>&?'W@KQ#JA@FN1INA>*M!U>_-O;E!
M/<"ST^_N;DPPF2/S9?+\N/>F]EW+GAK9IEF&Q5#`XC,<#0QN)47AL)6Q>'I8
MK$*<G"'L,/.I&K5YYQE"'LX2YI1E&-VFEYN(SG*,)C,/EV+S7+<+F&,4'A,#
MB,=A:.,Q2J3E3IO#X:I5C6K*=2,H0]G"7/.,HQO*+2[:BDR/4?F*,CU'YUVW
M7=?U_P`.OO/1NNZ_K_AU]XM%5KV[BL+2YO9UN'AM();B5+2SN]0NW2%"[);6
M&GP75]>W#!2L-K9VUQ=7$A6*"&25U0^"^'OVJ?@#XN^#5A^T%X3^).D>*OA!
MJ.J2Z';^-/#-EKOB"S77+;QA+\/]0T2\T[2-(O-=TW6=(\<6]QX1US2=2TFT
MU'0O$<$VD:Q;6-[$\2L9]!T5QFO_`!$\#^%M<\`^&?$GBG1="\0_%+7M0\+_
M``\T35KZ*PU7QCXATGPGKWCK5-&T&PN3'<W^HZ=X0\+^(?$-[:QQ^;;:9I%]
M/,J>5M/(?$CX^_"7X2W-Y9^._%J:5=Z9X0U;X@ZW;66B^)/$<_AOP%H;2QZI
MXW\5Q>%M&UM_"G@ZTEMKN!_$_B-=+T22XLKVV@O99[*[C@`/8J*^7-:_;/\`
MV:]`\8W7@'4?B5;CQ58?##P]\:M1TVS\+^.M4CTWX1^*SJ,?A[XD:EJ>D^%K
M[2-/\%ZK<:/J]E:^(;S4(--.HZ3JFFR3QW^G7EM#[7IOQ,^'FM?#VW^+6B^.
M/">M?"^\\*MXYLOB'HWB#2M6\%WW@U=,DUH^*K'Q-IUU<Z/>^'SI$4FI)J]K
M=RV+V2-<K,8P6H`[BBO-[GXP?"ZR^%D/QNO?'_A.R^$5QX/T[X@0?$>]UNQL
M_!\G@O5],M=8TKQ*NNW,L5D=(U+3;ZRN[&[\S;=QW=LL`DEGBC?.\%_''X8^
M/O%&H^"/#_B*:+QMI6@6/BR[\%>)O#_B?P/XQ_X1+4KV?3+#Q;:^%?&^B^'=
M?U'PG=:I:W&EP^)].TZ[T)M3A?3FOTO@+<@'K-%>6>,OC3\-O`?BGP_X&\0>
M(7?QSXITW4]<T'P/X=T/Q'XT\;:CX?T:YL;'6/$L7A#P9I'B#Q''X7TG4-4T
MS3]3\37&FP:!8:AJ6GV%UJ,=Y>6T$NW\.OB3X'^+7@[2/'_P[\1V'BKP?KO]
MI#2M=T[[0EI=MI&KZAH.J1JEY!:W4<MAK&E:CIUU%/;Q20W5G/&R`KD@'<44
MW<N<;ESG&,C.<9QC/7!!QZ&C>F`=RX.<'<,''7!SSCOB@!U%)N7`.X8/(.1@
MCU![]144\\=O#-/)O*0123.L44L\Q2)#(XC@@22>:3:/DBBC>61BJ1HSLJD`
MFHK(TC7-.UJRTV^LWN(DU32;'6[:SU.QOM%UB+3]0A2>W?4="UBWL=:TFX42
M"*ZL=4L+.]L;I);*]M[>[AF@36!!Z$'MP<\^E`"T444`%%%%`!1110`4444`
M%!./S`_,XHHH`_$CXZ?M+:[\1_B;I>N^'_@O_P`%9?A7J'PNN/BW\,IO$7[-
MW[-'P3\1^&OB59-XVTO3$UR#QG\5/#'CZ]UCP:T_@4ZYX2.D6'AVWU"UUV+5
M;ZWEN;>S,?Z+_L:Z_J_BC]G;P3KFO3?'B?5;[5?B(;E_VG/#_AGPK\=E%O\`
M$WQE:6\/Q$\.^#=(T'PMHVJ6]M!#!IUCH>CZ=I\7A^/1S%:QEGS].F*,DDQH
M2>22JDGZDC-.``````'``&`!Z`#I0!G:SJMIH6D:IK=^+IK+1].OM4O%L;&\
MU.]:UT^UEO+A;/3=/@N;_4+HPPN+>RL;>XO+N;9!;0RS2)&W@FB?M2?"OQ3\
M)/@9\8?"5SKWB70OVE=$\(:[\#]!T[0Y[?QEX_MO&W@BX^)&CPV/A_6)M+.D
MW%OX%L=1\3Z\WB2]T:S\-:5IFH3:[>V#6YC;VSQ:9AX6\2&WM;J^G&@:R8;*
MQA-Q>WDO]FW0BM;2W!4SW-Q(5A@BW+YDKJI90<C\G?@!^S]\6/`?[./_``23
M\5^)/`WB^V\9_L?_``)T3X:_&/X1V\FD/XGL+CQ#^S79_"?Q)>Z?9#6?[$\1
MZMX*\;:%I:);V&L2+J'A75?$&JZ!=ZC/%:Z;J@!]N7O[8_P1@TFRUK3]8UCQ
M!9#P=XE^(OBA-!T"^O;_`.'G@+P5XBU'P=XS\4_$#2Y?LNI>&[;PMXNT77_#
M&K:0UI=^*3K/AGQ7:Z?X?OU\*>(Y=+^G;*]LM2L[74=.N[6_T^^MH+RQOK*X
MBNK.\L[J%+BUNK6Y@>2&XMKF"2.>">%WBFAD22-V1E8_C1\/_P!E_P".GP<N
M?VF?%H\$:MXRUO\`;&^%WQ@TZW\,6?BS1]1M?A#\0_&G[1O[6'QF\(^&?$=Y
M?W=G8Z=X0G\-_M.6%CXJ\2>&I=>T_2_$7@3Q";6UU--8\.'4_P!3_@=\.7^#
M_P`%_A)\)I-6FUY_AA\,?`'P\?7+DR&XUEO!'A'1_"[:M<-,SS--J3:4;V0S
M.\I><^8Q?<:`/4NG6OY>_P!N3]O+]D+P]_P7+_X)E0ZU\=_!FG-^S;X*_;\^
M'7QS>Y_MA8?AMXZ^+_@7X4:-\-?"_B"X&E-;KJ_BW5-`U.ST^VLI;LQ2Q6YO
M3:)J&FM>?TQ>*_"^F>,M"O?#NL7&OVNGW_V<SS^&/%GBKP1K:&UN8;N+['XE
M\%:UX?\`$FGAIH$6X73]6M1>6QELKL36=Q/!)_G[_M^_\$+?B)XB_P""O/@S
MX?Z9\7O#]GIG[>7CK]HSXY?#*/7]4\8^*?$^C^&_@U_PC?C3XD:3XN\6:XFJ
M7=QKE[9^*]-C\,:MJ=YKEW=SS7*:[/++IJW>K?N'@3PYX"<2YYQ?AOI`>*/$
MGA;D6`\/N)<VX3S+AK@K..,L1FW&V!6$GE66XO#Y/EV:U5AHX>6-Q7]D.AE^
M(XCJ48Y9E_$.38UT?KGP?'G$&?\`#^!I8C(,NK9EB*E#,FZ5'AW.>(7"O0PT
M:F$<J&38FA6A%U>9>PJ.'UZSH4<5A:RC*I_H10W=O<0Q7$,@DAGCCFBD"MAX
MY$5T8`J"-RL#@@,,X8`Y%.DN((L>;-%%DX'F.J9.,X&XC.!R?0<FORSU+_@D
MO\&-7BT^27X]?MRZ7>06HANQ9?MH_'#5[:9G6-GABB\8Z[XH6QMH)!*MO#I0
MTZ/R9/+ECD2*W6#@XO\`@C)\+K$::=*_:O\`VT(7TBZ^TZ</$'CKX,?$."%<
MR8@N[?XA_`3Q*-85%=1'<ZW+J5Z&@AEDN99%=G_(WD\L1RO`<3\%T*<J5.2E
MQ%6XWRRO&I*$/:0K8;(>`^+:=*,*GM%>EC,2_9*G.SJ3J4:71/,/$!*#I\,<
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M.Q-O_8<O@KXB>`);%51WCD6]?51M$)M39E9S<BX(SS$+FCXO^!&6)VM"KEWC
MIF]2-^71^R\+,HIMI-N252R<)04VIJI#*-7Q!KS]^GP_ED&E?EP&(SUQ?)3<
MK-\1\.N:]I*K%7C!NG2IS:C/$2I87["U#]L/]EG3))(KK]H'X2;XK874BVWC
MK0+[;`?-(8FPO+H9;R)=L>?,8J0J$D`\TG[=7[*$KZ=%:_&30-2EU=&DTN/1
MM+\4ZY)?HL8F9[5-'T"]:5?)/FAE!#1!Y%)1'9?$XO@+^WSH-OG1OV@?V+M<
MF4Q12PZE^QA\6/![:K"AD1;C4=0\&?MD/'!>1*_GB*PT=+!YC+%%!:03$K!+
MX1_X*=Z8)(=/U[]A;Q"D**UK+]B_:S^'D<^(U(TY]/M/B+\0X].B20-"NIQ7
MNH#RI!/_`&,IA-K.UX8\98JW]G>.7@/6=]85>$O$3!)J,HJ7+6S_`#CAU6<6
MFI2I1^--*7LJJCNX<;0E[V<9).'9<#XZG)7IRM>5+Q&QJ?+5<&[1CS4X3A>$
MJD*E/U^?]O/]GC[)/>:7?_$OQ%!;7W]GW+>'O@;\:-4^SW'ER2@3&'P&$12D
M>Y3O)(9&`*L#7S%^U)_P4!U/0/!VF'X.^%OB9X:U>X\1P6M_KGQ3^!_C7PMX
M5U+P_<Z)J4QAT;5/&&EZ3976J3W)LKB"UA<WS64-Y-]G6&&=E]4MKK_@I/92
M,;[X*?L;>(8I5Q&FG?MC_M/^%Y+.17!WRR:G^S%XE2_CEC8H$ABLG@>/>SS+
M,(XOQ;_X+R_%C_@HSX7_`&#-7URU_9;\&_#ZUT#XE>$)/%OQ>^%G[2GC#X_Z
MQX!\.-%K-K>>)-,\(ZW\%OAP?#ND:S?G3?#UWXVUB;4I?#UAK3V3Z):7NL0Z
MWI#I_11^D!XV8C`^%?`?C5X+<,\7\=YCEG#>0\30XMX?X?P65X[,L=A:4,54
M>'XWXEXL]V/M:<*&1Y)F.:8NM*GA\%A:OUB"G\#XPY%QWQ+X9\991PAQSF?"
M/%F-R>K#(L\R_+,3E=++<=3JX2M"O4Q5##9GF5"FZ=+%0G4PF*H55[:G:K"G
M1K1K_J7^QY^VO\2/&7AGQ/'XZ^'7Q#^))T"[T#3-%N?A%\/M.U"TTJR72YTD
MMM;D;7=-(O+AK:&6U^64M%',V4&$K[GN?CGXF&E_;]/_`&=/CU?SR003V^G/
MI?PXTRZE$YC/ERC4_B7;K9S11N7EBNQ%)&R-$ZK+\M?RY?\`!O5^T-^W7K'[
M)WC[Q+XG_9"^)7[0OAK5OBM=VW@WXP:5\5O`'PE\1^([73M&M#JNDWVF_$_Q
M?X$T_P`6>'_#&JWEU9:1XO\`#?VL)?WNJ>%[\W$N@^;9?O\`6W[0W[3-O*#K
M/_!-W]IO[(R.JMX9_:0_91\07R3C:T?G6-_^TMX9B2U=1(K7,=]-)'*(D^RL
MLIEBTQ/T-/I!>!.+S'PE\2/''P^XQXSX&S#,LHSSB')?$OPNQ&&S.O\`7Z^,
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MV;OY7G:1X[_94\4W2S,K/&'TS0OVQ[B^6!PCJ]V8_(A?RUF93*AJC/\`MA^(
MK)!/J?[`7_!0_3[/>L<EW%X:^%GB-HG<-Y6=*\'_`+3WB+7YD=P(VFM=)GAM
MRZRW<EO;AYEYUX&>+=:*6'XWRC%-VC"67\0>$683J3T2A!8/-L3&K6=_X-.'
MM)2Y4J?OJ+_>LOSC,\#3A3Q.&X0S64*:@Z^:\-\<T:U1II^VJ_V7QYE-!5&M
M)>RH4:#3;C1B[6Y^/]KK]MV^D\JW_P""?CZ1L5I'N==^-VNS6\H!"K#;IH'P
M&U*Z$Q+&0M<10P")"/,,K+'3)?VD_P!OF[9Y;;]DKP!HT1`2.SOO&7QCUV=6
M5`&FDOK'X,:-`Z22$LL"VB/%&`K3R,VY=H?MO:9"R/J7[&G_``45TVQWJMQ?
M_P#"@?&&M"U5SM65],\+>/\`Q!X@ND\PHC+IFC7\L8;SI8DMHYIHK2_MT_#-
M&1K[]G;_`(*$Z=9[T%S?W'['/[5US!9PLP5[F:#2_#>HZC+%"#ND2QL+RYV`
MM';R;2!S3^CQX\.SAG7$F/BTK/!9'PICHN2LE34\FA%>WU35"_M)*4&Z;=2F
MSL7$^9TY*6'POASA79*TN&.+,4K7BV^3-_$''1]YI/G<6XJZA*,7-2Y*#XX_
MMZSN(+[P/\+?#+Y4R7)_9_\`VH/&A5/+WCR;'2-?TFQN!+)B$O)XBM)[3:TS
MV4^8XGTHOBC^VK>%WNO%7@;1&!2.*"P_8`_:9UV%P<EKB:YU#]H;1I8V#L$%
MM%!(A1-_G[Y"B=9+^WC^SQ:QO<7W@C]MK3K*!3)=7]_^Q-^WS;6-E;J?WMU>
M7!^##+!:P+F2>8J5BB5I&&U351O^"B/['48WR:_^T-#&A#23W'[+O[<UO;01
MJ07GN+BY^"L5O!;P*#+///+'!#"CRS2)&K,,H?1Y\?JB2ADO'N+BG;GI^'_&
ME27V6HU)9=G&'H\Z4EM2I.2M>-OAUEQ_X@4THX3/O!S!QC:TJW@MPAF5:2YD
MW*<LXS/&TY2E&T'[.C2I)13ITZ<Y3D_QPA_:/_:4U?\`:KUKXNZ?\7O$GASQ
M9X[T+PK\#[_1?#/@[PSJ'AG2?"&B^,)+ZPD\)>`?&MEXC6V\6QZMJFMW]K<:
MUJ>K3&]U[4]/G#6]PJ0?K"?A7XV\2RK+XK\>?\%*_'QD9HEMX/&_P=^!6E7!
M53$[&+X52?!_4K*(!-P-[<1F5XP4,JW#M<?RQ?#/_@N7^RCXG_X*":-\/+;]
M@_4YO@7XA^,UOX%\%>-?"?Q#^,7BGX[R:W-XN?3?"GCVW^'5A>36'B*^\0>(
MSI\TGPUT2%]8M;&]BL=+U'6]8LFLM6_J[;]J?XV^,+<R_![_`()\?M9ZRLDY
M6#7?C3\0?A;^SEX9="TA%Q-8^+/B[XB^*UI$^T$12_"5;Q-V)K2!AM/SV2?L
MYOIR^`$Z^!^D_P`197ETN-Z.!XJX2JS\0.$)Y72P&+GC%F&$S#'\8U\LR3+<
MXAB*E%XG)ZL,3C*<O95*L8T'"-?^:_HX\1?3%R#"<4P\7?I%91Q/BX5,BRKA
M',^$.$.&LWX@R/(,EP.(P-++:.?<0^&.79OE="AAGA*>&IX!XVE5=",ZV)YJ
M+A6Q'_9/^$FH71OM8_8H\??$F[WJRW/Q_P#CS:_%/SYPVYI=2@^(GQG^)47V
M96>7#I97KLKSD6?^D2K)[1X)^&\GP^=9OAM^Q3\`?ANZE8HY=)\0^`?"4ZOL
M5/.=_!OPKU%VMT3:I<7;7CJCC[-Q&9/.5L/^"E_C6ZMY+;1_V._V>-)N0"[:
MMX^_:._:J\2V*-P?.TW2XOV7?"LEVN"?+CUV^LU+X\Z41YEE;]CO]IKQLKCX
MO?\`!1/X]1V[L'.A?LW^`/@Y^SQH)P`/*_M34_#/QD^)RQ%=X9H_B/%<%BLB
M3Q,@KZ2CX!Y?E56%3-/'?AO(,5!*=;!97@.&^(\;RMM-8;,."_"+/^'L16BT
M[1J<44(NRDZZ3<Y?T%FW$7C/Q#0>%S?Z07CMG6!E%P^IYIFO!.(P'(VWR?5,
MTX0E4A35THQ]C*RBEJTV_IZ;5?VC9,M!X*^"VF1K&1_I7Q,\>ZLI.&/G;K7X
M6Z7%%#&NW,+<R8)$\0P%^8?B5^V3X<^#MU=6'Q6_:P_8/^&.L69\M_#_`(A\
M;WEYXHN;@G!B@\,-\0-#\1-.GR@6MII>HW$QD'RP^6/,N7'_``3`_9.\2PVH
M^+>E?%[]H6[@VM-<?M$?M'_M`?&*PO)5W'S)O"/BSXCS^`8!EB1;Z?X1LK-#
M_JK:/O\`2?PS_9>_9T^"]K'9_![X)?##X4P1J47_`(5MX)\/>!K@AMV[S+WP
MQ8:7?3,V]]SS7,CMO;+'<<^C/@CPHP;C5QOB%XV\:3@W&KE^&PO"OAQAJDE)
M?O,-GN5XSB3$.E)1BX>UX8P]1V3G"'-5IU/C'P1FF)ES8_C/C&O?6_\`;M#!
M=M)4N',FX=MK&#M#$6]VVJJ5?:?`$G[?>N>*[:VF^#]]\9?CNTKE8)_@?_P3
MM_:"E\-WA8+M>/XD_%[QIX!^%DUFV0;>ZMO&B12I(D[3FW^</3XA_P#!3OQM
M<)%X$^`^N^![.YC,L&N?M#?$;]FCX61QM(NY'N/#7P>TG]KWQ"ENI.8],NFL
M-2&42[U"%XY/-_5@^'=.(PTNLN,YP_B/Q$^#ZC?JC8]L=.U.'A_3P,"76`!T
M`\1>(`!^']IT3P/A5@WRY5X><19A&\W[?C;QK\7\XQL)/E]FZ<N"N*O#?+&J
M?*O=Q&4XB,]?:<W-*]Q\-LJE+GKYWQS*=DOW'B-XB8>&G+K[.7%E=)OE5W%Q
MZVLY2<OXV_\`@N#_`,$X/^"Q_P"UY\*?A)J=WK7PS^/=A\/->\;:SK?PB^#E
MQ8^&)?#L.K6GAZ*TU^Z\2_$"?X;Q?$=H?[/N8;/3-/\`!VBW>AQ_:;R*'46N
MO]&^J/\`@DY_P3!_X*-_`/\`8ZT/P'\7/BG\*?A]K2>*_%FL:?\``CXQ>!_B
M1\9]*\):3J"Z3+I4(U[X+_M<?#'PC_Q-)8;LZAI=SX?\13:(K+#;WMRL45K#
M_2MXTT.Q3PCXF<2ZJQ70M38"37M=E0E;25@'BEU%XW7(&5=65APP(XKIO[`L
M/^>VL?\`A1>(/_EG7[9FGTC.(\W\`N'?HWXS@/P?QGAUPQQ[C_$#+H9UX;9#
MQ=F\\RQV!QV">&QF,XUI\24<7['^T\9.&?5L)+C"IAEA<HK\25<DP_\`9M3B
M_P"(0<&5L3*KF6%KY]AIXN6-E@.)9T.)*52O++Z.7*>)QF=X?'YMC)TZ5%2I
M5\9F.(Q-*+C@X5UEE#"X&A^9GA[X-_MY_#V[BG\,?#O_`()D>(6A>.07>G>!
M_CM\&]5N%DCVR1/JJ?\`"Z[F&:RF_?I?S/?MJJ'[.UII#G[6?4)?B?\`\%'_
M``_;Q_VE^R'^R[XS=(94E?P%^VEXVTB6:6V`8S0Z9X^_9+TBUMDOXRRV-G)K
MLYM[D+#?WT%L3>I]Q_V!8?\`/;6/_"B\0?\`RSH_L"P_Y[:Q_P"%%X@_^6=?
MFF`XLX<P-&%"/A'X5.C%INCE^2Y[PKAYM*UWA>">)>&,+%MWD^2A'6T?@C&"
M^SROAO*<BPRP>18:ADF#3O'"Y7@\OPN'BTDDU1A@W3NDDD^6Z6S/ABS_`&G_
M`-KZP=?^$H_X)N_%ZXA$O[V?X;_M"_LG^,!Y$L?[@P6_BWXH_"V\GN8YR4U"
M%K>""VB(GM+W4OGC5+G]NKQ;HY">*?V!OV]_#\BB9938?"WX3_$:W$]JP%U%
M%-\)_CIXX>9(T)FM[L6Z6NIQCR]+EO+K_1J^Z/[`L/\`GKK'_A1>(/\`Y9TP
M^'-,)R6U4GKDZ_KQ.?7_`)"=>@N,N#:\_P#:_"3A/#TK6:R3/_$/!UU;K&IG
M/&/$5%-NU[X62LK)1;YCTOJ^(2]W'UV_^GE+"27I:GAZ+_'_`"/B1/\`@HQ\
M#[&)IO&'PY_;#^'T:2QHT_C']A?]KRULDCG4?9;B74]%^#FO:9!'=3;K6".>
M\CNC=+Y,MM%YD324X_\`@J;^P4DC1:S^T1X=\%RH'WP_$KPO\1_A=<1R0RB*
MZMIK?XC>"O"\L-]8,0=3T^15O=,C/G:A!;0_/7W3_P`(_I^,";65'HOB3Q$G
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MF6DD4<<6LM%I#_KMXX^`'P8^)FC:QX?^(/PV\)>--(U[2;G0M6M/$VCVNLF\
MTFZAF@ELC=7T<U[!&B3RM:O;7,,UC.PNK&2VND29?Y^_V8/^#9#]@;X%_M%^
M,OBIJFO?%OXMZ!H4T\7P[^&7C?7K/2M`\&R>(],\\7]UXB\$V_ASQ=XHU;P]
M:W4ECX9OIM2T1;`,;_4;?6M6BMM1@_;O"VC]#''\$^+$_%7$>,O#7&U/AV@O
M"BEDU?*.*<'//Y4\<ZE3&_5LGX9PN*]EBUE:K8/-Z^3X&ME;S%8;-*.95,)/
M#>9CGQ%'$X!8&.75L,ZS^O.HJE"7LKPTCS3K2C>/M+2IJI)5%"\'#F3_`*8?
M,3`.X#<,KN.TD'I@-@_I3Z_/.Z_X)S^!M(2WB^$'[1W[;GP(MK/!M--\"?M7
M?$OQGX=M6&#BV\(?M`W/QK\*00$C+6<&D0VA!($*[B:@_P"&=_V\/"'G?\(-
M^W;X?^(EE"C?8M)_:4_9F\/:[J%P5!\N&[\:_L[?$/\`9UO8F;A9+UO#.H./
M];]ED8,DGXC+A+@K&VJ9-XI9+A*3^'#<9\.<79'FDFY6C%4N%LHX]R:#>EY5
ML^I4X[SG&*;/2]OB8Z5,#4D_YL-6P]6'GK7J86IIY4FWT5]#]$Z*_-S_`(2C
M_@HWX(M=WB?]FS]GCXUQ)(0U[\'/VM_BI\-?$,\2[?G@\$?&;X6W?A^.5^=D
M$WQ=\L'Y6NP!O:P?VR-:\+2VUM\8OV(_V\OAIN53=:QX>\(67[1OAN(X0N\-
MW^R[\5OC!XE>W4,SB6Z\'6,C(N#`LQ$-4_"GBJM_R*:_"?$;DY_5\/P[QUP;
MF^;8N,%=RPW#F%SR7$TFT]*53)Z=?I*E%Z!]>H+^(J]':[K8;$4Z<6]+2K2I
M>QWZJHUYGZ-T5^>NC?\`!1C]@/4]2_L;6?VEO#WPQUO<$_L'X[ZW\1OV>-?\
MXX'D?V+\=K/X=:@TP)QY<<#L<$J"`2/L3PAKOPZ^(&CP^(?`GC2P\:Z#<\V^
MM>$/B#=>)])G'K#J6A:_J%E(/=)V%?/9[P1QIPM"G4XFX1XGX=IU7%4JF>Y#
MFN4PJN2YHJG/'X3#QFY+5<K=UJ:TL3AJ[:HXBA6:W5*K3J->JA)GHU<QXO\`
M^0/%_P!A_P`(_P#J6:)5O^P].R`;C5P3R`?$?B`-_P!\G5`?TKG_`!/H]I;Z
M=;2POJLDL>O^$V5)-7UR^CP/%.C[C);3WL\,BJNYOWL3*I7>,,@8?+_\/\NY
MN=Y1110`4444`<KXT\/ZIXH\.7^BZ-XNUSP-J-VUHT'B;PY#H]QJ^GBWO(+F
M5;6+7M-U;2V6\AB>RN/M%C,5MYY6A,4XCE3PO_A0_P`3?^CK/C5_X*/A)_\`
M.]KZ>HKY?.N#LDX@Q<,;F,L[5>G0AAHK+>*>*,DH>RA4J58\V$R7.,OPDZO/
M4GS8B=&5><.2G.I*%*E&'QO$/`7#W%&-IYAFTN(HXFEAJ>$@LIXTXRX=PWL:
M=6M6CSX'A[/LKP52MSUZBGB:F'EB:E/V=*I6E2HT84_@+X^?LU_&/Q+\'O'V
MA:%\=OBK\1M7U/15M[#P5K=O\*-+TOQ#.NHV$WV&\OXO"6ARVL7EQ23B2/6-
M./F0(AN-C-%+\1_LF_L3?M+^!OBTNM^*H_$7P?TK_A&=?L_^$Q\+:W\--<U-
M;FY^Q"WTO[#>2>*8C;ZAL=I9AI)>+[,-MU:E@7_=FBOQ7B?Z+7ASQ5QWPMX@
M8W-..\/FO"<,'#`8/#\7YCB<'B%@L=B,?3>(QF;+,N(,.YU<3.$UE.=Y;&,(
MQG05'$.K6J?SSQC]"[PFXU\2^#/%',<Y\2L+G7`]/`4\LP&%X\S;%X#%++\R
MQ>:4GBLPSM9OQ3A74K8RI3J+).(\HC"G"-3#QH8F5;$5?F'_`(4/\3?^CK/C
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MNQ("JI)(`K^>/2?@7\5?A3\*/AQ\7OV;O!_B'Q9\*_VF_$GP?T#]KOX$Z187
M6G:KX3^*D'QQ\':?H_[9?@_POJL%M>6VMV>CZ;:^%OVJ?#EG:6-[XX\!Z?X4
M^,%K#-XH^'/B0>//Z(Z0*`,<D`YY)8YSGJ23^M?<'Z.?B)_P4'\-_&#XX^$O
MBM\=O@=I_A#5?$/[!OC3PQ\3_@G8^(M&^(UI\0]0^+W[.NLVGQ0^*F@>`[6V
MTZWT_4;#X^^#)M1_9MM[F"UU&R\16=]K$-E=ZA97\06']J6[M?BQXJ\/_M2_
MLN_&SXJ?LO?M*Z7^RSX0UWPA=?$3X-^,/&'[/?[3GPN\7:YXY\5>'_V9?CS\
M']8TK3[R_P#'_A;Q9I7B#3X]'\"^(O!/[1OPLG^)6I7&DP:QIGB"Y\/WO[@[
M1R.>>3\S=_0YROT7`':D*`@#YL#_`&W_`%.[)_'-`'X9?#+XF77A'_@I-J?Q
M1^+WPZ\4?"F/7_\`@DO^QKX8UKPKX?\``_CSQMHGA/XO:/\`&O\`:*\?>.?@
MEX<U+P=X5UB#Q1XN\`Z1XNT5#X=T**ZURZTZ[T>>#3"-0MT+?V3/AK\8OA_^
MS+:?`+6/!]IX`U[]JS]K/]K[]H?P-\"?B=H^L-X?^#O[)WCGX^^*?C1I_P`%
M/'47@E+[1/"NM>)?#/B31M*U3X=R:@4T]_B!XT\,Q6=\/"&O6=M^Y^T9S\PQ
MV#,!Q_L@A?TI=H&,<8&``2!C_=!Q],CCM0!_,[IGPN^/"_LF1_L=0>&_$OBC
M5/\`@F9_P4F_9E\<ZAX1\+>&O%MYIGQ]_82^'WQW\&?M`^"O#WPL;Q18QV/Q
M+G^#OP[\16_@*X\(:+J>JZM<>+OV<T\,O#)XBUG0;'5/OC5KO2/VM_\`@H+^
MQM\=?V:O'?A_QK\+/V3_``A^V7X0_:&\?^#M8L=3\/\`_"1_%+0/A9X4\/?L
MXZOJ.GRS2_\`"P]+\7>'8?B=XW\!7B6^I_#U/`WAZY\8VVBZKXD\+V>J_K3M
M!SD9SU!)(_[Y)('X`5P&B_"GX=^&_&WBCXC>'/".B^'O&OC@:>WCCQ!H-J-%
MO/&]QI%F=.TB_P#&::8UK:^+-5TG3BNFZ9K'B"WU'5]/TZ.'3[2^AL88K=`#
M\X_#,>J_`3_@I]^U5\3OC:VJP_#C]I7]GO\`9+\,_L]?$JYT34-0\&>&;KX'
M:G\<[;XJ?!35/%5M:W-MX,\2:GXC^)/A_P")GAW1]8DTVT^($'B+57\.SZOJ
MW@_6[/3>E_:`\8>(H?C+IO@/6=4^*OP?_9^\=_LX?%CQ%\./B1\*H?$_A[55
M_:?'CF*]DM-:F\/6LETOC&3PE?VOC/X1^!/%UI/X<^*VL7GCZPUGPOXIU?2;
M71X/TW*@\G.?4$J?H2I!(]CQ05!QG/'H2/P.",CV.0:`/YMM)^*'[;$^IWFL
M?%CQM\<O#WQ.\.?M4?\`!)WPWXD\/>$(_$]E\/M/\/\`QA^"GP-\-_MPZ;HW
MAK1]+N_"6M?#[2O$.O?%G5_$^H31ZWI?PF\9Z3<:WIVK>%]9T".=>OT?XQ_%
M"P\2?LO_``W^*7QE^-_A#X777_!2#_@HC^SSKFN:CXM\>>'?%/C/]GWP9\'?
MVC?&WP2;Q+\2)DA\=:SI.EQ:!X-U#PK\5K?Q!#?RZ=8Z7JJ^,+BZ8:G)_0SM
M'N.G`9@..@`!P![#@]Q7E'CKX)_#[XC>.OA!\1_%6G:G=^+?@1XG\0>,?AE?
MV?B+7M)M]"\1>*O!VM?#[7[^[TS2]0M=.\0+J'@KQ)X@\.FS\0VNIV-M9ZQ>
M36=M;W[17D0!^-_ASQM^TW!X2N?AK\<_B#^T5X6TZ?\`9G^->H?LK_&C1[/5
M[#Q[XX^)GAG]H3XU:7\*IOB4F@Z!ID7B/XUO^SK8_LT^*?#7PR^(.BRZ1\5K
MO7OB;>:UX0U_6++Q%9:'T>@_%;]IR#XNZC9_$[6_&6NZUK/P.\8'QK:?"G6_
M'WARR_9J^+_A[]E7P'K7C/PYXJ^&VJ:%J/P_\>_"N^^)R:SJ'P0^/W@+6+/Q
M0GQ)\4?\*NU+1?'MGIMSXDT3]Q-B\<8QZ$C\#@C(Y)P<\\]:-HR3SR,?>;`[
M<#.%/NH!'8\T`?S&>%_&'[6'AS0O%/QP\/']H#Q9^T=XJ_X(O?\`!/GQ-I6E
M:OI_Q)\5W.J_$GPKXT^+-M^V%<^'OAC<S:9X?U7X\^#/#^IZ5KDOP^9-%\9Z
MQX_US2;*TLUUCQ/YU?LQ^POK>H^+/A]XY\:V_P`;O%OQQ\`>-/B/>^(OACJO
MBWX6?$OX7R>#?#4WAGPU8ZGX%T*+XS^(_$?Q7\4Z#8>++#7M=CUKQM>37ND:
MOXAUGP5IERVB^%]/L=,^V]H]SQCEF/&<\Y)R<]">1T!Q2@!1@9_$EC^)))/X
MDT`+1110`4444`%%%%`!1110`4444`%%%%`!UZTF!C&!CTP,?ETI:*`#`/4=
M.1['UHKY5^*7[0/B'0?BCJ/P=^&7A/2O%WC?PG\%[_X^^,;;7M<FT&SB\'CQ
M#J7A;PEX:T>>VLKYV\4?$#6_#OC"WTO4=0CBT'0+?PM>7>J+?->V=J/;/A5\
M2/#/QC^&'PY^+G@N:>Y\'_%+P'X0^(OA2XNHXXKF?PWXW\/:=XFT.:XBAEGB
MBGDTS4[8SQQS2I'-YB)+(JAR`=]7X:?ME_\`*<;_`((M_P#9%O\`@J+_`.JR
M^!]?M9XG\5^%_!.B7GB7QEXCT'PGX=T\VXO]>\2ZQIN@Z-9&[N8K.U%WJNK7
M-G86QN;N>"UMQ/<1F:YFB@BWRR(C?S3?\%)?VXOV3_@C_P`%:/\`@D5\>?'W
MQO\`"'_"I_`'PF_X*.:5XT\6^!CJGQ;C\-7_`(V\#_!'1/"D&K:1\)--\<>(
M+8:WJB/:6<S:3]G+1RO)+''#*Z`']/%%?BQ_Q$.?\$?O^CMKG_Q';]JO_P"<
M;1_Q$.?\$?O^CMKG_P`1V_:K_P#G&T`?M/17XL?\1#G_``1^_P"CMKG_`,1V
M_:K_`/G&T?\`$0Y_P1^_Z.VN?_$=OVJ__G&T`?M/17XL?\1#G_!'[_H[:Y_\
M1V_:K_\`G&T?\1#G_!'[_H[:Y_\`$=OVJ_\`YQM`'[3U2U)5?3[Y74,K6=T&
M5@&5@8)`0RD$,I!(*D$$$@@BOQE_XB'/^"/W_1VUS_XCM^U7_P#.-JM>_P#!
MPU_P1_>SNT'[6UQEK6X4;OV>/VJE4$PN,LS?`X*JCJS,0JC))`!HVV`_8WP>
MB1^%/#*1HD:+X?T151%5$11IEJ`J(H"(H'`50%'8"NCP#U&:_#SPS_P<+?\`
M!(&W\.:!!)^UO*SPZ)I$3-#^SY^U//$S1Z=;*6BG@^"$D,T3$$QS0R/%*A62
M-V1E8[G_`!$.?\$?O^CMKG_Q';]JO_YQM&^X'[2E5/55/U`/\Q2>5'_SS3_O
MA?\`"OQ;_P"(AS_@C]_T=M<_^([?M5__`#C:/^(AS_@C]_T=M<_^([?M5_\`
MSC:+OO\`U_20'[1^5%_SSC_[X7_"E$:#D(H/8A0"/H0,BOQ;_P"(AS_@C]_T
M=M<_^([?M5__`#C:/^(AS_@C]_T=M<_^([?M5_\`SC:=V]V_O`_:;:/?_OIA
M_(TTQJ>#O/\`VTD['(/WNH/(/8\U^+?_`!$.?\$?O^CMKG_Q';]JO_YQM'_$
M0Y_P1^_Z.VN?_$=OVJ__`)QM(#W/PG_P2H_X)]^$/VR-6_:W\-_LR>!M*^/;
M2I\0(_%\%WXF?2K+Q[KVJZ\FK>-M,\!3:[+\/]*\67CQ_;6U[3O#-M?0ZO+<
MZY:26VM7=UJ$WZ9*BIPJJOT`'\J_#:#_`(.%/^"00\7:A<G]K>3RY/#>D0JH
M_9]_:E,X:+5M==G>V'P1-PD!$RK'</$L,LJRQ1NTD,JITG_$0Y_P1^_Z.VN?
M_$=OVJ__`)QM?3\3\;<9<:U<MK\9<6\3<6U\FRK"Y%D];B;/<TSVKE628'G>
M"R?+:F:8K%3P.5X1U)O#8##.EA:#G-TZ47*5\:.&P^&4UAZ%&@JDY5:BHTH4
ME4J2^*I-0C%2G*RYIRO)VU;/VGHK\6/^(AS_`((_?]';7/\`XCM^U7_\XVC_
M`(B'/^"/W_1VUS_XCM^U7_\`.-KY@V/VGHK\6/\`B(<_X(_?]';7/_B.W[5?
M_P`XVC_B(<_X(_?]';7/_B.W[5?_`,XV@#]IZ*_%C_B(<_X(_?\`1VUS_P"(
M[?M5_P#SC:/^(AS_`((_?]';7/\`XCM^U7_\XV@#]?\`QO\`\B=XH_[`.J_^
MD4U=17X;>+_^#A7_`()`W/A7Q';Q_M<2(\VBZE$C3_L^_M2VT"L]K*JF:YN/
M@A%!!&"1OFFD2*,?,[JH)'1?\1#G_!'[_H[:Y_\`$=OVJ_\`YQM`'[3T5^+'
M_$0Y_P`$?O\`H[:Y_P#$=OVJ_P#YQM'_`!$.?\$?O^CMKG_Q';]JO_YQM`'[
M3T5^+'_$0Y_P1^_Z.VN?_$=OVJ__`)QM'_$0Y_P1^_Z.VN?_`!';]JO_`.<;
M0!^T]%?BQ_Q$.?\`!'[_`*.VN?\`Q';]JO\`^<;1_P`1#G_!'[_H[:Y_\1V_
M:K_^<;0!^T]<CHG_`",?C'_K\T3_`-,-K7Y#?\1#G_!'[_H[:Y_\1V_:K_\`
MG&US.D?\'"?_``2"BU[Q5,W[6\A2XNM&9`G[/W[4DDJA-$MXSY\,?P1>:V+%
M2T2W"1M-%B:(-$0Y`/W-HK\6/^(AS_@C]_T=M<_^([?M5_\`SC:/^(AS_@C]
M_P!';7/_`(CM^U7_`/.-H`_:>FE$)W%5W?WL#=^!ZC\Z_%K_`(B'/^"/W_1V
MUS_XCM^U7_\`.-H_XB'/^"/W_1VUS_XCM^U7_P#.-H`_9/5M#T?7K"YTK7-+
MT_6=,O(S%=Z=J]G;ZI87,38W1SV5_%<6LT9P,I)$RG`R*^-_&'_!-W]A/QK?
M-K&H?LL?!K0O$3R&9_%OP\\(VWPF\:-,<'S_`/A,_A5)X*\4"X4@,DXU;S8V
M^9'5LD_&G_$0Y_P1^_Z.VN?_`!';]JO_`.<;1_Q$.?\`!'[_`*.VN?\`Q';]
MJO\`^<;7T60\7\6<+5)U>&.)^(>'*M36I4R+.<QRBI4LK+GGE^)P\IV6BYF]
M#*KAZ%=)5J-*LELJM.%1+KISQ=M3ZG;]@#3/#T\=Q\'_`-J[]N#X,K;(!8Z;
MI?[2&O?&3PY:E%'E1IX8_:ETGX]:2+1'`)LX4MX3'F)3'&<#^6#_`(.`_P!F
M+_@L<WQ,^!:?#7XG?M1?M8?`FV\-.FDZG\&?`D7A/7/#?Q1O/$]Y#>0?$?P=
M^SQI^AZ=J&JW.D#PP/"/CK4?#VFV!-QJ6B:1%IM['>KJ'[\?\1#G_!'[_H[:
MY_\`$=OVJ_\`YQM;7A7_`(+D?\$MOCAXV^'OP=^&?[4`UWXB_$WXC_#WP3X(
MT.\^"O[17A>#6O$^N^,M$M=)T=O$'BSX1:%X;TR34KHI:6TVLZQI]E+=2P6Q
MN!-/"C_T'X&_2PXX\&?$7*/$/'9!P=XGXK*L+F6$^K<?</91FF955F.!KX)X
MBCQ?++Y\5X3%456<E4AFE2E6IRK8?$4*M.M+E\G,\BPV8X.IA(5<1@HSE"7-
MA:LX07))2M+#\WL)1=DK.":=FFFM?KG_`()T:'^TEX;_`&'_`-F70OVO+_4M
M2_:.TSX4Z#:_%*YUS4K;6?$(UI'NVL+7Q1K%H\T.J^+-/\.MHNG^*M2^U7\M
M]XAM=2N;C4M2N9)K^Y^U*!C''3_/'MCTHK^>.*<^J<4\3\1\3U<ORS**O$>>
MYOGM3*LDPOU')LLJ9OF&(S">7Y3@E.I]3RS!RQ#PV`POM)_5\+3I4N>7)=^M
M0I*A1HT5.=14:5.DJE27-4FJ<%!3J2TYIRM><K*\FWU"BBBO!-0HHHH`****
M`"BBB@`HJI?W$UI975S;V<^HW$$$DD%A;26T5Q>S*I,5I!+>SVMG'+<2;8HY
M+JYM[=&<---%&&=?B3X8_M__``=^,/P$\2?'KP!X?^(.IP>!OB*?A1\1/A;J
M&G^%M"^+'P]\?+XNTKPBV@>+-#U3Q=!X=M&F_M_P]XLT?4[+Q7J&B^*O`.OZ
M+XR\(ZEKND:I923@'W-15.*^MI9FM/.A6^B@AN+BQ\Z)[NWBG+K')+#&[.L4
MDD4L<4Q7RIGB<1.^TTB:EI\ELMY'>VDEHTBQ+=1W$4EN9&F%NJ><CM'N,["'
M&[(E(C(#G;0!=HKY\_9J_:,\(_M-?!WP9\9?#.E:[X3TGQQJ'C?3-*\.>,FT
M6#Q-#>>`_'/BOP)K-O<0Z'JVLZ7/,-1\(ZC>HNEZGJ$:Z=)!.\H_>;/>OMEH
M;DV?VF#[6L23FV\U/M`@D=HDF,.[S!"\J/&DI41O(K1JQ=6``+-%?*'Q(_:P
MT?X>_M%_#S]F"S^%/Q2\?_$KXG?"CXC_`!F\,R>#7^&-KX='@OX3^)_AWX1\
M</J>J>.OB7X*EL]6T_6OBKX)CLM.2RN%U2WU*YN+6YVZ9?"+M/@M^T)X0_:$
M^'O@'XI?"FQUK6O!OC#7?&GAK6I]9M8_"FN?#_Q#\/=5\6^$/&GA[Q?X:UV6
MWU6+Q#X8^)'@W5_A[K>D:7'J,EIK<$U_#/=:!`^JN`>]T5Q_BWX@>"?`?A?Q
M'XU\8^*=#\.>$_"-O-=>)M?U74+>VTW1(;?R?-&HW#.1;S!KBVC2U8?:I9;F
MVAA@DFN(8Y.G-Y:K<1V;7,`NY8Y9HK8RH+B2&!TCFFCA+>8\,,DL:2RJICC>
M1%=E9U!`+-%>#_'WX_\`AC]G_P`"Z?X^UW1]=\3Z9>_%OX(_!V>U\*/HDU_I
M.O\`QU^+W@;X->&]2U./5M6TN./2='\1_$#0[_Q!%:O=ZU#HWGW&G:3J$XC@
M?V[[;:>2UQ]I@^SKYVZ<RQ^2OV?S//+2[O+`A\F7S26`C\J3?M\M]H!:HJK+
M?6<"V[375O$MW+'!:F2:.,7,\RL\,%N78">>949HH8B\DJJS(K`$CPWX<?M"
M>%_B3\5?VC/A-IVC:_H^K_LU^+/`?A+Q;J^M?V/'HNO7'Q`^%/A?XNZ7JGAJ
M6QU2^NCI5IH/BNST^_DURVT>]CU>SU!4LGTY+6_NP#WRBJOVZR^S17GVJW^R
M3K"\-UYT?V>5+G;]G>.?=Y4B3[T\AD=EFWIY1?<N93/",YE1=H+,'8(54$`E
M@Q!4`LH.X#!9<]1D`EHH!!`((((R".00>A![@T4`%%%%`!1110`4444`%%%%
M`!1110`4444`?)OQ5_9^\4:W\5=4^,GPL\4:)X6\;>,_@C??L^^,[CQ)I,^K
MVB>%(_$6K>*_!7B[1([)X)I?$GP^UKQ3XVEM-`U":+0O$UOXIDAU"_TB32K>
M>Z]R^$WPU\-_!KX6_#;X0^#H[B+PC\*_`/@[X<>%HKMXI+N+PYX'\.Z;X8T1
M+J2&*"&2Y&FZ7;?:)(H(8WF,CI%&K!1Z!10!!<VUO>0O;W<$-S`^W?#<11SQ
M/M8.NZ.571MK*&7*G#`$8(!KY;\<_"'Q#J?[4?[-_P`3O#VCZ9!X+^'/@C]H
MW1O%ES!<:?83VVI_$:S^#\'AA8--7RKB_%XW@[65N9[>-ULA:VYN603P9^JZ
M*`$P/?\`,_XT8'O^9_QI:*`$P/?\S_C1@>_YG_&EHH`3`]_S/^-&![_F?\:6
MB@!,#W_,_P"-<OXVTJ[UOP=XKT?3T62^U7PUK^FV4<DHB1[N_P!(O+2V1Y78
M)&K331JTCD*@)9B`":ZFB@#PK]F#P+XA^&/[-G[/GPW\76\-GXK^'_P/^$O@
MCQ-:6MY#?VUKX@\)_#_P[X?UJWM[ZU=[:]A@U/3KJ**[MV:"YC19HF:-U)]T
MP/?\S_C2T4`)@>_YG_&C`]_S/^-+10`F![_F?\:,#W_,_P"-+10`F![_`)G_
M`!HP/?\`,_XTM%`'S+H_PS\66?[87Q"^+\]I;KX'\0?LV?![X;Z9?C4+9KR7
MQ5X/^*WQT\5ZY:2:8KF\AMX-&\<^'9H;Z1!;7,MS/;0NTMI.J_3.![_F?\:6
MB@!,#W_,_P"-&![_`)G_`!I:*`$P/?\`,_XT8'O^9_QI:*`$P/?\S_C1@>_Y
MG_&EHH`^<?VP/AQXI^+W[*O[1OPK\#VD%_XQ^(OP3^)?@KPO97=_;Z;:W>O^
M)/">J:3I-O<:A>.EI8PS7MU"DEW<ND$",9)6"*37T;@>_P"9_P`:6B@!,#W_
M`#/^-&![_F?\:6B@!,#W_,_XT8'O^9_QI:*`$P/?\S_C1@>_YG_&EHH`3`]_
MS/\`C7R[\'OA=XO\'_'[]K+Q]KEG;6_AKXL>*_@]JO@NYAU"VN;B]L_!_P`%
MO#7@O7'NK.&1KC3G@U[3;NWBCNU1[J%%NH0T,B,?J.B@!,#W_,_XT8'O^9_Q
MI:*`$P/?\S_C1@>_YG_&EHH`3`]_S/\`C1@>_P"9_P`:6B@!,#W_`#/^-?.O
M[4OPZ\3_`!1^%>E^%O!]K!>ZS:_'']EOQQ+!=7\&GQ#P_P#"[]IWX0?$WQ?<
M"XNG2%IK/PEX0UN\M;0$SZA<P0V%JKW5S"C?1=%`"#C\S^I)I:**`"BBB@!"
M0!DY_`%C^0!/Z4WS%]'_`._<G_Q->;_%WX0^`?CKX!UKX8_$[2;_`%SP7X@D
MTR75M,TSQ1XK\&WMP^CZI9ZUIYB\0^"=;\.^)+$0ZC86LTBV&K6RW4<;6EV)
M[.:>"3XQ_P"'3_["G_1*O'/_`(DI^U#_`//EKR<=6SRG6C'+,NRG%T'33G4Q
MV<XS+ZRJ\TE*$:.'R+,X2IJ"@U5>(C*4I2BZ45!2J?H'"N7>%F+RZK5XVXQ\
M0.'\V6,J0H8+A7PVX=XPRZI@%1P\J6)JYGF_BMP-B:.,G7EBJ=3`PRBO1I4:
M.'K1S"M/$U,/A?T6,BCG#_\`?N3\!]WJ>@]Z\T^&'QD^&WQET[Q3JWPT\4V'
MBS3O!GC_`,8?"_Q)=:8)WBTSQOX$U+^RO$VB2L\2B22QNC&\5S#YEI?6=Q;7
MUC/<6=Q#,_Y^?$O_`()(_LIZE\/O&>G?"KP3KWA7XD7_`(;U>R\$>)_$?[0/
M[4^M:)X<\375G)!I&O:CH\'QF5]5M]'NI$U'^S25COI;:.VG802RFOAK]C#_
M`((/P?!+QAXID_:,^)FF?'7X=^(='DEL_#WA7Q#\=/A+J^B^-DOK.1/$JW_@
MSXC:%:ZNFI:8M[I^LV^L174[NFEW-C<6QM;F.Z^:QF<\=T,URW!T>$<JQ6"Q
M,:[QF/H\1UY8;!R2BJ#K5*V1X?%03DIJ<</E^.NITVY4E&3?[?PYX;?13S;@
M'C;B/-/I#\?9'Q-DE?*EPWPGF?@OEE+.N)*#E4EG']FX3+O%/.<CQ$H4JN&>
M&J9QQ=PO[.IA\7"G1S&=6E"G_1GYB^C_`/?N3_XFE#@G`#<^J.!^94`?B:_.
MC_AT_P#L*?\`1*O'/_B2G[4/_P`^6O0?A7_P3P_9*^"WC[P]\3OAS\/O%FC>
M-/"LM]/H>IZC\<OCYXLLK674=+OM&NVG\/>,/B=KWAO4A)IVHW<*)J>DWB02
M2)=VZQ7<%O/%[E'$<42JTHU\HR"G0=2"K5*/$>8UJM.DY152=*C/A;#PK5(P
MYI0I3KT8U)*,)5J:;FORG,,G\"Z>`QU3*O$7Q9QF:4\'B9Y;@\P\&.#\LP&*
MQ\:,Y8/#8[,L-X\YMB,OP=?$*G2Q.-H95F5;"T93KTLOQDX1PU3[2N7,4$LH
MCDF,2&7RH5#32^5^\\N)695:63;LC4LH9V4%E!+#\2M=_8>^,\_@/X%_%[X/
MZ&OPZ^.,EK\(OA#^U?\`"GQ?K.F6VB?&CX#^$?C5I7B>QU74KOPYK>K^&XOC
M/\`+%M:\6?!7Q?#J5Y%JWA?6O&OPA\2-_9OBC0KKP?\`MK<2-#!+)'"T\B1L
M8X$9$:>0*?+A5Y66-&E?;&'D98U+!I&5`S#YP_9=_:A\$?M6?!BR^.G@[0?%
M?@WP;J/BWXH>#K.V^(2>&=-UI]0^$/Q'\6?"GQE>30>'?$OB;3+;38O&?@CQ
M';Z;/+JPGO=,M;;5)+:UAO(T'OGY,?ESXP_9^_:(UO\`:FLOB3IW[-_Q!\.^
M&]'^*7[>>B?$2\\%?%7P+IU[\5_A=\5?V?M1L?@[XCT7XAZU\1KKXC)=^-_%
M_A[PE9VV@3Q>$/"7P,\:3^']+T?P1!HW@]/B%<V?AA\"/VF/AE-\,9?$/P4N
M_BW\"O"/[2'BJ\\5^"HO#'P2\#_&SXF^"O$W[.7@GP'\./C)\8_A[IWBW1_@
M?XN\:?!#X@:'JW@7Q%<^#K_PFOCSPH^B?&+0?ATOB3PJ@\4?JQ^TY^T!X7_9
M;^`GQ7_:`\7:-K?B30/A-X%\0^/M6\.>&'T1/$VM:7X:L'U'4[;0X_$.JZ)I
M=Q?0V$<UV8;C48"T$$OE"6;RH)?;GO[".X-E+=VD=VMN+QK5[B%9UM?-$7VH
MPLRRBV\\B(7!01&8B/?YAVT`?S$:'^QE^UKX5_9F\#_"O2?V5_$^@_$?X=>%
MOAWXJ\!>*/#?C[X2ZA>Z9J7@K_@I1X[^-VM_#BVU#6/BJ^B?#/4++X'ZKHOB
M3P[K?P\T:WU[XGCQ1+X1\:>/_#T7PVTWPK<?3_B7PO\`$/PE^T=^QO8?%KX3
MZGI/Q!;_`(*S?M`ZO8?'V;4O!NK:1\7?A!\1?V=?V\_&_P`(]%T#4K#Q)?>/
M=/M?`WPV'P_^'^M^!/%.@:-IOAW6/AO#)H\FL:9_8.LWW[OK+`[^6LD3/M9M
MBNA?:K!7;:"3M5RJL<8#$`\D5SGB#P/X,\6:AX9U7Q3X1\,>)-4\%ZQ_PD'@
M_4M?T#2=8O\`PKKQMI;(ZUX;O-1M+FXT+5C:3S6IU+2I+2]^S2RV_G^3)(C`
M'Y??M0_`OXB>-/\`@H;^S1\;(OA#\9O&_P`&OAO^R1^U-\*?%GB7X-_%73_A
M=XDTWQ_\9OB9^S-K_@S3X+O3?C/\)/&]_IA\/?"KQM<ZQ<Z?=W&CZ7?+H$LV
M_4I+&>P^4_AW^Q;^V=X.^%?[$7@.RTB#PCK'P9^/G[?FJ^"O$&FZOX&UG7/V
M:O@3\:O@A^T]\/OV8K?XK^(=)U/2(OC#\3?"_B+XF_#.^^*'BKPC9>,=:\4Z
M_8ZOXK\3:[XPUNSU;QSXB_H5P/048'I0!_.C\=_V&OC=\;OV9?$VD>'_`-GV
M3P7XV;]@VP^#/QB^$VL^(O!-WI7QW_:+\#?%?X$_$+P1XETJY7Q#?^%O'&J>
M#+/P!\:T\&_%GQS?:#J^O?\`"YM,L]8O=)N_^$C@\/>^77[-OQT\4_M6^.[[
MQ!\.OC3H?A6_\:?#/XT?LG_&'PAXY^".@?#']GS3/#G[/6@_#23X/_$OP-::
MLGQ?T^^\!^,X?&.JS_#KX>GQ;\%OC+IGCN.+Q#?:<UAK\MO^V6!SP.>OO]:3
M`ZX&1P#CH/2@#\`S^S7\:/''[(^@^%M5_8P\7>`?VD-,\3?\$X/!/QWUN7XF
M?"S5=-^.UK^RC^U+\-OBQ\1OB?X;GT7XHRZ1XET!_#FC_$GQ?9?$'Q_IO@GX
MW>-+CQ5IG@O4?#=W<6IL]'T_#W[&?Q-@_:;\(Q:Q^SC"?V;?"?\`P47_`&FO
MBYINA#_A5[?#W3?V=/B[^P5#\*8YK?P!#XIW-H7C#]I>_P#$FM:OX$_X1F35
M)+G4;OQKK7AV"UO/M<G[TX'H.N>G?U^M&!Z#\J`/Y[?@K^R?^TOHWP;\-_#/
M]H#X$ZW\0?!^K_L=?$K]G_P;X(_X3'P1J&I?`#XK:=\<?C+KO@O6H[F/Q9+I
M'AS1O'7P?\6?!C2_"WQ)\!:IJVN?"FY^"NFZ5=IH,TFF,W1>&_V5OVS_``=J
M_P`:=9\1Z-JGQ2,W[0/_``3R\=?$227Q!X4BN?VO/AS\"_V8?AE\(/VA?[&M
M]0\1V:6^JS?$SPU>?$:Q\+?$D>#['X@#PM::#+(VF^)S*O[X8'H.N>G?U^M+
M@<\#GK[_`%H`_`KQMX0^(?P#\?:'/X3^&?C'QWH7CWXV_M4?%'X<?LA6'Q3_
M`&??"6G>#O@7\0_@C\'_`(>^)-2U#P;\;/C3\)_#=M;V'QS/BCXB:-H'@C7M
M>3P3!\:_$?A?4]!T>7Q;/J_A/H/@G^SGI.D:I^S9H'PAT2[L?"'QO_9E\+?L
MW_ME>!_BK-X#D^+@\'?LU07=SX(^+?B:+P)J'C?PCXAU_P`:277CGX.>+-7\
M/>,=7\->.M&^+G@+X@^'?$VOZ9X(L)-1_9SQS\,/AO\`$ZTTVP^)'P_\$^/[
M'1K]-5TFS\;>$_#_`(LM-+U.,!8]1TZW\0:=J,-C?Q@`)>6J0W"``+(``*U=
M+\'>$M$UG5/$6C>%_#NDZ_KECHVF:UKFFZ)I=AK&KZ;X=AGM]`T_5-3M+6&^
MU"RT."YN8-'M+R>:WTN&XGBL8[>.616`.ACC2*-(XT6..-51(T4*B(H"JB*H
M`5$4!44`!5`4```4^BB@`HHHH`****`"BBB@`HHHH`****`"BBB@`J&X:9()
MG@B6:=(I&BA:00K+(J,T<32E7$0D<!#(4<1[MY1@NTS5!=+=/;7"64T%O>-!
M,MK/<V[WEO#<M&P@EGM(KJRDN88Y2CRV\=Y://&K1)<V[.)D`/RJ^(O[57[4
M_P"RWK'QAU#X]6'P6^*?@31OV>9OC!X5U#X4^$O'7PXN/AS\4=4^)WA?X7^`
M/@?X]U+Q3X[^(5KX\T?XC:EXKDOO#_Q0TK3_`(?:I:P>`/',U_\`#S[/>:)%
M9]EXM_:T^(_@'X_^&_V.M8N_`NM?&CXE:E\(KOP-X[M-#UC2?#MIX-^(7AW]
MI?Q-XTU74_!$NMZE-=ZIX&MOV5?'MKH5E%XO@AUU_%G@I]4:(:9X@DU#3\+_
M`+'/QZ\3:1\5/!7[4O[5VE_'7X;_`!4\#ZSX<U7P]X2_9Q\$_!#Q##XGOKG3
M&T/QS+XVTOQEXYU&\U+P19Z='#X0T^/3[&TTZ[@TV\NY;^/34L;CT?4_V0U\
M1>+(_B]XG^(5WJGQ]TG7OA?K?A/XC6WAJWTO1?#L'PDTCXEZ!X?\/IX%@UN6
M.[T#Q'I/QI^+\/Q!M5\265YK]Q\1-9GT._\`"4>E^%+?P^`>$>'OVU_%WCSX
MM6O[-UAKO@'X>?$C1M>_:>\):W\1O%.@76H^"/$_C7]GGQ)\&+?0O"?ACP[<
M>-/#ES'K7C;P#\;/#WQ/\2:''XEU/5O#V@:'XDT[P\VK0V\WBC1_LC]E?XWC
M]I']G?X/?'(Z$_AJ?XF>!-$\3WV@F6:YM]+U.ZB>WU:TTZ^N(;:;4]&35+6\
M;0]6EM;635=&>PU)K:`W1B7E+#]EG0;+X>Z_X!/B&X>7Q]X[\8?$[XD^,AHN
MG?\`"9:YX\\<ZD]YKFO^%=0NI;VP\`7-KIK1^%O#-[I.F7VN^$_#5CI,6AZW
M;:WIXUZ;Z)\)>%/#O@3PMX;\$^$-'LO#WA/P?H.C^%_#&@Z;%Y&G:)X>T#3[
M?2M&TBP@RWDV6FZ=:6UG:Q;F*0PH"S-EB`=#1110`4444`?(7[7GB3]I[P=\
M/O$OCG]GKQ%\#_#2?#KP)XN\>:M;?&#P-XX^(!^(>L>'["74-%^'&E1>#/B#
M\.9O`5MKXLYK&Z\>,WQ`U*TO]3TN'2?A_J;V]RE[\[^+OVXOB)HOA']HWXKW
MG@K1O`_AK]C3P=\'O$'QW^&WB%I]<\77VO\`C3X4>#OCE\4O"FF^*=-O;#3M
M%N/AE\./'>A0Z#??V#J\7B_QA'J-M?Q:/HT<$LGT7^TK\&_VF/BIJWA2;X(?
MM->%/@7H&A6EW/K/A_Q%^SCX<^.">)/$RW]K>:!XAEO?$'Q#\(?V6/#'V7S-
M*TZSLI%;49Y-5N;R6YMM+73L'Q%^QK8>+H?&>G>)?B#JFIZ+\;_#OPKTK]IC
M3E\/Z?I[?&+6/A?I.F:%)X@LI=/O[>V\`2_$/P]I.G>$?B)INEV&L66H^#M-
MTS2?#A\+ZE;3:[=@%.X_:IUGPG^T!^VUX,\>V>@1?"C]EK]FKX!?M!Z7J>AV
M&I)XONK+X@0?M-W/Q`LM>GO=8GTB^73K?X"V5QX973--T<PKJM[#J<M^_DSP
MM^"G[1WCS7?'GP(\%_%"'PF+O]IG]F[Q-^T9X*A\,6FIV+>"I?!%]\'(_%_P
M[U&>\OM5C\4P66F_'/P?/I/BX#0)[^\T;Q(]SH=K;7^DVFG^B:?^S/IW_"__
M`-HOXR^(]>L_$OAW]HOX,_!SX+>(?AS=>&VMK:P\/_".Z^,\Z3/XB3Q!/)JH
M\4P_'#Q58ZQ9MHFG+;VMGHXLKE98[^2^3X0?LS6GPS\0^"/$>L^--6\=7OPF
M^$,_P&^$\FIZ?;:;-X:^&=[J?A34M677);6ZND\5>-O$`\`>`;#7_%OD:';7
MEAX.TH67AS3;V]U^]U@`^HZ***`"BBB@#,UJ75H='U6;0;6ROM<BTV^DT:RU
M*[EL-.N]52UE;3K:_OH+>\GL[&>\$,=W=06EW-;V[230VMQ(BPO^8.J_M-?M
M7?`[Q!\6?!/QHC^!GQ0N%O?V3/#7P<^)'PX\)^,_A5X9M/BM^UC\;K[X)V/P
MH\?^$O$?Q(^*>I:R_P`/)9?#OQ*F\4:#XIT&[\1>!M8M]-U/PWX7U>ZT?5-7
M_37Q/9Z[J/AS7[#POK5IX<\27NBZI:>'_$%_HP\166AZU<V4\.EZO>:`VHZ0
MNMVVFWKP7LVDMJNFKJ,<+6C7]JLIF3X-\&?L?_'C4O"?C;P?^T=^U?;_`!DT
M_6[SP'XN\'7O@O\`9[\#?!#6?!_Q9^'OC?0OB'X?^*]]J.E^*/&[^+?$EEXG
M\(^$KFUL+V/3-#CM-+NM,N;"^L+Z"WTX`\U_:!_;?^)?P0^#'[;\NF0^!?%7
MQE_8\E^"NJ1:CJWA_7+'P;XR\'?&=?"5_I6H:EX<TWQ/'J.DZY:V]UXXT$VM
MCXEN=.:]T#1?$+A;75;OP_9_4_[0_P`;O&WPG^)_[&/A3PW9>&+SP_\`M!_M
M*ZU\%/';ZU9:K/K.FZ';?LZ?'[XQ:;J?A.YL=6L;&SU0:]\(-,TV_?6+#6+:
M;2-4ODMK:VO!!=Q>;_&3]ANT^,WP2_:4^'.L?$/^S/'_`.U/J7A"_P#B/\3+
M/P;%/9V5MX%C\):?X7T+PKX)E\4(-,T#1=%\)1VEA9ZAXKU:\.IZUK^N:AJ.
MHW.H""'VKXT?`2\^+_C+]E_Q>WC&#P_)^SA\<9_C<;!/##:K'XRU*Z^#WQ6^
M#D^AFX?Q'I[^'+#^Q_B[XAU6*[2+7+I-3L=&1TELX;^*_`/HY3E03W`/YBEI
M`,``=@!^5+0`4444`%?"_P"U]X^_:Z^%FD77Q/\`@5%\&?$'A;P7-X'BE^#'
MBWPAXUUOXC?'G5/$GC#3M!U;PAX-^(>A^/?#>A?"/6SI^J6]OX*O=3^'WQ6M
MM:\3G/B*UT+P]')/7W17Q5\>?@9^U=\1_B1I7B;X4?M;>%O@YX#TC3=,AM/`
MFH?LP>$?BMJ=KKL<M_'KOBVQ\:^)?B+I$MGKVIZ5?-H^FLOAV6PT*S1REGJ$
ME]J9O0#SFX_;(\1K/XK^*$-MX<7X+>#?VU/#/[%6H:#/97P\6WNKZ[\4/!GP
M"OOB-%XCCU&6QMCI/QO\9PZ5'X1;P\\-UX)T6^U>37$UG5+2UTOTGX3_`!P^
M+_Q.\7_MW^`[/3/AX/$'[.WQYTKX2_".>:#Q'IND:EIGB3]FCX"_&C2]2^(D
M@U35;V^O-,U_XN:I::HWAJ/18M0T32+*TL+2PU"674&UIOV1O#DGBG4I4\3Z
ME%\,]:^//AS]IW6/ALNGP*MW\:_#$^AZS8ZNGB6.]CGM_"5WX[\,Z%\4M4\)
M)H[377Q$L7U"'Q!:>'+V^\+3M\/?LW>//`FH?MG>)_A[\8=.\.^.?VJOB+I_
MQ-\-^([[X8V_B"T^$/B/2O@A\+O@;ITB:!>>-K>S\?Q6FA_"G0M>2+5+CP_;
MR^(+O41=6]QH[V^F0@$/[,OCG]I'4_'?Q^^&'[0#?#;QE!\*M?\``4/@CXU?
M"GP5XF^&/AOQQ;^-?"#>)?$'@W5_ASXI\?\`Q5NM"\8?#&Z_LV+5=4TWX@:Q
MH_B'0_%WABY&GZ#K-MK6GC[$KY<_9G^$7Q[^%%GXKM?C?^T/HWQV.K76GW/A
MM-`^!?A?X)6GAV3=J5UXDO\`4(=!\5^,+KQ5KGBK4KV"^U'5=0U"S2%K,>38
MM<7EY=R_4=`!1110`5QOQ`_X3QO"&M1_#*7PM;>.IX(;;P]?>-K75=0\*:7=
M7-W;P3:QK>EZ%J&DZOK5II%E)=:B-!T_6-$N-=N+:'2/[>T&.\DUBR[*O-/C
M#X:^(_C#X<>*/#?PD^)-G\(/B#JUG!;>'OB/>^!K'XCQ^%IA>VTMW?1>#M3U
MSP[IVKW<EA'=6EF+[4X[:SN;B._DM[W[,+24`^!/"/[3G[2>D:]I_P``_BH_
MPCU+XK>+?VL/$G[/OPW^-G@GPGXH\,?#WQMX"\&_LW7'[1OC?XBP?"?7/''C
M/5M*\4^"SH_B+X,ZEX;7XFZSX>O?B!IPU^'5(M,M=8\+V!K_`.W+XZM/#GP5
M?0])\%W?B2__`."C\/["'QI^VZ=KKZ:;33];\<Z3J/BWP''!KMM-I&K:QI^B
M^$?$=G:ZY+XCL-$76M7T&4:O+8VFM2^K^"?V4OB];^&O"C?%K]HC2/B1\2OA
M7\4XOB;\%_%_A[X#^%OA9X8\"^;X*\2>!/$'AG5/`FA>+]:N?&&D>-=!\<>.
M+3Q=<7/C32-2O$UNTNM)N=%UG1K?5[A_BS]A_2-=\+_!;0-(\>W>D:A\,OVN
MM._;'\6>(-0\,VFLWWQ*^)/_``D/B_Q1XCMKRWM-8T"U\.:;K>J>,;NVLEL%
MU!?#VB:9HNCV5O<16+SS@&9^T1\=_C%\'OVA_P!F#P]I_P`2OV:=/^'_`,=O
MBSHOPHM_@_\`$'2O$OAWXL>-8+OPQKGB'Q;XK^'OQ8F^(EGX1@\4^$(=(6_T
M7X47/PMUZX\>Z;:ZCIMAXML=?U"PATS[^4DJI.,D`G!R,D=B,@CT.:^</B'\
M!+SXM^);&+XD>*]-\0_"SPU\2_A!\7O!'@*#P5:Z=KF@>._@UK.E>+_#%U>^
M//[=O9-7TI/'NAZ1XN2SA\+Z/JD,UD=$DUV[T&ZN["?Z0`P,?Y/N?<]Z`"BB
MB@`H^G^?YT4'H<<'L>N*`/A?XM>/OVNOA]\</A%>Z!#\&O&/P4^(OQIT'X3:
ME\([/PEXR@^,6E>"]4\-:WJ6M?&ZW^+Q\>?\(C(W@N\T:77M?^&EQ\'ELI?!
M*306WQ%'BN2Q@N>,^"O[8_B?X@M^R5X]UJS\.+\-/VX=9^(VD?"G1M/L[ZV\
M2>"%\-^!/'WQ<^']UKNM2ZE>V/B@^,_A=\-/$NH>)8HM,T'_`(1OQ-=:1I>D
MMJFGQ7EW<>B:I\"_VK]1_:%B^)T7[7'ABP^$5OXGTVZM?@[!^S!X/NM?L?`=
ML-,EU?P)I_QAU+XAWFM6G_"57VF)>^(?$B^%&OIC*(-/L=/CL-'_`+.W/AM^
MR-X:^'>O?#!X?$=_JG@7X!:A\1-2^`G@:6P2UA\`7/Q*M]7TK4%U'6DU">?Q
M5!X1\+>(O$G@;X=Q2V&CG0/!VO7]CK+^*-72QURS`,?]E[]I;Q)\3_V<]4^+
MWQ1T[1(?$FE?'']IKX1II'P_TO5X[779?@Y^U'\5?@'X(L]"TO6-6UG47U[Q
M98^"-#DNTN=4-I_;NIWMR&TW2(]EIN_L2_'#QW^T-\"'^(WQ*TGPSH?C"W^-
MG[4?PUO]*\(?VB^@6EE\$OVFOBW\&-!2UN=4N;F[U"ZDT#P'IDVKZKFWMM4U
MB2_U"QT_2[*YM]-M>4^'_P"PO\---^!B_`KXP&Q^,GA^U^/WQH_:#TJ[FTS6
M?`LND^*_C'\8/B9\7[E+-=!\87FH1R^&M1^*OB?P_I6H1:S$UUH36RW]F]Z+
MFXN.K_8R_8]^''[$_P`*=<^%/PUEO+K2O$'Q:^,/Q7O[Z^?4//>^^*OQ)\3^
M.K?21#?:QK.RV\):1KNG>#K&YBN(I-6LM`M]9U.$ZSJ&H32`'UM1110`4444
M`%%%%`!1110!!=.T<$LJQ23&)?.$,(5II?)(E\J)69%:639LC5G12[*&95)8
M?SO_`+,'[#OQJT73_P!AGPW\>?V:Y-3\*?"+5/\`@K/)\:/#OB;4?A)XRT$Z
M)^U7\>-<^*'P8TZ]T6#QMK.F^,+;Q=X<U"%+O3X+;5;;PSKF+;Q*ND/"EZ/Z
M)Z,#T''3VH`_F5\8?LD_MI^)OV&_%G[/?Q+_`&;O$'Q?^('CC_@EI\%OV?\`
MX97%UXS^"VH-\$?VDOA3X;^(.B_$C0O$FL^(?B+:P6@^(VLWWP^\6>%OBAX*
MO_$EEK:>'H_#_BNX\/MX6\/2ZK]?^'_V<OBYJ'[5'QA\2?'WX(_&CXKZ'I/Q
MD^)GQM^#GCW1OB3\#!\)?%/PC^('P0C\!_\`#._B[P;J_B#3OB;J'B+2[6\U
MCX9W'PF\50WW[/7B9HM"^*EWXVTV\A$&D?M7@>@HP/0=,?AZ?2@#\T/V&?@-
M\0/V;O&/C7X;>)?A?/<_#ZV^'OP[7X$?&RYU3PCJFN^"/A3:2:X^D_L1^+)V
MUZY\?:O:_LS75[/!\-_B!)IU_H'CGP1XFM8/$.LOX^\+ZQJ7B3]+Z**`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!I=`=I=
M0W]TL`>>G&<\TZOP2_;?^*O[1VG_`+<7QN^$_P`#O'?[0">(+3_@ECJWQE^!
M7PZ^#_V;7+:?]JIOC]K_`,/?A]XAU+P_XFL=0\!KI-]%;Z'H?B2+XB26?PS3
M04U;5M:%CJ2-K*?87PN_;D\9:KKO@/X4>)?@]XL\>_$;0_$WASX$?M$>,?A+
MX8\<ZC\-_A[^T+9_`[0OB7\0[M-8G\&3>$+?X,^'_%FK6W@"_P#&%[\0H]>T
M#Q+KFA17/A&]\/-=^)+<`_2NBOS(^'/[=Q^*7@7]ACXN^)?@UXI\!>#?VQO'
M?AI/A-<0?%G3+FYT32_$7[)OQ=^/UQK'Q6T?0[;2K"ZT_3-+\!>)_#I\*+=^
M*M,DUD>'?&<D]C=:;;6^F:-]_P`%)?`7AC1/AKXX\=^`_$/AKX:_'WX(ZS\;
M_P!GKQ=::SH^N7'Q#T_39O`SZ/X#UW1A'IR>!?B+X[T7XE^#?$G@;2[C5]?\
M/ZCI-SK,.M>)_#^MZ#=:3,`?I-D'(!&1U'IWY]..:8)(R<!T)SC`9<Y],9Z^
MW6OS:_98^)'Q<\4_ML_\%"?!OQ(O-3L-*\!V?[(4_A#P,OC:Y\9^$/"?_"7_
M``@\7:GXDNO!TD^EZ"-,AU_5+""37K;^P]-DN=>TRZO`MY9RV.H7?R'^QO\`
M$7XI?%3XF_M"6/B_Q/\`M>>(9/`'_!4S]H;X->"_&6@^-HKGX/>$?A3\*?$N
MG>(/#G@3QGI%YX@DN-2\*MI>FWW@'4KO4/"M]K-[<^*+9'\2"[@M=5L0#]Y*
M,C)&1D8R.XSTR/?!Q]*_+.T_X*@>$=+ET;Q#\2/A7X@^'WPIU;QY^W%\,9/'
MMQXLT'Q#?:3XP_84E^,6J_$:;5/"FDV:RQ^$_$/@;X%_$'Q)X=UZWURYOX=1
MT^S\.ZIX?@_M*TUJ3Y[^,_[8?Q$^%/QX_:S^(7Q0\,?$6T^%/PZ_X)B?!CX]
M6WP9\&_&&:SNI+C6_CK\<M,UWQ!I&JV`T&U\#_$Y/"VF:-HOBB\T6>[B']A6
M%KX?\3^(8H([Q@#]T**_.?Q#_P`%`8/#7Q7\9>!;_P"#NOKX1^'G[97P;_8Q
M\8>._P#A,?#S3Q>-?V@?A]\(_%_PN\5:%X2BLY[S5O#-UK?QG\(>%_%,-WK&
MBZMX=2:?7;.TU^VMKNPM.]^&7[:N@_%?X@?!OPCX7^'?BU]"^-6G_M,:GHOB
MJ[GL;5O"EM^R[\1M*^%OC2'Q]X<N(XM5T#4->\5ZYIL'A:P@?49C"+^+Q"VA
MZG9'3IP#[;HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`/GX?LV?#L?M,S_M8%_$;?%>X^#D'
MP&ED;6@WAAOAG;>+YO'\.BCPT;+[*MXGC&XGUP:\)QK9>0Z<U\=&"Z:O'6?[
M'/PQT;X[>._C[X6\1?%?PAK_`,3I;77/'_@CPU\3?$=A\(?%7Q%T[PIIO@;2
MOBWJ7PNFDN_"Z_$NQ\(Z)H&BR:Y:6UMI^M+X>\/:IXFT77-=T'2=4M/K*B@#
MY#\,?L4?!SPAX$_9+^'&AS^.;?PM^Q5KFFZ]\#+67QA=75UI=WHOP\\6_"?2
M(/$M_/:/=>+;+3_AUXY\5>%8;?5W?S;/5GO;I[C5[6QU&VYNV_X)Z_LUCX:W
M7P;U;0/$OB/X5VO@+QO\+?`7@G6_%^L2V/PA^'GC_5-(UK6_"_PIUBP?3?%?
MA*'3]0\/>'6\&:P?$.H^)_AY8>']#T/P'KOAW0-*L]+B^X**`/FOX'_LN^!O
M@9XK^(_C_2/$GQ'\;>/_`(MZ-\,=$^(7C/XE>,IO%6M>(H/A'HFM>'?!MW+'
M'8:3I%CJ,.DZ[>P:M>Z7I=E)KDWDWFIBXO(VN)/-_`G["/PR^&^I^-+OP?X]
M^.&CZ5\2?CCXB_:(^(7A:T^)D\'AOQC\3?%_B72O%?BR_P!6M;71K;4(="\2
M:IHNGQZOX2TG4],\-W&E)<Z*NG1Z5J.HVEU]N44`?"TO_!/#]G:_TWPQHFO6
M/B_Q/H/ACXG_`+2OQ:30?$?BE]3T?6O%/[76E?$G0_CY#XDLFTZ)-9T#QMI7
MQ@^)=FN@RM%8Z`GBR[?P\--FL-&DTSD[G_@F/^SYJ_A7Q[X2\5^)/CEXXM/B
M+^SUI'[*_B'5/&7QA\0Z[XA?X$^'O&.M^,O#_@N'79[=+Y[G2+KQ!J>EQ>,M
M1;4?'=]I$[Q:SXFU/49;C5)_T5HH`^,M7_88^#NNZIXRUO5=2^(-WJGCW]H_
MX-?M6^)KIO%RQB\^,_P%TKX?Z-\.-=BMH-(BM+32=+L/A;X!BO\`PM;6\6@:
MVWAV%M3LIC?:K]O\#_9=_8_^-OPS^,=Y\3_'WC;QYI%Q-K7BG6?%&F:5^UY\
M7/C3\*OB/<>,$UF]U6'3O@I\4OAKH]O\,-+C\1:I9^(-#\CQUXI\1>$QHEKX
M4LM=UO1)KS4KO]2:*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
&HHHH`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1KAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1) (Stock Option)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Option</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected VolatilityRate, Employees</a></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">66.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">85.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">93.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">1.20%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">0.90%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">0.80%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">80.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">81.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">81.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">2.30%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">1.60%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">1.50%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
        <td class="text">8 years<span></span></td>
        <td class="text">8 years<span></span></td>
        <td class="text">8 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors[us-gaap_AwardTypeAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The expected term assumption that is used in valuing an option on its own shares for employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" onclick="toggleNextSibling(this);">$ 1,075</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">1,101</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases, Future Minimum Payments, Due in Three Years</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" onclick="toggleNextSibling(this);">1,128</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Operating Leases, Future Minimum Payments, Due in Four Years</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" onclick="toggleNextSibling(this);">572</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">$ 3,876</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3LAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Other Tax Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RevisiontoDeferredTaxAssets', window );">Revision to Deferred Tax Assets</a></td>
        <td class="nump"><a title="lxrx_RevisiontoDeferredTaxAssets" onclick="toggleNextSibling(this);">$ 13,800,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_RevisiontoDeferredTaxAssets</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Change in Amount</a></td>
        <td class="nump"><a title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" onclick="toggleNextSibling(this);">35,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Federal</a></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards" onclick="toggleNextSibling(this);">715,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating Loss Carryforwards, State</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" onclick="toggleNextSibling(this);">460,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ (70,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RevisiontoDeferredTaxAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company recorded certain revisions to its deferred tax assets.  The revisions reduced the deferred tax assets and valuation allowance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_RevisiontoDeferredTaxAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`1N"\92`(``#8F```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VLUNVD`4!>!]I;Z#Y6V%
M!\^/FU:8+-)VV49J^@!3^X(M[!EK9I+"VW=L$E1%%(2*U+/!`MOW'HST;3B+
MVVW?)4_D?&M-F>;9/$W(5+9NS;I,?SQ\F=VDB0_:U+JSALIT1SZ]7;Y]LWC8
M#>23>+?Q9=J$,'QDS%<-]=IG=B`3SZRLZW6(;]V:#;K:Z#4Q/I\7K+(FD`FS
M,,Y(EXM/M-*/74@^;^/'^R2..I\F=_L+QUUEJH>A:RL=8E+V9.I76V;/&[)X
MYW2-;]K!OXLQ4G9TPWCF[PN>[_L6'XUK:TKNM0M?=1]CL&W'?EFW^6GM)CL]
MY$A*NUJU%=6V>NSC$\C\X$C7OB$*?9=-QZS7K7G)?6+_=+%GTR&_<I#Q^TV#
M+\S!07((D!P2)(<"R5&`Y'@/DN,&),<'D!SY'"4(BJ@Y"JDYBJDY"JHYBJHY
M"JLYBJLY"JPYBJP<15:.(BM'D96CR,I19.4HLG(463F*K!Q%5HXBJT"15:#(
M*E!D%2BR"A19!8JL`D56@2*K0)%5H,@J4625*+)*%%DEBJP215:)(JM$D56B
MR"I19)4HLBH4616*K`I%5H4BJT*15:'(JE!D52BR*A19%8JL!8JL!8JL!8JL
MQ?^2-<16#+'I]=]_E&G,F5J&#[N._)7_2MT//;>YT8[J[\'%_M#5`_PY^TR.
M2G?571.+-%=^"(>YI_;'=L^]LX.//2='EP=X*3*-=\^&.(A<:.E093I6"3IL
MC!VIRQ>^ZB31V,*JJ3ZRFTVMK^5O````__\#`%!+`P04``8`"````"$`M54P
M(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."
M2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA
M5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AEW)3E
M/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;
MJ)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$NGVBI
M^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````(0#ZPILBG0(`
M`-4E```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````"\FLMNVS`41/<%^@\"][%\
M^4I21,XB18%LV_0#")FVC-B2(;(/_WT)(Y5KH)UNA-D8$`53(W/NG"M:#X\_
M#_OJ>QS3;N@;)8NEJF+?#NM=OVW4UY=/-W>J2CGTZ[`?^MBH4TSJ<?7^W</G
MN`^Y?"EUNV.JRBQ]:E27\_%#7:>VBX>0%L,Q]N7,9A@/(9?#<5L?0_L:MK'6
MRZ6OQS_G4*NK.:OG=:/&Y[7VJGHY'<NE_S_YL-GLVOAQ:+\=8I__<HWZQS"^
MIB[&7"8-XS;F1DU#J3Z?T7Y1-*OZ'W*$+4>0'&/)<HQ%<JPFR[$:RKEER[E%
M<EPI+JJ5W1+*<6PY#LGQABS'&R2';1WH''99P:H2=B(+3N1[LF_T/?*-L`$A
M$!":#0@-`6'83C;0RH9=Y0:6N64#PD)`6#8@+`2$8P/"04"XTAES:7Z'<L?/
MFLJI"V-<?\EC>0Y(Y3[?>N6K8:2&[1QH',^.9`\C6=C`$@PL-B$$$D*S":$A
M(32;$!H2PK`)82`A#+O.#2QTRR:$A82P;$)82`@W*R&F;9,+'::AMYT4!_MV
M/VONY++C%"]2SH?U^1-F,7N%\`*Q.>7@;\,N)EA+PL:"0"P(&PL"L:#9.:QA
M#ANZ=:!W#+O*#2QSR\YA"W/8L=M1!]M1/VMEM6'?/G5AUU_0,`VAYQ?-[K,T
M[+,LFPP6DL'-BNZI;;BLT33TNY.`CPR>S0:/V5#N@_F'%5PJ=M;`J!$VI@1B
M2K,QI2&F-!M3&F+*L*UCH'<L&U,68LK-BJDI[T`$P@90V+P2R"O#YI6!(6C9
MO+*05X[-*P=YY=G>\=`[?E9(I'S:EU=6+CO8YV/4^M&]@L2P0P]FGK!Y*9"7
MPN:E8%ZRU\I,BU5?O8RU^@4``/__`P!02P,$%``&``@````A`-C#C%\+!0``
M[1(```\```!X;"]W;W)K8F]O:RYX;6R4F-URXC@0A>^W:M^!\OT.^!=()9E*
M2+*3JIE-=LAF+E6*+;`JLN25Y1#VZ;=M#Z9M&=?D"H31X73WUVWA\\_OF9B\
M,5UP)2\<]]/,F3`9JX3+[87SS]/='PMG4A@J$RJ49!?.GA7.Y\O??SO?*?WZ
MHM3K!`1D<>&DQN1GTVD1IRRCQ2>5,PE7-DIGU,!2;Z=%KAE-BI0QDXFI-YM%
MTXQRZ30*9_I7--1FPV-VH^(R8](T(IH):L!^D?*\<"[/-URPYR:B"<WSOV@&
MOM^%,Q&T,+<)-RRY<$)8JAWK?*#+_+KD`JXN_9GO3"_;(!_U)&$;6@KS!.$=
MU"%?7N!Y4?7-*A7/G.V*XZ9J.7G_P66B=M57(;7[=N6#@5U]Z0=/3`K79[-9
M^]D7QK>I.7P(\E.D7V<0?J=^G<@ZO$-&"%2*W$K#S9[<RR;[7$$)JZS?0V2N
M,]%G'-[H^\2MC&.5%211"9Y02!&YIH+*F)%UM;5`$E&`-+R^1F<;>:0:ZI0R
MPV,J.B(0:VNDSO5)(VL#?JIR%T1MR$IER`NV$O2M6!L!P)3)@K\Q\A4G!7L)
M^RJ=I'0EUP:K1!$*J8;B5T.B.#-SI#+OFWG06RKY?S7O=:T?<J8;^E%6(JRQ
MZ&NLRRRC>E\E<\VWDD-'46G(51RK4AHL`[W?UFC9E_G.8JC)81O,"_*HE02)
MN"H6EEDB&7?6UUG1(JU#J=_<_EOR-RKJ:E<L(YTY-%!KQ[7@O:-<DV<J2D:^
M,5J4NF$&"W3@M\B]*@H`G7QA(B'0.60--O!N#_^\A2P$#Z6`MJL[$*+(*V3Q
M?A_OMV"]AZF;,?)$WV'"'OMUC@EW+3C_5"K9<0'#K6:MZO`YIMFU.+QA+X8\
MO`B^M;"98X!=B[TKK:G<_NS$'3<I6>^S/%421DV,&V&.\7,M_J"#,VZ:AJZ2
M!0UF`!^X[?!NZ!@_U^+O`<:*)BN:<T,%@5:,7\G55C.[[)@_F,*]H5<15T_+
M"N=J-%SMJ$YP#188/,\"[YI)MN&&/,*\1'588-H\B[:5$H*^J*9Y:VB^PIU-
M%O#[$`36P=QY%G??X1ZFR]B4NFK!54KUMI/%!<;.L[!;,\'B:MS_75)MF!9[
M<L<E#'X.2;W!-C"(G@7B^%"!5+1\+C"?S<T3S\EQ(<C%40CCZEFXCL^5CB/,
MJV?Q>F*P0*N^B&ZJ,;">!>SPA!B0P;SZ%J]X4-B;EYA5WV*UW_T#`AA;?P#;
MD>;%TWJ)L?4M;$]TW8`?S*__07YQE9<88#A^]<;`.'=@HN5NB0'VK0$[+@0F
M6B$?<P>+#SD"$T<A#)YO`3SN"+KH*-1!SR)X7`BB:84"C"$L>J&-]R9N\@#C
M"(N>T*G>O&&&<GQ77.)A$5A8C^M@C`+,(RQZAH8.$:1Q4Z#\+''I`XOJ$Z-B
M0`=7/K"@'M?!82UQY0,+ZL[0^6F#X/WP]P4=;P(+YD&!3J$[D5@,'PXZ`[ET
M9QU&+&JMF3?L'\^KT"+VI`B.(<1&8-%G8_0`A;,9=LQ8M(Z>H#IE"3&ML.@Y
M&A?"H;GPA_AX^@XM8L=/8YW8\/@,+61/W1B:HJ$6"G%'PZ(7VKA.QQ#NQ=`B
M=UP(YRC$",/B0XX@O>WT#'$SPJ(GA`^<`_T0X4Z$16_W^,$3)\:=X5MF9/$\
M>/0<,H1ICBR:QX^@.,$19A`6$-FT3AH\#8'G"S$\IJE>ZN<<01@U1_7IX4G5
MY?\```#__P,`4$L#!!0`!@`(````(0#KRE?P%@4``)$1```8````>&PO=V]R
M:W-H965T<R]S:&5E=#0N>&ULC%A=CZLV$'VOU/^`>-^`#018)7MU`6U[I5:J
MJGX\LX0D:`-$P'[<?]\Q0[!G8+?W93?Q'(^/SXQG[.R^O-<7Z[7L^JIM]K;8
MN+95-D5[J)K3WO[[K\>[R+;Z(6\.^:5MRKW]O>SM+P\__[1[:[OG_ER6@P4>
MFGYOGX?A>N\X?7$NZ[S?M->R`<NQ[>I\@*_=R>FO79D?QDGUQ9&NNW7JO&IL
M]'#?_8B/]GBLBC)KBY>Z;`9TTI67?`#^_;FZ]C=O=?$C[NJ\>WZYWA5M?047
M3]6E&KZ/3FVK+NZ_G9JVRY\NL.]WX>?%S??X9>&^KHJN[=OCL`%W#A)=[CEV
M8@<\/>P.%>Q`R6YUY7%O?Q7WF?1LYV$W"O1/5;[UQF>K/[=OOW35X;>J*4%M
MB).*P%/;/BOHMX,:@LG.8O;C&($_.NM0'O.7R_!G^_9K69W.`X0[4%.*]@(K
MP5^KKE0.P-;S]_'_6W48SGO;VVZ"T/6$#&SKJ>R'QTK-M:WBI1_:^E\$B<D5
M.I&3$Q]H3G:YD5$@@NW_>W&0T;B3+!_RAUW7OEF0'K!F?\U5LHE[\#QM8>(Q
M;PJT+13ZJX*/DX!N#Z.O#V&X<UY!I&*")`B!')\A@B+2&T()I;QFQH`#O&9R
ML&5.SG-G+LI*N6Q]NE*RA$B*2%<0$85D2TBH(82O1_C>-%.C$'%#D#"F2R0(
M\<=X*T52/I`9`V1)B)DAT6U)-;JW@?@<@\AE2R(D'&,H91![U)X2NW`9X\PT
MAY&>3,A!<J^04Z.,',N0!"$^DMLR:VI:A=!K8S*95L_=SMLBS+:KS-0H8\;R
M)4'(=I(M"EC&I=0NV?3,-`LWTJH2=N$J.S5*\\C0?=Q[@A`CC_A`9@R0)55/
M8G7`#^:CIJQ,&+;Q!"$H3!1+GN(IM6\CK@RQRR#4_@G/>,G3*`G*RG@&<P*@
M1`A!GL*7^B2/YM0TWTDIV+')3'L<1;KX$98">LDG<HYFQE,G*O*<,!/1V!?\
M%%!`*"0#9`S@^OJD4+*J_.K8WVJ(P*I,BHC>[D02,1-)3[@LJNGD!$\RU_(#
M(R6GJN\*.2S*A!P+92(0,Y&3GI2,0$H1KK^H@AE#Q('[05X*5:!7>&+=)CSU
MH9]$1`SRO!.NZVU9,J2C][T]0Z07+J+-O$2^T*E/)56U>X4JEG23:LP$2P1B
M)A[0-G1*X?&A`!$O:5(/0GRDIRKC*R2QNA.23(D$KF"J"B!)X*AEF#B:'4(*
MIG4V3<>4]83.*BJBJN0K_+#`$W[L3"3";`(8;RW"1)%!?"$7-"D$CIY1(2A5
M5?-7J&(K(%19.!-Q:Q?C38]E0TJLS)A]8*3,5-%?88:]@#!C"B7"[!=*1!DS
M2,HA:R)2+Y^)J`J_ICI>E(W&([`O$,HL[Y()$X]WASMW(U@A2#F`)4ZVL.MP
M$5GEY]UG--/N$[/L2B8,GJ'`\WV/D4DI0GA"L.:0$80?Q:&K$93O>@.2V%R@
MKLVWV%A[P-HY88P;SV(D,T?HNA`N(Z:WQB?5,--'5X%I7<1@D;C;LE"GDXO)
MO.C,Q*R%I>14/=<)-Y/#,D\2C>51`F]>M0&\VX\%)F"0E$-\X3-IU<O9]`)G
MPW@$(%5\&>-[LBZ[4YF6ETMO%>U+`R$3D.CS*+[($WB1CZ]:9S;`._F:G\K?
M\^Y4-;UU*8\PU=V$4*0[?%+CEZ&]CH^]IW:`%_+X\0P_?93P6G(W`#ZV[7#[
MHA[M\X\I#_\!``#__P,`4$L#!!0`!@`(````(0#ZJIF<<0(``(@%```9````
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;(R46V^;,!2`WR?M/UA^+P82<E-(
MU:SJ5FF3IFF79\<8L(IM9#M-^^]W;"<T(9/6%\#G\IV+SV%]^R([],R-%5J5
M.$M2C+ABNA*J*?&OGP\W"XRLHZJBG5:\Q*_<XMO-QP_K@S9/MN7<(2`H6^+6
MN7Y%B&4ME]0FNN<*-+4VDCHXFH;8WG!:!2?9D3Q-9T12H7`DK,Q[&+JN!>/W
MFNTE5RY"#.^H@_QM*WI[HDGV'IRDYFG?WS`M>T#L1"?<:X!B)-GJL5':T%T'
M=;]D4\I.['"XPDO!C+:Z=@G@2$STNN8E61(@;=:5@`I\VY'A=8GOLM5VALEF
M'?KS6_"#/?M&MM6'ST947X7BT&RX)G\!.ZV?O.ECY47@3*Z\'\(%?#>HXC7=
M=^Z'/GSAHFD=W';A79CN(!(\D11^!*!R^A+>!U&YML2365+,TTF6%QCMN'4/
MPOMBQ/;6:?DG&F5'5(3D1PB\CY`L3_)%D16S_U-(S"A4<D\=W:R-/B"8#HAI
M>^IG+5L!V9<P2:&3S"OOO#;8@-B"]'E3%.F:/$-3V-%F&VU@I`>;?+`@$&4(
M!?BS4*<07CH*D2X&0$AC&VT6X3+.B9,+XCAYKX5JSA(KBFQ$CC;3*_+T@GS*
MU4M+#-D,I1;%6[$QUVBSC,U:)F\!+WH!U_Z/7GCIF#\991QMIH&?)_-!>X&?
M7>#'C?':<9CI`(IE1)MY"#-YNX\8)6Y$G"/)3<,_\:ZSB.F]@LYDX#1(XR)N
M81'ST.1!`?O1TX9_HZ81RJ*.U^":)G.HS\15B@>G^S`>.^U@,\)G"W\\#N.9
M)F!<:^U.![^LPS]T\Q<``/__`P!02P,$%``&``@````A`-L[O#R0`P``CPH`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#<N>&ULC%9=CYLZ$'VOU/^`>-^`
M^4Z4I&JHMJW42E5U[^TS(4YB+6"$G<WVWW?L(8!-[G9?=L/,\9DSX_'8ZP\O
M=>4\TTXPWFQ<LO!=AS8E/[#FM''__>?Q(7,=(8OF4%2\H1OW-Q7NA^W[=^LK
M[Y[$F5+I`$,C-NY9RG;E>:(\T[H0"][2!CQ'WM6%A,_NY(FVH\5!+ZHK+_#]
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M^X-%D,4D3O[.XJ$BG<FG0A;;=<>O#K0'Q!1MH9J-K$(H8:F,'Y55^T"5`.OS
M-H[CM?<,Q2A[S`XQT,L#)C`1^1U$-D`\$#"H@-PF*AQ5R-`?U"BOJ29(!QXM
M>(>03!=,99!/#$8DJ-XDTBU?9860DUSB.+%"($:WDXZ93PQ&B,@(82>CO!L7
MY`UEBV,[&\2DNO`!5)Z,9</0!B#,$G\$&%*@NR;9VE*4UY8R$F%A$9-H*9%/
MTM"L2C[UAVD4CWY#2/*J$.6UA2S-0#O$H)!EO(RL[<FG_BP,T[%=#2'I7$@4
M#YVFO):0Q+>$(`:%I$ED%2PWW'#$A]6&#'4%S(^=LMKAR4"`&X*8?D,BNW5R
MPYU.Q!OAEW?#*ZL=WCK3.\1@^"S)+'7YU!VE9%QMA"<P:N^DK\VV@+&`F'\/
MZ@M`@BBP$+F!"-,D(:-*4X8Y_.SC07!^&4<UB:SMZ$$HYX%DR:3Q\*S:"#@D
M`X<I1\VL>5,0'&6FC)&BKPJ"7I-A(?Y?AIIKHXQ957#LF7*LP[@C".KE1'=W
MR8"\NDWF0+W-;+C9Y^UJ3](>A*/T_O9,9RD@YG7!^Q]OS9IV)YK3JA).R2\-
MS/``AL=@Q7?'CJS@0H)G@&7/X3VB[=[@@%="6YSH]Z([L48X%3T"I;](8:QV
M^*#`#\E;?0/NN83W@?YYAH<?A:O.7P#XR+F\?:@GR_"4W/X!``#__P,`4$L#
M!!0`!@`(````(0#F.[73[@(``,@'```9````>&PO=V]R:W-H965T<R]S:&5E
M=#0X+GAM;(R576^;,!2&[R?M/R#?%_,12!J%5"6H6Z5-FJ9]7#M@P"I@9#M-
M^^]WC`,!@K3V(@W'KU\_/N?DL'MXJROKE0K)>!,AUW:019N49ZPI(O3[U]/=
M!EE2D28C%6]HA-ZI1`_[SY]V9RY>9$FILL"AD1$JE6JW&,NTI#61-F]I`RLY
M%S51\"@*+%M!2=9MJBOL.4Z(:\(:9!RVXB,>/,]92A.>GFK:*&,B:$44\,N2
MM;)WJ]./V-5$O)S:NY37+5@<6<74>V>*K#K=/A<-%^18P;W?W!5)>^_NX<:^
M9JG@DN?*!CML0&_O?(_O,3CM=QF#&^BT6X+F$7ITM\D&X?VNR\\?1L]R]-V2
M)3]_$2S[QAH*R88RZ0(<.7_1TN=,AV`SOMG]U!7@A[`RFI-3I7[R\U?*BE)!
MM0.])>45G`2?5LUT"\#-R5OW_\PR54;(#^U@[?BN%R#K2*5Z8GHOLM*35+S^
M:T3NQ<J8>!>3%6!>UCW;VP1N$/[?!1NB[B8)462_$_QL07?`F;(ENM?<+3A?
MKG#A&"X%J4VU^E'+(P3]"[@2HJ_[(-SL\"MD*;UHXEN-.U4<>H7.E+9-1@$,
M8`,=W'E$UT/HJ(;HM\<F`"8#E3<[<4$QPTYN)>NK9$+E+U+I*!1V!!&$]U.,
MV&A6`_EA'DA&@<F94)N%3.AHA(!\N#ATU>Q,HUEWQ7+]C:/_II*#D5RQDE%@
M0@'=.J+HNL5WAN;0JW.:6>ECHPD[&C]8I#&2$<TH,*$))S1]=^CHG&+6#K'1
M&(JUNXQA-".,46""L5[$T-$YAC_->VPT!F,5.C"];VMC-".,46""H5\JUU]R
MGPT=G6.L9AA&8SKD;KW`,!;,>@?FJS[`;+ZN&3(S.<V\J:DHZ(%6E;12?FJ@
M83UH@B$Z#.Q'3_\Z9O$8!GDW#?&P`/.U)07]3D3!&FE5-`=+QUY#LP@SBLV#
MXFTWY8Y<P63MOI;PQJ0P=AP;Q#GGJG^`@_'P#M[_`P``__\#`%!+`P04``8`
M"````"$`M$$>7H,"``#[!0``&0```'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6R,5%MOVR`4?I^T_X!XK[%S3Q2G:E-UJ[1)T[3+,\'81C5@`;GTW^\`N3AN
MI/4E,1_G?-^YLKP_R`;MN+%"JQQG28H15TP70E4Y_OWK^6Z&D754%;31BN?X
MC5M\O_K\:;G7YM76G#L$#,KFN':N71!B6<TEM8ENN8*;4AM)'1Q-16QK."V"
MDVS(($TG1%*A<&18F(]PZ+(4C#]IMI5<N4AB>$,=Q&]KT=H3FV0?H9/4O&[;
M.Z9E"Q0;T0CW%D@QDFSQ4BEMZ*:!O`_9B+(3=SB\HY>"&6UUZ1*@(S'0]SG/
MR9P`TVI9",C`EQT97N;X(5NL)YBLEJ$^?P3?V\XWLK7>?S&B^"84AV)#FWP#
M-EJ_>M.7PD/@3-YY/X<&_#"HX"7=-NZGWG_EHJH=='OL79AN0`E^D11^!"!S
M>@C_>U&X.L?#"48;;MVS\#X8L:UU6OZ-E]F1(CH/CLY#".]XGR6CP7@ZRP;C
M_[&0&$G(X(DZNEH:O4<P%:!I6^IG+%L,H7+,@P\>#7<0E05TMQI/QTNR@R*P
MH\UCM($1[MA,KFW6MVRF9QL",9P#@?1N!.+17B#I[$P0@GV,-K-0+!_]N@-<
M24#E;DAX%!K1R6-X"3$J1)/11:$#7"F,;BIX-,<05:=2_22B34<B`O-0_,$X
MN=A?"4+C;Z3DT;[@O%>U:-,1/`&^V\-+(Z_D8%IOR'FT)S=+>W+1)J:3S9)>
MA6$[/46()@K&98NC*KFI^)HWC45,;Q54<0!E.:-QQQ^S!4P"[%P/7\/N!YR<
M+V`E6UKQ[]140EG4\!(HTV0*%3!Q>^/!Z3;,WD8[6,KP6<,CRV'&T@2,2ZW=
MZ>#?A_.SO?H'``#__P,`4$L#!!0`!@`(````(0!/K.B(.@,``!()```9````
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;(Q6;6_:,!#^/FG_(<KWDCB0%Q!0
ME53=)FW2-.WELTD,6$WBR#:E_?<[^T)(3-?U"Y"[)\]S=[X[L[Q]KBOOB4G%
M1;/RR23T/=84HN3-?N7_^OEPD_F>TK0I:24:MO)?F/)OUQ\_+$]"/JH#8]H#
MAD:M_(/6[2((5'%@-543T;(&/#LA:ZKA4>X#U4I&2_M27051&"9!37GC(\-"
MOH=#[':\8/>B.-:LT4@B644UQ*\.O%5GMKIX#UU-Y>.QO2E$W0+%EE=<OUA2
MWZN+Q9=](R3=5I#W,YG1XLQM'Z[H:UY(H<1.3X`NP$"O<YX'\P"8ULN20P:F
M[)YDNY5_1Q8YB?Q@O;0%^LW920U^>^H@3I\D+[_RAD&UX9S,"6R%>#30+Z4Q
MP<O!U=L/]@2^2Z]D.WJL]`]Q^LSX_J#AN&/S2B$J4()/K^:F!R!U^FR_3[S4
MAY4_329Q&DY)%/O>EBG]P,V[OE<<E1;U'P21C@I)HHYD"F%V_F@293&)D_^S
M!!B1S>2>:KI>2G'RH#U`4[74-!M93*&$A3'>&:OU050*K$_K."/+X`F*4728
M#6*@EWM,-$;DKR"R'A)``'T4D-L@"L\4<AKVT1CO.)HH[7ELP!N$9+9@)H-\
M8!@I0?4&2N=\C14D![G,TJDC@9C916)@&$G,1A(VF5G<)V.\*Q_"Z\L69T[A
M-HA);>%)%L_'D>3HMI&,A*&7!KFY531>5]C-$3&)%8Y"$CO"Z+X63MX4-EY7
M>#9FWB`&A4D2S9W`<O1?*Z=O*ANOJ^SDM$',S*8<CJ/*SSZS!(;M:A;X96C<
M0ANOJYJ,F3>(>5WU['-5YV^J&J^KZDX)8K#*61J';K[HOZXR@=4X2/@\-=;L
M:EXF'">S`W5'&Z9)XD25=XA79/^QG'"OC$?(F9$-05#?RM>J0P!)R:46HZ.&
M^V.8NGO6UNV48'ZAZDJ`RPCG^;6Z=RP(@+D;!(O!X!6$B[MF<L]R5E7**\2Q
M@3420?/V5KSZ-F0!.Q$ZR+'G<"5:>]`[X*)JZ9Y]HW+/&^55;`>4X22%89=X
MI^&#%JU=PENAX8JR/P_PWX/!M@TG`-X)H<\/IG7[?S/KOP```/__`P!02P,$
M%``&``@````A`)_)7A8&!```L`P``!D```!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&ULE%==CZ,V%'VOU/^`>!_`A'P0)5EMH-.NU$I5M=L^$^(D:``C[$QF
M_WWOM0%_)#N:G8=).#X^/K[W^N)L/KTUM?=*>UZQ=NN3(/(]VI;L6+7GK?_M
MZ_/3RO>X*-IC4;.6;OWOE/N?=K_^LKFQ_H5?*!4>*+1\ZU^$Z-9AR,L+;0H>
ML(ZV,')B?5,(>.S/(>]Z6ASEI*8.XRA:A$U1M;Y26/<?T6"G4U72G)77AK9"
MB?2T+@3XYY>JXZ-:4WY$KBGZEVOW5+*F`XE#55?BNQ3UO:9<?SFWK"\.->S[
MC21%.6K+ASOYIBI[QME)!"`7*J/W>T[#-`2EW>98P0XP[%Y/3UO_,UGG9.&'
MNXT,T+\5O7'CN\<O[/9[7QW_K%H*T88\808.C+T@]<L1(9@<WLU^EAGXN_>.
M]%1<:_$/N_U!J_-%0+KG.*5D-:P$_[VFPAJ`K1=O\O-6'<5EZ\\6P7P9S4@\
M][T#Y>*YPKF^5UZY8,U_BD0&*242#R+P.8B0^*=%9H,(?&H1DD2+GS"2#!KP
MJ37BU9S,/Z`2JM#(D.:%*':;GMT\J%/8/.\*K'JR!N4AED-`INA"DDMD?T:Z
MG`1QXX"^[N8IV82OD*YRX.P5!TZ;P9G9G&SD8-)0.!^%,?%@;?('87?]S:+)
M#HZZ=F)[J?TC3F)SLD><N<W)[SEZ)<LR)-FP/$8.42A`(RK)THG*7G$267\8
ME<P%<@.PUH34/5@3T:T/QHU,+.QM[14GE;E<+0-GUYD:UI9R`[`<P(DR',A"
M,A*%HZZ3I>-$<?12F0OD"B`SHBHOB)/4_%O]]O2#E"S>-8>CKKF58TYQ$A6F
M.`W(:IE$XY^3QVPD3]5M`%;0EN_ZPE'75^KX4APC:"Z0*T`EF`1QI`O`LH)O
M1]T(QJI%U+:PB"+'@N*HT,P"]VB-HU,L#,`RD#XT@*AKP&TXBF/$P`7R$<"&
M-0MTNBP#!-Y$#T(@8=>"KC/9OO8#R?!PA^03@BY6>A.V"6R$]WD@JC^:1WD1
MZ7T,)A3)-#$B<N-.:O)!5/)M$]CK'IA0+=`VX8CNB2*9)D8$3<11X!RMW)QA
MV\!NIVVX/86H9FC;<?K7?B"9=HP>.KQ[%#+VE540QV9;27_<5PAVPW<<JF9I
M.]3G;\B:T5$EDDG5K:\]YQ,RA%"7GQTP;)#:SGB(X7)T?XC<[CN0]*+9'9)/
M"-J80Q.<.H%M`]O=`QNJ"]K1<(IA#Q=']&K:<!&\7")'M;0XT#M1+M3%4=UR
M&MJ?:4;KFGLEN[;RMK?;3*BZL.[)&BXD>/.8!N`:V15G^E?1GZN6>S4]P=0H
M6$(D>W7C5`^"=?+^<6`"+I#RZP5^&5!X>4<!D$^,B?$!%YA^:^S^!P``__\#
M`%!+`P04``8`"````"$`EMF:/S($```E#@``&0```'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6R,5UV/HS84?:_4_X!XGX#-1T*49+5A->U*K515W>TS(4Z"
M!G"$R63VW_?:EX!MW)E]F0GW'M^/X^N#V7QZ:VKOE76BXNW6)XO0]UA;\F/5
MGK?^MW^>GU:^)_JB/18U;]G6_\&$_VGWZR^;.^]>Q(6QWH,(K=CZE[Z_KH-`
ME!?6%&+!KZP%SXEW3='#8W<.Q+5CQ5$M:NJ`AF$:-$75^AAAW?U,#'XZ527[
MPLM;P]H>@W2L+GJH7URJJWA$:\J?"=<4W<OM^E3RY@HA#E5=]3]44-]KRO77
M<\N[XE!#WV\D+LI';/4P"]]49<<%/_4+"!=@H?.>LR`+(-)N<ZR@`TF[U['3
MUO],UCF-_6"W401]K]A=:+\]<>'WW[KJ^$?5,F`;]DGNP('S%PG]>I0F6!S,
M5C^K'?BK\X[L5-SJ_F]^_YU5YTL/VYW()26O(1/\]9I*S@"T7KRI__?JV%^V
M?I0NDF48$9KXWH&)_KF2:WVOO(F>-_\BB`RA,`@=@D10YN"G"[I*2))^'"7`
MBE0G7XJ^V&TZ?O=@/""GN!9RV,@:(LL6HA"H+*7SL_0J#)@%6%]W24PWP2N0
M4@Z8/6)@ID>,A<@=B-48)(!"QFJ@QW>JD5ZS&KH<XZB"]PA9*>)D![EF,#)!
MKUJF1[_2"@1HO<1I9J5`C!HKE3/7#$:*V)E"6K<^E#72E<21E0(Q2T5XM(R2
MV/3GNI_0*`HG&HP*8+BT)M7FQLFXN=)K5V)EVB,F594\12E=6H#<`*Q(%B=C
MK48IJ5'*@V]IM4N8`N"6(@9+(.$J'.,C^[H[)E#BZ#?R+YWYI=7.GXX!,#]B
MM/W6#$8**>O347JT**T?C11BM!2:P4B1.5-(J]V%/5*(01:S.)W.'[*HNPDA
M&LM&?@(:Z>A1F>T*IIE$'@>0UJ5N,=.8JO2@DJ"0O'\\!Y">!I<IBYE&BL-\
MQPAJQOM'=``AH:#DT]@AH:8_(M-4FR5(\7"4@)IBEF#MV9YHPC,DU2QF&K<6
M$1026#6*T5SO!I!.*"YS$&H*SKAO+J6Q!Q1>G'**AW-.EY$U/[D!B.(LF2@W
M>W5+#7%IC:WM`TCO%9<Y>G4K"D%U^(!234*&G=,L9C=N52&H$.:`S"A%$%*Z
M(F3&J.$/L_\CU*TZ9"X[L]?#?@#IA.*R.:'4K2W*_)&`#B`MC6XQ"*5N;5%F
M6\)L0@=0K%Z']HMH<"+;24;"Z55I%B#E97[DJ32;!="E_2X:0'J?N,Q!I]0"
M1QJ4B/?GDR)(3Z-9S&[<R@+7;KN;^35G`.$]9T8G1D`G35.;3;R5XUVV8=V9
MY:RNA5?R6PMB1F&+1BM^#>S)>D_EQ="RY_(K0=J#T0%W]VMQ9G\6W;EJA5>S
M$X0,%TN0J`ZO^?C0\ZNZCQYX#[=V]?,"GV,,+I[A`L`GSOO'@TPP?N#M_@,`
M`/__`P!02P,$%``&``@````A`$&"11=H`@``/`4``!D```!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&ULC%3+;MLP$+P7Z#\0O$>49,LO6`X2!VD#M$!1]'&F
M*4HB+)("2=O)WW=)VJH?!9J++>X.9V=W1UK>O\H.[;FQ0JL29TF*$5=,5T(U
M)?[YX_ENAI%U5%6TTXJ7^(U;?+_Z^&%YT&9K6\X=`@9E2]PZUR\(L:SEDMI$
M]UQ!IM9&4@='TQ#;&TZK<$EV)$_3"9%4*!P9%N8]'+JN!>-/FNTD5RZ2&-Y1
M!_IM*WI[8I/L/722FNVNOV-:]D"Q$9UP;X$4(\D6+XW2AFXZZ/LU&U-VX@Z'
M&WHIF-%6URX!.A*%WO8\)W,"3*ME):`#/W9D>%WBAVRQ'F.R6H;Y_!+\8,^>
MD6WUX9,1U1>A.`P;UN07L-%ZZZ$OE0_!97)S^SDLX)M!%:_IKG/?]>$S%TWK
M8-N%O\)T!Y7@%TGA+0"=T]?P?Q"5:TL\FB3%-!UE>8'1AEOW+/Q=C-C..BU_
M1U!VI(HD^9%D!#*/^3S)9T563/[/0J*BT,D3=72U-/J`P!U0T_;4>RU;C&""
MS`<??#3D0)6%Z'Y5C-,EV<,PV!'S&#%@Y0&37R+6_T#,!@@!`8,*Z.U,!?*#
M'*6#&I^]5)-/!YX@^#%"9F%@OH/U6>"B$DSOK-*I7Q^%DN>]%-<E(B;8*=1<
MGP4N2HPO2EPWX[,E!GG#V(IQ=M5-Q$S#X//1;#R_S(.G/4?,_UU+%!'=&G<L
MN6GXFG>=14SO%%3,@7.(QI?D,5O`^,"T5_$UO#PA3H8$>+JG#?]*32.411VO
M@3)-IF!B$^T?#T[W85\;[<#-X;&%KQ2'Q:0)@&NMW>G@7[#AN[?Z`P``__\#
M`%!+`P04``8`"````"$`=(-Y?0$#``!!"```&0```'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6R,55MOFS`8?9^T_X#\GG`+D$0)57/I5FF3IFF79P<,6`6,
M;*=I__T^8T+!9%M?DMCG?,?GN\3>W+U4I?5,N*"LWB)W[B"+U`E+:9UOT<\?
M#[,ELH3$=8I+5I,M>B4"W<4?/VPNC#^)@A!I@4(MMJB0LEG;MD@*4F$Q9PVI
M`<D8K["$)<]MT7""TS:H*FW/<4*[PK1&6F'-WZ/!LHPFY,"2<T5JJ44X*;$$
M_Z*@C;BJ5<E[Y"K,G\[-+&%5`Q(G6E+YVHHBJTK6CWG-.#Z5D/>+N\#)5;M=
M3.0KFG`F6";G(&=KH].<5_;*!J5XDU+(0)7=XB3;HGMW?8R0'6_:^ORBY"(&
MORU1L,LG3M,OM"90;&B3:L")L2=%?4S5%@3;D^B'M@'?N)62#)]+^9U=/A.:
M%Q*Z':B0A)5P$GQ:%54C`)GCE_;[0E-9;)$?SH/(\5TO0-:)"/E`52RRDK.0
MK/JM26XGI46\3@0B.A'7FWO+P`W"_ZO8VE&;R0%+'&\XNU@P'7"F:+":-7<-
MRET*G8\^*2AMHMCWBMX&@5T!N\]QX`<;^QFJE'2<G>;`C/<<=\S87QFJ4DKV
M8&X<K^>H\H/3WBX4P;3K.[T[A8[=>='XZ-T-RIBQO\%8CBF'*24R*,<I)?##
M7F:4DS_-:1'T.2D4YF50S45H)J4YBW9<5#WWYL;!W#@.-D9F%E,S@P(K=(L@
MM[ZU2[/[FA*UL^$N/*,N^R$\\SS7Z6NB)V&(KY9+(].CAMM,1[9A=,VY"-_F
M0J%CVX%O*.\T)_R;[R%\R_<0O^%;PU/?X=3WH/<*-7T;!=UICO8]<]W`,2JZ
MUX2WX3B,(GP(,"*.@XA1D:-_FE6H:78U[NY.<[KAB$+?2&8_Q+THFDS'"%^M
M/-/Y$`\"Q_?[\W4B^BK7%V!%>$[VI"R%E;!SW=Z_\:;?U2_(SEW#Y:1NH1Z`
MB[W!.?F*>4YK894D@U!G'D&+N7X#]$*RIKV+3DS"E=[^+."I)O#_=.9`SAB3
MUX4ZH'_\XS\```#__P,`4$L#!!0`!@`(````(0"^<,H*&P0``-T,```8````
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULC)??C^(V$,??*_5_B/(.B4/XL0@X
M+4';GM1*IVOO[CD$!Z)-8AJ;9>^_[XP=.[:)3KL/+)E\/?YX/#,VFT_O31V\
MT8Y7K-V&9!J'`6T+=JK:\S;\]N_+9!4&7.3M*:]92[?A3\K#3[O??]O<6??*
M+Y2*`#RT?!M>A+BNHX@7%]KD?,JNM(4W)>N:7,!C=X[XM:/Y20YJZBB)XT74
MY%4;*@_K[B,^6%E6!3VPXM;05B@G':US`?S\4EVY]M84'W'7Y-WK[3HI6',%
M%\>JKL1/Z30,FF+]^=RR+C_6L.YWDN:%]BT?'MPW5=$QSDHQ!7>1`GU<\U/T
M%(&GW>94P0HP[$%'RVWX3-8'L@RCW48&Z'M%[]SZ'O`+N__15:>_JI9"M&&?
M1'[\A]:T$/0$.Q<&N"-'QEYQZ&<PQ3`)EP*<A/^GIWE.<);(3&-_UU.^R&W[
MT@4G6N:W6GQE]S]I=;X(F&F.PPM6@Q8^@Z;"Q(%XY>\*HSJ)RS:<+:;S93PC
MR3P,CI2+EPK'AD%QXX(U/Y2(]*Z4DZ1W`O_OO9-TNIK/T\5J^7$OL]Y+:KR0
MY*,HD5J6#,TA%_ENT[%[`(D)X/R:8YJ3-3CNX]`OQD0&`EZ@^AGEVQ!*!];,
MP?JVBS?1&P2ZZ!5[I8!/HR"N(M,*##8Z/5B&"+`,&X3+8M,(:$4$/7RO#/:,
MB3?CHV+F*@Z/BM0H'";8A!$FM$)F6(N>F^%RC7NE2`UUYAL.EL&9$79E9$:T
M;D/`-F%>>#,J!7P:Q=)59%JA(WFP#`X"Y.@(`EI=A)4[P5XI4IDG)%XDJ\3?
M&:TP");!05B,(J#517CR$)0"$<K=9$*2R0S2L<3$G1!/FVFM@;$,#LQR%`:M
M+@SQBT-)[#TA?G5HB8&P#`X$GE]#Y>KJ0*L'X<5\KR0.A%<.F988",O@0#R-
M0J#5@QC*2=6#DLQE:J1P8GKO,_5^J)>#97`("!P8(W&09H_!K\E>H_(SB8G/
M8-Z;,-@6EP)[V.-N$-7:[#(E?IWV&F<__$HUFH%$>98!<DFPE8V0J`[GD/CE
M2I1&D1S'NGMF)`.('@06%P0;V@`BCY89'MW]2:+ZG0/D%>2>6#U1CLIZRT+"
M+9,Y2><SXF7OP1[F(L'2+"2#@F8W5Q*_<HG2J-BHDR_Q2]=HAN#H40_!P3XW
M!,>0J/9G!\5OF7NXIB#MKTFT9B"Q+&Y,L,F-D*C>YY!X<=X3W1^'(R9YJ"&M
M&4@LBTN"G6Z$1#5`A^2ADJTFV2>*;\$[*,9M*5-GMEC%\L\<%PI%71[5#:FA
MW9EFM*YY4+!;"\<H@;'&:FZW_;73O(#KXS4_T[_S[ERU/*AI"4/C*=[T.G73
M5`^"7>7]Z\@$7!SEUPO\C*!P)8JG("X9$_H!\\?\,-G]#P``__\#`%!+`P04
M``8`"````"$`DFUW)(<#```P"P``&0```'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6R,5MMNXC`0?5]I_R'*>W.#`$%`59)VM]*NM%KMY=D$`U:3.+)-:?]^
MQS$)\:1+RP.0F3,S9RZQ9W'[4A;.,Q62\6KIAE[@.K3*^995^Z7[^]?#S<QU
MI"+5EA2\HDOWE4KW=O7YT^+$Q9,\4*H<\%#)I7M0JI[[OLP/M"32XS6M0+/C
MHB0*'L7>E[6@9-L8E84?!<'$+PFK7.-A+C[B@^]V+*<9SX\EK91Q(FA!%/"7
M!U;+UEN9?\1=2<33L;[)>5F#BPTKF'IMG+I.F<\?]Q479%-`WB_AF.2M[^9A
MX+YDN>"2[Y0'[GQ#=)ASXB<^>%HMM@PRT&5W!-TMW;MPGH61ZZ\638'^,'J2
MO?^.//#3%\&VWUA%H=K0)]V!#>=/&OJXU2(P]@?6#TT'?@AG2W?D6*B?_/25
MLOU!0;MC;9+S`B+!MU,R/0.0.GEI?D]LJPY+=S3QXFDP"J/8=394J@>F;5TG
M/TK%R[\&%)Y=&2?1V<D8:)[UD1?-XC">O._%-XR:3#*BR&HA^,F!\8"8LB9Z
MV,(Y>-8IC*`0AD>7%-0VU^@[#5^Z,,"`DR!]7HV3T<)_ABKE9\QZB`EM1-HB
M=*6TVZPG\(%8QPYR[K%K26BI)M&:KXT`G'2L(A3Q#<3,AF1#R/0"L5B-WF2E
MI4L7O'0DQLG8CK$VF'''/,6"K">P8D)O>I5H^C2.N[9H+33.BAVCV`;3BXT%
M64]@Q889Q;$G01=;:W'>$Q3;8,)1V(Q,X$T0(,6`&6*?84!OZBRNDZM<M19S
MG2*N!M-R#;WH_@9/DPV9>8G]&=W?H'<BPQ:!_8$8%PLKG^G5?+06YW,9VN;=
M6AL,]+8WEXF=<SK$Q$%@8[+K&(NTON#0H=(;&*VU2<<!.B'6!M,V`5%)KVJS
M_VDMBLF0XO3R/FDMIHB&8&TP'44/U3T=Z%&.V16`136$\QB7L\>U46.REVDR
M0W`&M6PC#V84)90B3.A-!IAL@!G;HY_T3>PL]!F/AJ*?A;D"^L=G'.#C,S2@
M_BS'`3HITH^`LG=`-G-],UQA;BX.FSDZW]:PANB):NN/!_JZ6B\Q;UL;GF9!
M,==Z2<6>IK0HI)/S8P7O?`1G;B?M%J.[9B]"\K5>F/3EY'<*6&-JLJ??B=BS
M2CH%W8'+P(/..<)L/.9!\;I9)C9<P0+3_#W`9DKA=@\\`.\X5^V##G!J=]W5
M/P```/__`P!02P,$%``&``@````A`&_W,_\^`@``#@4``!D```!X;"]W;W)K
M<VAE971S+W-H965T-#`N>&ULC)1-C]HP$(;OE?H?+-\W3B#A2X35HA7M2JVT
MJOIQ-HY#+.(XL@UA_WW'-F0#7+B0V//Z>6?&0Y;/)UFC(]=&J";'211CQ!NF
M"M'L<OSG]^9IAI&QM"EHK1J>XP]N\//JZY=EI_3>5)Q;!(3&Y+BRMET08EC%
M)361:GD#D5)I22TL]8Z85G-:^$.R)J,XGA!)18,#8:$?8:BR%(R_*G:0O+$!
MHGE-+>1O*M&:"TVR1W"2ZOVA?6)*MH#8BEK8#P_%2++%VZY1FFYKJ/N4I)1=
MV'YQAY>":654:2/`D9#H?<US,B=`6BT+`16XMB/-RQR_)(MUALEJZ?OS5_#.
M#-Z1J53W38OBAV@X-!NNR5W`5JF]D[X5;@L.D[O3&W\![QH5O*2'VOY2W7<N
M=I6%V_9^3-7@!+]("C<"4#D]^6<G"EOE>#R)LFD\3D891EMN[$:XLQBQ@[%*
M_@NBQ+GWD-$9`L\S))E$Z2B;SAZ@D)"1K^256KI::M4AF`[P-"UULY8L@.Q*
M2#/H)'/!%Q?U&M@VL'M<9?%T28[0%';6K.\U2:\@X-);`7Y@=;%PN[<6LQ[@
MTUC?:T:]XLIB?&5Q6XV+0NLQ&E0S[T'!*FA2?^_#Y--[\B3N^^2B.88T/\E)
M?$,.FKGO8A)':1^^J@#F8="DVPI<]-;GL]NA@J`!MT$NM^T*(QT&H:4[_I/J
MG6@,JGD)I^)H"A`=!CHLK&K])6V5A?GTKQ5\=S@,21R!N%3*7A;N+]-_R5;_
M`0``__\#`%!+`P04``8`"````"$`.O"'E8P%``!,%@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6R,6%MOHS@4?E]I_P/BO0&;7)HJR6C`ZNY(.])J
MM9=G2IP$%7`$M)GY]^L;Q.>8H2-5;7/.A\_G<_E,O/OTK:Z"=]YVI6CV(5G$
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M]XS9)?%(1GDA&;J!D=()"$1D$XA'"&$^9'.'`+X)X#LD35EER9V$K,@2QD@-
M1C>K3DF&#<PQ@)BR:DZ.AIC*N@\E\[$(LE%03(/9Z#+&T)?-^-BT#Y"2;3U!
M2EDQJ34,G!J,DPAL8(X!Q%Q/QE36CY)O,$Y,;&".`<3<@)AZ?)P&55Z\7]RA
M!K/612#)AJY10C(7D&R6VRU,&#-^31Y04Z<,FNSE:IP=Y<74[DVM6S`UF.5D
M?\SXV.!3VNE.\]9GY"1+>3$CM-?48*89S?C8X,.,B-1\)TG#\&@SXD+1A*06
M-%,Y@)@JG07XM2-*$._%&WD9G01339&XIOK9?>ATLV=AK@64B"BMFPAL)'!>
MPO2S,+!Y[$Z%N1@86,G;/3">)&+4#^R<X%&R(-,>JQ6%@Y+-N]GH]II$Z1VB
MYDP2,7((J>%1LJ#ISIUSLM'IT5(ZB&@YXR1?1#Z>)POZ`:U!:-4QC[J?C4]Z
MM)14WFF-K6L4%&3)'ZE!9O6+A5_`63<C@]NCI"1R@I)13D@)-4U*''DU![-G
M8:X%-K52PHG`1B`_F"9'16U@;&'$L<#`2O#N@;UI,GH(=NY/DP$9?:,Q63VB
M=Y:,N(@MB3?H!8-9@*]O%.JNYN>,E'8C_25XI"S(]"YZ!\WFG&QTXD:A4'9Q
MVK0;T\)'E`496@_>:0[=2+O9Z/68R5HY!1VFBBHS8N1-E07="XF/C`P@5"&1
MLC(+F"@DE.V1UX1<4U2CE!K0_73(/`MS+:##*13E,;`1X_G1TL^"@\JS,-<"
M`\_+KOHJABOBC98%#16A),$O?0"Q)6O\Q899P$1%E`JBT7='RX@D''UOM`8E
M53J,RI;1&2<;G5X#0PWV1FM"BXDW6H,6*UH3HP7<WF@-7H^9$M%[PL9.,MH*
M$N6/E@&-A8PW7K9<A"HDVA2C!C!1R'D-I[Z&T]@KI`&Y(X8MS"[D$Y`O$U.)
MT>:/OE%9D!/8LS#7`D8LF9=A[4:BYXV8!9G*),EV&:.3/0,(0K>$HB%D%C&1
M&:C&^/A*)E39.[XL:/KXFG.RT8D[.8%BC&=,NW'>4#NF%O2CXPNZ\8R-7H_9
MM%K+RSE/++T9LR!S32$K*7_0BSU`Z$JB.5"W@"J04TESJ6>NPFK>GGG&JZH+
M"O'6Z)NXPVZTFLO$5%XFZ@NY:'3(*[YK?N9?\_9<-EU0\9-\-%YLY!'0FMM`
M\Z$75WU-]2)Z>;FG_[W(6ULN;[[BA02?A.B'#RISXSWPX7\```#__P,`4$L#
M!!0`!@`(````(0`?;>9IP`0``/T1```9````>&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;(Q8VX[B.!!]7VG_(<K[D-@!`@@8#1GU[D@[TFJUE^=T,!!U$J,D
MW?3\_99=N;@<0X_4ZH:JDSK'ESJQ>_OYO2R\-U$WN:QV/IN%OB>J3![SZKSS
M__G[Z=/*]YHVK8YI(2NQ\W^(QO^\__67[4W6+\U%B-:#"E6S\R]M>]T$09-=
M1)DV,WD5%61.LB[3%K[6YZ"YUB(]ZH?*(N!AN`S*-*]\K+"I?Z:&/)WR3'R5
MV6LIJA:+U*)(6]#?7/)KTU<KLY\I5Z;UR^OU4R;+*Y1XSHN\_:&+^EZ9;;Z=
M*UFGSP6,^YW-TZROK;],RI=Y5LM&GMH9E`M0Z'3,ZV`=0*7]]IC#"-2T>[4X
M[?PO;)-$H1_LMWJ"_LW%K3$^>\U%WGZK\^,?>25@MF&=U`H\2_FBH-^.*@0/
M!Y.GG_0*_%E[1W%*7XOV+WG[7>3G2PO+O5"/9+(`)OCME;G:`S#T]%W_O>7'
M]K+SH^5L$8<1XPO?>Q9-^Y2K9WTO>VU:6?Z'(-:5PB*\*Q*!S"[/9WRU8(OE
MQU4"5*1'\C5MT_VVEC</M@=P-M=4;3:V@<IJ"#!EH%TEOZBLQD"X@>C;?L'G
MV^`-)B7K,`?$P)X>,)PB$@=B-4`"$#*H@3$^4*.R5`V/ASI:\`$A*SUQ:@2)
M$2!,,%:#J1^OBNY\>&88RX(O+`K$S$<*(T`HYH3"GEJ5A;DF5$N+"C$&E1$@
M5+"+C-'85"IKC\J>.,3$>HU9%/.EI24Q`5$\7Z\'K43)\J$2E;65C%L!EQ`Q
M2ZV$AVS!V<"D`8D)6+,P'H="E,1$2;_"*FHK&(>""A"#"J)H%:]&!E1@`ABT
M8#Q.%I&@C'YLKEZ"BEH2HI".\8"8N9X$*Y>X<X1X[21649O8FMP#8MS$[APA
M9F"BCB'KL$UMV<2A`QG;W8Q0F@]L"QWG<7,Q!)ET1H32*1<9%]+N+X8F0VW#
MVC.'#N2>V3M)*D+YS`,1:$-4A-U;#$$H8K&P5B"YFZ9"J+'UVYJA.5$!=FMU
MH+L">H/3KQI#'Q5`[6X0X/"Y26/!^UDUP9UE<"<I.76X@=QA;9'=7`Q!=\C=
M24KN-C7F<+4HLBRE`YG['1_3$4I#C6NRW]&!/FBOWJ;4<4B_BID1H734KB9T
M#M^:O/B9VYPZ9G>2B.#4N6P1.FTY&+?;JP.YU_=.DHJ@OM9O+H[&]+BU.M`=
M\M[:5&.-+Q1*#O4-@QG(5=@:^:2M.(+PG<GB961-34(`/([9/1'4Y081#G>;
MM!='T`,1)N"1"+?#<8?#1?9QN`,9;69&Z(13'YML.70CT&R<1L>3!IY5U-%?
M^]G09F:$TE'GFM`Y'&S29AQ!W12[SHD$\>"@R*F53=0X+&W:;PA"-3SD86R9
M7J)9=CXBUFS)QQ<2G1OJ>,.V0\OZH/$0A!Q1M(8?:KT)-Q&,K^',.""H#.J$
M@PR'`TY;$$'=TKA:T`0\V/UP_W/Y@`[;/F"_X3I0=X]PB"``EPB\;>,=M13U
M622B*!HODZ\5M`&'$_$0Q5O^@6T.7-W&K'@"MW\=#X8$W,FOZ5E\3^MS7C5>
M(4Y0,IS%T$,U7M_Q2RNO^I[Y+%NXC>N/%_@WBX`+93@#\$G*MO\"Q,'PCYO]
M_P```/__`P!02P,$%``&``@````A`"EW5*H(!@``9QD``!D```!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&ULE)E=;Z,X%(;O5]K_@+B?$$,@:=5T-`D8D':E
MU6H_KBDA"9H`$=#I[+_?8VS`/@=%,[UHFB>O#WZ/OT[<E\_?JYOUK6B[LJGW
M-ENM;:NH\^94UI>]_?=?_-/.MKH^JT_9K:F+O?U?T=F?7W_]Y>6C:;]VUZ+H
M+8A0=WO[VO?W9\?I\FM19=VJN1<U?')NVBKKX6U[<;I[6V2GH5%U<]SU.G"J
MK*QM&>&Y_9$8S?E<YD78Y.]54?<R2%O<LA[ZWUW+>S=&J_(?"5=E[=?W^Z>\
MJ>X0XJV\E?U_0U#;JO+G]%(W;?9V`]_?V2;+Q]C#&Q*^*O.VZ9ISOX)PCNPH
M]?SD/#D0Z?7E5((#D7:K+<Y[^PM[3EW/=EY?A@3]4Q8?G?:WU5V;C[@M3[^5
M=0'9AG$2(_#6-%^%-#T)!(T=TIH/(_!':YV*<_9^Z_]L/I*BO%Q[&&Y?-,F;
M&SP)?EM5*>8`6,^^#Z\?Y:F_[FTO6/G;M<=<W[;>BJ[GI6AK6_E[US?5OU+$
M5"@9Q%5!/.BF^MQ?;5Q_N_N9*!L5)9BCN"MWYS,_^(F^;%44F,EC7]C/]^5)
M18'7,0J8?)P.1Z9V&)(PZ[/7E[;YL&">0_*Z>R96#7N&@&HL5$*GT8%)D@OU
M%R'?V]!_R'L']-MKL'YZ<;[!<.=*<Y`:^#UKV-K4'*G&?_),34B?Q4Q%-"K$
MU!'=XQC$XW-&18)!J@$'<C(E!E*J)6;T+ZCP/\8[2`!!-+.HF\<EC6M:":D&
M*:(%Q<X,PJEDBR0QE00,)3ZA&G\;F(]*J29@FTEC9!)6WD(F!84%;23.GP(,
MPWF0FLV4[2,&(081!AR#&(,$@U0#AA'8!!:,"+JW(1_:#$#9.DB-9@2#$(,(
M`XY!C$&"02K!=EBG&W\]_$PI-JS!?KI@35!L;3L%D&,D-9HU#$(,(@PX!C$&
M"0:I!,%@;1OXZ\"=UXOA#';L!6>"8F=HJ1RD1G.&08A!A`''(,8@P2"50#IC
M#P<-CI,%:X)B:WB+EAK-&@8A!A$&'(,8@T0"Y43./G0.I%H;8]1$K8>.)6\]
MG4+B4V3119$/4J-9Q"#$(,*`8Q!CD$@@+6[\P%QAPP))M3:&13AM-8OC`2,H
MMH;.DX/4:-8P"#&(,.`8Q!@D$C"/#6MLO6(;-83J!?4JU0(8/AD4B)K1H<30
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MA"2*J*6[.*M3O95I5E02#\S*0L,TB[:Z`\/ER9&0D)"($$Y(3$BBR(-AU3IC
M.A5EQ`.GLLHPG:(=\,"T4D2M5DQ"HHD(X83$A"2*/'"J/=IT*JJ)V>ETPL@B
MPW#HX8J(:96(<HA)2#01(9R0F)!$D0<.M4>;#D4=L>!0EA>F0U2"')@4R>7B
M[Q:JL:.2S*LW)"0BA!,2$Y(0DNK$\.@^+HF&CU%)Y.&22(G4CA\$[G:'!ORH
M))I70B)"."$Q(0DAJ4Y,K\LUD;M0$WFX)E(BM?VI+T/FJ794&MTDKILBHN&$
MQ(0DA*0Z,4W"O%R8M*[`>"!Q3:1$LX&C(M*VZRT=YB%I%1'""8D)20A)=6*:
M?%P3P94Q-KM#!_-!:72ON$@*E4;>6K"-*Y:Q.>:1(?GDNDRDR-1P0_.TVVV)
M)":]20@1%^'3:2^S(>^UY25J5;27XEC<;IV5-^\UW`"Y\&UIHM-]^A=7W&$A
M'K)GN+`$[DP?P.WW/;L4OV?MI:P[ZU:<(>1ZM84"HY47Y?)-W]R'J]NWIH=[
M[^'/*_Q#HX`[T/4*Q.>FZ<<WX@'3OTA>_P<``/__`P!02P,$%``&``@````A
M`"5[V(&9`@``1@8``!D```!X;"]W;W)K<VAE971S+W-H965T-3,N>&ULC%5;
M;]HP&'V?M/\0^;UQ+A!:1*@*4;=)FS1-NSP;QTFLQG%DF]+^^WVV(4T`J>4!
MXI/C\YWO8K.Z?Q%M\,R4YK++41Q&*&`=E27OZAS]^?UX<XL";4A7DE9V+$>O
M3*/[]>=/JX-43[IAS`2@T.D<-<;T2XPU;9@@.I0]Z^!-)94@!I:JQKI7C)1N
MDVAQ$D49%H1WR"LLU4<T9%5QR@I)]X)UQHLHUA(#_G7#>WU2$_0C<H*HIWU_
M0Z7H06+'6VY>G2@*!%U^JSNIR*Z%O%_B&:$G;;>XD!><*JEE94*0P][H9<YW
M^`Z#TGI5<LC`ECU0K,K10[PLY@BO5ZX^?SD[Z-%SH!MY^*)X^9UW#(H-;;(-
MV$GY9*G?2@O!9GRQ^]$UX*<*2E:1?6M^R<-7QNO&0+==/"I;B`3?@>!V!"!S
M\N)^#[PT38[2+)POHC1.YBC8,6T>N=V+`KK71HI_GA3;Z(-(<A29@<WC^R1,
M;N?Q/'M?!7M'+I."&+)>*7D(8#H@INZ)G;5X"<K'%(X^AJ2@M-2R'RP]1S"_
M8%<#^KS.TOD*/T.5Z)&SN>3$4\;VQ+#I6=EB!&`P-KB#G$?N3B8L:DV<MF\\
M`"*#J^0LXA7&[9127%(6;Y2)J_2J*XM"8T<FLC2;QMAXSFQPOCT'BA$PB0F]
MN5()B^8(G`^)9^GB+*;G+%RS9FD$GREA^QZA\`3G>N()9O>*)XN>>WHKI.OW
MQG.\I]A:NC`U9MQ=(<"YMF&\1`+WWEC"N_3GUD^[8*IF6]:V.J!RWT&Y$BC(
M@`[7Q4-B>W.&;^`:<6<1#R_@=/>D9C^(JGFG@Y95(!F%"W"E_$7@%T;V[HSM
MI(%S[1X;N*\9#'T4`KF2TIP6$!@/_P#K_P```/__`P!02P,$%``&``@````A
M`(OQ4,J<`@``:08``!D```!X;"]W;W)K<VAE971S+W-H965T-30N>&ULC%5;
M;YLP%'Z?M/]@^;U<`Z112-6LZE9IDZ9IEV?'&+"*,;*=IOWW.[834JB6]06P
MS^?O.S<?UC?/HD-/3&DN^Q+'0801ZZFL>-^4^-?/^ZLE1MJ0OB*=[%F)7YC&
M-YN/']8'J1YURYA!P-#K$K?&#*LPU+1E@NA`#JP'2RV5(`:6J@GUH!BIW"'1
MA4D4Y:$@O,>>8:7>PR'KFE-V)^E>L-YX$L4Z8L!_W?)!G]@$?0^=(.IQ/UQ1
M*0:@V/&.FQ='BI&@JX>FEXKL.HC[.5X0>N)VBS?T@E,EM:Q-`'2A=_1MS-?A
M=0A,FW7%(0*;=J187>+;>+5=XG"S=OGYS=E!O_I&NI6'SXI77WG/(-E0)EN`
MG92/%OI0V2TX'+XY?>\*\%VABM5DWYD?\O"%\:8U4.W,'J&R`R5X(L%M"T#D
MY-F]#[PR;8G3/,B**(V3#*,=T^:>V[,8T;TV4OSQH/A(Y4F2(PF\CR1Q$B3+
M+,[R_[.$WB,7R1TQ9+-6\H"@.T!3#\3V6KP"9AM"&D$FJ37>6JO#P+:&W:=-
MGEZOPR=("CUBMAX#+3UBDA$1@LHH!?07I*QU*I44(X_S9NLAKJ`3XG1"?/+=
M[D(PK_S*TWS&Z#$+5^77KBXFC/.L6&N)P9LQXGP1S9@]IG`YBZ,B&\T3SZ'Z
M%U)BK7.=>"3R.?&8W.O$T=D\T<DOZECK7.=<0Z_C,2>=9#FZ,=$I+NI8ZUPG
M'8F\CL<L7#Q9<?9B(F/GY[^;UEKG,HN9C,?X\J3+XMP77L=?>7]1!%,-^\2Z
M3B,J]SW4/`;OQET_:;8P:1+71J,!!L!`&O:-J(;W&G6LAJ-14$#%E)\5?F'D
MX/I^)PU<???9PDAG</^B`,"UE.:TL--H_$EL_@(``/__`P!02P,$%``&``@`
M```A`!N<+M'0!```3!$``!D```!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL
ME%A;;ZLX$'Y?:?\#XKT!&W.+DAR=7,AUI=7J[.XS)4Z""C@"VO3\^QWC!/!0
MG6W[4)+Y/@\S\XT'D\FW]SPSWGA9I:*8FF1DFP8O$G%,B_/4_/M']!281E7'
MQ3'.1,&GYD]>F=]FO_\VN8GRI;IP7AO@H:BFYJ6NKV/+JI(+S^-J)*Z\`.0D
MRCRNX6MYMJIKR>-CLRC/+&K;GI7':6$J#^/R,S[$Z90F?"F2UYP7M7)2\BRN
M(?[JDEZKA[<\^8R[/"Y?7J]/B<BOX.(YS=+Z9^/4-/)DO#T7HHR?,\C[G;`X
M>?ANO@S<YVE2BDJ<ZA&XLU2@PYQ#*[3`TVQR3"$#67:CY*>I^9V,#X%IS29-
M??Y)^:WJ?3:JB[BMR_1X2`L.Q0:9I`#/0KQ(ZO8H3;#8&JR.&@'^+(TC/\6O
M6?V7N&UX>K[4H+8KER0B@SO!?R-/90M`YO%[<[VEQ_HR-1UOY/JV0ZAK&L^\
MJJ-4KC6-Y+6J1?ZO(I&[*^6$WITX$.8=IR,:N,3UON"%W;W`M?7RZ1`@V"8/
MN+:+OYR'=W?B]YU\.0_80DTH<&U#^70>X7TQ7-O%7\Z#0+\H54&9SLUG,[%4
MCS2]M8SK>#8IQ<V`_0I=4%UCN?O)F(#K>U?=6Z/M,^CV1-*_2WZS"CJH`NO;
MS&?VQ'J#QDWNG+GB0*UZ'*)S%@^.;%_I>(D-*VR(L&&-#1MLV&+#[F'H0D.!
M[1^,1V"'GL&"HK65@V(-*N?8;:$DK!?*8WH-YD,*U1F+(<-GB+,<<M!]5D.&
MSQS]3M&00P.=LAY2?(9NM?F(X^I^MA]Q/)VS&W)0VOL/&"C@PY#B=Q1-2YAR
MO])2PC!%M8;V]8CGBL.:(2H;>H$-2VQ884.$#6MLV&##%AMVV+#'AD//H!4!
MAG2_"(\=+\U3$VK9[F9&D%QSQ?&;>4`)"Y!8BS[.2*B7;ME'/1_Y7O51ZJ.R
M1WV4,()&T;H/4Z=3OYDY&PTEJ)>W?=3QD.=='Z4PAM'JO8Y35)%#'R9VT)5$
MDP0>?1])(LVZ)#Y#N<T5QVLD>7(80X5;:#BS'0?5?:D1J$<(FI0KC>#8S$<Y
M1AJ!>"&6=JT1X'B"^VJC$6C@453EK4YPX4_OK9U&(+;M>"C//6)0QT>)'A`C
M8*2[BR87'#8^DDN:L5R=X$TKSA5'[:`G&CIH/B\TG-DL1'HO-0+U;#R^5QK!
ML0.G2Z()(=((Q&=X0ZPU@D,\%\6PT0@TM`.T:;8ZP0U]I.=.(X!<-$2,/6(P
M0I&@!YU!;-KK7$TN.!/VY6K./KTGN(21;"Y*:*XX2C:$+106JAUHCVQ4K27&
MD1XKC*,\(XRCEEEC'*W?_`^^Q3B*;X=P/-;W"$?3X8#A+GQ-)/GVB@^HS&V/
M61+&(J'].U<<-0K=T/%P3RTT`F%^B$JU1`2/=L$V>V>E$YP0SZ$($5SL88T(
M@Z?D!A%@`^NC;JL3*,,38*<1X)'@($GV&H$XA*"'!KS>RFJK2K(@].V.H$13
M;Z_J#2/GY9DO>)951B)>"S@^4)"MM:J7YCD9PRD=#MO(OH.7Z<9NM0"\XU[C
M,_\C+L]I41D9/X%+>^3#>"[5Z[#Z4HMK<_!^%C6\W38?+_"K!8=#F3T"\DF(
M^O$%;FRUOX/,_@,``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,`
M``!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;
MK4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V
M2$JR&,M+T@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MW
MAOU+&QZ2"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+
M/"$QS$VXB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8
MO,9*Z@&?B8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*
MUM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<
MG@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^
MUI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']
M?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]
MB.(NCD:"8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/C
MA\^.'_YT_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>_
M_/QY.1`R:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E
M)R-QOA7#$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG
M&V'D`/<X9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=
MD#AB[C,<*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I
M!'Z9E^D,KG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.K
ML$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S
M7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([
M-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$
MRI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;
M:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$
M5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WP
MNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<
MR\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO
M^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[
MF8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"
MFZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQ
MO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5
M<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6
M*KM1[ORJF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0
M.)C:`=$"5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\I
MQ&KIWF5)LI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"
MW>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-
MJF=9`<P*6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]
MX*$WU"$_@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^X
MT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4
M%3]F\=%]</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04
M``8`"````"$`YK@K[J`.````EP``#0```'AL+W-T>6QE<RYX;6SL7?MOX\81
M_KU`_P>":8L&J*T794L7R\%99[8'7*]!SD4+-$5!293-'!\*25WL%/W?.[M\
MS8J/79)+4I<DQL42+<Y^,]_,[.PL1=Y\_>S8RB?3#RS/7:F3R[&JF.[6VUGN
MXTK]^X-^L5"5(#3<G6%[KKE27\Q`_?KVM[^Y"<(7V_SP9)JA`B+<8*4^A>'A
MU6@4;)],QP@NO8/IPE_VGN\8(;SU'T?!P3>-74!.<NS1=#R^&CF&Y:J1A%?.
M5D2(8_@?CX>+K><<C-#:6+85OE!9JN)L7[U]=#W?V-@`]7FB&=M$-GV3$^]8
M6]\+O'UX">)&WGYO;<T\RN5H.0))MS?NT=&=,%"VWM$-5^HT/:1$?WF[6ZE7
MJA*IO/9V`.(//QR]\*O?1;^^^-,77XS_\^57__K6W/W[NS_F__;=E^HH&0;)
M!`ZJ95Z.*\7"GR/)HUB#VYN]YR)%%J`).7)[$_RD?#)L\(0)0;+U;,]70B`4
M5*%'7,,QHT^L#=O:^!;YV-YP+/LE.CPE!Z@/Q)]S+&"$'!Q%(_0[SH:@271:
M$!B,3C-R!.OD@$H&.5BMD_%]@4[,6'/^6&WLQXQ%M:C62]I8>;_(V;#-6"E7
M:!S_<;-2=1W2Q60\)F;%A'4TV'(]AO%Z&^QJWIMF,WVF7TO5C/'%/&]DP)DN
MTY2<`?77UV]Z,Z?\P<JTB]-P7Q%``DZN%2T(W8KXOM;)3Q]^TO.$U@UC5"J3
M]&GH9;GQP7+,0'EO_JA\ZSF&2PR+)S7ZZ>(YF2OZK?MD^E9(1#(2&-=M+(7Q
MD\924D]#$M*9)._:92HE8I9$V2ISEPG`-FDL)$%!\W83%(F`B9@U:OL.T?((
M_XK&*0ZWO+VH*P7@I99MIT7V3".U*1RYO8%Z/S1]5X<W2OSZX>4`E:D+2Q-"
MSRCZ'.?3C[[Q,IG2^DSLA,"SK1U!\;BF]7#L1>NK>WU]3\=%R$11E`C5]?5U
M!T+O[Y9K^4C72^K0(XGJ3W7XD8ST]9S\2!:JPW]K:3:-0T23!3*5IX066:J.
M+Z^7R^5B<K58+);:;*)IU,B;V*,M=V<^FV3U*LU,>01S0+"<+9974P`RUA9T
MJ%X1S`#`]7R^F$^64PW^T2FP>P2R;3I7AV85(1B(581@(%;I5"PC]<61`HVC
M@6,5(1B(581@(%:O)6?@Z\%910@&8A4A&(A5VOB3&*O0D!TX5A&"@5A%"`9B
M55KQ&6?@Y>"L(@0#L8H0],UJLJQ:W]_KM`V4K\S*ZV.ZDH.UX\;S=[";E6S1
M3.:P;HN.W=[8YCZ$5:)O/3Z1WZ%W@/]OO#"$O9_;FYUE/'JN8</+47)&\KOB
M3-@=@XVPE1H^6=N/,!BS.(_P1D-T-4*:B312X6O7VOA:FT^OHD64I*$=<V<=
MG;QVZ=B%O@)F)+;E*XYLZ*:#Q.Z0=05'A(68/L$S*-64:<$3P"<2EQ`\0X:.
M68=<5$=TAIB.Z`1!'=$9HCI"Z!0%5V+)G7>$C=E3@G5],1Y'S4C1<:H%(N`%
M'E,,`IV3MR?WE`*+<L^IJRODEUQLW$W)#ZU8"S3EG)'7DW-"@9:<,T1U9/TF
M89<1GK832'HN0')B;^;CS6#`0-&)"9Z3)!CG)]))CK9)A--=L;I<\4AKD%!O
MNA+6`0TB?(XD^YY0*-N^7/%(]1+[QG4!E!E;T[8_D(G_G_NTUH"6VNW-\QY=
MMP$7TY"K'<AE(>0E]*WCEU%=$;V!L<I.FI:>I!B'@_WR_NAL3%^G5]C0(>A1
MTA_/WMW1@BA[_]JV'EW'I$U!-1+SC>^%YC:D5P#1[8$R/+,2/)-8D`B>-N-K
M)>.#G83MT69\:#H5D@AV&71\<"[A\67Z`[G6*79JH``[=14>F0B@M9`@`!*&
M0$"NS8IM`.XY!`)8LB4(P$$S!`"GPBO:Q`%L(J9#@@]D0\+X70T).2;1DAFR
M0RW+TB^,7Z&ESJ3?5F9&^18</3,SO*D`T&K(LA0[5(I!M$.D92:`-Q4FT&'6
ME3/E00,A]3NP009@,(.@I,L`@C1091%Y7HER+HPI:I$[B74(<@J2BH:&`'`&
M@8"(F`PT_TXPAH%F8.P-`TW!&`(S!U=G":DQ@9E@9LB!,`">0:(BR]<39L;H
MT0P(PE`9$GG#=*@4B3$,E2,S*J9#I4@$8:@,B9D8*D5B#$/E2$3%4"D200"+
M#)(A,1-#I4B,8:@<F5$Q&RI%(@A#94C$Q*SC%#G";=.HB8KZIQ,8OKP7"@PE
MZ_]3LI[WW$[JI&S5!+*2TZ/E4[1T!#+H8@JMI2<`SDB:I\J3YUL_P2J3?%=N
M"]U4TU?)URA#:XN/_.@;AP?S&=:BT0;7\[Z5@AQ,V?C0RE:5.H-+MT\++`),
M<PS!U9RNZKF=^1//8+O;7`_A@B#=G:$QD+`8&@/A.\8@W0TEA2G,D@E$8>^4
M[2[(3*2BYR7#6MF,ZZMH\`E,UU('QQQ]?PQ":_]2,WEUB8ALK->#(TQ.Z>32
M(GG"->W=L5/?%M*=I9:GDK"-]V:`%*;6;C3IUQJ\>Z>L<!.%?*,CND<!["^/
MJNH.Z13A>(X\I@(H#]T4[8%(X3"/K@ZKT[+]$=*'KO*II-7'+1LPOJ2PK(,0
MTSD[[3=4(=3I#D$M?,W8)8&1S/<H2#A@BZ=3'021XCJ>[>JKD)BXA8MV;7$N
M^W0[]E>+P@4Q#7SX,W``G!+H57MXJ2FVU"N)N>J,*A)RI34,!MW4QF6.?>:P
M`5Y1@JM&S6:R3LW:%[Z&OMHEO#9I?LAJ\G,I@X"[JAJCEEMSYSWD*)]770;`
M?TF+$5Z-CPLHQC1P$[)*=VI45#<K6I&O8;B<HI5-Z@VJD[,'VR:ABA?_C>Q8
M)W]@3AD7A#>-$EH+NQ!7$^I:E&;3.IK_VDND%PHF!=O/O7^&R_(HN=1Q%APF
M_:2^<T47U[9-X4G),9C+EGCZ)S/M4-+;1PIW*%F@O`*!G7%;E`MU>"ZO16%[
MO6HR:80O65O70EC65.79LQ'"7TZ:F8!=JPCNSQT)P6?3$13-34*@\S86:5-)
ML+RH%J1\XYH^KT55B2L<=G620)]S^>=@.XFS*3.[3V#+J"HI").+`;;+J=W@
M.U?GR]LJK3VB[\X/O#N*[<9#5I(B&4+A#>MO(@FR="V)O4XTC$50YC=,16`V
M"A91V&"XHLS-&#</FTW<P@`QZXT;9#FJ63!22>W5.DV\;C"`^013AU!V1<-A
ME*UCA/C-HTN3S,]CZ562;5B[YE<V(NF&-;=P;$OT7IX6;,`WQ-LT%_4"3J(Q
M(;@V]&NHY'IQ7@G>B.U\L!6F@A*79?'EZD81CVV$6G2"%((-'ZI??G0*6VAB
MR,%F(TL88--8XG#?$,UG%3RB;HCX['1?_/Q;:XT0$O,)[2^Q/M>PV"C,?YC!
MTBLJN]C\;6*P\D8);S'0<#K&02LXH2"##@JW00CWCI>;H4NFN9-J!TQ>?YZ3
MX!$M30RP-UD-U$6,M7/9[O&=I0&;.B7'7(.7C(!O7]`-9V##&S:2I$P\Z2J7
M_]7+WE-05QF>8TDV^S2<T!O:E6&<-W$*5]MG8<@NT0K-13G:1<*>=89&.K3,
MI.R$FE."S0(-X7+S*@Q[I@FJA'HFD')&$V%^"*ZK4;-4"^-K2FX+Q^LA:<J^
MSASGR";KGVF7]TZ06"SF8H'U*B'FA.U#OZE>4-AP7$LD/-E,UP_LZO`402T7
M)^`IRLH<Z[*$=VG'$GS59F3A"1DL'QYI^=5F\P9P5E7<#2Q7`31Z"(;H)CM+
M,:])SR(5GCAP2LPCY[6L*I8+G"ZR!+@M:Z[S]=`^D?%=$IX/VEV75/PN%WB:
M*;^N-!?.(@F[4;`(SX\`*4G@G5Y2+VY*A*@\@'.69'-VC_%;4OV?I,=&>X0]
M:B%D=-X5<@WQUED=E.XC==*I:!1%Q"&ZVK9I'47`\R;M*G."J&WA`Y3P9N@I
MNJE=#]`*X8BE[MQ7`LXK=9^!'5$*D?Y=M09U($D(R<Q&7@J%9#&II8%0E+GH
MO1/A;HGHV3/LDV?2>RLJKN'``^FFX]\K%\KK+4DVZ38/F?DV1\N&IU>2:V#(
M?2^W<,LMS[F+#L8W*JR2E7HLR9E8%LQ%=66EY3()6"P+>B!U9:53X0RT1;+@
ML3RU94'Q%ZV/9N1.M9F]-&B%U,4%I\2R6-O/!6VO%?%([^F<X2(JB^#"LC(>
MP7)(1Z)R75D9CT`<E@4JUY65\0@(D2P-!JDK*^,16,"RP-WJRDIYU(`X)&LN
M:/NK0AY97R4W8!7!A65E/+*^.A/T52PKXY'U5:)R75P9CR`5V4N#/]25E?'(
MY@E-,$]@'3,>6=O/!6U_FE%9CY\*>GPD)>,.7B$;D2I?Q$:1E(PUULMG@EX>
M2<GX8OU;$_3O2$K&%,A#&FGP!W&-4HYFK'4U0>O>&;LDZ[(.0^89$1AKP]X>
M;8,\$RT11*X@1@J1V\D+27HRMQ^5-3PO+A7$Q@.91D4$W3\?;,,U0L]_4<@]
MA5-Q+.ES07%_]KS41JP$TN\7`?07T]A9[J,"=HDF.-:'2?U;1TP:"ZQYR!-&
MZHB!LR,TK/^19T'4$0-G1V+8I$KJ)Q$Q;]W#,66(S:5DZA81\<YR/YH[UG-8
M"Y.&D(BD]^8Q](W4_]B0F@H:YCUYRF`J@TT1=$%V6C.^AX<*)D8D]UM&L4-J
M:!'@?SN&R(SD+"2$M)5$A#Q8(3QT-F:3C6$"2TB$!_?Y3D6<9!1!&?\P?)=$
M"Q.Z)SY:HE%VVW2H_G?/V1,GJ=U#`QZJ2Y]%F:X'P%`[<V\<[?`A_>-*S5[_
ME3[.&9PI_M0WUB<OI")6:O;Z'7E.-D0QK&XAW;P+X-G+\%LY^M9*_>_]W?7R
MS;T^O5B,[Q87VLR<7RSG=V\NYMKZ[LT;?3F>CM?_`Y,YMAN\>IYH*_4I#`^O
M1J-@^V0Z1G#I6%O?"[Q]>+F%QV][^[VU-4?!P8>D$CR99NC8H^EXO!PM1XY!
MGWP+0EX%-GS*CY6-P7_(CJU4]":"3UL%`!MN@IHH,0K(@SL_D$%N_P\``/__
M`P!02P,$%``&``@````A`#K([\II?```!@L"`!0```!X;"]S:&%R9613=')I
M;F=S+GAM;.R=VVX<5Y:F[P>8=P@(\HP,D#1/.E79:M"TY5*U+`LB536%PEPD
M,X-DMI*961F9EEA7]0XS-P7,`,8\BA^EGF2^?ZV]=^R(C"23+9&NKJ[N1EO,
MB-C'=?C78:_]Y;]\N!@5/Y:S:C@9?W5O9VO[7E&.^Y/!<'SVU;VWQ\\WG]PK
MJGEO/.B-)N/RJWN7977O7Y[]U__R957-"[X=5U_=.Y_/I[_ZXHNJ?UY>]*JM
MR;0<\^1T,KOHS?ES=O9%-9V5O4%U7I;SB]$7N]O;C[ZXZ`W']XK^9#&>T^_C
MQX_N%8OQ\$^+\M!_>OQP]]ZS+ZOALR_GS[Z9]!<7Y7A>,([BV_%\.+\L7HR]
M`\9=I.</WAY]4]S__,LOYL^^_$+?^O<[N\7WD_'\O.+C03EH/_ZF[&\5>SL;
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M)0'SW60R>#\<C=H#_T&DPMJCJ<Z&K&?A>][]6O<SGWOWLR@H1\/>R7`TG`_+
M97)*NSKM76I+VWWS?+:`0+(VVJ_$;HPI63)6:%">E@CI`:OR8SE>++7:\0F*
M^LRI=5">+#%G<XNO&,PWK9[3#D?R"*-L3^+EE=VG5N>]#U<MA6]H/94K!NHS
MNN*%0\3QT)G6**T/%H!KP3GL8WOX/__T\T_MW[Z%RN>72P($-@N;4[FDO[^U
MO5-,4:((DD7YZ^+AQO;V=E&Y_.\MYLB1X9_+P:^+\23^.I1\AS'$H*L5A&8`
M/=3=-/MYNKV]JJ?'NP\W'NWO6`</=_8W]O:?-KN^FM\.!@.H?3)&*DBB;`['
M1;\W'2(EVFL$>6=\?SKL#Y=(+W\E2*/)!1+B'"$%MQ=G0,+BP6A259^W6S\&
M/U8+U%I8@MX<Z%@A=78V=I_X[)[L[(>973TE)Q<)KOF2>%DB)5NW[G<;BJUX
MC8X'89;S(4AJ3357?NB7TWD!`'&,4*`Q>S?1?F\ZU4Y[[0ZB2C%],9@L3N:G
MBU'16]9"2U\V]I2=6B7+-XIIIU9H-[C$,8E9"G2*;]^UWRSQT[I?.*^M^_;:
M[+C&')K\>^T$VM3N'[0''AHUE+GB6>"6T&'W_!MH33"P-'@CY4,/&7N^A#%7
MX;?<A-IM#^:-JZYEE7DX&8UZ)Q/L!;%_[VQ6>M_M!HX6)U5_-IPF'`'T%+`I
M3LME`>X\'-3EDGC_`3JC.S!;!$=+8AVNPA#J.S8<,/;1)$"<&O#9PFZ>]"ID
M=Y]58C0UJ-G?V-[%)KR/M'W\R"3(_;V-1X_WKI9++\9]";FR>#`H_5^?`VB*
MT]XPZ!/MR-'EQ?1\,L;\18EA_XVQ7*<+!JL/HPI<$FO?E6-F#<L+@@TNAF,S
M-K7H.8B]<DY[&]N/L)"9R/;^0Y_3[L:3W=UKYG2!UIB9N22Q7J##3A;#D3#S
MTL[XO@E;-O>G30Q&AJ>SR441WL7::+_S8@Q:1SC&35[YW/1NP([LH^/P]ML-
M#A%.M[F<E,#OL@#'+-,@^T)C>E:<L/:GR[JPL\WU.I:DI'D#!((6&P5TB"VF
MN0R&HP562+NA(X<@"Y&K5#@4NS`F@(IJ4RU-[=_1@^,U-=RISY>8[.T88A\)
M#>5J7P22&5#M:1PVFM<NM-^X5GZU]73S[\]7R3<3LEW\'J2([(V)M"/S>3^<
MGQ=07Z<06461-^X`^+J"IU=UT2"YYD)9[^>3T0!'X'\O'.ZN6HH7#5,]8!@C
M,,,O[1TQMF[_F,'*UX*5M'EX/:S$=K@.5CH9-NGD.X.5$ANK8:4M0'N4`>%M
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MPVHZP7\HV;&>_7;0\M_)P53(K##Y)(M\22,W'#ZKP-`Y;CMD&-`D6Q%W=`K5
M1&#;Y79[$''SYPC#@*!I9PWK=L67`)A_G_-T17ONZ>C>B3CV%N9/@P^N1(-V
MWDZV%$M;WVU`#**3:H4'4=+F6J)L]]5F&`=M,JNN(.370?Z9LEJ/X'`V]\MR
M4!7&EC<GV$:75R#+[XE^S(S-Q0Q7O)A6B_'_.!P`]TXNBP>!GV6P*3[07(?K
MUNYT.(9]FM\LX>7F0B26:VF2AAYJ]]MLPE@7VWLV>2^4<.67J*[>I5EQ]-?Z
ML-V+(["N.;7?O&8IUVUBV$WV1M(2'O8/N?#0.X"-)0%EI-SUHC3@"8'9\5A[
MP\PO0?3M25SY-:'"5=\=+:;3D7D[D+_0=1]K9H$YJ0V5NI(R@II2C'N)(*QC
M$U2*`A'Y,(.W/;PKNAFCK=131K(,MVO5E_O.4:A[E6B&4-1\6)U*`*!<F$C#
M62$CM<2)'.B(Z.&9>4S:(_YA=M8;QQ"1MN4']PAT6/E7O%K\\>!$`?7^_'^V
M.WA9?ABBH8O7V,07O7Z)(2R7;7"F//C;7_Y/>.-O?_F_!4N+=Z#@1]D4O?$E
M/\+E1-2P!4:]]YC?J/L9H1!W_T",X2\D`YW\=C&Z_/FGQ_BIGSY]N%7$OM_W
MD($^4=X3CH<")J1A6&^GB[&MH<?MIHUQ%@R7`-2EUE<FH+^#_.'+"?]?OQ6Q
M@=0LBE,;I*G$GCQ^E[FWU&*K+V3<8-$G4"D2T\=SC'8+I.CE\\5%ST"$O%9;
MJY89SU0@*F8ZI*W::^-"G27#"RZ2F<Z&%[W9<'1)7[/)XNS<@INF+8+=(WI`
M/S>C+FRF[;1IR0L`6#4G=!Y)K=+R#N?$E&5W#&:+LRN6H%\[)*&W#1PXLS/4
M(Y)#T6S&N&$VKI%RU79*SLO^^7@RFIQ=`EC</UF[-#>*,^WOV*3HF3(]?.?B
MX/VOFOO"<(6O-.F1>09[,SX\<Q_I%@'STCRT1I5_9947Z#!BY0N2,/"U0:3$
M7Q%!"+UB,65]V:Y+_(G]^63&W%AWCU[C/UK,"4GAUQH2)S."Y+$&:,%.MB,C
M4(TF4,U'D,M&P2X1)1TB@,;E>W@H>8(9J,VX8PE[_?,A_M@B;7(5MI4YXZY-
M_N.-8G(RE]6OADH)T;[H82[Q;[\YEH*\(;G2TB5FP[-S'O*-)AZ9!+[9D,T]
MA2;-K7-:0D4]]Z0R@7D)[#]3M!O:X%7UI\0FZ[Q:G,I?H>4/,3,M)+SI?%`#
MI2W%'`\8&8U5B]%<S"5NZS%PVVP:9U?"SEDG>CQ#`&FWD!;$X]6K#9='$DJP
MYDFI0"/(<P'9L`*AV23)EFAFB8F/%A=PI`F;(_P,I&#0[KP@D*<$!JG%UR1Z
M=(51U_]RI:B>*?7K:UR;)@%>RZ/&PFJE@T+B!?W?:_Y?]6<Q*8EDV_>^>/8E
MU.0"ZX*,M1W],GN.D/!77HQ9H.%<OWYAWUH>VZ^J*;K@JWM3=3/[L;SWS/A+
M2-SDON;:L.L"JT(+1@<>,W&>DBQF]V)\C66/<E_T(?IZCZ]M=+E)I@_[)T$R
M'`R1?&6UA4L$31XZ1=[B%7&%ZH1[XMDT_,$>E^+7L=$`=%N/CA7:*EP>LS0I
M#XY_SY^]14<PH&\!J63GI30&K>,M+R4K2Z3,U20C6+%^F@9DCQP*'/=VJSC:
M,K4&W\&&+"OJ@F4+ZZN-@8L!T.`II=2`]-A#";N>BTIQW47O'>L5)VTL)+ZX
M,,6#BC@'Z_5.3TD[L;UCJ"2JJ),+S]1AP&[!V:>9$69_2UQD^"VF%]!DIPTK
M8"D*0:4DINQ<#I&+<_KR<&*`RP808UG%`"N&!=%'P"82YK9@UOD"*G714K&^
M"S*'!D,F.W,%[,`A+4X0`DN4(\"Y@9L6B2WO74#3UKTG2!TK0>I%G2!U-UP:
M64ODCSTV@S5&H^(<<0Z#C4@H)0\JL^=<C).'`:YG5>"!S.X#=I1H%_:/5%$D
MB&6A03T(4H/*F14193:$D3CM*@Z:G9U\=>_Y<_)!^)]K)=(S',WEQ4DY^_FG
M9E[J+?.I".XVID-B;?`'?JH)/).+MBLMS^0@\4U)N;=;B`YA5DL=`<R0F:$I
M2E^:+D,`ZCUPTJ0:SAU2K7CH(K<_@J4M$Q'>+GH_]H8$L$?E)B)K4YEX157V
M(T&I)[,/@&VD+HKKZV"N!>WX$;3SI\5$H@9%^PZLB2P+R7]BXKHY([AC?@KJ
MN_AQ6.+0-)AV]3"R<1J0E[$@?1$R`3,\#I;IS0:>>^D0Q'2;QF9L<MD066%L
MES:R5CS/UUD1.JTPIJ$`6CT96Y=:R/(V#TT[R)RZ`*P*-;$S0/G^NQ"8^MM?
M_FKYAG/O4>Z#1@PQ[U/P%CV*4`L"6KX:<DNMXZ"E)1?JU_B1D&U:9?DR;0#U
M?A(HY9/*#%G;.-L@STSM%VH_$!7ZM[@H$:N#5;+T#0,+^:(F4$4J=RTY!3JC
M\&1607&:-9H@K!8PC-,$(#(QEZ6(1@/NK+3%<@6%Q@,<8J-RSF_&6[AD22%+
M%J0;,BR0"'<B@`Q28O8A#X2<<N'<D&.I#?H-]/F>Q.B-XA5VPF]IM<3A5B&G
M7\$V/_^TL_OY/V7Q353+IY?%.@>RC)\M,Z1!/=KGG'S>RU"Y#75S?WMK7T;B
M"$Y<JWTX^:-,!<ULK8YN"`-N;R+H3Y@[Y5FO$E0'T8AYDU+5/S&L>Y;+(<70
M9DAI[)Y!9D'Q<\B3ET20V!WK<!&9ZI,%\D!R^F11#?&&28ZY58QL,ODLI<SS
MY,I"A,G`DY(UN?'S3\>TE]+N5^1(SK$?Y!TPB>=`TRT94VS),J\`GJ@L1":#
M>X^566XBXRH<2?2A^.#D@D2=/G:;H+^HQCT1L0&S0QRA!VM$\E7)\.Z)L1'_
M/K5KVJP$B2_,"$2J]@142\4D_+^RGE?M[2$.8'16;9(=NJA^,ZS>?>)-[I80
MT2Q&L6.7R+#(`+8T>#IK84N5#.J,',`0D+'`PA1M@`(VHLCFE>N@&1-SC!<Q
M5`\UA0UH/D*EQ5V0D'1E2VI"--@>K0TP'S`[,!VAR##&\I_Y5*;)YI\PR63B
MUF;?<(RJ79@;H3%&6YRNJ0M:+DB"!,<)7$)+[HR.D^='>FMY=/7:R9"E2JY*
MP2T<[E#W:-(W,N(KD>O;L?D"C^3E<E81H\25DUMWC,M0EB?HEDXU!O*S,S=1
M4/T!!<(Z,GB-A%^,[:P=OK4%['(AJ$"OS]U-I3$N#0"^#CM-1T_W/[,)/_I,
MK!TLX99``T^ICSU[D7^0J=CH[.H>=K:WO0O[Q\I.S'%G:4$M:VT#R)S\#R<X
M:G!;!C>#.FZN8G/1<JY<HMZD9)I>G:/RS!S+V4E#FW?NM#N,2WVGO!W<_28\
M,00035%05S[F#9QA0XR#VOE_JE-[?(`XTUI%7ZQY(?5#C&XXWF\1>&=X1%_)
MZF$??^$H2:%49D"R!)6<6;@J;%"))(S=DV_GO(>W^Z0L";/`93]"^AX';T4Q
M`#IR\$K/M`,6#M`]QQH/2<+A>>`'AI.T+2KEK$IOT!#4.[H,KE<MW_2<OQ3<
M,-56FJO,J#,$H4:RMDSB<("Q_X[D>0!8G]S43-2$J`BMY[$3$[[F=.?T@R(K
M/%\G5B+!A7-.V2$G,SFI97^;`S7(EA=3%$,(\Q5'!T=+(J1FZ_39WL:MX+CO
M^Z^4QOT]II"0P0MD_7!.HNZ&DO,23U_E/V(/_BX1ZG$/5*.#H`13V;@7)*3?
MR7QR=;!6AS=$W@\??[96LW^O^[*W=S?CSWBH6P&C=]=:R!ON3X/NUNK@[W6G
MR".8$ZFX&T/UMMGFT9.[(3MAQ+5V_89DM?OP;L:_FFT$*?6_:79-I$<2%X`[
MG+Y6',:.)MT-I&OT+5/-^G:SH_9QF^=4^Y-.?X,+!/H\+*6L',7:B<V`!MU-
M6J34%_R-9AOKBU*G%$?#TX#;L)<]FN9XT3(AP#,Z".1Q&PR,_6U+TG)SY?N>
M?,#*K4//0OAH8(>,6'IX`?@%`\WBZ^X6[I-H<\98::<^U0$N,D?YP.R6ETK#
MD#NZ&'+0A5%[V%>&5SC:SO=I,A:@(,H6$-Z*N7EF#8%^AJM%<@\I<.K"NLPA
M/$=,R_<Z7JKE/3$?:SV`D&.@(S6U"FX23S,YV`YJOS14>6`K^XFIZ)G(V#H9
M62=9,%0Q%J:;G.:*H;#2K=/[VHF3TDL=:,:0A!NYX&."'_Q!V$4[$<^8O><D
M<:'#AO(M<TBJ3BON#V<<3Q;R!B;3DW`8'ACSMPC>]J'?2ZV^!WRU99Y3XB1W
MT;LT:Y?1R$5%(H]&K&`]V;5L&TWY')?G8+0QJO!&L?\:/VDV4-&</1SC!,`(
M:$YBB\0R;;X"^PHDF*0(77KF5QZ"Z#'?P#)Z$SBL1+(%=,_B>#Z0N2H\MQU7
M">DEFF9@F\PL"NQEI"4T;LNHP#$M6G1,607:4>QJK9@]]P6TE<JZT93'P3=@
M-3%\'[-\&'X(ZVAM=:R^NG""<>=9)!Z:EE\-OBX&*I1"2[P*MH[+P+P%M>44
M:U@#,=1!OW4,3Q--!Q(MHN?[W:BNX6D]&N]LH`V$;&N2DW-#*W]_9V]K)_J<
MZ_A$\6BC<.8J?A,K=AQAIX232%DT=$@^RD=EL3Q;Q?6Q9D91L_\GYO1N]YZ(
M)?4-T8HDDI3TI#-^79,M8LX$4ELE1"!AJD6)E3B>:V1Y#,'D;I5!X")V+'%Y
MZV/USE=237(2>YXI+0?/A'D>V%]:D*B"5&+(M/;:(5'">6F$04T5H65,(R^?
MX$,@\90#$O@[(%YUW$'V9Z&^"1K(\][5+>2&`RDG[#3C4W3:G+!;.=48U6A&
MFV@HI!W?FXF=%L1>JYE$U*L/6XLC@<O/?EA4',UJ.[/5XS8FD^L@UL&)PW=!
MX>UF/<5)-28?&B%3[70QX\F,S!Z3?`P[!24U&M[()F>,9Z_T)V2F2>N)X+*3
MA=G+DAY5Y;I2LAPYSFXKSXAEE=N<_56\>'AA9VE9,A][)"C\FR94`1!KJ!>C
MM_>69]/0-#@%=6)X-'Q'91L6EU[A"9=OB19L.;0G<2T+N5K-!^03"A,]MC0_
M)1(WUR7_$I)(,/(JY\)-07(JDY;)KX^27=T"Y'8LQ[N*?PJ!W-+JAZ-[GVKU
M5VJ.-R+V15F\0??!8W>7>ADZ=EPNS>L<[J(3SN7`F56,`0>2=D$*`50/-V7Y
MT0A0"5ORM7&^@]<NC8TF%#2Q:DKL38P"\B`Z6<'7`[DQG24M$T?"\W3X06*"
M[/&(S`17)9*:T3F]JV0CRN6<R+FKQ-O`K8D0$B"?/SNL<YX90)V]3!NV[,*I
M$JQX@(D2(C:(UN'$#D]#_R'U74$PJUD1GEK:7SBX*%2(5+5,C8YB&ZT@(C(^
M3A.9;V+PDCZG(<S6*RCN-5>N)>FG9O[4`XKYUXWX5<+X%O_`G>_[(?R<)NAG
MYH,"2PMA,XS13:E-A0D:G]?#2ME#0@4&R.KTT.9P4BA-L-NC`>9)5L81]%9!
M%U.EJ2JXMM14U`NG;)V=FRKF[\F!44!V-NS92F+1!G15UY_\VU_^GQ-`_1/B
M.\Y%^`(0(0+3?XDABR!=#T2-N_`PF>DJS[+9M(*<KJX"\JM;?V'[)J7-E&+R
M;&$Y[F*564DZUYC_C+`QZ"OT$M8VC"?G'886]&6>2"ZZ,N:*7Z@[,(_E8?(;
M^./$+#NQBM+GPPX'K>IA7QW>F(S:,^A6",]!!IQ=R/NP)NDVTJP;38%Q0.XD
M<W)VRV"%^M=!-_"7PPS"E?X$=ANHW8H\(\-"O@^1$L3+S"!@@L"'2E13)JWB
M2C37WDPSZH3=Y(*0V<#A;\PHK!?60=$1?8-D*ZEJ4R.PZ`/(J1Q@>5HS7?XD
MR@?#IRWQ)\3FXP^FM8YP*.<7,N^B;!=Y$>\H'4(&L@/D7*S&[?5U-L+1K#IX
MQ=FNMJ>]39.<]3&6M)5AWXA"IS,HP1;7&)2=S80Z!3&B[JKVXE0PW'S1H8UP
MW@A.T"[DTPN<$)/YV+>.F34R`+$U$Q_5-J@H24:*Z9`M%*@K4E,029N)1DK.
MM%@?IL(\VT8?)B.A-X6-:$82*8K^H!$-);>%3\S\KX7!<_<#I$,SV<FHN+#L
MJFPJHXUIB+N&PS865Y9ZM:"=A2Z1&'5CVI=,0SN+RQZG1>3,)41JJXS\4/U6
M_G)!KI6O6Y&<\L,]REAO/E"P,/8[/%T2KB]TO`8_R1@V/6$W0S-ADZR_B<P[
MI2XR]1GLAM,$+D0G:A"Y-&H(.1QW/O2`&B+.B-5(^ZK8A^[0_)?\*BM:_76'
M'F`!F7X^R_I$#Y+'J5:I$TBA!K'R%:L<XJY&N>%ELU&0-$BS;$5^+2G6[I_5
M<TO%YZ`UZN4U_^RXINP/$>4`+!@X),RO+;>?*;Z]LE27,7%&+&C;2-)V0$W;
M86?CHD1<#AX[8^3[Q"JP"0`26Z"!]M17%+O(Z7JAL9.%,QFYPQ9^G%SV1M!F
MZ'T)9S(PX)0.YV@]X,K9P!2?G0'3*-6P3I?BOB#N&3<)W[4K@UEH/T@_ANBB
M2VHD:2J)0L6[S0+-COJ*G4AWX_?DI8,XHMJA,QH)&VT=K@5"F_N.Y3!_]B9B
M1C7X#303ZIP5WX:RL7?B)4(V7ETI*:A[3\>V$A-L2H#QDJ#:?#*/-O%24LO*
M<J$`B]+D[&(3]$+CW469Y''P*A^FM5!HJ2,#X`-$&9NMA8IM;,9$0WF#SZEN
M'H,&88.@P1!%8+<,Z9KEX9Z;.OTJHGI5G?'DC/A,*5E)\UE:BXIE08]Q!#:<
M5AZ'8T<H'_+FM*G#N^`(%E*1M$[#,AT3UY)C5E'.XO2=RLFF?)&@(QOBC+5`
MN5DF@U8D_4&RKP4GZ",P*`,F$0[@-1ML2O22&>[U_DB15)X'[A=K1GF(6'4Z
M:]DV:,(Q:<,'OK0-S+95/!<XS894S:G);+DPM7`7#U-\%ZZ.%9&=\4SJU%J;
M46LD1&,U[_>3V3NC+HD6-I&I-E@_:2])L8#<?#AI1=)84K_:`!\,2V/,GR3?
M>*$3/^IYRFP9A\0[V'B4=<[Y+D=*85_4P673P`'Q#@TEAU9"(]+CT:Z=8*FY
MV[H]TD#BV`7J-'%%E/KE!]"L<BTY!"/Q%<]IF_-,YZD0J'8LA>&AL72@591$
M6TVUX52!D1.`=X.,.(G#DR'_J1HS,WLA;E8\W!QUM"2A(HI,2XVQQ*Q4/^6,
MV6`4L0/9!9JL>_=C+U(2VE^Y=!=&^(;-^`B5=.';;^6QXR]D3^/>'9\U!AF.
MW8FJP2.U]:J6Z[&S&E$-F)'=RTH)B4+&:("JLI.WN$,S!-BI+_#,!I6Q,M?W
M2.=H-K\V@A,OQWJ5=R+BY9<]SIB1P;I#QS5W'$MD3LDX6=ZU;UT\(3%?EQ8T
M[Z^DOQ6?"H7Y0G$)Q(C;?]I1[.;^.WS[+LU$&I!^/)7@#QWAAS(6[`P9P:/)
MI54!2\O-]H%I:U<V].'8$,(R8:']->B"?:GZ?_I;0UZ:7)H\:A_-82\B=QK8
M&)P7!^$^)6+M4FP,+M!P]%YIK?"J6Z`SY?;YM%2<PGWBOOD^E\XQ:2'M=11G
M,$]SA(50]C`&:DRR+ADPK`%F02.@3R]DG/O5!U?52VQU&16&H:S5_;46+.$C
MVP4M>>>P->K$;K:*)[P9G1/0E@-\%P!>>$)M)30'`Z*FS9.1AJ8V<?5XS,&D
MA2.L:WRR-_2T_S+'0,G/-''103&6W&%[I\S5NF`Y)JR2]:'1-5A-08O;6*W[
M.W=\[B?F+D,+4O!9K#MG$A%M#T2JK)=RL(ES;R:$$9@>\KN-M=C9^M0';G_^
M2?6/5FF8;H?=,6Q4"TV)<9=-D4BT<"%]`9T]-V$8):H;@G7BT-=DZ[S;/.J3
M?@.0"^<KHVII/O3F-^5\$5-?3/":(;=,BKI+:SBF`*Z-9W'R;SI?(P]\71#`
MV/KKLM\39I8LD,Z,=5:2:&[.Q;RVRB$"-B'/F58?'58?AP`.U!ZX(+GD.F-1
MD*"")6%5/-_@)/2>);%H(%B"<;P^AVS4Y@?1R2+A<#DMZX(&V2;$!;>4[_J4
M@J&KR11</QD[3K0(2EH_1"@%#`GA1VRB.CU1&PGHJ2@"D#!$TR^(@Q#]L-DM
M$8&T>_<JVL(_%Z)W=ZE)UBB[74!?25%--R:!?&$[^3'-E1]0`&B5K!$<]^>3
MBXGRU[EX!N4]64R!#DGEEQ^P!G3YC$`#B'>^&4N[^=#-,<9:ITR=DQ(2&%IM
M'3!&2+21_R`D(DE7:POS'8.^,/.9;Y(?3@2X075@1%WS]!1W%8OI:6W?1DF#
M/P-;P(X1P4=IW.HB.X66O^7]Y[3L).Q>RLA+=7!C26;E0[?3FVG\D:.-:YE3
MF*N)#"P0D?=MB+E?2D'>QESN+#`MJKJE"7SJR'0SI[RV5K(P:N*'WR5^\,G5
M'G"=:-P\56V/%^8OQ9?T!JG0?BVU=`Q7MQ]^@X.(6/.2`[6KH4B5Z5*Y):?U
MM]'&:'<3TH_KL?]@9^1#YBHU^S:3X'2G%/*FW4:[^[VE[MMO[+;>,/^@"BR\
M5'H;2$4*4(6GC]!O9;T-0KNW57Y)W9N9I^XQ6]1]I>X%O?D;!8Y0J?%!%%94
MY7"`5?M3[#-3);$=MPIK_(K%HJ:1N*TZ[@!^FN/\+:IM0#6V@(UK7;W"G!2/
M88"1I8RN,Y,>U>EF*:..RAU9C9IF2CH19K7[$?L=>7QRULHSU:B\->,XL2(%
MEM;4IH'KWE]9=6O^3'46#NI(U.M&/Z:2#NO$VL:+S,^K,/WQ&$]1\35!Q'=+
M]1=?C(OO2<%"VNV[MG[N]4_Q'F6-'1'Q&6#`5L77$_Y3J"[C\X.CKT/]1;LT
MJ?/UMU,#D'K_X.BMO?YJ`JQ0?YNZQY$';T(XSE#887`YNNU;I&.2?!KQ/5<R
MJG:(^B\.C@Z+8W!2OWBT_8A8U=%;FPI-1S3$?@<4)']F[K6(P8Y9G4\3P&DT
MJ2`WBRN$P:03J_(Q0?:*@VE5:-=JS,&;=>DKM2'E'^%2PU$8\)B!%A!G'(G(
M5-]@ZPI=\<2<PI;1&]^AWS!@)=D5<?'R25BHB;J,.JKN[:EPV2F,2XM*9(/Y
MLHP;X%>:F6"_XEI6:(MO^9,.$QSB58SU.AC3<G8(0"^U'Q8+<%HSB#5J>%A0
M7TMU2J8T-&<(Q2&W>3%)`73+S+?`<(QZ">^=I(*PO5/`'W&36*AIYZ%=`TK"
MKQ:5$0N!#P*<8TIC!``M4]D,N;4%#Z3SP3RT>,9XSB?!91BQKG+^6%,9"2*`
MYIR0B"&M.>925.G>Q<X<U;:4@!</%F<+]&'&CJ+RX`T3=<,]3N&:(,SS3:/8
MV5L$4"H^2,%(I3:PG=\BS^842_UK51S4123%:D,EE.$`Z!7?331)?J.%\1;L
M5C/3SD./7D(&>%Z&6I=@ON7GJJ$-Q+6[?,&8J<>L;*7XI.[QS'KD-_7H^T0;
MT8B)`9W3R63.9L%(]4PA@S#/HG&4X)<@M>(Z2NNFLL$$]28B=-XR-DWTV4U?
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M[8_]W;4YMOUY-R4$+VIMCSUHW?MSI32!_FZMR-4XW`%]C:@!W7U4X8!6B3V`
MDXPR""#"39'*/ST\:U7U_,^Z99\X%-&MO!W/.5=?PQ,WC,+]9]VV3^W,ZW1L
MU$J.\B@6,^CT9ZQX;27(FS\[QJP]]+"-DK0K,NJ)LB^4BH7K2/])EG(TMD[3
MR5&I-X4,<H0G&!C,:`LB*32`).0MT+`B(#+BU)3'P.5./_#G^C*O&2W3V<^2
MSO/PF"EURRVLS;A0\!O/5ZF>Y"N2_CWSFZ1C'HT=@]28)R$ZI-IB;5>6[/PP
M=W/;@^YCE(9'C?0&"\-H`>M8@'7A`W#'H]ED1"#`1+2DQNM<[Q2ENF8<?)C6
M/'=7U$O;6KHE3/)2>8O%#H;I_XJ%="V:8?MK"4RD&5ME7==8GMDMP]_W+KIX
M@FNN53)X-7CQ?G>M7T](RT)];$-%C4&+AX45!['%0Y*AWF\8IM1HA?=EA!;-
MJ$T%Q*P>,)1"IH+N%V&AO3$N3YCWMY:PD@]ISX:4#V8QOG(XVKG`)QX#Y%0U
M:[.(M=&OY1-?2+,6,B)O#>]*F!3)DJ7PN*[?HI&"2]A<EL-;;T=RJ>;12/P.
MX;QE.#BOJ84B=%:XK\T1OMYB66,]N7GJ+CIX0#=6($BBPT#-)_)5+8M:?(D7
ML[21*(>ZE\J]7F+MT(3%PK.6N^2+4MP0(B:ZG/VR#P*S6G$"R`:WC,6W-:K;
M4)#1?/IGM7(H]:M[RS=,=)VPG#\[J+7#2X+GL>@Q3H3G*RV_(._:QDL01]T_
M+]DPWG'[Y:/.>NKMM[*1-A]=S>&1`P:4XQ_CA'*_$B>PHM0*K$&":]3&YG']
MIV6QEF5Q=RX5H`R=[>+X#"Y^'0Z9OU>-PB!U),CJ@$%,ZT$76S41])C$4.Y%
M=?EGR38A&A&:EG>UJ9R,6A`S#3BE#F-62XP(]B2E.7UH^1$A$1$5K-,ZED]K
MQZZ4/?%GD9L"$%,^0"=K?+&(2B&MZXGQN/X4?^O7D:^6]&=.^J5YYYFB4(U?
M+!Y%;@OMH&SP1-M928<^47EZ1+#&B'*)HJ!09/H&'3G([KELM-YQ%;QK-B:-
MMK`4)DU7_:9`P75IMKX)F7+IG.FU<XH3L.SK^SMU@>[\SI+,E["L4W26VQ?!
MV]C=VDT%5UIB(TB-I3;VW$ALCN7IUM.;MB/RE_*OCP%[[I-=ET0M"D\R<V+1
M#C06O`'I0?.A\I!`CED4C7O$HWB,Q*%3(;GGA5#9W277?&*#<)4=[WKET]KP
M=RH@;VD"^VNUBQ1:S^'7#4I^X/L9>1_CLTTEMQ4K];WNYN+2[CXT6U=`C@[T
MEI,4W[&GJ,,+HO-DZZT0&_'>6]F'*M(R:\E52UL+UX+XHM0.VM?QBDF*PDM@
M+E\YZ1GZR$-+*5$J2+N-!WL/-]"[[9^OF'!@C7H8#W8W=G=NTL(22LLF@OP@
MC&GG<]>9CMEB<H2W)_!@9V?CX8WF%6BNGI?D7@1SG/92A!`%Y4C6HO<+Y!$)
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M;<3VU1<[^=P:9>#DY1,Y7:'+X83):7,-9!7]0K=Y-=!S!I`UB9S;'+B.2;=C
M">1DA(#8>!"B^2$,&'^PJISP@,_N(W3S,0?U*KO+Y\V$['-=A7;:P_UU*<40
M;FL,]S(^N[^[M_7DYY]X>G<WN=1;R"13H/A.MO%9=$:FNC;Y\8A&20EL+2+.
M?DB9[=(S;3<,[*GGYBLTN\'8U]*^+)G2B3CM8F."W7@L$$6+%SZ!(^E&E*#R
MBG=+">82]$CXI\+8-YGQDNWRJ=%?)#:=QDK&)I/.RN8%BKD)M=1B-JS?&H:G
M^0,:B9+6<6[F_$/NP"K+NEL4:Y\R[>R)SVX>[J+J+:;E/U9D4EEF:)__L`TQ
MO*!0OO2`7!S^CK0@%Q3I_A5(("LZ4=^F$Q$ZKP3#/VYQ9SCO=6=]ZJ9.G#_K
M?FLE,I#T[19.C8:4GC4U4??//*QU+AF].YL8;`GU7I6'56<]O?7"WP)^59MN
M#HP(HVB4L=E^X\6X^`,)*4M?RF3AP$`X1U%-3N=DYR_E53VG+)H=M3*(3\T6
M.W;5[N-EK&%!MFXDN:5WY*Q;JA3>?NOKQ7"D$,[2<'<>;NXO&8\O8==V"Y[T
M)-<E!A>>0QCZBC%5U:^49+^@AA]"("O1KH"9OB6$2X[7G\T^;W?U8._1QN[C
M)8/PP9.=C:?[#]MOZ_C&.L-:S=MI<21X[C]\FM57UE`-PNO)[M;CZ+_#O4?:
M=JC]<G_OR=9VP@QJ)&;XHI,ZEV!CE4D`Q.J$0>D>RI5UGC4@>O;58:[ZOU4G
M9FZ8EA+9X+:B;MW^H1?N1#_N?5AFS_S92F$^?Y:5XHYU((A4EE:8<][[T/3M
MBRC=+(EX()T-"'5M](F,,C-_I?)8;ZN`)2\LFJ!AYL5*HNDH+H9'0"I=&?/&
M%.K`2R966V1YRKUAR?@>JY9;^OK!R_F1:>_&:<TX%EQI,91B-EHZ%Y-<]+6W
MV',M%!H@9,+XU*#-/'<4&T?[XCDRX#8$/Z2N&2$!_/M13Q<)4TC"SPN'Y?#P
M&W_4]=KJ@?(A$TH[`7_HM`AW,:I\?;8:8>OL97?\(76TD9Y6Z'[`M!CDF>.&
MX&8(%4C>9//&FV-BA:G$'8.):Z@P!MZ+7N9.5*6_]^:0)%]4I1DQ8I%`5O*E
MY;U8+72.S<(/-Q#;@N9.A,9.A[D]R%;\<SEH_B/R>C>Z,NJZC>G\/2&/#GI=
MRC*2,JOKPYMU8G$;*%E55I;4]QO\=U:.5QR8E^@R684WC=PR7]?:L7K8FP[G
MW`JI*E\8\9W?M[])8P]GM=K/S9G?_M$A0P<IMU],K6O4&94O+4_GBSJRXRA#
MVK/VP4H\-_R@[6X?[#S9>/1X"5#HY\?+.*-C-ME0VVV_Q&WRJRZ9T7[QP3XW
M1N[O[BW]OO?XT<:CG:7XABBDL:0K!W&U[/'^/BU0N+_SI(9(:W6`^EDOAK1"
M;G2N1"0(<S!*P8FLZO-M09OG"%2.Z51KK/9+H'Q:;OX.9[P(3C63K!I3@]ZB
MXT-*:8QZ&92#!15`=,+7(`:CPNA5L5[4?<0JZ?34"84N4'5DAZ*,T9GAM(:Y
MAET'8F1#XC9!SFJ3N4?Q\5ISYERA=Z*&;(PWNRHE!%+`]G8HTQ"-OHO,M6*I
MO3@Q&E#(B*1'+050E).I7)D,T-`(>Q]"AB*A,*6&VECP@J-:U4.(\EA2X+@,
M>KM3X<::LY#M&@[%@W\D%<D-CM1)89&!F2`.4D&+TY+EA@@D^]W9\NJ'EX[<
MHK[0\G]BOWI'TMG]QSL/MYY$V^A.&%]S7JNC&]HZ]_<?;=?I'FOU``E_C`QK
M5IZHDT'7V%S."",9T'K@8V20.`O`XY%%*,4.I%K2=./Y;NHC9[PW_ZUW,?WU
M-R8K0RIK`WG<$27MW_'J@]V[UM#7Z*WE;:4<`LDJ<9AH+RY7YU*%FU^R&+0.
MZG.UA,ZTD=SE-W*!=#BC[:V'@L=<-(5M<SZ<IOROVK!,5TI,D?XZ7X!!B=IR
M^6L/DWWI=;BC2:+<_2.5GIJ,L>"?[$:E825*5$OSC8Q84H(.*5]EM/$U-A[^
M6@]#1BECV*SWWD?M]EQ;>`=GAPZ^&W1%M5DTO)9=4*4%TLDPIQZT]$26#2="
M1HY1@5A'=KFEA])O=1)';75)>>K,A-S7#:T45-P"RI=4;#1N.8.:.LMRRK*'
MP^($LJH%G5+1TVL8?M/,"_U4\8`.J7G;;I5NR.2E,+J6M4Y66TOLW52P[MVQ
MBMA@IPDFSQ3Q7:XG[G4,5"D9?K1L0%&3J-8X(.K:+%YEV$5,<$(A+RCHUMQM
M]Q]OUSE!UP#TC]8]M[+5P:%\NV,W,?P?>/@H:\E/]W[=86[E)P[OKI(RM[$S
M=^?-N25TR03N*+45QX[JA***1Y3M[E9J40'%7,J]9E'#)/MBBIUP1V7);6AJ
M"<`.Y>NAYOI-S,%%'S`A4N]XW9BX2QF!673393(JK%T@KC!#N(=.%8#\0%*.
M8Q64PH8%(M1^-$]5\7QFBFN&7#83]`>W)L;CZMY6U*2;\6Y-*GYZWB,+*0.0
M>"Y:!W868U%@N)`M5[P=^0"HFA6!^^/:P:"TPQH39.C<"DE$G"MTK\IDOU64
MP0.=9/Y!=FYB@Y+DQ&`\H4RF.M#H7)#O/'WZ4&09ZBSA/5'!?M%B,-1(00L7
M[D+BS8X77-C$#5_*O-<@2!+=7[\I'UVO;L/(.YN](9XIIS$H5L]",,:TO!@.
M1*S!WM8O0^52!XTBNG[$[FG:*M'#VQ;(R7Y5B(;0V#^9ZJM[SY^3TLW_*.5P
M]AP[W#,..TR`6V<J^8IT28=NI="5&68ZQ<V6TW.]O>[@N/FS[^(5LG\\X-XD
M52-NE>!;S90_A$1G7-^6"YT;B'[#CFN,EC=_=4(U`;V2.]5G6QBQ,>EZ@YF_
M3UZSUY1=O.`:=BXXX5!V53RH>?SS#>I`];<VM#JZIU52B2.O[KNLQ8<QT(#J
MG-*!\(;=`Y.\N=4%!BIA12K3+7#P(B2F%$TD**-[LHE87B9^C-H(6S2:&=</
MSL*@L)NRT'4\.Q>=-K"LU:#X\,>ZGYDI>/:VLN*;R=MYO&2+0FF3@578:[N]
MM2*MO;@-?'=_]\YM1(\Y9WFPFJJN#R;K5:YK_KJ5F>X]VMJ^4X=I3*^3!I1;
M'I*TV2TG:-NYBI%=4B^;V`L9G'K1;?>P$-B0ZP8/_IFNK@HH3`&`=-@/LQH8
MEOC:B#\MY!J^^R@AXE&(U!*;X^6RY4*JBM?QB.,/5G.[>,#`P)ERYXA+7JF\
MWLX.X7)843SI5^QTT',C<O-WP`IW'4J+P:H6*P276H(*MJKL-.40[)A'NH.D
M`>YC3!+X%,--VH`(\5Q6^:UC@=>:Y/GO(+":31-U92H*P#,F`I=AOCS\]RGO
MB(_K*(B%\,A-DU"QOK9+POWO23.$ER6M@RK"B5F'(^T*>TFE=`H)/20F"/[D
M[$UMF]]#KNN1')59UCZI.#A-`]0.^P"?-/O)NFCEL^B(R<F\^`$?+>7N90LZ
M4]?9!>WG*].SA`ZXFKBN>JPO:Z`AY]&J_#46]F,B+FA[!`-7].D6+"`8Y8&C
M(JY%!"MB"<L*4K(>]Y\\WGH8!;8D2^\LE/R70%4Y8@7BO+8LKVM7'F[M/OP,
M`JAG>%1RZ<',A!)2"H_[[O;N3O%`=,+Y;<FJ2N>VN8B5]JWJ1O,R0/TFYS9#
M.EL,!WKH-A0,J:0HX9+3DENEP"YQCR\HYV.4F)*;A`%/AJ<(3MO!#9.-&H-D
M-E\NS4?"/CD#^/<HG=D<B!CHM$WIC*=6!8UCR%T1W"LL-UL3PSYGTEB2ZIA-
MHE:RX\8VT;A\+^(O6D)RY2SOE-&R&W&S*<Y,U5S?\3P!+O*=9-3O2>JD`G-O
M=C8IONZ-WVT4K[8.P(:T-)\1*2C)/#MFL7QD)ZI)5UM/&%"6[J9.;?M__@E>
M-M,0=W3OT@]OEQ=#YUA/">1<MA*)M8Z_78S+GW_R`%[M/]A1<W9'F&Q,A%4J
M#5Q_8M-ZF`_-JBVBZ,=YZ6"]MKOCK\59*UHU1CCBJBFY'5I[Z9.#$""5H-V]
M>".>%2VLTPR&!2+MG<CQ5%#7S.MP\YF(++44-[V6$K_AS)=L2":6WL*PO$1'
M&[OH5PX6ANTW`N;/4..8U#=Y<2@E;<1:C[&/_]Y0^XFR$`W".6VFOP=T,;S0
M;8#,@N6?0M?\$1(1&G,D`W/*XM6LU717&$X.ER0;S+8-NK\CU_TR"S'/,#,H
M.,RJZ*H;+\&!$$H'AI5DC62I(5;D<V55&E4.2MV#>N)X1XN9&,&WN9Z`DR:[
M%,YK,O\GNV0[/WF\[P7O;3\:O8MZKYB3S^2!?&XX\6!(#=2XTP^$9GT'V(DD
MW=G:W7XD'1>J[-O:U#-&_!TSB^Q3357$E6OO=(^=9'$ECTS(Q#U9$%C4A;1C
M2/H$L\7>9'5$D2(;LX7Y6\R^&'/F5)#&W1\N>,.MM#('X^7KT0.*5:@\&X83
M>K/PK`=?K^(6;4MD-QL<&@.FAUCUI#U5&REWQHA%2(HE*JIRY^:R\5?GIE]\
M\9D^/S;@F.7O<!E,<[!:J#2/X8Q8+2XC-$B\:*EF3JX!SP=L]L"9BCHK)DM9
M>)U\@2:]Z@2I[(&7Q;ZQ>';^/20!J(PX79/STJGL4=@2UM3`I$N#G.^[>LQ;
M<ZI*/+*SO?U9E"D\6E++&I8O&X."..IQ#9#/HP53M/L[.ZD#VG:@"&3%#$=H
MN$187I.L78=?7WXQ?[9.QA)ZO[V9&K**I!L2R,5E4QPQ5[OVM;B_EU4\X7U3
MT:D!.\B9050^2QX%KRX7`#^23STSFA6*O'(V[6C>U'6`U^(SR1OG+\OCQDE8
M6Y\IL7LT/#7)7>^0)Y+K;T\75U9!:BC<RF62(C)6S-BF3_LJ7E^4-VW#%9Y)
M)*-7*W'SID6!&>A%I""C%&Y>,+'H6RA4>@4PO6%,O%;Q'#`R7+)6+PSY8^"O
M$TY$99#(8ESO5M=^:KW6&M@-IP^I[J5C,VMUL/;,NXZ4R.#H#IH<0P/+?I!7
MPN/FZ5AK;#>=_).=[-#06CVL/?ON68H3V>VUNKKA9'X90C85+N+,.-^E1JC>
ME8ZKIH,?+"%"1'=!VTU\4A\"?U-=>T[E4[,NHI*LBV1RZ&7\CL4#TG*!GCZP
M;");3K5HE!*E:LSVI4&=?$.0"G74Y1[E7?0:-;072G3:2R[=-@<<GD7O$\FA
M;(%:T#N>)59=TN1%;2,G3\=JTOX>U7JF6R!?3GKCB,.OD6(?26<HL0,6=H1`
MV\Y,ZX@`@%M@F73G7[JG6V8=RV6W4!7QZ*]\&U+&)/*,8-%^+%T(ECEFX7^/
MPUK'\ZJ-PF-TYHXBPZM/&C'>[]F$^Y1OA>+O[^W?L0.7DV#I<G,=GK1=#4?)
MH$BMTVVP]OW=[3H*OU8''TD^L($!Q.052Y,=0<(PX?","*JNG51PJX=3+%?=
M1@`]2,_5>>[E<U+B.IX/,%5"$H;F;TDL/MG:W?OL+M;,L5A:*,E$NTK*)DKR
MYQ2Q$9Q=>S+1['IUATD-F]<Y)G+OSK[>37\]1L+%&Z=35]H3BS]AL<[/95&'
MJEC!%R:R[%IQLY;3;?9`$)>)W%<DOD[-^Q;74#Y#+2+,W00??O[I'TV[:24P
M>H-3+DY<1;"LDE"SCE!,-XB.=T7O`X27T["[(&-LTTI^_P.B`R[OS>Z^P@;1
MW6INC6*J(J9J.K/+R/1+,'_,KJ\HK:U?L()&(U3Q3#I(("#_TH22=#YVDE,O
M]DUHI7$@N*[[Q!#B"R6G1]6DJF2HIUL21+\,/G/W%/'OQ?]G[\QVV\JR-/TJ
M1"*Z6P9HIT8/F5T&%!XBG66'W9:<V85$7U`2+3-#(@52#(?JJE%/$NCK>HIX
ME'J2_OZU]G0FB;1$.C(154!56#QGG[W77O-(-$(LUQ2EK@IVI_RJX)=L!]PX
M_):[B]*L;0?U:DJ#*LT#UL'X5RCVUUO)5ZV"D8\;LH`D.ALH_+,1BZ-_U0H-
M4:D@7X/*YPSG`B77>Z7A7D&?KG9W3;K3HNMU6U&]9$2Y:15;%D/0YL;[2"T\
M6#@XNYJ-4,,KEE;PS-C^B3M::S=>"UGW$"D*@/L2F3LPG7R6925]K+!3%C!Q
MI#!D5ZVUSH?7F%\+=B^>GD)UH?0SZQ-!6TF67+GC6ICKGP_A]K&<$W>VUOUP
M;'EEW?^;H:10)=R;P!F3&?F_#XWM\!^/\'1*,DJJMDA%F'<6@>T*2^'ZK<&;
M#]KE_=.K+T]#F3M6><+VRZ<O@Z+Q;XHPOL!E,3YU@9+]]"`^001-!VW\@L?@
MS%R_]5]4EYXH,`"__LS&]F9_Z^&C^I^]`+YZ2_5G]C6(^-2H.DR6K>35>*+=
MDB\I.>_:+()V=]=;#Z>&(9:;6"\QR`_+L3)E;$`T,:D6IBX7;7L([8<S>!&=
M&%/4_++)'>CD^(QX&CF%P)ML^XDW!N.WZ$?B/\6A3Z9S&J*CT!"XQ['8#SQ*
M2[_^WUN;.]M&5/:?.Z)#-25U:Q;WD?OF+RHYC*BEY!C&?K/GDQ/U6M)R(IL9
M]A]IR>1$\FE8%ZG%Z*6U/:34@W?3R>ET<!ZR#\`K>&8"05*F!NAO/[)WCXZ\
MAZ/;/PZ'QY_&/DCE-:EE\N_OQ[=5X*[8Q:4X1.[O$M@LM83V/#K>I-JJ`0#H
M&.H)@^Y]=5^%D10YD[[(]&K5N0/4"F;U%%'F\+/>Z]?/;(AS_(.G`P@F)7.7
M_7^FL)JBJUPRX4ABV_@6/@&O(N]9[T7H/,@?(2YR2=#5)H,[.M_@4UO2H?K-
M;DHV66AYMGF;D$`#_F+WFAQEX7\+[@L079A>`5+:;V)FW=[)#];C:.`ST7,N
M7T*?F,:AO(B"D+MR-^*5UT)C1,\"SLI&TUGC@ROQF#WJ/]S;[#_<7DNE3Q&X
M;Z0.X``("24FMC<?Z5:3]UG\+-V5L+<KVVI9U&6F\EH;Z:)EX!>TH.Q,0<+H
M:([I(C%!Z%T,07NJJ$W(,-OR=,!;PN'(EO3?Q@J$*R&#L=2,E.^@&J,:#S*T
MFPZ5H!03!RJK*@[>LEIF+R:R\*&U)+U61!8.=O1F)8++/DZ,N';`@@N;'*GR
M2[V9R$#_H'GG_(R,@*&7EN<T6Z/N*NSR2>.)HMS)AV$WB?-KB>B01/:>)WV[
MMN4LHRTO(^UO-7BZW@1LH\:S*\K!*MW=G3FMXH!;._WMG4?]O:TG"ZW.'=U*
MA,Q03N1U5*93SN81!9&AI$1Q_S'=:1T>LC-16RY',^(\,1T$PAZ$?!SD]$+G
M6)9=49>^7D20B9S<Y).42;N<T1MU69N,8,J:";;SP0_#WOQ"4%\)L-:LEH`1
MQ?5+Z8+/H+Y'\*%%NU)I255*5B'H*A1<Q>'W-M<2R]'V%3&VTZ"!>>@WWK?R
M%1%R%#(6[%6/NRIM;%A#K0();0R46>QJN7ZS65K^F\F_N2E@#L/X"2R!L8P&
M1"(11T!=:,;@E:A[.#UFW@,=Y(+I`M^6";.#SG@K4^5F2^7U=WPG:>2NVQ=Y
M@='F0AL@Z*7\=/>KM:".9PF2!&;>#<&<'EXR.2(<$J@MGZYZ'2&RW`I8RR*4
MQ+,<P>9RT^&I++4)5HQU/R%S4JQ/;WR@*3!2_4"&52[>\@&=NCZ3TPH5!!S!
M<%%+,?2*&;);3]C&M%054,I(E4.!T)\T"3T9K-_6(R1CM[QL1T2^;/"(GV[;
MN6Q;$'(XC_ML@M\W&C(56_>0=0$C;CQU65_1`6=S2]1:!:5_\Q546!TIQ$P!
M<<9C*C0IY4A8A#'N>7[F]PFI%")'9`KO:96:3A4XI$)4%.Z:T6IIZ.""GJXY
M+<J[E4_>J_=1:5<G5-;(5^UTACA>8#%'E`12:J(H/%;)P8ER[.4JA;:1<AW(
MEOTS/_[$A!DY.VI<N#>97ZIM7KR\ZOJFMT/<:N4@XBUOIX/-2`-0UDQHXQ?#
M\7/ELE<7;]E\C>;,>4N6?U92M`G3,>2*P0R2+&Z#W')`R*SN9GX3X27<K9Z'
MRR3I2'^'-WD"4&16K:!7$I(>^T=7%NS$(>OB?``JX>[3E'")!*'58GC;+2=#
M-[.0*>]1'V2)$LS/CV(S`[[C6=U(45TBV&:STTP4!(EJ<2!%'.AQC6A6@Z90
M+6)F.(A&WH<L<;3^5;#U-3*:H,#5U-6D<B18%I!ZT'N;2W5Z),YYG5+41NR5
M;XKZ:,G8!'(E>(/)N_V'#[?[CQYO%FZA\C9$ONW6&(LU;"]*-;8>[*44FQ9"
M+SE##>M<>S*EA<[Y.]$EA!Q!1<D:?$6/%2:?!1>R5!W+N["1Y*IL2RYI=XN_
MNIBAK'GE?.]@_Z"7>^1O4>7U3#D;^5U6<R90.*=G]Y9*I8PWH80:>`W@CB&!
MZ"N)3+PN@7666OE\S1DCBDU%2@5=&9.'P5;J.^3HNVZYS,4-:59!2M]L;:[9
M:@[83F``8-HH0,T$S)9O13\LC$:SMAV9&M:C.&4M`NILL!HV%UJV+<.]%%-U
M4RAY9>GRNWL/'D8Z6NA2V?BM7#H"FTZ38_?R;5Y<>'.`NYQ\[*ENGB(@6M=7
M4RI!V3HSS!\R@2&5=DR5UP159/IC:#%L"H!;3-)?/PY]VH-2KE"B"=#A@(-U
M:HK1@]Z_JL$/K//<;47^;FD#?^AM;-TCH]"00[2>BCH7`ON2'JBMW?7X%2*W
M*OU/LS_V-K;7>-3'ZSUJBVKZ1V,@&SMV:!20.+H[%PJFEX[IG'8([8M%9"PH
M\24HR.C`EM&/"^[3=#(__;02]67527Q/G;=")X#%PL'^'V0,>$#M)FBI1C.5
M6[(,0HMWB=;>9K(Y?BZ`BW5;Y;8QT17ZA0N@;"A:B915L5DHK41'/2D&F%=Y
M>E7^IH_D94,_*VE9XO_=6;06!5<:4_1]7TR'N)$L%&7]1`V'JE_7BAT[Z#IF
M/):5J/SCCS5/C#1%B=4,XIR&R`Y*B9YGT=][3'Z&OY"37ZY]^-ITD:=O"?9[
MIL1KJ\%M=+.X(99_2['ZAU]^_N7G_>31*9(:SK0=^BODL5\"0RB)F5W0O4KH
M^">2%31ZBLX$N4V=.W(5+@F105NKU)D_C?!!@)NQ=[2EUBMN2NMP=^TI+T4?
ML&@[UL=CTS[?V'P1_DD067A;[!>D+Q-I%-F+]F"AK"M+";U![_JFS)\7'ZY\
MD08&O_Q\*'*KG"*(92DBY-GXU?E24>EZT'O/9G08RS^!$8DEA-Z!LAVP1J<#
M97<P](=<`F0@SZ0F2-7/:6N601DU?A[5[D_G`[G&Y>-V3UOA%^$O4LL+X/B-
MX$/G0G6O*2<3S+V0?6B;#,,CS*V"1W8`^+'<<=/9^*1<@F:)ZV8/L3MWO>M,
MX`>@I:D1?]6N8'V,?`F&2>>7=?6)`.\R]+^9:X\76A^HWEI!7>A#2ZIDWZS[
M(-W7CD3+UR[YQBVOXLBKUB[:D_2DC/WR\RK.`\,*,W7NBINC'P57K'?5-3:>
M@M-GN=F9TSOW%D;3*UW$LP*=)^0&4,888@,&]IF$(?_=4:M<X7-2Z2UC-TDT
M7]'[LUV@L-W=/.V6]I6H(6L-G?=7@OD0^Y.UF]6K0'D&5&ZO]2#1HO36MT/+
M2%K%P;X.;UH-MMT]7^KFK"LA%PYPQYF-;8Q52F!G4<=X,KY/)O4QM0<,T^J7
M:F&H\*AJA\E1&RK(;1)G5IZ]KI7`$OS]E"E[\I)+WXLJ:M7Y7%%ZD=M9/V[)
MXQ<??_J"MI.3*]DUO3(_/C\N"=65?7E;%2GJL'*95K;.R+"X*SJ0U;+VH^@*
M:FUN)>3&R!3?V0=+'1&<RM>YC`%V1GA,6KBGJ^#>EA%/G2/^@+[TY+^'F*9[
M#`2=4%\L(V8\5EYVCA4IY?MH,IY'KZ"%,Q46U4@='(!:S-)BN+HC!;7][O`(
M!,L#G[I,`S=T^`>&9FKEU@4)#YG?-W-%AMA,;:;D'9*6;CBH1>ES6D$00"/D
M+8&"C,97C336B%!#1I6M9V.)TICY##R.S6C-*."ZJ+96)PA2,W]29LW6]GVK
MLH[93]E#JEL((+<@FX-9RI7%WWSCLBVM"YUA(C?+P@Y!P!1*0:1=UA=SN'LM
M@6W>`HK>B@Y`Z''/=-&[^50=L16&\IYRM>\\1$M\:';'=/!4>EG$>DP@SXA1
MKSB1M?6,LXPF_@7<1^2BZF[/;%=<D2+"VA7G4I^YJ1(KPBG'M(=FZ_@"Z0PO
M2,GB2U$;K6+O8'\=^>P^E<"<>2<R>0IU%^H??0)ND^7+C8:%4X&:RA[4]&-*
M=A6N-/5ZB^V/5,ZM[WE<U\R`H$<2A:!7&88W[:YL>WS$\R>G1-/`)?YYU7(;
MET]M:F<OS`,EZVAR_$-.&FYX7*Y_^GJ7RS,/=-HG[OB^.\3?JW'O[?'E)'0]
MH,]X1(F9:@!6H:5LD6N[N;;1/46$5V@AE@:&6,Q=LX$5G"&2*BQ=Q5FE:NXM
MM##LX58F?NX3"+%P*G7J@>,S05I9;&:2A=0W?E>_ZD##*S.4O]EYE`?$KP,$
M,`75^"'4;'PHJ7MF1G[6J`C^$:,3SL>$!R0#()%6!X#MM3>N<B^HYRT&']_J
MCK?F"81RLOXXAX6_?O#N06)3)L;1E4YQ!CI5?X)O#>G^&F,5JV%B.^I?NJ[Q
M8T';0,9Y\0"]]A"7006IT[)Y4B/=AZC/1U7PA;`/8=S8(['"#*.,+>N(L[3,
MT9M6"8D4B<V#:_DX)D;V]OH/-Q_WG^R4"3<WL&,Y33;WBOZG[7S-%4Y$U=;N
MD_[VWD[_T<[6XCR_XR-3VK3BX[\X(Y1@6B!*T/Y4M<*OY,KWP33\Z^#!LP?[
M"@?">C[2<TLO<2T51'5%1!RHA?'2G&?KP9.4.G0;%J:&EFDAT]42$I2L`"_.
MP_38#8C$T/,D06";%D!<`2KE8-4+M#`*QEYALI*$0K79?NLT]X['.E4K3,OZ
MPN]HF5+3W-P&;7OPCC4QT[RAF-QO2M.0$DM#H:6!,]0JB\'F)+G&&28W:.?1
M!%+ZAT(I>$X!&+IR#-"(*A0?`2&MH<S+X1&#;3`.Z36W:<C!0$<>]H_8'UM!
M9!;HS<O'WE>;3QIKMRZ;"JI;?_5J!2/LMK-!1O%[6]LMW*C;)WP(0%N_&&W.
MG&!KQ1VB96)J`1==9_3>VA9F<GM8]5K:*X:NX$T[0L#<_2RENC2//^:IJ(B,
ME8!JI22!HV,$7!#X<OL8'@1W,;M8-B,JK-`B;<\_Y*;GP(C%5+T8&/.?.W^8
M4T?1VZ!<GFC=N6_Z7L^?MC.%UR\NV#',3?:[EWY+&$>XW'!XR_W@#"GY;Z4*
MMSH;KT/9E%5J6;CASBQOP=.I;!:OR0$,X*K!`?QT>Q9`YD6[Q13OC`I+MDA$
MP2'"65ZD-8`?>]ON,_6I6%DF\..]-0'SH_>5+0%H</G3Y#,^$[0Y@<U)X838
M.=5KQ.)U!52[&+X&BBL)0?*VFB4"R"\&TA-)@\/H0S5FLE>)_!'W54\@/Z?L
MJ)!6$R+HI.AX_6;(]BX=='#<]+BSB>BXR`ZZJ+4USV+G?3-A>Y'%&'K`HCT:
M)@BT,Z\C0OBX;:AV,QT/7A1HS5+]+'C/0;`*)DJ2P#4%6EHHXH_T)#?XNLO.
M*-6:YL4O6UW%R4A&)$S0OB!%9G9,"UBF=_D,8)=+,\?F!;;K#,%<8`8-LI,]
M,))JLJKTD<AY@:C?(4"ZM*8N;4,#*OJN^:#"+8:T<&XOE6)7".ZF&T`M#_ZK
M4"H!ZNF^DL-J)<X%NB>LTP@)MH?<AM^ON@2!))KU'\VX"5[Q%FP(,M';RQB[
M=?R(I&K*BOD%5:I8%Y86`5^9(?ZUHG[22U+',/A*HM/KPC1+)IA\%1075ZJP
M"N4!&5]$(*O7I5<T"$UD2?<3P\9*3`)@%=#8WN[O[="M8/>.`XL=KF$G>%,$
M5W&:G?X6+1X>;6\NM#CL]%;^T88N)=V7P`.2S6H+E2)FCM*%=K,L&O<?/][J
M/]Y:CRLXW%O"VL#/+!8HJ90T<?"\PL96$\D'8;=W^SL[:VVO43]\*=H[4$$\
M?!67_^C)H_ZCS?5@><?5EZ?W&Z\HRJC!#9@$B1<UP1LTH`XS_.GW9"!X6'\X
M[#V/AB].VW95]HX=+>U\3=(8[TO%)=+N?#&_2/<1#DS@N_K;^R*W3/1CM/A-
MEOJLJ1\W^DJ,DY=^G^YOM!L:L4-4Y2)U<'ELS'[YD)(=&L]HS/#X?O29%%X0
MU"7E/K`[S"6?A^5JE0+1*Y6GB!^TS(5H_K;B)Q!F3;,PF(&+L0X/52)Z"*ZP
MTV)WK)`J8B9%<`Y9W".D?VAT(:++%$RC;@^!$"JQ%UO!3@[%Q,H#3:]1!1?7
M((O:4B4O+3430YF$"DNEH%P$=Y6/VE`/1UR-D3-P;6NZ+MIM?MWK,@*RDO$6
MMTRT[&\T/+%_940SLFO`"*_2Y9%OW^,(!F*MNQ"*+JF3$'JX>W`^Q?M("=@)
M*O()O2ACAMB8YJP*T*E+90ABA:E^@0(J9&_'5OO^Y=P:XB'N2!`[#+014+-U
MR89G9$MS$LA;^A2S85"6JKX(R0YG^&W^C@;/@\*<L265RYV?PW)880L:>')1
M2>H5>R0QB1)-[-#_H%Z5)N#@EU_!H[+U%3)3C`+V?_,.G$D+/3WZE]^]?`F7
MYW]^]WO2/5^J!P*=G_[E=RUY]5_CNGZUS@$FJCY:`4=OUZ%CA'T]YC,:S'`A
M$7A;+:UN-=YL,IM*L-#>EL3M[4>/^KN/UZJ<UD]?6HV+VX<-7MYE&U;,IWWE
M)1/[OV,+\*D$]B%B/"O34F0)FI^C>%EKVJ`AJ-F?-A"B+2$+TM1LI+5^R)%@
M!6^*=-P4E[A\NF&.?SK#(HVE?UM[O>QP<>F/2C&XYSB34Q^"5E'_\U^'*L9$
MG=HG#*;Y="]^"EW,WBEOL?[X6]HU!$^6LAN/\@3LCZ8;U9__3H6:PY/ZG^-'
M&C]L;&^':K&\\XV]1\$?6?SMX<[#YJ)4T#:_M;&#;VBW_O#&D[V`^\6B6S1J
MW:H_^7(R_4@&>,O"#W<?UQ_>8(ASXV][,44S?ZH&QR$*)6JXM,OZVP%4%FH#
MXIU/7I^5\#E>,_JB73/:<A@#XD:`J:'5XGA'W*R'GLRM7Z$\?*X&LQ<0QS<L
MG_PUU1-+,J>O%7)8Q5E^*S0:4STQNI2Z]7LKK^FHJ'1?^2JN@"R\R%9NP--;
M"OC5.+C9_MYZG-M(E=54`7.$G<`85WT#:!)JTXBU?G9EMH_$L\?L*>R'A<W(
M6T?C9Y8.+#<RN6A`XU?XC<TQ1&1I6^DW-O?UV=RN98TOQ$%_G8QN9]OR,M9Q
M@I495M_LTOH1]\(Z#M'2"4'<KJ'MY0&O*IN<8HNHK)-,<VO=''D@&6E9N:]E
M>2D3>*$3+:GIT4ASH65OB:\KN^W=!VL1:ZYQ5Z^;9/Y_,J^>NRHO5X)H7\ND
M`'&+-*86#40/E)07J5'^=OT6-!//M0S]$5=%C?\^G$[^H<GQ[@^@B%.I42;P
M%%X9]S1]:W7QNK;W.:_:?U*#[%[-!96=`?(A^?_ZXO$7-.4.4^EYNXX:<;RW
MLQ7;%DLM,^;'?Q3%MV;T8[PK1:DU?COK;6V2#?:0&3F/-_N/-Q^OC(,^V>UO
MW74GBVN=RM4+)22N@8.MB?!>(='Q([$WNK+*KP(<HUNEU9EB7%I&'.V0^7]/
M5@=+5G^T%L4CE\W5H2G\#YGB(P:4,"60`7_4FM105HXLX!8QEF:P"65C@7C$
M434XCS4LO3V\UE08Y72'CMNY^>H&336I]?:$'\#UX68^L]%"RR&;O&%I$DY+
MR$SNZD6RI([5!/)"7[FERK4:7\A:S<QNGAG3C*P/1#59P_,^\=/'P2O8TOPK
MIN`H92'D#LPLO\OE?:@,,;2E*K*!U;ZJ<$Z+68E%6`6'!H6C9RHCG3G6=\<B
M.I:])C9A>[SO+:#)$<B]6RQ&8=D\4E+D$`XDO1!N_<HPN'WT[X%5XOAYHDR^
M?-J(F'RG&$?ON6IS7RKCYB_R+=7?JCG\(TE&2=T(>OR%FVX).6SU=QXW8QG\
MM1FW^'XR#BR*L$']>XTU]E.FO9]:.DQ.17\54M&KI^IF;K^E&WR1"^TAQ>4[
M_2</UYI^CWBK)/]8R!U&D6\_%B(P,X+,H.@I->]IX3$HN9F7G@K]E(DF-VOQ
M8!<30G%8!>_8VNWO/=XE0SK@O`3K-;+UEE(O\7G\*T%),8`.?AR,K$N:L<S0
M'<WTC=G"$>'DS0Z)6Y9?2>7=A$XL%FJ>VU2CV*YJ3HWAE-EPRE53D5](TX^J
M$U/(&!HZFZN:V!B=VB*I[;ZN+#P4IJ1:]ZZ4*6LA:&Q69$',+G011_39VAK@
M8(J#[XA1(^]\HLE5+P2ZO:`RXE%;V\W+I]\.Q\./&$W*_JURG>IOG37YW<PI
MZI?G`V_TJWC]"1]CLO5]<X]IGK1*D6>62$D;=I5(SRWS^$"1!7[:W=S:^.&>
M,%O2+S1M.(-I_C@<$UAX-CG)?8;M]6,E`WHQO6JQ:1"E:GI2T#[.S\[N6SNL
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M2&R&K/B3Z3QT4T-D(B117LKAF`C-D<IBI5JH+Y>E[X[(7Y)</BY/FKNM5-YO
M:<8Y&`_.KFP2@0OTBT_\"Q7^5+4HO2']"8[9)KMEZ+':L9P1.N-`,)`?QC1K
M1+NEW[/NZE1B?FPMG8)RI^T;&F!D:\O#XT]CK1PG!>L<`LSQ=!2<^PA'`459
M?$(3UZ51T2]4^(!7X6BJS$):B](?H7IKTGF>UN>Q98Q8I=K[JM+FD:EY$0%P
M2P18F="/P]\$EBJ*[9].A]X,*Y:!I;^H_,M:1=3/UMM@JK+]48_\\G-LA%V[
M;RX@STIV1.$NPPZ-Z@SG:&5\(D12Q^&S"8H+V$K&W>7H@F8@P]Z&S5;>1NO#
MF.D:%<K`.Y#I9&!H^^?!!9IC/$XX^DGOD%E8([7QL;*VK,ZDB$*W[OK!M%#I
M<PDX&=2&<:"E0XDODQYZADV@CJ?3R158>W7_"-U0FI6UV;%-8CS8K`Y7<(5Y
MZ)S<FC_BV`>6?[Y/+P^I>"4L.R`5!&OSP+3UL6F!Y,AB!6)-SD8TCC:3R&V7
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MN2SI6RV&@BZT/$>_3:,$=?9*3I),2'`$>C6?&CL`CV+-KK7L<?!L#.X%<Q;8
M5!J#&#&O=L#&SF;J:;@.(+FG34A&$_<1VE%L%9X;A9=3HTW%B!*N1Q/S,4;X
M^0@%X9+*%F?A&T==X%OH0$LBU7_]QW\^4K$CO`(VM-`7;HE7"X#,5*8"+@I*
M*C74J!F8.9^G$@.GF%692E"V7(+^%#QXM5NH?\&<)7#=.!XK]R$WF9$F8YD7
MQ5U'\[&U7!.GG<=!VL@K>(J\.C!MGM4&HHD!X8QIU6;I(48X@]EDS+^NY`PZ
M87Q5;T2'>?%MAN'9FP5B)`;G6'928<+6%!!%8'1YQF<%II$T.:I.\O0O5RO$
M!36Y0/`RBCV3JO!9[_(+;YZ/3N[3-];Y)9W"U-J/8A-CY^HOZW#KD`Q1M#75
MB>K\@G+HUN!<@R(U03'-63/VREXBASVB#Z@I(U%I/!^,YPRF,/XM@,WF%TQ8
M3:S<(W`=>TR`,VW2N-<%`M"LB?+^7<G2_27VCQMV='HJYZ!TKV*4F>#&$/DT
MOD@R#@@#NHQ///,G^A'SYUDY=YE8>CGAP@<U5P8=]F'#QP_NI7T;BC@\#"GX
M"K(;!ZD\=5GEBT`9)&6]5+!\;D($L*T3@&@K&VR*M8+CT"*7!JL6=<=UCF)C
MD!)[10!@+4`BBDB8OUD>41S0QZY-VFB$XE.^C6P*+:!J'Q9$!NAMPK#H0,2?
M.B><(+2P^$1]&C)P^0G)9>GGD:T$TU8"36/PS$AUM/AG$.;`'WK/"/F'?*@$
MX8X4IO_ZO_]/$$XF2AHX'JT8,,^OG?\(FJ@A:;Y58ANMJF2#8;C\R;Z-9(#]
ML?Y+V%6I^0;'BJ86NTL#C@L+@VO0*!)^ASK>IL]V+5TE<-,AS<MO&KS.9@-1
M0":;$^G^!$.Z<D]5+E0_1+)888$CS<F(JD$P<6ST;OVE</+J]@+UYA4B_5<W
MD&QD`@YFH%[+,FI.BP[\*,FO&"-C715%@]%L51:692W?'YRA[(3*#GH[:)0+
M+-4:BQ2F<'K15CJ%>F<1SU@U&3)+8IR0@#B7#47PR9?P<EML5E-XVW!%>SQ&
MYX#I(G"PY,J[EBCR8UQ,&"@@>]FV[L3!AP?CV#9PQ,PD8=05=SZG93EL2U9H
MBUT3VH^RGF`GIHD1&3&<KMWHC.)D-`ZNQGLB(W0=)-Z!MJ@[*;>=R*95Y-ET
MH-F0S6)6*3893#LB1$+:\:D;:<^\4W'DGHIEZCO5N)>.6<Q_S\8:-U)B2I&.
MIMX?AA^1I@,?#^N7YPI:EQ:*O!RGD/ZI>EUSV04YCY(F)<AT]>KVN=[`__]=
M+*/0]K2.ZRH*!@8C,^R[%9H1U%4Z[68CUH-$7\G]62W8&`\>.!F127<WXXW,
MF*B^[M;7GQVAL,:AVM+F\*,_>A"X?6:LA3X]4CD,",WE9L4:U':7A\!0ZL[F
MCADP2M<`@MZ%Q^0(7Q"H'*1EDP=E'03X1I^<W@<?+J<3&V`0CRFP&<&`VS$*
MJ4F1>CPBF29S53B-5HJL,S*^RD<M,S'J9(4JH-)HK0Q>HMR&`^Q'E>D:\EIR
M"R<3F!?4WU.')ONBQ;&3EJ&X=M)/^)UMC=&:3"7G/A6/A=I`>@FQI;%:FS4;
MH0(T7P9SA4L9PQ)':#W,!E.*E'$R3067QH=?/4Y,`1/<'Q40_SJHVR%F-$^&
MO7W1$6IRKSU3^+!`BY;30?K>4,AI5BRYH/T:/U*(7,A0^%GJ:E-B1_#Y^/AD
M+!-NX./J[-3ZY>/H)ZY+@(S;,L-OT;OC6K1*8IC:>4F?81WS@0>TS0BO<TQD
M1G*::905O<]V%>*2V;*.^X:9!+]S^HNUQ/93>7B&O(O13"G4YH+'*RN)920B
M';Y*H7CG#=T]3T4,22[-9%P'%VB^E'1.J=U5EEQP6^ZFXY6J:\^P%'V!V\*Y
MJ=PFC0@3><^8`BZ.YO8'?["^:))J^C6064.HQ15<IC76$,Y$0522,78K#J^S
M*Y,D?')R%#AER-($./('FU-,(P#)9<&W;4]C-HG1LDUM/),?_W+HE-0Z&E\0
MYS#4C1P2C8K-2AW'.$3[U0T`_^E$KG)^"I\.F!,W'V[KY`\)9C`<'/$@8[AN
MM__E6(A-">2=%>Q.)Q/8U0P3M_PU#^Z-DT?,T:UCD_ZBB)HH1%;B]<>-Y\K?
MU7E:;Z)5&',5'K;`3M;4%D*%X03FV=!B=A!`AO-#T(H:6O"+!.EK8(P".$]#
M3^(WR&Z6*5\HME3%[;B):Q!K4?5A@1/F?G0)"K#G,'T"QXZ"E;J.(\_H$O>1
M([]Z&,@XGK^N570'P_:SEAJ%;"!K"WT(_/&&H_H%DGZS33<`\2IY)N-[US%G
ML_!8*^.SC2"JPKRFXNG;*AI(WRGXC6NEQ>VEHU?$==+<\G4&/(`N`AZ8Z@Y?
M+A>;'*/`!1)HV]5FGIK6U#EA'6Z`PE53_AE@*AD0*KOY%Q?=X(.4%E?<0IM5
M(-&DV]E-4(N@_T=/+^]P/#T]'/[$F5^1P3]BL(N[KKX;CB<D$_3>R'L+CW6%
M1;'[U66M6N:==:W]\QRU@SR_O1R:X=;4/Q6&FKT[U^UER5#!-SM[ZYU>'@9Z
MF,4K.O5+>"$6CF2$$[T$.=VOPZ^HJREC8%"D>]"#">_5^='T:D)X%Q?$\!Q/
M+:')F*`A*V2`<H->L.-MYN/O"LE$S%X$`RS+X?#5=V^4+Q`D3C!LS*7J(IW,
M3S@M[F'DS!3!IP_G;),XT2D:1!#ZQ1EB7$);]_W(4"#^ZJY_TCHO+GA"GW;G
MIL!U-)J,QFP?Y6=T+-G\\9*Y0+*.0QIH/!K^='S\%KER<9QS;)3;XEJ_[3+:
MZ9;9DK)`V^_%MF89Q.QL(=I8%A^WUHV/B,*,A_O_?7!^\<<WBM_C6)[)`CZX
M,NR*<"TQ,@S2ECHA&',Q4P;03%&AI5Y)[S`\U?(!+PV\"6[)2]LM93^DE!,I
M?4FQL2O(3,(D34O0OD(].7J9E8:_3X[4BI78D9&*8:,J57F1H!0X7(_V;O4?
M;CW$COW<LU=YP1$%5:5>Y?*P@M06CP@9%\"0:;Q%[/XC-*^O)6;'<H;W`FMP
M8#C&@G8F&T7$<IK-4'9LU@]`Q@O(N!^[S0-RA\PX\-V9!8<]H($PS,V37V!P
M"GM`S;64FXE2;L@/X9JBXT/WS9@N'3-S(4S?Z>5'M`F?C1,)ULYFI%$[8/Q(
M4+@-9"[DC3#CUX1`\7M$/R](&PK@Q7NH.PRS>`[RO'"."P<,@$3_3@E5ZCM,
MG@O(YV^Z=ILF7%>OW@T\)5H-#3:!BR3SDE68>@30$LK>I>C9[N^N:6:"@&M6
MH6XSWIK=([467&F#!'9*W#4V?SX@QV%^7N0^8"!,N*TBY!5MX6OO0T@5Z8<'
M81TRDU:;0+&UFY7NA:X2]%HLS>2IV7ZA;H5YR'M)>XS^2GR5J#-QYA8N?Q&Z
M)W4*2P6.R`_X9S6(&08XB3@5!B\OQ7);I=).3^`)/A:5H<BGKBZ85DY04GFB
MR7$,+PG>`&7979GO)GHM<,;96#YM3HX+JGKDA\%PPH:2BQXOR9`23^47'R:U
MI5-<0%@3DF/%DRPN*6;6MRTS_'Q([<X)9ZKREFP4!FF2PM'LPKE#RMR!4V6K
M-%;2-'BU=?,Q1A(N2<F(;G/)<Q/I('*8A!A)+%T^?8_YX_),@'E&I1)Y`_Y@
M]CNW/G1-=G+U>;'X]\$%&9HTB!\^'\V.SYR^_@83O^Q]BX/^A_]3__:K<>_/
M9`Y(^0+1<N:KT>S19$!,!H,M]K_W">&*\9DG98S?D%P)B0`;.8<</$:*R[NH
M#F9^#Q\GQ[#CZ3!)&I]`?P9VW(=STK33?&>E$0@]$T<]QPQ$I64>_042@[P6
M)I>=GHT^GDWP!RF?=7=[:^N>72UU^D>H@_[!RY9`?$Y_%28T$Q!UP7S,0SJR
MK/48Z.?1>7=)2R0DCWH(1KH9?<)(*PW+UBD).@$<5J-"?S+]@75`?L@(I298
M[%5^M;6]ERJ._,"T7AUY((WE<$W*CVC>+C0J=T8HL"FN"_^TK?$>6]?3%GVJ
M<<2]S?\6'07/G$CM<KVI7-ICU2$@:G8%6T`X'_R=6KP<S4@O%0=#X]"C4&;\
MV`SFPK]HYCY%]])?A6'U^.G30]X*^VH$;^3`"UY=W^ZQ4Q!!J-E$,S<!M?$'
M?9KS%[3FC-`T"[\5W<GQ8$9]%W$AU"7IF,IZP.@Y"@[')$2^V7OP*.5_]39\
MK>`)A`;")H0C,PU@-`;'^:HWRR([>1&1J4<ZJ_O,F9P5,<8@XCRO^)ZU^?!=
ML&J>4&S^</:EZ*N8.'E?IY^2(IG;4CSHO54R#\+2]TXGC]UBL+(MDV0!<&*+
MAGBPQ&KY0O!8VM_98@$DN3_*)63*3>&S6F&0IU**@\9%^)#N33*E77:88F6:
M'L#50],A:6#&A6%MV0PM'"Q1B2[/_@IB#&FR58]\VF]GGX"X56@[;'5XQK$B
M*<<:87>NP^'A$4U49//`:BM)]G#N&W;],CB98[B!56J8XV@8;6-+:@YSV()4
MYT,`=SH'-TI5^4:X5V0VZP]1TCA!B<UF2;4`NRY?#H"7>=?_E[,!&-O+T1B"
MD;7P'$-ZZ1<Z!6.W$7@(ELGKI^"'DONP7PQY2'B*QM%\/*!V6/PD(9T=L07K
MT&L&[J-7\I\A(LJ$R0;09,:MV%P,GA&#,+6YX(%^7ID!USC$EC3ZQ5<76A?<
M7$PM;0\L&C$O]*'E#Q!Z2-P`F(4/T-X3H[T!N6XO7UNC]WC`W-X+E,Z3.KIN
M?(B(TWCO?:@+:[S"8*7=EJ;@VP]I)=5HX+VQNTE_C$:[</J"[^XVFW6S]..=
MO<8767ISN]GNFZ5WGS3_O-U_LM-HZ;&Q^6"SN0O^V/P:?VPL>B"RH%F`8G#P
M'Y$5H;VZL=!)4,T3[?7W]IJ?WG[<?[C=:`^R07NF[:WF[K<>]I\\:OZ9-IY/
M'C47V7[2WXPC![+RKK4?[C7.N['U".N\N0BP:8#V(+?;/R@2#O8]P4%`>J<F
M"=+J-^)_-;#MVT&H`'PGX8WSUF34W_:/I)D?7S84_V?)2$,M[?L7KNI@_H"9
M@]QY$>."7<\]DUXE26__\0)7*BV*V02*J6VXL?`U+[R7&D?F-XARS5-MRTH`
MN,55>_V5]9*1(E',);B._R[.9F3/1D/0O(C!C8PBD.Q*$]N^I6,!"JDPRCLR
M5Y,*/U&25<>%J:P9!>C3*.#\S<60>?R257)&ZPMNQBTI'')*'!;XZ=$Q03NA
M.`\WUK$RD(0TT-N?"#I_QK_?[WV/Z_'/K#J\RBG7O_R\M7VO)<IS^?1P.CCQ
MI=\"DZFE'\V5FO[>PBJ2J9U7/,'L5[M60\3WH]D/A4U:132[.!"R>!ZL>^9G
MUIMW//>B0[J%>S3KR"Y*,8&$R.65F5+KY&E:+Q$F4R^2%89I%EVB&$'Y7.5E
M$JWYH6IU#;CO\PN@*^S!CCX7-ERWDI;(=DW>K2%#N6&PB1HX`G*G%=0#,S[1
M`O`^^HEEJY'.$E0S^7:G<R.9RAX-.,D+A`(=CRZM9T[&&+8(E&L`XB_Y\,[W
M+Q`#YX/C(;S_.!@'1&0N<UFQFP+"VIA/R!Y!/444Q!(.8&S!FWO(7Y^YY6">
MH3&I9-+7IZ,A$-<>\!D4_-2]9*:PL3P@1I$;MF+]P?#4K([W0\O5!&C9F]*"
MN?'Q5S&P!&$*`"4S?S;'QCB'[M:*RFIS`P$Z#U!^\9$R/H:83C,_8C0>\+,$
MMX.Y:W@A6#S9\0!%ZAX(-9@GPWTMM?NT;!WW$\C^"_X8WD+NNUM`CC.+\L5U
MDFLC<"I](W]48"P]0VRB]LF0A).-0?4%NHQ&XZ<Y<3RM)X9I=;%BKD4#FW"J
M@$>&W<'?.0.I+%V*PJ.3T`/`0B;NKL*]IA0"'#*_YHK^@K)"`@@B^?J"_1O;
M`!ANBTX[*_KAYX4/])UJ>DGK1E#@"KZTUZ4B7.B2NJ3'*SP"HZE?XU3DAZ\+
MAL%UO9Z,3^^_QH_`U)^9++GV)4RFE*NTO'G'M/C4E`%M3VFK,"#;GH,K5&%3
M>`_V?<1=B3%*QI'*SO2?X5&8TM&P]VE(>J@PW[1E,590<H3\=C_V*(/&JN)D
M9B`ST"IP[I#!;0+_>#0]GI\+V17=PVD.OR5(E=QIN$"GGH1GM68"K%4=A8TH
M<"!^RF[D))&/BVVJ&"#DZ"HBJS,VSZ#]6BP/MB..C?].ZHKN'3^S'+DRB_,A
MJ&,,"7G)K9(^Z3G4Z%6I2AEJ9MF4NSCG8!#BW/.`W6-BHALO\6?S.N./E=1+
M^1*)$P6@&Z#EP38PJK$\*T;'JH4K7KD`LM\=@%Z?)57./Z,C1^ECBJO?XVPN
MS0QI="EI$PYE3+0%^N)[#GSW447D8>G/^%[1)LJ9H73+BF``*=2W$3V%'B2M
MXNP[TA`]Q`I.O<I(MW\3^:07,QVM@F329[AH@9&2`K*W*)?H(Z^(,".L%T.E
MF`6.&J85N';+8CWCZLY2Y*E4&5(JJ)RGP=%<>UE?YVH0FZ?0:<[=#`+49!4^
M(",%BX28,Y8KS[H45(A>)R*%@#+QAI51D7`\*39@6Z!,2PF&J=ZU!5645FKW
MJ0%J2H@7^D)0M&PMD2&=V+L<0(P7D*N=)E,?08\)'(+W724*I"A.@:Q/B.7"
M6\R@`EDQ*1YT>UY40(X`J*YWT[X-,<LH9]R^$U?0*O*7XJ':%B$E_^-\RB_D
M%G@\A6VGU!WMAB>*PYESSAZ)Q<KVT?W<-*%X6!0WF]D]63#_"-W;*^4`JZET
MXG9H`N=B1ZQ*TH`V&1$*K=,8$1;;`BS9+MO3SRO<N4_W"0!Y-OJ!QM.L#\.#
M)IPG5&&J.XFP-`78G+]^(&*]__/WEXCAJB@.+JG>^US/V2X]S8[.(8#GHJ")
M"6Q&[!$^F76:?>;H"<G<@@S/&E_O]]YZN9%NZ9691(H%2"68=3@)#ALH6.W2
MR15D)EA+_K<ZS)!MIDOZ%NOGA_L'QQJQ/*/BA.1[#X?K(]4?O:7Q?51BLY?.
MZ89X%I',F8$EE[O(/%+RN`X"]LRQW:!C#W)_&VJT"@PQ[3*VR\+*)QZ;)CB9
MKHG\EJ\&%$/$*3LM6R_@PLF(3DY6E!2$F71IZ:^RT<%0_[A[IH_"UPN-0!M!
M\XO[]3,4NX9BU1%37S<I/;"^48;A!1^(`+>`:<Z1LZ--+K!9Y4S2IXR/B04;
M_$CRG1AO'V,QSF8>X83U_*A.1)9,YRI18+/GUMHSF`QU/F3"&FXWN1K*5U)`
MT8C[)=H%9=V(<"X:\$0>K[UH8\5AI/24[U>C0W!XBKS<>H+!!OB*!\#A/BLY
M[9P<A?&0'#7&O4_F%VBB24^)_4%-O6`OE_=CK,@1P#1;8(V9[VK/T1`4&$V4
M^XR_*&@ML&NJM$RKBZR[O#'3#RW($$O=?).FF\7HN\U_5*S3H"/J-17EQPD>
MIZ9^)0@1)\2%9`9Z^92+CL#M[,(=>"*4:$=GO^B+T,6S]PYF;4RAB],LX_X\
ME!HZ:S@_;?T6IM,9*[I\"BL@*"^1_M&W%UY_%XJ6]DD+10$Y,/QX&VGK+VA9
M?E_[F=Z=T^:C=[HM#1D*9V1OH^L\Q>:TFOIRH6T6CE5;ZD"Y5_>%17!4X9<)
MK_IV7DJV:N-#LK+5,M=UD<Z/Y^?!YZO>MR&!YT`)/+WOA.B04O='R*J$EJ/O
M,7S1!"A2AT"UZ-"<U7U\.J1/4KFI2^4$1`1,,A$<)%PI5EK_2C0E[?3)ANP\
M27P<S&M:GO6UD4DJP3E4"4[GBB76/%<?6SF[>"68HK:OXOCU;SP?'EWVWJ8T
MJ^[OV(/*K'<?7'V=<AMOU+/)';V@LEG'AA%:HOX>Q$N!A*LXDL/X7*4FH[E8
M<&$!;`Q1Z3?R3I+-]QZM%I,I$(T[8=Z:STG7_%I>ET:ZD^X-'U'6`8S4NF%1
M'K:+T!N$&C*A&H&'<K'<8[Z(.3C!R]LX2S-OZF"\,:C=C3^+AWJ*/26&4E!Y
M;P.S6:FJ]WH;'PZ>][YI,,6V!1ILY!662>.&EN#(8%#V;HN7%E[[O,4Z`*MO
MR<-??P*/3TQ?>SON?3=40M@%327H#`-2@7?>;^BE<IA?_`3"JWXM.5E[^Y?$
MD#`>H4ZD]4O+T+GF$VCW]4_TTS=,V[KQ&R^@I,NK_S&#IN9$/:SR^[E*86AD
M!?_QKD'U+2P!Z.N<S*%".1\_X4;]@P%N_=X;I70E@-4?\\/T_BKM+(+:.S:$
M@Y"VU_[._?(=/G/\O:2/50-Q0:E6*$%DT84.!]C)7/]+X@>H2$MNX_GP3)F&
MBG.F]DWU_2]S%U(*[B/$0*_2QDD(WR,O<:-4'1K$6?[8V(EBY6W:S'YNT2#)
M7#+#BMIRYPOVB]D@$G71TNF;-6CZY%^2/OD>E9D?@H;>9"ZW/5WW9L1((';,
M`KQ<F$HX':N;^1J`.40]NP8<NSX<L;ZSO?8_EU=>P;Q%4:,;>,DR>$Z*.6YJ
MLHJ_VD6FO62L"KMY:\'N4)^+`+^?[.GGU"@?8[?\*A#NU[7-!$['Q2_8W.-?
M#3I^P>:7YNQNQ5?H*TK4'AV4._0MX@1OO"X;`14:(5K&[V>59:;JL3JE1T;9
M.P@C+;IHG*YXWF1'OF(T+<PI-6536R&DVF@B683K^!;K9X785?)^[Y"<>_2J
MPH]G'^E]CYO^"G,P[^$6GWU+IP:EO&`R]'N-`57OATJDD3GQ%SF?^/]^VOH'
MMPQ%>Y1?8]1\:H`AZ=`-%=@=DLE\3D*\\Z([EZIOZ?W0$GI.$$=Q^=YW'`9;
MYS7YRRV.#"U=7V7_QS!\YSZNGOMJ-@FJ8$F;S0=2Q&B)WXR9UDLN@5%/!.##
M&-5:"4@GMDGE^LPUV$1*-(ZH?(8&;&_886-Y/_R2FWRF)/=QTZ0ELFHM>I3E
M`%4\)T)!541]\0\'O4-9#AH8E*%7?^J6#I5@D9GVUVZ3E;Z5UW*J]QH)G^4C
M[;X79'C*TSF(L24\1.ZDJI^I$ULKJD"VM^KOWW"Y>;N=23)T]4_X#VM<Z`U/
M-RM<*0N^M_P;>3NJ!]:5A!$;V:'7?&2G#J7R$6.:W0_4O'`1:;H%"VGV#^*H
MO6O1I7#O>5E,T\%FF7O8[-'#)C.WYI6+("1A0\S*>=4]Z%_CM9P71.=N]R$Q
M_;*O\6XV<T`ZY)G[+N_XNR!E-Q3<=5K_(D:0B@C^I%0->>`/Q):CDM`I.8JW
M$C,'ZT@9P6E*.L6"2![]FG4W:$0E69_M_">^B2'<](ARWQ($C:,6<@#N.J78
MS9RS??%:<E2ECDB&!D$4?JM]R<-2R65;_T;MZ>K!E+3:8.C22?#O!$O@(/1Q
MJ*_[<LXL,>LFH!V^'/UD55_UIU[GM-G.'9HOD^CAB4+XFK[0ZFN/YZ@>("'&
M-=IC?+/U9JZ)8WP['X4.RJ#PV8">F!^5!G!(:V7AIJ)APLWFD67@+?-&J0Z4
M:+#<*E4O^\T(^T5.]H9?7L%G*]L2H4G7>:;T)^A609X&PK=\$TT8)W_P;59>
M%NOP8KDZB%N7P4C@IA4#3>\9KA01]H76T7;2!V3?64B^HJ@+X[\E/LD@0AA<
MEU5A6N-"GTR?\SM<Z!T3XPL]V<IZTB=UW"27@)QKI;AV]X^))G@5K$7RKLXO
M/DU(_'V%N_#:[\;5"'QT\+W*QYUS]TT8A``@QMAGI=<M_ID6-M9.#]VZ@.M%
M`D>1;5S?`2Y;KT<&0"VGJ#]>!#7CF<3;ZU1$$#)%HN'U>+GK"UU'9(BVX8DJ
M')9[R?3;^BL9:#$;I;<1,+WA:$W)93<*9YI'H68Q(I)RNLWZ)^U'=7:AVU!#
M!WLV`2'5)/13+WZN_G[QR#LZKM!]E-P7!<[K#U;ZW'<NUPPDWLQ*JZ%!A0!B
MX%`\C(8.'A?$AF)C:(A4W<ON^U[-`PXI'B')Y4VK:?V%"_\;^44L/*E#X%;+
M?<+[>Y<+OJ0_SIVNAYIW%^OY$#T#X<L%EFSEKG5`!PN[0(R;=OI"([KDMR&2
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M':OED?KZU=]TY;W,6JD_D0;*0`N>`R#[%'.H32.,E9L'LNM,0YZ9Y12&TM37
MCH]C-U'VAI5E^&0Y"/&S7:\(Z?*PFS8W;[JA`NO??E2J%.-V[+9#K@XL,,CJ
M^L?2$O92#`G+M2=MS2)HG:\(7"`HC"8N;S1W\XN5;\&P'8R=WZD\GE.A.I]O
MV=<;;R6VS"O=A)M@]GZ8QACNJQ4+>>L1$IU?:GOG?>KU\Z4?34P&DX=TK<ZO
MQPL6T"U-T1XWZZ3SG19P\OJU^-CRRNC&:VYYJ=4MZEDE'RX0G1GSZKO'K+TN
M;>UFU;<P3)22%BO'ZM\I,J8*CW7]J=IBF(_*@HN62/WI!??>K0,U/U?+P8O<
M0//@Y"J[25U?>$&,0')&N6N4])Y4S8:H^H*EI*#?U6)2SF^YEHY8OS*WL8FG
MC!3\=-)*\R^(W05\ZQ2;$%1#:S6NN+3&6DK1AJ`L4QG#9D-7,M)-+,>R?C`_
MRBN4-DC@.1%$%!*8%*'CX!\"E]4?P)YH7K;*#^P5V:U9#Z]_!2^'^[BD$IMP
M].\2N;?WZ\\G_,7R_$!]X53U;OI.%%R>R6Z$A'N3`HOK5LAGE&_&%-/&\_F9
M.AR4+0CISP%$NQSK3%Z]F0D%*%B4#FX!EU=>@"G7/5(:@[20%\N3M?D/G1GM
MQ=ZL'[I@5KYRU:_P)4MZM#_J02J(>T,=*'50CC(1K8"0M&`T((LBU#=F4JCW
M-HJ(WF%<Z-NX4"]XL53<5$(%O1G;;O\]T&_`6?&*^I="6GZODD"PT)L-X'G"
M[_(+5;<?;Q5Z6F@;`=2!(KG`-.VY?8.W7M:W^^UD3,U*S/%8:*<INTHVJGIW
M.>R)&.'VJM]+?GC?:GZ7>[AQ=-MH>QBN'6,3HL'.2!%+&39Y7PN=N16];K-@
M)[+<:E'E4]*&W[GZM3@4;_S6G[M-<BIW,C\_PHD#?POXOS^G'&^JS),Z)MD#
M=_VU'T,^C05N6Q&X@1X.N23ZKXGCV8Y-T)OFI`[F<DXP`.:V[JL[@$6J8[)3
M4\%*-"K(_T;>E3VB%GV,%$@51"NXG[2GR#PKVW("A^>@><S(_S;1N,I=5$1`
M`R@Y&4T&CHHUY_#"0U)\ZWL*";R]K<V.A+2[O,X`.M5179M!=].F0S)R[_$:
M]EP!]!HON`*K&[Z;)$?)N7M_>\/DC.&TT5+M+F^T`AUGF'4,6]GG&E@?*=.5
MU57NH\F76B,7BQR=IB'7E$C$<G08<_.;7Q$`$=0%$_P2>"]\^);OM7"0^-3J
M$8#0P&AJ+JSU0:#EBU\5!N3L?!R&_M1)0J\4"UJ_^%5A$##.)=KJ^5_E<TN2
M_XW*XDZGIV@1/G8#&RLM.@6%ZM93D[]]"2;=^29:D&M="N=-$),/"$5)/1BP
M;5L$Q%<`X(U[^E)XWHB\NR!O':>L&2..T/<''V;TIF]/-;WVI16`,)TD1M-G
MP<UD/722E8'MJUH,Y=JNC*TLOY4&RUD7,2RXU;J.]/7NK[Z3+T7\.V"]"\).
M94OXF6\ER6_@OU^XDU\_[()B\NL`7\MF6B#8[2P)*8KF-$^NI$[=@`1,6K6F
M%%Y[RR,A[CU_1['?E.Q[;^<2,WW]L3IYQK7,_E=?!.5$R*.N+"%52:=2POJ;
MEF-B3:5CFO]K@C\D&_?:(F+UMR49-IJ=*5Y\>,]4R/_XST:RIB>&6-9(LZ]\
ML14B#Y44%RD^<FH>_W_.KF4%@1@&_HH?('CP+BP*@N!)#UY%/`@*@OK_SB2I
MNYNTW>)YD_2UUFTSF2&/MO9V;(+B+\!RE#,NI(,T!YUX#JS($C,OZ-F>^`PD
M`DAY"!&F'V<E@N9_WTAZ_N>?IKO9N[R6VDM#3V#->[R#P$L>H"<660XD+[%E
M@2ZX,%,I`NL*@+HJ6A]/0-H!OO0$GYGIDLH]JI^]DAT70/4'NXRB9(A"G4_<
M9LYVT*A+T`B%6V5-TRAPXA29K"8C)+-48P>`6:.8Y`VI]Y5OGP]E+)G'7..&
MGK2LDXECYY:KYHTFR%2B:DTUB+(%P+I=1,>PNF,3/4PHT)YQ;:M`[H]03_UU
M3`[=!\'7M&PX/DI?13%5#5'O9#G^=J!'U(WTB.J+USX".5=D<A7U^!@/ZK[#
M&]1`,30%0UA6T7N'ZS,A6J-,Q?Y,N&L!O3?T7/K!"7K/0/3AX3!L>(C_)K!.
M$)R3J6[ENA;J6P42*#`#0Z-D``(\SOT4"8E/H)/O>M9(=I24AF>F;2[D91=]
M36]W4@SY0/)IB7IJC@58$'B;UDE;"]9`ATUYXQM8O%[OU1<``/__`P!02P,$
M%``&``@````A`+/P&M)M`P``.PH``!@```!X;"]W;W)K<VAE971S+W-H965T
M,RYX;6R,5EV/ZC80?:_4_Q#E?4F<A`00<'63VVVOU$I5U8]G$PQ8F\21;9:]
M_[YC3PC8@?:^[)*9XSEG9NRQUY\^VB9X9U)QT6U",HO#@'6UV//NN`G_^O/U
M91$&2M-N3QO1L4WXC:GPT_;'']87(=_4B3$=0(1.;<*3UOTJBE1]8BU5,]&S
M#CP'(5NJX5,>(]5+1O=V4=M$21SG44MY%V*$E?R>&.)PX#7[(NISRSJ-021K
MJ`;]ZL1[=8W6UM\3KJ7R[=R_U*+M(<2.-UQ_LT'#H*U77X^=D'370-X?)*/U
M-;;]F(1O>2V%$@<]@W`1"IWFO(R6$43:KO<<,C!E#R0[;,+/9%61+(RV:UN@
MOSF[J+O?@3J)R\^2[W_E'8-J0Y],!W9"O!GHU[TQP>)HLOK5=N!W&>S9@9X;
M_8>X_,+X\:2AW7.SI!8-,,'?H.5F#T#J],/^O_"]/FW"-)_-BS@ER3P,=DSI
M5V[6AD%]5EJT_R"(#*$P2#($24'FX$]FR6).YOG_1XE0D<WD"]5TNY;B$L#V
M`$[54[/9R"J%$M;&^-E8K0]4*;"^;_-T';U#+>H!4B($MO((25Q$]0"Q&"$1
M\(\B(+4[$8&I8QJ/8HS7$Y.-<:S>$B$+6R^30'5G<)B@>'=,UW2-=1/"FC&7
M?.XQ(*2PM<C2V/56S[P.=^9P^UD:KZ<A=UE*A&160^H)K)XX'06PV>ZR]Q48
MKZ>@\!0@!*N0YDGA]:&Z]R_(,KN)='3DCHYK%XS5X[_M%^PS0I:V`O$L)JZ\
MZJG;82\>LANKQ[YTPY<(R2W[/([]3?#4[;";X3\]<,;JLA=>^!(AV'W/5SWV
M.;S+A[S&ZO%Z12T1\ICWL<_A)3!6'R1LS1ZS-T#*`8/M)C^]>".H>NYW%3R9
M<3B?[D]]X3&4!#'8\B6T?-+T_T*X*LQ(FC:>X*1R5'BGJAPPJ((D"Z]#U>#'
M%BW(;;DKX/'L(]/A5]R.+1Z[`6.O4FNI[BTNBSOEKF<;KN')1O/'VX#!-(MD
MGF>31#'*<`))EF:W(XHJ\*[&&ZYE\L@JUC0JJ,6Y@]F>P-$=K?A&*,D*;@^X
MLCU[!6\':X]&!]SH/3VRWZ@\\DX%#3M`R'A6P-"3>/GCAQ:]O:YV0L-=;G^>
MX)'&X%Z*9P`^"*&O'^9Y,3[[MO\"``#__P,`4$L#!!0`!@`(````(0"0;OL/
MR04``"$5```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULC%C;CIM($'U?
M:?\!\3Z&OG`;C2<*1-F-M"NM5GMY9C"V40Q8P&22O]]NJDUW%3B;EQF[Z[CJ
MU*4/33^]^]I>O"_U,#9]M_?9+O2]NJOZ0].=]O[??WU\2'UOG,KN4%[ZKM[[
MW^K1?_?\\T]/;_WP>3S7]>0I#]VX]\_3='T,@K$ZUVTY[OIKW2G+L1_:<E)?
MAU,P7H>Z/,P_:B\!#\,X:,NF\\'#X_`C/OKCL:GJ#WWUVM;=!$Z&^E).BO]X
M;J[CS5M;_8B[MAP^OUX?JKZ]*A<OS:69OLU.?:^M'C^=NGXH7RXJ[Z],EM7-
M]_QEY;YMJJ$?^^.T4^X"(+K..0NR0'EZ?CHT*@-==F^HCWO_/7LL1.0'ST]S
M@?YIZK?1^>R-Y_[MEZ$Y_-9TM:JVZI/NP$O??];03P>]I'X<K'[]<>[`'X-W
MJ(_EZV7ZLW_[M6Y.YTFU>XY7]1<52?WUVD;/@$J]_#K_?VL.TWGOBW@7):%@
M//*]EWJ</C;ZM[Y7O8Y3W_X+(*:C+TZX<2(436/G.YY&+(K_WTL`C.9,/I13
M^?PT]&^>&@\5<[R6>MC8HU`EK/3B>[TZVQ2K4:U^>>;Q4_!%U:(RD!P@:I0M
M!".*#42Z0`(5?R&A4G-(>+J.(ES(:"LADRQ^9KXY0-*Y7CJ!PEE`D53QG$BW
M=/6J"NGFDI$(`)$V@K.`(LC-"'IU[RM62[5$2"(`))FKS43"8U+QP@6(1&:6
M(B*@)LI)D1936PD11H@`)(:VASQ,!`84+B!C,;]#)/XN$6TE1#B.DP,$B+!0
M1-A<@%G./)/,EA-5(T$D;@W7JR0X23('B*F"2*5-<AZY`NP0_4YLK?-V;]%.
M:"OA('&&.4"`@TQB8BZ0.19V7E`%,L3B5@&]2J*3^N8`@>@B3K.4[+K"!3`A
MH\@21`R84E9:B-CN[]E,N-A<8(,;S&T64EMQZ`:R2R9B.TN8RAV]`ZU"^Y-D
MFS/`F&[(2)*)*;X#P!RT.-FYN'6$@68A#E8O31D``QPB(2)"LC!.;H#(`6`.
M6KXV.("J(0YD\',&&`@A9$CLA;'#SF#RWDQLZR1;"Z4DO<X-QC0B45I)IJ5`
M")Y(%EL?N`Q8+)=6@,*I1!>YEE0EU8->[R#GB>"NX"A8"9<H:PF4=FQ-PY$&
MBG"E`<P%9`FSFQA3V-9!MA9".M:YP4"Y6<BXK:79>ZY4)G%RK^-8#I<JK'70
MF1E3!5?I6,S(MB@8V,W(9?=JL*V$;"V%TGHP!%RIXR&+5_O.!;"$V1JA-G"L
MA+<:S,M8`269Z=Q@S-3++*;[#@%8QK,[?>!8`NEC:383+B3;W&#,2/`X67%Q
MM5(]&D);4%P/K6=K&>(@<ZX,2=+SW&"`0YI$H2TYC"4"X)YA#MM2R-=22,\`
MN<&8.J1Q8M,T'%RM9&GB#!;FL*V&?*V&$4DS-QC@P$6T.B8A@.`BM9.%.6QK
MH7ZW(">%B&JAP=SJD(B(=*O`B%!DF9TIS&);*_E:*R.JE0:C:K:H=D2?T=_'
M8";;DLE![=QG@W/N`;DP&.?9X*[@*%@5Y]TH(_ONLU;'B`Q9SEWU(^-1W#%B
M#E@85QS6`AG9&3(9`\8<QNG+8L%=<\3N*)-ZY]M2@WD9*Y)SK('X!F,F4*29
M.V"P%S&$)1$+[92B>@BLD#>5GI<)#^O!\'"%[X&Q4'(ZIX7Q`UP?6*AV@[-?
M,!.LCU2KQ5HG(R+%N<%`9QYBNB&0V>XHS`(KY(K%6BF=\Y:IBRN$#UPXKVNF
M.PC`HM`2Q5RVE5*LE3*F*F4P1BE3&:[.$0C!$O6<O\=B6RO591/52N=%Q%0"
M,/">+[=.K\8+(#9/KW`C!?<X;3V<ZJ*^7$:OZE\[)7U<J<>R"C=A.7O,N;Z[
M(.N%NB&;UX/%H.ZMKN6I_KT<3DTW>I?ZJ%R&NT31'N"*"[Y,_76^E'GI)W5C
M-7\\JZO(6MV^A#L%/O;]=/NB+]&6R\WG_P```/__`P!02P,$%``&``@````A
M``]UP.ZZ`@``5P<``!D```!X;"]W;W)K<VAE971S+W-H965T-C(N>&ULC%7;
M;J,P$'U?:?_!\GLQ!`A)%%*UJKI;:5>J5GMY=HP)5@$CVVG:O]^QG4`A:=4\
M)&'F^)RY>5A?OS0U>N9*"]GF.`I"C'C+9"':78[__+Z_6F"D#6T+6LN6Y_B5
M:WR]^?IE?9#J25><&P0,K<YQ94RW(D2SBC=4![+C+7A*J1IJX%'MB.X4IX4[
MU-1D%H9STE#18L^P4I_AD&4I&+^3;-_PUG@2Q6MJ('Y=B4Z?V!KV&;J&JJ=]
M=\5DTP'%5M3"O#I2C!JV>MBU4M%M#7F_1`EE)V[W<$;?"*:DEJ4)@([X0,]S
M7I(E`:;-NA"0@2T[4KS,\4VTNHTB3#9K5Z"_@A_TF_](5_+P38GBAV@Y5!OZ
M9#NPE?+)0A\*:X+#Y.STO>O`HT(%+^F^-K_DX3L7N\I`NU-[A,D:E.`;-<+.
M`*1.7]SO012FRG$\#](LC*-9BM&6:W,O[%F,V%X;V?SS(!=Z3S([DL#OD22:
M!\DLS1:?8"$^(I?)'35TLU;R@&`\0%-WU`Y;M)I!"9DUWEBK\T%4&JS/FRR.
MUN09BL&.F-MSS(`@P-Y+0,`7)*QU+)&&BXG$.6;6(T82\44):X528]1GD83S
MGL!E>NLQB>OSVZ"3BXS6FF,(JV?,XB$DS^@Q2U>U-,AZO5'`T/8+-;'6*7W<
M$WAZCTF.](-W1#^_2&^M4_ID0N\QGCX,!N^(/AO1(SOW<=@/C_5.9=*)C,><
MLAB:,I*Q>W*832>3I+V,]4YE!B)?+(_Q,DFP#$>?=Y);?JAJO5/5H<=>U6-.
M-1R\H^0B6#<?9.?<4Z'I_3B"3DKOW#]8@6^5^CON+_!XF)>3/KFS.?;3'`;3
M<?.KT2^4CN[X3ZIVHM6HYB7,1!AD,*W*+T;_8&3G+OU6&MAS[F\%+S`.2R<,
M`%Q*:4X/=O7VK\3-?P```/__`P!02P,$%``&``@````A`#F[M@0Y!```%PX`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-C$N>&ULE)?;CN(X$(;O5]IWB'(_
M)`Z0-`@8=0X],]*,-%KMX3H$`U$G,8I#T_/V6W8YB>VP+98+#G]^ES^7[;+9
M?'ZO*^>-MKQDS=8E,]]U:%.P0]F<MNY??[Y\>G(=WN7-(:]80[?N+\K=S[O?
M?]O<6/O*SY1V#D1H^-8]=]UE[7F\.-,ZYS-VH0T\.;*VSCOXV9X\?FEI?I"-
MZLH+?#_TZKQL7(RP;A^)P8['LJ`I*ZXU;3H,TM(J[X"?G\L+[Z/5Q2/AZKQ]
MO5X^%:R^0(A]697=+QG4=>IB_>W4L#;?5S#N=[+(BSZV_#$)7Y=%RS@[=C,(
MYR'H=,PK;^5!I-WF4,((1-J=EAZW[C-99R1TO=U&)NCODMZX]MWA9W;[TI:'
M[V5#(=LP3V(&]HR]"NNW@Y"@L3=I_2)GX&?K'.@QOU;='^SVE9:G<P?3O11-
M"E9!3_#NU*58`S#T_%U^WLI#=]ZZ\W"VC/PY"9:NLZ>\>RE%6]<IKKQC]3]H
M(BH4!@E4D#E@JN<@/=AXH1K#9]^8S!;!,GKZ/P@`*\<!GWV4\.$H'B9%)C/-
MNWRW:=G-@14*P^:77*QWLH;(*HLJ%4->87H+X7X6]JT+>P@RQD%]VT5DN?'>
M8*(*Y8FGGN5J;GJ2WB.F2P1.;2%#`=Z'GL@0PP/X800P#]H(>E"A"M"^@Q@%
M/5Y(@B&BA$@>\*133T2>S#C9U#/V9+##<KK#+E2#'06=/2*AV6=RSQ.9GO2>
MQXJ3?>PQZ&$]:_1R[2R6PU(13V&O:1,8D94)%*-G,<Q28@NI+62:8,#`XM5@
M^F4@U*T+\S&LHG"^L"#0$\G5',Q]^3(M"5I&SM06,DTPL$(#2^9H[@\Y$D]-
MO"CPS;YC](02CX3WZ-"AT=E"I@D&7?0AG7AJTXV;4&Z9&#V*[AX<&C0X6\@T
MP8`3)[55FK34B:<VW+C+$`X]"!<0.*#A968W08N&9PN9)AAX*P.O7W!"M;&L
MXA>C9^PSL874%C(4^I$LS)$86`1.T@_2)A_;@/:.4";L3NT(.W'*,XXBG2B9
MKIB0HKJ/<]LGCPC9AIL<+V@:.TY4,\2%#61F1YTO=JM,M9)Q3#A1ON_`8577
M:TD46-4S)FC2X6PE51Z5W>4]W$R/8\*)^CS"V06%8/DV(:UC(%8F'1*;C4JJ
M/`A)_@-2:V5"BB(]0@[3B[7;A+/.SIAH!1Y/Y8F23I1,*8@;++0[B0DFRO0=
M,*S>)IA]5L'E4BS.,4?)1$DG2J84E<>%58-,.%&E1[C)U&(1-R#GUJZ,X<9M
M0]I*.O&(>[IHI8Y`G.RA3B(CWL/QZEC3]D036E7<*=BU@:,U@--I4(?[__-<
M'.R6'I,U7/9`]X8'<%N_Y"?Z(V]/9<.=BAXAI#^+(.$M7NSQ1\<N\L*Z9QW<
MT^77,_P!HW!_]&=@/C+6]3]$!\-?NMV_````__\#`%!+`P04``8`"````"$`
M^^MGL88"``#`!0``&0```'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6R,5%MO
MFS`4?I^T_V#YO1C(A30*J9I$W2JMTC3M\NP8`U8Q1K;3M/]^QW9"(9FTO@`^
M_LYWOG-C=?<J&_3"M1&JS7$2Q1CQEJE"M%6.?_U\N%E@9"QM"]JHEN?XC1M\
MM_[\:754^MG4G%L$#*W)<6UMMR3$L)I+:B+5\19N2J4EM7#4%3&=YK3P3K(A
M:1S/B:2BQ8%AJ3_"H<I2,+Y3["!Y:P.)Y@VUH-_4HC-G-LD^0B>I?CYT-TS)
M#BCVHA'VS9-B)-GRL6J5IOL&\GY-II2=N?WABEX*II51I8V`C@2AUSG?DEL"
M3.M5(2`#5W:D>9GC^V2YFV*R7OGZ_!;\:`;?R-3J^$6+XIMH.10;VN0:L%?J
MV4$?"V<"9W+E_>`;\%VC@I?TT-@?ZOB5BZJVT.V9<V&J@4CP1%*X$8#,Z:M_
M'T5AZQQ/YM$LBR=).L-HSXU]$,X7(W8P5LD_`92<J`))>B*9@LS3?1JEBUDR
MF_^?A01%/I,=M72]TNJ(8#H@INFHF[5D"<RG%$XZ^J2@M,RA[QT\QS"_(->`
M]66=)>F*O$"5V`FSN<8D8\3VC'"5<K2[@8&`L%X=Y#Q0=Q;AK$[$V7T3#$#2
MJ[K0M/T'8C$6M;N&9.^0D:K)2)6OV23N2^1NH<$#,5DR&<?:!(P?35^`[:5A
M-S",8D./!A6YC.UN<PR9](7(DNE%[(#)?/,FV3R.XS%@.P3,DN0*`"OEH@2&
MZ2W<OS,$K6%CPIQ)KBN^Y4UC$%.'%H2E$+JW]HMZG[I^7M@WL,!^"TA_`7O5
MT8H_45V)UJ"&ET`91QDLD@XK&`Y6=7ZZ]\K"1OG/&OZ4',8MC@!<*F7/!PA,
M^G_O^B\```#__P,`4$L#!!0`!@`(````(0!)<-VC$0,``#8(```9````>&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;)156V^;,!1^G[3_@/Q>[I`2):D:JFZ3
M-FF:=GEVP`2K@)'M--V_W[&=$.QT6I>'`/9WOO.=BX]7=R]]YST3+B@;UBCR
M0^21H6(U'?9K]./[X\TM\H3$0XT[-I`U^DT$NMN\?[<Z,OXD6D*D!PR#6*-6
MRG$9!*)J28^%ST8RP$[#>(\E?/)]($9.<*V-^BZ(PS`/>DP'9!B6_"T<K&EH
M11Y8=>C)(`T))QV6H%^T=!1GMKYZ"UV/^=-AO*E8/P+%CG94_M:DR.NKY:?]
MP#C>=1#W2Y3BZLRM/Z[H>UIQ)E@C?:`+C-#KF(N@"(!ILZHI1*#2[G'2K-%]
MM"P+%&Q6.C\_*3F*V;LG6G;\P&G]F0X$D@UE4@78,?:DH)]JM03&P97UHR[`
M5^[5I,&'3GYCQX^$[EL)U<Z42<4Z\`3_7D]5"T#D^$4_C[26[1HEN9\MPB2*
M,^3MB)"/5-DBKSH(R?I?!A2=J`Q)?"*!YXDDBO^;)#F1P',B^9>"P$2CL_"`
M)=ZL.#MZT%F@5XQ8]6FT!,)3^*<8IH1`62J%OE=P;02A"EA]WN1IM@J>(</5
M";,U&#@?$R8K$AM3GC&J-*!DD@.)<>4DX>1=[;K><YMY>XW)BM3&E->8/%U,
M&$L0Y&0FZ)P&M0H-,`LQ3V\G`IVJK<&DNOXJ=^5LP7*16BYT"68QJ]TU`L53
M-O.T<%P93*[KD65Y>%LDH0TIYY!HD87J-T$L.=#-KT2L5AT9V87`1&PPA98!
M$S-,B_EO\J;!Y1P<^_&EB2PQ^:MBU*HK)K+YMP9CQ,1AY#LY*^?[R<*_F%O^
M%Y9_MS9JU]41.SH,)M5)27RW$^>[%TM+@KIH+B?TW(%JU77M'+*MP9@4A+YS
M4$I[]R_."\NY&[_:=44X$6X-QO1FE!9QEBR22[)-+\PQB6[-2VN97)CY;297
M3_B>E*3KA%>QPZ"'[F8UK9IK8PO7AIZ]P;0!TWS$>_(%\ST=A->1!DQ#?P&=
MR,W@-Q^2C7K([)B$.:Y?6[B?"9SAT`=PPY@\?ZCY-=WXFS\```#__P,`4$L#
M!!0`!@`(````(0`3"S<$S@,``/\+```9````>&PO=V]R:W-H965T<R]S:&5E
M=#4V+GAM;(Q678^;.A!]KW3_`^*]`?.=*,EJM]6VE5JIJGKO?2;$2=`"1MC9
M;/]]QQ['@`/1YB$)S&'.S'CF,.N'M[IR7FG'2]9L7++P78<V!=N7S7'C_OO[
M^6/F.ESDS3ZO6$,W[A_*W8?M/Q_6%]:]\!.EP@$/#=^X)R':E>?QXD3KG"]8
M2QNP'%A7YP(NNZ/'VX[F>_5077F![R=>G9>-BQY6W7M\L,.A+.AG5IQKV@AT
MTM$J%Q`_/Y4MOWJKB_>XJ_/NY=Q^+%C=@HM=697BCW+J.G6Q^G9L6)?O*LC[
MC41Y<?6M+F[<UV71,<X.8@'N/`ST-N>EM_3`TW:]+R$#67:GHX>-^TA63P%Q
MO>U:%>B_DE[XX+_#3^SRI2OWW\N&0K7AG.0)[!A[D=!O>WD+'O9NGGY6)_"S
M<_;TD)\K\8M=OM+R>!)PW+%\I&`5,,&W4Y>R!R#U_$W]7LJ].&W<,%G$J1^2
M(':='>7BN93/NDYQYH+5_R-(A6Z<!-H)_&HG)%E$09QF[_#B840JD\^YR+?K
MCET<:`_@Y&TNFXVLP+-.0<=ADH+:%A+]*.$;%QH8PN5P]W6;Q/':>X4J%1KS
MA!CX-AAB$![0&F[@&W!?*>1=22'+*#F?\,;07S#M+QSY4[E$L0E=6J'P@["B
MI1TZ8B)UZL-(HUO/H6\\2^O&A3!-PDF<F!`Q"<20D*BBS10$FF%0$)7`@$9:
M;9K4HD',E<9?9'V&H](G=YFDU6;*+";$)"J=V,>/@8RXTENNP;%(J\VU-(ZP
M>(A!+J+)#&3$):75:N=!!:75XDI\XPBY$(-<01"'81#-M-OR+I>TVES]L2,7
M8I`K)*&?!GTTH[0(:-.=O)39)NNC1C(-TB>6920C,\U!Y`3/5U&9;;;0*J,&
MZ=R"(`K#_E3'N8UEP.YZ@N,_FJXDLMD0A&SI,DW]N4*.->*J.00'?TS25T<7
M$$$Z)=GQ)HIQ0F.U,!P3,I'8,D$0A!SP.I_EN"\5\!:Z[3Y;*S0H52-\CVM"
M+`8#3";4(K'50H,P+SW",]6;D(O!"),)O4CZSM(G-1(,'[IAMHX3@C',;4(Q
MTO[8-1N"(E7'WCCNB0FQ&/),J$5JJP49RD60IE$V0Q9,J,6`3)FM^4UMM=`@
MW8A)"N.;])A1;L&$7"3]VU&9;3I;+C1(]T<49U'J]T..=+B'X?92T^Y(/]&J
MXD[!SHU:GK9K<]?L?X^!>I<;`VQE;7ZD/_+N6#;<J>@!'O47*<Q+APL<7@C6
MJMUHQP3L8^KO"19M"ON(OP#P@3%QO9`KHEG=MW\!``#__P,`4$L#!!0`!@`(
M````(0`UP$>,904``+03```9````>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM
M;(Q86X^K-A!^K]3_@'A?P-R)DAP=+ML>J96JJI=GEC@)VH`C8#?G_/N.;2#V
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MK4C0/RV]C<IW:SRSVR]#>_BM[2ED&_:)[\`+8Z^<^NW`3;#8-58_BQWX8[`.
M]%B_7:8_V>U7VI[.$VQWQ)<T[`)7@O]6U_(:@-#K[^+SUAZF\\X.8B=*O(#X
MD6V]T'%Z;OE:VVK>QHEU_TH2F5U))_[L!#YG)R1VTB@*XS3YO)=@]@(K%B^^
MXZ<1B>+_U^+*N$0^RGJJ]]N!W2PH,E`^7FM>LF0#GN=$S-&LJ8$=:CC[*Z>+
M11#T"-;W?9R$6_<=<MW,G%QRX*BL'*(SBH7!\\W=EMA0+=?AFPA*5[F00BPW
M\%9U',7J(OW:N<GQ=4;Q@)'JE-*D)(A2F90HB%<W6E"PLSBH,%J#XBB4G9+.
M,,-!24XHJHXGM,"&$ALJQ:")"4TQ4*3+_G-T9T-LZ][&R3TJL9FYY&2B.HCC
M!VO0`BYT.,ITN-3A(-'A2L(B4DTVU"[.87PO#(YBV<AS+CF)D!T&GN?I5RY4
M//`C@U"JA#"&CHX\5))@:H]-[4K*.8JUHV++)0=RHVP+2FRQ<-9#APV58M!R
MFYCZE-QR%.E+4>2YY&CZ4MP4%LZJ#QLJQ:#IXU,9]3!%'T>Q/G3D<\D)Q=XC
M[<6"K;JPH5(,FJ[L0UT<Q;K06<DE1]8DUB6Q^YDOL:%2#)HN`O-22=ARMH49
M*S*:.U^[L^^7+>9E=TMI6"K5HDOAC1[MG=+[B)P#T*O6PC:;WTRZ"R@,2VE8
M*M6B2^*=^P-)LK%K+3#%_9A(4BP*R@]B#VUL@0B!AYIHJ1-(Y*-+5#K!"Y4V
MK(?#&ST*1SD=1,X!/1PD)I])LJ7[#D%%42`\1,>K1'CD9>H?:F858J?WJ^F!
M\5&``E-+1TX*/3#<\XDDR7T*(P\)+S0\"#-T!DN$AZBG53,N2E,7SV<!$J_T
M?+@7-9L#RE,^DY9!&R.\T'#8-52#I8831\FS&-35C#\0SP<%$J]F7LX1/?-H
M&N5D&3;\'O+)-^X2=#Q*T,Z4.AXKMU:S^,4_OH,D?(H@\6KFY9#1Q.-MSX6/
MG;UD/D3GI4!X@LYNB?`8K:]F_$'F^:A!XM7,RTFDBT<UF1-)DC7_%`3!_7S)
M&[29(*?A4Q891:\Y('Z`KE"M#HS<\XF$Y*NYEP-+EX\V/B>2)',?.)&A7L<S
M="I*;7WL9.A45#-NYM[7IZ9X5%)R+V`T/;'S?";-J8U#)*[0<9*B?E7JN#D4
M5AQGWG\P9Y7,"QB+1YG-9])2]1D25V`<K2\1;CXQR6'_(/-0$;ALU,QS&(M'
M1R[W)4E6/8DS'Q5MH1.2`,LK=4(4I:@RJYGP0/_'(QA>=)CZ44O(9Y),/CSW
M&\F73A8\0NM+M#Y!Z_G;EO6^3DXJ^?)$OBSHZ'"B!;U<1JMA;SW<C!&XM5FM
M\J5-3C;P(,\K;P7@5<JU/M'?Z^'4]J-UH4=8ZCE0>=8@W[K('Q.[BN?V%S;!
M2Q3Q]0QOQR@\RGH.D(^,3<L/?H'U?=O^/P```/__`P!02P,$%``&``@````A
M`.P\[/GF`@``=P<``!D```!X;"]W;W)K<VAE971S+W-H965T-3@N>&ULC%7;
MCILP$'VOU'^P_+[<-D"(0E9+T+:56JFJ>GEVP`1K`2/;V>S^?<<X$$PJ=14I
M"3/'QV?.3";;A]>V02]42,:[%/N.AQ'M"EZR[ICB7S^?[M88246ZDC2\HRE^
MHQ(_[#Y^V)ZY>)8UI0H!0R=37"O5;UQ7%C5MB71X3SO(5%RT1,&C.+JR%Y24
MPZ&V<0//B]R6L`X;AHUX#P>O*E;0G!>GEG;*D`C:$`7Z9<UZ.;*UQ7OH6B*>
M3_U=P=L>*`ZL8>IM(,6H+39?CAT7Y-!`W:_^BA0C]_!P0]^R0G#)*^4`G6N$
MWM:<N(D+3+MMR:`";3L2M$KQH[_)8^SNMH,_OQD]R]EW)&M^_B18^95U%,R&
M-ND&'#A_UM`OI0[!8??F]-/0@.\"E;0BIT;]X.?/E!UK!=T.]9&"-W`3O*.6
MZ1&`RLGK\'EFI:I3?!\Y8>S=^T&(T8%*]<3T68R*DU2\_6-`_H7*D`07DA7(
MO.0#)UB'?AC]G\4UBH9*<J+(;BOX&<%TP)VR)WK6_`TP7TJXZ)B*`FL+C7[4
M\!3#_()<"=&7793$6_<%7"HNF.P6X]N(_8C03FG:?!9P0=BD#FJ>J1M%Z*@6
M,1[/3`!()E7!XL9_(-8V)+^%Q%>(I>K>4C5XM@HGBW06&CP3LTI"^Z[,8%93
M!?ME()\%K+NA1S-'AKLC;[I;9U,,E4Q&1,FUB,'KS&"BH7F^%X219XO;SP%K
M#UYV/I_GDY7O7[VVE,)D+Y7&5Y=T=JDTL2_*#"8Q2ITPLM-[.[VL,[?3UR&U
M1$:W(F=VZJPM,O86;F4&8^P,X]4ROS?Y:ZOS6<"2$M]*2:Z=U=FEE,7/*C.8
MT:^E728[$S(+&"%FT9GUT%)QI'O:-!(5_-3!/`70ARDZ[=?'0`_Q(I[!WAV6
MESLE8!WVY$B_$7%DG40-K8#2<V`BD#";TSPHW@]+Z<`5+,+A:PU_<!2VA.<`
MN.)<C0]PL3O]9>[^`@``__\#`%!+`P04``8`"````"$`)MQ-E1D#```@"0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6R45EUOFS`4?9^T_X!X+V"^
M\J$D59.J6Z5-FJ9]/#M@@E7`R'::]M_OVH8$3-9U+TGP/9QSS[G&9'7[4E?.
M,^&"LF;M(B]P'=)D+*?-8>W^_/%P,W<=(7&3XXHU9.V^$N'>;CY^6)T8?Q(E
M(=(!AD:LW5+*=NG[(BM)C87'6M)`I6"\QA(N^<$7+2<XUS?5E1\&0>K7F#:N
M85CR]W"PHJ`9N6?9L2:--"2<5%A"_Z*DK>C9ZNP]=#7F3\?V)F-U"Q1[6E'Y
MJDE=I\Z6CX>&<;ROP/<+BG'6<^N+"7U-,\X$*Z0'=+YI=.IYX2]\8-JL<@H.
M5.P.)\7:O4/+'0I=?[/2`?VBY"0&OQU1LM,G3O,OM"&0-LQ)36#/V)."/N9J
M"6[V)W<_Z`E\XTY."GRLY'=V^DSHH90P[D3=DK$*E.#3J:G:`V`=O^CO$\UE
MN7:CU$MF083"Q'7V1,@'JNYUG>PH)*M_&Q#JJ`Q)V)'`=T>"4B\.D]G\?UBB
MC@6^>Y;0"^<)2M)_]^(;7SJ/>RSQ9L79R8%-!IV+%JLMBY;`K(*(`AA(IHIW
MJJHQL"Q@]7DS"\*5_PS19AUF.\6@,6+7(]1$0/:L#7F\H:VJ8^TT'A-OIQ"K
MN=T5Q/Q,,FH&S`^:Z0-0JVL76`8!1&<"'=+68&(]<I7:;K`PDHA'$CKK.#EG
MK:H0_D`J7B26E,$,I`8+(RG8G`,W6BJ]C%55;5=VM@:3ZJ%'*+)G.BS'87S)
M?=1&.FUC=G&LJG8;MF.#6>@VD#>WNMR-RXO+:$9MS*9M#-)05;N-U`K>8$P:
M*`WL-DQ9SV4DK-X7UM,U\*^JMO#,$C:8WO_LDK/>>SM3G@HOIL(#QZIJ"U\>
M"[.K#<8XOD'1)'E3GRHC.(S?\*S+MO;",MV!>M=6>=>5KVA?.<T&MI$YB$9/
M,PIL;0,Z&Y_L_([EBKHZ;/X^;7B?35)'UF.U[4!GY_:\N_I`W+SCS)G>X@/Y
MBOF!-L*I2`%G5N#!?G.X><.9"\E:?:SNF807EOY9PC\1`B=7X`&X8$SV%^K$
M/O^WV?P!``#__P,`4$L#!!0`!@`(````(0"U$=.#G`(``#X&```9````>&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;(Q476^;,!1]G[3_8/F]&`BD:112-4'=
M*FW2-.WCV3$&K`)&MM.T_W[7.!`@E=:7!-][[KGG?MB;^]>Z0B]<:2&;!`>>
MCQ%OF,Q$4R3X]Z_'FQ5&VM`FHY5L>(+?N,;WV\^?-B>IGG7)N4'`T.@$E\:T
M:T(T*WE-M2=;WH`GEZJF!HZJ(+I5G&9=4%V1T/>7I*:BP8YAK3["(?-<,)Y*
M=JQY8QR)XA4UH%^7HM4]6\T^0E=3]7QL;YBL6Z`XB$J8MXX4HYJMGXI&*GJH
MH.[7(**LY^X.5_2U8$IJF1L/Z(@3>EWS';DCP+3=9`(JL&U'BN<)?@C6:8S)
M=M/UYX_@)SWZ1KJ4IR]*9-]$PZ'9,"8[@(.4SQ;ZE%D3!).KZ,=N`#\4RGA.
MCY7Y*4]?N2A*`]/N\C%902;X1;6P*P"5T]?N_R0R4R9XL?3B6W\1A#%&!Z[-
MH["Q&+&C-K+^ZT"!S3Z0A&>2"&2>_:$7KN(@7OZ?A3A%724I-72[4?*$8#L@
MIVZIW;5@#<RVA`4TPND8BH+6,HM^L/`$P_X"3H/U91NM%AOR`EUB9\SN&A-,
M$?L>8<NSM.G(0$#8H`YJ'JGK15BK%=&'[YP!2`95X2SC.XC5%))>0VXOD(FJ
MQ;NJK!6:-Q(1K:)ICIW#1(/R_=R0C@R3G#";42>Z.47Q,!;K33!4,#0@6L6S
MW`X3+()N;+YW-Q.W=X"+N'1DF&B!G9UK6?J#%NN=:UG.M#C,18L_`^RG@-G^
MP)VV*?KPB]>I=/?5;7G-5<'WO*HT8O+80'M"$#I8AV?B(;0SF=EW\'QT=Y`,
M#KC5+2WX=ZH*T6A4\1PH?>\6%"GW`+B#D6UWMP[2P'WN/DMXISDLN^\!.)?2
M]`=(3(:7?_L/``#__P,`4$L#!!0`!@`(````(0#DY.!<TP(``%,'```9````
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(R5R6[;,!"&[P7Z#@+O$;5YA>4@
MLI`V0`L419<S+5$2$4D42#I.WKY#T5IMI/'!MH8_?WXS'(]W]Z]5:;U0(1FO
M0^3:#K)HG?"4U7F(?O]ZO%LC2RI2IZ3D-0W1&Y7H?O_YT^[,Q;,L*%46.-0R
M1(52S19CF12T(M+F#:UA)>.B(@H>18YE(RA)VTU5B3W'6>**L!H9AZWXB`?/
M,I;0F">GBM;*F`A:$@7\LF"-[-RJY"-V%1'/I^8NX54#%D=6,O76FB*K2K9/
M><T%.9:0]ZL;D*3S;A^N["N6""YYIFRPPP;T.N<-WF!PVN]2!AGHLEN"9B%Z
M<+?Q"N']KJW/'T;/<O3=D@4_?Q$L_<9J"L6&:](7<.3\64N?4AV"S?AJ]V-[
M`3^$E=*,G$KUDY^_4I87"FY[H;<DO(23X-VJF&X!R)R\MI]GEJHB1/[27JP<
MW_46R#I2J1Z9WHNLY"05K_X:D7NQ,B;>Q20`S,NZ9WOKA;M8_M\%&Z(VDY@H
MLM\)?K:@.^!,V1#=:^X6G'4*/A3"</1)06D3K7[0\A!!_X).0O1E'ZQ7._P"
M54HNFNA:XTX5ATZA*Z5MXU$``UA/!SF/Z#H('=40W?;(!,"DI_)F)]Y0K*>2
M^%JR&B03*O\FE8Y"\480P7HP:/.,C";HR0_S0#P*3,Z$N[E1"1T-$9#WB0?K
MS32OR&A<WVVOR[$WP51P,((!*AX%)@S0JR.&KE>Z6]&K,Y:-,STJ,IKAJ(,)
M#'"+Y6;R6DP-XI'!!&WY+II>G:/->C(RFA&:"0QHOC]CF0N6PVU/V%;OLNG5
M.=NL>R.C&;'-`S#EM,L`ZPV%,RQFB)F??D5%3@^T+*65\%,-O>-!;_31?G8^
M>+I19_$(9FH[F'"_`*.N(3G]3D3.:FF5-`-+QU[!90DS%<V#XDT[<(Y<P9!K
MOQ;PYT5A`C@VB#/.5?<`!^/^[W#_#P``__\#`%!+`P04``8`"````"$`DCSC
M\D@.``"<1```&0```'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R4G-ERVLH6
MAN]/U7D'%_?;(`$V5L79%0:A>3AUAFN"<4S%-BX@PW[[\[?4+77WW_$F-\'Y
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M?\CVKSMD&^TD6N#SX?!5J,8/`L%X2-9ATP+5\>IA][CY]GS^U^%'M-M_>3JC
MN:?"9'MXQI7P[]7+7O0!W/KFY_W`QQ7V#^>G^\'XYGIZ.QI[_G1P]7EW.H=[
M83NXVGX[G0\O_VN5FM`[)V/I!)_2B7\]\:>WL\;).X83:8A/:3B[GDVGDYO9
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M0Z2]RSTZ^6_E7NB+W*NLS17H&\.W$JTTE,G2!BL;A#98VR"R06R#Q`:I#3(;
MY#8H;%#:H+)!K0$CT9@2*-'C4=>GA1B/+;U/>U:/G;<ZDW&7_`61)9$5D9#(
MFDA$)":2$$F)9$1R(@61DDA%I-:)D6G,H'JFU:PA,&88F/73AF=/&ZW2!!^_
M5EIT2EV/)K(B$A)9$XF(Q$02(BF1C$A.I"!2$JF(U#HQLHYGCROK`C=95[F:
MMV32KN/$Q+L@LB2R(A(261.)B,1$$B(ID8Q(3J0@4A*IB-0Z,?*)![*>S^:A
MZ$^OH=^N*/FQ*"S,5+=D@D>JUIOMZ;E34BVT)+(B$A)9$XF(Q$02(BF1C$A.
MI"!2$JF(U#HQLH^4Z=E7<XC`9HI;HO=F(DLB*R(AD361B$A,)"&2$LF(Y$0*
M(B61BDBM$R.?HB37EG@JGP*;^50$:WZMSXZM)46OU75:1BM&(:,UHXA1S"AA
ME#+*&.6,"D8EHXI1;2`CY2BX7"D7V$QY2\9^OZP@LB2R(A(261.)B,1$$B(I
MD8Q(3J0@4A*IB-0Z,?(IRE`]H;),N19%_OEIO_TZ/Z#'>MV*KM$W,ZW039]J
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M%UTK,Z\U\:QI/F?'!:/RHFM52NNVS:$WF5G;`K7AVFQV4>6YFKVM_HQF;Q$:
MM!]8A)9BSU^,M>9M8+,7OY+(:,-62T-KJ:6YC]A7S+X21BG[RMA7SH8%HY)]
M50K==IFH#4,SPZ*J<V5857N=D[DG$18]W<":63UGX5)RC*O6U=0LO:W1MW+Z
M\JT"/51:?<.O%=(CI2`BJ64%,3,GBMCIRPXB45I]$*E"[P:1N8.PLIH[?=E!
M%$JK#Z)4Z-T@*F<0OK5A73M]:4&8_4H4MZY^U1:]QLAMT01]HNM7]I)\X3F4
MJ$F72@O*G:N);[W<6"DM_8*^=B/-O!!*+;]?+JV=AO9#(U):9A#6I!<KK7>#
M2#B(U&EH!Y$I+3,(:^SD2NO=(`H.HG0:VD%42LL,PEIBUDKK5T$8_<JWMD94
M1=%P<PM$H9'>^>^L)?]":AD[U]RQI!;6:'K'LGRMG+ZH8TDM?=GF-+33&;F#
ML-<)3E]V$`D'D3H-[2`R=Q#6U)T[?=E!%!Q$Z32T@ZA<0?B>-777AGNS%UG;
M/%TOXNT<7R+THFYA(1GZC$)+B;1%_(JU0HF,IF_]:[XB]A6SKX1]I:R5L:^<
MM0KV5;)6Q;YJP]!,,4:=ZP'@"VX-5(E&QI+=MYIS(2VG[4)RZHWOIM8`7/8J
MJF%6$FEKN9#1NC<4"_VI-[FQ.VO4JRC?,3M*&*6]H?1]>V>-V:Q74;YS=E0P
M*GO#QO<==FRLZ;7J593OVG!DMMHO-FSP%*16DPBMIAPOI!J:2*$EHY5$1I.T
MSC2T9L.(4<R^$D8I&V:,<C8L&)5L6#&J#4,SQ;_8GO%Y>T8A7]9.(\]Z@"^D
MAC9[+!FM&(7*==]X:]:*&,6,$O:5LE;&*&=4L*^2M2I&M8',A(MM$L=25!S8
MM&>B%AF[`A//&JT+:6AH.98,K2^Y=S"^L9;3*^E%Z_(AH_5%UXJDEMJGL'?Q
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ME]T&`S5I*+6P!E#+H+73T&[22&F905@KNEAIO1M$PD&D3D,[B$QIF4%82^U<
M:;T;1,%!E$Y#.XA*:9E!6$_B6FG]*@BS7\&7WJ_:<VXWUWB&=/6?4+&Z6(ON
M\#3O6IPW$:3=NV-EB9<^PKLY:_C6/:VDEGBKVEW0T<7D%?L!NW8:VHF-W$%8
MK1L[?6D#MMDB2Y16'T2JD!&]'41V41"YTY<=1*&T^B!*A=X-HG(&,;9V,FJG
M+RT(HXOAE+71Q52_:KC9KQ3ZFZ)7JG5%KS^QZ^)EKZ)FFY5$VBHD9+3N#=O"
M=#R:6?-=U*LHWS$[2ABEO:'T32^9LEY%^<[94<&H[`VE[ZG6'DW/K'H5Y;LV
M')FM]HO=('SAS)X-%-*+7LGTHI?12B*C2>363__V<,V&$:.8?26,4C;,&.5L
M6#`JV;!B)+ZAUSQIFQMJ4]Q^XZ[]#L[+[OAEM]@]/Y^NMH=OKYC=O)%8V7>\
M_:[??!;4S;<^+(X65%\"M"3X=N"G9GO.XG-\:[")Q>9^4#OUQ[B`>&9;^I\F
MP2?<&POFDZ!NSHI8!O-I4#?SD<UO@KHY(V'SVZ!NUMP6QV`+1&OSE3'F`M'H
M+,'0"T1#LP3#*Q#MS1*,LD`T.TLPV`+1U"Q!H1>(2H,EJ/<"47"P!&5?(.H.
MEJ#4"T3YP1+4>&@MEV2.V.;.V!:0+)T23(V!&(M\'<R00>B48*(,Q#!D&Y3G
M@:CO6(*2/!!E'DM0C`>BVF,):O)`%'TL06D>B-J/)2C'`U$"L@2[?,B;JSMC
MUR@0>T)L@ST@Q.:28$<'K>V28'\&UW%)YHAM[HP-6RB!J+$Y@B4DHM1F"39,
M$+5+@GV3('1*L$.+^W'E`!NUR+5+@OU:9-0EP9XL<N"28&L6/=XEP0XM^K5+
M@G<D\.;J57@O`F\N"5Z/8/RX)'@E@NNX)'@-@O9Q2>:(;>Z,#7OM:`57U-A/
M1RNX)-A61RNX)-A=QUAP2T88/Z[8\+(+-BY)#(EX'\(]!"^UT*8N"=YM8?RX
M)'B?A=9V27`()A"',/@Z.`L3B+,8+,&1F$`<R6`)CL$$XF0&2W#\!4\IEV2.
MV.;.V/#6$N/'%?42$O$RBJ^#MY-H.9<DA$2\FF(;'%T*Q-$7EN"X4B!.P+`$
M!Y4"<1"&)3BO%(CS,"S!L:5`'(MA"8XJ!>)T#$MP!!`2UU,6Q_[0<BX)3O^A
MY5P2'`)$^[@D./B']G%)YHAM[HP-Q\N"A5."(V6!.(7$]X/#9($XC,02G"D+
M0J=DX8UAXQQ9D(CSINP-YTMQ/RX)CH/B?EQWBF.@B-HEP=%/1."2X`0HHG9)
M<!`4?<<EP>%/]!V7!&=`T7=<DOE=4#>G*:VU$T[=XSY=O7KA80Y#?<VYP?%M
M7-\EP=%KY-,EP;%I7*>1#+L0\),1;YLONWQS_+)_/5T][QZQVATU7^`XMK\N
MT?[G?'C#*A@_''$XX\<BFC^?\"L@.YPD'(DOX#T>#F?U'X0[['Y7Y./_`0``
M__\#`%!+`P04``8`"````"$`:;*V&Z("``"E!@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6R,E5UOVC`4AN\G[3]8OB].`H&""!5=U:W2*DW3/JZ-
MXR16XSBR36G__8[CX"9`I]X$\OKX.5_VR?KF1=;HF6LC5)/A>!)AQ!NF<M&4
M&?[]Z_[J&B-C:9/36C4\PZ_<X)O-YT_K@])/IN+<(B`T)L.5M>V*$,,J+JF9
MJ)8WL%(H+:F%5UT2TVI.\VZ3K$D217,BJ6BP)ZST1QBJ*`3C=XKM)6^LAVA>
M4POQFTJTYDB3[",X2?73OKUB2K:`V(E:V-<.BI%DJX>R49KN:LC[)9Y1=F1W
M+V=X*9A61A5V`CCB`SW/>4F6!$B;=2X@`U=VI'F1X6V\NHTC3#;KKD!_!#^8
MP7]D*G7XJD7^730<J@U]<AW8*?7D3!]R)\%F<K;[ONO`#XUR7M!];7^JPS<N
MRLI"NU.WA:D:/,$32>'.`*1.7S*<@`>1VRK#T_DD7433.$DQVG%C[X7;BQ';
M&ZOD7V\4=]X]JXOACEJZ66MU0-!8L#8M=<<D7B60/'/BUJD9AA,&/`/J\R9)
MYVOR#&FPWN;6V\`SV,3!@@`]N(!X+[APJG/A\G0^;[TPY"67>=.+/*="10;A
M).DB`+P+;S/K"C*,<':1Z%0HRQAY?8+LC:#KH0S#4HT*`5VZ4`BG=FY")7K%
M-VX8YWP$0.ZD3)>A:6YU#.H5J.P@N&7(8!3<XIR=QI-%&O#.8(SOE0A^W_CS
MZ#+?C:NW@W8:NUL=PWOE!/[.$5O^%^Y6Q_!>&15F_LYQ@[M_%GD<)</2="9C
M#T=I[&)Z4AL_%/R%E%R7_`NO:X.8VC=047<?@QJ&T39QY_=4GZVV?DB1L`*S
MHZ4E?Z2Z%(U!-2^`&;FXD?9CQK]8U4+L,$&4A:G1_:W@<\#A4D83,"Z4LL<7
M\$S"!V;S#P``__\#`%!+`P04``8`"````"$`+9:ZEC4,``#Y-0``&0```'AL
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M[@G\ZS1X:!ZWWU\N_V[?TF;_]'S!XYZ)(KOV!37AW\%A+\8`NK[]V?U\VS]<
MGN^&$_]FZL\62\^?#0=?F_,EWHO"P\'N^_G2'OXGO3P52T;Q513\U%'F-[/%
M>/([028J"'ZJ(-[\QE_.O-E<-.6#ZJ>J)'ZJDA_[P]IU>G'U_VQ-F!]=2?S4
M'374^J")*U40/U7!U<UR-IO.EXN/V^KAV<LG)`:!%-^_67CCU>17):_/%K^H
MDI_MIZ>?J/CE]WKJZ><H?M'5>OUH^$`D3S](\<MG^CJ2H[F;!>'VLKV_/;5O
M`Z06]/C\NA6)R@M$,#7^U2"ZS@A,S)UP_R+\[X9XJACJ9]`?]_Y\>COZ@2FV
M4SYKZN/9'AOM(::9"!NZ(')![(+$!:D+,A?D+BA<4+J@<D%M@!$TO`J)Q_];
M0@I_(:268*V!H:RCFO;014(71"Z(79"X('5!YH+<!84+2A=4+J@-8*F&D6^J
MID>9P$BPUBB;V6JLI<]T<E5P0TA(2$1(3$A"2$I(1DA.2$%(24A%2&T22RO,
M3DXK@3%[4>R#*2F=IOCQOM/FZG0=8(1$A,2$)(2DA&2$Y(04A)2$5(34)K'T
MP^N#TT_@3C_=Z[4D4[D*$.EI0TA(2$1(3$A"2$I(1DA.2$%(24A%2&T22YDY
MKXS`MC*23+$<,(;1W)Z8FZN3%C0D)"(D)B0A)"4D(R0GI""D)*0BI#:))18Z
MSPTC@6VQ))GX?8(B)"0D(B0F)"$D)20C)">D(*0DI"*D-HFEC-@3T;7$C5A]
M79[WNV_K%J/&NRXEA+NMF"+S7C%"0D(B0F)"$D)20C)"<D(*0DI"*D)JDUB*
M89'[.XH)=ULQ15:]8I),D`6-*;JPIVAX==)3-"(D)B211.V.1%Y,)9G9[YZE
M75EV==*5Y804A)2$5(34)K%T%7N!WQ&V\[>5U<B05J&)&,_]ZG=E=S?LO71_
M(XIBBA*%3'T5@L#=2GOL.4OMK'?0E>44%31RV7NIR!.[&U7OH"/7%K+U%JMB
M8^KK=9PG5\M8G.@@:XV,MZM"R]XK5&C5HXBBF,9**$H5LJ>$Y[RULMY+-S6G
MJ*"HI*BBJ+:0K9U8&W/:R36SI9U$,VL`+L;VD]N(G:A($^-5-VJF_GCN3,G0
M<-&]C1@6,RQ1;"H/-KHTH)#=+L]).IGV6G3-6F%';S<\IY$+BDH=QA+!K:S2
M7K(RS_.6CDRU%=I^(F()SCT1N32WGHA$Z+G6<2-6XDI^S4*&10R+&98H9NE-
M:LV4UVQQ;4A."Q84E;I@WX-*HSY6;16TQ1+K;4XLN0Y'0:W"6IPO0!E[^;@@
M9P.J(+*-2$U3WYLX+J$*Y,%%!X\8%C,L46S2+S)2A>;SKD(<QOGVP,QZ!UU=
M3L,4%)5]0=&5Q<1S-K%5[Z`CUU886VH,>59JP9VWET206L?=X+W2>1FBA0R+
M&!8S+%',$E)6`2%UK9GR,E!."Q84E;1@15%M%;3%$@MX;ES*A;TU+B6RT]?"
M&00;3Q7LTZJ;>4/#10L0,2QF6**8-<U5NU0.\Q<3DE*O'KJ^G,8I*"H50KH0
M`W,R7<V<[E:]APY=6W%LL<6>@!-;[A4LL26R,J;R@K*ZKM"C+&)8S+!$,4M*
M56L_'S+E965,Z644+&BLDA:L**JM@K988CO`B:6V"6;&E,C)F,Y2;>.I@GW&
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MJZ`MUCM;)9]NE11R,J>SZ=LH+V-&A@K-,:??'SX1+1A3E%"4?BI\UGMIT7,:
MJZ"HU`7E4M:?N]_FJMY!1ZZM,+;>8I]AI$_U=?#=$SU?;7V,-YA"9EI5R!)=
M%H3HNE41]8HI2BA*%5J8`U:&-U"NO.;]![B"QBJU5[]LJ"BJ->IBV0*^LSGR
MZ>9(H3DL_;A;.`N^C2YH37@9S)BTD7(S4$Q10E&JT&(JUX6+R<S);EGOH1]5
MKE&_A2QHZ%)[R=">/YF,G=Y5O8N.76O4Q;:U%9L-8W!>7U=JGV,.0K4OF5Z'
MUT9<E!![)DM(R0S5(N5FH)BBA*)4(2/5913EM&!!44D+5A355D%;*;%+,)3J
MIK&/M2YW*N^K;8XIGT+(LL;0=-ZH&UUPW$^I4#%CJD<4Q;ID/WX2BE*%,(G-
M5CBGKUGOI8=0KM`*"\>^^;ZSB"YHC64?RRCHGB-5O9>NL?Y5C?;3$9L.X^E<
MQ['<C)AK5/',,&CM'+%T3D<VRLL>VK*D,8XCY6:@F**$HE2A!9)JKR?9`6@O
M-=W'KFZY=NB?>D$K*[77AY55VDM6-O4F<V?;4&L/)H^(#86A_R]?<G(#8CT7
MM2<Q\XORLO*+9(;BD4]03%%"4:K0S#AJT:B??[E&_7NUH+%*[=7'JC3J8]4:
M=;'L$2SV/Q\I^%?[BE2+5XJ\0^2K_9*98B0R$L5&>1DHI"BB**8HH2BE**,H
MIZB@J*2HHJBVD"4@+CA2`?W9#=Y'\A(8O8?5%;$W90I!,&->+IV)L.F]=+H*
M*8HHBBE**$HIRBC**2HH*BFJ*!*W0T52E.-$RBIO>\I[;H?F]-1LFI>7\V#7
M?C\B8ZW$XOB*K]=,OW0?ZAV^QO73;F_E<C_`G28HZ/()KJLR_,LT^(*&,@6F
M`6ZL,'P6X+X&P^<!KB8PW%^A1=W<)$T:ZRNTCB7S%T&&:4VC(3D'(GE0"W)T
M('((M2!5!R*54`O2<R`R"K4@+:/5G&4-RYJUX/T6;%A+"(O(J+0>O-D"D5BI
M!2^X0.17:L%[+A!IEEJPNH4&W-/!(A<]Y2Q8R**GG`6+)+2:>Z98\N#Y<!8L
M35`/9\&F$&WCAB#VABC#6;`#1-LXRQJM7K.MQDX$3X'OSQ3]X2S8@^`I<!9L
M1?`4.`MV)-"`LV#;@3'*67!&@YYRTQ8',>@I9UE#@S6K`0X)T%-.'9P5!"%K
MP?D`-.#*X)@`&G`6G!9``\Z"0P-HP%EP*@`-.,L:/5VS/<6Q'%K`:8#3-+2`
ML^!0#2W@+#@U0PLX"P[/,!(Y"[X^!.+(G,XL?&)`ON4L:V\9K'%V2<O@^#L0
MQZW4@I/K0!RZ4DL*BSAHI98<%G'>2BTXK0[$L2NUX-`:_>$L.)I&?SC+&CU=
MLSW%AR;TA],`WXC0'\Z2PB(^:-"VX7L0^L-9\%D(_>$L^'B._G"C"A_-T1_.
M@H^[Z`\W&S>PB`^(M&WX%HO^<!9\DD5_.`L^O*(_G`7?7]$?SH+/L.@/9\''
M5O2'L^`&2B"NG-!6XSX)RG"6-=19L^K@3@8TX'3#=0IHP%E26%+6@IL44(<K
M@RL44(>SX"8%U.$LN%`1B%L`M*=KO)RY\;%9!;@=1OU3+$$XOO&0<>1'%&<%
MDL(B+BS16+B@!)4[R^A:"'^/\[I]:JKMZ6E_/`]>FD<LY\;=<>1)_NF._,]%
M[C<&7]L+_A!';#T&S_@3JP97UL9B4?W8MA?]'U0]NO[1UOW_`0``__\#`%!+
M`P04``8`"````"$`BH[(!F8+``!7,@``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6R4F\EN(SD2AN\#S#L(NK>E7+0E;#<J=P(SP&#0W7.6Y;0ME*0T
M)%6Y^NWG9Y),,ABLLGUIM;\(!B.X!LFLV]]_'`^3[]WYLN]/=]/H9CZ==*==
M_[@_/=]-__RC_FT]G5RNV]/C]M"?NKOIW]UE^OO]/_]Q^]:?OUY>NNXZ@873
MY6[Z<KV^9K/99??2';>7F_ZU.T'RU)^/VRO^/#_/+J_G;OLX%#H>9O%\OIP=
MM_O35%G(SA^QT3\][7==V>^^';O351DY=X?M%?Y?7O:O%V/MN/N(N>/V_/7;
MZV^[_O@*$P_[P_[Z]V!T.CGN,O%\ZL_;AP/B_A&EVYVQ/?S!S!_WNW-_Z9^N
M-S`W4X[RF#>SS0R6[F\?]XA`-OODW#W=3;]$F4BCZ>S^=FB@O_;=V\7Y_\GE
MI7]KSOO'?^U/'5H;_21[X*'OOTI5\2@1"L]8Z7KH@?^<)X_=T_;;X?K?_JWM
M]L\O5W3W0A;9]0?4A/].CGLY!A#Z]L?P^[9_O+[<3>/X9K&:)U&\F$X>NLNU
MWLNRT\GNV^7:'_^GE`;71R.Q-H)?;219?MI(HHW@5QM9W43I?"G]^$7=J2Z&
M7Q/`A\K!ZA`X?G6YA77Y%_4M=3G\FECCFU4TWR2K7SNZT@7Q^YGX,",'/_'[
MJ?@VNAQ^/Q+?3(V+83R5V^OV_O;<OTTP2='SE]>MG/)1!EMZ(.D>&8<61OA.
M:G^1ZG=3.(M!<P']?A^OD]O9=XS5G=;)N4Y$-0JC(<>K-%OZH/)![8/&!ZT/
MA`-FB'8,&</X,R%+=1FR<38WP&D#+SZC88J4/JA\4/N@\4'K`^$`$A]FF!.?
MZ3E)[Z;XK]-S*?4[5SII,L9:,%(R4C%2,](PTC(B7$("PMP/!"0I1BU*.1'Y
M8U$II?CYN5(Q*HW]Q4C%2,U(PTC+B'`)"1*K2R!(28<@C6NY(JE:[.7D*1@I
M&:D8J1EI&&D9$2XA[F.]=-P?UI$%)J!::?DZ(M5I7(JD6#Z=GEK0`5J,2J8Y
M2D8J1FI&&D9:1H1+2*APT0G5S"]):42*N#W%2,E(Q4C-2,-(RXAP"7%?YH!V
MQ3?N2TK=5\3KD*77(:/2V"&,5(S4C#2,M(P(EY"(L&\%(I*41J1)9-?R@J.2
MHXJCFJ.&HY8C01`)(T(:&(ACP#00C9+8+M0<E1Q5'-4<-1RU'`F":"!RY[5#
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M1&[,%AHA3(-*CBJ-2%S*EH,:7K#E2!!;))`XG`(-F*9`!LF!;?MP,_?Z4*OI
MF;A9;%)_W;4:)OQ*(V=LUAPUMJ#LPW6""R):>6LUC&E![-#0:=)DMIB8)T<&
MN?-0,V?2E1Q5&I'`E'T'-;Q@RY$@MF@D,D7AHS%6F8L[#S4B\S"*8MJ,A=;2
M\W"U3+W%K;0*IITKC9RQ67/4V(*R"U>X%J55MU;!6!;$#(U;)B:!N%6^0N)6
MR)V%V/6\I:3DJ-*(A*4*.JCA!5N.!+%%`PEG.S'/=@SR9J%_WZ?5]"Q,TX6_
M85H%T\Z51L[`K#EJ;$'9@^EJZ2T`K54PE@4Q0P,/IT+RBMH[2AI$YJ!2(W.0
MH4J7)'$I+0<U6LNQU7(DB"T:B<Q3`F-1I2]D+"I$YF"\87-0:>DYN%ZNO2XN
MXU'!M'.ED3,R:XX:6U#UH#_]6ZM@+`MBAL8MTPH;]WM'SUBG-,X.J1&9FTIK
M,[S)J`MKK>6@2J.US?QKC9P6:'C!EB-!;-$`9<IA`QRW"96)D([52"9,S@[I
M+7%%K-0VJ<IRHCB-/972JI@>J`RR#5=K1$8QL9VLELO(&S>M,62//<*@P38-
M/ISGQ#S/,0C!&Y\+S9PY57)4:>2$47/4\((M1X(4))$DX41GP#31T2A%4SJ]
MZ)V3"ZVU<`Y='%4<U1IA,S#MU'"MEB-!$(TMG,DD/),QR-L^O#RJT&I+=+/3
M!'XB9[5,))5&]+3F#^]::SD]WEA;;HW>KM5:+5.C>*]&VE`T47IOL<)UG[\-
M&>1N0YJMG-6*H\H@]=(KKTQJC4@[J"H=6ZTI:,T+@P9;-$*9G/#5*E$YB[M:
M:23?#)P^]C*]0FNML-DX6FPD*//0,OU2&?.(QQ;D(T$5))-AM.44W+"1,&J9
M&L5[-=)VHAG7NR.!9V+R=DGF*/("ST:X\<^T6@T=:K62N9<TE5;+A%-IM"'+
M$&]`[85=AAIKRZW1WP:LEJE1O%<C;4"90MF!]FX#JHR+#$"-P%Q'_40H,6J(
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M'"Z37?_MA`UD/<?Q;,3J(\,\665R,L,$DZPA&9ZYF60#R7!$]27I'-\L#ED=
MDXQ?,_J2188O0@+U+S-\/A'@<#CH+]P->@MG@[XFJ`#+-Z\!&6)6(O7BD@:2
M-B@IDA1EA@.H%Q^2%Y0)2?"!YY?A#MTKD:.IAC38YW&&[[6X5WF"0`+\2YI]
MP2`)%$C12P&.$V`FSW>\!,YSJ",DR9,HRY&\\S(X<J%)0A*<J5!/2()S5";/
M$-P:CE-HQI`$YR7X%I+D\3K+<7[FUG!CD<F#.Y?@5B*3YW<NP>5$)H_Q7-)`
M(H_N7()["/192)+'2_@6&L@%)&50@MLP^!8J@TLQ^!:2X&X,OH4DN`&#;R%)
M'J?P+30I"TC*H`1WK?`M5`97KO`M),'-*WP+27"_"M]"DCR.X5MHN...'[Z%
M)+C)AV\A"2[TX5M(@GM]^!:2X/8>OH4D>3R';Z$95T`B'U/X",%#$7P+2?!>
M!-]"$CP;P;>0!&]#\"TDP0-O)I]"N0=XU\5Z$Y+D$>8/'MIXF0(2^<+')7B\
MS.1#'Y?@#3.K@Q(\9<*W4!F\5\*WD"2'UWG0:[RO9_)-F7N`-W5X'9+@*1U>
MAR1X48?7(0D>UC/YWLSKR2/T`CYMXI(BPMC!\3HD2>!!:%3A,Q24"4F*"+,$
M'V6$K"U@+31_\#D$R@R2V;B_X&O_U^US]^_M^7E_NDP.W1/2A?F0Z9[5/PQ0
M?US5H6SRT%_QG;\\GTU>\`\X.MS\S&]PL'GJ^ZOY`T[-QG\2<O]_````__\#
M`%!+`P04``8`"````"$`?5\-,J@"``"Q!@``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6R,E5UOFS`4AN\G[3]8OB\&\AV%5.FJ;I,V:9KV<>T8`U8Q
M1K;3M/]^QQA(73*I-WR\'#_G]3DGSN[V6=;HB6LC5)/A)(HQX@U3N6C*#/_^
M]7"SQLA8VN2T5@W/\`LW^';_\</NK/2CJ3BW"`B-R7!E;;LEQ+"*2VHBU?(&
MOA1*2VKA59?$M)K3O%LD:Y+&\9)(*AKL"5O]'H8J"L'XO6(GR1OK(9K7U()_
M4XG6##3)WH.35#^>VANF9`N(HZB%?>F@&$FV_5HV2M-C#?M^3N:4#>SN98*7
M@FEE5&$CP!%O=+KG#=D0(.UWN8`=N+(CS8L,'Y+M71)CLM]U!?HC^-F\>D:F
M4N?/6N3?1,.AVM`GUX&C4H\N]&ON)%A,)JL?N@[\T"CG!3W5]J<Z?^&BK"RT
M>^&6,%5#)K@B*=P,P-;I<W<_B]Q6\+2.%JMXEJ0+C([<V`?AUF+$3L8J^;</
MZE$>DO80N/>0V?*]$.(-=1NYIY;N=UJ=$4P'I#0M=;.6;%.H('/BP:D9AC$%
M4P;4I_ULM2-/4`K6A]SY$+B.(<D800`^9@"[5S(XU65PM7(I[[SPFI=>Y\VN
M\IR:8;B.=F;Q<@3X%#YFWK7TM</Y5:)3H2H!\FT1^A@8G$O:2TQ0!NCSE3(X
MM4LRUJ%7DHG+90!`;M;29!4MQJ:Y@)#5*U#:B[WX/_Y6`7X8!*>&3*],B^C.
MM,L@=?:2=!W!?`\L%Q&R>B7TMQZ[%M1O$_`'IE-#IE>F_N`<F!J,TVAU,=B%
MA+1!"BUNWECT!X3_74FN2_Z)U[5!3)T:UR6HP*B.!],A=1U^J\^W!W]@D?$+
MG",M+?EWJDO1&%3S`IBQ\XVT/W+\BU4M>(?31%DX0;K'"OX:./RX8I@25"AE
MAQ?(3,8_F_T_````__\#`%!+`P04``8`"````"$`+\I5RH,(``!K(@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6R46EUOXS86?5]@_X/A]\86)<N.
MD:08B9RV0`L4BV[[K#A*+(QM&9(RF?[[/?P2>4E.TGT9C\^]O#PZO#P2Y=S]
M^.U\6GQMA['K+_?+[&:]7+270__475[NE__]X_,/N^5BG)K+4W/J+^W]\N]V
M7/[X\.]_W;WUPY?QV+;3`A4NX_WR.$W7_6HU'H[MN1EO^FM[0>2Y'\[-A*_#
MRVJ\#FWSI`:=3RNV7I>K<]-=EKK"?O@G-?KGY^[0\O[P>FXODRXRM*=F`O_Q
MV%U'6^U\^"?ESLWPY?7ZPZ$_7U'BL3MUT]^JZ')Q/NQ_>;GT0_-XPG5_RXKF
M8&NK+U'Y<W<8^K%_GFY0;J6)QM=\N[I=H=+#W5.'*Y"R+X;V^7[Y*=N+HEBN
M'NZ40']V[=OH_7\Q'ONWGX;NZ=?NTD)MK)-<@<>^_R)3?WF2$`:OHM&?U0K\
M/BR>VN?F]33]IW_[N>U>CA.6>R.''/H39L*_BW,G>P"7WGQ3GV_=TW2\7[+-
MS6:[SC.V62X>VW'ZW,FQR\7A=9SZ\U\Z*3.E=!%FBN#3%,E+5^2=@;D9B$\S
M<'=3L,UVIV9_9V!A!N+3TM[>[#:;HMQMP?N=D8BJ"\:G&?DNU9762^G,FZEY
MN!OZMP6:%XJ,UT9NA6R/6D9@,_,L.5;^(+,_R?3[);87Q!R!?GW(L_7=ZBO6
M\&!RJC@GHQFUS9#K*,OR$!`>L`+3F2Z6YO^A*],E73M190''GP7<;(8=PD-`
M>`#AAM7WN%G%)'J_Q+^>8H$>E<XI\IEG'2$\0H2/$"+HI@01B6*5,<IC$JZ=
M3L*6?B>IGI-FC2)$^`@AAR9+D).H(F=+5AHI]&:735)'"(\0X2-DVI),J_J\
MS&_<)HM;78Z@E`S"8&.>A&$#N2Q[+3R&!($(TRUA:MM(HI2-1ORFB1`>(<)'
MR+3READ8P0<"R1&4DD:P9KX^>;#!YJ19G@@1/D)8WA*65AR)4B8:\<6)$!XA
MPD?(M!F6/%0G8]L;7*GVZ+A]U!!*RD`%UL#KGR+0QV7-`L60(!#E*KW3K:35
M*-.6BOUORU8&\E6*(1Y#@D!T<FF.;G*USS:8^;LJ:3,EK#04J+0)59JS[.7P
M+(($@2A1Z9Z.Z*R2-E7"Q_=9=;NJI8FBX3SA>`P)`M')I3NZR95*6]R_W]%)
M^RGA92R6=E,9ZC1G.9TB2&0^1*E*1W549YTD''2WACQ1:CRJ13I%D"!9='+I
MDF[RC[O)N*K?XQH*NFD;JC1G.94B2&0^1(E*6W5$9Y6TVY)5TQ!1*8)X%D&"
M0'1RZ99N<J42R\IW;VZ9=EC"S)@N+M)SIUVHU)SEE(H@8<H7I30;2E9ZK",[
M*Z6ME_#QW=CLNPCB600)`I')Y9W;F_S#?E+YM,L-%/33;:"2RYI5BB%!($HT
M[>$L]G`+07$[59W`>`(3%*,$I)?&R\2TQ?K+9*"<>?/K+`_B<98@$)V<>K-:
MIFRC^GDZ=H<O58\&S>8S"8L]VT*J_W3OQ!"/(4$@2DI:9$(1[9Q$$0WESH5J
MIJ$=V5LL>/CF+LLNI2`0Y2.-U/'Y4"3MNX2GA@A/DX4M),]V!<O+H+6Y/$]+
MYT>*8TDP2E-ZIJ-I]SO35DKH&,C5K4T6D0W.1C<;=UF.D*Z%@8`H'^FL"3[:
M<`D?#6TV2@JVSL)'$#8G.,-D67!KX39KJ\IDNTT@J#`)A7H70;E*8TUPU7Y+
MN&H(7*T$-8L@;J'MG"4,E)I<&FMB<NVW9')CP?H*(52P0#73"67Y'26Y2[#T
MA8'R>`5S:N*VHQ1,O=I`\&I;MC80J%B(QY`P4&KRM#'GL3$;R+5/T!BU33"-
M4;+;X*3$788E*PR46"^X;6J]%!S(HNW9;Q:3M7%*\1@2!DI-3AU[7I/8F>$V
MZI%P;I;P`<,DE.B9^3&$94$6=UE.&ETYM6AIZ\YCZS80Z1B=!3YV)FZR/$@8
M*#6Y],9X'^7&,MU-HC*0ZYC`*6J34/KO'Q+2Z,K(LH2%&9A:N+0]XSK"QWL#
MD:[16=Y,W&1YD#!0:O*T%^>Q%QN(/G6QX#5:;;*,S^`-ZCJ\P[H,IXV>#2P!
M$?O-J?U^=(=5Z<%.TQY,VDE#I;_3(DB86J5ZJ*.DI)<FVDE;K&_+N8:P8&XC
MY2Q\6V6RMH6^/:VW91D8%7<I3C1=&Z_/0M&*M#LKF(IC(+^A;-;:]2Y/8&+&
MXGLFVLS7YZ-%4^D!+^/E<,G9@'(6>'-M!F[]O9BSX%T.=UFS=`:ZQ:+/Y9E7
MGJQVD39U!0>L9U-W97,6/K*8@5M8I9L\>F2Q6;HG$OM(V(S$^DL7=OWYH?[:
MM/V^Q=%8>@_I"P-Y=VV;Y8X]PD+*J:F,]`80D?JCOT)-U<O>+R3G=GAIZ_9T
M&A>'_O4"P<#IX6Z&]4]@55;NY9L!+'`4V2*B-GH4V2&BJ$>16T34%801MM[+
M$V-B'H9?X7"62T0RC,&;PE0$8_`:+Q5AB*C37,@@RQ%1-ZPH4B"B?@>,(AM$
M5)N$$0Q)CL"`9#YD3JH,D9,:0^*DPA`XI2]V]%[NUX0B!=M7^H5-<`TU(G4R
MPA'AR0CV#BX\I2)^3/V4UAT2IGBA4#(?RY2L7^P_)2>N\NV^PBTGOG3<4O<\
M&1&(R-M4/*;*;R%7JNEJ1*2?QV,$(M+5XTB5Y^"6:I0:$?DH%H\1B,@GLCB"
M9RQ42[41'JY0+17!TQ.JI2(5PY7BK!#/@R,/JJ4B.-B@6BI2Y1FJI1841P54
M2T5P'D"U5*1BLCO2D6)?X12?8HT]B3<.J0@T^,X8[$N<P.,Q%4-7X7P91VI$
MY/DTCN"TO)?'U#B"8S+F49'5O`OQ%P#7YJ7]K1E>NLNX.+7/,.FU>E$TZ#\6
MT%\F[>^+QW[";__2ZA='_%%'BU\5U_*M^W/?3_8+IE[-?R;R\#\```#__P,`
M4$L#!!0`!@`(````(0#INJO+90(``$,%```9````>&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;(Q4VV[;,`Q]'[!_$/1>RW;B)`WB%$V*;@4V8!AV>59DV19J
M28:D7/KWHZ3$R&78^F);Y.$A#TEY\7"0'=IQ8X56)<Z2%".NF*Z$:DK\\\?S
MW0PCZZBJ:*<5+_$;M_AA^?'#8J_-JVTY=P@8E"UQZUP_)\2REDMJ$]US!9Y:
M&TD='$U#;&\XK4*0[$B>IA,BJ5`X,LS->SAT70O&GS3;2JY<)#&\HP[JMZWH
M[8E-LO?026I>M_T=T[('BHWHA'L+I!A)-G]IE#9TTX'N0S:F[,0=#C?T4C"C
MK:Y=`G0D%GJK^9[<$V!:+BH!"GS;D>%UB1^S^7J,R7(1^O-+\+T]^T:VU?M/
M1E1?A.+0;!B3'\!&ZU</?:F\"8+)3?1S&,`W@RI>TVWGONO]9RZ:UL&T"Q_"
M=`>9X(FD\"L`RNDAO/>B<FV)1Y.DF*:C+"\PVG#KGH6/Q8AMK=/R=P1E1ZI(
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MXL'I/HQKHQTL=?ALX6?%82YI`N!::W<Z^'LV_/Z6?P```/__`P!02P,$%``&
M``@````A`+M%RB&N&0``D8$``!D```!X;"]W;W)K<VAE971S+W-H965T,3(N
M>&ULE)W)<APYDH;O8S;O0.-]1.9.AJG45AG['C'6,W-F491$*U$I(UFM[K>?
M'Q%`8OD]D^Q+4?6YPX%P;`X$`OGQ;_]\^G[QCX?GE\?#C]\N%Q^N+R\>?MP?
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M`W\<#G\JU?*S0DA\1:FSJ0:&YXO/#U_N_OK^^M^'7\7#X]=OKZCNC4IR?_B.
MG/#?BZ='U0;PZ'?_G/[^>OS\^NVWR]7JPV9WO5HL-Y<7?SR\O&:/*NWEQ?U?
M+Z^'I_^;E1;:U&QDJ8VL4$QM9/MO&UEK(_BKC2QN/RQO-HO-5A7E3/:03L^`
MOR;[#S>;S7I[LSN?<*L3XJ].N%R]+\N=3HF_.N7YG-"OIB+BKWDXU.F99[K5
M"1:JZF>?OK=LBV.=XA_O*MW"5*#ZARF?4X-GRKE`G<\-R-;;NPMJ*@XMTV1[
MWHT+4V/J'Z:@[VPE"U-GZA_O<^G5W%FF3I;<O=Y]^OA\^'6!D0N.??EYI\;!
M1:3,Z>ZE*_38X=#O[Y7Z[TK_MTM4/KK2"^@_/BV7MQ^O_H$>?*]U]JRS\#5B
MHZ%ZL3*;A"`-01:"/`1%",H05"&H0]"$H`U!%X(^!$,(1@=<P>U'WZ.)_EN^
M5_K*]\9K>P.<R@@<;31,DB0$:0BR$.0A*$)0AJ`*01V")@1M"+H0]"$80C`Z
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MM!\5QCBE.+:?.;Q!N&*&Y;T*75`@K_T02E@K990QRAD5C$I&%:.:4<.H9=0Q
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M(&>N8I0P2AEEC')&!:.24<6H9M0P:AEUC'I&`Z/10[[G3T232XXF#;JU;5NC
M&TR;SM)@ZX_BB=4RHWC**&.4,RH8E8PJ1C6CAE'+J&/4,QH8C1[RG2Z%VN>:
M.X?>2XV<X$6CE>HSQQ<`BV![([%:MC)F6TAH4,9:.:."4<FH8E0S:ABUC#I&
M/:.!T>@AOS*"%<>;8P^O1)8:N3UC1AO\L96QVH4]XZAE/)]J6TAH4&;,V_K)
MK99K_L8W7U@M8ZMD5+'YVFJYYH-]@<9J&?,MHX[-]U;+FE]<!\'?8+6,^=%#
M?BV>6-4L>55CD%M;L]8*?VQM+6@<.VJ9`J7:%A(:E#'*&16,2D85HYI1PZAE
MU#'J&0V,1@_Y3E<K,V<I8`(C]28]B/<UNO$&IW7P1B?66BL[B2>,4D:91OKP
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ML;OSTT9*8>7&<,E6*D:U37BF(S96RYAOV5;'J#<)C4^6USN[,3P5?;`JQO;H
M&?(K+5BJOQG,\1)^.2-GSRG6:&O;3<(H-<@>`LDT<BHOUVAG^T;!J&1;%=NJ
M.6'#J&5;'=OJC99]QH'1:-#TC)[G5\$2W@Q($_>7ZAIMO6AK&81_L=;:>1$T
MS4M&:STU_-7J9G<33%VI4;$#5*:1,[+E1NML=H71FMLK];/2R&U>%>=5&ZVS
M>35&"S/OZ3FP-5HVQXYS[(W6V1P'HV6<>;M:!3'_:%2F[/P&$.PDO-7UU'Y^
M$"1JA(9ANGJLT<:)"`VR_2PUR(;TF49>%<\Y.K8*K;6U\UG)MBJV51LM6ZZ&
M;;5&RY:K8UN]T;*V!H/L,XX&3;9\S[^UG?#WPT]W]VS%VPD:!>%Y,(O$6FMK
MUZ8)HY11II$;GK-6P:AD5+&MFK4:1BVCCFWUK#4P&CWD5P:ZF!2>KQ0/QL$9
M>>'Y)EP2Z72>$H?G6NM\O)QJ+:=/9(SR=^58O"O'DLU7C.IWY=@8+1TO[[:K
M8#W0LNF.46_LN*LB\NA@M$[F-GJF_3:@-@J<)=J;0^&\L>`NW=16!)J+&[1K
M=&-GZ,0@.TRD!MDA)]/(J?;<:%E;A4'65FF0M56QK=IH65N-1K<VR&F-EK75
ML:W>:%E;`]L:C98P%*J=!\?SQRA$\:#WS6CK-H--$)#':C,5Z6XQ<SAS<!!A
M)$8+XZJC%;3.U&C9T3/3R(T/C=;9'`NC=3;'TFC9'"O.L39:9W-LC-8<&RRD
MWJ=]97/K.+?>V#F;VV"T3N8V&HTI-[_WJ:T*IPV\V?OFK0VO]\T(;<,&(C/:
MV9:9H-I4X[BQ+_M2@VS#SS3RZIAL%2:AM54:9&U5;*O6R"E78Y#M:BW;ZMA6
M;Q+:9QP,LK9&SY;O^6!3@CP?!B*\6;'2Z-H&0['`$H&E`LL$E@NL$%@IL$I@
MM<`:@;4"ZP36"VP0V.@SOR9.;%ZL>//"(,_C6LUAB:"7"BP36"ZP0F"EP"J!
MU0)K!-8*K!-8+[!!8*//?(\'.P_'F8=W&%8S0@QI1Q=""6NEC#)&.:."4<FH
M8E0S:ABUC#I&/:.!T>@AS\/K8(>!1I?@D,"D[\_Y!CF#"Z.$4<HH8Y0S*AB5
MC"I&-:.&4<NH8]0S&AB-'O(]C\G:G5%-VT9$&495!MGY(M;HC4,"5LMTBI11
MQBAG5#`J&56,:D8-HY91QZAG-#`:/>0[_:U5?=C<>56_UL@)8S12T9,-59?!
MJYS$:MG*F&TAH4$9:^6,"D8EHXI1S:AAU#+J&/6,!D:CA_S*"%;U;XX]O-K'
M=VI39W%[AMX`P!];&71(0"=T3@2DC#)CWM9/;K5<\\&RI+!:IF)+1A6;KZV6
M:S[8,&RLEC'?,NK8?&^UK'D^)&"UC/G10WXM!NORXSC&ZV_UR9M:,+JU-2.U
M^+2U18<$=$)HF0*EC#)&.:."4<FH8E0S:ABUC#I&/:.!T>@AW^EJ6>@LQXY.
MGY>+[K(+IU"G!94W.-$A`:V%98CQ<,(H991IY.Y"LE;!J&14L:V:M1I&+:..
M;?6L-3`:/>0[7:TP):?/*T_/Z3/R-ACID,!:4*(]L\1HS7MFJ]WZ-A@-4JV!
M6<_47<8H-W:\=A"^^BFTUOD]SY+-5XSJ=^78O"O'ELUWC/IWY3@8K9,>'3W3
M?AL(5N/'CL>K;O7F&J.=N]O(*#'(;@^D&GGU.=MR4&X2VKFIT,@](L"V*D8U
MVVK85LL).T8]VQH,LL\X>@E]#Y]89:]YE:V1LF4G#SHBH+7T$8';Q?4NW&JT
M&J8#I1HYXV'&*#<)3YT0L')CN&0K%:/:)G2>;!%$&8W5,N9;MM4QZDW"^8WK
M[6(;7FDQ6`UC>O3L^%46+-/?#.1X^;Z>$:K2Y!=KY!X08)0:9'?8,XV<NLLU
M<@\(,"K95L6V:D[8,&K95L>V>J-E'WM@-!HT/:/G^4VP?#?#T<3]9;I&;QP0
MT%IO'!`P6GHG&5?][(+53FI4[/"4:>0.8D;+"]9I4C):IPX(&+G-J^*\:J-U
M-J_&:&%NMF-*V/-:HV5S[#C'WFB=S7$P6L:9MXMET-%'HS)EYS>`8!?AK:Z'
M;T^G$-R^3]AKY!X0T,AYJ9\89/M9:I`-YS.-O"J><W1L%5K+/2#`MBJV51LM
M&Z4V;*LU6K9<'=OJC9:U-1ADGW$T:++E>_ZMK81@7W[#6PD:O7%`0&NY!P08
MI8PRC=S0G+4*1B6CBFW5K-4P:AEU;*MGK8'1Z"&_,M#%I-!<?2J@5IQN<Y^1
M%YK3`0&=SE/BT%QKG0^64ZWE](F,4?ZN'(MWY5BR^8I1_:X<&Z,U!\O+W6X1
M'*9HV73'J#=VSBX_!J-U,K?1,^VW`;65X"S/WAP*]6Z$VS9FY(;LFQFY!P0,
MLL-$:I`=<C*-G&K/C9:=[0N#K*W2(&NK8ENUT;*V&HW<`P)&R]KJV%9OM*RM
M@6V-1DL8"M46@^/Y8Q2B>-#[9G3^@(#J=DCWQ@$!HX5Q]?1,G1HM6\N91FY\
M:+0P5SFV@G5"8;3.YE@:+9MCQ3G61NMLCHW1FF,#L?=I7]G<.LZM-W;.YC88
MK9.YC49CRLWO?6HSPVD#;_:^>?/#&YEGY!X00-2@6H+S(C[1R#T@8)!]J9]I
MY-4QV2I,0OO2L#3(VJK85JV14Z[&(-O56K;5L:W>)'1[GRZJM35ZMGS/J[V!
M<YX/`Y%Y+\'SO-Y>L(THWA!*&*6,,D8YHX)1R:AB5#-J&+6,.D8]HX'1Z"'?
M\\%6Q=3FY]N!3EZ@M>%M#(V";8S@R'YLM<P*.6&4,LH8Y8P*1B6CBE'-J&'4
M,NH8]8P&1J.'_`H)-B*.$Q%O.&PT<DYCQ`)+!)8*+!-8+K!"8*7`*H'5`FL$
MU@JL$U@OL$%@H\\\CZO8UQU\C,<G[D_]&KDG-!@EC%(/^;FKM>6YH2]XG8L5
M9QB0&&27@3&CA%'J(;]4;ZT,PU+QRG"KD=U?B#52\:\-4=;VQI[Y7EFK94:)
MU$-^08-5TUMS-I:@Y#Z-W(+.R"\HO=+3MJ!E"WI,".07-`CMCZV,0WBUOX6(
M004JCIO"[V"TUAO;7$9KCH<VF^M5,"BG1H,W9E2$ZS;-8Y'G>,V=?2=5_T6!
M1K<V`$@T6ES;R"0]LNG5C^\R%4*$74-=[XS\3U[N.(<=7MDTNO9BWG6PVQ=C
M<UUYW>RQWX3?"R56P5;WG&8.T?RR!Q'-T7<<N6!W>&J2*)\Q'&N&+`U*&*4:
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MK)9YEE2C6V]`/=E/4&SW68[M4/'`E3/R(XI-$'C%V`I0"=^(*(S6/'H*'WRD
M1H,CBIV::4+WG[G@:-(/'D69\",-K87M!>/(Q""[)YD:Q'M_NV""H1@RV'V8
M](-2S;,#CIB9(L1:RT$)HY11QBAG5#`J&56,:D8-HY91QZAG-#`:/>2-!O@1
M&FX/YV_OGI+XSM<HF`7">-EJF2I*&*6,,D8YHX)1R:AB5#-J&+6,.D8]HX&1
M^ND?U87F66FNC_FG?.9?&7EZ>/[Z$#]\__YR<7_XZP=&L"6^,?[T\<CG'Q':
M[VXC5;7P9BBYN3:_+Q1*%MM(72$JI%GL()F&=4IS`\G4D4/)"FGPL8M@;84T
M^"A#D&R09IX^0FOK"+?V2RF00.)X%/%)D(%8I@6\@NN;A1P6*TBFH2,H$V:2
M*,&D(*39[:(]AC268!B/8E&20*)&1DZ#(3M2`R1+\%-1OT_KDJ!D>_R$U+1B
M"_DRPD]ZL)T]'E%ZPM_7T>]HCYP@WBU06#&+W1*/+AF+(4E$20J)"JDXG_UN
M#6M2!<>0J.B"TZ20J""#)?OM-MIC6<82K"\CM89C20J)6LJQ!`LLI)&J9;^]
M1:E%OT&B%A!L+85$+2-8@HT9E$"JMGB[@D3TVQ9^P^)=LK:.8E&2((W:!.`T
MV(5`/I*DW6PB]1:"T^`E4:1>1K`$[XHB]4Z")7@_%`VB!.^%T,^E-/OM-<HF
M^6V_P3"#K5S.9[_!X(@]1Y;DR"<7\\&[N4B]SN$T>!\7J;<Z+,%KN4B]W&$)
MWLY%ZAT/2_!&+E*O>EB"]^#PM30(XG4X?"U)\%8<OI8D>!,.7TL2O`&'=R3)
M'F7;BV6+(8E%20*)>J7&SX,WIU$J2O`"-5(OV#@-3C&@?J2RX>0"ZD>2X+0"
MZD>2X-`"ZD>2X.P"ZD>2X+P"ZD>2X!`5_":-B?$&/1AG2Z3G6:)LD@2G7U#;
MD@1G69"/)-FC;'NQ;#$DL2A)($E$"<Z5H-32D^)X">I'DN`,'/PF^0#GWN`W
M28*S;GA228(C;VC7D@0GW]"N)0E.NZ%=2Q*<+T4,(?7Z/=*H4VI</S$DL2A)
M(%%GUC@-3B;";Y($!Q3A-TF20Y*+D@(2=9Z-\RDA*44)#B>B78MIX`-U"I6M
MX9!PI`ZCL@1GA2-U`)4E.`P<J7.H+,&9X$@=1V4)C@9'Z@@J2W`$']:DF18G
M\6%-DN!`?J0.A+,U',)'/I($A^_1#B3)'F7;BV6+(4E$"0YR1^J,,)<`Y[DC
M=528)3C6'14G)-M(';SG-/AP`FDD"3Z60)U*$GPS@3J5)/AT(E*'\CD??"Z!
MVI8D\5K%X%*OC]<8R?%9"UO+(5$?XK`$']Z@MB4)/J-!/I)DC[+M3Y1M&\6B
M!)^WH.:DY\%G+2BU),'7+:@Y28+/8E$VJ6?%:XS*^!21GS1>8QR=-QJ"<!S?
M^L$[4OR&S_3@'4F"+^R0CR1I5_#H_+8AR`<W>D3JY@@N&R[VB-0%$BS!91Z1
MND>");C$`ZL%2;)?(:["I^"<)D>:7$R#2U$B=8\&I\%%*)&Z3H,EN`\E4K=J
ML`37HD3J<@V6X"J42-VQP1)<0`2_2>T:]Q#!;Y($UQ'!;Y($5Q#!;Y($5P_!
M.Y)DC[+MQ;+A*ILH%B6XOB92=YGP\^#*FDA=:<(2W%P3J9M-6(+KHU`_4MEP
M913J1Y+@FBC4CR3!;5&H'TF"2Z-0/Y($%T6A?B0);J^#W\0^MT)<-;_N#UI\
M#HFZAHR?%->.H;8E"2X10SZ29(^R[<6RQ9#$HB2!1-WTQ"7`A5XHM23!O5ZH
M'TF"RP?A-\D'N'`0?I,DN&003RI)<-<@VK4DP96#:->2!-<,HEU+$ESLB5T%
MJ=?OD68OIL$]D?";9"V!)!$EN!(2?I/2X&9(^$V2X()(M&M)@DLAT:XE":Z#
M1-N1)+@5$NU:DN!>UDA=_\FUC>M9(W4+*$MP2VND;OYD":YAC=0%H"S!;:R1
MN@>4);B4-5)W?[($UQ_#FC2;X19D6),DN`PY4G?QLC5<@(Q\)`GN/48[D"1[
ME&TOE@W7ZT;J5E;.!U?H1NIR5I;@)MU(W='*$ERH&ZE[624)XBJQ;+BT&FFD
M4N.B:M2I),%]U:A328)KJR-U'S*7`%=5H[8E2;Q$7(7KVCD-;E:'#Z1("/>D
MHVR2!+>>H[8E">XP1SZ29(^R[4^4#7&5*$F01ET_S:7&E>(HM23!S>*H.4FR
M7R!RF#_;#T;R>(F("S_*P?G$2[6;*8W7\1(C+'YU@-/@)QC@-TF"7T^`WR0)
M?O@`^4R2JV/A7CY]_'GW]:&]>_[Z^./EXOO#%^S$7T\O]9\?OZK?_)[_YW6^
MQ//BC\/KZ^$);T;P@^`/=Y\?<,_ZM?H9U"^'PZOY'Q3WZM?A^<_I-\4__;\`
M````__\#`%!+`P04``8`"````"$`$(L['Y,2``!"60``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6R4G%MSVSR2AN^W:O^#R_=CFY(LVZPD4Y%X$,_D
MUNSNM>,HB>NSK92M)-_\^WE!HH7#B\C.C0]/-QI`XT"@0?#=/_]^?#CYN7U^
MN=\]O3^-SBY.3[9/=[O/]T]?WY_^[[^R?UR?GKSL;Y\^WS[LGK;O3_^]?3G]
MYX?__J]WOW;/?[U\VV[W)[#P]/+^]-M^_ST^/W^Y^[9]O'TYVWW?/D'R9??\
M>+O'O\]?SU^^/V]O/X^)'A_.9Q<7R_/'V_NGT\E"_/P6&[LO7^[OMLGN[L?C
M]FD_&7G>/MSN4?Z7;_??7\3:X]U;S#W>/O_UX_L_[G:/WV'BT_W#_?[?H]'3
MD\>[N/CZM'N^_?2`>O\=+6[OQ/;X#YE_O+][WKWLONS/8.Y\*BC7^>;\YAR6
M/KS[?(\:*+>?/&^_O#_]&,7#(CH]__!N=-#_W6]_O5A_G[Q\V_W*G^\_U_=/
M6W@;[:1:X--N]Y=2+3XKA,3GE#H;6Z!_/OF\_7+[XV'_/[M?F^W]UV][-/>E
M2G*W>T!.^'GR>*_Z`*I^^_?[TQERN/^\__;^=+X\N[RZF$>SR].33]N7?7:O
MTIZ>W/UXV>\>_W]2&HM^,#+71O!;C!S57VA]_-;Z472VF%U>78^Y'LD)91J+
MNS0IYV=7T<7-_`JB(PFO=$+\?E,1,1#&C/!;ZR_.9M>7T>52^>5(1C<Z8:3:
M3#OK;46,I"W4'SHIZGDDKPBM-I92_2&979Q=7UXNEM>O."221E-_'*IX:/EC
MN4KS15;[O;&*TG[HBY(ILC^6&3PP5=%J\C=VED@:7?TA[CE:T/-I=(RC*KG=
MWWYX][S[=8*I"BWR\OU637Q1K*SI\:1+?AAA&.AW2OVCTG]_BLZ#L?,"^O/#
M[.+ZW?E/#-D[K;-BG<C56(N&&K;*;.*#U`>9#W(?;'Q0^*#T0>6#V@>-#UH?
M=#[H?3!8X!QN/_@>??N/?*_TE>_%:RL!5F-XCA8-29+X(/5!YH/<!QL?%#XH
M?5#YH/9!XX/6!YT/>A\,%G`<C9%(CIY?'/JT$N/QX/3I&]>1JTEG,3\X?TTD
M(9(2R8CD1#9$"B(ED8I(3:0ATA+IB/1$!ILXGL;$:7M:9@V%,<,@V9%I8U):
MX-?OE=8'I4./)I(2R8CD1#9$"B(ED8I(3:0ATA+IB/1$!ILX7L<S)^1UA4>O
MBZ]6$UE,ZR4U\:Z))$12(AF1G,B&2$&D)%(1J8DT1%HB'9&>R&`3QY]X(H?\
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M?&^TQ/S@(+<5U6[(FJEDB:AB`]Y0$62WUJ1UN3A,4XG6LE#**!-;=M-,MN98
M5EE/[Z5;N8U.""VI7,&H9%0QJADUC%J-=%1+K=(ZC:PZ]HP&![E.5SNCD-.G
M'1,6YE*YE8JXH!TNU8-#MOAS?TD34II%5Z[K$M&Z&N,$T?QJMO2\FVJ5*6(X
MA@(R1KD8LLM$V6VTUA+3Q*'DL\@+3A1LOF14O2G'^DTY-FR^9=2]*<=>M'[O
MTL&Q[?8"M6VS>H$.]OQVD:#V:_Z0G!!ZAW28M=:Z-"N'1)`)5:2";@X),XVL
MML]%R]C::+2<`K-J-!2B96R5;*L2+6.K9EN-:!E;+=OJ1,O8Z@69.@Z"1ENN
MY]76[9CG_[7[;B_/5`#2][Q&&)Y6[_;"%&N=<&FFS(11RBB3'$W#YJ)E)H<-
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MDFU5G+!FU`@R2XB6;74:+4T=>T:#H+&.KN?5QM7R_.&Q,FUHG?$SH2OG63[S
M!L<ZTEIN8(`6V5IKH4?9+)K3(ENKF`;-M&UG7GM+=ALIU-1?O0Y>B-3D5').
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M"MJS-O44+W`^4_I>3YD0>HH9HQ.Z,BC1":_,($HUNC9/PDPCI\W)UD82FEFA
M$&1LE6RKTL@J5RT)C:V&M5JVU;%6+\C4<=!HJJ/K>15*L)Z7Y'E_C"I]S_,3
MLL\S9X021BFCC%'.:,.H8%0RJAC5C!I&+:..4<]H<)#K>2\:(2N5&4<=-+*/
MWQ@EC%)&&:.<T891P:AD5#&J&36,6D8=HY[1X"#7PVI[?ZQO^[/*%`ZPUXCJ
M;3S5W<WC=,TH890RRACEC#:,"D8EHXI1S:AAU#+J&/6,!@>YGE<;]C_Q_+3!
M=SROD9G%UK,)N8=$,V^=G1@M>1"DC#)&.:,-HX)1R:AB5#-J&+6,.D8]H\%!
M;F.H??B?-,:T;W<:0R.[,2;D-D;D+3J2V4'+-`:A3&LA[B1:N4EHK6DB;Q6U
M,5J2L&!4LOG*:-GFO;U?;;3$?,.H9?.=T;+->\O6WFB)^<%!;BMZ(87#XX)#
M!S.-[-::T+6)QB5:RT(IHTQLV4TSV7KEQ$XGM$_L&)6,*D8UHX91JY'5BSJ-
MK#KVC`8'N4Y7.U9KZ!R</NUDG2$RH>,G=K.`$AVA):(U'2_-KQ8WWDHZU1K6
M)C)CE(L=)T#H+]PW6NMX>+M@\R6CZDTYUF_*L6'S+:/N33GVHO5;CPZ.::</
MX!55IP_0"ME;18SZ[@I9(_N\3I!96"2"S-XZ%61&<J:1U?2Y:!E;&XWL^(%H
M&5LEVZI$R]BJV58C6L96R[8ZT3*V>D&FCH.@T9;K^3^,'\RG8($]*@5A]V;"
M5Y$WG-9:RSZO8Y0RRL2\-3N*EMG8;Q@5C$JV58F6V176C!I&+=OJ6*MG-#C(
M;0RU`0Y,A=B4^!M"C5XYKQ.MWYW7&;D\'5.-K+Z?,<I-0KO-O0.UC=$2\P7;
M*AE5)N$1\[71$O,-VVH9=29A^+S.R,7PX%AQ&\W;W<OS:\Z[>(WL\SI!)IJ1
M,$HU<AI%;_]-J#_GA!M&!=LJ&56<L&;4<,*64<<)>T:#D]#U\&]V\6IUY,5)
M-'KEO$ZTIM#^371QY2T;$Z,A/2#5R`I898QR21@^KC-2,5NPC9)191):`V+F
MG9#41DO,-QIYP5UOC=]RCIW8,C[R<NN-AN0V.';<-OS#.,&<XP0:V:=U@JSH
M(Z-4D'D@9AI9C9EK9)_6,2K85LFV*DY8,VH$F2'<LJU.(_NTCM$@:*RCZWDO
M3G"8GS@>`'>H`?7*:9UH80*RGO=>[TA$:SI/NHF6?F]-1<,\V#.-K'DN%ZVC
MN6U$*WQ8)U*34\DY5:)U-*=:M.`J4WN_;HUH.;;H((`+T043^ON)7K2,<[WE
MUB`:8Y7=_J!B`]8BX]6U]A1+<%9\$[+/ZN8ZXF#6H8D@,^Q2069-FVGD-#G9
MVF@M9ZVMM8RMDFU5DJ,I5\VV&M9JV5;'6KT@4\=!4&"MK3;UQSSOG0/,=8S!
M+'-7&GG3N??T6FNM5\[JM)8^38IF-Y$?YTO%D"E!IA'ZE\SZN6BY&P!O0MAH
MK=^<U8D-DU/).56B=32GVN1T=(A.WG6=Q$-4!V),=;LW%:+76K9WO>7Q((;&
M.KMCU(N)O#I&.58RGY!]5J>1=2:6"#*#*-7(/JO3R&GSR;QE:R,)S4ZJ$&16
MMR7;JC2R;-62T-AJ6*ME6QUK]8),'0>-`F=UB]<B$=X8'?7=2(1&]@U:1@FC
ME%'&*&>T850P*AE5C&I&#:.64<>H9S0XR.GS>`+P[#B[/,-"</JX`%_1'Y-X
MS@^^S."-O+5.:`V.A%'**&.4,]HP*AB5C"I&-:.&4<NH8]0S4E\P44N^R1-3
M>TQ?))F^G?"X??ZZ76\?'EY.[G8_GK#BB<8)_,"G;Z&L+N-A7&GX?!D/X\SI
M\]D\5L>V>(3XDL4%/JLRSA<D.7QPQ9.T\^M8S05L#7-UK*8$EF!^CM7,P!),
MR[&:(%B"+[Y\'"<D+_\5"C:NX7T^0R4#=E:H?*CN'Q?Q1[0'9[Q:P"<!CF=J
MK*9=3E%`HF9?EN"Q&JM)F"5XNL9J+F8)GJBQFI)9TD"B9F:6M/,E&F7<F'EN
MP1H7C1*28%V+1@E)L)Z%ST(2+(GB5;`$6`;%ZZ`D@40]^KC46/'$Z@G($BQ\
MXBPHP?HGSH,2;$O0/J%2%Y`400EV)FB?4!IL4-`^(0DV)6B?D`0;$;1/2+*"
M9!64K"%9!R78U,%O(6O8S,%O(0GV=/!;2(*M'?P6DB`"`A^$)A0$0E#3D`21
M#M0T)$%T`STQ)$&0`_TM)$$D`_TM)%E!L@I*UI`D00EB1_!.R!I"2/!.2()(
M$OI.2(*0$?I.2()0*OP6FEH0487?0A*$3.&WD`214_@M)$$`%7X+21`GA=]"
MDA4DJZ!D#8D*>O*80S`:?@M)$).&WT(2A*;AMY`$L6?X+23!H1=J&GKHX.P+
M<U5(@O,N^"`DP3D7?!"2X!`$]0G-\#DDZL""?8`#"K1/2(+C!N03DN"\$3X(
ME0!GC,@G),%1(_I.2((31\P[(0E.&=&K0A*<+*+4(<D*DE50LH9D'93@M!8]
M)&0-I[3P:$B"PUKTD)`$9[:8=T*2]>PJ3O%Z`+<"WI6(U6L/+,%K#K%Z8X$E
M>$,!S_^09#W#4P8GXIPFAT2=N[,$Y^RP%I*TLRA6KRV&TD2Q>GN1)7B5-%8O
M,;($;Y`BGY!D-<.<B#?!.`W>&H(DM-##&[JQ>HF3T^#M7'@T),%+NK%ZI9/3
MX%W=6+W9R1*\GQNK%SQ9@G=RX=&0I(TPZO%F-:?!*_/P6TB"U^3AMY`$;\?#
M!R')"B58!4N`EZKC=5""%ZEC]2(MEPWO3Z/OA"1XC3I6K]5RFAR2/"C!+0>T
M3ZC4N.&`]@E)<-$![1.2X+X#VB<DP1T'M$](@GL-:)^09`7)*BC!A1'X+90F
M@20)2E)(U%T!]@ZNB,!O(4D.B;HYP&EPI2I6UW18@IM5L;J:PQ)<G8K5#1V6
MX+I4K"[JL`2WIF)U.8<EN!F%74=(LH)D%93@HEJLKC.Q-5Q&B]6M)I;@3EJL
M+C>Q!%?38G6AB26X@Q:K>TTLP>5,^"TT4^".)OP6DN`2)OP6DN`N)OP6DN!*
M)OP6DN#F)?P6DJP@45<JN=1K2)*@!-=;X;=0&MQRA=]"$EQVA=]"$MQFA=]"
M$ER:C]7=;"X;+LJCIB$)[L>CIB$)+D^CU*&9'%>A48*0!!>;T0HA":XI(Y^0
MI$`)BF`)\"4"](-0V?!!@EC=:.>:XB,$Z"$A"3X\@+*%)/C^`'I(2+*.,(_B
M.Q*<3PZ)^EH%2_!U"M0T),'')-!WPOG,8O7E`+:&KT:@5X4D^%@$RA:2X)L1
MZ%4A"3X=$:NO"G`^^%P$^EM(LL(4$ER?X%$6V@.OHPN4*S0?XNLO:.F0!!]N
M@3=#$GQS!=X<)>>'$`$^;/O]]NNVN7W^>O_T<O*P_8*8T\7XX8;GZ1NXTS_[
MZ3,")Y]V>WS2%F$I?-`3WRK>XJL)%RID^&6WV\L_<,GYX>O''_XC`````/__
M`P!02P,$%``&``@````A``?%/T1_`@``TP4``!D```!X;"]W;W)K<VAE971S
M+W-H965T,3`N>&ULC%1-;^,@$+VOM/\!<6^PG:\VBE,E6V6WTE9:K?;C3#"V
M40U80)KVW^]@'-9.>NC%,H_AS9LW`^O[5]F@%VZLT"K'Z23!B"NF"Z&J'/_^
MM;^YQ<@ZJ@K::,5S_,8MOM]\_K0^:?-L:\X=`@9E<UP[UZX(L:SFDMJ);KF"
MG5(;21TL345L:S@MND.R(5F2+(BD0N'`L#(?X=!E*1A_T.PHN7*!Q/"&.M!O
M:]':,YMD'Z&3U#P?VQNF90L4!]$(]]:18B39ZK%2VM!#`W6_IC/*SMS=XHI>
M"F:TU:6;`!T)0J]KOB-W!)@VZT)`!=YV9'B9XVVZVMUBLEEW_OP1_&0'_\C6
M^O35B.*[4!S,AC;Y!ART?O:ACX6'X#"Y.KWO&O##H(*7]-BXG_KTC8NJ=M#M
MN3_"=`.9X(ND\",`E=/7'&>0012NSO%T,9DODVF:S3$Z<.OVPI_%B!VMT_)O
M"$J[[(&KT_!`'=VLC3XAZ"M$VY;Z*4E7&=3./+CU:(YAP(#/`OJRR9+IFKQ`
M&:R/V848^,:8-$808(\I0.\[*3SJ4_@Z?<Y=`(9\V?M\TQ$?\GY-DRC=[P(P
MD)4ELT@44H6866?,4.ELQ'PVPZ-@SYAR?D'9!T'WHQU#RT:&0+?>,<2C79KH
M2(^$!@YU+D8$O0.+R7(>7?`18[(>`9<'`A>QBI'`Y8C_[(-'QYP!N?;1OTS_
MAZK3!TT8ZO,18ZX>&>M;7N@+ER@,L.2FXE]XTUC$]%%!57Y^(QKO[C;S?;[$
M9ZMM-WLD;L!5:VG%GZBIA+*HX250)EXT,N%6AH73+2B'"Z<=7++NMX;'D\,,
M)Q,(+K5VYP4D)O$YWOP#``#__P,`4$L#!!0`!@`(````(0"U#PV5A0(``.8%
M```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULC%1;;]HP%'Z?M/]@^;UQ
M+H10E*0JH&Z5-FF:=GDVB9-8)'%DF]+^^QW;$`A46E\@]OG.=[YS<_KPVK7H
MA4G%19_AP/,Q8GTA2M[7&?[]Z^EN@9'2M"]I*WJ6X3>F\$/^^5-Z$'*G&L8T
M`H9>9;C1>E@2HHJ&=51Y8F`]6"HA.ZKA*&NB!LEH:9VZEH2^/R<=Y3UV#$OY
M$0Y15;Q@&U'L.]9K1R)92S7H5PT?U(FM*SY"UU&YVP]WA>@&H-CRENLW2XI1
M5RR?ZUY(NFTA[]=@1HL3MSW<T'>\D$*)2GM`1YS0VYSOR3T!ICPM.61@RHXD
MJS+\&"PW,TSRU-;G#V<'=?&-5",.7R0OO_&>0;&A3:8!6R%V!OI<FBMP)C?>
M3[8!/R0J647WK?XI#E\9KQL-W8Z-2R%:B`2_J.-F!"!S^FK_#[S438:CN1<G
M?A2$,49;IO03-[X8%7NE1??7@8(CE2,)CR0SD'FTAUZXB(-X_G\6XA393#94
MTSR5XH!@.B"F&JB9M6`)S,<4CCK&I*"TA4$_&KAU`KD*;E_RP/=3\@)5*HZ8
ME</`C)\Q4\3ZA#"5,K2;BPL"PD9UD/.UNL@?Q1CK5$R83".MWH%,$>MW$(LI
M9',+2<Z0B=[H5N\L'O4::X:![5P8/YC&6CE,8DL[\\.KVJXGYBB93[TWE^9H
MGD2C>:(2^GQ=U0N5QGJM,AR);+]6#N-41O[\*HGUU#R+I]ZPDB:"\PX7X9G<
MJ73[YJ:T8[)F:]:V"A5BW]LER=/QUJWY"M;<[@H9#;!]`ZW9=RIKWBO4L@I<
M?2^!=9-N4=U!B\%.T%9HV#O[V<![RF`H?0_`E1#Z=#!/P?A"Y_\```#__P,`
M4$L#!!0`!@`(````(0`)@WHM<@@``+,F```8````>&PO=V]R:W-H965T<R]S
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M]H<W2/&XV^_&/Z>D\]EAN_[UY=B?-H][X/V#I9OM.??TQ4E_V&U/_=`_CTM(
MM]*%NIRK5;6"3`]W3SM@H(9]=NJ>[^>_L+5,BOGJX6X:H/_NNH_!^G\VO/8?
M\K1[^FUW[&"TH4^J`X]]_TVY_OJD3!"\<J+%U($_3K.G[GGSOA__U7_\L]N]
MO([0[DR%;/L]7`G^S@X[-0>`^N;']/FQ>QI?[^=)OLR**&%Q-I\]=L,H=BIV
M/MN^#V-_^)]V8B:53A*;)/!IDE1?CDU,+'R:6)8NXS)C6?XW*DA-%O@T66+X
M]XOE`]%I#.#S7$*U9&GT=PK(30[X-#G^CW$L3!+X/!>2+,LL2_.R^+0;*]W9
M:4:TFW'S<'?J/V:PS*!WP]M&+5JVALQF*IA^7B8'S-&M\OY%N4]!T/8!K-\?
M6)3<K;[#;-L:GUK[P&9A^638IW%]"N+2NBXLRG$:[O,IL(_P^9381_I\JHO/
M"L;J,F`PC:T!.X^+LM)Q22\)IK&KM4\Y+0XUF`TUM-3`J4%0@[0,J$Q8,9XR
ME?5^#C'7UK"(E*E]BJFY<55D.1FLQG9(2Q+>VBB+2M@LR/S@ML>B**L\9K@$
M87M04-K@(DFOTP;QAP7NX:^LE#^Y>*U]TFN;M"&?!@3X)F45190U#>+4(*A!
M6@94.:QE3^7*2BN/\;#5VD<7FJ?5=62F^==H.)UXT/K#H3P0*@*8]&.(+NR)
M%MUI`THBJ%'O-PJEM,E\JK6/U3!MT./`DC@IW7[1&$X-@AJD94`$8-<,$%`H
M)4`W!NVCZTTRI]A&X[IQC+!O47!:E63[XW8PZ;H(8-*/(>9*#Y)[A]4ZA5+F
M9$K6VL=JG3:8UL6PVIR51D,X-0AJD)8!U0\Z)%"_0FG]Y/Y3:Q]3;I21QC8:
M-HW#B[4EH:2MW`ZE;0M@TH\AV@P$8X#W!%/B9%;5QLGJG+&8L2C4-'9ZYT1Q
MQR(<B[0MF(BZ;=^>@$S?U?'=CMS,:N-D%E\1962*-L;!-)&$MS0\(0/%43AM
M9`B4-T`\`NKV?QV!\Z[)M"K`S*]Z1LL1XZ2)+4!4XPG:()Q4WH9`'@)%")0(
M1#5AVDH#>&AK:8!HQZ3RFFDGW?`%8U',B`)HC(L>&1+?AD#^>7(1BI<W0$Q>
M"0</>:TG;/(5F:TU.VL.)=R)>F@0Z+"V(PG(0Y$"@>2:$H'7M)BO$A$>OEI;
MV'P9U8HU/-6J35PW.\[SO"!#TA@/W>N,D0);E(`QR!"1=<*1RZ*LJC(A602Z
M2$RV>HG019[<&@<E0#SCH'4)'@=20,TL\:+%H+'HD0'>R;1CXRV@=<*X8Q&.
M1=H6W$FE*3P,M-1`#&@C:J:==+U%2CO=&/S&F@T'\U"P"('R!HAI*_UQI4TE
M+M/R!-,G2J(V3EYZS054;W#4DV7K6+AC$8Y%VA;,0*F*``,M.C`#LDQJ=E8F
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MF?4*%@^$7SJI5^?.0!`>M7&RGO",10\-$$]2SXLP)XP[%N%8I&W!#/RB)_:(
M'D<R&"==;Q&55.8;W#M'VT^">2A8A$!Y`\2TL5*BDB'V*28R3VOC9#?0ED%I
M#DK3>4)W@KAC$8Y%VA;,(RQ]XJ]('^-DIAW(5+R:&H.;]8C!E@1;;XNG>RI'
MP22S"('R!HCIAW53_!7=9)SL-NJP\Q8%CR1N&QW=Y*01CD7:%L0#WNK9=U`Z
M'2>8W$D9N4W6QDFW"5[*XD8U"";[78O`A-X3.()I$T.@O`%B\E@U.>1]ZHF\
M!:H3[60UT5AT$^,H+7VKT0GCCD4X%FE;,!,LA!PF'D'$R'VI3FQ!%$>L2@G7
MQGCH1L?T<;FE">!9#D\%CA(X[=37]V[:\D8D'@2_($I<0<08%<'&25]\4=)W
M[0W"2>5M".0A4(1`B4!4$Z;MUT2)3Q.1RFOCI.>JTBMQ1=1"8UR\;6E#(/\\
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M'#=[^`L``/__`P!02P,$%``&``@````A`+?DOP$U!P``'AP``!@```!X;"]W
M;W)K<VAE971S+W-H965T-RYX;6R,6=N.VS80?2_0?S#TKK5(ZKK8W2"2D#9`
M"Q1%+\]:6UX+L2U#TF:3O^]00XF<D=;-RR;F')*'<SN4]/#AV_FT^5IW?=->
M'CUQ%WB;^K)K]\WEY='[^Z]/?NIM^J&Z[*M3>ZD?O>]U[WUX^OFGA[>V^](?
MZWK8P`J7_M$[#L/U?KOM=\?Z7/5W[;6^@.70=N=J@)_=R[:_=G6U'R>=3UL9
M!/'V7#47#U>X[WYDC?9P:'9UV>Y>S_5EP$6Z^E0-P+\_-M=^6NV\^Y'ESE7W
MY?7J[]KS%99X;D[-\'U<U-N<=_>?7RYM5SV?X-S?1%CMIK7''XOES\VN:_OV
M,-S!<ELDNCQSMLVVL-+3P[Z!$VBW;[KZ\.A]%/=E&'C;IX?10?\T]5OO_'_3
M']NW7[IF_UMSJ<';$"<=@>>V_:*AG_=Z""9O%[,_C1'XH]OLZT/U>AK^;-]^
MK9N7XP#ACO2477N"G>#OYMSH'("C5]_&?]^:_7!\]%1\%R6!$C+R-L]U/WQJ
M]%QOLWOMA_;\+X*$60H7D6:1$&@:N[R3:22B^/]7V2*C\21E-51/#UW[MH'T
M@#W[:Z633=S#RN8(AL=\*/#M3J,_:O@X">CV,/KU2<CD8?L5O+0SF!PQD.06
M0Q'%A-">TLN6SL`6B,WLX,R<G0IF,MI*R2RXK$`8EQ5$2B'E$I)8".&K"-_)
M:7H40NXZ1-H%1@_DB`G'B&N7%'R@=`;(GA`UQT?3GGKTT0/F<Q"RD!XK1T@R
M1M$702`YHF"(4,B8KE%2A`BD$#."L(0\=UB.>19&<R2UE7LHFQ="#R'&\1`?
M*)T!LG=,]IX\I$>IAX0*V)Z(B3'1,QZTPC7+-%9T=NF:0Y'9Q0F[9)6='N7L
MK&O1(X@Q[%04L@`7:`]']G9SK+AU&R&F98JU!J?XM)423"-Z_APAAE^X\)YK
M]J44G*)KS]+4MAG",B,LI^#J4<I.",GH(0;I)4'*O%L0<RB9N73-<9C9LQ-V
M`D3EAA-',^.I.$\#0J*^B!6C4AC`>J#?,5*6NO_:4$].%-B6W28B%$ORW(!P
M<^@BU,D%,3-C^8Z1<M/==X4;-F7*C15`+A"$W/R$;5\0,S.6[Q@I-]V3+;>Q
MJSDE(K!EP]^Y"0ME$P6+V("<OK88*=T12D#WWQL$L#U3)[$6G@L$H9/"R);9
MR*\@YBAENE4:\Y2<@5/EE*ENSC>88N^F3!F5'.Y6NJI-.(6SE:&*=M-P$L%2
MM33S#5<9![:0*%?=N"W7N1RPGU..S!^Y0!!R9#E5$*//!*XDULR&B7+3C=MR
M6Z0<]G7*D6V4"P09/\G8;F7\Z-J5$&Q^:>:;.&3O]C[=P&]0Q?Y.J(;,8[E`
M$&X59RPC"F+V0\6B45*[S&Q&4*?J9FZ9S@'''D\9VIPQ]>L*@9_`99SU[T(0
M1":"9.%0B@C#V/J!$)543B:BXS"[/X6,1FY`3J-9C)3N"-UX72'DBD*$ULGH
M(0,RZ9+:HV&V&?/409*%TM+Y868/1BE"G)P@\LJ0VLRDEM^8<@-"+E(L%,/8
M\2B+ZV))S,YUB/*DHC''$,6")AL7"XF@J8-)D47,VP6%""%"Y^(Y>KRD$*F4
MC&Q0*%>J+S/7%5T)61?))8),EP$>W-L%04AXN)#LO"5!@':F[Q*]+2_Z`7D1
M?-9,<@.:$C%(X<[.;C,$`HV/'ZDD`#]+TL#N0CV[KC$2Y8-<&4+6U7(#<BMY
M4IWYB=K%T(UO"XA<$9"0N2$W(%,F@93+0G$E1(`KJ2-+LH)*16"WH&RIALP)
MN*(=/%BY=+7#=Q\@3..A]H154DGGPYN6^0R4HF[>5CP6?0=[.ZEK)XM-BW0%
M`/*.WQ(+B0!L/+9833VO&PE+N):Z+"='CL.L*T9<X@QH*HR$/ZD5#!`E/-P,
M$#H:05FNRXQ:D9G(R@#ZT(!67500H[]XC4',UKV4VVU]42OZPIMS;D"F<%*5
M!JRV"X+PA4IM86"P"4#%4#OK::FHS/"T',T\\"QLN0$AW2Q+8MO,1C(%`21!
MPC2@)'9?1/#\8"'4NU1I%G17%">R!6DRP%4<E809\UVA""`()2]Y`A#P1N>]
MOJ1NZ\UHYMZU)S=TR>.*2I87<;,,^G_E0"4%D`-1[U*U67AW177X@V"NN,84
MBY'2':$$J.K,[6=%;2)6$KDB6I+$-N%-$A)[RA\22C)?OON$JJC4+'R$:D&4
M.6()EH]KZ"?428>+Q4CICE`?Z39NA63V$79W5T"RA8M<!?!C5AB%(N;%!9N8
M;5LEY.`[BDMN]([S`G<TLX1W'F(PX0T(WSA'"5?!@MAM%QXGZP\Y^@J'DU44
M.&^:D"A^IL&/&^>Z>ZF+^G3J-[OV]0*O7P2\!9U'\?-0#I^'QD\LV]D`'VVN
MU4O]>]6]-)=^<ZH/,#6X2Z!2._R^@S^&]CI^>'AN!_A<,_[W"-_A:GAQ']P!
M^-"VP_0#4F$[?]E[^@\``/__`P!02P,$%``&``@````A`-G/)P^(`@``$`8`
M`!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6R,E%UOVR`4AN\G[3\@[AMB
M)T[3*$Z5KNI6:96F:1_7!&,;U8`%I&G__0[@.'83:;WQQ^O#<P[O.7A]^RH;
M],*-%5KE.)E,,>**Z4*H*L>_?SU<+3&RCJJ"-EKQ'+]QBV\WGS^M#]H\VYIS
MAX"@;(YKY]H5(9;57%([T2U7\*741E('KZ8BMC6<%F&1;$@ZG2Z(I$+A2%B9
MCS!T60K&[S7;2ZY<A!C>4`?UVUJT]DB3[",X2<WSOKUB6K:`V(E&N+<`Q4BR
MU6.EM*&[!O;]FLPI.[+#RQE>"F:TU:6;`([$0L_W?$-N")`VZT+`#KSMR/`R
MQ]MD=;?$9+,._OP1_&`'S\C6^O#5B.*[4!S,AC;Y!NRT?O:ACX678#$Y6_T0
M&O##H(*7=-^XG_KPC8NJ=M#MS"]ANH%,<$52^!&`G=/7<#^(PM4YGBTFZ3)+
MLD6:8;3CUCT(OQ@CMK=.R[\Q*NE8D9)V%+B?*-GU=);\'T)B16$G]]31S=KH
M`X+I@)2VI7[6DE4*#C(O;KV:8QA3*,J"^K))%LF:O(`9K(NYBS%P/<7T$03H
M?0JH]T(*K_H4WBV?\RX*0UYZF3>[R/,J^#HL9W$"Q!0Q9AZ:.JQP?I'H5;!E
MC'SO0A<$LW.R86#5R`AH]04CO!K2]$YT2NC^"+`8`5"8MR2;9'W??,"8U2E@
M[J"^V65CKT?XXRQX=<SLE//Z_'_M-$RAOEER,ZC/!XQ9G3*N;_ZNOG@"X]Q*
M;BK^A3>-14SO%>S*CVVO]@=_F_HVO]?GJVT8.=)_@'/:THH_45,)95'#2T!.
M)]?0!!./='QQNH7*X;!J!P<T/-;PY^4PNE/8(2JU=L<72$SZ?_GF'P```/__
M`P!02P,$%``&``@````A`)[:HX:@#@``0$H``!@```!X;"]W;W)K<VAE971S
M+W-H965T.2YX;6R4G-MN(SD.AN\7V'<P?#\^VW&,3@_:+I6DPBZP6.SAVNTX
MB=%)'-CNZ9FW'ZHDED3]<B<S%^/.)U(EDA)%R8=/O_[^\MS[;7\Z'XZO=_WQ
M8-3O[5]WQ_O#Z^-=_[__J7]9]GOGR_;U?OM\?-W?]?_8G_N_?O[[WS[].)Z^
MG9_V^TN/>G@]W_6?+I>WU7!XWCWM7[;GP?%M_THM#\?3R_9"?YX>A^>WTWY[
MWRJ]/`\GH]%B^+(]O/9]#ZO31_HX/CP<=OOJN/O^LG^]^$Y.^^?MA<9_?CJ\
MG;FWE]U'NGO9GKY]?_ME=WQYHRZ^'IX/ES_:3ON]E]W*/KX>3]NOSV3W[^/9
M=L=]MW]`]R^'W>EX/CY<!M3=T`\4;;X=W@ZII\^?[@]D@7-[[[1_N.M_&:^:
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MMLJ!RD&=`YT#DP.;@R8!0[*_<P(MC;_D!"?OG,##7S.(7IED%K,$JU0Y4#FH
M<Z!S8')@<]`D0%A,:QHLGHZZ*+MF2C8BR@MIT=K+S*:=%S9`*B`*2`U$`S%`
M+)`F)<)62CVIK3R3':993VH_F<I>:$8OUX4VG5`77"`*2`U$`S%`+)`F)<)N
MRB$ENQUN[>;1KCV9^1W(+<<-D`J(`E(#T4`,$`ND28FPB%)Z:E&;K";S`<G[
MC(?IRFE(8SV9T4L2T1LYMS>=$/NH`J*`U$`T$`/$`FE2(NRGG2FUGV>RP])(
M3]*(`JF`*"`U$`W$`+%`FI0(BUQ)FV\_T^4@[G\84J<BK?4D"^DR"VDGU(44
MB`)2`]%`#!`+I$F)<`#M_*D#.*0.2R,]24,*I`*B@-1`-!`#Q`)I4B(L<E5$
M:E*[2A?30:RA,*:MCK0WH"RJMUE4HU075D0*48U((S*(+*)&(.D+5W$D\YO#
M._:5"&T^/.QU0&F`$56(%*(:D49D$%E$C4#2.%=<),9](!V/?3TB[/9(QOEF
ME,>YDV*'5:$O4F2D$-6(-"*#R")J!)*N<,5'XHHNSKXH$?:&.B79;5T-0JL]
M"7V%2"&J$6E$!I%%U`@DC7,51F+<1^+LBQ+JDV.S'H<ZA3:WN/'>C/,X=U*L
M6$5%1@I1C4@C,H@LHD8@Z0I7FB2NZ.+L2Q9A;UK%M(><#9WQ(<Z`%$K5B#0B
M@\@B:@22QKFZ(S'N0XG;URK"\*Y\20.=GX?&G11'M4*D$-6(-"*#R")J!)*^
M<!5+XHLNT+Z2$?:FQ4T(-*!J#$@AJA%I1`:11=0()(USU4ABW(<"[2L887A7
MU*2!GN8KNI.*@0:DQH!J1!J10601-0))7[@Z)O%%%VA?WPA[TY(G!!I0-0:D
M$-6(-"*#R")J!!+&34JEV#OE=:LC2[&`LBUZE@4Z2G6!1J00U8@T(H/((FH$
MDKZX4HI-L!0+*-F/-X@J1`I1C4@C,H@LHD8@:5RI%'NGYIY@+190%NCL>F\3
MI6*@H3Q3*%4CTH@,(HNH$4CZXDHM-L%:+*#T#@M1A4@AJA%I1`:11=0()(TK
MU6+O!1J+L4E79J6I.[OAVT2I&.A.D9%"J1J11F00642-0-(7KG8JI&YW>9`=
MG@,2*QHJKPJE%*(:D49D$%E$C4#2N%(Q]O.[K@G68@%E"SJ_[8I2'-0*D4)4
M(]*(#"*+J!%(NL*53J4X^Y(JW:(GH<J*YXX-H@J10E0CTH@,(HNH$4@:YPJ?
MQ+BV%GMOB_;%DC`\U$]D?W*ZRN_`)IU4##0@A5(U(HW((+*(&H&D+USIE/B"
M:[&)+ZF$O1Y-X^%_$Z025"%2B&I$&I%!9!$U`@GCZ-V5HG$ME_46H\0X@62_
M65T33^?LOBE6.(SD=,DOUUB*IDB<5,MX-2/'D94@W=.QS)@&E-J7(MEOMITG
MAY7N$;BS3P-ZQ\`@)0V,=Q)R(-G6VST=M]=IV"63-(2H0J00U8@T(H/((FH$
MDL9E>VGBY:OOK4QQGPUH)MR^S,_^4:I+0X@4HAJ11F00642-0-(7V=;;!1KW
M5THV[8U.&FA`%4HI1#4BC<@@LH@:@:1Q%)HTQ\9T<3W.3B7+4!YE<<Z/_M-.
M*L89D$*I&I%&9!!91(U`TA5NZRML-U._):;;34#D5K9D@ZA"I!#5B#0B@\@B
M:@22QEW92Z>XES)*C0M2+1+]SK)M+$D4O$Y:$3E?&%'TXTYRD^\W+"73<;QG
MD`/)]KWNZ;C;S0)*#!1(]IOM8ZV!OB#K'H%;VBR@=PP,4M+`>+Z6`\DVON[I
MN-O1`;9=H:F!*9+]9OM8S`#=$W!'<Y^`<#G@'?N"E+0O'BOE.+(MIWLZ;BMT
M;LO3+*(*D4)4(]*(#"*+J!%(&I?M(<DLNIIGW2DMR[,!97DV/[]%*<Y.%2*%
MJ$:D$1E$%E$CD/2%R_F%/.NLRNWU*+V0"5()JA`I1#4BC<@@LH@:@:1Q;K-(
MC&L#/1[10K_VD929T\C2HT?.A3$]+O/36U`DJ1CF3I&10JD:D49D$%E$C4#2
M$U=VG!GN.`'1\N%A;Q!5B!2B&I%&9!!91(U`PKAY:=N[H0_C7H]SJR+C'%`6
MYWP;C%+LG0J10E0CTH@,(HNH$4BZXLK&.\>--Z`TSH@J1`I1C4@C,H@LHD8@
M:9S;H?/E_$Z<PZ8>SP#KN4<N:\3U?!L/SO[-HR@5X]PI,E(H52/2B`PBBZ@1
M2+KB2OTQQ_HC(#K7\[`WB"I$"E&-2",RB"RB1B!I7%8$<?$QQ]*'44R[&T05
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M[#&&!QL?8P.B:_=V9+G7PA.D=;%;X;5%5CKR9&NYK`\#<A<RG=?HNWGRZ9L@
M1;<E/-4K1OZ;7^XC_(I1E*H912G-*$H91E'*,HI2C4#2WBOUX0+KPX#(7K9D
M$Y`PSBO2E0U+*92J&44IS2@.VS"*4I91E&H$DL9E]6$73"P"%P')29)GCB`5
MET"6M2ON)DY.Q3I^#2P'M_(_6A+9WEEC)YH[\4LB>ZI!!1O0E27!"M+::TOB
M2FFYP-(RH"S_YHF$I3C_+O-RA05B8E2,./\N,).P2-32C'S^C?:U"<MP:U2P
MC,KYEUL_E'\75.>4MJV69YG$B=(WN-(3R&24>643%.GRDE=6%5!RTZU0JD8I
MC5(&I2Q*-0+)Q7:ECEU@'1L0V<N6;`(2QH72-I9."J5J[BM*:90R*&51JA%(
M&I?5GETFP1ISX5&V!B"3!"E>`[=9$JBXFS@Y%2._!I:#D?R/2I*LDYHU8B>:
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M]ZZ%EOEHY:XA2RWT`PUTAU=JF5!+NYWE(YC.5^X]_X+.=$$M;;('';+';RG0
M0O;XLV;>,J/G^`M/:*'G^*#D+1/2H8\"%L8V(1WZ9%RIA<9&6:K40F.C\U&I
MA7Q-":;0,IV1/;-2RYATZ!/F!9T)Q8<^;UUJH?C0;E5JH?C01W=++5-J:3<)
M\`Z-C3X%6M`9DXX_K.<Z8]*AK_&4=,C7]!V84@OYFKX14FHA7]-;GZ46\C5]
MN:#00BI%#5(HRI.;BUX>DY?I"X:%)XS)R_3MO%(+>9F^K(8M5)*M7.6"+529
MT:HNM="OH7PI];5VCR_TM'8A+G$*5BF^7V:K+Y2R<$AK&E$QA!3!TD#7%+]B
M^,BT==$T*H!7KD[$9U,=O*J*+50.KUS5B#I4%:]<\8@M5!RO7`V)+71O1<84
M)\IB1*,N.9@N`&C4I1:Z!Z!1EUKH.H!&76JA6P$:=:F%+@=HU*46NB.@:51J
MH:L""D*I93VG^-.%//I@/9^OUG2%B2T;:MD46^C^>>5N55&'KJ%7[G(56^CJ
M>>7N6+&%;J!7[JH56^C6>>5N7+&%+I_)GG),:2)ZG6&7E^AG?=ZVC_M_;D^/
MA]=S[WG_0!OOJ+UI/OE?`/)_7(YO[L:Y]_5XH1_T:?_Y1+_4M*<KG9%[M_'A
M>+SP'S2HX0_^[:?/?P(``/__`P!02P,$%``&``@````A`)3_1_!_!@``NQ<`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3DN>&ULE%A;;]LV%'X?L/\@Z+V6
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MZ,?^.&T@G">(FG/>>3L/(MW?'5J8`2N[,S3'O?M`TI)N7>_^CA?HG[9Y&U?_
M=\9S__;;T!X^M]<&J@WKQ%;@J>^?F>FG`X/`V3.\'_D*_#DXA^98O5RFO_JW
MWYOV=)Y@N2/F4O<7R`3_.EW+]@!,O?K*?]_:PW3>NT&\B1(_(#1RG:=FG!Y;
MYNLZ]<LX]=V_PHC(4"((E4'@5P6)-MLH"N-M`E'>\0RD)_Q*S]TFI%&RY>G?
M<0RE(_Q*1QIOZ#8B4<R(O^,)HWS&\*O(KF9L.GJB8KS21355]W=#_^;`]H6:
MC+>*'0:20C!98IEZ+CJL?<VL'YCYWH4#!N4<`7V]#P)ZY[W"*M;2)C-M"+;(
ME05;21:VT(%R!7C`=*8+B_-_Z#)S1E<ERA2P\-?8Y\I"N10Z4*X`Q`V67^<6
M^'/EV"CL2U2Y`-<E$S9A,//-#:0PD'*-($*PK5:$U!(R%%8;O-Y90V$4PL_W
MC?+9:*Z5@91K!)&#S68AQU!.3H7,!!**8\\V2VX@A8&4:P2EC5%:OM^WN\UR
MVLPMSSPP)8&$\+,J3HC7,I^-U$P*`RG7"&*9()9JY1B*F0AD71P#*0RD7",H
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M9QLZ-'82P6!1`$H2G9VT2G@8XB=:F%*&"7F3AKDRV;1P%6J*N`H(J*@2Y,2`
M"@4ELU4I(5MR)IZ6Y$)347(ILV*&4"AM@7(B#.)8E(#X6IM4+`:*?BFA@)]@
M7!6FEQ9B0D81L;6R\OXK!XUD:P945*;"A$H)V9(SR;0DETJZ'/D,CI#<':QY
MA*IH&R-7!G)C$+K5=XZ,L%XN`5F6B]H%F\-8L"6TWBL*6C(5)E1*R)8<"[8Z
MY-049@G!K2FKHDTZEP:Q$*`HT;K68AE7"UA*R+):%&OVCS22FVO%$L(-?%6Z
M7%HE_)-.=/4F5$HHYG<RVK^4B:6YA3BL)1>R&H.8S2T&\37]R*5C`L:SE2E#
MRBKDA0^VB79(2V7`)0039F*Z$/YA%87VK@\B%1!,9*FB@*+50916T=+&E`KB
M=P(FQ63U'5)?^MNZ1V!]K]8U26C]$6)"A0F5",*DL&#S2B7PN:J^<,V>FYI:
M+B&MZ]:6*U^L5$D+$RH1A*G:Y9V:\BZA=>]M0H4)E0C"R;&$\SK]H/^&YQ=C
M`:6\0PGGC1\$NLQ*1RCG4JC944'L=8>%%U:"JWBM$6\(73.<FKRY7$:G[E^N
MD"Y@"C;#XIDHVZ704D-,':<1O!_Q@V6,Q##"J1DC"8QPV3%&MNHU2AN!9ZH'
MWH9K>`;/5[R[T'$*@6Q\@Q2^M<UY/(00GY]./5"8PO>OZ9#!O*W3AEE;)PUS
MMDX99FS-2TF:@=*:F>$>20OK"%P7,&N;3T8#B&:;!VALFEM'"A@IK",@J)#'
M%BTC29J)CS6MCM`II:P?,><#_1"LH6T$&@U@S2\C(]H.N-E&2O!AU[F9)R,^
MY+&/4&!MVQ;P=0,^MHKF!&KP'1_8,L1>G0CRV'9'3J*4M;4FZP)&6'=KCD!W
M#7GXB#>7!UY4;]6I^:,:3NUU="[-$0ZTSS^=!O'X*OZ8Q!WB//43O*6RZ\0Y
MPR-Y`V\S/A/U8]]/Z@]([<W/[O?_`0``__\#`%!+`P04``8`"````"$`3X&Q
MA:D"``"A!@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R,E5UOVR`4
MAN\G[3\@[NO/U&FB.%6ZJMND39JF?5P3C&U48RP@3?OO=X#$-76D]2:*7Q^>
M<W@/'&]NGT6'GIC27/8E3J,$(]936?&^*?'O7P]7-QAI0_J*=+)G)7YA&M]N
M/W[8'*5ZU"UC!@&AUR5NC1G6<:QIRP31D1Q8#V]JJ00Q\*B:6`^*D<HM$EV<
M)4D1"\)[[`EK]1Z&K&M.V;VD!\%ZXR&*=<1`_;KE@S[3!'T/3A#U>!BNJ!0#
M(/:\X^;%03$2=/VUZ:4B^P[V_9PN"#VSW<,,+SA54LO:1("+?:'S/:_B50RD
M[:;BL`-K.U*L+O$N7=^E"8ZW&V?0'\Z.>O(?Z58>/RM>?>,]`[>A3[8#>RD?
M;>C7RDJP.)ZM?G`=^*%0Q6IRZ,Q/>?S">-,::/>U74)E!YG@%PENSP!LG3R7
M.(,,O#)MB?,BNEXF>9I=8[1GVCQPNQ8C>M!&BK\^*'79/<O5<$\,V6Z4/")H
M+$3K@=ACDJXSV#RUXLZJ)883!CP-ZM,VSXI-_`3;H*>8.Q\#OV-,.D;$0!]3
M0+T74EC5IK#[M#GOO##E99=Y><!#UJ\\&4NW;T&8E)5GRQ'D4_F8A3-F6NEB
M3LZ*"-P]^V(#P*F0_M:84Q`<A-&9J7N!-]"X"]Y8U:49S3DIV:SD(@`X,[(\
MF=9L(T+820'#)P7>C!X%!2[G_#PIHN6K)S8BY)^4D+^ZS+=3[/7\N?H7R2HJ
M1LMM0(@_*0$^3R[C5P'^W$:KADROS$\$7/S_U.<B0MA9"BM\>SO\0/"743#5
ML$^LZS2B\M!#6^Q='-5Q$.W<`7BK+]8[/Z#B\0W,C8$T[#M1#>\UZE@-S,2V
M#2D_8OR#D0/4#M-#&I@8[F\+GP(&%S*)(+B6TIP?[!`;/R[;?P```/__`P!0
M2P,$%``&``@````A`/'5WQ<4&@``6HD``!D```!X;"]W;W)K<VAE971S+W-H
M965T,C$N>&ULE)U;4]O(ML??3]7Y#A3O!_`54"79-;:NMN2++,O/#'$2:@).
M`;.S][<__[:ZW9?_@DGF82"_=?%JK26IM=QJ/OSK/X_?S_Z]?WYY.#Q]/.]=
M7)V?[9_N#Y\?GKY^/-\VZ?_=G)^]O-X]?;[[?GC:?SS_[_[E_%^?_O=_/OP\
M//_U\FV_?SV#AZ>7C^??7E]_1)>7+_??]H]W+Q>''_LG2+X<GA_O7O'/YZ^7
M+S^>]W>?CT:/WR_[5U?CR\>[AZ?SSD/T_"L^#E^^/-SOX\/]WX_[I]?.R?/^
M^]TKXG_Y]O#CQ7A[O/\5=X]WSW_]_>/_[@^//^#BSX?O#Z__/3H]/WN\CXJO
M3X?GNS^_8]S_Z0WO[HWOXS_(_>/#_?/AY?#E]0+N+KM`><RWE[>7\/3IP^<'
MC$`=]K/G_9>/YW_THMVX?W[YZ</Q`+4/^Y\OSN]G+]\./[/GA\_EP],>1QMY
M4AGX\W#X2ZD6GQ6"\259I\<,K)[//N^_W/W]_;4^_,SW#U^_O2+=(V5R?_B.
M3\+_SQX?5`U@Z'?_.?[\^?#Y]=O'\T'_HC>\&O='YV=_[E]>TP=E>GYV__?+
MZ^%QU^GTM*?.1U_[P$_C8WPQNKX:])23=PP'VA`_C6'_XF8T&HYOKM^W'&I+
M_-26_<'%L#^ZOOFGSX3?XX#Q4UN.?LUPK`WQ\S>#O=:6^*DM\=L[AP4GX3%$
M_-3Z/?SZCL&M-NBI.CEE\9<.9.]4`/A%V_[JH>R9Q*M?M.TO'LR>2;WZY7=#
M-LGOV>R_?T!1^;K*;=;_X9#V3+I[-FLX,W[MF)H$JL_XW6-ZRB5^^;UCVD?V
MCW6C?OG-8]HW9:!^T;;O'].^2;[Z15O\PS'MFZ2K7WXMP,ON<G6\S,5WKW>?
M/CP??I[AWH$P7W[<J3M1+U+N]`5.GR6G2QZNO/=*_0^E__$<^<#5[`7TWY\&
MP_Z'RW_C&GJO=2:LT_,UID9#74>5VS@$20C2$&0AR$-0A&`6@GD(RA!4(5B$
M8!F"50C6(:A#L`E!$X)M"-H0[!QPB>2>,HRR^JT,*WV589.;B0$VY4'"IT;#
MF,0A2$*0AB`+01Z"(@2S$,Q#4(:@"L$B!,L0K$*P#D$=@DT(FA!L0]"&8.<`
M+YTX1]UTFO-28<PYO/-RX)]UDTYG.#BE=DHD)I(028ED1'(B!9$9D3F1DDA%
M9$%D261%9$VD)K(ATA#9$FF)[%SB91-W7BF;"N.*#+-W+K.=TA`_WE::GI1.
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M9U0RJA@M&"T9K1BM&=6,-HP:1EM&+:.=A_R<JKZ$D]/C63VXN;!?*`HWZZZ7
M`:?F5)RH;XA4<O%HY=RL;\+3^J1E#&-K:%#"*&64,<H9%8QFC.:,2D85HP6C
M):,5HS6CFM&&4<-HRZAEM/.07P*JO>&4P.FT[MH>7IHU0G68=$W5=W[JGNZP
M6&")P%*!90++!58(;":PN<!*@54"6PAL*;"5P-8"JP6V$5@CL*W`6H'M?.9G
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M_53L9V&TW@UZ:;1,T*.K6_>_H`VV,NKVH]?\T;71TD.X&EX'QWUC-*R?AOUL
MC=:[0VB-EAG"35`9.Z-P_#"_"(,6HND?];E-J-'(1CS5R*LX;7AU?/7B.+5-
MC+,K6YDIFV8:W=Z>;E>YL<1EVYQ1A6&.MQE[FY_4;"#EB5EW%9LN-'("61I+
M)Y"584X@:_96G]1L()L3LX$T;+K5R`FD-99.(#O#ND#\_*H&GW21T8T_.X&9
MJ*ZQ>H)$O\"Y"06GWE1K#>PL-]9HW)7?<'05G/8)VZ2,,N/F]GCUZ%V,@U,O
MMPJV%KJ8G6AF['EN#+L`!\/;X'FZ9)N*T<*XZ0+$"T#!Y7]I%4R`*W:S9E0;
M0Q/@,)@S;-BF8;0U;LP1#*\#K54P`>X\-W[IJ&:@5#I=D]"[/U'?<-KOD).9
M6"/4B?GTA+521IDQ="\,G?NQ104;SAC-C2\;1,E:%:.%,;2?N&2T8L,UH]H8
MVB`VK-4PVAI#&T3+:.<9^CE5S4`IIUV3T,MIAW"Y=R\'P6ULVN^TO#M`A\;^
M+#B8*R3:T'/?[P=G5,KN,XW@7CTN]"Z&04BY53!E5K";&:.Y-71''%R%2JWU
M?N`5NU]8]UW@U\&E=6D53.`K=K-F5%M#-_"@W[_16N\'WK#[K77?!3X.CGAK
M%4S@.\^-7X*J42F58-?`]$JP0XC8^)WV=9O3WC=CC5`01BO1R#%,V3!CPYQ1
MP88S1G,V+#5R@JC8<,&&2T8K-EPSJMEPHY$31,.&6S9L&>T\0S^GJE$IY;1K
M8'HY[9`_RQ@'-^1I7W<^[04RU@A7?*?(Q\&-,M%:GGOALD+N,^M>%?G@8A3,
MH7.K8,JLT,BYQ\T8S:VA&W@P1RJUUON!5^Q^8=UW@=\&%ZRE53"!K]C-FE%M
M#=W`@TOT1FN]'WC#[K?6O0I\?'$;>&ZM@@E\Y[GQ2G#P1J/VR/VG:8T0L?$[
MU<C)9*R1,\-(V#!EPXP-<T8%&\X8S=FPU,B)OF+#!1LN&:W8<,VH9L.-1DX0
M#1MNV;!EM/,,_9P&C5KS<#K@AJQ&N,ZYM1J<PU.MY<Y6-/)G*^/@UIQ([OFR
MPNXSZ[Z[=]X&\Z#<*IAB+-C-C-'<&KHC#F[-I=;RC@L%7K'[A76O`P^.Y=(J
MF,!7[&;-J+:&;N#!<=EHK?<#;]C]UKKO`K\.KH>M53"![SPW?@G^9E<8W^B%
MS3N-G%OP5".O#CO#&_MJ;J*U;NQU*F7#3"-G^I,S*MAPQFBND1-$:9`-HF+#
MA49.$$M&*S9<,ZHU<H+8&&2#:-APJY$31,MHYQGZN4:739K%#!0/;B$=\FYZ
M@[!A,=6&WEVE,[PU#=GQ57#72[31K>W,I.PGTPAW)U7E:C,2O]6:6P53Y06[
MF3&::W2*D%K&I=&P$5;L9Z'1*<*P&;RT"B;"%;M9,ZHU,A%R?WAC-&R$#?O9
M:G2*\/W.;VO53;P[SZE?2T%?]9^^8QQPOU4CYQX[U<@KJ,[PVG8$$JUU8Q^(
M4C;,-'+F-SFC@@UGC.8:.4&4&CE!5&RXT,@)8LEHQ89K1K5&3A`;C9P@&C;<
M:N0$T3+:>89^KE43TGGZH5PWAQ_N]\GX/IBN)QWR[G:#<?`$/]6&WFU#^\+7
M3,?;W?BV'SX2F8_#EP"F<%/VE&GDA<!?\6@M7&.[ZTX_N&\7['G&:*Y1SX1]
M/0AOT^5)Q89=L:>%1N^'O=1:I[!'P3QIQ9[7C&J-3F&/1C?!<]SFI&+#;MC3
M5J/WPVZUUBGLZ^!H[SS/?E&J!NE[11DL<L`UA8JR0XC1U,U4:WD5J+7<B8M&
M]IJ4LF&FD>,^U\BY@Q=L.&,T-[YL$*5!-HB*#1=&RXYQJ9$3Q(H-UXQJX\L&
ML3'(!M&PX=9HV2!:C9P@=IZAGVO5<7TOU^$%J.O0NFV9@>[CVJJ=,HH9)8Q2
M1AFCG%'!:,9HSJAD5#%:,%HR6C%:,ZH9;1@UC+:,6D8[#_FY#MJGQYO-^^]G
M#KBSJI$_?[T.NW!6RUP`8D8)HY11QBAG5#":,9HS*AE5C!:,EHQ6C-:,:D8;
M1@VC+:.6T<Y#?@6HYJ5SMI^Z(EU3TSNK.^2N$!\0BADEC%)&&:.<4<%HQFC.
MJ&14,5HP6C):,5HSJAEM&#6,MHQ:1CL/>3D=OM&]/'+_T5,C_VVMZV#2-[5:
MIU.74<(H990QRAD5C&:,YHQ*1A6C!:,EHQ6C-:.:T891PVC+J&6T\Y"?YC<:
MFIA/A9,OC?`>M=,ENPYFFU.K9=/<^7)>P$Y8*V64,<H9%8QFC.:,2D85HP6C
M):,5HS6CFM&&4<-HRZAEM/.0G^:@:6BNT$-N#FH4W(B#GM#4:MDT=[Z<[D#"
M6BFCC%'.J&`T8S1G5#*J&"T8+1FM&*T9U8PVC!I&6T8MHYV'_#2_T2_$[9;.
M9MTO=*;76LNY-\>,$D8IHXQ1SJA@-&,T9U0RJA@M&"T9K1BM&=6,-HP:1EM&
M+:.=A_R<!GV[TZG+_3FU-Q^ME[L.^K!3JV5/W9.A00EKI8PR1CFC@M&,T9Q1
MR:ABM&"T9+1BM&94,]HP:AAM&;6,=A[RTZS:9L(<6MUN@U:_1OC:P&1KRBAF
ME#!*&66,<D:%A_R1J%Z+-)*N!^,^#:@IHQJ<750Q910S2ABEC#)&.:/"0_Y(
M_JF+$72LU#TSS)5&6!!KDZ69;:[$VE(US^Q*UW`Y5F*UC*_4?*3UE5DMUU?0
M7LRMEO%5>,@_$,$C_ND:Q,_QPPZY[R%IY+Y>8K20_]-X^[T@QL1JF1A3]I49
M+7N$<T:%A_S!O?'T.N2G5XV\'ND@;(%.M19F8R;LV!A>'YO4PW[XU5/"-BFC
MS+AQRX0[XEI+]VA[M(RE\#Q[QV+TQE/?D?M/?1HYS=*I1N[`C9;]GC1AK911
M9@QM8><:.1W(PC/T1_+&@\V('VPT4N5_*L;!*%AP,=5:Z'F>LJJ17F;>&U\%
MM]J$;5)&F7%C%DF'SU2Y53`?77AN_(&_,=4?\51?(PS<^)UJY(VR,W072;-6
MRBC3R/D6*V=4>(;^2-Z8S:J7TH++K$;!B1FLLYAJ+:\^.U^H*2?WU\'77(GD
MGM:LI.P^T\B>BL%WXE9N,E!X7OSC\<9,<,0S08V\DU//\9RKDM9R3JB$#5.-
MG*.6L6'.J/`,_9&\,=E1^0LSVR'_Y!P')]I4&WIEVQFB^IS,W@0-Y40;>NZ%
MS':^'/>9-H3[;E'/;=`(R:V"3:WKQC\@P9R)OK`-9AHCGDMIY)W,G983=JRU
MKNTW\8E!MC!2C1S#3"/O9.[<.ZCP#/T1JDF/,"L<Z<F0?0Z=:*0.H+T>WX3]
M1*WEE&6LT76WE&70&P0VB5&P-Y64W60:>9_/=UFM=3JUPU=;"L^S?RR"Z=0_
M9ING6:,.(49375.-O`.BM>SW?XDQM-__I6R8&2WK/M?(N5@4GJ$_PF!.12,,
MOO\;\5Q+(SP8VQ%V6@Z*62MAE#+*&.6,"D8S1G-&):.*T8+1DM&*T9I1S6C#
MJ&&T9=0RVGG(RS4J0CRSC]R?,VJDGKB<,SNX<DZMELE\S"AAE#+*&.6,"D8S
M1G-&):.*T8+1DM&*T9I1S6C#J&&T9=0RVGG(3_,;$^HQ3Z@U0HO`)'#**&:4
M,$H998QR1@6C&:,YHY)1Q6C!:,EHQ6C-J&:T8=0PVC)J&>T\Y.?TC6<%_(F[
M<!ZFD3=1&MR$7PM8+9/YF%'"*&64,<H9%8QFC.:,2D85HP6C):,5HS6CFM&&
M4<-HRZAEI/XNH4I:-P'LTMS]G<'N#W`][I^_[J?[[]]?SNX/?S_A^HMY+B:O
M)][]A</)6/V)P^-<D"1]\\</0\D0-MV\@R2PP?<5J`:2#"`YWMQ),H3DV,T)
M):/;2-V(!&_C*\1VG-2&-CU\3M=S)`D^!_M8"MYZ(TB.5R^R&4-R;`&0Y!J2
MXY,T26X@.4[!0@E,1`L8B/H8OCCZ'D:/[;.ED2`SV(19DB`SV)R7)?GH.E*S
M/99@2ANI21]+\'<Q_Y!\3=3'"_H3?+BHCV1)-?'',/H#]<T?/%&U(G%D4$P@
M\B>F#T.;B$.;0J+FUOS9>-Z(8E&"!XU(S;39!L\;D9IPLP2/'9&:=[,$+0$<
M=GF4(T0MC0=/Q(A:DL20J,=`_AP\#"-J29)"HAX*V0;/P2@625)`HIX'V6:"
M\4S$\:!#@ZBED<:0Q*($S1E$+=F@(8.H)0GZ,HA:DN3#6TBD4PE=4XQ'DDQ&
M/8Q'JDXT#3$>21)#$HL2-`TQ'LD&O4.,1Y*@A8BH)0D:A8A:DDPPGHDX'C2P
M$;4T4O2Q$;4D00,;44L2]+$1M21!.QL5+TFPBAC7`;%VAJBJ;F(97$SQ'4JD
MOB'A>L,W(K"1)/'P!C;2.8=O%6`C228#7+6Q&I(_9S+`=1NKY"0)KMQ8:R5(
MAKAT8WD.2[#:.U)K>EF"1=^16MK+$JSUCM0*7Y9@Q7>D%OJR!`N_([7>ER58
M[!VI9;\LP6KY2*UP9@D6R4=JH3-+L%0^4NN=68(5\Y%:]LP2K)*/U.IGEF!Y
M?*060;,$K\#@6$OG]@0V$]$&[S%$:B4Y>XLAB45)`DDB2O`N0Z26E[,WO-(0
MJ57F+,DA48O-68+W%R*UYIPE>(TA4DO/68+7EG!TI&.`MY=059($+S&AJB0)
M7EY"54D2O,.$JI(D>)4)M2-)\-(7QB-)\.X7QB-)\`H8ZDV2X-4OU)LDP1M@
MJ#=)@A?!4%62!.]X8J32U1+O=6*DD@2O=V*DD@0O<:(2)<D$$4S$"/"&'BI1
MBBV&)!8E>$$/E2C9X#T]5*(DP>MZJ#=)@A=T<42EJ/%2+HZH),&[N3BBD@1O
MX*(2)0E>Q$4E2A*\CXM*E"1XVQY'5+I:3F`S$6WPBC6.J.0MAB06)7B[&D=4
MLDDA4>^\\CF'%ZMQ1"4)7I]&Q4L2O$6-BI<D>)D:%2])L%4"CJAT#+!C`HZH
M),'&"3BBD@2;):#B)0DV2$#%2Q+LDX"*ER38?P(CE238A@(CE238C0(CE238
M@0*5*$FPZP0J49)@\PE4HB3!;C.1VGR$,X<=9B*U!PE+L-%,I/8=80FVD\$3
MC"29((*)&`'V$$$E2K%A*Q%4HB3!]B&H1$F20J(V>^#8L',(*E&28*N@2.T"
MPS;8'BA2F\&P!+L$16H#&)9@+Z!([0/#$FP)%*GM8%B"G8$BM2L,2[#O%XZH
M=#>;P&8BVF"SITAMP,/>8DC4/CPLP3Y/D=J.AR78VRE2N_*P!%L\16HG'I9@
M(Z=(;<C#$NSG%*E]>5B";9TBM3T/2[`Y&XZH=`RP1QN.J"3!5FTXHI($>[2A
MXB4)MFI#Q4L2[-B&BI<D!21J1S..&AO<8:22!/O<8:22!!O<H1(E"?:Y0R5*
M$FQWATJ4)-BH$N.1[F;8KS)2FQ9RU-BC$B.5)-B<$I4H2;`C(2I1B@"[$*(2
M)0DV(T0E2A+L0HA*E"38C!"5*$FP)R$J49)@<]%([1/)(\6&HCAND@1[AZ+>
M)`FV$$6]29(:$K6#)'\.=A!%O4D2[,.*J"5)`8G:/Y.]81]65)4DP7:LJ"I)
M@FU84562!+NQHJHDR022B2C!]K7(J6030Q*+$NQ>BYQ*-MC$%CF5)-C+-E);
MC?(QF/0PW\%6\"S!3MXX;E)K#1MJ(Z>2!/M:HZXE";9[1M32;`.;-^-S)`GV
M7<:QEB3811D12!)L@(P*D238SABQ'267IP?[ET\??MQ]W5=WSU\?GE[.ON^_
MH&M]==S_^OGAZ[?3/UZ[M]G/_CR\OAX>\97C^=FW_=WG/?ZH]97Z,Y%?#H=7
M\P\<RLN?A^>_7K[M]Z^?_E\`````__\#`%!+`P04``8`"````"$`R]"UR/D*
M``"G+@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R4FMENXS@6AN\'
MF'<P?-^Q)6^QD*11MK4O&`RZ9ZY=CI(8%5N![:I4OWW_%$ES.:=353>=KN\L
M%'\>4B2MN]^_'UX'W]K3>=\=[X?!S7@X:(^[[G%_?+X?_OE'\MOM<'"^;(^/
MV]?NV-X/_VK/P]\?_OVON_?N].7\TK:7`3(<S_?#E\OE+1J-SKN7]K`]WW1O
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M(48!]7(&_?:`L;L;?4.=[I3/BOH$KL=:>XA:%6DW/HA]D/@@]4'F@]P'A0]*
M'U0^J'W06&`$#:]"8JA_24CA+X34$JPT,,J&GFK:0X=L?!#[(/%!ZH/,![D/
M"A^4/JA\4/N@L8"C&@K?5DU7F<!8I:PJ"^<S5XV5])E.K@JN"=D0$A.2$)(2
MDA&2$U(04A)2$5(3TMC$T0JSD]-*8,Q>A%E3<NF))9TFH1&+D`TA,2$)(2DA
M&2$Y(04A)2$5(34AC4T<L?`VL<52Z]J->,M<7O:[+ZNN?^'I@A/NO8AZ;JT4
MZ=_?_1JU)F1#2$Q(0DA*2$9(3DA!2$E(14A-2&,31['YKRDFW%W%%%F:&I-D
M@D&ZEF8X7[BEN;DZ:>EC0A)"4DG4=D>\0C))9O8\"/U74WYUTHT5A)2$5(34
MA#0V<71=_)JNPMW551%+5TDF&$I+5V_*;ZY.NJLQ(0DAJ22VKI)`5_&R#\?!
MU!V__&K7[12$E"1K=?5162=NUOIJUUD;FS@"B_.,M8714UI@5TA%Y!99U,Q:
MDEOS#ME(LC0D)B0A>5)",DG<T@_F;B?SJY/N9$%(24A%2$U(8Q-'+.R'.;$$
M=L629.;4V&+L=F"MPL9+N1,,Q_Z$VQ@/W<>8HH2B5**I/(/T$UP2]XD";S7)
ME=.B?Z`EV9L6)&U)2/4S#=5.0T$0W'K:-'9>9PC$$8,;@YZ[@Z`0^JS56VLO
M:*[9AF$QPQ*&I8K90BMDM9IKM+@V6M#`DJ)*!YH>U!J97(T3Z(HE]MO,[`[D
M/AS;'JW"2J$I%@JS+"[(T4,%HLG^]!(&$\]EHW/#12>/&98P+%5L8O8-F4+S
M>=\@#LS>OCXW#KJY@J8I*:I,H.C*8A)X>^3:..C,C9/&E5ILTCFIY>;=D5HB
M2*WSKL6I5RPAEF@;AL4,2QB6*N8(*9N`D+K57'E9J*"!)445#:PI:IQ`5RRQ
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M;W+OX+$.5*!XHUENI#:-FQ[2V`K5+&%8JI@U8S.%YMC$F48#[PHT-UXZ?T%S
ME115"F'9$`4Z6P9CK]NU\="I&R>/*[HX"'"BRP."([I$SLJIO*"P;FL34!8S
M+&%8JI@CITP'.74+N?*R4$$#2XHJA:PEMZ:H<0)=L<26G1-+;N4=L=3N'K5E
MJF#AG>_6@?2R9N1&H3DL)M`OGY@&)A2E%&4_E3XW7EKT@N8J*:ITH-S*AO,Y
M*4[98VO!:9PTCMZA=Q#ZT25=[^\>D!2REU6%;-$5@NBZOS'U2BA**<H46E@%
M2U&AT-S<[Y<T5Z6]S+:AIJC1J,_E"O@/AZ.0'HX4FF,+8NINX6WXUCK0GO"*
M69,VIBBA**4H4V@Q[5>WR6(R\PHH-QYZJ`J-S!&RI*DK[253!^%D,O9Z5QL7
MG;O1J,_M:BL.&\QB$*ISCK6-4@C:ZKQK[>4(*2,=(0E*5*3EE5*4*60M=3E%
M!0TL*:IH8$U1XP2Z2HESA*54/XU#L3(R%^VA.N;8\BD$+:S2]-ZH:QTX-E-J
MHY@UU6.*$AUIZB>E*%,(\]I^"N]2-3=>>J@+A99XD9G'#[U-=$E;K$PN*]"_
M1JJ-EVZQ^5&+[NB(0X<U.OIZ-)2'$?NEII"[1MQZMR-K'>B4-CG9Q,K-JN.$
MHI2B3*$%JL+H24X`VDM-][&O6Z$=S*B7M+%*>WW86*V]9&/38#+WC@V-]F#6
M$7&@L/3_X4M.'D"<<5%G$GM]45[.($AF*1Z+SSMP&K900E%*4:;0S+IJT<C,
MOT(C\UXM::Y*>YE<M48F5Z-1G\NM8''^^4C!/[HW[`K$XBN_E9$?.!S:TW.[
M;E]?SX-=]_6(6EH&>.U<\?4CG4_]KZ(>7^'CG3ZEST-\U".:\ODDPB^WE'^:
M1I_0-6K(PVF4LQ:4;B2DI3&HX$@H3"THY$@(32THWDCH32TH6O2%LZQ@6;$6
MS/YHS5HVL(AZH^U@WD>B[*@%TS\2U4<M6`4B4834@G<_-."&`%L`])2SX#6/
MGG(6O$+PU-S`X86`\>$L6+C1#F?!EAG/UN\,O?+`SADQG`7[8SP;9UGAJ5?L
M4V.?AE'@^Q.@/YP%.S2,`F?!1@VCP%FP7X,&G`6;,M0H9\$)-A+'+CIR.*9B
M3G&6%318L1K@"(6><NK@)!5M6`M.3]"`B\$A"AIP%IREH`%GP9$*&G`6G)F@
M`6=9H:<KMJ>XM(C$T9BJ@[N&2!R0J057#I$X%%,+[A0B<3:F%EPM1.*(3"VX
MF\7X]*\2KT9Q`8OQX2RK8(;^].NW%X/+0?2'L^!>#_WA+!DLXAJ*/EL!B[B-
MHA;<Y:$_G`57>N@/9\'%'?K#65;HJ;@IINW@&A[]X2RX04=_.$L&B[CNI=EP
M6X[^<!9<FJ,_G*7&0B%O!#VI&ZP3K`$_?*$WW%Q<PR)^7*%/AM^IT!O.@I^K
MT!O.@A^ET!O.@M^FT!O.@I^HT!W.@A^BT!_.LKF-\*,[?>;L-L+OVI2OL'BP
MPJPQVUE#BLG.&K)EE+&&'(L`:RBP!K"&$J\"UE`M(_&K*-,/O(ZYBEC/HX2K
MXFP>X:L3FF>-)::_4?`**,-BP?$*RW+/1]<`?#W\MGUNZ^WI>7\\#U[;)VR?
MQOW74R?YH;'\QT7NO`:?NPL^&Q:;L,$+/@AO\6W%^`9[SZ>NN^A_X$%'UT_,
M'_X&``#__P,`4$L#!!0`!@`(````(0"T]^"?70D``&TF```9````>&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;)Q:VV[C.!)]'V#_P?#[Q)9\D24D&;3N`G:!
MP6!F]]GM*+'1MA582J?G[^=0)$46BT`Z^Q+'IRZL0Q;)(NG[WWY<SK/O[:T_
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MJ7WOK?]G_;%[KVZGIW^?KBUZ&^,D1N!KUWT3JLV3@&"\8-;E.`*_WV9/[?/^
M[3S\T;W7[>GE.&"X-\+DT)W1$O[.+B>1`Z"^__$P#]'"Z6DX/LQ7V[M-M%P%
MX68^^]KV0WD2MO/9X:T?NLO_I%*@7$DG*^4$G\H)W/VD[5K9XE/91I]N'Y&.
M)/"I?`2?]A$I'_C\-`?,FK%]?/[?'&+E`Y^?Y;"08SKF0KX?]H_WM^Y]A@F&
M4>M?]V*Z!@G\JB10(SFE!;+S(+2_"/6'.4A@P'N@WQ_7T?)^\1UY=E`Z*=<)
MJ$:F-42N";>Y"Q0N4+I`Y0*U"S06L`#;B3(2[S.4A;J@K(---6#Z('3X:0UM
MDKM`X0*E"U0N4+M`8P&$'Z:8Q4^/G$`Q<ZV1"W=K&G<J==:KB6O&D)PA!4-*
MAE0,J1G2V`@AA'GO(2109"VLK%QT,BV52JO0,&)(SI""(25#*H;4#&ELA##"
M*F0Q4K/N+@(\'$^';VDWKJ=ZZ(3VR%3G4ZJ0K:'%D)PA!4-*AE0,J1G2V`BA
MM?T4+:%-:2EDW/3&A2&3R,8>Y'"[HVF;3TJZ?PJ&E`RI&%(SI+$1PA1;P"<&
M4&A3I@JQF$H$3,6B&BX#9V[FDWPBR9!2>96;N%A8JTE'>5W1KJLGN?;:V`BA
M+.H^LU/HW!0HI:80BYI$5I@-TTP-@RV-))^4="0%0TJ&5`RI&=+8"&&$_<[#
M2*"4D436\&/BWT4T_DPJ;4S?YPPI&%)*)#0K;L5T:H8T-D(8!:@"/91&F'+2
M4(`4MU@Y4RM3:FMDA=$*'.ZYTMIN9?)N-IO`<50HE959LDH.53_57.TTM]IM
METYS#?%-NTB4!3R/`UDM8#O1^9=J"%VDL4QAZ`\-Y0H">0T5"B)DI7\+JKBO
MFOMJB"_*1!0`'B:R+B!,)!3APXSB+G8R.)!:FTC6=<L@<E:+W&@8JM)H+:M]
ML>:42LN"*F,HUJ%5M-XXKFNCH5TWQ`]E+DH%#W-901#F$@)S[383%0,F.&AJ
M*.=0H2"+1,FABAO6'&J((24B*@0/$5DXP$Z'F`8*HO,U=FKO3*FIF1AOXK6[
MSAH-[;M0D)6;)8<J8RC&<+=:11N:0+71T*X;XH=2%U6$A[HJ+FSJ"B+S4&+6
MI,MQ=A7C:D&%@@@QJ65!%3>L.=007Y2)J!(\3&3Q0`910F0>!H%[>A!#+!-4
M='2T73N+6VX4=#\7"B+I*MU84&4,1\\XPKLC.#6M/3?$,^4M2@4/;UE!$-X2
M(K-00F06,J@()&1Q*#E4*<CR57.H(8:4B*@0/$1DX4"(*$ATBEE)8^?4D052
M3<W"]7K#-LQ)0?=SH6RLQ"PY5#F>HZVS`-1&07MNB!M*7!02'N*ROB#$%03B
MVF\62,R:<#F'"@417M+0@BIN6'.H(;X(D]!?^(PP+7P41.9@&+MS4&FIO7"W
MW3E#G!L%W1^%@NQDY5!E#,4<7$?N]*^-@O;<$#>4-ZUF/CI)AKS*49`]-Q44
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MC)`.5)"]#842B^S5BD&%UK+.*0HB_<`,:VUHW#<:&GU1AJ)>,0SU)4DHRQC"
M1$(;+,C6&#N57J8,(X1E:;%,D+Z@I<>E4(8;+)/&D&>"-"238?)E&<8L$R8M
MW6+S48NTGT3]8_KIPTQ099>9M&FH('%(-`QC]TRKU)`<1FNU=(JFW&AI.H6"
M8C1CW/,.5%&86Y_*^#*&JR7;!J2AE;3-1RW2#A0EU"<Z4%9<)`$5!,P.E!5"
M6@TKM>D(=@.$A\IQ2Q*G)*,6.YE:3&K$&^]6Z8WDI6Z`6+IQU%,#-`XG?\6[
MJ@R7>+/BD)TMWT[E>]FEO;VT67L^][-#]W8%R>T.)<0$RT=;S-@DQU1`'CF2
M"I+:*\G"'6S&!R9FLX.-3X+'X2_CG89CD>+1>%R67#S$8[(GJG25X-V%1_ME
M#?]C9><XPLZ;B'V5FV`?11L^21INDA2+)K?!5@?J/@GV,K3CDV#_2DJO!-L8
MNLMG@WT*L?DD:1@B-E\7H%)$;#X)JD'$YI.@*$1L/DD%B2B9>!^@_D-L/DD:
M+A&;;S@S2'*O!*<0Q.:S*2$1%3J/`&<2Q.:3X.2!V'R2--@E*<YCW!M.OXDX
M"'()SKB).`]R"8ZZ2>F5X,2;B*,@M\&Y%KGNDZ3!%K'Y)F$&2>Z5X`8%L?EL
M2DC$K0./`/<IB,TGP:T)8O-)<)&'V,;]PIU9D(A++-X.+N@0FT^">SK$YI/@
MN@ZQ^22XDT-L/@DNUF'C&VW<I\/&)TD#S!^YKS`^F#]>20$;<<'*F>+N&'Q\
M$EPA(S:?!/?$B,TG21&UN,7G[>!=(Q%W^5R"MPQ$[9/@"0-1^R1XR4#4/@D>
M-!)QS\_;23$(OK4R0^+XUJDL2@I?/E51@B<[[C_#Y/!M'%F<X!F*ZU=Q@F<E
MX(MI&/$;H-?]2_N?_>WE=.UGY_89F]YR?*6^R9\+R2]#]XHK%OR:IQOPZY_Q
MWR-^UM7B+6!YAWWXN>L&_44T,/U0[/$?````__\#`%!+`P04``8`"````"$`
M\$[`YC0&``!+%@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R46%V/
MHS84?:_4_X!XWX!-`@F:S&KXV':E5JJJ;?O,$)*@"2$"YF/_?8^_`&-W9OLR
M3(ZO[SV^]_K8</?YK;DX+U77U^UU[Y*5[SK5M6P/]?6T=__Z]N73UG7ZH;@>
MBDM[K?;N]ZIW/]___-/=:]L]]>>J&AQXN/9[]SP,M]CS^O)<-46_:F_5%2/'
MMFN*`3^[D]??NJHX\$G-Q:.^'WI-45]=X2'N?L1'>SS6996UY7-370?AI*LN
MQ0#^_;F^]<I;4_Z(NZ;HGIYOG\JVN<'%8WVIA^_<J>LT9?SU=&V[XO&"=;^1
M=5$JW_R'X;ZIRZ[MV^.P@CM/$#77O/-V'CS=WQUJK("EW>FJX]Y]('%.0]>[
MO^,)^KNN7OO9_TY_;E]_Z>K#;_6U0K91)U:!Q[9]8J9?#PS"9,^8_857X(_.
M.53'XODR_-F^_EK5I_.`<F_8E+*](!+^.DW->@!++][X\[4^#.>]&X2K3>0'
MA&Y<Y['JAR\UF^LZY7,_M,T_PHA(5\()E4[PE$Y(M(J(OPNB'W<22"=X*B8K
MLO9#QN.=V&LY#4\5VY]BOS,1;OG*\903Z6I--]&6K]R<Z(G,\8QGQ5#<WW7M
MJX,V1F[Z6\$V!8GA3*9:<AZ3CQXHF?4#,]^[V&A(:P_TY7X=T3OO!=4LI4UB
MVA#=(E46K*+,;;8$\AG@@>E(%T7Z/W29.:.K`B4*F/@OV*?*0DW)ED`^`S1N
MJ/V,F\H80]&76L8"/1^)L%D'(\_40#(#R>>(1@3=9"'"4%09LV:U6R^8"*.`
M3DP,)#.0?(YH3-!1,R:RNU9L7PWGNGQ*6KX[5:J8-6>H<I](A&L-[Y340#(#
MR>>(1B?4Z*BP#-7#"B28U4,@6SS&Y`74UY.7C4:*?SY'-":1QN2CQ#!KG:%`
MY@RE#=F)74F#<+>@-UF,_#1((\C.TDD75*H8JA.1R&YJ&(%HJ:(D7'`9C48J
M<T1CLK,R8:C.1"";#5\_]<E&#YF.XU,)*8ETHTP:1=P)V6X6.<S%^)J?(!I+
M@E/.DC`.ZSPE!*)J[:D)90J*1JM<0K;@3"[-:A&AHMCR*E(BH;58(+*T*$PJ
M#<+P/]*830;*:2ZA@&]3/2M,*RW$A(1JQ`0$8LIM2@0$*@K*3"B7D"TX$TA+
M<*&;6G`!3;VS:(N4J2;:;2/[(J2[A81GDX4BFTO(5B\FF!9F0D<U9@+2FD5"
M4Z8R8D"YA&S!F3Q:@DO5G#>+@*9FV>J[)<6EC*4EQ*X899&2A54V64VI$1-M
M16.2:6$GE%1+C8"TCA$0^*A(&3&@7$*VX$P/+<&E3,Y3(Z"I8Q9"D1)A$$(6
MWDO-:*4(YW*BK7!,(BWLA')JJ1&0UC4"`A\5*2,&E$O(%IPIGR6X$$0MN-1(
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MR`3['5+?VAL*SMI;?#\0;[--U9VJM+I<>J=LGZ](6,#.ZA$6'R[0"3&K,R8O
M1A*ZCA.0,D=2C*36D0PC;&WF'.0<7TAL(_AT\L!?KI;Q\4F%+VJ)4SBR1$B"
M&.]_9N2'-?S;`B=DAP7RO;H(D6(DLXY`;Q'=-B>A!-YLQ%*,9-81"!&\V>8D
M9!,G.)7-Y>"&$;,CW!S),<).<G,D(1&\\5XS5AK!FVT$IRZ\V49P8X8W&VM<
ME>'--H(+,;S91A(2P!L79X,;6M,Z@GLDO-GF).@R*Q[&"3^SEC'"&&^D9L92
M+-YJOXUS:T[02G@9L3C:Q>Q=QAS(T&+6@1P=)@:\D2R^\-V*4_5[T9WJ:^]<
MJB.V,SZ+044Z\3%0_!B$$CB/[8!O>TP4G#,^VE;XH.2O8'QLVT']`"5O_`Q\
M_R\```#__P,`4$L#!!0`!@`(````(0"^9>;M#@4``-00```9````>&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;)18VXZC1A!]CY1_0+ROH<'`&-E>#9=)5MI(
M4;1)GAG<MM$`;0$SWOW[5-^`OFAF\[*L3U=7G;KTH9G]Y^]=Z[SA86Q(?W#1
MQG<=W-?DU/27@_OWMZ=/#ZXS3E5_JEK2XX/[`X_NY^.OO^SO9'@9KQA/#GCH
MQX-[G:9;ZGEC?<5=-6[(#?>P<B9#5TWP<[AXXVW`U8EMZEHO\/W8ZZJF=[F'
M=/@9'^1\;FI<D/JUP_W$G0RXK2;@/UZ;VRB]=?7/N.NJX>7U]JDFW0U</#=M
M,_U@3EVGJ],OEYX,U7,+>7]'VZJ6OMD/PWW7U`,9R7G:@#N/$S5SWGD[#SP=
M]Z<&,J!E=P9\/KB/*"W1SO6.>U:@?QI\'U?_=\8KN?\V-*>O38^AVM`GVH%G
M0EZHZ9<3A6"S9^Q^8AWX<W!.^%R]MM-?Y/X[;B[7"=H=T2TU:2$2_.MT#9T!
M2+WZSI[WYC1=#VX8;Z+$#U$0N<XS'J>GANYUG?IUG$CW+S="PA5W$@@G\!1.
MDL7'._M"L0^>8A]X>,=^*^SA*>RC]^)X/%=6HZ*:JN-^('<'!@^R&6\5'6.4
M0I:B."+R7"[H6DVM'ZGYP86C`848`7T[;I-H[[U!_6MADYDV2+7(I07M`75;
MZ$"Y`CQ@.M.%HOP?NM2<TI6!,@DL_`.-F[206PH=*%>`P@U:IW,+_;ER=!4F
M:E6Y,`S5V!FWV88SW]Q`"@,IUXA""&9C14BVD*+0;=BUZF&L,>%&8;`P,9#"
M0,HUHC"!R5HQ$5.V20">KDW]DA%VKB1#:LT8RAYD`HD7.@92&$BY1A0ZL4)'
MAJ6H&I8CX:H?''F`QUR\,/#5XA6SD>1?KA&%2:(P^:@PU%IER)$U0V$#BLI.
M9Q#&.XW>8C'S4R"%('T++OH@2T51E8A`F(ZS,YUS1"E5@+0Y*V:CF<H:49CL
MK$PHJC+A2!2Q_`,?:?*4S^M+"P.4:#421@ES@GQ=XTJ^OF7:K[!$\'ZR%(S!
M*D\!`5&9>VY"A822V:H4D"TXE4VS6XBK*1QY&2D3T)8G"%72&I,+@SCF%4"^
MIN'%8B"=E@(*V3%5JT(UTT*,2ZE"C$-`3+K-$8>`BH0*$RH%9`M.!=(2G.NF
M$IQ#R^QH8Y%3U81QB\1<H.!!FYO%0'(M!61K%]5+"S$NHPHQ#BFS(J"E4`4R
MH%)`MN!4'2W!A6BN9X5#RZQH2>=PFZ)5B;GD1(GV2BV6]:4H?(NM6U0K%UX?
M22+BTJH4BT/*"'$H83=%<>4PH%+XBME]09U?*I`+*2F#2.CFNE@<BJ$5\QL"
M^;H&B8T)C--L98J0M-JR,Q@^)-HA+:4!DQ"5,)71A?"'5>2JJU210Y"(;%J.
M.!2M#Z*`EBM6*:W8JT`E157S'5+?R`TDDL;CEWE^4>WP<,$Y;MO1J<EK#_4*
MZ/&;X?DKXI'=5C0\HU\7U*6.!RE<Y"QXF,*%RL0?M^DC9&8N9"A*,Y@<<P7.
M15I85TI8H=-F[LE0`MYL<7)8H1TP]Q2P4EA78$`@CFT/O``@CJT`H/S@S;8"
M^@[>;"L9"L$;FQ2MS*"8X,VV`KH(WFPKV3:%FZ299Q:G&5,[/4:<P@7+M,\A
M>:O]0UI::[*#))A"Z`%V4'G;0K&#Y&P+Y0YR8PO>[`L^-6_5!?]1#9>F'YT6
MGV&4?78)'OA7*?\Q\5/@/),)/C+I@7"N\-<##-])_@9D\TS()']`TM[\]XCC
M?P```/__`P!02P,$%``&``@````A`*;4$#9W$@``W5(``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&ULE%Q94QRYTGW_(K[_0/!^@=ZAPO8-]U+5U?O>
MSQBW;6*`=@`>S_WW]ZB5*BTG+\/,PX!/+I52IJ142N+#O_]Z?#C[\_#\<G]\
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M7^_1`M/M9\^';Q_//]>R?:-]?OGIPZF#=O>'WR_![V<O/XZ_B^?[KY/[IP-Z
M&WXR'OAR//YA6,NO!H+P)4GG)P\LGL^^'K[=_GIX71U_#P_WWW^\PMTM(W)W
M?,"7\/^SQWL3`VCZ[5^GG[_OO[[^^'C>:%^T.E>-6KUU?O;E\/*:WQO9\[.[
M7R^OQ\>]9:J)*JND+DKPLU+R;N&F"..G"-?0W#>^!KM.)N.G"-0OZM>M6JMM
M3'Y#L"."^"F"^.8;_!@,IP_A9V791;/>ZER?.N<-R1N1Q$\G>?,^&VN50_"+
MR`8.>>.;-><%\XO[JG?E6Y+.!37O@\;[&HJ8DOCQWKB^Z-2N;AJ=MYU1:SM)
M_.+,;5_4FE=_Y\::\XOYY9]UD?-++7#,N[JH[MQB?I%OOK.+ZLXOYA<1?5\7
MU1O21>:7]W31I1W<ITFA?_MZ^^G#\_'W&69:&/WR\];,V[7,*)/I0(*_FB`P
M3]T9]L^&_^,YNA=#_P7HGY^:G<Z'RS\QX]P)3Y=Y:C%'SW&86<>H[:?`(`7R
M%"A28)@"90J,4F"<`I,4F*;`+`7F*;!(@64*K%)@G0*;%-BFP"X%]@%P">=6
M'D9L_2,/&W[C8>>;K@.\R^N).QV'$^FGP"`%\A0H4F"8`F4*C%)@G`*3%)BF
MP"P%YBFP2(%E"JQ28)T"FQ38IL`N!?8!$+D38S1TIQN7!L8*'8S+1K,1NZEK
M>9J-RK4]0OJ$#`C)"2D(&1)2$C(B9$S(A)`I(3-"YH0L"%D2LB)D3<B&D"TA
M.T+V(1)Y$\NJYDT#8T:&6##-7B?NM$R-NG<G(7U"!H3DA!2$#`DI"1D1,B9D
M0LB4D!DA<T(6A"P)61&R)F1#R):0'2'[$(G<B<1&<Z>!3^YT$V17D%.>?UH!
M>X3T"1D0DA-2$#(DI"1D1,B8D`DA4T)FA,P)61"R)&1%R)J0#2%;0G:$[$,D
M\AV2S=!WD@E=F&3U]<?]W1_=XVFWXR9<PQ[[U"+7P?0J/'9W=<IS+-)HG3*G
M^E6M&8_I045WD9(34A`R)*0D9&01V>D96\85C\GB8$NR7$PJNK-E2LB,D#DA
M"T*6%@EL654\8DN28:PKNK-E0\B6D!TA^Q")O(^=WS_QOF&/O6^1.C:HU93=
M:*5YKX@%`6&15CC3-UI)ZP<5DVM]3HJ*BB?\?N+28<7D%)6$C$CUN.()52<V
M3BHFIWI*BF853Z@HL7%>,3E%"T*6I'I5\82J$QO7%9-3O2%%VXHG5)38N*N8
MG*)]B$2!A:U2&%AN^C!P'$`6Z<21D,P//<O4M$66TXPB8DT[HS0:5^UD2A$&
M'W,Y*2F$)_QVO99LZX;"U+9?0A4@_E!)'QK1A\;"(];66O56K&1"2J:D9"8\
M;UH[%R9G;>OJ)OPOR:46]-DE?78E/&+[5;.3]/2:E&Q(R59XWK1])TS.]NLD
M"O;AAZ)@0_%""S8#Q\%FD98/BIY%PL@2J:M3/?&4I`P<Y.,O)[G"(C<W55XZ
M%#%42-QX*5G3B#2-'9.W8.(@KVI*<C.+!!;,12RP8,&:EJ1IY9B\!6L'>0LV
M)+>U2&#!3L0""_:1ILB/ILZI.?*$QYX4J(D)*%AXDF'5$RY;6):2B_G&Q_.V
MC;)FZRH9SP.6R1DJ!&K?G*:%VD4[&5I#SU`YG]6,&!H[06M@HWESE<P5+#-E
M:.;46`/K%VF>,_<,SL`%JUDRM'*"SL!FLMRO66;#T-:I<3V8#O>=9W`&[B,U
M<>B8.E!0T7,+CBD?)Y.`0`@=I[<G4!0G5A!QXK@&S)4S5`B$R'""0X9*%APQ
M-':"WH@)<TT9FCE!;\2<H04++AE:.4%OQ)JY-@QMG:`W8L?0/A*,?6J*09I/
M;9$(=0+7PUU3XH>;,;.'TT&R4O6$*YSM!6K'"6R2`PPT]?5ZDA[EK+[PZDV&
M7[MH)B8-/8-K2\EJ1@R-O6#8XF06F@A7U"]D^)35S[QZ:W@GF5KGGL$9OF`U
M2X967C`T_":>Y-;"];;A&U:_]>JMX>VDQW>>P1F^C]3$(8B,10U!@R<KDH7"
MY,)4LL`5Q9N%$&_NZP/A"@1S%BP$"@2'#)4L.&)HS((3@0(CIBPX8\$Y0PL6
M7#*T8L&U0($1&Q;<LN".H7TD&/O4U+&T:<76MR#H7-,UYW_&@5&6T4X6Y)YP
M1:N'%<0B$`1Y.UDH!YIZ&ITYJR\$DNRC<=%*4N6A9W!M*5G-B*&Q%PP-3W*D
MB7!%_4*&3UG]S*LWH[-Q<9-,6'//X`Q?L)HE0RLO&!J>3-%KX7K;\`VKWWKU
MQO#VQ4VB>><9G.'[2$T<@J8<IX6@E.G"$+10E*U8*(HW"P5)Q\"<1-O8=0;E
M`@6"A4"!X)"AD@5'#(U9<")08/V4!6<L.&=HP8)+AE8LN!8H,&+#@EL6W#&T
MCP1CGYHBF^936WR+IA4+89X+8S49PSUS(2!=/2P49ROM9&D>B&"DGD9GSNH+
M@:#>KITW21XT]`PNIDI6,V)H[`7#%B=+\T2XWC9\RNIG7KT8GO3EW#,XPQ>L
M9LG0R@N&AB?]LA:NMPW?L/JM5V\-[R3SX<XS.,/WD9HX!$TY+@C!OROFUVSY
M+@I-"Z$E[GL]X8JR&,MU[8_+!\)U[7=5.0L6`D59C-450"4+CA@:"Q08,7&0
M-V+*@C.!@B_.&5JPX)*AE4"!$6L'>2,V++@5*#!BQ]`^$HQ];:IA@:^K#:^M
MDD4^M5"TZ#72@D7/7!["=!,L#GV!;ER5M7V5K'H#Q^$7K)SU%`))NH):1#(\
MAY[!15W):D8,C06J+*0Z\,1Q>`NGK&<F4&5A6N6=>P9GX8+5+!E:">0LY-KO
MVG%X"S>L9RM09>';E=V=9W?V[B.E<2R9DEP02W\[;T@)SUO<-1?(XFRC)U`4
M4):KXRL"`^&Z]ANBG`4+@:(TQ>H*H)(%1PR-!0J,F`@4&#%EP9E`P1?G#"U8
M<,G02J#`B+5`@1$;%MP*%!BQ8V@?"4:^-D=U;_IZ<_R)C2TR@%.]]/.)/][I
M"A2M=HUVLH/O"5>X;#A=N/AW6N[:-_5T2U2Q^-C*65,A4&0"']T(%^98\SE<
MBDW6[9(UCQ@:"U1S9G<:Z3(]J5B\V5/6-!/H;;/GPE69W4KRI`5K7C*T$J@R
MN]6Z3O9QZXK%F[UA35N!WC9[)UR5V>D%R7VD.0[*I'K[=Q,0CA/,;!,N<@+!
M1C?A]02*(M`*MH+$Q0GZ.2EGP<)Q>?5#@8(5O&3!$4-CI\L;,7&0-V+*@C/'
MY8V8"Q08L6#!)4,KI\L;L7:0-V+#@EO'Y8W8"108L8\$8U\G55WR=3H!5=5>
MGX$W.\ELT\78/&4OP;4PAOH,#1C*&2H8&C)41E#<:%/V"U;8:G:UY<`HD`7R
MY?:>N:%LPMU#?88&#.4,%0P-&2HC*&Y)4CTC]R47ANI<57,0?OJQ*FP^JOK"
MAEM#WO&X1!\7B@>>R^G*G7ZOJ_!<H:YD7AUZ+J>KC*"X(TQ]17.IK;M$+K50
M>$?*O,PP+O4V]@6ZQAZ_.M*LUQ(;!Y[+V9BSKL)Q^1X>,E1&4-PX4VC0&F<+
M$%'C+!0M#HUT[N_5+5<T%XM@Y[0Z-^MISCU@F9RA0J#H^THJ8#\FBU.-ZG=E
MI#GN"[-!U?K";ERCOK!0M`A9*&JX</D-XJ!.7#E#A4"!^J%`P=1;1H)Q2_['
MGK'.>T:!XCUC*QE\/>$*4WR!Y'R]UKY*]GH#ELD9*IP:=SK<25*7H6=PXZ",
MU,0--WL%S85V#Q&YT$)!L;!7MU#42@N%I\/,E3-4"!2D[T.&RD@P:DDC2=_=
M0G+"XXQ(H&A@4.;:$ZXP/@5"3/F)J)&NN`--/5<967WAU4NQ+I[1AYY>>3;2
M$O='DCE6_<$98D-R/S_E]@2*&F^Y@@$U8,&<!0N!`L$A0V4D&+<DR8NJEE3Y
MC^N.+BZ_F\4C'ISM9*#UA"L,6X$0?8%GKY/SK(&F7O&L9%P^*2F\>O%L.F@]
M@VM+*9"U,NZ0,&>"Q?:-UO^\F=S@5$J@<"P+%'6*%>SX"L1`N#K^LE/.@H5`
MX5AFJ(P$XP:&J929Z.R.N\$9DT#Q4+Y.]LX]X8JBV>KJV`I>H]9(9`8B@^O>
MSB,YJRFT[_,:*UP8`=;]Z8V>,M(<=T683+W#UYQCF3018R)8&WL"1?TA7'[7
M,W""?M>3LV#AN'P_#04*!GP9"<8--/F'6X&4!LJF!TZP3YCM:\7'P_/W0^_P
M\/!R=G?\]61NXM^8=*G"[>/I8:.9&7,@G5#0Y9FQBBEX</WYM%E*)+IXB'T*
M^Q2O9WB<Q7JZ#3S<5O#/3>C7%'VNU[//JDE=&-M5*0CMS+B3/]\'I:]2$-J9
M<2[+(,(SXV.F(-`SXVJFE(TK=*36'LS&L%KK`LS`L%JC]$'IJQ1,OK!:D\E!
M,;,0VX9Y%^[7*)A=8;5&Z:(]7;4]R`A@M=;2/BA]E8)D`%9K,CDH9K74K+Z"
MU1IE6&]G)K%E&63IF<EOF=*M7V==I$U,09*:F12.*7U0^BH%26HV4"G(53.3
MU[$VI*RP6J,@,875&J6+]G35]F##!*NUEO9!Z:L4;)A@M2:#?1.LUBC8/F5F
M7\'M0;D.(U[S#XHM:(\V&6#/#@M.F\YD^L`.'#(:!?M>R&AC#KM8R&@4E#LS
M4]1BJU'US$QMBRDH=F:FQ,44E#PS4^EB"BJ?F2EX,075SLS4O9B"<G%F2GQ,
M094X,Y4^IJ!6G)F"'U-0,LY,W8\I*!-GIOS'%-2',U,%9`K.@#"[ZY&(^4"5
M02$?D:AIZX/25RD#4`8J!<5\1**F#35]1*)&&8)BJJW<'A3P$2$:!77\S-1>
M60;G=IDYI&$*CN\R<U;#%)SB9>;(ABDXO<O,R0U3<(B7F0,<IN`L+S.'-DS!
MJ6=F3K&8@L//S!QF,05GH)DYTV(*SCXS<[3%%!R!9N:$BRDX"<W,J193<,D!
M+=5F"EQL0$LU"NXWH*4:!;<8$(D:I0L+S'$B6X`CZLR<*C(%)]597Z7@A#HS
M9XPL@X/JS!PU,@7GU=E0I>"&"GI4LQJW4M"C&@674]"C&@574!")&@4W41")
M&@474A")&@77S="CVFS9A4Q7E<$=(_2HIJT/2E^EX'H1>E23P94B]*A&P<TB
M]*A&P?TA1+Q&P34B1+Q&P6TB1+Q&P5U!]*C6![@RB![5*+@YB![5*+@MB(C7
M*+@AB(C7*+@HB(C7*+B`B99J%-S#1$LU"JYCHJ4:!5<P$8D:!=<N$8D:!;<O
M$8D:!=>MT5(M3\05:[14H^"F-5JJ47"?&I&H47"A%I&H68!+M(A$C=('I:]2
M<'\6D:C)X,XL(E&CX.HL(E&CX*X\>E2S&O?CT:,:!=?DT:,:!9?A$8D:!7?B
M$8D:!5?C$8D:!0]?T*/::H:7#^A130:O'="C&J4/2E^EX*$#>E23P>,&]*A&
MP1L']*A&P4L&1+Q&P8,&1+Q&P;L&1+Q&P>LD]*C6!WBDA![5*"M0S/L5GN/Q
M2`D1KU'P5@D1KU'P9`D1KU%*4$J5@A=>:*DF@X=>:*E&F8!BWOFPU7CHA4C4
M*'COA4C4*!ND(=HJM[W.\%Z/O[%#<J+A>Z2.&M[%E[OJE_'\#A&HV=0'I:]2
M\/P.$:C)X!4>(E"CX#$>(E"CS*XSO(KD-LZ1Y&CX`JFAAB^1&&KX"FFAAJ^1
M%&KX$(F%AI=(^S1\A*1/P\=(^31\@H1/PZ=(]S2\BU1+PWM(M#2\CS1+PP=(
MLC0\1XJEX<5U5FAX%RF,ND=$DG"J,R>[RC$2*`U?(;G4\'XGPU\5X'@H.AG^
M)`#CXTZ&%_Z,SSH9GN<SONID>&W/^+:3X:D\\,NJ`?B;@S]OOQ^FM\_?[Y]>
MSAX.WU#=NSI5MY_MGR>T_WBUU['.OAQ?\=<&40!$(1Q_1O*`/V5Q=8%JYK?C
M\=7]PWR@^L.4G_XK`````/__`P!02P,$%``&``@````A`/U&(7""`@``SP4`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&ULC%1-C]L@$+U7ZG]`W#?8
M<3:[B>*LDJZV7:F5JJH?9X*QC6+``O*Q_[Z#25@[R6$OEGD,;]Z\&5@\'66#
M]MQ8H56.TU&"$5=,%T)5.?[S^^7N$2/KJ"IHHQ7/\1NW^&GY^=/BH,W6UIP[
M!`S*YKAVKIT38EG-);4CW7(%.Z4VDCI8FHK8UG!:=(=D0\9),B62"H4#P]Q\
MA$.7I6#\6;.=Y,H%$L,;ZD"_K45KSVR2?81.4K/=M7=,RQ8H-J(1[JTCQ4BR
M^6NEM*&;!NH^IA/*SMS=XHI>"F:TU:4;`1T)0J]KGI$9`:;EHA!0@;<=&5[F
M>)7.UX^8+!>=/W\%/]C>/[*U/GPUHO@N%`>SH4V^`1NMMS[TM?`0'"97IU^Z
M!OPTJ.`EW37NESY\XZ*J'73[WA]ANH%,\$52^!&`RNDQQV/((`I7YSB;CNX?
MDBP=WV.TX=:]"'\6([:S3LM_(2CML@>N3L,S=72Y,/J`H*\0;5OJIR2=CZ%V
MYL&51W,,`P9\%M#],LL>%V0/9;!3S#K$P#?&I#&"`'M,`7IOI/"H3^'K]#G7
M`>CSC6_S90,^Y/W*DBC=[P+0DY5ELT@44H6826=,7^EDP'PVPZ-@SY#RTHU3
M$'0_VM&W;&`(=.N&(1[MTD1'3DAH8%_G=$#0.9!.81:B"3Y@R'5"0.:[ODD2
M?1GH>QC0GVWPZ)`S(-<V^H?I?::"O-G[</GM(=$)@0GHB;N<IG"!PO!*;BK^
MA3>-14SO%)SR]!&-]W8U]CV^Q"?S53=W)&[`-6MIQ7]04PEE4<-+H$Q&#]`!
M$VYD6#C=@G*X;-K!!>M^:W@X.<QO`O:C4FMW7D!B$I_BY7\```#__P,`4$L#
M!!0`!@`(````(0!PC`+O^14``%YH```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;)2=VW+;NI*&[Z=JWL'E^QU;E&19K"2[(I*BJ#.G]LQ<>SE*XEJV
ME;*]#OOM]P\"31S^MNS<Q/'7C0;8.#=!^.,__WZX/_OS\/1\=WS\=#[X<'E^
M=GB\/7Z]>_S^Z?Q__S7_Q_7YV?/+S>/7F_OCX^'3^;\/S^?__/S?__7QK^/3
M[\\_#H>7,UAX?/YT_N/EY6=^<?%\^^/P<//\X?CS\`C)M^/3P\T+?GWZ?O'\
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M^/?LX<ZT`3SZS=^?SC/D</?UY<>G\^'5A_'D<CC(QN=GOQV>7^9W)NWYV>T?
MSR_'A_^W2EW1>R-#9P0_G9'127U(NTSQT^D/QA]&V7ARW>5Z(B>4J4N)GU+<
M#X/1Y94I[(ED$Y<,/UTR/.\)?72#+AO\?-<##<2-YC_ORF&``G19F/^X%('C
M3Y0-U>A2>B><?IK!E:3`?UQ>$U_)G->%;21=XRIO7FX^?WPZ_G6&'HNG>_YY
M8_K_(!_`F:Y9.5?V#0WM_=:H?S'ZG\[A132A9]`_/X^NQA\O_D3+O74Z,]89
MQ!J%:)C6:\R6*:A2,$]!G8)%"IH4+%.P2L$Z!9L4;%.P2\$^!6T`+N#VWO>H
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MG$A-9$&D(;(DLB*R)K(ALB6R([(GTH8D<O$`^_&P7XB/.QX[V:'K:*@9)>O&
MPFD-_6Q;,JH8S1UR6WLSMM6LM6#4,%JRK15KK1EM&&W9UHZU]HS:",5.-QNC
M8##JG6XW3%@V2H.<F5TX&OLX='JZ5B\TI6R0CD2B->EVKX/A)+M*.D3E5$8V
M)F+J8,ZH%D-AF2B[A=.Z0@,+NF`RAC5L?LEH]:X<U^_*<</FMXQV[\IQ+UJO
MN[2-;,>MP.S:M%9@=W-1*[`(K4`:1F&"+;9A""H%37JMRJ&H0FW"`-62T)M?
M.(3:$_,-VUHR6K&M-=O:<,(MHQW;V@ORS]A&"6,/FVV;YF&[G8L\;-$(ZP??
M6D?).JHP&SHX_>JJZT+9Y6"<)2JE5Q''50X%0^*<42T)IYWM\3B):"R\7`PW
M;&7):.43!H\V2#KBVFN)^0W;VC+:24+Q278Y&<:KB;U7$=MM9"BN-+,1#"KM
MK47RP&X<85",SQQ"90HJ'+KRJ&14"?*AIKE#0>75#DU\WU@P:MC6DFVM..&:
MT89M;=G63K3\,^X9M8*Z9XP]CP$]]'P_+1F>K`4LNHK65UFRU"M,?!<))^@U
MOE/QO.2T1EW#'PZO)]?)U%6)(3]`S1V*AK'W9+<06[:]4C]K1.[S6G)>*]$Z
M^6AKT<*&,'!`TO4VHN5SW'*..]$ZF>->M,29T^$P6=NWHM)E%S<`LW']E:YG
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M6RN'`EMK0;ZK;=C6EFWM)*%_QKT@;ZN-;,6>-]&!4^->LA#);#0A'/<$7?K%
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M5XSF#H4A%J\5;$O23?/":XGYAM&2S:^\5F@^"1BNO9:8WS#:LOF=U_+F^4"`
MUQ+S;83B6C3;Y:`6^W',;J.CVG(HK"V+WC@6D/5:4J"*T9Q1S6C!J&&T9+1B
MM&:T8;1EM&.T9]1&*'+Z\)4M><?CI:A#210RC8@YK6!#53*J&,T="KL(:RT8
M-8R6;&O%6FM&&T9;MK5CK3VC-D*QTY,]L+3TH=UYABW=H2C<1X<$-"6.@XB6
MC9D-)Z-I,AI43B,(1<T9U6('2[,@GI*\UUDXK=,QSX;-+QFMWI7C^ETY;MC\
MEM'N73GN1>M5C[:1Z;@-)+OQO@WPKAM;$;-4#J.-C$I!/CQ0.135I[45H%H2
M^N7$PJ'PB`#;6C):L:TUV]IPPBVC'=O:"_+/V$8)8P^_LLL>\B[;H3>."#@M
M=T1@.KB<)(V^]!K]].)0,![.&=62\+43`EXNAANVLF2T\@G#SIH$/]=>2\QO
MV-:6T4X2VC>NT\%5EHPI>Z\AIMO(3EQER3;]K86<F>V33:1#X0$!A\(#`HPJ
M03["/G<HJ+O:H?"``*.&;2W9UHH3KAEMV-:6;>U$R_>,/:-64/>,L>?-1EM9
M?)FM2.IAB]XX(.`2OG%`0+1<)#F['D^2W4XE*GYXFCL4#6*V4*>S6XBMUPX(
MB-SGM>2\5J*%<>3U"7`M6MA?!UI)S]N(EL]QRSGN1.MDCGO1$F=.!UF272LJ
M779Q`S!Q@*`!O-GU7"C!OT^8H9^8MA(>$'`H/"`@R/>S2I!?SL\=BJK8F@]L
M+9Q6>$"`;2W9UDJT?!!IS;8VHN7+M65;.]'RMO:"_#.V@CI;L>??"B4D<?DA
MAQ(<2I;FZ0$!IQ4>$&!4,9H[%"W-;2$"6PM.V#!:LJT5:ZT9;1AMV=:.M?:,
MV@C%E6&V\T$WZ)=E+CX0-G>W\\?(TW=P.B`P5)24I;G5.KU8KIRMH$_,&=7O
MRG'AM$[GV+#Y):/5NW)<BY9=+&>3R2#9.F[8]);13NR$;B>/[D7KU=S:R'3<
M!DR0(&@#;PZ%+AH1M@V+HB6[1>$!@:%#?IBH!/DA9^Y04.VU:/G9?B'(VVH$
M>5M+MK42+6]K[5!X0$"TO*TMV]J)EK>U9UNM:/%0.'HE&M'Q.!KAT.D#`D[I
MC0,"HH6M4=^1L_04;25:OI;G#F%HE[5M+5K8R0>VDGW"0K1.YMB(EL]QR3FN
M1.MDCFO1LFL#K?>)AL]MR[GM1.MD;GO1>C6W5C2ZW*+>AW;^2[VOTT_:AC$1
M'Q!P6L&+^-*A\("`(/]2?^Y05,?6?&!K(0F#`P*"O*TEVUHY%-A:"_)=;<.V
MMFQK)PF#WB?(VVHC6['G36S@U+B7+$1&-I:`<)5OZZ.KI*W/G!;VZ=))"D8E
MHRI"<4'-#OY409.7+_C4/=W$"/)=MV!4,JHB%)?J%S>O(]Z\"O*[@<*A^"W$
M:!0?PR^]ECBYBE!<4+-7^A7WV;U5&)8<.106U**XH(-D-U>ZA-#R!>T3`L4%
M3?8DLA@;\=[#H2A.FHW24^M.Z_0NL10M.WJ-QY?#Y*N'2C1X&V5"2*%O^R+S
MHKU3C<-Z#DU]=RT=&ESZ<:3J6?<Q5^PRLY),ZS8;?C"OC^T5*GS_R<BN/J/Z
M=>@RFJ%&26T6+J5$Q*[3T_VE5_#5;4W;`34NNUD.2=G'_8'HD5TE1<5S",43
MNX530UD$E8PJAY3<Q^':`]XRM\:85X[J101&-YYSNN2?SLT#^XE_E`R&A=.Z
MCK6277KIM>11*H>F:/G>?.;;9>3(<3B%>D=V."FUG<I,@_)F1TD,KW`)IVXZ
MGTZS9.E>>@U?8FMZRC/\.)QG@N+UTXG8F'6:<*J?T0J'!I=^!"D55O6L^UPA
M=D\X?;B:'DY?_5[<C&AI95LTC=V6]@Z7,*[L=(=8>BUY[,JAN"V]6MGAM!-X
MDV>7L45Q9=.A6J<EE<W[M-)K^!);TUIEF]&=.[49J%.G6A15MM.**IM9)=8N
ME<H.YQ`D[;KUZ?$0$28JFT.7L!!T%*IQJS:VN\[!*(V_E<XT%+SK;!HLRX#B
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M`1]H?L.V`OEHDLWH,C=!`"X;8C2YB06P!*&:W(0$6(+P3+Y7)0C+Y"9`P&FP
MC4?9-+\AY)77:AJ$N7(3&6%K"&WEC2I!A"LW<1).@T!7;L(E+$%P*S=1$Y8@
MI)QO$&YD"2++N8E@L@0!YMP$,EF"H')NXIDL03`9/5N3S%"VF5JV`I)"E920
MF.@4YX,@)&I!DR`6F9M8%:?!"X'<!(Q9@I<`N8D;LP2!_]R$CUF"^']NHL@L
MP6N`W`2368+0?VYBRBS!^TCXK9N/TOXSG.3F512GJ2$Q+Y98@A=)J&U-@M="
MR$>3S%"VF5JV`I)"E920E*H$KVA0:NU)\:8F-Y%\K=1C^$WS`5XAPV^:!*^-
M\:2:!&^/T:XU"5XBHUUK$KPX1KO6)#BJ`;]I8^(,:<P+7WZ>`I)"E920E*H$
M+_GA-\T:WO7#;YJDAJ16)7C-CW:MI6D@:50)WO.C7>MIADBC^0#G;9!&D^#8
M#6I.D^!<#6I.D^!X#6I.D^"4#>I'D^`T&ZQIHS(.M<&:)L'9-K0#38+S;,A'
MD^`<&]J!)IFA;#.U;`4DI2JI(#'';;CMX&@4:EN3X(04ZE27#-`.M++A#"+2
M:!*<.T2=:A(</T2=:A*<0D0_U20X>8C:UB1%-L5*4.OUQ1`C.4Z(L@]J2,R9
M5I;@#"MJ6Y/@1"KJ1Y/,4+:97C9("E520F*.$W()<$(4I=8D."B*FM,D^,($
M/M!Z5I%A5$:(C?,I,HRC."G.DAH2<P*>)3CQGIO#ZRS!877DHTDV&3R*+R8Y
M#3Z.S<U'F"S!-[*Y^1:3)?@N-C>?9+($W\.B!)IDEHT@T=KU+#.[",VCLPRC
M,CYVXWQJY%.K^>";Y-Q\QLII\!TR/*I)\#ER;CYJY33X*CDWW[:R!%\BY^83
M5Y;@^__<?&?.$EP#D)O/S5F"VP!R\]4Y2W`#0&X^/F<)OOS'KDR3S%"VF5HV
M?$F>FV^(V1J^'L_-I\0LP1?C:*.:!!^.Y^;#8DZ#VQMR\W4_2W!C0VX^\F<)
M;FG(S;?^+,%E#;GYY)\EN+,A-U_^LP3W-.3F`@"6X/(8^$WMIP.LQ7"G!J?!
M/2$HFR;!K1^H;4V".SR0CR:9H6PSM6P%)(4JP=T:N;EH@<N&^S10:DV":S5R
M<^T"I\'=/_";Y@/<]P._:1+<\8,GU22XZ@?M6I/@QA^T:TV"6W[0KC4)[M6"
MW]21`FEF:AI<TP2_:=9*2$I5@AN9X#<M#2YF@M\T20U)K4IP)Q/:M98&MS&A
M[6@27,J$=JU)&OC`W+[%-8?;T9!&D^"2--2<)L$M:*@Y38++T%!SF@1WHJ%^
M-`EN'X0U;;S&)82PIDEP%R':@2;!_8/(1Y/@VD&T`TTR0]G,!6GL'=QNA]K6
M)+C!#K6M27"1'6I;D^`^.]2I+L%:3"T;[HQ$&JW4#22-*L%UD:A3+0UNC40_
MU22X*1*UK4D*+,6T/H]K3>$!;>V$2TI1,DV"*T=1UYH$%XBB=C0)[OM$[:@E
M@\1<^LCU5D)B[GYD">[S1*DU":[U1+UIDAF6&EJM%5B@:;VMP$"MC=,%!E9M
M-55CHM+X"A._QG>8J#M^T6_^\4=??MY\/VQNGK[?/3Z?W1^^(5Y\V<6]G^S?
MA[&_O-@[L\Y^.[[@S[T@\HT7._@[/@=<:WKY`>]HOAV/+_(+G'?1_V6@S_\1
M````__\#`%!+`P04``8`"````"$`V+6FLM`&```H&@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6R46=N.HS@0?5]I_P'Q/B%`FB0HR:@)=^U*J]5>
MGFE"$M0A1$!/S_S]EK&-L<N]FNZ')CD^57:5J\J%L_OZO;D9WZJNK]O[WK07
M2].H[F5[JN^7O?GW7_&7C6GT0W$_%;?V7NW-'U5O?CW\^LONO>U>^VM5#09H
MN/=[\SH,#]^R^O):-46_:!_5'4;.;=<4`WSM+E;_Z*KB-`HU-\M9+CVK*>J[
M237XW<_H:,_GNJS"MGQKJOM`E735K1A@_?VU?O1<6U/^C+JFZ%[?'E_*MGF`
MBI?Z5@\_1J6FT91^=KFW7?%R`[N_VZNBY+K'+TA]4Y==V[?G80'J++I0;//6
MVEJ@Z;`[U6`!<;O15>>]^6S[N;TQK<-N=-`_=?7>SSX;_;5]3[KZ]%M]K\#;
ML$]D!U[:]I50LQ.!0-A"TO&X`W]TQJDZ%V^WX<_V/:WJRW6`[7XB(F5[@YG@
MO]'4)`;`].+[^'RO3\-U;[K>XFF]=&WGR31>JGZ(:R)K&N5;/[3-OY1D,U54
MB<.4P),KL1<KYVF]^8P6EVF!)]-B>S^]!%CL:`<\N?#VTW:LF1)X<B7NY^W8
M,BWPY-Y8V*NE1QSZ/TZT89/I5I#=IFY>S6;'HA;=RS$&PF(H#KNN?3<@L6"W
M^D=!TM3VB5JV^VSV*1X@+$M"?R;\O0FY#SO=`_KML/*6.^L;!%C).`'FV#+C
MR!DDR(C:4`4B%8A5(%&!5`4R%<AG@`7V3TZ`8/R4$PB?.($O/^"`\(JC6,P9
M7"14@4@%8A5(5"!5@4P%\AD@60R),[>8[RZ!(:VEW57V+J"<E3M9?T1(B)`(
M(3%"$H2D",D0DL\1R<:5WD8"0[2#V"R$E>T**,EUA)$("1$2(21&2(*0%"$9
M0O(Y(AD)A4*WD00>C>3Q%C#$$Q8A)$1(A)`8(0E"4H1D",GGB&01%'*=1026
M+:*(.PM$AH"SIJVUMTK\AHPD'!%IQ92(B)%8HA5SY;Q/D5BF%5O)8OE$@OV3
MO`/GS=P[K%XOUN#.X5J7KT$['L$\H0E=]AI%YEYC"#WRQVK,D)F+$"=&G`1Q
M4L3))LY\AYX4XR>2:CQI.6>'%3>2P+*1#)D?4_;6DZ<Y3B2>(R%#A"<BQ(D1
M)T&<%'$RBKCBR,CGB+3#T`OHC"2P;"1%'#C49M&^5HQD)&<\JI<+3W%"R,9%
M$D4,68T2]L*)OJBI@&02ACS1AD!>0HKH&4,\NBB9GK-!V:S-1))\13H6G;-&
M7/86A\#O,W=M)[UC'W)D+&?-_"7F97T*F1`4ST*$BVQ&$6?A8H?QN854PJ6V
MHY0R38H%,@:Y2ZW3N(!LG5`K>XWT09H\LFE_!$<CSXB`02YLRN0U>#]3O48%
M5^.+!G,4@VCW3ZI*Q'3-6#&'!"OAD-"5<DBP,@X)5BY!LKVD"]+92[LCR5X*
M@;W<!4>;0K-EAQP2"XHX)!84<TBP$@X)5LHAP<HX)%BY!,G&D?Y'9QSMBR3C
M&"0'B5HQ2&<$(2Y20"G/(2-(.<!D:`YL%EOY#U)".1=CK"3A$].44&9-L4#&
MH(]20FOM1RE!&BR=%VGC!3/Q>`AL"BEU%Q42QN*%=Z.V(5R-T!QQB)=>3U-)
MF%HAE7`I6GR%?6,>IGQ4"&0<TI=?/@KY.V6\O15JY>`C79S.;:R[$[,&$"XD
MK%PXW">]SE+QRI&Q5J+Q#KG@K!O!K!BS$LQ*,2O#K%R"9'M)7Z:SE_9K4IBP
M%FX]1<Z1W%&`"R3C&&MN'&+%3-`5K`3K2C$KPZQ<@F3C2-^E,X[V8Y)Q%%)R
M`%42QN(YL%6*0&@S@@B3B$,T!S:+I?P'W8BB).820DG"(9H2J)*@63,N\$%*
M:*W]*"5(8Z?S(L&5EH1!<CU&E82R1#U6<B:$R\%1L^@N(@8YM![#!9M<C[>:
MPH*4)%S)!RT*$LB8P$?UF`G`8RH`N+#0:TIZ1=54W:4Z5K=;;Y3MVQVDX(7\
ML)M@>C\*2>V3V(<"K8Q`;L/5J6X$[E2?QQ*C2`3DKE6C*7!\N$K!,P2N#_</
M&']>^<_@#3P`9=`/M$N"TN>3"H%EH`+ZH78D@I%(.P+UT"=E`VN#LNB3ZH%'
MLHT/;R48AR80UJPS_P@CI#_",B&,D#8)CT`;"&O6C4`W"&O6C4!3"&O6C4!O
M")NO&X$6$?92-Q*L?+A/P2L+/#\8J[42%$?//^KPT/-#'1YY?J3#8\^'MV8\
M;^+Y\.Z,\=3SX0T:XYGGP_V`!E_[^<BW)@/@^OY17*K?B^Y2WWOC5ITAB9;C
M;4%';_KIEZ%]0&F"&_1V@(O[\>,5?I&IH&U?+N#@/K?MP+_`Q-8[_XWG\!\`
M``#__P,`4$L#!!0`!@`(````(0!>)/_J;`(``(,%```9````>&PO=V]R:W-H
M965T<R]S:&5E=#(R+GAM;(R42X_;(!#'[Y7Z'1#W-7[DM5&<5=+5MBMUI:KJ
MXTPPME$,6$`VV6_?P3AN7H=<L!D/OYGYS^#%TT$VZ)T;*[3*<1+%&''%="%4
ME>/?OUX>9AA91U5!&ZUXCC^XQ4_+SY\6>VVVMN;<(2`HF^/:N79.B&4UE]1&
MNN4*OI3:2.I@:RIB6\-IT1V2#4GC>$(D%0H'PMS<P]!E*1A_UFPGN7(!8GA#
M'>1O:]':(TVR>W"2FNVN?6!:MH#8B$:XCPZ*D63SUTII0S<-U'U(1I0=V=WF
M"B\%,]KJTD6`(R'1ZYH?R2,!TG)1"*C`RXX,+W.\2N;K"2;+1:?/'\'W]N0=
MV5KOOQI1?!>*@]C0)M^`C=9;[_I:>!,<)E>G7[H&_#"HX"7=->ZGWG_CHJH=
M='OLCS#=0"18D11^!*!R>NB>>U&X.L=I$HW2\726I&.,-MRZ%^$/8\1VUFGY
M-W@E/2M0TIX"SYZ23:+Q-,[N@)"045?),W5TN3!ZCV`Z(*1MJ9^U9)Z"@LP;
M5]Z:8QA32,J"]7V9S48+\@YBL-YG'7Q@'7R2P8,`?0@!^=X(X:T^A%?+QUP'
MPRDOO<W+;O*\-<>P#NEDL_$`""&"SZAKZFF&HYM$;P59SI&7*O1.,#LG<?\[
MG0D!K;XAA+=V808E>LNI%.-L*.4,.3E#(C^!:19',%7'5GJ/<WQO`;U/4IY<
M\,/0AU&1W%3\"V\:BYC>*1\#\(-UN&NKU"M[:1_-5]T=),,'N!HMK?@;-950
M%C6\!&0<3:%N$VY1V#C=0N9P/[2#.]&]UO"SXS`M<03.I=;NN('`9/A]+O\!
M``#__P,`4$L#!!0`!@`(````(0".*^CJ_P,``(0-```9````>&PO=V]R:W-H
M965T<R]S:&5E=#(S+GAM;(Q738^;,!2\5^I_L+@W8"#)$H54NZVVK=1*5=6/
MLY<X"5K`"#N;[;_OLPT&8R/U$B63QW@\S_/B[-^_UA5ZH1TO69,'>!4%B#8%
M.Y;-.0]^_7Q\=Q<@+DAS)!5K:![\I3QX?WC[9G]CW3._4"H0,#0\#RY"M+LP
MY,6%UH2O6$L;^.;$NIH(^-B=0]YVE!S50W45QE&T"6M2-H%FV'7_P\%.I[*@
M'UEQK6DC-$E'*R)`/[^4+1_8ZN)_Z&K2/5_;=P6K6Z!X*JM2_%6D`:J+W9=S
MPSKR5,&^7W%*BH%;?7#HZ[+H&&<GL0*Z4`MU]YR%60A,A_VQA!U(VU%'3WEP
MCW</"0["PUX9]+ND-SYYC_B%W3YUY?%KV5!P&_HD._#$V+,L_7*4$#P<.D\_
MJ@Y\[]"1GLBU$C_8[3,MSQ<![5[+1PI6P4KPBNI2G@'8.GG-@QA6*(_BD@?)
M9K7>1@F.UP%ZHEP\EO+9`!57+EC]1Q<IZ:'F4AH^$D$.^X[=$#06JGE+Y#'!
MNQ@V7TCP7J)Y`"<,^#B@+X?D;KL/7V`;15_SH&O@U=1@4Q$"NUD"]'J6D*A<
M0NY3KOF@@2E?[.=++#XD_4HB(UU^"\!$5G)W9XCT4KHF56V9*DU=YGBS`G<'
M7V0!.&6SSXWIB^`@&&>F[EG>0.,\WDA4+6/,Z1'=RZGDC46@S,!XO1HERP*;
MJT?`[XF^S%ADZ=M:](,-$K4Y->(Z*H?4>+P\\F2!3=4CX.(H+XO\\C*+?I`G
M49M3(ZX\#$V:ZTNC;+4Q'5<5-MD`609F"X<?RYB,#@P2%3RCU8'RB)3)&"F4
MB6N\VHX]QGUVDC%-`V2+7$B4/-"3%8Q(G1/XUIQ#59D''I&>["39:*-)SDC5
M0[;"Q-]H&(A>A6Y25"4X:].F"[2>^-B)QVY^!LA>8;VP@IT@/:TFOKA1PCUD
MTV\6Z#T!FVW`31CNH1CV-LG8.,>L$8#MD#D[<-.FGG!:,`YABSZV(SB</07;
M`>DA]^S%=L:T0IQ-AJ"JF+'IN,W.R<(8C*$9GH`H>$8K*WT!B>V,*9%Q$DU_
M753)C*Z/X/0PI-'"-(SM#!HKW>RI2J]*.V=*I3T0Y5UC-ET'R!:Y,!#EH?-9
MZ>9,57I%>C*%MYEEI9NKV).K-%J8B+&=*V.E&R95"4US?YIC3W#F'7?#HYX"
M/FB:R68:+8Q%N/?XS%2P?9`&R)4)=]LIAZ?EJF)&YTE/&LVGK+[SZOMF3;LS
M_4"KBJ."71O8F[QN&M3<M>]C^6LSQ]/=O;Z#A^8;N!JWY$R_D>Y<-AQ5]`2<
MD?Q91)V^1>L/@K6@'2[(3,"E6+V]P+\="G?."$8$.C$FA@^P<FC^/QW^`0``
M__\#`%!+`P04``8`"````"$`@MHO>B01``#'4```&0```'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6R4G%E3&TNVA=]OQ/T/!.]M4`D05-CNL%2#:J[JZ+[W
M6<:RK3B`""0?G_/O>Z4JMW)8:8%?C/G6SIV5.X?*J7C_S[\>'\[^7+_L-MNG
M#^>3=Y?G9^NG^^V7S=.W#^?_^7?VC]OSL]U^]?1E];!]6G\X_WN].__GQ__]
MG_<_MR]_[+ZOU_LS>'C:?3C_OM\_QQ<7N_OOZ\?5[MWV>?T$Y>OVY7&UQZ\O
MWRYVSR_KU9=#HL>'B^CR\N;B<;5Y.A\]Q"]O\;']^G5SOTZV]S\>UT_[T<G+
M^F&UQ_/OOF^>=^+M\?XM[AY7+W_\>/['_?;Q&2X^;QXV^[\/3L_/'N_CXMO3
M]F7U^0'E_FMRM;H7WX=?R/WCYOYEN]M^W;^#NXOQ0;G,=Q=W%_#T\?V7#4J@
MPG[VLO[ZX?S3)!ZFL_.+C^\/`?J_S?KGSOK_V>[[]F?^LOE2;Y[6B#;J2=7`
MY^WV#V5:?%$(B2\H=7:H@?[E[,OZZ^K'P_Y?VY_+]>;;]SVJ^UHEN=\^("?\
M>_:X46T`15_]]>$\0@Z;+_OO'\ZG-^^N9Y?3271]?O9YO=MG&Y7V_.S^QVZ_
M??S_T6BB78U.IMH)?FHG<'?"_DK;XZ>VGYD\3Z2;Z73X*?F\N[V^OKJYG>%A
M3R1$LSZ4$C]U0F1]POY.V^.GMI^@;"<23"2.ZC\ZR<WI%`C1X9DF)O23RW>S
MR>7=])72J&<9DYJ`7[TM)<(TIL1_)(2G'Q.E&%/@/SK%R<JZ&!O8H6$FJ_WJ
MX_N7[<\S]'8$9O>\4F/'))Z@!G63U%$]-E+TE7ME_DG9?SA'C:'Y[4#__'AU
M,WU_\2=:_;VVF;/-Q+58B(5J^<IMXH/4!YD/<A\L?5#XH/1!Y8/:!XT/6A]T
M/NA],%C@`F$_QAY-[+=BK^Q5["5J<P&F,B(OT&(A21(?I#[(?)#[8.F#P@>E
M#RH?U#YH?-#ZH/-![X/!`DZ@T2$IT-/+8YM6,D98JTU'EW=N(.>CS=7T&/P%
MD81(2B0CDA-9$BF(E$0J(C61ADA+I"/2$QELXD0:`[@=:1DU%,8(@V36L''E
MA7@TFD8FQ$02(BF1C$A.9$FD(%(2J8C41!HB+9&.2$]DL(D38KPC[!#K$?N=
M>COMOV_N_YAO#S,#";TR/X1>AH"Y)C<FSD02(BF1C$A.9$FD(%(2J8C41!HB
M+9&.2$]DL(D39[Q9?R?.RMR-LR96>Q[)M=T-HHGW;DR.1E)A*9&,2$YD2:0@
M4A*IB-1$&B(MD8Y(3V2PB1-ZS$-^)_3*W`V])E;H1^*%WGM;)D>C8^B)9-KU
M.&M7<Y?\:&,&MVCBS8F61R-Q71`IR75UM+%=>^-F?302UPV1EEQW1QO;];4[
M)/='(W$]V,2I,[5&M2:2,OPH[-:-)E;=C.3ZZC@@)412(IGV8U7$2*88.8]O
MF6ARXQ9I>322(A5$2B(5D9I(0Z0=B5[AJ;;2C<0J:D]DL(D38JQ[0B%6V`WQ
M2*XQM!T#,;UTX[`(V$23F6N4:*/98:(_F<ZB&R^<Z6AQ-:X\51$S(OE;LEJ.
M1C=84Q^?.9K<NL]3D.^22/66W.JWY-:0[Y9(]Y;<>FWTZS`.MF.GSB<(B%WI
MK[WN#_9N:]`(S4&:_$*0F0,D@LSR(A5T=TR8:635=RY6QM=2HQO3*@JQ,KY*
M]E6)E?%5LZ]&K(ROEGUU8F5\]8),&0=!!U]NY-6RS1K1*/+_WCXCT,=5A-IC
M\/JA(*Q+K$;M+2T6VNK&C(@)HY11)NY-Q>9B9=8I2T8%HY)]56)EGJMFU#!J
MV5?'5CVCP4%N9:BEG549\GI1VS1^T$=TX[P&(G_XTPDQWJ@]C.MK?RI@=.DT
MJ496V\\8Y2:A7>?>0+8T5N*^8%\EH\HD/.&^-E;BOF%?+:/.)`R&I3>Z.!X<
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M(\A,(5KVU6EDE;%G-`@ZE-&-O%J"6I$_OE;&I:G3?T8T<][ED=<Y%A-MA2'(
MM"F:5HO5E>YE6"[Z\VHQ,16::>2,:V_);BF^QO;J-?!"5)-3R3E58G6R8+58
MX;%,\?V^V(B5XXL[WE@VJ[A=,*$?W5ZLCM&]G'EE'L3D4&:W1:@%KM4B7NV+
MXX+8:2DC0DLQ?7%$UV:`3-1A"]YXUZ;CI8+,O#;3R`I"+E;&UU(C9[ZMW1M?
M)?NJV%?-OAJV:ME7QU:](%/&05!@OJW6O:<B[\^WQW6R$_D1>2.ZMZFQF(Q6
MF&];C=1O18FVFMV.;ZOIW=6E]TY)Q9%YRV8:.6/G6[);ZH2W:CWQYT>OO1:<
M4\DY56)ULF"UR<DJ/O?1T%-S'QVMK.)V;WJ(7EN9Z$ZGWK)H$$>'Z+I]5*V6
M3[44_WTYKJZ=EJ(7W.9-N)B,:&90(LATHE2C6_,FS#2R@I!+0N-K*0G-J%`(
M,KY*]E6QKUH2&E\-6[7LJV.K7I`IXZ#16$8G\M%KNQ%>'SW8N[L1&EV9U\V"
M4<(H990QRADM&16,2D85HYI1PZAEU#'J&0T.<B/O[4;(3"7B70>-[(,T1@FC
ME%'&*&>T9%0P*AE5C&I&#:.64<>H9S0XR(VPVC?XC5$E4O9>V];(O)H78F50
MPBAEE#'*&2T9%8Q*1A6CFE'#J&74,>H9#0YR(Z\6[+\3>67O15XC,XHMHA&Y
M1SZ1-\].C)5,UE)&&:.<T9)1P:AD5#&J&36,6D8=HY[1X""W,KPMA=<FP!%O
M-0BR*V.T<BMCXDVH$IT05J8RC@D%9>+>O$%RD]":T]`9G+$27P6CDMU7QLIV
M[ZW]:F,E[AM&+;OOC)7MWINV]L9*W`\.<FO1VU(XOBYXZT#=*%2]R:ZM$=V:
MW;A$6UDH992)+[MJ1E^OG,KIA+"2PA6,2D85HYI1PZC5"'L#DF.GD57&GM'@
M(#?H:L5JC6/'H(\K67O^&8WH]!%=R(C/Z,1J/%V:SJ[NO)ETJBVL163&*!<_
MJ"^S=O>714MM]<HY';LO&55ORK%^4XX-NV\9=6_*L1>K7T9T<%R[;4"MNZTV
M\.KP.:[3G;:AE^ZF92XBC>Q9A$9F;9V*E>G)F496U>=B97PM-;+W#\3*^"K9
M5R56QE?-OAJQ,KY:]M6)E?'5"S)E'`0=?+F15VO14Y'WUR;CVM6)O$;N`MKK
M3HMHM++/ZQBEC#*-K"$G%ROSQELR*AB5[*L2*[,JK!DUC%KVU;%5SVAPD%L9
MWA+].!3R4CP:T2OG=6+UJ_,ZH\MPGFIDM?V,46X2VL.>?UYGK,1]P;Y*1I5)
M>,)];:S$?<.^6D:=21@^KS.Z.!X<+TZEX4JLTX.DT@[<G6]K9)_7"3*[&0FC
M5".[4ACEG'#)J."$):.*$]:,&D[8,NHX8<]H<!*Z$?[%*G[*JWB-7CFO$ZMQ
M:_]N<CGSIHV)L9`6D&ID;5AEC'))&#ZN,ZJX+=A'R:@R":T.$7D7CVIC)>X;
MC;S-76^GM.4<._%E8N3EUAL+R6UP_+AU^)O[!-B'\5>K&MFG=8+,CF'"*!5D
M7HB91E9EYAK9IW6,"O95LJ^*$]:,&D'6:1W[ZC2R3^L8#8(.970C[^T3',<G
MW@^8CNB5TSJQ@O&OI[R)6(WG27>3&[^UIF)A9FR91M8XEXO5R=R68A4^K!/5
MY%1R3I58G<RI%BLL14SI_;(U8N7XHH,`?H@NF-!?3_1B98+K3;<&L3@4V6T/
MO[E5H=:@WKZ11O99G4;V69T@T^U2069.FVGD5+G>O3!SVJ6VLN?:[*MD7Y58
M&5\U^VK8JF5?'5OU@DP9!T$\UYZJ1?UOS+4/]MX,8MP7\(9S[^VUT`E?.:O3
M5OHT:1+=3?Q]OE0<F8EVII$S<HX/=3J[I4[XB[,ZSJGDG"JQ<I<:WHNI-CF=
M[**AI^8N.EI9Q>W>]!"]MK*CZTV/!W'$9W7([G1+\<[J#O9>2QGW2M!2Y.V\
MT%;V69T@TR%3C>RS.HWP0WSEDM"X7TI"LY(J!)G9;:D1?HBO2B/KN6I):'PU
M;-5JA!_BJV.K7I`IXZ!1X*P.'S*?CKQ>#R/#\8/E\;O0Q_7+M_5B_?"P.[O?
M_GC"FV$R4^^B(Q\_E6ZGU[%Z:J3V%+2J6#T\*VA)L2H#*VA`^/(ZI."3[$^'
MT'FYS/&I]F&VX?,H'H+V4V00R/G35?PIF/$\NH2G0W5[6:#_QZJ)<#$***JE
ML((A(%8-AA6,!+%J-ZR@]\>J^;#20%&MB)5V.D6U''91O:?&^QC5$E+P#D:U
MA!2\>Q&UD#+'$\R#3X`A.U;]DY\M@9($%8S.L>JMG`:#=)P%E1R*ZKN<!E,H
MU$_HJ0LH15#!+`KU$TJ#R13J)Z1@`H7Z"2F8-*%^0LH<RCRH+*`L@@HFH(A;
MR!LFGHA;2,'\$W$+*9B&(FXA!:LUQ"#4>;!H0TE#"E9E*&E(P4H,+3&D8$&&
M]A92L.I">PLI<RCSH+*`HI9*W`ZPSD5T0@J6NXA.2,&J%VTGI&!YB[834K#M
M@[B%1@KL_B!N(07;.XA;2,$N#^(64K#9@[B%%.SI(&XA90YE'E064-0&32!N
M4-0^#2O8/T/<0@JVT1"WD()],L0MI&"#/E8;P9P/]NECM1_,"O;F8[4MS`KV
MY#%>AQ1LV,9J.Y;38/LU5INKK&`S-59;I:Q@:Q3YA!2<C<1J*YW3%%"*H()C
MD5AMK',:G([$:G^=%9R(Q&J;G16<@N"I0\H<RCRH+*"H\P7VED!)@@I.E!#1
M4!H<+,7JT(&]X7PI5F</K"RB*W@+C4@XUT7<0@J.9%'2D(+35-1/2%E$>,O@
M](Z?((>BS@A9P9D@O(64=G(;JRM6@310U$TK5G#M+587KEC!;3?,9T+*/,*8
MB%LKG`8W'*"$)C6X31BK"V><!C<)8W7OC!5<*(S5]3-6<*\P5K?06,%=PEA=
M1F.E@:+NI+'23M#K<0N4%5SO1=Q""J[T(FXA!3=Y$;>0,L<3S(-/@`N@L;KM
MQT^`2Y^QNO3'"NYZQNKN'RNX\AFK*X"LY%#434!6<",;]1-Z:MS&1OV$%%S*
M1OV$%-S-1OV$%-S'1OV$%-S!1OV$E#F4>5#!Y7;$+90F@:(N-'-)4RCJ7C,K
MN,Z.N(64'(JZY<QI\/D'8A#JC?@*!"4-*?C,`R4-*?BT`RTQI.`+#[2WD(*O
M.-#>0@H^L$'<0@H^JD%T0@H^G$%T0@J^GT%T0@H^HT';"2GX7@9M)Z3@0S+$
M+312X'LRQ"VDX(,QQ"VDX+LQQ"VDX/,QQ"VDX"LQQ"VDS*&HS[^XMA=0DJ""
M3_$0MU`:?)&'N(44?)B'N(64`DH15+H[#$BAJ4N/F5A0&#`1"PKXRA./'!K&
M\<TFL@\I^`(351!2\#TE\@DI!69;P0<H,4D-"M4=1H]0(6M,7H-"@[EK4&@Q
M=0T*"XR>H2E3CK=$B'=X&X;X'+/9<`9W&)I"A4@PRPT**2:Y02'#'#<HY'<8
MED)Y+#'W#0IS#!;!F0A>6J&5ZV(6IZ%Q+Y_%^',1W$.J68R_]<"\F\7#@5\<
M-P'PU^6>5]_6S>KEV^9I=_:P_HJ='?QA,VP*OHQ_B&[\93]^U'SV>;O'WY7#
MY@_^)!C^8.`:7_9?OH/QU^UV+[\@XXOCGR#\^%\!````__\#`%!+`P04``8`
M"````"$`%)M#J'H&``"<&0``&0```'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6R46=MNXS80?2_0?Q#TOI:IBV^PO;"T2+M`%RB*7IX56;:%6)(A*<GNWW=X
M$<D9*D[V)8F'AS-GAL-#FME^_EY?O9>RZZNVV?EL-O>]LBG:8]6<=_X_?S]\
M6OE>/^3-,;^V3;GS?Y2]_WG_ZR_;U[9[ZB]E.7C@H>EW_F48;IL@Z(M+6>?]
MK+V5#8R<VJ[.!_C8G8/^UI7Y44RJKT$XGR^".J\:7WK8=!_QT9Y.55%^:8OG
MNFP&Z:0KK_D`_/M+=>M';W7Q$7=UWCT]WSX5;7T#%X_5M1I^"*>^5Q>;K^>F
M[?+'*^3]G<5Y,?H6'QSW=55T;=^>AAFX"R11-^=UL`[`TWY[K"`#7G:O*T\[
M_\`V6;3V@_U6%.C?JGSMK;^]_M*^_M95QS^JIH1JPSKQ%7ALVR<._7KD)I@<
M.+,?Q`K\V7G'\I0_7X>_VM??R^I\&6"Y$SZE:*\0"7YZ=<5[`%+/OXO?K]5Q
MN.S\:#%+EO.(A8GO/9;]\%#QN;Y7//=#6_\G04RYDDY"Y01^*R?Q+%PE+%EP
M)W<F1FHB_/[IZ(',1%3@2S[D^VW7OGK05L"UO^6\2=D&'*O4%0U=#%B3@J,/
M'+[SH?$AS1ZL+_LX6FV#%ZANH3"IBV$8D8T(OBC`0Y.!DOP,&0[G9/A"<7;I
M:##L0A)Y1-#(D+H5><R66V&-4;9K[#&5F#C2+#+;@M*+41!1ZT4T6^I5=\O-
M9^Q\(&W*'<\)`8F)%Q:(+988E&D031R"6XG+]8_G,].*+BD^A9(B*YQ*#"%%
M&B73($H*<J&DP@30<G.XC#B>,B(KGTH,8406,],@RFCI,GIGZ?@,RBG"JY)*
M#.(4QS$&91I$.?'CAVY=%M_M)SZ%DDIPO%1B$"FV).N;:1`EM9X@M4CNDN)3
M**D%(24QB%0<TR;7($J*P9%`2Q7.84^\U5!B`N5$VC=5($**MI1!.:RFM/>=
MO<>D=")%2*@B*!`BQI:TKPS*(<95DG;6FMT5!2:5%1,C79,J$"(6)V2G9@;E
M$./22HB%<7B?F)1C3(QN1*8T&_:_4=K$J9A&.<2XOA)B[^@#DY+,(ULAZ694
M*%0QMJ2-;U`.,:ZQAMAXL,'MAN\Y"`X3Y-FI3/9!ADSH)&-<*(W;#QT;8@Z)
MJ?06)$[7@"W)/LO4Q'C)R6(:7!L-#9V=E$R4G31%"YUPQFP3=HN55;N5HH?<
M*I/MUC9AMQ/:&":SQ%RNI("A`,H$7*T*.1JC4!#:H%9&%A"-$(OAF)TPX^49
M359VR(3=3JB9W`(Z@M0N.[U0F>ZG-Z)P>D9<,`\L7CJXU"<47)KLC@]M$W;+
M][YI-='Q8;B&U7OS$`FE7*"02D%0OBLJ@&KB1,.'6&=T<EI+]'86R)V/DI,H
M:<+)897XR,V47Q")@B@3T+:[D$AM9E!T-X=85'1R4B10&:7)WLUB,O\^YHA$
M"'RLE=-NN9GTNS+9_6Z;<,WX/B<-0?I=*8$ELJ$R@5>S49=T.X\HW._F-,(\
ML*KH]%PM"97)3L\V(;<15@G1$M&*G[1C!('`!1Q-]],;43@]<_)A'EA6='!7
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MNWV_U6;Y$`FQQI=(.A(F&WZT@7-G9`$C0I3H2!2!-[&AG9$81N(I;Q'$@=YV
MXQRBQ>8`R^:.0%_"G&D&2Q@1]VJ'P0I&)KVQ<,._HDW$89"//*:)MP.+@=MD
M/C"2P=>7*6^0J7R%)=Y2!OG`EX*I.9`/W.LG1D)@#;>[J1%@#3>NJ1'@!O>H
MB1$@,!D?PD]&AV).UA+:2;QK.QG.(0_Q:.V,P%LX?'-W.<$C^6$R/SYA`I_R
M@DS9>5-.V:$8D[6`91+]&&BJ\&1^R\_EM[P[5TWO7<L3[*>YT)M.OJ[+#T-[
M`XF!A_-V@,=R\><%_@M2@IS-^<7ZU+;#^`$2#O3_5?;_`P``__\#`%!+`P04
M``8`"````"$`D;%!7W@"``#&!0``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6R,E,N.VC`4AO>5^@Z6]X.3$*XBC*`CVI%:J:IZ61O'22QB.[+-9=Z^
MQS%D"+"8#2)_CK_SGXNS>#[)&AVXL4*K#,>#"".NF,Z%*C/\Y_?F:8J1=53E
MM-:*9_B-6_R\_/QI<=1F9RO.'0*"LAFNG&OFA%A6<4GM0#=<P9M"&TD=/)J2
MV,9PFK>'9$V2*!H3287"@3`W'V'HHA",OVBVEURY`#&\I@[\VTHT]D*3[",X
M2<UNWSPQ+1M`;$4MW%L+Q4BR^6NIM*';&NH^Q2EE%W;[<(>7@AEM=>$&@"/!
MZ'W-,S(C0%HN<@$5^+8CPXL,K^+Y>HK)<M'VYZ_@1WOU']E*'[\:D7\7BD.S
M84Q^`%NM=S[T-?<2'"9WIS?M`'X:E/."[FOW2Q^_<5%6#J8]\D>8KB$3_"(I
M_`I`Y?24X00RB-Q5&1Z.!Z-)-(R3$49;;MU&^+,8L;UU6OX+07&;/;!:#R_4
MT>7"Z"."N4*T;:C?DGB>0.W,BRNO9A@6#'@6U,,RC48+<H`RV#EF'6+@MXN)
MNP@"]"X%^'V0PJL^A:_3YUP'X9J7/.8-'_*\"AVYLI-&XPX04H28M&W(M</T
M(=&KT)8^<G*#/`?!U+LV7+>JUPB8TH-&>+5-TW4B*/<VQ[WSR"]*$D\&HVYL
M/J"/.BM`O+(W[6KHV9OT\)=5\&J?&91[>_Y[]+Y*K;UA^F[.O^Z#SDK?W.S&
M7+@W86<E-R7_PNO:(J;WRM</M7=J=UU7B1_QK9[.5^VZD>X%W*Z&EOP'-:50
M%M6\`&0TF(`C$RYB>'"Z`>=PQ[2#>]7^K>![R6%M(V@_*K1VEP=(3+HO\/(_
M````__\#`%!+`P04``8`"````"$`ENG(#D(.``"<1```&0```'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6R4G-ERXKH6AN]/U7F'%/<[8`,97)WL:L#S?.H,
MUS0A':J3D`)ZV&]_?MF2;>E7LNF;)OVMP<M+@[5DP:<_?[T\7_S8'HZ[_>O=
MR+F<C"ZVKYO]P^[UZ]WH/_\._K@971Q/Z]>']?/^=7LW^FM['/UY_\]_?/JY
M/WP[/FVWIPMX>#W>C9Y.IS=O/#YNGK8OZ^/E_FW["LGC_O"R/N&_AZ_CX]MA
MNWYHC%Z>Q^YD<C5^6>]>1ZT'[W".C_WCXVZS7>TWWU^VKZ?6R6'[O#XA_N/3
M[NVHO+ULSG'WLCY\^_[VQV;_\@877W;/N]-?C=/1Q<O&B[^^[@_K+\^X[U_.
M;+U1OIO_D/N7W>:P/^X?3Y=P-VX#Y7N^'=^.X>G^T\,.=R#2?G'8/MZ-/CM>
M/75&X_M/38+^N]O^/`[^OC@^[7^&A]U#MGO=(MMH)]$"7_;[;T(U?A`(QF.R
M#IH6J`X7#]O']??GT[_V/Z/M[NO3"<T]%R:;_3.NA'\O7G:B#^#6U[_N1BZN
ML'LX/=V-IE>7\^O)U''GHXLOV^,IV`G;T<7F^_&T?_E?J]2$WCF92B?XE$[<
MRYD[O[YIG'Q@.).&^)2&-Y<W\_GLZN8:5__`$-(F;'Q*0^<\PRMIB$]EZ)P7
MZ[6TQ.?OW23&5!,K/G_O)F^E(3Y5K.?=I(/^TEQ2_*%,S[Q-1_4(\<?OW:B#
M3M1>MN]-9[:GH[J0^$-%?.;-JD[D]+W(.?=F53_"V%"7/;/K.JHGB3]DQ.?>
MK.I*3M^7/NZ^XW;4-J-]M3ZM[S\=]C\O,(6BC8YO:S$A.Y[P)L>Y'#K=R,<$
MM!'JGX7^W0@]$6/Z"/KC?N9,/HU_8"K92)T%ZSBZQE)IB.E$N%V9P#=!8(+0
M!)$)8A,D)DA-D)D@-T%A@M($E0GJ`1@C[5WNT<E_*_="7^1>96VA0-\8KI%H
MI:%,5B;P31"8(#1!9(+8!(D)4A-D)LA-4)B@-$%E@GH`M$1C2J!$3R==GQ9B
M/+:T/FWTV$6K,YMVR5\261'QB01$0B(1D9A(0B0EDA')B11$2B(5D7I(M$QC
M!AUF6LT:`F.&@=D'TT:K-,/'^TK+3JGKT41\(@&1D$A$)":2$$F)9$1R(@61
MDDA%I!X2+>MX]MBR+G"3=96K14MF[3I.3+Q+(BLB/I&`2$@D(A(328BD1#(B
M.9&"2$FD(E(/B99//)"'^6P>BN[\$OKMBI(?B\)"3W5+9GBD#GJS.3UW2JJ%
M5D1\(@&1D$A$)":2$$F)9$1R(@61DDA%I!X2+?M(V3#[:@X16$]Q2X:]F<B*
MB$\D(!(2B8C$1!(B*9&,2$ZD(%(2J8C40Z+E4Y3D@R6>RJ?`>CX5P9I_T&>G
MQI*BU^HZ+2.?4<`H9!0QBADEC%)&&:.<4<&H9%0QJC6DI1P%ERWE`NLI;\G4
M[9<51%9$?"(!D9!(1"0FDA!)B61$<B(%D9)(1:0>$BV?H@P=)E26*9>BR#\]
M[3;?%GOT6*=;T37Z>J85NNI3S6C%R&<4,`H918QB1@FCE%'&*&=4,"H958QJ
M#>F9%\7+8/;XV\RWQ0Z6>FIV6(A]`'3[FQXM)9KK"\*9/M.L>BWERV<4,`H9
M18QB1@FCE%'&*&=4,"H958QJ#>F-(0J<WVF,MB#2&D/62,/&D%KN35O/NY-;
M:HE>I6\*9H'8P!$S7+_`#!7JO#LW<[V=HX&*\AY;6*)8[SU5J//N7E_KWK.!
MBO*>6UBA6.^]5*CS/KVZU;U7`Q7EO=:9WH*B<AJTH'H8B]+(>#1(I`V;5NMF
MU@VNE=+JD<\H4.[[>PLEFJ*H&#SLJ6G:*T)+W5W<&RJ4,$H998QR1H5$@RY4
M2C2X[8I1K2$]Z:)PLB6]+:A@J.YD(;8`13NXM\U8<">.,1264N/JMC-:,?(E
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MI#5]ZW_@*V)?,?M*V%?*6AG[REFK8%\E:U7LJ]8,]11CU-D>`*[@QD"5:*(M
MV5VC.9?2<MXN).?.]'9N#,!5KZ(:QI=HL)8+&(6]H5CHSYW9E=E9HUY%^8[9
M4<(H[0VE[^M;8\QFO8KRG;.C@E'9&S:^;[%C8TRO5:^B?->:([W5WMFPP5.0
M6DTBM)IRO)1J:"*%5HQ\B;0F:9T-4,B&$:.8?26,4C;,&.5L6#`JV;!B5&N&
M>HK?V9YQ>7M&(5?63A/'>(`OI<9@]E@Q\AD%RG7?>"%K18QB1@G[2EDK8Y0S
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M[2YHZ6+RBOV`#:V&9F(C>Q!&Z\967X,!VVR1)4JK#R)52(O>#"([*XC<ZLL,
MHE!:?1"E0A\&45F#F!H[&;75UR`(K8OAE+76Q52_:KC>KQ3ZFZ)7JG5%KSLS
MZ^)5KZ)F&U^BP2HD8!3VAFUA.IW<&/-=U*LHWS$[2ABEO:'T32^9LEY%^<[9
M4<&H[`VE[_F@/9J>6?4JRG>M.=);[9W=('SAS)P-%!H6O9(-BUY&OD1:D\BM
MG_[M8<B&$:.8?26,4C;,&.5L6#`JV;!B)+ZAUSQIFQMJ4]Q^XZ[]#L[+]O!U
MN]P^/Q\O-OOOKYC=G(E8V7>\_:[?XL:KFV]]&!PMJ+X$:$CP[<#/S?:<P1?X
MUF`3B\E=K[;J3W$!\<PV]#_/O,^X-Q8L9E[=G!4Q#!9SKV[F(Y-?>75S1L+D
MUU[=K+D-CL'FB=;F*V/,>:+168*AYXF&9@F&ER?:FR4899YH=I9@L'FBJ5F"
M0L\3E09+4.]YHN!@"<H^3]0=+$&IYXGR@R6H\=!:-LD"L2VLL2TA65DEF!H]
M,1;Y.I@AO<`JP43IB6'(-BC//5'?L00EN2?*/):@&/=$M<<2U.2>*/I8@M+<
M$[4?2U".>Z($9`EV^9`W6W?&KI$G]H38!GM`B,TFP8X.6MLFP?X,KF.3+!#;
MPAH;ME`\46-S!"M(1*G-$FR8(&J;!/LF7F"58(<6]V/+`39JD6N;!/NUR*A-
M@CU9Y,`FP=8L>KQ-@AU:]&N;!.](X,W6J_!>!-YL$KP>P?BQ2?!*!->Q2?`:
M!.UCDRP0V\(:&_;:T0JVJ+&?CE:P2;"MCE:P2;"[CK%@ETPP?FRQX647;&R2
M&!+Q/H1["%YJH4UM$KS;POBQ2?`^"ZUMD^`0C"<.8?!U<!;&$V<Q6((C,9XX
MDL$2'(/QQ,D,EN#X"YY2-LD"L2VLL>&M)<:/+>H5).)E%%\';R?1<C9)`(EX
M-<4V.+KDB:,O+,%Q)4^<@&$)#BIYXB`,2W!>R1/G85B"8TN>.!;#$AQ5\L3I
M&);@""`DMJ<LCOVAY6P2G/Y#R]DD.`2(]K%)</`/[6.3+!#;PAH;CI=Y2ZL$
M1\H\<0J)[P>'R3QQ&(DE.%/F!5;)TIG"QCJR(!'G3=D;SI?B?FP2'`?%_=CN
M%,=`$;5-@J.?B,`FP0E01&V3X"`H^HY-@L.?Z#LV"<Z`HN_8)(M;KVY.4QIK
M)YRZQWW:>O72P1R&^IIS@^/;N+Y-@J/7R*=-@F/3N$XC&7<AX"<CWM9?M_GZ
M\'7W>KQXWCYBM3MIOL!Q:']=HOW/:?^&53!^.&)_PH]%-'\^X5=`MCA).!%?
MP'O<[T_J/PAWW/VNR/W_`0``__\#`%!+`P04``8`"````"$`'(0:_I4```"I
M````$````'AL+V-A;&-#:&%I;BYX;6P\CD$*`C$0!.^"?PAS=V?UL(@D65#P
M!?J`D!U-()DLF2#Z>^/%2T/14-UZ?N>D7E0E%C:P'T90Q+XLD9\&[K?K[@A*
MFN/%I<)DX$,"L]UNM'?)7X*+K+J!Q4!H;3TAB@^4G0QE)>[-H]3L6L?Z1%DK
MN44"4<L)#^,X8>X"L-JK:N`\@8K]`ZCT2[0:_R/V"P``__\#`%!+`P04``8`
M"````"$`&WAO?L4#``#'#@``$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**``
M`0``````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````"<5]MNVS@0?5]@_\'0
M>R/GLMDBD%6X=K(ID,+9RLT^$C0UMHA0I):DG;A?OR/)=J5F3&S\1I%S.3-S
M9B@FGUY+-=B`==+H471^-HP&H(7)I5Z-HN_SNP\?HX'S7.=<&0VC:`LN^I3^
M_EOR:$T%UDMP`S2AW2@JO*]NXMB)`DKNSO!8X\G2V))[_+2KV"R74L#4B'4)
MVL<7P^%U#*\>=`[YA^I@,&HMWFS\J49S(VI\[FF^K1!PFHRK2DG!/4:9?I7"
M&F>6?G#[*D`E<?<P0709B+65?IL.D[C[F62"*YB@X73)E8,D_KF1W`.OD_;(
MI75ILO$W&Q#>V(&3/S!M%]%@P1W4<$;1AEO)M4=8M5C[T:Q5Y;Q-_S'VV14`
MWB4Q"K2;S;(KVUW+J_3ZLI'`55^RMM`BP8,^QKGT"MQL^<BM)R!?7W8Q-RA:
MQ"V@?149<H/=:H_Y8E]T6VUINL@/,4R,=D;)G'O(V6>NN!;`LC>1'N1[(@QA
M(FD*\%A'U4O-0:'G(//HI^:98V;))J8D,;V1JBP4H)W<`'OX'V'T]3/_;I4)
MIV.9V177\D=#V2;',VRWYHN6S]9ER>VVCC63*RVQTY!C;"R$66M/QOX-!*9G
M+X+D9=@T&L5%G3=2!=$6#9IF<?OO6FZP)>H<US0@5>ZP(]@35VM@7X&[M6V+
M0LJ.G4/:LWM0.4,JL0R-DX*[Z;-MV8<PJKK2I.@7'&<EL#E_!3IS?QF3OTB%
M@^!`I+HQ=S2'A6>SA9*K0.['UG*]VI'M1?J"9=NR*HS&EA#'&%&6TK?TK%.'
MU/58`9R].%%))#/DOF437DG/%4.FB6<V7ED(I+.N3].6=9UK1H]?N,UI\Y]!
MPU)Z]HAM2?J?&*7XPK0<;/+^@,-<.[2**$B5;X#S;"T\3E,DUZ3@=G4DN`P4
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M`P``__\#`%!+`P04``8`"````"$`,L)3<#4!``!``@``$0`(`61O8U!R;W!S
M+V-O<F4N>&UL(*($`2B@``$`````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````E)%?2\,P%,7?!;]#R7N;_IDBI<U`94\.!"<.WV)RMP6;-.1&NWU[TZZK
M$WT1\A+.N;^<>U+-][J)/L&A:DU-LB0E$1C12F6V-7E>+>(;$J'G1O*F-5"3
M`R"9L\N+2MA2M`X>76O!>048!9+!4MB:[+RW):4H=J`Y)L%A@KAIG>8^7-V6
M6B[>^19HGJ;75(/GDGM.>V!L)R(9D5),2/OAF@$@!84&-!B/-$LR^NWUX#3^
M.3`H9TZM_,&&G<:XYVPICN+DWJ.:C%W7)5TQQ`CY,[I>/CP-J\;*]%T)(*SO
MI^'HEZ'*C0)Y>V#[-]=$B+N*_M8J*89TI7#`/<@HO%<>TYV4E^+N?K4@+$^S
MJS@MXBQ?Y6D9SJQXK>C)-<ZS":C'`/\BSLZ()P`;<O_\<_8%``#__P,`4$L!
M`BT`%``&``@````A`!&X+QE(`@``-B8``!,``````````````````````%M#
M;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``
M"P````````````````"!!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`
M^L*;(IT"``#5)0``&@````````````````"G!P``>&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`V,.,7PL%``#M$@``#P``````
M``````````"$"P``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`.O*
M5_`6!0``D1$``!@`````````````````O!```'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+`0(M`!0`!@`(````(0#ZJIF<<0(``(@%```9````````````
M``````@6``!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L!`BT`%``&``@`
M```A`-L[O#R0`P``CPH``!D`````````````````L!@``'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"+0`4``8`"````"$`YCNUT^X"``#(!P``&0``
M``````````````!W'```>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+`0(M
M`!0`!@`(````(0"T01Y>@P(``/L%```9`````````````````)P?``!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L!`BT`%``&``@````A`$^LZ(@Z`P``
M$@D``!D`````````````````5B(``'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"+0`4``8`"````"$`G\E>%@8$``"P#```&0````````````````#'
M)0``>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+`0(M`!0`!@`(````(0"6
MV9H_,@0``"4.```9``````````````````0J``!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L!`BT`%``&``@````A`$&"11=H`@``/`4``!D`````````
M````````;2X``'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"+0`4``8`
M"````"$`=(-Y?0$#``!!"```&0`````````````````,,0``>&PO=V]R:W-H
M965T<R]S:&5E=#0S+GAM;%!+`0(M`!0`!@`(````(0"^<,H*&P0``-T,```8
M`````````````````$0T``!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"
M+0`4``8`"````"$`DFUW)(<#```P"P``&0````````````````"5.```>&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+`0(M`!0`!@`(````(0!O]S/_/@(`
M``X%```9`````````````````%,\``!X;"]W;W)K<VAE971S+W-H965T-#`N
M>&UL4$L!`BT`%``&``@````A`#KPAY6,!0``3!8``!D`````````````````
MR#X``'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"+0`4``8`"````"$`
M'VWF:<`$``#]$0``&0````````````````"+1```>&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+`0(M`!0`!@`(````(0`I=U2J"`8``&<9```9````````
M`````````())``!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L!`BT`%``&
M``@````A`"5[V(&9`@``1@8``!D`````````````````P4\``'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"+0`4``8`"````"$`B_%0RIP"``!I!@``
M&0````````````````"14@``>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M`0(M`!0`!@`(````(0`;G"[1T`0``$P1```9`````````````````&15``!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L!`BT`%``&``@````A`/MBI6V4
M!@``IQL``!,`````````````````:UH``'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"+0`4``8`"````"$`YK@K[J`.````EP``#0`````````````````P80``
M>&PO<W1Y;&5S+GAM;%!+`0(M`!0`!@`(````(0`ZR._*:7P```8+`@`4````
M`````````````/MO``!X;"]S:&%R9613=')I;F=S+GAM;%!+`0(M`!0`!@`(
M````(0"S\!K2;0,``#L*```8`````````````````);L``!X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"+0`4``8`"````"$`D&[[#\D%```A%0``&```
M```````````````Y\```>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!`BT`
M%``&``@````A``]UP.ZZ`@``5P<``!D`````````````````./8``'AL+W=O
M<FMS:&5E=',O<VAE970V,BYX;6Q02P$"+0`4``8`"````"$`.;NV!#D$```7
M#@``&0`````````````````I^0``>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM
M;%!+`0(M`!0`!@`(````(0#[ZV>QA@(``,`%```9`````````````````)G]
M``!X;"]W;W)K<VAE971S+W-H965T-C`N>&UL4$L!`BT`%``&``@````A`$EP
MW:,1`P``-@@``!D`````````````````5@`!`'AL+W=O<FMS:&5E=',O<VAE
M970U-2YX;6Q02P$"+0`4``8`"````"$`$PLW!,X#``#_"P``&0``````````
M``````">`P$`>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+`0(M`!0`!@`(
M````(0`UP$>,904``+03```9`````````````````*,'`0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L!`BT`%``&``@````A`.P\[/GF`@``=P<``!D`
M````````````````/PT!`'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M+0`4``8`"````"$`)MQ-E1D#```@"0``&0````````````````!<$`$`>&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+`0(M`!0`!@`(````(0"U$=.#G`(`
M`#X&```9`````````````````*P3`0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L!`BT`%``&``@````A`.3DX%S3`@``4P<``!D`````````````````
M?Q8!`'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"+0`4``8`"````"$`
MDCSC\D@.``"<1```&0````````````````")&0$`>&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+`0(M`!0`!@`(````(0!ILK8;H@(``*4&```9````````
M``````````@H`0!X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!`BT`%``&
M``@````A`"V6NI8U#```^34``!D`````````````````X2H!`'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"````"$`BH[(!F8+``!7,@``
M&0````````````````!--P$`>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M`0(M`!0`!@`(````(0!]7PTRJ`(``+$&```9`````````````````.I"`0!X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`%``&``@````A`"_*5<J#
M"```:R(``!D`````````````````R44!`'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"+0`4``8`"````"$`Z;JKRV4"``!#!0``&0``````````````
M``"#3@$`>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(M`!0`!@`(````
M(0"[1<HAKAD``)&!```9`````````````````!]1`0!X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L!`BT`%``&``@````A`!"+.Q^3$@``0ED``!D`````
M````````````!&L!`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4
M``8`"````"$`!\4_1'\"``#3!0``&0````````````````#.?0$`>&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+`0(M`!0`!@`(````(0"U#PV5A0(``.8%
M```8`````````````````(2``0!X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"+0`4``8`"````"$`"8-Z+7((``"S)@``&``````````````````_@P$`
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`%``&``@````A`+?DOP$U
M!P``'AP``!@`````````````````YXL!`'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+`0(M`!0`!@`(````(0#9SR</B`(``!`&```8````````````````
M`%*3`0!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4``8`"````"$`
MGMJCAJ`.``!`2@``&``````````````````0E@$`>&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L!`BT`%``&``@````A`)3_1_!_!@``NQ<``!D`````````
M````````YJ0!`'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"+0`4``8`
M"````"$`3X&QA:D"``"A!@``&0````````````````"<JP$`>&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0#QU=\7%!H``%J)```9
M`````````````````'RN`0!X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M`BT`%``&``@````A`,O0M<CY"@``IRX``!D`````````````````Q\@!`'AL
M+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"+0`4``8`"````"$`M/?@GUT)
M``!M)@``&0````````````````#WTP$`>&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;%!+`0(M`!0`!@`(````(0#P3L#F-`8``$L6```9````````````````
M`(O=`0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!`BT`%``&``@````A
M`+YEYNT.!0``U!```!D`````````````````]N,!`'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"+0`4``8`"````"$`IM00-G<2``#=4@``&0``````
M```````````[Z0$`>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`
M!@`(````(0#]1B%P@@(``,\%```9`````````````````.G[`0!X;"]W;W)K
M<VAE971S+W-H965T,C`N>&UL4$L!`BT`%``&``@````A`'",`N_Y%0``7F@`
M`!D`````````````````HOX!`'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"+0`4``8`"````"$`V+6FLM`&```H&@``&0````````````````#2%`(`
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0!>)/_J
M;`(``(,%```9`````````````````-D;`@!X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L!`BT`%``&``@````A`(XKZ.K_`P``A`T``!D`````````````
M````?!X"`'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"+0`4``8`"```
M`"$`@MHO>B01``#'4```&0````````````````"R(@(`>&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+`0(M`!0`!@`(````(0`4FT.H>@8``)P9```9````
M``````````````TT`@!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!`BT`
M%``&``@````A`)&Q05]X`@``Q@4``!D`````````````````OCH"`'AL+W=O
M<FMS:&5E=',O<VAE970R-"YX;6Q02P$"+0`4``8`"````"$`ENG(#D(.``"<
M1```&0````````````````!M/0(`>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+`0(M`!0`!@`(````(0`<A!K^E0```*D````0`````````````````.9+
M`@!X;"]C86QC0VAA:6XN>&UL4$L!`BT`%``&``@````A`!MX;W[%`P``QPX`
M`!``````````````````J4P"`&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`
M"````"$`,L)3<#4!``!``@``$0````````````````"D40(`9&]C4')O<',O
>8V]R92YX;6Q02P4&`````$D`20#H$P``$%0"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3KAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Other Capital Stock Agreements (Details) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Nov. 30, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">55,608,930</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">17,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OfferingPricePerShare', window );">Offering Price Per Share</a></td>
        <td class="nump"><a title="lxrx_OfferingPricePerShare" onclick="toggleNextSibling(this);">$ 1.005</a><span style="display:none;white-space:normal;text-align:left;">lxrx_OfferingPricePerShare</span><span></span></td>
        <td class="nump"><a title="lxrx_OfferingPricePerShare" onclick="toggleNextSibling(this);">$ 2.25</a><span style="display:none;white-space:normal;text-align:left;">lxrx_OfferingPricePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_NetProceedsFromStockOffering', window );">Net Proceeds From Stock Offering</a></td>
        <td class="nump"><a title="lxrx_NetProceedsFromStockOffering" onclick="toggleNextSibling(this);">$ 201.9</a><span style="display:none;white-space:normal;text-align:left;">lxrx_NetProceedsFromStockOffering</span><span></span></td>
        <td class="nump"><a title="lxrx_NetProceedsFromStockOffering" onclick="toggleNextSibling(this);">$ 37.1</a><span style="display:none;white-space:normal;text-align:left;">lxrx_NetProceedsFromStockOffering</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Payments of Underwriting Discounts and Commissions</a></td>
        <td class="nump"><a title="lxrx_PaymentsOfUnderwritingDiscountsAndCommissions" onclick="toggleNextSibling(this);">3.4</a><span style="display:none;white-space:normal;text-align:left;">lxrx_PaymentsOfUnderwritingDiscountsAndCommissions</span><span></span></td>
        <td class="nump"><a title="lxrx_PaymentsOfUnderwritingDiscountsAndCommissions" onclick="toggleNextSibling(this);">2.0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_PaymentsOfUnderwritingDiscountsAndCommissions</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">$ 0.6</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">$ 0.2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockIssuedDuringPeriodToInvusShares', window );">Stock Issued During Period to Invus, Shares</a></td>
        <td class="nump"><a title="lxrx_StockIssuedDuringPeriodToInvusShares" onclick="toggleNextSibling(this);">149,253,731</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockIssuedDuringPeriodToInvusShares</span><span></span></td>
        <td class="nump"><a title="lxrx_StockIssuedDuringPeriodToInvusShares" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockIssuedDuringPeriodToInvusShares</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_NetProceedsFromStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net proceeds from stock offerings, after deducting fees and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_NetProceedsFromStockOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OfferingPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lexicon completed the public offering and sale of shares of its common stock. This represents the price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_OfferingPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PaymentsOfUnderwritingDiscountsAndCommissions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for costs incurred related to underwriting discounts and commissions incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_PaymentsOfUnderwritingDiscountsAndCommissions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockIssuedDuringPeriodToInvusShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period to Invus, L.P. and its affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_StockIssuedDuringPeriodToInvusShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001062822-15-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-15-000013-xbrl.zip
M4$L#!!0````(`&"";$:_-$3]R"0!`!AH$``1`!P`;'AR>"TR,#$T,3(S,2YX
M;6Q55`D``[/T`56S]`%5=7@+``$$)0X```0Y`0``[%WO<]LVTOY\[\S[/_CU
MYW.,GP29:7,#$F2K:1([=G*]?KJA*=CF5")U))78]]>_"TJD*(F2)55.))MM
M)U4$D'B>W<5B=P%2/_WC83@X^:JS/$Z3GT_Q&W1ZHI,H[<?)W<^G7Z[/Y+77
MZYW^X]W__L]/_W=V]B_WZOV)2J/Q4"?%B9?IL-#]DV]Q<7_R>U_G?Y[<9NGP
MY/<T^S/^&O[]Y#;-ACH;/)[\KF^">`#WS,_.IK<:O;WA#$<WH78<X<`G;*,;
MV^Z+FYN^%IB$^.\/;TE$A-:,,.'8K(^B&]MB`H<6"ZVPSR-G<K>'FVP0OS5_
MG@";)'\;I>.DR!Y_/KTOBM';\W/3]";7T9N[].OYM/&<($S/$#ZC^+2Z;)QE
M0'[5==-6<R&;O["OX_9KH*&ENWZ([MO[FY:6"^+DJ\Z+]DLF;2ULXCQE!(OZ
MJF_?OKTIKTRS.^B.Z/FT1W4!Z.?/-;U-\TV8Z[K[0_8PUWV@'T;W838,WT3I
ML&2!R0Q.$L91WDZA;#(7X'D&29HDXV$[I'Z1G1>/(WT.G<Z@E\[BJ+[NZ8OF
M+\CT[4KBUCFT5AWS.&JG``TM!/)BE*WH#RTM%XSSL[LP'-77W(;Y30EDVM!B
M&]"2I0.=MUY3MK1?9.30?E'9TG91D>F[E7)RSJ&]ZFH:^@MSHI;GI'&N:]':
ME4^Z%LVN\3I[3O(B3*+:0A^6+/H;+7MCQW'.R]:Z:]YOZPBWQ>?_^O#^.KK7
MPW#6.7ZZ\UF-!ES4WWXR@[W-RY8K?7M2#O[VOC0\,Y'.JNGR!I"<3IN-(GX^
MS>/A:`"<SLO[3'Q=E":%?BA.8D`=*'/M)_;'9U4.5?4!#QT7C^4WU5=QWWQY
M&^OLI(2BYVA4MNGU?CM]AX`,LHA-R$_GBQ=/1CE?&F8ZR@BF5MJ?&Q@DD14*
M%HMWE5DA7-U@UM:\0B?]67],P`QG`_;KWM5WLR&K;Z826B&S'MR6?\+7X*YT
M?C$NC*;,DG>P`IP84V'$P<\0>'JGONNTY:^((^B5)D2.@3Y8CW5&T=[ITT_L
M&.C3^<FP1^T?!7WV3/1!^_^>KK'_OB[`O9@`U__/&,!YZ7"4)O#77#[$>=T+
MOAZFR7611G]^T,,;G7U/\=5^5=\9H)/O)E_V8?"'T2".XF*"ZZ0?0Y])?#\%
M_W8MQ=-W5;<ECC^=MPXQQ72^#.H`S;S3\P'I^3GFLYK,YZ.)A^B6\1#=?SQ4
MRHP<D<S(EC(CSR2S2=R]I4N1_7Y<P#P-!Y=AW.\E7CB*BW#P8MW+6K[/ZVH.
M+?%H3+3.:([":`[%T]!=C.9*%V&<Z+X?9HFIOKY8:VDG^AW-Y%`6\9W,I(MQ
M7X=Q[!2M?,YTF(^SQY=M'BTLN\ADP\@DBL;#\<!L!5X4]SHSW3)];Q3Q5?>2
M*!WJ%VLV&W-_91%+;V),78Q[J#%NHP9#GK4&TYG`H9K`088H.ZU`7?SZ\E>4
MG8VCRX%?DYE,`X^#K6)_AW5WMYIT%\0?5!!_"!GA;D%\YV]?8=C>%8E>3XB^
MT_K2>877M'+LGOYW8<A!A2&'XG-VRORZ1>GUY'S;'^#LK.-8#W%NGY-TNC[&
M;,3H&G<'=G]\,;BA9WQ(1:M.U2\_E=CMU'Z7;GX?=_!<S^-LK_%NX_A'G!TX
MG.>Q.OW_"/T?SG-:7>7HAU>.#G)=Z%*_8]7U]JE?YP,.R0<\1ZJX8VS0V<4!
MV<7AE`6[^L$QE@2WG_]=->"X9_;VD4`7]1WKZK[#4R/=ZGY`J_OA;`1U7O^X
M/<$.^5]7`_P!-<!GU/\Q'.-_KAW1A?-S\EN8]3\_CO2<Q9<K_\7(&,'Q6?D<
MI9E5+W'ZCCN>!WK>K5/^:SG+UG(6HE/^:SOK,'FG][][Y?\,M_FJ59C?'X_*
M)US>SG-IE*=J,D>_7[&!YG1F)!J!H>07MTJ/TKRB^1)4N9K=*]#M[.LC2C2?
MT.@2IU>@QR_7=55-1^,,\BO]<A2ZFMPKT.SU?9H5GW4V?(E3=36YH]<L[7SO
MB]C%>5J/W0Q]J9KM<I9CU5P7#[U4S7;9Z#'KMM)B$,;9/\/!6+N/]<=?0;9A
M%MT_OM=?]6!.Z76?7C(:%WG9@1Z/TBOM;L9Z9@UK:'?6,"\6_#JM`7?6X.=%
M/`1_>7%;]ZX_J#B/!BFLE$=XEF9;\]A&#J_97MJF$7GYYK&&]M%;`^N\QXOT
M'M_C>:PN$CV62/1(K*%;2SIKZ/*2%V@-EUD*]R@>+P=P:YGTS2G7D4'N/BZ=
M<WH?)OWCT_P&#&=JGU$\>BW3';5L3CB/"YW5?5ZXRE?P/?K\85?]N^-X8'Z`
M';I5'WO#499^U4>V";B3-6S$_M7:1K<"O`8M!^,LB0O(C*%?$#^83R]]VJ^F
M?/16L&NTUUG!C[""0XL&W^LPU_?IH)]#Q_HOKR@@V%0`K]9/=/G"R_`0.U<%
M.@]Q8![BT"RDRR@/)Z,\--MX+:O&2ULM=HTG.WT?770(ZD;X$[U61_`*"//@
ML``1[)D_1D?"'R/#GZ)]\E<@5O:)'##_YM/CB)V9_S9^>GS2?R:Q?3P]/GUS
MP)%(S*P1VSYOC_<L,>-CQ$';6,/'B#-DG6&^;Q]#CL7'D&?Q,6;&*!T=[HN&
M%N<,B(%M,V>:_??H92ZB`A<I_$GQT8@.;>ENT)Y?[S%]K\\!3[>%M^%L)S&R
M?XEM_AXL?S@:I(]:O\2WXJSD]KSQ_<&]%VLQ`^PLX3M9PC/O`VS\OK-.M2__
M_6>+9;W.$K[_)'^.\MW&[[7K5/LZWG.'NTG^0R?Y]WA_>Z?7[Z_7[_&K&^UZ
MO=)YD<51H?LE^R])7.17UU]>C&[7\COZ"'RCQ;E3\>M:I)^.Q#N+.-*(W&RP
M\8,N_L]ML'%3_M]B@ZWL_RSOYL:?/A^'S';P(H@^T_O,CTAF6^\3/-,[X.D1
MR6RKN6GZ.WO>RIWN%!S/W-R^H/X\<Y,>D9W1+>V,/I.=L4_D:&2VY<$4T]]Z
MGKEY/&L`W7(->*X?@:%'9&=T2SNC^[&S,<3CI<#&>7].4,/RM9[Z79RGC&#Q
M]LNUJNY2-35N;&[3=M?\/LQTWGKC*<^RPPYW!KR7.KLVE\_=OA]_!9W,2<U<
M\W$\U%E8I%DSK]F4Y=_FT"S<JC&(TDDZC)/5PSS!>7Z<Q;M5;3.&3\D(4,;I
M&N&/X.,.HM?C;*VI^%^N-KEK7\=O)61V?9/=!8/P[F1JGE?Z=JZF<CJ9T6%4
MG#$F,6;()JYR/825YUM289L(;/DVLN3IN]MPD`.II9O70WKC+#/?Q7D4#O[0
M8>9/ILX&HTMJ2>Y2WV.($\NS7*&\R>C"1TB)TW=GE2=;-U(-1:71>%CWN"RG
M:P#?Y1M@H=0B3$EB>Y:45N!)Y#L5%A<QY_1=\,<$QLI15N`P2#=%X4D2$!LQ
MY`FD")6N[WL^!FWP@"C;1J?EDMB&HQYE"<4$X>9:"1RN`N$Z%NC%<6Q!D*`^
M%YPBY`94J=.Y-&/E2$LX3"UC@^&%#)3%?!\%'(P?V\SU<*6(`%F@"%@,?YL?
MV-RZ'L\OUPH/OL["02_IZX??].,&`Q/J2L2I`Z-1"R!P:HEJ8$ZD-[]<K1QI
M$<?LYZY+YYI?C`M3+#%/P,R!,N4M_@DO=3H]Z>LH'L(T_/D4->""95B(*DO9
M`A//L9EP:077DY8X/3&>H;QUM6H(PC'0PG0._AJ`BUPF$_!*C]*L@.;K(BPV
M,FM&'9=[#J8<1,D"C&POJ-V,4M;INS^,`W]JI`4X03S0F0>F=I=FFRC8EL1W
M?(YLYG!.J>U3,7-VKL].W\DHT@.S&.G^27GW)J:YX1:@7(YO!G$4#-*PF`<R
M*5J254H4MF4'+N-,2N4013!BM;&[#G4;2BP#"FK9J/RG":PQ^`*L*WT7YV"<
M2?$Q'&[DD25EKD\EI:[R&',$PK+"8V,7YOY[_U\][^+CR>6O\NJ#]/POGWN>
M?'_]]Y/>1^_-N?*;P.:'7\#VSW0P3B`JF\AU$RL*.%;<LAV'@7^V8=5R_:"V
M>";`,WQ,F\,OC+`P_N]Z,/@M2;\EU["FIHGN]_)\##'K!HX"40P^DDKPCCYR
M&&HH#5'+7\2Q8J02S^`A>VC^:++2HPPLQ00:R96.!F&>FVBX_SG]50]@F<FN
MPX%N,S'6-+$SWM0I.$WENLR%26=QXGNVQ(IRGV+/LIQ`+-E8;6([@9O1JA[T
MR[UT8*X')[D=<NQCSBV.L*>01S!A+LR1RAI=@A:1<P<WD;>,WP)N3U*V)<QD
M0$@D<I#CVHHX,(4HP0H^4M_9%.L&<O7NP^1.]Y+Z[6P7M]>/P]%]FCSV`',O
MB2['670?YOI]'-[$`S#!9:LF4ZMNT*$-.IP16'X)^&:%`\D84Z)>#!$3?)&.
M8]MBQF8'A'NF1]?3`X-2EDL9@RF`P<`LK/P)/0YSQ*>+],X(P>B0^+'U_)BD
M$+%PAU'B@R9=:H-#GZJ/<+EDC9@1>U_T4CT((_#Y][^D:?];/!@LACG3Y^A6
MS22(%2R?(5>JP,3B@<=<5.E&>@Y;Q$ZXW9Q)R^.W8:L(7&9QI+<$Z#J>0SSJ
MB0!#!B.$8P=6%4>XQ/:7%VW4#G`.1!-E\M7\6,3-0"M]4_026$/+,+<'*"%`
M*Z[`F9F(2)N4/8*&\.YI;\7FP@YLP;+E8LLACH.0]"53+E..8!2Y5E/$TYP7
MO8$4C=<,=@`XXZ?TK8;PKO\Y?*CMYTJ7*\SG5$;_&<=Y^2OB\U:W3)`NN./F
M!*`XX$X`,]S!GN>#V4N75SJ"1,9;FN#8%HS/E+0;QOUS7%QRFAP%4UP**;&T
M`]NFV&4(5QQ][EDM'"VQ3XXQ1`-%FN4R2<;A8'*ZZ!<3[CW)HQD#4P\P^TZ`
MO8`SS(5)^JKYSKTY556)#&E,I]4H5B)=V$,O=]I+/[<5;I@HW!6.([BE?.H%
M5'JUCX6%?\D-K`&]$E`+!9AC\5\0-I=$@JWX%JP(@CC8#VAE,UB1H$78M`WW
M$HHFTNJ=XA?)+SJ]R\+1?1Q)\[M&5_JK3L8ZR-*A_P"N(@D'WC@OTB&$Y[(`
M$=R,2^.;Q,T0MT'\GCU>W*IT&$<0Q$^]R2;1#)D+9L#A"1PHVS-)#?(Q<6MG
MX&*Z[.[PFP;EYZ;S8T6W'"DU11>0P*(N&`P.'"O@!`3):M%ABEZUZ):#L*;H
M?`@KA;"1AWUE<0B?%4:5Z#BAI'61M8Y1=$4:@`N(UA08VB4D+6))KER?*04)
MG>/9')(E3"2',,]V1)N$'+8O"56H9X*8INMQ7T_OH/3`A"[)JC#K:==C44<@
M!UN6=*FI'7I<H)GKD4$;Q3K.V@#/&O"]4;X>^7KE@&8L183G!K82/JA$(03*
M$9XDV.&HQ6DVE/,4F#6P/T0?(>WXH/MQ9(JJ.32#MM;Q6._!((&@3#@*,@DG
MX#Y'\.\L2L)N&P\N5O%X"MT:8I]#0!Y'09@-\]T-2@K+D=QV`V1!@D>8)[TZ
MZ+.%UVI0EKV*3CNF/9!8KQ.8$A+L2+D*$B9?V1!$U?5@#U;D-A*4[DKBU[0J
M`R63N0\QR^=T*=Z>O7VA&7!;S7J4]!@2OD,(+(D.%I!`S;)J,1<\E1%?F5#,
M@J?5.&98RWGR(7R(A^/AE;XS=;<T>Y1)WY3I@1L$71_`AX,S2_1\S;3E0?A5
M/`+";&)3Q[,(P8IC)!%5'K6(\HCBP7+5&<WQV`IC.S53T,K_.A$A)+'!CG`@
M+02I-S8KB4>%[0J)7=),'<I-5D%6$EE`M`![:FER,$C-#SC"VF&XQD6AC4^.
M(1L.;Q8JAD_0:!84/`M+"=%X6>]`=H!A300:BE+!?<]72]6:)1*;X7N2E#(_
M\)"6;VS:`RT&`:+K^-S'3KE7Y2-AM.,J9HR/VDNTK`UXM4-\DMG[&-Q"O@]E
M008M"*=*^H['B$4)HQZP<BABG#(DE](^3#:@M8ROG=*5CM*[)/ZO[F]4$VP"
M1\HW2&Q,!<P4Y5J^D@:XBRS!YHL^4^!L%?`9B@647T:W&<"Z#!^'BQ'S%M/:
M<6WB>6`N-O-]!7)UJ`2\MN]"S@'Q]!)2NCRMYY',8)HWF^^Z'X&8Q2W/]GT7
M.99P?$E9O1]!N5@J*A'1A#4_\CRB/6U"(!\<(1,NP;[P?,=E7&"S">%(YA*+
M+0MN">`&VP_O]4,,J"[#N%^O:&%^O[29C=864:6R,*R9KD=MZF-J8YO[50B`
ME%A:2_'\&K0"Q!)*X*-A1O5-H\D'JLY;KOQNH#Q7(>RYOB\4MRVOVB\0/G/8
MTG8(YFUH5X%90GT-#9/->-#!QHB;=1Z;24RXE.!\&;.(#UF\76^=,2);ZCS"
MXI"@D'G(;4@:<&-88RZ2:8?[L/@0/KJZW-[L7Q3W.H/ODL:CA_D%V%*6F]<"
M%H^]Q$1J(`_S*L'M*F^VH[!4S+4I)0IY'/.:G.>YJ(7<HD+V!GPFC(^ZN,S2
M2.M^;I0[N?KV5F>+)SUF[]U9N</@2^E9"E3&_``Q&6#%*H*.$DO;-U3,A03K
MD.R(EZW%"RLBL1W;@W01LD;;]9@-T0M$9P"6>BU+"\+.]H"K;\KMDNJPXM.2
M;28>A("5*Y@.)NQU81Z[M#YQ%@3!@F!G!R+)+"EO1;$MR"5QSNV]@C!MFR'J
M"&9#A.M*I$":%@@S0)3152!-Y6U3E%.KGAWU^:MSTE=NX"`6,,8YD3[V.:M/
MCEBVY&U5?`BC('RJ/,Y&F-91^)@FU>/.=9WZK]*"7,^WO2!P.;60V=\#RZUH
M">*Y;:X&B89I[PQSQG0:P^07MU^2OLZ^9;$Y$F7J7Z:TET\3KS@WSP\NIU)/
M>!K&S0F?P',X":0M7>37^_R$XJ6-\/D$:BMD^R*TWA7YEAMP(2D0X1;WA(4L
M&R:/C2W'YI:U%`)1M@=""_LW<_NZLJI)7-Q.]](;)^ZV+<HICTL/FP,FGI+`
M$`)06>^-^Z*E'(_>V)5/V!GE2J+ETZ=[=")8"H8\XMHXP,2S(0GFJMZ=$J)M
M*]!L0D!:WTYQ`WP+W,91,39^TTOSXEJ;5`PZF[^L.:"VPA(ML_/,;%^I0%#+
MABB<@P<G$O`&Q!5+V[.<-BWQ"30K8)<1?+F#6_8R?P!;<YC2I,[P_2\Z,=D'
M])/]89R4Q_.,*+9FYPH%61`5BCBP,H&/=*4+[#R;NSXD;$LU"[&2W,Z8=Y4!
M]-;F%R^A8Z.:L+4$E`UJ#1QE^99#`XLX`<Q%D,#_LW=MS6W>2/:_S/NF`#2Z
M`>S#5.$ZXZW,)I5H-K6/LDT[FI5%E2AYX_WUVZ!$\(*/5Y&2'.DA54E$B=T'
MP.ENH"_2"Z52GZ>BW>$0#(M\*`#3L_&>CWYEL^O1U62:T;<W`)IC'Z$3<&0$
M3DGTTM8-GK20,BK5`2`/UW]8XD7]OUY43J[W0RVIP4\FHP/.K;,"@_5".Y1D
M<P2(HN6!!]=%^1+LLF)K19G+.W7'PJH^_N:F)E[==U.??^3!*$VS`F8,-LNX
MF;1HY<'1X'#]T^B"D7QW=9^._]OHXO/O_-^^TL?G^>CO=;@\JK_".K?;JQ(3
M1>.D9X,,7KOF'')H:M=[M&[F';X`Q(ZP?.UO\8:X^W+__?F/ZU'%,TWKD/@D
M\'Z?.8@#NW>GSH1]*Z,U%C>`=-[JY*(/@-ZZ'%M.?+VQ'7`H'KL@>V/P,G#?
MJ>WKSK@KBZ)PB.>C*\5K!5C2[$0DN60^7SGN.['2SK@GFT($3]YG)0.S$%![
M/N78=>CY],^,^T^?/K'S7]/0/@Z%I:=F'V55PNRTD<G5NSLJ@+-PAKVIH3S4
MIUJ-+<B\Y#4Z+E.)8K32-6=0&PV`E'VS$-Z8H32FMS7:ND;'935002A-)62%
M?&QT00NS<P0"_:M=H[/1S9<3^%+SQV#BX,`&G4,D6SCP<ZK,@*\%?7_YZ\_X
MWZ>$>DG!YP7S4-I9R`J*)DC(-F")-D'1,;:B'"?5:P+S4'Z87Z5!SDEC]HD4
M9FN-A7F*E1/(8.H_%9A/YLK,+:,BH=%6AQUY>UJEYY7J*(1AB.W)(7Y^?GTR
M_V3AN=&2#(H@B&2]TL@>?7N-U[F\`7]<IV/A^92,EL@\[35*&RD9-R.5%'UX
M!<#_U_B2_\RT5.IYXJ>E9&`+O@#SN74<1DFK0;72*0]JZ!;A!RM/N4![P?.R
ME^KQ891:>MK*2KN0E"1M(PJ#RC1[3-&]+=4CENKQT=12Y0/;=!F]BXKY#;Q"
M'5N?">DR#B[520.JE[147YLL-Z>^J%Y<%"&--U9XM$HX);03R<RH3AJ(0XOB
MX)2+L@:(EP+_<>E+89"(Z$SRUC@?92CMAB$J&*RB:8D'KQ'^XU*2SU'&E`(R
M+6E=4BZVI>E(E88N>'X@^O/`_\O%Y'_*S6BTV&!@]IVG8)[%=+R,);CB=)&Z
M$$0?->G&/&L*X82PIP!_$PPO`OG'D\XB\K[6B2`Y[6S*63ACJ+4XDV0&24<(
M]RJ1?SS?+/6/4;)V-6&63Z2"%=*:]CSIPU)O@SGR\M%O]2\8^6>(]&#))_6I
M%$E""_['D`+M9B2DO!HF(7D2`WP`.B]YG8Y+652[B&8O(,0`!9/SU!(T#<7!
MDG8A3V*I_V3K=%R"\W69G)`N&`X?C-1&MCP`R'XP'!?J)/'$\ZS3%*DPOKJK
MW[&2U#5MZ#*9I4/M4J&^^!A)B2*"]-$YLE(Y$;&U/(C>I($D7J?EXXW'[AH]
M,WQ];?PB?%@J@+5&19>Z04'[>?];)=0`?%;8Q_N;WPU\??KFTN[SR7%P1-DC
MZ1)]\EDEQBXFD-'14`JY%`KIT?<W+Q2_E63&Z0]K1NV&/-#-#2@DD2`Y??:.
MSAMD=[#=CJ$+:TNHY`_F"3'>JO9+7X3-#330J%B;")6".1I'J$IS!X-W?D-"
M[1,2Q7>_")N+<;2-)2K+/&.4CV!S;=)>.Y:KDODG>OTBX*,=OM,M0I=EOR#-
M^V_SCPQ+<]Y)4UM17$WN+NN`N,F]:!<'<GL(3#Q&V(2V9C4!'P%BP'V`J(/)
M-,#M:+18HITG5._Y@#WZ5B\%HK<Q:_9+%!-_AB(8^<!N7NVWDM9O=7HN]/?=
M]Y/[ZN^?[VXF=_S1L_%04\;)26I,7;2@(`8KM'(F9$RJY3UI'"IG5\;HY2>G
MHXJ_)S33(I#'H@!*Z@!6$SG,3*`<0+>W;".*'$`!E-(`;A\8UHFZ3>,%OIT"
M^5AM?0PRU_P)FX(C8XM0K:&$M66P/X,S1FQ>\QVD'%:4?_6AQ6L:32X^7XU&
MDYV=P^7&TU3J?2V9@MXQ2^O:_5!F"K6AG[9=/3$L]V781:;C:+!P9<"D4,GF
M'JQ*3N.K42WV7;Q86.B"/ZT?JA^[&?U>A[9^Y<C]P_C+J+]P6$+&%8$BU"9T
M14F12G(U(8^1P:R=Z;M&OWQ(/GZ<M@<^OZQ=6-Y=Q?/KB]OSRRTPQ.@RJ0(E
ML/)>2ST=PL$PL`M5WU;Z^FRWV%G^Q:*Q4"Z]!0$,UDH4RGB7E0'A=.TBQP@(
M6[)(786ZA.]`_5]&M^<75Z./^?SFJO:(V8*!%<*G0MYCLNPI*Q_,_6'0J$B*
MKC;ZQ>M_=C.=S/5MEPT0K74@O(-IX)Q`85UV5MY8[T7?W>4IE=\R-T&3@X".
MM[`B7>M_4YIW^8C4S1)Y2M&WC$2(H009BXNU1%LEF\BQ?Y$-1V](8K7U2XT<
M\(D-DWX>PZ29A^L<&(/LRZ?B2&"9`B,@N""[*2LO'Y*##%.N#8L8BI"MYJ"1
M8WFJM,RH"(\*^V$S2_,"7BP8N]LEE8N)(2D2"4O1,0>,4P!,H;"<H7@/P'>@
M_9YF"3$'B1!\G;Q'2?ALY12"%`*'NUV;MQ>O_SYFJ2A`-D:"`U&1*"-,NZHQ
M#RA2WI7.,WN\\K?]I^]__.0^F9/>,`7ZY`*&POY8$G7OD\]L*$H:?#7@D-T.
M'X&U>CT:AA-3@">+$J-@S4N(O`ERT=/]3TK6$1T#,'"\OL8_W06%:;RZ>B=4
M4\RN)O6)=%R'C8T^_G9Q^_M#$QB_V@3FX<-[!ZHFD$.R)AKI(7I?=%:M\0'V
M[D"=^KB@Y]$$?QHPMKAUD)`B.L?*AQ@X(G74WAS9(/0CXL22[?O.P-CB**:$
MZ-'6B6:I"-[U*K3W:YVAO\(0)%\,&+-&07ZI4="AAZ1XM@4VL#>4=&2G'QS-
M"ZUBZ#HX`QDX"(J-8C\%$-L.B#?*.'0<K*+(*K-Y;'M"V=1U3-=@Z/L$8LOA
M(,W!:B'RM6=YJO&?;:^_P0\`(1;''IT(B'M[DZ:MI.XO_\_&[ZZ^W@V9T<&6
MB&+I@JIH$[-EUP^`K-514NN(J,M0(\OE]M.[B/1(!;H6B(L*:'9=23-K*Y$]
M%&>P^G7&J%KW"VYH,+#43B$8D(>K<)]TE?^H_?]/T?DP!A#LC!104@JE(ONE
MC8JBR@.M0A8&$1TDX:""D]GO?WQT$V/@:,MH(""R)(BR:0J!7;H(;8^9UDH[
M3^K<4:HM>ASK16N))J1C1](!*85.%(%>A58H*I*W`\H-K-7>0BZH>N]Z+DRP
MK+0S[=]Y55MZCEIK^*ZQ]I;&Y11!"P`-K(8F6S)[",U70NK:PVE<&FNPAV"=
M-M_J1Q]^.NM)^LOJ4/=!#19/$@3MA>05XL#&9Z'JV*76TC;KP5H2J9?%7R?)
M1I'?70W0V;LI'\-Z.G/1E6A,(1N3RXK#DMR:[AN3A]X%:VAF>/^MEWDFRD9Y
M?WI_>?&Y;XTX*/%*.^Q`L91<AQF"]76GM)8YH93N=GOU$6R3*+W$W<8Y?&L8
MC@`X+JJ=L=GV@6.Y6]_Q1$B#6\.NB+U1GAW$KQ=V*^,$'LQ#&GU8/_L@I3K<
M$I7,!15R^,J23V>8Y]J[:#4OK9+I$.9KI-E![(<Y,CNPR>)@`<6!MHW3:<L>
M-"%":/VE?1&=U'IXJZR39@>YUTQQVKI7A)6.936HC7$1B=I[/6]R9P9I!+?*
M/32_:>V'S\:W*R,\=MDH;&8S%#*Z7G461Y$YG#>*S>QA)-5/<9(/LP.VB3Z5
M9@>I+X9H<(W@2\V1C2L9=1*:,O.)RH$!K\5HVMI0!FVJ)E+&;I7\8BT;UN%4
MZ\8X;QOPX7D?R"RT*R$4/FPQM]9(R@Z,S+!F".9%"7KYYG1>O8;I5(=APMZX
ME550HBCE?=2^5CJ5%!I?.U@S(FY5T'6B]$(OS,RZOKX9?ZWO%/V\G.W<$0J!
M<"[4KK2*5+12M*)0;63??W>8.]:*LY/D[;Q.-=[3W##:Q2M30LV*L(#%MCNX
M.J5V)]RWRK2+&K^,/MY]J*MU*!OR@:R9N)%BG<(G#6EH;&BS&QSVN8,J`W+-
MU3E[][=_//`\Q\7349AGO]^,[SYS\'P]OIEVKE]U`788(:3JU:^V24NC4#-1
MM@D9F4]H/WU]<4_M*-*"#A>?OZS\PG[R\ME-(&W(7F$LE@A5"]<%Z.Y"0NJE
M<5P#W[\L'`/_'^/WLWS$+]6/V2O,*V"*S\3!-ZED/5.X:`8^0.AH4.D6X*WY
M^@7YJL6YI^Z5&3:/#4X1R9B@#:7(0EOOO:!6[@\I#P6GRP.:]I)M%Y5.D7FI
MF#"+#^SRVJRL8WOEYNW[C!R,+7`W+?>.6,_^R+4`[/J&X]UR=_5QFL&WZB,(
MW&AS8XXH2\R4@71(M?ZJ601D-W-+X#$HPA8)S\9GHS_.)_[+/Z_JY+H)*_CK
MM\GMZ,N>HE-QDETR[7PQ(O%Y5K'Q#GC?/4'('41?*]M<I]_8M:B3!:;3PVJZ
M0">V[@:#+8=Z10`D#O(MATM!*.6H39?5HG,FE5@*.[JO'Y#L'\R;GU<-TG;)
MJ,XG8$]&A!"<+9C$?,8J>P[]D$\M!B6;??U4LH<GQ7_W'^X'HC`QU5F%L;;J
M'R)&V'!')'R='6`S&.V%XZ4O\RE>B<_?JH`<F]X_.FT6XB`Y-]UE91`<XD1#
MQ425''@.=5IZ=K)=-"]!D#Y4T/L1<?53_SFZ/0A6X'B7,$8=T&GPZ'U.,W%K
MTF$WF,.)06&')'F$R)L0]H:]I5K:'D01OLYZ\:UHND`>&"0!PSMA%YEOF)Q_
MO#A_7WN77(PF!V&<B@D@,U@'SOE(/L>V=>M8S0YC,MV.&);C4&DWP2L0G>0S
MQD3*AQ]%"MC@E=#O""FDZO;$;N+.4M'2Z)IMWL4T`.)_OQQ-:SV8EK]4)_#_
MIO__YYOQ]>CF]ELU@[?\LVH=!R:Q;%L+7WQ$#MY5P2RC#!9SJYY`T?.<E4YW
MN^<H<C\1&)N6.F5T#(,4,:I21PUQ.-*:=8?2)9D#J7YGGA2,=4F*/XXG$SZT
M/WTZ._]C3\*+0$32H('HM67/)\\GHLO4>0YJG;Z[B'9<M38MI5(P]4Q]8E6"
MULK&UC`0BNR6\M\>\G".HMAP!N5^Z\)1L#6H./Y)M3RU:-#SCH>&NJM-R4LH
MA5U68EB0PX3=A+;SR/;'.!.]`AE"1-^\)2>Q#R.9^YTS!PC[K[O)[?1YYVR\
MYA>&*^5^&?'18A=V].OHYNO]4,>+\<>'2<SU`P<6[$B)I)REK.NT8`P8VTM=
MQ-Q5(Y!V*^QY8HU>!'Q/GY3MI/3,X\S/%!696BXQ6Q83>N?X;4%.D1*NV6@Z
MS:Z%BJ;P0;'S)PY!O@ONWL[&4;-1BV""S4+P,<B1'3P#KAEVCL2&LK'?@#]:
M+GR,AJD'C)#)@M;`[E7SJ[/M$V3?T#]:)KZ.+EHB&VTPTI>24VEC4+,(70;J
MZX%^2YIFM)"]L`"1#*+WSH;&&$&8CK"-5O(U$38\CS.C9!)1%&^$">Q=UN$N
MK;0?;.Y2IMX6Y`3.#`FK5%T"`3D6CB9M"K.S0;J_&G@[&T=U9@0D#H$S"8RY
M0,HED)T_-4%W"?<&_#&=F:`E%"\`R*$"K<!!;I<I1KYB9^8@]/=Q9JPM"NJ<
MTYK?XX*QTK4DCP(X5%;X2J#?4FKAV&7)(3!GDTZ.Z5N:YLQH*EWX8_@3KXFP
MGZM</FM,X(,4,I024X+09I8&ZA^JWQ;D%#<S46!0&FT466&MR]&-SZTW;V?C
MM,Z,+I$<14\R^HR>MWYL`6HJ_A4'J$_1I4"3K"Z\,SKGXBW5].5Y`8=7;^B?
MSID1BFJW-@E(J.MCE6EUH)E@J%?*\T!_>3G^W_.K#Z,RODGCN_>WG^XN^R2)
M@W(?F'.M8\O'AUZ7HOGDE_:LEX(;SC%;@&$?R8ZIT\9RM1B2,R)*7MPDE9,X
M'W=11%\2<#R=%I[2?_I4+J[XKS`#Q/'DMC9VG57.K&V(L5XCH1V;O!1$]"G'
M8$WM9%*$ME(52ALWZHXR'4F1+5=ZQ"&",L8(29"T!8[CU+TB(DM7-I+=TRJR
MK:V`1RT104;F:Q.=KHW)[U>$5[-?$2E6<G`.TF8R&=V^^W)]?G%3F2<ROWQ>
MWUYE_4L,2,OG0[&QJ?<7RE/M2>\R)JTX0MGX$C,HP4%";MDI5B-$#O+9,^'-
M8IS3!1^$](BJ:U9P&B&W[`)/('WQ";(3W@I7^TT]"%FG7??%1R#%2L+*CK).
M]J-UISS(5$<9(QKE?"8_3Z."@2P:HR6)7K+=)-E$QGS&/0EGHP>37"I,QNWI
M6\C5WN9_^:LV<M9M8:LD!UD\31A*#A9`I3KL66:8SW01?3FG!(VH!P0:M`";
MY=J8(2281I!C3JD,))&R0]TLL>TK'H'LK)?FKG+]?73YD8W:K^>7HQ_'5Y]_
MY"!Y/L.D4L[EFI*-37AFY1(F[S`5)O3`ME2QW"Z`=A"3&6K^>)!4Q]1G8_IJ
M*NP'LH5R`JW0'!+Q8DSUL=[IU#UO*+#:#2S#06I]/;^XK-[%PR_^.OIP=S/-
MT!Q<D^;TMK\;OK5__?O%Z*:VW/CV8VVXL>0CY\DM:U[GTK1/#TBV[3W?\_*2
M\X(-(7O+SLG89DCR/NA,N9.D5G!:J^US@-(^\^[J^NYV,OV`W()!K9E5FOC,
M`AA,M?:M5;-K,AW-.EEWUO>%@=J662`@NL!TE;(EM#GC_`:-W>XNY8R-]W>&
M`&SKLZ:5%L`4&&/M&9$]`K1L0Z$W9G<=7WG]S+R00R)9FRYF`P"VF)A;U9)+
MMG/<%'M$!DZ])1Z!RB'$0-D6G4%``,]6!%T]'^U&,W=;@B7$U0?:%P_"5F:0
M*"-)6QL0>D8BN?EL(:E=9TF?@!F.C,`V9L#_)^]:>]LZDNQ?&>2[,_U^++`#
M]*MF#63B3#+!8CX-%(E.",BD0<F>9'_]5%U)?44V>2]Y25&/%6Q)EB6QJFYW
M=57UJ5.>@&Y6J.04"YS:3!ZQ3\G!=/=8Y1_=C?QUM;RY^7FQFEU<S_\/_WDQ
M7\39Q^5JM@N=_Z_YXNOLYO9?[[L/7;/J6FGYXN:W$<UM4,PDC`0#YR999;SK
M.^E`#=ZK'*O2"S#0#)/[C_-+_-TW'S[FV>?ES?QVQ&*8C&B;'><*!"9,PE6&
M!?P/8P:S\M=OL?[+8_7RD$LTD*S6GLE@>62F%FUUBDU"N>_1\FI,]=-OR]7M
M/V:K3_O;3&"@6C(4Q3WFUT8%X>I\$LQY6^;'MV:SGW^J]P+UY<;VH_0>@.;Q
M&J^M<$Z+"A?W1K_V=:9.X>6#<\9(C1$>N)PS*`Y]<<?P:>?;ZS'0!"_O'*>`
MER>PBB#9V;/JY=%\K_I<'+?8_AZ+>%8DAD[.83:!?Y7M"9TSALIO?O=-\/+,
MZ`+)&%Z(SE`G[4.IF;@1+4?`6[/9!"]/+<8F::4ZA#DQ%]G:7\]+.\?II=F,
MFCZ?.I87&(MZ*$D8E:4-@29(5"^OVEN.(PVTIM(+,-`$+V^B"1!#SHPY$:$8
M&K!X;S$*N=ZVQ?;W6)@:&FX#GH$6NN)0L;56Q*1L<IYW^Y9(7HVM)KAYI=$T
M(L7H,].)<RU]3]686]3*VS/:!#^O#6=6!UL"#[QPGO4#U,<6)]IH_K49[23A
MO("(P2EG-#`(-+-.AXK#9&D8#/L&##0EG,]%%Y,LLZ!=R,JSH&L;3C2#*(77
M;[%#PGD\"[6!PB)83ORXNEZ44?M&2W]AWMK^FU*VP4C+@U1,Q.1$USQ05Y=4
MJBF@OT&K37#U!&5T#+AE*@91@&<>Z[6#S4V+RK-9[0X"1NC0F^T8EN,].J/-
MY;C0G`D?8W8I5+:SI-L!'](JO^\E_9K\9]-Y@I-.68ODI`2BRB>N?,XJ(7"1
MOC'"_O=0SV*"_?V'LT1FIB,+$N,=8:FH4J=LX%<:J)/P7.R]&9Y#]PE.-('V
MWJ>L,.RSUD?F;*V*1(QQMN%4]L5H/(L-)KC$@CF#AL!U<`Y-@&M!U3S+BK#%
M!LSJY[/!28)9'HHJSC-C/&$TB3V@LOKA"MB"S;1B_Y/@692>X/M`%!7PB9<2
MBDV1&.(J]6_QJIVC\)R^[Y01)W>Z@+?$3V"E33P!J[Y/^-!.)I=>;6)S7Y;N
M4WP?HWF(DCDI4I8Z1?&`T;/X\-DV+`Z7+WH/3'!^,L<87<S,92^2$E%!+5^6
MS%I`)^/:J2<TPA!L^01W<H:BO>0]+U*#S\[W]^-<V`9Z=$C(MQ5:_"1Z3G!U
M*GHO(KHU/.@];O%H^DF/W)4&B+R_JSN;VOOO;+H-LU9I#&QL+BR$Y*I?=[HE
MH.A"._?2])W@TG(IOB0?N7$*W_`YNYK=>1E;GND#8,=GTWO*197"]+^DB#X<
MC$Q,:U/#&:E#4_4]!&I\(KU/$K85[T0I/'"B*PL<CR/!ZH4<1J]'A6WG4W2"
M_XI%2*9S$!;?%2G0$OWP*`%'I*EG4_N`N^JB`P<,R[S012L,T7PM-2NFVZ%J
MTN.?EZ;O!/\E38HZYR)-Q-P$`[.N`_*>!C&W\+6#X-%G4WS23;N(F'N@3^(2
MEZ[2)L3:=Y52.XKF$$CT-L7)V=`D1OQ`'>-?\0>H6?PV7:Q6?\P7OV[I.B?E
M^5!;G7,T1$=9$X$%C"9IR,4#&[_1#2J%.YKIM*;#7E*=0@\QH`<N*"V=R,R[
MP(W"/%E5U$.RJL%M2::$?!XU!CFI<PJI,`<6(SPBUE9]=9/E+9,9FU#W;&H,
M=IQ1>28$KA@&-U9'T*[Z0F%:K/26(^]4>NS;#?BL'2:6^1*-M3:#5#R6Z$/M
ME'08'$U][&/=><]CLDGM)X8+X[Q44K@8`,-E6X?"8G+4HN?>G(7&>E-RUD3'
MS=&=T[R26&2/PV1A$*'SVDTSUK3",$*A%H3`5,S.6U<G"IL".0W!O<YNFN=N
M=@LTFD.@Q5C.2H**$BIY3]C"7+6WZWZ9-IOBB[)0D6,2CME-H=YVKU+?UR[:
M$81OT$1CSBA&+762!3,_HM#%-U'9&L@KO9$=-\49058.N(T<8H*,WH>SVD'G
M(0]U&)S2-'<D3>\7EY3US/+L[N/!S"N%AR@#I;P1/:G"!)\]&D&0&FW><:V=
MVV<S;!?PA)J-T+5X)XB0(NJHP:`F+/?97<DMOLXR^R+4&B%XL0Y4"!@;N(B)
MNP*16*TV*MYR77MOC3V17LM/G^9W)07Z^8<ISY>[.M[76N0P-,9%E@BG;81B
M+E5_(GV#X_O3[S?S_UK,K__[F]O5E]DW?_KS=#G4FAQ2)6TT*R@-P;S`@:N-
M\<DT8WC&Y;CG,_SA8O5AU='!775;&:W9<:V-9H]KR:/&J,9P+S&#C$S(*$(M
MJ'J>-H1[>`F:],L8?_1\Q\4Z7@VU6PW,W(F078&56G!\N+9'(%K!T].K<3<P
M-7RY_6VYHINP0W-X"Q+#32"7Z`J5N6L$!6H-G/,PM-6S.IQV#W&FBSV4L^-*
M5LQ"X:)D1BW>1M;^9F_69@8^A=AW4VF'4X53TX0:"#E&HR*Z%QLS8>GJC;I1
MQ6]167,E-\AQ=J@R35WUA.KF)$A;5H2SH`-P2!4S([+;-C39"FT4/U[=#Q@=
MW5XLKM#1;JU//AVM/><A18%^NEAG7(#0S[\%;;>M:N68="./^)$^1R@NGE!Q
MD%+'XAR^8SYG7.D]2,P&M4UQS87<`$D]D>)/N:DI.$L8R$2?\:0.4KI0:<EU
M%'GBICZ-XD^YO87RP+,J^(;O'##H[QFUXVKB]MY#\0F%[F`E.AW-K/9<)P`H
M_0!WQ]K+7WQ$N\3<4@D>%6VP>!U5$,&P;NQZ9IB@^0JN13,VQ5B[`3`=$VV3
MSWW[^,U].%1=,098T1C>&09*2U.#4;!^2]L4<34VZWR7/-/E'LFLZ+;?$X8A
M6<%<B3RXF@'3S<V6SB7%E7UZN4=2)Q2!L&<8FF:EA,Q%I)KKVM!R`U#'E=13
M[;VX7>&+WOPX^SI;3)B;F;,40;/HDP!KC0>P-0HMD-KTU6U<AVT(<*!T8\FU
MP'W/2@S>"F<PL\NIQW$+VX`X!6_6[5'BC7+A1ETXF"RU2SE`C**B#&6PS9,6
MJ,X!YLNS7V[?+VXP)^P84I>+KP2N(`KF[M.;;F[Q_'+&#\J;!!=*^:)UL9PY
M\&!2RI%&3&-PJS=IU_N\B7\KF.DEWUNX0U7ZD:B!UU6Z?Q0_K3V)M7S;<:(.
ME1"=YD[KZ(S(44%@3K"R!O=<T:__YB].^&^YL^H@A>Y$&U"HUMC&CQ+].,&P
M@:;P.J><3GB`I82G7-0*C^D4>,LDZ/AF/K5#C`%1WZ-\>&S?HDZSNYP7'_4E
M_L?%K^/2/[:]0M$9>&<C37=UC.8]]^<@UZWM,0-W0NX2?DBP5A],*HBQO*./
M'E\S:U:G)`>,,C&S@.XO"Y<`K2ZXU,&F+7>%:IO1'PNP(=['V6HUN[KSWNBX
MR^]$A3^+L\7LX_QV@J>.+DIEO,3H-((5<,<@[I6/+,6A`40CHAPG]H@++TQC
MT&QS"@+WI*-)P.%>[!RT:7@FSB7VB&N77D+2SC(;!(3"B=3Q7FR?O&@0%G9S
M:1PA^G?SBU_FU[LI/G>W/7$A?.)2H"M4(F>%3KX>YHQOB?30`^IAP1\)<X34
M0X&T,7C^*).)N;M0IH&'4<W$I-LFM;%'2GU_W`XA67<O#16`H%R2P-4N)^UU
M3:!PJ;0\VGZ[L.LR3!)SD']<L8!!4RA"0`&6*0GHZ;XWR[PH)A%6'B?G]\O%
MY12+6B_QG$N.8PC%H\M!^(HNB[E%R'%TQ8,V[069*NY@"5398FPA)#:@X#2X
MIF9^B<?V[EL8ZX\0%]?S';/V^C(_L-RL:&0#YOW*J\*YCZ'G)$5[-[@/9<UV
ME[9#FN,D'S)WTC$'XM'WN#QT4$K'"APULKU'QV^PIY.\ZW<^S-2"B:C0D9GD
M'68L7FM3UX?AJNW`LL9P/BQR)\8D28=,6T`R6IH8<'*'RSF:A^S/%.*':DR+
MN<,&'G**I.\Q-5A>SFXPZ[F9T9TY#?Z@2_'EYT\'.P\44UN7*;0H1+1;1!]_
M*L[:X%EN5B\/E>_$R@T](%]`AUA",BJ4(L!96W<MAMUMTX?VRCRA<A\^SRB(
M7_Q*??\=QO+C<O7OB]75@5O$1EDPE\?H)!+10T8MZYXNKD5^"ND,VWX\[2';
MZ70:G+XD0@'G3;%)I"2C@URIKSVP5B>M]8XC]PEUZE(J?.3?+2\OK@]+4_%L
MLYZ#8>C4F$)?(+GJ2^:NG6ABNK[2B0JN"3JB+8W`/#"(0T?L8O&:YYRUZP:L
M/^@2P#4;2UDN1C0A(2;).;2H%'C`@YHZ,ZDQ)J:LZJ(*%II%Y8P;.4GVD!,_
M2?CO^>W:`WGP%P=6\#&FMX:*MUXGIV3@IE9#2Q:-`A(SDI$39EB\TZHV&)AD
M((Z:DJ+VN'B8#H'UA5[1E/\4X_9I57OXVGVV^7CZ'NZD^^3SIBOHQ<WQ?#M9
M&793BZ'3QG3-8MC@-(?DO.R)@EUJJK/6LG'UCU7A&6PT.-PH>B.S950"Z>[<
M8JGU=2':KCYKU,B1\.0VHLKAW>]ZF`=XV++(D<4<.4\6<#UX+GBNW,B"M47[
M=_O$OZU0QRLQ>)CSI`LF$B`*%&K`9*P"`HPUS?GP;I_0>'\E)I>`P`F&06,,
MCFEGO`B8"E4.*&%:#JC=):`]RBC'E'U2XCQ&81+HDKR7&.+68A4SID';#Y1]
M#I9T:J$B1Y-!!8T)7I$8E!OK:KZD?=L\L:]QQPL`>PH_C-PRN,\<GE9)9A.2
M+*Y./"7XV98>OKWLO5MX&@;<W7#-?_E"R_Z'ZXO._]S/?&VP9]NKX.QQV&9M
M@,(\@T*`/XRP>9UPJD)H2B\=7&-=@W&A3J%&6Q5_K$;R2@1G`XUK58FQXFT_
M?#;EQKOHUCV>1XVV2OY8#8L;UQD9,*$N%#V7)'IR0]$B"S;G&TY1X_,*1>F<
M*'Y^/;L_\QY/%3WX9L5C+JJI#!:]"M%JD4*H:D2YI0K2K*IQJ4Z@QMA-2\;]
M8%7P)BC\1,KH^]&7H8VT!?7H/H,:(S<O-(Q:&EVBI,G46EL?^\R,M=4S[L5F
MQ'2@&@_SRA_NNC%FFE]VLVBOO]SNYZ/$XY0M<>]$#H%NZH!+[E.MV3AF=@*3
MW[%O']^*CDAUG`;R[_SONS4HIH#QS-*`.QI@1;?0=2(/GGH#&C!]-@W$@`;@
M3<;0(OLL`.,R'KVOL_ET`3VD@3F;!G)`@\`2#=A,E%]RI07'7*NV,KC-COOG
MTD`-:("K!;SF07+@D66=P#_";VT.P%W7X'S[8&@GYYBD)#H]GDUF"<.^ON"5
M^>;YMKZ3V9DT4,,[F>,I@(>9`>!$G![RPVQ=6WRP\B6L(C6XDSU5%9@')D7N
MD":"U00Z^LU6FN?Q16IP)TM<0$PZDUS`=#BQ*'D]EX7>;"M>U\"=38.AG9R-
M@I1DBLQF)2WQ@-3)T9AD[EQ%U&IS/@4&-G+AAO#M`F),.N#38*[O5DZ#CX#[
MB1I\^GR]_&,V^VFV^CJ_G&TOQGR_[%AF9E>AJ_/]8WE[<;U9K/E^>?O/V<X@
M?:QF#SDHSZTS4?L0(VZB6.\BO4TM<0O;1#D]F2+G,===PR$L5_=?HN_CN]=/
MOV0<+X5;A2DSL-RU)O=U:XSNOOG+#_R?ZF]GL--6#=:,5_%^?^NHB;IN@?^=
MW_[V\V+YRPV*0\Q!=ZW']"L6EYBX=Z_V(]$(K7!%TT*^>4CI_Z!!/70=\WYQ
M>?WEBJ[)'Q;^P:F5)8X`S$5`R)AM8+[P6N2)LIWM[MW&9/>SJ?92##J2Y.4L
M!$#T$8\3!K9(5AZ-EFTOA-^)CDKJ_[-%1_)-P86G*RI(6@E"F.-ZK1B(+:WI
M7&WDFV_"H#_-;F^ONU]R^":/,8"VKFB"7T<ELG(V=R.PT?@B-1#/=U)OXI>?
M3IMG,]K(LL-8'(R1+DMM,0*).5M&1HO<11ISM*4K1[\NH]WL>)T)]'/HZ%Q*
ML:2@32HV&0BJ3P+:6S1-DZ).8JM!)9[#3$/L=L!Y2;YHY4IQ/H,+/9R+YA@U
M%4#OQ6F6U(LSTW#G?9;`W1T]N+)1I%#;=C`Y:+N*K#W1&?KBS#1T7R198@$*
MC7#78`+WR=359(IJ0@UNT9V=V4P/A^6'19[?=%RS^.,?/MY=MQY\D`ETREX(
M*Q0GFC1MI,68OX"`%`,F!`.]"H."'"/R6).DQJ":4]M33,)XS0EHT(D<DI%M
M@^PY1!XY^33#30;::!]#4B8[3]S\)'(L.4'+X&WD^NW7`8+/%K/5Q345_Z\^
MS1?SFUL"FWV=W0,G#EX@"5/F2%P!W63Z(G3IF8I3C.W]KV5J_1P:D>@XZ4?6
M2NAF"Q?0O$B)QZCSK%Z>BN2;AEIN^08/[9-*/[)L@DD>(G$LA0SX`X%!160H
M*$V4R;WB1TB_7%[]>WZ]!2$Y=++@&9LT#<73T@492L`M6`]@WLX15$IOKH_[
MU]U3F$&`11`J<18UX#<ZYF7PE9G*&+L--[^/,.\_?4:W3J[\P\?OEHM?OT,+
M7MWMO?^975.=XN<).PL?;O(:,'E(V=AB#'Y>"]7%#M%2[B70*508V5Y"*,!L
M.X',VD!FBIO*FZ)5BTUX#A5&]IA1(CHA"AUV$KUT?^%!`S5DPVG`I5;KA`L3
M-.F:,,B?PVKY*74T6U_PZ+]'!F,T<#=?KO9VS6[*[[ASEZNK^>)B]<?[V]FG
M#H-"*(+E]37^Z$,+Z<&K,'BFM52)T0V5TS*Z4@F)LVKOGCNJA`TO\X3Z/)_=
M1I9^%#Z8["'@PM%)<6&R[$>-M2UQ'57#!A_&F[3;R'[CDD.P"K+3EEP&.NB*
M/`&Q"16XIXHPZAGM=GP?<U*X0(!@?UXZ2S=B4"F:`7/6(3>Y1S?MJ?J6\4`R
MD(!&J"G+3'`FU@,IISB4"YQ4S+'J)<,(P_V'O6OKC>-6TK_(`(LL7NJ15ZR!
MD]CP\7G81T$>)P)D*:M+LO[W6QS';*O9TSW3(VFLK(`@=F(GKF*355_=OLI>
M.S12,#Y2P^@D4NXMUFA0>4]9'[`UOKWRY^?7]Y7-\>QKC>$JHCH_O[G??-K9
M#;K'Q7`V:DG1%8XW$V,7\FKHFRE]7$"CN=IU8CZ)I@MW2TGG*^5**;9.:#,Z
MH#;44=N,^X0I`/VLNBY!"I51V,1Z%@2%R4)I=;242]\-#F,2Y"?5]</F?'.Q
M340<7MLR',02>39C,D?C+.`P_@`3.S'$J'"PCU2/H,;"9>2;Y8HM@L-PQ"02
M-<S'AD[*_@-I=Q(UEK(*E9NQ!(YCL5;$K`9EARZ+T+-%C:>$'T&-T5CWX10?
M')E;%CL6[X1DGQ,B-1U\;Q?DB$UH4:)CY5^X2AS!U11A)>XR"9UC&][:+%3N
M"?11+=VD1Y9_B;FK,L*4*)+D2Q0]6,QF**Y"_Q0,+=VAPQ38SN:UD<B56<Q8
M,A@^_%!2\@$2P\K6O8DA=4$<+9G;*:D>19$E-VEDB1"RT":C$@XHMVR;"[H+
MJ-\L^<@G4V2II3EFHPQ;*,>_F;]!R+I1<0AR<XLE'D6)]S<;CLH_C<;&V&UN
M_U\KKQEYOF:^.O44-6N4BVT,X;Y`CSPYWNLBY16"/HFN"S=1:WXD"G/P.6=R
MC+'=0(D[X5S`PI)E/IFJ"W>5M'*1D4WQQG%@F@.4UK'C6/4)O+9DQ%>H^BW^
M7)NF3]KXNA'50TBB9`$1VQ"<A=1O7`,8Q]0/!#A,N(6[Y$0VHDBGBO<Z&Y,9
MJK2(+?7;#H'L^-D<(=P26B=)FIT$1H^V[BM1`XKB(^TKR%*/+_JR<._Y,ORZ
M.3QS0"%X7TMS"G6,M<`UK'[UI/L!EQYP/Q#@,.&6LK\:2A'1(92D$J+5U)R5
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M>#`<HW(4?&]39%3)P0(U9GQ;E]OT^;8QG=6D&&L$G0"7/PH*R281.&:P0!2C
MSCZUFEG=T=*E=)Y*S@F<^8`AS`0E:]>#J/$ON6)<>P;L2;I$1\=CO8>@:YE1
M3,+,<7Q=U2`->E-8TH&GNN<Z!*%H!-%WE1=6<Z#4>D'.*@-8Y7VES,%6_TVJ
M#[;!6:7=H3+Q>6[73/Q^??EI<W/[;8_(88>'WI=8@L(MC2QEU+X='NC0X0%I
M$4;\H4L"'2G];"<KEDJ%*W-@W"^CL;:TMBSE16>=T<*8JF*M]*L8AC,9#B=]
MT<ZF[*SF?QXHU7U?U`6.VG&7N%.\O?L(.'>@#`-579SLM:\[@[U%W49:R?:K
M.1#)T$H!7T1,R6;%*553)K[.*^OB?..\XHB[,RY]2_F\QJ<ZG#7`4(:DO1(<
M1HG@K:RKZ8=&3<2YS:4OYQ"6`*&L2[)\B@YDRE+HRK[53$[N.T%?Y"$L84%7
M5#""O.)PVOC@<NW=;9N'^K:P9WT5IPXF*T*REC3:*(,CS7Y]8/;$OO>K'Z_X
M.0]G52R)P=2>>A$#^Q1C'8:6A?+4,ZJ_R$-8,AGL/I1E:"("$:.JA*DT\*QR
MF>LX>SF'L&0R?%(<97$LIH(TI?C*6O#]$$R90.G'O8KS&E_<KNW74`S2:_J\
MQKQ96^<MM4VZ!2:X;<485#[X\P^3;:E_L<[7U]0NB*@-&E5,J^0(E7H,.:I8
M'B7;0CDB@K6ZKC9W`K+,?.MUVTB'.76F3XZJ$;.R75_]]G%S\Z4NYSDP2LB)
MCRP8$ZWP7J;B7*L:,I#I#;*P9K3S^L<_?*=4JT("B,5X5[*N*R:RD"!T:S8+
M'*I.5*#%3M$F$?<^$LX=7PJB;I6`6B8G[4HJU"3T?%!]=0YF3F])Q%_.[NYO
MMH_\P^:/LZ_;I-&[S^]O+J[.+_XXN_2?[S8W_[TYNRD7?QXX]IA9+")*HF8V
M`QN=Y'P*2*Q5T4%UN19GQW/9:^5<J^S;JU]9NX]_;2[_W/S"JOY^8!:"XY-4
M2?BM]HS0C$/RPY8]/5&1=J-MA4?)NE[K==\7V#3;@K9.NI`#3R1M_;Y*AVI[
M9L.3-=(=J=_U_8&,\1`852;E;:A)!/Z(;#:&12^N,V-'Z<?2':??Q]]O-@=^
M0"FPL'6),CJ^IBG(0JV;*DTL_``S[I-<)^61BOYU?9B:WH!V-3T5:XC`'C`-
MG%657WO"GNHCM?SK>J>.:QF3L\%H^:UI"27[C%+IME\:1+\E=]XK[*`:WE?0
M6?=EL7#X21J4,BY84MBP'+O<+J4U;_9W"/K+]<W=;V>_;?YU?79U^^[JP^;L
MDF-)CB2W=/^UG>]+[3A^]_G[;]S#DO^8?\_6>TP<4,K@A7*>$K+OTEH&R>!T
MHO&I6]!QN(0/%/QU<Q?/;G]_?W/]Y\6GS:?P]3^WE<&F7%R=\4WC__K\[N+/
M=>,AQ8/6C+.38V3K6"N#K:TU0+_`2G%@\!`V[B_<H^FTU%>(@#KK0HK`YT+D
M0FLX9OO6LSG!>.7\"71:`/?6!PPR8$$.8ZV0VJGVG:#([B%)QP&<>T*EOI45
MC[M\2FOOR*$5P;D0!<K08G-K4C_@2-8)NX]2$](]FE(+MT\0";9LD%V`2-%)
MD,.N`%TZ)$0TGO8]@4Y+M$HZJY!,W1@GK(NDZU#+]ZV'L6?H?P,,\V&O-[52
MJZ%5>_WU@V*<#"9(E"03VPN96_^><_VVHC>$."J_[2_=HRFUM-S;6(^RR$Q>
MQ<H95FAH(`??3\$1"+O7EWI*I9;NGRG.>U4W?Z'2/A+(5@@J3O>T7E8;*1])
MJ6$4^'`.-^>=H>A1@_&5]8-$@S\,'?J/,3'Y_D""PV5K></MYJ\*4;^55BL_
MYO551:P/LHO^_/S^R_UE71"][2.OO^UF\_OFZI:#KF]_VE*3FRHB*&%4BDK6
M/>C*M%:5:/L+>#I5/WW:<MR<7=;^V[=7\>R/B[NSRZ7JBT!;+&:P[*%T0HX@
MACY7Z&GY3J8>_^LOUU?;FOI2FY7$XFI!S97BE$G)4>L`SR!_'I4^;.[.ZFJ+
M[]2-2S?1(8<;E4(AR.2`BG##BE,.`'^^U_?Q9DOI]76?KY88RHJL.(R*##.B
MY8_8?+(V,)>16*U4O^#@80Z!;!&"'4[MLP#%6"ZWABH1^W3J&ZG)=MAGK6AC
MOO-1-B[8X!/?YQ0$7XJ2!TML<^DY(21MX?/CB#8F,G\HFC08BJY\:,#841C[
M?99;EV(GR`84&-U!^[6BC1G*'UJ&3-:$+&TP'K+%$$JS#(Y%[E^017BT#SH?
MY!5K4&5T$$IRCI"@!41\IR9<:T^.<J1LS^Y:*=2&8*U%J3UW0A$.*66#O4$[
MG:JK7*O(S@8;A7$<;O"KL'8@Q&??U`T*GTR]_5TK0VYI/`>S0CJRL?(U#"NI
ML$^OG$RE`UUKB4:JXAQ_K.R,(JM^J-%2Z,F)3_[Z#G&M.?N0.&YGI)>P6"]L
M&'8.Y[YT\QA*]1M'1K1S'/-$`2G;.C&JM?;-M09I)LA-A%/Z<<Z[7R4R*OUH
MH350"@0LDQ:(K=_;1>QAEC3C$<(C1)MUK2D%/C.J#06,UDOE[VVY&)E*[UI1
M(#V::+.NE8VWTJ`9PGGG!7C,NB4?A"L36(E&Y,O'2#:[\0R,U#XEM)%$Q.QI
MD$Q+.9$^%6+<*7ND;,_N65W"E*..SA3D.$AM:1Z^E]F#F.,2>&955WE6!FN)
M;UB,&ACZ%N<!6A>!DF5N?.1YU3O`LW*8:H52F!+#!"AL?]H7BSG^/"H=Z%D9
MQCF^<G4[>?$N`B.B-@U7K)J`W*=^?8=XUNJV,)BD?=0Y`_"/+9''`>,Z/-1R
M>']/MAR>I_/L*3$%GTU`!<I9FUK%2%GH2;D%:?'PS#LA#A5QJ:P0)7HD="$#
M^S$^OV&A!CN,GM]9H!X5Z(\6<<%Q"**8B!0[L+H*%S';-JQ?,O4M!%+)$5/^
MGB(>D9)E.\'(+OKDE`.3#$=1S6[(8B?(2&LI0T]+N70AC\BEU,I89.OLDG12
MEN#Y:P_01?0E%\F8\$G$G`5_60=/(8*+)126$8UK0S5"]6;X39T8VO%RCA-S
M%@B2]KXN35*2!2P24.1&QQ:SZ!#]&P42S%.(.0L*^74'DI6'&V6BZ/EUM!<$
MVDX8?T/V:<2<9>7P_":TSRJ3RP4+!-UJ3`AA"B%*->);>10Y%X(FE=F)&BL+
M\+<$6YG.&\%0[2V>")K0RJ<0<SXWR<B^KO,R_"F=HY`*M`0@6NJ#:8[WX$E.
M<_8-!7ZYH;*X%7:.TJ'7JL4%=41U(IABO9Y"S-DW!#IPV`G.@*:@=:4L;"M>
M4X;^#2E$^R12SC9K"UFD)IUC720(->D5&XV\-%-N2"BS\C2W\[^WY?[N_F;S
MR\75Q9?[+^__;E=+!^\O,5"78"=KM-2"&(T,]2]?^E(L@ZD=4L]+M4:351W6
ME9%81,8"UH24E4@J-B.!<KS,==N@OL/-[B7<&KW>7M66T-I,>&`/<D:-LEJ4
M+"7C:]JV-7P/Y47N=-.[K-_>\JU3;]L)ND(_8;$P`#$Q9H:;49.TC5F>I.F_
MW9AR:(6$*S7\ZWJ%?DF+XD@&_EM")>J:KI;U`Y_ZN`3$#K^PKWP[M&/3LFU5
M_'Q]LUVQ>5@#)0F.^=@2*P^V:-#H@V@.+O?7D/^]$SL"@TZ4AQ(/W'>K!D*(
MH0)CV:S05*2H@_6M9&Q=GRA!,_9PG0`'RS=[(80S/L?:AUK8:<CLOF<]:B,6
M=B$6VA&O_?[RK>U-CH31"XD9L)+NYBB$&8ZP)SD"W"GACG[?/86<[7;'$G/&
MPC&TKN:??I@QTT%V-U*AH#523F0B_W-ULSF[K"MH_^OZ\A/?Z&'QTK_K@JYO
M;`@W%[?\2^F^KNOZMJKVU\W=N\\?S_[W<.9:OAR8!'^2*!.F.GC3`!%%Z%DF
M>D6?0(V3GM7S5V[Y,22G?*Q;>*IY`VC3%4;'B3&NUV_P&(GOY+/5UI:D/)9*
MOIE4,T8<#';O_/705Z;C4S:UFJ6<#!:\9;SB6MHZQ]D>LM>#/KA(`(6<C38F
M]J^`)%));=37Z#YZ?#WMU14+]'7CG4E"JT@URA"JD2@DP+DZTS_LJ)<V7O@H
M#!JAI'/2>*D\->9".3&I_&:T!?$?>5K/#C2\L%"'Q<G%$E6A4(;R84A])>OU
M*SP6U"!/(D"FQ#]QKD@CH76O5<SW_\U0/!G4,`%<$G([O*M+<`*IL>AF;>96
MG;T>].%-]%9@96'SR@8^>,Q.-*B1BIT;['\][0.;(Z(H6MK($2&;\&)D$4.)
MW_1[D/^Y1[TT#`M2Q*+9"JC"/]:%-JT/F@^O&\A^8_0_V<F=J&<.E?&V!"0O
MA0^@^&<-\/FH^J&\UZ_P6.U\(167H=8XK9:)4AD8`)/JQW%?#WUMDZ'+`DAY
M*%E*7^IH4TL?Y1R[IJO7@SX&:E3.6U\H.9T2R&VNM!5?_`1Q^.MIKX8:)8,&
MK(U;E959.*]<6Y>4L.\^/\E1O[VZ.[OZ[:+N(OU6:!GOZ%FDR;'\:ED_"#(Q
M,G"50JUUFUKH<()6>K2^<I<<*X6=;:RP1>8LB".;J`PI8X?-#Y4,NA=6K1;V
MI1%!HW'1.E-TXB_J-'FM6MNP$*Z#&CWE[1YJG_285FT90F=C<MDD(="#E2C;
MC4F^+V*^\.-88GH%]AYUL!<(K$W99QU:*ZJV/?_E"S^.)<[79.JN<I%K.!D-
ML*V(P_2[I#UHHI_E5$Y/&*URE,I[987F.";Y-&PU%*IG=.VH<7_V8UIC6K*L
M[*(H@X@<V+%+$MA(/)S!1>#[PHYCR;1H%XV&NE.>$40E.8`P9-45S@V$OL3C
M6#(M@N$3.<D`,LE,(0>#K28FLN_<\>._F;7-2<(+&R$8S:)3S5>DT$@SD&+W
M(954;J+!:U*2U0+/=G!:QND,#!F@2UL0?1[X^8PT/?>@TFHBS;*GP/QKUP^;
MBM<NBXU>Y,3V-((LM6&M!-FJ(2+:3FX%$Q=DISA'2;XTW""BRF@923C23B$?
M?-L>!%+WW)KC.9&GDWPA+5H7\F@/GG&0\)1S%$,$$6SN[XH<#PP=*/J'S>W=
MS?WYW3::B]>W>RY&_K$U5+B2ZD[,5,N4H<B4;6&0[^OV,%]ZMB@<]X5.R_%`
MUN^-KN6:?^<?]VP'SVX9-/R0!CKX>F<G"L>6&4OQ3B6B'V:DB:"GD74/3WI9
MI*,U6+CF;+E3JD1Q;`GK);>DAXUR$#JR#6?5<VNPM'[75D+T#,5'C@9EM#JV
ML9D02Q<PN]&>Q)4:O/N\_;6WM[?W9U?GF_[:_WU]_KW[TF<GLRK@&%#(BJZH
MI$9";,GW3/VC2S\GRGJ9<59FF8)UA72*47F#J7(/)V5K,`Z%;%=U-<?*_/':
MG__/_<7-YH<%A@>_4R<JNVVRX,@@@D"9!MHGF[NV-*F4U-."3\ESA.`+SQ.U
M2!JH]AVAH5*TI,8W'L+$LC*H?6#/(?A2;0Y)N>"U-5&;X/@OUT884^D1EI1`
M>MJT'"[X^YOJNNZ^OK\\N[KS5Y]JOO2/+QWHVN/B"%4WJZ)EZZ(M_YAQ"`N+
M[6NQ2')>AYVB/9I&"S?*60.IZ%K"$.QP18BAN2R4?0LRV%%KT`E46KAK+BL%
MX$EH6=L>HW:NC?_`_[%WM;UM';GZO^SW!//"X7"^+#"OBP"[;=%V[\5^=!.E
M,>#$@6SG;O_]Y<CQ2#KGZ!Q)/I*5M"U:)+%B<\@9SD,.R:>8WB&AB0.RYX*6
MB_<+!M"/?(4_72U_7*X2].]6`<Q/B^4O'ZYVY'\V5Z(V%Q(K,RI+3)J#RYQB
MR2UU%:3M7,9//X+CS-=";JQG+\%F60OL7HL6)J*/D7<5*@@^6-,:!`MV7>[)
MUK+Z^IU_N/]PNZR/$H?%B4C%.!T82_,U78,NOVYK9^"WN;/N5C_H;W]_'%PO
M=BVA*\^S1!]O$8J);PVCL7C>/0)J1W:;91'\&42OE_NA&A>5G$S5><6B1.^M
MC*9UZ$/<ZA%[$GM"X$<ICA9V-"HG)+3`[@?`^92E7X]U(Q_$R83]\>'^[O[J
M4WU>.TR][%6BTDKGX@-IEV/TK7%,;-<6[2GQABC/$WN4KD-&F3!J8K52O8C!
MK*F/+="IQ%YYF0-;!Q&3TRM.N6*(/^S69.6)?S>2(QSXV8?+-KI?O6!_1K$^
M]-:R;+TQF47RIGB6;+=O%XMW=V5Y^S'>,E!;WM?'QQY1V'2$D:1@EV6"XJ!.
ME40%V`,$X'@CIJ'Q,7VND!%9=LK\%(@\+Q]`J%3-7I#,L2;.O5\[W1BP-W2@
MDFBXG;(/RO3<%4R5[T<IL_*4&'X$I:.BW!*-'/3UMD@=BW/>!4R`030Q2MXZ
M+"T*Y;709MT:Z](`)XY2=O?^.78)NYGR]B'$**KD2(S/G0\,0,Q&!8PB->Y#
MIJ1YMO!3B=,Z7\>3XL""%ZI")M$&*9`8;4HZ@_!3#`,^6G1&*<7XR61T$EM!
M#`C5RYT2R$Z>_1EKV,A$K?*9<Q#[H&2,XK,OQ,%=T40QM.R8UF+L-?Q`T>9=
MUL0F\ZJ^P`4/R/_X&(+Q;9,E&)B;TADZ^Z)KFYH)HX.Q"L%)_I=*)*?70ZJ*
M';^EYUG6+U<WBZ^L9G]P`!QO;VX6;VN!ZMV/[Y^3A^-%.6`4XBB#3E8)O;Y=
M-$'O?N3#1=T\W.%BSK_,B=VI=26O16M2\*;Z$)/7R2_5']"MI$*UVXV\V#*G
M'IHR8[-@<_:600\6YV)[#C<#KZ@U.0F[T<(<RZRT>W/E_BA5OIED03MMC0)K
M2P-S(=M>#UWW;6=_T>9;TL3&S,(7#JQM=%9*WI@VB.9:G*0^NM/CA^\L:YK:
MA8J\+!1D$IX8_?'5O3&GN#]+5,D1N'?@HMY?WQ\U?=(:D)*1AK2>+/O[#*$-
M]`$WQ%K0IR19__B]I9K:'8[UJ$E;*Y4-"A+E]AX58Q_[#TUS/T*JJ9<$5R<*
M@.#K0@O*=6)LFRONH3_\:&@2[FZIANW\CV5/TJFX/QF/4#!8DQ,6+"FE-4-S
MS/W!K(KAE^U*.2+.<R5OI3X[_V[XX]<_/B^VRH+"P_6JB)L_]O3+-Q\_+V^_
MK.K0I^D!!"K/OC,Z9Q%)DFF%U\'U[T'CI.@9[M)44FO>'^X7R_:925HE]))]
MDJE[PKO$-T=3@H7<9SZ7LOM`<7E*V'?Q*(WW?`ZLI*2URRA,<W28^J,W-7#P
M=>F++P]+%OIAN>#/E>O_UE]-G01KM<B1?3L[^F(,%4;!+:Z,V(OHK98]-'%I
M:OCGU:=W4P7[.?HLV7$SS%=\^HM<F]_%?CY,(5[\^5^-T/MP>_/NCC_8?G.`
M5\P8?=2>;XG*XL'WFH'F$!#[S*`DNH_*IU/*6/:8.`PUO'L+;^!2:02<4XT%
M*O;QL+;:G,V:\"(77"UQ@,AP+X?BA`<.VUL'IH0XD>NZ-%T<?+,Y0!0*G,?$
M,5(B5=KJ5>E?[_QQNO3]L._:JQO7SCD,VI+.)@"VI[_(T+D/]ZP^&]H[=O%'
M7&P8V14`!D36`[KZOKCN$!#]&G`K]#F=V:DN-L<H/]L@L60PLE;(0`ND[3B!
MQ24N^+E7FH%L*(%2V1HDX*@NMH27\+Z7"2(IYS\,!_>%BB+(BY!"L*)$9RS%
M5C=$1O>+CJ7&/3=OM]WR,*'';F%'C*A-\!:DL]'*;*#=PL;H?M*MRU^YM\P_
M?^WC7>?>:BOO78VBCWB(B**@5BY'"J"1L1]`Z]UT?I2T<%20YX@\52H7,`80
MC,^`0@2O;&@^O@C1\_'G$'GJ_8I/G-14QY]PV(4*)+:70P/]Z6M'BORY5?$^
MZYVS:!<4$!2=2ZB5_@':`!>.BOKI2(#M$M%=DAPI[A2G>@I@B_,9+9\\GVPK
M!C5%E]P_>J;#:CNSN%/O2-:;))RU)D53B<RT7B<9@^Z=.-EM_-Q3W+M%[2EC
M3Y)JT]CMRI<<VR^DBK9)2ZVDU2K$ZI7+.MEG>EDT4GT=C\CS',FG7B2UB])[
MZ1.1@*BUMZWNH*@^Z3$Y)'4>R2?V21&)[Q`1LE:Y3B?6D-MH+YOZPW')*>N.
ME_Q^>?WV?M/-')AH-=D[H*P42^T<^^@@6CY8Y?Z`!-#=73T@PC%"CMW2P2&#
M!4W@R!'R.52Y,8E98WI)OR.%?&IV8L7_O%@-<:J-%/6_-X_=?>]^O4W\Q_+`
M0?TQ.;Z@E2R:@7UFM:8Z<J$^A\7L52^L-=TNC\.$V[VNXYK)2"2^`8/)(CGO
MG?+:UV8RQZXP%-'G]EK-S]@I?K\U9>O+=>\OO^Q1B+<I(3B.F:(KI*4/R:7(
M$K.$*?*5$6V?4%N/"?A5@HZ(VR-W-L9\I<7[Z[?7!T)E%4RTB3QQP",S(T^3
MUBSS@/TA7Y6GQG7HR:>%>O8:QHM(/>HDE%4LM@C`VEZ_Y\I^NU5]=`-END[Z
MP#5\67QZ.`(N%ZUUM-IXQA@HV9NPTVC"QCX%&,/\KD]^_,E[BC-!0R<T!TNL
M"4W>4-VR["):SK+T'S%6=!C/D6:4*:N@9>`8BR6&C=X(CA_6920L4O_)MXL1
M#I1FE!#+!VDRI!SX\J%*/,.&:,&O[3]0*MT]%@=*,\I[I7*4E'6PNCZ9<DPN
M36.4JF%!'U/W4-^AXHQV9_+)JO,2ZE&RL>@(ZXLPI'XIHU*J>^`.$F>""BY9
M#`:)4B2OLW.(L55G&Y>&IJ$\3YK1?<R1!/'=Z@4?+4D^6C*-#L)"OW$).QQ:
M!TLSNH]%+"R,RRY:Q?%N##JT5%Y,I8]9Y+,\S@1_FPV9E1"*,KHRW*CB8]O'
MH?A^RZ:$'IX^5)[1PN@L*:9,405="FN)0X_U^[[L-^LJ,GMXG54W0KBZJ^#H
M8\7+5[7BZ>#KPDFH)*%U1KWF_T7KW+KP'`;:<L%MOR\.RW&4J!,>P:)!74#D
MP.@].X[?UIVAQ`%?+V,,G0;$&46=LCFY8E-Q;&$4P*;GH]JTJD)/JU;03*+Z
MY?+JT^^+QWSM^B-?:SI]9;QZ'`+XYE-%@H]!>JWR_/7#U:<?/Z^JYLKM\OWB
M>A5"/([8FQPPN/J^O>SP.A99%;__FY=\]_,O_YX:#N.S!NFE<-'(@!9\:F;F
M\&(S6?+4LB.UWD=])]'-F6SR#_X6]W<O8A"H=)V1$9P,H13OT:B6;+/"NR&#
M8*<<YUR*>1%K_._B^O</K%3_9;&\^GVQ^F*-3]M0HE.;2VT!;D8GQ%[=\*7O
M?$I:-/RO:'<KL'QMU?GM-:FZ,QGTA]M5MF3Q[H>'JMSQHH\Y#Q<C6;[.2E92
M\LUK1,GKO"4']$,-BJ!`G>EP==1R*<:`$QD#$L?"5G'PS)Z.\45)V,!0$G;H
MZM'R;%?/"QOC0"\W\Z'9='$E14,F<RQ/7CFLX\O;&SJ'B[#;Q3E]5D-=G'<[
MPH8SGK5-&Z+6F2``5DIM/D#1KNL@4*#<;4."/Z4-_V<ES8L`0$6^&&V%S)K!
M.2CC2QN"I*S'041.YP*`VXIY$6M<%`#,-F1/1F1CDI'>2&T;`!0&<<0[OH"]
MSG2\'J_,']\?/!I%;&I6>B%2"BA%$=H'RV'.4R9'VZVBY*=SH-!J[7`.9+UK
M"2=1T)>KZYNKWVX6'.ZN3'*0GH`\!D/"QR*"-B@:.7*=([G5A]K\!1@"*^9P
M[1,KF4==7_=R_N]B^?;ZKG[_75A53=Z?^>/GF]L_%HO5&7_\QI,SIX4S6?@0
MR4)`/N"Q-3&7[(>F"TEC:*:H8=?:SZW9:71YN&:5]&0#%$@ZHH%0)P^T1Y"P
M]5S9-&NUI>]+L].8[W#-!L&AE=08>/,B43!JW<B"V0V-/)+H]LK@7J!F.]?:
MUZ\L?N+;?`!CS^0C-E&``1ES%*!-A`P6ZP/V^LW:[4P#J=?6GD3?8QJY#"O,
MY$\VK6!E;2\VPA%I$;R&RB#^]-X<NE.L-ZU@\$]JA9E\SZ85HH[6.NMDC6/8
MJ8-8OW$!T$Y$K%ZK[^,L+%J^]=?;^ZN;-Y\XJOAT=_UV1VS2?S+<1'?%)-[,
MKA9YA6BT@61:10?IU*L3`#P)[AA=TP4HL?^8N15*U&(^QR##!X58&59T&Q)?
M%=KG$=CGU?6[4V+_F753B3%I(XN-#(-73]>JK$M$2NG><5]K);]I'7Z^7J[^
MSLA#H-HGL7`X?`,RT6)"AA*$(D=3I[H]O5-D&@HY7DDU5VY\MP+.KV!]&@77
MX9K12:L21VJ.]V_EG'K:S,$,O;*^<IT11]^%?O?*C!VNWZRM!\]>UX:((2N5
M<1U_6#LTUK:.8YHIBWDF!7^M3JCMEV?W$#)G@]9(#(P)@LYQX_',D!K*$K\R
M,U]K`^L_OWY/Y"!\8/"*F&*MUS4FR*):7M=X.Y2:>"4[E!7?A7Y/Y"#X;D,+
MEJ)6D(4.`B0V2E--<DB_"/-F?DZMWZDJHHYKF)L.V9'$Z!U5Y4:MZRB/-MH]
MDQBL)%(SJ_@4]4)[:E>?5KL<2/"E!A!ML.!)*,9K+3"+8;!PSMEY+[@7U.Z)
MJ;R5$PP=)$5$4QQP[+NF\M9YL#9$6L1O4[L#8P).B!R4"X'=+J%DV%`YE+U:
M3[W<GH#6RFX`Y@TM!M9_?OV>"#F(`MJ6G$2MMHC6Y9P;,LO>#2$'W24#^B[T
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MU->+:_84Y3A><-2%4DE=J<C8L5)LW1$RQD'-:BV^LSU[BG(<"*X`!"A:95\)
MMD5JPU`HX!!=FM(HYGU!.YMF#RM!F,G[;J(#ITJ)'.*J7'@[>P8)H@U?4ZH[
M&&6S!&&6<O?#-'(95CA!452H7'50D9EF?RTJ[7"#%N#2B!6,_)-:X01%44*0
MJ)/Q*DV8%6P2">TI.?68PS>M`'/447^+5CA!4526X)5FWX\Y*300O6MC$C!%
MM=L*\M(]TMVAA1O[&V/>+.C6J6#_XT(AR$4$/B$118,Z5@BS.W[$0TH%9]7-
M19EEON3I%AMQ`&!$GXU%0T64.DOPZ9@X74:Z::SYRRRSYERW\!0'L`1:2P4)
M4?)_8H,?H#N!=],L\-V<EEXIR26XL514U"7[XCV``%\IX]?S"[M3I-:&P<-Z
M<V?6SH69YC2NS-31OC&2"T%4/D!13..[RK$[QFYM&OW:T5^F.:D[PQ*SYB,C
ML4[JBEY':L5_`KJT7INF,8>`L8LVS4#MRR4X-"V#M&C).LF!8Y(64LOK:Z5'
M7J;LG*?F0.U<F&E.X]`HDQ.5$LG%D$!C!FP.S=OB=YO&S7EJOFW3G,:AZ>CK
M3`>O%5*P1G*42>OHTH[@,W?(>^Y%FV;T+>YE?!E8CQZ+(2M160[YU^R1*G;9
M-HX>NC&?8B['(*?Q8.!C"@$B!Y7":.VEI]8I7Y!V7B[JM9P3+7^+!CF-WU(Y
M%6^M4L$(]F$`M16\C7F%G0V;\C7.>=L_QR"_36?C?AL/9VN+XO;[]X%CX(U.
MRLE84&NH'4,AK&=0I^+&B,A/MX13::ICG9\7'Z^N/ZW&O_//9VT\7-U4_@NY
MNZ!DX[DSD\D,9Q(KT)#D4*!1W82@\&]__PG^0_\ZB;;V7<:L:MR=_MWU\]4>
M:J2B+57P4<A"+L!>MLTKBDHI5J/YCQ0SZO&(=73T>+N\KW]\-+D%9.$1D;3#
MJ"DH4-*VB=`^].;L.P8`KO.8VY?A""''!NG7ZE.VA92^V)`BU?:)I_T-@7H\
M.$HH8;M/SE-25E?_YN[N8?$NK5@.'GWHRGQW/RS^;_6E;;F_`JY?=C>:HBJ*
MY?.&=Q8HY[QK$U!%4L-304R'>F$_P>98"XRM1=J@7`#'MUOQ4:*AD)/FT-;E
MZ((<*JDP!@4Y??:UG*,E!2GZ6`A"44E([\!`0V"=1/)+F_8<70X$8.N=LTI`
M6;(HZMML)F"?DH(?4H<20*A/JH\-^-92[N=K;!2!*JF85[)$&R349&D;5>CB
M8.LS:MQ?(X/+FUT[I^I;+E9"M((WB`@AJ8)V36(1PM"PKU?&JDO3SHE:`[SS
M2IE`B8^0RG6N?VAU/\+9H9%QKY0ZX#0=K9T5*)[TN[N95-@_N!#XP@B5I\SI
MC2D@TO<I,&NEA]EG6=MRS;>2`UWF!CW/:H!A_=AR\8&AX?47CBS>WGY<3-7;
M!L<0BZP!%9"H(+O6)PT);\18$'39JGGW[KKNMZN;GZZNW[WY%*\^7]]?W4SY
MB5"SM"@27RV8/+L&:!G!%%-O6`=OF`[O\65K9?\[-B3C,IA@G=?HV2\H[QH=
MNH`^0Q-]0VKHTEQ-#0V0V5G>%8S!BE8Q)@7K\@HKQGC0+UL/ORX75W</RS_V
MVA!@1"*/":+7Y)1VNO'GZ#!*%WLV)4Q1ACHE&1>!1S(Q1H=%QA5N3(:A8[?[
MI8)&Z>"%CO=1$/KY]T%4W@II'(<:P7)4FP.ZE8I89V#,:%_+9:OFJ/O`5XJF
M8H4S$EPQJ03,*W5@K0N5/<)6ELYV>0\N6BT'!%TJ"O?_[%WK<^,VDO]76+/9
MK4F5[>!)`/;EJOC,YFXNR>Y,ZNXK+=$V-Y*H$J69\?[UUPV*U(.T;,FTAG;T
M94;F`T0WNG_]0`,(@LB$X$=!G,$TYFZ`%=(UKFI*!B/?R),ZB`][6H38@'9X
MA`>!CN*`N$;)DAE:2A:IQG%9KX8/^U@$`RX259K$,J*!QUQ#:&B9X$?&)^[Q
M?,?VF8S]3V<.#5&1=B%0A-%D6N"YL-4ID-)KG)Y'R=81:/OW\85(/+K9"'T:
M&!%J'NN0@U0`Y^IM:6+7-+S%M\"T@PP*.!XN]0F@J`]*$_JN(G4F+S1M!Y_*
M)\79O6?7TPT-+KH05&HFN#"!`OO"Z_UWA(@:L$+?!'_V-$"ABH*8&5P>Y'M:
M4B^.ZDDX/&OS#2K</J8IXH3[(0M5J&+-0N[AKB)+/.+1]@QYW]CSV!&31K#`
M$]3SW8!+3W+/U#D;*41C@HJ2[6-.^D+B\>V4$IY4.O`4]3CSN(KBM5*6IC__
M%IAVD)WR8^ZY`H(<8DP@!/-%M1$E,,H3O$7&GA[V])E=3[=382AB$X*CXP*/
M8A&KT+#:E'/2$A"]!?[L::<"S8RG-5>&N0"\H>*^J*<6Z/9BUC>A</O8*6$4
MEY1'1HK`E2ZCN#W#4H84-XV"B'ZQYY%T&S/@I42&@:D"/T72R):F+XGSX^;L
MR].FE(Y/X='-5$RC0#(I21`25U'?,%F+16R:)Z>_!:8=9*8@3/"5*T6D05L\
M[<DX%/6QY?!/4\1Z%RV\=-H.`G!-`'<C'V+)P*>2U7N6$=$$X-Y9J6.D\WC(
MJ>::,I][$#902OW:HXX::S3>A+[M8Z5<PB+I^XKXD8XB!J$FJ2-RCXM#)P6>
MRIZ[?#1,9T5)3NM&*`_W'$MB`L:\P$14R("%IBXXI(%HF"!FE'1;9C(WNG!(
M#X]N0H3T<'M"[E+EQKB;/,;!U70=TTV];P'&HU-]V)R]D$P9I94,%)A)ETA:
M[Q%!O2:E$*HHPEM<C6.3^W00YS!ZE(808F#.,(P(975)*C5!(VMH=Z/^UN3M
MB\$Z#`WE,HB$"@.7<UGM_.9&`B+V;1K/E39N'Z1VO[P4Q-%X)+1R#?&$A(BQ
MKK02PM<-(KEHF45['H5L!UYRP$<=L4!K)2@E,?57@D8X;4SR,]=UM\\5[*2'
MQW>Y7<8`(3%<(9&./:I)[4F&KMN<Z>T<0`Z@^B"\#"@(H0YB`D+'?(C+B*A3
M.UHVYRXI=7'CBF]/[M/QTM.&J5ARK-CQ*/B_4217:3[>R%Y)VN+V'IN\?6<`
M#&>^#R,'X358/J!K5;D'!J+AE)UK8S3O`9W[X&4(GB<0XP41"&;D&\F\.GWD
MAF$C/W)N:[R[I7#7@A8&,2<1ON'$!-`KB!I$'5VYGF[JDB*TK0S]V3T\.EZZ
ME$1,$BD-#61HW%![-8H0UMP`MW/!.X#HPTJ`\.1BH1AEADIA``IIC24&8HHF
M7"J`U,YMXO[D/ATN32P#$T,,S!AN&X$'U=50XKO-^D9)6^:3CDW>ONZESTS`
MJ"M\$4%\'VNM:TW5GFZ8A'/P++F1/1C'_8HT%2`F\TE$)2!F'&A9Q[O$\QJ!
MPCF5V[NE/I_$78OKW-AC+`9_*F22@2,L@U"O<L*FZ69I0=I*BY_=P^,'Y!%7
M(O"Y"&,N(^J#.:L=3"[\AJDX[]Y.'$#V85E9*CQI7!J"BC$PU#)4-:E*Z(;5
MIAQ\$]-2:'ML<O>8_".N8&#GB(J#P(/!E*M%T*Z@#3A1K&6IU;')VQ,R73R[
M#2+B,"#2!'XLJ%^GD")J&D44,.Y$X,[BWYS0?2`SX#1VM3!*><KSN,O"54C.
M6@ZY/6=\^]29W21N=*9<#[6?DQF#W5(B`DP'2/#`5H6D=K405%J69^DM"]W2
MA_W[N`O7(Q^XQ[D!98@8#\!7\NJ]P<"(!BU]I$S3PSOYP)D-N_AH8AY$FBA7
M!KY+O5"%O)9G-V@F7QJVL=F!O?NWBX>@:3[UC<(=/(7!TRA7"[CAGP9L-@1Q
M[_YY`Q#7&>;?B_G_I/.[AT_;VW&L0$30M&G*`]\WQ-/N:K6\XHU=-,Z9EH]T
MNMFKSL@XNM6GS%-!R'#--J&1`$@5M<SY@6G(W&MAS$%^`?&5Y"%7!(P]5RP*
M^6H9N_3YKBKA/C/CZ5Y#+'!5/L20'N&A+9JG]42:`K_PE3)@W^5T@0L#KWV/
MNCKR-=>,UJMR055V%;WTF0O[.!U$ACXF7WVF`N+%P`U=[Z-MXI;DW3="S4<J
M43F>A^@I3G&=J/(CPJOI`AES09O@K]5C%O4%R3A^M6FHM!\J[L4Z),:G,2AY
MG;TT<2-U]%H8<Q#X2^H1UQ.^+WUP#T5@8E);0A+)QM+J5\*,/39Q,:Z/6X!S
M$L;@?$*<06LW/@R#'K@"QR@(C4C@@R3$(F!19'BD3%@7!7(2-"HR7@D7]@%_
M)G#?/@]<?>Z+6!`W,G5U'["DP8)OA9J/E'<2HHVD(0`^B[&^)B*F]OP#T1(X
MZZUSWH]*QM'!WTB!NS6A/9<L8![N:EH[N[0/7LX1ZS0-^+P<S)^(/>6Z`>%2
MU9,HE+$>6,(7+L.,`=PT'@3A!XK&`1-:U;`'3F`/8.\HRZ85EX$)!%.$NXRX
M/N!?/9<6BT:Y[BOAPEXS-$P`)L0Q"\`(&,U)S.O@QX5HL'O4_'V2C//9//MW
M.@S3ZSD68R:301I]Q9++/8\]E>BI1"J06G#7!,H02C"2"6DHM"\;`:PMLUOO
M_>[.;/4;*!WADS^!C'W(B^+7R8.;.CXA4Z5\BH>I$0@Y*3@:KH;_ZAW22+/N
MA6UU?&=OGM?S1\(L(T)I&&"':QB!R,HC53D+Q!&\)1&_51;WHGU_Q$N():>1
MH"KVP0#&F@'GZ]/L-%&-N>5S5Q[<=]2&<D_4T2C_@G(5IC?I#%3C4_+5*XIT
M'MSA7JD_3[QQOIC,GT3,NOA#?XV,F8<ANP2!"XWG5P,1B*BY/92=/UXG9]\N
M;M"WM6MK>1KEKS<V5;ZVN:N?%-G`FPS#;+28/[P%X0X770<$!BP0FG$A6!!'
M]4FQG"FW)9<O-"C6)DX=UMD7H9?_@_YC5Q:#"FD(`3(5,T$0,T[J[;2UT6WS
M*Q(L.=/]I9?MHI=J$F!=.,@ND.Y!Z%DM"5$1B?VV[?XD1?>EO_3R7?0:NSL)
M]:F.E.:1*URO'M]`J[;-'X%>04U_Z16[Z/6\4&I7N>!B^2P.E1=Y]?@:[;=M
MCPKT2M;C\=V)5[X!HRB4&QC/Y9X.=.#5\33SQ0/T4MI;O!*[\4KXTB,Q>%ZN
MP--+:!2S^D296(2JG5ZSM;-EK^C=B5=QY'$?BRVTY!ZHKV2K>=&H_7QM287;
M7WD6N_&*>4;A5MXA8RJF8')-7"=60*_;3KT&>I5Q^TOO3KQR0Q4)#(E)I"(J
M<=J]3I.'+F^UOP;"#]%C>G>ZQ%1Z$'K$OJ]EP'1$_;C>G`2NMMHC\,.V:K>?
M0>_HZ^SKY?I!'_^;S>\^WH^G=_GD_F<@Y^?)X!-0Y(\@Q'S2409^(!4H'`]"
MZ0$0<[_>&C*.C/_N/_\VFE\-L\].,;\?I3^^NX$FSV^2<3:ZO_R4C=/"^27]
MXOPS'R>3*WNO`(?_DI+I_.K=WV[G5UNOC[))>GYGZ;^DC/SUP7?P>MLWL\E=
M.LOF#[[W`]XXL!'[YY>R<]?Y:%BVNLYMYPNPVZGX[2##SQQ@^47CTS\`T4^A
M'\?G'**DV\GE*+UYF*Z#^)&,IU=_H2YI<N:IW9LF0Q3%\^M\/L_'<&WZM=%E
M^W<V&0*#+H6&![JDX=>)\U^+2>I0>>:`%JDSYT/Z-0.^._"Y%((O)YO,<R=Q
M"F@"I#&_<6:I3?XZR>TL70[;=)9_SI`0YR:?.?.[U+G))A#"X15X`R\,@/9L
MD(Q`]3^GHWR*+^*]03K#1!G^S*"EX6QQZPQ008?PD>(,/C\8+6S3'_Z/$LX<
MN%?^Y&=.,LKAAA6:!.0EQWRT,P4]'R>#=#&WWQM@9JJPF=G"&>=#3%UC<]BI
M(AFGSCR9W:;PZ:2`:WF1;O?!>8^/EH.M&2-7O\WRVUDR+NI+].K["^<3/+3&
MDK+?R";GE_QSR3#H^3\A/+=_?$H'=Y-\E-_>.Q^R@<TW>=7;SG0QP^S/W`'6
M?[G+!G>VMYAC0S)'Y?-#O+NE*PD^.(%W\M'H_CS_,H&GBL5U`8.3S.Z1R1LO
M.'\'-<3LI//A0^"\7Z.QNK%.X]EZ+ZH;5%TAL?-T-$KMZ2@H#%,8U'MGAG)>
MU/("O<7W*^Y=K#Z..#K+KJW)>"[(#("GL\N_V.0"*74'C$U>'HMY.<DG:2GX
MWPGI0#LCN/K<3]KV&H/AH%#/AB"0<.=F`6._2PTV./-ZX>3W"1*<.-;6.K\M
M9H.[9%VRSYRAE84MS+E.YU]2D-MU*4=MJ21D0_*<S"Z:MP\4\`#RMQ:E8XF/
M.G,E.7,9ZT9X2F^F`L&!G3R!1M#)R$N$7AF;BFTH8.G7@4V*6=P]FNK0CE4'
M1S*QQ(P6.(N(^%<*3FY/1F@B<'6_/#EA':1`4I*Y<YM`*^LR@[\M'J&T).6T
M`)B/4:5[:5EAO0V05O!FZ?4]/IM_J>Q&W6H.Z-;2V@KC'&M@1_<.)SAJE#QD
M8">.!PHRW#836Y2NV8BFJ[2A,J5Z9./%"-S=-%\4T(>T/C_#=G*SZ16I%4D5
MM2MJ?ENS2W@G6789"!D7-?';[58$3Y-L>'Q-_8Z2;J4U+T=TI9#5T%J6+\'I
M6-11?L:X.I/4=`U$&R`$XSU,"[`A:7FS'L6'F,$0G7#;DN(&XB"47'@+A#RI
M)\F/)P!<7G0L`GB.'(CS?6F]K\&XVH^"NC>I.C12>5$[7:DDA.!YZ;5:,SI.
M_DB=Q11_OEH_+-L0,G0M05"M4UV.%S@3I4O]!;Z*]XNLL"[8L2B6Y*\=`=&-
MC7HL">!VE7L@52,[2P<IF-)B(Y9810\6VR'P+I;:^3Y9MZ\?ZF<^K9[9L+(+
MZ^B5C*P^>6M//;4Q2#8;`K_7@@#X.`(*VA\[9[F,YLZ6H1QXRL^*WIX>O'WX
M";[GM(5P9Q@I_0N"&-O995@*/DE:GLY41G@M\E0*TC5\>I$ZV8VU`E\P"FL,
M1;$`;FT.U\TL'P/'6AE^X?Q<NL00*L#W&LW-TEMD1PZ!73+%$!SXE95O_#[)
MT'NP11I%'92/D]D?J66?=0Z245K)$+P]7`#E@/W@,-A`'CN&+VTR#)[,<AO2
M6/<%GUPF"%I)J#^]/OA)90\L/ZI/M_4<PW\0V'2Q)NM;["\[:EMZH`\K!\0.
M%+RW,E]6C!;C8ZK_BWC/I3-F9^[7<BII63M2U`S()H,%SJ@[R0T,GHTU*I_P
M`>]MJ>(8S27S,DC'TV8K!W`KBET?T#,0)O@?/@8NY7%M2I<(:TFR(@)V93"H
M6-PNC$7IX]8Z8E_>U,4VI=WF+#9N7VW7J7PQ1P2I1FRS?1L6@!I/ET"V/B0/
M``I:_6+UT4JQ%E.X]VCGM[3K#@.O2;[F%-5^!>:A(,Q*E]4EVYS;CPG%'LA2
M\:O)+!C,;&2OP[,#<(**^N4'OHKVX(CN?9>2;,E<CNTX`7XD:*M+Q*_)?G2\
MP<=]R`Z.`5FOTU(%`'T&27&'=CW!(;K.)O7@V!N(6NLAAH7ZI2AMY!:'63&8
MI260EWEF&[]"D`]B-LYG.*X06+S&$7G`HE7^1,W(-3:5&8407`"<U'*$#;;$
M5HS=20>_DQ>Z<\^\'OJ.PF3;L#AS77:F-/DV(7!;H-O1$%!Z(5>A=:>#T2)W
M:YB]!0VERVD=QXXH8[Q;V5I,P0]<HV6ZE:E:SIDL86<T2JZ7JKV:LRE-Y\_3
M`ESWWVP4XGST/CKOBS1U?LGGJ4/=,R?8?!?GHK9G;XKO>SI=">]=SYS!*$UF
M/[Y#1'OW0^NT;K\S%J4/!MA1.0"/>;`VNXP)S3*,;$Z"66&_7H"Q3XMBW5A9
M?PF>F*2E9EL!0:=Y5W,=8_$>:<ZNLUQ+O#ZS'+Q#+FUFBS8BJ;6<B\V.E8K6
MXN:5%GU18!H:-.ES6@;6-TDV<S[;K2&6X]C6S&;PO(K`DR/FDX6\<+N/X)"$
MM)AG8YOVO[8.U^B^A%QP>ZZ3ZVR4S>_/D2OH%>`ZJ](I2\!M6X`?F_V[C.S+
MJQ"#0$N6US9F`3HLI[/Z,U:BX:MEBVCG0).SFVR`L)E-I@M,VZ"?A<'?)$?[
M4*2SS]8_7P;K94(!([VR4MOZ[1AN0E2XEA)>MG;A_'<*=('E'Y<IE6J2_-)Y
M3[]?/9]L]OJ8P3D5'7EW%3BM9XJ+*^<]ZPF=NF,Z6U2]E.OW?(/B-5$&R/C7
MHJC*Q.S+@_ME>+')F'6160:8``5VXA-#@5F^N+T[&NLJWWM-OFGIA7?"T1)M
M$UM34V7<X`=8IK,J4-W)0/"L5]>A&;!=\&XR0\Y^7(O`+?>*2I&;Z+MI(NL)
MV4T`'F5U5P`C9LBN8?E9T&Q<C95B``AL+'_#QS8_],!'5LTN,UA5-]'XVYE7
M1#KL2C[*RH*"HEJ.5CGNJS6ISB@OBJ5</9O.BBX+T1TY^1>B6W,R7-13M_?@
MZSGE'&TG;;^X\%>RTB%_V05[_?SE'8++"\BPN3"OG\?=U/+L#OZJW__QPUZE
MQAO%V`$XY=YDB/_AXEN`,WP]!),)2+>8I?L4*/LN#4S$J&:1B,-(,;$Z4M2+
M6'`J4+X*JIR5_;'&<7MQ;<5E%X$T&N[LYKY;MCR_3OFHH7[34*\RQO@CW1J"
M;&T1[ETZ`O]C_E:\04O?L6CIS,R4TX4X18-%<\5E%V(WL//-3Q>\M6:KJEB4
MW$M2E<0N&\&_U[\[R6?C9%17TL[S*3;\==5P.4$U2$>CY3,_OB/O[-_%-!E4
M?^^/EA!+WV:3LI/)8IY7%VP!17GE2S:<WUVZ!OMS;6N+SVTN<UJDE]6/AJJN
M.CZK?]D<*'1W\N,[/`EN!H-4_K&"T?EP]7/6VH3MS8_O.'&G7S?:6&N\K;W5
MJ^;0%]7!;XI#7Y0G(D]$]IW(AU1UB4:?TYFMJEK"0[E*X&H#'G'%P#KVK?^]
M7%6P?JD$)[SR:#?7`+D'B[(VN;WJKGRWFUE+V*T66$R_.C8'X536]1!F+MNT
MIJ;18"LZM_-R:2)77#&',=,\O%;/9E?JV><'79T'.'T2SV>*)_\&TMGDY2N2
MUVI')0=W@-J#XSV3R!PZ<@.N].5=-@2O]221KU8B?YKE1>&LMFYR<.^FW9F#
MDV2>)/-;2";N*):>1/,DFM]<-*.Z+B+&M*#=VO'D<_9$6%^`5WOQYQG2=CAW
M>B8]_84Z]0+2TRML>F]+$_)%D4R&Q?<G$3H!T,L#T$$V[3H9_'$[RQ>3X?ER
M0F@P2-.;FS=F[(*'I@J[4LU-YXR#YS3,%S@E]*P4X$.#TQ>V?G<T]CTJIT^U
M#$_GEI7B3ME%N3ICKOOMF=87^<'W]EY\L`^'^H-NO;.D)S@[P5D78J<99<>3
MN][+T`G23I#6(W$\0=H)TDZ0=H*T$Z3]62'M%'1V#&>GN:.KC^E@`?=PZ^]Q
M,B\7Y>`R>-S<>%*NS=E=WOU*D[I]-`(G(]DW^>D=?T[R\ZKDYX0_)_EY._+S
MDM.2Y+4[4@%2CYNKS,OMPX:IW=?V$-ECCY6/=1EE[R&"W4<T4C;79'>=>NB+
M@)QR+SV`]3^/:KU$_O.D8B<5.ZG82<5.*G92L9.#V#?5ZB";_>JCL-\O/EXX
M<]S]:C&[=XHZN?T26O;JE(D1>B;UDU=S/R8Z?1GSES9))\OSAG6BN2'221M.
MVO!GU8;WW547-,?\Y4HM.E>BTSJOD[8\T9]B]&1!.HA#GABRZM<>H'S*Y\G(
M*>[RV?P<3]5=W]RRLTCWJ,6$3]]FX%1I^!B/7X"5+P%[[(S^?WOOVMPV<K2!
M?DZJ\A]0/ME3WBI(2_!.[WJK=$V<<M:.K<U[\A$$AB)B$.#B(IGY]:>[9W`C
M08FD`!*D^JUW8Y'$9::G^^G+]'1W&I"&>!2<QP'3AF:[,$HR2AY#8('QD?&1
M\;$1O,KXV,A0T\NIN560ZBA8M;((%N,GXR?C9_/P$[WPUH"MS`;'-/>/D/5'
M+C?NU--H&&T*3?<'B/41I0;7N3/2NZWJ$K^>HTU3N*%N5Y@M-H8:AIH#1>F:
MP@<,,@PR##(G&^KBM"L&(08A!J%2IPK^8WMG]\C/3]0:MO3ZW-^Y>1UW(VCN
MR,L=>;F/*T^2)[F#J#;,/&U2=Q/NQ_O"?KP;!ZV8.4^@C5^S&)(;[KZ*WI&-
M8CKNJ<O,UQSFX[:YS'U[X[Y7W1FWV=;?47-;3?L*C&;<&9=9:&\*\35"$/?&
M;4QOW"ZW*:J8?"?1IJ@ST+NCFC::MZ%94]@'[^,3KHW/@F$T8S1;RW8U]I%D
M2&-(8TAC2&-(8TAC2&-(8TACG_/@:';T>T<O)R%WQFV.#F`=V33^:1Q]F'^.
MBG\8?YA_3H=_N#,N=\:MEFC<^(Q#+WN%]=<C6G6$/UG$6,18Q%C$6,18Q-A`
M;)IH<6=<[HS[)'%&AMX:]*J2IZ8L>=T:B17/"8L$-\9E:6!I2.Y[6UF7S]4E
MKR_/@@LTLK`<RIH:L/ZHP`GAMK@-[R1QW&U1N"%/I:C7;U>&>MR/AX.EA\^V
M9I!DD&QF5('QD?&1\;$1O,KXV,0X$S?%K3%\Q?#)\,GPV3SX)!]\?SU.CIOQ
M#A+0W#]`GGQ/W(J.1#>%IOL[^5P?4:I'-J,]THUV37WD2FC3%&ZHVQ%F@XVA
MAJ%F'S$Z!AD&&089!IEZ`UU/D(4SKAB#&(,8@Y9\JB&;.W6TQ-W;P')$6^EF
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M\\,_9+LJJU48=Q*,C^*[`ZN#*Q0Z8,C!*UU7FP)=W,69Z\!0"GLY5`L2Q,>Y
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M"&-K6A@DT"T`P@>1HC3\.#<#?)L%\P5^\FB)PPA0>^J["`AI59/!SR3!:T;R
M&Q!Y[5ATH`2P%'`3?0DX#%CCV7)`CF>Y,2I>H%9Z&7SIS\3:U;%\R8NYN84P
M7,T),P8@XLV%A5RGX?L4_\$::#,137V[&A6YI.PV4(]?8(;`C[`(3SUQ`ZUY
M?3,87/6,BU['Z!K&;>>V?=-*M.9-MW5SZEHS(Z26=@&K7$>6\6"B-AV49EBX
M`$8`FFX&?!_!?UJ0#8Q4'^!!'DWA4H!V%^0N((E!`/#L\0)49A2A$@;6MN"9
M3I0:J."``Z#@*R/\&3A92`$SQZ@/?(#BB6DYKA0&&,+?`7$>A>OJM,3_@*>*
MA?8V!`W]&P!C-A6C_6,U<K`95Q?%`XE`XW<>Q$40F-Z]0`J56)V;V)"C]NW(
MN&FW;FZ,JZXQ[/8N+Z4T#&XZ-X-1[=)0=>#E):Q+'U>Z5^8(#JR$_/,1&,D#
MSKJX!^/M^7R=#<'@OW$(:+LX1/2["7!%]R48,05%"XH4.-P&A3Q&48\<L+(7
M9&J#I*-$!^)!>#$ZI($_T^P@O@<M&5JXF["0.A,N</TYKA#>YYB>A7HU,H-[
MT+P@8HXM%]7*+W'FX!;N]VS4R*`R9V2:XX-,L.<78.(E9L=\"I_`_+S'D*\F
M)A-A$?!H]\)#2\)%14TZ^YL'XNG'D38#5M*U>QRS1^^Y!X%63@Q*;P!"BD,6
MUM3#)P/<2>:#+Y$P5N#,Y:`!'Y$H,",3U7GR"+!08H0\9QR86,X'<"5\&KL:
MPPQ'&T==HWD_S$/A:9^G9C`SM:\77U>782>G";2W]LF*?/#+R!734P>5>K`2
MPP%SF"EL(6,402T%,NTM\G%BOK;!OTQ^2;\S?OZ1'-KEV6AO<[?1C_E;,B!:
M(US(JC,16`XJ=SDJ$!PUDYP]'4I!M^`6ATS^")X".A3=`4U$SIPL\[<?_S^C
MU6G_J(&,H8^>2.COGH/VQ5?T'4*,'7BF;=+K_V&"Z[(R?44R6[L3X#FAQ9"?
M%+AIC>?%XY8DNN]W>*[DF90;,QXGO(0%DNP(2RB^@VL4@N;0M<!?`.8NSL8P
M;<>[UVAC4%J`2A1B>C3BYAPX`H9&ETCL!(Q^/)OZC]+RS)AS#<LYTGM:Y1C@
M$CDX,GS#.48%,H<7QV6#"7J/;P>5`7YF^-(W:O,X"&.@BT9R/XNC6.K.^3SP
M4:6NRMK<-3T8Z-=X_%]06C0`$9!9#O044L5D1']T0`N/Q<ITX#<[MB*<DP4\
M0VH0AFVZ19/?'RN#_SYVI1DN1P97$SJ4398>;\*8/=\!FV#AV0%J8D6#FS@`
MTQU6'P3<]W3E'^,XP&<-A32$9W.70@;@,Y01!<:+-D8!F)`L,GI/4YZ:#X+>
M-W&"4#&+7"R:MS8C%QLN"%;FCP!4,B^@><$O*M(S4FX[W8Z6S_)3E^>%-ZR;
MQ[EV5WB<#:X2$,M<?6JRO/!&WY*/%M&C$)+6<S,@?ZD0-/`P#$,P2_&3I2?"
M+$N%6,K%W(053:@`:QC/P:##09N+F0JN5!L4E)D.[0Y87V`5@GJI9.^`%'%"
M53V_K`+$F]846"40E@!PDC:KG/];\T>8,\DJ/.#^'F-=,I9%O/G=F<%'X-0Z
MB-!I99JY2FK`A!1GF-;4`4Y,5E)%EX!S\N)?T/_@G\<>,!&\!-QCWU.V[-OQ
M.C+50!BEYCO][L^#]L%(1-9ZC@[`8]<QL1'>!D22&!V!71\'=+Q(0M[*(PFS
M8A+1);(OOT+':T.1")\"`\^/)-Y;_KU'X4HS];]@'!27Q:?%X*:Y^(0%A2E!
M[WKRVB@7'@:)P.>9J428(<#0&#A\CO$;P%%G(C%WJB`GQPDI-LD)VD4`!:SQ
MT>QU(E>J&D`J>*:NB1#0R"3-)*T"1#",G>`W)(LN:OI'O%>0`IXY]EDT=236
MS8$SX2?S7L;#/7`?)>'6P/IZW4QN6Z)CS7S$RIS!`J(E`G1U_#A$>B`RPG7)
M#`'A)60DRF%F>O$$7$1<6%K->#Z'^Q(8CCT9^7I&]13,:P*H><(U>4Z(5R$<
M\?W^'J-O]*(Q`)VT)RBP]TVD5@0J*B"UR&"=B/QWWT66#;,@FV88NI8+:ZGM
MLZ^+V7SJ`_-\L!!</WC6^8^YI:<@)E&&^(,<G\3MR0&+(H^9#C]O*#U.'2!9
MP<11UQ>\&2)2[IG*L)%C74-J?7F`0`.)8C`06P$!3#F<P+!IVX566*K2Y>&S
M][Z?+*@4KY)]7D04Q%%PG?U'LMM!L3^(`(%,L2D:<$JV\=($(15N)EXM.9G-
MMVB6#;%WK]7;+23T8GWO9Z=3.O[23,VGYU/,J\X].HE"]%\<]$[9/76<4^\X
M\:V!FR5VP1_*JU@)V6SHH];"0:-^U=*?:&OFF:=Y)N]CAB)XH(2!G#T&=A,H
MLAD966L\>R;QTR0N&E7D?%O.7,D62J`310+U#YDO<B=A)<!:M$LJ$\+""E0N
MA2F(2*]B)6A%^4+,/5MPC[)G5RWBM7:KM/F?-**KLT<;;00<S/RT!6:6.1Z9
MG[`XE-F@-/34M&4>!(P,>TU30A>XQY9)J501^<1>B6JG)]W#-V&BVM%<3>*9
M6RIY1'9DKG'R=-J=I4CZ<E2LW$@(DY0OX"M`M>6M(3F/N1_*R"B-78X:W69/
M!ES15[<)'Y'!8]=.H[*KX<UHBGNOF#^'Q+-4-$[I+1CR!:9Y@2T?NY%>"%UD
M*9_Y5<`Q+B-NJ@U+O69*\$SSR%(WW;0LC`$`.*@,P.2]N<`+A6#](.]+)*-2
M&0IIU%9Y(>FJP$+:CHPE)BR2Z&KERJCGYR>F8CAY=T8QH>.IG8%D'&;FMB^-
MGV+;<@IH"^2"1W0?13Y6!UY*SX38F^I%5(B2:"!MODUC=6;9S)6)$J9OT'/,
M*+ZC.R='-,;!!GY\/Z784+ME#*K<`&3P2^[+A3CI,ES^?*P3UE?N(%$T;W43
M28HL?`(V-L>8WK7()&5]+`CS.-1NL1*J*/#=W"YT%L1!B`!1#5"-NXLB1,C4
ME1QD/_M6,Q\=R\44$CD#Z19I%#<%D:=@:LLQV+Z0(=F9$)&2O(F3Q2O,PJ@(
M?CTA["117:$6O(C"F%N#`XZ6`K<EFBX0,ERLA<![E(N:Z`3/DD$WW.G"K!]$
MD$"X>?QX:L[T@G!*BF*G.;#@[]WJ278VI:(@"<D69$D+/JI-ATHLZ;HC:WF+
M+1FX[]$&P"+C5OQEXGS'#15*;I,$RB/%\T*'1SO-,*,5WIS'5O6@?#)])C-F
M*./D@@RN-%).,H1F0K9/DP;YTR2,+.P/\I7^C<*&2!-.85:4V`,0CD:;1#<,
M@!>1S79L0BJ5`*^V]]/GJ7!3QB`%IEC"G9R]L?Z>XC8W`0S:T6-,N(?_:&]6
M9M4#>WCW*GH/7PA3;<`\:=@EC[#5N86EA^2-L3P&CTG;N0LRII!F8Z7HSN1P
MY5$`J1%I'.!`*]/+D]_"*W#D&73*'2$<6QYJ'6\>1\7MNSB4")M*J+2N`O^_
MTE12[UX:?7)BX5UNRFI'4BVYW%'3<[\G)Q;N?=^6AQ7ROZK3(3`GM-(\=62"
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MD@JXYTMQJQW1J2SRAL9O18)BG'>K)543ZRI4<["[$F?YE9^/DA]7#I7<B>_`
MTA\\H$T4JSSIOPG/GSF6]D_,IH/Q5K2&)6<ZL[\^>-H_8A#9=JO5RY)?5;8K
MF.%[8^6_=GKGK8HQ[-$$@YWV"%`^)<EOT,H%8QITV"V>L$KSM0-A9H&S[*"7
MC_X]"%FP\#U8FS`2,\T"FSP]FH5!0!74[/1:.LPR^=W+%5W99+T+1W'N/OSM
MG_E#*\J0+TO]DVZ2B'`T>&0-<]+F<U(PZ?DS?2E/#D^8N4+Z?;CX@U(^22.H
ME)_Y1^S,YY@4"4.3>5,XL['C.QXA.F@%=/<FT:,\?*].#N22'DT5\Y$>7G8*
M#T^_*2<=1YWL?Q"!UQZ,+U]/&BJM_!YQ^*]&Y<RKB"`G>4$SQ__^B4<E0+V&
M&!W_NB!V+&/AW`%I&7:=!&88!;',.467EAC[.3I7J0#J31X['HVP=#@*HS&I
M-TZ,JS][MJ2`55G>>>;+_]<?@_<O[AW/D^X_%5O2,6G;FB;QI'PNOJ'WC;[F
MB4=Y*]P@.6^\T!(C0U.V1?])J*`\67522&9)YXZ<3%2J>ZI?X/&$)DE1%7F^
M2.X&))$6`O#0CP,*KZA-8U,&]NA$((Y?CI;BK0Z@MHE;1Q/<?S&I0$<D#XOY
M>%B,CBHXR0X3[1N`ZP+3SNA*E6$F8`.7%TTIS)4`9VG"R4M5I(Q(*@UH@K_D
M[8Y2$/C^,`[F;APJ\D=R+&N*MN2.>\G@BWJOCAGXR>`FIN/*(VGT)!E,6L,J
M,E)`I5F(=@J[TV=1NC\F/^\-4-MZU^A59Y]35!>7.*,.UO*A=5Z1D\Y3BU[0
MO#/SNS.+9SE1$M_G5,PA2P3/0NI/+`YR0")\.FTNUGB$Z"D]UJTN=*.J+&5G
M^BIRX,Y[%6M:E1T`*P\F<))E<N\\4(R:J@'(TTN+5+Y7CAV@T(Q%>H3E2=28
MFC(*0!9*-'4*!S`H>#`104`GK53>!IHU<B<"#[PNR-=.MDPL2\9>Z/`F*`J?
MJB,@M)HNA2/"J1!KJI#=;69@`#KX]W+SB*P^1&R=IH':<2Y(118!-)M1F`0^
MU%?)5JV7/\F8A<C3LC++"JI'EK62#R_)BR*UZ><28E+8?,H**"GSLGEUEJ6J
M+@FHAU@%QE?Y`!8@^VZ%78;7HUYKT+WN=ON#WNCFMC6Z;"6%7?J=JRX7=ODY
M1W-5$R%'=8Y8U!6Q^)3NVWVD^DR?,A&O!(??E2'412K86#7%L1WT<:D^5)@O
M!X5LH`I%A7/3$FN+0JF\6,"6F8S4R5I3V5ZYA/7<63Y,U:14S+FC=I9MM<_V
MCQA<;9#AH4R6_*<96(D2(6LJ&_!200^5`"#Q/O=FN$:=!9>C(O,RN;CPRMZY
M5D3QXG34IFV8/SXI?TF,$8J\8N4"N06;#TQ+2QW<BB@PD?G.D!'1A'=RFYO%
M]^$8GU1YCMR*OH]-/)KB!R7[F*HX4(YJ21P8;J;7/%N_<(,*94]6)C.7:I.M
ME";;>"3(-'NSV5I5![3W6<ZS^M&O7W!*H$D6'#^=5@G6)U1,39.JL!:K.H$)
MUI=;'HFZ2*U%S-Q,@$6I@K3H"88H9S+Q%,$CRS61%_*&1D7C+2@/LN<QZK-$
M;=JU.Y0C6W$\=G\%^P$11T>,Y^V*`PB%[=7PM/97]\=4E2'UOFM]5],@8`/]
M<E<H$1"I&(NRHV%(9Q9&4ZCF=:$LB0KQ%LWKE&G5-@P=?LC<D"S*).MC)YL]
MY8Y!P7MP\H[&:M'?2M19?S?MT*]0F6T0N2@_"*H4'G[./]3#_4FWT+S*:.7/
MALH%QXU;=<W[-ZTW]!D=RN3S]C&71\>.IO`GS$FUCR(3=!Z*=\D?*YH[&U2^
MZW;:3JI;:#.54O;YOMTTEO=OANT?GFU45>R*I6XT=KVOOY<7'GV[\M%N<C?:
M4NZ*I$X'VWGS-*6*W<]6N]Y70TGU%A+0E5>4,GXY:2U"S6J(6QZ&O%40_Q],
M^[JA?<U-X6ZOX\QMWV[*%BQ)M4I2#90Z-).]I>TH/P[!/`PW;FFZ$Y^MIE-;
MEA"32:,8\.4>-MIW6S!?Y0RWELQ-(5!U+4^?8ZBC:'6JMP:5\4OCUQ[OJZC!
MZ7$JN$KPI;^+<FO7H-RV4&5U2([1JJQ7>5-6]R`"\GHT\Z`.R:F4?(<6J0J[
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M:8^9Z]^4/URX5+RT[*%R'52?SO0`%";NZ,EY%3S2HNI:I[/DK+S:$.2CN`=I
M^1SXH/NH8\M>^D3+(_=8K95:^<R$JN^+&=>NZ<Q4OW0:VSP;FSR^:=)9;L4N
M,F\#"P,'H4@P9XQ'X9/61<F1S[%PL;%0KO$1=GU#OK.Q!;ML&D>]J55U/'6V
M2,>F<I@23!4*;3SY)))37ZH%M:RO1.G"66M['0O@F1Y5J<2*Q:KJ9J"Y#@BI
M3;WCGU36)6>0MCE+M'0,R<,]/CFT+T[X;<?#1_WKT8UQ.P#.[5]>M`9=XW*8
M]%B_[ET.3KW'>H&,N-Q7,OL?*5JMTBW`)K5-%UGW<+V8M9X__2>UIBRV(^;`
MF-0-*3W6;.4GD&^M#C+U[;Q813'"#H21ZIGE.3,\`?'4D_`15%YN:;2JOD`V
M8-"K<Y=RI@I?PZU36.FS/T`4Z>!U*CYX5#J(<QI2C;%`I#(2H!J.O5!8<:"J
M:^(WV=!E=8LY];JU1$QNA"QFY_BYULSR!"4>QDYJ'BF0*+2=W>#0AZS&BVG1
M@0."2V-:%.HRJN4`T0RE28*'B;8'BN>E?1D>U+E0N$'VIM\&%BY[U]W^I7%M
M&/WV1<>XN6Q=]Q)8Z%P.C5.'A4M3E2GY+`5.IJE6@P=W3Y[AS62$SN8G@I34
M4!695"R5NT:U]3CU0>>=^8^>ZL9.YZH<(8O[@\93;Y4MS&"AT].ZZNBPM'-!
MK\H#:+8L+IECI6=J/99R[EI&+'#LM1B7G;W=@%F-SN7M97<P,@:]R_;UH#>X
M[G029KVY,.K7854[M-4?H$7B/GE\\R3-[_V4H:EBP4H-$PJ#H=+#U:NH!?T'
M3_O-?Y#9@<46]%EY*!,-H8F@1MP5G)>34=7AH.HB#DZ^7,`<1HL%"MVD185R
M'"IY5>^\W?NAFD'GE_6K\!SP'K"79JC9,1[S;1LKC>WIY_2S[&6/C5JHJP&5
M>TCK<F6UJ[5[<$CP1SWID$#U';`,B9#]GY/RW&DC`0O&C"X1>?%C9Q('24G9
MI(\'VHE!":D?\]4M3#2I,'8-SKYF(^RHD$29A;>^>D5%_3IJP:@:0XY[02PT
M0"33H;*7?<A4LW5/DR]%#EEFQ`_)+WEFU#6Y>/)H;0(M&8RW^[K"F7QC\M0C
M`<[Z/SQPH=V:P;VO79K>-UW[[?SB7*<2]@&00R3%O^60QYA[376KL:X[!@^T
MH*+FTA7+>D8$<`Y42"PIY1**F2/CFK*/DAD$=-;-EP?^LUL-HM'JH30C+5PO
M'YP5-%I]A*[J!V1$G*D>\%[9DW7"H:+KB,5N$"W`EQ%"UE:43P(PD#VE9+D_
M>"PZ>G;:29?Z@7C?Y+$I615&A3ZS*H'T)&[04X>H8]=F[(&E(KC)ZB^41B#D
M=Q(59"8??=F9`H4+?06*YN77&6UTDK@T+*<P/OULPROR3:SFZ,*G+<\+?'*N
M_3XG\R-14<4:YA3;4Q6'L[I>?S6H-E"9UE<S`_Y2L\H5/@NG9B#KX,N-C-D,
M=PXB=#,$!BFRRL>IOE1-H;%&4P@J<IR%"E(\E**R=`]RNNJ"4L$A:%K,87MT
M;@P'%94/R&A1H`-BU1/4E31]FP6#9)VLM.%+C@II^X)J#$CCO-U:W4O>:>HX
M1YK^\NQ_7+N4I7M4Z38*;7%@E#K*8M'8JHBN3,M?+=!`"V(5MXH]ZAF?J++S
M8O>][%QJUI<]V793;Z,P.)4:?Q*%5X2)^C&9H2CC=+4?-278P'"")ER8MJJ<
M(B$#14>R@0P.>,*2?7S0#*7M'W-YL'1E,@\GL.*9[.97374&QOS"?1\FQ28P
MN#5[[Q,2H@HV52LN:XI;DKI:Z[!0!#)_ORP$"=[`U%2%'R@<3-4?)%<7MPGS
MZJ3LC?FG28A(H1?/S":JJ@Q\,A4F=W:S)]E@6F$IS2<$#.[124*IQ2;J(BD;
M3X_P^6`M,^E.3+H*'=06*PQC<@+SJUW$,&"+F&HE5J-6.E47(\+:UNCVIE.A
M[CG)?KZ3!G/)CI"U;<TP%%%J1#U5TE%Z0B7/E_D),Y3$_TEW+.7[I&;+:ILB
MUYD4*:TJCM-%M!^*!1?3!\U$-/7MI?X?2\T+2Y]-X\4H0<'("E$UG%$+!0H6
MY`<BFXJ=3K$FR<+)8L*\8B];K++EK*+[Q>9U^,\[V;RK%`9&SGJB-Q,3M*SL
M(%T0W[URS=`X;]7#-J=7J(U6)@>526>'!^'F8F5)#[]"*A=FLUBRE2&:2]08
M#OMW4R/&\2*UJ[.-=[C?^T;=&Z/`M&5Q+GA1N*14I4)"O8'N"CPP4G4@<0,;
M-]AEM7(PEZ15!,_[(_;3BZ1>`(J"&P@J+(Y\V?8'KU$EU:F4<'-3O8X5!N3'
ME1VC?X(^N3=AH3[Z9MD^[8YFV@5PG8O]0G)[1:G93<X@?!G*&G"EY5G'L>/*
M9"_9`\3!]*Y<LPIL/`!<^7^^;[M82T!7!:K)*%2Y8BK!;)^]:;J5M_?`9I)G
M,BUNEJR5VNZG]@S[+-G6.A]6OAN'?N':E)ETQJZ/^XN!<^]084=9;1<LP+PI
M*%-_@>GD=\I44E6RD(E4=]W4-*UJ"V!3`@[/VYUJ=@F4.9V2APHHJE*[0-.O
M8AZEN[4=-)UA3$)MR!4B/5)"$FDUNGAM^FF@9SY6824*VW&44)SK9:P\;Z1X
M&;TI$AN(F6J%%'M24=C+4Y(KG#GT.3.X&A\.N+E=CR62/?6D3!):(2=,=G23
M!<%TMC'NT5DNN*0R!QPKZ**_[15[F/A;]2(X-8,NS'>V0J$`M95U3"D(V>-4
M[7DJ)U]VLQ?!@U@J3ISVS"H`)9IGV$Y9RE28/@8SG>5:!2*W6AB>5A<(5\:=
ML5?S:=%?;L<XH16'LH,V6;1:7]<NY-S_GLS]*\Q=H5'1"G'3//+MEB(?NRDG
M=+0_)=X;5=X"=+]E8P<5U^O-5_S$+7%8%8*H>!;+_E(V)E!;3I+7<DI"H=B\
M&!DH;6!49.JL5G,H-T7-("`TIX>LKYNZY7O6^[]:ZO;*+Y.^[]A5'C<:)J[_
MF'8.U(N^<5E.4:XIO=);M.&E(OS@H`1R7TVUE><(53T1JG5U=0LG<9)2NIEM
MF);3]2=K5W@IO^S4Q/@BK]S`H\8C3;3;MKPQABF#LGU93W;I(_Q&:U\UU$MW
MA(LB#Q=EYD.YJ9?;TENB]G9-J$YK<;CX,A=?3BG+Q9>/O8A1LTO&<O%E+K[,
MDL3%ETN9C(LO<_'E/1.(BR\7ZUT.>Z/:*=*4M=\I'G%*"JX2?.'BRT0(O4*D
M;<KJ'D1`7H]FYN++3RNCOMX>K39[8VW$VHBK+V^2X#%L&^UM7$_62:R3MK'^
M7Z%.JD&P6#&=OF*Z@Y^$.8E$4(MXU1!3/ZB4#0=ZK]6J3,">(4]3F(0U6\WM
M!6BKO_'ZK:J]JQH<LM9`[_>W\5IWH]IK*VS_6K7B1ZRILI2;P_IQ`\*];;=T
MHT)!W)`^&0?5MZ=1.9/Q-F)EZK.8,U</]W5K;M;3%(K6U(^GA'PGL3%9IT>P
M#<V:PCX56A_KV^H\70)Y367C8O7C]/=/DZM<>Y(OE,AK7V%1B*]8LNH2\]\_
MJRSI;:HDM]H#8WAQT^\9QFWGICL8]"[22O^C_DV/JR3_?/-'C*<I/U"M=3QP
M?_%H!O8K*99<I>3)CWAYL;G1,GT_N^9KJ45]D&929?2NKQW,A_QQ96,TZF4%
M`TS;GT>J1!#^HGVE8H.?9*%)'%92CP(/"F'E>O%'#(-V%^EA:#RV@&>/D[+T
MMV(<Q-C0J(VU"N6O'EPL7T)?ELY?W^SQ:=F#T<JS2Q^[4BZW]*KT=RJ=2WVD
MR@:3>[_1KK2`1KVET(]'8I)@\YK%5#5JP_0HZ'U@JJ+BZ86R7J:LE4JG?V7K
M,"%"5?G60VZ*J1S&^FMUS78"8<%5\C8\2Q.[D;EZ!DK6IISC\&0+,3Q,%X7%
MX<D7R:Y<)FDO.A89!0Y5Y9(_K_TA]IQ(>SN?PL/\F?SN1W6U9%9Y^SP[1:F1
M!1N>YPCXS.3IZ!',07P7@>6D10#W>$H(3X=4`H)8$F?F!VD1)CH4.3.#;R+*
MSD;Z<5"LL*K.+MJJ9`4MW=ISEDNE$K$I3_EJIB6:QT)S,5P4P2KNKQY&5?7Q
M88(K5"PESM_]1P$^BRRL)H7"QJ9&8405:(@<1)D2D4BZFH"$9XV?YF8H3X,[
MV`8%GE`0@^1.K*+AQUC9,EL9:8R?:U]E15U\,RQ"OF)LOJ*D*JZLSM%E70W3
M\WTK<RF=_S_!(TAEBG@(C]6F;1C+86T,:S<3&A:*4BI/22&=QJ("@2;BBN/;
MM!+(NUB!)?Q9FTIZRWJWV?'!Y,U47<1VL&T$QBCQ#7@R,+2FPH[=-:V4/FTY
M?`D=6;5`>#^-3G6?6Q4JMBPKTY,1!;;*2FD7P(UJ*B@)P)*&V$4R#K"T(4E"
M09:>6VYXA:JE++YC$:B51GY[@[=>"PMBXW_5H)PD7JE,_.9+E;)7^#9Z=<SO
M"3Y0'"#+G])4BT;"T\9&&=U.K%RHF6]NL\>)U</I*S"!):%4]1HJP"(KJ"0U
M4/6\I9PJSGV1H-W6>YV.WNZV*R7!/FNK='2CT]('[8H6L=1/`%M(H.D;1UC+
M7=;3WAN7ZL.AH0]+SA&\9(52IE2`17VE95%CY:JD#I;BS_W-&/BQW=4[G=6L
MPRIGG(?H-8N^3S8>C`;ZH&(D>FK*)9Z"'ZQUN#:T6E]HA9;;="\^<+O+KD@3
M[-$UD<[??._L1H54M.LDH)*K&E.^-K7&0@L!RO)0*$4IGQ_[RX.E3T0S=WK]
M9I'+'=ZU66RU]-;E^&JIF?A[*JQKGZ%C].HL"=#EPG.R#;'(M[M1SOPAS)1.
M[59:*0$+76K24-8B5_")RH(^4;Y)]CVCQH-4CR]1JJH1B2X?4+H&U)$FK5)I
M9M]3VYI(`SC#(([S798R#;'=@JI,C7O;P*<):&,-VL.M7;M^"UN6R2W77<GJ
M/.O-3\T'*DU<%MDLB6+NTU'Y:X4TU#7*8,`"@?ZCEU3-\H1)M6ZQJ;)0_:(D
MQ=8(1@$2B"#AUA$WQ!<9TY+%LDE4GGKDRB.,?"E<*07KPF-;A>36XN6ZB'ZA
MV4=I:'Q]6]!GPN6*NP\<"-Q3U9,FF%W["0.N9['FA`(-3*_:2R20(UK-7;"C
M"F@9>FM0/04.%_W!OZJ9RO81G[W&/]J#@=X=[B_^L7FD8RU25]?QJ=Y,E1.+
M?Q1<]`LL@0U>='W1C6*%7W2RM#">S3#8@1D/JGVP&H9BF[(:T4)Z^UE.#6Y^
MAZOCYC*D[]^TVR^L0]KI[KD.Z6C?=4_W?-_P2,;)Z]",<?(ZO,ZRPU66`]TF
M<%!SQ<J7T0?C5MC:X=W4L4%W'R*_:LTAV7ZS#\G67URVU.EGQF+&JH"Q*JM2
MQXS%C)5GK-5DK4I/K^^E&'\#[(MR^A;*C>L4@Y]'R_L]MAF9&]<08/'>7+P/
M4;6CX?7OU38E<UOUW-:,OB2-XK;_HR^$K5T`2;"/UDV"?)\1^9@+&?,8\XZ9
MVQCS&/,.SX6,>8QYC'G'CWE<'V\]SW[*$H8P87LL[AW/PP_^A%(XJY+T!I&S
M<1"P/\+549^VAHY$';W3VJ8YTVX$?!7%>EDN&[1#>]RLV(B&@T>"8.<EA]49
MOQB_FH-?K]&N,/1>N[)6ARR7+)=L5[!=L5^[HK=Q$WO&+\8OMBOV(I4MO3O@
M>`7+99/EDNT*MBN>L"N&E668'S?3O!2_CN\T3.4D_)L\G7Q(X&)@WR)9_)#`
MT]5[K<HBI4T1@+IM():(S7-T:CY*44.KTO/^D`6"!8)5A+JOHW='E?7/8XEX
M-1)QNBJB?5[=L4T6B%<C$">M(KJ5[8NP1+P:B3A=%6%4&-`[%8'@-/#UM$T2
MZRN+VC6(;HV#G?T1KC$:^FV[79G)^BR%,C:ICT252V!EE1I8\JHXVE>;%.[?
M$NC6GYK0%"&JVV9FV6H"X9JCU7J#^M/\6:NQY+%66]%J@_H3^9LB1*S56*OM
M4ZOU._5;C*S56/)8JZWF?K"O5FLX]]2BMG,GX$Q+WB/=1*MW]$ZG\C+BKUM]
ML\"<\!9JY[S'6Z@L$*Q!4@TRZE66A\GZ@\7EY/7'B!/Y62!8?Z3ZP]#;G<K2
M-%F#L,"<N`;IGX\XS[^*J%^#PNQUTO;6#R;"J?#H=8/HUCC8>9IPS]3J/M6-
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M(2?+=DVRO9.$-GU[L!$M)!N#5.WS-F<1,]"P$=%`(V*@=RI,VV`C@F6;C0@V
M(NH)YW"-0P8:-B(::$3T]-ZPNH+V;$2P;+,1P49$+4;$@",1FQ(@MUGT4X3;
M(F77[VU@.:*YCB?.IH(@R6BW?LB]I+\;T?JU#6UY@>FSXP$:1N^Z0Y"-*E?\
M;BJT1WJYL#43V-:\%YH((V=FXC?W@0G/M.%O;6(Z@?9@NK'`32Y_'CF^%\H+
MX$([#C`K/X+'X?Y7B)MA\/4*$;8<HQ(3I8^)$K:P_,#$M[]#8LMI7`M+S,8B
MR""^8^A:NU62F[H+E?2]302&O)J`OLN0-=/;'_EAU*O&W$ZC?A2!V-NP_VJ<
ME_0*;#:#P)A[H\HXY`F3J+[Q=U85ZFXT#T0X%U;D/`AW<9Z;2OH7HEOD1Z:K
M.5X$`!4ZUBJ$B:0A*8,8@]@1@EBWH\,51\8B?^VT>Y4->Z]L\M=NOUTAP3?"
ML!4++1`ST_$0K"QX:F!:40P@%XE@ED<V/W]>$D@D<OE*CV:X-Y+USE?WBQJ_
MSMWS:M245"7%A=8UH#XLU(EHEE*^O8A.97HZ603F_7T@[M$3*K$E\(*\M"42
MB`R+O^4E+_EMGQ+X/Q'XQR>"E8UZ&69?'C4X4*QEF[A!18.5'_'R=PY8THXE
MG_0U\JUOVJ7OQ9++OX@0I,)")25_^MUS(NT"2>Y$BW=5S.J_<1@YDT5=,>%-
M_SJ*N,YUN2N3(*66`"3];X=6$.U?7?LHOCM@4Z2!'2<*-6#.,S&;N_Y"",UV
M`A`D/W@Y>,F=H%9;[_6;8K[28X8M?=@Z0HMEU-6-JER8<&H"9"Y;+:#I@DS.
M0Y)S\]$,[/!<T]!07?.K-C5M:<3F;-C2V&(E9E$:*%G=_C\@6\&`2MIT-)ZK
M8-B#BMRT.0`/,=:*-0SS>0#60;R9S83M`%.`GM:T)1A;0K%5>V\5OTSTD,+8
MC9#9*IE&;Z!WJW)<I9B]3*[,5?=P;=B^*D:N"+`SCEC'`DVSADY@RV>-:7`R
MSMKKC')6&\(LMP,3&S!<Q:/8PPL<3W,=$5,,*L!/N+&/9-,B'V;I89!*7B^=
MX!3D`./"$I233T58P(=-_#A(G@+^-S@C[@PD1-X.O[JN_XB<[8!'HH7Q;&8&
MBU)HE8\UE6\"'VV`(35AR9;#MC'X.927GXU-W!RP_-E<>"%Q@39W3?#@)S#)
M)=5T(E*TN[^V#JER]Q2R9EJ`;GFXP\_YAWI^,#/=0LJ(@=>D#Z8\`\T2KJNN
M>?^F]88^AW/32CZ7S/_.F0$G_R8>M2_^S%Q)-7IT[&@*?\*<5)88K(UKSD/Q
M+OEC!;>S0>6/RJ;Y',/2T\T;'+:EL;Q_T^__\&RF2#$=1=UH['I?;]\OW/=]
MW;V\<+=#U,_4FCWH66H+9%4$.9D9[6:69+<U(CGOQ)(7-Z\INW]>VQ]_T2?I
M(\%\75L%,,GU8F:KGMDZS&S+S/9_B8=^H3STOY&'?HT>^BUZZ/]&#WU38A]?
M*6!6%T<EP754]FFXA+X%!S.:^G$(SGC(35,/H!:.FJEVI`]75]JXVOORUF5U
M=;J;0\[&">_^"->8`S]=O5U=K=&3/_'#PM4@<[3QW,9'"PNI+Q4V76_\TK\4
M:([/YZV<A'^36W'LFS07@9N#+7J_Q7TY6"(:%0(Z=+,Y;B'`X8>-:?MO2D9C
M/XB##+5T:M<[P_H[0J\R2GU$XJZSQRA[FV<(G%#7V=%J]C*[W>QVKR'AK1],
MA,..]X$J)E:3'](HS=^IJ0?#>E*];@.`!>ZD_?H1^_7LUV],V]]\3YTS*TDJ
MV)]+]HJQ:`N-UME?N>15Y=D8FZ&C&W69#-L0N`YB-0XZ6;`;M)W6>/>:$QJ*
MIM@>8II-6?H*;;2CJ95\!$?G*QJL_(B7%ZH>7:1%P.3Q(2Q[)((',";Q+/"'
M,(Q-SWKZ'$<SBAU51>Y:*Q5<G%*1/*QRDBLBM\>)M?OZH-/11_U*:P/A#"Q_
M-O,]39ZJIZJG05X>'"4/6CR'JY(ZNU0=()?;G2\($*9U0/"7I0O7G>/?8S$<
MHZOWAEU]4));LQ,I49GC*[`N@J0J4=%\,!V7SK4C&2=Q%`>JJ$OX1+4"\4>,
MY0P<#P\V.`]"5BE86U3TRI^!YEQH4Q/K)<S!FK>H7$(<(K&%$\&X-3..IGX`
MH[:)SD!Q6%-<`,4#@18%P@SC8)&6C(+WN[%<67F1:<'``KAIO-#F<6#!"[&(
MHBR:.!>>-C.#;R)2)2/F@?.``A+!=$.LT0!<H6/]""R]$$X6R32I=$3*5.'3
ME6*2OW_Y*0[/[DUS_N[:"2W7AX&+3Y.K7&F'+\+%RO=7?AB%A/&76/WAL[F@
M4A-WP!F7+O#>KW_Y\Y]^*7O61]^[_PC$MR_"4$3AWX5KW_K!5],5Z;U4LQ4^
M?!&3]V]NKQ%A_M7]S]WU&\VQX0N8\]GMS?6@=6ETVI>=SFVO=WT[O+FZ[G0N
M;T:CGM$U1F]^70+J/,<]4]B@S%"J2^?3QY6S5I(T&M*&&!RIPSJSFO&6`<,X
M=EP42(F5+O[/U`1\&`L0OD!8KAF&SL1!&8=+Y.),D\4)3:Q9*J452VFAUT^]
M(<:F2^`>3@4(+Q6T/9@5]PS+%^%]']I>UJ1)(#9KJ(%4+);DPF\\(B#1'8!N
M+#"V0O%)<SX/_.]TK[O87,MM3XZ_MCOGPXP6\!07P+`B)<>L430$'Z>.-07!
MFZ.UA#H]XX]0`.%!=8(6!-%R11B"T(62+_`WY"N'ZB_%+I5E\M"L=(#-G``U
ME`9Z*%3BVC2?BNXKAY<MC.$=>-OHG!LU\;8R8W:I`-58QL3"U`%:O[9DL%7N
M:B1G95I.+8II61)_'5DG/U-=X%)$@B8DG1@0Q"D8@&@STPQ?4MBK<<NJ2DAN
MJG5P]6V!K01@\6SE#7P4#\+5VD#9>8P^"'V)HAM*I"*:APZ,!0@&#H&+D(96
MO+P&+0Y_,A$!,99PR$$,_!EX'1'Z*G!]XA@$83*\9#U?8MEO8(T7+/D;,\"N
M"N%G$9#Q_YF\HFTL]W[_^JH]N!W<7O3[7:-W,S*N+Z^-87M@]&_:5]<WM5ON
M^[(VUT3(?@.F^H@RA*4]KV1\@$BY6E)N)\#%Y[O)\Y/X`U40=4(2Y3A*N38J
M:YWAQ;3A"TRV)HZ1"SF<)V$^$!/?<@@['L$Q1CZ@L#6ZZ+881WHQBJ$_%:L`
MOU5Z\CAHSX^4PXP6M;#,&'QC&/="DT51(\=VW!B]^6W%X!E6+K`]EJ"A"C27
MBTMIU7]%H_YO@1_/X1G;\+_1[AB]?O]F<&$8P^O+SN"VW4WXOP_2<##/E0L0
MOG]C]%]8@;"[]P)][6.I),@3Y`DVKH9DDU*W#E+R*QMLKX;$Q\TS8IZF5/WE
MK53(%>V/CXXY=EPG<M"NB4ZW_%SCTF,VY\7:,^`/SXYH=N^<?7DD'-A4+.0"
MG2L,*0,<E259,MHQMSW+;94=6V!N8VY[EMLJ*S7%W,;<]@2WW6&_=3;DCM>I
M;10W[5:6^>C9JK:DJSI`;C\@UC@ET#!F:AQ]F'^8?YA_F'^8?QI('ZX0L)Z:
M5V8XI9T2"__`XP8/IHMYFH<4SL:?A^2CL(6CL)V!WNZO]A_GT[!\[+[QAD#C
MN8VQ9I5IAFVC7;^X-84#&&\8;QAO&&\8;QAO&&].&V_8E^*:S5N2\.O4#Z(S
M/,2F.53N<;9E_.9TZZ6V6X;>:U>6Z=:4%:];0;,>/F&9Z/6XA##+`\M#C1X>
MRP7+1<..N=1A6[7UUJ"ZIJ[/T.=49*K.S>C6L;LRE$\KMZ++]J3IR]U\G"UX
MK[M:)KS2P,M1E!:O+BKS'&U?$K8YDI+VG:$^&`X.3]&CX+RZC1:./C-*,DHV
M#R4KC$LP0C)",D(V@E<9(1L=J6*D9*1DI&P$KS)25NEQCW3X[_`4/0K..TA(
M\V1R,.CC:AV*K/#8+KL)?(QK>REEG<O\P_S#_,/\P_S31/KP,>3UU/Q$#=A<
M'\>/B:SN3N;3WA,P&I]>79-3N4J]DTB^KSW`M@7=FL)!'$([(7.C\=S&AX'X
M\"'C#>,-X\U!#A\.]'YGR%##4-.DW4%VU=A5JQNJ7KN75L$6WHD</J@]\M2I
M*-GA&':6:\*T)TAX]*D+M<>@2HAW%+Q4M[7&1AFC&*,8HQBC&*,8HQBC6,U.
M)@,8`Q@#&`,8`]B1`5@N5/939,+T2Z_/_9V;E^MXXFPJ<\6-=NN'PT_L:`?W
M5&>VXFMS3RE@(P8LZ2F.![`O/^=?X_G!S'0+8&#@->F#:?4U2[BNNN;]F]8;
M^@RL;26?2PAUY\Q$J/TF'K4O_LQ<T3@S,[AW/#E(,X[\Y`NIWNB;1\>.IN_Z
M@WX&12!1KCD/Q;ODCY^7I2@;>#[$FTEBOS2?<H,H,8WF_9OV"##A63$O`HZZ
M=;3KC8.=[^SN>F./)\F3;/HDC_Y,U@DV&]W</'J:4O5W(I7],ZG<5NX@FV9&
MVJWI!-J_33<6.]A+3>;$QGF!F_/B@4L+[H,=-7^B70M+S,8BT#J&KK5;QL:E
M!X^$`YN*A=SW>TV7^<KJBC/:,;<]RVV55<=B;F-N>Y;;*JOKR]S&W/8$MU'2
M'1MRQ^O4-HJ;WCJ>%DW].`3/-?SQU;!5#?5K9`2@#I#;#X@U3@DTC)D:1Q_F
M'^8?YA_F'^:?!M*'2]>LI^;5NFXEAQ3.QA]8XX/7A7JE`[T[JJY<:=,7'^_C
M@]<G8@<TGML8:KBF#.,-XPWC#>,-XPWC#>/-*>,-NU+<NV$[$GZ=^D$DRP[O
MUELV'?K)]48?&7IK4%GCTJ8L>-WJF;7P"8M$A6TJ61Y8'HY>'FKP[U@N6"X:
M=L:E%M.JWZZI0]VK.'Q?^4;TB12PM-;M1].7NWDX6_`>]_*L-"3#O3R-]E#O
M#?J'I^A1<%[=-@N'GADE&26;AY(5AB48(1DA&2$;P:N,D(T.5#%2,E(R4C:"
M5QDIJ_2X1SIXW8>GZ%%PWD%"FB>3@4$?5VM0[-2$AX]PO4!*6><R_S#_,/\P
M_S#_-)$^?`1Y/34_1?";YOHX?DQCK;V'(;=DK99Z)Y%Y7WN`[17V93TB@&N6
MNN"30+6RU6O%HZ9S`.,-XPWCS6'PICW0!T:+H8:AIDF[@^RJL:M6-U2]=B^M
M@BV\$SE\4'ODB1N>UDG"HT]=J#T&]5J[GO+V#:,8HQBC&*,8HQBC&*/8@9U,
M!C`&,`8P!C`&L",#L%RH[*?(A.F77E_R]R\_Q>'9O6G.WV$+:NI`?;FX-%W3
ML\37J1#1WP(_G@.?W<'L+UW?^O;K7_[\IU]6;KIV0LOUPS@087HET--#HGT1
MD_=O;J_;+:/[K^Y_[J[?:(X-7YA6='9U-6RUVJV;WNWML-7NW5P-^E?7QK`]
M,`8WM^UVZ\VO2XN0)^B=,Q.A]IMXU+[X,W,]1N9N=QU/G$UE7KS1;OU0^2(6
M%FO+A]#'E:3]K#6X]D]A(H6?+S/RU(QS;/S?.(R<R>(0RF7#$9*@T6?'`S48
MO>L.`><J#;!.A7;EST#L%UH<`C\]F('CQZ'F>/,XPG\T6V#ZG^.!%&@17#[!
M%7F@%?$GFD,7I>5?J!S,3"Y4B)>'0C-EWW??TTPM$%8<!/BHL1DZX7F.7NE?
MN3[QN<@OWHI89F/#^-P8J#F?0&$C;#,CN&(L)5@+483A20'\#C_<^P','GY>
MT"TN]22%.?CC_PHK<AZ<:(&#]2V'GO+H1%.Z4-$"Z&-KD9],#W^"461#*9T,
M$GCBNV#+X*3IE7)`M@,3BMP%S,NEU\&3\67FS(]A'6%88;S9N.#&=!!FY`"=
MX>8"Z9=(^>[(I8<@7K.$ZRHKX/V;UAOZ#/K+2CYO`)G:NL&7;;@\.G8TE1+X
MK-XL:O#-+]YNSP>4^C8:_#GT+UJI79QG%?&F=O_EAC;,="MCI59%I_JT:VE`
MS?A9^R/V433G@6,)0DT3!5=H,S/XAA(X\0-0^X"0."DEEKKV.'6L*5QMN;$M
MM-_/OYYK44#HLM!"1,JM]KS66D$LT2S1+-'/2G2[(-$^'7\(8:S.!,:-*GD<
MBN"!.%5IWK=2=%&S%P$`Q3UTX+UFD+>.=(4',-<@\,$U(WTN'Z9K(K+.=VDO
MS,+.PL["OJ6P=PK"GA?SV'M2T*/,8TJ?,/@9W)M'#_5Z/)NC";Z!YU1NF[\&
M`&B4]ZM6&`![)J*I;_NN?[^0OAZB."X7KE]FCI'WYOF1Y@F`^A#\97#B3`\>
M9`,#Y?POS0J$[41:X(3?5OPWJ17PR;*[/#AKV2LV\"1IR4/0-_X#V)7+[#7+
MA4J(U^9S%P:'')UX^^7L!P\"]QIGJ!ZQ[&Z7>?%@[*)K3L/REX>B7%Y;3&"I
MX6EC_P']4AS52R-&*N]/!3.)4VP,$M`BO,,PHESF:UBHV5@$&2T[AJYA0.ZE
M(Z#'$PWW-1<8=:>249\?>1!@%W61NZ>@+3%/,@\T^#G_4,\/9J9;V(,P6GD%
M6YE)LS1R:;08+9B3"N0#G[CF/!3ODC]6$+/<"LH4;K_TB/8&5@P-YOV;KO'#
ME@:4NG'G^]K[?B%/D"?8Q`D>?56GT6[*8;2E;EA3`</HU5`"8_,-UJ<I98'B
M$4$UM"K?2LOMJ^1*8:%]EVVR[>!]-)D3&Y='LCDO'K@WR3[8$7V`Q#;7UIKD
MQ\V!3<7"YZH!U<%^VU<+VBM#JGV=%T>[&.V8VS;EMLKJZS.W,;<]RVVKD2/F
M-N:VZKF-CNVR(7>\3FVCN.FMW"&)0_!<=]H?.TZV>A&N/14!J`/D]@-BC5,"
M#6.FQM&'^8?YA_F'^8?YIX'TX>+7ZZEYM:[?\2&%L_$EK[AT8_X^HS/0V_WJ
M>@PW??7Q/J[=>"*&0..YC;&F[N(^3><`QAO&&\8;QAO&&\8;QIO3QAOVI;C_
MZY8D_#KU@TBV+LL=P=TE>-@^[`YK#36H6H;>:U>6Z=:4%:];0;,>/F&9Z/4J
MR\5C>6!Y.'IYJ,'#8[E@N6C8,9<Z;*NVWAI4EFG[''U.1:;JW(P^D38XUKH]
M:?IR-Q]G"][K5E37>-V:'46EVIH*'I?0]B5AF^.HA-SI#/7!<'!XBAX%Y]5M
MM'#TF5&24;)Y*%EA7((1DA&2$;(1O,H(V>A(%2,E(R4C92-XE9&R2H][I,-_
MAZ?H47#>04*:)Y.#01]7ZU#LU,J;CW&]0$I9YS+_,/\P_S#_,/\TD3Y\#'D]
M-3]1$QK7Q_%C(JN[D_FT]P2,QJ=7U^14KE+O))+O:P^P;4&WIG`0A]!.R-QH
M/+?Q82`^?,AXPWC#>'.0PX<#O=\9,M0PU#1I=Y!=-7;5ZH:JU^ZE5;"%=R*'
M#VJ//'4J2G8XAIWEFC#M"1(>?>I"[3&H$N(=!2_5;:VQ4<8HQBC&*,8HQBC&
M*,8H5K.3R0#&`,8`Q@#&`'9D`)8+E?T4F3#]TNMS?^?FY3J>.)O*7'&CW?KA
M\!,[VL$]U9FM^-K<4PK8B`%+>HKC`>S+S_G7>'XP,]T"&!AX3?I@6GW-$JZK
MKGG_IO6&/@-K6\GG$D+=.3,1:K^)1^V+/S-7-,[,#.X=3P[2C",_^4*J-_KF
MT;&CZ;O^H)]!$4B4:\Y#\2[YX^=E*<H&G@_Q9I+8+\VGW"!*3*-Y_Z8]`DQX
M5LR+@*-N'>UZXV#G.[N[WMCC2?(DFS[)HS^3=8+-1C<WCYZF5/V=2&7_3"JW
ME3O(IIF1=FLZ@?9OTXW%#O92DSFQ<5[@YKQXX-*"^V!'S9]HU\(2L[$(M(ZA
M:^V6L7'IP2/AP*9B(??]7M-EOK*ZXHQVS&W/<EMEU;&8VYC;GN6VRNKZ,K<Q
MMSW!;91TQX;<\3JUC>*FMXZG15,_#L%S#7]\-6Q50_T:&0&H`^3V`V*-4P(-
M8Z;&T8?YA_F'^8?YA_FG@?3ATC7KJ7FUKEO)(86S\0?6^.!UH5[I0.^.JBM7
MVO3%Q_OXX/6)V`&-YS:&&JXIPWC#>,-XPWC#>,-XPWASRGC#KA3W;MB.A%^G
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M#56OW4NK8`OO1`X?U!YYXH:G=9+PZ%,7:H]!O=:NI[Q]PRC&*,8HQBC&*,8H
MQBAV8">3`8P!C`&,`8P![,@`+!<J^RDR8?IEU^]M8#FBN8XGSJ8R$=UHMWXX
M/-6>&MSR$M-GQP,`CMYUAR!AE8;VID*[\F?`<`O-!I[T_$B;F@]"PR]4NTC-
ME"W#[3@`6=<BN&4!DPTU`8.RM96);CD.%3=6PD"SM87E!V;D^-X[)*@<:M(C
M.M,<JEET]Z4CH,?K>YM(:7_K789,55\J>1(,:?6,^2X/.M?N`M,+)P+88RRB
M1R$\S44V"C4S$%H`]+CWX!8;&\XC)YE6%)NN9IN1P$;@EA-8\2R,3,\2\#M<
M9)EQ")?CM9%Z]+FFY?@V]:@'/X>297,<DH]:TPA$&#DS>)FMQ2%RLZG-`W\L
MKUF<C4U\E^-9_@R&-H>?3&NJQ1'\^C^ZVI/?S@,'!VP[H>7'0"588W&N?8W'
MH?@C!D'5K*GIW<,KJ6FAT":F$V@/IAO3)/&;KXO9?.J#D'VP?$][FTRBW?JY
M\$OZO?'SC]H\#N"YH0`=X84.*!3BK'2*BY3$`<JEB56!<"Z!P'O\0`-NE'_#
MJ(KO3Y^</4N-W+0L26:</KX751?1#Q8I$E1MB!8.K@K$5,#``#U</PS5*CTW
M]6<GE<S`UL:+:KC]K\9Y5X.K7'A1-8*X!(T5(>-^8"_AB@KIVSYO'S]]J\%H
M797FJIS&H_/1\=.X*J4CD<9WP5FE.:#UJ87Q;&8&<&E(DY*0C+A6@+&QZ9*R
M":="H+8)`H(ZB5A@^?B60]<].M$TM8CR6F4"R-HXFZ@:PKY6FVB+45>#PN>5
M>0O9T_N[^0;]?3@V*^VBBYY,[BF%H`UF4N3=(?R<?XWG!S/3+40I#+PF?;`$
M!DNXKKKF_9O6&_H,/K>5?"ZATYTS`U'_33QJ7_R9N1(*`YRY=SPY2#.._.0+
M&7>C;QX=.YK"U4`(%0T`+G/->2C>)7^L+&8V[GSJ21HAZ)8>\]H@>87&\O[-
ML/7#L[&'8A1$W6CL>M]P+R\\DF/WC0NO;GQ(L8XTQ%5:;AXT>SI05G]O>GE(
M[V-Z2&^'&@?,LR=QL':O;/>6?'0_#L'F"7^LE=,:E+%=9PC\4CD#9J0EIK6F
M+&JCJLV"2G.TCV)CH1%G28YC7ZK7TUN=54^H:GH=!=OLY(`<GTI=)F%A!$9[
MR>4YHV^J)/-5&A?!F(>,OOJ3=7'9N;D@'RKR,?`Q`WPLAG/#R+>^34%%B8#[
M;.%](WTXY#9;;(-L3-O/Y@)W55`&<3L*)4Y^'L/[I!!2+-+R9[-$X.J0M!>?
MECH:$7W;`:W;.OR9J56>K._@6>5L6Z__<5HB_H2;L4VI]UJ59E71EQIRMT;Z
MJ%VUM+(I?$SZEFWDO2W<835S6V_OH>X"*UY6O-L$75ZKXJTC:9H5+RM>5KQ-
M4[R&WJVP2P`7"3EYS9J+6H&D13!(_+1)["IM:'J((-;1">9;P]![^XM5L65\
MC%IZ3R;S:NYCHXYN'O7FY_[.=)[^IKHQT/N=FGH>;4/0HV"\"FVAAI\";1P5
M&WDJU'1#7YOB83)Y"I0.Y0%O@QJP0#Y,>9["=M"XDT?LPGC\7V%%Z(7-A!G&
M`9T20P62/POF::8&=#D+A!4'=/)D;(9.>)[+`DS_@O&$(AF`XUEN;`OMWO?M
M1\=U5PYIR&-K?\1.J`8%-NF5+US3,CWX^<H/YBJ5'_W*=JMED`E:=!7A__\1
MNPNMTR)5UU+'>")P1QT4=C689]Z-KW[ZN:7SO95'2M(YZT\0$J8PAX7T[1`)
MGYP_!-K#`^`BQX.!F&YR\E+..L13C"Y`&\[$F<"@Z'S@S(?5@Q]M@5FLP($V
M/F<,WP$K.(&PGSZFD/S]RT]Q>'9OFO-WMW#7OW&4UTYHN3[.(+P#QKUTP>[_
M]2]__M,O*U?F4F?_*>=L?_*^)#QRB2SRN^?#/(,''/T';QY'\+/O67`7+6KZ
M`G)$X,,7,7G_YO8:#99_=?]S=_U&<VSXPK2B,^-BT+XU^E>7@V'7:-_>WK9&
M@VMCV!X8@YNKSFWKS:]+<IF7H&?.!)0!-Y^)X#,1R_?QF8B3R"_G,Q%\)N+8
M>);/1'``B,]$''E\Y^3#-WPFXM7O5/&V,Y^)X#,1K]<&X3,1^Q91/A/1^`WH
MTQ)Q/A/Q$NKQF8A7KV_91GX=J9E\)H(5[YX4+Y^)X#,1K'A9\;+BQ?OX3,0K
MB#37%+7B,Q%\)J(1/,E;XGPFXE@W/_E,!)^).'9;:/V9B`U3J2M,D"YD8/]-
MI=-?>/:'-,W]@M+/L^SM;7*KAS?=BTZK?]%J70W;PX$QN.QT9&YU_^;B8GA9
M>VYUU1SPDBK_]'$E62VA^9-\M&'Z^'_C,'(FBT-D'S;FW,HG=;C":.MTKD/7
M/HKO#GJYV)[(%9%J)+5T0F/]X1!3`X?Y'CM.9=?HFN<_I@_^/#6#F6F)F%`Q
MU-XBS_X#?&FQ^%'7/GC6N2[];OEF"X]8J#Y(9?VK@)0P,'AN(,(Y^O$(HMAA
M))R9KJO-?!<D'=/UX5Y$4]F""D!YL>[@##XI=F63ILT'30=YU$D;.^D%53;@
MW-/]N8HY9#U1Y,F4U8,I^14XU[2_;7B4!]_R4DG<M+?'7]N]\V&E'79T[7'J
M6%,@V1RH1HVS<'[BNR7",&&*O4VOTS]O5=M`*`U`S0,'C&/DRC7-S^CXF$M]
M=CP1@<H`8C@3Q\P.5@&MY)$S``YY#$E*3ZYQ#]X3+5(1+^7_XX"MG<R+QHS^
MT]*)M@QTQ7<16`YUU`->_YRPQZ<YR?);$T^:3>B8&0#,;WXD-,/X488^GH+K
M0ORRJ>AA#,\'^T`/=0XQUUA1'LCTA)6%EO!"(+4(`J2H^3W?,A#I@U^;I$QD
M!U`)ZMHD\&<)/!6%>P?QU%9IWTAV/FYA3&7!"6DE<V=QS9D/KMO_B%-U;1Q'
M>$TDPD@VXX3YAA%P@1>#H;$@#2Z/?29G3B.R)>;X$,#MV',BV=DS84PG7&LD
M8*=-@'9E(,#=H;C'QZZU69+#QW"#,IZPE64V'!PVBG-Z!AC--3R.2\,O#!SD
M(PSI3^3+-6]4E%@6`+0`"^_-O7+;L[#;^5>;NF:?0=ZLQ39NV:@UZ(]N+CI7
M-X-._ZIW<3OLM1*W[/KBNKW/(Z^URH/\B)>_<R)XG[4D(1_297U7"4"7<=:R
M."H9%':5`OBL%$W-XIGN:?G#E`"O$U9R-8!-I8I!:<.8`_X`.MST+#QEGO6$
M/<_1-WER6B=`#@$40PA/>9P*Z5ZDO1>!2G%1V$@+"3NDUP)57`=&D=F5:RDP
M<8(0%U+,$Q\F1])YX)-JP]'Y&8'6V*Q+Q$)U&>'(J3TN.DNI;U/L(:DK-PJ_
MR+"C9+P?)LMO3B9=]E#/UR9Q0&<L32LYU1^(G#*'*W*3Q8Z\\I+$4"@=Q(4M
M5V@=B(;:S%Q@28`,F7T)DGBPSYG)(@Y84R"G"\`6H#;)V!0:&)8Z!@?Y%LGY
MKL^JPL2C'[O(:#9XJ)%L!:W+`@6N\TV`?,`W'LJ47D*>`NL@]X^Q#_6N50PV
MA]\":F?\_RD`A)_[H>E^FN"!V(_.@[!WQ>^KZ\M1?PA@W1EV>I>WG>%EOY?@
M=ZMWTSEU_/Y0T,9TOICHJ4F"UH?E]"J77I44_T!/1=5`*?BPJW5"9!V-J7"E
M;%)+<]FM^\$1CPAF1;@G4-Q`5@H"L@Y%PQC,,S40%%_41&/9*1Q\=!PQ6.<?
M/'+&G`@E[$&4%CN!`5,YF`V5%CSU6J%JFJ62OE0U]PXUV7-=HDC2G1VOC+VD
MO3J2)X[`/*(M<0W/6B>!)YPHN2D45@A3M*81RYHMD0(=:C-/<BC#3J48+)4$
M72])2K3+O19I@/03W^=@5Z<54L)X,G$L1T6XU"37K4?FM^EY'PX?_0@<&<'2
MV_ZCEQ5QR9K69]HAW!;&=L&C(J`!BL_$G?E]M_V`BTZ[9XQ:G7[W^N*JW[N]
MO+DQTOV`WNB6]P-^EA36@,3/%$G@/8&-QYL$HU+#)RP/A6`K;\0+)8Q)!#N5
M<X5`>`O&.2B<C0@,\JQPFO!B:CX(:6[D0C*V,X$WPD4`D<H.+;.9I5$)+P@$
MO,L#&_IWJK,5H7\Z$]'4![]AD\$CDN0,_A1A*0ZDQF+A,*-'(=:.9QFZLO'A
M`VGF:]X?HP\!5I\I$1)G!,^4E[CF(^DQ`<.PHH0<LGDZ?)"QA.)`Y83RB`MJ
M$W<KSD&_Y*B1F[V0J9%*L08"N$U&/G+JALS),VE.GJ$Y>8;`;@$C`3.9.)B$
MAC@;,&G-7,*EB;WF5>-X,E71)@[\![`#GC$P67:WJD-'.UV>-(32':SBGED)
M#[S-<>:/:*CL*_";Y`-EI%Z;&+33)LN>V]NOG@#8;=1H.2*HHM24V.B5R,>+
M&]Z_7#HV,$N.HWA;#979AB^LS#;8N<+:KO>U]_W"TYS@T6>"OZ!(U3;`LB:=
M>W"`=.[C*3-W069!/@MW4QHS6YY`/<1&\6*5Z=]<QI!9[6E6V_AP+@-=K?JW
MYN-27#+S^,X'E42EGO9Y=P6^/9)SSR3<268;0ZS35;7,<94JUN&Q0]UO(LJE
M"E&6"6T;3/S@T0SL;4H*U*ME3^'<8GUSKJ$P2J^G]XS*3A@V92WQOI<<!6R>
MW=TX9<0X<%(XT!GJ_1;CP![=IZ,W*KZ($,B*26MX*`5SG/VYS/O'[`MPK)R(
M:Q4]2<%N2S<&]=?,;PK#U*V5V7=DZ<K=UQGHW1Y+%_O)6Q3M,^>4Q8[I@,$:
M]5:'T!V=;(UZ^JC;9W.1W<:Z]-#1B<2PHW<&/18)]J`V)NY7K")Y)G.=,8-6
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MI7\QT4X;%-FMKVM[F,&.P6[?@1`&NTTMP)^H2TS9]7O;3\M1I_:^?,?;O1W[
M7>VMN]-?C>'Y0(,GN65U`789?KE1G20TA$E_9/P1FX1:U`Q3]=7+=Z?'CJ=S
M/PRI]VC63C3$E&/?<B@YXM&)IF4M2BW5`9E^+^1+)'WJDPZ>MK!C*Z*;J=D?
MC&H>!_!>$9YK2:,Q`!41JH:IKB,>J,^SE>]4*GM#8SLZTTV:>T9B-@>"!XM\
MM[U<6D>^Z6=AP+DVHJJQ+)"/6I#FFG;+QZRAM94TH\,FA0X@)+6KU4SP@N/`
MDOU1S>^J2RUUF\0F]]3?&1`OW[6YT&/-$ZJ57FD/O/,2KFVD@!TW/%R<3!L[
M/96OJ0G<Z@/K3P0P*X@0UL2B%I3:;Y\^%FM)(_.:\WG@?R?1<Q?[P\J!T3L?
M5@N6^^SD]]=NOW7>KG3\.I8QPXZ<S@.L1&DW951GFRSK6-R;U.U8?)\#%B(B
M`:<9LK\VO-KQ8HF;A=_;:]]9!F!?Z!/^=YVK(MH8_NI6O3QKB%I.M-\C)^V/
MJE08KA+2/T^W4IIA0W%J@#W^+_9SQ:1%+00\=$"1F5[2&QPTU,R)Y!OL6.!E
M_J,'2G/JS-/NYED#7=^R8E)N<VR0[L<AK`6V02?E1C^F?72E^9"T7M7&"^TK
M,F72(Y2@:]A.IO4!FZEX,)XOLJ0$\(HM2FERF6^:FW`QZ5KS4<Y&]<-=PW!6
M/(M!4X-TR*KX2=_Q#/K@/\N-<=!`U$=4TLA[\\`AL\)'$P/TM!."R0+3=-W2
M[K/4<3U"!1V5-D*-07Q0^@H/=['F()($OIK`LF3-V,,X1*L#>]B6T.0Z#A(C
M`1OV:L+#T9^,3L)YE=$8#*5`$#OL#0\Z5:L;'=8:4"V`ZQ(!7,^Y`?:JEDN,
M?(7\6\H/^=[:`3&R-"FI1[3PQ,2177OWIZ9;.EQ1$<'V-NIJ!KQ?@Z*B,1?:
M?Y\8G.QK(A6V:=YO<^G5(^H5&**:5JZE\BU"<94[>AX`,PA3?C?Z]$X(0Z:P
M!>)8B7:%E]U)]U]=&F!,04BCH$P;(X'+-,SXY::FBNET*M8;<HI@8:&!XOE)
MX.8)]2'^B-&8`+LDZPL$*Q2[42@C"$!M^,'QRVV,B[UJ#&[7OM822B3#=FP*
M@)%ACE_$'@H+6/C_4\R=J/KS*L(HJWW=][;CU9A`3\Z)1:,\L]QR7M;OYU_/
M"]XU]G+_!WA48D$?[\1WD%CI<F=FF2@WY.Y46%;J86,TZN$K$D,P$#-$1!!G
MY5#"##P)80!<Q8'$T=0/*)."1M%NM;J;/TJ.-O>,K5S\N>\Z%A$,GIRR*`:)
M`;_"B,8#[S5=&ETN')NS6L'OAZM#M$MRWX(++;RPW$]DO&H87F%$T<.CDU80
MFZ[4.2D/X,["9BSP-)@E?__R4QR>W9OF_-T'>L*=^?W:"2WPF.)`@`A&EZYO
M??OU+W_^TR_)A2"G%Y;EHV/NW7\.?`_^A$7%#8X+S[Z2L9`/7OX:&)TS=T68
M/I#"8O#ABYB\?W-[C>O_K^Y_[J[?:(X-7X"&/KL=7G4NC/95[^;V9CBX&-T.
M6^WK=KLW'`RNAMWAQ9M?ER`O3^T[9P;T043YXL_,]>D'^]S6>PF;T,>5QK=?
M!#;7U3)*:\7E8'56S7@_>-H_S06AE!356\!\8&G0%SG:?XT`?"BD>.G#/]K;
M!-S;K9]O+[Y>IA^-GW\$D`\Q)EQZ^^]S&]5(_OZ+K[\7;O_-SV$YCNNL-0*'
M+;LA"0].`G\&R.)%`<A4*#?IKF!)0=2#,/?(=',1&`>&@./5+KY>:7?^W+&T
M?JM_#A]_U]2KDG`E[<O!X%VA4Y7V0$Q!SV#(4%6\3=08*<B9;PM7FM"N2PB0
M&Y25#.H<['6'%#^1@ZX#E4M6A((1N=])+@H@7:J`58AT)DP$+^JW!5\E(TEB
MG9$S0W+#+X\P6+DYF5SCA)G>M<_3&&M^$H_@F\`7$Y?,&'Q>8'HA>$KXQ'O?
MQRA\H(4B>'`LN66<SDPS(PIDSG#)9;`87HBZV5(H/A8:&#`>!:+@!QE75K/U
M0['Z?$6L>5[LZ:&3B70HZ>8)(#KP*AE'.A&"](DS4WZ,7`+913L4R75C<>]X
M'M+*G,#5VJKJ-GJDNOORF7`76'BF[<^)4([<=I[C`H%"`G+^T_3,^W2(RJ*"
M6X3R*)7/FVVM1ZMS@P>KH%TQY`?.*V9)DSJ<I-))]AA!826F?3..=C<)%B_B
M>^#N/#(B<"3@!H`!0"5!`WDEAT^9D8$+_;N79`N0W3WV8Y*4&_@<%6WD"Q7J
M!V%!5'-(LA&&_N8C_\!W\"3O/(=L&6X9/2F]('%@:#O(>H&@[`6PF5+6Q`T@
M2B?`$8C5$9C9"*S"".YI!)8<@10)N$8A96JK37P_`KD`[,HH`)*71&TL)[#B
M&8+?@:1;>TZH<P*=E^@TST3BF4P126XKEV6@CO3)T62%H<(D$MFO1<I7;=XJ
M3-F";?PIN#<]M1-YE8X6/L#C/F/;+$_N(7Z:I";$UW3T)8;W!G9RYVK8NKAJ
MW_0Z_8OKF]ZPUQI<71O#]L`8W`RNNBVVDW_.KPIQ]2<9V(,%8A.YJF.;<B?M
M\]0,9J8E8LIX!9P!M_*\8,HN"38BM++F<A<MA4>4R0Q(<0TP^H@9<."/SY5+
M3LZO_"1WO/\1NXN,@`.=`D+GZ;XU1H)]R1+2[$(HQH1UM2'OT?:[C/_,"_/1
MXDB"/]IZPE,QHC@4B7T&WZ4/2!^+.DWM$R5?+58ZP^)F=O%=`):8X)=9NU$@
MS"BY>!J#O.+S<&.WTL!EO0EL1\K74^`9J7$HW2%,]@:03\C'`AX44MEET<YH
M&OCQ_50+371:8-'`1YHI"`)?26VOA-CJ2D_](?H5QB7@>^"FN;F0N:.TBZ/%
M,,]`LX/X_@E>LGS7!2-*C0\,,S.X%Q%NW"AMI&OPKXG=M3`B&UJ!,T^Q,1+6
MU/-=_WZA@96$84/-O`^$5%$Z6#GP2H]><P^>C]H3RIPY_*14,]@6:KAB+*?E
M(K-J9A"@8I4:6UL7#56),>"?66B,.;B!-1>TS%H\1W<2@V43>*F/]HQ#N2CP
M3C!MP'I$2X227$C"=5JRG.662GR.="^0/SV7Z^*!,BTL@)QY"2E-:TH9N>EB
MAXI>Y)/FK_3'9!R20>;!<"SDBT@DU/>Q'8`FTV-$A&F[=#1`1H%QYR\#(NFG
M`V^2T[V:W!:(>\KZ(;XA3D2K'%^>3^V5O4"1D`!V4AY,-$C7Q[PO$+SE+EKB
MIYLP$9H@O`SM.;F2J9^>&,QQWC<@)P/1'V@_%A0F!5\CH#U(]=CG>6E;*[%J
MHZY@,7[&@`D]BIHZ?/9#8+/(D92Y5!M3NUF&EZW^[<7-L'_5OS&,;N>J?=$=
M)I;A\'9TPY;ASXK`VF?7?+H>83-,P2-5G@F&(`;80&\0]S/2&`Y`-2)D:#X`
M<H-_",N@,%`E06K=EO'VVX_;IS^B6J''$?*%I.?`JXY`.-&A=5U*23R+@,TU
M`8CH+\0:Z/ILXO$M9RXC5.FUE#A*.1(PJSD>_DA#D`Z"L:"--S-`'QMP*YXG
M.0<K<_@J@WE)IFF!,J3#RO,[4P>>,F-;K>(N$AJY*KI!-BZXV*!4DM$77H+@
MC<DC%("C]%?PX)V)(T],8!;H6@K34U78(_>\"&NH[37=<-`_QL2YGF%4-NP]
MY^./JLM4Y"2Z)FU&GT0271E>)<BX!'U@%SZ`^8VI]_F,^00I"W:DY%``>;7_
MHBLSFI+;\41=&DZ=^'&P<OFVAN>NMF'1P`S058T6:.)$\*@;T`GD)NYF5`Y&
MH]N+8;M]<]LVC+;1NABTNXE1>7O5Y6WYZ.>$XB1)*;F/P+S<=81+Q\W1C-RK
MG5D@N$@(CMNM)Z)&CC.MB;`5XV8^Y@D_TP5C%Y'/W5,HT-%*&%`Q''[./]0#
MJ]9T"U43#+PF?3#5&]`LX;KJFO=O6F_H<S@WK>3S]@#WZ-C1%/Z$.:GR#Q0I
MFH?B7?+'BN1D@\K7P<H*.'1*JY]M4$J+!O/^36_PP[.U(8IE+9(;=[ROO>-]
MQI['N>O[=KYOWX0YT0E64$7UL`7B1KOIP]&6&GU-`<=N#2T"7M3L!7,<15`-
M?<H-MAM5"\/6?@\%&//:1_`B*JNDQ\6WLN$.#E`=M*K2VO7SH4S%SQ_TVI3&
MC'FU8EX=;-EP3/S@:?_!\`6C8/4H^&RCM=?';J6N,K,:LUHMK+9Q??PCT:N-
MX[^&T:<F_JI`/NMHR+:]_#'_L'R=%'TV=CAK;C=1OS9[*P]VQ*'IV6$3VBL<
MV)%\.</A/G%,A^@I+=*?1)AP7HM;V9B&RBM\^G(R=L[VUS/L%2-=Y>CVBLK6
MGT)5^I'>[0]KITA3UA[O>V$O9$8:1AI&FAVH81BZ,5S-^&2H.>K049TDO(T#
MSY'=$>A4V'?\>Z<6VLW?E'XYM7IG`XX`5!\!J"/"=M"&DP.]U5E-FMZ14YH"
M%74;=BP1)RT1':.R8,.I2`2'^)XXF"@/9_O!(DL7YP#?U@&^RNR5!K'=\<)V
MI40\*)X;;7W0J9^YFH)&'-1BZ=JC='6Z^JA7F0-Q\M+%<9R?/V*-FZGOVEB?
M+P`9?KZZ\"N.XPS.C,JBI(S0)^RV#G7#J,S*:0I6<""')>(%$M$:<6B3`SD;
MT_8R=EP<6BW&R$E';XS>6;?^S5Q&Z]?H8:8U<]KUQS":@D0<Q&$1VZ.(]4:Z
MT:KLQ-S)2Q<'<7[^:'HV.V&584Z]CM<A\_QJT-Y-D0$.3AR?7)P8?3:W56HX
MF7UR7L$S-&+<8;DZ>;EJZ_U^=9[`*Y&H.H.JK6-W%>ZP?#OU$UFMJGJ"\8QZ
M`ZU'%-'8/D;=.#70&&(=F_YDPAV5J!XV@VR@=WH<?&3I8NFJ)?NYHW=:G/Y<
MJRE_8K%]$8;OM`O+BK%;$Q8RML4\$):3-2`T9]BB2C:Q.]ZPPS&;ZFR1-X&#
MF#Y'1I_7&]A[V^GK[<'>0GNK?%/?KF7E&G#CRG<L<2QQZR5N:.BC;G5UZUCB
M.-3^-!5_$Q$'VH\"ZSC0?I0\QX1['80KJ-HNJ%K;C[&)WXLZ!S4]=%9=@<+G
MR'<:%0SU5H4%#'<F65.XYZ6!5P8S!C,&LT.!6=?0._WJRGB\>C3+N:D_4?_?
MLNOW-K`<T>KM@/[R[M^UMO9.#_AB9\25(>X$,[W1N:'!96[93M@N3R2_W<7_
MJ6R,[?-!I4/4L0_WHW!=_+>:(7:&YZV,>RJE)Y`Q$'(?TURSIZEK4_-!:&,A
M/+C6<LTP="8.7!3Y,,501*$V%:ZM3?Q`"TW`L;>A$-IO?B2TOJY=R"O^GESQ
M%:[X$4E3P0):S6@9?_XT[JF_?_DI#L_N37/^[K,*0GT&1HXN//LFB4-=.Z'E
M^F$<B#N8RZ7K6]]^_<N?__3+LS=^]EW'6J0W@6KPD!I?Q.3]F]MKG.B_NO^Y
MNWZC.39\85K16:]E#$>W[9O1L-<U+D>=7O=V>&T,VP.C?W-Y<7O[YM<E+,H3
MXYG6ZV7JJ!S*<OJI+FB3'_'R=TX$[[/DDS[G`X$I'=]5(U2?2Z.,FAD(S3*#
M`&7'C&"1PHBN2(4-OH]#0&`MF@IX:6`BN<Z0=-I,1%,?4`],"OI5I'V48]E'
MV74F`F4*?U12^3AUK*D6F-X]K-8D\&?P8P"B"7+;;6D+;#EZGE-*Z5__-!U@
M'\_T+*&#Q,]-1S7HF3D>2#!\XYJ6+$PEYS0U@WN)!^+[7'@ACD!S/"L.`F&7
MOJ*\S!4]365/B-QDPRE\!7^KZ:V9N[PV$#,8/A+1Q7=H<-^L=`A?@?4`QRP0
M);C)$X^F*V<Y%A'>E$W/G!/G_`_G4I&D+PGL9E*^C7P/VU?MSO#B9G#9N3"N
MK[M=HS>0\CVXN;CH7M<NWQO<4W"M<'LACP'X.?]0X+R9Z1;<!@.O21],AJ1F
M@>)5U[Q_TWI#G\%*MI+/V\_VT;&C*?P)<U*6.Z@=UYR'XEWRQPJ898/*[\)D
M!GNG-`:]P48.#>;]F][@AV=]@:)'DMRXXWWM'>\S]CS.7=^W\WW[)LR)3O#H
M$PN;W51]/QMG>VW&>),:`;]+(^"C\[!5PY.&L5;CPJ;I<)_KZUE':HIZ)FGY
MIP]&'IH/+\B333Q,#1S+':)@C'G58]XK;+?^P=/^@UX=HV#U*-AA=EMFM](`
M&K,:LUHMK-8Y,;W:./YK&'UJXJ\]Y"]RFF(3^(?I<V3TV=CAK/FL0_W:[*WC
M:='4CT/3L\-&)/<?>V[_E3^;Q[!J<@<G]"?1HQF(6MS*4ZY4WCFK[D!.<QBO
M<4A7.;HU/F.,V[OG[QOIW?ZP=HHT9>WQ/LY]9J1AI#G`,0Q#-RH\A]'TQ7\I
MU!Q)Z*A.$M[&@>=$,29B@24]<;[CW]R`<%UOB.H:,[.V.N%N:P.]U>%N:RP1
M+!&91'2,RH(-IR(1'.)[JJG.&$]V^,%BI\(='."3`;[ZBUTR;+_.4JKZH,.5
M5%FZ6+KJ*`/>U4>]ZDZ@G[IT<1QGS0D[CN.L\4;.C,JBI(S0)^RV#G7#J,S*
M:0I6<""')>(%$M$:<6B3`SG;UYGAZ,VV/G;OK%O_9BZC]6OT,/_?&EK&GKJ;
MR2+&(K9-LL!(-UK<RXV#.%OL>7DV.V&584Z]CM<A\_QJT-Y-D0$.3AR?7)P8
M?3:W54ZM2T\=7L$K:7O/<L5RM99<;;W?WUNWN5.1*.YN]01Q[_S(=+F_U5&@
M&?>W.DJ>8\*="N%>8?"Q,]`[/0X^LG2Q=-62_=S1.RU.?Z[5E#^QV+X(PW?:
MQ9JF*V3`JU8(],7QAAV.V51GB[P)',3T.3+ZO-[`WMM.7V\/]A;:6^6;^G8M
M#]?6GB6.)6Z]Q`T-?=2MKFX=2QR'VI^FXF\BXD#[46`=!]J/DN>8<*^#<-Q[
MO5;RG48%0[U580'#5]]ZG<&,P8S![%!@UC7T3K^Z,AZO'LUR;NI/U/^W]/J2
MOS=HT5S>G/E?L8FMJ-W%K8,-LAW3_>!-L#4Q[M%LTZ#YNC\<WHY:5\9PV+ML
MM3MMXW*4-&@VAH.K@S5HWG4=7](VG3ZNM,GX*EQAX<982G0MI;IV;4;FDVSR
MU-QS//W?.(R<R>(0VF7#$9+4Y5MC=X>`:56.]VXJ--D^>RQ`X6K4/1ZX.IIJ
M%LB&Z7A:[)FQ[>!BA)$9J7;M_@08?38/Q%1XH?,@--</0\V&E=$I+N*)2'X%
M$H97SGQ/"Z?84UU>`Z_0A&E-M3_D`N,#7\I*"N@4`A+9;&%AY4`0T'<(,2H#
MMZQYW2[$HYGN<=2K?=!V&?6[5R0[%0VO'*0*O7QT37RWQ#PBAL\X_>FPZRX@
MG;NG8%=B;#4/%?@Y_U`/595;L)D,O"9]L(0!2[BNNN;]F]8;^@PF@I5\WEXE
M45=P^!/FI,P68'G7G(?B7?+'RKIE@\J'H#-KI5\:@-L@BJU:E'=/M)GZR7>+
MYPD>^P2/+_^K83THC1YW97^BPY[R&+0;4(,;GZ!GIN3&Q54SXC_-`/R;CE%5
MS(?#L,QN3[#;/V)/:!TN9<K<M@]N^PJNKIB-0<\RRS'+[87EKH6E.&YCE<IF
M7<UL>-1LQH<`:H>QT^_G_GNR.\(I[0=0@Z\1?XY/J=6Z%;.\8Q9[8!CAQL<3
MFWVOL5A[]8JN`=RPE\0X!F06"Q8+%@L6"Q8+%@L6"Q:+JKR2!ATYJ).V7\2#
M\&*Q3=>;RL6F\0GAU9TG.(7C`NT!5Y3:&T.\8E7-./.Z<:8_Z#/.,,XPSC#.
MU'S\<<0XPSC#.,,X4Z_?9.C=877'K)N^^`>)VIQ6<.8CGE*=!/Y,P]/@M(=\
MT$!-4^A2&:X<$WR\[;3T[J`R_%CE^B-B`$YH:K!9TA0F>9THT>[KAE'YP1Y&
M"48)1HG308EN2^]T*@NO,DHP2C!*G!Y*=/1NM[*]WM<!$IQKLIZ(5[Y')P&I
MK5!2A8L#J!Q`W2(",NQ4UU/A.9J<-E(=$2B=OIW#2'1<2-3NZZWVD)&(D8B1
MB)'HP)&<[HB1B)&(D8B1Z+`VD3[JK):!9B#:6QCI\-&BP@@,?%J^[/,9?5-[
M1&FEKKNNC<W0L:@DNNVX<;1Y\4V.:9]:3+MUWN)]KTJ-(K9]&"-.#B,JBS(S
M1C!&,$:<)$94%G5AC&",8(PX.8R0+#!L&^W*>*`IZXGW<4F6PP4^OF)<(]3B
M4-B:XU&_NSB"`6"+QPTB(ENPX\8%DRI=G8-64NH9'7W4JS_/Y%2$^8CDMG$:
M_U6*5U?OM^O?*6#Q8O%ZI>(U&''I'!8O%J\ZQ&O4T?NC;>JVOV[Q.M*=[(I(
M2!^W:PFPC6&4SJEQS2BJY\-&Q--.%;^9?YA_F'^8?YA_FL,_IQ8CKY*:7+:<
M\Y.WI$:G7UDWV,:O/,=$3DCG-Y[;&&?R][6W:NK'.,,XPSC#.+,#SG3J/_79
ME)5GG&&<89PY#,X8>M=@SZG6H,UIQ6:X:CGG0.=.A??T7G6YE'Q2@G<.&"5.
M$"6&>K]=6=R$48)1@E'B]%"B8^AM@ZLW,$HP2C!*K$4)HZ^/JFL=^SI0@G--
MN&QY`W'G)`*H&`(9#>K?%'X=2'5$H'3ZA@XCT9$AT4AO#>O?S&$D8B1B)&(D
M>CJ4T^]QV7)&(D8B1J+#AHL&>G</*;NO`XF.-/VE,`*N6]YL9GR=46VN2<P[
M7\TW?IK")*\6(WC?BS&",8(Q@C&",8(Q@C%B5XRHK#SKZ\"(4\N?V7=`A.N9
MUUH1MJUW]]"MNBE2B_?Q:>'#6`*O4KPZ>FO(]<Q9O%B\:A*OKC%B\6+Q8O&J
M1[QZW(UC8R[)>7H_1>;8%:77E_S]RT]Q>'9OFO-W_XK-(!*!N[AU/-.S'-/]
MX$W\8$:E$NY@[I>N;WW[]2]__M,OR2U?1`CCM:87GGTM'H3KSV?@B-U\GPLO
M%)_!0;(6Z"HAX;Z(R?LWM]?MEM']5_<_=]=O-,>&+TPK.KL=C'HW?:/=Z;1&
MUY?M"^-Z-+@VANV!T;^Y[/7[;WY=6H@\4>^<&7AHOXE'[8L_,]<+:^YVK&M^
M-I75SXUVZX>?EQ<V[U1VA]7YE/(C7O[.B>!]EGQ20D7:4<_145.$#-^M<,$N
M+*85WF/GWB/4>\BM=<)(\R?P9QB%X/1:<1"`CPN,0.ZOZ2W.PCEZO_BM&6J/
MPG7Q7Q`=UQQ3_?@'H07K7@7K[3PXD2/"<^UN"E=E+W)C6VBV$P@KHMN29YP%
MPB4_&W%Y*DP[&R]>!GYV\@4-*!GR>0YJT[_NA#7U``#N%QJ0'^_1)@(>A-.+
MDM]@<%HT-2-Z-/C[+M"1_/_ULX+/4Q/F[?F:Z8(0>9(,DSB*\1GPFL(P'Z?"
MRP:J:5_C<1B97@0RI\W]@&J3X")$4Z%=2:JG7?L&/X?:'(@$7(PX1^]./T0!
M/"*DE\U!B8'TPMO&"WB0$]AG<Q!PF+A<)C^`>>H:7$!W`C%@W/`%RFL`RY3-
MU@_N3<_YGRR90N_S86"!]B`\VP]@(;5;(%]^3&$4V_3TW`1@Z:T@!M*FJS<V
MD18Q<),FPLB9T2+#L'$HYKU``CSZP3?B.U?@C_AN?&0Z1F!ZN!70,H3ASDQX
MO7>OQK,ZF(QM@#QR-'9^$/AD+YZ-86KPZCG,%P8"X_4"X.W<V^U8EH])5@A?
ML("WWN4F._,]!T@<)H]13T%ND529!_X]4)B6>7FHBOTEUV<2HT4^W0KHA$^<
M^V'H`-+#=Z#9[J?`4,1Y+MSZX(A'>K1M1B9\1J:"9ZD')(,DQA#).A8Y*70B
M^,6!?\+BU`J,F*Q;".(`Q`7.D&2$;P7";*ADU`)6-T$9*(K1J(`"#XZ=\&<V
MC$#<FP$:(XJX9A335(0)O$AD,V=R+?P(Y45]$^+[Y?+G%P+XR?&)Q=V%)AY,
M-Z;A$AW3P0-=;&"P8`9#UIR)9MK_C<-H1LN/S.()"Z9B!C"!0#/G\,HY"!H0
M2'*/C\*<JDK-0=FQ!`!`>/ZT_E[1P1LHU&4%'`6Q!2@#,X>;ODBFN4AYYMH)
M+=</`852#;Z!1NYV0`%?WG0N^YT+X^:F.[JY'4F-W+L==6^ZM6OD*A5NOL])
MHF\SHFE74S.X?Z9D]QZ&NKL5^*QE4X,E0_=]\+1_F%Z,8H%,I&L?Q7<'F*N`
M$&,?A)F0B#0["CB&R)U(X9%G!F"!@\R$\'K`57'O6"!-P+RD0B5^3'PK1F`(
M_1BT0T@"!S<@KX,]A;K"#N+[@DI6L`"P#Z(*UNR<`"`$R+AW'?#N_@?Z_.W'
M_Z_;-HP?2?W;CCD6D7IA!,\!78K@HXG(F>/`\'*CU6G+RRT04\?S'7`\%IX=
M^#.AHXD`6A"TK,0!,BH0#`,3S"KZ"B:,LP<=!WI:J50%6+:P`&U]LC)B-Y(6
MATD:$!YDH4UE`],JO4,@])W@"Z9EM'N:`"7I+X20,YZ9`2Q?WFC188:AA3;4
M@J88QG/4"JA&:&QP'XP=K_9HBZ/XAE[KAZ<,$@G%Z5B7,#A3X'C_S/POV!Y1
MJ@S*9JA4`FD4I60%<):M_2&=%/P6>>YI?&6Q+;NOL#)H@7H1JD;0,5:D#%_B
M6EI22Z(C&-:A;SEDD#PZT92N"`HX^CAU0#\_.JZK.)AVS,QP*NTNVT%3.)07
MC,42>U7BX/RU=S[(3'VXW`56JL9U>BMGI[R4,"4+BG@(J`,2;HE5N:QJ6IV:
MII79\L6UE#Y93=-IG7?KF<Z/.KD,M%)54;Y?$^4?<YYJ:L!7\NAK,#W1A\D&
MWC%T`LM*'@_0_@D1V4F$0*^(UMWS48VT#K"WG?V,&Z\<1/J^*EZO"Y&6)W4O
M/$`A&0XP;7!D'#*G,`J13,N1OADX8Q+]5Q(9T-P11`D*`,W`&IC"G?@,RF](
M#)H%D`]ULZB(3/6S+)BJ&.!&VZ(8E$A)&$;@&IU)?PZG#O.65EQ"/3^EGG!%
M%@!X0"\2"$GN.CFM?HERA`NK8BA#JY2/%%,<WY+>RMC:W%Q(/QU(O*3$I([6
ME4:@^-Q8"*\@-DD8R`7KWW%EF.59.1F;+NG[<"I$!,\7,(ZJEK<V51]6QH1U
MK^WV,9.M8R!+013JVO4%V.+>(XR0D9:M(B;MF\[0N+YNCP:#SG7[RKCL]Y(]
MC/Z@U3O]/0RBH98C8F6[%K*G&@7B`OGX_R4Q]+D(PM@D#24PF)A8X2#8`=CD
M]T+I=5"&``2V<!WR?Z<H#9:ROLB$#QX<#"SD00);X`H[B=;"SQK8/!/GN[PE
MB1?B7IN,G&*0&'B.8&2!UP;"#'V\8('N4[QN3^)E7N(>EKQ&'W=?H[\J[$Z9
M]X$04FL$"7<E&U!C\(?2O2'UJUK?Y7T1]>NYED&-1HV3ES;#<J^C72`5A+97
MPL[`:8LL"*.9V@S<:&<.#`8F!W%R.J#DD4N1%A2!R)DX*L*M&!YY-)VA=.`3
M'9<\AZ:8A<>ERBS<GHTKE"$N`9-UE)L(JC*FL-'2>-0/B>GHTW[?;`[<0]0(
MGWR6(@G<Z[K^(]E6C[YFP1K#.IM$RYF(5F%F5PX\N+C0QKT&]J6KTC'>OVF]
MH<_AW+22SQLH$&W=D,JRP!\=.YI*D7LV&Z*8<K'YQ=LEHD?^?)N\C.=B>\7D
MER[.\T5+JP*?[?[+DY]@IENEH.R5A^\R!$%C&5Q#5'SXKU*4"!<B<7BL&%RH
M&89F,6R-V]DV#`P8G\H%/+<3MD$F"TL'2T>#I.,#*:>`K$(S#;]0)IST1<$A
M\518X"&5DJ(\Y6U23*&0*1M)+!FO1WNB<`>^CM)TR#K%;:YQ:H+F%'O9)@U9
M,+[[<DD\*J7:&!L4_42Y_9FN'BV6$V;.A,P?D(::KIDS'V-'%*#'E;VG8(:@
MSVA=%=)PP)1R75I[R2>)9>7*[3YE2RG+%LVPV+4I,VF5+<E:<R@K*Y(QH7D<
MS-%X0P[SXTA%N"SAS*.$4]/\FX+9B+&W26;'EAND&(<I>FQHV\D)(&_#,,!2
M=B83@9M59:;B4J81V(M6FN:1?VY">S/9C94VZ7I#%I8@EO%0^5`2M;4/A*5T
MG9FC;'MY;RZ7K-1YA!==//7`9#*VIC;F@&QBGL\_RH]'P4SJ!]BEAG6:M@+7
M.D$&4ED:%C(37DF.+PPQ\>^=,.^#(Y]06@Z^9.D=Y)_3\'+Y,HG_$F1A@A6#
M_GPU2G6T%GUSP$=&2]-\N2QNFG(GJ@=8.)*P>1KMGCJP9,F>`-AU2:;B0_YA
M2Z$9)V$L9$)0A(LDI"J3L?"3=#`I'2!]"C*[?!_F1%X4?\F_V)E4Y_0U+VC"
M=B[;N4VR<T$G@7;V/3`DQBDB)(FS),H^\"M:#)Z&&<:H5X2CC)8U^<MY0S=(
MMM941#:)X6)&IP4ZS-+`XK#`M51Y):A<J(_C!D_?>&W8ZV1I/`9IO$M<SKP^
MC('3@PBL;]"TRDC$C<IEH]K!7/9(.1YD**J+T2B+LLPL)>&4'L3RP_)S2O(#
MVNR1/-\L1S%)#,&S!(E1/!;DR&;13:5G]AL[:9YMVIC1XXDI<!RE'XSQC<)Q
MKB5_Q$SW^3+/YAYP,8U=1*O'PI+MY=1.H;B;S&-.3@)))/9\Y3K%M&?E/?CN
M0[(W]\5?F&ZTR+895T<&Y/?27!0_L.EE:8YMNNN(`8,P07<\7B.#+NKY*DR1
M;E#+S+;<#G7I015U2L7.S"G0*DF$2)W<R;UPLQWN)P6D)'GCF=R+0J;&5VLJ
M[-@5GR979CC%_V[^B)T'TT6AO?#LKU,_B.Y@UA\\S,LB6;[#^6^3RC%L&1<7
M1N>FW;JX:!NMP:#?[R:I'!?#J\X^4SGDJ;S-12GWV(*&:"V52L+/^?=ZR!-N
MX52XT<HKE<K4^-+(9V9P[WARD&8<^<D7\N0^?2-U>7^$XQECXE9P1OOK\U"\
M2_Y8`9]RZR!31/W2T^T;:'<:S?LWG59__GU+TT+=.MKUQL'.=W9WO;''D^1)
M-GV21UK=OU)C[D5E18S><W5%).PJ4ACS[QHEPVK_3XO^;[>&)/*9I&I6'KA%
M[1&E(C.JC'8CYFCM>=$+VCY)LEZUM<FNI]5\HCGLV3D`=Z[2\HCX=88E)-"]
MN/+#Z,7^/-<39HY\(4?^+<#C0[][X"_*8BI_,QWOH,V*F3.9,TLY\R-\?J8:
M!+,FL^8>6/,F3<:Y-9U`^S<FV[+-V1!FK8%66]'G!=RV.W4:QCW-A;I!#=S3
M*&QZ2PE=?AR:GAURRQ(&H#T`T*DULZB2UW`K3)Y2I(([V:985:)9-,XZ8#G9
M?HQ;0B\*`3:]*F]U/8F?(]])-"TV.@.]W:^LC]?N1&L*_^!]7#3],)J4X8SA
MK)JD.*.]/[YK/`\QI#&D-8@=&=(8TAC2&-(8TEXKI+'363&<\=[1SU^%%0>R
MH-?,3.I;R^(:>!P9BV4^?0+Y2(.Z350"K"2;QC^-HP_SSU'Q#^,/\\_I\$^=
MVY*M8S>DKG#V$T<68\(F0(+:S>S">Z^H]VFO77OHH2D,PK&7!L#ZZQ&M.N*?
M+&(L8BQB+&(L8BQB;"`V3;0JB&8?O1?V^_G7<RW"8BUQL,!.FBJX78>4'9TP
MM5N&WAMN?)K[.=9IRIK7K9)8\YRP3'18&E@:6!K4?6^KRRY87?/Z4BTJ%R(^
MY\72LJ$]U398@U3@AVSHL@Z/W4&YHU[S(59O/,.BE5A%,ZG?6)FGN]=DPLW+
M#'"FX7,TKH&4=<!>6S<Z#4A#/`K.XX!I0[-=&"49)8\AL,#XR/C(^-@(7F5\
M;&2HZ>74W"I(=12L6ED$B_&3\9/QLWGXB5YX:\!69H-CFOM'R/HCE]:Z\ENR
M]?*1!#.;0M/]`6)]1*G!=>Z,]&ZKNL2OYVC3%&ZHVQ5FBXVAAJ'F0%&ZIO`!
M@PR##(/,R8:Z..V*08A!B$&HU*F"_]C>V3WR4VQO7=;M=VE>3_6[_6\<1LYD
M<0B@V'"$W)&7._)R'U>>)$]R!U%MF'G:I.XFW(_WA?UX-PY:,7.>0!N_9C$D
M-]Q]%;TC&\5TW%.7F:\YS,=M<YG[]L9]K[HS;K.MOZ/FMIKV%1C-N#,NL]#>
M%.)KA"#NC=N8WKA=;E-4,?E.HDU19Z!W1S5M-&]#LZ:P#][')UP;GP7#:,9H
MMI;M:NPCR9#&D,:0QI#&D,:0QI#&D,:0QC[GP='LZ/>.7DY"[HS;'!W`.K)I
M_-,X^C#_'!7_,/XP_YP._W!G7.Z,6RW1N/$9AU[V"NNO1[3J"'^RB+&(L8BQ
MB+&(L8BQ@=@TT>+.N-P9]TGBC`R]->A5)4]-6?*Z-1(KGA,6"6Z,R]+`TI#<
M][:R+I^K2UY?G@47:&1A.90U-6#]48$3PFUQ&]Y)XKC;HG!#GDI1K]^N#/6X
M'P\'2P^?;<T@R2#9S*@"XR/C(^-C(WB5\;&)<29NBEMC^(KAD^&3X;-Y\$D^
M^/YZG!PWXQTDH+E_@#SYGK@5'8EN"DWW=_*Y/J)4CVQ&>Z0;[9KZR)70IBG<
M4+<CS`8;0PU#S3YB=`PR##(,,@PR]0:ZGB`+9UPQ!C$&,08M^51#-G?J;HF;
M_/W+3W%X=F^:\W=?K:FP8U=\FF#-<OSO)@N;7'CV5\P$NQ/![$,6/;G#5]T!
M72Y=W_KVZU_^_*=?5A]W+28B"(1]9WZ_"$-!#_OHF&/'I=,NQ6?`&GA(Z"]B
M\O[-[76[973_U?W/W?4;S;'A"].*SOJ&<7T]N.@9PRNCU1E<7PS:-]?&L#TP
M!C<&7/_FUZ6%RR_",_UGR]9]I2'O!O<4D*FQW79E*UVC!7.JJI/N\(6-=`?&
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MAO&IFW7L-+'3M)5P#5KL,['/M$,:10`^DA<+-@8QLJ=W>URNF=TC=H\RB1CT
M6RP1[!UM3-Q/$?Q6B[7V3";RZ5AS0[T_K.E4^!9D:PI#L2MU!(KM]0@G:$2C
MNH:#KUTX7^Z*=;O'KC%E[3Q[-:^=+5"4-Z.M=]O<A(V],O;*LAR)OMXW*C,1
M3T4F^-C4AL>FW*P.")^=.G36=8,8L+D0SAS'9Z=>CG<++1"N&>&WOF9:?\1.
MZ.#./9:Y^+J8S:>^M]`^6/5LY1^=E?'6&.K]ZG)C5GGEB(Z7'''UP29;;"<O
M/X,NR\]6\L-[*]M%BG*F?"UQW2KMJJHJ7S5>U7%'*7:'3B>SK=EB6Z&&9;%E
MG_(I8GT48?A.>S#=F/*]-=,%<#`]JY;DN3H*KQU66"O>R=F40*=M+S?/WSQB
MK7ER(E?Q1A&+7,TNZO$G,V#-J@H<U"W8L*(.%8U/M=E?ZXJ7M$=M3&V<JEWZ
M%Q/MM$&1W?JZMH<9[!CL]AT(8;#;U`)\>=^?K1KUK&GV<QM'<2#^Z7C.+)Y]
M$5YDNI_-!34+NO6#3TD-T8_"#'=H_=.ZNNI?WQB#V\O;BZNV,1S<7%XGK7^Z
MH^MK;OUSP-8_W1>V_AGNO1-/GSOC-+\R?S/Z0AQ/KQR`62V:"NT_P@RT&P_G
M\239#S7.7#>?/8;^69+V2JE#,QEWO:C:-`6SK/)$(G88=V*H8_`'#;VUAVR6
MIJP]WG?@>C`G@"_;U(4\W:1-0S=:?+"*-?,VDK--R:!76)S,J+2W."NCUZ",
MMN&7TU5&O4%EE2::LK9-5D6M8Q<<.A]0&=(6(GR=FC<>CR);MJ9=R1+:OL0+
MK8.4-=0PT(>#RDK1[T[/H^"["D'SY?N5+]AK7+-[^4\3GDB;G9\F'WWO_DX$
MLVLQCK;>J#2ZH^[`Z'9:O<[U97?8:O7:5W*CLG\S:E_U>:.2-RIYH_)U;:_P
M1B5O5+(D\48E;U3R1F43",0;E<78\+`WJITB35G[@P2_3@Y?>*.2"*%7B+1-
M6=V#",CKT<R\4?FT,NKK[1&W46)MQ#N56_,2>9[#MM'>QO5DG<0Z:1OK_Q7J
MI!H$BQ73Z2NF._A)F)/H,*V8CD[*A@.]UZJLS]ESY&D*D[!FJ[]4YSAJO'YK
M;GT_HS70^_W*.G)R$L@KUXI8P$^SXB`0<._<#VKKVGYJ^O%MNZ4;%0HBUQ%C
M];F!^G1]'+\(9MLJTBVXCROJ5$V^D]B8K-,CV(9F36&?"JV/]2FH>QO8+CF<
M^Z/:$\FWFZ7*KLFS_<WW'D08"?L+_&_@6/#7UP@N_]USHO#"BIP')UILG73;
M;1FW?6-H=-JCRYN1T;V]N;V52;>]V]O.98>3;@^8=#M\8=)M?S\YL+G[>OM^
MX;[OZS8WJW@_N;([JK0JLP%WSY9LF+?<N%J6!_61&YYM^G5J!M55069F:]HA
M@$8QV__1%\+6+H`DYKW0_A:8\-1K,Q+:K>D$VK]--]ZX<\7Q!0]971R5!->1
M$=-P"=WM\`$S575JX:B9:D?Z<-1Y/;=]BJ,P,NE,G&:"KLR.H.E:NV74GQK*
MPGNHO*Y#QIJ[>KM;6:&7DX\DLW`UR!QM/+?Q<;M"0LTYGV^HUU(Z+8.(8@;"
M9M^DN0C<'&S1^ZUN591HB@#4;:RP1)SPH2CCG.LW<OAA<]K^FY(SV`_B($,M
M+>+TSK`R_?S*&\"Q[.TC0^!D#G&"VUU=*BF[W8VPH^LDX:T?3(3#CO>!FNS6
M<&#GT)I_\R**?':'!8[]^N?4.?OU[-=O3-OTW$594L'^7+)7C$5;:+1=FC'4
M<]K^L-T9C+I,!N[.P(+=W.VTQKO7G-!0-,7V$--LRM)7:*.]O`W,#H=)UQQ+
MI6,QEV8H["M_-A=>:&)=#GK8ISG^N?O9U/Y%I]MN#6_;%Z-6^\;H]UK#Z^1L
MZM7H^JKVLZG+[)`_=]H=@B15S1\%/N`3L.!]ME]X!+:SGP.;V7VC8SG)NN-]
MPR,9)Z]#,\;)ZW"P`^%\@J]I]&F<!Y8.M]_LHFCUG^>K,IC'C,6,E6>LRK+V
MF;&8L?*,M?%&%A>4>>$);UT3WRTQC^`?$5A.*+1YX%A"L\W(Y'WG0^27O;ZB
M("J>QMQ6/;=Q"9KG2]#<),CW&9&/N9`QCS'OF+F-,8\Q[_!<R)C'F,>8=_R8
MQRFD&U>F&HM[Q_/P@S_1%L+<ILO7L9"S<1"P/\(=1XYHNZ-W6MLTX]Z-@)P#
MRG*Y7]/EN%FQ$0FB1X)@YWNHNW<43,/XU5#\>HUVA:'WVCV62Y;+!LLEVQ5L
M5SQA5_2J.SQWU$S#^-50_'J-=D5+[PXX7L%RV62Y9+N"[8HG[(H]G'8]"J9Y
M*7X=WVD8KNW]^H"],<#3U7LM+GG$$L$UP++"$_TA"P0+!*N(M&)4M[HBMRP1
MKT8B3E=%M,^K.[;)`O%J!.*D542WLGT1EHA7(Q&GJR*J+%]W*@+!:>#K:9LD
MUG.3H$,KXA-M$M1N[Z_)]>ON$,"2QRV""I9`M_[4A*8(4=TV,\M6$PC7'*W6
MJZX/)VLUECS6:IMKM4']B?Q-$2+6:JS5]JG5^IWZ+4;6:BQYK-56<S_85ZLU
MG'MJ4=NY$W"F)>^1;J+5.WJG4WD9\=>MOEE@3G@+M7/>XRU4%@C6(*D&&?4J
MR\-D_<'B<O+Z8\2)_"P0K#]2_6'H[>IZ/[,&88$Y<0W2/Q]QGG\54;\&A=GK
MI.VM'TR$4^'1ZP;1K7&P\S3AGJG5?:H;A]W*+-X74_!UVP4LN;RQ6-A8'`UJ
M9ZVF"%'=3BK+%FO%K=S>876RQUJ1)9>U8G5:L?ZJ9TT1(M:*K!6;I!6KK,3.
M6I$EE[5B=4<KJHOBG+I6Y"34Y0YRPK.K[AW'.+2-_NN"_K/]>.R*%[6&;(RE
MT.[H_59UQ0.>HU53Q*IN>YV%ZH1WCMOG!N>NLD"PECE4SU'6,BQ4KT#+5-?E
MD@7BU0C$:]8RU7:@9"W#0O4*M$QU/0]/12`X"_;94J8F`F$]\<@&$;)Q./0R
MA557\\CJ=&,-^RU]?=2NKJOKSB2NA5R-0TZ6[9ID>R<);?KV8"-:2#8&J=KG
M;<XB9J!A(Z*!1L1`[U28ML%&!,LV&Q%L1-03SN$:APPT;$0TT(CHZ;UA=07M
MV8A@V68C@HV(6HR(`4<B-B5`;K/HIPBW14JO+_G[EY_B\.S>-.?OOEI38<>N
M^#3Y.C4#<6F&PK[R9W/AA6;D^-[7R+>^?9KCG^&%%3D/3K2XPU?=`5TN7?CQ
MU[_\^4^_//6XS^9B)KSHXM$,[/SC_FVZ,;WC(@SCF?RN^&A8&@_I_T5,WK^Y
MO6ZWC.Z_NO^YNWZC.39\85K1V>!V-+B^&%[VKUJ=OC'J7-Q<]*^-87M@]&^&
MO?;EFU^7UC._-G?.3(3:;^)1^^+/S/7HE[O==3QQ-A4$MD:[]<//R_Q!GQT/
MP#1ZUQV":%7-,&L9XZE1;C"S`KBV8.#YF>#G_$,]/YB9;@%9#+PF?3"QHV8)
MUU77O'_3>D.?0=:LY//V:_+HV-$4_H0Y*6,"Q-<UYZ%XE_RQLB39H/([JJG8
MCTHWP3?8DZ6QO'_3'?WP+*`444O=:+1WO9%?N.Z^G6_<ZKZC/QPTV@V)1OOR
MVU:/>AZ4>A9@H`BJH1]]>I0P.O9=.\EMF`LK$K;V;]\%I>B"FCVDU?R:O(I7
MSGE?G/#;V2000ON`KQ)AI'TQ(\'<Q]RW3]R[$\&,>:XRGMO\>/O^^>^`/+?Z
M'GKR-?BUL&Q/E]=LSG"WP>?M3%58U$;9J2^7GFMAB=E8!%K'T#6,(+Q[,<J<
M'I&:$:H],0AFYF'F8>9AYFFB\5<3(S6>>;:WAAJT65OKV9K9W/470H258%0S
MB;9BJK^<;/W^#Y4%`II#L\8!&G/:S\9YFUF-66T?K%9_Z5SFLWWQ66,2>U[>
M8'(CVAQEP=>-@?VU!_,^32:.)8)0,SU;\WSO3"BS5;.=0%B1'U1COYX:H@];
ME=D.#-VOB&_:YQUF'&:<'0"'N::A7'-B!B';?<?DK-:^N]NI9G>WF=2K`:?Q
M/C[JU#1<;Q#5F/V8_9C]F/T.M$>]3PH>'?N]]FA@M7O6IP9NPQZ';IKJA#>9
M;UKG(V8<9ISMR5-9]7/F&H[Y<<R/8WX'W@1N)CGKL!0-SBSC@,M^DA@Y7Y99
M[;AVH!M$L=?*9R=FOW(2XZL.6R[O6;=/X$1R`Z/C'&5@9F)F8F9B9CI"9FKH
M">8&,A.'"?E$<Y5D&U67\=\@FC4.X)C3?FZ=#YG5F-6.:FNZ011[K7S&P4`.
M!IZ.E<HGF@^^9\W0_8KXQCCGM%AFG%T`A[FFH5QS8@;AJ[/[JFQ=M7NOJ6(;
M*W&/C_DBYCZLCW=_[826ZX=QL%5OJNMA]WK4Z;:ONX/N;>>Z?6M<WR:]J8S^
M;?]D>E/)CWCY.R>"]UGR28J*V@=O@NVBD.ADYGZ%`3E@]IKPVU4<`@^#`;RZ
M";X+_VD?Q7<'5D;SYR(P(Z"@`W][0AO'(5`G#+50#DK7'J>.-=7F@3,S`WBL
M-O&M.(0;X.9HBN9W:"%P+C1_0E],8L\BOJ$YS('E9J8E8A)?+98M6_#:>P'O
MH6OP+GBD?(`/?^!/Z7/2-SARE,67XOVV>!"N/R<:PC.67CD/?#NVHA`&'M#-
M42#,*+EX&@/3X/,$B,6Y]C4>AQ'0VS%=F"K\3S(K[/5F>@L)X\.V,?@YU`)X
MKQ?#J*;F`U!."'@0#/-!V-HD\&>:'<3W^:&ZKF-ZE@AU+3*#>Q%I#\`#MEQO
M"YMRC?W`E*1+QIJ?&DQ51P*$P`>:!<.%!YF>Z2Y")TR&.9_")W"/[VGJX!X+
MG'E&;1<[E]CXE&\>"*<?1]H,_"H8D;"F'MZXT(`OA4=/#X$:5N!(&-`B7W/@
M83!@<RS??H\3\VAP]P%032XG"GQ@6NFGV1R]=GCL.#"!#*'IBO#\:?Q;Q;#G
M@:8(3*5-^B3(77CV!P\M'UBISZ[IA9]]F/)B`Z"Z:%^UN[U6Y[;3O6Y=CJZO
MV_UN`E07_?;%R0,5:HHS(JN6IVLUF)0SD=*_[C+1`W&S?`#$_P$5K=S+-?$=
M_Q;(U,B?(+^10&8AOL<K`S&%"V"U-6`9*5LA\L?9F&8RE[HP1.&RW!A-!G@(
MJBY_G@$9-OP)'&K!(G^,/7R;`WH2O@+92`(2\!SY7`F03J!-3/@?D/4XAYHP
MQD1F270`9YUH2I]+)Y=.'IX+0B>%'4CIDS!+C`8@2Z,B#L+3'[$3R,$!"&+G
M#D#UX`'$&^\1WZVIZ=V+%&ODM$PT"<[+UD*NOIQ;Z1CQ071[2)-!<($ADDX#
M>4/YLAU)4!I=-B%0=_#VP$1&/T.F1PHZX;FF;?O.#5^X1$%"ZW19U`^KC\&G
MV`(0=`9#)+*.!5)V3#T<835]RXJ#`/DGF@9^?"_7,P+!IS_,^1Q$239\S#]S
M)J)2@E\0![]4ME2T5+6I(<2P@112T[S#C?1BNEWV_J032"72K4O^*EM+RP\C
MN9"H;^,(-3!)8>P]@-3A@CTOB(]FN#=2_=5HG7=!<8)"][V*J"-%&+A!))V>
M)'\MLZVIR<8WPCX#JR,P[U,NWB.O&.>=BB%_(<S@&:M@0\7X7["4G<FBY@:S
MF[GS3=#E=!_JT4P-(:L4-1SR'9`-G`_@,S,JZ"C23QKZ!??T_:5K@AR#5^F#
M(8?@-?7+%<;=RL7R=6?@3&!K6VWFV\)-]%1(#W>\>4R&.=B>_Q782!EP,_-%
M2]]S*2P3_8=U=GJJ%(MS)JL=="#:JD`XF+X%UD/F<X$#8#M@00=HWRH5X2LW
M)3#M#)9TPJ6Q&H74JJFKDIN'G%MN-F#%>QK2/%#^!MGKTHO*%BM9&#+^026!
MR*.]4IBB/W<\>*).]X)K%T8I?4%G^9KG1YH'`!^&THE+[`$3J`]>":HD7%_X
M9P:.$)C5J3=78!H$VG)JEB[,+6#Z/`[F/OF+DU1Y)IST!$?J^=5$9S00]])/
MC<*,:SW`R.C1UZ;^S$</QX]##3<)YWDC3'P7@04.GO1'0=><H5;!,<BID/\B
M!R;UT5@`:SA^``\!MHQ=NM9!(T593&II\RL9X\M0AZ7P+0<);L^#<G/AUXEP
M(B!N.;72%G\/:6M3E,N\,:E-867]@)R[_%7>6MZ71$6!$UO[7-O[4$4?+!.E
M"\L"'Q#I2->!)[]-?&C4'UQ<=RXNA_W+]O40)G;3[J3QH=;PJG:WJU+-\4*]
M21]7VD-^C6<S4\9@\E&CC.Y:0O@J5>PKU:AKO.-+4P5B/H.$PSLK=(TU5*6F
M94D!Q^4$J:'^DZ2P)X!<G@4Z)._\2F=6>1Z2#VAT2>0/(8D,9U#-[N+,?T2?
M!B,^CNV8&&P#]XLZW:JWHM(##,C%]L:F2_$L#7!"`S5"`"JC2]GPX.KS5;N4
M[;JZN/!W::'<**.AJG@Q,N`\$'-3^@+XBC5<AVN/OC,J)G+)?S_7OIY3`#*0
M5HYEB3G9F1DZ@8*"1\W11DS-P<S405=H9G[+3"')?WG]&TW!:LW93P%%"O$E
MLY3SX7JAHI)H\Z#N=-2C[#2>*(-&-"H*NJZY)UH)XY22(PEOEPTG#1_C12J>
M`<9:'"3FD?3KS@'%H]ATE2V"P:_8M95IFK=+4^*P&[4_<;LRPZFNX?]J-\"W
M8,RFZ_YU"DM^AOV:`4?1Y"26J'C_!H$6#'E,C')=,`_OIX#EK@-#01Q.WRHE
M$2S'>^!2%WT.8#/B9.)>[&H^@]=,X7.@N;C_(Z,/%DY,9!,[_3@5+=V^YH*5
MF*N*KA&WH1M36'?BCY`\ZM_/`89Q\PM@;J$!E+EJAP;WUM%@C!(O#9PD)P+U
MCZ"_YE>I]"T7\!%^16"#;QY,QT5?\@SP_PSW><!QLQ)&(\3&>\P@<&24(?/_
M<N[:'[&/0`GF[#<12<\EW=[*'K<VX)"XC`^.>)3>XC/#REU`#EPLMQ(PDDM[
MA+1!2CH&7=#`)NE(QA.9<JPD3HN"/E#O6)2.]'</UL&EJ-Z]Z2A["G<GY!9!
M&%O3PB"#O`H),5PN5;'<+0!^DKN9Y.V!/8>`D',#28+7C.0W(/+:L6#(`7<,
MPTAI2=G^6PY(&9AD[Z67P9?^3*Q='0KUXD"SN8&=:*_XN2&XPLAU&KY/\1^:
M'4FTB17<OA3<ERS<3EH.^:!R=5;&+HF&6]K)F@&+1O!??A^`M!2(;A[XX%+:
M4X_0ZH2W:;2K,%Z`=HLBU)=HY\$SG2C=`',Q!P`YD&),E'`L94%NS/N`FA/3
M2DQ`&,+?`1P>A>OJ%%_X!SQ5++2W(2C3WP##LJD8[1]9<395<2[S$?G%><L)
M@&U_.TM5;RSM=54J'SVMSER&S]T%P_[^8/\BB1A]`=0`ZQ^LH_JA'O<Z<2>?
MME>RH%60#B&)='NX-^^B)QS(<$>:MA8(UU2;IV1'F')G/DT"P]P/F0-1;D(6
MS17PJ?Q'2@)`'6'[\3B:Q&XVLLC\)M0V1.*(23N%##A0%G@N!0VV7-S^$2@C
MSD"]J#T.F+/GS\#4L5QRWTEB??@E2!]`P0WI]JL0!ZHV%`L*2)0;=O^7OD?&
MYQXHM3-)M\#\,0VTH?R7LBU8NO87-?!I\R2+I5U)2^2+$WZK-D!0V`Q:]N;U
M@J(C!ZU$YL#QD`%M;0Y6#>5&(K=G$\C;4@',X%S+.V(FF%NSN;3(<.]OAL;8
M4T_"1Y`'MC3:%<T,[#MW34ONSF5?PZT8!SG[(S9I=RP+S(%S$P4Q75488X%(
M921``8H]<EK0`4L\V73HT@E:2CRE$+GCYS(K920=C4?7MY*[$`-^]QS\]#62
MX;MG7-LI``INZ&+,$%QI&`2.:9'?NTZ60[F40'IT34N?_,%[L7V0F&1590I9
M2;(STN<V(`!.(JD%4F6\*5YNY<BR#MW5U/R#V5WTI))*H#L-*(LX+UE5N,U3
M&0M48Y571SVL&U<'5^Z!%8U623?:PU*SNB&MY<92/SFJ9OBUISCFMJS&PG7$
M@U#&6[0"WT6T?E*=LF'&1W'X*`X?Q:GI*`[I?P1!O1J4_3`'+:A]IJ77OEY\
MK49*FFOIY;;R4UIV7D[+38-N_[1^PVVT?X*^0$;[`#Z.$\68+OKQXU5S[(=-
MIW-G`M,ZEG8+[`-\_<&S5O7?P1EHT\GT!@VRX#8==*>DLMU+!:/,Y4#3?']B
M4N"KXUN4:^%&8%I6M"EP"%GHEU2Q:SS9VR554"J6A:>CT-6:U.P%;.0%?`[0
M%H^D28MI763U563N%QXNDH<OI\90HH2TJ$%4+8>BA=D9G.)I29D5D1UKS([R
M@"V/&Q:N,TGS4E1&H_0E`GE616418AH8F);=EJ:.8Y6PX3]Q_UU@1)4\]SG8
M'M*ZG#D>6,KPC0L&OXHH!_*`S;TZ(:O.;)J4G(SY->7GACZB`S"EM)`9'E3)
M/<V<X?GOPAE.2GR"O]7TULP]4&F8F#Z`1)1[_9@N57[6->?O!6"O/YHJ66I,
MV0.YZ9ESXIS_"<Y*V:.$?I@AXR6>XT??NS_[2-[>!7%WC5N5^"J77I5+#<8D
M.<Q)2;*5U%XEN*_W#NT?R$ME3N54N'(/@<X,R=0NS%93!XB<;&J/4W"D4&O(
MC<O<R3++":QXAOZQ15_8E*"7Q9H02>B<@,PWE@?J\(BX',C,7-`.@CI?BN=(
M89ADEMEBXF!<4Y.37)T$B:$;^B`\H3HMB,*$:.7%Y*L79P%/O1;YXU6D"M5+
M5T\YX2%V)<)X);BKZ+7'9*I,8CP])3>&L%!3F#N?E9[A3L,7:L3I00<B)"92
MPQ,IAQ&/)JS9$2$D>:#4<R0IT2[W6J1!L@.3.ZL;QI@TY*B,=37)=>N18;&>
MQV5\-&X11QC"\!\]M9,-'EZ&;+F"`M5&[ZN*@^8V]+,,45R#<>RX>+1;YEW*
M&9,\4%$&TQ6Z.N.-B0"TK967!RK?4$'&E#K$W3DWJLVU25._M+ZND$C[>S*[
MKS"['U_ZGC5P6(GJJ?\4,MZW=0W_)HQ^#=G_YOOV(S"0EJFC^C1/^C)'[OZF
MII`.4A7AMQL"<G)X)4B*Z5`%!;@'W)&-]I[S-3"FY0]SY&EN=:98Y5!C7145
M7U?G;53R,.:IJW3KLE,TYSGZ)D_."FC0$.C(<R@5YAJ\O4_H)[Y;0M@R-QRH
MXCH%1%U+@0D8NKB08IZ$OG,D!3,5#U?3Z/R,0"6GG$N(I0+OGLP/P,SJ*,E?
M2N>ALN2S"C7)=,HUV,KA[63290_U?-"L`64<R>-]A9Q;67!W!88+%57*=^UL
MN4*8>)%C/DQ("*4!C6;(."VVDNI_2B9W9C(M27,*47]->-(:",)-+"-BCD?*
MG"H82;H&TH,VSC=PP?$;#V5*+R%/@760^VES04YHS<2!6U")RVT^IV"IID]R
M7JZTM\B5K4JO[W'(%242`'/L<=#5I!JP([G/XPT4E,,T5\2R"H]L?TF/=P:%
M*CZDHP#RPMBDFF2"SM18!#0`0P`^B&4$&%*KZ:!/T!D+I/:51:80++-4UMRV
M)VA1&S<6)9;1\2G$ZHGS7=Z2Z":9UT:[@OE44HGK9NCC!0LZ8KL.YAJ_Y,=M
M<ZI$T70O&@OAW`="!</2#>_DF/_8CZ;)?G'R:V$/&'UEH`$&_>2O=+#8>9"G
M66+DFOS6=_%UQ0SB@HDC]?,BER9J:C-TRN<N5@60G)P.*'FD.EV8:/4D<**J
M`"F&1QY-9VC3&=:D]$KR'!E%52-+HIJ%V[-QI6?F9,4PE+?T!/K2>-(D4+G[
MCYD0Z4$[\EV?>E9BLDQ\3!^GD.VCKUF8CQTX)M%R)DH\A5TY\.#B$LF:=L)U
M5<GE]V]:;^AS.*?\7/I<,I+EXBS:NB&5];QX=.QH*D7NV;+.Q:+2FU^\==N-
M;0I,/U=GIECDNXOS?+FR'K;;_:=7<],"W"^::IT\?)<A"(6=Q(P.!\*_2E%*
MPSYQL50Z5U*&$@`%!N9[&QV+V*12-TL'2T>#I$/&!@*R"LVD+(M&5?1E:#Z*
M`T^>HT(C0$E)49[R-BG6>,M52U4A#K0G"G?@ZY(S4EAT-RF;BOH[I]C+DOO(
M@O'=ETOB42G5QMB@M^H46F[U:+%RU7#EQHXRU'0,NH'1(\^PX<K>AYB[*F2$
M":PK^0M8A#8^-P0DE/$TXI/$LG+E#KFRI91E*]0QN*3<XQ+,4Z"3C@!%Z`;9
M2?7!M!ZQC+Y9PIE'63`NV1/.FXVXKS+)[-AR@]3QECTVM.WD!-0.H)^K(5EB
M*A;+'.)Q0UEH@VS<W'.+IPM))G%:ZPW9+.XI'RI/,:U[("PEEN]2MGU2HTC6
M5`I$N?,(+[IXZH')9-)ZHD`V,4]V`)<GJ&`F]0/L4L-ZJ;!V"E+9UA@RDRHH
M9>$0$_^^6`":"C6:X"E0_+7XCC2&;,X!I.`Y:.4G_DN0A0E6#/IJRIPQ^!3!
M1V[YPG6PQFB4)=7:,^[,5>N*YRH5'M863U\D85>3\J<IF_PA_["ET(R3,!8R
M(2C"M++F<J5U_"Y["C*[?)^-0E'\)?]B9U*=T]>\H`G;N6SG-LG.C:B\LN^Y
MM,F42*C2(23*OBMDV1A`E2"B6L&.,EK*+=&"H1LDYVY41#:)X6;%B\#BP&I(
M95DJSSQ]X[5AKY.E\1BD\2YQ.?/Z,/94XAQFP^8J:BX9U5B<WDM.2Y&AJ"Z6
M&5JTGYJ3<,H09_EA^3DE^?F0I#%(74*N9Y9?D1K%8T&.;!;=5'IFO[&3YMFF
MC1G]U]PY3E556&[93<3J5K&9[O-EGHWLQJ$\Z-6CHNGV<FJG.+)=EBNBM(B&
M1&+/5ZY3K"JH^.Y#LC?WQ5^8;K3(U2A>&1F0WU,Q$`NS->EEN296:M<1`P9I
MO>2T%5*@GJ_"%.D&M3SQD-NA3CU^)W<B6U9F$;G&3:!5D@B1*F23>^%F.]Q'
MP3Y'R_QKTR_4GC2NV77NA/6-JH==63)&[CWYD]QIW>U<H5P\>Y,=4:%@D:J!
M?Q;.L;!]("4`2S_BO\5=\V#=J\QTMYV*#X4B>Q'MX,M&]DF/*WK&65+.#!/)
MI\+,U0E/BA"I+^QG3]7<K6(%80[M<">_.2(76*$*`2HNLGY6\)DVU0!.Z$R[
M)\F@<O4Q4%L8)N%3.E`M?\Q?HZQ(50!CK9.$.>6.EU982C]$V$1'`E664#C&
MY#XGL,_0P5MDE3P=/(8W4T>F91=L^&(U5<(/[DU`/#.KHE"(7</XJ<=-;DQA
M%-OT]$)@U[("1-%T]22L$:AGL4L8-@X%6WH!`1[]X%N*W'9:G2$=8QIE"K,0
MMAK/ZF`RM@F$&HV='P05U8NQ-@J5;8#YDCDAO`"Q,WN['6<UR^0YM-A>+.5.
MS'S/H0T#]1CU%%G"0B8E^?>!JJ*\/%3%_I+K,XE)S!E`)UF(+`SI3$K29X]2
M1CTJDB\+/V.E:C,RLZK)17M(,H9(]R`*G!3B\9<'!ZM<%Z=68,2L%X$M@+AI
MZ6)4.:XLW*$JJ@'-K+0F!XU*M5^REX<A*TQGA_S,**:I4*R:R&;.Y%KXD:RG
M0=^$^/[5)!89M<0I@9[+<F3RI^3"E5P>T\;,P2SK)^D:11M]^9!XJ6;&DC52
M.7,]06[,RHU9N3$K-V9M>-UN;LS*C5F?@'QNS,J-667V!C=F73Y3QXU9N3%K
M)8U9UQTY30\0K*B6_!2I0T4ZSV0-"!VR$M.$XYK,BCL9RV5?$VE68>.]'T@L
M5JS:/8=IG>+,W5/8'VR!LLUK7_R<?ZAL`Y'N*4;^'!^<VU*L;!-W:>1RFQ:K
M(?\\QD(5P1G%@.>A>)?\L6)&E._[IEN,H\+6XQ;;MC26]V^ZHQ^VW#%6-QKM
M76_D%ZZ[;^<;M[IONXW\L1]%_FQI`QZ$)2\]^<_R^L)7=$B`OMEFGWS]MOAH
M-^MYM*6QO\GFOZ*.DF8U=V/^7:,VQEH"M@>EGMRGJ(9^]&FEC7AJZ?P[M6&J
MHNS^*8=>.99K>C=U;%`?AW`SF?,VY3SL?',VP0*$'Y)6DE_`K6#N8^[;)^YA
MMV;FN<IX+AUN^TWC^.^`/+?Z'NDNJ_:ZF_I7!Q[N-OB\=<YIH^S4ETM/$@G1
MD@#(TT[TINFJIT6DZM4:0S`S#S,/,P\S3R.-OYH8J?',L[TU-#:M;[A_YMEG
M*OIO64),)B<FAS=)JE8E&-5,HJV8ZB\G6[^D1^BN@8#FT*QQ@,:<]K-QWF96
M8U;;!ZNMY@@PGQTKG^W(543D2HG4V@]M,NZHCSB5&U\;`_MK#^9]PBXO0IT:
M\GSO+,V\DT?X_*`:^_74$'U8TCR<W>L3B\W4P#?M\Y*.I,PXS#C/`@YS34.Y
MYL0,0K;[CLE9K7UWMU/-[FXSJ5<#3N-]6U<UX0C`,44`F/T:04AF/V8_9K^,
M<)OM4>^3@D?'?J\]&ECMGO6I@=NPQZ&;ICKA3>:;UOF(&8<99WOR])AK&LHU
M'/-KCM'",;]CV01N)CGKL!0-SBSC@,M^DA@Y7Y99[;AVH!M$L=?*9R=FOW(2
MXZL.6R[O6;=/X$1R`Z/C'&5@9F)F8F9B9CI"9FKH">8&,A.'"?E$<Y5D&U67
M\=\@FC4.X)C3?FZ=#YG5F-6.:FNZ011[K7S&P4`.!IZ.E<HGF@^^9\W0_8KX
MQCCGM%AFG%T`A[FFH5QS8@;AJ[/[?J)>0677[RV>FJ/.QJV3:I26IX9SX'['
MOXE(^X@M@^<BP.YJ,]_3OF+GX&H:'FOX?#=YOB6?3YV)L>\;MDB-L5E`UGDQ
M:<^F)>W9LE[J=%O2\9B>([OI9=U4S^700^SIYEL.=7JDEKF6[Y%D8@\K6XPC
M75OJQ+>FXRH:\8]F@/W?5`]O/U(ME$76#A'&O9#MX+W(L1TWQNY>3S?Z3/[^
MY:<X/+LWS?F[KT[:E?'"LL!_Q)9\GWU8*$>$=\`4ERZ,Z]>__/E/OZ2WX$BG
MOFN#OW'S1^Q$B]_\2%P[H044CP.1WD6M[N'#%S%Y_^;V&JNF_ZO[G[OK-YIC
MPQ>F%9VU;KO75_V+F]ONY<WU]56W.VCWKHUA>V`,;HR;]O6;7Y<8.<\!S_3X
M*@.M>L7RA:Q+'U=:6WR"=089,><H/[)MLW9Q'PC9B;L*`$CZNC)$Y2$J024D
M>$6H],'3/H$OCL"""3NZ]E%\=RR$%%CM_;48'NB]5DN'BZJ950:0B%T%D#0C
MS90M,O?90_FO[?/V:JAVI[FA^E!Z`[N4SN,Q\`?,92*P&?E2%U,/E,X\\"TA
M[+WV%_]K9W!N5-PTVYR`YP-*RXXMFEX,<A<\PO7XP0:L1U4A-16NN!.&U+-T
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M>L/+P:A[.1S<=*[[HW;_1H9%^C>7%[U.[6&1`_O>">FTC';5N."YL$3Z5V(=
M!&B-`C]&N(C$432$(!U"PFRR:STL8QP0UVIC#"2*$*]U*?H'T(L7AJ9+OP.K
M(Q(!JP-DB^`!5`HP9,E0LK_ND*E=UW\DKI_`C;8?CZ-)[&8CB\QOL-".!V^#
M\8<.\"J!O!;&UE2;F+3MC](#5BW\B1L$&H*@.`-)`ZS'(<*</7\&&MMRG1FJ
M`@(8"CDE#XBFH`GAE:##06.`2.+&`(JF,Z8&TZ4S^;_T/23,XL%T8R*-C\K*
M`H]"&R_4OV;H;"V?&TE:039_#\6GR4T8T33##830N+Z^'*#XW5R/ABVCW^VV
M1XD0MB\'EZ<NA+]+YDY)5E$0##E['HBYJ9@57E$&V"ALL$;`^3/@,1E/__T<
MK!?M7GC`Z*Z[0$D0<](0:>@:[2!XU-P5*(T`W&C=P0*8]ZE1-`.QT43*",CP
M)JB7F0S*2W97C(X2`D/U`WK)3(H=#!BN%\I^``.*Q,!1C[)3%2%U%8T*W[SN
M'OD66YEA^'<I.?"^=<,)Q(/P8C6`U"BPXR#9W@!;T?'M<^W"BF)XK#3O0B74
MMH-Z5YL$_@PN]L,<<;:5RJ*,D?@!5W][-_']R`/]^1$^:-_IJ\!'KIE&T?S=
M3S\]/CZ>?Q\'[KD?W/_4;K4Z/^'//^&%;]3UT6(.UX,$"!``^PT]^Z>5A\/7
MO_R$3W+>X?_"Q_\?4$L#!!0````(`&"";$;Q4]\4!AH``(X;`0`5`!P`;'AR
M>"TR,#$T,3(S,5]C86PN>&UL550)``.S]`%5L_0!575X"P`!!"4.```$.0$`
M`.Q=;7,<-W+^GJK\!T;Y&I@8O(_+SI4L61=6Z8Z*9,?W;0JOY)27.\SL4"+S
MZ]-8+B6*W!?L+`:DE%R53_8*W6@\W6AT`PW,3W^YOI@=??3]HNWF/[^H?L`O
MCOS<=JZ=G_W\XO</Z.6'5R<G+_[R[__\3S_]"T+_^.7]VZ/7G;VZ\//AZ%7O
M]>#=T:=V.#_ZP_G%GT>A[RZ._NCZ/]N/^M^.0M=?^'YV<_2'-V_:&?!<(+1B
M=73[;_#CGT8O_-'UHOUQ8<_]A7[;63TLQ3D?ALL?CX\_??KTP[7I9S]T_=DQ
MP9@>?Z;:V"+^%[IKAN)/J"*(5C]<+]R+(QCT?)'`?]7RQ^OXPU?M/]%EZZJN
MZ^/EWWYNNFC7-02VU?$__O;VPW*(J)TO!CVW_@5@<'3T4]_-_'L?CN*?O[\_
M^8K!S%]?GNO^0O]@NXOCV.+X9=_K^9F/2EC\`>!_N+FX/._F-R>VFY_,+8@2
M)?KQO/?AYQ>SZ_X:`*A816Z'_Z^)Y,/-I?_YQ:*]N)P!$,=32/K:#[J=+0X4
M^`&7`G+_ILW,'RKVUTRR2+U8^&'Q'W[FWG3]!QT9[9!P$\$DTJ1J>P?=)+(E
M:G0[60[)?M&SZ!@^G'L_O-,]V,ZY'UJK=^.VFS*+?'[N0SN\@[YV"O2X:68)
M$BUJ,T5F>=*L:"-!#FE>Z<7YR[F+?_SZWU>P#,^B^X%?3N8?_6)8.J-=`N[#
MHY3,B:H>P:K4"-*,8W].6>3O9C-MNGX9>$%G;UOKYPO_\JSW/LUD4AD4D3;5
M6/;D4T3V1#/9CTT>R2\NVEL#C`;:S0<(Z"%9:%.DW4DZL80K358'2/J011F)
MR>$2DT(2IUIN(H,\TLX7W:QU,4^]'Q\E2+F#,+=T'P;X_R4JIR$Z_S>S[M->
M4FYE,*FTW<5E[\_!_;0?_=MN,5[J38RFE/[#T-D_S[N9\_TB+KC#S5CQ-W/*
M(?]K;X93,VO/EAY_)\8;FD\@2:IGW4$VG60[/>@.L@DD2_.46XFR2+7:R0,_
M_"NXX>'F9!ZW[);=W?W=3B'WX)%#YMN9=0+^&'K[Z%]^TKW;B>16HLFD2IT9
M2<132[ESEB013RTE/41*6DI*=HB4;'(IT[Q/`FD."=_HMO\O/;OR?_-Z<=6G
M99M;B2:3*G4^)Q%/+>7.^9Q$/)F4:3:80)I#PK]VG?O4SF:[Q'G8+F??B5L6
M&YKGE"1-->M;YY`#7$YWX7_3U[N%6-,TLP2I<WX+R302[9S?6T@R2Y1F,!L)
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MS]["&N!N*X_S##*A@V<QVJPVG-Y/N;'_W0_+Q=WWL2BJFW\`+IF6I*VLRXTP
M;\3P=)'#F+VFPSF7&Q]D4U[W-E8>O_8?_:Q;RO'K]64L*LVDO;0^BHYYZ-N8
M.ZQJKK/'2"D]/(_Q9G6U>W14<O0?_?P*^-H.6L5`)M=@-_$M-[8/_BR">Z_R
M*H;B0'%+\.IJ,707OL^KY9&=/@-4V@<23HS'INX*(A&/8G[1"YB0W45TMSJ?
M_6_G_=1C3#U[R=G',QGSSK.<G'V4&W/BKN`(7N7&\/O"GX9?%T,+?B+76-;S
M7#LFJV?V:K;4XUMHM&H:Y<]T\?RV5W\]^+GS;OI^URXQY;I?9T8Y>]]^27O*
MGB8'-N4^=<;^4J](Y^QRTR7H:?J86F,[[BYG[&G_2\B%.Y\:ZK$W@7.*L-^M
MWI(]3X[^F`NV6?M/O#);IL_U06[1OLE3]#VYEI.NF7[N<=D?]#CK[%=1XZJ7
MY2M&02_,\LVAJP4ZT_KR.$:3QWXV+.Y^6<:7"%>K]Y#^=?5S\_49`)B_GT%`
MVMGFZP:-X974+%2(\5HB@VN&B,`*2:Z#$)@2Y1\8RBR^Z=3U=XA-/()75WU_
M;QMUXT!6[1HA`ZN]`H8\.,0,-DA[KI&OZXJ:6EJOR:[QW+.!E[T]ZGKG^Y]?
M``R??'MV/BS_]9:#[NTCT_CZ^:E5B^-%C/PC1]0._N*./KZQ=;A:NKR`@,B3
M*W?#@CB\TGU_`S-V>5-DB]*3Z)L:_B=P4$A(3%"0OD9*N8""-0J32O+*?`/&
M,$J371F\2MC*MD*$-::QKGE3"\]@1@DD&1,()E"%I)(.U5I5F'!&J#?C+(%\
M8Y:0"9X2BG]<B_-W/R0L"%O(&F<IKC31,#Y#$0G2(DD,0<)Q;RL5:DKD.$.@
MWY@A9(:IB$$\W&/X?/K_^7;AZW9A9UV\8+@S9$CDTRAA)3:4(4D-0]H$C+#`
M'E&8-2(P9SD+XTR&?6LF,S%N)6QH>:\E-;9\W+BI6*"\8@X9I22BG@CDF9`H
M$%V[.M!0U7Z<-?!OS!JR@%-"Y7=U&7&G:[A?G`$.;XORMY$UNO):!QT`.&Y@
MD(0BQ7U`C!$6#/&!>?;\`XJ#\HS,^)2PA(>WOM=H_:Y)XRJB%*,$1E`)8*04
MS`IA$#%6$$H!(:Z??Z1PD(8/P**8*S^9#WI^UD+X<CO@[7-Z$TEC)0>4@T><
M5`;5@DJ(>JH*6>^)M$Y(C=WS7^0/TG9&;`HOY'_OYG:?M?Q+^P9PJBVA&E45
MQ">,2(F\!D.OE1*.B*!D/7*+H.1R?KC>,P!30NEO6VW:63O$FQISM_F9MC7Z
MWT7::%\'2&\D4I)5R`7C$&&51Q6#J-5",*O$SLANHAV0?<:Y9F1$>`[R:QB/
MAL58B1HI7&OPYKBVUL`/KG[.^V!Y5?=P0R0'7F7"6!\\3,Y;`';MD*YIW0!(
MTL$_B$,*AIB5$(]AF-C:F*`JBEW%1VY^E+&#0U7U*(#-`5&1[?+;PO\4O3]L
MVH3@<%VK.JX%"C%9462\P0C6<F\,Y:)RXCEG*IF5G@&?(EM=SBTKD/7LG6[=
MR7SU$L>V3:WU%(VSQG$'G3#PA`@+B.,\MQ72X""#]1"^B9TG?$^9QV36?SZ8
M2IC!^WA>/O?N5]W/XS=W7EI[=1$UX=UK'UK;;HMX=Q,WC&%=45]#ANXL"A2"
M1^8PK)[2:6T=8TS1<<91)NW);!R3(%;HJ.1.T-N'>^[?.K]]KBO>(8-L[C3\
MIJ^WGY[LPZEA3F!3<X,TT37BW&DDO0;TK9:5TEPQ-7(CK$P"E=N]3`Y?"7/Z
MK5\^TGB3%'$\;MS(JI8,>XY,116"7!&64U4%I"V+H7B%*SLRJQ9?C`)].U:1
M!:+"^75:*MU4PGK,J$#4*`(&;#ERJA:(6Z.9K3&A9N3&69GP<M+<\C"@"BM\
M]W'8X\9-Q:3TF#ADA%.(NB"0EQ5'B@H6O+/^V]E:V$]#FS4]'IJ2117O]$T\
M\T\OI_B:H#%.&D$#^+]:PV2H,$95#)JYMIA(@A5GZAM1_"B%;:BF.!BE0C;0
M7WFWU]S?2--43E%&2=P:9A91[PDD31J6,P=SQF`LI1B90Q1?`3)90C:@2AC#
MZ]4FV.KV\VY+6$_0V)J32F&+'(4@20N#88B50KI2%@9.E/<C"R/*[#-D-H-L
M*!6)`KKY6:P)C)\I20@#'K=NL,"5$Y`,5YQ*9*DUR&H=P.55K-*V)H:.C`/*
M;"1DUGX>B)Y@^B<=I6ZD:0`@+TT\(%8DEA'S&E(;ZY&&!8^HVBI.GG6=;:YP
M,"="I1U`D@FL)VA4;1357*(0C$7!,H4JB1T,T1#N*D$]'[D;5'P1."P=R`5/
M21?PF[Z^-_Z]/,$FTH91K;65`M6\=DC4$/,0R@R25FI5.RDIX]_(NI#%(60$
MJEB1S;Y&L9FH"3)8SZV#F)=3I&-QN6:*(^%PH()RH\*SKI[-90Y9(;IG"#\=
M/[C`F/-68\)G*0O=;EQ_G>F=[]O.G<QMW&WUK_WMG]O.RO=@TS!A5,T-02H$
MCFH/2[ACEB)N)!>LM@;4_C3E0?'>!@SA7=]];`'[7VY^7WB0?_7!COG92SNT
M'W?MZ:8S:8PPW)(`(8PV$FDB6#1.`8%L[9SF1`IEQTWB,EL_TZF]*XAIH<KY
MT`[WO]^ZODY^U:@A,`8I)61+@@(_ACF,QTE4R\`9\51@._*J3!G+F$IACROG
MQR-6)B*\[+UM5^]#7<[\ZN6$EQ==/ZP^";0U*MQ-WD@11%69@(35%K(AF%C"
M28LH)LHQI8*ESSI5+&0K$V%9PHJVO-.[ND/V^];E.8F^J35SSH8:*:/!04NN
MD-001W-)A!<0/GDWTN>423D+V=%48&XWI,=/H,5?FE?G\1&ND_GG:X.GX<%#
M7.^N>GL.Z^]=C+RNXGDLJR8(HSVV$E'(N5&M:X;J2BO$(X:RKCRQ(\^NRB2E
M$YM,05S+O!^@>[_Q6<NU+PBL(VBTEAH;R/*4L``@U7'1C@E[+;#13F$L1SJ:
M,KEK(4>3#;TB%P)U.X]QV.G\=;NX[!;M[6<1=KZ>LY6N(=8K;6U`'M<6^:`K
M5#M<H]J0NHHWGS4?67);J/RID*GD1K'(V?F]N.LTK+Y0-#][U2V6+T[%^^_+
M0H!M1^F)+!JK'2S'!*,`*2B2KJ(H>,A"22`F!!<JID<FVO)[\C@3XEER^_WS
M5W57[^BOWF=,V'W?0-F8BGFFC8`9A"GX7,>0UW%G4:BZUL$J4X^LS%#?E1_*
MCV.1].K!5M7)?//'J]9E5PGD3;"2FL`X,A(<L540T9E`-0I<V-K1VIJQSQS4
MWY4%303FTYC1N]Y#KNCN9L5J,L1/0'^Y*;R78:4P;+!TDF*OD:'$H!HP04)*
MCVS@1E)+E3)XY-XA_IY6NV+P/HWQ+67^@MG^QK:.0>,<9I6&_BL7%-+<$Q0H
M_*<WE#%*C==X[$N`W]7.]&1P/NV"N*K*C=NFCZHS1RV1VQ@V.BAG`U&(&V.0
M]1)P\HX@5D&\P`BWMAYYX[8B_T=6S<SX/HWU/2@"V\O0'M`VG$G*G+)(ZA#G
MF0A(>BX0KQD.S@/X9N260D6_<YLZ',H2YK,!GMM7.@\\Q%_#I`D&0R+#X]BQ
M195F&''-8!(1`]A07;FQ>U1ECM^>^A`_#Z9%#O'US>TK]]U+"TCU?N/#;=L.
M^9.9-%16JM*Q6IH+`NXY6!0(),^*U1!_$DL]'IDS5D_JJ0[6^,,J@"DA+50=
M8KUWBS>`8'P-]#2,LJQT+DV-M;'Q16HML4;2$IC"(014&^IJ8VMEZV^Q9B"[
M94T*Z9/XK+2WO[>1-0SPXT'4B$@9$"%UA805$5$E6.",,3DR+'_:"&IROW08
MB$_AB?ZFAZN^77Z)-W[\Q=N([N(T)%K1_MP::B0-M1/(2DD0@`ZH8T*0Y$:P
M^$+`,W\D^HD\TS30/F&\_OGTZ9!X?0V31C@).,":CQWD1(1"=D3C_AVK9-`J
M6.6?]\/U3QVOY\&TM#,[62RNXI>$3L.]=\L27==:VL8X;ZE4&"D5*+*QZC0H
M[I`U5!BC!37N67\392KU;G%4N8`L&3B]Z?KW_G)5H95L/3N)&\.UL#7WB'L)
M\]$SAVHK)!*"!T.DI52-O,#SM%N;V>UG"BB?SOO<O\^XM_NY3]Q`V&AP//I4
MOE9(Q6-TZ52-<.#$$\'BYPB>\SKVI/[G0"1+V`]8^\KTDZUF$TG#.5><>X^$
M#!9YJAAB%@=D*7:4><>D/_SRZ'?@;#("6-K%W/.3RY/&_>+G/3DU1C%CXR/V
M0OB`3-`8>5-AB#`)H17,%_J\KY\^@?.9!M8GN;)Z_RG&^W?:BEY=!15^>09R
M>VKXI5T3M+>68868\1H)7U&D(,!$LC+,$N>"8#LK02<[]EP)&:WE]H.K5V`>
MJW,]T,4O/G2]_UQ;YQ>_7@^]AGD#EM3?G(!^EM>?@1+4!_*=G<P'WT/ZO_W`
M=*I>&VL%N$85$*\\1DS7!!EL%=(0V6M74<K5R$WF8AG26,MY?);ZC%`N\M[!
MW6ETTAQ=T[J)G\FSM1(1:HV,<QY9*PEDB<I@%[@@YED_B/AL=/[PQ80L6)>)
M@)=U!ML,YZY)PX0TW,=*!X,)+)\P#.I9A8*L*X8EK57UK*WE8*T\BF1'`U-"
MM7$Z]-K&JMY=)3T/FS;"4XY#?/3-,(D\BR7`$K)_+"AS-8]5Y,]ZXVV<:AY]
M?>%@5(H\A]7:6$*;H.8'+1M52XN=B+5*@B).'468*XQ([;G@SLO*C:QB+G-"
MG47+AX-2=*U?%4PGK?1W;1OOB7%4.%3Q>&Y.,45460:)C^0<0"*D.ES14^Y-
MY';=.2`JLSPO//03#Z->@WW.NF4=Q$KHK6OV%KI&NLI8S!VBU`-H&->(<4J1
MD=A[K"5S]MM8R,=I[]$RGA>K_W]DH/Q*D,<BOK.W!/[JYX#*+-:ENXMVWBZ&
MB-%'O]M][*!LI!6N(N!PO6<U4B'>U-%4(!(8L]8HI\?>M"MS+I+7@>1'J\C=
M\'@[YLM#*V#V_=G6L&(]00-VSV05XR4,>;+!`)^PE458"TZ<CM^&&;E-7::8
M**\M9`.IS"V0V[V.W0[A0<O&^N`K\&Q(,&D@4H:ED2@="^T8=DK`@BD.KVV=
M,J!\KCM'AP-=)!N)ARLP^N[KL'RW'6TG;(@TD@7(J(V%=50Y;!!QRJ"@@I'_
M6]ZU[39N`]$O(BI2O`)]662WBP#=2S?I0Y\$7AVAKK60E0WR]QW&3M9V;,66
M34IH7P(;CGB&AT.*,QS."!V8">='O?X/M>KBM&>ZHW9BBHE#*1%*+4NOP(:W
M2AD$5KQ`0@78TA<%IZ410>/SKP\E/IJ_Z"G))2@:XU3T<&WIG6/19\&&BQ!#
M$KZ8>3U;S=M<..]C4<?Y$A_`RY=8O\^-N!FU(;4WA+N`"@5_0NECFAK"$`Z8
M4B984>(W8\G3]V8=NEU'-]_/\).O;;VP]7<]OUY\!HIO'_S\A_\$:^]=;T&Y
M<]JMI*%@^FN-*.PED1$.)J^.S''.2VJ%\')@";I,I:@&#WY/U8$<-&9QQ9_2
MI[^\;F\?FDMIVKJY2CL:B"<..6$4<M(QY"6QB&LNA-16JS`P#BU359-1%&PX
M>]/4*T#O/0D:U&"E-7$BA.@"-1@I*C$*AI>($\5*7I0BJ&F7S1I/MP;R-TGM
M^JVY;R^I7+&]BE"N&0P)LE9*Q`K!@!M!$17.E(4-UI-)Y[D=3[<&TC=-U:I_
M7'3=BNV!?5N""5L0A#FL[-Z!I<M9O*OEJ"N]+;C#`[U5F0JYC*=:P^B;F&J]
M"YUO+ZM=6TU64G"PEI5$Q!B"B@)+Y+%WL,*[TF'*J1X:A<G_LPIV+H,I_0_[
MC?*=V)YT3H#;F$XJH<NAL?=Q-&)JA457=X_7B]"T*T5Y_BT9^,IM<[VP``(#
M_^Y!MRY=5_>BO>%C28N:3HGZ4,M14&E>U,33YB4@X)/7R_O6;V5FR(.67'/[
M4--I[E[4Q*/YL6G<0SV?)P=8LY<<)S%?&T=6.3!&]8-OU+]<Y1#]V/;?K=C_
M0&4Y84P0`NTSB;26'FRRPB"!I:>FH,:\734J4P]?HB#B"=.5;MM'V!)LO9N/
MZ?;A5JI28QTH+E$\J$1288R$Y#@6UU#,$X59,30G9)8M\B6&^'"9U03TY;#!
M7O4`/ES!][K;DOXYPO(45>IOJ2J]P"+R7AA&D)<2HX(9@2SGQ"IC*9,#+RCD
M\7+G4*>+4SB*2L64X8WUR^7^.-U3=.J-IBJ/+3'>!"289]$2C1FC"$7>>B5]
M:8T<&B>0Q[V=0ZDNS^%8"]5."OK-`E#0IW5@Q')_A:A8KN7$U>Q<N`KF:E`>
MNA><#3!I2XL<E@QY9:5V@@K%)QUHF6G)&X'G431XNP[,*<JX_62E`L9%O#A#
M2D`V5`BDO(XEO8G5VC!JAMX&R>,=SZ%79U,VBHH\A?V=M'^/#U2:D2!I$9-C
MX("4$B42QEL4O.'8BZ`)&1A!D,>;G66K/I"IG'KP8DX?5T"B[[&*">Z8!CTW
M&A>HC)O%DCN%#//*..W#$4=H1UZ%VN#ZY8;--S^/L8#K+*_/M?<V[^7LZ=@9
MK572:VX=U0@6?`]6EBD1;&J*^"8@4@=!"C\P@V5><_7\P6S&(#/EX<YK+U,Z
MS^8&5F+_W)=VIA?KNH*QFM)+Q'E^Q-0>SX/`J2F.:_Z5_EYW>OX4B?QNUOK$
MQP`]F,EI/@R=F.CG!/#[DO)G`4M^SM(#FFXQV@>:>"1C0<%%MRZ45"]F(,("
M/MK$LZ8?-O7$Z4=/SOBR:^]M#+U8S'8N=68!2\_N:\S$G-[XF.S=NS_N==OY
M=OZXSBNHY^]UIT>"3<US/WIJQOM2(7[5+?QRY[L:`':^I9,H;KS;1]C9UK-%
M'0!L:XHW\]K6*0DY"OYP3=V1!(H)0'>RZ,/;Y^:N:;L8)K:GQ,58@C9/L22K
MC23HW-.YR;=Z^?=4Y4H^_8\2[SGXX.>-]Y$%^BG(*KOP[[!FN.W"K-.3;!IC
M^=EW3ZLK;/I7B=^CBWQDF2:RKF8U2(X3J3=KT=A\/>W1ZKA[6%=2F<Y"WR?:
M-.;A.A$=O,,;^*\(,[)`-WX6Z=F($H[O<'AB]<#5_;)K_O'M1.@[*&V](^[8
M<D:7RJL3R$D*E=P=<@'ATKE-CA,NM4%TE!!_QK(M'Y9=#8K?+\ROO\2?#)`)
M7_X%4$L#!!0````(`&"";$8A(;0GW6<``)$;!0`5`!P`;'AR>"TR,#$T,3(S
M,5]D968N>&UL550)``.S]`%5L_0!575X"P`!!"4.```$.0$``.Q=W7/C.')_
M3U7^!V?N-1X3($@"4SNY`@%BSU6>M3/V9.^-14NPS2PE^DC*8]]?'T"6Y"])
MA"B`DO9R#S=:&MWX]0>!1J,!_O+7QU%Q]""K.B_'7S^!S]ZG(SD>E,-\?/OU
MTX_+8WK)3D\__?6__OW??OF/X^._Q]_/CG@YF(SDN#EBE<P:.3SZF3=W1[\/
M9?W'T4U5CHY^+ZL_\H?L/X]NRFHDJ^+IZ'=Y+?)"\:R/CV>LCIY_J8=_7&>U
M/'JL\R_UX$Z.LK-RD#53.'=-<__EY.3GSY^?'Z^KXG-9W9Y`S_-/%E0K6^C_
M.IXW.]:/C@$\]L'GQWKXZ4@)/:X-^,]:?M%_'38+@M>-@Y/G/RZ::MHWK'_Z
MT[:`$'(R_>NB:9TO:ZB8@I._?SN[G&KC.!_7338>R$]*74='OU1E(;_+FR/]
M[X_OIV\8%/+Q_BZK1MGG03DZT2U.:%5EXUNI[57_KNQT^32ZORO'3Z>#<GPZ
M'B@H&M&7NTK>?/U4/%:/2E<``?BLJ;\8DC=/]_+KISH?W1=*9R<ND'+99'E1
M;PGX'9<><%]EUX7<%O9;)E90U[5LZK_)8BC*ZC+3C%H0KB)P@L;4VBUT3K`9
M6G0]F0UD<5;H@>'R3LKF(JN4[]S))A]D[7IKI[2"3X[E3=Y<J+Y:`7UL:AF!
MH4>MIK",Q\R+5A+80,.R^HZ.A_J?Y!\3-6,7>OA13T['#[)NIH-1&\!->/2%
MV=#4'5CU)8&9<VS.R0K^LBBRZ[*:QFBJL[-\(,>UI+>5E&8N8\J@%[2FSK(A
MGUZP&[K)9FSL(!^-\F<'U`Y:CAL5^ZMU16Z"MI74,<*9)<$62-^SZ`<QW!XQ
M[`FQJ><:,K"#=ER713[42]K7\9$!RA9"V^@N&_7_4ZV<W^C!7Q3ESXU0KF7@
M%&TYNJ_DG1I^\@=Y5M;=4:]BY!+]95,._K@KBZ&L:CWA-D]=X:_F9`,_E]?-
M^761WTY'_%8=KVCN`(GIR-I"Y@Y9ZPC:0N8`F=E(N9;("JI9TD^-PXD:AING
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M+6_,P3%>0^N;,K"!]J(JE7<U3WKEJ6+5>Y/5ZCH:5YA,IQ`36L<86R<5$UI7
M&,U<L)W2!K[O4B^+Z&!03J;Y:]7K6/T<F`T_9M3N<1H.0ALQ<8_:S`\VX6$'
M<]U4DT$SJ51G3/WQU@3C:AI7F(QMWDKJ"J&I?=LH;>"[E(4<-'+XWY.L:G35
MH\C'V7B09P7/FJP-HQFU>YR&-M^(B7O49GZP"0\KF-=M6+TMN]JL?&MKQE:D
MFXQ&6?5T?G.9WX[S&\7_S1A:%KG)=O]F7/K#/7M2Z[DA?]"N84>2U7S[DTUO
M^7XL&KJ\*ZOF2E:C#:J_7/77HR[*:=;Z>>6IWJ9*#O/F>U[_84GT-O9[(*GI
MD&^UE_[DGF<?3T?W65Z9K/RVY=N?;"]]G]^<E>/;,S4'#)\KC^T(:=#!7DAK
MU8?-^^E/]M]D,YW<9:6+HLKQI>)B:4I:R[H_">U&#+N+'+KDFK;GW)]\:C4E
MLVJ@*X^Y?)!%.<61/-[KHE)+UC/KHU>9FRK7:X=9S;7U&,FDA_V0U^I0NT%'
M?4K_(,<3Q7=0JE8ZD+$E["J^_<EV*6^U<E]57NE07%$\$[!)W90C6=FU<L=.
M]T`K^3N$CO6QJKL>-:&W8N*L5B]D.=+#;6;/_]?SWK6,IGLO-OO8$YE;]W)L
M]M&?S(99P0Z\^I/A1RW/;Y*ZR=4X84N6Y3R7RJ2"L+E8LY^O)5N<@\_'S<DP
M'YW,VIQD[PND5IRTGQ^>UP?T@ZD$64O)5$=`ZK?.D);CXZ&\R29%TQ'>2CZ.
MP):C+!]OC_4-&ZM0IYR/1W)T+:NN.)?QL`GR3O&J!I-K>;Q024>H:S@M!:R<
M)'^.],Y4FUE+C<G2M0W/G<K'1HZ'<NB\VZ7QV:+W:=^J]Z(<+-/N5+,W67T]
M5>^D/K[-LOL3/7R=R**IYT^F`]JQ!V9W=?QE]CC5*8HW)\"4:/*TD:,%G"*[
MEH4:%<M!VDZ41CCAZG_,$T%`"&`1B@%G"(88QQA"]E;(0M])4E9S#?<GY=7K
M+0(3":<$*?-1%)`0440HCUA,/-^?21=RS'B;="\>1*O!45D-9?7UTR)LF;U8
M&\T#^F88^\8I'6A#@5</IF_^ET%1JG#FZZ>FFLB7AZH'Y?5),7U1U$O_',[W
M[QSQTV]9,ZFDW@6</WZBC_E&K\1*)BGF,(8T$90G,1$$<X$7:DM"W/J*6'*B
M-8.N@5-MZ`%M#F5+6U,GZ]5?9L#YFUB@U4'>4*6)(!!Q+X#4\[R81PE%P5Q&
MB#R4+HV*G'G&RFC,P"\L&'*MK]A0W)_32?IWCC?2')QO;.(3'Y>$^DGZM[+0
M-[I-(53Y]40K]ZK44=T2&[=0I![W8\*B&`<@(@@P)&`XP\N(H$%?]EVV;'`:
M9=A53"=#GLG'7'5UJ4!,M^GJJW(.:)4EUY"D(J(>]XA@F#+?@Q"$`9XC%K'G
M=S(E/!13VM/,-K9\K@1ZW@`12F9#>ZXB2P/`,`1>$BLM1,`+@<>B.7*,@["3
M3?T#LZDE[6QCUXLL'RX&"P6CQ9[OFZ<^#@&.0P)C"GP4J,D`D3E2BEFWZ!L=
MF!VWU$HG^\V2'HL#I><W.J?]^@*:YB)[>K,S^]ZF&[!($QZ`4'@)9@G`&(8^
MP?/IGZ/$IYWL'!R*G=UI:AO;/VD0LWYY7D\3Z-^S9EDBQH0LC02#C$,,J!(@
M]#P>`CY'SCB&G6P<'IB-+6EG*[M^\*I-K+N6.(5J4@D$]I@?".XQH3QR/K-P
M`2GI9./HT&QL4T>VWN#3YY*VMM%Z&4D*HIA03V"`U(I/.2H)X&+,4<-/MP@9
M'YI5M]>,+5N^7'*T@35?B%(FB`",$X8PT,LU$E&\F$-(F'2R)SE@>W;6C=UQ
M^%OVF(\FHXV'X!E=RA)?J'"0BICB$,<$>#"98P=8>-V2$MZA&=:2?NS:]D)6
M^DQ`=KOY#/M"FA(1^VP*.N0`Q5&<1(OQQB=AW,W"!Y-WLJ^BK8S\7=Y."JWA
M)WI_7Y4/63&#TV;BE82I'R%$DU"P!"(?Q[X*%L0B#$11Q[SQP62C;"O(LGF_
MR^%DH)5K_C8;,4D)@)Z?8)\03D'$U.0C%D[+H>B6KP('D[!RJ2S;;_@"QUD^
MRKN\Z6\9I"(,:>Q'%'G(BUG`F/+MF30)\5#'G82#R7&Y4M169G\)\W4UY[1[
MHW![%5W*O42-5FIU@-4/#)0$+)YCYX'HMBX&AY;@LJ4?NY'9Z7A=9KJ%+!6)
MCP*!8A@3W_<(A'[L*>2()%@@@KNMC<'!I;7LJ,>N87/#E,=*PA2+D(D0(H%Y
MP!/`/0;T3!,B%`HO3CI&8X>?S^JH(+OFO2J;K-C8ME.J%,1`!8M,))@G,%2Q
M1.3K\08G-"$Q%E$WPQY<2LN*=CI9]?2^EN,?]TK41=^K3+FD:2K\$'N,>B+Q
M"%"K`."SZ4H>^WZ8A`'N9K^#26%MKY).1F-WNC#Z]/5&U;OBZ(M)-;C+:A6Q
M9==Y\>I*__=&[<`J11[A000X]6CDZ\4\XO.E7P)9##H9'1Y,>LN]REXYQ2\G
M;^OGW=;4+SM89+&@?_U7^QQVM/ZL@/W^W.K1](-Y/1V&6%P`=69P".)CXY0A
MWPL\$/B4@H1PBJ-0)'KS5<UUD.#6XP&.I6H[]/"V80J\A'$:ACQF((Q\@"F@
M"VE`V&UWW?)AAVV,4%J4?F\/-RRD>OZ8@#Y!6HZG5T6M/\^PEBX-8>1Y?@@B
MP7E$?:CF&#)7#@]@Q^3#QJZQT1&&KO9=Y286%--'(?H[F*TEZ$O;ITQXGD=#
MBC@%'O-BG26=RY40RO?WA((E>Y7NM/3G\8+^K=]R!&&?C-^_T6?W3NG$Z+<W
M*XLE!O_0-F64!#[A:M''`,8>5_-I/)?'5U-J7\8V6QIM:9/2KC;ZL.["MR\'
M<IQ5>6DZH[]NG[(@H"S@+`P\I%X'M8I\F0:%6DUV6P$?UDR^A4)Z,?0,WH]Q
M?2\'^4TNAZWC]TJ:-(K\,$&0)3&)@AB%-([X7#ZD1L(#F,F[V>N]]2UKZ,_G
M"?L[F^_8`78XUK,BJ^<?.C4=[]_3I!@BD$#"?!PG(82!0&PQEP6,=*L/V+PR
M9*=C_I9*Z25\>P6Q]37_V#B-0LJ2`$<@3A(O`E00?R$18C0^@)&^NY7>!W2V
MU/-G,/S^#NR[M'?_=GZYI7/)K:1+3+VT?:J&04H1B!GT`4-A2&`(YW(!$/8V
MC9NMTRPF;&VHHP\STZ(H?^IM#E%6O)Q<-S>3XN/W"MBDJI9O67?BDU(>02H@
M(0E,<.1S$@B\T$,4=MO/=E;U:]$M7*JI%W<9#"8C7;BHXE%Y7ZG0=';?XWTA
M9W>:TE%9-;-/_,UOK[XHLN=/@+^_PGJ9)UGJ(H5!R`&(/1IPP;%`*$3)8DRE
MI-M,XZS&V*:3[4:#??C?A>(EU<LQG$Z>%UEU7DT5-YQ6"%S(ZLU%]DN\RXQ!
M&G""&8P3-2D+K"9D@</%?$P3VJU@REF1LD7?<:*?_CWCN5Z/3IJ[LLK_J:L!
M##WB/6$*1>@'"40H(#`.?:)^><^2)BPD'3>:G54R._.$+?6R*P\XK>O)QM9_
M)DHIQ!Z'(E#A=Q`B#P@8AG,)M=-WLKRS2F?'EN^DDUU9_7S2U$TVUC>(;&CZ
M5Y1I@'SDTPA$/!*1(%Z`(9C+"AGM=DC)63&T8_MW5TS/FXD=8@(#ZA0(-<2%
M1'@("TS"&`=>,)<Y0K3;AJ.S`FJ+SF!?.3T[Q`:AP!JJ%!"N"XM#3B!G1`#!
MYLD>):.@W:[L<5:![<8!ME3*3@S?&@&LH$C5^EH0%C&U^&%*."^$T6*4"Q#O
M>!.NL_)KEQ;OI)$^K'U5R:R>5$^OL*ZQ])+6>CM-K6`8#HF/J*X89R\!#0I!
MM_#>W0T#%JV\O3;<U<_'<JQ(&YV1>-NEQ>KNERYV><4]U_CE\!4:_9W4\^9.
M5A=EW52RR:NIP5^WF&XS7BF$<3$]5]I>#VZSFS2*N:XRXA&G"0@2#D(:<8`A
M#Y2S4&]'E>2=1-0W516E>@W:;]VWPC]5$9*'H?`Q]!*4>#&B$9SKSA.HK_O5
MU]:M[\99RMVK>V\+Y9<HXY6HRU2UOORB$[\4<3]1,PP(?17EXP2&GK<P9>3Q
M;B&PX\+ZGMVHW8FMZ[F/.&N9'&U[_RMI4I"(**"(QS&AD/IQP,!"/DA#MK^U
M'X[M:>`]VVCPS^<I>U<L<B@.LC/'>'V%O@;,U"`\^SCJ^MR,$7VJ`@R/))#Q
M)(A@1%!($)_+'=.HXT4'KE9S^Q1H655L+RM#MZ=_9]\FUO_H#?&'K)@>S5GS
MD>9^^][EHG4Y/I-U:`MEZA'"8\(I\P&.,!*<<3)ULQ`2'+5?=.&JM/U.#B>%
M_C;,4ORM9Y=-Z%-])R=&(0YB$'LP`CA@_EQV72R^#TM#:_;[4.]N7T..5W.U
M''R^+1^4_O0[J9W)G_W6;N2_<J/GI^G+R[MB=;:T7>HCA-7X34,2Q2%2*O4B
M,1<ZBL!^'F>V:\[2GG[Z"'6^9?];5E>JN_K\ALOK>4U5\W0I!Y-*F4*VQ\3&
M/%*.5;!'_4BM0Q,!*%0S_T*+$$3^_JVFMK1CV:^F_O4\9F]65?OJ*#O8UE3C
M9_LQZ46CE`48"T*$8$$2`1Y&!("Y!`CSWK['9[8.<F"9]UN:7573BW%EU4P_
MW-X\*^"^K/.FW=JKJ5(_"`$(1(+]F!$E<(3]9"XCB>F>U=?W8'YKNNK#'WY<
M+O9F%PIH=8?51"D-,(_4LCVFA#*<)-&KH!S&P9X5PKOW!FNJZN5T[5U9-5>R
M&KU:^[<ZPVJBE"149W$PQ#$`*(0,^0NE(1%VNU/!666[>V>PIJH^G&$3'_@H
M3Q02B('/<(022B*88`KG\M"8[=E7Y]R;?EL-]17X+4D%KM_>74V4^IA&'"<B
M4.MNC'#,P*O@&?K[>:6*DVR"=67U>RIW.>SE3UO'BFW8ILCCD>^K=5A"`8H@
M)D'(%\,DP][^)2!LFG[EN=_>-/G_?K=<6WN3QCA4=]N%FV6%WFY\F9E_51JM
M]=72:RM[U](I.46,(P@XXK$*!T(LXL6LCOVHK[MB#>,>5ULL-G74RU'SARPO
M],P^N^SY)>R;'5[6>];UVI/D9AS2P`>(J;=,X1#<9YX2&L]E#WC8[<HA9]D2
M5_[A1EL[]I27D_"_5LK1?XRKV5N@?3^6-V4EK[+';CYDQCOE2"U,(/!]'(=1
M$M`X#MAB:$]HMQHF9]F7'7B7$SWNJ]_IX=:5W[WAG4(/"QH2CT,2$AY12$0T
MUY>`O-O5.\X2/?OD=]OH<;=^9W!/3QMM&J$@(BA12F8>3E`R_2[.3%Z0P&Z[
M@\ZR1/W[33<]N:N(,RD6<UPJ5Q9*5665S2Z7.<L':D4DZ6TEI=LZN;:.=UHD
M]P+N0;[^((P"^ELY'JSX\Y7Z56?3;X":5=19["9%C">1QZ(8"::_\$X2H"_\
M@4QX((B#UNR@\_*[[87=H%;/4F>I6EC'A(0QBR*D9A+J)0&>:Q41V-=F_/K"
MOIVXT>HJP-WH?F\/@.E]D/.;5Y*V[``L;9^JY9I:RL,X27S.DT`PH$WSK`P.
MX[YN8^R:_._=)]Z?F+:@U%[BPP^ZR9:KHS4_NR&GE";Z:$#B$X\BM5(#(B;!
M7!<"";&_6P%;VO9]]-B+WOZU?6GOTOO[[4*;N(Z;CYB2$**$<))X'H`@(,2#
MWAQA1.)N]VFY2\/O,B"RI,/N5OXN'^1X(O5UM;IH;MB47#TIRNF]H%P62NAJ
M12"].9/4XZ'R53_!!#`0>EB],6CQCI".=_Z[2\#OAV<XTJY-G]$7">5-(V5W
MCUG&(HT2+T!A@'!`*8Y)A`A>2.1'T;ZEU/?57RSHUJ:WS+(WW7WE(X.4LXC[
M%$4JP`^2&'E8>?Q"FD1T\Q1W2?!]]92M-;NUGZP]([ZF=1IQP#E+<*2&0(QI
MP$G,%HN]I.,WQ-REL_?*`SJKL;NYOV6/^6@R^BYO]=9,63WIU+8:IV0UR+/B
M6U[(NBG'2XM!-F>2"A4I1S0FU">)$)AC/KV_\%E#$'9+B#B[XG=/G,.1=K?V
M&;U-4V_F(>](4@@Q@AX'-(A!&)/X_]B[MN4V<B3[2[A?'G'M\4;WRN%6;\0^
M(6BI)'-6(K6DY+;GZQ>@6+0L\5($`;#DG2<K'`6P\F06D)E(G/26;=QK+7U>
MIK8:Y>^X[.$T++.T?_G-S1Z[Q<-BNNS\T^Q:_3U9[-P?MCX<)(0:<DUAG-T9
M:ZU>L2>NWM)(";,T7HW7]_P:+X%B.5U?SB^[;Y.ENO]KEAR39;H=\'T9I3O*
M"';.$IUAX8!CA"@F"$!*IU*3M5Q09E+`5R/]':EUE((WSVRFM_<?N\5_S#^O
M4RCJ/C7;V6D?VQ\/B$MN#`=2`^95#*6]M)L86OA,7J%J9,`CL(0B0&:K?+TG
MN6\/*^:M?>I^]6B0EFK@&4$6(6R5]N+'O@4`S60Y_(7SE*>#F*?F#[_]\>IG
M+[\LYD^W7SYU#ZE@=79K8_2Z4_7#A@?&B`<4*<>T(I9QY=4FKZZ%RZ2@^X63
MDW6`K5@_=:B(J';Q5$K"]2I*+&P1H&YV-3W+3ZX+IN".GZY[UGCQT"4MS&Y_
M[R;+[EHME]TP5K']`P/6`#"B4[=%`R`#F-KG2CV*/:2'3Q)K5S5M??WA=4J[
MAP>;Q#5$`,:89!8C@E@O.8W?]A@JCTHI;V<M43%\1EL=E'<+[$`)4?ZDP<=`
MD&#AD;/*:T.UXQM8!2>M3GHSZXQ*V$N1:WH96/Y_O0NJD(:>"^X5T!YKS+3@
M/4H(63?>PJ,6IE'RTF@>TO^VR^UHC:Z(Z5<SQW.:X2F-TRER'FIC@"+*2(-C
MM*5ZN0C-O(53+0E1R8<K`4T+E:^DCB;Z*;[?Y"Y&O2F`W*/RK<\'R92$2A`A
MI87:2P$H[.5R))/_MUJBH9+*2T!3,U=P*')^=5'^G4?.C@,OH";1S4U_`N[(
MJN,?D4A2K0^:Y/N-G)6V%EN@&>266@*,\;B7G!OZ'B+GP<K+B9R/PV>TD?/'
MQ3S*^/C]SZ?/_^RN'B_G%XN7-S]_!N!`P'ST7('BN'NI5'$'.`08$J5(#Z)@
M=N34WB6LXTWGX;H0MG`&CI+A(*MSQFS!`DFB4V0-H@0S("!@8(,^<G*\P7!%
M_9]B:2?A^F^;2]B,+M!]WZ;6WL1^?LVE?WI\6G1_1)W=/]VOC_B7]JD[S$!Q
MW$1!4(JU4%A;%WT89#$W&R_&H\P"K7,%PKDN657,1F0]'V:7?\__NYLLAL<L
M`^8*WFD)A8/&&AYA9E:;Z(YPR*054LB\LLYS1=:5;2@;MG&94?S5KIPA;68+
M5E!CH`,(.H<%T8PCFC`Q$%.N9!Z78+6K1V<WI5S@1F5,?OZT*&9+F\D"QAA:
M::7Q'!-//-9.1400U,I#EWG!N=K=I'.;4BYN([*DT\TG1*&!IAP[K8U1#B,O
M^1IF;['(JT:K=IOIO#9S)%AGR1K7KBV;+>=WT^MTB4]/[B:SJ^[/+UVWDY"K
M<MKV,;Y'0F%(8OKMPP%I*J&TAA'J8L!E*%;8:JDLH-91=-#V*TMU,.W\TX.!
MQI6**B6E,<Q[Q"FW<BV-8;F.1.$$\RE*>)U4/D7ZT::/-U+]>=7-)HOI_$"*
M>.OS@0H)%)#(RABK&6$4)[H'PRC:RA2.2P-GZG.769P`2(L=OG^]OV;+A^YJ
M>C/MK@^FT7:."4(H(QFQFF)IN/;>`-A_1!X`-=X$[8GZ>G/25!:A7\\21I<V
M'8L!G$'QO>3F;K)<7MS\^3B_^I^AZ_WK,<$S0)2SPG+,4@V+T(SU\DF0V9.@
M=A^>PFO^B:"T4/K+5SSXF;]].!C-':;`>PZD`T(0PD0O$4`.OH.5/E]+KQLM
ME8+G5U#\>!?V<^J[O9Z?<Q+K@Q/U>?FXF%SMY4_?]GR0R!@"@5,`:<6UH7'W
MZN42UHVL6K-@6%<"CB:?\_:RY4<S62R^3V>W_S6YVYN?&S0^>&&5A$YZ936`
M0'D"T5INQQ0?V5GEB;H;UD;O)(2:N'5;^G_N\^BV/!X$],8A(!2%4'!()4:^
MEXJC3-J8:N>+9?5>`)`FZ_S55>(?6'[JKKIHG-%__<_N<4"[C#W#@O1`.&@Y
MH"P&*<0[Y/M%TV%L1D9#6%;M!8%IM\W_H[N[7O?S^'T^N_U]^K6[]I/I8K4V
MV>DRY1:WLT5DS1,(X(PX`JE!!FIO,(H8:$4)EW&3)2-C'RQL(!61:G*F]_BE
M6_P$R;[CNS</A^@M6\VCXQQ]79TJQ(CM<?/6N;RFZ]5.ZLKJ_F0XFGO^0SW^
M`%+HXBWWWM,H#6+2;^2@.#.NJ\886..3SD.B917LQ[O)K&\7OF)#CEO3@'+7
M;<."BT$OBN:J($^DZD9ZKC92.M8J3]<^LBN(2@O=_S:?7_\]_7&8N47/_2.!
M<N>IQ411;1DT\4L0F[?W/%.GU?RV@CK-1*#9=OMA]CB9W4ZC,_F\U.S_;G<-
M"<X@CN-"9H3&0G+LD+&;O49DGJ=6<[L*ZK<0(HW=JT1+=8R']>/Y``%V!"`C
MK"%6(,BL[H'RC,.1E4.5UO2)<+1SL@YZ5X$"C)D$3&N&*9<0$*<W!FJD&)=;
M53R!>J3\3>ZT3R>?IW<O.UX.R([O'A2H(AXS%G<7:I1PR%&ZD=#AS-OMU:B5
M"VJX&"8MTV0?)]]33F=X@NSG`4$`*8Q!R*:2[Q@82&SZ/*\7+I=$LY:V2ZAH
M1W[L)%P::7SQU%V_A6"_TK>/"<Q#@H"P$,7@4A'M&'&]?#BZ&N,*E^KHO0@T
M+51ONYLNOMOUNMO#8;UO'Q",48@Y"*&/8C$-):,;M\-`,;)XJH+2B^#29%.?
MSV[368WM/@\X_-CR='"(<V(<(=@09&(HP=7:BAF(D>3(NLI7T/7IH)S'>SO*
M:PL6&DB80]HXQ+"GS&G32R199F.4:H%5#36?BLD9%O!!@?3.,0%+@35E7D(M
M8AR)-0.^ET]ID!=,5VN%4=!#+P5)ZQ5\D+ZW#P@0<Z02.;MP!/`(&A9L(QDV
M><2$U3I;E`S'2N#1\N.^G'Q[L1@=]8WO&AJ(\-1(:ZT@B,=ET2B(>VF%TYGU
M:M7:653XU@M!TRQ5>JP)[!X4A)746L6(Q5XGWQ1#T4L88<U4_GNH5BP&2F,7
M;ICO%BCB-*Y?E'MM?'QMAAG=."@`97+PO(?#RGP4FA2?'F[QL*WD=/>HX(EU
M@CJNK"?0,&R$(+V,$;C,WNCOX0BS'"HM-)\.S1^_#TB<__Q@X()!0@4V2*5(
M$E(%9"\)@#9SB7X/1Y@G`=&FR&3M0:SN-1RJ&]_R=!#""(@`!L91A:4""&Q<
M32Y-7K5PM>TW5R%ORDE.!:+52CV?#=+LZT<#P)@F5A+GD;"*0^3-)@E$(!Q9
M$7@AM9Z(0I,#CNOK%:J3NX^3Z?6'F9D\3!\G^PJ%=HP(&@#".(0<(Y2J5;GB
MZUP2@Q2ZO+8FU3;=0AHN`T8+17]*#-RS[MI-%K/H%"S5U=73?6I1W%W'J&]Z
M-=VW`1\>'+!S#EN76J)93P%E](?$TF=R[U3;DPNIOS@NC<XT^Y=<A7QQE7I8
M=%_23<BOW8?9U?R^^WV^3)51%S>7DV_[3SJ/F2DHX+U03`B)&&!*1HS[+0T"
ME-DML%K>O-02416D%@9SN>@FRZ?%]T$[_]N'@Y<4`F*C-)9S0(RF[L<GH%E>
ML7^U\J5":C\9AR;7^]++?9G?1427SW+OT>S;AX/B1"#/C48TFJ;E0+#^!``Z
M`_,.PJJ5+172[,DX-,Z/J=GU47H^-#2D6^G,<*P%LXQ:$7>XC;30Y[)9OX?"
MTL+0O#"$XJ1Z/[CM-O(O+V[2!61_-__[?7+<26Y@5`]FS&BN-%9R51\6L662
M>WNP[4AEJ8[DN&,62B"U9L@I*)AC#.FU-(+DEF?7Y[@;K(3]''?'23_YQ3GN
ME$(R1@G"<$FPLIH+TX/AHYO0R!1.X3L:K,]A''='`=+$52K*;*802LV]`>"<
M.:P=X9AOT(J2O@/FHSQ]#:8XRT/HU[.$]A:0QW'7W`#:*SYQ.$3_Z>-B_G4:
MG27]_:]EZKVX(5Q65X_3K\_.X>$SK>,G"P8"CS0'6#$.H*#K[/%JYR48-&N7
MFNUVY[H.U;%J=/_Z9OJ84CU[3\3ZAP+7$D+N-79``"6%9YCU$B@EZ+BT75-%
M;^]>YV'4YCSEGT]KGI_+^:<NNJ57TQ7[RX],W^6\W"I2X^?2-1P`8K@*K4T)
M2"(3\_P:5:SXR*ZI-+2\$:#=IK;R81'WXDG28/S[KENI<G:M[N>+Q^F_5O^_
MM[[R\/!`4^VPD1@P(:RQ'&K2APN203$R3L#S*OY-D69Q?%M8U8?[A\ETD3"\
MN-FP'?W$@_37WK;0@\8'J;EU7E()%*3$&$P25=):;H%'UB9Z5'95`^#]AG7W
M;?%M92X0K8TE_4\P7R:SV]34IJ?"NKCY\_O]PY?Y[/N'"%'$YN/3XNK+9-GU
M^=AMZ>S<J8+FVF(#$&.8*,RT]JS'3QD.\IH;UR.N&X,)-<*Z273_9;+H=&K(
MDPYJ8TQ\:+O;/B!(I[CABAF`J2'(4<G[[T1I0D=V%7`45E04T1:V\EN$-D%S
M,;/3Y<-\N5+7Q<U!6H^]XX)$$26-!%(`1[DPEZ9/I2BO1=X65H\;;TR64Q+8
M)M'B"Y?MXL9/9Y.(WNS6S)>K`NY$`;GB2=@7`0Z<(ACOG(!066$AQ,01XTDO
M/869%QCK<?.-R:PJ8=SRGMPS;)>3;^Y;6E$[W<VB/H=<D]LQ,BAO:+H[(B"-
M[IO3,GY$O:P<D+P(KEKMQZCLJ2RT38*WV=5BU8"[>_[W!2[KDM<!R:KADP1I
ME?<$2"((H(3%:(-M/B3A,[F!J]VV'I5Q54/Y/';VEDK[*`M[.SPPKQQ'+F(*
M&;>4`0\W?B1%?F2)]1KJ/&@Q)Z-V'EOYN.@>)M/K?GE=KZIQAWY!"'B4]0R9
M,#C`F43,>IN"6&8=!GTV65ED\JX;5DLYG<6>*N!XIETOO>^/5?MXB]HV06!6
M4R:<)0#%."0E0MP&:.<R"Z2K99S.8D$%<#OO_K6FNDMY^C<D:%D[VKX)0_0=
MG*94:@XX@IASJ>`&>$7R+*I:]NFL>UQ!',]C8:\(>HXRIE=C0UQZG:>4<Z>-
MT0A(Y.A:7NVQ'EE?AK/8S6F0C:M.J4A]4H`XAJ4F76Z#SB5&*`;[2BV-+,B[
MVUMM^VI8+U`-PS-:T7,CJT+5;GLF"Q@KJH"&6GF#M0&,^3Y;JYT7><=P+>E:
M"E>[E<.J2;7;Y/LZ'Z*N_O=INNAV=LS85PTW>)+`N8G1J;?)`23<.VPW8&OH
M,CL&MZZ6*Z+BU]5RM3!L5#-YU7772Q\13%VR+FZRS&CX+`%J1FE$V3J3$F[>
M"KS!`""<U\&H=>U;%3NJ!N)9EJ-A_2SW#0N48RN=!-PBB11C)"[SO922P+P#
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ML:H82VGLSK>PO.21/WIE>3DX0*H0Y]0#E%9O[3`Q_49LN.1Y==2MHZQV2\L)
MV+6PEFC7:R,?;".[A@0%'48QCE0*4T<<C&AMO@6!85X7M=914PW+*(18Z]7C
MQ?*W.NW?`LW`I63`3$%J1R2'W&.."%#:2MOONP92DF<]K8.DVNM*>2#'%2D5
MB9!"7&"Y``Y(!0U%`@O%-@@`E.G]5JNL;VA*U3!L847IS5.>*?Z3,MM?)W?I
M2_C8+:;SZ]=5`7OLZ)AI`L&*"6E)_)@H2$1TBH,>!49D7BEA2V+[W!B[(DKG
MLQ45K7^Q^!X-_2!=^I#Q`7CNXJ=(4B\68!#D4HJ-W#JS27!+VL6RUG$:/$WN
MDCX]/#P3TDWN>N;%#[.;^>)^=95H0)YNX`R!`0T@=UX8!RDU4$F_\>RBFY<7
M4[?L'YW-*E@%H#:%?(_=HEL^)N+XN%'N+=O[Z<D`B8(86(`EE!(AB*#OKP?9
M^!]YE3'U>*!*:^A-A=XIZ+3:'9+4J:%6_//'<</L>HLKE&X3WLV73XMNP/IP
MZM2!(X?BM\8L)%AJ2QQE_5&*51Z-[*)5X3VE(7(M[.RO6?2/[J;_ZJY_W(,>
M=FA]8&3TSI&PT?]WA#`DHO>/:!\`6&39R%:<=JJ=UX0QBSMEQ9VP3/G`[OIR
MWO-OV&XYO9UUW7*7(SIX;)`6`(LA,/$/8X$"@/:!FC4XDQVE6O:^N2G4`O*%
M,;2B"G_9I^(E;>&[H@RWUFGJ,)*`&X(MUX*GB]5>.8B89@?WM\I2'4D9#BVP
M-MTT8%1ZX(UGB1/U61J(FZW#QU*&#U;"?LKPXZ2?_-J4X1$&C9GCC"+CB.6$
M4]2#04CFI8NVE.&#]3F(,OPX0)J$_T6)HB4%VBCN%$YE;!0JP3;R:<W\>Z,,
M'ZROP8S1>0C]>I;0W@*R*,/;&\`YSKM7EP2'E.2]?C0@Q$1<$(W2C#%(7(QF
MV6;7=')D154%M_T3D6B2THF^0WJUY>%+MZ\?#1HH)#R5UFL2;=YA0S;;'E%L
M9!UN\Y7QIAGJ23BTT.KOTZO$2S%`J:^>#$HYBIV((@AK!$_%R60M"^::Y%'S
M5XN*B^GT-!A:+L`#%MY`&;&((8KC#A+M$G)@^NT#$V_R%MQJI6;%E)@I?POM
M;6Y*KQECANRC.\<$KJC`$`+E9/0Y&`<R<6(_RP<-'UGJJN"&6@J2-A_LLHN_
MD\Y[;33,N_GJ2N'ZQ?=^Q7O&!6^)5%"E8@'BM</:RAZY1).>5T5:;<\MH*\W
MWW@Y=++RTF?F]*96<>P!(Q3JZ&U$E\/97D(&?=Y=S6J??CG]-P*LQ<+P6S>+
MJ-PEGI[K^ZB,A,CC]&MW>&DX,#(()*!DW"(1%U?I8@09A5W+BKW)*P6MMN^7
M7QS*XM/"%E;\7S_Z%40#7]SN]?&V#PC>&`RTB])8)QU3T<D15BMNO?,R.DWC
MJK<KK_DBL)S%$3S&`0R,,N\`TJFS.O@_]JYLR6T=R?[1!/;E$6NWHVV7PW;/
MC7Y"\)989<W(DD=2V=?S]0-(HFJQ%@HD(9:GWVH!2>0YB40"R$PPK0'%L($G
MRI277SU8X%S_-'=%I"C#CS5SVW#\V#HN7Y!!6"$E-$4.>\7WQPDXBI<7'EDR
M0;6S>Y\-1LEXM_/S]8N6@6B&HX?J#9<".(4IT6HG"XD3TLC*(_1(;#<@BHS:
ME!7R?C%?/%?!\QR??C`8)H5U1*3<-0:CL$@T6Q$$`3TRB]WG6.X3ES+#NK$Y
M*6$H;?).YP^QWSNCM)BO='VW2#5@=K7NZY7[*TYGD9/IO%K^W,"5PG/2]O!B
M-MN(O%7[DR9BL*\&X"6,9`G/O*#`,*HL;C!6%N7MSP^6SM.KN1D+J.44]Y(;
M,8Y=U\",!L023X0VW,1?4LG&G6P$V+Q51,G@^VX*TQ600BF!K?S*9^T"AY19
M8;EP"C'A&*"2[ZVM='D'`B6#HW.)[0)#"3I=M9Q'ZY(2Q)K+PJ:WFYMX9@_K
M>G*"X#-/!N.10D(93N(*R1@AZ7Z)19#+]#7E*Z"\7V!**,$?]?3^2^R:^AZG
MI_OZ_4/"ZN9NT_N;A_5J7<WCO'3?7C?R7A@D2I4RE2:*"0&(8]8T:VD""<U;
M=SZNT$:L,T4`*[:,>1;P_&C^HBV\N8MSW.%DU#8'DIU?'K`0SCJ*J$(`>TGB
M(GX_H4H#,ZO;OH98H.+@75/='O-'_KZ8I9'SF$;RJ;Y-E0]35OYRNHK_LO'7
M^?U6]`:(#"7L^LF@F%%$`*$IY]@"2U-J=C,O*"GS5'.PO=6"ZM12DPLS4"8Z
M[A<I6ZCHB:?"YB8@MPGKE%(A*>C^"(HPQ496EOF*6M8?B.4SCC8ESK[$05`O
M5RG/_S$$X%6E'`$+$#,<">N\UBSZ-''U"PV$SB/#[=G[Y<:5<B2M18A9&U7$
MQ8G:>TK\5AJ'&#J?0'6EE*/6))Q..;I,^O&G'&V'53(2B_FFAD;+U*-#SP6(
M7=IS)E@`B"0G"'O8@&.5S3/*95.06O-[3$UZ`*;(ALGS;IY-/CG8/F!)*#(4
M6.DQYH0HZL2C7,2^@A2D;GR]W#/I$:7?1PO*L]\V_6@$Y%_%&6_*Q[Y[YK<>
M=L&?MPU$86&TCU)X[8`6*:!_+P^'(TM6Z<C)K[YT)S2*1,)-)AMTJUFJ?_-F
MOKOW[BS3)Y\+1DHD$.5`,Q.7!T*D6SMV<A*4F:(TV'*K7];[1*9,P/PZBEM/
MF@W\L]0??B!(HV44R>NT,E0:`T51(QG2+.]:[,'"I_KEO!=(B@SWV]N'KP^S
MM'(^MLEP?NBW?4?``&"+9935`"BD\$ZS1GZJ=9Z#/UC@5<]F8""42FC)Y[27
M]+#\V6[2/]`Z`"2P9LPS#J'4"%)K7+-\IE3E30"#Q5_URWQW/`J[==MR0T\.
MW-IY>+\\%IB@@"''.7/$"6@,Y'LI15P<C\O9ZW'7IT=42G!_?*/TX![.R\8!
M.$Y,U&9,C&":.PP];R2*BCW^1,C\W;V.6)1QZ?_K85<Q[O/BB#>ZT=(_JU4]
M258O3DJ;^+R/=91I-5W7G^KE]^EMO3UC^%C?+NZW=)VK0SSTIT/$UP/N+16$
M0`(26:I!VP$__DND<C5O9,AFY7`^+6NW_K6LW?;?![2K_<,!D[B<PH:I.&6+
M.!"51GM;*RD9F<?9@WX,ADUGA@>I'BFXD<088>)R2@$))16PD2'Z:'GCOV1<
M?V=^>X*FB)NQBP-\;H_4<IG2B1,L^N=CD]U5(>I'M9S<?-M$B_\M-EROWLRW
M%NN4B]+KAX*1$`$$@71,)S`Y%V`_4)C)*X9>,H`_V[VY)H[%'-_M.'H:"K,9
M0(>%/^<87_2R`(UW<06H!7?06>T!!J9!A!B7=QA>,M*_D^,\)%97U)ZM=7Y?
M_]C\Z_1Q>)L7!!!-.>`6*R:]DP0XC.U^W`B35VRB9-I`SUK2#9]KVY4.BO'\
M^8"=BW(*+)WB4'$M+-K;4^<R[V4NF5LPA/7(A:?X/NJFM[L+[:.E6ZW?U>LO
M)]V:-H\'AB"TDF$)O<>2,PP=VYM)+_.,1='L@5RM&`">\::208HQL8Q:;3QF
MD%/^.!MRE'E!3]$(_ER:N^#P[V#\RT+!H8PN%R%Q7C5$<465(/3QF()F!N._
MAIW=D4`Z7-!TNL#UYL_9]'Z;B?W\L_O(Z.;;?7W&IH/QV0H>^=RP(S/UY<U\
MM5X^M(W&/O)$X,A8AZUREC""D6>6>ZN)L((SP=#9%+T2\IV+RS[0.D"%E+$>
M"06`=4YI(/=R*4\R9Y6+A_O)X.S.G"SZQF&T8=KILN;U[K+FS[&K9Z*S#S4/
M`AJ%L8MX2JT0`09(TT#!M"\5KW]14'8G2E^6).X.2@FOXV4WS\;B'GX@>(<0
M4M&?<E9B1Z"26#62Q144&6](=C>BSK#>"9W?B?_RO)\)QAX#[=>A^_.NH^^J
M]<[O_%A_VUVP?G/W(?J>M]-OU>S-_'V<>S[_J&??ZW=Q(OIR;@K(?F\@1"+!
ML)/1I?6,1H]6Z08G`T#FWL-0JX6^'8F2V(U.Q_Y55\O//Q9]J=;N=8$Q""U0
M##%-D+)<H)2+O$7%,3FRP/&K:E0>9.-4I/CUD[=E9+TP(."E2C<N<D20!4+&
MW_8N(-0C"Q:ZOC)E@#9*=?*+AU/QREGO"T1@3"UF.@(4S35B&.U=#,IMWM;8
M8)%%5U>F#,S&J4O3[[U:IO2^0`D7P$&N/%,&"4VD2'._Q%10S&%>P?C!HIBN
MKTN78S8R75)W<971KSH]>V5`'!"#H`9QP'$6?X.,)71<NA"895JGP4*6KJA1
M76`KK50M%2588A50(JXD"*?"HSAULP8VST">.1DLJFA(\B^$HC2AYF&YW.P#
MM^)UUSIX;#F#`$51HH9R*`W"C4P0TKQ\^<'"@8:D-P^1TBRG"L87$?WX0-!8
M<V8]4=$+-SZNZBS9[SQQZ_,.9`8+\1F2ZVQ0BAVA[LXV7]3_>W5GF\IK*@15
MA@$;_:IT6IU,IE)&$@?.NPYC/=N4@AO%K1!&*N0UDH":1BY&U"CNNN_,28NS
MS<MP&/79YMOHLTTV=PZM_E[/)GZQ_%3-:OUS\Z>6!YZMWA$@MA0;Z24$0"''
M`'3":FHP098)GUF3M_PI:&OR#UCB(9`J-1<?[OO[ZFN[@[)SCP=@-`&<8RXL
M1]`A#9W:2JTEA5B-^]BT9V9;ZTYG`/^_J,\H3UU?@=9<_QP^)^0&4::8TYK&
MM2L#<2V#`&Z,M)>H5#K]52>;CJ"\II`+IYDV45T%BJL7H[G3UNUA`F[D<T<^
M4>UB+_+0^9WX'Z7QOS;MY>E^;N'.V/5?&V^RU#3<U(6T0#A-N=P#9&7FEOSE
MI\]7L^J=(2E/<BL'[]@C@1.").1*`H8]@Q;0.#AVT@$`W'CM>A>J3K+>&9W?
M30=&9]O'0'UYRC\L%[=U/6GN*?Q>+]?3:.O.'+J=>"I003A'`BCME;00<`%Y
ME-$8K!WR,"_6J'@H9.Z^8W_(9)6=>?')1\F:ZR,_5NMZDRPV^1`GP_B/ZOYH
M'9JLEX6X*%4@%6X$G$%FH$XI:)K*-)0,SLS9+QZX>"G_Q0`K/P\\D6K[8S*G
M']/)#VP],9QX1Z#`<BX$<`0X*:1$<&-EO0*$*"=*N8=7,AA#X302/?FPG-[6
M'?5D^XZ`(#>00B`UU9IH[#G0<9P`IHE@:&PU=*^@)UDX%=.3U>JAFM_6J2+!
MV?7CT[8!,ZJ142S"PX472E(FHSP(8F0(A7GVH7B,8"?>.^!1@M]_SJNOBZB-
M_UM/GG;W_-WUIQ],U^5")G#TE(P2%**4N)@DM=!0;GQ>(?7BL7RYS/<*3OGI
MP%?3Y;DJJ4>>"`HP1!UTC',J@1+`;%PB`BV.WC+).P<H'L?7CZG/125K_?#'
M8C&95?/)ZEW4O/L3:X-?&@9@HNV!3`.JL"0\_;A?VQ)*\DI>%P_.R_+[NX+1
MC2I3K;ZDZK=GJ6H:!HE\7&]B#2GG2FB&+0'[WL',.R"+Q]9UHRH3C/)V],*5
M^^4O"13["!_P4FKBG"6"8-D@@+G(S'P>K'#6L.:V1Z1*Z$IC<=XNJOGJ9OZQ
MKF9NE;IMJN7RYW1^K[XN'N;KF[NFX2G?^_*7!80%I]``;9".OHA'RL310RE2
M3EK%QW:?=M^Z,SAB65.#?IAN*C2MS&*6[EU95K-CD\.!IL%3ZZ"R0D7?`DF+
M,80D]M!)'SMM668MG->QA=<=CRS&WL8IZ3Q9SUL%3*5F!""GM3-Q+<B=UWMK
M1&FFW1[]SEEW*(H%QF_.C8]5&'LU8?'$`*@H(LY`'HDR5'`+!;),,B_LJRWY
MY;TB3F*3JB4R+Z-<G#1R$9:9%%\J++XM)RW"XB_#8=1A\9WC#XU@R%F'G/?4
M.&.M%@T4'*-1WL/<B=)6\8<7@?*:XL^@5W%5SH$$$AHOK3!QJM])AC3PXXU3
MZ494NT"T/'1^)_Y'%Z,R!MJOO1]R>?PA=B#Z@XQ1CK4$A`EG=2.1!)DT7R&J
M/->J=X;DM<6>`2.U@!YYQEG\7%Q;0]E(ARW@X[7K7:AJ&X26A\[OI@.CL^UC
MH+X\Y9]NO]23AUE]<_=8KN3F[FGZ^\;V?8XK"AU[\-\G5.'25\5%%&:$6TPT
M1MI@A)G>HQ$GNLP:[\6W3S*7@@/#->`>R^)V.T3F$S=?3]<_W\SO%K%%>E7S
MOPY;+JOZ]C_N%]]CGZ=;-8X_O-3>^*?0?.K)UT_MLIQ[)&#-E5,`8&D-B(X<
MI80Y*C!P&BD'SA8W&4BF8SLKIYH'(;U2VC&DI/7>"NC$7I;X0UZAEIZV5OHC
M8M$[$@-OKG10@_V@.^Q]MW@J($$$XA!`9PG$D#*J5`.%PZI41D`K-[P?3D\K
M2`=PVL_,EU)^U.'ZM5&ZEPYAFBK/(6>\\$A0W_0942G'YV;WRL0!=CL!\SI(
M'8W?/!(NA^9PZ^)\K.^GT?6KMM[\$28/-0T<$P.9M99XC@BC1AB^ZS\&WA;;
MXSKMY`XR*?>`QU!\FBCG,E7UG-1__:/^>9+0%VT#QEAJK+$!0F+&4_E8W$B@
ML,L+N>C]='Y`1KL!TC^ENV)\?KJZK6:IHJ:;3VRU/C9,CS4/+"VK@!$>"ZP]
MEI)+W<@1%W9YIT^]'^</0FQ/F`PU7/UT5B]-[,_]8GEZL#YK&5)P+L><8<R4
MBC.));:!`K.X.L]BM/>4E0&':A<XAO.'TFG'&6\H-0G",\VIM`QZ!)F3%&#2
M])<8E4=?[YDG@RYH,W`8CK?MA8*GK>O!ML$"+XP%EA&EA`0\FI.](T@@RO."
M>L\D&93)+H`,1^FCQ??Q+^>V%EZT#DIK:12#4B*BF*5,2M=(097(VU+H/4]D
M4%J[03(TL5NE:T_MD_9!NQ1E#212&&"C//5R[ZE38_.J`_6>4%*`W'Q0^J=7
MQ6Y--EV;5?='*'W6)A@``6%0.T4L$<`:Z/>3AX>9]ZKUGFPR"(U=@!ALY;GX
M^G4QW]P4_NE+M:Q7-P_KU;J:IZ#GT\O0$P\&(H'Q%!D-XHI:&JRLVR_!G+=C
MN7M]R$5I?_`,1?T?]6SVC_GBQ_Q37:T6\WJ24DH?83K(^I%G`C<68POB6MLH
MR343$:F]1%"-)>]C0,+[068HKO]S,7N8KZOE=@5V;/(]V#8(@:#B)%T@'@61
M%,9)II$`09\9.O&:=IBZ(3*8Z=YNDGRLOZ6T\/E]2D\[ZE>=>B1PQ[@$$1]L
M*>&24$;WNRJ*H;%DC@QIKOL`9BBB/SS\.9O>^MFB.E2$ZV"[`)!&@E$.!?40
M2HTTVZLH!+GQ3J]IKRD?C>%B5=S_/&P"5%("Z?1[K7Y4R\FQ?*"F!_U^;'<W
M!SSRT8&CNY(GI*M5/8GN42I;46T5;%G-[S<1#/KG8Y,/VSNJ-MU^VR)?J?O+
M@_,X98IA%Y7#$!.7S-!L0IJH2[<;G_5BAHZ).ROBZIB,YQ*B>OM&4):G>C2>
M`*J@XT1Y2!L,/>&E+H@XF4954E6.AMF5!7JT>5H?9M4\G<2>B>-_VBQ`C("#
MQGG)B3,$@XA^(SK19E2A0U<D_F4MRGP(2X3^-MT[&^/]O&%01DHGK.*`:<7C
MY.ZI;B1AAIKQA1UU(^0(JYW0>,W\CB8"Z9JTEJ=S:Y#.)]8^:Q>@1=`"@J16
MGF@IM?6JD4,9,\H;/:YON;M@6"1K(QN71\GFD]8&8HC/!>V%=81!+F5<]6L,
M,$(-JA:@$1>IS]2.EX[I>$#]M\KV@^[H9L97K*E7T-!4-RIUW<RJU2I./NDL
MZ<QD>_29X+DS0G/"$1:60:`598U\P&7&_0Y\Z<KU)]Z^\"RA+T^[>-8>_=HX
M6,@L!Q$8R05F&E)JW-[%9&K$$V`/+"T&@N=W('YTT\@H^"[/\\=D[,Y,`/LV
MP6C,!&""64P$9PAK)O83&C:E8HU?F<'/Q:\8_^^>':0=TX!MJR"L=09Q#0BQ
M2$K"G-^C@"4'XS7I&3P<8K(3#J^3T]%9Z[)47D+AD>*;FUG@YEN"R/T5C==T
M56^NTE"K7>G?F[M-`?:;NR=!7@?8RW]90.D^L530W<1%$9*$I_N`=E(BE1MR
MT_?A_16/TXIAFZ5!'^O5.G9D74\VG_SPL+S]4G71HNP7)H\(`:XT=<Q(#Q"E
M<K^N97$<%=IP';DFE<(W2YL^+];5;!M$^OE+M7Y7_=3U)KAP\B+"(VUI'-.@
MBUX2E%0\6EH#43324C%M%-E+16A>+=3!*@E?2VN&Q#1+4]Y.OT[7-_.#7;I9
M?ZF7\6_S)U9S=;/\5"U7%ZA1?U\(UE$!$#((1!-L-$BUGO?;?W$X%5J@C%S'
MK@9XE@(V?7B,=;]`MUH]'+`4T"$$#(ZC2$@,&>7[);[,O)UBL.N_KJ4V0V#9
MAROTSPA]IGI<_J;`E0%48X^H-TX:Y1P'6_F\$@KG%2\9[,*PD3@__0/;=16V
M:KS[2QR>ML\'KZ56@*;$9:<A%%Q)U\B"#<SSD`>[7&P$:ZT^X<Q3C<UDN)T#
MHZN>[L%;?UX<4N-+]*7+2P.B0!*#%/&`2&XL4FP_(#A0>;/28+>=74V)"F+<
MHV9MNJ47\X?5-H:^LU:U>&%@FFFDB4=>"`R19\;[1EH@=%X*Y6"7LHU+H_K'
M-TN;['19WT965F_B9ZO9UGK^+96>.J8NQY\("GI&=.Q<].`UU\9:1/Z/O2MM
M;B-'LO]H`V<"^(C3HXC>=H?=/?,10<NTQ5B9])*29[2_?E&4JG3R*+`.%%L1
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M-O?[M5/9UOF7(A=*@C8VL.0J((?`0^,M*"SRLNGPV8621T>^B-*17>#^?EMI
M[2&Y<:-O;ZY6Z\7_5:T>=F9^=?ZMR()W07&%/'/>4\&H;';!!"!SB3ZG>'<I
MV$^)R[]FB^LJ\3:LUKO"'7U_,A)K06HA*&(\*.L=I8VKC27*O*?\G(+PA:E@
MX#X[#ZUO7G1Q>6]]LZ62L89)@36@M"]EQDN''O+8M*UB:(<F3T^H3:KUC0O&
M09I[DAKN,4B$N*HQ=!H-=5UTWZUOCJ9*;ZUOV@%]5JUODN-`P.,D.D)@);6@
M1"VZR.ZLVIIC(Y7U'*WX?:UOVD%8<FL4Q9'D4H.R4CHJ<%KR42V)](*66]^3
MIY#]/5+RT)BR?H?7:YO6-P.I=7AUYK6^49)YYP-3WED!AFBL>2V'120OWWDR
MK6]R+?<I&!:Q@9Y`'Q$BI/&<,XV53U@B)8#6J!IJ7+G+2"8[AF@HD@?J.V6[
M0;>XE7'"3!V>H?7!P),CK8,UTCN?B5YY$Y2TTNF@A=0TN1^U?)B3S+C@:&'!
M7E6\Z@?4Z?5+PH(:Y1AU,AC-+69>N`8Q9?/*["?3+RG76^L*SRFTS='.2RP\
MQX0YB9QDV#<SP*<94*[7U(&6#O?/R8/G'!1?G.]1A+Z'UW/+?DD!(8D-"981
M<#@M:J`;DX=DGD<YF7Y)N08_%[\R>^N```^<!J?`R\1E`LPV,EA3L$G/T,.>
M)CMY.$Q3I\59ZV%566#X89>E>LAMW&8:;"Z6]]=@_FN^^'YU,_^J?\W7L^_S
M[7^L;K0-L\5Z5^'%2".)/GC*P3@/%(7@B-,*U[I@E@UU/CQ<?DKV27'1BIG"
M)'F:6GY[P%IV_JU8=;;A2B)LDO7!!CF/6.-6,IU']))+E<8B^JG03XS*+V;R
MLZ9OPQ!\WP@B`,<L2(VLTLP3EO9`S18(69F7)%YR354!M.]0(5.8#,]7M@_K
MU::7O,#=7XLF>$\,J@(%PHKDH$K=&!AM3%[E8,D57F4X,3G@%T'HG8&'8WRU
MSBQ\=Z.((2VH((E(&RJAK<<^A.8LA5*?Y]R47(W6VP0832G#'$>M+O_GOA+*
MW:[32G4OQ7WF_)NU>GO/J=J^+`)&-&"%L;8$."!$<+/Q)S[DT;3D@K5LFO:-
M[23,<"W<Z):XU4`B>,T,P4"5)X$E'X_+)I&".G5^S=M&,\9]ZJ6(&7)0_I^+
M]?:9!H$>/>\WOA8Y8<(%I)0+..&X-3H-I@!Y7"^YO&TLS_MT\(L@].$9_4K,
M\8Q^JZ%$0(SRP+1$"C.EP'#2[(.JKAA94Z'DYG@CFOT^-5/$/#F`0%BMO\T7
M-[?K^1"&_XVO1:8L8S+M^)%7$COCT[^-NZE(WMU]1;?^&\ORGXY^$8P^-*G?
M$',LR]]R*!%I0A/^4@ON%54,S),(&"*9C5C^EH>HXZJFB(ERW)ZGRI#J_13U
MU;<B">`,\5IXRY3&#"G91!DL5IE]K]Z/4;O'?F)<'ND8]<@11$T0,803`&L(
M1E6=01,[`)UY^5#1O2D+X'V'&IG0;'A<V;:=/B^6-^O%<K.X[#MS[)C/1YJV
M3M)KXY1206LM-0Y-B8U#>7<*%-U,<^1YT*4Z!IL$7PZ+_:5U&L6G>:7R]'N[
M2B#,+F]N9]=_SM<_R*$Y,>QH(@<I?;#"^R"244**TL;EE*`RKZX^V\/8HK4S
MA1FS>\'<A0+N<<9DC"8Z[FSR:CG7P)6C`#0\5OP$E'E]\%F>"Q>OG2DX6D_L
MQF#>U<YO1J(83_]CW@E5W1[-$3>/%17N#)N?%I"B>9(.)K8J/)=U(./_XJ/1
M.&^]49)6U4,)9NYQL^YBD=LP_6Q/BDM0PCBM4%_TSGIOA;HE$PL&(<H9E4H3
M0JBRP3J!%0/&-#W<Z[TGU";5"I49<`A<,$*E'Y@*Q)(&0U!Y!_3EM4(]FBJ]
MM4)M!_19M4(UR%-*"'-$57?Y:>F1J45G&#+CQ*TY-E+%_M&*W]<*M1V$);?*
M]%0Z(-P$KBD6C&`K:"U)H!:56[J?IY#]/3/ST)BR?H?7:YM6J`.I=7AUYK5"
MY9QAS1&2!G.>AD\E5X]RA#-OA9IKN4_!L(A0T03Z2FH,"%?7`4NGDF]'DY*:
MB<J-UN4N(YGL&*+!9!ZH[Y3M!MWB5L8),W6,,L(NNUIZ:QS3G(.@-@$.BF%?
MRP=)\"RN3*:K9>["VQ6>4VAN:*VGA"F$B:E`T8239@9(0T6Y"V`'6CK<Y3`/
MGG-0?''+2!'Z'E[/[;I:*B^1EFDE102DPQP;&NKQ$Q3RMLV3Z6J9:_!S\2NS
M`Z+&6FB$")+(@11$0(*EYC!E!9OT##WL:868A\,T=5J<M1Y6E6U4N.^ZZIS3
MH>WR85;+VTW:7[RX^OAY1Y,W=#W4IZ-15BOF,$M+(C"BD2'-&NF4&HQ`@Z4(
MM#VJ*U03I7(YIP]K,6.+0'"5*"(<,$<5HR`E;CQ&$O(J;$NNM"IU-G2MJOSI
MLB\KZ,N.K*!'.6>OY+Q9V=5RD]R+2MQ[H1?'K`,#CB-R%KQ(6R1.L:,Z,$%"
MY2]K0R4$*4G6-"BY\"I_&I2KEDE0_K3EHJ2!1DD#8(4E\=@2:D/:<5;KMZ%8
M.<5T7@U*R55:DY@T7>MMG`3-%T5E[PF:6P(F*R@(D$1"&:C7%#.X;^L+EG.M
M#WIK[PF:\\C`&^<IQD%Q%;S'F(8:0XU89A^-XA(TCZ9*?PF:K8`^JP1-`@:"
M$$9HDU8)X:SGKA8=@\VLSIQ,\/E8Q>]+T&P'8<D)?)H1K(P+1""E/146/*DE
M,<X5'(7.4\C^3+X\-*:LW^(BTF.H=2H)FAB4=<@#&!V0"CH(SYIE$U2>=S"=
M!,U,RWT*AN_9;L=E:%6'/III)`Q&@DJ-&=4UJH)Z5NXRDLF.(=+>\D!]IVPW
MZ!:W,DZ8J2.<W3\/2?V5-+7Y]/FOPZ?Y^YZ+F#J.DE,B"+.6*I)$P[6<R:_(
MB\1/Z\[ZHU7],D^@0V"GE^&+I2.44E?UWS?<`>*8U_(I(_+VW-/)\,WTW+K"
M<PJ)GM3S)`GQ@"`@X:1.8M024<U]N1Y4!UHZG/&9!\\Y*+XX/Z0(?9>>X6NT
M1R@@&3BC)#AMP*-Z_,D[._<,WTR#GXM?F=F@M&HVDSPDFJ8#54$"M8U34V67
ME6O2,_2P)RTT#X=IZK0X:SVL*@L,1>RR5/4!?]J6W&Y-VL>;J_GZSZO9\J&+
MU.^KY:^T:9E_[:_)?-LQ1)!&8*T)!"RJ[K8!/5RHF/"7@@[5P&>XK);LD^)"
M57(F4R(G4:RDX25#)I&E4-TE0"RF4C-J&T-&(*\\N^34XH(G4M?:FO8<.UB,
M,O00HA:4AF`"1KQ:]@EPXVOT$7=YC2M+SC\N;ZZ<I)%SF@]E+CRMJR6T\`I;
MYIRQ7'AB+%.U_D@XG"HYN>3DTF=4URJ;]I3[YW99'G4)>CZ$R--ZKYQDA#J/
M6/(!G&T"2IC@O,/:DB^4*&_"G*21<YH/92Y!+<<8J:=6(N>))(`"4<'R9MNJ
M-<X+4)=\X43I,ZIKE4U[RCW<<CGR*O1J%-$04!YSC9/Y"PPID?SNQR"JS^N1
M6?)-%>5-FU.5,FRM?GMQ7AB"_DKUNQM:I(8ER!4R@B`/7%/'&I:`H'D;FI*O
MMF@[+2:JJ8'K*[>GQYOG0VBJ*^MQ9'^R`>&_Y[/-[?K^('O0CSW4C^(='^UW
ML6Y&9&;7LX3[YZOY_.;#>G7[<['\'A;+]+O%[/HQNV-V3ZW?CJ@>/?75D5B6
MN"@(U56B0+#8&O`$<Y%X204[&&+L&[&[MP0[5!9ZS.-1Z8")P90)H!AQXGGE
MX6TE9\Z54?$YG'I7O2-8;"GG$UF;'_^Q2-9[?7EU]]O\U_SZ0/+1<2^(%AM$
M'*W.[R5EB@KO\0-<W`>9MU3W7/[9+0]VDZP[W(;8?;VYQ+P6X6!28JOW1&E9
M\AJ`44J,QHHZ`K3&@5E6<*)JUXK>Q:,>8?S[TJJXQ*I)L6E$%ETL?][>;+:`
MX(.I=GN>BI(HA$@0@@L*F&KOC:IE-$JYLG*?>M+?+I:<C-=8G"!9G'AX*@K-
M',*@%>,!@0&A9+WF<VHR[Q_J+8UG/$[DX346)V@6)QZ>BN"%!$R$,:;J$J`"
M-KR641&1=U;86[K*>)S(PVL(3OC-S>)'VDQ^_-:,N_G!+3;5MBTA=9`D;5X3
M`R->:O!:!L4)-5(Q6Z,@K1NJ8*,HUO0(X*"FQ=P]@<G,-HO-\5OIMYZ,V#EP
M6@.U#*'`!'.`&J>.91Z>]MR(8Z@]=`>`#=)09[7>XG]SDHEI\9:(@V0N.,82
MM((&XP.1"0-AO;:$A#")C?-IVGW9IJ=W]`8U,X]CKJ*>^L?JM@KY'[U-WO-X
M\MLL"50BZ14W#)D$AJ^D3[_1-KC!ZCYR=L>=4J8'M/Z>UJ;0W7(G:NW1S`Q/
M'3O;7.GEU^J?ZLSTU^SZF:_W*,$>XAS]CBA!B>3)V2"T=E(RP<'7)S7,#W>#
M24O:#'TPU1>@0Q!*_YHMKBMO+ZS6G]/`/\\O;]=)9?.]C>AV/A09D90FHTT#
ML\`M-EK4/B.$`'EK4_\QF*$ITQF"0W#D8EN:]:.]I=G_8"2.6D.M!B,M$FF'
MJ$0S&Y3C>>73_<=FAN9*IR@.P9=M/M)OB]F7Q?66TNU(<\3345#NM*)<62,E
M3WM3R^MH-CB3V?NR__C,T,SI'LHAZ)/-G`.2NN0J&IQ<1:$EKYH5.$<:%('E
M]6OKK6QD--)TBF)_*8/[4NI>#&+HE+HG"#X,[NO'Y:=JA5\GW6VWO7\M5U\V
M\_6OR@781N'3?UXEC5XO9@]8')]FU^'GH@.@7J/[FFH:B$$X.$JI`N2T.WQ1
M>?'('IVFU]&G(B9:$24PP]H:"Y9;RAX0!<!LJ*WW<2E]HU!I5U!G'`U,(26P
M1N9NVROM^..+U\\E+1GMG')68!^,@""HKL'!%.>5L`R5`#@X0W8?=)P,[:#!
MZ=.!>RGQ\9'MOKX=TY99RJ1'R;E&#@L5L'W`VVH+>A)'*J?PJ#]#VBGB[TSO
M&_>2#X#.BN!MB+VCEM!>5?5>%\M&F(_?/M_]^'FU6MY=I!%>+"__N%U?7LTV
MC91W;W`O]U61((.QY&!96@,9LH(J4GMI+J#!&M^WW!2/Z:@.A/58V=W_6MQ<
MO<)N\QR\YT@W$GY(.OQMM=DDZ:]OOU;UAWZV7J8_.\H_[7L,T2O/%$=5APHM
M$"=(.5/CKUAFN7;_9Q-%;<H*4]($)\GG^<W-]?-RT_YGQ9./1BZE1J`T.!&4
MQPZ$4C7"%)N\B$3_QRYG.`WRM5(R[S<[I/WGCKX%O7XO,FUI,%PX002QD@6/
MFD67@LOSE?L_*IHRV[M4R,`'"/WV'/BP6GW]]^(Q$MO7^Q^.048Y!:G'<,P1
MQJN_C4189QD/V!"72$H"#_<767'PQ/*#N=3]R/1X%T(]XN,O@7[V1`1OD.!.
M>R.M)X"!(%[+9Q@4<1IP@E9VWM!\"@K%1N2;PU=SNTE8;3:?[S]\*"*_][GH
MB-":"HU\E?QJ'$+!U>``0GGE!(/=R)RIZ%UW/76`T!"NTL/P#M]=^/3O(C4@
MC&24Z*H)#TV0:-%,*V)QN0'KCO3S4NL=H#-=;1<7M"U!R5T$6%?SZ]GE;'ES
M]=+]>A4_??67D5N07")O-5/4,&F=-HT!XWJHACQ'[AY.7[F[P>%$/=61TS_6
MB\N=C>YV_'FT@AL/-`@N@TOC!4)D/5(L16%%X)UK[!0PLM3V-.I]:(*]];>1
M&Z0<4B!8<@VT!,JUK<?H&<J;8KV%HSI26`=(]+<S?N;#];89OEBF'^=_SOXS
MR"<Z:+:WF5_^U_?5KX3UXMY72#^\=!'2KZ);76[[,EXLOZW2<`[E\QUZ)#KE
MO$OV5EC,#&55OC=X#HJ)8!0A9J2<O'F::+/K!N+?5S?S@\EUNYZ)7G/@$*01
MR!AAO",>U3)*[>A`Z^R;^^+N%/0ROM81',5ND*OPVGU7T^OKU;^K+&9SY^;?
MYNOU_&N25V\V\YL#>^5C7Q%1$)8(XM-6$W.AF68)M!HRZ0_.DE$2V4XGP&H0
MN(;85;T<YL'MU=L/1"1T6H]%FHB:6B2KO'=>2R80-^7NJKM7WJI'Q,Z)$\7M
MO4NEPO@4V'Q,!C9!L_Q>)1#8V7I]EY;D;</H%KS8\Y9(D3>&FL"=`TF-9-S;
M&@/L<=X-9YWO^7OS2OJ#:A2ZI!]L^O^+FV<C_S3?S*NF2&THL_]-$2O*&1/.
M*\<\JLJN:'C`PFHI\US8S@,/P]&F4[A&H<[%\H_UZG*^:0:MEU]=U2QM]?/>
M?3Z>.P=>%0EAEF`O!2%$&R1Q@-J,6Z$RXXR=!T&&(T^W>(UE>.K?^?]4]SO,
MG]WSL/QJYLNDM9O-VQ=!V-6F%<,Z^%Q4G'.%D2764^8E@@"J1I5"I@GK/%=F
M4!,V,*:C,+7^Q?T^M`WIGC\92=75.(`GFE&D!>,4-[(21O)B[YU76`_'GY/@
M&<>YKCH&M/*CJP>B=:`)4Q:$\0&,5`;A9C&W/J]?=^?WQPWH,F>@,HJ^/ZR3
M3]]&W]L'(G`#3$J$$IU98C6EO%E^F95Y^^G.+SX;3M\YJ&2=MCWY<I-6^6E^
M/;M)OUKIR_^]76RVL#ZO1MEU'I?WMIC`41Y+0W4:G_?,*FL:Y\MDSO;.[_?J
M7/O#03:D*6B"ST\RCH\P"&\]%IWWR<PAJ;$@4LB@&=&UE)ZJO`XKJGAB](#-
M*(O!ZZ!CFY7A]=-1&BG!RR2O"L82%>3C+DTIDWE)`YH<(;K#:&!>M+,)+QC/
M@B`A*.*$)$YB&JJKTA\D`R/RK`&>9"`U'Y;^LCQ>)T>,TS9I=WAY7]9$BZ<C
M"1Q3>Z\YZHDU$.K#5+#6C%14\&9\]%`&Q>Z'HI:&$4;5_[=W;<UMXTKZ)RWN
MEZI]P74V53/);)(Y4_O$TI$8AWMDT47)GO7Y]0M(HGS1A31%D(PG#S/EV`39
M_74#Z&YT-RBQT@!BC<7UT0W#M&,WQ9Y+"WJ55ID(FLFF4YSDL"%_XNR8##(J
M(/#>6TXQ9D)162]K3$LZR<X_?<BXC=IT`&B(G?DDK1]GMWGCN7C#R`Q8[KF@
M!G')$'=$$5&'*ACG8,+7$?0@OS8:<356[UL_)I=`,3VU&%X=#A:>NM]\+ZMB
M\]BP69P>D&%J/0!$.AQL5R$)<Z2V6!G@8*B^&6/O%+V@,X[<&^?_N2&9\,Y)
M#IQ05B*,F,?(UMPQ:2=<HW:MN!JE?Q5"[TT/)K<!3$7\/03]/^</1>1Y4QX%
ME,Y%]B\,R01U0##LG5(*2:L``+BF&%$YD?RVE"YCSQ`-,9>/(X>OJ:X[DNVN
MR;DPQ]_ZJDQC0BT65@F$K;`.BT/$BD'746&2E=2EC#$DAFX(1>J4/GLI!502
MXAF57%C&/3)&<E)S2`WK9APF*]]+J1R]@32QM.IM';A:+7X-LCM5VGGM*S-N
MO!2>.A+65J2TDXX]&>2`3R3M;`@5&@C"08W/?>;</E6NC>WY<D2F#1>,>BR$
MI9X2["`1-6_6=&Q1GNS>CI3JT0]"@QPII:T=_E3=S%;%O^LTS#WFY6KX#UYN
MM97NNXGQC?EK9G97;.(5,^7\7^JFRE_VK!SPDV.V,WOJ;+2G;2^,>-'?YK'-
M"67+-V16.ZP=H0`KI#7'4#EN,<<`(PDX:SPN'X/_]FW0SH[.H!5$:&RL<\%*
MEA)"06J^H21#M5BY>&[9NPS/-DKK"Z?)'F(>N@KM>(OY\N7J+4W33HW+L-`&
M2^414+'56$S+H#4X0J-N*8F#-4WK0>CG&JCU@-80UN(K,AOCE">?SS1Q&'GM
MM);8@<`2E@>^I,%XNL'JGN15ID/I_6C!Y$+54Q+^\$+?&GL?UNO[?&'O8]/@
MW_.J*!?;DJKUQ_RO[9\N[PQM7I`)#`-@EEM@F"+4<P]9S3DGOF,R:BHW,KG%
MD0*T3J<;G[Y]R[<$Q(YE@8HM">?.-4X^G'EGG64$(Z8%)H9(35U-)78=>WPG
M"U"G$FUO`'42X\=\LRW9S1=K'UC>ZE=-S#EI7AJ3::B5%+'O(+#8!%WSQ!S6
M/<BZG3HD"RPG%6J/.'62[>^SQZTC_NG;'\'EKOZ*-Y6O;N*EL/&08ZU6L>SU
MMEBOGX=@7@O[32_):&`$*:L@I8AB@@G"^F#XTHZEI,EBPDFEGQ*X(3;X)_H/
MFTX\.8O5T9>V]4O#LL!26,98V(N`P<*&G^C!C&'$3"PFG'HS[Q&J3NO#&6/B
M:_EA]7"_*XX_NRRT&9LQ217@TFG,`%'24T+MG@?%#>>=Q-U[??$@JT$"O-(=
M"%P(ZJ8-8(?M\BZO-H]A<8RHO^C7,L2W>F@W>L6"NR?H]^5LM7E.59MP=?/@
M#'A"N`*8>XLAL)XKQ'9]:HGGUH]T2?C3K#O+0OMP]>579"BLHEX(:*F$RA!M
M/5`U`DZQ4=N5IA#DV7!UKSA--F9]EDO]^#50WA"Y;C$Z$TJ#L#`']PR2\!_0
MSATD(?TTK^'N7PM>FS6]`S>(N7L6C$!"8TBSQ>C,2.$=!E``20E1EEF$:IZ-
MYV"Z8>Y>)=I66ZY&[N^A-9,+BT]=6897DAC,O]_DU8':WUYX(B<4X\R(L"1C
M`\-JC!U02B(HJ-8U;UZ2P92AG4/5J[3*%`@-(7U_7P7([ZN8]>>+_XL_K1L5
MX/R@F(46$-)0<&.=EDA):`\<BHYIE\FBYBEUH#>0ACHD;3?YCU2:<QKL?0,I
M0E(0@@P]J+0VIML)6+*(>DJ!7X?,$%+^-9^M\^_E<A'CNX=_?+B]J\J'70"E
M4?QM7Y'!8*!+H0S#3L=[@92EH.:>.4X[Z46R6'M*O4@$V1`*H^^+Y:)8W<2N
MI/L?WZ0MK<9GDGK-.&?*8ABL+4PE$#7?B-!N=>#)XNXI524%7H,L++/5HGGI
M.#R4J;`L(DLT-,@Q*34V3S$BJWRWMC+)0N])%X>NH`PAUL^Q[*PA$'5X)M.!
M1B*4I/&^!T^-@9H>`G_&=ZOF35S1GSS<U!6>P<3;.&V?/94A+0@BAGO(":*`
M:@]-S0/64DTW2-1!#J<D>14./Z9,)Q?"&5:4$XK:-?55OCPP0]0A02TF3AI)
MF?%`/BUAV`]V7]&5F^[U)TV]XC2$1JCY_/[V?ML/V.9W53XOMD?_X>=EOB_B
M4K=EM=FG!)SE[X+N]/6)#!/B@N6#C)*&>J8]8X?8!C-32YM,J&4C(3KJ"O4Q
MOZ1CEX9E)-XWACUUCD)LI=8:'9P:%O#_0>)("5>GMZ.4+@?G0GK*.`U??RU7
M-[\6#_EB5^+^7_ERX<OJRVR9M\E/:3$ZDX1($SP[9YFVDA%NPR817#6L@0R^
M0&,U6.H$E?,\M,]0:7A'!HDS2@2'5C(D"".*<EYCP`#JEC+7<XI*K[(\FZ/2
M+U*335(YSZ9^W/ZJ1:I*ZW=D!&$#K?308L25##*1L@;-^8YG"8,EK/2F$J]#
M1(GP&R0P>);V5AU$VPS/J#0"8@85-PQQ&9@7L.8Z]F*;;E`B@61;Z\[5`/Y=
MU&=R\8\?1&O&-$73YH%_SN?A&\&_BZ4RV[*X<A5^G*?M97+YJXE;QES^>&JX
MU\$6FF^VA0DF_/%FV&\EA_;XDVD!_9(O\_DF7_SW_:S:Y-7RT1>KV6I>S)9V
MMIF-\]4QV_&8,GQD%8SN`T6'XOFUF=UM6R.U\2+?])X,44`(D)A*!'A8G9$R
M^WY=`CA@&H_+4ON3E[AY0XN>IK=D2'OLB0?QVAL+H6,&[''@7N+!NJQ<]"D3
M2?9\PYZ>49NL?_GL;B3]>,QLC6ECB_G6;\F$EXIY9`D3%@83QAOF:N`LUD-5
MV71MZM.?8ARU`4R%X2!IK&<)7O]9;+[;(A:VY\%>67]8?<[ORK`#+7;==(/9
MN/M%W'WOJ_C0H\U7Y6UXX^&A=:.K,0P!&?&.4R\$XEY3`A2S&-9+BW%<3M?7
M3:)?KU-NIRR$G]-@.`E,SF?_&VG_"#DO^4.^NMS.J7XD@Y0HA`.YD!BBN69.
MZ)IZ172WM.1D21##V)T=P1E"M(?&Q[LNP+]>3H`Y\71F/*$*4L;CK0M0*X.E
MJ7GB7'0[LDJ6CS",P*_':0C9?\PWK:3^XKD,&L2I5DI0QK2W$FI_6)Z@%Z23
MO)/E$0PC[VL0&J3Z:%:M@C:NZ]9B>K8NYF%3LL7R?A-C3V=EWS`RT\$/,DIY
MIB07&G)D&*MY9=ITZ_>5K`IE&&WH%[,A].//O+CY'@V1A[!NW>0?[R.,G[YM
MJ?]TOUEO9JM8*M%>;;J],(/!`E,4!*0!$8)C!J&OD?%<=C,>DA6J#*--@T"9
M[O3H<E0Z<1S^((X8V+F]J_+OT9UXV"[3OP?\5IOO^::8SY:O_C5*E/S8J[@4
M`#YZ.`,6,Q;L"\&0]!0((<BN0H9A*75S\[W$7#6&M%\\F)$P)R@ER!!&M$02
M8FIJ;IRA0]6Z7VXP?X40SK7^[L+]9*//!ZZ^S//5K"K*MNWBGS^?(:P=!MS&
M>U$$Q#*VM#U@ZF#C'0NC1)0[RO.<6EP!R!`&1$W>'ZOU73XOOA7YHC&4=79,
M!F*;6T\,5\(33+RG"M?\*8\G'(2]4EY'YU7](O3^-&%R<<BI*,!;!'^I/V@P
M*_/8J3;>7+5KA[F[Q$JMUV4LN,@7,?3Y.5_GX1O?H_V9/^3+<ILDM'_TA.![
M?7\&,<$"J\"[%4HR[@@1-18"@,%NN6W99_1ZHV%,^%*KTB_Y*O@YRUB\L[@-
M8EEO8B3M(>]/F1J^D%F-B!$4&!.`P$)":56-!]8=:^?3]:4?7IWZ!3"AZWE_
M>SNK'H.O7-RLPN(YG[W(L"N7Q;Q(Z'RV^OK^-^N8_U<\/'>1QJ''S-;?XW\Q
MT_-AMLQWK<J_?"^KS=>\NOVP>LC7FZ1IF"WI+%<Q87)WKU[P[JM\46P^%^M_
M392LD=/OGHB*Q+0),)P?E#FI5;RT%$@,)=1.4K^[ME1P2)49J5#KB."F@,/I
M`9DFEEKEK*1:,FQ0X`KMN0-.D:FDRUTMG*..>CV@,=E`Q!%WK7H`7QB5Z1B^
M#[NIDAYS;I13W-3`6`"'*O9_4U#B6ADWJ4QG>(9P3(^9;].C]<*H3%`".%4`
M0@R!8](@+&H>J6!DNF&*7B37N(!<B]3[U(K)A2RFI@P]^)OQFIVP_=Q7^:?5
M+WEY4\WNOA=S5>6S]3X7)][(Y(+Y5:UF2W._WI2W>;56FTU5_#,>GVU*7\7+
M6,ZYF[U](//:0``-X,P99I&D\+!?(XKUQ"ZXZ]'P&!7'<;3J:^F"M[!Y#&Y"
M<!NB,Q&F1/`;EO'.M_GI_C$#?3FS,N`E#(4(:"8A4][41@#2"G>S9U*F<4U+
M#_L&>.RHR"]EN?BK6"X_W-[-BBKE13SMZ'FBXZ@/P&0)2US7V(Z^C_EFF^V0
M5_&^N7+UXJ+.<4B:1N1MR,NFVE%T,4P_,EK;(MHB)O+$Z&"@<#*1P$N4C1EU
M.Z+K55AUNUNUB<2][449MS[8ZL(&TT422C&3=:H!XY3[T=LH-;'3OO2UU9LR
M)'2P`)D@BGH/(;!J?R5$P(,8-%1!PL5X7BH1GZU_30'=9(-_3<R>_FU36^;.
M+\T@%D(X`HE#08S2<U8?N`;Q.3N41G:LD.U9=8Y*90:"=9BZJ2[,-#<7ON*U
M&1:>>PV$`A8$(6FDO*U1`I+SZ08MAU"-7K3Q*J1_ZN5IM"87-GUOZCBF&IYP
M)B[JU[/G,RJA5]H"2XA2&F"#P`%,;@;;35L&K@:R]/J`:NP0U#[P]CF?ES>[
MSXSK:'[9F:O/*LUC9DP8L1MP"`J.Z73N@I!_%HM\C]YOL_\MJYJT-MYFRS=D
M)":6$22LY`8JPVWXGX,<.@N``[HQ7IS:S3SB0S^^X&2M'P\E^7O)OL'U[/SV
M,*.Q4H1[K,($9M9@YPZX>>C$%-S1WG7@K!\Z%(Z3]4U?<MO@<QX_G`F@M(,.
M.X6!P))@(DD-`V=@XMV6!A!_V3.$@Q3FSVX#."](;4Q).#LFXV&K1X)B+X`1
MU&GEB*WYBW^:KL=WC;!>5^CW#,_[4X/).5B3D'X/:0-'B]R'NW6^VA\+SV[.
MYI@TC<N`0M9;2(GQ$"JNE)&LIMUX,]C%4NT\GU1&10JL^I'S;_./LZ+Z+5_$
MFO(/JW7X\_TF[R#XIA=ER`$E8RJ5(A8;8KWV>,^=ET9WRUE.EKPQK";T#%X_
MJO%U%@S.8NZ#'[KNH!"GAV>2`Z2Q`99B1R2-]Q^(FA.'9;=F+,E:\PRK!KU`
MUH_P;=C\P[>[;`''0S/$%):6:(8"4$!9STT-CS?"=]L%DG7@&5;H5\,U=@SL
M;,RI>!5T&CDT=K)X<(HT[8-S\`QMB:-3^VY0+TE2516ORXQRUH]/C_P^>XR_
M4G_-JD6;P-WU+\^P=K'QI"9,V;`52B\<W\6'%1,4CM5!YA`N:&1Q?8[']I&]
M*[^1"<\M!Q9!B[%"D%`'4(VAEQWO6N^[;\V`JG(V]#<LT),-`.XX:JY%>_%<
ML%DA4B9P[KF+-Q0JQ7#-O&1ZJ"ARQ[#?8*)_?6/H%1@.TCNE,RY/G*T6\5[+
M5K<WI?A<Q@V62$.&`**0R6!#[Z][#J@2H/!THXT=M>/U`C<=4'^J;#_H3BXR
M^@-KZ@@:&OV`3]MNG(T93$?/9C[6Z'BJG3$(.\KI,SL'`C>Q\KQQ17K4N^XZ
M,+MU&NIJVOI94?UCMKR/O6[N;W?-6V/I1<RA>2B7X37+8O-8S3:YN[U;EH_Y
MR7;X@].0>6HXQ<89"8D22`$-?8VI(6:H/@1]*6C_GL?413*^FL?Z25_E^8?@
M`57Y>O/Y&3>#Z/@E`C("A038"6.UPAP)RN#!V)=03.QLXUTH>(_R&%^[Z]D:
MVU>-LW2_^')&G'->8^L@5=2$Y<%)5^-GH>\6($IV2/,N]+D/04Q'D6WQ4"SR
MU>+S:+;(20HR"0$PU$E@#8#:>4/J!/.`)X!L6@=1[TJQ^Q#(=!3\'P>[*O+S
MZ=NW8AX3@%:+C^6JYLX657BVK(95_#=1ED&!+9"0`P`TAU8:B@_X(VVZM;!/
M=IO%NYH0*04U_D0Y99]-89ITH"N#6@GKC<;2,0^D@%P>S$FJ=+>T1/9SDHPJ
MIO&GR'.3;PI3XPWT9,93Z3FAU@N&@'?0,G:('P37J].4X#^GQ"CBF<Y4>&XD
M3FE*O(&NS&OO#270(4B"UD"A$:RQ9]1URW`4/Z?&J&(:/<GN4J;8JYUMJ#K.
M/:1?\NHA('U&H,NM@A>QT_B^2O;?09YY593AN?6F57>AGK^4:2V"J!TEA@9I
M>^8P(EO14Z.#^=#8_C1Y76@O_+ZA4K2_[V4^;"^>2"AE#%P9S(CT-;:>='0H
M^ZX='4N?SM>8CB:!R2:=[2ZK?;HZ9,]Z0PK:A5$91(@:CRGVSCN,"=?[^X@"
M,-;02;9#'UE%RE3H#I%5<8;:Q@2>B^,R%&]#Y]HBBIV`R'-*><TG%E!,-WFL
M%^FUTXBKL'J_NC&Y+*WIJ<3PJM!J80TN1.Q1D^^2D-9?R\UL^?SO<7']6&[^
M)]\\+;O76K1=OIE!*C1WA,?:)(J-=VQ_L5;`ETC:[80K7<'M1"RQJ<CCA];W
MG41\63UKAP3'F`0G"<D09Q`8IR$&F/,`/Q6FEH16'2^]2%>`_-YG1A]"&CLJ
MD_AJ^%8T_+&.SL%Z4]R&#?<B+?_Y'_%/_PS""__X?U!+`P04````"`!@@FQ&
MTH,_=`C6``!=*0L`%0`<`&QX<G@M,C`Q-#$R,S%?;&%B+GAM;%54"0`#L_0!
M5;/T`55U>`L``00E#@``!#D!``#L76MOXT:6_;[`_H?:3@;SQ6[S_0B2&?`Y
MZX73;MB=21;!0J"ILDTT12HDU6W/K]^JXD.2+5ED/2AV1@&2[DA4W7O/+=YS
MZL'BCW]_6J3@"RS*),]^>B>_E]X!F,7Y/,D>?GKWR^VY<^M=7K[[^]_^\S]^
M_*_S\]_<FRO@Y_%J`;,*>`6,*C@'7Y/J$?PZA^5G<%_D"_!K7GQ.OD1GX#XO
M%K!(G\&O\"Y,4M1F>7[>-`7JOZ$//_^`_W,7E1`\E<D/9?P(%]%5'D<5\>FQ
MJI8_7%Q\_?KU_=-=D;[/BX<+19+4B^Y7>Z_`_W?>7G:./SJ7E7-5?O]4SM\!
M%'E6$ML]C+27/[VZ_JM*KI9MV[X@WW:7ELFN"U&S\L5O/U_=DCC/DZRLHBR&
M[Q`:`-1X%'D*;^`]P'_^<G.YUSW[`E]QD<$'G(>/L$CR^6T5%=55=`=3Y`=I
M[;&`][N;2(MBJP4,D8TAD@T,T7<'&JZ>E_"G=V6R6*8(GPN6`"@\KEY[*\P]
M`L,'&B_?PO5E@[P=_H1N:\C7Y==-\G:Z[FQ!-A?1AU\VR]MYOCZ+[1QY%:6<
M.\>K)O<[G>++KM#?FBMQ\V^486*]*:X;+<.G"F9S.*^+YU;;()G_]`[];98^
M%4^SV]5B$17/U_>WR4.6W"=QE%5.'.>KK$*L]#%/DSB!I7-75D445[-04Z5`
MTQ3;4%W5"DW#"VU?D6U?5SS9L^09,3&#V?DOMZU'Y"-Q)M\-`>IU#@I8YJLB
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M!]Y0O9H?<AM5>T1__WL)N]13,;!`1E-^N*/%5'3>!FJ$.H,=Z%U=!F$WR9HR
M+((W*PD%&`?K!Q$&K\S<PB^PP'-&M4TE<%4M]%3$_JKJV)(N.2ZRZ:B2*6FJ
MZO:I)%P,C5Y3SD#GX:`:PP?6'F/`,1%EK3O'!7/`F&Y,4.D&<<X"JW8`GY8P
MQA/D50[N("A@G"-E_R_T09(!&!49GA#'D^2@[)"/<0CO60=T!R#:-X+CA>P4
MAFS<8LD%=+V!\O&Z>H3%#K;195W3#3-4S="V-<<))%/'YCP?*5?5\X9H2%H;
M@HL^<0NPRTEJ"/MIRC'0&U;@*8`3(B_W(/.&QF3%<B)"DSF,G&\78QFR.MG\
M!J9XCA_;Q/]>9O&J*/"<OX\^EF>>JZF*%!B^;%FA*9FA+V'AZQJAZ1NVJE$/
M9]E-CRI+HVP.&G\;587_"UJ?L13`7K,,ACDD@V*@/&X>6,0L<PK$#[,/@MEW
M",XO*Q.IFJ*B>VOHSAM$BF%]M.5"N>E#17Q`5Z,10_R(+O21YDSS)1Z6H.+O
MZ+9OF:[GV%J@259@A,@Q3[9#Q7'-7@IP/&^.6HG+/77@#+31D)]LQ$,]`!:6
MS:%3#E-(),]2_F?((>U,QQ1RR30=DM_7LQL@V<C>'#E.ID"0N@7E$L;)?8*_
M06WB'Q1;W0'_',^=%)O)GJ]C)3,N60GYSI]0`M]KDD5T4B<W$R,\X+W3->-`
M+8+[_P$S6$3HEIH[\T62)7BMLDJ^P%F`7'%\U5?L0+)"1Y-4&<L2S])UV73M
M0!#[4_LS4?YOXB&_V(Y(''O0YY2[!A@EG>.H@&\KD\*4P"@9G8@6>-A(>;05
M[9'4P#[P^>@!YM1^>XJ`/61Z3<`);A&JX+;*8_)H"KI@@3MZ749,57<#V_4T
MU3#\4/9DQU608[XF28ICZI8@34#IS405`8GFG(0#-N,1QR*TV>2N!D9(Y#A:
MX-O)H3`=,$(N!:J`UWQ?@J@$Y49>XXVP1J;YW=CR(7G&O'U[%,\:,#W!<X&:
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M5$.SP];94/.D(;+H.!X*UE5M4'@8U88%FK@`"6S'Z/<,K(/#/UR'!^KXZE$U
M^)V$V+>`'KDG]--YT^\$`_GOJ/D7HCN%I.@-X7K<+C$1Y7MD$/(IW:4#F>\R
MB_,%O$7J"F*1U1Y:Y3PEY4Q6%-T+55T-@S!05<UT';4UZ7MZK\?R>-CYAEGH
M#-P]H^^6>5&!JR2#2'ZBB(>2$E.2^E'+6/D91A"U5Z!S"[1^'<112'%_`Z0W
M2C0/:"=2:+F$DO/O>7R*GI\OHB2;*6Z@&Z;K*[H:6+(2FKINMD952^ZU_LC'
MDN#"Q[_8;56Z.DA.M:YO;IBJG8"T<*MW!]$<L^+5S@RO>0,!GG;5&QI,O[I'
M!5'ORL='D>+[^Q*Y7<Y<UY)].=`U3_<-)S0"5>GF8Y"C@QZ:&]NW;ZRZ#JRC
MHV>Z7^6=<I('3E[L22=PB@)=5]=OI/XWK_L8/9./G:]1,3_;_AG9!/([H4X2
MVMBEGG-FWB"'8_6!B=#)T<+/IW$KBJ"L#WGV!985G),[JR3GN&Y^CUW]D%?_
M"ZMU$#-9MUPST$Q=LBQ=]<+`T)368<W6#>[D)<3+Z=!8%UY=W]!X@$2XH\RA
M(,$SK#:H3@2[B>D4''GNZ/UA&.,Q=06V3G`\QJ/)$2OW">T7WQ(+B@6"A@]'
M2,WQF;&F]S`OFH_P=?),,0U9\@)75B75-)'KNN6U4;B.P7^L-Y[KT^'0ZU6%
MWZ:!WUYR!GZ%R<,C*:+XC*X'B$HEGAS`N^K^B8`A9VF3>*?"GI0=Y\B4*K[/
M3(QGS]J)!;Q)?2/H/PO_[DSH,4B9K6?]V9F:$9VQZ)M'$OOMA46>+)(*SQ"5
M3H;\)N?FPVSKU/S`E7Q5-2PU"%U#\0+;4]W:KA'(FA_VV1#+PXZX\K?A'7E8
M:LL_RJVQ7)`=L#]V;(3I-LF^B33K]M@>$.S;(\L3O2ELE.4:3RZHFPT<?+QA
MVD_*.,W+50$_P:?*13!\GLEJJ/FJI&FR&>"=3&H@!:T7AJ4-V@O+V;1@\4]Y
MDXT">C_A?42\>3+'VE?P._86$'?'7F89!N8;HE505B8B.D5%EX_2M:D?/PA7
M%3+X,QKC+U:+&TSH:;-F6"(!>KV$^/"&[.$*(F%;;PQ=.^<[V"W?<63+=BQ+
M<34[:!6IK/H^W>,&(CT:<6-G'09HX@!U(.UZ;'V$?1<+J(.A?G)`:!+[E>SI
MY6_@XCI;ZIK-_^!X99Y+`GKM^Q\CP1,AA9&#WKNO?SS(^\T;D(/5O6B9($?(
M`W3.0P%AS6KM,,!V5-NU=54U`U7W--=UF]5YPS0=R>QU*AL/.^)J1OV^@,:]
M^O`4L':0<N*`"[0#)@[&AIANXH`#U/TF$7K`L6\2@2>24YA$X!I/+JC+#16^
MV-QCGB+<RN"/55(]?\@KN$MYNZ;C*:ZCJ:A(VJ;B*89MMPZH]L!G:;E9%2Q@
MW[[-ANI3?ECWU*!'@7F@SMSP\:^@]A(OF,&)S!;TQO`MJ<@]#U.1@_P#>RGY
M!$'73]9M;"0N?TVJQ]OGQ?(QSYXO$3Z76;P^%,'R3,?4C-#7#&3>,CU?]3U-
M,2S+T`SMT%M%N=H2=ZMN>@B^(A=!ZR/`3N+S\R@U'C><!^B\8^!->=(=)]S[
M";Z>N.P3?;QAG8+PXQY3+K`?#A2`5WE9;LVZU@^[>ZIFZK:A.9KM^*;GVI+:
M6?,M;]!4)J4)P=(.>_5R99OJP!):!/MIN!'`&\8"-+@)46:[D7E#AC%".1'-
MQ1I%SK5_L58;]_E#A*?RKN_7'S^3)\\M7W$5)P@=/W#MT+;\T.H\"`QKT(M)
M.9H=MRJAH1#QD^[4"IYH4U:K<8!FJF"],1ZGBNU%;$AE8X=]JM6.0V2'*B`O
M\"BK8F.]>0P]"&U%\R5=<21)<GTS<#2]-:EHTJ`]_RQV1JY[9]U-27>(!1.D
M-+5.')ILQ6T`D"/4MRV4>A<T.FPG6<$H0WFS9+'`0Z_<KKK'CDTK\-$_GA3J
MNFW+GJFY<F/1M12%3:GU-S/Z>)%5C0U`D%)]B0&/?;QX=;0S%O9#-$1>#<=U
MDL6(+I)#\HD6G'Y3\O^=I_C1/&*R2.Y6>";U4XXGRV:2K[JV9[J6+INV)GM:
MJ!B-.<\.';WW:XL8;`@N0JUG8-,U\"DG$\%#9MQ98.RQF#$2@L,JT23`&[!"
M,1*(E!M0,O`_*U3%9?T,H+;,LQ>+$AW85U<>B-L(X!Q\K^E@D:0IQK[*7_PJ
MR>H:B+^Y7V5S\AJ_&'F4Q%&Z]9K>_)Y\]['('XIH43*_N6<_V/M6.CBD9PJ+
M&SS"R/GVVB%\<`6?$M3V+;)*'C@L/^6M![/0="1?LD//<CQ54A39T*W67NA*
M:F]"8#$B6I;6K@'L6_V8<HE+6NO>D++&!&4/4A@+Q8'Z="(`#B"&L8#DQ0PM
MQ$E9KA`#X`>#2HSVJ_*_11KFF:%+9X:B@++."BKY257B%[8MT+7D'6Z8,.`3
M?M_V0_W"M^_E-;N0U[F2[]-5B5_FNESA5W.7$.1+0OW58U2!APA]TWJ(*:7`
M1SY@WZ+XCU520!"E:4LWL-Z?A/YOR_$S_&4![Y[QM?E7O`T>7XV?:X[0):BM
M`NYHC1MYO=$A]K$7CSXT!?KB$D?.^>:B(+`;&$/41^=>5#Z&*,3.IBY[EB)+
M@8O&3Z8LX6?>S=:F9?4[(XV+H9&(K/4/8`<!]I"E%M/#VI_01D&4CM2F`N9P
M<AL%U!/!?5L$MZ]3'"`YYKXT(:)CCV4'V7$":!#A?8R2>3=61'9GJF7(EFO8
MBNO(JJ;C;6UV:\NQO%[+"$P&1B(X[->Z$&#/*$KQ</3Z\YE0X.AX[$B8#:<M
MH=@QT%7Z#%0)TY4LK>D*-07Q&[.3#)-!!AS4^+SA+_SZ4?*&](\MIUS7G-(]
M_K)K*S+^99<F0H/)8I5640;S58E\@$^PB!-\BAJAA^VFUR33DDG+,QV/`/R;
M<A5EA+_P5U'C,XID47:\\[+A-N+E5C_Z7I:VN+2A;UD]4U3S3)?M#6+>(F7\
MBG%8)@\9K+_L6LRWL58P?>-SK<K[*&Y/ET=`1_,Y.<0J2L'WZIK/\?ERR,7Z
MA/+\+DT>2*91U*W_45JB3.$,$'&QB#Y#L%KBOVY.JR9;%IH&RS/P]3&)'U':
M$$&CQLJD)-.HNO27VJWG^M,Y>7@6-=,:+6IV*+&\Z+#'EZ=)#-$/<)***"N;
M$%<9GL"M;;5-H.R1(T%0=I)BCEPJD,@@.J3$C6%P<<>(TN1?2*O\)DNJ<E;_
MJ2):!3EY#&N)DK&(8KBJR&PP?G%[7I(H2[#(YZNT?@`==X`2=0M01<4#K/#[
MWJO''"$[+U8/(,9'.^+WP^/.].DQ*5%X2Y1CLKF>S#9CI4SZ2;6>!>(E8%Z6
MAP/"A;J:3$BPT,>P0Z@P`M+SA<AU20NCI/AGE*[@]3T^Q6[S=)*J?=A\%OBZ
M;(128'F!;%F*H=I6N]O"UP*UUXO7N1L5+&2ZDH^=!<1;<'T/L+_`V3STI^K.
MB!CT$F6>\/=0/<="?I@2:KS\%C`?\A;K(V%/IZ0N,\R0&:QYCL@?/%XG6J4F
MHAT#YRWIL:DX$$MCKCFKA_';Q(XX>T-'K;F<*`1\?;S.=\OOA,\@N,<=Y`OI
M((T:VO6C;:9OFP!?$5DB)?'>6.NBBK2!&9.HA(U8<9/X!_@@Y`71BGA^8+E,
MGS$-1V!9Y'?179(FU7-S=&Y2OUT+75/D$9('B,D1XY.KL_K399%@2_.DC/,5
M\A,Y"/<0]:8KQ+UUY,QT/:!?[J-P$5U["K0N)*Y<<$V@H/]G;+4QY#?=\09U
MLYD9>HKG*Y;L(-.&)/F&[+<V/=]2AE(^M:&Q:)Z03/OBI-9#@%VDH!AZ6/M3
M^2B(4M'W9,`<SM&C@'KBY3\A+V_]B"QB=-$W`?+BZWU]]`!',W?M"?$R>RP[
MN)@30,/X]Q7=;UE6I,#50TOR5#WT)2]$;-^N3/BAXMB#69C-W%A<_'J<QTXB
MC$`/X.7Q,*9DYPG"2\'4X\%\XNM_&[[>A10OVGZSPQXB;SZ]?4H4SBFB743.
M$RSJX?1E5N^LF\FF:SM2:,F:'[A(2]BZT@W?T4B^_P9M%B-'&4:C$EB[QSCJ
MZP\EW?!9"(H\AL[C`\@V9!8"Y&E#P&E#P&E#@.`-`8>SWW03ID[P<DID,]T"
M9D?:<C1@9F1P!9N2I&**X\",""4PU/+INNL9,R^T0]GS;4^S9/QPG6TZ5K?^
M81L!BX`:8.8H$FKM'Z,$&((GG8H2!"4/'744%-FDE"`T3V+J)*9.8DJPF.J1
MD/JI%3PA1OH3GM[;Z!TBQ-"ZH`R00Q15:**"B":2`Y*(&AS&):*?HR?\1J"9
M%ZBAIEM.Z#J68;FV+"E!:U2VPEXOJ^!CZ8@+0XV+7-8L>@/+LAHD`E-^"T%'
M@9/'ZH\(6$]BZ2263F))L%A:U#<NZEAD.0ZOQ#70O%B)$[<0U]2.P6MP0VO.
ME*01>S"]5M[H(&(42!]1W\9E^P'.[-!5/6+*\&7--=W`[&:K5-MPV372`&-'
ME$EK+[E0^Q"$6<22('#YZ:4CXLI#-0G"]R2<3L+I))P$"Z=E=^_6:=]$I&B/
MQ*FGF3"0=Y#_`[\]ZLI@4451DB:MJVCBZ26MJ($:IJYNX`/NL'GQ[.`]=U^Z
MEU#/5%/3G,`(O4#15,M5%2D(NWW1FMGKK0V<3(VEK-8>@M;%5@K0\#\#M@-4
MU3BP4FJJZ2!*H:?&0?:DIL2IJ1<Z2)JXO+JL#S>#7_`WKV1/L;Z7HO9>2NI?
M_)(E.*NW.+EEM]UY$16?855OJ49)BU+8"BSTZ_DJKE"3)4HDO@+S'?G1U3^0
MVNER@ZY,<G*4->E6^,JZ7X&K3G1]VA!=ZYW6:R45M9"4*R3%6M.[/#_#GZ8)
M7&T(P1?31+6CI*4]/JS[!1%&6]OGB29;+7#SKP^AP]4JCI;D33,!RDIRAP!S
MZGFKJ*H/@L8OEFL[Z8NCO#>C.T/(HC_K;?"U,&[D+;D*N]`BU4R,[0VX64+L
M\D`:V,[WKH[QTF'<./GI[KSEJPKKR_96VVZ?E`34598PKCH7FDCWJ=<F6UL"
M=1'-\3"!].E7'G-3JWNK]B&MRE[NIZ14.42S2Z?R`HE5I=[@^PMWW4V=+"N2
M&EBJ;?N.;'J>9H6=3O:5L/\QLWS-'E.]=OXR3F5Q2@"3K!6-/4>).S'8N6A?
MT?"?=/!)!Y]T\-%U\+8FC6%11>3\YB6R@##MCHG.XE6!;Z_H'N%!GGUMN_^>
M?MI,Q4;X>.63FAZFIM=SP47'+$WCN]QM^\@=[N'P2X+*D]!G7WN1Q7#YS<(X
MTY;B3)'UD^7LX#%/)'>&KY)%4LU"PW!<U70T29-<3_<\-%9HK`>VI/5_MQT_
MDT>=6%[?U,193O.A0T%GFVD6B#?/&>=I0,UG"EH@Y"<)?I+@)PE^DN#_YA)\
M9]_'>US*M=6V#Y#I[(/>O^@(C_AU-EF^]<!0LXNF7-V5\(\5K,_E>07=,!3*
M`3=!"]AKM%`VD[0>AQ1Y#.&\['Z\QRI\PI>U/61S/8`L`41X!TY]OW<M'83P
M\-`(]<RZ?V^ZN<?#Q:JL6C??&$&5Z[>Y8B2[-Q#E=0I181V<0I'K'-O2@&*]
M@U);3'NP11U5S_4/)M"&#;+63^MC54#LU6+2EP)-M6Q=L=!?+!F9]MS6J*^'
MPX\2I+8TUI!J\Q`=(I'6/M+(>WID!PR@1@&5<MPT&3PI1DFCX$HW./JT^]BY
MS7V:B#6>N_V;S4F`>+=IA%G[+LDZOB9?U(?WK8<&1*@VQ/37DAQ\5\!:?.+Z
ME,S;;:)(;RSR`A,\HJV-S;8M-6]M(Q7UQ/*^3!WB*N8,3XFBV(/9Q4R<(&)\
M..<R(^^T"0-5TT/-55Q;525;45170C8U.[!"[?^YN];>MI%D^U?X82ZP"WAG
M^'Y\[!=GO<A.!DD6]P+!0J`EVB9&$GU)*I/LK]]NOBPYDLQ^D>T`BXW'EEA5
MIXJGJOJ9Q/RGXHD*6G!3#F52WEO>I&&5V8VC`5%U.W&6`%/%%AP-H(HE(G0^
M"9T.KXTIJ1\2H4W/;L@\^K83=!AQ;R7@A-:D#"!MRZ0M!$(`2?)_,1PD%J<A
M2D/73V,<8.)@&SELKBGT_3"U(>'?/B`N:L$<4,@<\2D!KDP>T(*KNDRP%*0J
MLH$6:!?(!VJ;@HLP<:<$;GR-3@K\UDQ*"X(@22:&3V63;5<.=)`?H93$F+@A
MB;W(8[U(3`!)8)Q&\EEAFIP%4T*KH!+NF@BI3"Y0CZ:Z1#`[D"HR@'I`9Z#_
M=HRI89KKX_P6&&["YX/3:+;G-&42U8O`,XWG;Y_J?/^O)VK<*&R5>F%L(V"G
MQ$Z<&'J.A]I38&+/"TD8Q)/)7>3AFAF]5<GJ=1+9PBH$V`3JUHT5'U\O`Q,'
M,>N&2_@VH??KIKS+*[:(Q[^T@JJ?S>YN\$'EEEI5]D="O%@UU?GA]_:D"NLC
M^#@N!#A>XS%,)7RW,.!H.N'DK`JKH=]MJH*MW++RIGAJ;]?Y2W=0QE\O+R&X
ML5"VSS99*_$?V5.VOS";?^@#9UQ=T9[AT:XJ&>R3SD!G(N!2VI$)%A-RC93^
MI:*WAB>KH$?Z5N2WQQ?G#KF-%22W^_6PHNE=T5\GM?+M!`>1@X$-(H\=B.'C
M8=\A<1%T)F<='<)U9Z7]NLK9^JZ_;/+NI[^R4NWTWJ^3FN[&HM_YF1VATRT,
MVPZF\)"T%C=-R'5+>X@O%W;:ON(/8]W!D5.7=HOHS#S-/S1)[5XFH?4%O[&_
M37N7?K;.7`_X\IZZR]<#=HODV`)/^LEL.UZJ-RCQO5JCY.=5F'5=KHON)K[V
MOKV+-P5VWNN'^"@DX[-N^F^6^W.K0_OU@-W2W&'5*M4S[]<+'J^2K-LEIVP!
MZ[KI3@SK3P.X:?]0Y6N6!S>G*QG8D5?EMJT[-E:[5KQ[%)5=/O4G8<FOIA.(
MW4O5@L[7P(1J0JM]Y4Q\PE.-$/JR-M^H.#9H^B4'?V;5I@9W=5-EZV;E.([M
M8X)`ZMBQ"T%*(H*=V,4!0'&2H"D)34Z"OM35Z66-BEF=9M;G0;=_\^0G21PY
M,M%\>(KE'!E<I_'9500N,9<:V$S@*$66E,IC:B+O'.J_/639T^KC^C'?'+:,
M^=A<#;N68H/*'=L!TD8<J"K&D6U&A-^>/],W9ZV2G]@F@15.(0YQ0&(/!L2A
M+9L=)(."E"TGM4?S:Z5[?J8WI"W"F)K]I<3'QEC'UK#-!<<?'.8@6I.LSZU1
M4SEQ`1]?3T5FNY=SPFAFS[Y@Y=Z4UHS[K+YK;>GQ_86Q]2_YMJF'W[3\_3?;
M^5O/X,H=<8;PEW/VPOEA0</+I=\SSNSS.WVE?LMV.?A:U"N_G31RJ`S;#E'L
MH3")!AE1BB<MY15ZL.8<P'2QF#*T^J+J\+(W'T;3"%@;/'P<.AT9+>QWC,(5
M`A,"RQ`.$M.]5!`M@DR`RUU6[%=)8,=!#,($L:.G:;OMN_98[9)(B`LF/GH^
M-N@4$N6#J4CQ,8(&D(0YX55\M+)")WT"+W!"9A@S\&I_@1N$0)C,#ETE0K_3
M4E`2^P23U$\(1E$(7>"`8!"";'?2\9MB3];,#5TKP+01*Q4X89K&#/H0XB,&
M#G"T\,()#E=H00PO0UA!4/E21<CPCEP)MS3/ZNTW+_C+C6)(@L`'3D*HAG82
MA=Z@*_0@YAK$6D+!&1E*K'Q9QFT3QZ5,]YC0Y$H_P+1,-:4#TFN#34MZT!`.
M7Q:#ET-0RSMD<D8ANZ=M^2W/VWWMW4%6_\QW=WFU(@F!:1*C&(,41#'P:*\[
M"'0"=]+UC_)2-'/[H%A_+$=_DM?G3CE>FI?`<AI7SP,C)^$*(JB%>2\"=(4^
MY4$UA`,5&%*JCC?>^G98B82V65V_OV\%MP6U$WDPP;Z'XQ2"`#D^B?!(?PFR
MN8I482F:V:C5IYU<:]\EH7Y8`L*)!>,LZ/&1$"=P>JJ^2[A<*]VDL32$>Q08
M\K*(4@3-9.XYEM/77`"3V(E(X+@^CFT<^PX968YPED`"CY^9;<1Z6Q'8IA&-
M9L3D&&:9SO)[2*Z0BP1^AK"*C`6ELF#BY)$/K,MKB0JEMAT[T$W94EGLT$(I
M!.,"`COF&EB;_E3-K-$J(E::<"`SC2'T@,)'#-/PT,(&H_E72(`?(D/>?0'%
M2]GH$'G3^X8HC-B^/"_%24AB2BINZ*-1!()<I0+/<^=YV\5*`RY\.-YX#=`(
MO?/+U`!'$+SVWG,"9=*;SZOZN7=?R'QU<W&7!GG?%?O\EO8V]0HBZ,>1`T([
M!9X/28QM=]`L2#VB=.9-7AW-7#-E1?'5!<6J9^44.%#1'-R\ON,C0VFW69^9
M&59KAW%3=:\B+S,QI\ZMAE#WG!;S3KJI!EM_HNA&W.M?Z0>;^I;=-5>4F__-
MBX?')M^`+WF5/>3M'W'6Y.-^SA5)B1>$$)/0L],4NQ@DSF"&CWR^34F&Z6YZ
M"KKI)\#J&ZLSG6V[[HR_L0;SK=[^[B,60\!B$%@M!G-E,5W1I3GE&1!8,^='
MK3%E5E85<ZZ.%*PYS-YZOM8-CZKD/HL;9ZL$WA^:NF'GA>T??CNTO2T"/@Z2
MV'8@;7(=:&-B^^-<F`]FS?7\VKVA;'YDW(W5F3=SHA9P_CRI6*_?ETNV7"XW
M,H]^YQF-F5(\"GZ07"@!@.)L)^N*)?+9BYQ,^KM6?Z^*=;X*P\#QTQC8*`$^
M<?W8=\:96AO%D\Z^-4WGMYK[OFLX!K.MUN[EDJ)<!,V>*F<+'D,2J'#<F)Y9
MKSERGGRK))1^O"RL!A9]N5FAVQ8:B_ZU*NMZ!5-"7&BS59@1BFP[CL%87``(
MP7+CS=/T>T.9^/OQO];$18>,)P;!$L/"ZOUOTM#O*ZXW,F^>\<]LH[=\T?"#
MY$,I"+2.PHJX8X:-\E-&C$]3=4I[Z3!VHR0D$4#$(6DZ[LST/*)V#'9&O0W(
MB]</$.2;&-/;I\X93XI2J:&AI#[%+A%%AATLP.U2F:R\0&"]E6R]!#3*3B?0
M[3Z.;<+E^H_;NC[D&WRH:"O=J=)J71]M5JX';3:KT+&]U$D<!R`W#$+;=IUQ
M$;!+4KXDK5Z\`;EV*DD.1AWQ)/<69?7NFY@3E_7<<MTCE],T;8_FA?Y:"M+G
M1U,RB48+O]MIK1G,^;JV,<PG9:>0`!^Z3N@EQ$U]G[A!/![2YN&$:\^68:H;
MD$\F5]UGN,FX]DUQ8,W4P2T74PLV<6K#R<P^CLNQ.ELY/1%F2@XV%!W5#9U.
M)\XV,TF^/A7]O76#&:O`]2.<VDF"4X>JUU8IHZIAJ#;!:]#/@"P^G75'\\3[
MPB5"8)YY2=W>7[*SY'*\D;.29[RC<592)A;>2F;4"8'B64EY=\S9WWZGZ_5<
M;?M>D/H@MA/'3Y(04L/&542Q$\S<X:I5WH#LR-&4G&%)`[M<Q>$U6Y^[7&0M
MVNFJ#2I3>UTNY^KM=O7$V5O)ZHOAH[[CU>G(V7K>M*SN\Z(Y5,^M^\I/D._'
M.$(V26('0T+_'8?F$S>=L^<5T<^`K#Z5?X_,6ZSG%0J!>7I>W=Y?KN?E=+R1
M/>\9[VCL>65BX:UD1YT0*.YYY=TQ7\][1M>KN=H&KD<UCT$4D,1+_!`>K2BV
M7;6;1>=6WH#L.+D].<N2QO6\RL-KIIYWR<A:L.=5'51F]KR<SM79\^J*L[>2
MU1?#1W7/J]>1,\[SMDIF=]N\/]S"34,,70(B@OP$.+Z=Q.-B-.0D:-Y97E[M
M#,CHG"MKF'$+G8$DX/RYYG=U^GWQ=</37&YDG_N=9[3.[(I&P5O)AOH`4#ZK
M*^>*)?+9U70,7-N%;N"&(8*N8[/K]\9E5R$(N"Z`-T7GMYK[S#H#25D$S9XJ
M9PL>0Q+H&^M2U3ARGGRK))1^O"RL!A9]N5FAV^;.V,]M]*>RR;:W^Z8J]G6Q
M[DX0]@+7CPF`.$F2%``0`R<=+\C%MK]`NI93^.WEZM,1PM9F:S1ZD;/VU43.
MK&EZOJ!9/$>?QLOD2#$Y-U_UGO[$K"9X?JRLK`@3/2E9I</X\O'=Z[K?7=#]
M\I&*'W)V01_]/2JI)=FZ.63;3WFU<U=!&,<D11$A:43+"COQO'%P.PX3_IO7
M#-/_#67KZZ?$CA!81QA8#`21W&V8EWA2N6&JOXW,KCZV]&7[>1W\6O(W--Q,
MJ@5,A>A<:6"JKO-6"I<''BZ9XJQP@!&(2!"`,$BP%X9>.FX%@ZEMSUDIZ-#_
M#54*U\=2C:D4M$39/)7"T@&V^!B`PM@RLE(0<+#&2D%GN/T@E8)6B!17"OK=
MN<3-1"\&0=S$#^C_?(*CQ$WH3W8`Q]OD;1PM=!<1IY9O*.N?]'#+CM]+1,4\
M@_;S!(0A_?S;'J&_Z"J-P_+RX6%25ET6"'WW`DFY9HE>^E1A9P4Q000FL6?'
M#J1J!\09NW\G\O@79"^CYAO*D2?=BX(<N5!<S-[DZ@P)0WI9`[*D%E_-TY:*
M!HA)>7)A)/0UF7+.>353;K]67U>HW-*?R^ZP$+#?O"O65.<</%1YM^L*W-5M
M1[OR09(FD1]&"!)`0MK.PN?UY<A][3`DQ=+T,=6)CA8M6:Q>2^M93>OSH.B_
M)Z8?U6!ORO6!?:5]E(F@GR@X/_@OV)X!T7*XX_8,S@?-&3;6A.W"S*K+JE)K
M0'+V!D<*?,F/J!D7]7I;UH<J_Y1_;2#%XX\5@0A0NHW2!,$H<"+;A_%(NA!X
M/,6^2KF:J_<I+R)GY:T4]6FE]%*`"V><+_E)0?RLI_69:6JUJDZG/35%+@>*
M5ZI6';XPI`S58EJI/Y1Y"D50UWE3_SW?;N[+ZF.VS4>23CQ*SC[PW#"*4M]/
M'8)<['D00%JI>BF>4AB*/UW?:]GI9#&E+*J5Q=02+/PDP.,H].8!4:RP$P9S
M6B%WT?1+A9L\5B84:@JL*)4&$`^C?,C7K/==K\O#OF'7,E7EGOZX?E$#AFF(
M<!(GH0-A2H+`\6T/NVX00-=)HB"90B^*1.GCFDY!ZUE#ZU1%0=Y1!3$'"2T`
MM1@C*8%\&CM-P^0252E&U`3>4FU2J2\`>1CM=K\N=_FG[&O^+`<@Z,41\&P<
M)$[@V\1+J+@P\:,4QCYZ[69'X>?JXZI.&ZM51Y"7A(#B("'=@(DQ#C=PT]CE
MC+&7J$0&%Q-X0TK_4E&`<`XVI3E%A.TUZR7^5C;TG[MMOB(@"(,PC6%D0QA!
M@EUBCP(!YAI:$I>B>2"I5\QZ#GZ+Z69];K6;RAH*P)PV8C0/CGR$*PRAEM&@
MBPA=&?N11]60D1X%AI2J`XZ3C]AD8C?ROMV6?V;4;/@-Y_=Y5>4;*K_M`<'7
MHE[9:83<R"4$QDX0T>[/IQH,\F/"=;N<,J&:V6K4TQH59:L2!E7;=Z]5EN9O
MJBXO?:G#?AJ;+0(['[FI0UP+VTU%\`KY*7>"(5RHWJY2<_1R,N5+6;ADJ_Q7
M=@0P\B/H^<!#=HP<!(-!6F0'7+PH*$(S"YY[^3K->`E/%,)I]#8#>GQD)@2<
M%MXZ#\T5EI+$TA!.DK6B5!I@$_EFDQ<KW(\HW.[ORVK7LMZ[8I_?-OFN7N$$
M$XP!C)#C4Z$N]E`XR$M<%ZZ^Y-5=^1KG2(OA>6^.-9)X?>I^Z4%V5VR+ILBG
MKCF0A_0Z`\V*)2<']6I91WI9GYEF5JN:&!/5^?KGA_+++]3PCH3H#R^YYS50
MSK"/,AP7YA]U=I2*`TRRYJG?/^5LS<'^X5U9URBKJF]4&;9>M5YY-H'0@VF`
M<1A[,/8#@@85'.)P[8-0*7?VZHCMW!K4M9B^UHG"DC63E`O$"JFYT)>MKH2!
MGZ7FNH(B1R&FPA>&5F=*3'NE9%,'GSB'TA\0_>^B.1'_(:]S^LS'E9-X@>]'
MF"38)[;K`<\;)AX0B&.N>0#5LI?@4O9SI_/IZWQC#6K+,JJL0P19=49?*&!6
M&3?,PZ_7\>3A6$6>,95G59GW&M<JA5&<;V_WOU?E.J]'R6"_P?F7?%L^L7IZ
MY;H^<AT21Z[K`FC'3AH.XX4H2@#7%8K*A2_!N+=[JU=Z?+?;QOM(;UG*E?:)
M(.?.Z0X%I%O(>&(>UGT%41[:5>4<4WE7F7VO$:]:(*4JW>%WY"O;_9J?[(+=
M;V"^S^^+ICY_G@0JZV:5!$&0.#9R$?%\$MMA&B:#KEXH7PYK5W"IFGG\0V_9
MS>E.>T8C@W4WUL4-^<Q$!?6U_C`0+\*-B@!%E?H<SI^MJI=U$&?I/UL\F)JG
M9L5@0A,QLT/$\]WPBV[YULI-8L]/0^("W[-!Y`>>,XIU?9?K,%U964MDH?&7
MG8ZR:8077<&,H!%8!>0^&=-YV/D4+!ZB%8395,X4-><U^I."26*>KWG,JQ7"
M(7#]!(41)&D(XP3:SCA"@PC7O2&"(A:9O6.:24_334-0=$9..7@J)M^NXS;3
M+!M3@FM"C0M*4_F'TXI7I\D$0!%GFU^KLJY780!#/XYMFQ*<3WG.\X)Q5,)'
M,5PU[)8F0;:9)H*+;49MY-Z:5C-9MIF(H"#;J`=/`=N\@ML\;-,JP<,V?%":
MRC:<5KS&-B*@3-N#>R1J6#;X[4.^S1KZJQ*L__]0U`5K$]_??_RV>WHL]]]N
M*2:K%"8)<6+H`1H'A/@H07`<((73"A^=\N>LBD:]K5YQJRFM(]6M\MX:E+>8
M]CQ;?W7YYSK1F>(:"19\DU[AV+-M@'?$MG6_WUO_.&R_69Y]8]$L0O__7?ZU
MH+I9]%$Y<U^QIZ[*]A:@#]_0_V:#L1_RNFF]^#M][&-6Y_WYML_GJUE_%LWC
MJ4O;;_Z]W+)CM+NET76Q.VR;;)^7AYKJD/?W7-+@>,Q?/OJ&_;+*[[Y959XQ
M0"NV;*[]8%4^5-FN_MEBWZD/&95.569_RGJ=J26[FL78V0</%C]EQ9&"/SFV
MM2NVVV$`NJCK`WV4X]VX7G03.(E5LR&\]K&TV=W1C]5-N?Z#R=[D=?&PS[L_
MCD\L3[%VV7PI&_:K[[/U\!)0H+/-IHV5;&O]Y`6C#FS`FZK8G2I<WFV+A];3
MU.I!_VQ;4T\Q#[2OUR[[([<.3^S'G_SGYQ0G$OH'T@+ES\=B_4C=MMU2<_9U
M43=,G\#^GTZM;]UO-WE_JMX@M,K7>?&%6OITA#W[^+8]<J]U4I7MZ][$`_5'
MU<L:'D&]QXXLR:AWBFI#5:HH3U3LCI*:/8R!RP(CVQ;_R:UW_^?8GGO3_>O1
M8L(J66!83]09NVR='YIBG3$3=D]E]\[5UJ[<'+;=.DL6`#4-"ZO)JH>\L3(J
MXK&DR&ZJPX.U9H>\;VADLV#Z]%C4U+PGZN/V2!7VU<U`:@TEM>U(:E4^/+Z+
M._;78O=$;6;@W1\:=@A>MBNKIOA/!Q_5F^I7%W?;O/UD477GMF1U75)3V;O5
MOD'T[:.O:_NQK-]3T`;_\/>3-VQP(@U+:U\V5-O-@<+.OLR.K6):42]1N=0^
MV8,;Q!CO3.TY!W^:</R#;A/+^=*18`,];A,_VA*SPH305MV.@1.Y<12GP'?!
M()-XB2O21@L)FK.9/M)+KJ,6@Y2OK]:.IH*Z<@J06EOL<R!-:+2EL#6LW9:S
MY4+3K0`@\8&^[_=PKV(8QR&)J=@DA<A-TOAY+5*20"PUQR`@;XD)AS.G'L@.
M"(H@+3@ZJ!ED!4.%7/C.,W#X/6@\HX@2D!O&<4I,>FU\41HN$<8[YE<_C=PT
M35P<Q2Z.'2]%031("V'D"I(<CX@EA@S;(N*W7&(!(1>(W/RE"S]5]==5Z'3S
M%%_=)8BF>6PD9,5E`A('93+GL+'#ZK!N#FP`#^PW?5\*UDWQI15\[E!X#-P4
M^9"XB1L%7F`[-DPQ]A$.(AR3U.=A)"T*:.:K$YW[(=AN'/U9;?X+%V;TSS2R
M6]PU?%2HQRM:F%($V2L\JM51AK"L7AO+&2.?9PHZS8JJO;+MGWG&I)T>/!T3
MVTY0DH+42=B&'`_Y:7<Y!X;TYTDSF7(2]+W-3*_N'D;K6#/!4Z(E<>28>YP/
M3[$I1AE<I\U%7$7@TI2#&MA,F%E09$FI/*9X#YL>A#YS7?U,=I[M.9Z';<?U
M"4X1"8`#!Z&1$_(=."TE27.M=^%]X3UL6@[,:?7:?#@*4_F19DO67U>1NE)H
MJ4'8D(I*D3$O#Z%6"-'4>V?W=;EM%PIL/K*%,.T+^OZ^/ZV'_G6DRC3TD(N@
MGQ`4@C"(W-CW,(Q30!P7N=%K)P.H%J?OE3M6TGK6DJU_>-93^.I9=7ASW3V[
M".ZBE\^JPG_J[;-3P;E4@&F`UX1J3(=9I=ZHY*S31JG=4?\.MC&.(@+#($GM
M%%&IT2#%\<*(IS#C?+3F2FS41O#"#UZ@IA5=&C'BHWP.>+345*=`7"FB!!$S
MI&H2U;Y4$C:BW/!QG>^SJBC;,^XC=E1A2*(P<!'Q<>1'@3L(\WV;:_A>3,)<
M3'%C#6J)7;(AB!\G<VB#CI-`ID*EESZ.T9C"(D+HF48F8D9<XA0)2*932R_C
M7_OZ*?\O>=>V'#>.9'^%#S.Q/1&:61($07+?`!+H=83'<K3=NP\3&Q7E$F4Q
M1BIJZ^)N]=</P%N5I*H2KB3L>>BPK;:9F2?)<Q*WQ*J^K:N;OJ5]GH2DP"G%
M,<DYGT4X0Z-!0A!3HA=M*ZXIIG?L*CAR3?=J"P,L):EF$ACUZ$8503?L<PZ@
M2PQD#*HO+&0>R$LFL@2->J'S_M#5OJ0DH3'(P[3@`ZV49&DR6$($*;64UWC\
M=(.A]S+W,5A#3;&V<0.8]LA("BNW]<W["W=86(#/%TXQB.!<6:,+AL)FJ&_5
M>G]TCRL`*.,#L0(3A%`$:<I*--JAN5)W7^6'.]_$U/GS7\H[DE1!DJ,,I_BH
M$<;@BLX$K:T-0L_!N+CY1Q,W3YA"W_]7FW:,@)!FB:)9M\_?]@87),0@8TE>
M,@+YZ(K&!1PG;R!&2O,IR@]WS!)%<\_=:\1<]K>J.\ZLL_ZMCID<:3B%2WG)
MK7,EZ'V9F#)>0G&!,K11\X0R]/UO++T^BI3QOCU]7XUF,*9)3#/^]*PLLA2'
M)(*]F3@E4*DWGNJS70],]E^VJTW].+8*[CH/5,%M)7WEGC9L<J3A$C$USA@\
MF8DR7@!Q@3%T(?.$,+3=;^R\.9KCD$6"8`D02.*48LY*41H6PVQ)#%F1J1S'
MEWZH$D&H'[W_+/Y)L.F]T1Q\O(V,VJ##*BAZ@XV91A@2(PMI<#SYVM7]/C.2
M4`Q<^OL>[Y'KFY(?ABPI3K(XBD),<Y0`E(8Y)(/!J$B5=F_H6W%<(ASN6:QZ
MSU3G(`P`E..%:;!3(XH#;(-3\\U/G,7G`IV88^H)OU@(I+']NJD?^SQQMT]O
M?<%*F..(US:@@(S0F)3Y,+T:DR)7:JMA9LGY'.C1O5@W!_?$Y5FK^[UH%->U
MD>LO.%D=7W#2W`9_@E<A"*_$KW&*VJ?\*;Y":7S%"QRQ]"5F3>Z?U,]\FB1'
MMO*9*B^JY=#IJ\H&TIO^I.9YF"[63C;@]83P+`7S^I"E-8BDB>_G:LVI]I[;
MQ#</];H6-"L^TL%L!K(H1VD)LH3&.2UP2NA@-F8%5J$^4UN.R:]WK_W0EL\<
ME*:_^"I$T57[*TPZ^@-7&0!&]&><(CD"G#([:A1XG)CGOLU$@F]`=8$&;8'L
M"1%:"Z=Q\RXJDF';X.C=V.^TN!-=6+<+5A1Q2"BW4-*<(LP'NEE)<%HRRG*`
ME&:G-4TXIKZ#0\%]LVU[`7_9UUUC8$6VTL50CJ0F@$^-FUJ'@B/\>I<F9J33
MN%P@(D,@/>$?TR@:JV^7Z:S7`B6(T1"0D+$L1(2$21P-M,:-*76;57_Z)//<
MS:NY+M.IKK=1TYSBL@J8Z=36W/-9*O-8TL!YPB(&`;PU;Z4(A3IW=!UHWXLK
M7Q($"A!C@#.2`!HSG(YGIF)N-=1B#X7G.^8/X4,@DC=P2+/6Y@X5U!39PQ%@
MNOS1N1/\)!SZRUPD<L!$AD8T$/2-2'1".$<EVG!(D\F[]BZ5[3C5!`F*2YB+
MZ^NSD.(X@03W9F#;H7U=?6V;]<L/>U1-2'T:>?=IO/)&?MC3>S74(HITHHR;
M')4XP4J+1D9\YIEF>0'$!>[0A<P3WM!VO['SYJ@6'^)*FP_-NGE.48/5`N59
M26&6L!"@B!L&V;!)`(*0*/5G-C3E>MID^#[$S&1WT4_=^G<5K)4;-9NB*EFG
M3`>H8LG2PG?LV5B[],Y-7KY<A.I2)6,'8T_(R58T+^L;FR`IE#I#,<5XH&*[
M<[W><^.']C2DNFTVU7BQ1[6EO^\V2XYRO5YNGMKC5MSKE=@HW=S?MWYW)+`(
M61ZE29DQQ+(D+%""RZ&?#<0E@"KCKSG]=#R.>]8*BM-D-^/\I0U'7`*F/",T
M:TYE2[KO(YVJY>'1V+(;FA]".^[KU2>W__MM>%?!LP"[,ZA7P?,8@R'(R0M/
M9^FZ6,3._Y)XHCE>0/&JN/;`)QVUXZ[TJDJJ=75;[Q:H("$L(8,9*=*"_P&1
M45QA6%*M`;Z>J:D&^BWSB"LFOW2.:6F,!I(J^N`(/1-N%[>H]#X%/_5>35V'
MGP'G32;5A],K%C0(XR2#F<(BS3X?JMW1W&4:):C,RC2C&*",HC#)T[&@SZG2
MT1VU)\]1SRK2BR)4<J3B#B4U*OD@-D@\*Q7Q;K>IO^QWHM6?N)3XXW)3K:<N
M\I[!<X%,]&#TA$(TG6]LO$F*=$&7F[78;_2QVGP25Y>3Y;9>B;VP]?V>?UJ+
M@@$,,ERD,$&L*+(\&7?^0T!SI6E%4UN.YQ5/#Y%YG3E>Y2Z<OA*7KM>K;J]^
MY[@B[1A#+D=$4Z*M1DV#9P%W+?C4@4I&4,NW0'7"2V^@=8&I;.'L"7=9"Z=Q
M\SHJ\MO_5O77.W%ITC<^7OQ:?=@_?*DVU[>M"]?[W7;'7SGNUDMO<D!CT;(%
M8I1E(:2H+(8-)#""2:A">XY<<,R&K7O;8"]VW-?K=M/]OET?6$U$DZXR)\>>
M'B1-C50'AX/>XZ!S61R0Z%-YY/;\?*N'[P4:=IPP3]C9=93-I%^!S@IXP8EH
M4]WQD73]K3K4Q[Q8OK[E@VPN+W4C;HC?5,MM55;=K^-!UCC+:$D3D&`0QBR'
M-(K'07=>1.JKY&[=<<SQW>KOZCB$X.N2L_U/@M/_HGP>?H+\**RW^Y,:G37Y
M9]X_'\FWMRH+8A?SA/,=OC?&^*W%_&D2Z`FS3QGQJ4T!4X)MS/B_KKGY^_J/
MZN:_F_:\U,^<M82[U^M/U6J_:6]'Q9MZR_]7V5Z?VOD_1+/`J,`P"S.2I&E<
MAF6"LGP<;>`\MZ$#SIUTK`X'_X]%09Q2J]??JNU.IP/C?`DU$PZO<FE=3HXR
MW8<7_-QF_/V0\4.001]ET(49='$>2Y(G.F2:,@UUFNPM\5RSIL-!4LDF3HQ"
M$]]7KHXF0UJ2G+87%.0Y!GF6C*>M(<(H4NOGJV_'^:S[,3%IK.(982BG"E/!
MIT;LDB.$*S\6_BY@>(%I;2#O"5E:">55YV!;\$A3UN%"W>O;XJ@3RR_5O9@1
M+IKM;CM,\%<W'Y=/;9EXN'N7E`C#**(%"D.4AWF:)T5[]RY*TX(E2FT=7/OB
MF/KH_^_KW9/X<KE;XAO&ORTW-ZK\YSPA<ASI4R[4>/3@N6#,8]^#WOF@]?ZJ
MFTCONQ`-$<QY@;@AYA=X=ZIL>L+-DX7;S//1J-YC57]=U[?U:KG>X=6JV8M-
MMU\_-O?UJCZ^1IV5<4KC#`+&<L#"$A-$.^LDB1!3:M!HR:3K1=']PX/8-R\6
MU0X.!P>/@\%EU3NP+"$NQ]4S@*U&R6^`.R?GRF%W@5HM@^\)@]J.ZN7M6RY`
M>Y,/V[O5/XG6@]?M31+T]VJSJK?5QTV]JK#8RB(JM^O;_UG>[SL&?VC6[=]?
M`%CF91:*J]9+!G(H+E5N/4DH`9A)M=!V:-XU3PHG@L[K8'`[:/T.ENV^+^&Y
MH-'6][[N$IM'VG\I29XNTW.92#W)C"*I?O=)N6E6>U$!M362[\EYYJQTD@Z#
M0;$W9]VLM_P!>T[M3UT/U*!Y[$[WW2W;OQ-40R(?VT3RI$5A^&=.^,%#TXUH
M=G=5<+NL^0^6FW]6N^#;D-UAOU;WW'7[%\6V+O'_OFXXU?Y-6EL%YJUB1J#7
M2_TLG-#."5(ZLXY.$6$SV?>AHJ^_5-L=M\R'.ZV-C_S#N%M*><-2"L(4DX2B
M(F<A2)(<#-X@D!)IC77G@F.=/3C><70PN.Z&UAVF2D)O_<B2FN;^.`E2T%X_
M$J6GOY^Y!CX..1HE=7-(8Z>6RW:FEBOJ$]?H7?"E"NZK[98K*%?D+/FS^#>O
M)-=83;5Q/:>H[A/E@ZI.$&4SZ=NOHJYM_]=N`_CGN^7N[\LG4KW;;O?53;?Z
M,-:;'_EGL,`Y3K.R+"(`8I)C1`H,1P]@@J05U:Y9QRK:]<CM=\D+=P/NK_BF
M.X^O@E<+-<)K%5ZVG`4)L9PO`6H"^=UAKZ"#\^5`7_O:H]C!>CP[LNTR\W*T
MN!.9>N@R5;<A"=7<[L6$[:YY+I+[-6?W=G!Y,I?&LJ@$\SDI=),K'^3/462-
M\Q==1>;>UP_U[GI]TH=V4QC_V?IHS+N]WGQ:;K:GW"MIDH4`%"#DP]N"A"`C
M='`/<VF6UL`)?7(LD&TDP?7Z%4^3@:>#;I>IB"@XGF?<BHFH3_B7K04BGS+'
M$@KK:7K5Y/??+[,*^NUIAO7$_=?+*GS%Q['=C'$[AMW=U=M@^2`6VHZJ@/."
MWTM]UXVU?<+SV6HQF=T7!8^/FVI5=_MK-N)XX=:X`K"7J'/EP0RO@@^UPQQA
M-_-^@2I5QV#T<!+VE.4XSR(*0%C$O-S)\CA"23I8#O,,2A<4=LPYKA4&=7AV
MVMQ8(2PA+2'KTX.LIMA>XZL@KM/CK*>;`]Y<Y,9YX6%0?/#=^2!7"JYSZF47
M:Q^$R7)$C;,7TV`E]-=UO7O+C10784)B!A)6T+S`E*9AYP;#&8ZESK&ZLCWU
MVF?KLV5>=)$2]:7.J;-AN,;YO21"?TESZH3H2==18KJQU[Y-S)2RI8Z;Y%JE
MS0SX(&@NP[NP.FD?1N5-M=MA_]')R6)&<H+#!!8XHR2*LA3G=#`>%Y'\'A]K
M%B?<.KL=MVG:6`BSA[F$@LT"MYIN?0](Z^UXG0YQ/6'J)YO[><3]8[_W=-S*
M*F8<GTT?NI8I6>PDMJ;:P=X'2;(?U)D-J#8ADY2?]@7LYA$_]M/8GYM3VGC*
M(Y"$.2P`ABR$>5J4`*-1$-,0RT_HN77#M5!U'W&_2O3Q:#'@](#`!J^Z39N,
MK'F3,46M^^&2I:*,WB3-AEP>+[N]VI?:C?"<RZ4)H&<U=)(L>2&LTT3:3/X)
MF$MPZP=IUOMMUPOCE#>((`((9(!E61P!A@K&!F_"C,2&\FO#A=FDMZ/PUON^
MFX@S)K>2*FW)G3I+MN3V>TN0L<Q.G2C;$MOIZI<V8<,NE\W9`R'S**\$QFJJ
M:S-I_BJNU2C?5EO[H,HI;5EOJA7'?ON.VUG>=V/NG\7YW@6.&(*$/QN`@J2D
M*$L`Q[$U8/++AP8V'&OEZ%G0N38<@&^=4R%9$Q@E9&XB!-5TS`OP%"1H(A!-
M=V!^:-9_I0^/]\U3506CS_]Q?F?F^J_5\-=OQI3P7ZNN44!0\\I=I*>;+SVY
M5^7Y`0YC(3J/]#FEL9`;'Z3$1AB-W5=62PSP>KU_;BXL6<)BBN,DQA%*&:$$
MC^M\*98?5QG8F$P,.M?,^4P#1A4Q<(N@KAC,")Z.&+@%T3LQ6';9F4$+7@']
MIA;HI\8K+3`(XZ06F,*BI04O9@/;04I[2GT!8,[*@HDFPFD>HP3Q7P;C,)2[
M+<.NQ:EUXM4J2>MKU[##@/H,(%=7D6G0-M04_X#65YQI`/=5?TY/D0T-R=X\
M87ZW_"8V*"Z#;;4[U;[L1+NR8-.(^;>;X*;YK16^UE`E'K\+?KOC8'7&>N.V
M=>]LNB55T/QU\5`3+01U02%M06;:2X5_0\,G-'IX:GHOHFF14XAA6H(DA0R&
MH!A'="G%%OJKV'+%L<*>[OM!#GT_3M.2RW8@UI(H(<U^Y4]-LW_DU%GI[C)'
M"CWM^*+R*CAL!".9D7-"/5VJ?5#P":.5:R+C!F3=(]ZRWN`PICD,RZAD(`NS
M*.&>#=[@+);O`.[.!<<:?_*HLBMQ<)@H"3WW(T=J.OZCI,?HT/D<:9KH(/JD
MVJN-[#G-=9\J'[1V@B@OGVUW`ZK!(4!IA^*($J[W(0E+/L`'C(71X!!%<6%V
M,-"6%ZXW@IX[PN:*QMVF3$)HO<F6FM;^8(DR/98X1\(F/ZHXJ?Z:P'QV;^@4
MJ?-!A:<)],W3CVZ@M7@BLMNW*NMFDN89PJ1@,$9)6(:(HG$*/H_2S.XQ2;N^
MS7:`X_3ZY]:A4,R0>!F=]SOGBNK_[YUNVT<UYTN[\_.;\TZ@VT=?[=C))'GV
MHN"8,7SE8Z$NTR!_)?%X"_+Q/<EXL^$?6B4^2?+TZJ+DUO$/[<+6]6T7*M[O
M[II-_4=ULX",EBQ/\I#"DM(XA7$V[JX&"$G-S\_GW10%2G_3^;,;T8]B"KX\
MG;H1O9,PKF#CBF+/?X?H5"]'GC[WERN4[R/M&C7*#!EW<TFS[<2<T+'Y7P)?
MKGZ>#X"7MT3/G(K)U>S;LN:/O:]8L^FVB8.B0!E.TSB$"<L+6L;QN`0>9:%4
MN[S9G?P>M6T(,KAM-DHG8F9'>V*M<_HV>"!Y*B^"U]KW,E$32*#VN_&#*:$^
M#HX$T3`Q<E/0'S?-8[79/>%UVP?PL77F"Q^*+E?<8,A@&A8LI458Y&6:Q[#O
MMPX9'VI*;;HU,N".A@:WVDMR1L>"?PRN_9_*_)X9B`HS=9.!J3?G9@"JW%S9
MI?C/S7I9P<R'^2L[@32V7R?5*GQU5]WL[ZOKV\&ZF,':';OP6;#>`D"$6)9%
M99)'N("D9"$>[%.,I$[&6S?JNDKN_12US>#I53O-O'OY3;7^RK*4??`EZ]<Y
M<-<3`DV8W523DK!=J@YM(^]+M6<]KI?5FQO@I/GQK%7R])D_"?]>;Q<9)F%:
MI(AD$>3_A812-)C.621U6ZI->XY9\>(G>A4(-WF-P1U5I4,K6,LQX=0P6R1!
M282=,*$$;!=(T";HGO"?U9`:=^^H+=83ALOF85FO%T6>,1J'?*2;)Q#B$I4`
M#*9YF1I:83T%>SZP7N>J-=Y30=N0]QP![8#WWL1X6N8[`*?#?!JP^\Y\.B')
M,I\V7-+,)^8(]YP>1I-_K\0L("\OXR+BE65,0XQS$&4)(>/P.X=*;*=KPS'#
M#6YU-U5_:FYWORTWL@UGC/&3XZ\IH%/CK,&CXU%JY]34%'4&FPNT9(JF)U1D
M'$9C]R53I!RVWZSKW7Y3<:9C]>_B=]O!(DLXJ9$H2XN2DAS@/"I'BUFJ-.EF
M8,8Q\8R>M<0S^*9(/"8HRG'/1`"JT<]I[.:BH/,076`A"[AZ0D0V(FFLOW2*
M=/2*]=(T@2DNH@2`/(,0%,G(>J0H2A4.4GVV8^+A?[O9B%?FZ:#>BK2CC)8<
MU[@$2HU@9B]KY,L97=`\80]M]QL[[XXB3[ROEMOJKKF_V7)J&O_P[N%QTWQK
M]U4,/!4!B/(,%RBF!-$HPV42#O8131,5`K%FU#6S#*X%Q[XI<HL]A.5(9Q9P
MU=CHX&);[YR&>2ZFDL7O`H593X$GW&8_KL;QNZO(AF1?WXM>(MSZ\-L3QO.$
M$92F")=Q%(4D3O(P&XP#F#`5*K1CT3$/#IZI4I\E..5X;WHDU4AO<*JEO/$/
M/C">%'(7Z,XN\IYPG>6@&I<OJVK-Q]_`W@+F%24H(8D*0%&>D[@`X\ICB>6N
MS=)XK/,1X5KU9)X*)I)UF!LX%"LM039S%5(C`)=*)764/"$('<]?ECNZP9MO
M`7A?KZMWN^IANP@9Y./*,$X99YFP9"D^6$Y+)M7)VZ*Y.3<`V%KQ5P#7<,'?
M#:X6U_N#?P@7@]9';U;[1]1T%OO5(?>$L&Q&)+O4KPN6.<']O&FVVP5(*,B2
M,H8T+_($%2S,#_M)8Z9TBM30U+P[FUH?;?&;)+:&W&8?5HN\]B:BTS):ZXP.
MFZF![#N3*48CRV(Z($DS&%ZM]@_[^^6NNBFKQTVUJMOS8?SW]U5[QG%]@Q^:
MS:[^H_WY62<7,804E!$H<%XD#!&&T+B2B(H2+];55V%%CNTF<TOJ`\Z[#_@X
M`NGO^"B2X#B4JV`,IOVVC\.Y>GE2Z,JH4IPNQW*<ZU=RM=AYVJPZ87-;6;C`
M^Y,GVA.%F#[N9N8OS%;=_*':+6`**%>TA-(DBLN<$`+&>4?$B_C%MVKSI3&N
MFV5,J1#(L5>VJCSNHZVJ60I9PYK9-J16*^:+6$Y;+W-7=*IE%7@]84([L<A6
MRNH`F7::&D[6HS)D.4Y3B'`*P[",R[+O;Q6SM`"RJXB&5MQ]6V=;_&@T@G#:
MGN=\YPC+&'OR@=F*1J[AC1Y(&HTD3G?3.>[V+JXG[9S:;O</W<_:4]R?J]]W
MA$/TST44L22E&!-(293!$))AR!RS",1*RXL3N^9XNNZX*<6%KES/;MNX"L:X
M@J/`M-M53)-B2=[U-[N*/&TOL7VCC$"$%;1QS=<SPT96+DG"/.GW14)FBOYL
MEXX9DB#76:VLZE$""\('Q@6(<E:$%(`LA@#1)(M#2D(2O[E?5OEY[CBCI.\T
MFZ0IX:'0$\T5+GHMT&3QD;SL_A#;"4;2#M^';F9:?C>&>9?\?F^J>E'VZ7^W
MOFTV#^U+T/7]R7+&B8(B@/.2L3*+:#;8$D:ECB<9&7!<[@U^!4>.*;8;,\/O
M,A=.!ITB+VJA=J$2VE:KOWUMOOTGC[<K@OAO7M8^E[`XP1=6H)N9.^S$T%A\
ME\PX9?A1VUP'9#`#:11&M(11'"4HP7@P26-,#:A%R<X,#',5C#]5:N5E!58M
MQG&&J#GQ*(#IAH&.L9$G(BU$_>0CO5`NTY(!/$KLU/>[B0H&XH3`/`:T8!D#
M6<(&"R#)I2;$-!X[%?<HML[2`4B>5AQ@H\DB1MVN5!GC;!LK`VP\X@-5ST]\
M_EK!Z]8B[\<=L#%),<4\[+PL0I8420+'V@?3T&2,(V]DABID:IU\?V%WMS7\
M//HBS.*X+(^ZP$A]+72]JW=/OU1?:S'CL-Y]6#Y4BS2&183*LH0L!1`E15:D
MO9TX9*74X5KMASO^.CJ?@H-3@?!*02SU$'M;,IV#I2:<JCA9X)%3")SA#R.P
M/.`-,_^;?U%W=DUNXU8:_BN\G*FRJ_@)$'L'$.3$%6>Z8SN[E<J%BBVQ;6[4
M9(>4>NS]]0M0(B7W!X4#`A3G)NYV/#KO>4$^.B#``T-7#9@3B2!3DV\_5)OB
M^U^+'ZL@"`@+6)"X,0D0CC`G01^(!JD/`P7TT^<AQ5&5T\ERA"XP*\"NJ<+"
MIF%:M`!X98P7STP8!8:N88LAAG8"+Y`QS0HE9B3[IA%1LK)=Y]M_%GF35AN>
M[XH5\ED2N$F<!7'`LH`03%@?*XXC3Q4;V@$LD^.HRSD(<Z0R1TASI#8`/?3]
MNPR06:R#,43/-0,<><N+-U`RV;H%T&1Z#K7!:PE<AV3EMF@2$>)KW?Q8L2CT
M<(!1$"!*O23C(>^G18$\R@16A<`^>YX:I-/D]*+`!0C0+M7RPYY36L6'JDG&
M*H^?\A^M._2<6@`G)LE_47-,L0'T[$]VMU_%&6(X(AQYF>^AE$1N$/:?'R94
M&0N@#YWKV9X4H_&$7\T8]>?[QCW1?+H_;H?!9YPRT(5GFB!/%G"/Z^E^Y9FE
M1N*@N_JV:,IZTQ<7W,WBA+L<A93&Q,6BR!@6"D//5WY(J??I<]WG!U4ZLP=-
MU]3O?7N&:4)`V2N#//C)A`M@T#-L08303.`55$RQ`L2,TZ0D$W_3KBAC)*'(
M(\0/*>(1(B3M0T4T!N]$@G[^7-PXGT1WRC3(`?9.G1TV;=.D!\`Q@_QX9L0%
M@NC:MB"&:*?P"D6FV:'!D0.V#L%82EB8NL2G@1LD-(LR,BRR1+(-B!9)(!%F
M9LGQZW4:34`.0GEBR[QI1%'SS3A3SLQ0HHJ.>8OCBE82;Y)%WQ(EME`1:=-%
MV^9?5XGKN2'R6$I#'L8N3[QLF#AE'@]5>0+[5,L,&<0X4@V`&D!O+I/"GBTP
M.J@Z8H`'/Z7\!@/T;%G`?:\IO)YZ1<#W3-0/#W75O;?9O=+9WNQW[2ZO9+_Q
M54C<)(O\A+DH2D@24)X.JZYIQI6.I3,4:J;=%)W$PZO7[PXO9[?.F4SXYHI)
M]JHN=<SFK-;*A[ZIYG9AC!@TOB7#A+,+X)');%YNUC!G$H!<_U-LMW^MZC^J
MST7>UE6Q^="V^Z)9X80'`7<CS!-*,$-Q%`VH3#T*W/6E&V4>7DEU[_\MY3F]
M/N<@$$PJ;3M5(36'DUI\TC'1&)G><&442E.=7`R/)B?R`D5FK`%0Z+_K[;[:
MY<UA];A=Q;'OR7Y+W/5%/!)Y8B;6!_*]#,/H`_WT>:@SJ#IL:H`\;M$T394Q
M-OW28HNZ5<:(\LR#49+H^K48@F@G\((<TZR`S+@.^]$^%8^RN6OU]?,NW^W;
M%4X1)F[`<,"C$),P0M&P&XTB7_D!RZ0@,\VRCELI!W7.01Y\=J5II?*\RKZ+
M>C,JL('F9E*O6C(^AYKFXF)8,S6/E_,F$\8`R'.[O]N6ZVQ;Y[N5ZS,_1A'V
MXBCS/,)\A@:\>:X+K%,@GSP/8PZ*G$X2F"L@HU1A8LLC+8*HV6.,&F>YCZ)"
MQZ/%\$%+_`LHZ%N@UA_O<[$MUKMB\_=]WHC;:ROJG2JOUF6^Y?DN'UI[,<JB
M3&Z!37F48<Q([/M]BV8WPY=V89H,9>]FZ`4Z@T)GD"@W:>6:/?=,>0QHQW<%
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M`:N\I*[:>EMN#@=#BI_6/TY<"U'LN5[&:!0G/&-)P"GN8Q*2))"2;E(@R_7;
M3]K>.0=UP*)LFI%J%=AL'L*@_:I]SK^.?UZOKAJS:Z2(,N+R0BHF,[G4%BY#
M(*?^T8I:+&UWI9C]%NV*QX1'E&(WC46Y%?IB`ASV45!,E-YNU?QHRRP2:N2W
M]:!'$T=0O]0`9-$J&'+><FD!U/G9HQ'.:)JY$++HJJ^-7%'0*B=OO]%J(_^0
MI\<^B=E;M6N?HPM'+/02+Z&,4)S2`,74ZX/S($"@<L=(1-MUCU#7G9O<_7"F
M4[<&,F.S8C$TN\/`JNB2N0M@E9*'8Z62T3%8"-D,)_6\>+)@V40.?BK$'+.4
M*WMCXE8Q"=*,H2B.O8`2%B8DRGI-B:_6`WD6(=>CYBD!9QZVFAJZ*<B]PJ@9
M(S%DP!;+:[4!`&/<\+@NFNZF<U6"OA6#E;\+OC3YIA!!;W;?BH:NU_6^D[0N
M1/B[;7$,[B4B!HZ]-(T3/^*A*_OJ]P4YS4`UL9F(ENG>B>PXT,ET>IW.2:@F
MP0T9KH;J^;V&,1E@\P*XJ^3F"&#-CL9"2&HXJ=KF!0Q?%5D7\M@`^83S4]G^
M^[0B?';DN'R7@GDL2@/J^3%U:8SZV*Z/E=Y[,!K0_BK)2:,C13HGE?#5$@,&
M*Z^:S.LM>/7D;5NON>E/Q;?Q911SMB\$>69S>KFL8MHP9>!]+KX^G+\_]EIH
M%K.$\#2((P^G(7&]**##R@Y.0!N>3<2SOMNYDWCV9J0V[8RXJP:[N8V%L6[,
MTVNB3L&U$=*9]'PAH#.:4FWO$@5B[K:I'XMF]^-67)4[45S*R?9CUZ;YV?/7
M(.1A&%-*T\0->()YS(=UJ-`GH-K.6%#+P.MUBGF75-I-S@:MFG-><X:KX>\J
M7L,8J&3S`N:\JE:.@-'X:"R$CN;SJBU?QD!.?GAXS,M&!KQI!)X?ZS;?OM@*
M_5P+26,:>1%&-(TQ0R0(,K_7XF&U8VBL"K#,SY-F<04ZO>K^#83WYV\@:-+4
MSK"HD?7J(P*CK,9@+("Y.B:/\-?JF"V$Q79SK&>\"8",_JVN-W^4VZWX>OA0
M[<2U7]YMB]<5A''$J.N'41P1'"'&0CSL)L`<*77PMQ#6,H][I5V%==(Z#<$F
M75<#[Y4,A^%6S>L%$%;=S1&N6AB2A=#41F:U]>L92,Y/Q5-1[8M/Q;K^6I6O
M;6)G!"4\BI'`-N<\Y7[J#LCVB5KC7W/1+'/R*-`Y4Z@)1P/&JC%Q7D]A*!RQ
M<P'\N^C<"/;,N;X0VAE,J+9U@8+9UA;B'\O=1%QHV-;=8X/T^V-1M?VB><8]
M$F:<4Y]QYF8T3,@0&H=,J3^HR7C6^7:0V-4F9R*=HTIMV!EP6A5W\YH,!9Z:
MOXN@WT4C1_EG;A@60T"#*;U@H&F[U)>SY=D1+&^+35(_R'C=FOK-8_=&M:P[
MY4*[F+'+YZO]-LL$I8AC-PPHCCT:,)(FPXN+F>)A#S;CVU[NEI+?WTG-SKGH
M=\Y!]G%F=Q3>K5VT>N"T,CB*J^-7'A?@:KG^D"R`M1I>CZVQ6QRYA;#8:HK/
MU^"MVZG,ZC1OJK+ZVMX63:?J>:&<ACC*:)(F)`PQ"S!.Z+#CB;H$M`-]:BS+
M#.[ER9,T#Z=;:=:FDSU5P^F<=L+0^;:3"R#C!=M&*&C*\(40SU@ZM9WK$M*O
MZ_57>#J6/A7M[J'[K6_FDV$7)RRE$4<!<OTH(^%1`$NR(&,J#;R,!K2XO?FM
MU^J.U<N@5;/+EUG?`6V_KN:_7A\PL^.@UAL,8M$KU+-G\Q*ZA]E)K+9]A4)G
MXNMOQ6:_+6[NI8R74CY_JYO=EZ)Y.-/4]>,\T3H)H\@GA`2(<(XI2<+`[96%
M.`5U(9M!CNUY^C$#N95%ZG_W^@W=)?)>?/[#^;T-G:G/,'B*$_=EC1O\*_"-
M8?J)N]?N0SO=Y+$)_'PCN)#J=LZ,GT_OYS9;K4;FQ=WNYFY;?NU*E]-W#TV3
ME&`/)5Y`$X]R+_,]SL*8QPCQB%PZO7K29]N[[:4BYTR29H&K;1J@EIW#/+VR
M5<M$M>KTC:3?*D2G>K2$FG-R#K7!BP9Z'H$(]Z$2,;JKJ*/5RJ,^37@FWX-T
M>9I2YI+L$`HCFH4,=.:`QN?/6.MUVY:[>JZ[)4Y*^\(!?(J`CI]JU9IM*X'+
M*(9<M-/[_Z55(T74%&,74A5-2N%YG_[)=BC31UXX\KJ1(;^(_Y1^+]M5["4T
M"%(_0X11/W03ER1]+,0RT,Q4*X!E_OQ\M[QSI"[Q!2R406&C9Y\:;:P[!\.-
MEFE6V/*:,2-PF>3C0N@R+8?:X(4UD2^\?LC+:I6EON]3%/&4DR`-/4H"VD=C
M,0=MU=,,<17&'+1-I8RJB7J<L>"?"=)<M&X6UAQ4`&@#='.AO(%F<8$X6J9H
MSJ@^EE7Q85<\M"OL)SP-.$UYB,)`D([CH82*D>_JSZK48UBFSK/J?]+4"6"<
MSO3)CF<:C[).DIQ_25%.I^JZ$Z;!'.5)$]S.A:!F<AJCDR==6T`%SI<CVOZ6
M[_9-N2N+]E/QF/_HYM_RV*.R6I>/\I3+WXOONR]_%-NGXF]UM?O6KL*0^#$*
M4A)&/$-1FOF4]:(282:T#K*G9.9RZ92`;&;<IW`X[^N8A%-6CDS#.>3A'!+1
M**TL#I]Z!;:,D9M6J%D8-&M%G;;?%VH_^^.X$&[/E.PKE>1<%MOY#OAGD3=?
M_JA7"'D>=RGR$0M]RG'LQZ37DB("G@(;%[!,XDOU`AZU3<XK#Y$%O-L8G5FH
M?GE@KL_RH[FF$`X=JS\CN<$Y3@&VGJ$6.2VNU&+ENQFA81HA[(<^=V,B?AN6
M7CP&>E/#DH0ELUHF8)W6:@-EB]?&QVA&8H\/ST*8+44:I39HQ/ZTW(9E.9G<
M&J;:8W<F[I95&`=!Q`/$A"I1[_LH\(=5K0AS8A7=2@H63&ZIWS:XU4;)$K>-
M#]!\V!X?FV506VHT"6W0</U9F0U+<BJR-2RU2.SRJ5A%(8[=U,,T0S3Q8Q:2
M6#ZB(4$41P'V0#T=[2A8,K&%?NO$5AHE6\0V/4`S$GMT;!9";*'1*+$AP_6G
M)38HR<G$AEMJ@]CT7MP&@QX?NV'B>\P57R08B=\\A*2>E!%7_&2KS(:)6""W
M<YG`'.@&#I=Q>ML;*?L`5QZD:S/\)Y/-8%QOW/Y\)-?,4Q_F4XS5XOF*AUR>
MJD9"\>41Q9F/L(_Z*C]#KBBLZUV^A3/ZX@>#N#MHT+ZE?VOJ=LHND,M&P>EH
MU*,IQ+LBO!2!I&S5`B&CKGT$'$`#M&"0[)M&`&F5!1PCS_5%!`$=[)'$#_I0
MGA?QU5/1W-4ZE9MJ!,B%?RY&&P]'86??_!-8H>PC'!DV#)Q6*T&<LTZ3HQA%
MJ$#-7"!;P"F,($;/#BW2_"XR/49C`<.(9R%U,Y)D+D4\'';[8YXQ?=@`@LS.
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MY(/6_P*6;38&0:VDN[+_L"\D(?;`OEZN<_?#^44J=LKJ5V<0[9Q4ZP#23`$(
M=W:D.+0X3`LI'&UF6,]VS0/A*R3<E[N/==NN,".>AS,6I&[L4A)G*$!]!$KC
M"`)5P,?:AN5Y$5.)VW<+?_(.,4D->I;\@</L0[6N'PKG%RGEUW?RU^/T];9N
MNF-.Z&[7E'?[7=<>=5<[<@Y45SL1;BO_V8=*C$G1SOW,_N3?"+(T3%X(BG24
MOSS%7B]Y9730S?_N^_:EM3QLKUJ7VT)<5(=K2H;^4D,Q%[O$=3TO\SAW$24A
M24/2:Y5GGT`@=!6!EG%VEI.\&YL^*V?]&N?D/Y$_KV7)LC]4*4;*Q>N,O1I;
M%S_L,$H_&_$A(><%ON7__:<I3FV,TLAWP54OBH5\JUS7@WI!=RFX5].C`&W9
M/3T3/V^+XTE=]$$62?]W>.P7D3A@"0E<%,<\X=AC(>MC(R\&=4DQ$M#R-]&Y
MQJZ=?GXF#MS3R83!:E\/LWL+P_VYO'?.(+!SF"HY;*GSTV771O!KU/2%X-1L
M3B\:1!DW3!EW'QX>\[*1:+ZYE\M?'\NG8D/;MMBU?RFVFZQN!(E7A&&>9B0B
M+O6B,$F"D-`A>!R`&M69B6@9>">1<@4D[]0!.6?(6370S6\JC'0_^]DMI'<2
MG8-&1XI\?U\W[\7$96;:*5DW@CNSUB^$=X:3JFU>K4:.K%Z1E.($4Y2X092$
M?AH1W$>C+(SX]%.I+X:PS+3/NWK][^,IQ^LS749.E;[LGQK(9K`.1JZWSH9>
MQ"'/(UB::.1".#0U"Z73F(&F*)/FM[RLY-SVIN)E^UBW97?T\_T!="OBB^DJ
M\V.?NH$($F"2)'W0C,7NJBJ^R@=\7]2Y,RV@TCU$#O?0"VW*]Y/4Z(@YSJ93
MF&]E/?#8R.>4NQ_=Q*?XS[Y\U.@5/-%M-3S-X+`6I3I7CT\&A;EGX@ZOCAW]
ME:>,[[JS\3J'S[<PWI3;SO[?\O;T[^5??"D?[HIF^+N9N3=J^`C^S`S40BAH
M*)G:QK4,74@ZF]/>W&=EE5=K<?DE==N=ER>4K.M])>(G69K&GD=YS#TO"-,P
MR<(^?N2YH"-?C`6UO>!SIE/>MQO9#;QLV[W0*U=]6O`DU)S=BNLQUW`:N,;R
MS.1!I-.I[)@WZ)Q[H431OK'%#],CL!`&FL_K^2*%'>,`"P_W1=/(50^Y)O(E
M_YY^EQ5JP8JJN"]W*YHE$8HXB[W(\X.4$<'A/BQVPT"C7IP:<IZ*L5?I[/+O
MSMU!&GC-8:*WJLL-,_BIN=)P]/"XB"RT.4=QSB]'>;_.OLPPZM;H"H,9GQ>"
M-F/IO%A7,&F3^I)"M6X*,<?FQ>'/LV7<)'\L=_EV6,,EG&99Z)(P#MTH1)&(
M/:`TSD)0D6<PK.UMBM_$;T7[;'_.X4&XK#ZV97Y7;K7VZICT7G'EX3JV`Y<?
MCB*=7WJ9OTKW3[MDCE*OMT5&W<:QI0CS8[$01-K([/FBA"WS)H"3K@\UYZ=B
M791/W;&K**,I]E-$B8<PCY";><.SRLC/(HTRT$C<>6K!7WJMOXK)\?&>%C=R
M?M0K]T@>!4\&IX[WNLBTY;=)6/8:G4\*'L_$R)>^@>@XP?;%<G%*3A>).-FP
M"2R\;8K'O-ST1>VQEA4S\YO=MZ(Y/K5,78R(CWC&41!2Q-/`[=^<H=Q/LFD%
MI1$)EHO+-PCY>)#N%`?-AT*SEK*=XVONFKM<+(V3+DEG'R(C;#VJ'J;D<G`Z
MP<?],5<'K8JM(/0:':?%PMALEA?Q;,'4*;-^&?2T@_L0'7$6H3CEH>MG+`YI
M@-*A=$Y3Q";.^'5"7@?(!_8:8JZ>U=H3?-LNFYG<=P:?O0BS#)*^9AYL2C_%
M_<62<EI6EZ?RTTTS,(V_S7_(FEEN[5ZOFWVQ^7AZTK=RB9NR*"(,N]CW`HP)
M]8:'"C1D1B?VDY3,,]4_W=:;\]MZF.H_'E(X*V3/GIL:F_U/&[*ISP/L#Y.5
M)P2W9T-S%.Y\5!F<F1\;C-FK]2#!R'@MEM%FLU1^V&#0U`D,[XOJ3\534>V+
ME:B>TRR*,$Y9DC#?)7X:'0.S+&!F<`T->E4R;_HUYN:@=C*#P9;KXM:*S2;)
M.BS??[ID[4P$?>88"):Z;B^6B]H)743@-*LL=&5;>0&B.,DB-_+2-!#U,_)P
MK\#G;@AIVF\P+&@.#V_I_[M*7PUK7=@NFZX&OBOY#2.@1M>UQ;9:&\&BA;%8
M"!]M9*;=4@UHWE1B?JB>BO:-?A5!0"/J,H_1+`E8XB*4]1OJ69K%V$`?RRGA
M;>]Y>M;'LNREFN]C.6D0)I%T+O^-$G40O8A607!GX9`U,4S+AJV1#-6@:\Y,
M]3Z6Q].KOM1T_9]]V13]NVG=ZVVTV@PON*TP3K"?9EP^V`UQE@8\Z=L8,R_%
MOL8LW6#T>:;KM^+OO^5RS=_4JY8F!T`-N'.;K@7:7J3LS7:4.;PV^>[P[N6[
M_Z?N_)[;MK4\_J_PH3O3SKA=`B`)X)$$R&YVTJ93IW=VIP\:6:)CWBN)7E)*
MXOO7+T"*E.S(,@`")//2*HZC<\[WD!\<_&YT3]_6W<U)FLHJ7H&J@U3,!*8N
M(GMY4J<K\70.`5[E^;K.1/BWRTTNKP!\S0601&$H\,U3)D]7RSA!O0L^1$#S
ME&!K=AW7JIVK;:5J?:.ZU0PHXG,B\37Y^4QWZ>?YYO5Y$%1=R&L(=9".N3#4
M16C?'G?L2#[S$K0M@YN?+4*,.$VICSFD,(ZB@"7]F`,-@,E.S4'V)B@SBY-[
M0VM++64-JTGK:EJK']^I"#E.L7CFBDYY:*+M7&!F)9:W2D!S@8R+ON,]=4\"
ME:S<;/*5W/1>?[@_=R6-1'\]QB#S>0P2&/J$])UWFD1P2/%GP[[C(O!TE=]`
MGKF0WJSJ&UOUH=7?37>?8EMOGWR6&9D0C/JR:M2"-I,T%XRZ#/&-VM"^G`[F
MB!81BZB?<003GF4DP@C[4>\!"XB%6743LV/-JC^>3TP<NHF)2U-$SF:(WDZ!
M[9DAJ^H[GQ&:[320E>D?Y5S,A*@N(C.>[M$4;R@_^Y.9+EV<!@/(&8THIDD8
M1CYCHIX^>H))&EF88Q]B?N0Y]OO^9#/K<^R#DC"(I&/I;Y6HIS/F9CS'?D59
M?<C:2-.\86LE0C7HVA/3:,3@W?$$R@_WK-QNRUUSD/B"PM@75L,@C5D<!XF`
M?S]4@1#7NKUMN+51IX3Z(SE%/W35..G5TLN;Y@(V\</[7+M4M2"X_JB`>ZV'
MC`&\.Y.Y]<]K')RPOW]1,,7>_3"Q9P)#BP%=Z;G;D$I[+B<KJS_SQ^,LQG/+
M&`$$DI1&:9P$61I1GG:[C%B092:;?2Q8'6=>Y^3=2]P9SNP,T5EO?L>UML-F
M>>[+RGLN[I20>U,RA3D?"WK/!7,6(WIE_L>:6`-K.GD!C\#"EN=W^P4(8XAQ
MF/F0@31,4A2PKBO/,,5:M^!8,#?N0A]YVOI=657E%U%JU_:+.3VEAU1SSD2V
M5<XU-X")C&T]Z>(L"KISS;0K.B/!Y\(ZBQ$IU70#Q%)FG4#KD;,O[,4@1=#'
M/(Y1F`8I$)WDGJT$@=B@E#.V-5H!U[K77REQ@IPFU\Q55:.96R6-&'9R:7)N
MO:;.%5H-%G0FC!H>1VGY21M0>YU5@,VY1!>&]Q8T20.*`<X0AH$?)YSRKJ_+
M0!C$IH68#=N.J[+VX*Y+DQ<#JC`KFNN79&/+/:0^^_&\9_K3\?RT2S,7$Y9K
M"GHJUFXV,S,32#H+[TI59U]&!_/#"U%>8N*G/HT!"R%!)(YZ#WS(;:RO,3$[
M[?H:"X2UF0+;L\)6U7<^&SS;*6`K4[_*N9@)25U$9CS5JRF>,C^E>;DL4OQ/
M[I?YO-Q(D/^15T6Y?GD4T2)`<40H#P3$0S\-(8NQW_D0!333(:A5PR,PM+A\
MWEF#5KDPN?F0GR+1A*C=/*AA=+(4Z(&4=1(W'\X\O?%:7[T+!Z:-C%(=*:_`
MU$E&9H)3-[&5(SS25I`:"])7U9.`^C^6FT.^\#.<,A@$-.3<9Q!@2DEO/&'^
MXK%Q^G:_K/9#B*IK5^<]?NFB_BO]DIK><N_=Y9^*W4Y61N6]]Y0O*RLHU=9_
M"$-=BFX-GDM9G[9>>HV;LV#F"^FT86DJ_:PI:1R4$AZ'26:9BXBG40)B`BF%
M:0PR*LK<SG@:@>3(Q72WMDG%MZSJ4[%ST`X3<WF^^5LT_([?4E7]OZNW5#DH
MH[=43S+EM_3V\/BXR>5PWG(C/<@VY9=WN_NRVC:78O=+CB,_\0%.,\)2$(8,
MQ#3KITA`@K7N<+%ET_&<Q+F;\D28U::L#U6[(J[;=2'ZA+W?NMLLK$FO5KI,
MH;I>\?),\(:/TD?OS,GI]D\HJG>%C+;UGPD;K8=5NGULM2\%$.3(Z_T?RV+]
M>[Y?@"`&R.<^HD"`&`((LN[^;"Y^H'6BJ^YW.^9=\\8U5]+)5:K%T3GM$_TU
M]5*#ETNI]"#5>>))5VX\X<SH!_,_D^(*<4Q%FPE9C-W_YHC](3)H]7<DG'X7
MT8F/ITVSN_6%`7[>UQ,]P3!,84Q9Q$&`:,*#-(RZ(PEXG$&F@Q;GSDQ7>^W:
MD,Z/"A"])1O[7MUG4'V0:3;),QA_DKX+,A[S].Y9GB[NBCV%,%V!-U3T-_K$
MH^1S)N`>+]X+/>D1A59N&O[:5?ER4_P[7_^Z+';OR[K^L'MV`E@&":<138,@
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M7^[R\E`+'_*O>;4JY!K+_4/^\JMOY`^K_.[)$Z!LCEV5W8[F%ZOR4[7<UK]X
M\M_(+6I[^=C(OUH>?9;[?9K=/Q>_N(NX&2WK'?P!^-ZVV&R*H^='%`!T`Q&^
M"2GPZO9)?;&G7MI>=VF6?]E_8_E<:W@)*T+HY7I=R#^*OO(/*.Q]>`4Q(NK.
M_^6F%IF2&6C>F^WR7[EW>)0??PA.WU,\L]#MH;GQOCP4JP>1MLU&A+.KB[K9
M;1;Z_]&Z]=3^=-U<T"6^IC-:Y:N\$.V4]WBFO?SU3;'*Q3^02:J6N_H8XD'D
MHSK:ZKY"9*^9*179*:JU<$F>SU\5GQ[:@Y2EN/+!:)I'[_W_`!_!F_;_2#3X
MQZNC'T4RMLM5?M@7JZ4,8?M8UDV4M;<MUX=->^><?`!J\5AX^V7U*=][2V'B
M0;01WKHZ?/)6(M'%6CS9\F'Z^%#4(KQ'D>/V3&?Y3]N4%SV<+F=Z?>B?SG9"
M^1?E>DW"HZG"`#S68,HXN5"%V4?1Q'68@X!*5]36[%?*S6NG7NS'_.L^V<BS
M!#(>)00%.(A%[1>E?IJ&/@<$\I`E(0):_4E3&X[[D=(M[T//--TNH[%R:EW%
M,433JY$:O<['V:137N/5V"-MKXASI4<X5,Z9]`0'AU':?<ITEXJL'G+1*N8?
M[AOF):*Z6(NNSZ-HLYMWL#G'I*V0ZN,HV]-'>8O[R3,,`?0#DOE1G$04!`AR
MG`(,29#Z?DRT=KB.X([K28YC!$WG4,;PLZS8Y*'GIRANVI.!CI6G*+JZ4'07
MFXR0/,5U*//*FV97<TC*!'1E'-YTZ!VN_;4%+N,E=B9`'S/BE\MBQA;;H)GX
MO6R&(^55]O6^*E;B4^/67[MB_YI3!/B0B,H8)S@EE&%&HK!SBN,D,VLA7'@R
M8N/0N^^=_#]"IHE@>*/@)%6Z[<'463)O"I03-*<FP$!N)?J[3./LP.\TV%>9
M[UYB`]Q?7L?>>+$0W8^,!!&1U_+Y$`,2,M1T22)(6<9\,ZP/L3@BOE_=E'6D
MP14$N)1<%\]CJ6V.X0%".V;M%>V4F&I#^]FQTTI0KS+2GF1OLK!=NK(XS;['
M7XMZ@8*`@-B/(XJ3*`@R[N.L,X(QH"K,,_MFQVP[>>/]+?U1Y9>A3-<YY5XA
M/1YIB'.%.76^^N53^?D_V^@D<=#QLV0-.F/-Q?@O,&683A.S8Z#SI8U'1;,N
M^FWYS[+Z*/Y-_>%>#M0>;RC>/]WFJ^,ED[S<+HO=@A.09C'"?A:D&8AARD$/
M(P@PTJF-[%EUS)#&4:_Q5+;<S?1$=\FWZ":=W/7^;AW6+9(LZJ]6*$TCO1Z<
M;*KNI&)2%O%*U60_$3.IG!P$5KI^A@TVT?R6;^_R:L%"0C)*LXR%*08\PA2`
MSD)`>*"['4;Q:QUS3WIBL"U%51,U5#F20X]%31_M[]:-*39[M):O<,1`I9F`
MPL3S"ULIC()7?]7S:E_<%RNY=DK2IEE\=32)P@B`,$L)2A@5]C%!:6>2)K'6
M/6-#[+B&P9EK;7O<.*?+AR%"*@)C)`TU"7)9OLF@\KI(URAC0=JY8,=&*"\Y
M9$T>]=U:MQ_E@7&'ZJSJ.5J,0\)QB&$2TYB1-,6,T[[J24*M4U`&F'&,I;]N
MO<ZULRZ![J:L`2JJ06DD`?68=%F[J9#TND17B&1!UYD`R48D+W==V1)'?8+M
MH:SV\JJ*L\U=1XLTC2'C*8$D`2"((`M0WPD+LDAOL82Y&==3:=*S]@(6I>V,
MUE54G"@;1T#-V;&+VDV%H]<ENC8)-ES7F>#(1B0OI[MLB:-Q(-)+0SBBD`#$
M"`[2F&*8DAAVAN*$:2WJU?_V$<9K+D\IRQ^:\\A`1C4,N570="YL,N3HD,9<
MNID`9D``WYR9-$R*H:?$-A-S),:<I%D81(0$)&'@;&(.(JWJ9H"9R0"C-;=N
M0T_UP>,1I#083#92<<Q3="_/S%L4=B8<LA&)VB&Y^N)HW";:+:V\;/OR3X^T
M#'R.$0HRGL8@P)#0,.)]\<6(UGI'IXY,1S>S:7VW65$CX&P28HV1TTSV#]'Q
M"D='2<],2#M.K-_<HSJ:P`/KR/?%+G^WS[?UPJ>4)Y3'#`&"B3!_-CA'<*@W
MHSC0UE3,M5)*:D@ZI)YTHZ8U8$KWO,:_>926O5S:]:6^T#-!G[5PE"I-4YDT
MRLWV,+=3SUL>ZU;+<]WR6E`S2PB&@`<\`1A%)$OZWC=!&.K5DT,L.897Y]S9
MT%ISIF'='FJ8UU>N>G.AJVI%.):D>@0;HJ:CDN^*4%=K.AL"SX1<EH+YIBJS
M)Y$RM>+/RV(CM]1D974K2'F:%(VW9;67_K"RWB]"!`(F.N/BJ<@XDC>81J0S
M'_(HU.&7+9N.2=:[^?-]6?U<"T?/%@3<>+VOGG362Y9UH5N@61-?#7)3Z*Z'
M.ZN2.^&?HH972&@["S-AHO6P2K</KSU.KE:'K3QK,%__6@E6/S_6-\G%DYQ_
M7'Y=\`#[&00(D23":1@G2<CZ4<XTUKH=PKTWT[*U<=U[>2KV66SR2$OSN=L1
MDCF8R!/DT2ZKSY)U,9TWWET3A2?"F`_$U60WP[OEE,X?_+8#5F\2G$CMM+&0
M9?[),>B3+(ZHSR&-*,<QI!GN',L@YZX;"SUO9M98M#VF$=H$S9RY:Q/<I6N\
M-D'&\)VU"<]DM]PFF*7T.VX3#`.VT"8,D=I"F\`.526*V`4.0DR#%).`^20-
M4I:E?<\%I%#K&('AUJ9E^M%+:PQ7UG@HHUW(:Y7!;RH[,EV/_AC14U?LV=-1
M.R!E^IE)I4PW`4Y6Y>NBO?-</'A?EM6Z/:HI)DD``T3#@%/F!YQQ%*9A1`.<
M12@,E4Y1LF#&,<\^-#=2"/^\<]<,SX<;HJ8:P$824H]<C7J-5YHB.D'6ZQ)=
M894%76<"*1N1E-8?.AM8:M:<@B@DP,^RC.,0H8C$(8TZ@PD-H\%44K(R$91,
MUJ4/D'(`DJRK:(E(4ZQ)?U4@71YIB3IG'.D%HD(C`VF&P>CWY38_GLCD<YQA
M$C*(:01Q&L0!`9U9C'VM[3)#;4T"IAM/>FBZL'RPO`,PY4A9*[!25G4\:)WD
MTD67@=!S!IA)."H8,Y9)8Q?QJMS*\;+XL'\H11_SJ=W*$_+,]P.:HD!8I4&4
M!KBSYF-?JZPR-.$87:U7#;MZO\PJ*E,)U3@U@GIZ>#(2SM&6XDO27$'10"UG
M0J"A47RSP]B"*`-X<^0;R=*48C\E,:<0P2A#D'?V(LK!,.(H&IF$.69EDKF0
MIMQQH*$-\DQ3#[TFCQ9]-!6=+7]TXWB30$;"*#/HPV-S$_+NDYPP/"^WSC:7
MP"P$B*$`<O'?%+(DROS.-&.)UKYA&_9&Z\B]VPGGMLW599I$LB*K&IS&5E2/
M4[UWS5J(9YVX27>L*:AV!5\V-9\)R:R&5+I[1!7YUER#_6?^N:C%R[LO>7Z?
M5Z)+*<%:U_F^7I`P]4F$LC2.8TAY[`O-.GLPI$I+EP<;<4RRSC5YPWOG7%LR
M-.XI,FVXE-=!-JJ*>O2:BX#K<G60B\*;IF@>0CYS27T\[R%OKJ5=[IZ\*E])
MJJV]55[MY5KXZNAZ+>66%Q2N.\GW0O)E$\,OGB>_X_2KXJ\/*_DKXJ<7?K_9
M*OUYN3DT?GK+S:;\LA1`_$6YO9&J-JT(@,<VY"V=+S0<UE(S<6MA+X[2\C.K
M6??^HWLDXNZ)>&F:/8@'-W^WB[?E8;=?)"@(.2(\)A!QPE-$PGX,`*1J[84S
MXX[;D=Y?KW?XY@(/;[S6;;F1I75<LVJVGQ2U$GK2?.BU2,JI$!U)>29P[OW(
M\_;33S=O9L5)J:VK[I6ZVUFB9E*$NXNO'.F)MS;\L$`T"+(HI)CP"&>0,8J#
MSF+((JUIEP%F7`\V7.D?WWA9+AZXY<;:X,/;H@X=<["JI[VAAMF,+A@-*BB+
M.A.,V8A$>0A!4QQE-'U3BK[NPJWH!>7Q;OU>"+]98)91DH5I(.I3&"<I3:/3
MNC]?[^I$9TY,BK7&54VHN4N'&O)FD0D](%X8L;CQ%#+3])D;YT?&IJG&5Z#J
M/&TS0:[[.,N1WP?3R?3TZV.^J_,DW^7WA2A<&291F"%">)B%`4I!0#ISG(%H
M\3FO[DKMV71-*SHO^;E#)O/!1]>\'X_.C7V<UBL:J<P&&ZHZDW=P<!BOS04/
MDD7]3I_^EOK3JRS'#=;M^WW<U)!PCKB?1`#SD`<^8QGB*$H#"BEF(=:ZW<>&
M0<>%3.>CO,KOK.ELW#RVJ88;HNS(K5:\C*ZT7J%B160WEP,I"'<%;%9UGPGE
M[,;T\NH@^X(I\^^/JA0V]T^WA[M_YJO]Q_)#=;[W]+E#S;K`$#&4Q#CU0Q\#
M'X$@CH/.$1)QK6V@]JT[)F/GL'?T6$[:E977.^V)\N_EVVRVJ-A!8M2P.6U.
M]!CJ)!U.F*JMZA7`NLO03&CK,,!RK(?=)8>/JR.Y3X,DS#B#HAZ.?`+\R.^;
M!)BZ([&B_5FRV&RQM9/T.."Q@\R,0>1IEG`;*&N+RIIY^AZYK!OB$#(;R6DP
M7WM6E;_O%W&FV,\(2((`1O*CCX6]SFJ8F*X4-S(UW@3'>3?5>*;63$[=V5KG
M2AK/V#[OZ[^?P;KP2UHIS=X.$GDF>+,5S:NSN!9$,H16G1WVARK_K=@5V\/V
MC^53<]HR/^3=<5(D#%%"8I3P5/@`.<*L]R*#5&OWG673XT)-+D!I'/:.'GN=
MRY[P^<;[/?^Z]SY^R3>?Q6^4N_W#,/P-3XP)#D?-R2`\VDS'".Q\2UAEEEK+
MT"S9:B^ZJZRU+*)M]K[;??Q2_F^^K.I%EB84D!0PSK"`?L03AH0W(**<4$(#
M!_C5L#X7`M_(=UXNM!:>>XWK;MBKDQBK^'64$T<$UDG'E.P]J3H<OP89^KX(
M;!*@&82-I73`8?%4YJTKG(2,@=2'($T1"9((PU"ZP@`*<4RU[O=S87]^+):^
M.Z:Q1GIL\]A-9IP3624I$S.Y5]8*E?7S]-UQV2!$8S*;RFF?S9EX*UI/$$*`
M4TY9AE&0!1E*TEAX`D$29R#-M,Y5=&!^=F26KKL%LT9N+'/935I<8UDE(]-2
MN=?5!I3UD_2],=D@0E,DFXIIF\@+8==/0HS2)&$L3A',*#X.FF0<$:U-X;9L
MSH6]\D5W`]NW9;=*6*N*.QP!GB='A\-36?_OBYCJ89EA4E,VM1.5DN5&;A:_
M?<CS_1]+.7#\D.^+U7)3QW?UOEJN]@M"0(A\2&(8P0A$Q`\(2T&410EG01R_
M=;&S+3/N7LJC<U[CG??</>_OSD'595769-4X(VAD><V."AHLL]HY/F]K<8%@
MME6<PZD^-L,IW3QLNAN:Y+Y#^>"E_W<H]D_RW*ER)^G8K%Z-(!8210!GG.,8
M09(0VAGE(=1:,CK,DN.*K7?NQFO=\T[^F2W('RBL6G4VGJ9Z^-?7T,W.I&OR
M7"FZ[,@ZDU++4C`O-R%9E$@95B]L'9=QBA+.]^,H#G@,?.8G,<`]&5,::]V9
M;&;!,9Q>ODVFJ](-Y5-#D7OEAB%HJE7C%W6YPIYA.LZ$.0.#*&T^6IJ,$6:V
MY>YV7Z[^]5N^O<NK!8MIB"@'B#%`B,]1'">=(11EJ0Y?]+_=,5M:A[S&(TV<
M&"BEAA*W(NEAY%P?[^_6G;$1\HT>5_!AKMU,T#$@@-+68Z2)C#]ST4<K5OM\
M_6[W67QN1I<67+`I#D#"1%>:!5%$1<>M,P9`]/_L75USH[C2_BNZVSU5F2W$
MAT"70J`]J9JSF9J9?<_%7KA(3";4<2`%=F:SO_Z5P-C.EX.$!')FJK9J,S&Q
MGGZZ]:@134LJ+5$;P;!T[$&!8H]*4D04N1LF).9IDQ.3`\;.AS!F1$U>).6(
MHHPCT1)5&6E$I3.N)-5EUWV45752;2[7UYL5N;H2'4>;S_E57MR+=]SZ$F62
MA"YA+L:IFT:AE^"`13L0(8ID5$?OR(;5:`>V?65TN84+LBU>T4E]"UA2H33S
M/TRYYJ->3M$>L]XC!3U4L,=Z!K9H)Y8[*2:/R*`9CU@BCX:,JZ8(:EDYO;K:
MW&Y6&1?O)+_CJE"TCUSXSZN\;?9<+LEM5:^+?]K?]^\5?^)AO^:?B7O1.Z'W
M"S=`"82Q0X*$)1'S?>2G^PUY'$LI[52@3(OPW@ZP/#"D[9:9'5AP!N[Z-__%
M1WEOP-3BH(GW8[HQM6MMD93)[7ZJ-O,0+]'"9=L=M+U#_935%W6[J;X4?>?S
M3WG]Y2:K\T60X(BZ<4I3KG]."%F$=O>L)"52S00U#6E81'8H02-@<JG(ZO9X
MFAQP#X%&8)3NQZ*'ZV')VPPTRV5M>X:_=`QSC*+M2H<2M#`!QPF^'.?:4)N5
M(>P=45S-]%NBI[JM>M8_Q0!IBEK8#M5L#_?\)U\N7(:\('5]/\!NC#S,?W*Z
M45.*,))ZR6KD4%-K7ZMV#<AV"$<IGSRS*HIGE-212M=A`V0`GQ.HVU.F!JN:
M,L56JIFZ-4=5;"1)H]3KO&DV?$3B1D[BLH"2.$"^`YF+4#^B$-"QRC5PF)E4
MJVC1:5"LH6RJJY4!(O4HU?D;'$ZF4AT02862I-5B=9*U9(`R*9$S2I4N-NMF
MG97+HORV"'S/]T@(PR1D(<-.$+FP']:E1.KLL+%CS:1/U1ZB!I&2(E==J4SQ
MJD>N+H90.IEF':"1%"X5EBU6+R5S!DB8.DTJ!5FOWI9"QI,YA)GC1RS"*(X"
M)^B'#GVB6J*E/-XT15O:ML>T4#Q,T:9F5T[5#JN][-H5&\#;L*JPT:Q;HG):
M37J]<DP372IJ]^SV%;;-YA!*L)M0S""C--X-R0A15#GI<295M[$;8*,(E=8T
MHUR.T;*Y][V.<#1,MY29M4^OU$UY7:=&TJ.N3]N;V!!%#-.0DB"A?#P'N>$N
M^0O\1*K+@^H8<^B2TA:7,HF*>F2`O_%:=#;/UM8KY,B(D"2=M@J0K!EOB8\2
M+8.%YVN=9\VF?C@8<!&&7L`B&B'L^21*/$SW.V<^@E+/!56^W[#@])`>2XZD
MUBCQ-DQG3%,FIS$[MAZIS,3J\@(E1Y1E#(&6J,HH$RI]\22I)G_DW[>5IT7Y
M[5-=E?S'J_9]YH:42WK#`XL+6GEX35%>%7>KO/F:_[V..07_6P0,1@X*XR@D
MT/59P/]SD\2G"<(<8RS5'6$20(;UBML`]@#!8RO:.L^M':*WW:,+>U/`7\(8
MT%HC^W;S-"X=IHS6>5-.2B=SI!$-UD'^$=&>U+>6J/RT-E<S3B;%<QB?50TG
M17.UJOAJEN\QN-1GR,<.A-AE7AJ'L:@LCMPDB/FJQB2?N&H<V/CCUX-2__3M
M4O\)F![Z^'4FDF6?Q78PST`+]#'-8(]U3E&6H?+HHUH#'K%$9,W8]LHYB08(
M'"^:!R.G"%&?\"%1Y$8H=B,W[D9F!*5$JG>WAN$F$L@7)[`NG90@=Z0ZFN%5
MIR;^];4]7-9".1PE@O+$VRY]"A8-%3Q5LA3:@M"LN1&I*O^?&/X^6XGD]>7?
MMOW36,"35"]B;IH0%M,@3L.M\'HL"GVI3-$@#,.R>-`N0Z#K;CS%#P<XU9HS
MFG3-,/&TQ"MRHJK%(8:;FLC2>41G)_"1)?H[A:6O]E`Q3.[(-DZ!FS(84^H0
MGU!,O9@O"OU@?N!ZB_N\OJS&-7)Z:PR9&7T(1V5BGWICHJ%<6C?SE(P8U)A(
MCI+!\Z5MK<^GZ&?1MGR5_GV7ETV^P(A@2"(_PCB!,<.1$\!^L-2G4L?;JXU@
M."MY?MZ$@`>VZ"03$44.A^48YNF32Q]4F3.B-B^2<T1MQI%IB=J,-*+2&5^R
M?7N:)E\W_\Y72U;57W@V\+$JOWTL[O,ERXJZK<W=;V$M`L?!?A)%#F/8B0,O
M=0E,8DPH(R%/&)#<JJUW;..K>0<7"+P?KJOZ0Y.)]EL",VA!GP$!>UO0O@<N
MVQ=-KT.&2=I\GI"3.NTN,-/^2(;-(]IHQBN6:*8AXYYV*S)(X6"-W0T5/QR>
M2/)[76WN^+*]WS&#-(DH##"*8$!BER4TY1@<S,*`9YJNU/Z4MD$-YWW["7L&
M+A_`XZ-W>K22&JJ/\&'R.0O7<LHYB.;Y-_"',GE$-;4[PQ+!U&]793B*567R
M8Y%=%JMB7>3-?]K2Q7QY47[.KS9US7'$65,T?Y;599/7;6?+\_)NL^8?<QKY
M7[5=Y_9844PBRIP@XG!CBGTG0KC'FH;44Y+4*0%.*+\'9H'>+E"58&<9:$T[
M`X?&@=8Z\-@\5;V>U/.2VFZKT]77`7W^MFCAT.BF(8O,'%%AVX(T"P>O+5[S
M.638,:9M`3Z'D2_%R3MYV;1CDKH6]99B8SE^V%^R/5.5?,_JKCU$7)6;IMT;
MZG>DVU__SO]ZW9R7G_*ZJ):+&%/";V2@[_L(^2YQ8C=-0HA]Y/L)QH/:8UD#
MUO`"V.+_<"D,`(=&@@,K1<9\>-W64M":>K8]Q::UMGUV>_#89_O23&>R*.ON
MC)8YH-4&'PPY.-<&G.;6S9]A,B1,)`X"M@&O3+BHG23\]28'Y4:<D@2J:_"M
M\R__J7WU$%SN8J'>QT+W429,;<!MMLS!<M,F8^N;MA4--PQL2KZVM^W=UP\\
M7*XXKN*>?\K';GX;>RSQ!)YY(;.R+BAL.!C9*CXJ2V>O9=G7?_/BVPW_B-SG
M=?8M;S],LG6^RU`7R(6$!BQ,D)]XV/=0%,'>,.2R0578IV/->\S?SD#/"]@2
MTUT"!#4'SZ`L6\`UA*8=B>"T47D"F>*/&Y!VI9S3!J9Z3OJ]CY9L&RUM:@J6
M(EJN1;1TG0_%Z6,_D]:AOITQJ]47=S](VJN1L(GS8MVNEDB<+X\8=OFPO^1E
MP[)GAJTK6I7-9K46]G56%GWV'_@L#7T$`P\F'F%^Z#*7&T%B+T(LB@8U(;(3
M^>DGQ&!=@0/[-6Q<V>2?P3FN3:!/.I]]Y_$DFZ+:!/Y$MDAY`%WM;9PE^9S0
M:T<331NCQYJDTDIRGB605J*T.%E\.R6./(8@AI&;0NIZE"4.$GO)L0=Q@@>>
M9'"BIOT`Z::QW:^3<K2->>NTX7MZB>W/R&TCU^(,>=H(MGE']\?*L<?M]MH$
M='"`_HA9ND;VYDSC=0?!X)<VOES=Y,O-*K^X?JOS2%LAOG"C.'0#%/DD8`Q"
M)R%QUQ0*H="G;B#S/H;NL4UGRENX0GB'M?QI8<LV8=+ND6'O2<SI#,F\3[L?
MC+S1($GHD9<53+G&DO<0C)E731/AFOO?G:_SV^9C4>;M#XLP8<P+HX0G4]@/
M`@_A@/8H@I!)G>&H>6C#>CMH;K=(-;>YD_7`,(&=D7PY?1W.._A+X.U^MJVU
MW6,ZCZBK(;]8(JZFK)-L6S>*Q%G>0&Z7`.@2[.*0W\L2&E-$`^KYB>=Y&#D(
M05^JW_+DX$[RS6/%I'EZSP\3?:N=+K<LS.5OZU\W?B-[GRT$+%F!YK/?X"O&
M"HY0:3?4(WV@JZSINKPF*"9)@A,:PI3%(6*A1_I!H0=5>PPIC&1X?=DA`BTD
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MK*197?++FD6*4Q\'3NKX+@F=P'5P$O<&8#]5VZJ:'?6$B^&!K>`[-_8%$6R>
MJ.#9<^7<&7T&A-G@5V'XOT!ONBAF[HU773-G=XKL0CH[X&E65XL"R.RZ:]J?
M0Q9C:V+*MA7:'F)>6[;M03CK6OXE7Z]7^?9TM"@B#L($)2'#*4Q0B'&/V(.Q
M6NG#]#!/>;4^L'/>A5DJ+F99B4V%A$5+[Z!H.(55]L"0Z995E0!YG^NH$A-F
M%TYUYQA?*9M7('<OY?B$>BP.PB1T0Y=&/DL==P<6)6H[NY,BM'M];(Y)HM2;
MM3/'@=E%<;H0F'0]'.5]JU;"HPXRL`CJ"8@37_\TD:!IZ=/I$H6W.VE5+L4Y
MM$M6E!E'E:V^K+-UM^9N7W>*F<=\YL38=1,(4T0=)PT0]D.^$'NNU(M&.L>=
M\*W.'5BP0POV<$>_SZG!!\/6D;GHEUL=QK)M^*W--ZD;],:F/@=8HL9&3'OU
M34W=]`U6SO/RNJIOMQ4HSP?OG]*UE981X[<KS$U\%"40TXA1E/80$B^6.J-0
MY[B&E?,`JJA0>V$2@]T3>;7J;:U.&":=<_$O)YU:J3>BHQ(\'M%1$]ZP1$>-
MF%:9#V;9?9=71VU$UIP4U]=YG7/&FO/R<WY7U:()RFVU*==M'VWQ"YXR4YXY
M\XL>DKRL;ODW[B[JRP%%$\1`M#L,>1;M.P0E'NS01PY-0[RXS^O+:O!6C!V@
M9?3CT+[A]^?'=*/I;M,/C!4/>GMS06?*MFO:UF+0FPP.;-Y>J5Z,;H<SAF[A
MV('6X)Z.93%C9I]G$B\>V_BQ*XPL63-M8^7IUI!E\.16ZF.W6C2[:_>P=O8L
MW,#Q?0=[`7:=,"38)=3I0:0.A3+W/'I'-GS7<WS7X@ST@"57.<WL#UNLYB->
MYT[1GO,Y2\"EN#RB_&9\8HF`&S*NFB*LI=M\W>?E)F\6,/")Z_$OA#[UXS!&
M:13WWT_\6*ICXN`O-2R"/8[)>SYUPQZ9/M(,63(SY'$_Z\"D9/C@>+ZXR^M,
MY"?GY55UFXLZQP5E?D!@@$)"B`MC0CU,^Z'",!IT3OV8[S<<Y0(#8-Q58`ON
MZ+)N).)?8.5(\(_AT))Y,,J$2E](2<Z./_+UP2"0NF$0$Q(%",4LP3!FNPP=
MLLB7VXV2^V[CFT:BAW&U*I;M?3K'!@2LB:?%(TJ.3`@UZBR9"HK@*QW1(QG^
M?9W[I[SNCT<LKOA-;5*L-CQ,%K$C#@,G#!$<1C$,78I0/RR**96;$&-'FV>*
MB!,CQ#D5MU79'4EQUM8T7;7;85OH$T^C-X@\,K%TN<"2J:;-G,I,I$I.QR?=
MY/]H3V>[N&XA7&S6S9J'W+80Z1`-#$-&`H??`3E^%(4>@I#U:%B(`[E9:@B$
M\<G;`FS`GV*[X;QL3Y;9=!O5@V;U=E*3V2:U&N]'YKIA1UHB`::MK":=';)U
M@N)XBHMV9^0_N4"R8"[_6A;$*:6NEP9A$*5AUZ&7(.BDB50UH/2WFZ[Y:\_&
MZ1#)5O/),S6P9L\H27+[K6EW!%"'!OS5X9F\$N\I(<?J[93)LT1]1ACPM'9N
M)!42)T2JG).^*Y\F3;.Y[?9BT[_O<M$Z_+Y:\:\11='\MCU/;^]6U4.>-PL6
MT##P:$HQ]$G$I2^&K#>`^C26._S1%M2F-6[\Z7@''>@.[#X#O>7@_W:F?^:F
M\P]ZXZ6/N[/%*8//8+0%L+E%8((`>H?Q(WL2HBW`9>)([9!#5M4@[_&<M><.
MYLVZN&UOIVZ[EVG$2QC;`PG%Z8/B&$0>8=]OBJL;D(&FO;^ZJXNK'!0-R'L9
M6E?@>K6Y6F_$68G;8PVS[:&&OQV(%,A6305NLP=PR:_+KXM2'+?8B&OKZG+[
M/LZ'W4&,3S`MBX9_92-F`/]-G:\W=<G_]K+:K-O/^>7E;T`<Y;CW@;CR&6YQ
M<9O?<U=R&/?;]F7;87C"P.\V-]6F63WP?]S>5>)8QB40[FSV(XL>:>T7M=]=
M\;L(,1`GI+@N^-6]\5]OLO5NS.PV%^8>'W_YN'9+_*K,^(C9"JRJ;UE=K&]N
MF_[B[I#)UK(&W*TV#?_S^V*9ETONX8+;7CZ<=>#VQTSJ.4ERHGGS0LYI[]RU
MYOQ'ZXAY=K2C=0CGRKT_%\W_6)WGYR7/,;D>?SZ`O_!AA!TOC6@2$R]THP!!
MMT>/821YZKH5D$\WZQ9F`V$WZ`T'C[.FV9*F<3$T=<8]6?A8DVZ_U\B9*]>>
M+(+43Q.O.<0/U\+E1>]RL3#Q]*^W@F=D76JX:;H6?O?<RC9SYJE@=P7_KQ#G
MC'\ONS2S:4\?W^7P=B5RQYPR21:G)2K>70JGAQ5C^9M&I\VX<?HUKV_W.:>?
MIBF+O22%`0DH3SI3G/:P$\@&=>ZS!>OIIFN[35)AL$U;6Y+!,M>&J+DXL28O
M>R\A,O>>I[E044_`]IN3'-P[3KM>],&DNV9JWG]WB=9(.HSOD(UQTXRI5;+=
MS_[\:%L/0\>A08J=A#HP3AGU6;*#[PP[A-,VS.\@U>H-![8]3E2,HKER+_,!
M9%\.]MYB9^ZDS'P,C4C.=L^=^\>5W>[8K]GAD^?^&>?^Z>V_Q*/F2_Z/K%B"
M7W<IWNZ99_OY3;7B2</N$:EX>ENO'D2*M\WF=L]#=RG=+]O4[Y>F31?MS/!>
M=.BDF=ZXD'JW&=](6HQG?CK<-F,&^+A(Z>+ZF@M!W9!R^4=5]N8D1<VOK>IF
M`2,O<3`,'<>)0YA@&G@[L]R8.O-FAGIM>0<9XT%Q4+?N]YRT;V5Q5C[T(@UV
MO,R>$6B.R+FRS/F"T;[L\V<<.K-GK//%HWI!9748)N5AF"Q[I#]++7^66EIU
M(R$USR:]P3"C`._VQL,07<9O2$RZV9(2SC>-BDF4,!I[.$7,P1$,\:ZT(2"Q
M:T]EYUA+3O<FY=6R/9MS0R/!:$.)Z)1Q:,W]R<\0[$/0IEK3*4/1RA+4`7<]
M=J6^"EZ<K6955W2]N[37*%F35KCJ=?',A:]O&4-9@%GH!PF+D.LP<:0HVKV"
MY7@SO<2DTX+337&?5$#:G%5H#;DYBVJGC#9K$MD?-=#FWE.?.N`L*M@]N215
MPF>3%_CJBJ%WEY0:(6F28F"]+K6D1/@MHUC,&`U\F+K0]^(41K$+>Z-0D%)[
M"H?'6O(.DM(G):&GD#1HC44;RH^G#$/[LM4?/0+G3E_GBL23+VWND]]?CF2_
M)U?U;%-2;"(RWVUR;(2L2>NF];IX<%_HCU7Y[6-QGR\YO'S=_#M?+5E5?\E6
M>?S0_NHK_[[V^&#H)8%',1-EW<1-D0/3*(D#ZOD<0\0&U3WK']5P$BJ`@A8I
MZ*`"@?4#O_O_T'"T8O5O?P\$8+4CT#5ZX'@Z-R_Y<JF77MZ-=*\>3.,+JX8Y
M5UC2[=J`897I*-:FG']DM_GV)%>'QKX3AEX8):'+M3N&*>G&CG$`/:)'-"4&
MG%<OSX"`JGI.N![&QXJD(;*UZN-@GB=6QCUW2J*H0+WU>JABTV`I5"9LL`HF
M^>7ZO&S6=7LWV^JM$X4TAJ[O14[B1&D<A-A+8I\0BOT$)UA&\Q2^WK#""41@
M#TDMYU-A;9AN&29,3J5DN3*B1L\9.:(](^BS1&G&6%!IBZ51*G*@6J'ONQB&
M!#O(8P@F3A`'_7B.XPPJ[1D]R+2*,BY'4F=215\,D3A*9>;-?5[C9[#F*%!J
MI?*HV'%4?Y2)&:Q"G^KJ*L^7C3@0FE;E?5ZOB\M5+F`L@L@/0S=R2,P(3J`3
M1C#D0U+JQ:G+AO6#TC&.82WJH0'A7G``#@ATDEHTBL]A<C05E7**I,JB$44Z
M0M$14=)!K"6ZI,642G_<R92U/!ECKXJ'1=]?UN*QX*?=0\`%O]TC3AJCQ`D1
M1!3&'!:_Y\,BAZ,>]0;7HI@9WK"6/9UWAW<BCUYV`AURL(<N\XS=D&L&E&;,
M[Q4Y63QMATA4*LSO&+7R`HY[76>B]\/JR2M=HMSU>E/R)>VRJNOJ.W=.6QL@
M.BSL?+KDMIYM?]]V/Q`^SK[5>?N`=/33?R567WMD;]9%-CQG-VQA-5F\C]I+
M.(#6_2AZCGP6TP(N`B<)PRAR4M])<82Q"]O-#$8<WR=I-&*C<LRH4^\V'&#M
M_]'V96GACMI]&,6]RG;$5+2/W)]09'R"_8HC!`[>P-#A!$ON'`P8=G2+0Q]U
M.M7RDZ@>A`L7AA0&T,%Q$,=^[+'0B;E<.RCV(^3&4+-:#AS5%K5LX>I7RZ'<
M:U-+`[0;4LLW&)]++3L"QZFEI!-.1RUE#9-72R7JY-2R:389)X16S;I9>"B(
M74J0GSIAQ"*"`X3Y0"[T7.H'4#Z'E/KV2=1OBP@(2"H*)\>7A)(9HTI%L8:Q
M9$Z5#LEX2WV4B+-)9=0,>$E-1E`Q6#7^++/;B@O5/_GR<$Q1!5XV_#Z8"Q6*
M/.B$E$0!=/^?O6OM;1S'LG^%P`ZV=X%40Q+U(O8314F]6:0JA:H,>H'^$*AL
M.=&V(WHD.5697S^D9,G.PPY)D;)J9[ZE*K'ON>=2YU[Q<6FA-.968YMX`4D]
M&0D9:<JPGAR@`\^?FAU`27D92ZR8UDS(J9SPC*#3B`Z=)NJ$*&EB>"8*I<L;
M:F08CGH_'`ZSW&++=[S$3OP@\)"%0XNTDW>N'4-"H!NHOPV*VYCZW>_@,&=<
MU(LUY1V-1[WS2?"I\H9GALJ1[W.2+$[P'C?0)/S6)D_L3+1IM!LGW\A4:1%;
M`_^=TB4;6LOZ(Y/!.[Z"8!%6E-E^9'D8(C?@/P[[@%S/%;\'5_ZK#6O/``CT
MB&160!68$EAN-DN2G*I,SH_$ZJ]9GM16=B]+@#=5L0;LB]P+<)7_*)AB@`W[
M\_NV;P%O;\3^LV[X66_F"JVX4#VUA[N[H][@V[98+]FON^8$65D\9&NPRA:\
MSW;1-;CGY],']R_`3?XCJ\'WHKGGEP(<;(G*P%^@^ZL%'HKUNNO`5%3+#YNL
M:I[`PXXUL"I*5N!TC9B6X"^.]6LX?(#96F3U/>_)7]2@RC?,=T9*UX^?5L4=
M^^SZA9'^BT<O1+\*\+%%9O61,(<%Y!'HJ9;'02DY$#8L/F?%\A8YJ9/:,+*]
M(,!AY,/8M08KMB^T7J'XU9,E!XX(<$A*ZB=.E4QV,,*2:G:8BB"5]&"$J'^E
MAW?3P_,_Y7_7]D31EQ;ZP+Z;%J1'P*S2@CSZ-]."(@F*,Q@G=R1Y,`VCQ$H1
MBMPDB=W0A:A'`(/059_4&&5VZGF.%S<!J&[&-!$`E5F0R;@?.3&B3OL$<R22
M>RP-1F*6,REZ/#LYN:*1/&'M[$OV*YJ5]77Y)<_62<UMDZRJ>%LP_$"W97.]
MZO^POG5@&'@VL2+B1-"V4@<3IN*>Y^`$Q3@0NG?(H'G#6MH#`2UDWC>8@P8=
MZ@O0XP8=<-YF;8`NJ:HF0B.FKF>.BIS*&@F($;V5I_6$[AJ,T4STUZ2'=+(!
M+S/%$?4O6(2NU\QZE:UO4R].;!R'./)<!\40VK;+["0H9:9C/Q*>Y%#Y<L-:
M.D`">TPRK_%*?`G,=)BF2D[@SL*2Q'2':;;4&ZGN)RS:"P#JO'ILKW1=#$#;
M8T^[R9!?ZOW4PYH)P>CI@C>(.39A,(;#.4P9C,)/-0TF&:F]RLKE@0GHH<AW
M+2>)HH1801@D:314UYXG-"^@\KV&!9:C450-68($9-4@-W**.B$M$CIJD!YU
M">43>`?J64\HG\_Y.*:<BJS-0315H=/Q@T:R,T%-U\623TBTTQ)\)-77J^L-
M,]EV._Z<5>R_[O.F6&3K&G^KVS/&MTG@1P3"&"7(M1++LTB0=`V-(8H]]-Y.
M<+/&S:G+(62PQ\S?//>HP7/8X(\>N&@[*,.AD3L+?_X0*1^'-Q,JX?/N2LP=
MTT+CD9B#:IIWDDXYN*6N/FKHXL]7+>IW^X-Q7=-%P7'^7C3W7_(Z9U]ZC\ME
MG#_F:[KAP/NMQ#9T80@Q`\.J:N0'B>N&/;C0LL1W3DR&R'"AW/JQN^!E<7@1
M3-[AXY?)[7SIEK.KG3?MTO1R[T__`:D[7"8+JT#"G65$Y1+P/TDP92[6F6-0
MU5+VN\$MRL5ZN^SN>7POL./OJ]%$[+&,/GG@YI#AIW>:GO-9,50!_):7_)60
M8</+AZ(L>%W2%(_#<:(X<EP2LKJ$,%PP1#:*<0\/1JG0N>:I,<VM"KCK_.GV
MPSWSR'#J&!U<O97`E'$U7`O\O"$U4P],&5I#%8%\B*>L"]XA6$-EH"N$/UEM
MH,UMQ>I`+^UB]<%OE"Z_%^OU,`T1AEZ:\![^7A*XEN^&'AF,I)[UW@EYM2\U
M)^<]%,7Y4GEZ)$35*$UJTBA%EYBRO?3RF#XILS$'E5$'3W4,",D]G(.=<GG)
M1DAYQQLF=3<%[<]?W^0_FH@Y^.>MA2&,<&AC.X9I&,`HB084GA4)W5]NR+3A
M^KY'*[D14S>_IR5W!M0J:C*OI_90^VO+]F#!'QPN:/%.?6N'')LG]ET:"LM,
M]ER:\HY.,K8E=?.R9*\+^4WVXRV;."9I$,$XLN(TA!'R0]S9]/PD#%,IE1QE
MR+`F=M@``R>]07T<?V(J.!EU<IJW9VTF^G:*IQ-JIH7>F6B7'E^H@?$GN=N&
M'_GI%I>O5Z3*ET7SI:C_'*I(WW+#"$4!"=(X2F"`TB1./!^YH9^Z\-T&BYJL
M&-T_L\?&MV)TZ`"'I[Y/9BRI<AMB)B17>>?+.)*%=[B<IN+$5A9-',[A?5*C
M-]3(0).LG)X9Y@9O,E;`W49N[,4XB9''M!`2QPT#I[,66`EVI>YR5#1AN%IZ
M_MAT#TL+3/861U4&Q:JF"<@;H^EBO!FID]YFYD2%-)+*F=1&8[V@6L?76+6)
MGF[8-[37U4:ICQ&*'(Q2&`0$)S@@O<G8LH6.Q^FP,[WN<&AJ=U./XE-1@`Q1
M.5J%A%B<1HGV%,G(D0*Q<]4D%5?>$R9E>D;40NSSNVML0\^U`@];M@UM*_$1
M<6#8F_1"7ZK=S!@[YU(GM1NN1S&J6B"9(5.3/IWGINL3)$D53/+4SE6A5%QY
MMW12I4==H:Z*,K]L\H?Z-D$1]A+7MQ![&;2C!'FIM[-H>YB,>V,3-S.Y/HU5
M)`D&%07)#'GCW]HX+M`".[L<#13)J)$\KW,5(P5/WM,B57+$IK;W4^C7Y6\Y
MO:NRS7VQP%6>U5_RQ[S<YORR[>0'>\++;$VV=4,?V,..FZ8JOFV;?-G0M.(W
M(MRF$;$MFUB!GQ`_=I!G#^@<#T:Q\-[EZ2`9EKB#5:CK$NQ=`:TO8.<,X-Z`
MWATP^`/V#H&&@LXEF0GV"4,KL+HQSZC*:>\_3T`E5E;F&5BU%9@=X%U#W+P/
MX6((8?9&"'G[A0QLAK:`?.6FH0W[7-5]W>B=R]HH/K:R,WT,Y[`"=`:OZ5D?
MG$D+@QN:E$W1/-6$MVFKGJY7[(VJ6!3K?-=!\S9&#&9(^+5)D8]L'Z>DGYIV
M(@S%VZC-`.MTI01]G7DNAM2S$DH]G;._\.9EK;M<L7J'+_K>MY-F)@V#98H:
M9-IQHER<_&N(O#U$IJQJIATJDY0[O(U_WH^+Q7Y<+'>._02%T+M1,58AZ1L/
M_R]*)XUT:*VI=(=)>$+XZ^(^7V[7^?6*9)N"/33%W[MC;'_;,CC=6KX=AVX8
M01(G"0X=A&P[=&,80`LZR&8`9&:&==@S7/3T$-NM<,]`7H`.IN)&'RU<B\TA
M3TVS7,V@@V$C\\H"M)V88-9)^DQFFK6Z1,V-45G5Z]MW=;;X^5U:\FY>[>X`
M&$8$(IPZ%HY"DB#'B;S>:!@YR>UC7GVCPHHWRI;,0W@(2_A9W#UO>UCGV0)S
MDJ53SYP6=N?RM.EQYN5SII$B377%?G&);T6.$M>S(':B*(`V3H+>O!7X4C>(
MZ+)Y]OI":UTAP;6.VL(,S?KKB_,M7@ORIUQHR$=@+O*GVRVI@D.5-HFB@R[^
MO*SK;;Z,MU51WK%7NX(NO]YG;"A_RK^WOZIO0V@SY8V#V"(^=KTT2&V_MQZX
M:2Q;?6@Q:KP,:7&"#BCHD((.Z@7HP%X`!K?["]G3J;J8%]3'Z2F7E$=-7!LJ
M!$78.UD1:J5_+MJHV:M7-:(!TL16_*Y7J[RU6!4+/MO5VKSEA]-BWX6.'X70
M)2Z*O*2W!),8"R_2J7V]X1*P!P5:5/SAZQX\F94-1=X$UJO,4R:G5V=D2V+I
MQCQK:JLM_?W.O!_>.F_75.YSL-E^6Q<+?IUS1RUOV%)G7<E<MT\]_XG?!,T^
M]\`^7G.%>/N.Y4T;E@T+2_O)T<LM;S)Y;(5D'.US6-08Z0'5-@9E5/M3WGS>
M7>/-ES;:_-%;OXWL"*.0^*%GQ9"PO)"Z9)A3L'VAABGCK1C6<(8-]."ZO7==
M7=7CDU&G<6P*2/ID1,HI^WPXE!#ZR;A4OZJI9+QN>E[;5?96O@>Y9P5^MF)C
M'BS9"_&BX0E@E?,;G5@6V/4]K4?+^"F>CJFY%F[G(.IZ'*&ZAYV,Q'_.GG8W
MG/RU9%1]KPH^4/A2-U^CKC&_;>KAH:AK?O7)K<>,.CC&MN<Y'G2AZ\!H6*GQ
M'$M8\_6:-9P$>K"\6#J$"P:\H+M@;D`L(VF:(R"0)\Y'OESB^*EXE\@MY^-?
M/=DLLOH>T&VS6M/O[2V`"UHS_HMRL:TJ]KI1Y>MLMY5K>QBJY;-0+?9^[3^Z
M+*I\T:R?NF;=_%V#_<FVW?W.`I^5(.]F\^N<?8#],#IG2?%_+(F9">(<LIHA
MSZCQ)T!RJGX/8I@8XX..\(%]RPRPERC?CZ%%8!BSG[QAQ=1WB2^S9#G*T(2Y
M;3]EW#Y\+3[)2?AQG(I-O4]&IWJVDF/2R!3[*99.3*QK(7<FT^EZ?*$&1I_T
M%4"O9^UOZ&7YN*V[R?M;'WG8"E`20=]R,4H]UXMWAG%`@D#N<I^QUDSOK3BZ
MM,7+CQ9HO\8E?7?+:*(%ZN_).=:U<C@#>F4OO9F29K7J^M/VX5M>\:Q1YM]W
M4SA%1_ZR([^=?G\9@*M?/__:UM1\^CY;K8HUOXAD_(2."&O':F*MC,^A%-;K
MT*M[9?12)5[X5I0-I^;I,QN'#:NU^=:8]B:[H8VH';"OA[;CX,0)(X(C*W5C
MXB0PLE#,RG#12FVT(8/EV@[;!6C1M8_2@$^E(ZZFLNT]RD[5;MKHGDL!I\^A
MEU6<9JH4MLQ>T?+NJGC,E]T]"/^=KY<IK;YFZWRW*]Y-"`Y3DB+?"5W?Q5X0
M]`!\RQ$JZ?1;G7#;+(<*6JS]U2(<[8<5K3ZTB]ACS^>,#H"8")Z'>\F23R?M
MAO?3OL.BT(Y:79&8B4X:<.SHKEJ]U`GKYG&S5\.67N2ZB+B8[X.(8O:^'<2A
MUYNVV'_+**8.>X:U\MT']4ID][LYML7D<6JBY811#\=&%%&`N!-:J)/VF:B@
M5I>HN5$J,_D7;8OUDN_E^)(OUEE=%ZN"GR,_L'^;NHZ/L061944H1HZ-2=*;
M=8@OM%*ARY9AQ1L0@D.(X(:V3R5@*`&'*3,KI8-@@2F_B;F5$[F9TBHQU3<Q
MO6H3?7N:[RI:UV"15=43G]][S-;;'#3W60/NLQI\R_,25(>1:"B_TYIGGWL>
M$+[\SK//Z+F^]VD[-M.GD?`YS//I=(>:&9<R6>,J*Y?'+4(K]BV+!*$'8]^Q
MD8-@W%N,L),*)XQQ9DQ7QWQ"3YN>C614($-,1Z9D!3PG'B52PG1\*I[8X+S.
M)1&<).M8#M##\!SD7Y,G5/OPDQ%]O&##<-ONPHOYT9U%T;7Y/@K"M0BR[8!9
M3&P4N23U7-B#2%$L?H!#NV7#J>$`+S@$K$_F],="((.<-0QR2>5GC(!$[CEK
M),:^G&0'L5D>QN8,>4F6R&.IREA`YI"]S#E'IQC34GOA\CL^M"]+-L(>6ONX
M7'XM[DIF?Y&5S;[I8K^,&V.(K2#%MH]M)R6I'1.8V(&=Q(SFA(CMU])NU>!*
M7H<5'(!MMS8<P#WHRZMVN[*!*,ALZSIK--3457]4!#=SR7)U=&>7,=+GH*`&
MO:.3C%SE32A=0]K?BV6^:V$;/7W,_H]6`Y3HZ4N^H14_GK&#7W?KO$$,,7:#
M%.+`"WR.*R$]M-1.%/O%FL,SX<:5OAOZMR?0@M\_VA?\_P8'0._!Z*TL!L,H
MN\EE'A%4W_YB('B&-\0H,RZT5<9\/&>R?#RIRT>WUTQ%MW"N>&Z][28:6IC5
M]`E,,+1"B%SH(K>W%/@6E)%^A:\WK.0OGGJU*[=56!-36L.$R0EGC^,\[81?
M4W%"T4;P-A.!&N,!U3:().7C4_;`5.V9O=WEMP&.+"?T8!I:)/22""=NW!OD
MOY)1$74KAL6$`^-5Q7-14;TH>P298N(R#8^J&G.>6[&/<G)";,;S.!/-T>`(
MU3W$)!7H547US/;5L'W/]:PP=)TP1@&Q,0EBOA-C9SZQ(J$;XW3;-*Q..W`7
M+^1)4I6T$2RF4>?@5DZQCM!ZSLW"@J2=D#3=M,]$X+2[1<V.5IG5DE>V+S=U
M7GX>[E"[M;`3I['MN22U;1Q@3)#?&R4I$>^_.]J28:'K\`$.<)C@:2&"/4:9
M%9#QS`HL.TU*JIS"S8]/B06D27E56R_Z_.R>P]T-A^`N+_.J79=ONSWN"+_/
MJH<,?,5?NP7Z;+'KM\47X6VKOS*1*2EXH-704JN_:G'WW>/[!KS'ZK&5)6W1
MF,-"DCYGJ(D!.RIY?%Q\RHKJ8[XL%MGZLJS9K[=-?H#"22R,$A\1[/+VE'$:
MI?UB58I()'3\SI#I2=++AT,Y9,5?"QKL4(,!]H4NC1P?$)4D-&DL5++2SQ>&
M,;EKTG`83&;'PW1U1>0SV[__6^C8P7^9S&_O,2^<\+2%<)894)]W)U.B9A(5
M<^1-QC@J%BDKR>H#VRBPG`@2*_9@XB*/'XD/>]L)1.([K749/$<^W$$%+59M
MZJO*N$KJFX!L#0EO7CR/R6T3\&TPH[V(PV6Y^'66>>QMEH6SU\@@S3)GC?7I
M9*;20IAB?HKS-3=V^.[H^!BBV(U\Q_4L"\=I0/J)QY2$Z8@Y0`5CY\A+/4QM
M4JE"LDHZ,LROAE0T"VK'9"##%!O,/GOJ9YMX7I,KG'1&Q&66"6>,/R>3S6BB
M!,^>5A4;H>W]X_7O17/_]>EA<T_+ITO&!AM_-_F/)F+>_WD;!MB"+@P\)PBL
M)':08]NQ'3JQ'P1^*G'CHS:+AE/.(<[N@HL>*>!0N\=3ZF"C-JH%<LY96)9+
M/.\0S/D%?W"@H$4J==!)']<RAT?/P;E:)GIVG.D;W;(4`^J\*KI[)?LK8;*[
M*M_%IR@!LQGP:\L>BV5[(QE+/KR_]:HHLW+!_X=]DO_'@D%HIP*73,G6M&O+
MRWZWR*LF8]^SN[AR66WOP"(KE\6R;7\-P,U]7N>'1K_G++=E[.<E`],BL*T+
M\/T^+T%_;6;^@^EC4?/?UV##O+W/V'?0S7!0J\JSOVV+:G>OYH"-^7%790_C
MDZ-HT(]E2.V#9@YI4K]3U.1S)M77C55KJZ+A[8>'PUX$QRB$)+"0Y]HP#B.4
M=G8\$D5):@OU&5/X7G/:O$/3=MA6/&NJ1)1,YS##A"F>QI<E3K#?UVMGCPG*
M&%[FH!VC\%--`T2V+W]>UMVAT&N69:K/E)G+&Y9U^`#:X:CY)5EK6F^K?*]0
MV+'\)+2@#SU((H\)%$EZ/'Q>2>JR*E,@#!?:AX^,[*55QG@_K=BSHEQ.V7>0
MV]JH!0V>HP8];+#'+5B&F[E609'B$QMBC4=M)CMDS?OY\FZ&:8@5*]2NJ[NL
M+/[>G]:_WO!)-GXKX9`,HB1!*8&>E[+W"N3%A+AA9]5-,0I<D;)MO!5SC_HA
MMNYY']`IUG0:.)6H\*;E5JW>&\NQ6/GW+A/'BD%]%,ZA--3H#34RSB3+QD/#
MA-FC:SX7TJ'XS`9=/QJO5VDWR9*MO[+_Z=Y\W])1%`9>A&(+!HYCQTGB^4[0
MXTQ#RY8I)R<'9[C,//&D2E:=TX=-K!J==<344]<%>.9,&[M#=_B$XN`0V'LT
MDP)6=U1.%+9G&P`S*7C/YS^=R9.HW$Z*T#7[!>6"^)@?3K`RQ)\8^T=^?<-^
MJEF&Y"K:-3,)$0.*_(@$@8M]A*W$"Q/;=PA+G2YR7+7N4I/!,YR$#OL5/?,)
M/%L-XQ+'W/JP./8GX-"ST4VHI@N^6"*;>=SE4MF90FZX=96NP)S(9F<<!3/)
M9^=DX&B?JS,%0SBGW;`_OUX=6&Z;Y,20\-S)7N1@'"=>2NP`]<9B)XIETI*:
M!<.998RT*+;*4F1:+`>8)UE.QCD>+N&'BMP3FQU5Z7,TUWJ3N1,Z.X[IF4CE
M2">HSL$G*5BO-31[6S8_YOR^^5N<!,CU$X@L[-H0VFF$O!Y&REX'9*1,M^T9
MB]R+)U.MCY?V6(F)X3G#)">3;\;DN#Z>IS&8))TGM--48&:BJL;<H].,;TDE
MUE#:7NW[`I$X"2P21&[*?HIXJDAZC%[D2<GTI,!^%@V7E.YI@RNFZ[.-JYSH
M:TS+5V=KM*8S%B<RQEE"/I-T<A[?Z0R>.9F-*VV/H-TI(+QN@Y8O&QKO=]/'
M^9J!J]I9%"OV6>J#28AL8OM6R%Y1W.&E!"%/^%R.7K.&DTC70:MO8#;`Y==9
M'0`&!XAEMKEHCL#I7'!F\N64_J?B76*KT?GX5SV_`ZX7#66U,#\4XU[LS\.4
M[&EJ3\OPF]W`5;'(2WZHAJ7A`^%C?XC[8S;=T:M7+>GZXSV'AWCXMRSHPP,_
M<I.M^[T4=-5;_^7EJ1[0L,\V55$S]T#>%!M^SA7\Q]7_VA9T_A/0;5/S8\?<
MSE_+@@^D=AFTO@`D*[-EUEK\GVR3E>WQH((?:MUTZZ=U^ZGL@9^+[4\>;3<L
MY[!_;K*G#N_A^'SI3)U7CXP=!GD?V=&G@:3&T;%-6V8&XQPV<!GRC!I_DC7D
M;\(>G*)I\OS0?I!8GNM[;NAA'$8H<-$_V+NZYK9Q+/M7^)#:[:ER3Q$`/\#M
M)Y(`>C*5S*02[]96]8.*EAF;,Y+HE:BT/;]^`5*D9%F2\4EQM_JIW8G#>W$`
MG`-<`/?BP3Z*8_G\0C:-7D^[!W<M*X@>]OJZ[1QV:ZH]+<3-%=LY\G_HM9)>
M5UHZ/1]&Y5.Q;JIY]=2Y/H)4GQI`BD)M-`8G+--F[9(0:0O`&4GT;O8=6B>Y
MJ,X5Q"&F(<T"'_-EP6"=,F.!UC!Y/7GNV<FN5.B@KB_-C@&W)LS3P=I<E!UC
M_H<DC[B%7NS@&$&*WPX;12$V&'<3EF&35DF(L#%HZA+\M9S7#ZOJ7^7]+":`
MD)SBF._*,4Y#DF3Y<"F0^E*GIB;?'U5<]W[I4KL*<HJ:Z0@T$X$<%R]-W7.$
MVQ\B9R)R?:[%]=`Y(I^4^)NG<EW5]U8E;#\"9/1*8[Q,39QTFG!.B;3A4)"=
MS\5SM=PNOY8/VX6`\"5=W>?#>/U<+<I-4Z_*S8P!A.(T2U*44,8PP23/AN-=
M"*5NC3LP.XI([;SU]NYZ:<L.O</>WF-E.K;7`[*J=A7P=<3N_PCNJNIX%?S_
M$$T3T5SN1N)Z/Q)?.^DMBNUJ_N@M^][KMXWF:165QLQ%F;4^\":COO9;]D:4
M'8&GKM7?"F[JP!Z$.(`^`6F8@2A+,D8BO[>7)4SJF;&QD5%UN'7.`O<K(ZFH
ML"Y!--'3J^&GJ90N<?Q#%VWHXJ8=48/X;0;ULRE^1\-`1NIT1\[4A$V['>=D
MS`P8.=&Z?:9B-CSQ\5>R[>H^_;U8W\\2`#(09R'@G4US0D@6L=Y2GB12B9D,
M/N]8J&[_V]M[Y0FWO-8O%8K5Q$U"G-Q#IB9+5T1+08K<HZ8M0G_=+EY$-OIP
MKT#K<EY6/T3*>N\#"O_L"U9>M,FBA-M=815!W;?E<[%Y`W\O._-U.:A+X?US
M5<__*5+C+^LM_\UR>;=^:>N";9IRZ<W+!=__5'?K@F^+N`LBM;U(@H]"_\;W
M_?[OA2STG^^,#R4.VS__M5S52_[-MOZA>/NRW8BO[+7M:5US3\M&F!&58KQF
M73P]O8A?:LKYXZI>U`\O(BE^Q3=B/1Q<+Y\69=-GS?=CX_W8R>%P3HS,QLX4
M9,BP!;6UB60L/;=U.^S2)5_K_.#47C4OWU[$")[%%%.?1D&01CCP89K!).Y=
M`(D?FVF2OMTKB94XX.YF:/K9VSOM=5X;D[-!/^AJW#A=8$?\IHN^J6:.TPLV
MQ/2\0+8JRM7D`SC4UMV-D%VW_5NQ?/KE1-^=5-?OQ;Q:5(VH-R-V6]7J^[K8
M-.OMO!'9&OF''UO-[2Z<M!KK1L'.=HZ2M)EW\60UST+3WA5#6_!)JF3UL/Q2
MKO]:WWWIMNMI>P%J!N,DSD5EB,R/6$IQPA(R/`7!3$$.-0VXUKV/OWX6U1P]
M[IBW\\SK7%.B5UWX9%1L!.04Y>K*H*F(SPC@Z:G,?ZXX;;5<SH?M<M-?-;P@
M-3?>9GOWCW+>""GHZX9Q_;BOFLV-5PVQ/ZXCU6+3_I(0ETXP-D_EO/I><;E:
M;46V$&'O'_7=IA,X$144(;P7OF=L"X,-W^)?69=/_"\^P)L`A*UNE07?5?%_
M?&!PP0UN'NMU8ZY(IWOLK/08=O`D-,:T#;7%$:^J&KLH(GU^:K/SSA(29CZ+
M`D@@1"3-&-Z'#_F"2KXDIL['QU"+_NBD=TJ5\I0!D]0(EUAIZ,/H,"FJ@DNX
M3!7AH@CTI/O(?Z48CEV*AX=U^2!8O-RU2%<11/WD^NY07*QP^A'>E_A<MVNF
MPN7:_A_SN!D0DAS.)^N1G=O'=;U]>/Q:/G%!KU8/A`^9610%S`]A2J,L#4@4
MIRP=LHMEF,J_^;)E\!I<[^T\]097/>&K$K?9PEM&%JX`M06IF!+**JIR!;3_
MORG-R0?2S6XXO/[6>A@<XGZ#N4;)]=Y9W;+<^9/0,MMMJAW.%NTB'Z3\7J[Y
M\+LMGM/-IFQ3GGVJBKM=*+9-RWY0E(^%/J08I7$2PC#@0ISN:HZ0C`"U8E*N
M?'"LC(>U&WK'/>ZYU[G>QJX/G-<NP&&Y8R[KY93Z1$U"%;MC5R3#NU[M)TV(
M3S#O6)TVD4R1SIMYMKR%2UBE*9L[4:W*^X,*UIN+157;W]C7C=H5V`@P\S%D
M"$.?!M3/@C2&G7,1]5D@M8\9UR/'=+YKA'=8<7KS;B7DW:\=-$:SX-)(O2K'
M_M/K4#4M&*\OG2B#%?@OZ,2XW3L1U1BYT?4U9Y2YHAR8/N6ZJ'@2$$1I0D"$
M&$XPA9'OQ[TSL4^D3CC<>C!EQ=`JJN2HH[1%8>0^&E$$KE*<20MA-9ZWV&/3
MY76;C7R?QZU#:L3;;<V<&:`L#M.`9%F2PA1E80X&@S"-3%?WDE8FS;]Z-9X,
M(-=G6?MHFS.I',[7*N)T%D5%ME1#?L*,J-@0"=;3@<9MC.-U^.734(<CS@C&
M/B$Q22D(*:?A=/`1I+Y2><]1'9LP?XX1W=#N3X=!CC&Z<L1E[G$,_)HUEFSV
MA^W@AVFW3U<91FB[C5"(G0Y0U9^\7C7KZFXK;A4(-W+NWT$.,F[/3RC,"0UC
M*(H.)@'IC6=I+/4JP*[%D13CT,N626X\X:AZ#D;+>"L1_XA0ZS&Z"<HN&?HR
M<.]3KR7@I\6IMAIUFBRM0B9W(9*;W-2+-FG*?59PF_/RVV,ISCSO.$D7\V:6
M)C$F%((\#`*4,.9CD!.^#R!^F$>,2MW8-K?B;AX>^N;MG/,Z[[S?>O]D`PBV
M,%6XB#<NMGI7\$PQEKO4]BX2YZZSV8-P"A?9++:F=C+.%%=IW1V,?+M>B_<]
MO;$$YGD`?)KZD'-?EH<X[8T1[@52697I67"\"MNYXQ6M<_^A6J5>#S2YI95[
MO-0HO/.'KYMVD&E0BJ6J\J>`N;!4,@-R(DLCPT8<UX&W`(E\M?=B\RC26?+_
MT/_95C^*A<C=EC9YL5Z+_#K_52RVY8QADB:`)BPEF0_\E''=V1FG?".J=`O6
MCD77U,.]ZY+NB1_*O9]CU^.6`>O"]+(+]D2FF^5&'9?&=@"9_#5U\:;ZMEPO
M/ZY^E)NF3:0XPX#E%/HX#0'`,0@3!%EO*X9R:5Z-#+B^8"Y\^ED\B_>JO5<W
M_'_FB^V]>/'!_S'?%LZ[7%[#;X@;T!\"Y*O>.-?"6&Y=X!Q>M67!`;('#HU]
M__L$)I<N=YM`.!&&,FO#\;5L<T#D=QKSN7B"M?G:IA(4L>B_E<UN*3)+^'Z&
M`A+[8822/&`4,M3;1"A7NFQA9,@Q'_6^[1(J"N=NO%79E@<3I<!^%SN_CGU0
MJ+HK,0)8<G,R%K:*>Y0>UJ\'L'+/AEW+V%N5"S!=VK'80'<B/&6G+<?[%WL`
M*49(_E(N[EF]%AF./]6KAT\B&2HKJG6[9-M?7YL%?AP%-`!A#G.0L1Q![D"6
MAD&<)#A2>Q-BU[)K9NN>B#UR;]O,/B)Y]U4"!))XO1LXL(W[5.:EF\:=##2X
M@5!ZYK;GX:]"'C,2<TJ(@Y2RV,\2F."`]*$.1BC-5*:GQN<=S\$O(K]6=2]>
MTXL"`=T5EKJ]PC)_%?!47%GH`"FWGG",H=HJHKOL<Q3O')G#W@)R@:@,T)L(
M&YFTH+8VE$S.3&8^_WC"2,P8"[DI&"5L,!(B"F9-W10+C;.2=[^LQ":#$]+3
MX5;\$S/B4$1*XX#$*DA&!R/7/`V1/0611FLB]*#I_*53#T4(I$GAR[I^*M?-
MB[A:TJ2K>Q'@;0OL\!W*C,8H@IQ_4A`C!%B>L#@=;-((JBP[C`PY7X!TOK4+
MC[)W;!_AF,^W2U'HK+SW[D7-GWG59:P6OUXL1:J6??FA#RBZ@7'0_MT'#&Z2
M(+P1T=JG<M[PA>3B9>0)=PGW"_//2G=-9#K::4OM8#PK3M9?Z_K^]VJQF(4Q
M92%!01IF)`(Y\"D>OL]BM8DI_5''D[#W0U&KY3&1DVDG<*@I]/M(.&&*WNP%
M5E`&9R(,H.YW;3@J=/;\'U<-'P;5W:+LI+]EDAS&"!.:XPSA)$;BJN>P%\"A
MTDS7-N)XYG<;V&IPS&"WKP6API[?-7HZ._^]3T,0@+MUC0#`"73>"P.8`#H1
M<C%OQZF0@#DP.@''O_$F[S8<P$<T\&&.21X0#$%$LOY<@D4Q4#H2T+,P"NV8
M1A95$%,.+CH"RR2^N'?I>B'&O0]R448-&*?$+?J-.!]KU(9$,=PX"WV$HL2/
MLBQ"89P`/Z#9P%EY@M7CC.]^<I0`HT%@\7U,5"**5N'0"25>)8+X;NA0&I:)
MS'15KT\&"Q4;+3V7#S)='M_"#M.`H2CB>Y\P3S&%-`P'BQ3EOLHRP<",X[5"
M_XI@L?=0]?6%"89R?#`2?&H<<>#4!!YCG(?H`J%8P'4B)&.C);7U0:=Y(_-+
M\2*N4O4')-A/<)Y#2')`_83E"<K[^^<,4[FR2X8F7-]5ZJ\+/G5N:5ZT5,5-
M<C'B'C+%Q4F/ULZC:U^J?`W,I?6+&9(3H1K35IRY0FD$B@K%K+?E_5MNFT4,
M!-#'!,#4AVF0T2B@O4'$"%9D&4TK[HE&.':XVE'G&ET`I>EF!.R4&:>%[=22
M9WS2.0W/9=XQA'0ZU&/:D+?L8P4:E2Q$;;F!K^6/<K4=Z"[/4QA1``#CIJ(,
M)%$XA&IR@)5.@S1-C+31:@O@=#<J[ON2'NO.4_4$0UI0RO'0""BJD=!0`&7G
MT;48Z#0P%^C'$,F)<(]I*]XF`3('13[,4Z\>Q+,Z4MX-SU,HC.,@IT&`\@#F
M28SB=$=PD1^!7"F%IL[WQ^>;!?>R>R%ZS_T<.T#Q%J)+D0D#0"<R88R:<!R+
M,(;#("(Z(R`'041AEE,8(282<.6]I22"1.6D0^/SHYQZ]->J]7<&.L#IAC^M
M8F8>]KQZK%,IQBD-WE2(Q*`%[\8T%<'07><?G,JB!*,LC%@",HQH@++(9[W!
M-/-5\_AK6G&LON1H:3]<N9Z_EF6S);\*JEJK?D>`FB[\KW95XRP\\LM_#4@G
MPD,6&G)Y$Z`-C=8^X/"B"(IA*@JO8QKX<4)RA*/!&LJI[E9`P81C/OHTE:6_
MU)0QQ'`B\\6T%1?V`-J@*.OW;?%\L&@XL!M@%N8)(00',$XQS5.`>KN89DHI
M*8V-C:7F3?%LL$,PQU1-Q$>!4U/+117C5UN)-CO,U87]'&02^FZ,]D1HRUY[
MSJB]):#4;H&?MHA)$A*21@%!+!,Q1P1P;Q%FH1*)&9AQ3%_=/>=]]$^?P4R@
ME..ND5!48ZT.P-=T==7;XJH<90'5B;"3C9:<NCQN`QR=&.LLA''(UVYAS+*<
M\:]&*`J'^(L/$\W@ZKO?'26J:B6:^CY$RF%4J^AHQT^O%S:5BY=*HS01;M!R
M_7R$5+'Y\GFXZ^6RZG)[BN3#]:JI5@_E:BY,LH!0'-(X)2P`>81RC(/>)$TP
M4\J^;6#']>'DWK4N]?:A<XI,802G''.,A:0:DQR#F,N!Z"9Y^7F$+G"-#5PG
MPCU6FG*<GMP:/-+<)))]-"_#1?<81R`(,<IA*@Z709CZ26_%!T1I?Z3X:<<,
MU'FC^M1%%1XY>G&(C!JC=(Y<[Q'+:R`N$(<F8A/A"EWO:RO#1CF/UBYL\ZVI
MY__L*B)@G&,`?>3G-$Q1DOK0'V+.<9(K52G0^;YC;AA<\C;"IQOOPY]]X#T5
M:^^'<.\7+[SQ?=_;/!9KD=-SVSS6:U&S[A=O5?=_6FTVXL9TF_!SVVP:_@,G
M;T6ZT<)>CG-<PZY&/'O$OW6(MP[=>!];%$=/+/8&F@M49`+D1/C(J`EOLH>9
MPJ&TCZI7!W9\A,*$)#EE$),T!I#EPXVX```E6E+^^`@[IGIU0$BO&2GQ_7.<
M%,/P)@I`2T4A"&Y0D+PF*=DL?I8Z07[+Y0Q_]7T6AWX"S'0,RCM;*RW\)L))
M^OZ?V$09`"'_LN[^OA(WNHK%EZ*Z_[C*BZ>J*1:SS/>#*`8@1A"*I.IQ&N_>
M"D<@!#12>E>G:<,Q-^W=\D2Z\Y^KE3?O/%-]7*>+H1RGC`&?&K4<("=<\CAR
M^7O(N7E6=QJ:"P1C"N9$>,:X&<</ZJS`(LTZ7\NF$,6T:;%>\?W%)MUG]!5E
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MF"4A\`/"K9`X]H,\"^F>S[,HFZW*!^'VK3R?:EB1FK))-V7?."1_/VGG6!]1
M*QI.G9OFQ@,W$'?!,@R"7:#,*$*F`[0<6;H"5XL/!T`/XV0C<]U;0"[0F0%Z
M$V$LDQ;4UH:2:MES8>&Q7G!L-MT)YBR-`PQ9G&<PY(1&8A]'_6,O0'.@]+Y<
MX_.CW(0L6U]4RY=K8"5''8YA4J..0V?^W=M=0DB;9EW=;1N1%,UK:N]+<87+
MUF]AND`H!IA.A%!,6G!<R=P4#)W+U.GJ_H3="/,54QZC#$<D"@GFN];!+F!4
M]X:UGK%1R.;@VO50^4N9?,QQE:.B42%5(Z9/1SC2=W!T?6W[)#X7&,D:M!/A
M)WOM.7_KVP90[W+7XGG]O,MLSNT=6F^&>LS[;,,(4X(03AD),4M)!N*`0A#&
MD`19XK^W6[!JRV$\I:M7+J;9JVG7>,++;CLA=3/1(=#W-=^Z\U5(6Q-Q>H"_
M<F]\X(_83\#0<AJ`.T93`>8$JSG!]<K,YJ9-M<.!J+@Z&PQE+UG!Q]V\_/98
MELVOZWK[5*T>;L7R?I:D#,`,H"".$/!#2$.?]+8)"91R#ULQZ#ALOY]8-][=
MB[?STVL=]7I/O=]:7V69SB[@<DNWT;%6DQ1+,#M9U<E`=V%E9Q7YB:SN[+:I
M=CA4]3EP^/$O5;GF'WA\^53^X/@^5YM9#C(?$A1D(OE1D*"84K"S'E*F]O;/
MDLD1>7#PCJ\UN&L&M&>$L3+QC06O/O7)(^N:Z2Y@)<=U-L">'MM9:=5YOK,'
MFCKC?6Z/%<KV#>-;/TB]+*K5#.=!F*(H0`AF*4@0@1'JG0CR0"G]FEW+(_+?
MH;\WAUNO@^G;>:U-C78Z0Y$A1^\'7:)4`MHM4\I@)D.85K&?&F_:;=PY^G0`
MH3J+?EP];9M-R]K@<[F\*]<S#!/?ARR.PQA%`*649DEO,DL2I>SU)G9&9,C6
M+P_HLI\.B(I<YQ@__25@Y]@`H?=;Y]W5".XM4#)T9@#OU,C+I"GGJ,H8'B-B
M@CN3<1H0'T1I$H3,C[(H3G"_APY1EBN5336Q,SHQ00O$)`VB/C&YP,\6,<$I
M$1/4(B95>"=,3,I-D2`F/7B,B`GM3$949,B`<99E>0BBA($L[$TF,%9Z'6YB
M9W1B0A:(21I$?6)R@9\M8D)3(B:D14RJ\$Z8F)2;(D%,>O#(Y]7:--6R:,J_
M?Q^,#S^0:C-?U&*7N?.!!9#B-*(I9DD(48:3(.]]P#E16D)9-3PB=;47V52S
M<UD%68[)KH:O&K7U;HHW2`<AKX/HQK483@7`"Y3GI!\FPH%NVG:<3<P=@#H'
MI0<C,RLVU:8]K0"$1"1-(Y0'OL^"6+Q.&$XK`J"WM]2T-84K(C?>OF>\CTVY
M]-)E5QK>]`Q5#W[EPU/GR*NQY"$=MOY<_<3T%$!R1Z5&T$Z$^*PUY_SAJ`68
MU.EM/VO%I-W-V=U90ISFD"'L8YJ$6>!G#`>4VX[YGZ0Y(Z$6QYD8'(WH7J]&
M#,\ZC2!6Y+&QT-4^V50#UBVG70!+AMAL8#TU=K/2IG,49P\P^92Q76W+@UO&
MYU>2@-LDC`1!A$",6":RL@D7<LI]@TSITIM-NXY9;^?JT2U[M>V8>^SE>/!:
ML*O1H0W$W:2;E8?O`D&ZZ(2)\*23IAVGK74&G\;F]\3]9%:M^)]5Q>);P_?H
M8KCFQ9/P>/.I6K7,OIG!/(C"-(8H18P`EH,\BW:KU@C%@5(>).?.C+A]/K=W
M'IKA#>WP^H9H[YQ=]9WJUGH"W:9_^*+38]YOHA5M%.2*&W8]V*5V](Y[=")D
M/UY[S\8$1@%:/LMYL7D4U5_X?\1;Y!_%XM55Q+TZS7"4Q"R`.8O3E&`<Q&%$
M>P=$QE&E].?6K#HF>N%A5_U(_'#@ZZL[U'M_5=.;VT-?CL&O`[P:5=O#W$V6
M=%D(+]"N_6Z8"+\Z:-AQPG5'T,GG#_U15`OQGH_5ZV_<^K=ROEUW%?T"B!$*
M:8!8D$=A#K(T[J\=18Q%2L%5`S...7'P[.?O]?KG#??-VSMGAQ=-,)8CPI'@
M56.^B\B.G=CS+$`7>,T"JA,A,ALM.<[,:0L<::KZN/I1;IKE.8*$!.49RM,H
MP_G_MG=MO7'K1OBO"&A:M("/(9*2**%/NIZFR$F"Q*<MD`=#9U=>JV>],B1M
M$I]?7Y*Z['J]7I,2*7&=OB2^K#4S'X??#"^:,;%GA1[N"=*+;$^$KD:*4DQ9
M>]K)(:BQR/*1U(2@BA'5&#R5L-5II$XPEB2(-6$M6=842OQ0D+T.&Z<?$XV1
M'?D>LKTP<%T;F'9H=V^@T"K&0J5=9,A3S&--)?`]'>6PF12D^2AM:I#%>&T\
MODK8C0.T$Q0G$W)->$ZJ284Z#QU>:_28U,B-O0!89H!]UW8=%$81[+<`'0N*
MD-U(48IY3CK#C466C]PF!%7P]*,_V:#[:N^+S4W_`^W(;C#/24)?$XJ39<WS
MI4C'@\17B#0L-E6QSI>TE4)_P%%]N'E:![6O%A@28O4#/[%AB(A&R/=,-P(A
M`"2O#$SWI?63*K$*][SWE-V=/E;T?8I]??_R)Q<"_/>NB/FP>J4JQD.@=.G,
MXS*LBJFZ\>$K:RH.VA&B5`V_#L5.59I73./%<CK#MK>)0L^#+K2Q&3AAXL<D
M6\6H$VI!1^BUY'&25)]*/.YU^M-;CEZG*O#D/'Z8#$K!$X@#%'<=8^>ZOW@2
MJ5-'$5(0UB09E&0,7S/901`-;BG;2B/<Z!$Q2>!#S_4#9/HV[*3!0.SH=*`(
MU03UM+WIR-:QO-#Q4=($J(EQT=,6L3-1T'%D3G#/2"@U(9VQ5KS0\740*#*[
MO+8*(`)-A#PB+#2!Z[E)'#B=`G80`,G]73FE3DA&Q]J+_LPZN[Y3T]F5%WC.
M5&H6S`73*I%NKK-E6KQ`GLJZI`^&)F2HP##QQJV#H!O6LK4594(7!8Z3.!@`
M+X#`CL*X$95`V_:%EH]#GJ^8!A]W%1W3>947+SY.4PV5&'L]1FDN>CJ"R0DB
M&H.@)I0SRH13#5@'P<'_1D%Q=U=LF*#/K+WQAVU=U>EF29*^:\>U30?&&#NQ
M%;L@#`'N9;I.DES?9V5>T!VULN9CE5'B1.;,H6;<TZ=]X^.B[?8L^HK`*#CY
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M5?EJDV55\^MK9&$4H=#Q$X1<$G_]`/8IJF=;7"<($L4I#D=4/58^H[BAX8BN
MT"JV+T08;=FIRBY&M?H;;XGO&O\@>0L[Q'OW+A1<"LL<BM,Q:*91$(LBC0)&
MHR!%O0>ZU[%;+<\`L,!-P.F!'G;Y[\/&^.=V_6`@\\(@$="D9?N_Y]2IR:.R
M,J.1FPQ#NC%\\O`E^9[>LOZ4534[\/E('GM+2,WXP&IZ&/ZJS)KB,M_R^O9@
MFM"_[*<*_:;*[[9KLAC.BFU%=,B^9^4BIUE!?9L=/OJ"_I`PZ(-19NF"L&9)
M.Q"S#Y;%JDSOJDOZ)W3^UM1QZ&_25F5BR!V;MD>?VQE\3_.47K\WP#3N\O4Z
M;Q7/&Y<$Z`(B?&%[H)WG+U)%_\3B,=20YD0T"E0WZ8*!1SY,<$YWF=,;9/<Z
MT-!!5'Q@X!:_K?,5&^C+7OUT79%QHOBSB7.7_IX9VWOZY1MK]YC\D8#V>61.
M?;O-%[=DT-9K8LVFRJN:JF.;?VZT>FA^2@(\D]H++;-%EG\EAM[O04\_OB;!
MC/P!':(R)<&NL7!+AJ-L976/(&-'<\:4#$Y>+HE*94W&.%_=-HDDQ9:Z1;K.
M_\B,=_\!)H(7S?^(I!Q&P8X<[\E8W*6+;%OGBW3-EA)%E3?5C>Z*)3UZZMRE
M(EYAU&FYRFHC)2)N"P+LLMRNC`7=EJ&W'HDK7=WF%;'NGHQPD]+2OVP&/._)
MZ?@X+[>]:S:[&)=C;\ARD<ESEV+E,I$.]V`E6U0HH^VAZ=C54\E-'NCBT+/"
MT`U=/_!-#WBV"SK!"%M<6PORI)U#,B:V"\@Q_YY#BV?ZC49:M]DWWJ#G)I\D
MJ/CWS*GLX'!YYI<D.*V:$N</NX]\;,*F_RTMETT64?W,HMC;3;.`NPX]`$T(
M3"]V`JHHQJ[9,X03!B)[@!.K-M>L;G*#]NV2M^03FYI>'_I(_KH:>+XX]:#R
M;0)J/)X#%FM']O&,/5MH!X[]S[7V&,R@BS8')^/;&$73T\:L"^-]QE+0I"AO
MLKS>GAQ]-8<Y4L?IU$'0/`ZAR:[>7-8?'D#-.0AB1[M-A(S8,J,1QT+C<0NN
M09C$&(#`Q3&(HR`QD1EVFEAA+%3;6(%X/</-"VGC9&/#&5'F'1;!J,'@;W?X
M&G5[SF^+&#]_0#1_4!"&^J4;`&K&31=R5VCAL1L$*L$<2]+-\N9]]HW]JKHV
MR5+&Q!'R'2^)/<N,$8KZ$.&&2`(QBXJ<B8POC$TSKV_8_OY+N?Z4$_L`0?')
M/'0(])[`@ZWBF[3C0).23>V$HS@FPESDQ3X&/@[<"/:I7!Q;0G78Y$C48YK*
MSI$$$!^?%JD!6WHF1-1L/J`)'3[&;F!J(XZ]WF0XU"B!!&8H9,->D&(B?7;(
M2C.FJOXEJV_)HM:!`$2>@SR0),C##@*QT^=+B2>4L4@1J)@(/V7WW6'Q`16.
M>9UJ,+I\K#<YL&*D]_B%JY[H.ATO#*JET:@YYUM8SR!W@O*D`J\)X\FUZ=2+
M6W(`X^:[]UG=O'=*7TN^!C9"5N3841`FR`'8QKN%((98Z+A&[,F*&8SNEZR)
M'A//I$<8G)@RP[#29&X,5+Z0X2XRWUL$MNDC#&-L8<<-$AC%;B_3Q9'7OAL4
M;Y9\$V"4,/%WA#J]Q-\0FF6?0<6+=KR@:C)QY-@B\J*=&$!C7K1#`?9-%,(P
ML6%"1'B1V;^T!,EO1"?3`!%33J%S?,F.%S]-9LL8"UY^R4X,#/Z9L;C-EMMU
M]N'FE[1N.\%\N'E7;%9767D79;_55[1;S%7VO0Z(L;]?^Q9R+!PA*T`P"!%$
M3N"192[MLN`$9B+4KT6Z<,5)6J<O763N-*;?49U_HK>7#:JUZ%Z;]#'@W':;
M$W[!'3A.Y(TO3&6#ZFPPI:>N$"(*ZBE*5#4^NA"F,OL.Z50MD`/(]N>B6-([
M_$SNM1,')K8C/P[<,(8.<*!I,W$V^8WE),,X54S&A-39*=9.5MZZX:-1%&5%
M=0`.)S]^[!2SVR-PN$AL&)S:<=5`,YZEI#&P""R`VNK@P;;*-UE5?<Y6[(4B
M_WM>74<0^V39Y9MQ9,=6$)EF$G5"'=,TQ0Y.QTA2S$*=3D:GE/&%JB7,0./0
MY#T4G0I(03;BA4[1FO($*B>7ES+0U(6,Y!CS9-$I#R)^8FID1,5=FF_((M?!
M@6LAZ$<@\A"A/!]W0B`,A<K@BCU9=?K3*&-\:=01)APQE#@)1AE`0PGE17#4
M4,H^#J<H9!!>NE#&,.4/*6($!-R4T"5$[P@)O26,5%U#'$:A92<@@!%((IC8
MB=4+"FVA_$3\Z8JIH5-(D!(&H,1'"VH!$J.&W6J':F,P=::FAR=XG*"(X=AI
M0A,C#"ADN9%86[=LG2[237W;R;NV0\>U73,.?<M#@>6&D1_T*RC;Y[H%.O39
MBJEBIY$AR!J#P3K-&5/@),88,T`DU'9.*53C*LL`2,N=F&!7:(56YUAG=5OG
MA15S:6IUT)VH/:3#HKPOVH(CM&Z)<9>5JZR\W.U6I555+')6B8;5FSGRO#?0
MOG2[\B==G9.#PA[9]P5=O;<%8MX@YW)7^Z6_`7A?TGITQ=>L9)^ZH>U$V?%G
M]W?LC;+U`[W%2^])YTOZ2ME-S@X.B*(9*[.25O1K^D+[LJM2L]COOT?_IG[H
ML;HTCE8B6;4`C*XL\M1SCH2AL3ZF0]6",>H7<J;:L`#4E2OZ2-WO.L1V$#LH
MP;:;1$2B`Z';R0(NYDI91PF8+A3U=9J88L/85A`\H:BD#K?!H6D&R`9%*770
M:1>J_A^K'BLE,6(]\J*7P]8PI],K=@VTX7@`&P,(9TVKMH0/K<NT"Y>!Z46F
MYV#+CH#O.LCVPTY0;)G\"ZE!3U>](?NH%-60I<(PS#@BEW*X!+=G9T)*I(:G
M:L2DE^SL"VCFA'P/:W/2*I8GX]FC(1%<90'W$K\0N9JX0DM&TN+&?[#2HC2@
M;+*F.&3_[&5VDY6T]&B=?C?6)"CE:UJD(VU?#F&&+/.EL2EJ\K1JNZX-RIA=
M:'P<<`;$L='EXH[XS7/Q:92/Z1"<QAE0R)INPIUZJYIX!VMP7BQ^_W5#)LRG
MS[^VW:,`BFP3.@&&5A@B#Z+8`LT]K=".$89B#7O'2%(<KG;*M?W/F'K&7XF"
MPLTQ1T+*=XHP'9IBT>PDD//U]CT!UHGC!CD@:W+T(,F8)PU_Y4&DOD9E<]?_
M[8;HS/*-BC7AO+I--VWQLO?%YBNQ*%N^WS(#'#?`P/>ADP`,(M-*S`1U!K@8
M"74LUT=KU;G_^'*(?3FRWN:VI6Y-K-X52^P-)U\RTZ>JBRG?D3COE&BCL,(%
MD8[NHU=A3='1/'7K1CN/TB1>:@B,K$J=BH=.ISC^[XPV4,B6_M>L3%<9*TX:
MD<5NDN9E4T<;!:X9(@?&/H8A0*YOH;"SS8..KUF('V_0:XS^'2I&"TM31MF@
MP!@4F::ZBG[9@03WU"9QF-8SSR"G&.N4YYISO.@(\Z8C\OSTQ\E4)&(V?1(C
M>\`UR&\.BJS[&*$D"1)@VCY]I]:Q@[C3W[0CL=+FNBC]:O*4PY8.VJ0AHEXT
M=ZJAT(%T32?X?>?,L@7U34%4N=.KC_I#<9DLLH\:..VB]\OIB>/CV`.A%45!
M:.,8!J'E=0;"Q!>K7W$V5KW:^']VVQ72_56O1&):5SV73..'V[\0=`H-4A9Y
MCON#Y302@9LIZ9$]]!ID1?]BFS5]5F>C,/(BUX(HBDT+AB`*DTY_`(%UO<E6
M]-;BE0ZYCZ#N7/'":^+%$S,UC!V-^1KN<(CZU-R)B0H_TCSOX/>=,\LG'H_E
M+.G"0'=Z]=G`4%PF"_:C!DZ[6,YQ`!.CT#6C&+K0,1/H):'=7S#Q?2!6(>]L
MK'HU.QR'''YV.QS2_56O1&):5SV73..'V^$0=`H-4A9YCON#Y302@9LIZ9$]
M]!ID16VW[KW$+H".%P/;!R3!2RS3PW'4OR!#?N-HM<DAKOYKV^?H$=!PJV.`
M<\V=I"AR*,W3$"$G.K,,X\F(SI)##/>K5Y\EC(!FLCQ@[/!QUF293O^#5&;_
MWJE%2_N:`89F[-@^BBS<VX41U\6.LS'FU>QV'"'P(TM)X5V.LQE(KB([9V#'
M*TTF?BQ?%"EC=`;VB/CDL*I)5[>9\:USD+1UD+W">"FKJ;=B&V&T+)!QGY5U
MFF]HB;RZ,(CS90R.UFU3"I!Q3T08Q<X_TZ8[O/'7HC2VF[S^FU$TM9?8!\E'
M:J)#2>3V[KO<EDP"T:[,[HNRIM\U73G'UR&:?^"/Y,&ZJ,;MDUI463HGO(HS
M)1_1IMII=>MOEO0_JBRA$:IFE%>+=5%MR[V^?X'ON@FP/0`\RW,BUXE#LU'`
M]&&,(I%C/GE2%2>F5$-6JHU]L:<K^^%;]I(:&UC!K22)L/-M!,V#N%CF]3S8
M.SV-+_.U+^7&\,3&B?QQT&3;0X%AA\W1%4&WQY7[#O6.?$5^V/V(_$.3)O*3
M_P%02P,$%`````@`8()L1G8+='OO=P``V_4%`!4`'`!L>')X+3(P,30Q,C,Q
M7W!R92YX;6Q55`D``[/T`56S]`%5=7@+``$$)0X```0Y`0``Y%W;<N,XDGW?
MB/T';\WKN@R`("X=W3L!`D2/(]SCVG+5]KPQ:`FVN26)7I)RV?/U"^KFFR1"
M%$AK['F8JE8ADR<3!XD$F`!__>O]>'1T9XHRRR>_?8*?P:<C,QGDPVQR_=NG
M[Q?'XD*>GG[ZZW_]^[_]^A_'Q_^(OIX=J7PP'9M)=20+DU9F>/0SJVZ._AR:
M\L?159&/C_[,BQ_97?J?1U=Y,3;%Z.'H3W.ILY'561X?+U0=S?]F?_QQF9;F
MZ+[,?BD'-V:<GN6#M)K!N:FJVU].3G[^_/GY_K(8?<Z+ZQ,$0'"RDMK8HOZO
MXV6SX_JG8XB.`_CYOAQ^.K)&3TH'_8N6O]S7/SQK_S.8M8:<\Y/9OZZ:EMFZ
MAE8M//G''V<7,Q./LTE9I9.!^61]<'3T:Y&/S%=S=53_^?WKZ3,%(W-_>Y,6
MX_3S(!^?U"U.1%&DDVM3=T+YIW7^Q</X]B:?/)P.\LGI9&"AU(A^N2G,U6^?
M1O?%O74`Q!#-S?^+HWCU<&M^^U1FX]N1=<1)%TB5J=)L5.X)^(66'G!_2R]'
M9E_8SY5X05V6IBK_9D9#G1<7::VH`>$F@4[0N/9V@UPGV!Q[=+N8#V11.JH#
MP\6-,=67M+#<N3%5-DB;_=8LZ06?F9BKK/IBG]4(Z'53SP@<&;59PC,>-Q9M
M%/"!1J;EC9@,ZS_B_YO::7A4AQ_[R^GDSI35+!@U`=Q%1U^8';NZA:J^+'`C
MQ^Z:O.#/1Z/T,B]FB9=]V%DV,)/2B.O"&#?*N"KH!:TK67;4TPMV1YKLIL8/
M\O$XFQ.P)F@^J6Q";Q<+F0O:1M&.$2YZ$NZ!]*6*?A"C_1&CGA"[,M=1@1^T
MDS(?9<-ZG?HT/W)`V2#H&]U%9?]_YI7SJSKXZU'^<R>46Q5TBC8?WQ;FQH:?
M[,Z<Y65[U)L4=8G^HLH'/V[RT=`493WA5@]MX6_6Y`._,I?5^>4HNYY%_$8?
M;VC>`1+7R-H@UAVRQ@C:(-8!,K=(N57("ZK%3IZ-P[$-P]7#Z:3>LIL];OEO
MC2!WT.$#\WQDG=IX;)]V9\3/M!@V>G*K4&>H7$>&DW#7*!M'B9-PURB#?5`&
M?:'$^Z#$G:-TBSX.HCX0ZC0K_B<=3<T?)BVGA=MJ<ZM09ZA<Q[.3<-<H&\>S
MDW!G*-TXZ"#J`^'O>3[\F8U&37!>MO/Y;,<MBPW-?2)QZYKUK7W@L"$G'YMO
MZ7TSB#5-/2-P'?-;1+I!U#B^MXAX1N1&F(T"/M"<%]?I)/OG<C?L_-84;NND
M1L%.T3D.>E?Y3K&Z];*CN!>DU8TI9'J;5>EHMO9VWZUV$.T8H6O/.VOH&*]C
M[[LJ\('V2Y%;=E4/]<K3YJJW+JO5;3)=87*=0EQD.\;8.*FXR':%T8V"S9(^
M\'TU];)(#`;Y=+9_;9\ZL7\=N(4?-^GN<3H&H9V4=(_:C0>[Z/"#N:R*Z:":
M%O9ATO[CM0O&S3)=87+N\T;1KA"Z]F^3I`]\%V9D!I49_O<T+:JZE%%GDW0R
MR-*12JNT":.;=/<X'?M\)R7=HW;CP2XZO&#>]L+J>=G5;N5;>ROV8MUT/$Z+
MA_.KB^QZDEU9_<]B:#[*7%[W[Z:E/]R+7\IZ;LCN:FKXL62SWOYLJU_YOBX:
MNKC)B^J;*<8[5']U];P>?9'/=JWG*T\[F@HSS*JO6?G#D^E-Z@_`4M>0[_4I
M_=F]W'T\'=^F6>&R\MM7;W^V/3[[_.HLGUR?V3E@.*\\]F.DPP,.PEJO''9_
M3G^V_]U4L\G=%'515#ZYL%H\34E;5?=GH=^,X>TRAS9[3?MK[L\^NYHR:3&H
M*X^5N3.C?(8COK^MBTH]]9[;,WJUN2JR>NVPJ+GVGB.Y/.$P[/4::G=X4)_6
MWYG)U.H=Y+95G<CX,G:3WOYLNS#7M7.?5%[5J;B5F`O(:5GE8U/X[>66#ST`
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MM<%663Y(=A%/`L&#,`94:_L')U"0D"O(D"*4:BK5<V-&]:TJ>;%THC=KOEDO
M15;5CY;FK.031@4(<$!#1"F(%>((PJ4]1"O19,]36HAB<)070U/\]LGF9?9?
MKDQ1+&:=+?>^S#A2O1K/:3%X1:[G@HL6)[>S-W/'@YML-%Q*UW?B=-F]>??.
MMN:M1M_)R^'7]:!<NX`\\+&)F*2"8NM)3"(8,-M?@9(8$<8()ACM.C87#IR1
M[BHM+V?,FY;'UVEZ>U);>6)&5;G\96;W,8"+^X[^LO@YJ7>$7Q^X76/K=H%$
M!IB&G&"!N5!41AP$*^L4:XX\[VRD.G=VWH%WGPS-_G@3/?P]K::%J2L5EC\_
MB/NLW(5+&Y4D3*$(B5@+%4=<<Z8T6WD@)DS^Z_/+%P6:&.7+Q_VS;`%<Y>,T
MFSC3ZIE4$FN.L`(A$@"`2-%8X'!I(\(`OV,>>>CXK=S:Q]%O$K)L3F).*S/>
M*42MA!+*8F7_)X$.0\ZAI#B""PLCAE#;D(3^!:CD.22U]>EVUFQ(]_Z6C^JK
M+&<(BNQR6KO_6UY/X)LRO,T2"5!!Q"6-6`@IQU!BC<@"K^1:A.\XG+3HM+P+
MI[8BP9FYS^RC+BR(61E$^2U?`MK$@BTBB;9+)P6XEDS(`"`$2<B6B'4$@G<<
M"O:D@3^O[L.#>97F_.6TMC8[<F&36!)"R1`$<62]0"$@$$BZ1,Y82%KR(?@P
M?/#DV7TX\27-AJL@96$T<.%E\R1@!+*(<!0)&."P7OCQ)5+!9-OT`'\8#NSI
MT59]OUC/KRX9.+^JWW,^O92L^I(^/*O6><F''50DL0HAT2!F,H:,(1)PMDR2
M%8Z#MON;X?OG2'=>WH<W#S6(Q7-55LY>R'Y-JW7[:2YB"=422848%-8``H`B
M4"V12\4:]PPW\(-\&'YX\NQ>G'C%R%V8L54X078B##4#,@BU`E);-B]G0Z61
MX"WY03\./WSZUU?D.)V79C?-,.M$$D@C+H!F$*LXLB3G(5K%.AOVVJY$V,=A
MQ/Y>]<6#QXO^=F#"HU`B-==0*BXQ@_62FE/!5O,>)W%++O`/R876?O4[=_R1
MWF?CZ7CG:6,AE\@XT#9U%CH2C+"(0X#B)7;(-&B[804^#BD\^=8O+[Z8HCZ/
MEU[OGE$\BB9<1X&<@28*XHA&,5W%N8"3J"T[/L!^IG_W[D60K^9Z.JI[YT'<
MWA;Y73I:P&FBQT;!)*`8BYAH&2,<L"BPR9%>I<R8MGYU]@%V.7T[US,UOIKA
M=%!WBWL4<5*2<(A`$+.`<R4@E7;"U"O"*Z3;[H/"#[`1VJ6C?4>6%8ZS;)RU
MB3#/%22:$!$%5&"`021#*>VX6%@3<X!;OU7[`'NG73EY+\H\+J?JDR.SQSLM
M:S;))0K$-DK:51BS?V'06B"C)785ZK;['O#C;)SZ\JW?+/9TLNU-2X-8HN,`
MAQI'*.)!`#A"000L<LQCIC%G;?<^X`?:+O7C6K^DR!RWPS8*)DP3J0G"FJE0
MQ5`!">O9D6!,-(CBUIGK1]XG;>E<O]28G5O9F1<SJ01&T";64L=,Q8C8W(D&
M=9QCL8AYQ#1M2XH/M%7JQ;.M&'%Z:WW__=::NGKV)AJL:9KH@#`@!=`QX-"N
MMF`@9SLU+`A(3$+6MN\_P-;H_NYLU>'RIJZ[/WWZPO=%[?V7:3&X2:TWL_0R
M&SWYU-)+0K10E6#`54BA$D#0H-ZLP6JY/(^1C&!+PJ`/L&W:O;L[/HJT_8/(
MK4\=K=1>S=4VGC/:))!$B!($*`A#)J""B(:Q[2<L%0EY`$3C>YYNRJWK%ZFC
MO)P5G+^X7>OIUY*WG!5LJ<FN;#F3%"&L<$A)1(C]CZ4_<-2Z:N*`-K%]$2+O
MT]$]#U._9P3]C=98(D@`9@!CQ>((*\4B%7$AM:`<-+.SF]'ZRGVK_E_%[4=V
M;!FK.^E)0@!L:&<,:,U!%`8QLGQ=^$*&4>O]X5U'ZITI+O.W&:O.=,C[<W3/
M(W7=G2NK@>KAA/_3C[5NNR>Y;7#8K+\I2C1+)HS!,`"("400@3;/QG49(]&D
M7E*)YA,FW82+U<W43<>%GS=,((BE$H2H2$)"`VCG)[&TQHZ#]S(U^^S7W*-#
M^SAFMP(X_UI@?454/JGK<!L.`V^52PBBM@\(I%HI*@)D%QQ\::<*4>L=_\,A
MSKX=O(DG'MS9!VU>P&P\Y+NV?2(U`$`0@96`0(*H?AFZM"OFXAU<0^"Y?W/_
M7NV#+8L;C.M75W^8\:4IMC#E5=M$"AX&7,%`2FAS(A4($2WM"8AN6QAY@"S9
MLS]SOY[L=?JY&)A)6F2YZ[3SM'TBPU#(4$D2`FR'$HO58]35$NBV^WV'QQ#?
MT\T>;NR%'@MXWR?EK1ED5YD9-DXU&V422@,28R3CB-,PPD1$5*V2.!M[WT\@
MV;-_7[+%DT=[#2ARE);E^=7\(X:.0>6E3,(0AC'B,F!13!`*-9:K@!E*WK:T
MZ0`+XGP'ECU=V4M6\@1B8U1YW3BA1,@X9!1&<0PH%)H'*XNP%*W+KP^8'.U[
M]65NLJ\[>XTE9PY7S[QNG$@<@!#`T*99,.9*,&ISK.4@XJSM?'.`=9&^HT=;
M'_;!BL>/(ZSY&,0:8JQMGUCW"(%A)%$`)2:$(X*6=D%(WF,NTJ)3<_^N[(,B
M8C3*?]9;BCHO5#Z]K*ZFH]>?F)/3HEA?"=-*3R(414(CSF,4,QHH'FJV\@,E
M;<MD#GD5M#^ENG1Q+U0;#*;CNG;<YN3&]M,@6USO?SLRBT]8B'%>5(LONB\_
M5O1E5-]!O^:+1>M8Z.D1"0J)@C`"(E1:,8TQP?'C)CIOFS`=<C;M@:!OX_T^
MN/MEV6NS-/!+6IP7,\<-9^]#OYCBV3?/UC#334$2*LXDBF*;7FIF4TO-R"JS
M%+%H6SMZR'G8_KSKQ+?]LVI>]BRFU4U>9/\T0V<VO11,D"9!&".,0XXB$G#[
M-S"W-):$MWX9>H"'6#ICT9X^?2OVG);E=&?FS(42@1A02(=V`1L2#*!&A"PM
MK`=,2]8<X"&7CEG3RI]OQ9CS:556Z:2^#&U'VCR13$(<X$!02!755',0,@27
MMB(IVM9;'>`YF(ZYT]ZI/;\=;9$#.4@G4-O02K@&F&G&2<1"$"YMIKBYY/A?
MYYHACT3R[]B>R;1#ZK-%*H%<U>="B.)(2:ZAELLM7FNC%FUO/3S`PS?=D&=/
MA[X):1HSG@T2"25,<TFE761*:QP@B*ZB:XA5ZP\_'.#)FR[9TLJ;?3#E6V'2
M<EH\/,&ZA25K6M>OC.U*43+"`RSJPT+R,8'#!+:N*7W?.]_[>[+;*O'(3,Q5
M5M6[3IZJM!\5-I9EOVZ:2*$X"R0%/,0P4"RR<7;V=:Q01E&L&T\`=K14,)-R
MOF5W7MV8XDMNT9HJ*V8D69A1/IX#<#EMU5:E74@!$C,0V`5X(".[_H8R7GJ(
M4_!N:KOW(<?+I44_ONYMI'H]<[7G@`41!MBZGX=`2ZM92;;H$Q)+3ALKQKL9
ML,KBG)CA$\#EUMZ?M7AD0./GV;SH3^SB`S"D`X9`C&/K24'1TG=`XW?PM:W]
M:?/R[.0;.+Z/_&R-74]0K[-Z>VE<*WT)5D%LLQM(`KLJ9C$B`-"E7RAX#Q\"
M?2,>-;/8>^^\%6N;"O(VRB0PUC046-FH()`(HE#"E7U(D'<0#GOJ?P>VM?'X
M&S&J>5S.!N,J:SMS*/KS^9B$1O617Z6H$C$,;8)(Q,J+4("V)6$'6+]S<%&S
MKT[KD?I/O]166R"M:5_-(+^>-.P%.\DGUE3`8R15'%)$.28<JZ7=D:"M[^-Z
M)V3=FR[K.>NU4[I=9]87$=8?^+%_U#5(=^EH=MQQLJYJ=K^5I\N3FI:DN^BP
MG0B@BK".@T"&`15A1!8?=@="@^B-#OFO-V&WW21G'4DD&-,PY!!RS(EB=KD%
MECY`<?`.ZI<[Y,7+[?^.O/[V`]SK#E/OXYQAQ>,(0:J!U!R+(&3!W-N(<]2<
MD'5T*F5P8X;34?UAZ+7&--[QX2*?U)_`8)BP,((10!2R4*YLKP\+?L3Q[<R'
M5^<G_7O</9,LS>#S=7YWDLTLJGD6+/Y>,RQXPK#YK\FCZ1LVA]:V2P*,F4UA
M!.$T(AAK!:A>XJ<4OJ<[/_SV9^[/JWVL+_Y(_S<OOMG'E>=7REPNB\RKAPLS
MF!99E9GFS1MG'8EB,-8BH'9!%VMH)SD%5UZT(['U+>&'PZH]^SWOQ[.]E*'8
M8=1\/\BJ42)#FPUQKK4,8PH5H38O6EJ`F6I]4?CA<*/#7EV3@[9R:R_$,$65
M766V_^8.N,W+K&IFRF:I)`@)A*&.61!);@VF+(A74[G-LM_/7EL/U/'FYSZX
M]/UB54NS<D`CE38+)2)DBH8418(+R>*82L577HO"=W2HK7LF>7-S+[<#W.1%
M]<T4XR=+A48B;19*>"SJG3N&6`0A)DCB8.4TK$G;2XP.\)1:]T3RYN8^B+0+
M?U[;0PE'#`:241P+3E',!%K:(R+YCCY*WSUM]O5N7TGRFAV+[64<FX62@`FJ
M6*Q#NU1EF$42/EEHH.`]W9W6R;+=NXO[O<-D/>SUOS9&IWW4)A@H&@1VI1L+
MB"EB/"1J%9@E>P<[CCZILO%FE,X]_W9!SJ4BHT$R`9RKB"LA`V@7(];F)WDD
MHZV_)72`Z?I;A+NV?NXGYJ6C^BWYXR3_N\T5ROH#.EL/L6R5LV-'1XPBJ+"*
M;&9!F(Y6"0(+Z#LHH_?>XZ]"ES__]G+CSEV:C>JQL_@>PF/VN;B'I2[3*+=>
MJ..F(0D#B*6-^A:'5H$$UFBVM#U4I.WMDP>8FG7%K6X\_<8L>[P0Z/?"#I+O
MDV(Q@NIQ$YFKO##?TOMV_'/3G2ALUU8(!@&+"(U#$46A7*4IL6A;8GN`L^@;
M,+.3/CA4SM9AOBO./M.=(,"T(!PHQ`E75""NZ=)?&JEW=!OG(7%VGSYX6\XZ
M7,_8))M0'%*.8^MD"5B,X]E75A?VPABU?7M]@)MS_7.NG8_?OB9NZ_>S#KTD
M3E-`910+FQ0%!*!0<TSF%<:1U(%N?-O51TG<:TO6O0YX7J']_^Q=6W/;.++^
M2[A?'G&=S5:R3F4\I^H\H129MK4E4U[)SL3GUQ_`%AG'UH6"0(I1]FD\,P1$
M?/VQT=UH='?.E\N9/!A"*9)2XJCTHM:3J0I`@QKA[@QN)/7(I)W)=`.(HV>-
ML9A'SBV6DW4MSX^S:56O*G6SK*J2.?+[?F:OEN@Z02!*>LD)>Y:N8XQ*_6*7
M4F6,0:?*CO_Q_M\JM5RF+L?IO0_,C^\^2W#:*`$U]])H3B$'1(L&!ZC5&62N
M]46,=]5Q^@+]Q)]VV>SXX;YP;KE4F!%H'+::.B-5*F*#C`?0>KSW[E?O1L`6
MPJ3MX5^+>KKE?U_&OU9Q?7'YAR31%_JQ("354C)M."?11U+`4=&@2B0Z@VS&
MOFBVW4(XC6P&*<05?^GB^M5+[\D`V/A\L-A@CI!V$6'KJ#>0RQ9BI,_@%M<8
M2/&VEE<!40P2&GF'S60S''OS`@Z<*2B7+J\Z+($B$&/HM:0-%I[XW)R4$=+R
M2"Z\#9;TBO,PE2B/_C@[90D4_)E`C'4<&*Z)CW_I)"K7H$@U/<\,JE,KT1-*
M</=WL,4\_W`?9?S7?<2T?O@\>=K2<F7;HT$R1)RTT@$`$:12`@2:-^12YY8"
M'Z%&/(U@%T7QSV?(E^I;53]6J2M1ND]Q];"P\;_,%\\M7&PUCXM>;G%-#I\D
M`,NBOL=.2&@@`R+N.J3=9V1V>\L1:JZ1L*HGR93D6ZI%/'MXJ*I\MFV:(G`'
M*&&4"*J4T)(3*=H58<[/*65@K%PK()>23%M[_OD\>S]!L(9;K`B/1@1UF@`1
MOY9V-<[GLFR,A_QC9=G14CF:8SO+7.UX.G`+K35.\*AZA5#42FU:8]1E]Y$?
MXW']J-B3+8)\JGR:?)_=/=Y]J6Y2VLIB^90.+J-^K);3V63^:3:O5@^+>F-B
M\.&3!!^]:ZZT5%@Z[X45]KGEPPM"".7&V4;8!6HDQ.I),D?S+:6PK`YCUYLA
M`2%!$+!040V9EMI;UKHB6OK<<X(1=H4:%Y>.DT,6<RZ_NSK"?+^<K2K_6%^I
MOR?+K7O:QH>#A%!#KBF,LSMCK=6L/40Q4NYMA/#KM'XZ/5M*2*`<3RX7E]7W
MR4K=_54G0VR5+LH^K>+J#B+0UEFBXR`<<(P0Q00!2.F4=KQ>%Y39G0U'V!=J
MI,PJ)9H\RLUN[CY7RW\NOJY#9.HN]<S>RJW-CP?$)3>I$X<&S"LGI)>VC7,(
MGUU&=H3]HD;`HB)"R*;+>A]UW^^?DW9V4>7-HT%:JH%G!%F$L%7:BQ][+0`T
MNZ'`?^/?6VARG`#R*/+ACT]O?O;R=KEXO+G]4MVGRUKUC9T\;*=-M^&!,>(!
M1<HQK8AE7'G5GGEJD9^+^]^@]R8J]2*4OM/V4I2TP2E5W(YO6=736;&D_>T_
ML#]';^_0X#2P&#.!G=<102<-UFV)<6+W!K'Z.MC?^N:'IN`>,E&`V!.+`2&0
M.P.PQ]$P:M!(QM&O?W!:GA@;NE/VAOC)ON5U\BW\);YI1*%@''G+N:#&2@[4
MR^TIFL"&)Z]$?7%?I6VDOOE835;5E5JMJD,*46\?'BR`#!@B`&-,,HL10:Q9
M.8T[TF_T_78FP=9\V&(XC[=&T9XTV/Q)@Z<0$2P\<E9Y;:AVO$5(<')&*3AE
M"5.D4E&&!,;+T7[K:"FDH>>">P6TQQHS+7B#$D+6G0]/AZ!2R3I;ATEF"/YN
M_+X_=DB@W3TP8`T`(YI)Q$S2$YA:T:P4TNP$[A'ZV+WJRJ(H#ZL/-W1YVJGH
M7CT?*'(>:F.`(LHD+X5ZU1HZ-+MJPL$:[%NU_+KHF3^E1+Q53^4#.P1AGE<=
M%>:7)*^Y^WZ?4H=V$&;C\T$R):$21,AH$&LO!:"P69<CV<UJ1JAN>J)+"5A/
M[<F_*04W4D\>,HH5U%QR1Z1@EC*%+&;Q7Y#0!)[\[FQ_GKS2UF(+-(/<4DN`
M,1ZO5RZYH;^3)]^9!#F>_&$X#Z'D/R\7\74?GOY\_/KO:OIPN;A8OB[K\_-:
M]CCP!\\5*(X;G4IISH!#@"%1BC1X1.S/LB]5"7HLA@5^=$3<V\0J8[;H"4@2
MK2YK$"68`0$!`RWZR)T1&7ODRS',S)+#K^R*.PZ\@)I$ES/]"=*6TZR4:GU&
MMG&OZJ\HRL/S:>4?'QZ7U:=9G<[BU^D_*_M8[:]R>-A$05"*M5!86Q=QB&8-
M-RT2'F4GG(Y0PY6BQ$ZF%<9[1,S[4%_^O?C?:K+LKMPZS!6\TQ(*!XTU/,+,
MK#;Q`^>022NDD+GI\2/4=Z?E7S;DXZ)@_-6J'`G;V8(5U!CH`(+.84$TXX@F
M3`S$E"N9VQ=@A-==3T[#7-!'142_>%P6XV$[6<`80RNM-)YCXHG'VJF("():
M>>BR#V)&>!_VU#3,Q7Q$+#R>>B$N&FC*L=/:&.4P\I*O8?86B]SLVA'>H#TM
MWPX$^F2Q^:+%KON-S..X9SCMHKW"#,'2*HY>.B%1HX%A>T,S?4?F?Z+"RT%-
M0XAW48Z<ZM9'S!^L2MF>5BDHI!(":2)=@QW$V;T51N3TE:?1UMC^<(+H6RW4
MJ\5\=I7*0NC)?%)/JS]OJZI<2>LMT^]7!GL&!B6YL`Y!0TD4H?=`1-]&2V4!
M-<R[O=>->E(%40HO%S3V'<?]]&"@T>:@2DEIXLM[Q"FWLEU-OBLROH^SF%C?
M?IK'X#F$?=>^X)_3JIXL9XL]AV@;GP]42*"`1%8"9(TPBA/=K,LH>@8\.5:@
MVWAQ!(R#T&/]>G_5J_MJ.KN>55=[#[>VC@E"*",9L9IB:;CVW@"X7I_U`&3?
MQ1PQ3?+D^VZ#+X/HH`K%S">KU<7UGP_1N.BJ5-Z."9X!HIP5EF.6LLZ$9JQ9
MGP39/3)'&)(MK5B.A'((JKQ^Q;U:Y?W#P6CN,`7><R`=$((0)IH5`>3.Z+RH
M@%3?WLP[%LY!=4F7P^SW#P>DJ832&D:HDX(9BA5N5N0H.J/"D:6U1RZ&0[#B
M)5ZV/L3<X;'M?#Y(9`R!P"F`M.+:T+B3-NN*IOX9]-@I(=2W5>(+0#G(SK+Y
M^LZ#F2R73[/ZYG\F\YTQZT[C@Q=62>BD5U8#")0G$*W7[9CB9[3_'"GW3@W@
MCT-WD.UH0W^X71O2AL>#@-XX!(2B$`H.J<3(-ZOB*+L$WP@-VK*<*0#F('O3
M=)KJ(JV^5-,J$CONQ?^J'CJT@]TQ+$@/A(.6`\JBDT>\0[Y1U@YC<T963%G*
M%`1U.+/F']7\:MVO]N.BOODX^U9=^<EL^:P3?]3,V&ON=)PG$,`9<012@PS4
MWF`4,="*$BZC84#.J.IU87+UB/(@Y_H/M]7R)TAV'>&_>SA$?]-J'EW/Z"WJ
ME&5-;(.;M\[M[>;[ZYS6E^7-T5`.[F%U]:P"2($#;[F/OF=<#6+2M^N@.#L<
M<WBEZL7#9/X+4>(8%(>\^O)Y/HFKK:^2S?[<=21NISO(L6M8<!PS%*FN($_-
MPXST7+6K=.P<X[K'>]\%$1V"-W\L%E=_S^;S'1QI'@F4.T\M)HIJRZ")7Y%H
MW][S;#Z,T,8MR(=,]`8S+SY$@=0WLVAXOZBXW?IBVY#@#.(X*E`C-!:28X>,
M;?='D7VX/$(3M2`W"J$YL"F:2HL>8HW^>#Y`@!T!R`AKB!4(,JL;H#SC\(S2
M1TNSY$@HAS-(]UJB@0*,F01,:X8IEQ`0IUMR&RG.QP0M'M0_$+M!*KS,)E]G
M\]G#K#K@M&?[H$`5\9BQN"-2HX1#CM)VA0YGUWH98?N3@NPHAN>0X=?/DZ<4
M[^L>>/UY0!!`"F,0LNE*4'3`)#;-V8,7+K]H_/B84D*\6^*N1V$Z$%N6CU$2
M[R#839C-8P+SD"`@+$0*($6T8\0UZ\/1M#H?E[8?SA2!=0C:V+4TUAWH]G-F
M\X!@C$+,00A]7!;34#+:FED&BC/R>7L@3!%,!S%B%O5-.K>TU=<.!X$;G@X.
M<4Z,(P0;@DQTV;A:?P$,1&\_]X;,"/W?'GAR/*"GL70/LG"#A082YI`V#C'L
M*7/:-"N2++M)Y.'.;^]^3Q\4.1;/$VPZG0(E6\<$+`76E'D)M8B^/M8,^&9]
M2H/<8,D(6_L5](1*P3GTKM.)*YL'!(@Y4JEQDW`$\`@:%JQ=&3:Y%<%'V*FO
MI,M<`LLAE<KEY/LK)7B0;MDV-!#AJ9'66D$0C^K8*(B;U0JGL_-K1]B>KP<=
M4PC6P<+WA])G^Z`@K*36*D8L]CK9\1B*9H41UFSBC##X4CJ27P+0@<W=;G9N
MH(C3J#<I]]KX^-H,,]H:9`!E%[\\/+KR*T7V\Q$<)$E_?[>\3:GYVT<%3ZP3
MU'%E/8&&82,$:=88@<LM601'&%(IR))RB`[!FI3T\O#4X2#HYP<#%PP2*K!!
M*GG[D"H@FY4`:+.WE1&&40IRXR@0ATE.6V/_?)-QW[V>#4\'(8R`"&!@'%58
M*H!`:Y9S:7)O9(S0W,@5YKLTM&-!'&IW6=2=6/'VT0`PIJD*F_-(6,4A\J8-
M$!((S^B23B%*'(G@((=]5U>S)(]4$6EV]:$VD_M9-.5V'?5M'A$T`(1Q"#E&
M*&7U<\77<48&*72YW?Q&:&048D<9((<@R9?4#Z:NKMQD64<C:*6FT\>[QWFJ
M"Q0]\]ETMLO@V#\X5?ARV+K4#MMZ"BBC/U8L?7:-PQ':((6H4QS3@?(*FI=\
M=LNC=HSBN:WJU>Q;]:&>+NZJCXM5RL:\N+Z<?-^=;7#(3$$![X5B0DC$`%,R
M8MQLPQ"@[`[U(TR"+*6:>@5X"+)=+JO)ZG'YU,G2>?]P\))"0&Q<C>4<$*.I
M^_'Y:)9[D:M[RJ1\H4Q=W20I7/XJS#D:RF$*J,27NUW,HTA6+^O>08[W#P?%
MB4">&XUH9+?E0+#F8`LZL[]Y>+&,R=ZC;H58<32&`X=?57UU$$?V#0VI9!`S
M'&O!+*-6Q,VY72WT^5V*1IB*T$^@M@2LKTC4<W'6%H/5Q76JY^'GB[][*-*Z
M\6<.*=:Z<X+@/,72.X&8)AQS2XQ*J:D16R:4P'M3-_M2WGE%6YF%$DBM&7(*
M"N880[I9#<F_"3.B@%9?XMU=O/4P7(?9WHL4;U4*R>A!"<,EP<IJ+DRS+A]M
MF%^?+\<*M%OQUH-@'(0>18NW*H0H4@X`SIG#VCU_2@U:<:5G2),\^78NWGH8
MHH,JE(]Y!1<E-S#:.9@QH[G26$G3:%K)O<UMU#O"P'EI59*+X1"L2&63XJ;Z
M>;GX-HN&G'[Z:Y6:P[?M!-3T8?;MQ7C=?RQ[^&3!0."1Y@`KQ@$4='V8\(P(
MP>`<-Z@,.BP&QGF@TB/7LX<4@=MYJ-L\%+B6$'*OL0,"*"D\PZQ9@5*"G@]3
M^A3O^[(C>?@.<ZSW[\=U.<#+Q9=JNJBGL^=";S^"MY>+<MJKCY]+-R,!B&X\
MM#;%E(E,#9_6J&+%S^CFX("L'8&DADGACC*>SIYE'_^>5\\DJ*_4W6+Y,/N_
MY_^^,XU[__!`T_4&(S%@0EAC.=2D,6XD@^*,2B6?EC3O<L&+RV8(1GZXNY_,
ME@G#B^NV*.)/Y1(C9#LHV6E\D)I;YR650$%*C,$D551<KUO@,^I-/BI.]B&<
MW:3<%AV^G=0WJ7=F4VWSXOK/I[O[VT7]]"%"%+'Y_+B<WDZB<-:Q]4W'&KE3
M!<VUQ08@QC!1F&GM68.?,ASD.KHCS`$:!?T&DM,@(9;;"+M.?3]3KD%5K_9M
MT9L'!.D4-UPQ`S`U!#DJ>?.-*4WH&=T*'P4#BTIC")[],9G5"9J+VLY6]XO5
M<P;>Q?7>2EH[QP6)(DH:":0`CNO"7)HF"*J\%KG;;O?3W:&S149%OI*R&<0Y
M?V6I7ES[63V)Z-4W9K%ZOFJ2"F0_5PK:Y7!WG"(8[YR`4%EA(<3$$>-)LWH*
MLZ^T'U[Z[?>B9$_R&?+V\PMLEY/O[GM2Z)6NZNIZ9Z;OGI%!>4/3[3H!:;1:
MG9;Q`VS6R@')=9B[ITW]UEJRK'0&<9GK:<HFK&SU\L]7N*QSY3N$)KM/$J15
MWA,@B2"`$A;]--9^B\)G-WT88?F/41&S-PF=AJ/O^ZL<Q,[WPP/SRG'D(J:0
M<4L9\+"UHBGR_1_?#*TW^V#$7M(=#?QIZ/9Y6=U/9E>-=E\K]6ACO"IB?!`!
MNTP8'.!,(F:]31$$9AT&S?&#LLCD7BD?89SQ)%SL008GVK#3^_[8-`YGXZ8)
M`K.:,N$L`2AZ<"F"Y5J@G<N^G#'",.-)V%<`\]-NO>L2N^E0Z%T!U:S->->$
M(9H]3E,J-0<<0<RY5+`%7I%<-G8/.?Y6VW-!49R&I&_JY1W$QS=C0]3\SE/*
MN=/&:`0D<G2]7NVQ[K_=V&]!O>-0'U<J8I$4Q``Q4]RD:\70N53CD<$F15<C
M"W(K01R^`?=^FVG`U)S>\#\A`U_:TA9*AMTQ6<!8404TU,H;K`U@S#=1?NV\
M.,<4Z]Z28<OA/$@R[.1I'<A2T_\\SI;5UGYPNY)E.T\2.#<<.6^3^4NX=]BV
M8&OH>&Y]^O%&8_IDR=N<VK[$,%!6]K2JKE8^(IA:WUY<9S&Q^RP!:D9I1-DZ
MDX*MW@K<8@`0SFTM.D*E-R0'>Q/`2;3AJ\;PA^B_U_WD*<=6.@FX11(IQDC<
M99I52@)SS^VZ6WN_D\;+!_X4.N[3Y.%QF2I$I`J9\WDU33)>75QW9-WALP7'
M(K:*0P^L@JEXA&CO&VJILUNBCC#!ZX0ZK[P@QN6#%/$]`C-,`F\QTM9[P3CF
M@+4(&))[066$-3T&I&)O^)^0@6W^3PDO>,=DP2""K)'1ZY.:4@:,X;A!A(MS
MJL'8OQ=<#N>A-^8/J]5C?/5HN;XJ0-IQ&]XX-D3K`\3%4N*448KH^,&UA@C&
MV4W\1GC5J4\R[-AT2\`^I'OA%\LOU?WZ7D%GGNT='#B&&&HGF5.:>,>D=<T!
MCB'>YQYH=/=H1^)J],*WTO"?3J^];B5TL&)[/3A`JA#GU`.4-@_M,#&-#6&X
MY+GW14:X8YY<LQV!^Q!,B]_$^@/IS*]M0X*"#J/HMBN%J2,.1K3:[TA@F-LH
M>;PI`0.2JQ#H0RNO5]KW.;]F`S0=-5F'F8+4CLC_9^_*EM18DNP?S<2^/,;:
M+1MMIJNVMGY*0T56B1D$,J!TK_KKQP-(:F-)(A<29IY4JHI,\!,G/-PC?)%8
M1BH)0\9Z[2O+P6'.<@DXP(K'%U)K[4_"L/S35OS2`O2[5"@@;;#C1%%EQ`X!
M1++]AO.SCRYU0M(%#3O#OP\&IF^>3A7AGW2-\FLT3:OH<[F8S,>O(V^.</"<
MUQ2,&J&T9[`0.4KU9HU$%0J"Z=Q@Y?./C"]1>S?W5*1#A"_',P,K9['X#8OD
M9/.;.L\7*,H`RYBE3H+($2RU5CNYK>L^[W?+K)_K:8'97ZRNFU_-`+X=8E$?
MA,5&$:U3Z<2H06]7<@>!NV\_\()883:^+5J=!V\O]2\>?_Z<KC$83:M2S>]F
M]_/%C\T<GKXNJ/F&0B"+L`Q1N8`Y=]CHN'.3P&?*I=;YS0NNZ8Z@&W#["4`'
MH,OE*O68`LOQ:+CYBY$%9@93Y!'5&)8)P03'*B'8PR]R0RH'>.C?^NR^"2EO
M@FQ?NUJ2.O5'AA^?;EMGXSU^12I?,)TO'Q=E#;W4]-6%)('`.A4>,ZJM9X&+
MZB;9FTAN*"V[Y7VP1]3[X.@_9N!L3"?_+L=/!5_JQ1F=>!+<9*(\..*!,4$4
MN.&$5YZX)U[<D*;KCQ;S+J<@JS;>ND;5,MU'E..O\ZI&FB^7DX=962X/&>ZU
MGRVT1\A3C!S\X#PR"/'JM,4[FEW][NQPW%_EXMO\UHC4U30\HU*?38&>-]1[
M7LB[F^9`VQPB^&MN=Z"W;RBBH(XXRW1PP@@NB6*P9%4T`1-'3M=G[LB1RFP/
MA#WR/J7T":XCB@ZDDY4TF-["'M#9_![O#W0>L+WXVJWT!P*)+!5!"DY<8%XR
MR4DE%V/9.9`#(DS3":W5'^@\&'NA1ZO]@31'UAD9#$U1T1P;)7;R62MR+Q^&
M3).\^:W='^@\1'M5*._S^@-Y'RP/E&@D'>A8:97DE43"BEP/=X!Y7&VKDEP,
M^PDH6I<+J!/J_7IH08A0`(4S5@B!60!77^RD"?J&`FZ;3.6;R*!&*/9RSC:?
MK;_:\G3UC]=#"XL,49%K'RT#+1JH8[O%PHRX(8,C?R)?GX(UP[`/1KR?W*7:
M7C4(\6ID84S@-"@007FG9$JV85M9J+0LM__7`'>-UOC0#,(^-XT:FT7!!?-$
M$$[!%@).8XE<90A1%EWN)C'`*BRM$2`3NSYF?E?G95OMKX[=</"90AJN*,;(
M!`V6MY!(IP8X&_FPD[==#R77@&@+SGX4Q;*$STG!#AY(/9VO*Q)LO_A1[7'D
MN2)ZI@TV*82+11NH];I"+O53RDV'&*"-T<)<O]$M[2&;=<%QX>8_W!M)(Q*,
M8PO6%9A8P5<2"AQSRT0,4.6TQYV>P.Y#(?VMG`$JTU28<?QC,ILD1%:37^5I
ME73BR4(1A5.$%E&@U'5P1H*P6UEI=+G)#`/,T6I?*;6+;1\\6M>;?6JH!HMC
M\7#4'M[_0!&=H\@&D,8''80!HTYY:Z2/(6HP$GN+^KY"UK0"Z46,YG.,Y4)P
M$0,B%L6HD+`6<8HK>$"FW%HR`RS@T3Y%FJ+9*SN>VEK4X<?3:'`3B2/4$*,L
M)X%&V'2K\R(*XN4&^`_0Q>["C<H&LL_`V-/VR:N1!;."@C4?G=0*!4,YLV8K
M"X--M/L25'UG][;(C698]J(T4CKGQ_EL_I+%IVER_,'"":U\8"KEO`L,PA)5
MG3@Q@FQ_F\TUT:553/O1*I7*2UG"Z?YA,GN$[_T47V/+^WDJ\[?MPE4NPU^P
M$\-L3F:CQ>\U7"FH+MU<S*?3M<B;)7-40W7VJ06*&L-DJ2BBXL@);GP5!L2,
M)[G73@/,X6U5S0UE0OHC_3FM`@\UH1/.(N999,HZZ>`_J9[Y5C:&?*[3-MP6
M@:USKBFF/94AJ&61OQA72,R%5UZJ8(A002"NY4[9ZY![W75^'L@U*:(F$/9!
MA3!:S$"YI<3RJH?TY&[=(77Z"`OP"#E./%FX2`Q1QDD&?JES2O.=8\M(R+;2
M]4W;6^V"V@>!_EE.'K[#5S._8&=]*#\^_OA6+C[=K[_]I\?5<C6:P9;Z4)]7
M>2\L-$DEZ(UE1BB%6!#>5:<?##.>>U*0/.,;YELO8/?F-;[(ZGA2NZ"#/]W#
MOKR_>$:=:_[&+R^H4L$'3K@AB$;-`J8[(T`[G-VU8H`WNVV[GWT"?TFJ/J7H
M_7T^3:ON*5/OC_(NU0-/U8L6DR7\R<-_9P\;T2L@,@C<]",+(YQA"BG+I:0>
M>9[*T%3[D='ZAN(5>J1BS570\^SU$Y_[1LH:]#[R5+'NR1K6J0I:&Z(5WUVP
M,F'$#?5HN2!#VYN`RZ2#KJOO?H=%!).4RM8\!>9TDP_Z]O-R\T(/OZEPVEEC
M3>3$414T-1HICQW&(1"+U$G=/*S\4.T](<)[($T`DR%&SF(EC2#9.3H#VFDZ
MG^?C>:+G`=QK6M=&X*1DYK-U.:F:^:+[GBLP#>EJ@E&%,-&2$1IQ):<W/G=#
M&!"1FD[P(9ZT`&<O1UHOO^;)W-&]XPNJ&2PHCKR.E$K&#`_J22YV0Y&X+<WO
MZY.L%E#MR>*LRN]_*-/IQW$[\^78@AFJG(T@1;0!697R5W;R2'Q#.6$-Y_.M
MP=@(R5X"(<?C29J7T335#7LWVS:X/LF2H\_!;JV)(EPB*QS8P$JE)G-;.1G)
MSB(<H#_2+F/:1+6?_)`5B%N.JQ/]D[39_T`!QIT&D:)-KI.Q%!E.*LF(%?QV
M@J_;Y4LK</:B9N[N'G\\3I/!?\B#/ZURZKZCH#`OGFJ0U2&LM(K!BDI^;FVN
M]3O`J.R6U4]'"/?!L*_ID.=Q\;N>D;-G=(&(HE:(*"3&VA+,O0L;F2+AW.1N
M6@.,G6N7-<VQO(;R*<@C<!\E43Y$:P5FV))*(B=][A8U0).F;8\Z%\.>':--
MV;]G]\'U?*0WCQ5"<21(D%($%A1V#LL=]Q7@UY>[=,%Z_;4G^K#'U!37?G3*
MH1/UO3KE]>`"!<D<:$G*G!)6!HJCK"0"A=E;_OP5,J4QFOTXU__]N*T]^W5^
MP+=;\_S;:%F.TWX,IM9Z-K^4(--RLBK_*!>_)G?EYDKK2WDW?YBMWW*J`T37
M'UT`OA')Z+EB##.4)LM4:`<4;[L+<"YK!S8K604`GI?'7;TMC[OY\Z$;OEH/
M%Y1)\"Z<,&"(*EC$QI*=IM><W9#_U@*W.L.U,3LZJ7^MI-/,.>64L09IK+G"
ME0S@M>3JG0%Z:5UPHR58>S&NMJ'!+_6@62Q2'8L$B_W]-&3;*='\.5J,/_U<
MY[[\#0:NEN]F&TUYS#!K]8,*IS%!!",-WE("4TJ%=HM,N-ZZ*ET%00<Q![VY
M"ILU^#Q*;;WX]@M_RI4XZV4%=C%(C*V2`0=O(Z+(58@P%W(C2ZZC(5,C)Z-+
MG"_(O,VN\+'\<_VGXX=A=5Y0(-A"D/34"!V#9BA0ZG=K3KG<RDS7T4&G988U
MP_;2^JP!J5X^7]`00$Y%=3`2&VF5)SL]'@++S<:[CO2J+K16+K2]W^"LOZVY
M`Z=WD33L<O6A7'T_:L;5>;P0!&.O!=4X1JJEH#B(G7J..E=)74D"52ZC.H!V
MN!G`F%/*O.#>ND@%EEP^[>"29+>NO)(DIER*-,'P__.1SLMHP1I,3,;`%G#,
M2,.-8OSI<I5GYR,-^2ZR.4,',AW7>JN).3)4DB"9%,I&XH/:+6DE?3;ISC[P
MOUBWZ$XN-<^#]1HN-:F5!J6F7I&3%"B@/=I=PQ'X2RY1SCZ]OSJB-`:SV[PR
M7WY;??HVG3QL:@N]_.C<Y+%7+SV5(79@>!$M:%Y*4Q@_-\Q%873R;HCGS@ID
M3\9<=+.4TK=]ZDKY%3"R\$'_<V0]'7BBB%Y819ED!C8:$5`('%7R<8IOI7%@
MX^F==P%GK\O*IY#>Z1(/:GF9X(*6J0$Y-0X;CR/!WC+EE1">GW:;NUM>[V;P
M%1_KI%KN&5U@0XSSL-,:A'P(QB(=-W))82++]O6N9%G5GM8]RZH9E'T8,N_G
MLP<`]D?ZME_A4T\D5.X;7BCL3%([46AK"$,.:5=))6R\@83<5N;T=0>DYE!>
M@B`GDRCW/U#$0,`8$]P'KVE@V&AJ*LFL\C>4']=L8D^P)`O-/GCR<FF\KQ$_
M?N")0A+G`_4F>"88!<2\W"TH)4AN_:X!'MRTJ4[:0;,OC?)U2^D/H]7V\.A+
M^7,3L;#\=/]Y,9G=37Z.IN]F'\&H^_IG.?U5?IC/5M]/[4W9[RT8TT0)&C3C
M/@H.KJ.Q%4X.Y7OD0V==!E/VJ*B^<!\</_]5CA9?_YRW1<OMZPHA,/;(""(L
M(\9+15(]I@TJ0>@;R@V^*!OSX!XF">'3C_8LS7IA05#4A@4N)&'$(Z7A?[OM
M"-L;BF"_/!$S`!\D%>/\\5A::=;["J8HY9X*"P#!-D$$)3L#FN=?K0PPW/WB
M1,S`>Y@\G/QJ52.F]Q6<284"EB8*XXBR3*MDKVC*%:<2Y[;`&V!H_>5Y>#[>
M`^.AN8=I:I>*+UY9$(F8(]@B6*Q2P/^P$`F=8#6"GW*UX@#CZ"_(QB:0]TW(
MFB0K//,&&05>%Y-<10+FAJA@BP+EJK'S0]T[;^'0)7'.A+%O,KC'14*H)B>V
MHXM(O108$1`%V"VQ=H16,F',<^O=G1VC_JM<?)M?L5;)P[-OCJ361F?1Y.F!
MPE(KA8_,@,_B(OC/GNU.H:6/N3>#9T>>7SM3LB&]Q*7[JSKYEXYI81XA;+5V
M"`=F8#T1"7@9DS(U@S]Y]SC42W>MI#/2*^6T(=$2C;BKY!+,W'PL2]UIK7'I
M?AZ4?>G?]V!+CM?=G9=_+Z?C.%_\,9J6]O?Z5S5OXFN]H\#4<^ITU!@A0X(`
M1)6WW%%&O%`QNQ_.<*C4RNSOT<]=X'M9?GT<_:AW@W_J\0(YRY"45"HO"0[$
MXF`V4EO-,<UU(`;(J@Z84)MKV8!?2^P0X<*(8"T'/TH@L(P)HM7RC)KT5MWI
M^I130RBO*78H6&$=D%R!?^V=E<'ZL(,)A1O3-?D36R]VZ#PT^X\=.J%&W@Y>
M9WY;O*Y,[Y$*EDN]`\CK[%/0P5]2-E,BC8'LGQJUS)=#CQ22,:*Q-!H)&@7V
MB,.2VDJ'$,IM:3Q`-=)D:H^R)!O-ZPI!--%RI;AQ`GFB;$I=%)5L`=WN97.;
M"B47S3Z8\GDQORO+<=42_E>Y6$U`\A,7*$>>*KAB4A*%C(U&>XRDPNG`PCEJ
M`XDX-TYF\+HE8Y;G7:%ZG#F'&[,]_\@GR=[-`,MRN?HR6I7K_,7QYW)QE^;H
MX6!QOJR7%>#4&91JPR,I4IZ)35F1ENNDL!W-+@HT>!\HGSN]@=W_MO5,JLV/
MRU38-,TMKKV1'7E'P9&74BD4&`I::4WPV@Z(!C%FPNE>@-=J*S=75%UA/!".
M?5Y,[LJ&'-N\HR!8.LPQTI9;RRR-$EE88TA8I@2YI=8B%^!8%L:]<6RY?!S-
M[LI4\NBDX?U\;$$%M\09`?!(%9717&B0AV!*'.,X5R]=45Q=(\XTP+(/;OQC
M-OHQ!R;_NQP__[KAKU04\MC=Z/$'"PE+0"@*EJ$SBF.2DJ62I!X[+EW,;3AR
M1?%ON:QI%=C^M[`XFBQ.E?<_\$1AD"`\X""DY!H9A=S:!&384_`L6.Z=PP#+
MO':[/>4BFN6G_7,^'T]'L_'R`[#VX8@/]F9@@1SH/"PLXH9J)M./NY,JQEEN
MKYD!%EUMU;]J"F2S:7:CY??4\N'D-%<#"TTBB9A:S*4TR@KJ&=I]._RZO7QW
MT6C7.LV90/:O^\\\F3G_)06G$>!#46O+0O!,,:HK!*A4V<4*!E@!M=LMHD64
M^^!9I>G>ST>SY:?9EW(T#<OTM=UHL?@]F3V8'_/'V>K3?37PF(]S_LL*0I7D
MV"'KB`7;*Q+C8.5Q3DS0WDB2R[O_`\?(G:.=M9W9Q\FZ7.;2S:>I9>AB-#VT
MH>T96D3N`S9>&;"EB/:48LS@&P8=X4M[D5UZZ=:/AIMCF37;[V$;/3W1+T<5
ME&LK&"+!VN#`7Y<AVIT6Y#Q[K[GA$]GF,/8:.+^^51U8*4CD,&?62AUH4$8R
M;>BZMI_00MC3&\U0P^9C-"QHZE(!;1$U=URR2BXFLLL5#&C_;&=::X3-GP?E
MU<2;.B5(\(&$&+D+SGNK*JDD);E.XH`(TLJ<UHHW/0O*:XHWQ=%P;R722&,7
MM5<.C(>M9,2BWIH37RK>M.[$UHLW/0_-:X@WI0&!>2$$E]1JQ(0*WE82:93-
MC\%;Y<V42&,@KRW>%#EM%8XD"BG@X\"QQ+J2CGIT`SE\;4QMW7C3\]"\LGA3
MYA`VG+#@L`1/R'$E*]FB\KDI>H-W`=M4*+EH]L&4/^Z^E^/':?GI_JG4R*?[
MYRG@:R3J%+\_]U6`!A5,>LHL)=910H7=K1O8?;-[D@R=6QE\>-UJHENH.SZ#
MF-]ME/%L'&:KR>KWN]G]'$:D5U5_:^M(8G+Z&&(WI'`V$.]`>4>'`B&*,B("
M5Q0%BRR5)T,VCJW097GW'P_S7_\Y+B>;Q0D_O%Z3\*NB`N`9)H=.&XX-+Y2.
MQM@@B-$^1J]P4)4L2:C<4BD#6EOYTS=O';_ZFKH!#W;K9K]74..I@BBFB,0(
M!\\PQ5QP8RJI`C4WD&?4SJ0>9T@#2+LCRD%GX.V@U.684)Y*U9'@HHI$\5A]
M9\+U#6R\K<[<'C9D`=F+ECAF[)]Z9-VO*AB`67N'(I@CG.T6B`DH=]<8T/%!
M'_HA%\_V^;&QK[Z4#Y.T1VZ<U@.\V#>TD)0Y++SW+$K"!'?*R>WWIRCZ&SAN
M;&\*YZUBV147',BY2&5,Q^5?_U7NZPUX<&Q!*=666NJ0TE3(5&N75A(8&G)C
M0(:O'=I@0S,PVZ?#M@9@G"SO1M-40C3,QGZT.J0>#@TO1/(GD5.1*FHCU5IJ
M6\D!'FWNM=6`#H@Z(45+>':E)N)D6BX<?)^'^>*XDG@QLDB1U9)*0:DP!JPC
MSWP%!14BJDPV#"B_JD,5T03*[FS+=%]VPI9,0PH5A95<>Y':T(F@.:*L^K[,
MF=RI'U":5"=3WP##[N;\<]5[]\B.L'=LX5%4SB,OF#%*(PEJ;.=4,4QR+<8!
MI3UURH(F8'9'AZ==*L)O3GF6KT87QOXO>U>VY,:M9'\)^_*8V#R.L2V')-_[
MB*#4M)IABM1PT1W/UP^*[*I>U-S`6L!R1SA""IE5A<P\B4P`F0=&6Q!8:\)`
M."ZT]K44'%3NIE-!34V=0N(Z=78-BCU@SX?%D]]'XZOR>J0)4$0M!!YTLR+B
MUN62IQ74_=0#,/(5VCXT(`WK;C>T^>3+`3@\^TVT"",FL/'`'%/(61R:@!=P
M]MV;!75&=0*!:Y38V<["\NO7Y>+#9OGYKP_W227K=]O->C-95-7NQ[<9CCP8
MF48V<&(-$MQJ2\'Y9IGL@\N^_+"@?J<N-QW:4VU7L/GW=#[_[\7R/XL/T\EZ
MN9C>5?W>T]=NZ3KY3)364>H0E\Z"ED:HI*E&(@QC:%+J$"SM:+4KG/QK.=\F
MTZSVJ^1#R<:KOXU*$0R2(8=($D1SG`)C+0'!(;O<[9^Q<WF=-CL+-_L-M/?3
M;Q57Q.)+U<-Y,`<]]DB47DB-DGZHXTQJQ@5O=MQ`D#&T.7498MI0:E<@^7W[
M:3[['.;+R6L%0*_^+B)BB!)<8L4#QMH0(QIX8Y1?&_O/V,/,UV2W16?^?[:[
M2K.JPWOV?0K_F:SN6FI\>_75I^K.CCX4C7)&BE#QVVB+#1@0=E^N)Z7WIZ]R
M[*BJ."TXY\OU=C5]]V?*+"LZGITIWD^K5L>['</3+LTTD_7T[O>'Z^K.*1V]
M\LW1.`$,8V\%0D(C+35O])5RW!'4-;4)FI?%RKTJ?P`W?[@>"I?K[BXEU(X:
M5NG/$445VC='<F^TUR=#3M>EX8_6?XH/6*TFBR_3'1K,WS\@9"?CJ4[9UKX1
MP<F*6BXPQ`%[R2!@7NLP,#F"NX3:!-+!>O)^S=!'A\/O\\FB*L`YT4SW]&<1
M4X(\MCYHR;QE%!&&:RF8L2.()P-:_B7+=K[B^X3/R6:[YS^,8+7VRH%$PH!,
MV6_@II9$6'[R^K_;@5">`0^@($M[?>!@C_33O?W/?A>Q(]@A1K2!P(S6Q@6H
MY0!K1W2)U/`3R36:[Z75+ELOCY(M[LZ>C[KX7#1!.<\$EEI++PQ%E)!:JPZ1
M$07&3#2]3*R&-T(OT*[HS':\X//)>IVF@.K$Z<1$>?"9&*2WRD@F"55.8&2`
MBUH^Y+.KS@O:CRUGTFS+"GV@[.D03TY_/_XX.BR<1$DQ6BHJ#.;<^B:I$&/H
M?FO1JLN6U=D'0-Y7SG)BVFE^$ZVA0B&AA*-,24&H$:J91JD=0:UR.=-,KM9[
M0\VOTZ^?7JTZ>.5743GG+9$&,>:(UDSXT&B!ZC'L-5UAM]<LGZ6W(G+R0^[P
MRQF<*M>_//I`*[I(ZK7GEEF=5M.VUIAR++>BI:"B^G+FJ-[-=1S@!XX?=A'X
MW;=J:/Y_IZO/L_5T=^\.K!_XJ]_]N;OY8'>64Q=_'3J6R'I9)-6UG-5-"C8M
M@XAFLKJT[$%*`OGE-`6"LD=(+'NV2Q;ZWD_7FS20S?1N]\G?MZO/]Y-K$)C]
MPBJ3)4B"X5Y8'1#A7#>K8)&"S(BVU@9"85^VR4+BQ^5F,M\7M7Z\GVQ^G?QM
MIKN"Q;L71V35YLDA]%WTD@@:9$IA+"8I^]$@C`762,5X+H5OB?L2`R&N2WMD
MH>R7V=?9YMWBU2&]V]Q/5^G?%D]FZ_6[U8?):GT!!-O[0G2>*T2()2A-_=:@
MBK"\V:1,KCBB!>U`^!S,6%G@K<?P6/-_`2[/>CA2K;`G!%F:/%!IB@67S7:2
MSKZ.IL3UR4"0Z\(.;:1^?RQFFTQH7?ZF*,$B;F@@/%BO+7@OT5Z^``IH+F-5
M06W%0^.L<Z-<N]I=URNA2Q*\<Y^/P6@#B%=-]MY@K"1H7\M"+<Y=3134I#PT
MP#HR11ZL=@%\'[?3LJ:Z8'3S<?F:"UR"M6M>&@E'FED"+""FI74$1.-,$D%N
M)"VH&7IP`/9HGQ91N1N662ZVZWVQY]6(/..%41AAB&&!!*4H)D'8$&IID3*Y
M;;<%]667B<;V;9.%1#=;33\GBZY_3I^=S/>S]D\5E=TAJ!U^(@(.@IDTN+3:
M,=)8YPAKYG.23_-=4`OWT&!J3?O7H046B^UE:/GAB8A<X(%ZH)P"%C*8M!QN
MDDH)V0W_;Z<+[6N_#;2\B+\[^0Y=GW[1\Y$P'9Q-P-=*:BJX2'_4LC"4SW+\
M=D+0M2U:/A#X;;GP7[_-EW]/I\V`6SDD.//%$7MIM6?`I"-<LL`0L<T<+'TN
MT5%)'>9#([%O([6T(7LE-+-?&`$E_;*T@G&!**0P3Y+7TH*B8^AR'QJ2?1FG
MO8VU*]%XS3LC4.Q-\D!DD$L1@H2`<"VS%S2[7^KM*&$(^W2W*[=?%U^+U-:_
M%+G42H"Q@:7T!CDDO&@R'(UE;C4Q?CNB*,=J15>D_K:M:FP?RB?7L-W<+U>S
M_YO>O>(#G7TKLN!=T%PCSYSW5#*JFMT&(D1V6O%VCE*2W6[)#[Y/9O.J+#@L
M5X>VI+K^9"36"@524L1XT-8[2INE!58H]W`1OQWN%&B^X0AN7I27%T1P@S%&
M:6*Q$#!2Q$#P\N%(%ZS2^F1RW]$4<U,$-RX8)Y(/*&JXQT(AQ'6M0P<H]Z*5
M@O;%VP129P0WEYFA5(*;I$,B/$Y2("2LHE9H64LAKZ!5+@=,`UK^&,'-98HO
MF>!&<Z2X`J&M4HY*G"(S:ES1RQ%!*,^`QPEN+M->N00W6C'O?&#:.RN%(8"!
MUW)81')KSDL\8QM\(KE&\T4LV6Z`X(9(93SG#+#V29=(2T%KK1IJ1G!O]I5H
MZH/@YC(C]`'M>C/QR1;Z2<:`@\_$M+(U02NK'`20"F@*';5\F)/L_8#R0#8L
M/);=&.3V&)6PI$8[1IT*!KC%S$O7:$S;7,**$NL/!H_2;5GA%AB5P'F%I>>8
M,*>04PS[QF_\N":RZZUZFE'I,G46R*@4$%+8D&`9$0ZGJ51`XS)(Y29/)=:4
M##[-Y&J]3$8E(847G`:GA5?)`XA@MI'!FA%-)!EV.\*H=)G>BE@$#LRH9*QA
M2F(0*`!EQBN'2*VQJO0Y$VDEEAD-/D?U;JZB`?Y0>;4[4US_O-A?W/GOZ>S+
M_69Z!]^GJ\F7Z>Y_5G?_ALEL=:@,?J"11!\\Y<(X+R@*P1$'&M>V8):-X`1J
M"."VY3.]&/46'.QIP>WV1`[2^K=BQ4'#M4+8I-",#7(>L68YP"#724K<$+]=
M)[G6;#?F!B]F@6>4<OTXQ[$11"$X9D$!LAJ8)RRM>YME+[(JMW2VQ-VI4;A,
MB\:\!4=Z'E%_6BW7G2Q1#G\MFN`],:C:6))6IE6C@F9R`F-R^\=*W%>Y70>Y
MWG!%.,/!I>`Y^65KD:6]4<20`KE01&KA)5B/?0C-:1&E/C<A*W'!7[#S#&;0
M?@[KEI__VO>EN.TJ1<B]%/MZXE>[KHZ>XEWZLB@PH@%KC,$2P05"!#>[@,2'
M7(B/L_4H&^)=V^4FIO]:N,$CP$4#B<(#,P0+JCT)+.6E7#7E+=3I-WJW(H)`
MES8MPKM.RO]MMMH]TVB@PY7&*U^+G##I`M+:!9STN)NP&IT*D>LGXVQ4&FJE
M<;WABG"&T[/!#V(.%VPN&DH4B%$>&"BD,=-:&$Z:=5_%YY#I1N.DSQLPW'1I
MU2)\[(0&PG+UYW2VV:ZF?02<5[X6F;:,*2<M\EIA9WSZLTF1-<F]ZW&DY(!#
M19SK+5>$-YR:$%X1<ZB(<^%0(@)"D_X52.XUU4R8)SN-B&33C[P=SM^068MP
MLO/6>%5=4>>G\S]\*Y(@G"$>I+=,`V9(JV9'QN+3C>C_+$[(X18XU]GMQOQ@
MH./Y,T<0@2!B""="6$,PJCIEFGT6`=G77HV4O;(`GVG1FC?D28\1=<<%^O-B
MLYHMUK//75=1GO/Y2--247DP3FL=`$`!#DV#F4.YMSN,E&YS8!]JTY2].="G
MTV)_NKBTY_VTZDM*_VZ7BQT!RW8R_SA=?26G_*G?T40NE/+!2N^#3!,:TI0V
M:;(2.K>H?Z3DH5>Y5]&6O05O.QRH#VD!=^AM&:.)CCN;,G'.07#MJ!`T/'8\
M!I3;33Q2JM.AO*U[R]Y"<OADSNDM(SSXS4@TX^D_YIW41*>_(6X>6_[<&SUJ
M$6E@6_:[L6CT7-:>@LZ+CT;CO/5&*UJUQB8U<X^;>(]E/@W\6P5"D08<CBSU
M!<-:062I!%LBP'/`5!*JC*%,.(DU$XSQI,Q3+M#11'-39*G,"(>$"T;J]!>F
M`[&DUB$(G5N`4=!I6)M`ZHPL]3(SE$J6:I"GE!#FB*ZN7@3ED:FE8%AD;X"7
M`Z8!+7^,+/4RQ9=,ENJI<H)P$SA0+%GR3$EK20+-)N`J$$)Y!CQ.EGJ9]LHE
M2^6<8>`(*8,Y3\.G*JVR&SG"&UEJBQ/)-9HO8F/C!LA2`0N$JRN(E=/!()J,
MU+@W-Y!]KV%Y>,Y$4Q]DJ9<9X?:X*[TUC@'G(BT>D\*%9MC7\HDD>";(2JP^
M&'S2;,L*M\!=::VGA&F$B:F4`H23QF^4R;\!LT!<76_5T]R5EZFS/.Y*[14"
ME>9O1(1RF&-#0SU^@D)NAEYB@<;@TTRNULODK@0,$A`B2"$GE"12F&:;15$V
MHHDDPVY'N"LOTUL1.?G`W)4LY7>(\I1O:B"$4&V#;?R-9M\Q6F*5R^!S5._F
M.@[P8U?FYHQR%[K-<K%=IQ7%BRM4GW-Q'#K$Z.'3T6@+FCG,4CHB&`%D2).?
M.*U'-+7V";<?[M0MRHJE^D$.4VLQ8XN"X.I(6#K!'-6,"J5PD^F3D-MG6>+6
MXW@]J6TSY[O:L=J!3P=J!Q[EG/P@YV9IEXOU=KZIQ-T+/3LG_O0XCLA9\#(M
MBSG%CD)@DH0JDP!#E0A*D4P7*G$C:D@7*M>D-^$NUX6ID@8:%0T":ZR(QY90
M&U(>7^4-AF+M-(/<JOX2MV3^(0[7MLV'*Q][T>934/D8E>`-`<NH),X'A1C;
MUP0*6Z'CY*'<6_G8-#+AC?,4XZ"Y#MYC3$.M0T`LFTVAG)FG32!U5SYVD1E*
M+1\CPH@@I9%@TK0LG?7<U5)@8;.;T\H!TX"6/U8^=IGB2RX?`T:P-BX0B31X
M*JWPC2L:E]\W4AZ$\@QXO'SL,NV56SZ&A;8.>2$,!*0#!.E9+0<7.C<JE;B'
M,_A$<HWFBSBJNH'RL>KL#Q@@:3"2*:'`C$*M54E]-BE">7C.1%,?Y6.7&:&7
M$_CGR\D_%K/-^OV'/TZ?R1][+F+J.$H!11)F+=4DB89K.5-,R-V]*Q!LP\+D
MY8%_BT:YO=I%K!RAE+J*J=IP)Q#'O)9/&YF;^I>X93QXQ&[+"K=0NT@]3Y(0
M+Y`(2#H%28Q:(@I\3$O*ZZUZNG;Q,G665[MHP",4D`J<41(<&.%1/?Z43[S5
M+K8XS>1JO<S:15JU:Z=H3I,341V4H+8)P%75QG@FD@R[':E=O$QO12P(!ZY=
MQ"[E<Z(RG`K4`\5,-',L!\@M0!EW[6)N*M2WN8H&>'W*D18BVYW2WVWNIZN/
M]Y/%`YO%;\O%][1,F=YU1TA\Z1BB4$9B`"("EA6K8$`/EYPE_2M)1T!@,`18
MV_*3CLTY$G<:Y&[[%H>7HKQ"EHJ*=YI83!4P:ILH3T1N?VN)&^ZC=L*V+7W;
M_GFRO+_O(420E(9@`D:\RJ>)X,;7VD?<Y9)^E;A--D8_N\J:8_*E,@/>Q37D
M(+W&ECEG+)>>&,MT;3\2LE=J)>XFC=\;VS;W;;OKOW;IP*"A[_D0(D]YAG:*
M$>H\8BGW<+99XF."<\_`S]\6T7MG6TR_)%3<?7SSN=Z-.B:7*C,"7CC&2#VU
M"CE/%!$H$!TL;U;K`#CW/&6<_.:E>V/;YKYM=WVX@&[@(/C#**(A0GM<495:
M%QC2,BT9'@]E?"XUWOG$Z&]QL`"[]MO[?;DX+^:2[EJ_VQM:I(8EE6MD)$%>
M<*".-2@1DN8NY\9)J'ZI2]VHE0?HF]N=:*Z?#Z.@KCF%-2C),>)642,X4@Q[
M+(EB'H$Z?8/4,%USNR*F!ZS`YR16DG"GZ(])M2:-Z:\KVN5.OSQ*@@EB*B`!
M1FC,*'&RUEI2VP@(0-N$SH5]<JWKOY?,M1&J.7UYK03X"K!FO#>9"!%E-))&
M>J6MM$KP6D].FA&PG_2"T^Y5WVU@:L+EK]/)>KO:E^"T$Y)>??6ID'3TH:B2
M#VM;]8=@[94DU+*'BR:=27\?*"0U8W:S]>?YLAKV^AP'/OI<I(AB2AW"A'D7
M;'5GA:EEE5C0D022E@R^[$ZU`SC@`Z,";L<18;V>;BHFI5]FDT^S^6PSFZYA
MTWSXE$N>^7CD5'E'J8+@N`K@#);,$\PE<2S-=F9@YS1_F\E\D@+!A_OI=//3
M:KG]-EM\.46@<,[C42=X$H,IDX*F6$(\K[;.]I([-QINA-:!<,AIV]-U'_G=
MDV$W?_VO65J,KC[?__W+]/MT?J)KX;P71(L-(HY6U=6*,DVE]_A!<NZ#RLW8
M"D)9-T`XC++VM-TKSIY&BA]%.-D\==%[HK*,`Q6,4F(`:^J(H+4>V!DIUTVB
MKA5@',)=!VKO%7X_+[YM-^N=0O#)SIHC3T5%-$(D2,DE%9B"]T;7,AJM3][J
M=X/0:M?VAQ!VM:Z'PA/)PM/#4U$"2SF]`,UX0,((J54=$3@UV3>*%;2E,3R>
M\G0]%)YH%IX>GHK"2R4PD<:8BEQ'!VQX+:,F,K<0J<`:W.'PE*?K/O#DUYO9
MU\EF^N[/9MRO["J<!-@EKXF!$:]`>%!!<T*-TLS66E#6C:AKN1_$=:C\GE>6
M3]1D)NO9^OPEY6M/1NR<<`""6H908)(Y@9HDEF67<Y4<*CM>2[:@YEXA]0C_
MZI@?OBZWU;[CV6O'(X^GW,"20!527G/#D`F*^22U3/\"-K@1-6JV9O_3V]?7
MJKD7+L?E:F>SS541\X*W1)R$=L$QEOQ6TF!\(*K2@?5).?EW.)0,M58@\9(=
MLC.5]QLF7YG@PVR1_FTVF3_2YDSV!02_G,'R<.VK([%,<)"$0L53$"RV1CS,
M`()*-J(^OIX";2]VZ(7P:K*^A\5=]4=5I/!],G^6`C_ZW1%XGOV.J(26*<&U
M00(XI9CDPM?R,S^F&_GZ@\I+%JV.C/'_[%U;<]NXDOY'N[A?'G&==54VR4[.
MJ?.(TMA,HBI%S)'DS'A__39ED[Y*I""0DC7[,%4:AR"[O_[0:`"-QA1D-+]F
M\T730V.]^@*"?ZFN;U?;#;X][-O=*#&B*(40AT;F!'?8&MGV<Q&CR`T!SWI^
M,3'=BJ$_!;^NMEE2/P[W</L;)N*IL]09895#$B;L6G8]27N>6ZSKK(?7B7E6
MU`)3<&V;,?XD1>$PP@UHG23EWFC*M;-*;;,'>;N9(KS-KCI^SLMT4[.NO!FF
MH%XVZWHT]3"ALQ@F=-(HWE36\YYT*`J66ZGY#"O%G8QP12UPNI3!%X*<4>XN
M$\%9+JAQ!$4"&")D/*54"R1")*=.#WQB_P?Q;SXM?V]BJA4P;[ND]\]E_<>Z
M6OUJ@J[M%A;\<PU\7,RW5AR<2ECH4PD3HXF68#OCK!...\I:1`5F%[#X59)6
MNU843F.-B;>/6B7OMJ6>AV\>O6Z7O+#&>^V=Q"%:*:*D'>"8XMQCR6?$NM-3
M9/<VT]$&F91XQP/W4N/A.U1C?3O!O%HIL*/BW""/I8[8/>#MC,LN@7C.'>`X
MWHWG>8M8Z)WUB(.V+0I^#NPM:##HOA`DA:$5X?B`JC?>7%#IS_-S_*>S8U;]
M"?>].>=_M>SD__3UR]V/G]_KY=T5"'6UO/Y\N[K^/EMWBMWMFE1DO"H19#%6
M7#@&N#/D)-6DU=!'=$&W:)V6(/6D=CK5&8M_S3??7V&W?@[><Z0[#7^#T>A#
MO5Z#]HO;FZ9F19BMEO#8(.<]M@PIZ,`T1TU!-B,1)TA[V^*O67:%H<OVZ/G]
MY-P-_`X[V)=JLUD\/[0^?H]Z\M'$E3)(:".\C#I@+Z36+<(49Y=1..<-J`OL
M0OD6/><^L]ZA[:[Z7*-^+S'C:+1<>DDD<8K%@+K!G@J?.WTXYTVS]]Q32AKS
M!-LA)6MKC;`9$D)@R&J$$%$XN$"9M@&&YRBYISKT'GT\3:V$0VJ:]+PB8>>5
MPUP+A;FQ)'H`X0&!B"VY@&7DDC0XL%)")LKO;"7L(#X6_%P2UB@7$5<`K'4P
M<U5"MZ@&Z7)+\YS1O&D*[I[.(N..1[_5]<V?\\6BS.#3OJUOO'GY7%(*5.=2
M4QXD0X(I[AZNIZ8Z<M2;@CE.]^_$7,(\=3-;?IN#:>\+RSQF6PSIV(>]*"%#
M*7`$&PS!DY+4!MNAP9'-S<,_M^$FGP7UA/!.T_\>,F).W`VIBY$&*9LD7(HB
MH<S<5Z'E(G"$>Q/OQ^F&CP4,6X'[LE=VM$@B6`0>WP2K7"`""X)XJY]EXE*2
M4/+MNK-TY#$X3A&I=4EV]G8-T]#U^DOU[3X$V)\^LK==\D0:0Z5!H3D":3U"
MT;=Z"@@FWC]?BEGZ)7,*XCH)?^[%Z\W8>/9<HE9(JQ@EIBG>30&2QWY%B,,7
MQ(\R]GS)DB/0G((5;5\8DL;PZME$I/..;>>N'D=/(H^LT\?Q"ZI;4-I['(ME
M7AY`72UFU[/EYOO+2=&K;?Y73R;NA.(*!6>8II8IYXWM-.7F`JIJ%K!-71+#
M(VW<;O!_7LVO=][_L>/QY"2W05"8L*OH05Y!B&HEQ4I>4,\N;NUC@,PR^=/$
MCKZ._=:SB5ND/=)",O!=1@G*C6ME#`SE=NTSW#4M9.P"*(X[Z;Y:PL_J'[._
M2FVZ/'EAWYS[C4>3<%YA*S2G39EP"VY0=([/H-@;1HX3_'22'K;6M:]9,MY%
M::FWR$=%K1;*F%93I>*EK&P=9>171UJ+X3E9KRI;$O[(WF6<I4H:BCS7F#,4
MJ(Z!"\UDA-E&_R1MI*VE"I@[6W0"?ZPW5>^AK%UM4C!<<!&5E<A::8,G`74Z
M&G\I]R\<9=Z76SN%P)QB'MIL0=W;9K&H_VRV4.V=?[`+B+Y=ZNY9Z!KZBH2B
M=$22`',VS*5AAH'^K?8J]!Y]/'\J%61`/0G(4U#LI9B]*V%O-TA(PIC$8$QB
MACJDFB/-O-5,(GY!]"EO['H$A(=S9UU=_\>W^M=_WE3S>]K`CY=L@3\E7U]O
M;SN\6GZM(0#H.^;3UR1Y[8.'J;YTF(%238T.T>JC2?]9ZU*3Z5_5ZH_ZW;B<
MPK">PL6L/_T$,#;SY;<F(]S-5JL[T&-[Z=D!?F?/6Q)%P5IJ(_=>0'BL&`^N
MQ0`'?`'3C7(TZ'$^Y6`^"=7@AX/_GV^>2?X[F!?$^7X(W?:_*6%-.6/2!^U9
M0$UE#]J&H\XH=0'I5M-1KBC4)Z'=U?+SJKZNUIW09GGCFU+R]<\&OD-XU_.J
M1`AS!#?WSA%B+%(XBC;*<%)G[T"<T3+E=,0KB_6I'%[[M_!7<R=M]>QRZ^6-
MK9;5U_EF_?;EM:Y>'\3.`I]+FG.8PB-'FOS,H)"(0K>H4I'M.L_HT,6DKG-B
M>YR$Y>T?[@/J0PC[O&4BS?U8401B&$5&,DYQIRMA)'='[XR*EDW'O:.@/<U$
MI"G@=]"<HVF0G!>&,.T$S->BL$I;A+L`Q(7<Z^;$WY$T.8B>A"N_K6#^<PA7
MM@V2X%8PI1""KL"@1U#*NY"!.96[RB$/YDJ]F2W>.5=R$,W*'7CRY>Y,X>_5
M8K:!/]7F^M^W\_6\T?%Y^8A=FU-Y;TL`C@Y866I`OA"8T\YVP:;-]C+J@KW,
M='!/Z8*Z5<,GAY$&.**WFB4?`KA7I`R61$D5#2.FU3)0G5ND5?^-W%$!7$\R
M@+W>MSAD-'O=.BFKE`@*]-71.J*C>IP-:VVSKT9%%^RAQL-W8DX=YHM>]!86
M)8E1$R\5\0K3Z+AL-1-6YGHA_#=;H,^'=.J,H$(5GX_,"**&-;[84*N(1%9Z
M9]I9AA`!GZB@P9NKW7TI0;L;):,L(XQJSKQVB'GG:;M/+"C/OF[BC/K6\0:N
M1T)S"B?\IK`]64`[VR0LN,(HQN@EIU0HPW7KAH35_`)*7)0T\A#>9,!Z,MI\
MG/VH>C-^>EHFY&64BCLBM2`R,,-4U^ND1!=PNK:@O8<P*!O;*7C4^5USN_E>
MKV!RW>-[WFZ0*/<1(:8#A=!%:28":P,6@22ZH+J.(SB>(IB>ABV][F97DZ1B
M"%JBH(S7A!(1*?'=Z*[]!9VZ/=:\O6S)0G0*ONS.-OHPX"SN@-:)1(ZINY]P
MT4"<%;%-N!/.V=P=OS/*EQC1[Y0'.&M]_O?JUWP-^&_J5^LHN^:#>YHDQ0-2
M@L9@C"':&P18MQ(3KB\@77`4^]6CP'N:<Q4OI6XKA=]?7;W'Y1SZJF0IXYXJ
M;Q2A7OE`5;=0(W#()ML9QCUCD&TBV$\[U&6-<(EJQJ+@6BHO9"3.:<E:#;D3
MN0'U&0YL8Q*K&,!GEEF_+>1BEC<?P.YOG8,_]I5)NJA5Y(&!3R?&!AW$8TB!
MY`5D\4U!OXG@GW3J]Y"(^)!Y.&3F][Q%LDXJP2-5RO/(&0V8J58W[[)O<SLX
M26^*DT)CDJL,OI/M'94LCWWDSE$TDG+AE3*!:20CLR[<G[?WUKA^YS9.#WLL
MO_3*;31^X7%W<(ODD"(.F6],)G)$@J)&:DY@4DE(6\++6X_1!2S-'$^-G346
MQX1ZW,[Z:?5MMIS_;YM;_N"[ZF6A3KOS]7U=N+=ALB'HZ"CG$6&DN7>./10@
M8M%`7'>:#OU4;@?BUHOY3:O$YR=F^O3U]2W3!Y8F+OVII)7D5GM$)2'8!Q@_
MB&P1C>IB7$!!:KV<>9S6(B-[BB;-V\U^SC>-U""=^;:JGM^)=*2OV/V!7F_1
MWS1I0[5M:OC(0+ECUEIR7Q!+2&F0[$W&'2D`:*3]7B^@IZS#OV_GF[OF8/EA
MCF#P.Y*5QA%K&+68:DD<$5JW&%#M+J`J;GDZO"J/.P[8)^N\1>N7C]R':60\
M`JK8*J*;F^401$Y44D2)QHCW9AV.'<0_B/\P!-S38WC%\YVM$_:**4L=#`&F
MT1QCQ3J]-;N`&J7E*;`S6"\%\Q0K,%UX<"]F<]"S7E8'%$=_JUVBRCJJ323(
M-.5]FUQ5WNJI+,D]EW(PG:98C2EJ]UVET@N@/`6;7HC9F\?QYO/)LD!)M,%:
M30,"E:CN]-*.7D#%NL+VK<NC.HGOV=MSAB1S#'Q#\C90&QA'U!!K)<4F=#X=
M29%[F.`,-U1']4:CH#W-*`=C_=5Z?5O=^-OF5J[/U6I>WVP+'*P_5G]N_VG_
M<#?D!4E1#%W32X^<,!!&R(A%J[ED,?NXT_L;]S+8\-8\J#3D6:E$G[X"](T`
M35URD&(KPLY9QEL/IQA\\()1(JRBS#%M>6BEI"'[TMAWYX#R:5$,W"P*?*PV
MV[(_U<TZ@LI;;K;"[&+"OC;)8FNT:FXU0)XZX&EDKAO;L<A-\3G#3(Q1"5$0
MXRQ>?)[=;6>/G[[^<PD&^',U;_9EF\6:)J.HV:6!,.S'?+U^NN/QDB@'O21Q
M4(08;S#GA%-&&:&V&[UY=CF:,TRB&)4Y8X(^14CS*'\W4#8I;DUUIGV!S+YF
M"50"]RE@_$2.*@^_>#=%$,Q-ED3Q?JDU`LQ9?FE'\/2/^FKYZ_:^L-=.=S2D
M;1*:&R1UL%0@9G3DC/L''8QTLO<ZR/.O;S2)%QH!ZW'7^6&T_5FM-G?@'QL`
MGI6J/&YE_ZTW]RWI[VN3"*:((1C\-9%<T2`%?MADM<YZV[NF/9+??A#Y\V(&
MLCZ1^[`MN4->DXC;UD%"&&L2:;#2<M$B(42\@`.\!=GPTI./!_3T/;7LY2OE
M>RR*3"(797#(:2\U98_9"(SVSI+'7J;<R87A6W#[7Y$(!`-1*=Q<6&(<LSXB
MTR(0C+B`I>^"+-BY/%D4Y$F"^5T"V[M_@!`]>W$#6B=E+()805B%&?R';`BB
MU5G'[/SH,R+6>#08.B)DPWU2BC4R]V[4#6B=G%8Q4(05TIPQXX4GI-49>O,%
MY/Z,PH"A[,I&>@IV-9N-MP!\)^U_5S_^V%LW=T<+Z)748>B0-"!C-,&*6]MY
M?\W^#BS*L70]!KI3,"?>KI;S#431@$"<_]7\6O>29W>CYN`+(&2QDLX'JXG1
MV#]FM&:?,3O#G98Q^5,,X*FR3H8YG5?=04K.I'&8$Z(58\3QKCM8YW+W:\]P
M%V9,LAR'ZA0,^5#-UE634[L]-]/^S]6/GZOZUWWZ7R]UAKXB88@KM3).P/R_
MN:G:>(Y:[460_'+V9\;DU$AP3T$V>PNHS9??FILT'GX>Q+1![9/FT0HIA?$4
M0W1)N4;=$1+">&Y%M3/<JQF39F-@/8E#FRUO^EU6]U`RS5$!SRQV)`BM+76D
MFXUX$W,+?I[A=LVH3BD7T"DH\7M3RZ1GI:A[)EF0D2FC>7-E:.3.8<M;^:7K
MOU?^_83)HZ\'Y8(Z&2EZ'<63IQ*QBA'F9,22$8ZXC=BU.E"K<S/5SG#^G6&W
MMRR?A=M)5_P^#,BL[F^<4&00Y2,J(PR+R$=I'EV@]#&7*6<X>3K=DG(NVB?E
M5]\U2/L;)L(#4=Q3%K337+B(]".(-%[0->$ES3Z443D83\$F<WU]^^-V>P6/
MK\!0U_.M`>'WHGHXX6Y^U*O-0_;-3OWV\*[4)Q)E+$#`2)S1CD=AHQ#=$IAP
M$V1SZWN&+JMOC3+OE:,GLL=)?>/':A]#]S5+3)(`?9.'P#'UNCE0WLU"!>`_
MU7@[Q>&24WC&PS$^60+/H7>EC$SJ/4D_@]LF+*63%!-B8&BRSE@PL(?9-;5(
M>\Q[UTW'3O[Y4"^_?9C_JF[N"S#]5[6XB?7JRVQ1#<_^Z7E'PBPXHZ*+6A#%
M!#-<RA8#@4AN5NU["GT.Y\/.-*"R:$^RK+=38GNW_=.`;*#![TB,4(>]CMA3
M(HV&>%#K5O\0LW>_SI!M(W#BY=+@2*B?EG6#[GX9TCQQ[12F`AOI!)$:E(=9
M\H/6S2T%E\.U$9@PF&O9@)^69D,6I`:T3IHQ[9AI3H-:KP63'C!]T!G!GR]Q
M47MZAY:+=]9!IG97;OU[=;V8K=?SK_/FCMXGXNS*-.]OF2(CPL`40B-DM=<$
M&Q=:^4E^.?0SY$OY<&L<C+,XTFS+'4R/O8T215X@Y*3BU`N"-='4MU);0W)W
MU\]P;7LD9I2$-XL4.Q:7#N;)H>])##F-L01%`M:6N:9:=JM;A/'];Y#_<QQU
M1D9\^D6;DD7*BY^Y"I$)HWPT$7G,!`2>^F'M-!JI^N_8F_JTPC%G(Y\<U`M"
M0.02K!2**&&)(K;56@1S`?=1%K3\X!,*F?".VR/!;S1:7V_K.FQKQ]1+^'E=
MLK+P_F_T]<]AK6'0;&Y<D%A%R:(-2.`@O6?."PV8HA/5%_Y8_;E3\N7-_0U+
MZZOETV?FR^OY3_"(0_IRB=<G'C'P65HE#28,AH<FA;U%#MM+N>ZZ-(_JDYOB
ME)YA?]GB5JK1/K\W:"CR=:##[?5F6W4"C+?Z=G"(4BA%[0U!!FPH[6N6.+.$
M,F,(\=(8YJ6S=,LR+KT0LG=XGT!3T\R/MD&NN=[,?VVO\3BL!$3.ZY*'V95C
M-I"F#`+E"",;6V041`3OWQ66)<C+C+_Q,1_;Y[U&):]`^_GV?J-@>!$Z<JMQ
MQ`X&.>F\)%)YC:+FO;NH4VC:4Z;K]<,)>YA$>Z0E`<(2II&7`K326@J'+,JM
M8?O>>NY@X^[KN3F(9JU"O?KJE^I7M=I7J&U(,YA?6<JBHYY@2HU&'!D+DAN*
M)&*4YJ9(GN'"=5$NC(#M%!MGVUL+#G(?.UHDCCF#T#]2&;6&X2\@R1O=G`?P
MJ+N@JJ.C^)`RL$YR[N/M.*41M_GO:GE]N[U.KO;P9WQXD+GC1<E91@G:5KJ`
MZ262T:/&I5H1(:[2-#>\/,/%[_$'J=)H'S^`S9Y)M'XJTF8K$CQ=P6>^PX,>
MO.JBWI627>S=T/<,UUY)ZXQF@2$51`0,'-:1&(`]DW%G>`YVY*%P&@-,0,+?
MJB6,YPMXSMS\F"_G#4(P/=NYPU?F[2F`WL9#V*`#4M$P1''3&9WB'$NK<Y-/
MSO"([:F)6,@$$U!Q6][UC]FZ>>!'<Y_RUKIEB/CVNY.DW`9M':-">#``-I8`
M!IXA1(SDN3=YR?^GX2@&F#P8;+SXZDUGN._QY(/G$2/E%+9(<X<Q.'W0RF$F
M0Y2Y1Y[4A=.J(*;3KPN.O07QI5I4U]"__N=VM@*[+NZZ2VNA>\W*[,SN_T;?
MSNRPULD:RR-G6#8&E3#2J,=Z$BC*$U6:?BWTU?)K#1;XO_*NK+>-'`G_I.5]
M`/O"<V`@B8-)9@;[1&CLCM.[MMJ0Y,QZ?_V2LEH^I6[1?4WG(8!C=[/)K[XB
M6<6J8A)5FP.&=@T$IZ0U7`$/D!"4&<SY/I=4.#N#-()>N%`-`':_<\9Q1#J]
M]G40-4XR,UH@8R3U#@N(%'*42<*YI<(U)ECVG8%FJ@C=,NXWWKC<^X1+8)M:
M"4A[["-;M4S4A8X9`'8X>(F'N[US&@K=FA6';\OK&/$A]HQ/)A]]_[K?'W8Y
M``VY:">T$H27BOFX3V;"0FF$-\S5&%BL9U#ZO%=F5$,A/P3[#G=X_4>Y^6[+
M=,57L;Q(\4:_%K?5*IW!WZ0XFJW3-/TB;6.3L;:\N+?%LKJ)+>X?6C?FM`W3
M@4"\X]0+@;C7E`#%+(8/R`M@'!\L,&V(E/Y>&/FR;.T4Q3:$PAR;2,SB-H&^
M_M`BR^ZD=@*B@!`@,94(Q'VH1,J`&@<'S"R+R/4W9?>)_3!NIA_%\O@UNO4C
M`5*B$([=A<00S35S0M>]5T3G%LF=X&+?DU1?^9>R@!TD>N&V2.[YY=79,EJ.
MQ8?CM<'>>#H83ZB"E'&E%():&2Q-/2;.16Y5C`E.,\.0Y?T8#\&;3\6F%6.>
M/1>@09QJI01E3'LKH?;[I1EZD1N`,,DB2<.PY3WX#L$3MU@M4PIR?1VT7JS+
MB[B=L^7UW::X/,*<AC>#CDNX4<HS);G0D*=TY7JL3&='2YT<S#(?+G6+^!#L
M^J,HK[XG`R#%"%X5G^Y2L=?S;]O>G]]MUIO%,B7`MR==7H,ID]:K='FA`D0(
MCAF$OD;&<YF[83HYS&4^7!Q$$&,ZX+M,.Q[$_ZZ(I#H:3%&.`B,E%%"/":F:
MCI2*/-0Q&J="2.N,M9Y3X"201M:C!P#,H/!V+US(.T8[#>R>M7@_N27OPDUL
MZ7N<_<H?VPW7YRVBWXM->;&X?O&_;E0[SK;KZKJ\3&ZNIUW960GQK\^_VJ3L
MN>T%Q^,2C[&53I(X<U-@N-O*A&%IJ6QTAO9T_%8/H?&$[=F#@<2UAU*"#&%$
M2R0AIJ8>C3-T!O?8#23ME\=J[X%YB!WCOH-?+HKE8E56#6=D;SX?$-8.`VZY
M9U9`+!6AOAZ7='!&V5ZY`CW$BW?`.`@]=MW[;;F^+2ZVU6P:3Z,.OA.`LYA[
M8K@2GF#B/56X'I_R>`:5#3J2[ZO#^6X0'71":7.`\_KA`"QFC#(N&)*>`B$$
M07N,-,I=B2;H/NUZ*LG%,"NR?!M.K%^&$[O_IA\+M5Y7J0Y6<9G.,>M,#/4L
M$V/WZ$$CK*/V`\0$"ZSBV*U0DG%'B*BQ$`#DGOI-><[)($(U/O1]TW"7AZ%>
MYF%T1\2&+P2K$3$B[AU-!`(+":55-1Y89U]K-^6I;3@J=@M^SS;TW<W-8G5_
M_NU+>;6,R_G%XEEEG6BA7)2=^<):?:O1)W92*X%`)RCA@D30,9.*0K-;RS2E
M6C1&Q_6T-3G6]S:^L78-!!_W9`Y'?GLOD0=6:>;JT4/F9Q-BWA,G7NYO^@!]
M"OJ]^TVJ1ER4/Y[Z:WI(7FG5([-8?T__4HW$'XOK7:VT+]^KU>9KL;HY6_XH
MUIMCA0B'ZVFU3.7('IPVY]],5(ER\VNY_L]D.]9I@L'!K[1P=QY_,3!`A)::
M&^YMM%:Y],YN3XP$BQ8F',FO^:S?J;]-_LVW7PB:6&J5LY)JR;!!1/"'\'C!
M@5-D+LD"'8KY==C?^W$=*,;T>4?U?8OK:(Z\%70ZZ(];524]YMPHI[BIQV@!
MG-%-C^\5<A-GLD$=A3B/5W&?--\\7N`=MSV`4P4@Q!`X)@W"HAXC%6Q&50P[
MD73CC).+["CL:>,&/?Q2<%(KZ@@#,D[*4#M)/=V-$%)E9G1)3-^33BZF67ZI
MQ\*:Y\M?BNIJM;C]7EZH5;%8[X*??03`Q>W?:KFX-G?K3743$5:;S:K\,T7N
M;"J_K?)V:"/7V0>"UP8":`!GSC"+)(5[-!#%>@;6:I>4J"8@@W$8^;5RT=+9
MW$<3)YH\R1"*DW"T>:Z+S\4JX=H;51N_'*R,>`E#(0*:2<B4-_4D@;2:4X7)
MR7&X:^%,P3/S2U5=_E5>7Y_=W"[*U=.B<&.Y%1Y[\NH.M0EWK?>B].UZ^*G8
M;(/3BI6I;FZJY39H=NQ.=>OE3W&_Z_-OGY_.8PVNH".O!`2=1Y`;Q`0GD#%K
M_"Z>T6H.\$@E8AZCMV)?M_C=M_':'WLM$";BRNOCS"F,C<LPMHK7(Y4R.VMB
M0KN?[H3]>H?=%:Y#6&:_K8OS;VZ]*6\6FZ-IG\\?#%9(2Y6*UH;0C!%D#2?U
M2)C(KI0XH;U%;PQY%Y*#6.N+=8I=>''F<<+4TN;]P*DFT$"CM%3<*<R$@O6X
M+<:Y%W=.J(YU?W-,#P"/1ZQMV;HRY1,<&]?)?&O7;!`2.Z\9%0)BE6X>E+OH
MPXA2W)'G!NE.J-KUP#3L!?<AV/EUM;@L8G^W%>)?'T,WTK#5^P&:.#PNH(O&
M'Z*6``SVXXY&8.ZT-Z%:U[WQK0^`1_%^GW9'5)O7`Z3:40TU=5A!E%*M!*M'
M#1#/K:\PH<K5?>[8N\9WD)#RXBJY%_85CTXC58NW@Q;:2.NPH)`[(@&D6.VM
M%6YR?>`3*D/=&Z>ZAW<(2AV\%;;]WK]M$P$32XA02CD#<+1YK+![LX<@F3MA
M3:@8=6_DZ@GC04I2/KI%5U$G;JOUXOJ5@[0]VW*:"]()12'E3#G!-9,8>U2C
M`KG*K:XO?P+F#8#W$"RL3S*B[IQ%:)979=P^GLJ]]HT$(JA6`!$JJ.24:4WX
MWA+GEF67!0`_`>5Z@WG`<GK11JFNEN5I#OK&=X.6S%@J6%0N:ZVSR(&]8B&I
MLO.+?P8W?=?H#L.F(WEEC>Z)%F^':"A+$@%42$>SQBMBY'[,G.CLF+R?P:W?
M/;Z#6)&[$E[/<\G.MP6:ME-N,HWCVI[VFLV>V(S6@F&.V70MI^("*JRE,_LS
M,0_S9[&?X2"@?[S'J/[7?HUL>#,XPJE7QAE)"-?;`-N]UT8!F>MLA3^#=[];
M;*<0P%3;S4]-YK$#7HZN&J/'"+TZRYE0LMNQOG6:5M9Q%!&4!F*BG3768N\D
M<W*7\<FXY:BQ"F1/^X!]<?2F\[OVM]2T:BD@H>.HF2"*>@]ARE'5-1[$-.,Q
M@UBCUI0X>#U-'U`/9-(<[??;OVU(5\MO-$`LA'`$$H=\2O_CK"[.P3AU=@9D
M[)T[;]V:.(0PIDO7CT4J2]LY81^:#5AX[C40"E@0A:21VNWO(DI`9I_\3I"R
M0U"I$_9F268*_-VF3'QHD9MW6D.!6Q]A%S;NJR2A%#-)]PL<Y7X&T:)3FU;?
M)8!AJ?B&37&4<4^>#U1"K[0%EA"E-,`&@;U><S.G];HO@1_D53[,4[#U7_OW
MQ[97=R$A3TI9IRHR\8V'%_9)9!W?N7K@H^6+KS:7?S^QH6`55H![!9F"R!L/
MK<$.<NAL)+\SC?N2ONU<MTW0^Z.\+'9<T?<?%_^N5ON1Z/M]^,YN]"?8OMFM
M1\W%2A'NL8J*RA)HSM2X>>ARPQ,F-*7U3:B#5O)00AEB_7S>\0:+^/7#00"E
M'738*0P$E@032>H1<09F>57K`/*O.@9^""I]6MQ$<)YUM;&RR\%W`H\;!"0H
M]@(809U6CMAZ?.E/\R'6>X3[\H*NCN`<Y+CNI18]ZW8;Z[%E"X&DBJ@$"2NY
M@2H=4ZJ]UCF@9U3`8,PYJA]I9)7C>-65L]LHP%W)A,75P;HO3>\%H)#U%E(2
MMPU0<:6,9'7?C3<SN)BG-VE6_>'<#4<^7GQ:E*N/Q66ZG.1LN8Y_OML4&:1I
M:B@@!Y1,!;44L=@0Z[6O=Z!>&CTC-]:P+.H8^&YH]75Q42W+"Q]M_74&F=Y^
M/4@.D,8&6(H=D511SD4]$H=E;F6%"04[C4.A3N#NAC@V;J+BMW.6K=>O!L04
MEI9HAB)00%G/30V/-\+GKEP3BF`:AS#OAGH*7L[63I31G9]O7EDPS5[M'+#P
M0.\ZN8NCT=UZ]*V@G$C9-)H(RR'3W-/:NZ^89-*/[5M].RY5K5:+Y=7#[7+Z
M_O&9SXO[]#OUUV)UV=[#^LYO!.&YY<`B:#%6"!):Q_='#+VDC1A.WR3HE$D'
MG:K#RF$(!\=#YYK+8C][+NY1(5(F#L)SI^/JI!3#CTCJ&?CM1Y1]U1WRXV55
MM,'E<63+RQ2UGQR#S7<+]O"YP`V62$.&`**0R;A;AON9@0`UHP."3#:URL48
M5`B#4#NM)P\9)HUQ;:^>#3[5./54.V,0=I13X7@]'@C<C,HJCTN'5[<AOD\0
MDY@S#^'5YL3A_8T'K!WU(NZ4F+(6&^F?("8HG-,5G*.O[X.+*\OSD]U+ORA7
MOR^N[U(>^]W-5BW7*>4GA5W]J*YC,]?EYGZUV!3NYO:ZNB_>K,PY>!^"IX93
MG%*^(%$"*:"AKS$UQ,SHKI<A"5C]/<0YOHJDVEQ^511GRTB`8KWY]<EH!M&/
M8QT(!`H)L!/&:H4Y$I3!_5PGH9C1X=`LE*-#68ZO&;6FI_L(QUDRGGTY$.><
MU]@Z2!4U<6IQTM7X6>AS?6L3/.6:A2YT(<3I*($M?Y27Q?+RU]'V3V_V($@(
M@*%.`FL`U,X;4J<#13P!S"U&,,&3O%DI11?"G(YR_+[?"Z;QG'_[5EZDV,7E
MY:=J68_.EJOX;+4:5FE.ZEF``EL@(0<`:`ZM-!3O\4?:Y%KC$RJC/$MEZE/(
MXRO96WO**:A81K\"U$I8;S26CGD@!>1ROP6F2N>&<4^HH/2L%*Q_$8^O7D^W
MJ5-0JQ/Z$XRGTG-"K1<,`>^@96SO:XFF9J8Z3:B6]JS4J3_13D>-GFYLIZ1.
M)_0K>.V]H00Z!$ED#10:P1I[1EUN..V$JHC/4JWZ$_$DHC*/A16^6%4G%5:(
M+/8:$(ZE8(1S(2C8U8LWZ2JR1FWJ/65[1XXOQ>I'Y,P!:EYO.Q9_2C4XMNG_
M_XO,+%9E%9];GY3$W=WW@H]+@2<22IF<:@8S(GV-K2?9!NN$SLXZ9=CA'.[1
M9#)$$,39,LXUQ9<HYNW<^F$WBH9`Q"-O!8@0-1Y3[)UW&!.N%:[':`V=TYGM
MN!QY>55"9S(9D7>-D8='WPLH;C@8UQ91[`1$GE/*ZW%B`6<4$MN)M-LQ*`O;
M0?+".]&Z-M%<'7\I:"WBEM)18JA-5\0YC/:K4D0SM^S]%(_N)S5'CBO'R>A$
M-'M2J:WB(?)S_;7:+*Z?_CV-\E.U^5>Q>1S_>[4CYYL!4J%YJOL-XL8-&^_2
M=<4[?(FDV>74IZ<GHS$S1T,&D.7?6E<>).*KU9-J<'`,!7JS(P%Q!H%Q&F*`
M.8_PI\OA=Y+0BLUH]9F]5G4AX"EXL+;+^JDE"'M-`SCLV&KW8F"I5(3BG##%
M"0`6V_HN1.RY01-*F7WJ1'V2N+%.SM2',3TZ5+>":G7?:Z<?"A!ZRIU2FD1:
M"P*(EJI&$R(LY[,3Z(I6+?)G!Y/'%*:8W];)"%EORIMHWQZM3_#/?Z0__1D1
MBO_Y/U!+`P04````"`!@@FQ&H2\9H\X5``"8'P$`$0`<`&QX<G@M,C`Q-#$R
M,S$N>'-D550)``.S]`%5L_0!575X"P`!!"4.```$.0$``.U=6W/;.+)^/U7[
M'WC\<N94C6++EC.3U&2VG-C.Z)03>VUGLV];$`E)J"$!#4`ZTO[Z`X!7D2`N
MDAS1H5X2F40WNOL#NQOWW_Z^C$+O"5*&"'YW-'QU<N1![),`X=F[HR\/@XN'
M#^/QT=]__]M__?;?@\&_WM_?>)?$3R*(8^\#A2"&@?<-Q7/O:P#9G]Z4DLC[
M2NB?Z`G\[$T)C2`-5]Y7.+E&(>?)!H.,E9?^6K+@+?/G,`(>B&.*)DD,KSG9
M)9R")(S?'27XKP2$:(I@P$4+H:AYK4#E=0SH#,:?0039`OCPW=$\CA=OCX^_
M??OV*H3+Q1S0"+SR271\>C(<#4_/AD<>UQ^SMURV/]>*+R<T?$7HC)<\.3L6
MKR>`P:+XDBX=N&."<1*I^0<Q/8Y7"WC,"PUX*4B17]"9B=8)1`&DT0-A%@/L
M%WHL&WI_.Y.EAV_>O#F6;XNB+%`5Y&R'Q__Z=/,@,3SBD'J>!!5%"T)C#S?`
MF`(VD:0)&\P`6$AK#4Z&`V&OM"G<$!_$LD%F-%(+)>$Q#&.6/QF4K%YQ&8Z\
M8T=Y*`DAVY%`DM?6$@F4=R61Y+611+J6U")/DT3\-<CI!N+18'BZI1CEA^DF
M1DZW$S'>'`/J"[@Y<GX\X*X@!!C$A*ZN^=]VHH64KG&Y*ID(&=\(&8>OMY%1
MLL9P)ERVO4Q5JMT*XF"8G&)[`=3>UD:.*N7GE'"7XFPFRA9R5#$YEW\%EHA4
M"$3-YXYU,NB_FI&G8Y\D.*8KX:+.;'R;BB[_8U`RV52:A%*>^*RL7:V2L/AK
M(R^[QC>`R%F6G$;\V%X"N/3GSB(41/+7]D(@_`19[-Q(*F39[^V;"`;(EZ%X
MZ"))297^')0,-I2#(=]9BIQ&_-B!!/&"NHN0$\E?.B$`QB26G.2S_.EB@?"4
M9(_X0Q'#W^:!_!Y./9FOOLVBJ#ZK/5Y0LH`T1CRYJB3WDL&<PNF[(Y'B#_)$
M_M\^"%_Q/#@OTJA@/<60\8J3^$DHU;@IA<PY"/_][HAQ>X<P5_Z[:Q7`J:M6
MG`1AU&6E0C!Q58J3P+"K^BPH=-6'DS#>3=ZL[0D.C[R$AWB'[X)2@&>RT\V^
M\F[^PRI:S`E>C7V"QYCG*Z+TE_NQIC,L)3+Q*63(I2C;V>^GP[/1\.3$&WB7
MB/DA80F%_(\JRW0((F?J":X_>YSOJ]^.Z]SJ%24,!K?X=_F[;K>,.BNBHZQ]
M[/:$Z]^3FBY[F@.S!5Z7,`8H9+N"+6>G16]T-AJ=G&Z$GO=35L/_'G!<,_PC
MF(1P9S!FW+0HGIV-SDZ&&Z*85M`_$!F#,?L#AL$UH0]`.%M;P!J4>@<Y?*-R
MD)*))[B(D5A/\.D]!,X>L(V!WN<-WZA\G@*0'KNXNF5=G5H+O=Z-#=^HW)@2
MF)YZK?<@%`.T#W,(XSM`N3)S&",NG3TT&A8Z=+@/&YY+/_;`#2BC"O^=,?,D
M-V^=7>^P@9@SC.^X1>S!J-#HH\A(%44R<D_0]]C<KG%#0:J/&"-5Q*@:O[^1
MHF)+QQC1I-1'AY$J.JR#T-.H\`&P^04.Q']7?R7HB4=(GO/S)V,YNBI[`-:P
M6#$S9+QG"E\E&'H`!^F/"FOYL,+\@%[3X*X>SH6G(5D^4[@^:RS[ZQ=M$'!T
MF`XL#7GVF<*3.F#:5S=+PA!,")62<+/?(!]B!B]F%$)''VODI'>PYR<J!UME
M*D'+V'HEWP-D-4,[.U9;AGJO>GZB\JH6`/;8H9HL[^I-+?GI7>GYB<J56@'9
M6R\:12B-)"*8$1PC/(/81T[8M?,PS%;]HO2<!;LT`E89'O`I3)&YGN$N<"IX
M&>:G?E$Z2@U>A8?TAH=OJV'OTQUB=VJ!W=F&V)T>L"O-XAS93)P,LXF_*&.:
M%K?>!C/,2(@"L0*W.K#N`E8;!]-H_$EC-+[*:WUHOH=1K#1%82)V.Q6=V^N0
M?-L,(#4G`U#G!J!*IAZ9IKUOR?<`669H$G'EYCQ_1D_PAK`=0-?@:(#PU`W"
M*GM/\#]`F1K^(2;^GW,2!I`R,<(4K[;&4L'2`.;("<PJ___QTAKZ!N<EG,2W
MDQ#-I"CVWU^=SM`U&RJZ9H*%5^'1<],[]\#:Z`V9^U#1ZZI#T>>.EMJL]IVK
M-GHS+(T.53LL_>M#U<SJV&]24QOZ2D-%7ZD)24^[1_EN=-X-O>+=Q7@UQF+;
MN10L?V</CPTS'5HG1:>IV"5?^2DZM2E?K\*X>-\WZ-),9\Q[D-PF3_#B&Z"!
M_:>DIM;'_]%K1?Q/&7D%)R]E=4"#&\$Y&=!ST<>>T6M%2M""3I\S`YV-[?,#
M/1<S4HTLP8A4_Y(%G8W/=H+4F052(V>DS@Y(56P\V@E2(PNDSIV1&AV0$@9Q
M3,-U//3)^.BU(AEO1:FG.?DU0/2?($S@)PB$B=Q6+JFI]8G=4)78"4:>Y.15
M61W0*-<0V2=V>BYZUS94)78MZ/0YL=/9V#ZQTW,Q(]5([(Q(]2^Q4]K8,0CI
M>.B#T%`5A%I1ZFD0^DA(\`V%H34>!8$^U)S^J@@U.6U?C>RZQK5.I_=*I[\J
MXD?.HK_+57,+./J=&IG>U9S^JG`UI>E[ZEMXID\B^`B6#F:OTA@\S+G"PZ3D
MGJ3OL;F=\U85K<';G"N\3=7\?4Y1F^:T3TQ5M&8H&NFH&HK^Y:`5<SI&@":E
M(0B<*X+`.@P]#02W=`8P^D^^P>-V`:GC`I9V#OH@<:):RE)E)F<;2W8'9.C:
M0HCM`;++74]4ZUPT./4WG6TUM*-W,_'1^[H3U6H++5Y]=7WQ'-(/8(%B$,H5
MC!ML4M7Q,,SDJ_;_2W9>QB]=5MGCC:D:XSK[0#,KP^26:HN_'JX>.\)V:[NZ
M0B,GPVR7:A>_";:>^L.[]%C7E5@[]E>"%DX+SY3$AE&"4X4'S/FD2\UR3@<H
M<.P\<*!E8NBVGBJ\G1J:/H\E:"QL/ZB@96*&J3&Z8(*I?^,,*@L[QB$-"\/(
MPZDB`+5!U-/`<P_%LI,+7]Z%@?",FP?SG[YC+FY@8UA_H3HM)N7HE2R]=9X'
MH*K6<,W)[;@9IOM59\288.MO8JXWN:-/M&)F6`>@.AG&#%]O_22+:>+'">5&
M^3`7=P6ZH*4@UOO$<]4([1H?+V-T0`)NX/[:>>B=WKEJ1%:)2Y\]7=.ZSOZM
ME87>JYVK1F!;\.FI*WN`(?1C&/PC`306-ZQ>(PRPCT!X"6)@#9&!C<&]J<8?
M<HY>P=(K>'J"Z0&IJHE=G9X=-X/[4PU.&''KKRO4V]S1*5HQ,[A'59?8`K^^
MNDK=H2SKMPEL>-O!YC7H@.;.]:QY&8+I%)C:_0C>3^M_]P_])(H`7=U.']`,
MHRDWPEJ7BX3(Z5!(2W:&E1NJV\PRSO(XF)+W6B\NXWZ`4&7S[`D3O5_T)%S=
MCD%55*"%^?1D=-K<SV</<_Z,>66-!^A5R(CCS)H'EC_,"8T?(8TVN:!@YQ6;
MFTIC(L*AJ0@A?E8?JBZE&0AQ^GS_@26>1&[@3!?V\%A.88#B>\3^W'6[::W'
MW$Q>;]-,JO7*_$'6[(FJ#RW""2GGCMMNJM/W[$Y&H^$OS]0^>MS_LX(NWQ(S
MCA8`4:>U'QM78/06PRW2S'*33UGC`7H5,J5];J<W!,]N>&<L2*\4W'$;T-5D
M#AUOMF@,9<VBM*A[("O/KDX\-`Q'N)XG?EA4:(X@S]A,#D%$C]]G&,LQ(TC%
M4>@$/_!6L.M^K+H.<RAI'"+DT"QXG>GHU$(L')75>K+>0S-00?1,PU)VPU,R
M5#3'E^W!_BG_=?C(U3!LLTYXBRK,J/^Z!>J'A<?V+>">JPFH+R[:NX1/,"32
M5E?+A;B_:==?O:$RL^-OSA7:MXJ\<MDJ*M5[>?V'!M*"64R1F,_+[F-\OC%,
M;55FE[%-5E!675X,>1BCW`*OY^E4V-1H[E5L,VYI:"B'7H4)P">($W@/?3)+
M*]]Y"VE48`XKVZ28685>I<8#]"ID'N!,?"*5P\;%!!6G2`D^)"PF$:3/Y#E<
M:S=[D6TRU$R:M9/7Y0Q9(9!72'1P*1LBBVK0?J\6U:C7G+IL,U.B:TNHWI@.
M34@)I=@W_![P6L0J)MX9`,\0F5HJ,4>G;6;C9:4#6:M7K?;0#NPA<MZMNY/*
MC`'H=)L)M;9VT><MP#N`S7ZK\$XJ,[>1;3+;M(U,-&VD?_N/[6!S78CMPE2+
M^=G)Z&RXS4*_WJ[,MH+@"X.WTRL6(YYF[1S?&G-STKC-8"BO3!0KJON!\?[M
M>,F"MV"Q0#Q!EL^R)QB35(7TH7@&PW1QNV@2X9(N_\UMET1"8!A<0JZVCR0%
M[^R'@#%N81@\DC]@&%P3^@#$0E\,(OCN:`,Z%(;BVWMW%-.$_\V2"0<G3@39
M1TJ2Q;NCY82&Z"V*873DQ5S!_$E$,'?(=#7F;X3B1U[Z?))>B?SNR)=KI_+'
M"T@1"1XE`X19#,2<SW'3"(`+0($?YQ*51J$4X%FZ]/\KBN</JV@Q)W@U]@D>
M8_\BHRML85U\<Q.(03D\JQN@JFF0T"RK5ZAJJ]HC7,;O0QX6+76KEM]$.4PP
M3J*W<<YF8P7;L92+(7C/]0:!"0KY%P;915P<!]_`TKKXWK`TJ"H^NFGZT:F5
M4Q?HGCK5V]/7=];4];(JV44%&6*WT[M*L&EJIBO2094@YG$LON-X-%11OMJ_
M1WR?H##@G-@'$HIX1D%8B*Q\]8QQ+(`3]S#6U,08O:U*=DW/UD:7394U=X=4
MYJWJK=&19O_-],-<Q.$Q+D(1S[;78_%=0OTY[\SFD6M5Z+H1Z3[@MS0%@2$0
MF?^\O'8DTU3UIFOM6*%';O\[BGS85*;^^N5DTM)Q3@C-IP]NN`*8P?($R\9W
MZ4#0O?`GEENBS'EPYT)DIQ1BN:6QH:A-T2ZJV+)MIJF@N6`GU6,D1('HV%;3
M2@5^YH+=5F]M*SV/@]<A^:95TT3P<M0M3Q2WU5=)\1(5UO>DMJ!_.<:0X_YS
M$@:0LO0V45LS:"D[D",2GKS2&'$I+N$D'F-QC%,ZA\\[+SRMO>>J2'V".TB%
M=P:S2KJQ&?%&PSY))-033'1:;Y1R".%O)R&:J3_P]M?[Q^\23B'E<?(1+(M,
M_![*0=9'<N'S!L=0&DVK^7NIV8;4+R>=O(2HB2?J%H:(0C\FE&=U.`'A[2*M
M6ZJ:2:PKL84"8H\/V_1S:I._7`Z:'FDO[EJ6?<@6;73E.]?.FDIS7X?TH*E*
M=`"T?);L%G^$9$;!8H[\"PI!OE[TFI+H:LD=.09AL5CJ(N9831+I(*ZX7O&*
M?1`S:6(J[Y)$R$<AS'Q]:8?O4-,SAA3;CWA++6-R347+W)G9*@SW;IT4P*\H
M@)GLES`4R0!N)A5V1;NGT7C!K-1IENN>+I_\SP#13]Q!\HQ=I'5"'&BAG`5A
M][1]!#RI0?XUH!&ST+&U^+XT:\U]TO[&6`ZJH"<H(VLCNS45ZEXG37DQ=UTM
M4Z'NJ96//]<U43S??\[Z!\FGN7`:;SC%(ZGV+;0ENC;`W@I*Y2K..B[J5_N'
M1@:83V")HB2ZAS.QXH;0E1PQCGB&((X<_<1S)YXO8+%@*U/&D6@OB;F[_F)>
MDNFU;1;INFY9'+H(0^(#F>BE,P,Q%+D2]^$T/5^QHJLUR<O3O;)MV5[[5J*7
MIW\VW66ONY+@A>B=[2C\#PQ42JZ][;I&7Q93RD/C'5A%E<ZR^E6'=;D!(D;4
ME\$TGG8MX*_);US\8BK47>W@$O&,ZPZ@H,C'`)L7>K6^[N[`6R9S>NINNNE=
M#(3D\M=4TQ3K.F@/7%1Y"A/CS4VM74N1O0\NWB">6]SB3+0YB#^!U7LX9BR!
M@;R>E#_#<K0W'15EM_Q+RN?'BJZH6/=7*+Q+CGNWSV<8WU'B0Q@PT2A3N:=3
M*#H`N<:&,MU=:Y4+*9<>W4&:G9*6:M7V<HNQ$\EB^VY3WFZ26``H/B5-<[0M
MO/>6UA3T,\%7T2(D*Y[ZYS,43IK:,]B7]JV]^=:KY^M]>YN"W1M!TEPGW5#0
MJNC^!S.R')C=3K_@`-)O%(E%;V)N1!Z^GPU0()Z7<7!RY5R).N=+6Q%6G1Q7
MA]90IGO-5G_38ET]Z]+[;[RUF>VU-;D7^=S![31;8)V=]QE7ME)MPV#O\RPU
MX;]@%%M&UXTH]QYJUR_4(RQ^@&)\A8LI_F!KRFF+=<X=J564?6*Y5D@*+O[A
MF"1B/5%,+OGSCQ"+WC\O=Q%$"",F5_8^0:4EMN'VHQ@L/XX1K)T%N9FY6GG]
M*,:2KF'2/*!F$V.U\NJRL9Z0R%_$6':QB"\_U3ZW@:Y(]\846Q,$ZV.EZKG"
M)H3=RX_TEQ(V=;8LO?_\2/;<&T>Y5/:/OU^51;*D7JY/R#.`?+TQ*X:`LN[J
M-:%3R`4/QF*I#1?K*T2S.?_[0L3:&2Q6!Q16ZX0H^Q\%V=@.Y7YWQI(H55V<
M(BR:XB5Z0@'D3IB[VGSH@&UM^4UJW'M2_.S:WDZY:Q,>#0>J@9KO9G6S'#\F
M%N(JM^_3QNLU;>[/<W-UV*3[;-9V]?^PYO\G$8<3R:TA>_8OKI+\F![FJ;`"
M_6[QM+W.'\O&8K/Q-86PNH$MU_99#&RH\,>W[C[\R69RO%PLTB,S"4Z$=K7!
M5;DAB>5]DZW-[535<P[9=L:DM>Z>?"G&G';7!=VM+!WI@S9&XRJ&F*S*(FI#
M@(8AQ(I7S))0C..SU"I(U>B_;[T=^0*^H])NGT/'!.O(M\'2=4]W"64)E_*1
MJ+;0,L>%'L_">>^3<E9:R0G&;4VC8=)1*U3BAH35V0)V##JE/1<Z.\G@$C(T
MP[P3T_0ZYK+=FSQ1:ALW-4A?J]35%=Y;G&J?%%$>`]^8##&5ZL`DB%+$[`(^
MWFDAXIQD&(B3=+,I\(OZ%'A66*_TAAR[.P/JH*;VDL4-S&;BUW&CI=_[I9P;
M3Y.?1S+&3TG=.=B5[4`.6Z[[OEJ*S8HN:ZPV)=[_<$!EM7LN>:"+X?;E]Q^R
M5;*Z)K3;\>C<XF6[*Q,:$="5J@,1,4U#*F?/"J]</?(RWQI7NBHGDNYN;LHS
M,"%])G"^;%D,4M;4U13;TQ%K.D7&N!9>M$7V[X*:XI6'P&ET6"O4_9;6^$!T
M[<U4N"NMKB'G&%>W/9J+=;E_UR9\=IZ!4<FRW`MLG<WS>>R*=K9E/I*XW#9M
M+/42VR5J\?NZ@AWH4U0.O*R?&=_RKK,;BG-YRR@K4F.YI589S33ENO(=5<ZH
M62PH>0)A[2`%FX+=]W\*Z0NO)G&Q4+=!T%T,[V&0^$*.=C=O2[1O)1_''S]E
MD?9JN9#G.#[.><6S^3U<$"HW)%8R+/OBW6VTCV@6U70HU%.^ZK8JO#G]'YGD
M,XN12'.KZJA?=U@ED4(HST_0C*&X$NV]U]8NL./HT2X8[=\:RRNQQ&E!$8/7
M"0[D-%VA8<O+#N>82I$?R2-<`G81?<'B0"O&@7A8,2F<1E$=58<M\)6GFV(/
MI#RG1YS;DRNI>O$2]/C$@]NL$N=5+SJ@1WH_*O/G,`+\S_\'4$L!`AX#%```
M``@`8()L1K\T1/W()`$`&&@0`!$`&````````0```*2!`````&QX<G@M,C`Q
M-#$R,S$N>&UL550%``.S]`%5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
M8()L1O%3WQ0&&@``CAL!`!4`&````````0```*2!$R4!`&QX<G@M,C`Q-#$R
M,S%?8V%L+GAM;%54!0`#L_0!575X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`&"";$8A(;0GW6<``)$;!0`5`!@```````$```"D@6@_`0!L>')X+3(P,30Q
M,C,Q7V1E9BYX;6Q55`4``[/T`55U>`L``00E#@``!#D!``!02P$"'@,4````
M"`!@@FQ&TH,_=`C6``!=*0L`%0`8```````!````I(&4IP$`;'AR>"TR,#$T
M,3(S,5]L86(N>&UL550%``.S]`%5=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`8()L1G8+='OO=P``V_4%`!4`&````````0```*2!ZWT"`&QX<G@M,C`Q
M-#$R,S%?<')E+GAM;%54!0`#L_0!575X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`&"";$:A+QFCSA4``)@?`0`1`!@```````$```"D@2GV`@!L>')X+3(P
M,30Q,C,Q+GAS9%54!0`#L_0!575X"P`!!"4.```$.0$``%!+!08`````!@`&
+`!H"``!"#`,`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQH">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Property and Equipment (Details 2) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BuildingsReclassifiedToHeldForSale', window );">Buildings Reclassified To Held For Sale</a></td>
        <td class="nump"><a title="lxrx_BuildingsReclassifiedToHeldForSale" onclick="toggleNextSibling(this);">$ 59.1</a><span style="display:none;white-space:normal;text-align:left;">lxrx_BuildingsReclassifiedToHeldForSale</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LandReclassifiedToHeldForSale', window );">Land Reclassified To Held For Sale</a></td>
        <td class="nump"><a title="lxrx_LandReclassifiedToHeldForSale" onclick="toggleNextSibling(this);">2.7</a><span style="display:none;white-space:normal;text-align:left;">lxrx_LandReclassifiedToHeldForSale</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale', window );">Accumulated Depreciation Reclassified To Held For Sale</a></td>
        <td class="nump"><a title="lxrx_AccumulatedDepreciationReclassifiedToHeldForSale" onclick="toggleNextSibling(this);">$ 38.0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_AccumulatedDepreciationReclassifiedToHeldForSale</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccumulatedDepreciationReclassifiedToHeldForSale">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Buildings accumulated depreciation that has been reclassified to assets held for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_AccumulatedDepreciationReclassifiedToHeldForSale</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BuildingsReclassifiedToHeldForSale">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Buildings gross carrying value that has been reclassified to assets held for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_BuildingsReclassifiedToHeldForSale</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LandReclassifiedToHeldForSale">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Land gross carrying value that has been reclassified to assets held for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_LandReclassifiedToHeldForSale</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">572</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPZAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Incentive Awards (Details 2) (USD $)<br>Share data in Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.23</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.59</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" onclick="toggleNextSibling(this);">$ 43,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" onclick="toggleNextSibling(this);">$ 325,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" onclick="toggleNextSibling(this);">$ 462,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
        <td class="text">5 years 10 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
        <td class="text">4 years 8 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">23,603</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">23,306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">21,525</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">20,476</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.42</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.51</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.84</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">4,502</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">3,490</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">3,441</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.68</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.13</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.84</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(223)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(572)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(636)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.46</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.66</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(3,334)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(950)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(1,231)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 3.54</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 3.98</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 6.93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(648)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(187)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(525)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.97</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.94</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.78</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">16,921</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">17,378</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">15,582</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.27</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.56</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.77</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Quarterly Financial Data<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SelectedQuarterlyFinancialDataAbstract', window );"><strong>Selected Quarterly Financial Data [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Quarterly Financial Data</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2014</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,472</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,336</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,447</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">593,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,216</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,976</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">512,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SelectedQuarterlyFinancialDataAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SelectedQuarterlyFinancialDataAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Debt Obligations (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" onclick="toggleNextSibling(this);">$ 1,859</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long-term Debt, Maturities, Repayments of Principal in Year Two</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" onclick="toggleNextSibling(this);">2,015</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long-term Debt, Maturities, Repayments of Principal in Year Three</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" onclick="toggleNextSibling(this);">16,293</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-term Debt, Maturities, Repayments of Principal in Year Four</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Long-term Debt, Maturities, Repayments of Principal in Year Five</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Long-term Debt, Maturities, Repayments of Principal after Year Five</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" onclick="toggleNextSibling(this);">87,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Gross</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebt" onclick="toggleNextSibling(this);">107,667</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term Debt, Current Maturities</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">20,167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">1,710</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term Debt, Excluding Current Maturities</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">$ 87,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">$ 20,167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Measurements (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">$ 137,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">$ 37,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">201,521</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">91,077</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">338,787</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">128,576</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Other Liabilities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Other Liabilities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Other Liabilities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">17,638</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">27,710</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">17,638</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">27,710</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value, Total</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">137,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">37,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">202,073</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">91,629</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">339,339</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">129,128</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Other Liabilities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">17,638</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">27,710</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">$ 17,638</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember]" onclick="toggleNextSibling(this);">$ 27,710</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_EstimateOfFairValueFairValueDisclosureMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Available-for-Sale Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Trading Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a, f, g<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial and nonfinancial obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance', window );">Disclosure On Geographic Areas Revenue From External Customers Attributed to France</a></td>
        <td class="nump"><a title="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance" onclick="toggleNextSibling(this);">94.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent', window );">Disclosure on Geographic Areas, Revenue from External Customers Attributed to Entity's Country of Domicile, Percent</a></td>
        <td class="nump"><a title="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent</span><span></span></td>
        <td class="nump"><a title="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent</span><span></span></td>
        <td class="nump"><a title="lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenues from external customers attributed to the entity's country of domicile as a percentage of total revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenues from external customers attributed to France as a percentage of total revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZBAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Arrangements with Symphony Icon, Inc. (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 04, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2007</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_HoldingsContributionToIcon', window );">Holdings Contribution To Icon</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_HoldingsContributionToIcon" onclick="toggleNextSibling(this);">$ 45,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_HoldingsContributionToIcon</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LexiconSoldSharesToHoldings', window );">Lexicon Sold Shares To Holdings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_LexiconSoldSharesToHoldings" onclick="toggleNextSibling(this);">7,650,622</a><span style="display:none;white-space:normal;text-align:left;">lxrx_LexiconSoldSharesToHoldings</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LexiconReceivedCashFromHoldings', window );">Lexicon Received Cash From Holdings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_LexiconReceivedCashFromHoldings" onclick="toggleNextSibling(this);">15,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_LexiconReceivedCashFromHoldings</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LexiconPaidHoldingsCash', window );">Lexicon Paid Holdings Cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_LexiconPaidHoldingsCash" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_LexiconPaidHoldingsCash</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonFairValueOfBaseAndContingentPayments', window );">Symphony Fair Value Of Base And Contingent Payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonFairValueOfBaseAndContingentPayments" onclick="toggleNextSibling(this);">45,600,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonFairValueOfBaseAndContingentPayments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyBasePaymentDiscountRate', window );">Symphony Base Payment Discount Rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyBasePaymentDiscountRate" onclick="toggleNextSibling(this);">14.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyBasePaymentDiscountRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentDiscountRate', window );">Symphony Contingent Payment Discount Rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyContingentPaymentDiscountRate" onclick="toggleNextSibling(this);">18.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyContingentPaymentDiscountRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyBasePaymentInShares', window );">Symphony Base Payment In Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyBasePaymentInShares" onclick="toggleNextSibling(this);">13,237,519</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyBasePaymentInShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyBasePaymentObligation', window );">Symphony Base Payment Obligation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyBasePaymentObligation" onclick="toggleNextSibling(this);">35,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyBasePaymentObligation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentMaximum', window );">Symphony Contingent Payment Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyContingentPaymentMaximum" onclick="toggleNextSibling(this);">45,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyContingentPaymentMaximum</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentPercentage', window );">Symphony Contingent Payment Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyContingentPaymentPercentage" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyContingentPaymentPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyRegulatoryApprovalPayment', window );">Symphony Regulatory Approval Payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyRegulatoryApprovalPayment" onclick="toggleNextSibling(this);">15,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyRegulatoryApprovalPayment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyRegulatoryApprovalReductionPercentage', window );">Symphony Regulatory Approval Reduction Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyRegulatoryApprovalReductionPercentage" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyRegulatoryApprovalReductionPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyRegulatoryApprovalPercentageLimit', window );">Symphony Regulatory Approval Percentage Limit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyRegulatoryApprovalPercentageLimit" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyRegulatoryApprovalPercentageLimit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyPaymentInStockLimitation', window );">Symphony Payment In Stock Limitation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SymphonyPaymentInStockLimitation" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyPaymentInStockLimitation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentInCash', window );">Symphony Contingent Payment In Cash</a></td>
        <td class="nump"><a title="lxrx_SymphonyContingentPaymentInCash" onclick="toggleNextSibling(this);">5,800,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyContingentPaymentInCash</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentinShares', window );">Symphony Contingent Payment in Shares</a></td>
        <td class="nump"><a title="lxrx_SymphonyContingentPaymentinShares" onclick="toggleNextSibling(this);">4,662,780</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyContingentPaymentinShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyContingentPaymentTotal', window );">Symphony Contingent Payment Total</a></td>
        <td class="nump"><a title="lxrx_SymphonyContingentPaymentTotal" onclick="toggleNextSibling(this);">11,500,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyContingentPaymentTotal</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenUpfrontPayment', window );">Ipsen Upfront Payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_IpsenUpfrontPayment" onclick="toggleNextSibling(this);">23,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_IpsenUpfrontPayment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">$ 1,428,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="num"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">$ (2,210,000)</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="nump"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">$ 9,887,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_HoldingsContributionToIcon">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On June 15, 2007, Symphony Icon Holdings LLC contributed $45 million to Symphony Icon in order to fund the clinical development of the Programs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_HoldingsContributionToIcon</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenUpfrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the upfront payment under the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IpsenUpfrontPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LexiconPaidHoldingsCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the cash paid to Holdings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_LexiconPaidHoldingsCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LexiconReceivedCashFromHoldings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_LexiconReceivedCashFromHoldings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LexiconSoldSharesToHoldings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On June 15, 2007, Lexicon issued and sold to Symphony Icon Holdings LLC 7,650,622 shares of its common stock in exchange for $15 million and an exclusive purchase option that gave Lexicon the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_LexiconSoldSharesToHoldings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonFairValueOfBaseAndContingentPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonFairValueOfBaseAndContingentPayments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyBasePaymentDiscountRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date discount rate for the base payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyBasePaymentDiscountRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyBasePaymentInShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the 13,237,519 shares of common stock issued to designees of Holdings on July 30, 2012 in satisfaction of the base payment obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyBasePaymentInShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyBasePaymentObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the $35 million base payment obligation that was paid in common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyBasePaymentObligation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentDiscountRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In connection with its acquisition of Symphony Icon, Lexicon paid $10 million in cash, and also agreed to pay Holdings additional base and contingent payments.  The fair value of the base and contingent consideration payments was $45.6 million at the date of acquisition and was estimated by applying a probability-based income approach utilizing an appropriate discount rate.  This represents the acquisition date discount rate for the contingent payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentDiscountRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentInCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent payments to Symphony Icon Holdings in the form of cash.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentInCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentinShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent payments to Symphony Icon Holdings in the form of stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentinShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the maximum amount for any contingent payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the percentage of consideration received that will be paid to Holdings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyContingentPaymentTotal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent payments to Symphony Icon Holdings, in total.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyContingentPaymentTotal</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyPaymentInStockLimitation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The contingent payments to Holdings may be paid in cash or a combination of cash and common stock, in Lexicon's discretion, provided that no more than 50% of any payment will be paid in common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyPaymentInStockLimitation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyRegulatoryApprovalPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and any Recapture Eligible Amount attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  This represents the payment that will be made upon regulatory approval.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyRegulatoryApprovalPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyRegulatoryApprovalPercentageLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed 50% of the payment made as a result of such United States regulatory approval.  This represents the percentage by which proceeds of Licensing Transactions must exceed regulatory approval payments in order for Lexicon to have an obligation to make subsequent contingent payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyRegulatoryApprovalPercentageLimit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyRegulatoryApprovalReductionPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million on July 30, 2010 and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of $15 million and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to 50% of such sum for the amount of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product.  This represents the percentage reduction of the regulatory approval payment by previous contingent payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyRegulatoryApprovalReductionPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements (Details)<br></strong></div>
        </th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 31, 2014

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2014

</div>
          <div>EUR (&#x20AC;)</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2005

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>USD ($)</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenUpfrontPayment', window );">Ipsen Upfront Payment</a></td>
        <td class="nump"><a title="lxrx_IpsenUpfrontPayment" onclick="toggleNextSibling(this);">$ 23,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_IpsenUpfrontPayment</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable', window );">Ipsen Revenue Allocated to Development Deliverable</a></td>
        <td class="nump"><a title="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" onclick="toggleNextSibling(this);">1,600,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable', window );">Ipsen Revenue Allocated to Committee Deliverable</a></td>
        <td class="nump"><a title="lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable', window );">Ipsen Revenue Allocated to License Deliverable</a></td>
        <td class="nump"><a title="lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" onclick="toggleNextSibling(this);">21,200,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_IpsenRevenueAllocatedtoLicenseDeliverable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueRecognized', window );">Ipsen Revenue Recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_IpsenRevenueRecognized" onclick="toggleNextSibling(this);">21,400,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_IpsenRevenueRecognized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones', window );">Ipsen Maximum Regulatory And Commercial Milestones</a></td>
        <td class="nump"><a title="lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" onclick="toggleNextSibling(this);">30,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_IpsenMaximumRegulatoryAndCommercialMilestones</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumSalesMilestones', window );">Ipsen Maximum Sales Milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_IpsenMaximumSalesMilestones" onclick="toggleNextSibling(this);">72,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_IpsenMaximumSalesMilestones</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TxEnterpriseFundAward', window );">TX Enterprise Fund Award</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_TxEnterpriseFundAward" onclick="toggleNextSibling(this);">35,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_TxEnterpriseFundAward</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem', window );">TX Enterprise Fund Award to Texas AM University System</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem" onclick="toggleNextSibling(this);">15,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TigmPerJobPaymentAmount', window );">TIGM Per Job Payment Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_TigmPerJobPaymentAmount" onclick="toggleNextSibling(this);">2,415</a><span style="display:none;white-space:normal;text-align:left;">lxrx_TigmPerJobPaymentAmount</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TigmMaximumExposure', window );">TIGM Maximum Exposure</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_TigmMaximumExposure" onclick="toggleNextSibling(this);">14,200,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_TigmMaximumExposure</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TIGMMaximumExposureThroughReportingDate', window );">TIGM Maximum Exposure Through Reporting Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_TIGMMaximumExposureThroughReportingDate" onclick="toggleNextSibling(this);">$ 2,500,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_TIGMMaximumExposureThroughReportingDate</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the maximum regulatory and commercial launch milestone payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IpsenMaximumRegulatoryAndCommercialMilestones</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumSalesMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the maximum sales milestones payments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IpsenMaximumSalesMilestones</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This is the amount of the upfront payment allocated to the committee participation deliverable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the amount of the upfront payment allocated to the development services deliverable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the amount of the upfront payment allocated to the license deliverable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoLicenseDeliverable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the revenue recognized in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IpsenRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenUpfrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States, Canada and Japan.  This represents the upfront payment under the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IpsenUpfrontPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TigmMaximumExposure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_TigmMaximumExposure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TIGMMaximumExposureThroughReportingDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Under the Texas Enterprise Fund award, Lexicon has a maximum aggregate exposure if Lexicon fails to create the specified number of jobs or obtain credits.  This is the amount through the specified reporting date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_TIGMMaximumExposureThroughReportingDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TigmPerJobPaymentAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Under the terms of the Texas Enterprise Fund award, subject to certain credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay $2,415 for each job Lexicon falls short.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_TigmPerJobPaymentAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TxEnterpriseFundAward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In July 2005, Lexicon received a $35.0 million award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine using Lexicon's proprietary gene trappying technology, which Lexicon completed in 2007.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_TxEnterpriseFundAward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In July 2005, the Texas Enterprise Fund awarded $15.0 million to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_TxEnterpriseFundAwardToTexasAmUniversitySystem</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Deferred Tax Assets and Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred Tax Assets, Operating Loss Carryforwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 255,518</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 238,608</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">40,173</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">37,453</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred Tax Assets, In Process Research and Development</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" onclick="toggleNextSibling(this);">95,946</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" onclick="toggleNextSibling(this);">83,375</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">7,648</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">7,703</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Tax Assets, Deferred Income</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsDeferredIncome" onclick="toggleNextSibling(this);">4,457</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsDeferredIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsDeferredIncome" onclick="toggleNextSibling(this);">4,760</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsDeferredIncome</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred Tax Assets, Other</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOther" onclick="toggleNextSibling(this);">8,681</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOther" onclick="toggleNextSibling(this);">4,712</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOther</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">412,423</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">376,611</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon', window );">Deferred Tax Liability Related to Acquisition of Symphony Icon</a></td>
        <td class="num"><a title="lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" onclick="toggleNextSibling(this);">(18,675)</a><span style="display:none;white-space:normal;text-align:left;">lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon</span><span></span></td>
        <td class="num"><a title="lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon" onclick="toggleNextSibling(this);">(18,745)</a><span style="display:none;white-space:normal;text-align:left;">lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred Tax Liabilities, Gross</a></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxLiabilities" onclick="toggleNextSibling(this);">(18,675)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxLiabilities" onclick="toggleNextSibling(this);">(18,745)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(412,423)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(376,611)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxLiabilities" onclick="toggleNextSibling(this);">$ (18,675)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxLiabilities" onclick="toggleNextSibling(this);">$ (18,745)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilities</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,519 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the deferred tax liability relating to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Liability<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph b(2)<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences net of deferred tax asset attributable to deductible temporary differences and carryforwards after valuation allowances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation:</font><font style="font-family:inherit;font-size:10pt;"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash, Cash Equivalents and Short-Term Investments:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, short-term investments consist of U.S. treasury bills and certificates of deposit.  The certificates of deposits are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash and Investments:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon is required to maintain restricted cash or investments to collateralize standby letters of credit for the lease on its office and laboratory facilities in Hopewell, New Jersey (see Note&#160;12).&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, restricted cash and investments were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.&#160;&#160;In </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, customers in France and the United States represented </font><font style="font-family:inherit;font-size:10pt;">94%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> of revenue, respectively.  In </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">, customers in the United States represented </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of revenue, respectively.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, management believes that the Company has no significant concentrations of credit risk.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information and Significant Customers:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon operates in one business segment, which primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, government grants and contracts and compound library sales.  In 2014, </font><font style="font-family:inherit;font-size:10pt;">Ipsen Pharma SAS</font><font style="font-family:inherit;font-size:10pt;"> represented </font><font style="font-family:inherit;font-size:10pt;">94%</font><font style="font-family:inherit;font-size:10pt;"> of revenues.  In 2013, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">McNair Medical Institute, LLC</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Taconic Farms, Inc.</font><font style="font-family:inherit;font-size:10pt;"> represented </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">57%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;"> of revenues, respectively.  In 2012, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Taconic Farms</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Deltagen</font><font style="font-family:inherit;font-size:10pt;"> represented </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">68%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> of revenues, respectively.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment:</font><font style="font-family:inherit;font-size:10pt;"> Property and equipment are carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-Lived Assets:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Indefinite lived intangible assets are also tested at least annually for impairment.  Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition.&#160;&#160;In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values.  In </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, Lexicon reclassified its buildings as assets held for sale, and recorded an impairment loss of </font><font style="font-family:inherit;font-size:10pt;">$13.1 million</font><font style="font-family:inherit;font-size:10pt;"> (see Note 6, Assets Held for Sale)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill Impairment:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.&#160;&#160;There was no impairment of goodwill in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition:</font><font style="font-family:inherit;font-size:10pt;"> Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements revenues include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The delivered item or items have value to the customer on a stand-alone basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&#8217;s control.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It can only be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It would result in additional payments being due to the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subscription and license fees are recognized as revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses:</font><font style="font-family:inherit;font-size:10pt;"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, stock-based compensation cost for all outstanding unvested options and restricted stock units was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;years.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&#160;&#160;Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The following weighted-average assumptions were used for options granted in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Risk-free Interest Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Dividend</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Rate</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2013:</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2012:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss per Common Share:</font><font style="font-family:inherit;font-size:10pt;"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options, restricted stock units and warrants are not included because they are antidilutive.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Restructuring Charges (Details) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
        <td class="nump"><a title="us-gaap_RestructuringCosts" onclick="toggleNextSibling(this);">$ 5.7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestructuringCostSeveranceCosts', window );">Restructuring Cost, Severance Costs</a></td>
        <td class="nump"><a title="lxrx_RestructuringCostSeveranceCosts" onclick="toggleNextSibling(this);">5.3</a><span style="display:none;white-space:normal;text-align:left;">lxrx_RestructuringCostSeveranceCosts</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other Restructuring Costs</a></td>
        <td class="nump"><a title="us-gaap_OtherRestructuringCosts" onclick="toggleNextSibling(this);">0.4</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherRestructuringCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
        <td class="nump"><a title="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" onclick="toggleNextSibling(this);">5.6</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment', window );">Restructuring and Related Costs, Cost Incurred to Date, Research and Development</a></td>
        <td class="nump"><a title="lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment" onclick="toggleNextSibling(this);">4.9</a><span style="display:none;white-space:normal;text-align:left;">lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative', window );">Restructuring and Related Costs, Cost Incurred to Date, General and Administrative</a></td>
        <td class="nump"><a title="lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative" onclick="toggleNextSibling(this);">0.7</a><span style="display:none;white-space:normal;text-align:left;">lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation', window );">Restructuring and Related Costs, Cost Incurred to Date, Stock-based Compensation</a></td>
        <td class="nump"><a title="lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation" onclick="toggleNextSibling(this);">0.1</a><span style="display:none;white-space:normal;text-align:left;">lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve</a></td>
        <td class="nump"><a title="us-gaap_RestructuringReserve" onclick="toggleNextSibling(this);">$ 0.3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringReserve</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of costs incurred to date for the specified type of restructuring cost in general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of costs incurred to date for the specified type of restructuring cost in research and development expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of costs incurred to date for restructuring costs as stock-based compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestructuringCostSeveranceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount expected to be recognized in earnings for severance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_RestructuringCostSeveranceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of costs incurred to date for the specified restructuring cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>32
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D
M,#4S8V9C96,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q
M.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A
M.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0F%L86YC95]3:&5E=%]087)E;G1H971I8V%L<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3
M=&%T96UE;G1S7V]F7T-O;3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-T871E;65N='-?;V9?0V]M<')E:&5N<VEV95],;SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E
M9%]3=&%T96UE;G1S7V]F7U-T;SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA
M=&EO;E]A;F1?3W!E<F%T:6]N<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E8V5N=%]!
M8V-O=6YT:6YG7U!R;VYO=6YC96UE;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-A<VA?86YD7T-A<VA?17%U:79A;&5N='-?86YD
M7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?
M5F%L=65?365A<W5R96UE;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^07-S971S7TAE;&1?9F]R7U-A;&4\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M
M96YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC
M;VUE7U1A>&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^1V]O9'=I;&P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y$96)T7T]B;&EG871I;VYS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^07)R86YG96UE;G1S7W=I=&A?4WEM<&AO;GE?26-O
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET
M;65N='-?86YD7T-O;G1I;F=E;F-I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y/=&AE<E]#87!I=&%L7U-T;V-K7T%G<F5E;65N
M=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%<75I
M='E?26YC96YT:79E7T%W87)D<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D)E;F5F:71?4&QA;CPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D-O;&QA8F]R871I;VY?86YD7TQI8V5N<V5?
M06=R93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E
M<W1R=6-T=7)I;F=?0VAA<F=E<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-E;&5C=&5D7U%U87)T97)L>5]&:6YA;F-I86Q?1#PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970R-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?
M;V9?4VEG;FEF:6-A;G1?06-C;W5N=#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C8N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U
M;G0R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V%S
M:%]A;F1?0V%S:%]%<75I=F%L96YT<U]A;F1?,3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S
M7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G1?5&%B;&5S/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,P
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S7U1A8FQE<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E8G1?3V)L
M:6=A=&EO;G-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#,S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^17%U:71Y7TEN8V5N
M=&EV95]!=V%R9'-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4V5L96-T961?475A<G1E<FQY7T9I;F%N8VEA;%]$,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?
M;V9?4VEG;FEF:6-A;G1?06-C;W5N=#,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S8N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U
M;G0T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#,W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M
M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?
M06-C;W5N=#8\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,SDN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0W/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#0P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V%S:%]A;F1?0V%S:%]%<75I
M=F%L96YT<U]A;F1?,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S7T1E=&%I;#PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970T,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A
M<W5R96UE;G1S7T1E=&%I;#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#,N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y!<W-E='-?2&5L9%]F;W)?4V%L95]$971A:6QS/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#0T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD
M7T5Q=6EP;65N=%]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0U+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N=%]$971A:6QS,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970T-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]4
M87AE<U]$971A:6QS7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#<N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);F-O;65?5&%X97-?1&5T86EL<U\R/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0X
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^1V]O9'=I;&Q?1&5T86EL<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970T.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E8G1?3V)L:6=A
M=&EO;G-?1&5T86EL<U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4P+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&5B=%]/8FQI9V%T:6]N<U]$971A:6QS7S(\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!<G)A;F=E;65N='-?=VET
M:%]3>6UP:&]N>5])8V\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?,3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970U,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S
M7V%N9%]#;VYT:6YG96YC:65S7S(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-30N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y/=&AE<E]#87!I=&%L7U-T;V-K7T%G<F5E;65N=',Q
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#4U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^17%U:71Y
M7TEN8V5N=&EV95]!=V%R9'-?1&5T86EL/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4V+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^17%U:71Y7TEN8V5N=&EV95]!=V%R9'-?1&5T
M86EL,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970U-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5Q
M=6ET>5]);F-E;G1I=F5?07=A<F1S7T1E=&%I;#(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3@N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%<75I='E?26YC96YT:79E7T%W87)D
M<U]$971A:6PS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#4Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^0F5N969I=%]0;&%N7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C`N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y#;VQL86)O<F%T:6]N7V%N9%],:6-E;G-E7T%G
M<F4Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#8Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5S
M=')U8W1U<FEN9U]#:&%R9V5S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C(N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y396QE8W1E9%]1=6%R=&5R;'E?1FEN86YC
M:6%L7T0R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#8S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S
M:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!
M8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R
M=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E
M8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E
M;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB
M;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-
M:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R
M7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K
M<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5%4T%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@
M1&]C=6UE;G0@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#`Y+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@26YF;W)M871I;VX\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E
M9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M3$5824-/3B!02$%234%#155424-!3%,L($E.0RXO1$4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT
M<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,#`P,3`V,C@R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I
M;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!
M8V-E;&5R871E9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,3`M2SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y$96,@,S$L#0H)
M"3(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XR,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R
M:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y&63QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R-2PQ-#4L,S$S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@5V5L;"UK;F]W;B!396%S;VYE9"!)<W-U97(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5F]L=6YT87)Y($9I
M;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3F\\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET
M>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%!U8FQI8R!&;&]A=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-C@L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P
M9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E
M8R]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$513T%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T
M<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3,W+#(V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,S<L-#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&]R="UT97)M(&EN=F5S=&UE;G1S+"!I;F-L
M=61I;F<@<F5S=')I8W1E9"!I;G9E<W1M96YT<R!O9B`D-#,P/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#(L,#<S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$L-C(Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT
M<R!R96-E:79A8FQE+"!N970@;V8@86QL;W=A;F-E<R!O9B`D,S4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#,U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E=',@:&5L
M9"!F;W(@<V%L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L
M.#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S8T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV,S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S8X+#DX-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$S-"PU-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE
M;G0L(&YE="!O9B!A8V-U;75L871E9"!D97!R96-I871I;VX@86YD(&%M;W)T
M:7IA=&EO;B!O9B`D,S8L,C<T(&%N9"`D.#$L.30U+"!R97-P96-T:79E;'D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#@P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L,S8R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M;V]D=VEL;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L-30S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#0L-30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/=&AE<B!I;G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3,L,S4W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,L-34W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#`Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-S$L
M,S<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C<T+#$V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&QI86)I;&ET:65S.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT
M<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPP
M-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY+#<Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`L,3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPV-S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@<&]R=&EO;B!O
M9B!D969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#8Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0W5R<F5N="!P;W)T:6]N(&]F(&QO;F<M=&5R;2!D
M96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PQ-C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<Q
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0T+#DV.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#(Y-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU
M92P@;F5T(&]F(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(L-C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,L-#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@9&5B=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<L-3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L,38W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!T87@@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$X+#8W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$X+#<T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@;&]N9RUT97)M(&QI86)I;&ET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPU,S4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,BPS
M.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@W+#,U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P,RPY.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!C;VYT
M:6YG96YC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U:71Y.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL("0N,#$@<&%R('9A;'5E.R`U+#`P,"!S:&%R97,@875T:&]R:7IE
M9#L@;F\@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0N,#`Q
M('!A<B!V86QU93L@.3`P+#`P,"!S:&%R97,@875T:&]R:7IE9#L@-S(U+#8T
M,2!A;F0@-3$T+#,T.2!S:&%R97,@:7-S=65D+"!R97-P96-T:79E;'D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA
M;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,S@Y+#DY-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,3<U+#$P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PQ,#0L,C4R*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#`S
M+#DU."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@9V%I;B`H
M;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8S*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R
M96%S=7)Y('-T;V-K+"!A="!C;W-T+"`Q+#(X,2!A;F0@.#$T('-H87)E<RP@
M<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M+#,Y,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q+#4P,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!E<75I='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(X-"PP,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-S`L,38S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I
M97,@86YD(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T-S$L,S<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R-S0L,38P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S
M8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?
M.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970P
M,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P151,044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M0F%L86YC92!3:&5E="!087)E;G1H971I8V%L<R`H55-$("0I/&)R/DEN(%1H
M;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!I;G9E<W1M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,S`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0S,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;W=A;F-E
M(&9O<B!D;W5B=&9U;"!A8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D97!R96-I
M871I;VX@86YD(&%M;W)T:7IA=&EO;BP@<')O<&5R='D@86YD(&5Q=6EP;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-BPR-S0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@Q
M+#DT-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64@<&5R('-H87)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!P87(@=F%L=64@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@
M875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K+"!S:&%R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C@Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW,C4L-C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3$T+#,T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F
M8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW
M,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T,#0N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$572T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O
M;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-O;7!R96AE;G-I=F4@3&]S<R`H
M55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2979E;G5E<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B
M;W)A=&EV92!A9W)E96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(R+#4Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPQ,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#<X,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V-R:7!T:6]N(&%N9"!L
M:6-E;G-E(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,BPX-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#(R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#@Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN
M9R!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT+"!I;F-L=61I;F<@
M<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&]F("0T+#`R,"P@)#0L,S<V(&%N
M9"`D,RPV-S,L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#DL,C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#DL-C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#(L-3<T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92`H9&5C<F5A
M<V4I(&EN(&9A:7(@=F%L=64@;V8@4WEM<&AO;GD@26-O;BP@26YC+B!P=7)C
M:&%S92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,BPR,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PX.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E
M+"!I;F-L=61I;F<@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&]F("0S+#`V
M,2P@)#,L,#0U(&%N9"`D,BPX,C(L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-#$Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,3(Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,#0S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);7!A
M:7)M96YT(&QO<W,@;VX@8G5I;&1I;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,RPQ,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]P97)A=&EN9R!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(S+#(R,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-"PU
M.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#DL-3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$P,"PS-C8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`R+#,W,2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#@L-#$U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YT97)E<W0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,BPR-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PY-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPQ,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!A;F0@;W1H97(@:6YC
M;VUE+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,C4U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N<V]L:61A=&5D(&YE="!L;W-S(&)E9F]R92!T87AE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`P+#,V-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#0L,3(V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$Q,"PR,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);F-O;64@=&%X(&)E;F5F:70\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS;VQI9&%T960@;F5T(&QO<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P,"PR.30I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`T+#$R
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,3`L,C$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]N<V]L:61A=&5D(&YE="!L;W-S('!E<B!C;VUM;VX@
M<VAA<F4L(&)A<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#`N,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@P+C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S('5S960@
M:6X@8V]M<'5T:6YG(&-O;G-O;&ED871E9"!N970@;&]S<R!P97(@8V]M;6]N
M('-H87)E+"!B87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3,T+#0S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4Q,RPQ,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.#DL-S`W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T
M:&5R(&-O;7!R96AE;G-I=F4@9V%I;B`H;&]S<RDZ/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@9V%I;B`H
M;&]S<RD@;VX@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#8U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;7!R96AE;G-I=F4@;&]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,#`L,S4Y*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3`T+#$T-RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Q
M,"PR,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T
M.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970P-2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P13%"04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1A=&5M96YT<R!O
M9B!#;VUP<F5H96YS:79E($QO<W,@4&%R96YT:&5T:6-A;',@*%!A<F5N=&AE
M=&EC86QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&%S
M<V]C:6%T960@=VET:"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#`R,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PS
M-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,L-C<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!A
M<W-O8VEA=&5D('=I=&@@9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#`V,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,RPP-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L.#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T
M83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970P-BYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14)#1$D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L
M:61A=&5D(%-T871E;65N=',@;V8@4W1O8VMH;VQD97)S)R!%<75I='D@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5&]T86P\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"U)
M;B!#87!I=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%C
M8W5M=6QA=&5D($1E9FEC:70\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^06-C=6UU;&%T960@3W1H97(@0V]M<')E:&5N<VEV92!'86EN("A,
M;W-S*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y4<F5A<W5R
M>2!3=&]C:SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%L86YC92P@=F%L=64@870@1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R.3<L-38X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T.#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#@W+#`S,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M-S@Y+#8R,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@S-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E+"!S:&%R97,@870@1&5C+B`S
M,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@P+#,X
M.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-BPT.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPT.34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&-O;6UO;B!S=&]C:R!T;R!D97-I9VYE97,@;V8@4WEM<&AO;GD@26-O;B!(
M;VQD:6YG<R!,3$,L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,L,C,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('1O
M(&1E<VEG;F5E<R!O9B!3>6UP:&]N>2!)8V]N($AO;&1I;F=S($Q,0RP@=F%L
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L
M.3@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=6YD97(@17%U:71Y
M($EN8V5N=&EV92!0;&%N<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#(T."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:R!U;F1E<B!%<75I='D@26YC96YT:79E(%!L86YS+"!V86QU93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:RP@;F5T(&]F(&9E97,L('-H87)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L-3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K+"!N970@;V8@9F5E<RP@=F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#`U-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<L,#,W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97!U<F-H87-E(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3$P+#(Q,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q,"PR,3$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N
M<F5A;&EZ960@9V%I;B`H;&]S<RD@;VX@:6YV97-T;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@=F%L=64@
M870@1&5C+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C8V+#8W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,38V+#8P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@Y.2PX,S(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,S`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E
M+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3$R+#,W-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPT,C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPT
M,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!T;R!D97-I9VYE97,@
M;V8@4WEM<&AO;GD@26-O;B!(;VQD:6YG<R!,3$,L('9A;'5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL@=6YD97(@17%U:71Y($EN8V5N=&EV92!0;&%N<RP@<VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DW-"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:R!U;F1E<B!%<75I='D@26YC96YT:79E(%!L
M86YS+"!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP
M.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PP.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<'5R8VAA<V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X-S,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@W,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#0L,3(V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3`T+#$R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^56YR96%L:7IE9"!G86EN("AL;W-S*2!O;B!I;G9E<W1M
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%L86YC92P@=F%L=64@870@1&5C+B`S,2P@,C`Q,SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<P+#$V,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3<U+#$P.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#`S
M+#DU."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,2PU,#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y"86QA;F-E+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q
M,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$T+#,T.2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPP.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-RPP.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO
M;B!S=&]C:R!T;R!D97-I9VYE97,@;V8@4WEM<&AO;GD@26-O;B!(;VQD:6YG
M<R!,3$,L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PV-C,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=&\@9&5S:6=N
M965S(&]F(%-Y;7!H;VYY($EC;VX@2&]L9&EN9W,@3$Q#+"!V86QU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW-#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES
M<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U;F1E<B!%<75I='D@26YC96YT:79E
M(%!L86YS+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-S8V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5N9&5R($5Q
M=6ET>2!);F-E;G1I=F4@4&QA;G,L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VLL(&YE="!O9B!F965S+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(P-"PX-C,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VLL(&YE="!O9B!F965S+"!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C`Q+#DT-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,2PW-#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<'5R8VAA<V4@
M;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X.#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#@X-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,#`L,CDT*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3`P+#(Y-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96%L:7IE9"!G
M86EN("AL;W-S*2!O;B!I;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@=F%L=64@870@1&5C
M+B`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M.#0L,#$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`W,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$L,S@Y+#DY-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PQ,#0L,C4R*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-C,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R+#,Y
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)A;&%N8V4L('-H87)E<R!A="!$96,N(#,Q+"`R,#$T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,C4L-C0Q+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T
M83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7
M;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5334)'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-A
M<V@@1FQO=W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!O<&5R871I;F<@
M86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N<V]L:61A=&5D(&YE="!L;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#$P,"PR.30I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,#0L,3(V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3$P+#(Q
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&-O;G-O;&ED
M871E9"!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A
M8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@V,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,3DP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);7!A
M:7)M96YT(&]F(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,L-30T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@9F%I<B!V86QU
M92!O9B!3>6UP:&]N>2!)8V]N+"!);F,N('!U<F-H87-E(&QI86)I;&ET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#(Q,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#@X
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#`X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<L-#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPT.34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@9&ES<&]S
M86P@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,2PV,S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!D96)T
M(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@=&%X(&)E;F5F:70\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E
M<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/BA);F-R96%S92D@9&5C<F5A
M<V4@:6X@86-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PP,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XH26YC<F5A<V4I(&1E8W)E87-E
M(&EN('!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,C@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#8P
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/BA);F-R96%S92D@9&5C<F5A<V4@:6X@;W1H97(@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC<F5A<V4@*&1E
M8W)E87-E*2!I;B!A8V-O=6YT<R!P87EA8FQE(&%N9"!O=&AE<B!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$Q
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#DY-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@9&5F97)R960@<F5V96YU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-CDW/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#,X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-2PV,C(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3$L,#<Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DT+#0V
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M(&EN=F5S=&EN9R!A8W1I=FET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0=7)C:&%S97,@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PW,C$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#DR*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E
M9',@9G)O;2!D:7-P;W-A;"!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$W,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C
M:&%S97,@;V8@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(R,2PY-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3$Q+#0Y,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,S,L,C4P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%T=7)I=&EE<R!O
M9B!I;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$Q+#0T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(Q,BPV,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,S4L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@
M*'5S960@:6XI(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,#@L-#$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY+#4T-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DW+#@P-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V%S:"!F;&]W<R!F<F]M(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D
M<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:RP@;F5T(&]F(&9E97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,BPR-S`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X
M+#$P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5P=7)C:&%S92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#@X-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@X-S,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!D96)T(&)O<G)O=VEN9W,L(&YE="!O9B!F965S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX-"PQ,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT(&]F(&1E8G0@
M8F]R<F]W:6YG<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PW
M,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PU-S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PT-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!F:6YA;F-I;F<@86-T:79I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S
M:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@9FEN86YC:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X,RPX,#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,X.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-BPS.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@:6YC<F5A<V4@*&1E8W)E87-E*2!I;B!C87-H(&%N9"!C
M87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY.2PW-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#`W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$U-2PX.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE
M;G1S(&%T(&)E9VEN;FEN9R!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-RPT.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,"PT,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#8L,S`Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,S<L,C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S<L-#DY/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L-#(S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M<'!L96UE;G1A;"!D:7-C;&]S=7)E(&]F(&-A<V@@9FQO=R!I;F9O<FUA=&EO
M;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PW-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#@Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A
M;"!D:7-C;&]S=7)E(&]F(&YO;F-A<V@@:6YV97-T:6YG(&%N9"!F:6YA;F-I
M;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^56YR96%L:7IE9"!G86EN("AL;W-S*2!O;B!I;G9E<W1M
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K(&ES<W5E9"!I;B!S871I<V9A8W1I;VX@;V8@4WEM<&AO
M;GD@26-O;B!B87-E('!A>6UE;G0@;V)L:6=A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S4L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D
M7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C
M+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@3W!E<F%T:6]N<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/<F=A;FEZ871I;VX@86YD($]P97)A=&EO;G,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<F=A;FEZ
M871I;VX@86YD($]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT
M.C$R,"4[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IB;VQD.SY/<F=A;FEZ871I;VX@86YD($]P97)A=&EO;G,\+V9O;G0^
M/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG
M;CIJ=7-T:69Y.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\
M+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N
M.FQE9G0[=&5X="UI;F1E;G0Z-#AP>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY,
M97AI8V]N(%!H87)M86-E=71I8V%L<RP@26YC+B`H)B,X,C(P.TQE>&EC;VXF
M(S@R,C$[(&]R('1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3LI(&ES(&$@1&5L
M87=A<F4@8V]R<&]R871I;VX@:6YC;W)P;W)A=&5D(&]N($IU;'DF(S$V,#LW
M+"`Q.3DU+B!,97AI8V]N('=A<R!O<F=A;FEZ960@=&\@9&ES8V]V97(@=&AE
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L
M:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT
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M8V]V97(@86YD(&1E=F5L;W`@<&AA<FUA8V5U=&EC86P@<')O9'5C=',@9F]R
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M/"]F;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U
M,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P
M7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T
M,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#L^4W5M;6%R
M>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]F;VYT/CPO
M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ
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M,T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN
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M8F4@8V%S:"!E<75I=F%L96YT<RXF(S$V,#LF(S$V,#M!<R!O9B`\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/D1E8V5M
M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q,SPO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/BP@<VAO<G0M=&5R;2!I;G9E<W1M96YT<R!C;VYS:7-T(&]F(%4N
M4RX@=')E87-U<GD@8FEL;',@86YD(&-E<G1I9FEC871E<R!O9B!D97!O<VET
M+B`@5&AE(&-E<G1I9FEC871E<R!O9B!D97!O<VET<R!A<F4@8VQA<W-I9FEE
M9"!A<R!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<R!A;F0@87)E(&-A
M<G)I960@870@9F%I<B!V86QU92P@8F%S960@;VX@<75O=&5D(&UA<FME="!P
M<FEC97,@;V8@=&AE('-E8W5R:71I97,N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A
M;GD@=FEE=W,@:71S(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S(&%S
M(&%V86EL86)L92!F;W(@=7-E(&EN(&-U<G)E;G0@;W!E<F%T:6]N<R!R96=A
M<F1L97-S(&]F('1H92!S=&%T960@;6%T=7)I='D@9&%T92!O9B!T:&4@<V5C
M=7)I='DN)B,Q-C`[)B,Q-C`[56YR96%L:7IE9"!G86EN<R!A;F0@;&]S<V5S
M(&]N('-U8V@@<V5C=7)I=&EE<R!A<F4@<F5P;W)T960@87,@82!S97!A<F%T
M92!C;VUP;VYE;G0@;V8@<W1O8VMH;VQD97)S)B,X,C$W.R!E<75I='DN)B,Q
M-C`[)B,Q-C`[3F5T(')E86QI>F5D(&=A:6YS(&%N9"!L;W-S97,L(&EN=&5R
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L
M:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT
M.'!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US='EL93II=&%L:6,[/E)E
M<W1R:6-T960@0V%S:"!A;F0@26YV97-T;65N=',Z/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q
M-C`[)B,Q-C`[3&5X:6-O;B!I<R!R97%U:7)E9"!T;R!M86EN=&%I;B!R97-T
M<FEC=&5D(&-A<V@@;W(@:6YV97-T;65N=',@=&\@8V]L;&%T97)A;&EZ92!S
M=&%N9&)Y(&QE='1E<G,@;V8@8W)E9&ET(&9O<B!T:&4@;&5A<V4@;VX@:71S
M(&]F9FEC92!A;F0@;&%B;W)A=&]R>2!F86-I;&ET:65S(&EN($AO<&5W96QL
M+"!.97<@2F5R<V5Y("AS964@3F]T928C,38P.S$R*2XF(S$V,#LF(S$V,#M!
M<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N
M.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD
M(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N
M93L^,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/BP@<F5S=')I8W1E9"!C87-H(&%N9"!I;G9E
M<W1M96YT<R!W97)E(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E
M8V]R871I;VXZ;F]N93L^)#`N-"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
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M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E
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M;&]S<V5S('1O(&1A=&4N)B,Q-C`[)B,Q-C`[26X@/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`Q
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M,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXV)3PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!O9B!R979E
M;G5E+"!R97-P96-T:79E;'DN("!);B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR,#$S/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR,#$R/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!C=7-T
M;VUE<G,@:6X@=&AE(%5N:71E9"!3=&%T97,@<F5P<F5S96YT960@/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^,3`P)3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3`P)3PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B!O9B!R979E;G5E+"!R97-P96-T:79E;'DN)B,Q-C`[)B,Q
M-C`[070@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^1&5C96UB97(F(S$V,#LS,2P@,C`Q-#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/BP@;6%N86=E;65N="!B96QI979E<R!T:&%T('1H92!#;VUP86YY
M(&AA<R!N;R!S:6=N:69I8V%N="!C;VYC96YT<F%T:6]N<R!O9B!C<F5D:70@
M<FES:RX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R
M,"4[=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C0X<'@[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4]
M,T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
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M;7!O=6YD(&QI8G)A<GD@<V%L97,N("!);B`R,#$T+"`\+V9O;G0^/&9O;G0@
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M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N
M93L^36-.86ER($UE9&EC86P@26YS=&ET=71E+"!,3$,\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@
M86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^5&%C;VYI8R!&87)M<RP@26YC+CPO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!R97!R97-E
M;G1E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N
M.FYO;F4[/C4W)3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXS,R4\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@
M;V8@<F5V96YU97,L(')E<W!E8W1I=F5L>2X@($EN(#(P,3(L(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^5&%C;VYI
M8R!&87)M<SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P
M,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SY$96QT86=E;CPO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B!R97!R97-E;G1E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD
M96-O<F%T:6]N.FYO;F4[/C8X)3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR-24\+V9O
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US='EL
M93II=&%L:6,[/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0Z/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@87)E(&-A<G)I960@870@8V]S="!A
M;F0@9&5P<F5C:6%T960@=7-I;F<@=&AE('-T<F%I9VAT+6QI;F4@;65T:&]D
M(&]V97(@=&AE(&5S=&EM871E9"!U<V5F=6P@;&EF92!O9B!T:&4@87-S971S
M('=H:6-H(')A;F=E<R!F<F]M('1H<F5E('1O(#0P('EE87)S+B8C,38P.R8C
M,38P.TUA:6YT96YA;F-E+"!R97!A:7)S(&%N9"!M:6YO<B!R97!L86-E;65N
M=',@87)E(&-H87)G960@=&\@97AP96YS92!A<R!I;F-U<G)E9"XF(S$V,#LF
M(S$V,#M,96%S96AO;&0@:6UP<F]V96UE;G1S(&%R92!A;6]R=&EZ960@;W9E
M<B!T:&4@<VAO<G1E<B!O9B!T:&4@97-T:6UA=&5D('5S969U;"!L:69E(&]R
M('1H92!R96UA:6YI;F<@;&5A<V4@=&5R;2XF(S$V,#LF(S$V,#M3:6=N:69I
M8V%N="!R96YE=V%L<R!A;F0@8F5T=&5R;65N=',@87)E(&-A<&ET86QI>F5D
M+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT
M97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z-#AP>#MF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI
M;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C0X
M<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^26UP
M86ER;65N="!O9B!,;VYG+4QI=F5D($%S<V5T<SH\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#LF(S$V,#M,;VYG+6QI=F5D(&%S<V5T<R!A;F0@8V5R=&%I;B!I9&5N=&EF
M:6%B;&4@:6YT86YG:6)L92!A<W-E=',@=&\@8F4@:&5L9"!A;F0@=7-E9"!A
M<F4@<F5V:65W960@9F]R(&EM<&%I<FUE;G0@=VAE;B!E=F5N=',@;W(@8VAA
M;F=E<R!I;B!C:7)C=6US=&%N8V5S(&EN9&EC871E('1H870@=&AE(&-A<G)Y
M:6YG(&%M;W5N="!O9B!S=6-H(&%S<V5T<R!M87D@;F]T(&)E(')E8V]V97)A
M8FQE+B`@26YD969I;FET92!L:79E9"!I;G1A;F=I8FQE(&%S<V5T<R!A<F4@
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M:&5I<B!E<W1I;6%T960@9F%I<B!V86QU97,N("!);B`\+V9O;G0^/&9O;G0@
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M+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US='EL93II=&%L:6,[/D=O;V1W
M:6QL($EM<&%I<FUE;G0Z/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[)B,Q-C`[1V]O9'=I
M;&P@:7,@;F]T(&%M;W)T:7IE9"P@8G5T(&ES('1E<W1E9"!A="!L96%S="!A
M;FYU86QL>2!F;W(@:6UP86ER;65N="!A="!T:&4@<F5P;W)T:6YG('5N:70@
M;&5V96PN)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@:&%S(&1E=&5R;6EN960@
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M8V]G;FEZ960N)B,Q-C`[)B,Q-C`[061D:71I;VYA;"!I;7!A:7)M96YT(&%S
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M;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q-#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/BP@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&]R(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z
M(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q,CPO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/BX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[
M=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C0X<'@[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L
M:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT
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M92\^/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
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M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ
M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\
M+V9O;G0^/"]D:78^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN
M9STS1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F
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M/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P
M<'0[)SX\='(^/'1D('-T>6QE/3-$=VED=&@Z-#AP>#L@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/"]T9#X\=&0@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`@
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M8FQE/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ
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M,C`E.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
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M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
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M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4]
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M/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T
M.W!A9&1I;F<M;&5F=#HR-'!X.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(R-CL\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
M.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY)="!W;W5L
M9"!R97-U;'0@:6X@861D:71I;VYA;"!P87EM96YT<R!B96EN9R!D=64@=&\@
M=&AE($-O;7!A;GDN/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT
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M,T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
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M-C`[)B,Q-C`[5&5C:&YO;&]G>2!L:6-E;G-E(&9E97,@9F]R('1E8VAN;VQO
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M<F=A;FEZ871I;VYS(&%N9"!O=&AE<B!V96YD;W)S+B`@1F]R('!R96-L:6YI
M8V%L('-T=61I97,L('1H92!#;VUP86YY(&%C8W)U97,@97AP96YS97,@8F%S
M960@=7!O;B!E<W1I;6%T960@<&5R8V5N=&%G92!O9B!W;W)K(&-O;7!L971E
M9"!A;F0@=&AE(&-O;G1R86-T(&UI;&5S=&]N97,@<F5M86EN:6YG+B`@1F]R
M(&-L:6YI8V%L('-T=61I97,L(&5X<&5N<V5S(&%R92!A8V-R=65D(&)A<V5D
M('5P;VX@=&AE(&YU;6)E<B!O9B!P871I96YT<R!E;G)O;&QE9"!A;F0@=&AE
M(&1U<F%T:6]N(&]F('1H92!S='5D>2X@(%1H92!#;VUP86YY(&UO;FET;W)S
M('!A=&EE;G0@96YR;VQL;65N="P@=&AE('!R;V=R97-S(&]F(&-L:6YI8V%L
M('-T=61I97,@86YD(')E;&%T960@86-T:79I=&EE<R!T;R!T:&4@97AT96YT
M('!O<W-I8FQE('1H<F]U9V@@:6YT97)N86P@<F5V:65W<R!O9B!D871A(')E
M<&]R=&5D('1O('1H92!#;VUP86YY(&)Y('1H92!V96YD;W)S(&%N9"!C;&EN
M:6-A;"!S:71E('9I<VET<RX@(%1H92!#;VUP86YY)B,X,C$W.W,@97-T:6UA
M=&5S(&1E<&5N9"!O;B!T:&4@=&EM96QI;F5S<R!A;F0@86-C=7)A8WD@;V8@
M=&AE(&1A=&$@<')O=FED960@8GD@=&AE('9E;F1O<G,@<F5G87)D:6YG('1H
M92!S=&%T=7,@;V8@96%C:"!P<F]G<F%M(&%N9"!T;W1A;"!P<F]G<F%M('-P
M96YD:6YG+B`@5&AE($-O;7!A;GD@<&5R:6]D:6-A;&QY(&5V86QU871E<R!T
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M92!A<'!L:6-A8FQE(&-O;F1I=&EO;B!I<R!M970N)B,Q-C`[)B,Q-C`[07,@
M;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!S=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@8V]S="!F;W(@86QL(&]U='-T86YD:6YG
M('5N=F5S=&5D(&]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@=6YI=',@
M=V%S(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^)#$P+C0@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@=VAI8V@@:7,@97AP
M96-T960@=&\@8F4@<F5C;V=N:7IE9"!O=F5R(&$@=V5I9VAT960M879E<F%G
M92!P97)I;V0@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE
M:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O
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M(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS
M,2P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/BP@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P
M.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/C(P,3(\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXL(')E<W!E8W1I=F5L>3H\+V9O;G0^/"]D:78^
M/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N="US:7IE.C$P<'0[
M/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT.C!P
M>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE
M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N
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M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T
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M86QI9VXZ=&]P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SY$96-E;6)E<B`S,2P@,C`Q-#H\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M;W`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M<FEG:'0Z
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M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^.#`E/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C`\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUR:6=H=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE
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M<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIT;W`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.V)A8VMG
M<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/C`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M=&]P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ=&]P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O
M/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M.C$P<'0[/C`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A
M;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M
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M;W`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V
M97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[
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M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C`\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUR
M:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V
M,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P
M-3-C9F-E8R]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY296-E;G0@06-C;W5N=&EN9R!0<F]N
M;W5N8V5M96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE=R!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S(&%N9"!#
M:&%N9V5S(&EN($%C8V]U;G1I;F<@4')I;F-I<&QE<R!;5&5X="!";&]C:UT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4]
M,T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DEN($UA>2`R,#$T+"!T:&4@
M1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D("@F(S@R,C`[
M1D%30B8C.#(R,3LI(&ES<W5E9"!!8V-O=6YT:6YG(%-T86YD87)D<R!5<&1A
M=&4@*"8C.#(R,#M!4U4F(S@R,C$[*2!.;RXF(S$V,#LR,#$T+3`Y+"`F(S@R
M,C`[4F5V96YU92!F<F]M($-O;G1R86-T<R!W:71H($-U<W1O;65R<R8C.#(R
M,3LL('=H:6-H(&%M96YD<R!&05-"($%30R!4;W!I8R`V,#8N($%352`R,#$T
M+3`Y('!R;W9I9&5S(&$@<VEN9VQE+"!C;VUP<F5H96YS:79E(')E=F5N=64@
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M;F<@869T97(@1&5C96UB97(F(S$V,#LQ-2P@,C`Q-BP@86YD(&5A<FQY(&%D
M;W!T:6]N(&ES(&YO="!P97)M:71T960N($UA;F%G96UE;G0@:7,@8W5R<F5N
M=&QY(&5V86QU871I;F<@=&AE(&EM<&%C="!O9B!T:&ES('!R;VYO=6YC96UE
M;G0@;VX@3&5X:6-O;B8C.#(Q-SMS(&-O;G-O;&ED871E9"!F:6YA;F-I86P@
M<W1A=&5M96YT<RX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I
M9VAT.C$R,"4[=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$
M;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M-#AP>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY);B!!=6=U<W0@,C`Q-"P@=&AE
M($9!4T(@:7-S=65D($%352!.;RX@,C`Q-"TQ-2P@)B,X,C(P.T1I<V-L;W-U
M<F4@;V8@56YC97)T86EN=&EE<R!A8F]U="!A;B!%;G1I='DF(S@R,3<[<R!!
M8FEL:71Y('1O($-O;G1I;G5E(&%S(&$@1V]I;F<@0V]N8V5R;BXF(S@R,C$[
M($%352`R,#$T+3$U('=I;&P@97AP;&EC:71L>2!R97%U:7)E(&UA;F%G96UE
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M:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R
M7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970Q,2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-A<V@@86YD($-A
M<V@@17%U:79A;&5N=',@86YD($EN=F5S=&UE;G1S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@86YD($-A
M<V@@17%U:79A;&5N=',@86YD($EN=F5S=&UE;G1S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A
M;F0@0V%S:"!%<75I=F%L96YT<R!A;F0@26YV97-T;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4]
M,T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/E1H92!F86ER('9A;'5E(&]F
M(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@86YD(&EN=F5S=&UE;G1S(&AE
M;&0@870@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N
M9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO
M;F4[/C(P,3,\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX@87)E(&%S(&9O;&QO=W,Z/"]F;VYT/CPO
M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ
M8V5N=&5R.W1E>'0M:6YD96YT.C0X<'@[9F]N="US:7IE.C$P<'0[/CQD:78@
M<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT.C!P>#ML:6YE
M+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.VUA<F=I;BUL969T
M.F%U=&\[;6%R9VEN+7)I9VAT.F%U=&\[=VED=&@Z-CDP<'@[8F]R9&5R+6-O
M;&QA<'-E.F-O;&QA<'-E.W1E>'0M86QI9VXZ;&5F=#LG/CQT<CX\=&0@8V]L
M<W!A;CTS1#$V(')O=W-P86X],T0Q/CPO=&0^/"]T<CX\='(^/'1D('=I9'1H
M/3-$,S`V<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[
M/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO9&EV/CPO=&0^/"]T
M<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV
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M<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.7!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF
M;VYT+7=E:6=H=#IB;VQD.SY'<F]S<R!5;G)E86QI>F5D($=A:6YS/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z
M,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
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M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z
M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP
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M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F
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M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
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M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z
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M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^
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M;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C(P<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY5+E,N('1R96%S=7)Y('-E8W5R
M:71I97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXR,#$L-3@T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR
M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
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M,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS
M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/C(P,BPQ,S8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS
M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/C,\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@
M8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U
M8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@V
M-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C
M:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M<FEG:'0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB
M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`R+#`W,SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R
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M;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@
M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C,S.2PT,#(\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.R<@<F]W
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M<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@
M(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,SPO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
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M(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M<FEG:'0Z,G!X.W!A9&1I;F<M=&]P
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M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
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M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,S,Y
M+#,S.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ8V5N
M=&5R.W1E>'0M:6YD96YT.C0X<'@[9F]N="US:7IE.C$P<'0[/CQD:78@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT.C!P>#ML:6YE+6AE
M:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.VUA<F=I;BUL969T.F%U
M=&\[;6%R9VEN+7)I9VAT.F%U=&\[=VED=&@Z-CDP<'@[8F]R9&5R+6-O;&QA
M<'-E.F-O;&QA<'-E.W1E>'0M86QI9VXZ;&5F=#LG/CQT<CX\=&0@8V]L<W!A
M;CTS1#$V(')O=W-P86X],T0Q/CPO=&0^/"]T<CX\='(^/'1D('=I9'1H/3-$
M,S`V<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@]
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
M861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0Q-2!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@
M<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E
M;G1E<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY!<R!O
M9B!$96-E;6)E<B`S,2P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R
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M:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE
M.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HY<'0[9F]N="UW96EG:'0Z8F]L9#L^06UO<G1I>F5D($-O<W0\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS
M<&%N/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
M;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^0V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT
M<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
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M8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXS-RPT.3D\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C1P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
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M;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q,CL\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
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M='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q
M,CL\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
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M.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C,W
M+#0Y.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M*#$\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/CDQ+#8R-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@
M9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
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M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M
M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE
M(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
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M;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^*#$\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+7)I9VAT.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/BD\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P
M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CDQ+#8R.3PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
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M<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HT<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$R
M.2PQ,C8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P
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M='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
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M;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B
M;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P
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M;3HT<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O
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M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE
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M;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXQ,CDL,3(X/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
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M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
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M8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^;F\\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SX@<F5A;&EZ960@9V%I;G,@;W(@;&]S<V5S(&9O<B!T:&4@>65A<B!E
M;F1E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N
M.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL(#PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^
M;F\\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX@<F5A;&EZ960@9V%I;G,@;W(@;&]S<V5S(&9O<B!T
M:&4@>65A<B!E;F1E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD
M96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXL(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O
M<F%T:6]N.FYO;F4[/FYO/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(')E86QI>F5D(&=A:6YS(&]R
M(&QO<W-E<R!F;W(@=&AE('EE87(@96YD960@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SY$96-E;6)E<B8C,38P.S,Q
M+"`R,#$R/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^+CPO9F]N=#X\+V1I=CX\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1F%I<B!686QU92!-96%S=7)E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE
M87-U<F5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[
M/D9A:7(@5F%L=64@365A<W5R96UE;G1S/"]F;VYT/CPO9&EV/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ:G5S=&EF>3MF;VYT
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M,T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/'1A8FQE(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF86UI
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M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY,979E;"`Q("8C.#(Q
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M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O
M;G0M<VEZ93HQ,'!T.W!A9&1I;F<M;&5F=#HR-'!X.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(R-CL\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT
M;W`[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DQE=F5L(#(@)B,X
M,C$Q.R!O=&AE<B!S:6=N:69I8V%N="!O8G-E<G9A8FQE(&EN<'5T<R`H:6YC
M;'5D:6YG('%U;W1E9"!P<FEC97,@9F]R('-I;6EL87(@:6YV97-T;65N=',L
M(&UA<FME="!C;W)R;V)O<F%T960@:6YP=71S+"!E=&,N*3PO9F]N=#X\+V1I
M=CX\+W1D/CPO='(^/"]T86)L93X\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z
M,3(P)3MT97AT+6%L:6=N.FIU<W1I9GD[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CL@9F]N="US:7IE.C$P<'0[)SX\='(^/'1D('-T>6QE/3-$=VED=&@Z
M-#AP>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIT;W`@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
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M=#MF;VYT+7-I>F4Z,3!P=#L^3&5V96P@,R`F(S@R,3$[('-I9VYI9FEC86YT
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ
M,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ
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M(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS
M,2P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P
M,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+CPO
M9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT
M+6%L:6=N.FIU<W1I9GD[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M
M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT97AT
M+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P.C$P
M<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MT97AT
M+6%L:6=N.FQE9G0[)SX\='(^/'1D(&-O;'-P86X],T0Q-B!R;W=S<&%N/3-$
M,3X\+W1D/CPO='(^/'1R/CQT9"!W:61T:#TS1#0Q)2!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,3(E(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,3(E(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CPO=&0^/'1D('=I9'1H/3-$,3(E(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CPO=&0^/'1D('=I9'1H/3-$,3(E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ
M93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z.7!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A
M;CTS1#$U('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD
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M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O
M;&0[/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO9&EV/CPO=&0^
M/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG
M(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY,979E;"`Q/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L
M<W!A;CTS1#,@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
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M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3,W+#(V
M-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR
M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R
M9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A
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M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,C`Q+#4R,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@
M<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^,C`R+#`W,SPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
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M97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[
M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CMP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXS,S@L-S@W/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P
M>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[
M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CMP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXU-3(\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O
M=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B8C.#(Q,CL\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O
M=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C,S.2PS,SD\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O
M=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
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M;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG
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M<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC
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M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N
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M969T.C(P<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q
M,CL\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D
M;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXQ-RPV,S@\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T
M;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^,3<L-C,X/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B
M;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W
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M,T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C
M;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH
M96EG:'0Z,3(P)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z,3!P=#L^
M/&1I=B!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'@[=&5X="UI;F1E;G0Z,'!X
M.VQI;F4M:&5I9VAT.FYO<FUA;#MP861D:6YG+71O<#HQ,'!X.SX\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[;6%R9VEN
M+6QE9G0Z875T;SMM87)G:6XM<FEG:'0Z875T;SMW:61T:#HV-S9P>#MB;W)D
M97(M8V]L;&%P<V4Z8V]L;&%P<V4[=&5X="UA;&EG;CIL969T.R<^/'1R/CQT
M9"!C;VQS<&%N/3-$,38@<F]W<W!A;CTS1#$^/"]T9#X\+W1R/CQT<CX\=&0@
M=VED=&@],T0R.3-P>"!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#EP>"!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#<Y<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0T<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0U<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0Y<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0W.7!X(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$-'!X(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$-7!X(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$.7!X(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$-SEP>"!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#1P>"!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#5P>"!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#EP>"!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#<Y<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T
M9#X\=&0@=VED=&@],T0T<'@@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T
M9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HY
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z.7!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS
M1#$U('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE
M9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD:78@
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M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[
M/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO9&EV/CPO=&0^/"]T
M<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP
M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG(')O
M=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY,979E;"`Q/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M+#`W-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^.3$L-C(Y/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S
M;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
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M;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/C$R."PU-S8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L
M92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/C4U,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P
M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
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M<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
M965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P
M>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P
M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
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M<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
M965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P
M>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,3(Y+#$R.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P
M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E
M;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,3X\9&EV
M('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D
M96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE
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M='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB
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M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P
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M9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O=W-P86X]
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
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M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(W+#<Q,#PO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R
M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R
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M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R.SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P
M>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
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M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/C(W+#<Q,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@
M9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N
M92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXR-RPW,3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$
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M,3!P=#L^5&AE($-O;7!A;GD@9&ED(&YO="!H879E(&%N>2!,979E;"`S(&%S
M<V5T<R!D=7)I;F<@=&AE('EE87)S(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z
M(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS
M,2P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/BP@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P
M.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\
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M0V]M<&%N>28C.#(Q-SMS($QE=F5L)B,Q-C`[,R!L:6%B:6QI=&EE<R!A<F4@
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M:61A=&5D('-T871E;65N=',@;V8@8V]M<')E:&5N<VEV92!L;W-S+B`@5&AE
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M;VYT+7-I>F4Z,3!P=#L^1&5C96UB97(F(S$V,#LS,2P@,C`Q-#PO9F]N=#X\
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M1&5C96UB97(F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@86YD(&EN8W)E
M87-E9"!B>2`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXD.2XY(&UI;&QI;VX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@
M9'5R:6YG('1H92!Y96%R(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/D1E8V5M8F5R)B,Q
M-C`[,S$L(#(P,3(\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
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M8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F
M(S$V,#LS,2P@,C`Q,CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N
M.FYO;F4[/C(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXN/"]F;VYT/CPO9&EV/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z-G!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C9P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ8V5N=&5R
M.V9O;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M
M=&]P.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M
M<FEG:'0Z,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SY"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$Q/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXU-2PP
M,S,\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@S-2PP,#`\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^,CDL.3(P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE
M87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^,C<L-S$P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\
M8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXH,3$L-3`P/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M<FEG:'0Z,G!X
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY"86QA;F-E(&%T($1E8V5M
M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@
M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ-RPV,S@\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG
M<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
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M92!O;B!A(&YO;BUR96-U<G)I;F<@8F%S:7,N)B,Q-C`[)B,Q-C`[5&AE<V4@
M87-S971S(&EN8VQU9&4@9V]O9'=I;&P@87-S;V-I871E9"!W:71H('1H92!A
M8W%U:7-I=&EO;G,@;V8@0V]E;&%C86YT:"!#;W)P;W)A=&EO;B!I;B`R,#`Q
M(&%N9"!3>6UP:&]N>2!)8V]N(&]N($IU;'D@,S`L(#(P,3`@86YD(&EN=&%N
M9VEB;&4@87-S971S(&%S<V]C:6%T960@=VET:"!T:&4@86-Q=6ES:71I;VX@
M;V8@4WEM<&AO;GD@26-O;B!O;B!*=6QY(#,P+"`R,#$P+B8C,38P.R8C,38P
M.T9O<B!T:&5S92!A<W-E=',L(&UE87-U<F5M96YT(&%T(&9A:7(@=F%L=64@
M:6X@<&5R:6]D<R!S=6)S97%U96YT('1O('1H96ER(&EN:71I86P@<F5C;V=N
M:71I;VX@:7,@87!P;&EC86)L92!I9B!O;F4@;W(@;6]R92!I<R!D971E<FUI
M;F5D('1O(&)E(&EM<&%I<F5D+CPO9F]N=#X\+V1I=CX\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^07-S971S($AE;&0@9F]R(%-A;&4\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^07-S
M971S($AE;&0@9F]R(%-A;&4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C;&]S=7)E(&]F($QO;F<@
M3&EV960@07-S971S($AE;&0M9F]R+7-A;&4@6U1A8FQE(%1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T
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M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ
M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[)SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B!4:&4@
M0V]M<&%N>2!E<W1I;6%T960@=&AE(&9A:7(@=F%L=64@;V8@=&AE(&YE="!A
M<W-E=',@=&\@8F4@<V]L9"!A="!A<'!R;WAI;6%T96QY(#PO9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/B0R,RXX)B,Q-C`[;6EL;&EO;CPO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B!A<R!O9CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN
M92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^1&5C96UB97(F(S$V,#LS
M,2P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
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M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.R<^)#$S+C$F
M(S$V,#MM:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN('1H92!Y96%R(&5N9&5D(#PO
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#LG/D1E8V5M8F5R)B,Q
M-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
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M:&4@>65A<B!E;F1E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[)SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B`@5&AE
M(&9A:7(@=F%L=64@;V8@=&AE(&YE="!A<W-E=',@=&\@8F4@<V]L9"!W87,@
M9&5T97)M:6YE9"!U<VEN9R!,979E;"`R(&EN<'5T<R!U<VEN9R!S86QE<R!P
M<FEC97,@:6X@<VEM:6QA<B!R96%L(&5S=&%T92!S86QE<R!A;F0@;V9F97)S
M(')E8V5I=F5D(&9R;VT@<&]T96YT:6%L('!U<F-H87-E<G,@;V8@=&AE(&)U
M:6QD:6YG+CPO9F]N=#X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N=#QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2!A;F0@
M17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT
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M(&5Q=6EP;65N="!A="`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD
M96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R
M871I;VXZ;F]N93L^,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A<F4@87,@9F]L;&]W<SH\
M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N
M="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E
M>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z
M,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0W('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
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M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
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M<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R
M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N
M="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HY<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q-#PO9F]N=#X\
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SXR,#$S/"]F
M;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ,2PQ.#`\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R
M/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE
M9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D
M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M1G5R;FET=7)E(&%N9"!F:7AT=7)E<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C
M;VQS<&%N/3-$-"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXU+3<\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/C<L,#,R/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C,M-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ,BPW
M,S<\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB
M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z
M,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E
M<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXS-"PY-3(\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB
M<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT
M9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3&5A
M<V5H;VQD(&EM<')O=F5M96YT<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS
M<&%N/3-$-"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXW+3$P/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M-#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY,86YD/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN
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M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF
M(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O
M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,BPV-C0\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S
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M9RUL969T.C(P<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W
M.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#,V+#(W-#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+7)I9VAT.C)P>#MP
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#@Q+#DT-3PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+7)I
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M,2PP.#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
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M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB
M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C0Q+#,V,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W<W!A;CTS1#$@8V]L
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@
M<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M:6YD96YT.C0X<'@[9F]N
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M.C$P<'0[/B0S."XP)B,Q-C`[;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!O9B!R96QA
M=&5D(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;BP@:&%V92!B965N(')E8VQA
M<W-I9FEE9"!T;R!A<W-E=',@:&5L9"!F;W(@<V%L92`H<V5E($YO=&4@-BP@
M07-S971S($AE;&0@9F]R(%-A;&4I(&%S(&]F(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z
M(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS
M,2P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/BX\+V9O;G0^/"]D:78^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y
M-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F
M8V5C+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X
M97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA
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M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ:G5S=&EF
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M*&QI86)I;&ET:65S*2!A="`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X
M="UD96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E
M8V]R871I;VXZ;F]N93L^,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
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M>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z
M,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
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M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&-O;'-P86X],T0W('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB
M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M
M=V5I9VAT.F)O;&0[/D%S(&]F($1E8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX\
M+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HY<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N
M/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR
M<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT
M97([9F]N="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HY<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q-#PO
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
M;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0W('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X
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M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD
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M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E
M;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C0L
M-S$R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C
M:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
M861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X
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M;CIB;W1T;VT[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD
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M;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/BD\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@Q."PW-#4\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+7)I9VAT
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/BD\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C(X<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY,97-S.B!V
M86QU871I;VX@86QL;W=A;F-E/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B@T,3(L-#(S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P.W!A9&1I;F<M<FEG:'0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
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M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE
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M;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+7)I9VAT.C)P>#MP861D:6YG
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M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D
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M;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O
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M9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
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M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M
M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/E1H92`@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A
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M=&%X('!U<G!O<V5S+B`@3&5X:6-O;B!D;V5S(&YO="!B96QI979E(&ET(&-A
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M86YY)B,X,C$W.W,@;F5E9"!F;W(@82!V86QU871I;VX@86QL;W=A;F-E+B`@
M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E
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M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY!="`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL($QE>&EC;VX@:&%D(&)O=&@@
M9F5D97)A;"!A;F0@<W1A=&4@3D],(&-A<G)Y9F]R=V%R9',@;V8@87!P<F]X
M:6UA=&5L>2`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T
M:6]N.FYO;F4[/B0W,34N."!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/B0T
M-C`N,B!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DN)B,Q-C`[
M)B,Q-C`[5&AE(&9E9&5R86P@86YD('-T871E($Y/3"!C87)R>69O<G=A<F1S
M(&)E9V%N('1O(&5X<&ER92!I;B`R,#$Q(&%N9"!C;VYT:6YU960@=&\@97AP
M:7)E(&EN(#(P,3(N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GDF(S@R,3<[<R!2
M)F%M<#M$('1A>"!C<F5D:70@8V%R<GEF;W)W87)D<R!O9B!A<'!R;WAI;6%T
M96QY(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^)#0P+C(@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!B96=A;B!T;R!E>'!I
M<F4@:6X@,C`Q,BXF(S$V,#LF(S$V,#M5=&EL:7IA=&EO;B!O9B!T:&4@3D],
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M.R8C,38P.T1U<FEN9R!T:&4@>65A<B!E;F1E9"`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R
M.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[
M,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXL('1H92!V86QU871I;VX@86QL;W=A;F-E
M(&EN8W)E87-E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O
M<F%T:6]N.FYO;F4[/B0S-2XX(&UI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL('!R:6UA
M<FEL>2!D=64@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!C=7)R96YT('EE87(@
M;F5T(&QO<W,N)B,Q-C`[)B,Q-C`[3&5X:6-O;B!R96-O<F1E9"!I;F-O;64@
M=&%X(&)E;F5F:71S(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT
M+61E8V]R871I;VXZ;F]N93L^)#<P+#`P,#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD,#PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M
M9&5C;W)A=&EO;CIN;VYE.SXD,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!I;B!T:&4@>65A<G,@
M96YD960@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/C(P,3,\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P
M,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q,CPO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@<F5S
M<&5C=&EV96QY+B`@1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$S+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!C97)T86EN(')E=FES:6]N
M<R!T;R!I=',@9&5F97)R960@=&%X(&%S<V5T<RX@(%1H92!R979I<VEO;G,@
M<F5D=6-E9"!T:&4@9&5F97)R960@=&%X(&%S<V5T<R!A;F0@=F%L=6%T:6]N
M(&%L;&]W86YC92!B>2`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD,3,N."!M:6QL:6]N/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^+B`@5&AE<F4@=V%S(&YO(&EM<&%C="!T;R!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&5Q=6ET>2!O<B!O<&5R871I;F<@<F5S=6QT<R!F;W(@86YY('!E
M<FEO9"XF(S$V,#LF(S$V,#M!<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT
M97AT+61E8V]R871I;VXZ;F]N93L^,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS
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M-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
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M9F5D97)A;"!A=71H;W)I=&EE<R!A;F0@,C`P-"!T;R!C=7)R96YT(')E;6%I
M;B!O<&5N('1O(&5X86UI;F%T:6]N(&)Y('-T871E(&%U=&AO<FET:65S+B8C
M,38P.R8C,38P.U1H92!#;VUP86YY)B,X,C$W.W,@<&]L:6-Y(&ES('1O(')E
M8V]G;FEZ92!I;G1E<F5S="!A;F0@<&5N86QT:65S(')E;&%T960@=&\@:6YC
M;VUE('1A>"!M871T97)S(&EN(&EN8V]M92!T87@@97AP96YS92XF(S$V,#LF
M(S$V,#M!<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O
M<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@=&AE($-O;7!A;GD@:&%D(&YO
M(&%C8W)U86QS(&9O<B!I;G1E<F5S="!O<B!P96YA;'1I97,@<F5L871E9"!T
M;R!I;F-O;64@=&%X(&UA='1E<G,N/"]F;VYT/CPO9&EV/CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?
M.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C
M9F-E8R]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY';V]D=VEL;#QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY';V]D=VEL;"!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=O;V1W:6QL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O
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M.V9O;G0M<VEZ93HQ,'!T.SY/;B!*=6QY(#$R+"`R,#`Q+"!,97AI8V]N(&-O
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M<R`H3F5W($IE<G-E>2DL($EN8RX@87)E(&EN8VQU9&5D(&EN('1H92!#;VUP
M86YY)B,X,C$W.W,@<F5S=6QT<R!O9B!O<&5R871I;VYS(&9O<B!T:&4@<&5R
M:6]D('-U8G-E<75E;G0@=&\@=&AE(&%C<75I<VET:6]N+B`@1V]O9'=I;&P@
M87-S;V-I871E9"!W:71H('1H92!A8W%U:7-I=&EO;B!O9B`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/B0R-2XX(&UI
M;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXL('=H:6-H(')E<')E<V5N=',@=&AE(&5X8V5S
M<R!O9B!T:&4@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A
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M,T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/D]N($IU;'D@,S`L(#(P,3`L
M($QE>&EC;VX@97AE<F-I<V5D(&ET<R!0=7)C:&%S92!/<'1I;VX@*&%S(&1E
M9FEN960@:6X@3F]T92`Q,2D@86YD(&-O;7!L971E9"!T:&4@86-Q=6ES:71I
M;VX@;V8@4WEM<&AO;GD@26-O;BX@($=O;V1W:6QL(&%S<V]C:6%T960@=VET
M:"!T:&4@86-Q=6ES:71I;VX@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P
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M;G1I='DL($QE>&EC;VXN("`\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI
M;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C0X
M<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M
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M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T
M.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970Q-RYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E8G0@3V)L:6=A=&EO
M;G,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1&5B="!/8FQI9V%T:6]N<R!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@3V)L:6=A=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
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M=#HQ,C`E.W1E>'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I>F4Z,3!P=#L^/&9O
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M,C`Q-"P@3&5X:6-O;B!C;VUP;&5T960@86X@;V9F97)I;F<@;V8@/"]F;VYT
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M93HQ,'!T.SX@0V]N=F5R=&EB;&4@4V5N:6]R($YO=&5S(&1U92`R,#(Q("AT
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M<V]L:61A=&5D(&)A;&%N8V4@<VAE970N("`\+V9O;G0^/"]D:78^/&1I=B!S
M='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIJ=7-T:69Y.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\
M+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N
M.FIU<W1I9GD[=&5X="UI;F1E;G0Z-#AP>#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SY4:&4@3F]T97,@87)E(&=O=F5R;F5D(&)Y(&%N(&EN9&5N='5R92`H=&AE
M("8C.#(R,#M);F1E;G1U<F4F(S@R,C$[*2P@9&%T960@87,@;V8@3F]V96UB
M97(F(S$V,#LR-BP@,C`Q-"P@8F5T=V5E;B!T:&4@0V]M<&%N>2!A;F0@5V5L
M;',@1F%R9V\@0F%N:RP@3BY!+BP@87,@=')U<W1E92X@(%1H92!.;W1E<R!B
M96%R(&EN=&5R97-T(&%T(&$@<F%T92!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4]
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M,34N(%1H92!.;W1E<R!M871U<F4@;VX@1&5C96UB97(F(S$V,#LQ+"`R,#(Q
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M/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F
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M($-O;7!A;GD@=VEL;"!D96QI=F5R(&9O<B!E86-H("0Q+#`P,"!P<FEN8VEP
M86P@86UO=6YT(&]F(&-O;G9E<G1E9"!.;W1E<R!A(&YU;6)E<B!O9B!S:&%R
M97,@;V8@:71S(&-O;6UO;B!S=&]C:R!E<75A;"!T;R!T:&4@8V]N=F5R<VEO
M;B!R871E+"!A<R!D97-C<FEB960@:6X@=&AE($EN9&5N='5R92X@5&AE(&-O
M;G9E<G-I;VX@<F%T92!I<R!I;FET:6%L;'D@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^.#(Y+C$X
M-S0\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!P97(@)#$L
M,#`P('!R:6YC:7!A;"!A;6]U;G0@;V8@3F]T97,@*&5Q=6EV86QE;G0@=&\@
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M+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X
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M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E
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M=6%L('1O('1H92!S979E;BUY96%R('1E<FT@;V8@=&AE($YO=&5S+B`@07,@
M;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@
M8F%L86YC92!O9B!U;F%M;W)T:7IE9"!D96)T(&ES<W5A;F-E(&-O<W1S('=A
M<R`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO
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M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M
M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/E1H92!F86ER('9A;'5E(&]F('1H92!.;W1E<R!W87,@/"]F;VYT/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD.#$N,"8C
M,38P.VUI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@87,@;V8@/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO
M<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SY$96-E;6)E<B8C,38P
M.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
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M96TN/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^26X@07!R:6P@,C`P-"P@3&5X:6-O;B!P
M=7)C:&%S960@:71S(&5X:7-T:6YG(&QA8F]R871O<GD@86YD(&]F9FEC92!B
M=6EL9&EN9W,@86YD(&%N:6UA;"!F86-I;&ET:65S(&EN(%1H92!7;V]D;&%N
M9',L(%1E>&%S('=I=&@@<')O8V5E9',@9G)O;2!A(#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L
M;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#,T+C`@;6EL;&EO
M;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B!T:&ER9"UP87)T>2!M;W)T9V%G92!F:6YA;F-I;F<@
M86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^)#(P+C@@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!I;B!C87-H+B8C,38P
M.R8C,38P.U1H92!M;W)T9V%G92!L;V%N(&]R:6=I;F%L;'D@:&%D(&$@=&5N
M+7EE87(@=&5R;2!W:71H(&$@,C`M>65A<B!A;6]R=&EZ871I;VX@86YD(&$@
M9FEX960@:6YT97)E<W0@<F%T92!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C@N,C,E/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B`@
M5&AE(&UO<G1G86=E('=A<R!A;65N9&5D(&EN(%-E<'1E;6)E<B`R,#$S('1O
M(&5X=&5N9"!T:&4@;6%T=7)I='D@9&%T92!F<F]M($%P<FEL(#(P,30@=&\@
M07!R:6P@,C`Q-RP@=VET:"!T:&4@;6]R=&=A9V4@;&]A;B8C.#(Q-SMS(&UO
M;G1H;'D@<&%Y;65N="!A;6]U;G0@86YD(&9I>&5D(&EN=&5R97-T(')A=&4@
M96%C:"!R96UA:6YI;F<@=6YC:&%N9V5D+B`@5&AE(&UO<G1G86=E(&AA9"!A
M('!R:6YC:7!A;"!B86QA;F-E(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0R,"XR)B,Q-C`[
M;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B8C,38P.V%S(&]F(#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L
M;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V
M,#LS,2P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/BX@(%1H:7,@96YT:7)E(&)A;&%N8V4@
M:&%S(&)E96X@8VQA<W-I9FEE9"!A<R!C=7)R96YT(&QI86)I;&ET:65S(&]N
M('1H92!A8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970@
M87,@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T
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M9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO
M;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL(&%S(&1I
M<V-U<W-E9"!I;B!.;W1E(#8L($%S<V5T<R!(96QD(&9O<B!386QE+B`@5&AE
M(&)U:6QD:6YG<R!A;F0@;&%N9"!T:&%T('-E<G9E(&%S(&-O;&QA=&5R86P@
M9F]R('1H92!M;W)T9V%G92!L;V%N(&%R92!I;F-L=61E9"!I;B!A<W-E=',@
M:&5L9"!F;W(@<V%L92!A="`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X
M="UD96-O<F%T:6]N.FYO;F4[/B0U.2XQ(&UI;&QI;VX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@
M86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^)#(N-R!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DL
M(&)E9F]R92!A8V-U;75L871E9"!D97!R96-I871I;VXL(&%S(&]F(#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C
M96UB97(F(S$V,#LS,2P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BX@(%1H92!F86ER('9A
M;'5E(&]F($QE>&EC;VXF(S@R,3<[<R!M;W)T9V%G92!L;V%N(&%P<')O>&EM
M871E<R!I=',@8V%R<GEI;F<@=F%L=64N)B,Q-C`[)B,Q-C`[5&AE(&9A:7(@
M=F%L=64@;V8@3&5X:6-O;B8C.#(Q-SMS(&UO<G1G86=E(&QO86X@=V%S(&1E
M=&5R;6EN960@=7-I;F<@3&5V96P@,B!I;G!U=',@=7-I;F<@9&ES8V]U;G1E
M9"!C87-H(&9L;W<@86YA;'ES:7,L(&)A<V5D(&]N('1H92!#;VUP86YY)B,X
M,C$W.W,@97-T:6UA=&5D(&-U<G)E;G0@:6YC<F5M96YT86P@8F]R<F]W:6YG
M(')A=&4N("`\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT
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M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N
M93L^1&5C96UB97(F(S$V,#LS,2P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS
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M9&%T960@8F%L86YC92!S:&5E="!A<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P
M,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXZ/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L
M:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I>F4Z
M-G!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C9P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R
M;6%L.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL
M87!S93IC;VQL87!S93MT97AT+6%L:6=N.FQE9G0[)SX\='(^/'1D(&-O;'-P
M86X],T0T(')O=W-P86X],T0Q/CPO=&0^/"]T<CX\='(^/'1D('=I9'1H/3-$
M.#(E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D('=I9'1H/3-$
M,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q
M-B4@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@=VED=&@],T0Q
M)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CPO='(^/'1R/CQT9"!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR
M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HY<'0[/B8C,38P.SPO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
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M+7=E:6=H=#IB;VQD.SY$96-E;6)E<B`S,3PO9F]N=#X\+V1I=CX\+W1D/CPO
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR,#$V/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M+7-I>F4Z,3!P=#L^,C`Q-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N
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M=#MF;VYT+7-I>F4Z,3!P=#L^,C`Q.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!C
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M,C`Q.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S@R,3([/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CL@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\
M+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/E1H97)E869T97(\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^.#<L-3`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE
M87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ,#<L-C8W
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\
M='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXH,C`L,38W/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S
M;VQI9"`C,#`P,#`P.W!A9&1I;F<M<FEG:'0Z,G!X.W!A9&1I;F<M=&]P.C)P
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXX-RPU,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P
M,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV
M/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P
M9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E
M8R]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY!<G)A;F=E;65N=',@=VET:"!3>6UP:&]N>2!)
M8V]N+"!);F,N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%R<F%N9V5M96YT<R!W:71H(%-Y;7!H;VYY($EC;VX@
M26YC(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^07)R86YG96UE;G1S('=I=&@@4WEM<&AO;GD@26-O;BP@
M26YC+CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
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M($Q8,3`S,B!A;F0@3%@Q,#,S+"!A;&]N9R!W:71H(&%N>2!O=&AE<B!P:&%R
M;6%C975T:6-A;"!C;VUP;W-I=&EO;G,@;6]D=6QA=&EN9R!T:&4@<V%M92!T
M87)G971S(&%S('1H;W-E(&1R=6<@8V%N9&ED871E<R`H=&AE("8C.#(R,#M0
M<F]G<F%M<R8C.#(R,3LI+B!4:&4@86=R965M96YT<R!I;F-L=61E9"!A($YO
M=F%T960@86YD(%)E<W1A=&5D(%1E8VAN;VQO9WD@3&EC96YS92!!9W)E96UE
M;G0@<'5R<W5A;G0@=&\@=VAI8V@@=&AE($-O;7!A;GD@;&EC96YS960@=&\@
M4WEM<&AO;GD@26-O;BP@82!T:&5N('=H;VQL>2UO=VYE9"!S=6)S:61I87)Y
M(&]F(%-Y;7!H;VYY($EC;VX@2&]L9&EN9W,@3$Q#("@F(S@R,C`[2&]L9&EN
M9W,F(S@R,C$[*2P@=&AE($-O;7!A;GDF(S@R,3<[<R!I;G1E;&QE8W1U86P@
M<')O<&5R='D@<FEG:'1S(')E;&%T960@=&\@=&AE(%!R;V=R86US+B!(;VQD
M:6YG<R!C;VYT<FEB=71E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X
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M871E9"!*=6YE(#$U+"`R,#`W+"!B971W965N('1H92!#;VUP86YY(&%N9"!(
M;VQD:6YG<RP@=&AE($-O;7!A;GD@:7-S=65D(&%N9"!S;VQD('1O($AO;&1I
M;F=S(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^-RPV-3`L-C(R/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E<R!O9B!I=',@8V]M
M;6]N('-T;V-K(&]N($IU;F4F(S$V,#LQ-2P@,C`P-R!I;B!E>&-H86YG92!F
M;W(@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SXD,34@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@86X@97AC;'5S:79E
M('!U<F-H87-E(&]P=&EO;B`H=&AE("8C.#(R,#M0=7)C:&%S92!/<'1I;VXF
M(S@R,C$[*2!T:&%T(&=A=F4@=&AE($-O;7!A;GD@=&AE(')I9VAT('1O(&%C
M<75I<F4@86QL(&]F('1H92!E<75I='D@;V8@4WEM<&AO;GD@26-O;BP@=&AE
M<F5B>2!A;&QO=VEN9R!T:&4@0V]M<&%N>2!T;R!R96%C<75I<F4@86QL(&]F
M('1H92!0<F]G<F%M<RX@($]N($IU;'D@,S`L(#(P,3`L($QE>&EC;VX@96YT
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M,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD,3`@;6EL;&EO;CPO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B!O;B!*=6QY)B,Q-C`[,S`L(#(P,3`@86YD(&ES<W5E9"`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C$S
M+#(S-RPU,3D\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T
M;R!D97-I9VYE97,@;V8@2&]L9&EN9W,@;VX@2G5L>28C,38P.S,P+"`R,#$R
M(&EN('-A=&ES9F%C=&EO;B!O9B!A;B!A9&1I=&EO;F%L(#PO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#,U+C`@;6EL
M;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B!B87-E('!A>6UE;G0@;V)L:6=A=&EO;BX@("`\
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M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#0U
M(&UI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX@:6X@861D:71I;VYA;"!C;VYT:6YG96YT
M('!A>6UE;G1S+"!W:&EC:"!W:6QL(&-O;G-I<W0@;V8@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC
M;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXU,"4\+V9O;G0^
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M:6%L:7IE($Q8,3`S,BP@3%@Q,#,S(&]R(&]T:&5R('!H87)M86-E=71I8V%L
M(&-O;7!O<VET:6]N<R!M;V1U;&%T:6YG('1H92!S86UE('1A<F=E="!A<R!T
M:&]S92!D<G5G(&-A;F1I9&%T97,@*'1H92`F(S@R,C`[3$<Q,#,@4')O9W)A
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M<F5S=6QT:6YG(&9R;VT@=&AE($Q',3`S(%!R;V=R86US('!R:6]R('1O(&5N
M=&5R:6YG(&EN=&\@82!,:6-E;G-I;F<@5')A;G-A8W1I;VX@9F]R('1H92!C
M;VUM97)C:6%L:7IA=&EO;B!O9B!S=6-H('!R;V1U8W0@:6X@=&AE(%5N:71E
M9"!3=&%T97,L(&EN(&QI974@;V8@86YY(&-O;G1I;F=E;G0@<&%Y;65N="!F
M<F]M('-U8V@@82!,:6-E;G-I;F<@5')A;G-A8W1I;VXL($QE>&EC;VX@=VEL
M;"!P87D@2&]L9&EN9W,@=&AE('-U;2!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P
M,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/B0Q-2!M:6QL:6]N/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^(&%N9"!T:&4@86UO=6YT(&]F(&-E<G1A:6X@97AP96YS97,@3&5X
M:6-O;B!I;F-U<G)E9"!A9G1E<B!I=',@97AE<F-I<V4@;V8@=&AE(%!U<F-H
M87-E($]P=&EO;B!W:&EC:"!A<F4@871T<FEB=71A8FQE('1O('1H92!D979E
M;&]P;65N="!O9B!S=6-H('!R;V1U8W0L(')E9'5C960@8GD@=7`@=&\@/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXU
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C
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M<F]V:61E9"!T:&%T(&YO(&UO<F4@=&AA;B`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P
M,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C4P)3PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!O
M9B!A;GD@8V]N=&EN9V5N="!P87EM96YT('=I;&P@8F4@<&%I9"!I;B!C;VUM
M;VX@<W1O8VLN("!/;B!$96-E;6)E<B`T+"`R,#$T+"!,97AI8V]N('!A:60@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)#4N."!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN(&-A<V@@
M86YD(&ES<W5E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXT+#8V,BPW.#`\+V9O;G0^/&9O;G0@
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M;G0@=VET:"!)<'-E;B!0:&%R;6$@4T%3("AS964@3F]T92`Q-BP@0V]L;&%B
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M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SXD,3`N,"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
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M(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#0U+C8@;6EL;&EO;CPO
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M,38P.V$@9&ES8V]U;G0@<F%T92!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C$T)3PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!F;W(@
M=&AE(&)A<V4@<&%Y;65N=',[("@R*28C,38P.V$@9&ES8V]U;G0@<F%T92!O
M9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO
M;F4[/C$X)3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B!F;W(@=&AE(&-O;G1I;F=E;G0@<&%Y;65N
M=',[(&%N9"`H,RDF(S$V,#MA('!R;V)A8FEL:71Y(&%D:G5S=&5D(&-O;G1I
M;F=E;F-Y+B`@5&AE(&1I<V-O=6YT(')A=&4@87-S=6UP=&EO;G,@:&%V92!N
M;W0@8VAA;F=E9"!T:')O=6=H(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT
M97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS,2P@,C`Q-#PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/BP@86YD(&%S('!R;V=R86US('!R;V=R97-S+"!T:&4@<')O
M8F%B:6QI='D@861J=7-T960@8V]N=&EN9V5N8WD@:7,@861J=7-T960@87,@
M;F5C97-S87)Y+B`@4W5B<V5Q=65N="!C:&%N9V5S(&EN('1H92!F86ER('9A
M;'5E(&]F('1H92!3>6UP:&]N>2!)8V]N('!U<F-H87-E(&-O;G-I9&5R871I
M;VX@;&EA8FEL:71Y(&%R92!R96-O<F1E9"!A<R!I;F-R96%S92!O<B!D96-R
M96%S92!I;B!F86ER('9A;'5E(&]F(%-Y;7!H;VYY($EC;VX@<'5R8VAA<V4@
M;&EA8FEL:71Y(&5X<&5N<V4@:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI
M9&%T960@<W1A=&5M96YT<R!O9B!C;VUP<F5H96YS:79E(&QO<W,N("!4:&4@
M9F%I<B!V86QU92!O9B!T:&4@4WEM<&AO;GD@26-O;B!P=7)C:&%S92!C;VYS
M:61E<F%T:6]N(&QI86)I;&ET>2!I;F-R96%S960@8GD@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)#$N-"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&1U<FEN9R!T:&4@>65A<B!E;F1E
M9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^+"!D96-R96%S960@8GD@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#(N,B!M:6QL:6]N/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^(&1U<FEN9R!T:&4@>65A<B!E;F1E9"`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY$
M96-E;6)E<B8C,38P.S,Q+"`R,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
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M,#LS,2P@,C`Q,CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/BX\+V9O;G0^/"]D:78^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S
M,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U
M,V-F8V5C+U=O<FMS:&5E=',O4VAE970Q.2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG
M96YC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ
M,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ
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M871I;VX@9&%T92!I;B!*=6YE(#(P,3@N("!);B!-87)C:"`R,#$U+"!T:&4@
M<W5B<VED:6%R>2!E;G1E<F5D(&EN=&\@82!T97)M:6YA=&EO;B!A9W)E96UE
M;G0@=VAE<F5B>2!T:&4@;&5A<V4@=VEL;"!T97)M:6YA=&4@:6X@2G5N92`R
M,#$U+B`F(S$V,#M4:&4@86UE;F1E9"!L96%S92!I;F-L=61E<R!E<V-A;&%T
M:6YG(&QE87-E('!A>6UE;G1S+B`@4F5N="!E>'!E;G-E(&ES(')E8V]G;FEZ
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M;&5A<V4N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@:&%D(#PO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#`N-"!M:6QL
M:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[
M=&5X="UD96-O<F%T:6]N.FYO;F4[/B0P+C0@;6EL;&EO;CPO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B!I;B!R97-T<FEC=&5D(&EN=F5S=&UE;G1S(&%S(&-O;&QA=&5R86P@87,@
M;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"8C
M,38P.SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
M;F]N93L^,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
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M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N
M93L^)#$N,"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R
M.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/B0P+CD@;6EL;&EO;CPO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M
M9&5C;W)A=&EO;CIN;VYE.SXD,BXR(&UI;&QI;VX\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@9F]R
M('1H92!Y96%R<R!E;F1E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X
M="UD96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXL(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R
M871I;VXZ;F]N93L^,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC
M;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$R/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^+"!R97-P96-T:79E;'DN)B,Q-C`[)B,Q-C`[5&AE(&9O;&QO=VEN
M9R!T86)L92!I;F-L=61E<R!N;VXM8V%N8V5L86)L92P@97-C86QA=&EN9R!F
M=71U<F4@;&5A<V4@<&%Y;65N=',@9F]R('1H92!F86-I;&ET>2!I;B!.97<@
M2F5R<V5Y+"!W:71H;W5T(')E9V%R9"!T;R!T:&4@=&5R;6EN871I;VX@86=R
M965M96YT(&5N=&5R960@:6YT;R!I;B!-87)C:"`R,#$U.CPO9F]N=#X\+V1I
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M,3`P)3MB;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=&5X="UA;&EG;CIL969T
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M;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X
M.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR,#$U/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M=#L^,C`Q-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/C$L,3`Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`Q.#PO9F]N=#X\
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M=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U
M8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C,L
M.#<V/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB
M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
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M<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
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M;VXN/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
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M+7-I>F4Z,3!P=#L^)B,Q-C`[)B,Q-C`[3&5X:6-O;B!I<R!F<F]M('1I;64@
M=&\@=&EM92!P87)T>2!T;R!C;&%I;7,@86YD(&QE9V%L('!R;V-E961I;F=S
M('1H870@87)I<V4@:6X@=&AE(&YO<FUA;"!C;W5R<V4@;V8@:71S(&)U<VEN
M97-S(&%N9"!T:&%T(&ET(&)E;&EE=F5S('=I;&P@;F]T(&AA=F4L(&EN9&EV
M:61U86QL>2!O<B!I;B!T:&4@86=G<F5G871E+"!A(&UA=&5R:6%L(&%D=F5R
M<V4@969F96-T(&]N(&ET<R!R97-U;'1S(&]F(&]P97)A=&EO;G,L(&9I;F%N
M8VEA;"!C;VYD:71I;VX@;W(@;&EQ=6ED:71Y+CPO9F]N=#X\+V1I=CX\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@Q
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W1H97(@0V%P:71A;"!3=&]C
M:R!!9W)E96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D]T:&5R($-A<&ET86P@4W1O8VL@06=R965M96YT
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R($-A<&ET86P@4W1O8VL@06=R965M96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SX\9&EV
M('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SX\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[/D]T:&5R($-A<&ET86P@
M4W1O8VL@06=R965M96YT<SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN
M92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU<W1I9GD[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US='EL93II=&%L:6,[/D-O;6UO
M;B!3=&]C:SH\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX@26X@3V-T;V)E<B`R,#$R+"!,97AI8V]N
M('-O;&0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SXQ-RPU,#`L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E<R!O9B!I=',@
M8V]M;6]N('-T;V-K(&%T(&$@<')I8V4@;V8@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD,BXR-3PO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B!P97(@<VAA<F4@:6X@82!P=6)L:6,@;V9F97)I;F<L(')E<W5L=&EN9R!I
M;B!N970@<')O8V5E9',@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E
M>'0M9&5C;W)A=&EO;CIN;VYE.SXD,S<N,2!M:6QL:6]N/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M+"!A9G1E<B!D961U8W1I;F<@=6YD97)W<FET:6YG(&1I<V-O=6YT<R!A;F0@
M8V]M;6ES<VEO;G,@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M
M9&5C;W)A=&EO;CIN;VYE.SXD,BXP)B,Q-C`[;6EL;&EO;CPO9F]N=#X\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B!A;F0@;V9F97)I;F<@97AP96YS97,@;V8@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD,"XR(&UI;&QI;VX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXN("!);G9U<RP@3"Y0+BP@3&5X:6-O;B8C.#(Q-SMS(&QA<F=E
M<W0@<W1O8VMH;VQD97(L('!U<F-H87-E9"`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P
M,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C,L,#`P+#`P,#PO9F]N=#X\
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M:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O
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M;B!.;W9E;6)E<B`R,#$T+"!,97AI8V]N('-O;&0@/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-34L
M-C`X+#DS,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B!S:&%R97,@;V8@:71S(&-O;6UO;B!S=&]C
M:R!A="!A('!R:6-E(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0Q+C`P-3PO9F]N=#X\9F]N
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M,#`U/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^('!E<B!S:&%R92!I;B!A('!R:79A=&4@<&QA8V5M
M96YT('1O($%R=&%L($EN=&5R;F%T:6]N86P@4RY#+D$L(&%N(&%F9FEL:6%T
M92!O9B!);G9U<RP@3"Y0+BP@<F5S=6QT:6YG(&EN(&YE="!P<F]C965D<R!O
M9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXD,C`Q+CDF(S$V,#MM:6QL:6]N/"]F;VYT/CQF;VYT
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M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B`@06QL(&]F('1H
M92!N970@<')O8V5E9',@;V8@=&AE<V4@;V9F97)I;F=S(&%R92!R969L96-T
M960@87,@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&EN('1H92!A8V-O;7!A
M;GEI;F<@9FEN86YC:6%L('-T871E;65N=',N/"]F;VYT/CPO9&EV/CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A
M.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X
M,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%<75I='D@26YC96YT:79E($%W
M87)D<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY%<75I='D@26YC96YT:79E($%W87)D<R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET
M>2!);F-E;G1I=F4@07=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ
M,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US='EL93II=&%L:6,[/D5Q=6ET
M>2!);F-E;G1I=F4@4&QA;CH\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#LF(S$V,#M);B!3
M97!T96UB97(@,3DY-2P@3&5X:6-O;B!A9&]P=&5D('1H92`Q.3DU(%-T;V-K
M($]P=&EO;B!0;&%N+"!W:&EC:"!W87,@<W5B<V5Q=65N=&QY(&%M96YD960@
M86YD(')E<W1A=&5D(&EN($9E8G)U87)Y(#(P,#`@86YD(')E;F%M960@=&AE
M(#(P,#`@17%U:71Y($EN8V5N=&EV92!0;&%N+"!S=6)S97%U96YT;'D@86UE
M;F1E9"!A;F0@<F5S=&%T960@:6X@07!R:6P@,C`P.2!A;F0@<F5N86UE9"!T
M:&4@17%U:71Y($EN8V5N=&EV92!0;&%N("AT:&4@)B,X,C(P.T5Q=6ET>2!)
M;F-E;G1I=F4@4&QA;B8C.#(R,3LI+"!A;F0@<W5B<V5Q=65N=&QY(&%M96YD
M960@:6X@07!R:6P@,C`Q,BX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI
M;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT
M.C0X<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F
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M8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,3`P)3PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B!O<B!M;W)E(&]F('1H92!F86ER(&UA<FME="!V86QU92!O9B!O
M=7(@8V]M;6]N('-T;V-K(&]N('1H92!D871E(&]F(&=R86YT+B8C,38P.R8C
M,38P.U1H92!P=7)C:&%S92!P<FEC92!O9B!R97-T<FEC=&5D('-T;V-K(&%W
M87)D<R!M87D@;F]T(&)E(&QE<W,@=&AA;B`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P
M,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C@U)3PO9F]N=#X\9F]N="!S
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M9'5L97,N)B,Q-C`[)B,Q-C`[3W!T:6]N<R!G<F%N=&5D('5N9&5R('1H92!%
M<75I='D@26YC96YT:79E(%!L86X@:&%V92!A('1E<FT@;V8@=&5N('EE87)S
M(&9R;VT@=&AE(&1A=&4@;V8@9W)A;G0N/"]F;VYT/CPO9&EV/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ:G5S=&EF>3MF;VYT
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M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SXU,"PP,#`L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E<RXF(S$V,#LF(S$V
M,#M.;R!M;W)E('1H86X@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M
M9&5C;W)A=&EO;CIN;VYE.SXQ-2PP,#`L,#`P/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E
M<R!M87D@8F4@:7-S=65D('!U<G-U86YT('1O(&%W87)D<R!O=&AE<B!T:&%N
M('-T;V-K(&]P=&EO;G,@86YD('-T;V-K(&%P<')E8VEA=&EO;B!R:6=H=',N
M)B,Q-C`[)B,Q-C`[07,@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E
M>'0M9&5C;W)A=&EO;CIN;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^+"!A;B!A9V=R96=A=&4@;V8@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC
M,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXU,"PP,#`L,#`P/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:&%D(&)E96X@<F5S97)V
M960@9F]R(&ES<W5A;F-E+"!O<'1I;VYS('1O('!U<F-H87-E(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C(L-3,S
M+#(T,CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B!S:&%R97,@86YD(#PO9F]N=#X\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z
M(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,RPQ,S`L-S(P/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^(')E<W1R:6-T960@<W1O8VL@=6YI=',@=V5R92!O=71S=&%N9&EN
M9RP@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SXU+#@X,2PX,34\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@<VAA<F5S(&AA9"!B965N(&ES
M<W5E9"!U<&]N('1H92!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS+"`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C,L
M,C(T+#,S.3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B!S:&%R97,@:&%D(&)E96X@:7-S=65D('!U
M<G-U86YT('1O(')E<W1R:6-T960@<W1O8VL@=6YI=',@86YD(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^-SDW+#<P
M,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B!S:&%R97,@:&%D(&)E96X@:7-S=65D('!U<G-U86YT
M('1O('-T;V-K(&)O;G5S(&%W87)D<R!O<B!R97-T<FEC=&5D('-T;V-K(&%W
M87)D<R!G<F%N=&5D('5N9&5R('1H92!%<75I='D@26YC96YT:79E(%!L86XN
M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E
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M,3!P=#L^)B,Q-C`[)B,Q-C`[26X@1F5B<G5A<GD@,C`P,"P@3&5X:6-O;B!A
M9&]P=&5D('1H92`R,#`P($YO;BU%;7!L;WEE92!$:7)E8W1O<G,F(S@R,3<[
M(%-T;V-K($]P=&EO;B!0;&%N+"!W:&EC:"!W87,@<W5B<V5Q=65N=&QY(&%M
M96YD960@86YD(')E<W1A=&5D(&EN($%P<FEL(#(P,#D@86YD(')E;F%M960@
M=&AE($YO;BU%;7!L;WEE92!$:7)E8W1O<G,F(S@R,3<[(%-T;V-K($]P=&EO
M;B!0;&%N+"!A;F0@<W5B<V5Q=65N=&QY(&%M96YD960@:6X@07!R:6P@,C`Q
M,B!A;F0@<F5N86UE9"!T:&4@3F]N+45M<&QO>65E($1I<F5C=&]R<R8C.#(Q
M-SL@17%U:71Y($EN8V5N=&EV92!0;&%N("AT:&4@)B,X,C(P.T1I<F5C=&]R
M<R8C.#(Q-SL@4&QA;B8C.#(R,3LI+B8C,38P.R8C,38P.U5N9&5R('1H92!$
M:7)E8W1O<G,F(S@R,3<[(%!L86XL(&YO;BUE;7!L;WEE92!D:7)E8W1O<G,@
M<F5C96EV92!A;B!I;FET:6%L(&]P=&EO;B!T;R!P=7)C:&%S92`\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C,P+#`P
M,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B!S:&%R97,@;V8@8V]M;6]N('-T;V-K+B8C,38P.R8C
M,38P.TEN(&%D9&ET:6]N+"!O;B!T:&4@9&%Y(&9O;&QO=VEN9R!E86-H(&]F
M('1H92!#;VUP86YY)B,X,C$W.W,@86YN=6%L(&UE971I;F=S(&]F('-T;V-K
M:&]L9&5R<RP@96%C:"!N;VXM96UP;&]Y964@9&ER96-T;W(@=VAO(&AA<R!B
M965N(&$@9&ER96-T;W(@9F]R(&%T(&QE87-T('-I>"!M;VYT:',@:7,@875T
M;VUA=&EC86QL>2!G<F%N=&5D(&%N(&]P=&EO;B!T;R!P=7)C:&%S92`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C(P
M+#`P,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%N9"!A
M(')E<W1R:6-T960@<W1O8VL@87=A<F0@;V8@=&AE(&YU;6)E<B!O9B!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K(&AA=FEN9R!A(&9A:7(@;6%R:V5T('9A;'5E
M(&]N('1H92!D871E(&]F(&=R86YT(&]F(#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P
M,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#(P+#`P,#PO9F]N=#X\9F]N
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M="!E>&-E960@:6X@=&AE(&%G9W)E9V%T92`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P
M,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C$L-3`P+#`P,#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B!S:&%R97,N)B,Q-C`[)B,Q-C`[07,@;V8@/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO
M<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SY$96-E;6)E<B8C,38P
M.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!A;B!A9V=R96=A=&4@;V8@/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXQ+#4P
M,"PP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SX@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!H860@
M8F5E;B!R97-E<G9E9"!F;W(@:7-S=6%N8V4L(&]P=&EO;G,@=&\@<'5R8VAA
M<V4@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SXQ+#`W,"PP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@<VAA<F5S('=E<F4@;W5T<W1A
M;F1I;F<L(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^;F]N93PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!H860@8F5E;B!I<W-U960@=7!O
M;B!T:&4@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<R!A;F0@/"]F;VYT/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR-S<L-#@P
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M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=VED=&@Z,3`P)3MB;W)D
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0V
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.7!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF
M;VYT+7=E:6=H=#IB;VQD.SXR,#$T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
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M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([
M9F]N="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HY<'0[9F]N="UW96EG:'0Z8F]L9#L^,C`Q,CPO9F]N
M=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE
M.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HY<'0[9F]N="UW96EG:'0Z8F]L9#L^*&EN('1H;W5S86YD<RP@97AC
M97!T(&5X97)C:7-E('!R:6-E(&1A=&$I/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
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M<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
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M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/C(S+#,P-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S
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M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^,BXT,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M,C$L-3(U/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR+C4Q/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR,"PT-S8\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE
M87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/C(N.#0\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L
M;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W
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M:7IE.C$P<'0[/C0L-3`R/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U
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M9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+7)I
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/C$N.3<\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS
M1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P
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M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@U,C4\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SY/=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D
M;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
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M92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/C(S+#,P-CPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HT<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I
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M;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL
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M;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D
M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.V)O<F1E<BUT;W`Z-'!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^,38L.3(Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M8F]R9&5R+71O<#HT<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X
M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L
M;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(N,C<\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N
M9"UC;VQO<CHC8V-E969F.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT
M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB;W)D97(M=&]P.C1P>"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/C$W+#,W.#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.V)O<F1E<BUT;W`Z-'!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F
M9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[8F]R9&5R+71O<#HT<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S
M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ-2PU.#(\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E
M<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CMB;W)D97(M=&]P.C1P>"!D;W5B;&4@(S`P,#`P,#LG(')O=W-P
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M
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M92!O9B!O<'1I;VYS(&=R86YT960@9'5R:6YG('1H92!Y96%R<R!E;F1E9"`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q,SPO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M
M9&5C;W)A=&EO;CIN;VYE.SXR,#$R/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('=E<F4@/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD,2XR
M,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/BP@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M
M9&5C;W)A=&EO;CIN;VYE.SXD,2XU.3PO9F]N=#X\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0F(S$V,#L\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/B0Q+C,W/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DN)B,Q-C`[)B,Q-C`[
M5&AE('1O=&%L(&EN=')I;G-I8R!V86QU92!O9B!O<'1I;VYS(&5X97)C:7-E
M9"!D=7)I;F<@=&AE('EE87)S(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P
M,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS,2P@
M,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/BP@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E
M>'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/C(P
M,3(\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SX@=V5R92`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[
M=&5X="UD96-O<F%T:6]N.FYO;F4[/B0T,RPP,#`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL(#PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^
M)#,R-2PP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P
M,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#0V,BPP,#`\+V9O;G0^/&9O
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M<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXU+C@\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SX@86YD(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^-"XW/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('EE87)S+"!R97-P96-T:79E;'DL
M(&%S(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS,2P@,C`Q-#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BXF
M(S$V,#LF(S$V,#M!="`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD
M96-O<F%T:6]N.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXL('1H92!A9V=R96=A=&4@:6YT<FEN<VEC('9A;'5E(&]F('1H92!O
M=71S=&%N9&EN9R!O<'1I;VYS(&%N9"!T:&4@97AE<F-I<V%B;&4@;W!T:6]N
M<R!W87,@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SYZ97)O/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R
M.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/GIE<F\\+V9O;G0^/&9O
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M=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
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M+7-I>F4Z,3!P=#L^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M
M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/D1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,30L
M(#(P,3,@86YD(#(P,3(L($QE>&EC;VX@9W)A;G1E9"!I=',@;F]N+65M<&QO
M>65E(&1I<F5C=&]R<R`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ,#(L-38P/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M+"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXX,"PX,#@\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^.30L,3$R
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M=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/B0Q+C<P/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('!E
M<B!S:&%R92P@<F5S<&5C=&EV96QY+"!A;F0@=F5S=&5D(&EM;65D:6%T96QY
M+B`@1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,30L($QE>&EC;VX@9W)A;G1E9"!A(&-O;G-U;'1A;G0@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M-3<L-#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E<R!O9B!R97-T<FEC=&5D('-T;V-K
M(&%W87)D<RX@(%1H92!R97-T<FEC=&5D('-T;V-K(&%W87)D<R!H860@82!W
M96EG:'1E9"!A=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU92!O9B`\+V9O
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M:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I
M;VXZ;F]N93L^1&5C96UB97(F(S$V,#LS,2P@,C`Q-#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE
M.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
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M+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE
M.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE/3-$
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M=VED=&@Z,3`P)3MB;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=&5X="UA;&EG
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M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL
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M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z.7!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\+W1R
M/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY/=71S=&%N9&EN9R!A="!$
M96-E;6)E<B`S,2P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@Q+#,X-#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUR:6=H=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
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M.C$P<'0[/C$N.3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED
M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^*#$L,S,Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M<FEG:'0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
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M=F5S=&5D(&%T($1E8V5M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO9&EV/CPO=&0^
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXS+#$S,3PO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R
M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S
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M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ
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M;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN
M;VYE.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!A;B!A
M9V=R96=A=&4@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C
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M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ
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M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B
M-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T,C(N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY"96YE9FET(%!L86X\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0F5N969I="!0;&%N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5N969I="!0;&%N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CPO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#L^0F5N969I="!0;&%N/"]F;VYT
M/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI
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M;B!S879I;F=S('!L86X@=6YD97(@4V5C=&EO;B`T,#$H:RD@;V8@=&AE($EN
M=&5R;F%L(%)E=F5N=64@0V]D92XF(S$V,#LF(S$V,#M4:&4@<&QA;B!C;W9E
M<G,@<W5B<W1A;G1I86QL>2!A;&P@9G5L;"UT:6UE(&5M<&QO>65E<RXF(S$V
M,#LF(S$V,#M087)T:6-I<&%T:6YG(&5M<&QO>65E<R!M87D@9&5F97(@82!P
M;W)T:6]N(&]F('1H96ER('!R971A>"!E87)N:6YG<RP@=7`@=&\@=&AE($EN
M=&5R;F%L(%)E=F5N=64@4V5R=FEC92!A;FYU86P@8V]N=')I8G5T:6]N(&QI
M;6ET+B8C,38P.R8C,38P.T)E9VEN;FEN9R!I;B`R,#`P+"!T:&4@0V]M<&%N
M>2!W87,@<F5Q=6ER960@=&\@;6%T8V@@96UP;&]Y964@8V]N=')I8G5T:6]N
M<R!A8V-O<F1I;F<@=&\@82!S<&5C:69I960@9F]R;75L82XF(S$V,#LF(S$V
M,#M4:&4@;6%T8VAI;F<@8V]N=')I8G5T:6]N<R!T;W1A;&5D(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#,W-BPP
M,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXL(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT
M+61E8V]R871I;VXZ;F]N93L^)#4Q,2PP,#`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^
M)#0Y,"PP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX@:6X@=&AE('EE87)S(&5N9&5D(#PO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^1&5C
M96UB97(F(S$V,#LS,2P@,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC
M;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O
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M8V4N/"]F;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q
M9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R
M-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H
M965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N=',\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]L
M;&%B;W)A=&EO;B!A;F0@3&EC96YS92!!9W)E96UE;G1S(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L
M;&%B;W)A=&EO;B!A;F0@3&EC96YS92!!9W)E96UE;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4]
M,T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CPO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z8F]L9#L^0V]L;&%B;W)A=&EO;B!A;F0@3&EC
M96YS92!!9W)E96UE;G1S/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE
M+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I>F4Z,3!P
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M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[9F]N="US='EL93II=&%L:6,[/DEP<V5N(%!H87)M82!305,N/"]F
M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^("!);B!/8W1O8F5R(#(P,30L($QE>&EC;VX@96YT97)E9"!I
M;G1O(&$@3&EC96YS92!A;F0@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0@*'1H
M92`F(S@R,C`[06=R965M96YT)B,X,C(Q.REW:71H($EP<V5N(%!H87)M82!3
M05,@*"8C.#(R,#M)<'-E;B8C.#(R,3LI)B,Q-C`[9F]R('1H92!D979E;&]P
M;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;V8@3&5X:6-O;B8C.#(Q-SMS
M(&1R=6<@8V%N9&ED871E('1E;&]T<FES=&%T(&5T:7!R871E("A,6#$P,S(I
M(&]U='-I9&4@;V8@=&AE(%5N:71E9"!3=&%T97,L($-A;F%D82!A;F0@2F%P
M86X@*'1H92`F(S@R,C`[3&EC96YS960@5&5R<FET;W)Y)B,X,C(Q.RDN("`\
M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X
M="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C0X<'@[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
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M=')I<W1A="!E=&EP<F%T92!I;B!T:&4@3&EC96YS960@5&5R<FET;W)Y+B`@
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M86QS+B`@56YD97(@=&AE($%G<F5E;65N="P@27!S96X@<&%I9"!,97AI8V]N
M(&%N('5P9G)O;G0@<&%Y;65N="!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P
M,#`[/B0R,R!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B`@26X@861D:71I;VXL($QE
M>&EC;VX@:7,@96QI9VEB;&4@=&\@<F5C96EV92!F<F]M($EP<V5N("AA*2!U
M<"!T;R!A;B!A9V=R96=A=&4@;V8@87!P<F]X:6UA=&5L>2`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.V-O;&]R.B,P,#`P,#`[/B0S,"8C,38P.VUI;&QI;VX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@
M=7!O;B!T:&4@86-H:65V96UE;G0@;V8@<W!E8VEF:65D(')E9W5L871O<GD@
M86YD(&-O;6UE<F-I86P@;&%U;F-H(&UI;&5S=&]N97,@86YD("AB*2!U<"!T
M;R!A;B!A9V=R96=A=&4@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.SXF
M(S@S-C0[-S(F(S$V,#MM:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('5P;VX@=&AE(&%C
M:&EE=F5M96YT(&]F('-P96-I9FEE9"!S86QE<R!M:6QE<W1O;F5S+B`@1'5E
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M,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/E1H92!#;VUP86YY(&-O;G-I9&5R960@=&AE(&9O;&QO
M=VEN9R!D96QI=F5R86)L97,@=VET:"!R97-P96-T('1O('1H92!R979E;G5E
M(')E8V]G;FET:6]N(&]F('1H92`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[
M/B0R,R!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('5P9G)O;G0@<&%Y;65N=#H@/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M
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M>&-L=7-I=F4@;&EC96YS92!G<F%N=&5D('1O($EP<V5N('1O(&1E=F5L;W`@
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M<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M;&5F=#HP<'@[=&5X
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M<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I;F<M;&5F=#HP<'@[=&5X
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M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M
M86QI9VXZ;&5F=#MP861D:6YG+6QE9G0Z.39P>#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SYE=&EP<F%T92!U;G1I;"!C;VUM97)C:6%L:7IA=&EO;CL@86YD/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W!A9&1I
M;F<M;&5F=#HP<'@[=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C0X<'@[
M/CQF;VYT('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[<&%D9&EN9RUR:6=H=#HT.'!X.SXF(S@R
M,C8[/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^5&AE(&]B;&EG871I;VX@=&\@<W5P<&QY(&-O;6UE
M<F-I86P@<W5P<&QY(&]F('1E;&]T<FES=&%T(&5T:7!R871E+"!U;F1E<B!A
M(&-O;6UE<F-I86P@<W5P<&QY(&%G<F5E;65N="X\+V9O;G0^/"]D:78^/&1I
M=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIL969T.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\
M+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N
M.FQE9G0[=&5X="UI;F1E;G0Z-#AP>#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY4
M:&4@0V]M<&%N>2!D971E<FUI;F5D('1H870@=&AE(&QI8V5N<V4@:&%D('-T
M86YD+6%L;VYE('9A;'5E(&)E8V%U<V4@:70@:7,@86X@97AC;'5S:79E(&QI
M8V5N<V4@=&AA="!G:79E<R!)<'-E;B!T:&4@<FEG:'0@=&\@9&5V96QO<"!A
M;F0@8V]M;65R8VEA;&EZ92!T96QO=')I<W1A="!E=&EP<F%T92!O<B!T;R!S
M=6)L:6-E;G-E(&ET<R!R:6=H=',N("!);B!A9&1I=&EO;BP@=&5L;W1R:7-T
M870@971I<')A=&4@:7,@8W5R<F5N=&QY(&EN(&1E=F5L;W!M96YT(&%N9"!I
M="!I<R!P;W-S:6)L92!T:&%T($EP<V5N(&]R(&%N;W1H97(@=&AI<F0@<&%R
M='D@8V]U;&0@8V]N9'5C="!C;&EN:6-A;"!T<FEA;',@=VET:&]U="!A<W-I
M<W1A;F-E(&9R;VT@3&5X:6-O;BX@($%S(&$@<F5S=6QT+"!T:&4@0V]M<&%N
M>2!C;VYS:61E<G,@=&AE(&QI8V5N<V4@86YD('1H92!D979E;&]P;65N="!S
M97)V:6-E<R!U;F1E<B!T:&4@06=R965M96YT('1O(&)E('-E<&%R871E('5N
M:71S(&]F(&%C8V]U;G1I;F<N("!4:&4@0V]M<&%N>2!R96-O9VYI>F5D('1H
M92!P;W)T:6]N(&]F('1H92!C;VYS:61E<F%T:6]N(&%L;&]C871E9"!T;R!T
M:&4@;&EC96YS92!I;6UE9&EA=&5L>2!B96-A=7-E($QE>&EC;VX@9&5L:79E
M<F5D('1H92!L:6-E;G-E(&%N9"!E87)N960@=&AE(')E=F5N=64@870@=&AE
M(&EN8V5P=&EO;B!O9B!T:&4@87)R86YG96UE;G0N("!4:&4@0V]M<&%N>2!I
M<R!R96-O9VYI>FEN9R!A<R!R979E;G5E('1H92!A;6]U;G0@86QL;V-A=&5D
M('1O('1H92!D979E;&]P;65N="!S97)V:6-E<R!A;F0@=&AE(&]B;&EG871I
M;VX@=&\@<&%R=&EC:7!A=&4@:6X@8V]M;6ET=&5E<R!O=F5R('1H92!P97)I
M;V0@;V8@=&EM92!,97AI8V]N('!E<F9O<FUS('-E<G9I8V5S+"!C=7)R96YT
M;'D@97AP96-T960@=&\@8F4@=&AR;W5G:"!M:60M,C`Q-RX@(#PO9F]N=#X\
M+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^
M/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E
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M:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT
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M(&%L;&]C86)L92!C;VYS:61E<F%T:6]N+B`@5&AE($-O;7!A;GD@86QL;V-A
M=&5D('1H92!A;&QO8V%B;&4@8V]N<VED97)A=&EO;B!B87-E9"!O;B!T:&4@
M<F5L871I=F4@8F5S="!E<W1I;6%T92!O9B!S96QL:6YG('!R:6-E(&]F(&5A
M8V@@=6YI="!O9B!A8V-O=6YT:6YG+B`@5&AE($-O;7!A;GD@97-T:6UA=&5D
M('1H92!S96QL:6YG('!R:6-E(&]F('1H92!L:6-E;G-E(&1E;&EV97)A8FQE
M(&)Y(&%P<&QY:6YG(&$@<')O8F%B:6QI='DM8F%S960@:6YC;VUE(&%P<')O
M86-H('5T:6QI>FEN9R!A;B!A<'!R;W!R:6%T92!D:7-C;W5N="!R871E+B`@
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M:7-C;W5N="!R871E+B`@5&AE($-O;7!A;GD@97-T:6UA=&5D('1H92!S96QL
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M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8F%C:V=R;W5N
M9"UC;VQO<CHC9F9F9F9F.SY!<R!A(')E<W5L="!O9B!T:&4@86QL;V-A=&EO
M;BP@=&AE($-O;7!A;GD@<F5C;V=N:7IE9"`\+V9O;G0^/&9O;G0@<W1Y;&4]
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M,'!T.SX@=7!F<F]N="!P87EM96YT(&9O<B!T:&4@;&EC96YS92!I;B`R,#$T
M+B`@5&AE($-O;7!A;GD@:7,@<F5C;V=N:7II;F<@=&AE(#PO9F]N=#X\9F]N
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M;V=N:7IE9"!U;F1E<B!T:&4@06=R965M96YT('=A<R`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD
M,C$N-"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&9O<B!T:&4@>65A<B!E;F1E9"`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
M/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXN/"]F;VYT/CPO
M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ
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M,C`P-2P@3&5X:6-O;B!R96-E:79E9"!A(#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P
M,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^)#,U+C`@;6EL;&EO;CPO9F]N
M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B!A=V%R9"!F<F]M('1H92!497AA<R!%;G1E<G!R:7-E($9U;F0@
M9F]R('1H92!C<F5A=&EO;B!O9B!A(&MN;V-K;W5T(&UO=7-E(&5M8G)Y;VYI
M8R!S=&5M(&-E;&P@;&EB<F%R>2!C;VYT86EN:6YG(#,U,"PP,#`@8V5L;"!L
M:6YE<R!F;W(@=&AE(%1E>&%S($EN<W1I='5T92!F;W(@1V5N;VUI8R!-961I
M8VEN92`H)B,X,C(P.U1)1TTF(S@R,C$[*2!U<VEN9R!,97AI8V]N)B,X,C$W
M.W,@<')O<')I971A<GD@9V5N92!T<F%P<&EN9R!T96-H;F]L;V=Y+"!W:&EC
M:"!,97AI8V]N(&-O;7!L971E9"!I;B`R,#`W+B8C,38P.R8C,38P.TQE>&EC
M;VX@86QS;R!E<75I<'!E9"!424=-('=I=&@@=&AE(&)I;VEN9F]R;6%T:6-S
M('-O9G1W87)E(')E<75I<F5D(&9O<B!T:&4@;6%N86=E;65N="!A;F0@86YA
M;'ES:7,@;V8@9&%T82!R96QA=&EN9R!T;R!T:&4@;&EB<F%R>2XF(S$V,#LF
M(S$V,#M4:&4@5&5X87,@16YT97)P<FES92!&=6YD(&%L<V\@87=A<F1E9"`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/E5N9&5R('1H
M92!T97)M<R!O9B!T:&4@87=A<F0L($QE>&EC;VX@:7,@<F5S<&]N<VEB;&4@
M9F]R('1H92!C<F5A=&EO;B!O9B!A('-P96-I9FEE9"!N=6UB97(@;V8@:F]B
M<R!B96=I;FYI;F<@:6X@,C`Q,BP@<F5A8VAI;F<@86X@86=G<F5G871E(&]F
M(#$L-C$V(&YE=R!J;V)S(&EN(%1E>&%S(&)Y($1E8V5M8F5R(#,Q+"`R,#$V
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M;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO;CIN;VYE.SXD,BPT,34\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX@9F]R(&5A8V@@:F]B($QE>&EC;VX@9F%L;',@<VAO<G0@8F5G
M:6YN:6YG(&EN(#(P,3,N)B,Q-C`[)B,Q-C`[3&5X:6-O;B8C.#(Q-SMS(&UA
M>&EM=6T@86=G<F5G871E(&5X<&]S=7)E(&9O<B!S=6-H('!A>6UE;G1S+"!I
M9B!,97AI8V]N(&9A:6QS('1O(&-R96%T92!A;GD@;F5W(&IO8G,L(&ES(&%P
M<')O>&EM871E;'D@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C
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M<F]U9V@@,C`Q-2P@=VET:&]U="!G:79I;F<@969F96-T('1O(&%N>2!C<F5D
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M;VYA;"!P97)I;V0@=&\@;6%I;G1A:6X@86X@86=G<F5G871E(&]F(#4L,#`P
M(&IO8G,L(&EN8VQU<VEV92!O9B!T:&]S92!,97AI8V]N(&-R96%T97,N/"]F
M;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F
M8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW
M,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T,C0N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY297-T
M<G5C='5R:6YG($-H87)G97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5S=')U8W1U<FEN9R!#:&%R9V5S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5S=')U8W1U<FEN9R!A;F0@4F5L871E9"!!8W1I=FET:65S($1I
M<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H
M=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#L^
M4F5S=')U8W1U<FEN9R!#:&%R9V5S/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4]
M,T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C
M;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH
M96EG:'0Z,3(P)3MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/DEN($IA;G5A<GD@,C`Q-"P@3&5X:6-O;B8C.#(Q-SMS(&)O87)D(&]F
M(&1I<F5C=&]R<R!C;VUM:71T960@=&\@;F%R<F]W(&ET<R!S=')A=&5G:6,@
M:6YI=&EA=&EV97,@86YD(&9O8W5S(')E<V]U<F-E<R!O;B!I=',@;&%T92US
M=&%G92!D<G5G(&1E=F5L;W!M96YT('!R;V=R86US+"!P<FEN8VEP86QL>2!S
M;W1A9VQI9FQO>FEN("A,6#0R,3$I(&9O<B!D:6%B971E<R!A;F0@=&5L;W1R
M:7-T870@971I<')A=&4@*$Q8,3`S,BD@9F]R(&-A<F-I;F]I9"!S>6YD<F]M
M92P@:6X@<')E<&%R871I;VX@9F]R('1H92!T<F%N<VET:6]N('1O(&-O;6UE
M<F-I86QI>F%T:6]N+B`@5&AE(&1E8VES:6]N(')E<W5L=&5D(&EN(&$@=V]R
M:V9O<F-E(')E9'5C=&EO;B!O9B!A<'!R;WAI;6%T96QY(#$R-2!E;7!L;WEE
M97,L('!R:6UA<FEL>2!I;B!R97-E87)C:"P@9&ES8V]V97)Y(&%N9"!S=7!P
M;W)T('!O<VET:6]N<RP@<F5P<F5S96YT:6YG(&%P<')O>&EM871E;'D@-3`E
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@=&]T86P@=V]R:V9O<F-E+B`@5&AE
M($-O;7!A;GD@8V]M<&QE=&5D('1H92!M86IO<FET>2!O9B!T:&4@=V]R:V9O
M<F-E(')E9'5C=&EO;B!B>2!T:&4@96YD(&]F('1H92!S96-O;F0@<75A<G1E
M<B!O9B`R,#$T+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#`N-"8C,38P.VUI;&QI;VX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXI+"!O9B!W:&EC:"`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD-2XV)B,Q-C`[;6EL
M;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B!W87,@:6YC=7)R960@=&AR;W5G:"`\+V9O;G0^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+B`@3V8@
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#`N-R8C,38P.VUI;&QI
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M,C`Q-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/BX@($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!R
M96-O<F1E9"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!O;B!T
M:&4@86-C96QE<F%T:6]N(&]F('9E<W1I;F<@<F5L871I;F<@=&\@=&AE(')E
M<W1R=6-T=7)I;F<@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#`N,2!M:6QL:6]N/"]F;VYT
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^(&EN('1H92!Y96%R(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/D1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
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M.C$P<'0[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXN/"]F
M;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F
M8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW
M,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T,C4N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY396QE
M8W1E9"!1=6%R=&5R;'D@1FEN86YC:6%L($1A=&$\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V5L96-T960@475A
M<G1E<FQY($9I;F%N8VEA;"!$871A(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5L96-T960@475A<G1E
M<FQY($9I;F%N8VEA;"!$871A/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ
M,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CPO9F]N=#X\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z8F]L9#L^4V5L96-T960@475A<G1E<FQY($9I;F%N8VEA;"!$871A/"]F
M;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M
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M<G1E<B!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T
M:6]N.FYO;F4[/C(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L
M;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q,SPO9F]N=#X\
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M=&$I/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
M.V9O;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P
M>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M
M=&]P.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL87!S93IC;VQL87!S
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M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HY<'0[9F]N
M="UW96EG:'0Z8F]L9#L^475A<G1E<B!%;F1E9#PO9F]N=#X\+V1I=CX\+W1D
M/CPO='(^/'1R/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP
M861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z
M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY-87)C:"`S
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB
M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD
M.SY*=6YE(#,P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI
M9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I
M9VAT.F)O;&0[/E-E<'1E;6)E<B`S,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR
M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.7!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY$96-E;6)E<B`S,3PO9F]N=#X\+V1I
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M9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
M;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C
M;VQS<&%N/3-$-R!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SXH56YA=61I
M=&5D*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C$L-#@R/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CL@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\
M+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/DQO<W,@9G)O;2!O<&5R871I;VYS/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXH-#`L,S,V
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXH,S`L.#,U/"]F;VYT/CPO
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXH-#`L-#DX/"]F;VYT
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M:7IE.C$P<'0[/B@P+C`V/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
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M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M:&5R:70[9F]N="US:7IE.C$P<'0[/B@P+C`U/"]F;VYT/CPO9&EV/CPO=&0^
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@P+C`X/"]F;VYT
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,2PT,3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A
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M;W1T;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V
M97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^
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M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B
M-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$514$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L:6-I97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D)A<VES(&]F(%!R97-E;G1A=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G-O;&ED871I;VXL
M(%!O;&EC>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
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M;VX@86YD(&ET<R!W:&]L;'DM;W=N960@<W5B<VED:6%R:65S+B`@26YT97)C
M;VUP86YY('1R86YS86-T:6]N<R!A;F0@8F%L86YC97,@87)E(&5L:6UI;F%T
M960@:6X@8V]N<V]L:61A=&EO;BX@/"]F;VYT/CPO9&EV/CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^57-E
M(&]F($5S=&EM871E<RP@4&]L:6-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H
M=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M
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M9F]N=#X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',L
M(%!O;&EC>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
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M=&\@8F4@8V%S:"!E<75I=F%L96YT<RXF(S$V,#LF(S$V,#M!<R!O9B`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N.FYO;F4[/D1E
M8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX@86YD(#PO9F]N=#X\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q,SPO
M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/BP@<VAO<G0M=&5R;2!I;G9E<W1M96YT<R!C;VYS:7-T(&]F
M(%4N4RX@=')E87-U<GD@8FEL;',@86YD(&-E<G1I9FEC871E<R!O9B!D97!O
M<VET+B`@5&AE(&-E<G1I9FEC871E<R!O9B!D97!O<VET<R!A<F4@8VQA<W-I
M9FEE9"!A<R!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<R!A;F0@87)E
M(&-A<G)I960@870@9F%I<B!V86QU92P@8F%S960@;VX@<75O=&5D(&UA<FME
M="!P<FEC97,@;V8@=&AE('-E8W5R:71I97,N)B,Q-C`[)B,Q-C`[5&AE($-O
M;7!A;GD@=FEE=W,@:71S(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S
M(&%S(&%V86EL86)L92!F;W(@=7-E(&EN(&-U<G)E;G0@;W!E<F%T:6]N<R!R
M96=A<F1L97-S(&]F('1H92!S=&%T960@;6%T=7)I='D@9&%T92!O9B!T:&4@
M<V5C=7)I='DN)B,Q-C`[)B,Q-C`[56YR96%L:7IE9"!G86EN<R!A;F0@;&]S
M<V5S(&]N('-U8V@@<V5C=7)I=&EE<R!A<F4@<F5P;W)T960@87,@82!S97!A
M<F%T92!C;VUP;VYE;G0@;V8@<W1O8VMH;VQD97)S)B,X,C$W.R!E<75I='DN
M)B,Q-C`[)B,Q-C`[3F5T(')E86QI>F5D(&=A:6YS(&%N9"!L;W-S97,L(&EN
M=&5R97-T(&%N9"!D:79I9&5N9',@87)E(&EN8VQU9&5D(&EN(&EN=&5R97-T
M(&EN8V]M92XF(S$V,#LF(S$V,#M4:&4@8V]S="!O9B!S96-U<FET:65S('-O
M;&0@:7,@8F%S960@;VX@=&AE('-P96-I9FEC(&ED96YT:69I8V%T:6]N(&UE
M=&AO9"X\+V9O;G0^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q=6EV
M86QE;G1S+"!297-T<FEC=&5D($-A<V@@86YD($-A<V@@17%U:79A;&5N=',L
M(%!O;&EC>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
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M9F%C:6QI=&EE<R!I;B!(;W!E=V5L;"P@3F5W($IE<G-E>2`H<V5E($YO=&4F
M(S$V,#LQ,BDN/"]F;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&4@86YD($]T:&5R
M($%C8V]U;G1S(%)E8V5I=F%B;&4L(%!O;&EC>3PO=&0^#0H@("`@("`@(#QT
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M;V8@<')O9'5C=',@;W(@<V5R=FEC97,N)B,Q-C`[)B,Q-C`[)B,Q-C`[5&AE
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M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYC96YT<F%T:6]N(%)I<VL@
M1&ES8VQO<W5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT
M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z-#AP>#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M<W1Y;&4Z:71A;&EC.SY#;VYC96YT<F%T:6]N(&]F($-R961I
M="!2:7-K.CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B!,97AI8V]N)B,X,C$W.W,@8V%S:"!E<75I
M=F%L96YT<RP@:6YV97-T;65N=',@86YD(&%C8V]U;G1S(')E8V5I=F%B;&4@
M<F5P<F5S96YT('!O=&5N=&EA;"!C;VYC96YT<F%T:6]N<R!O9B!C<F5D:70@
M<FES:RX@5&AE($-O;7!A;GD@871T96UP=',@=&\@;6EN:6UI>F4@<&]T96YT
M:6%L(&-O;F-E;G1R871I;VYS(&]F(')I<VL@:6X@8V%S:"!E<75I=F%L96YT
M<R!A;F0@:6YV97-T;65N=',@8GD@<&QA8VEN9R!I;G9E<W1M96YT<R!I;B!H
M:6=H+7%U86QI='D@9FEN86YC:6%L(&EN<W1R=6UE;G1S+B!4:&4@0V]M<&%N
M>28C.#(Q-SMS(&%C8V]U;G1S(')E8V5I=F%B;&4@87)E('5N<V5C=7)E9"!A
M;F0@87)E(&-O;F-E;G1R871E9"!I;B!P:&%R;6%C975T:6-A;"!A;F0@8FEO
M=&5C:&YO;&]G>2!C;VUP86YI97,@;&]C871E9"!I;B!T:&4@56YI=&5D(%-T
M871E<RXF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!H87,@;F]T(&5X<&5R:65N
M8V5D(&%N>2!S:6=N:69I8V%N="!C<F5D:70@;&]S<V5S('1O(&1A=&4N/"]F
M;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V5G;65N="!297!O<G1I;F<@1&ES8VQO<W5R
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS
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M=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT+"!0;VQI
M8WD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
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M<W-E=',@=VAI8V@@<F%N9V5S(&9R;VT@=&AR964@=&\@-#`@>65A<G,N)B,Q
M-C`[)B,Q-C`[36%I;G1E;F%N8V4L(')E<&%I<G,@86YD(&UI;F]R(')E<&QA
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M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26UP86ER;65N="!O<B!$:7-P
M;W-A;"!O9B!,;VYG+4QI=F5D($%S<V5T<RP@4&]L:6-Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4]
M,T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US='EL93II=&%L:6,[
M/DEM<&%I<FUE;G0@;V8@3&]N9RU,:79E9"!!<W-E=',Z/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)B,Q-C`[)B,Q-C`[3&]N9RUL:79E9"!A<W-E=',@86YD(&-E<G1A:6X@:61E
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M96YT+B`@1&5T97)M:6YA=&EO;B!O9B!R96-O=F5R86)I;&ET>2!I<R!B87-E
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M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=O;V1W:6QL(&%N9"!);G1A;F=I8FQE($%S<V5T<RP@4&]L:6-Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F
M=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[9F]N="US
M='EL93II=&%L:6,[/D=O;V1W:6QL($EM<&%I<FUE;G0Z/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)B,Q-C`[)B,Q-C`[1V]O9'=I;&P@:7,@;F]T(&%M;W)T:7IE9"P@8G5T(&ES
M('1E<W1E9"!A="!L96%S="!A;FYU86QL>2!F;W(@:6UP86ER;65N="!A="!T
M:&4@<F5P;W)T:6YG('5N:70@;&5V96PN)B,Q-C`[)B,Q-C`[5&AE($-O;7!A
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M86ER;65N="!L;W-S(&ES(')E8V]G;FEZ960N)B,Q-C`[)B,Q-C`[061D:71I
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M9F]N=#X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@4F5C;V=N:71I;VXL(%!O;&EC
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS
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M;&ET>2!I<R!R96%S;VYA8FQY(&%S<W5R960N)B,Q-C`[)B,Q-C`[/"]F;VYT
M/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI
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M(')E=F5N=64@86=R965M96YT+B`@5&AE($-O;7!A;GD@:61E;G1I9FEE<R!T
M:&4@9&5L:79E<F%B;&5S(&EN8VQU9&5D('=I=&AI;B!T:&4@86=R965M96YT
M(&%N9"!E=F%L=6%T97,@=VAI8V@@9&5L:79E<F%B;&5S(')E<')E<V5N="!S
M97!A<F%T92!U;FET<R!O9B!A8V-O=6YT:6YG+B`@5&AE($-O;7!A;GD@86-C
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M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0[)SX\='(^/'1D('-T>6QE
M/3-$=VED=&@Z-#AP>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\+W1R/CQT<CX\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N="US:7IE
M.C$P<'0[<&%D9&EN9RUL969T.C(T<'@[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C(V.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.G1O<#L@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT
M.C$R,"4[=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/E1H
M92!D96QI=F5R960@:71E;2!O<B!I=&5M<R!H879E('9A;'5E('1O('1H92!C
M=7-T;VUE<B!O;B!A('-T86YD+6%L;VYE(&)A<VES+CPO9F]N=#X\+V1I=CX\
M+W1D/CPO='(^/"]T86)L93X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS
M<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[(&9O;G0M<VEZ93HQ,'!T.R<^/'1R/CQT9"!S='EL93TS1'=I9'1H.C0X
M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ=&]P(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.W!A9&1I
M;F<M;&5F=#HR-'!X.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B8C.#(R-CL\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M
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M+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X
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M('1H92!R96-E:7!T(&]F('1H92!R96UA:6YI;F<@9&5L:79E<F%B;&5S+B`@
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M+B`@4F5V96YU92!I<R!R96-O9VYI>F5D(&9O<B!E86-H('5N:70@;V8@86-C
M;W5N=&EN9R!W:&5N('1H92!A<'!R;W!R:6%T92!R979E;G5E(')E8V]G;FET
M:6]N(&-R:71E<FEA(&%R92!M970N(#PO9F]N=#X\+V1I=CX\9&EV('-T>6QE
M/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD
M:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ;&5F=#MT
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M/"]F;VYT/CPO9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.C$P<'0[)SX\='(^/'1D('-T>6QE/3-$=VED=&@Z-#AP>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A
M;"UA;&EG;CIT;W`@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N="US:7IE.C$P<'0[<&%D9&EN9RUL
M969T.C(T<'@[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^)B,X,C(V.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.G1O<#L@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG
M;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/DET(&-A;B!O;FQY(&)E(&%C
M:&EE=F5D(&)A<V5D(&EN('=H;VQE(&]R(&EN('!A<G0@;VX@96ET:&5R('1H
M92!#;VUP86YY)B,X,C$W.W,@<&5R9F]R;6%N8V4@;W(@;VX@=&AE(&]C8W5R
M<F5N8V4@;V8@82!S<&5C:69I8R!O=71C;VUE(')E<W5L=&EN9R!F<F]M('1H
M92!#;VUP86YY)B,X,C$W.W,@<&5R9F]R;6%N8V4[/"]F;VYT/CPO9&EV/CPO
M=&0^/"]T<CX\+W1A8FQE/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.C$P<'0[)SX\='(^/'1D('-T>6QE/3-$=VED=&@Z-#AP
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\=&0@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIT;W`@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
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M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N
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M+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E
M+"!0;VQI8WD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@
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M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP
M96YS871I;VXL($]P=&EO;B!A;F0@26YC96YT:79E(%!L86YS(%!O;&EC>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F
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M=#L^)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!C;VUP96YS
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M82!S=')A:6=H="UL:6YE(&)A<VES+B`@4W1O8VLM8F%S960@8V]M<&5N<V%T
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M<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD96-O<F%T:6]N
M.FYO;F4[/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXL('-T
M;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!C;W-T(&9O<B!A;&P@;W5T<W1A;F1I
M;F<@=6YV97-T960@;W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!U;FET
M<R!W87,@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E>'0M9&5C;W)A=&EO
M;CIN;VYE.SXD,3`N-"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!W:&EC:"!I<R!E
M>'!E8W1E9"!T;R!B92!R96-O9VYI>F5D(&]V97(@82!W96EG:'1E9"UA=F5R
M86=E('!E<FEO9"!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.V-O;&]R.B,P,#`P,#`[=&5X="UD
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M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5A<FYI;F=S
M(%!E<B!3:&%R92P@4&]L:6-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ
M,C`E.W1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HT.'!X.V9O;G0M<VEZ
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M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q
M.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A
M.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O
M4VAE970R-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE
M<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y38VAE9'5L92!O9B!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!3=&]C
M:R!/<'1I;VYS+"!686QU871I;VX@07-S=6UP=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^/&1I=B!S='EL93TS
M1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT
M.C0X<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/"]F;VYT/CPO9&EV/CQD:78@
M<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O;G0M<VEZ93HQ,'!T.SX\9&EV
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN
M92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MW:61T:#HQ,#`E
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M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
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M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E
M;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I
M;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SY%;7!L;WEE97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C8V)3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.G1O<#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^,2XR)3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.G1O<#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS
M<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1'9E<G1I8V%L+6%L:6=N.G1O<#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXP/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P
M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+7)I9VAT.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/B4\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT
M<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T.C)P>#MP
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M:&5R:70[9F]N="US:7IE.C$P<'0[/D1E8V5M8F5R(#,Q+"`R,#$S.CPO9F]N
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ=&]P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E
M;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N
M=&5R.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M
M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.G1O<#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R
M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SY%;7!L;WEE
M97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIT;W`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT
M;W`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C`\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN
M9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M/"]T9#X\+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/D1E8V5M8F5R(#,Q+"`R,#$R.CPO9F]N=#X\+V1I=CX\+W1D
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M,T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z
M,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M
M<VEZ93HQ,'!T.SY%;7!L;WEE97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M+W1R/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ=&]P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E
M;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIT;W`[<&%D9&EN9RUL969T
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M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!A;F0@26YV97-T
M;65N=',@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!A
M;F0@26YV97-T;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!#87-H+"!#87-H
M($5Q=6EV86QE;G1S(&%N9"!3:&]R="UT97)M($EN=F5S=&UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@
M<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ8V5N=&5R.W1E
M>'0M:6YD96YT.C0X<'@[9F]N="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN
M;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.VUA<F=I;BUL969T.F%U=&\[;6%R
M9VEN+7)I9VAT.F%U=&\[=VED=&@Z-CDP<'@[8F]R9&5R+6-O;&QA<'-E.F-O
M;&QA<'-E.W1E>'0M86QI9VXZ;&5F=#LG/CQT<CX\=&0@8V]L<W!A;CTS1#$V
M(')O=W-P86X],T0Q/CPO=&0^/"]T<CX\='(^/'1D('=I9'1H/3-$,S`V<'@@
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R
M.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/D%S(&]F($1E
M8V5M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$
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M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H
M=#IB;VQD.SY'<F]S<R!5;G)E86QI>F5D($=A:6YS/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T
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M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR
M<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E
M;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@8V]L<W!A;CTS1#<@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HY<'0[9F]N="UW96EG:'0Z8F]L9#L^
M*&EN('1H;W5S86YD<RD\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X
M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L
M;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S='EL93TS1'9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.CEP
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HY<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^,3,W+#(V-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@
M9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@<F]W
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C
M;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O
M=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG
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M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.R<@
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF
M(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D
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M;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
M861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP
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M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M;W1T;VT[<&%D9&EN9RUL969T.C(P<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SY5+E,N('1R96%S=7)Y('-E8W5R:71I97,\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T1V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR,#$L
M-3@T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C
M;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO
M=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE
M(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(P,BPQ
M,S8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE
M87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE
M(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C,\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U
M;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
M861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[
M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z
M,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
M,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@V-CPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M<FEG:'0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
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M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`R+#`W,SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\
M+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^5&]T86P@8V%S:"!A;F0@8V%S:"!E<75I=F%L
M96YT<R!A;F0@:6YV97-T;65N=',\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X
M(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C,S.2PT,#(\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP
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M<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D
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M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXH-C8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M<FEG:'0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
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M;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
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M;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,S,Y+#,S.3PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N
M=#X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I=CX\9&EV('-T
M>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU<W1I9GD[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@<W1Y
M;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M
M:6YD96YT.C0X<'@[9F]N="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P861D
M:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M
M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.VUA<F=I;BUL969T.F%U=&\[;6%R9VEN
M+7)I9VAT.F%U=&\[=VED=&@Z-CDP<'@[8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.W1E>'0M86QI9VXZ;&5F=#LG/CQT<CX\=&0@8V]L<W!A;CTS1#$V(')O
M=W-P86X],T0Q/CPO=&0^/"]T<CX\='(^/'1D('=I9'1H/3-$,S`V<'@@<F]W
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0Q-2!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY!<R!O9B!$96-E;6)E
M<B`S,2P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
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M<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG
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M="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
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M='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
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M<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B
M;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
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M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q,CL\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D
M;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
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M97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C.#(Q,CL\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M
M8V]L;W(Z(V-C965F9CLG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
M965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P
M>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
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M;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C,W+#0Y.3PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T1V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N
M/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR
M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R
M9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#$\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS
M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/CDQ+#8R-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P
M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
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M<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
M965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P
M>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
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M8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B
M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#$\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG
M<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+7)I9VAT.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BD\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C
M:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CDQ+#8R.3PO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R
M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO
M<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S
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M;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U
M8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$R.2PQ,C8\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A
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M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P
M,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P
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M=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M
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M8FQE(",P,#`P,#`[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
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M(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O
M;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ,CDL,3(X
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^
M/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X
M7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T,CDN:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U
M<F5M96YT<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A:7(@5F%L=64L(&)Y($)A;&%N8V4@4VAE970@1W)O=7!I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N="US:7IE.C$P<'0[
M/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT.C!P
M>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE
M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0Q-2!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
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M<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E
M;G1E<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY,979E
M;"`S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
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M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
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M-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT
M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/C,S."PW.#<\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C
M,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT
M<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A
M9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/C4U,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
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M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F
M9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D
M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)B,X,C$R.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
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M9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F
M9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D
M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S
M;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M,S,Y+#,S.3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$
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M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR
M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R
M9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$W+#8S.#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
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M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P
M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG
M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D
M;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE
M87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R
M;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z
M:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R
M9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P
M,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/C$W+#8S.#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U
M8FQE(",P,#`P,#`[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ
M-RPV,S@\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P
M.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C
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M92\^/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[;&EN92UH96EG
M:'0Z;F]R;6%L.W!A9&1I;F<M=&]P.C$P<'@[/CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&-O;'-P86X],T0Q-2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG
M+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[
M)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([
M9F]N="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HY<'0[9F]N="UW96EG:'0Z8F]L9#L^07,@;V8@1&5C
M96UB97(@,S$L(#(P,3,\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@
M<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M
M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
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M<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
M<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY,979E;"`S
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF
M(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!C;VQS<&%N/3-$,R!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@
M<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXY,2PV,CD\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS
M1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS
M1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
M9F8[<&%D9&EN9RUL969T.C(P<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B
M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,3(X
M+#4W-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
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M8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B
M;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-34R
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@
M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C
M,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S@R,3([
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@
M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C
M,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ,CDL,3(X
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R
M/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O
M;'-P86X],T0S('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
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M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C
M.#(Q,CL\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[
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M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M93HQ,'!T.SXR-RPW,3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
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M;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
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M>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D
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M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG
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M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P
M>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H
M=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S@R,3([/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@
M8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X
M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L
M;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C
M,#`P,#`P.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B8C.#(Q,CL\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X
M(&1O=6)L92`C,#`P,#`P.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[
M)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO
M;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L
M:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X]
M,T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I
M;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,C<L-S$P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C-P>"!D;W5B;&4@(S`P
M,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U
M8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O
M<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(W+#<Q,#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^
M/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92P@
M3&EA8FEL:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG($)A<VES+"!5;F]B
M<V5R=F%B;&4@26YP=70@4F5C;VYC:6QI871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^/&1I=B!S='EL93TS1&QI
M;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P
M<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT
M.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.VUA
M<F=I;BUL969T.F%U=&\[;6%R9VEN+7)I9VAT.F%U=&\[=VED=&@Z,3`P)3MB
M;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=&5X="UA;&EG;CIL969T.R<^/'1R
M/CQT9"!C;VQS<&%N/3-$-"!R;W=S<&%N/3-$,3X\+W1D/CPO='(^/'1R/CQT
M9"!W:61T:#TS1#@P)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,3@E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\+W1R
M/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD:78@
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
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M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M
M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C4U+#`S,SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C
M:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P
M,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#,U+#`P,#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<B`S,2P@,C`Q,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR.2PY
M,C`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S
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M<FET.V9O;G0M<VEZ93HQ,'!T.SXH,BPR,3`\+V9O;G0^/"]D:78^/"]T9#X\
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M96-E;6)E<B`S,2P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXR-RPW,3`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B@Q,2PU,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X
M('-O;&ED(",P,#`P,#`[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z
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M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$W+#8S.#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R
M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N
M=#X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\+V1I=CX\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@Q83@R
M-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8PT*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D
M,#4S8V9C96,O5V]R:W-H965T<R]3:&5E=#,P+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N
M="`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY0<F]P97)T>2!A;F0@17%U:7!M96YT(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^/&1I=B!S='EL93TS1&QI
M;F4M:&5I9VAT.C$R,"4[9F]N="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P
M861D:6YG+6QE9G0Z,'!X.W1E>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN
M;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0W('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S
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M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
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M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE
M9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D
M9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HY<'0[9F]N="UW96EG:'0Z
M8F]L9#L^,C`Q-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH
M:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E
M:6=H=#IB;VQD.SXR,#$S/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M.#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M;VYT+7-I>F4Z,3!P=#L^,34M-#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SY,86YD/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,X,C$R
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#LG(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P
M>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^,BPV-C0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB
M<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT
M9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C(P<'@[<&%D9&EN9RUT;W`Z,G!X
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#,V
M+#(W-#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
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M(S`P,#`P,#MP861D:6YG+7)I9VAT.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
M:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF
M(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^,2PP.#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ
M-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CLG
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M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P
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M>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/C0Q+#,V,CPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F
M.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N
M;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/"]D
M:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R
M7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE
M<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY);F-O;64@5&%X97,@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O
M9B!$969E<G)E9"!487@@07-S971S(&%N9"!,:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT+69A
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M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=VED=&@Z,3`P)3MB
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M;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT
M97([9F]N="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HY<'0[9F]N="UW96EG:'0Z8F]L9#L^07,@;V8@
M1&5C96UB97(@,S$L/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P
M,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED
M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
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M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M9F8[<&%D9&EN9RUL969T.C(X<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
M=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-"PW-C`\+V9O;G0^/"]D:78^
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M>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D
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M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E
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M<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
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M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
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M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
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M>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
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M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#0Q,BPT,C,\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUR
M:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@S
M-S8L-C$Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P
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M+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
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M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C
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M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P
M,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUR:6=H=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X]
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M;3HT<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
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M;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N
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M.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O
M;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/"]T86)L
M93X\+V1I=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3D4^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1&5B="!/8FQI9V%T:6]N<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$96)T($EN<W1R=6UE;G0\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H
M961U;&4@;V8@36%T=7)I=&EE<R!O9B!,;VYG+71E<FT@1&5B=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT+69A
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M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=VED=&@Z,3`P)3MB
M;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=&5X="UA;&EG;CIL969T.R<^/'1R
M/CQT9"!C;VQS<&%N/3-$-"!R;W=S<&%N/3-$,3X\+W1D/CPO='(^/'1R/CQT
M9"!W:61T:#TS1#@R)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CQT
M9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,38E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^/'1D
M('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\+W1R
M/CQT<CX\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HY<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T
M.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X
M('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,3X\9&EV('-T
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR,#$U/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
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M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`Q
M-CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/C(L,#$U/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S
M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB
M<B!C;&5A<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT
M9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/C(P,3<\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SY4:&5R96%F=&5R/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M
M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.C$P<'0[/C@W+#4P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\
M='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U
M;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&]T86P@9&5B=#PO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,3`W+#8V-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS
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M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#(P+#$V-SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+7)I9VAT.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M
M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
M>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^5&]T86P@;&]N9RUT97)M(&1E8G0\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^.#<L-3`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D
M;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[)R!R;W=S
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M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q
M.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A
M.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O
M4VAE970S,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U
M;&4@;V8@1G5T=7)E($UI;FEM=6T@4F5N=&%L(%!A>6UE;G1S(&9O<B!/<&5R
M871I;F<@3&5A<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.V9O
M;G0M<VEZ93HQ,'!T.SX\9&EV('-T>6QE/3-$<&%D9&EN9RUL969T.C!P>#MT
M97AT+6EN9&5N=#HP<'@[;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F<M=&]P
M.C$P<'@[/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MW:61T:#HQ,#`E.V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MT
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M;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE
M9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D
M9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
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M96-E;6)E<B`S,3PO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL
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M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ+#`W
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M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`Q
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^
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M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C(P<'@[<&%D9&EN9RUT;W`Z
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M+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG<F]U;F0M
M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M
M8F]T=&]M.C-P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C
M8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
M;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^,RPX-S8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O
M=6)L92`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\
M+W1R/CPO=&%B;&4^/"]D:78^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?
M8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS
M:&5E=',O4VAE970S-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D5Q=6ET>2!);F-E;G1I=F4@07=A<F1S("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D5Q=6ET>2!);F-E;G1I=F4@07=A<F1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@
M4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3=&]C:R!/<'1I;VYS+"!!8W1I
M=FET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
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M=VED=&@Z,3`P)3MB;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[=&5X="UA;&EG
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M97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O
M=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[
M9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SXR,#$T/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
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M(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HY<'0[9F]N="UW96EG:'0Z
M8F]L9#L^,C`Q,CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@
M<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D
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M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG
M(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD.SY/<'1I;VYS/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG
M:'0Z,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/E=E
M:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL
M969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A
M9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV
M('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N
M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[
M/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@
M<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X]
M,T0S('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T
M=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z
M(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG
M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(S+#,P-CPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
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M;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXD/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^,BXT,CPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US
M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF
M;VYT+7-I>F4Z,3!P=#L^,C$L-3(U/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXR+C4Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K
M9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG
M+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR
M,"PT-S8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB
M86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M=&]P.C)P>#MP
M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
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M9"`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
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M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C0L-3`R/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!R;W=S<&%N
M/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN
M:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,BXQ,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@
M<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\
M8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T.C)P>#MP861D
M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z
M,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E
M<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B8C,38P.SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O
M='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL
M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C,L-#0Q
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A
M<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH
M:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/C$N-#8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4]
M,T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E
M969F.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS
M1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXH-3<R/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+7)I9VAT.C)P>#MP
M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$
M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O
M;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R
M:70[9F]N="US:7IE.C$P<'0[/BD\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
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M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z
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M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.V)A8VMG<F]U;F0M8V]L;W(Z(V-C
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
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M;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
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M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MB86-K9W)O
M=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE
M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT
M+7-I>F4Z,3!P=#L^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N
M/3-$,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ
M,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR
M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ+CDT
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CL@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C
M:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B@U,C4\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I;F<M<FEG:'0Z
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X
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M;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I
M9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS
M1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O
M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C(S+#,P-CPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[)R!R;W=S<&%N
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M
M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
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M,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN
M9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^
M,C$L-3(U/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P
M,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$
M;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A
M;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E
M;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II
M;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXR+C4Q/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!R;W=S
M<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY
M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A<CTS1&YO;F4O/CPO
M9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\
M9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P
M<'0[/D5X97)C:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG<F]U
M;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O
M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1O=F5R9FQO=SIH
M:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D
M97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.V)O<F1E<BUT;W`Z-'!X(&1O=6)L92`C,#`P,#`P
M.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,38L.3(Q/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB;W)D97(M8F]T=&]M.C1P>"!D;W5B;&4@(S`P,#`P,#MB86-K9W)O=6YD
M+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HT<'@@9&]U8FQE(",P,#`P,#`[
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M8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C1P>"!D;W5B;&4@(S`P
M,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/C$W+#,W.#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[8F]R9&5R+6)O='1O;3HT<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R
M;W5N9"UC;VQO<CHC8V-E969F.V)O<F1E<BUT;W`Z-'!X(&1O=6)L92`C,#`P
M,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(]
M,T1N;VYE+SX\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC8V-E969F.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V
M97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U
M;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P
M.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HT<'@@9&]U8FQE
M(",P,#`P,#`[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y
M;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXQ-2PU
M.#(\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ-'!X(&1O=6)L92`C,#`P,#`P.V)A
M8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C1P>"!D;W5B;&4@
M(S`P,#`P,#LG(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
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M>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O;&]R
M.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O
M;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF
M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P
M=#L^,BXW-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L
M+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P
M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ
M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F
M;VYT/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CPO9&EV/CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V-H961U;&4@;V8@3F]N=F5S=&5D(%)E<W1R:6-T960@4W1O8VL@56YI
M=',@06-T:79I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[9F]N
M="US:7IE.C$P<'0[/CQD:78@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!X.W1E
M>'0M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z
M,3!P>#L^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
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M:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z
M.7!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US
M:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1&]V97)F
M;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[
M<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T
M;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS1#$^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HY<'0[/CQF;VYT
M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.7!T.V9O
M;G0M=V5I9VAT.F)O;&0[/E-H87)E<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR
M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1O=F5R9FQO=SIH:61D96X[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C
M,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M.FEN:&5R:70[9F]N="US:7IE.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,2PV
M,#0\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE
M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L
M96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@
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M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3MB;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M:60@(S`P,#`P,#MP861D:6YG+7)I9VAT.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^
M/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ
M,'!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M<'0[/DYO;G9E<W1E9"!A="!$96-E;6)E<B`S,2P@,C`Q-#PO9F]N=#X\+V1I
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M8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C:V=R;W5N9"UC
M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
M.W!A9&1I;F<M8F]T=&]M.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P.R<@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,RPQ,S$\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.V)O<F1E<BUB;W1T;VTZ,W!X(&1O=6)L92`C,#`P,#`P.V)A8VMG<F]U
M;F0M8V]L;W(Z(V-C965F9CMB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y
M-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F
M8V5C+U=O<FMS:&5E=',O4VAE970S-2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-E;&5C=&5D(%%U87)T97)L>2!&:6YA;F-I
M86P@1&%T82`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY396QE8W1E9"!1=6%R=&5R;'D@1FEN86YC
M:6%L($1A=&$@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y396QE8W1E9"!1=6%R=&5R;'D@1FEN86YC:6%L
M($1A=&$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y
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M.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,C`Q
M-#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO<CHC,#`P,#`P.W1E
M>'0M9&5C;W)A=&EO;CIN;VYE.SXR,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$
M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^.CPO9F]N=#X\
M+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N
M.FIU<W1I9GD[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CQD:78@<W1Y;&4],T1L:6YE+6AE:6=H=#HQ,C`E.W1E>'0M86QI9VXZ
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M.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`Z,3!P>#L^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W=I
M9'1H.C$P,"4[8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W1E>'0M86QI9VXZ
M;&5F=#LG/CQT<CX\=&0@8V]L<W!A;CTS1#$V(')O=W-P86X],T0Q/CPO=&0^
M/"]T<CX\='(^/'1D('=I9'1H/3-$-#$E(')O=W-P86X],T0Q(&-O;'-P86X]
M,T0Q/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/"]T9#X\=&0@=VED=&@],T0Q,B4@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CPO=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/"]T9#X\=&0@=VED=&@],T0Q,B4@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^
M/"]T9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\
M+W1D/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO
M=&0^/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T
M9#X\=&0@=VED=&@],T0Q,B4@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T
M9#X\=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D
M/CQT9"!W:61T:#TS1#$E(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CPO=&0^
M/'1D('=I9'1H/3-$,24@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0Q,B4@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/"]T9#X\
M=&0@=VED=&@],T0Q)2!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\+W1D/CPO
M='(^/'1R/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D
M:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR
M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.7!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.CEP=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0Q
M-2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O
M;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M
M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.F-E;G1E<CMF;VYT+7-I>F4Z.7!T.SX\9F]N="!S='EL93TS1&9O;G0M
M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CEP=#MF;VYT+7=E:6=H=#IB;VQD
M.SY1=6%R=&5R($5N9&5D/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D
M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HY
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/DUA<F-H(#,Q/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O
M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R<@
M<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M<VEZ93HY<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/DIU;F4@,S`\+V9O
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M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A
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M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z
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M8F]T=&]M.V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[<&%D9&EN
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0W('-T
M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[
M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M<VEZ93HY
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z.7!T.V9O;G0M=V5I9VAT.F)O;&0[/BA5;F%U9&ET960I/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1&]V97)F;&]W.FAI9&1E;CMF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L<W!A;CTS
M1#,@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUL969T
M.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I
M;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIC96YT97([9F]N="US:7IE.CEP=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HY<'0[/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N
M.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D
M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.W1E>'0M9&5C;W)A
M=&EO;CIU;F1E<FQI;F4[/C(P,30\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN
M9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF
M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE
M<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[(')O=W-P86X],T0Q
M(&-O;'-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N
M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I
M=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M;VQO<CHC8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X
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M97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
M>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT
M+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@
M<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT/CPO9&EV/CPO
M=&0^/"]T<CX\='(^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M
M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#`N
M,#8\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
M9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O
M;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T
M.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A
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M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z
M,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P
M<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I
M>F4Z,3!P=#L^*#`N,#4\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y;&4],T1V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUR:6=H=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L
M<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I
M>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O
M;G0M<VEZ93HQ,'!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$
M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN
M9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG+7)I9VAT.C)P
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M<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS
M1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH
M97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#`N,#@\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUR:6=H
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W
M<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL
M>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F
M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
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M=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D
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M969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#MP861D:6YG+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS
M1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P
M=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[=&5X="UD96-O<F%T:6]N.G5N9&5R
M;&EN93L^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S
M='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z,G!X
M.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR
M:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI
M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I
M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
M+7)I9VAT.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A
M;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@<W1Y;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$
M,R!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN
M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF
M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO
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M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXS-C`\+V9O
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M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE
M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D
M9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T
M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O
M='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D9&EN9RUT;W`Z,G!X
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M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP861D:6YG
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M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M9&EN9RUR:6=H=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F
M;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXI/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A
M9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M
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M97)T:6-A;"UA;&EG;CIB;W1T;VT[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M
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M="US:7IE.C$P<'0[/B@R.2PP.#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
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M;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P
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M9F]N="US:7IE.C$P<'0[/B@P+C`U/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T
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M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
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M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@P+C`V/"]F;VYT/CPO9&EV
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M,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT
M;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$@8V]L<W!A
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M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B@P+C`V
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M=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F<M;&5F=#HR
M<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#L@<F]W<W!A
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M.C$P<'0[/B@P+C`S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R
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M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I;F<M8F]T=&]M.C)P>#MP
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M8V-E969F.W!A9&1I;F<M;&5F=#HR<'@[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I
M;F<M8F]T=&]M.C)P>#L@<F]W<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N
M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-3$S+#`X,SPO9F]N
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M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CMP861D:6YG+6QE9G0Z
M,G!X.W!A9&1I;F<M=&]P.C)P>#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P
M86X],T0Q/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.V9O;G0M<VEZ
M93HQ,'!T.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N
M="US:7IE.C$P<'0[/C4Q,RPT,3D\+V9O;G0^/"]D:78^/"]T9#X\=&0@<W1Y
M;&4],T1V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F%C:V=R;W5N9"UC;VQO<CHC
M8V-E969F.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.V9O;G0M<VEZ93HQ,'!T.SX\9F]N="!S='EL93TS
M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/CQB<B!C;&5A
M<CTS1&YO;F4O/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E<G1I
M8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[<&%D
M9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ
M,G!X.W!A9&1I;F<M<FEG:'0Z,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$
M,3X\9&EV('-T>6QE/3-$;W9E<F9L;W<Z:&ED9&5N.V9O;G0M<VEZ93HQ,'!T
M.SX\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE
M.C$P<'0[/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1'9E<G1I8V%L+6%L:6=N.F)O='1O;3MB86-K9W)O=6YD+6-O
M;&]R.B-C8V5E9F8[<&%D9&EN9RUL969T.C)P>#MP861D:6YG+71O<#HR<'@[
M<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4]
M,T1F;VYT+69A;6EL>3II;FAE<FET.V9O;G0M<VEZ93HQ,'!T.SXU,3,L-3(S
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.V)A8VMG<F]U;F0M8V]L;W(Z(V-C965F9CL@<F]W<W!A;CTS1#$@
M8V]L<W!A;CTS1#$^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MF;VYT
M+7-I>F4Z,3!P=#L^/&9O;G0@<W1Y;&4],T1F;VYT+69A;6EL>3II;FAE<FET
M.V9O;G0M<VEZ93HQ,'!T.SX\8G(@8VQE87(],T1N;VYE+SX\+V9O;G0^/"]D
M:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/"]D:78^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y
M-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F
M8V5C+U=O<FMS:&5E=',O4VAE970S-BYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<R!297-T<FEC=&5D($-A<V@@86YD($EN=F5S=&UE
M;G1S("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5S=')I8W1E9"!#87-H
M(&%N9"!#87-H($5Q=6EV86QE;G1S($ET96US/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@:6YV97-T;65N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#,P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,S`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@Q83@R
M-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8PT*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D
M,#4S8V9C96,O5V]R:W-H965T<R]3:&5E=#,W+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2D5!
M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,@0V]N8V5N=')A=&EO;B!O9B!#<F5D
M:70@4FES:R`H1&5T86EL<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;F-E;G1R871I;VX@4FES:SPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C
M;&]S=7)E($]N($=E;V=R87!H:6,@07)E87,@4F5V96YU92!&<F]M($5X=&5R
M;F%L($-U<W1O;65R<R!!='1R:6)U=&5D('1O($9R86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.30N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C;&]S=7)E(&]N($=E
M;V=R87!H:6,@07)E87,L(%)E=F5N=64@9G)O;2!%>'1E<FYA;"!#=7-T;VUE
M<G,@071T<FEB=71E9"!T;R!%;G1I='DG<R!#;W5N=')Y(&]F($1O;6EC:6QE
M+"!097)C96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C
M96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P
M9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970S."YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14Q*04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M
M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%-E9VUE
M;G0@26YF;W)M871I;VX@86YD(%-I9VYF:6-A;G0@0W5S=&]M97)S("A$971A
M:6QS*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4F5V96YU92P@36%J;W(@0W5S=&]M97(\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%=I9&4@
M4F5V96YU92!)<'-E;B!097)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY-"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2U7:61E(%)E=F5N=64L($UC3F%I
M<B!-961I8V%L($EN<W1I='5T92P@4&5R8V5N=&%G93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3<N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='DM5VED92!2979E;G5E
M+"!486-O;FEC($9A<FUS+"!097)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV."XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2U7:61E(%)E=F5N
M=64L($1E;'1A9V5N+"!097)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,4M!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@4W1O
M8VLM0F%S960@0V]M<&5N<V%T:6]N("A$971A:6QS(#$I("A3=&]C:R!/<'1I
M;VXI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VL@3W!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M
M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@
M07=A<F0L($9A:7(@5F%L=64@07-S=6UP=&EO;G,L($5X<&5C=&5D(%9O;&%T
M:6QI='E2871E+"!%;7!L;WEE97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8V+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDS+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A
M<F0L($9A:7(@5F%L=64@07-S=6UP=&EO;G,L(%)I<VL@1G)E92!);G1E<F5S
M="!2871E+"!%;7!L;WEE93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2XR,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP+CDP)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`N.#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@
M07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@1F%I
M<B!686QU92!!<W-U;7!T:6]N<RP@17AP96-T960@5&5R;2P@16UP;&]Y965S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N
M="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!&86ER(%9A;'5E($%S
M<W5M<'1I;VYS+"!%>'!E8W1E9"!$:79I9&5N9"!2871E+"!%;7!L;WEE97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($9A:7(@5F%L=64@07-S=6UP=&EO
M;G,L($5X<&5C=&5D(%9O;&%T:6QI='D@4F%T92P@3V9F:6-E<G,@86YD($YO
M;BUE;7!L;WEE92!$:7)E8W1O<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@Q+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@Q+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A
M<F0L($9A:7(@5F%L=64@07-S=6UP=&EO;G,L(%)I<VL@1G)E92!);G1E<F5S
M="!2871E+"!/9F9I8V5R<R!A;F0@3F]N+65M<&QO>65E($1I<F5C=&]R<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BXS,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C8P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-3`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA
M<F4M8F%S960@4&%Y;65N="!!=V%R9"P@1F%I<B!686QU92!!<W-U;7!T:6]N
M<RP@17AP96-T960@5&5R;2P@3V9F:6-E<G,@86YD($YO;BUE;7!L;WEE92!$
M:7)E8W1O<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C@@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XX('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^."!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R
M<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($9A:7(@
M5F%L=64@07-S=6UP=&EO;G,L($5X<&5C=&5D($1I=FED96YD(%)A=&4L($]F
M9FEC97)S(&%N9"!.;VXM96UP;&]Y964@1&ER96-T;W)S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1T<^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S(%-T;V-K+6)A<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL
M<R`R*2`H55-$("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N+"!!;&QO8V%T:6]N(&]F(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M
M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!.;VYV
M97-T960@07=A<F1S+"!4;W1A;"!#;VUP96YS871I;VX@0V]S="!.;W0@>65T
M(%)E8V]G;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3`N-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I
M;VXL($]U='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!6
M97-T:6YG(%!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,2!Y96%R(#0@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C
M96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P
M9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970T,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P151-0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V%S
M:"!A;F0@0V%S:"!%<75I=F%L96YT<R!A;F0@26YV97-T;65N=',@*$1E=&%I
M;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E86QI>F5D
M($EN=F5S=&UE;G0@1V%I;G,@*$QO<W-E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@86YD($-A<V@@17%U:79A
M;&5N=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^079A:6QA8FQE+69O<BUS86QE(%-E8W5R:71I97,L($%M;W)T:7IE9"!#
M;W-T($)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S<L
M,C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S<L-#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<RP@1W)O
M<W,@56YR96%L:7IE9"!'86EN($%C8W5M=6QA=&5D(&EN($EN=F5S=&UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^079A:6QA8FQE
M+69O<BUS86QE(%-E8W5R:71I97,L($=R;W-S(%5N<F5A;&EZ960@3&]S<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^079A:6QA8FQE
M+69O<BUS86QE(%-E8W5R:71I97,L($-U<G)E;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$S-RPR-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-RPT.3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-E<G1I9FEC871E<R!O
M9B!$97!O<VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<SPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A
M;&4@4V5C=7)I=&EE<RP@06UO<G1I>F5D($-O<W0@0F%S:7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^079A:6QA8FQE+69O<BUS
M86QE(%-E8W5R:71I97,L($=R;W-S(%5N<F5A;&EZ960@1V%I;B!!8V-U;75L
M871E9"!I;B!);G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%V86EL86)L92UF;W(M<V%L92!396-U<FET:65S+"!'<F]S
M<R!5;G)E86QI>F5D($QO<W-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%V86EL86)L92UF;W(M<V%L92!396-U<FET:65S+"!#=7)R
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E53
M(%1R96%S=7)Y(%-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V86EL
M86)L92UF;W(M<V%L92!396-U<FET:65S+"!!;6]R=&EZ960@0V]S="!"87-I
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`Q+#4X-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ+#`W
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^079A:6QA8FQE+69O<BUS86QE(%-E8W5R:71I97,L($=R;W-S(%5N<F5A
M;&EZ960@1V%I;B!!8V-U;75L871E9"!I;B!);G9E<W1M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V86EL86)L92UF;W(M<V%L
M92!396-U<FET:65S+"!'<F]S<R!5;G)E86QI>F5D($QO<W-E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V86EL86)L92UF;W(M
M<V%L92!396-U<FET:65S+"!#=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,#$L-3(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3$L,#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&]R="UT97)M($EN=F5S=&UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A;&4@4V5C
M=7)I=&EE<RP@06UO<G1I>F5D($-O<W0@0F%S:7,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P,BPQ,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,2PV,C<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V86EL86)L92UF;W(M
M<V%L92!396-U<FET:65S+"!'<F]S<R!5;G)E86QI>F5D($=A:6X@06-C=6UU
M;&%T960@:6X@26YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<RP@1W)O
M<W,@56YR96%L:7IE9"!,;W-S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#8V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<RP@
M0W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`R+#`W
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDQ+#8R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!A;F0@26YV97-T
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V86EL86)L92UF;W(M<V%L92!3
M96-U<FET:65S+"!!;6]R=&EZ960@0V]S="!"87-I<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S,Y+#0P,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.2PQ,C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V86EL86)L92UF
M;W(M<V%L92!396-U<FET:65S+"!'<F]S<R!5;G)E86QI>F5D($=A:6X@06-C
M=6UU;&%T960@:6X@26YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<RP@
M1W)O<W,@56YR96%L:7IE9"!,;W-S97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE
M<RP@0W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M,SDL,S,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,CDL,3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C
M96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P
M9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970T,BYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15=/04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^1F%I
M<B!686QU92!-96%S=7)E;65N=',@*$1E=&%I;',@,2D@*%531"`D*3QB<CY)
M;B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M(%9A;'5E+"!,979E;"`Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN
M9RP@1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<SPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q
M=6EV86QE;G1S+"!&86ER(%9A;'5E($1I<V-L;W-U<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3,W+#(V-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S<L-#DY/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!=F%I;&%B
M;&4M9F]R+7-A;&4@4V5C=7)I=&EE<RP@1F%I<B!686QU92!$:7-C;&]S=7)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#$L-3(Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$L,#<W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G9E<W1M96YT<RP@1F%I<B!686QU92!$:7-C;&]S=7)E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S@L-S@W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(X+#4W-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M3&EA8FEL:71I97,L($9A:7(@5F%L=64@1&ES8VQO<W5R93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET:65S+"!&86ER(%9A
M;'5E($1I<V-L;W-U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&86ER(%9A;'5E+"!,979E;"`R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E
M="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N
M9"!#87-H($5Q=6EV86QE;G1S+"!&86ER(%9A;'5E($1I<V-L;W-U<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R
M+7-A;&4@4V5C=7)I=&EE<RP@1F%I<B!686QU92!$:7-C;&]S=7)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G1S
M+"!&86ER(%9A;'5E($1I<V-L;W-U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W1H97(@3&EA8FEL:71I97,L($9A:7(@5F%L
M=64@1&ES8VQO<W5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQI86)I;&ET:65S+"!&86ER(%9A;'5E($1I<V-L;W-U<F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E+"!,979E
M;"`S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L
M(%-T871E;65N="!#87!T:6]N<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S+"!&
M86ER(%9A;'5E($1I<V-L;W-U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<RP@1F%I
M<B!686QU92!$:7-C;&]S=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YV97-T;65N=',L($9A:7(@5F%L=64@1&ES8VQO<W5R93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R($QI86)I
M;&ET:65S+"!&86ER(%9A;'5E($1I<V-L;W-U<F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W+#8S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(W+#<Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EA8FEL:71I97,L($9A
M:7(@5F%L=64@1&ES8VQO<W5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3<L-C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C<L-S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E+"!4;W1A;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L
M($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@
M0V%P=&EO;G,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<RP@1F%I<B!686QU92!$
M:7-C;&]S=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S<L
M,C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S<L-#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<RP@1F%I
M<B!686QU92!$:7-C;&]S=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,#(L,#<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.3$L-C(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT<RP@1F%I<B!686QU92!$
M:7-C;&]S=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,SDL
M,S,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(Y+#$R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W1H97(@3&EA8FEL:71I97,L($9A:7(@5F%L=64@1&ES
M8VQO<W5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L-C,X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C<L-S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,:6%B:6QI=&EE<RP@1F%I<B!686QU92!$:7-C;&]S=7)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W+#8S.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<L-S$P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X
M,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q
M9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970T,RYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M.
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E
M;65N=',@*$1E=&%I;',@,BD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@3&EA8FEL
M:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG($)A<VES+"!5;F]B<V5R=F%B
M;&4@26YP=70@4F5C;VYC:6QI871I;VX\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YC<F5A<V4@*&1E8W)E87-E*2!I;B!F
M86ER('9A;'5E(&]F(%-Y;7!H;VYY($EC;VXL($EN8RX@<'5R8VAA<V4@;&EA
M8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-#(X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@R+#(Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#DL.#@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E+"!-96%S=7)E;65N="!W:71H
M(%5N;V)S97)V86)L92!);G!U=',@4F5C;VYC:6QI871I;VXL(%)E8W5R<FEN
M9R!"87-I<RP@3&EA8FEL:71Y+"!'86EN("A,;W-S*2!);F-L=61E9"!I;B!%
M87)N:6YG<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M+#(Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY+#@X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F%I<B!686QU92P@365A<W5R96UE;G0@=VET:"!5;F]B
M<V5R=F%B;&4@26YP=71S(%)E8V]N8VEL:6%T:6]N+"!296-U<G)I;F<@0F%S
M:7,L($QI86)I;&ET>2P@4V5T=&QE;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$Q+#4P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E+"!-96%S
M=7)E;65N="!W:71H(%5N;V)S97)V86)L92!);G!U=',@4F5C;VYC:6QI871I
M;VYS+"!296-U<G)I;F<@0F%S:7,L($QI86)I;&ET>2!686QU93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RPV,S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W+#<Q,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,CDL
M.3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`U-2PP,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%-4<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^07-S971S($AE
M;&0@9F]R(%-A;&4@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E=',@
M2&5L9"!F;W(@4V%L92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<V5T<R!(96QD+69O<BUS86QE+"!,
M;VYG($QI=F5D+"!&86ER(%9A;'5E($1I<V-L;W-U<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,C,L.#0Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?
M8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS
M:&5E=',O4VAE970T-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P155(04<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0Q/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H1&5T86EL<R`Q
M*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE
M;G0\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,W+#,U-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(S+#,P-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M=6UU;&%T960@1&5P<F5C:6%T:6]N+"!$97!L971I;VX@86YD($%M;W)T:7IA
M=&EO;BP@4')O<&5R='DL(%!L86YT+"!A;F0@17%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BPR-S0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#$L.30U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R
M='DL(%!L86YT(&%N9"!%<75I<&UE;G0L($YE=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,2PS-C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!U=&5R<R!A;F0@4V]F
M='=A<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N=#PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@
M86YD($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDL-#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$L,3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&=7)N:71U<F4@86YD($9I>'1U<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R
M='DL(%!L86YT(&%N9"!%<75I<&UE;G0\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N9"!%<75I
M<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#`S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L,S$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,86)O<F%T;W)Y($5Q=6EP;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A
M;F0@17%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT+"!'<F]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-S,W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L.34R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,96%S96AO;&0@26UP<F]V96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I
M<&UE;G0\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0L($=R;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#$Q-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#DR/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"=6EL9&EN
M9W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0
M<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N=#PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD
M($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU.2PQ,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQA;F0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N=#PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P
M97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPV-C0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44@^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q
M/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H1&5T86EL<R`R*2`H
M55-$("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"=6EL9&EN9W,@4F5C;&%S<VEF:65D(%1O($AE;&0@1F]R(%-A;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3DN,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&%N9"!2
M96-L87-S:69I960@5&\@2&5L9"!&;W(@4V%L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BXW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!$97!R96-I871I;VX@
M4F5C;&%S<VEF:65D(%1O($AE;&0@1F]R(%-A;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%0D1!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY);F-O;64@5&%X97,@*$1E=&%I;',@,2D@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E
M9F5R<F5D(%1A>"!!<W-E=',@86YD($QI86)I;&ET:65S/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(%1A>"!!
M<W-E=',L($]P97)A=&EN9R!,;W-S($-A<G)Y9F]R=V%R9',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4U+#4Q.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,X+#8P.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@5&%X($%S<V5T<RP@5&%X($-R961I="!#87)R>69O<G=A<F1S+"!2
M97-E87)C:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`L,3<S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S<L-#4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!487@@07-S971S+"!);B!0<F]C97-S(%)E<V5A
M<F-H(&%N9"!$979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.34L.30V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#,L,S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!487@@07-S971S+"!487@@
M1&5F97)R960@17AP96YS92P@0V]M<&5N<V%T:6]N(&%N9"!"96YE9FET<RP@
M4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($-O<W0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<L-C0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPW,#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(%1A>"!!<W-E
M=',L($1E9F5R<F5D($EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PT-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#<V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@5&%X($%S<V5T<RP@3W1H97(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-C@Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PW,3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!487@@07-S971S+"!'<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#$R+#0R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,W-BPV,3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(%1A>"!,:6%B
M:6QI='D@4F5L871E9"!T;R!!8W%U:7-I=&EO;B!O9B!3>6UP:&]N>2!)8V]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."PV-S4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@L-S0U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(%1A>"!,:6%B:6QI=&EE<RP@1W)O<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$X+#8W-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."PW-#4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!487@@07-S971S+"!686QU871I;VX@06QL;W=A;F-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@T,3(L-#(S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W-BPV,3$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!487@@3&EA8FEL:71I97,L($YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@Q."PV-S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@Q."PW-#4I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X
M.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E
M=',O4VAE970T."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13-,04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^26YC;VUE(%1A>&5S("A$971A:6QS(#(I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D]T:&5R(%1A>"!);F9O<FUA=&EO;CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979I<VEO;B!T;R!$969E<G)E9"!4
M87@@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S
M+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E9A;'5A=&EO;B!!;&QO=V%N8V4L($1E9F5R<F5D(%1A>"!!
M<W-E="P@0VAA;F=E(&EN($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S4L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG($QO<W,@0V%R<GEF;W)W
M87)D<RP@1F5D97)A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S$U+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!,;W-S($-A<G)Y9F]R=V%R9',L(%-T
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-C`L,C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YC;VUE(%1A>"!%>'!E;G-E("A"96YE9FET*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@W,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A
M,3)?8C0X.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O
M<FMS:&5E=',O4VAE970T.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^1V]O9'=I;&P@*$1E=&%I;',I("A54T0@)"D\8G(^
M26X@36EL;&EO;G,L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,"P@,C`Q
M,#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#$R+"`R
M,#`Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D=O;V1W:6QL/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O96QA8V%N=&@@1V]O9'=I;&P\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C4N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]E;&%C86YT:"!0=7)C:&%S92!0
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-Y;7!H
M;VYY($EC;VX@1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3@N-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q
M,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T-3`N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5!4$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D1E8G0@3V)L
M:6=A=&EO;G,@*$1E=&%I;',@,2D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E8G0@26YS
M=')U;65N=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,;VYG+71E<FT@1&5B="P@36%T=7)I=&EE<RP@4F5P87EM96YT<R!O
M9B!0<FEN8VEP86P@:6X@3F5X="!4=V5L=F4@36]N=&AS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.#4Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@1&5B="P@
M36%T=7)I=&EE<RP@4F5P87EM96YT<R!O9B!0<FEN8VEP86P@:6X@665A<B!4
M=V\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#$U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG
M+71E<FT@1&5B="P@36%T=7)I=&EE<RP@4F5P87EM96YT<R!O9B!0<FEN8VEP
M86P@:6X@665A<B!4:')E93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,38L,CDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;VYG+71E<FT@1&5B="P@36%T=7)I=&EE<RP@4F5P87EM
M96YT<R!O9B!0<FEN8VEP86P@:6X@665A<B!&;W5R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@1&5B="P@36%T=7)I=&EE
M<RP@4F5P87EM96YT<R!O9B!0<FEN8VEP86P@:6X@665A<B!&:79E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@1&5B="P@
M36%T=7)I=&EE<RP@4F5P87EM96YT<R!O9B!0<FEN8VEP86P@869T97(@665A
M<B!&:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-RPU,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,;VYG+71E<FT@1&5B="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P-RPV-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M=&5R;2!$96)T+"!#=7)R96YT($UA
M='5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#$V
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,;VYG+71E<FT@1&5B="P@17AC;'5D:6YG($-U<G)E;G0@36%T
M=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X-RPU
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(P+#$V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q
M,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H965T-3$N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5&4D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E8G0@3V)L
M:6=A=&EO;G,@*$1E=&%I;',@,BD@*%531"`D*3QB<CY);B!-:6QL:6]N<RP@
M97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`P
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D1E8G0@26YS=')U;65N=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M($-O;G9E<G1I8FQE($1E
M8G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#<N-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M=F5R=&EB;&4@1&5B="!);G-T<G5M96YT($EN=&5R97-T(%)A=&4@4W1A=&5D
M(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N
M,C4E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$96)T($EN<W1R=6UE;G0L($-O;G9E<G1I8FQE+"!#;VYV97)S:6]N
M(%)A=&EO/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,CDN,3@W
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5B="!);G-T<G5M96YT+"!#;VYV97)T:6)L92P@0V]N=F5R<VEO;B!0
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C(P-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5B="!)<W-U86YC92!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E5N86UO<G1I>F5D($1E8G0@27-S=6%N8V4@17AP96YS93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T($EN<W1R
M=6UE;G0L($9A:7(@5F%L=64@1&ES8VQO<W5R93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=O;V1L86YD<R!-;W)T9V%G93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=O;V1L86YD<R!#87-H(%!A
M:60\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@
M26YS=')U;65N="P@26YT97)E<W0@4F%T92P@4W1A=&5D(%!E<F-E;G1A9V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@N,C,E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-;W)T9V%G
M92!,;V%N<R!O;B!296%L($5S=&%T92P@0V%R<GEI;F<@06UO=6YT(&]F($UO
M<G1G86=E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`N,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0G5I;&1I;F=S($-O;&QA=&5R86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4Y+C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQA;F0@0V]L;&%T97)A;#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%6D)!23X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY!<G)A;F=E;65N=',@=VET:"!3>6UP:&]N>2!)8V]N+"!);F,N("A$971A
M:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`P-"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,"P@,C`Q,#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#$U+"`R,#`W/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQO
M<W,@0V]N=&EN9V5N8VEE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y(;VQD:6YG<R!#;VYT<FEB=71I;VX@5&\@26-O;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-2PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M97AI8V]N(%-O;&0@4VAA<F5S(%1O($AO;&1I;F=S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#8U,"PV,C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE>&EC;VX@4F5C96EV960@
M0V%S:"!&<F]M($AO;&1I;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,97AI8V]N(%!A:60@2&]L9&EN9W,@0V%S:#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4WEM
M<&AO;GD@1F%I<B!686QU92!/9B!"87-E($%N9"!#;VYT:6YG96YT(%!A>6UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PV,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3>6UP:&]N>2!"87-E(%!A>6UE;G0@1&ES8V]U;G0@4F%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3>6UP:&]N>2!#;VYT
M:6YG96YT(%!A>6UE;G0@1&ES8V]U;G0@4F%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3>6UP:&]N>2!"87-E(%!A>6UE;G0@
M26X@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPR
M,S<L-3$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3>6UP:&]N>2!"87-E(%!A>6UE;G0@3V)L:6=A=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4WEM<&AO
M;GD@0V]N=&EN9V5N="!087EM96YT($UA>&EM=6T\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-Y;7!H;VYY($-O;G1I;F=E
M;G0@4&%Y;65N="!097)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-Y;7!H;VYY(%)E9W5L871O<GD@07!P<F]V86P@
M4&%Y;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4WEM<&AO;GD@4F5G=6QA=&]R>2!!<'!R;W9A;"!2961U8W1I;VX@
M4&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3>6UP:&]N>2!296=U;&%T;W)Y($%P<')O=F%L(%!E<F-E;G1A9V4@
M3&EM:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4WEM<&AO;GD@4&%Y;65N="!);B!3=&]C:R!,:6UI=&%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-Y;7!H;VYY($-O;G1I
M;F=E;G0@4&%Y;65N="!);B!#87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-Y;7!H;VYY($-O;G1I;F=E;G0@4&%Y;65N
M="!I;B!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M-C8R+#<X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4WEM<&AO;GD@0V]N=&EN9V5N="!087EM96YT(%1O=&%L/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PU,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<'-E
M;B!5<&9R;VYT(%!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(S+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@9F%I<B!V
M86QU92!O9B!3>6UP:&]N>2!)8V]N+"!);F,N('!U<F-H87-E(&QI86)I;&ET
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0R."PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#(L,C$P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#DL.#@W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q
M9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@Q83@R
M-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE971S+U-H
M965T-3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5*14%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A$971A:6QS(#$I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!,96%S960@07-S971S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T
M960@26YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-#,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-#,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG($QE87-E<RP@4F5N="!%
M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q
M.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A
M.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O
M4VAE970U-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15%#04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*$1E=&%I;',@
M,BD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@
M<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@3&5A<V5D($%S<V5T<SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I
M;F<@3&5A<V5S+"!&=71U<F4@36EN:6UU;2!087EM96YT<R!$=64L($YE>'0@
M5'=E;'9E($UO;G1H<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#`W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W!E<F%T:6YG($QE87-E<RP@1G5T=7)E($UI;FEM=6T@4&%Y
M;65N=',L($1U92!I;B!4=V\@665A<G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@3&5A<V5S+"!&=71U<F4@36EN
M:6UU;2!087EM96YT<RP@1'5E(&EN(%1H<F5E(%EE87)S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$R.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG($QE87-E<RP@
M1G5T=7)E($UI;FEM=6T@4&%Y;65N=',L($1U92!I;B!&;W5R(%EE87)S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!,
M96%S97,L($9U='5R92!-:6YI;75M(%!A>6UE;G1S($1U93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#@W-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T
M.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE
M971S+U-H965T-34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4S2T%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D]T:&5R($-A<&ET86P@4W1O8VL@06=R965M96YT<R`H1&5T
M86EL<RD@*%531"`D*3QB<CY);B!-:6QL:6]N<RP@97AC97!T(%-H87)E(&1A
M=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^3F]V+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($-A
M<&ET86QI>F%T:6]N+"!%<75I='D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S=65D($1U<FEN9R!097)I;V0L
M(%-H87)E<RP@3F5W($ES<W5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-34L-C`X+#DS,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]F9F5R:6YG(%!R:6-E(%!E
M<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C`P
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,BXR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(%!R;V-E961S($9R;VT@4W1O8VL@3V9F97)I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`Q+CD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,W+C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A
M>6UE;G1S(&]F(%5N9&5R=W)I=&EN9R!$:7-C;W5N=',@86YD($-O;6UI<W-I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM
M96YT<R!O9B!3=&]C:R!)<W-U86YC92!#;W-T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S=65D($1U<FEN
M9R!097)I;V0@=&\@26YV=7,L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30Y+#(U,RPW,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%34=!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY%<75I='D@26YC96YT:79E($%W87)D<R`H1&5T86EL
M<R`Q*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO
M;B!%>&5R8VES92!0<FEC92!A<R!097)C96YT(&]F(%9A;'5E(&]F($-O;6UO
M;B!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S=')I8W1E9"!3=&]C:R!0=7)C:&%S92!0<FEC92!A<R!097)C96YT
M(&]F(%9A;'5E(&]F($-O;6UO;B!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!3:&%R97,@5&AA="!-87D@8F4@
M27-S=65D+"!%<75I='D@26YC96YT:79E(%!L86X\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI;6ET($]N(%-H87)E<R!4
M:&%T($UA>2!"92!)<W-U960@3W1H97(@5&AA;B!3=&]C:R!/<'1I;VYS(&]R
M(%-!4G,L($5Q=6ET>2!);F-E;G1I=F4@4&QA;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN
M9RP@17%U:71Y($EN8V5N=&EV92!0;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,BPU,S,L,C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(%-T;V-K(%5N:71S
M($]U='-T86YD:6YG+"!%<75I='D@26YC96YT:79E(%!L86X\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3,P+#<R,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@3W!T:6]N
M<R!%>&5R8VES960L($5Q=6ET>2!);F-E;G1I=F4@4&QA;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PX.#$L.#$U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@27-S=65D
M(%!U<G-U86YT('1O(%)E<W1R:6-T960@4W1O8VL@56YI=',L($5Q=6ET>2!)
M;F-E;G1I=F4@4&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPR,C0L,S,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R97,@27-S=65D(%!U<G-U86YT('1O(%-T;V-K($)O
M;G5S($%W87)D<RP@17%U:71Y($EN8V5N=&EV92!0;&%N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW.3<L-S`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7)E8W1O<G,@26YT:6%L
M($]P=&EO;B!'<F%N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$:7)E8W1O<G,@06YN=6%L($]P=&EO;B!'<F%N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7)E8W1O<G,@06YN
M=6%L(%)E<W1R:6-T960@4W1O8VL@07=A<F0@5F%L=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!3:&%R97,@5&AA
M="!-87D@0F4@27-S=65D+"!.;VXM16UP;&]Y964@1&ER96-T;W)S($5Q=6ET
M>2!);F-E;G1I=F4@4&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG+"!.;VXM16UP;&]Y
M964@1&ER96-T;W)S($5Q=6ET>2!);F-E;G1I=F4@4&QA;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-S`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!/<'1I;VYS
M($5X97)C:7-E9"P@3F]N+45M<&QO>65E($1I<F5C=&]R<R!%<75I='D@26YC
M96YT:79E(%!L86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E<R!)<W-U960@4'5R<W5A;G0@=&\@4F5S=')I8W1E9"!3=&]C:R!!
M=V%R9',L($YO;BU%;7!L;WEE92!$:7)E8W1O<G,@17%U:71Y($EN8V5N=&EV
M92!0;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S<L-#@P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA
M<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3G5M8F5R(&]F(%-H87)E<R!!=71H
M;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPW,S,L
M.38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@
M4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3G5M8F5R(&]F(%-H87)E<R!!
M=F%I;&%B;&4@9F]R($=R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-"PU.#0L-S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C
M96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#%A.#(V,S!?.3<P
M9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E=',O4VAE970U-RYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15!:04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^17%U
M:71Y($EN8V5N=&EV92!!=V%R9',@*$1E=&%I;',@,BD@*%531"`D*3QB<CY3
M:&%R92!D871A(&EN(%1H;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O
M;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT
M($%W87)D/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3
M:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!'<F%N=',@:6X@
M4&5R:6]D+"!796EG:'1E9"!!=F5R86=E($=R86YT($1A=&4@1F%I<B!686QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C(S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C4Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@
M8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@17AE<F-I
M<V5S(&EN(%!E<FEO9"P@5&]T86P@26YT<FEN<VEC(%9A;'5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0S+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S(U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#8R
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y
M(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($]U='-T86YD
M:6YG+"!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!4
M97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#$P
M(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($5X97)C
M:7-A8FQE+"!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A
M;"!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S
M(#@@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE
M;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@3W5T
M<W1A;F1I;F<L($EN=')I;G-I8R!686QU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N
M9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L
M($5X97)C:7-A8FQE+"!);G1R:6YS:6,@5F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@4W1O8VL@3W!T:6]N(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P
M=&EO;G,L($]U='-T86YD:6YG+"!.=6UB97(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(S+#8P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(S+#,P-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#4R-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#0W-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($]U='-T86YD:6YG+"!796EG:'1E
M9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(N,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(N-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N.#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!0
M87EM96YT($%W87)D+"!/<'1I;VYS+"!'<F%N=',@:6X@4&5R:6]D+"!'<F]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU,#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#0Y,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-#0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G1S(&)Y
M(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($=R86YT<R!I
M;B!097)I;V0L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XV.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXQ,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XX
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($5X97)C:7-E<R!I
M;B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(R,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U
M-S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-C,V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M<R!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!%>&5R
M8VES97,@:6X@4&5R:6]D+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R
M:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N
M-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$N-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N
M="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!%>'!I
M<F%T:6]N<R!I;B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,L,S,T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#DU,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q+#(S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO
M;B!!<G)A;F=E;65N=',@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@
M3W!T:6]N<RP@17AP:7)A=&EO;G,@:6X@4&5R:6]D+"!796EG:'1E9"!!=F5R
M86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,N-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,N.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#8N.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D
M+"!/<'1I;VYS+"!&;W)F96ET=7)E<R!I;B!097)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#8T."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.#<I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3(U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT<R!B>2!3:&%R92UB87-E9"!087EM
M96YT($%W87)D+"!/<'1I;VYS+"!&;W)F96ET=7)E<R!I;B!097)I;V0L(%=E
M:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2XY-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XY-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S
M960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A
M>6UE;G0@07=A<F0L($]P=&EO;G,L($5X97)C:7-A8FQE+"!.=6UB97(\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#DR,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#,W.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#4X
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($5X97)C:7-A8FQE
M+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,DM!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY%<75I='D@26YC96YT:79E($%W87)D<R`H
M1&5T86EL<R`S*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS
M871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R
M9#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M
M8F%S960@4&%Y;65N="!!=V%R9"P@4W1O8VL@0F]N=7,@86YD(%)E<W1R:6-T
M960@4W1O8VLL($=R86YT<R!I;B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P,BPU-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX,"PX,#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-"PQ,3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D
M($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM
M96YT($%W87)D+"!3=&]C:R!";VYU<R!A;F0@4F5S=')I8W1E9"!3=&]C:RP@
M1W)A;G1S(&EN(%!E<FEO9"P@5V5I9VAT960@079E<F%G92!'<F%N="!$871E
M($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2XU-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2XY.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2XW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@4W1O8VL@
M0F]N=7,@86YD(%)E<W1R:6-T960@4W1O8VL@=&\@0V]N<W5L=&%N=',L($=R
M86YT<R!I;B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4W+#0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L(%-T;V-K($)O;G5S(&%N
M9"!297-T<FEC=&5D(%-T;V-K('1O($-O;G-U;'1A;G1S+"!'<F%N=',@:6X@
M4&5R:6]D+"!796EG:'1E9"!!=F5R86=E($=R86YT($1A=&4@1F%I<B!686QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3T=!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY%<75I='D@26YC96YT:79E($%W87)D<R`H
M1&5T86EL<R`T*2`H4F5S=')I8W1E9"!3=&]C:R!5;FET<R`H4E-5<RDL(%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!097(@4VAA<F4@9&%T82P@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(%-T;V-K(%5N:71S("A24U5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H
M87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB
M87-E9"!087EM96YT($%W87)D/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!%<75I='D@
M26YS=')U;65N=',@3W1H97(@=&AA;B!/<'1I;VYS+"!.;VYV97-T960L($YU
M;6)E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(T
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($5Q=6ET>2!);G-T<G5M96YT<R!/
M=&AE<B!T:&%N($]P=&EO;G,L($YO;G9E<W1E9"P@5V5I9VAT960@079E<F%G
M92!'<F%N="!$871E($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2XX-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2XY,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L
M($5Q=6ET>2!);G-T<G5M96YT<R!/=&AE<B!T:&%N($]P=&EO;G,L($=R86YT
M<R!I;B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@
M4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@17%U:71Y($EN<W1R=6UE;G1S
M($]T:&5R('1H86X@3W!T:6]N<RP@1W)A;G1S(&EN(%!E<FEO9"P@5V5I9VAT
M960@079E<F%G92!'<F%N="!$871E($9A:7(@5F%L=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A
M<F0L($5Q=6ET>2!);G-T<G5M96YT<R!/=&AE<B!T:&%N($]P=&EO;G,L(%9E
M<W1E9"!I;B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$L,S@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($5Q=6ET>2!);G-T<G5M
M96YT<R!/=&AE<B!T:&%N($]P=&EO;G,L(%9E<W1E9"!I;B!097)I;V0L(%=E
M:6=H=&5D($%V97)A9V4@1W)A;G0@1&%T92!&86ER(%9A;'5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M
M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@
M07=A<F0L($5Q=6ET>2!);G-T<G5M96YT<R!/=&AE<B!T:&%N($]P=&EO;G,L
M($9O<F9E:71E9"!I;B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L,S,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N
M9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($5Q=6ET>2!)
M;G-T<G5M96YT<R!/=&AE<B!T:&%N($]P=&EO;G,L($9O<F9E:71E9"!I;B!0
M97)I;V0L(%=E:6=H=&5D($%V97)A9V4@1F%I<B!686QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+CDR/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S,%\Y-S!D7S1A,3)?8C0X
M.%\Q.#%D,#4S8V9C96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M.#%A.#(V,S!?.3<P9%\T83$R7V(T.#A?,3@Q9#`U,V-F8V5C+U=O<FMS:&5E
M=',O4VAE970V,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15E"04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0F5N969I="!0;&%N("A$971A:6QS*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$969I;F5D($)E;F5F:70@4&QA;G,@86YD($]T:&5R(%!O<W1R971I<F5M
M96YT($)E;F5F:70@4&QA;G,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F:6YE9"!#;VYT<FEB=71I;VX@4&QA;BP@0V]S
M="!296-O9VYI>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,W-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4Q,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0Y,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%4%=!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N=',@
M*$1E=&%I;',I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D]C="X@,S$L(#(P,30\8G(^55-$("@D*3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$T/&)R/D554B`H
M)B-X,C!A8SLI/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;"X@,S$L(#(P,#4\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/E531"`H)"D\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]L;&%B;W)A
M=&EV92!!<G)A;F=E;65N=',@86YD($YO;BUC;VQL86)O<F%T:79E($%R<F%N
M9V5M96YT(%1R86YS86-T:6]N<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y)<'-E;B!5<&9R;VYT(%!A>6UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27!S96X@
M4F5V96YU92!!;&QO8V%T960@=&\@1&5V96QO<&UE;G0@1&5L:79E<F%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27!S
M96X@4F5V96YU92!!;&QO8V%T960@=&\@0V]M;6ET=&5E($1E;&EV97)A8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<'-E
M;B!2979E;G5E($%L;&]C871E9"!T;R!,:6-E;G-E($1E;&EV97)A8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PR,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<'-E
M;B!2979E;G5E(%)E8V]G;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(Q+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEP<V5N($UA>&EM=6T@4F5G=6QA=&]R>2!!
M;F0@0V]M;65R8VEA;"!-:6QE<W1O;F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<'-E;B!-87AI;75M(%-A;&5S($UI
M;&5S=&]N97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E18($5N=&5R<')I<V4@1G5N9"!!=V%R9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5%@@16YT97)P<FES92!&
M=6YD($%W87)D('1O(%1E>&%S($%-(%5N:79E<G-I='D@4WES=&5M/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y424=-(%!E
M<B!*;V(@4&%Y;65N="!!;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y424=-($UA>&EM=6T@17AP;W-U<F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#(P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1)1TT@36%X:6UU
M;2!%>'!O<W5R92!4:')O=6=H(%)E<&]R=&EN9R!$871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R
M7V(T.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K
M<VAE971S+U-H965T-C(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!2$%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E)E<W1R=6-T=7)I;F<@0VAA<F=E<R`H1&5T86EL<RD@
M*%531"`D*3QB<CY);B!-:6QL:6]N<RP@=6YL97-S(&]T:&5R=VES92!S<&5C
M:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY297-T<G5C='5R:6YG($-H87)G97,@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<G5C='5R
M:6YG($-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S=')U8W1U<FEN9R!#;W-T+"!3979E<F%N8V4@0V]S=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@4F5S=')U8W1U
M<FEN9R!#;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XT
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-T<G5C='5R:6YG(&%N9"!296QA=&5D($-O<W0L($-O<W0@26YC=7)R
M960@=&\@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2XV
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-T<G5C='5R:6YG(&%N9"!296QA=&5D($-O<W1S+"!#;W-T($EN8W5R
M<F5D('1O($1A=&4L(%)E<V5A<F-H(&%N9"!$979E;&]P;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"XY/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<G5C='5R:6YG(&%N
M9"!296QA=&5D($-O<W1S+"!#;W-T($EN8W5R<F5D('1O($1A=&4L($=E;F5R
M86P@86YD($%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<W1R=6-T=7)I;F<@86YD(%)E;&%T960@0V]S=',L
M($-O<W0@26YC=7)R960@=&\@1&%T92P@4W1O8VLM8F%S960@0V]M<&5N<V%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R
M=6-T=7)I;F<@4F5S97)V93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,TI!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY396QE8W1E9"!1
M=6%R=&5R;'D@1FEN86YC:6%L($1A=&$@*$1E=&%I;',I("A54T0@)"D\8G(^
M26X@5&AO=7-A;F1S+"!E>&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#@^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-O;F1E;G-E9"!&:6YA;F-I86P@4W1A=&5M96YT<RP@0V%P=&EO;G,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V
M96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C$L-#@R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#8W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+#0Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,V,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(L.#4T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R+#(R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PP.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQO<W,@1G)O;2!/<&5R871I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#0T-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,"PS,S8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C8L,3$Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,P
M+#0W,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-BPY-S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,S$L,C$V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(X+#8R-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-2PU-34I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`P+#,V-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#(L
M,S<Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$P."PT,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VYS;VQI9&%T960@3F5T($QO<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPY,S,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T,"PT.3@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R-BPP
M,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@S,"PX,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@Q-RPT,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@S,2PV-3@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R.2PP.#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R-2PY
M-S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@Q,#`L,CDT*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,3`T+#$R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Q,"PR,3$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS;VQI9&%T
M960@3F5T($QO<W,@4&5R($-O;6UO;B!3:&%R92P@0F%S:6,@86YD($1I;'5T
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#`N,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@P+C`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,"XP,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N
M,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@P+C(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(%5S960@26X@0V]M<'5T:6YG($-O
M;G-O;&ED871E9"!.970@3&]S<R!097(@0V]M;6]N(%-H87)E($)A<VEC($%N
M9"!$:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.3,L
M-CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3$T+#<Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4Q-"PV,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,3,L.34U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$S+#4R,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q,RPT,3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,3,L,#@S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3$R+#0R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4S-"PT,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,3,L,3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#@Y+#<P-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#%A.#(V,S!?.3<P9%\T83$R7V(T
M.#A?,3@Q9#`U,V-F8V5C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S@Q83@R-C,P7SDW,&1?-&$Q,E]B-#@X7S$X,60P-3-C9F-E8R]7;W)K<VAE
M971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M
M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL
M92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C,N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(W+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S(N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S4N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,V+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,S@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Y+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#0R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#0N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#0U+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970T-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#<N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0X+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970T.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T-3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4Q
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U,BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T-3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#4T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U
M-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-38N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4W+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970U."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8P+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970V,2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#8S+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%\X,6$X,C8S
A,%\Y-S!D7S1A,3)?8C0X.%\Q.#%D,#4S8V9C96,M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Details 2) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</a></td>
        <td class="nump"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">$ 1,428</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="num"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">$ (2,210)</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="nump"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">$ 9,887</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</a></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" onclick="toggleNextSibling(this);">1,428</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</span><span></span></td>
        <td class="num"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" onclick="toggleNextSibling(this);">(2,210)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" onclick="toggleNextSibling(this);">9,887</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</a></td>
        <td class="num"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" onclick="toggleNextSibling(this);">(11,500)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" onclick="toggleNextSibling(this);">(35,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</a></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" onclick="toggleNextSibling(this);">$ 17,638</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" onclick="toggleNextSibling(this);">$ 27,710</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" onclick="toggleNextSibling(this);">$ 29,920</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" onclick="toggleNextSibling(this);">$ 55,033</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,521</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,073</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338,787</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,339</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:676px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="293px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,576</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,128</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="80%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Long-term Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of base payment obligation with common stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2012</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,920</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2013</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent payment obligation with common stock and cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13467-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13476-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6447952&amp;loc=d3e13220-108610<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="306px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,521</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="306px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,075</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,627</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,126</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,128</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Incentive Awards (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock', window );">Stock Option Exercise Price as Percent of Value of Common Stock</a></td>
        <td class="nump"><a title="lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock', window );">Restricted Stock Purchase Price as Percent of Value of Common Stock</a></td>
        <td class="nump"><a title="lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock" onclick="toggleNextSibling(this);">85.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan', window );">Total Shares That May be Issued, Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan" onclick="toggleNextSibling(this);">50,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan', window );">Limit On Shares That May Be Issued Other Than Stock Options or SARs, Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan" onclick="toggleNextSibling(this);">15,000,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OptionsOutstandingEquityIncentivePlan', window );">Options Outstanding, Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_OptionsOutstandingEquityIncentivePlan" onclick="toggleNextSibling(this);">22,533,242</a><span style="display:none;white-space:normal;text-align:left;">lxrx_OptionsOutstandingEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan', window );">Restricted Stock Units Outstanding, Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan" onclick="toggleNextSibling(this);">3,130,720</a><span style="display:none;white-space:normal;text-align:left;">lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionsExercisedEquityIncentivePlan', window );">Stock Options Exercised, Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_StockOptionsExercisedEquityIncentivePlan" onclick="toggleNextSibling(this);">5,881,815</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockOptionsExercisedEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Units, Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan" onclick="toggleNextSibling(this);">3,224,339</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan', window );">Shares Issued Pursuant to Stock Bonus Awards, Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan" onclick="toggleNextSibling(this);">797,700</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DirectorsIntialOptionGrant', window );">Directors Intial Option Grant</a></td>
        <td class="nump"><a title="lxrx_DirectorsIntialOptionGrant" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_DirectorsIntialOptionGrant</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DirectorsAnnualOptionGrant', window );">Directors Annual Option Grant</a></td>
        <td class="nump"><a title="lxrx_DirectorsAnnualOptionGrant" onclick="toggleNextSibling(this);">20,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_DirectorsAnnualOptionGrant</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DirectorsAnnualRestrictedStockAwardValue', window );">Directors Annual Restricted Stock Award Value</a></td>
        <td class="nump"><a title="lxrx_DirectorsAnnualRestrictedStockAwardValue" onclick="toggleNextSibling(this);">$ 20,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_DirectorsAnnualRestrictedStockAwardValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan', window );">Total Shares That May Be Issued, Non-Employee Directors Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan', window );">Options Outstanding, Non-Employee Directors Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan" onclick="toggleNextSibling(this);">1,070,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan', window );">Stock Options Exercised, Non-Employee Directors Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan', window );">Shares Issued Pursuant to Restricted Stock Awards, Non-Employee Directors Equity Incentive Plan</a></td>
        <td class="nump"><a title="lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan" onclick="toggleNextSibling(this);">277,480</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" onclick="toggleNextSibling(this);">26,733,962</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">14,584,704</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DirectorsAnnualOptionGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Under the Non-Employee Directors' Equity Incentive Plan, non-employee directors receive an annual option to purchase shares of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_DirectorsAnnualOptionGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DirectorsAnnualRestrictedStockAwardValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Under the Non-Employee Directors' Equity Incentive Plan, non-employee directors receive an annual restricted stock award of the number of shares of common stock having a set fair market value on the date of grant rounded down to the nearest whole share number.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_DirectorsAnnualRestrictedStockAwardValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DirectorsIntialOptionGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Under the Non-Employee Directors' Equity Incentive Plan, non-employee directors receive an initial option to purchase shares of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_DirectorsIntialOptionGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Under the Equity Incentive Plan, no more than this amount of shares may be issued pursuant to awards other than stock options and stock appreciation rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options to purchase shares outstanding under the Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_OptionsOutstandingEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options to purchase shares outstanding under the Non-Employee Directors Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The purchase price of restricted stock awards may not be less than 85% of fair market value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted stock units outstanding under the Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_RestrictedStockUnitsOutstandingEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares issued pursuant to restricted stock awards under the Non-Employee Directors Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares issued pursuant to restricted stock units under the Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares issued pursuant to stock bonus awards or restricted stock awards under the Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Incentive and nonstatutory stock options have an exercise price of 100% or more of the fair market value of common stock on the date of grant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_StockOptionExercisePriceAsPercentOfValueOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares issued upon the exercise of stock options under the Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_StockOptionsExercisedEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares issued upon the exercise of stock options under the Non-Employee Directors Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total number of shares of common stock that may be issued pursuant to stock awards under the Non-Employee Directors Equity Incentive Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5G">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Assets Held for Sale (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AssetsHeldforSaleAbstract', window );"><strong>Assets Held for Sale [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Assets Held-for-sale, Long Lived, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" onclick="toggleNextSibling(this);">$ 23,849</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AssetsHeldforSaleAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_AssetsHeldforSaleAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of assets classified as held for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Useful Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">In Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5-7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,315</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,952</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7-10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,117</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,092</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15-40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,274</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81,945</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,362</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255,518</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,946</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,457</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,681</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability related to acquisition of Symphony Icon</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,745</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(412,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(376,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,745</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IncomeTaxesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IncomeTaxesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Operations<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OrganizationAndOperationsAbstract', window );"><strong>Organization and Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Operations</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) is a Delaware corporation incorporated on July&#160;7, 1995. Lexicon was organized to discover the functions and pharmaceutical utility of genes and use those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon has financed its operations from inception primarily through sales of common and preferred stock, contract and milestone payments to it under drug discovery and development collaborations, target validation, database subscription and technology license agreements, government grants and contracts and financing under debt and lease arrangements. The Company&#8217;s future success is dependent upon many factors, including, but not limited to, its ability to discover and develop pharmaceutical products for the treatment of human disease, establish new collaboration and license agreements, achieve milestones under such agreements, obtain and enforce patents and other proprietary rights in its discoveries, comply with federal and state regulations, and maintain sufficient capital to fund its activities.&#160;&#160;As a result of the aforementioned factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OrganizationAndOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_OrganizationAndOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt Obligations (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation (Details 2) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" onclick="toggleNextSibling(this);">$ 10.4</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Outstanding, Weighted Average Remaining Vesting Period</a></td>
        <td class="text">1 year 4 months<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted Investments</a></td>
        <td class="nump"><a title="us-gaap_RestrictedInvestments" onclick="toggleNextSibling(this);">$ 430,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedInvestments</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedInvestments" onclick="toggleNextSibling(this);">$ 430,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedInvestments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">$ 1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">$ 900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">$ 2,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 137,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 37,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments, including restricted investments of $430</a></td>
        <td class="nump"><a title="us-gaap_ShortTermInvestments" onclick="toggleNextSibling(this);">202,073</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShortTermInvestments</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShortTermInvestments" onclick="toggleNextSibling(this);">91,629</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShortTermInvestments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $35</a></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">1,035</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">790</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Assets held for sale</a></td>
        <td class="nump"><a title="us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" onclick="toggleNextSibling(this);">23,849</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">4,764</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">4,636</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">368,987</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">134,554</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $36,274 and $81,945, respectively</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">1,080</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">41,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump"><a title="us-gaap_Goodwill" onclick="toggleNextSibling(this);">44,543</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill</span><span></span></td>
        <td class="nump"><a title="us-gaap_Goodwill" onclick="toggleNextSibling(this);">44,543</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets</a></td>
        <td class="nump"><a title="us-gaap_OtherIntangibleAssetsNet" onclick="toggleNextSibling(this);">53,357</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherIntangibleAssetsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherIntangibleAssetsNet" onclick="toggleNextSibling(this);">53,557</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherIntangibleAssetsNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">3,409</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">144</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">471,376</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">274,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">13,064</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">9,715</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">10,120</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">7,674</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">1,618</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">195</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">20,167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">1,710</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">44,969</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">19,294</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">12,679</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">13,405</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">87,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">20,167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liabilities</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">18,675</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">18,745</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">23,535</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">32,386</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">187,358</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">103,997</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 900,000 shares authorized; 725,641 and 514,349 shares issued, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">726</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">514</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">1,389,997</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">1,175,108</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(1,104,252)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(1,003,958)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(63)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 1,281 and 814 shares, respectively</a></td>
        <td class="num"><a title="us-gaap_TreasuryStockValue" onclick="toggleNextSibling(this);">(2,390)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValue</span><span></span></td>
        <td class="num"><a title="us-gaap_TreasuryStockValue" onclick="toggleNextSibling(this);">(1,503)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValue</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">284,018</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">170,163</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 471,376</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 274,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of assets classified as held for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Goodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net carrying amount as of the balance sheet date of other indefinite-lived and finite-lived intangible assets that are not separately presented on the statement of financial position.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph g<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Property and Equipment (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 37,354</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 123,307</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(36,274)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(81,945)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">1,080</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">41,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Software</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">9,468</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">11,180</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">7,032</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_FurnitureAndFixturesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">7,315</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_FurnitureAndFixturesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember]" onclick="toggleNextSibling(this);">12,737</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_EquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember]" onclick="toggleNextSibling(this);">34,952</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_EquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">8,117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdsAndLeaseholdImprovementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">8,092</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdsAndLeaseholdImprovementsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_BuildingAndBuildingImprovementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember]" onclick="toggleNextSibling(this);">59,104</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_BuildingAndBuildingImprovementsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LandMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember]" onclick="toggleNextSibling(this);">$ 2,664</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LandMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBCDI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit</div>
        </th>
        <th class="th">
          <div>Accumulated Other Comprehensive Gain (Loss)</div>
        </th>
        <th class="th">
          <div>Treasury Stock</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2011</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 297,568</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 480</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 1,087,033</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (789,621)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">$ 21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">$ (345)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">480,389,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">6,495</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">6,495</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedtoSymphonyDesigneesShares', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedtoSymphonyDesigneesShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">13,238,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedtoSymphonyDesigneesShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</a></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue" onclick="toggleNextSibling(this);">35,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">13</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">34,987</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,248,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" onclick="toggleNextSibling(this);">1,054</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,053</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of fees, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">17,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of fees, value</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">37,055</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">18</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">37,037</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
        <td class="num"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod" onclick="toggleNextSibling(this);">(285)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">(285)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(110,211)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(110,211)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2012</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">266,678</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">512</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,166,605</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(899,832)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">23</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">(630)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">512,375,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">7,421</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">7,421</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</a></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,974,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" onclick="toggleNextSibling(this);">1,084</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,082</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
        <td class="num"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod" onclick="toggleNextSibling(this);">(873)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">(873)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(104,126)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(104,126)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">(21)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">(21)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">170,163</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">514</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,175,108</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(1,003,958)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">(1,503)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">514,349,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">7,081</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">7,081</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedtoSymphonyDesigneesShares', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedtoSymphonyDesigneesShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4,663,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedtoSymphonyDesigneesShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Issuance of common stock to designees of Symphony Icon Holdings LLC, value</a></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue" onclick="toggleNextSibling(this);">5,750</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">5,745</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,766,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" onclick="toggleNextSibling(this);">323</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">321</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of fees, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">204,863,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of fees, value</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">201,947</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">205</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">201,742</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
        <td class="num"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod" onclick="toggleNextSibling(this);">(887)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_TreasuryStockValueAcquiredCostMethod[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">(887)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockValueAcquiredCostMethod<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(100,294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(100,294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">(65)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">(65)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, value at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 284,018</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 726</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 1,389,997</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (1,104,252)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">$ (63)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedOtherComprehensiveIncomeMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember]" onclick="toggleNextSibling(this);">$ (2,390)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_TreasuryStockMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">725,641,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedtoSymphonyDesigneesShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation. Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates. This represents the shares issued to designees of Holdings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SharesIssuedtoSymphonyDesigneesShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedToSymphonyDesigneesValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the shares issued to designees of Holdings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SharesIssuedToSymphonyDesigneesValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Incentive Awards (Details 4) (Restricted Stock Units (RSUs), USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock Units (RSUs)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">3,131</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">4,242</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 1.84</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 1.93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">1,604</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 1.72</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">(1,384)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 1.90</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">(1,331)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Fair Value</a></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 1.92</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Quarterly Financial Data (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SelectedQuarterlyFinancialDataAbstract', window );"><strong>Selected Quarterly Financial Data [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selected Quarterly Financial Data</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below sets forth certain unaudited statements of comprehensive loss data, and net loss per common share data, for each quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2014</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,472</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,336</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,447</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">593,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,216</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,976</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated net loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing consolidated net loss per common share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">512,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SelectedQuarterlyFinancialDataAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SelectedQuarterlyFinancialDataAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Benefit Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BenefitPlanAbstract', window );"><strong>Benefit Plan [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit Plan</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Benefit Plan</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code.&#160;&#160;The plan covers substantially all full-time employees.&#160;&#160;Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit.&#160;&#160;Beginning in 2000, the Company was required to match employee contributions according to a specified formula.&#160;&#160;The matching contributions totaled </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$511,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$490,000</font><font style="font-family:inherit;font-size:10pt;"> in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;Company contributions are vested based on the employee&#8217;s years of service, with full vesting after four years of service.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BenefitPlanAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_BenefitPlanAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e2410-114920<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 80<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35742057&amp;loc=SL14450702-114947<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 60<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6G">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies Restricted Cash and Investments (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted investments</a></td>
        <td class="nump"><a title="us-gaap_RestrictedInvestments" onclick="toggleNextSibling(this);">$ 430</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedInvestments</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedInvestments" onclick="toggleNextSibling(this);">$ 430</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedInvestments</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Restructuring Charges<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Related Activities Disclosure [Text Block]</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, Lexicon&#8217;s board of directors committed to narrow its strategic initiatives and focus resources on its late-stage drug development programs, principally sotagliflozin (LX4211) for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, in preparation for the transition to commercialization.  The decision resulted in a workforce reduction of approximately 125 employees, primarily in research, discovery and support positions, representing approximately 50% of the Company&#8217;s total workforce.  The Company completed the majority of the workforce reduction by the end of the second quarter of 2014.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently expects that the total charges associated with the restructuring which will result in cash expenditures will be approximately </font><font style="font-family:inherit;font-size:10pt;">$5.7&#160;million</font><font style="font-family:inherit;font-size:10pt;"> (which includes charges for severance of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.3&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and other restructuring costs of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4&#160;million</font><font style="font-family:inherit;font-size:10pt;">), of which </font><font style="font-family:inherit;font-size:10pt;">$5.6&#160;million</font><font style="font-family:inherit;font-size:10pt;"> was incurred through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  Of this charge, </font><font style="font-family:inherit;font-size:10pt;">$4.9&#160;million</font><font style="font-family:inherit;font-size:10pt;"> was recorded in research and development expense and </font><font style="font-family:inherit;font-size:10pt;">$0.7&#160;million</font><font style="font-family:inherit;font-size:10pt;"> was recorded in general and administrative expense in the accompanying consolidated statement of comprehensive loss for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  In addition, the Company recorded stock-based compensation expense on the acceleration of vesting relating to the restructuring of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  Future payments of restructuring charges, which have been recorded in accrued liabilities in the accompanying consolidated balance sheet, were </font><font style="font-family:inherit;font-size:10pt;">$0.3&#160;million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ESMBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">$ (100,294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">$ (104,126)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">$ (110,211)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">1,928</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">2,863</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">4,190</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of assets</a></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" onclick="toggleNextSibling(this);">13,544</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</span><span></span></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</span><span></span></td>
        <td class="nump"><a title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</a></td>
        <td class="nump"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">1,428</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="num"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">(2,210)</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="nump"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">9,887</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">7,081</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">7,421</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">6,495</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on disposal of property and equipment</a></td>
        <td class="num"><a title="us-gaap_GainLossOnDispositionOfAssets" onclick="toggleNextSibling(this);">(1,631)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnDispositionOfAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_GainLossOnDispositionOfAssets" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnDispositionOfAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_GainLossOnDispositionOfAssets" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnDispositionOfAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCostsAndDiscounts" onclick="toggleNextSibling(this);">100</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCostsAndDiscounts" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCostsAndDiscounts" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
        <td class="num"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(70)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">457</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(1,028)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(128)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">1,713</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(2,601)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">(Increase) decrease in other assets</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">(9)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherOperatingAssets" onclick="toggleNextSibling(this);">96</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and other liabilities</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">1,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">3,119</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">(995)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">697</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(438)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(293)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(75,622)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(91,079)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(94,460)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(80)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(1,721)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(492)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">2,170</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">130</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">85</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireInvestments" onclick="toggleNextSibling(this);">(221,953)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireInvestments</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireInvestments" onclick="toggleNextSibling(this);">(111,490)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireInvestments</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireInvestments" onclick="toggleNextSibling(this);">(233,250)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireInvestments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" onclick="toggleNextSibling(this);">111,444</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" onclick="toggleNextSibling(this);">212,625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" onclick="toggleNextSibling(this);">135,850</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(108,419)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">99,544</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(97,807)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of fees</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">202,270</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">1,084</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">38,109</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
        <td class="num"><a title="us-gaap_PaymentsForRepurchaseOfCommonStock" onclick="toggleNextSibling(this);">(887)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRepurchaseOfCommonStock</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsForRepurchaseOfCommonStock" onclick="toggleNextSibling(this);">(873)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRepurchaseOfCommonStock</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsForRepurchaseOfCommonStock" onclick="toggleNextSibling(this);">(285)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRepurchaseOfCommonStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt borrowings, net of fees</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfLongTermDebt" onclick="toggleNextSibling(this);">84,135</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfLongTermDebt" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfLongTermDebt" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt borrowings</a></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLongTermDebt" onclick="toggleNextSibling(this);">(1,710)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLongTermDebt</span><span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLongTermDebt" onclick="toggleNextSibling(this);">(1,574)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLongTermDebt</span><span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLongTermDebt" onclick="toggleNextSibling(this);">(1,443)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLongTermDebt</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" onclick="toggleNextSibling(this);">(26)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">283,808</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">(1,389)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">36,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">99,767</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">7,076</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(155,886)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">37,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">30,423</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">186,309</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">137,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">37,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">30,423</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
        <td class="nump"><a title="us-gaap_InterestPaidNet" onclick="toggleNextSibling(this);">1,761</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaidNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaidNet" onclick="toggleNextSibling(this);">1,897</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaidNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaidNet" onclick="toggleNextSibling(this);">2,028</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaidNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
        <td class="num"><a title="us-gaap_UnrealizedGainLossOnInvestments" onclick="toggleNextSibling(this);">(65)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrealizedGainLossOnInvestments</span><span></span></td>
        <td class="num"><a title="us-gaap_UnrealizedGainLossOnInvestments" onclick="toggleNextSibling(this);">(21)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrealizedGainLossOnInvestments</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnrealizedGainLossOnInvestments" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrealizedGainLossOnInvestments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesIssuedToSymphonyDesigneesValue', window );">Common stock issued in satisfaction of Symphony Icon base payment obligation</a></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue" onclick="toggleNextSibling(this);">$ 5,750</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue</span><span></span></td>
        <td class="nump"><a title="lxrx_SharesIssuedToSymphonyDesigneesValue" onclick="toggleNextSibling(this);">$ 35,000</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharesIssuedToSymphonyDesigneesValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesIssuedToSymphonyDesigneesValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs.  Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings $10 million and issued 13,237,591 shares of common stock to designees of Holdings on July 30, 2012 in satisfaction of an additional $35 million base payment obligation.  Lexicon also agreed to make up to $45 million in additional payments, which will consist of 50% of any consideration Lexicon receives pursuant to any licensing transaction under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates.  This represents the shares issued to designees of Holdings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SharesIssuedToSymphonyDesigneesValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 958<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 11<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28367520&amp;loc=d3e92212-112881<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Impairment<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3095-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheet Parentheticals (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted investments</a></td>
        <td class="nump"><a title="us-gaap_RestrictedInvestments" onclick="toggleNextSibling(this);">$ 430</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedInvestments</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedInvestments" onclick="toggleNextSibling(this);">$ 430</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedInvestments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts receivable</a></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" onclick="toggleNextSibling(this);">35</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" onclick="toggleNextSibling(this);">35</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
        <td class="nump"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">$ 36,274</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">$ 81,945</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
        <td class="nump"><a title="us-gaap_TreasuryStockShares" onclick="toggleNextSibling(this);">1,281</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockShares</span><span></span></td>
        <td class="nump"><a title="us-gaap_TreasuryStockShares" onclick="toggleNextSibling(this);">814</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_TreasuryStockShares</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">725,641</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">514,349</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5074-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt Obligations<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Obligations</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Obligations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Debt.</font><font style="font-family:inherit;font-size:10pt;"> In November 2014, Lexicon completed an offering of </font><font style="font-family:inherit;font-size:10pt;">$87.5 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due 2021 (the &#8220;Notes&#8221;).  In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as long-term debt on the Company&#8217;s consolidated balance sheet.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Notes bear interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">5.25%</font><font style="font-family:inherit;font-size:10pt;">&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Notes mature on December&#160;1, 2021. The Company may not redeem the Notes prior to the maturity date, and no sinking fund is provided for the Notes.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of the Notes may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially </font><font style="font-family:inherit;font-size:10pt;">829.1874</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$1.206</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Notes in connection with such a corporate event in certain circumstances.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the issuance of the Notes, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> of debt issuance costs, which is included in other assets on the consolidated balance sheets.  The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Notes.  As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the balance of unamortized debt issuance costs was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.3&#160;million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Notes was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$81.0&#160;million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mortgage Loan. </font><font style="font-family:inherit;font-size:10pt;">In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$34.0 million</font><font style="font-family:inherit;font-size:10pt;"> third-party mortgage financing and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;"> in cash.&#160;&#160;The mortgage loan originally had a ten-year term with a 20-year amortization and a fixed interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8.23%</font><font style="font-family:inherit;font-size:10pt;">.  The mortgage was amended in September 2013 to extend the maturity date from April 2014 to April 2017, with the mortgage loan&#8217;s monthly payment amount and fixed interest rate each remaining unchanged.  The mortgage had a principal balance of </font><font style="font-family:inherit;font-size:10pt;">$20.2&#160;million</font><font style="font-family:inherit;font-size:10pt;">&#160;as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  This entire balance has been classified as current liabilities on the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> as management intends to repay the mortgage when the assets that serve as collateral for the mortgage loan are sold.  These assets have been reclassified to assets held for sale as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, as discussed in Note 6, Assets Held for Sale.  The buildings and land that serve as collateral for the mortgage loan are included in assets held for sale at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$59.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, before accumulated depreciation, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  The fair value of Lexicon&#8217;s mortgage loan approximates its carrying value.&#160;&#160;The fair value of Lexicon&#8217;s mortgage loan was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes the aggregate future principal payments of the Company&#8217;s long-term debt as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  As discussed above, all of the principal due in 2015, 2016 and 2017 relate to the mortgage loan and have been classified as current portion of long-term debt in the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,500</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EESAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information Document (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 09, 2015</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">LEXICON PHARMACEUTICALS, INC./DE<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001062822<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">725,145,313</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 368,000,000</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityPublicFloat</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Arrangements with Symphony Icon, Inc.<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ArrangementsWithSymphonyIconIncAbstract', window );"><strong>Arrangements with Symphony Icon Inc [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ArrangementsWithSymphonyIconIncTextBlock', window );">Arrangements with Symphony Icon, Inc.</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arrangements with Symphony Icon, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 15, 2007, Lexicon entered into a series of related agreements providing for the financing of the clinical development of certain of its drug candidates, including LX1032 and LX1033, along with any other pharmaceutical compositions modulating the same targets as those drug candidates (the &#8220;Programs&#8221;). The agreements included a Novated and Restated Technology License Agreement pursuant to which the Company licensed to Symphony Icon, a then wholly-owned subsidiary of Symphony Icon Holdings LLC (&#8220;Holdings&#8221;), the Company&#8217;s intellectual property rights related to the Programs. Holdings contributed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45 million</font><font style="font-family:inherit;font-size:10pt;"> to Symphony Icon in order to fund the clinical development of the Programs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a Share Purchase Agreement, dated June 15, 2007, between the Company and Holdings, the Company issued and sold to Holdings </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">7,650,622</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock on June&#160;15, 2007 in exchange for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15 million</font><font style="font-family:inherit;font-size:10pt;"> and an exclusive purchase option (the &#8220;Purchase Option&#8221;) that gave the Company the right to acquire all of the equity of Symphony Icon, thereby allowing the Company to reacquire all of the Programs.  On July 30, 2010, Lexicon entered into an Amended and Restated Purchase Option Agreement with Symphony Icon and Holdings and simultaneously exercised the Purchase Option, thereby reacquiring the Programs. Pursuant to the amended terms of the Purchase Option, Lexicon paid Holdings </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> on July&#160;30, 2010 and issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">13,237,519</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to designees of Holdings on July&#160;30, 2012 in satisfaction of an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> base payment obligation.   </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon also agreed to make up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45 million</font><font style="font-family:inherit;font-size:10pt;"> in additional contingent payments, which will consist of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of any consideration Lexicon receives pursuant to any licensing transaction (a &#8220;Licensing Transaction&#8221;) under which Lexicon grants a third party rights to commercialize LX1032, LX1033 or other pharmaceutical compositions modulating the same target as those drug candidates (the &#8220;LG103 Programs&#8221;), subject to certain exceptions. The contingent payments will be due if and when Lexicon receives such consideration from a Licensing Transaction. In the event Lexicon receives regulatory approval in the United States for the marketing and sale of any product resulting from the LG103 Programs prior to entering into a Licensing Transaction for the commercialization of such product in the United States, in lieu of any contingent payment from such a Licensing Transaction, Lexicon will pay Holdings the sum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15 million</font><font style="font-family:inherit;font-size:10pt;"> and the amount of certain expenses Lexicon incurred after its exercise of the Purchase Option which are attributable to the development of such product, reduced by up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of such sum on account of any contingent payments paid prior to such United States regulatory approval attributable to any such Licensing Transaction outside of the United States with respect to such product. In the event Lexicon makes any such payment upon United States regulatory approval, Lexicon will have no obligation to make subsequent contingent payments attributable to any such Licensing Transactions for the commercialization of such product outside the United States until the proceeds of such Licensing Transactions exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the payment made as a result of such United States regulatory approval.  The contingent payments may be paid in cash or a combination of cash and common stock, in Lexicon&#8217;s discretion, provided that no more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of any contingent payment will be paid in common stock.  On December 4, 2014, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and issued </font><font style="font-family:inherit;font-size:10pt;">4,662,780</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to designees of Holdings in satisfaction of a </font><font style="font-family:inherit;font-size:10pt;">$11.5&#160;million</font><font style="font-family:inherit;font-size:10pt;"> contingent payment obligation as a result of receiving a </font><font style="font-family:inherit;font-size:10pt;">$23 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment pursuant to the license and collaboration agreement with Ipsen Pharma SAS (see Note 16, Collaboration and License Agreements).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon accounted for the exercise of the Purchase Option and acquisition of Symphony Icon as a business combination. In connection with its acquisition of Symphony Icon, Lexicon paid </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, and has also agreed to pay Holdings additional base and contingent payments as discussed above. The fair value of the base and contingent consideration payments was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45.6 million</font><font style="font-family:inherit;font-size:10pt;"> and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level&#160;3 inputs. Key assumptions include: (1)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14%</font><font style="font-family:inherit;font-size:10pt;"> for the base payments; (2)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">18%</font><font style="font-family:inherit;font-size:10pt;"> for the contingent payments; and (3)&#160;a probability adjusted contingency.  The discount rate assumptions have not changed through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, and as programs progress, the probability adjusted contingency is adjusted as necessary.  Subsequent changes in the fair value of the Symphony Icon purchase consideration liability are recorded as increase or decrease in fair value of Symphony Icon purchase liability expense in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, decreased by </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ArrangementsWithSymphonyIconIncAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ArrangementsWithSymphonyIconIncAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ArrangementsWithSymphonyIconIncTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Information about a series of related agreements in 2007 providing for the financing of the clinical development of certain of its drug candidates.  These agreements were amended in 2010, when Lexicon exercised is purchase option and reaquired the clinical programs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ArrangementsWithSymphonyIconIncTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWKAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaborative agreements</a></td>
        <td class="nump"><a title="us-gaap_ContractsRevenue" onclick="toggleNextSibling(this);">$ 22,593</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ContractsRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ContractsRevenue" onclick="toggleNextSibling(this);">$ 2,109</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ContractsRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ContractsRevenue" onclick="toggleNextSibling(this);">$ 783</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ContractsRevenue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Subscription and license fees</a></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">261</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">113</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">22,854</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">2,222</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">1,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $4,020, $4,376 and $3,673, respectively</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">89,279</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">89,682</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">82,574</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability', window );">Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability</a></td>
        <td class="nump"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">1,428</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="num"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">(2,210)</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
        <td class="nump"><a title="lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability" onclick="toggleNextSibling(this);">9,887</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative, including stock-based compensation of $3,061, $3,045 and $2,822, respectively</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">19,411</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">17,121</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">17,043</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss on buildings</a></td>
        <td class="nump"><a title="us-gaap_AssetImpairmentCharges" onclick="toggleNextSibling(this);">13,102</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetImpairmentCharges</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetImpairmentCharges" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetImpairmentCharges</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetImpairmentCharges" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetImpairmentCharges</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">123,220</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">104,593</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">109,504</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(100,366)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(102,371)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(108,415)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(2,253)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(1,971)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(2,114)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">2,255</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">318</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Consolidated net loss before taxes</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(100,364)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(104,126)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(110,211)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">70</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(100,294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(104,126)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(110,211)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Consolidated net loss per common share, basic and diluted</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.19)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.20)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.23)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing consolidated net loss per common share, basic and diluted</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">534,432</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">513,117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">489,707</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">(65)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">(21)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (100,359)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (104,147)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (110,209)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the change in fair value of the Symphony Icon, Inc. purchase liability. In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated based and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ChangeInFairValueOfSymphonyIconIncPurchaseLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 940<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35710027&amp;loc=d3e41242-110953<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph h<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.&#160;&#160;Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.&#160;&#160;The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; quoted prices in active markets for identical assets, which include U.S. treasury securities</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.)</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; significant unobservable inputs (including the Company&#8217;s own assumptions in determining the fair value of assets and liabilities)</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.&#160;&#160;The following tables provide the fair value measurements of applicable Company assets and liabilities that are measured at fair value on a recurring basis according to the fair value levels defined above as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,521</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,073</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338,787</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,339</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:676px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="293px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets and Liabilities at Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,576</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,128</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not have any Level 3 assets during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  The Company&#8217;s Level&#160;3 liabilities are estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the Symphony Icon (&#8220;Symphony Icon&#8221;) purchase consideration liability are recorded as an increase or decrease in Symphony Icon purchase liability in the accompanying consolidated statements of comprehensive loss.  The fair value of the Symphony Icon purchase consideration liability increased by </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, decreased by </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, and increased by </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.  The following table summarizes the change in consolidated balance sheet carrying value associated with Level 3 liabilities for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="80%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Long-term Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of base payment obligation with common stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2012</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,920</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2013</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation of purchase consideration payable to former Symphony Icon stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent payment obligation with common stock and cash</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.&#160;&#160;These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon on July 30, 2010 and intangible assets associated with the acquisition of Symphony Icon on July 30, 2010.&#160;&#160;For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents and Investments</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents and Investments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of cash and cash equivalents and investments held at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="306px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,521</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:690px;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="306px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="79px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,499</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities maturing within one year:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,075</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,627</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,126</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,128</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> realized gains or losses for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> realized gains or losses for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> realized gains or losses for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 6.H.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13728-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section H<br><br> -Subsection 3<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and License Agreements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ipsen Pharma SAS.</font><font style="font-family:inherit;font-size:10pt;">  In October 2014, Lexicon entered into a License and Collaboration Agreement (the &#8220;Agreement&#8221;)with Ipsen Pharma SAS (&#8220;Ipsen&#8221;)&#160;for the development and commercialization of Lexicon&#8217;s drug candidate telotristat etiprate (LX1032) outside of the United States, Canada and Japan (the &#8220;Licensed Territory&#8221;).  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize telotristat etiprate in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize telotristat etiprate in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon will be responsible for conducting clinical trials required to obtain regulatory approval for telotristat etiprate for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and will have the first right to conduct most other clinical trials of telotristat etiprate.  Lexicon is responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Agreement, Ipsen paid Lexicon an upfront payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$23 million</font><font style="font-family:inherit;font-size:10pt;">.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$30&#160;million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8364;72&#160;million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of specified sales milestones.  Due to the uncertainty surrounding the achievement of the future regulatory and sales milestones, these payments will not be recognized as revenue unless and until they are earned as the Company is not able to reasonably predict if and when the milestones will be achieved.  Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of telotristat etiprate in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of telotristat etiprate.  Lexicon&#8217;s receipt of these payments under the Agreement triggers its obligation to make certain contingent payments to Holdings (see Note 11, Arrangements with Symphony Icon, Inc.).  Lexicon and Ipsen will enter into a commercial supply agreement pursuant to which Lexicon will supply Ipsen&#8217;s commercial requirements of telotristat etiprate, and Ipsen will pay an agreed upon transfer price for such commercial supply.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considered the following deliverables with respect to the revenue recognition of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$23 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The exclusive license granted to Ipsen to develop and commercialize telotristat etiprate in the Licensed </font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Territory;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The development services Lexicon is performing for telotristat etiprate;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The obligation to participate in committees which govern the development of telotristat</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">etiprate until commercialization; and</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">The obligation to supply commercial supply of telotristat etiprate, under a commercial supply agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the license had stand-alone value because it is an exclusive license that gives Ipsen the right to develop and commercialize telotristat etiprate or to sublicense its rights.  In addition, telotristat etiprate is currently in development and it is possible that Ipsen or another third party could conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Agreement to be separate units of accounting.  The Company recognized the portion of the consideration allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company is recognizing as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performs services, currently expected to be through mid-2017.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the inherent uncertainty in obtaining regulatory approval, the applicability of the commercial supply agreement is outside the control of Lexicon and Ipsen.  Accordingly, the Company has determined the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  As a result, the Company has determined the commercial supply agreement does not meet the definition of a deliverable that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the initial allocable arrangement consideration was the </font><font style="font-family:inherit;font-size:10pt;">$23 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment because it was the only payment that was fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the allocable consideration.  The Company allocated the allocable consideration based on the relative best estimate of selling price of each unit of accounting.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">As a result of the allocation, the Company recognized </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$21.2 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">of the</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;">$23 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment for the license in 2014.  The Company is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> allocated to the development services deliverable over the estimated period of performance as development occurs, and is recognizing the </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> allocated to the committee participation deliverable ratably over the estimated period of performance.  Revenue recognized under the Agreement was </font><font style="font-family:inherit;font-size:10pt;">$21.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Texas Institute for Genomic Medicine</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;&#160;In July 2005, Lexicon received a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> award from the Texas Enterprise Fund for the creation of a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine (&#8220;TIGM&#8221;) using Lexicon&#8217;s proprietary gene trapping technology, which Lexicon completed in 2007.&#160;&#160;Lexicon also equipped TIGM with the bioinformatics software required for the management and analysis of data relating to the library.&#160;&#160;The Texas Enterprise Fund also awarded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the Texas A&amp;M University System for the creation of facilities and infrastructure to house the library.&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the award, Lexicon is responsible for the creation of a specified number of jobs beginning in 2012, reaching an aggregate of 1,616 new jobs in Texas by December 31, 2016.&#160;&#160;Lexicon will obtain credits based on funding received by TIGM and certain related parties from sources other than the State of Texas that it may offset against its potential liability for any job creation shortfalls.&#160;&#160;Lexicon will also obtain credits against future jobs commitment liabilities for any surplus jobs it creates.&#160;&#160;Subject to these credits, if Lexicon fails to create the specified number of jobs, the state may require Lexicon to repay </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,415</font><font style="font-family:inherit;font-size:10pt;"> for each job Lexicon falls short beginning in 2013.&#160;&#160;Lexicon&#8217;s maximum aggregate exposure for such payments, if Lexicon fails to create any new jobs, is approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$14.2 million</font><font style="font-family:inherit;font-size:10pt;">, including </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> through 2015, without giving effect to any credits to which Lexicon may be entitled.&#160;&#160;Lexicon has recorded this obligation as deferred revenue and accounts payable in the accompanying consolidated balance sheets.&#160;&#160;The Texas A&amp;M University System, together with TIGM, has independent job creation obligations and is obligated for an additional period to maintain an aggregate of 5,000 jobs, inclusive of those Lexicon creates.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Lease Obligations</font><font style="font-family:inherit;font-size:10pt;">:&#160;&#160;A Lexicon subsidiary leases laboratory and office space in Hopewell, New Jersey under an amended lease agreement which previously had an expiration date in June 2018.  In March 2015, the subsidiary entered into a termination agreement whereby the lease will terminate in June 2015. &#160;The amended lease includes escalating lease payments.  Rent expense is recognized on a straight-line basis over the amended lease term.&#160;&#160;Lexicon is the guarantor of the obligation of its subsidiary under this lease.&#160;&#160;The Company is required to maintain restricted investments to collateralize a standby letter of credit for this lease.&#160;&#160;The Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> in restricted investments as collateral as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;Additionally, Lexicon leases certain equipment under operating leases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for all operating leases was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The following table includes non-cancelable, escalating future lease payments for the facility in New Jersey, without regard to the termination agreement entered into in March 2015:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ending</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">572</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employment Arrangements:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon has entered into employment arrangements with certain of its corporate officers. Under the arrangements, each officer receives a base salary, subject to adjustment, with an annual discretionary bonus based upon specific objectives to be determined by the compensation committee. The employment arrangements are at-will and some contain non-competition agreements. The arrangements also provide for a termination clause, which requires either a six or 12-month payment based on the officer&#8217;s salary and, in some cases, payment of a specified portion of the officer&#8217;s bonus target for such year, in the event of termination.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CommitmentsAndContingenciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_CommitmentsAndContingenciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized differently in the financial statements and tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of liabilities and assets using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criteria in determining if a valuation allowance should be provided.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of Lexicon&#8217;s deferred tax assets (liabilities) at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255,518</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,946</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,457</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,681</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability related to acquisition of Symphony Icon</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,745</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(412,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(376,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,675</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,745</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The  </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;"> deferred tax liability relates to the tax impact of future amortization or possible impairments associated with intangible assets acquired with Symphony Icon, which are not deductible for tax purposes.  Lexicon does not believe it can estimate the reversal of the temporary difference related to the assets acquired with sufficient certainty such that the related deferred tax liability could be considered as a source of taxable income in assessing the Company&#8217;s need for a valuation allowance.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, Lexicon had both federal and state NOL carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$715.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$460.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The federal and state NOL carryforwards began to expire in 2011 and continued to expire in 2012.&#160;&#160;The Company&#8217;s R&amp;D tax credit carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$40.2 million</font><font style="font-family:inherit;font-size:10pt;"> began to expire in 2012.&#160;&#160;Utilization of the NOL and R&amp;D credit carryforwards may be subject to a significant annual limitation due to ownership changes that have occurred previously or could occur in the future provided by Section&#160;382 of the Internal Revenue Code.&#160;&#160;Based on the federal tax law limits and the Company&#8217;s cumulative loss position, Lexicon concluded it was appropriate to establish a full valuation allowance for its net deferred tax assets until an appropriate level of profitability is sustained.&#160;&#160;During the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the valuation allowance increased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35.8 million</font><font style="font-family:inherit;font-size:10pt;">, primarily due to the Company&#8217;s current year net loss.&#160;&#160;Lexicon recorded income tax benefits of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$70,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0</font><font style="font-family:inherit;font-size:10pt;"> in the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.  During the year ended December 31, 2013, the Company recorded certain revisions to its deferred tax assets.  The revisions reduced the deferred tax assets and valuation allowance by </font><font style="font-family:inherit;font-size:10pt;">$13.8 million</font><font style="font-family:inherit;font-size:10pt;">.  There was no impact to the Company&#8217;s equity or operating results for any period.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company did not have any unrecognized tax benefits.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily subject to U.S. federal and New Jersey and Texas state income taxes.&#160;&#160;The tax years 1995 to current remain open to examination by U.S. federal authorities and 2004 to current remain open to examination by state authorities.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company had no accruals for interest or penalties related to income tax matters.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IncomeTaxesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_IncomeTaxesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Benefit Plan (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost Recognized</a></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanCostRecognized" onclick="toggleNextSibling(this);">$ 376,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanCostRecognized</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanCostRecognized" onclick="toggleNextSibling(this);">$ 511,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanCostRecognized</span><span></span></td>
        <td class="nump"><a title="us-gaap_DefinedContributionPlanCostRecognized" onclick="toggleNextSibling(this);">$ 490,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanCostRecognized</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the cost recognized during the period for defined contribution plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Assets Held for Sale<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AssetsHeldforSaleAbstract', window );"><strong>Assets Held for Sale [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">Disclosure of Long Lived Assets Held-for-sale [Table Text Block]</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets Held for Sale</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexicon&#8217;s buildings and land have been reclassified as assets held for sale on the consolidated balance sheet as of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. The Company estimated the fair value of the net assets to be sold at approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$23.8&#160;million</font><font style="font-family:inherit;font-size:10pt;"> as of</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, which represents estimated selling price less costs to sell. This resulted in an impairment loss on the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">assets held for sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.1&#160;million</font><font style="font-family:inherit;font-size:10pt;"> in the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, which was recorded in impairment loss on</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">buildings in the accompanying consolidated statement of comprehensive loss for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  The fair value of the net assets to be sold was determined using Level 2 inputs using sales prices in similar real estate sales and offers received from potential purchasers of the building.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AssetsHeldforSaleAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_AssetsHeldforSaleAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PropertyAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Useful Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">In Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5-7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,315</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3-7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,952</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7-10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,117</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,092</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15-40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,274</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81,945</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,362</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings of </font><font style="font-family:inherit;font-size:10pt;">$59.1 million</font><font style="font-family:inherit;font-size:10pt;"> and land of </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, as well as </font><font style="font-family:inherit;font-size:10pt;">$38.0&#160;million</font><font style="font-family:inherit;font-size:10pt;"> of related accumulated depreciation, have been reclassified to assets held for sale (see Note 6, Assets Held for Sale) as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PropertyAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_PropertyAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Goodwill<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Coelacanth, now Lexicon Pharmaceuticals (New Jersey), Inc., formed the core of the Company&#8217;s division responsible for small molecule compound discovery.&#160;&#160;The results of Lexicon Pharmaceuticals (New Jersey), Inc. are included in the Company&#8217;s results of operations for the period subsequent to the acquisition.  Goodwill associated with the acquisition of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$25.8 million</font><font style="font-family:inherit;font-size:10pt;">, which represents the excess of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$36.0 million</font><font style="font-family:inherit;font-size:10pt;"> purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 30, 2010, Lexicon exercised its Purchase Option (as defined in Note 11) and completed the acquisition of Symphony Icon.  Goodwill associated with the acquisition of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;">, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is not subject to amortization, but is tested at least annually for impairment at the reporting unit level, which is the Company&#8217;s single operating segment.&#160;&#160;The Company performed an impairment test of goodwill on its annual impairment assessment date.&#160;&#160;This test did not result in an impairment of goodwill.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GoodwillAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_GoodwillAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3JAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Quarterly Financial Data (Details) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 21,482</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 419</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 676</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 277</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 1,410</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 238</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 214</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 360</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 22,854</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 2,222</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 1,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(3,447)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(40,336)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(26,111)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(30,472)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(16,976)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(31,216)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(28,624)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(25,555)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(100,366)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(102,371)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(108,415)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated Net Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (2,933)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (40,498)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (26,028)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (30,835)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (17,414)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (31,658)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (29,080)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (25,974)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (100,294)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (104,126)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (110,211)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Consolidated Net Loss Per Common Share, Basic and Diluted</a></td>
        <td class="nump"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ 0.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.08)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.05)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.06)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.03)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.06)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.06)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.05)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.19)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.20)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.23)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares Used In Computing Consolidated Net Loss Per Common Share Basic And Diluted</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">593,694</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">514,796</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">514,623</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">513,955</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">513,523</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">513,419</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">513,083</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">512,428</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">534,432</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">513,117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">489,707</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialStatementsCaptionsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CondensedFinancialStatementsCaptionsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Incentive Awards (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td width="34%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except exercise price data)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,490</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,334</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,231</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(648</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(525</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at end of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,603</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,306</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,525</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at end of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,921</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,378</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,582</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,131</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt Obligations (Details 2) (USD $)<br>In Millions, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Nov. 30, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2004</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromConvertibleDebt" onclick="toggleNextSibling(this);">$ 87.5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromConvertibleDebt</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage', window );">Convertible Debt Instrument Interest Rate Stated Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage" onclick="toggleNextSibling(this);">5.25%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionRatio1" onclick="toggleNextSibling(this);">829.1874</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionRatio1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionPrice1" onclick="toggleNextSibling(this);">$ 1.206</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionPrice1</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Debt Issuance Cost</a></td>
        <td class="nump"><a title="us-gaap_DebtIssuanceCosts" onclick="toggleNextSibling(this);">3.4</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtIssuanceCosts</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized Debt Issuance Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnamortizedDebtIssuanceExpense" onclick="toggleNextSibling(this);">3.3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnamortizedDebtIssuanceExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFairValue" onclick="toggleNextSibling(this);">81.0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFairValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_WoodlandsMortgage', window );">Woodlands Mortgage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_WoodlandsMortgage" onclick="toggleNextSibling(this);">34.0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_WoodlandsMortgage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_WoodlandsCashPaid', window );">Woodlands Cash Paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_WoodlandsCashPaid" onclick="toggleNextSibling(this);">20.8</a><span style="display:none;white-space:normal;text-align:left;">lxrx_WoodlandsCashPaid</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage" onclick="toggleNextSibling(this);">8.23%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages', window );">Mortgage Loans on Real Estate, Carrying Amount of Mortgages</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages" onclick="toggleNextSibling(this);">20.2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BuildingsCollateral', window );">Buildings Collateral</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_BuildingsCollateral" onclick="toggleNextSibling(this);">59.1</a><span style="display:none;white-space:normal;text-align:left;">lxrx_BuildingsCollateral</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LandCollateral', window );">Land Collateral</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_LandCollateral" onclick="toggleNextSibling(this);">$ 2.7</a><span style="display:none;white-space:normal;text-align:left;">lxrx_LandCollateral</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BuildingsCollateral">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The buildings that serve as collateral for Lexicon's mortgage loan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_BuildingsCollateral</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed under convertible debt, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ConvertibleDebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LandCollateral">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The land that serves as collateral for Lexicon's mortgage loan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_LandCollateral</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_WoodlandsCashPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a $34.0 million third-party mortgage financing and $20.8 million in cash. This represents the $20.8 million cash paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_WoodlandsCashPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_WoodlandsMortgage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In April 2004, Lexicon purchased its existing laboratory and office buildings and animal facilities in The Woodlands, Texas with proceeds from a $34.0 million third-party mortgage financing and $20.8 million in cash. This represents the original $34.0 million mortgage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_WoodlandsMortgage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Conversion Rate<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509012<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13476-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of the outstanding balance due under the mortgage loan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 6<br><br> -Subparagraph (SX 210.5-04.(c) Schedule IV)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27047687&amp;loc=d3e5864-122674<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 29<br><br> -Article 12<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph c<br><br> -Subparagraph Schedule IV<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 948<br><br> -SubTopic 310<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.12-29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6589523&amp;loc=d3e617274-123014<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstateCarryingAmountOfMortgages</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Incentive Awards<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EquityIncentiveAwardsAbstract', window );"><strong>Equity Incentive Awards [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Awards</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Incentive Awards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Incentive Plans</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Incentive Plan:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In September 1995, Lexicon adopted the 1995 Stock Option Plan, which was subsequently amended and restated in February 2000 and renamed the 2000 Equity Incentive Plan, subsequently amended and restated in April 2009 and renamed the Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;), and subsequently amended in April 2012.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Equity Incentive Plan provides for the grant of incentive stock options to employees and nonstatutory stock options to employees, directors and consultants of the Company. The plan also permits the grant of stock bonus awards, restricted stock awards, restricted stock unit (phantom stock) awards and stock appreciation rights. Incentive and nonstatutory stock options have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> or more of the fair market value of our common stock on the date of grant.&#160;&#160;The purchase price of restricted stock awards may not be less than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">85%</font><font style="font-family:inherit;font-size:10pt;"> of fair market value.&#160;&#160;However, the plan administrator may award stock bonus awards in consideration of past services or phantom stock awards without a purchase payment. Shares may be subject to a repurchase option in the discretion of the plan administrator.&#160;&#160;Most options granted under the Equity Incentive Plan become vested and exercisable over a period of four years; however some have been granted with different vesting schedules.&#160;&#160;Options granted under the Equity Incentive Plan have a term of ten years from the date of grant.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total number of shares of common stock that may be issued pursuant to stock awards under the Equity Incentive Plan shall not exceed in the aggregate </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares.&#160;&#160;No more than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares may be issued pursuant to awards other than stock options and stock appreciation rights.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock had been reserved for issuance, options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">22,533,242</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,130,720</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units were outstanding, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,881,815</font><font style="font-family:inherit;font-size:10pt;"> shares had been issued upon the exercise of stock options, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,224,339</font><font style="font-family:inherit;font-size:10pt;"> shares had been issued pursuant to restricted stock units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">797,700</font><font style="font-family:inherit;font-size:10pt;"> shares had been issued pursuant to stock bonus awards or restricted stock awards granted under the Equity Incentive Plan.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Employee Directors&#8217; Equity Incentive Plan:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;In February 2000, Lexicon adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan, which was subsequently amended and restated in April 2009 and renamed the Non-Employee Directors&#8217; Stock Option Plan, and subsequently amended in April 2012 and renamed the Non-Employee Directors&#8217; Equity Incentive Plan (the &#8220;Directors&#8217; Plan&#8221;).&#160;&#160;Under the Directors&#8217; Plan, non-employee directors receive an initial option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock.&#160;&#160;In addition, on the day following each of the Company&#8217;s annual meetings of stockholders, each non-employee director who has been a director for at least six months is automatically granted an option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and a restricted stock award of the number of shares of common stock having a fair market value on the date of grant of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;">, rounded down to the nearest whole share number.&#160;&#160;Initial option grants become vested and exercisable over a period of five years and annual option grants become vested over a period of 12&#160;months from the date of grant.&#160;&#160;Options granted under the Directors&#8217; Plan have an exercise price equal to the fair market value of the Company&#8217;s common stock on the date of grant and a term of ten years from the date of grant.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total number of shares of common stock that may be issued pursuant to stock awards under the Directors&#8217; Plan shall not exceed in the aggregate </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock had been reserved for issuance, options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,070,000</font><font style="font-family:inherit;font-size:10pt;"> shares were outstanding, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">none</font><font style="font-family:inherit;font-size:10pt;"> had been issued upon the exercise of stock options and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">277,480</font><font style="font-family:inherit;font-size:10pt;"> shares had been issued pursuant to restricted stock awards granted under the Directors&#8217; Plan.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Option Activity:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The following is a summary of option activity under Lexicon&#8217;s equity incentive plans:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td width="34%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except exercise price data)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at beginning of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,490</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,334</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,231</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(648</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(525</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at end of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,603</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,306</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,525</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at end of year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,921</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,378</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,582</font></div></td><td style="vertical-align:bottom;border-bottom:4px double #000000;background-color:#cceeff;border-top:4px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average estimated grant date fair value of options granted during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.23</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.59</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.37</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The total intrinsic value of options exercised during the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$43,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$325,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$462,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The weighted average remaining contractual term of options outstanding and exercisable was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5.8</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">4.7</font><font style="font-family:inherit;font-size:10pt;"> years, respectively, as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of the outstanding options and the exercisable options was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">zero</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Bonus and Restricted Stock Unit Activity:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended December 31, 2014, 2013 and 2012, Lexicon granted its non-employee directors </font><font style="font-family:inherit;font-size:10pt;">102,560</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">80,808</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">94,112</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively, of restricted stock awards.  The restricted stock awards had weighed average grant date fair values of </font><font style="font-family:inherit;font-size:10pt;">$1.56</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.98</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.70</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively, and vested immediately.  During the year ended December&#160;31, 2014, Lexicon granted a consultant </font><font style="font-family:inherit;font-size:10pt;">57,400</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted stock awards.  The restricted stock awards had a weighted average grant date fair value of </font><font style="font-family:inherit;font-size:10pt;">$1.60</font><font style="font-family:inherit;font-size:10pt;"> per share and vested immediately.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2012</font><font style="font-family:inherit;font-size:10pt;">, Lexicon granted its employees restricted stock units in lieu of or in addition to annual stock option awards. These restricted stock units vest in four annual installments. The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,131</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aggregate Shares Reserved for Issuance</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">26,733,962</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were reserved for issuance upon exercise of outstanding stock options and vesting of outstanding restricted stock units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14,584,704</font><font style="font-family:inherit;font-size:10pt;"> additional shares were available for future grants under Lexicon&#8217;s equity incentive plans.&#160;&#160;The Company has a policy of using either authorized and unissued shares or treasury shares, including shares acquired by purchase in the open market or in private transactions, to satisfy equity award exercises.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EquityIncentiveAwardsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_EquityIncentiveAwardsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation:</font><font style="font-family:inherit;font-size:10pt;"> The accompanying consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries.  Intercompany transactions and balances are eliminated in consolidation. </font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash, Cash Equivalents and Short-Term Investments:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;">, short-term investments consist of U.S. treasury bills and certificates of deposit.  The certificates of deposits are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash and Investments:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon is required to maintain restricted cash or investments to collateralize standby letters of credit for the lease on its office and laboratory facilities in Hopewell, New Jersey (see Note&#160;12).</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade and Other Accounts Receivable, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services.&#160;&#160;&#160;The allowance for doubtful accounts takes into consideration such factors as historical write-offs, the economic climate and other factors that could affect collectibility.&#160;&#160;Write-offs are evaluated on a case by case basis.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon&#8217;s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company&#8217;s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in the United States.&#160;&#160;The Company has not experienced any significant credit losses to date.</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Information and Significant Customers:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon operates in one business segment, which primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Substantially all of the Company&#8217;s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, government grants and contracts and compound library sales.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment:</font><font style="font-family:inherit;font-size:10pt;"> Property and equipment are carried at cost and depreciated using the straight-line method over the estimated useful life of the assets which ranges from three to 40 years.&#160;&#160;Maintenance, repairs and minor replacements are charged to expense as incurred.&#160;&#160;Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&#160;&#160;Significant renewals and betterments are capitalized.</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-Lived Assets:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Long-lived assets and certain identifiable intangible assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  Indefinite lived intangible assets are also tested at least annually for impairment.  Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition.&#160;&#160;In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill Impairment:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Goodwill is not amortized, but is tested at least annually for impairment at the reporting unit level.&#160;&#160;The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value.&#160;&#160;The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill.&#160;&#160;If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized.&#160;&#160;Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying value of goodwill has been impaired.</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition:</font><font style="font-family:inherit;font-size:10pt;"> Revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements revenues include both license revenue and contract research revenue. Activities under collaborative agreements are evaluated to determine if they represent a multiple element revenue agreement.  The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting.  The Company accounts for those components as separate units of accounting if the following two criteria are met:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The delivered item or items have value to the customer on a stand-alone basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company&#8217;s control.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables.  If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting.  The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable.  Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative estimated selling price.  Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future milestone payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved.  A milestone is substantive if:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It can only be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It would result in additional payments being due to the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subscription and license fees are recognized as revenue upon the grant of the technology license when performance is complete and there is no continuing involvement.  Royalty revenues are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed and determinable based on information received from the sublicensees and at the time collectibility is reasonably assured.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses:</font><font style="font-family:inherit;font-size:10pt;"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;The Company recognizes compensation expense in its statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, stock-based compensation cost for all outstanding unvested options and restricted stock units was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.4 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;years.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives and forfeitures.&#160;&#160;Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss per Common Share:</font><font style="font-family:inherit;font-size:10pt;"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options, restricted stock units and warrants are not included because they are antidilutive.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BasisOfPresentationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_BasisOfPresentationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 42<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 31<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 33<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5093-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5212-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EADAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Goodwill (Details) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Jul. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jul. 12, 2001</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CoelacanthGoodwill', window );">Coelacanth Goodwill</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_CoelacanthGoodwill" onclick="toggleNextSibling(this);">$ 25.8</a><span style="display:none;white-space:normal;text-align:left;">lxrx_CoelacanthGoodwill</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CoelacanthPurchasePrice', window );">Coelacanth Purchase Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_CoelacanthPurchasePrice" onclick="toggleNextSibling(this);">36.0</a><span style="display:none;white-space:normal;text-align:left;">lxrx_CoelacanthPurchasePrice</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SymphonyIconGoodwill', window );">Symphony Icon Goodwill</a></td>
        <td class="nump"><a title="lxrx_SymphonyIconGoodwill" onclick="toggleNextSibling(this);">$ 18.7</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SymphonyIconGoodwill</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger. Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.  This represents the goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_CoelacanthGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CoelacanthPurchasePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 12, 2001, Lexicon completed the acquisition of Coelacanth Corporation in a merger.  Goodwill associated with the acquisition of $25.8 million, which represents the excess of the $36.0 million purchase price over the fair value of the underlying net identifiable assets, was assigned to the consolidated entity, Lexicon.  This represents the purchase price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_CoelacanthPurchasePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SymphonyIconGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>On July 30, 2010, Lexicon exercised its Purchase Option and completed the acquisition of Symphony Icon. Goodwill associated with the acquisition of $18.7 million, which represents the assets recognized in connection with the deferred tax liability acquired and did not result from excess purchase price, was assigned to the consolidated entity, Lexicon.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SymphonyIconGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETMBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
        <td class="nump"><a title="us-gaap_RealizedInvestmentGainsLosses" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RealizedInvestmentGainsLosses</span><span></span></td>
        <td class="nump"><a title="us-gaap_RealizedInvestmentGainsLosses" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RealizedInvestmentGainsLosses</span><span></span></td>
        <td class="nump"><a title="us-gaap_RealizedInvestmentGainsLosses" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RealizedInvestmentGainsLosses</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_CashMember', window );">Cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_CashMember]" onclick="toggleNextSibling(this);">137,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_CashMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_CashMember]" onclick="toggleNextSibling(this);">37,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_CashMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_CashMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_CashMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_CashMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_CashMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_CashMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_CashMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_CashMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_CashMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_CashMember]" onclick="toggleNextSibling(this);">137,266</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_CashMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_CashMember]" onclick="toggleNextSibling(this);">37,499</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_CashMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember]" onclick="toggleNextSibling(this);">552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_CertificatesOfDepositMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember]" onclick="toggleNextSibling(this);">552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_CertificatesOfDepositMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_CertificatesOfDepositMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_CertificatesOfDepositMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_CertificatesOfDepositMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_CertificatesOfDepositMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember]" onclick="toggleNextSibling(this);">552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_CertificatesOfDepositMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember]" onclick="toggleNextSibling(this);">552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_CertificatesOfDepositMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember]" onclick="toggleNextSibling(this);">201,584</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_USTreasurySecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember]" onclick="toggleNextSibling(this);">91,075</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_USTreasurySecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_USTreasurySecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_USTreasurySecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember]" onclick="toggleNextSibling(this);">(66)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_USTreasurySecuritiesMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember]" onclick="toggleNextSibling(this);">(1)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_USTreasurySecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember]" onclick="toggleNextSibling(this);">201,521</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_USTreasurySecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember]" onclick="toggleNextSibling(this);">91,077</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_USTreasurySecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">202,136</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">91,627</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">(66)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">(1)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">202,073</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">91,629</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_InvestmentsMember', window );">Cash and Cash Equivalents and Investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_InvestmentsMember]" onclick="toggleNextSibling(this);">339,402</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_InvestmentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[invest_InvestmentAxis=us-gaap_InvestmentsMember]" onclick="toggleNextSibling(this);">129,126</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ invest_InvestmentAxis<br>= us-gaap_InvestmentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Gain Accumulated in Investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_InvestmentsMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_InvestmentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax[invest_InvestmentAxis=us-gaap_InvestmentsMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_InvestmentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_InvestmentsMember]" onclick="toggleNextSibling(this);">(66)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_InvestmentsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax[invest_InvestmentAxis=us-gaap_InvestmentsMember]" onclick="toggleNextSibling(this);">(1)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax<br>/ invest_InvestmentAxis<br>= us-gaap_InvestmentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Available-for-sale Securities, Current</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_InvestmentsMember]" onclick="toggleNextSibling(this);">$ 339,339</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_InvestmentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesCurrent[invest_InvestmentAxis=us-gaap_InvestmentsMember]" onclick="toggleNextSibling(this);">$ 129,128</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesCurrent<br>/ invest_InvestmentAxis<br>= us-gaap_InvestmentsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.3(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 325<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6485959&amp;loc=d3e22529-158502<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 3<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_CashMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_CashMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_CertificatesOfDepositMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_InvestmentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_InvestmentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_ShortTermInvestmentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_USTreasurySecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1BAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements of Comprehensive Loss Parentheticals (Parentheticals) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
        <td class="nump"><a title="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 4,020</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 4,376</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 3,673</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense', window );">Stock-based compensation expense associated with general and administrative expense</a></td>
        <td class="nump"><a title="lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">$ 3,061</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">$ 3,045</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">$ 2,822</a><span style="display:none;white-space:normal;text-align:left;">lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock-based compensation expense associated with general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock-based compensation expense included in research and development expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-09, &#8220;Revenue from Contracts with Customers&#8221;, which amends FASB ASC Topic 606. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. This standard contains principles for the determination of the measurement of revenue and the timing of when such revenue is recognized. Revenue recognition will reflect the transfer of goods or services to customers at an amount that is expected to be earned in exchange for those goods or services. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December&#160;15, 2016, and early adoption is not permitted. Management is currently evaluating the impact of this pronouncement on Lexicon&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15, &#8220;Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.&#8221; ASU 2014-15 will explicitly require management to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted.  Management does not expect the adoption of this pronouncement to have a material impact on Lexicon&#8217;s consolidated financial statements.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 01<br><br> -Paragraph b<br><br> -Subparagraph 6<br><br> -Article 10<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28359718&amp;loc=d3e22499-107794<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28359718&amp;loc=d3e22580-107794<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Direct Effects of a Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510796<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Indirect Effects of a Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515603<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Accounting Change<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6503790<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507316<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.10-01.(b)(6))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Retrospective Application<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523989<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28359718&amp;loc=d3e22583-107794<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2KAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Incentive Awards (Details 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period</a></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" onclick="toggleNextSibling(this);">102,560</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" onclick="toggleNextSibling(this);">80,808</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod" onclick="toggleNextSibling(this);">94,112</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.56</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.98</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.70</a><span style="display:none;white-space:normal;text-align:left;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period</a></td>
        <td class="nump"><a title="lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod" onclick="toggleNextSibling(this);">57,400</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Stock Bonus and Restricted Stock to Consultants, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
        <td class="nump"><a title="lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.60</a><span style="display:none;white-space:normal;text-align:left;">lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant date fair value for grants of stock bonus and restricted stock awards made during the period under equity incentive plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant date fair value for grants of stock bonus and restricted stock awards made to consultants during the period under equity incentive plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Risk-free Interest Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expected Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Dividend</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-align:center;">Rate</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2013:</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2012:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officers and non-employee directors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>105</ContextCount>
  <ElementCount>322</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DocumentAndEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001500 - Statement - Balance Sheet Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BalanceSheetParentheticals</Role>
      <ShortName>Balance Sheet Parentheticals</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003500 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/StatementsOfComprehensiveLossParentheticalsParentheticals</Role>
      <ShortName>Statements of Comprehensive Loss Parentheticals (Parentheticals)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Assets Held for Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/AssetsHeldForSale</Role>
      <ShortName>Assets Held for Sale</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Arrangements with Symphony Icon, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ArrangementsWithSymphonyIconInc</Role>
      <ShortName>Arrangements with Symphony Icon, Inc.</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2137100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2143100 - Disclosure - Other Capital Stock Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalStockAgreements</Role>
      <ShortName>Other Capital Stock Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2146100 - Disclosure - Equity Incentive Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwards</Role>
      <ShortName>Equity Incentive Awards</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2149100 - Disclosure - Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlan</Role>
      <ShortName>Benefit Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2150100 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2151100 - Disclosure - Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RestructuringCharges</Role>
      <ShortName>Restructuring Charges</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2152100 - Disclosure - Selected Quarterly Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>Selected Quarterly Financial Data</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2304315 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Debt Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsTables</Role>
      <ShortName>Debt Obligations (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2337301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2346301 - Disclosure - Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsTables</Role>
      <ShortName>Equity Incentive Awards (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2352301 - Disclosure - Selected Quarterly Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>Selected Quarterly Financial Data (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2404416 - Disclosure - Summary of Significant Accounting Policies Restricted Cash and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashAndInvestmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Restricted Cash and Investments (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2404417 - Disclosure - Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Concentration of Credit Risk (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2404418 - Disclosure - Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationAndSignficantCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2404420 - Disclosure - Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-Based Compensation (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2404421 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Cash and Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashAndCashEquivalentsAndInvestmentsDetails</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Assets Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/AssetsHeldForSaleDetails</Role>
      <ShortName>Assets Held for Sale (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Property and Equipment (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyAndEquipmentDetails1</Role>
      <ShortName>Property and Equipment (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Property and Equipment (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/PropertyAndEquipmentDetails2</Role>
      <ShortName>Property and Equipment (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Debt Obligations (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails1</Role>
      <ShortName>Debt Obligations (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2431403 - Disclosure - Debt Obligations (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails2</Role>
      <ShortName>Debt Obligations (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Arrangements with Symphony Icon, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ArrangementsWithSymphonyIconIncDetails</Role>
      <ShortName>Arrangements with Symphony Icon, Inc. (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2437402 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2437403 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2443402 - Disclosure - Other Capital Stock Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalStockAgreementsDetails</Role>
      <ShortName>Other Capital Stock Agreements (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446402 - Disclosure - Equity Incentive Awards (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails1</Role>
      <ShortName>Equity Incentive Awards (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2446403 - Disclosure - Equity Incentive Awards (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails2</Role>
      <ShortName>Equity Incentive Awards (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2446404 - Disclosure - Equity Incentive Awards (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails3</Role>
      <ShortName>Equity Incentive Awards (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2446405 - Disclosure - Equity Incentive Awards (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EquityIncentiveAwardsDetails4</Role>
      <ShortName>Equity Incentive Awards (Details 4)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2449402 - Disclosure - Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/BenefitPlanDetails</Role>
      <ShortName>Benefit Plan (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2450402 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationAndLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2451402 - Disclosure - Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/RestructuringChargesDetails</Role>
      <ShortName>Restructuring Charges (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2452402 - Disclosure - Selected Quarterly Financial Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SelectedQuarterlyFinancialDataDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element lxrx_OfferingPricePerShare had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodSharesNewIssues had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">'Shares' elements on report '1004000 - Statement - Consolidated Statements of Stockholders' Equity' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '2425403 - Disclosure - Income Taxes (Details 2)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '2434402 - Disclosure - Arrangements with Symphony Icon, Inc. (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '2437402 - Disclosure - Commitments and Contingencies (Details 1)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '2450402 - Disclosure - Collaboration and License Agreements (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 1001000 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 1001500 - Statement - Balance Sheet Parentheticals</Log>
    <Log type="Info">Process Flow-Through: 1002000 - Statement - Consolidated Statements of Comprehensive Loss</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 1003500 - Statement - Statements of Comprehensive Loss Parentheticals (Parentheticals)</Log>
    <Log type="Info">Process Flow-Through: 1005000 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>lxrx-20141231.xml</File>
    <File>lxrx-20141231.xsd</File>
    <File>lxrx-20141231_cal.xml</File>
    <File>lxrx-20141231_def.xml</File>
    <File>lxrx-20141231_lab.xml</File>
    <File>lxrx-20141231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies Segment Information and Signficant Customers (Details)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EntityWideRevenueIpsenPercentage', window );">Entity Wide Revenue Ipsen Percentage</a></td>
        <td class="nump"><a title="lxrx_EntityWideRevenueIpsenPercentage" onclick="toggleNextSibling(this);">94.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_EntityWideRevenueIpsenPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage', window );">Entity-Wide Revenue, McNair Medical Institute, Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage" onclick="toggleNextSibling(this);">57.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EntityWideRevenueTaconicFarmsPercentage', window );">Entity-Wide Revenue, Taconic Farms, Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_EntityWideRevenueTaconicFarmsPercentage" onclick="toggleNextSibling(this);">33.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_EntityWideRevenueTaconicFarmsPercentage</span><span></span></td>
        <td class="nump"><a title="lxrx_EntityWideRevenueTaconicFarmsPercentage" onclick="toggleNextSibling(this);">68.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_EntityWideRevenueTaconicFarmsPercentage</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_EntityWideRevenueDeltagenPercentage', window );">Entity-Wide Revenue, Deltagen, Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="lxrx_EntityWideRevenueDeltagenPercentage" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">lxrx_EntityWideRevenueDeltagenPercentage</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EntityWideRevenueDeltagenPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of revenue generated from Deltagen, Inc. that accounts for 10 percent or more of an entity&#x2019;s revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_EntityWideRevenueDeltagenPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EntityWideRevenueIpsenPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of revenue generated from Ipsen Pharma SAS that accounts for 10 percent or more of an entity's revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_EntityWideRevenueIpsenPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of revenue generated from McNair Medical Institute, LLC that accounts for 10 percent or more of an entity&#x2019;s revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_EntityWideRevenueMcNairMedicalInstitutePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_EntityWideRevenueTaconicFarmsPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of revenue generated from Taconic Farms, Inc. that accounts for 10 percent or more of an entity&#x2019;s revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_EntityWideRevenueTaconicFarmsPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Other Capital Stock Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OtherCapitalStockAgreementsAbstract', window );"><strong>Other Capital Stock Agreements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Other Capital Stock Agreements</a></td>
        <td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Capital Stock Agreements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock:</font><font style="font-family:inherit;font-size:10pt;"> In October 2012, Lexicon sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">17,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.25</font><font style="font-family:inherit;font-size:10pt;"> per share in a public offering, resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$37.1 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.0&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.  Invus, L.P., Lexicon&#8217;s largest stockholder, purchased </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,000,000</font><font style="font-family:inherit;font-size:10pt;"> of these shares.  All of the net proceeds of this offering are reflected as issuance of common stock in the accompanying financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, Lexicon sold </font><font style="font-family:inherit;font-size:10pt;">55,608,930</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$1.005</font><font style="font-family:inherit;font-size:10pt;"> per share in a public offering, and sold </font><font style="font-family:inherit;font-size:10pt;">149,253,731</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$1.005</font><font style="font-family:inherit;font-size:10pt;"> per share in a private placement to Artal International S.C.A, an affiliate of Invus, L.P., resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$201.9&#160;million</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions of </font><font style="font-family:inherit;font-size:10pt;">$3.4&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.6&#160;million</font><font style="font-family:inherit;font-size:10pt;">.  All of the net proceeds of these offerings are reflected as issuance of common stock in the accompanying financial statements.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OtherCapitalStockAgreementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">lxrx_OtherCapitalStockAgreementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>lxrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
